Bayesian JJ 0
adaptive JJ 0
trials NNS 0
offer VBP 0
advantages NNS 0
in IN 0
comparative JJ 0
effectiveness NN 0
trials NNS 0
: : 0
an DT 0
example NN 0
in IN 0
status NN 0
epilepticus NN 0
. . 0

OBJECTIVE IN 0
We PRP 0
present VBP 0
a DT 0
novel JJ 0
Bayesian JJ 0
adaptive JJ 0
comparative NN 0
effectiveness NN 0
trial NN 0
comparing VBG 0
three CD 0
treatments NNS 0
for IN 0
status NN 0
epilepticus NN 0
that WDT 0
uses VBZ 0
adaptive JJ 0
randomization NN 0
with IN 0
potential JJ 0
early JJ 0
stopping NN 0
. . 0

STUDY NNP 0
DESIGN NNP 0
AND NNP 0
SETTING NNP 0
The DT 0
trial NN 0
will MD 0
enroll VB 0
720 CD 0
unique JJ 0
patients NNS 0
in IN 0
emergency NN 0
departments NNS 0
and CC 0
uses VBZ 0
a DT 0
Bayesian JJ 0
adaptive JJ 0
design NN 0
. . 0

RESULTS VB 0
The DT 0
trial NN 0
design NN 0
is VBZ 0
compared VBN 0
to TO 0
a DT 0
trial NN 0
without IN 0
adaptive JJ 0
randomization NN 0
and CC 0
produces VBZ 0
an DT 0
efficient JJ 0
trial NN 0
in IN 0
which WDT 0
a DT 0
higher JJR 0
proportion NN 0
of IN 0
patients NNS 0
are VBP 0
likely JJ 0
to TO 0
be VB 0
randomized VBN 0
to TO 0
the DT 0
most RBS 0
effective JJ 0
treatment NN 0
arm NN 0
while IN 0
generally RB 0
using VBG 0
fewer JJR 0
total JJ 0
patients NNS 0
and CC 0
offers VBZ 0
higher JJR 0
power NN 0
than IN 0
an DT 0
analogous JJ 0
trial NN 0
with IN 0
fixed JJ 0
randomization NN 0
when WRB 0
identifying VBG 0
a DT 0
superior JJ 0
treatment NN 0
. . 0

CONCLUSION NN 0
When WRB 0
one CD 0
treatment NN 0
is VBZ 0
superior JJ 0
to TO 0
the DT 0
other JJ 0
two CD 0
, , 0
the DT 0
trial NN 0
design NN 0
provides VBZ 0
better RBR 0
patient NN 0
care NN 0
, , 0
higher JJR 0
power NN 0
, , 0
and CC 0
a DT 0
lower JJR 0
expected VBN 0
sample JJ 0
size NN 0
. . 0

Eltrombopag NNP 0
for IN 0
management NN 0
of IN 0
chronic JJ 0
immune NN 0
thrombocytopenia NN 0
( ( 0
RAISE NNP 0
) ) 0
: : 0
a DT 0
6-month JJ 0
, , 0
randomised VBN 0
, , 0
phase VB 0
3 CD 0
study NN 0
. . 0

BACKGROUND NNP 0
Eltrombopag NNP 0
is VBZ 0
an DT 0
oral JJ 0
thrombopoietin NN 0
receptor NN 0
agonist NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
thrombocytopenia NN 0
. . 0

We PRP 0
aimed VBD 0
to TO 0
compare VB 0
the DT 0
response NN 0
to TO 0
once RB 0
daily JJ 0
eltrombopag NNS 0
versus VBP 0
placebo NN 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 0
immune JJ 0
thrombocytopenia NN 0
during IN 0
a DT 0
6-month JJ 0
period NN 0
. . 0

METHODS NNP 0
We PRP 0
undertook VBD 0
a DT 0
phase NN 0
3 CD 0
, , 0
double-blind NN 0
, , 0
placebo-controlled JJ 0
study NN 0
in IN 0
adults NNS 0
with IN 0
previously RB 0
treated VBN 0
immune JJ 0
thrombocytopenia NN 0
of IN 0
more JJR 0
than IN 0
6 CD 0
months NNS 0
' POS 0
duration NN 0
who WP 0
had VBD 0
baseline NN 0
platelet NN 0
counts VBZ 0
lower JJR 0
than IN 0
30,000 CD 0
per IN 0
?L NN 0
. . 0

Patients NNS 0
were VBD 0
randomly RB 0
allocated VBN 0
( ( 0
in IN 0
a DT 0
2:1 CD 0
ratio NN 0
) ) 0
treatment NN 0
with IN 0
local JJ 0
standard NN 0
of IN 0
care NN 0
plus CC 0
50 CD 0
mg NN 0
eltrombopag NN 0
or CC 0
matching VBG 0
placebo JJ 0
once RB 0
daily JJ 0
for IN 0
6 CD 0
months NNS 0
. . 0

Randomisation NN 0
was VBD 0
done VBN 0
centrally RB 0
with IN 0
a DT 0
computer-generated JJ 0
randomisation NN 0
schedule NN 0
and CC 0
was VBD 0
stratified VBN 0
by IN 0
baseline JJ 0
platelet NN 0
count NN 0
( ( 0
? . 0
15,000 CD 0
per IN 0
?L NN 0
) ) 0
, , 0
use NN 0
of IN 0
treatment NN 0
for IN 0
immune JJ 0
thrombocytopenia NN 0
, , 0
and CC 0
splenectomy JJ 0
status NN 0
. . 0

Patients NNS 0
, , 0
investigators NNS 0
, , 0
and CC 0
those DT 0
assessing VBG 0
data NNS 0
were VBD 0
masked VBN 0
to TO 0
allocation NN 0
. . 0

Dose JJ 0
modifications NNS 0
were VBD 0
made VBN 0
on IN 0
the DT 0
basis NN 0
of IN 0
platelet NN 0
response NN 0
. . 0

Patients NNS 0
were VBD 0
assessed VBN 0
for IN 0
response NN 0
to TO 0
treatment NN 0
( ( 0
defined VBN 0
as IN 0
a DT 0
platelet NN 0
count NN 0
of IN 0
50,000-400,000 CD 0
per IN 0
?L NN 0
) ) 0
weekly NN 0
during IN 0
the DT 0
first JJ 0
6 CD 0
weeks NNS 0
and CC 0
at IN 0
least JJS 0
once RB 0
every DT 0
4 CD 0
weeks NNS 0
thereafter RB 0
; : 0
the DT 0
primary JJ 0
endpoint NN 0
was VBD 0
the DT 0
odds NNS 0
of IN 0
response NN 0
to TO 0
eltrombopag VB 0
versus NN 0
placebo NN 0
. . 0

Analysis NN 0
was VBD 0
by IN 0
intention NN 0
to TO 0
treat VB 0
. . 0

This DT 0
study NN 0
is VBZ 0
registered VBN 0
at IN 0
ClinicalTrials.gov NNP 0
, , 0
number NN 0
NCT00370331 NNP 0
. . 0

FINDINGS NNP 0
Between NNP 0
Nov NNP 0
22 CD 0
, , 0
2006 CD 0
, , 0
and CC 0
July NNP 0
31 CD 0
, , 0
2007 CD 0
, , 0
197 CD 0
patients NNS 0
were VBD 0
randomly RB 0
allocated VBN 0
to TO 0
treatment NN 0
groups NNS 0
and CC 0
were VBD 0
included VBN 0
in IN 0
the DT 0
intention-to-treat JJ 0
analysis NN 0
( ( 0
135 CD 0
eltrombopag NN 0
, , 0
62 CD 0
placebo NN 0
) ) 0
. . 0

106 CD 0
( ( 0
79 CD 0
% NN 0
) ) 0
patients NNS 0
in IN 0
the DT 0
eltrombopag NN 0
group NN 0
responded VBD 0
to TO 0
treatment NN 0
at IN 0
least JJS 0
once RB 0
during IN 0
the DT 0
study NN 0
, , 0
compared VBN 0
with IN 0
17 CD 0
( ( 0
28 CD 0
% NN 0
) ) 0
patients NNS 0
in IN 0
the DT 0
placebo NN 0
group NN 0
. . 0

The DT 0
odds NNS 0
of IN 0
responding VBG 0
were VBD 0
greater JJR 0
in IN 0
patients NNS 0
in IN 0
the DT 0
eltrombopag NN 0
group NN 0
compared VBN 0
with IN 0
those DT 0
in IN 0
the DT 0
placebo NN 0
group NN 0
throughout IN 0
the DT 0
6-month JJ 0
treatment NN 0
period NN 0
( ( 0
odds NNS 0
ratio VBP 0
8?2 CD 0
, , 0
99 CD 0
% NN 0
CI NNP 0
3?59-18?73 CD 0
; : 0
p CC 0
< VB 0
0?0001 CD 0
) ) 0
. . 0

37 CD 0
( ( 0
59 CD 0
% NN 0
) ) 0
patients NNS 0
receiving VBG 0
eltrombopag NN 0
reduced VBD 0
concomitant JJ 0
treatment NN 0
versus NN 0
ten NN 0
( ( 0
32 CD 0
% NN 0
) ) 0
patients NNS 0
receiving VBG 0
placebo NN 0
( ( 0
p=0?016 NN 0
) ) 0
. . 0

24 CD 0
( ( 0
18 CD 0
% NN 0
) ) 0
patients NNS 0
receiving VBG 0
eltrombopag NN 0
needed VBN 0
rescue NN 0
treatment NN 0
compared VBN 0
with IN 0
25 CD 0
( ( 0
40 CD 0
% NN 0
) ) 0
patients NNS 0
receiving VBG 0
placebo NN 0
( ( 0
p=0?001 NN 0
) ) 0
. . 0

Three NNP 0
( ( 0
2 CD 0
% NN 0
) ) 0
patients NNS 0
receiving VBG 0
eltrombopag NN 0
had VBD 0
thromboembolic JJ 0
events NNS 0
compared VBN 0
with IN 0
none NN 0
in IN 0
patients NNS 0
on IN 0
placebo NN 0
. . 0

Nine NNP 0
( ( 0
7 CD 0
% NN 0
) ) 0
eltrombopag-treated JJ 0
patients NNS 0
and CC 0
two CD 0
( ( 0
3 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
placebo NN 0
group NN 0
had VBD 0
mild VBN 0
increases NNS 0
in IN 0
alanine JJ 0
aminotransferase NN 0
concentration NN 0
, , 0
and CC 0
five CD 0
( ( 0
4 CD 0
% NN 0
) ) 0
eltrombopag-treated JJ 0
patients NNS 0
( ( 0
vs IN 0
none NN 0
allocated VBN 0
to TO 0
placebo VB 0
) ) 0
had VBD 0
increases NNS 0
in IN 0
total JJ 0
bilirubin NN 0
. . 0

Four CD 0
( ( 0
7 CD 0
% NN 0
) ) 0
patients NNS 0
taking VBG 0
placebo NN 0
had VBD 0
serious JJ 0
bleeding VBG 0
events NNS 0
, , 0
compared VBN 0
with IN 0
one CD 0
( ( 0
< VB 0
1 CD 0
% NN 0
) ) 0
patient NN 0
treated VBN 0
with IN 0
eltrombopag NN 0
. . 0

INTERPRETATION NNP 0
Eltrombopag NNP 0
is VBZ 0
effective JJ 0
for IN 0
management NN 0
of IN 0
chronic JJ 0
immune NN 0
thrombocytopenia NN 0
, , 0
and CC 0
could MD 0
be VB 0
particularly RB 0
beneficial JJ 0
for IN 0
patients NNS 0
who WP 0
have VBP 0
not RB 0
responded VBN 0
to TO 0
splenectomy VB 0
or CC 0
previous JJ 0
treatment NN 0
. . 0

These DT 0
benefits NNS 0
should MD 0
be VB 0
balanced VBN 0
with IN 0
the DT 0
potential JJ 0
risks NNS 0
associated VBN 0
with IN 0
eltrombopag JJ 0
treatment NN 0
. . 0

FUNDING NN 0
GlaxoSmithKline NNP 0
. . 0

The DT 0
effect NN 0
of IN 0
tunnelling VBG 0
on IN 0
epidural JJ 0
catheter NN 0
migration NN 0
. . 0

A DT 0
prospective JJ 0
, , 0
randomised VBD 0
study NN 0
of IN 0
82 CD 0
patients NNS 0
having VBG 0
postoperative JJ 0
epidural JJ 0
analgesia NN 0
was VBD 0
performed VBN 0
to TO 0
determine VB 0
whether IN 0
the DT 0
tunnelling NN 0
of IN 0
an DT 0
epidural JJ 0
catheter NN 0
influences VBZ 0
its PRP$ 0
migration NN 0
. . 0

Tunnelling NN 0
of IN 0
the DT 0
catheter NN 0
subcutaneously RB 0
for IN 0
a DT 0
distance NN 0
of IN 0
5 CD 0
cm NN 0
reduced VBD 0
the DT 0
incidence NN 0
of IN 0
inward JJ 0
migration NN 0
of IN 0
1 CD 0
cm NN 0
or CC 0
more JJR 0
( ( 0
p JJ 0
< NNP 0
0.01 CD 0
) ) 0
compared VBN 0
to TO 0
a DT 0
standard JJ 0
method NN 0
of IN 0
fixation NN 0
with IN 0
a DT 0
transparent JJ 0
adhesive JJ 0
dressing NN 0
. . 0

This DT 0
effect NN 0
was VBD 0
more RBR 0
marked JJ 0
if IN 0
the DT 0
epidural JJ 0
catheter NN 0
was VBD 0
sited VBN 0
in IN 0
the DT 0
thoracic NN 0
rather RB 0
than IN 0
the DT 0
lumbar JJ 0
area NN 0
. . 0

Sixty CD 0
two CD 0
percent NN 0
( ( 0
n JJ 0
= NNP 0
26 CD 0
) ) 0
of IN 0
tunnelled JJ 0
catheters NNS 0
remained VBD 0
within IN 0
0.5 CD 0
cm NNS 0
of IN 0
their PRP$ 0
original JJ 0
position NN 0
compared VBN 0
to TO 0
38 CD 0
% NN 0
( ( 0
n JJ 0
= NNP 0
16 CD 0
) ) 0
of IN 0
non-tunnelled JJ 0
catheters NNS 0
, , 0
although IN 0
this DT 0
difference NN 0
was VBD 0
not RB 0
statistically RB 0
significant JJ 0
. . 0

Outward NNP 0
catheter NN 0
migration NN 0
was VBD 0
not RB 0
reduced VBN 0
by IN 0
subcutaneous JJ 0
tunnelling NN 0
. . 0

Interventions NNS 0
in IN 0
the DT 0
initial JJ 0
prodromal JJ 0
states NNS 0
of IN 0
psychosis NN 0
in IN 0
Germany NNP 0
: : 0
concept NN 0
and CC 0
recruitment NN 0
. . 0

BACKGROUND VB 0
The DT 0
Early JJ 0
Detection NN 0
and CC 0
Intervention NNP 0
Programme NNP 0
of IN 0
the DT 0
German JJ 0
Research NNP 0
Network NNP 0
on IN 0
Schizophrenia NNP 0
( ( 0
GRNS NNP 0
) ) 0
investigates VBZ 0
the DT 0
initial JJ 0
prodromal JJ 0
phase NN 0
of IN 0
psychosis NN 0
in IN 0
a DT 0
multidimensional JJ 0
approach NN 0
. . 0

Two CD 0
intervention NN 0
strategies NNS 0
are VBP 0
being VBG 0
studied VBN 0
by IN 0
two CD 0
large-scale JJ 0
multicentre JJ 0
projects NNS 0
. . 0

AIMS NNP 0
To TO 0
present VB 0
the DT 0
concept NN 0
of IN 0
the DT 0
intervention NN 0
studies NNS 0
, , 0
and CC 0
to TO 0
provide VB 0
an DT 0
interim JJ 0
report NN 0
of IN 0
the DT 0
recruitment JJ 0
procedure NN 0
. . 0

METHOD NNP 0
Comprehensive NNP 0
cognitive-behavioural JJ 0
therapy NN 0
has VBZ 0
been VBN 0
developed VBN 0
for IN 0
patients NNS 0
in IN 0
the DT 0
early JJ 0
initial JJ 0
prodromal JJ 0
state NN 0
. . 0

For IN 0
patients NNS 0
in IN 0
the DT 0
late JJ 0
initial JJ 0
prodromal JJ 0
state NN 0
the DT 0
atypical JJ 0
neuroleptic JJ 0
amisulpride NN 0
is VBZ 0
explored VBN 0
. . 0

Both DT 0
interventions NNS 0
are VBP 0
evaluated VBN 0
in IN 0
randomised JJ 0
controlled VBN 0
trials NNS 0
using VBG 0
clinical JJ 0
management NN 0
as IN 0
the DT 0
control NN 0
condition NN 0
. . 0

RESULTS NNP 0
Between NNP 0
January NNP 0
2001 CD 0
and CC 0
March NNP 0
2003 CD 0
, , 0
1212 CD 0
individuals NNS 0
seeking VBG 0
help NN 0
for IN 0
mental JJ 0
health NN 0
problems NNS 0
were VBD 0
screened VBN 0
for IN 0
putative JJ 0
prodromal NN 0
symptoms NNS 0
at IN 0
four CD 0
university NN 0
centres NNS 0
. . 0

More JJR 0
than IN 0
388 CD 0
individuals NNS 0
fulfilled VBD 0
criteria NNS 0
for IN 0
both DT 0
interventions NNS 0
and CC 0
188 CD 0
( ( 0
48.5 CD 0
% NN 0
) ) 0
gave VBD 0
informed VBN 0
consent NN 0
to TO 0
participate VB 0
in IN 0
the DT 0
trials NNS 0
. . 0

CONCLUSIONS VB 0
The DT 0
screening NN 0
procedure NN 0
appears VBZ 0
to TO 0
be VB 0
feasible JJ 0
and CC 0
trial NN 0
participation NN 0
seems VBZ 0
to TO 0
be VB 0
acceptable JJ 0
to TO 0
a DT 0
relevant JJ 0
proportion NN 0
of IN 0
people NNS 0
at IN 0
increased VBN 0
risk NN 0
of IN 0
developing VBG 0
psychosis NN 0
. . 0

Randomized VBN 0
trial NN 0
of IN 0
intensive JJ 0
early JJ 0
intervention NN 0
for IN 0
children NNS 0
with IN 0
pervasive JJ 0
developmental JJ 0
disorder NN 0
. . 0

Young NNP 0
children NNS 0
with IN 0
pervasive JJ 0
developmental JJ 0
disorder NN 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
intensive VB 0
treatment NN 0
or CC 0
parent NN 0
training NN 0
. . 0

The DT 0
intensive JJ 0
treatment NN 0
group NN 0
( ( 0
7 CD 0
with IN 0
autism NN 0
, , 0
8 CD 0
with IN 0
pervasive JJ 0
developmental JJ 0
disorder NN 0
not RB 0
otherwise RB 0
specified VBN 0
-- : 0
NOS NNP 0
) ) 0
averaged VBD 0
24.52 CD 0
hours NNS 0
per IN 0
week NN 0
of IN 0
individual JJ 0
treatment NN 0
for IN 0
one CD 0
year NN 0
, , 0
gradually RB 0
reducing VBG 0
hours NNS 0
over IN 0
the DT 0
next JJ 0
1 CD 0
to TO 0
2 CD 0
years NNS 0
. . 0

The DT 0
parent NN 0
training NN 0
group NN 0
( ( 0
7 CD 0
with IN 0
autism NN 0
, , 0
6 CD 0
with IN 0
pervasive JJ 0
developmental JJ 0
disorder NN 0
NOS NNP 0
) ) 0
received VBD 0
3 CD 0
to TO 0
9 CD 0
months NNS 0
of IN 0
parent NN 0
training NN 0
. . 0

The DT 0
groups NNS 0
appeared VBD 0
similar JJ 0
at IN 0
intake NN 0
on IN 0
all DT 0
measures NNS 0
; : 0
however RB 0
, , 0
at IN 0
follow-up JJ 0
the DT 0
intensive JJ 0
treatment NN 0
group NN 0
outperformed VBD 0
the DT 0
parent NN 0
training VBG 0
group NN 0
on IN 0
measures NNS 0
of IN 0
intelligence NN 0
, , 0
visual-spatial JJ 0
skills NNS 0
, , 0
language NN 0
, , 0
and CC 0
academics NNS 0
, , 0
though IN 0
not RB 0
adaptive JJ 0
functioning NN 0
or CC 0
behavior NN 0
problems NNS 0
. . 0

Children NNP 0
with IN 0
pervasive JJ 0
developmental JJ 0
disorder NN 0
NOS NNP 0
may MD 0
have VB 0
gained VBN 0
more JJR 0
than IN 0
those DT 0
with IN 0
autism NN 0
. . 0

Combined VBN 0
descriptive JJ 0
and CC 0
explanatory JJ 0
information NN 0
improves VBZ 0
peers NNS 0
' POS 0
perceptions NNS 0
of IN 0
autism NN 0
. . 0

Authors NNS 0
examined VBD 0
the DT 0
combined JJ 0
effects NNS 0
of IN 0
descriptive JJ 0
and CC 0
explanatory JJ 0
information NN 0
on IN 0
peers NNS 0
' POS 0
perceptions NNS 0
and CC 0
behavioral JJ 0
intentions NNS 0
toward IN 0
an DT 0
unfamiliar JJ 0
child NN 0
with IN 0
autism NN 0
. . 0

Children NNP 0
( ( 0
N NNP 0
= NNP 0
576 CD 0
; : 0
M NNP 0
age NN 0
= VBD 0
10.06 CD 0
) ) 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
view VB 0
two CD 0
videotapes NNS 0
of IN 0
a DT 0
boy NN 0
engaging VBG 0
in IN 0
typical JJ 0
and CC 0
autistic JJ 0
behaviors NNS 0
receiving VBG 0
either RB 0
descriptive JJ 0
( ( 0
AUT-D NNP 0
) ) 0
or CC 0
descriptive JJ 0
and CC 0
explanatory JJ 0
information NN 0
( ( 0
AUT-D NNP 0
+ NNP 0
E NNP 0
) ) 0
. . 0

Children NNP 0
responded VBD 0
to TO 0
measures NNS 0
of IN 0
attitudes NNS 0
( ( 0
Adjective NNP 0
Checklist NNP 0
) ) 0
and CC 0
behavioral JJ 0
intentions NNS 0
( ( 0
Shared NNP 0
Activities NNP 0
Questionnaire NNP 0
) ) 0
. . 0

Children NNP 0
rated VBD 0
the DT 0
typical JJ 0
boy NN 0
more RBR 0
favorably RB 0
than IN 0
the DT 0
boy NN 0
showing VBG 0
autistic JJ 0
symptoms NNS 0
. . 0

When WRB 0
compared VBN 0
to TO 0
descriptive VB 0
information NN 0
alone RB 0
, , 0
the DT 0
combination NN 0
of IN 0
descriptive JJ 0
and CC 0
explanatory JJ 0
information NN 0
resulted VBD 0
in IN 0
improved JJ 0
third- JJ 0
and CC 0
fourth-graders NNS 0
' '' 0
but CC 0
not RB 0
fifth-graders NNS 0
' POS 0
attitudes NNS 0
toward IN 0
the DT 0
child NN 0
with IN 0
autism NN 0
. . 0

Combined VBN 0
information NN 0
improved VBN 0
behavioral JJ 0
intentions NNS 0
across IN 0
grades NNS 0
; : 0
however RB 0
, , 0
girls NNS 0
( ( 0
vs. FW 0
boys NNS 0
) ) 0
were VBD 0
more RBR 0
responsive JJ 0
to TO 0
information NN 0
as IN 0
evidenced VBN 0
by IN 0
differences NNS 0
in IN 0
academic JJ 0
intentions NNS 0
. . 0

The DT 0
combination NN 0
of IN 0
descriptive JJ 0
and CC 0
explanatory JJ 0
information NN 0
about IN 0
autism NN 0
appears VBZ 0
to TO 0
have VB 0
a DT 0
positive JJ 0
effect NN 0
on IN 0
children NNS 0
's POS 0
attitudes NNS 0
and CC 0
behavioral JJ 0
intentions NNS 0
. . 0

Implications NNS 0
of IN 0
the DT 0
findings NNS 0
are VBP 0
briefly RB 0
discussed VBN 0
as RB 0
well RB 0
as IN 0
study NN 0
limitations NNS 0
and CC 0
recommendations NNS 0
for IN 0
future JJ 0
research NN 0
. . 0

Economic NNP 0
burden NN 0
of IN 0
childhood NN 0
autism NN 0
spectrum NN 0
disorders NNS 0
. . 0

OBJECTIVE NNP 0
To TO 0
estimate VB 0
the DT 0
associations NNS 0
between IN 0
autism NN 0
spectrum NN 0
disorder NN 0
( ( 0
ASD NNP 0
) ) 0
diagnoses NNS 0
and CC 0
service NN 0
use NN 0
, , 0
caregiver NN 0
time NN 0
, , 0
and CC 0
cost NN 0
outcomes NNS 0
. . 0

METHODS NNP 0
We PRP 0
used VBD 0
national JJ 0
data NNS 0
from IN 0
the DT 0
Medical NNP 0
Expenditure NNP 0
Panel NNP 0
Survey NNP 0
linked VBD 0
to TO 0
the DT 0
National NNP 0
Health NNP 0
Interview NNP 0
Survey NNP 0
and CC 0
a DT 0
study-specific JJ 0
survey NN 0
to TO 0
estimate VB 0
the DT 0
annual JJ 0
utilization NN 0
and CC 0
costs NNS 0
for IN 0
health NN 0
care NN 0
, , 0
school NN 0
, , 0
ASD-related JJ 0
therapy NN 0
, , 0
family-coordinated JJ 0
services NNS 0
, , 0
as RB 0
well RB 0
as IN 0
caregiver NN 0
time NN 0
in IN 0
children NNS 0
aged VBD 0
3 CD 0
to TO 0
17 CD 0
years NNS 0
, , 0
with IN 0
and CC 0
without IN 0
parent-reported JJ 0
ASD NNP 0
. . 0

Regression NNP 0
analyses VBZ 0
estimated VBN 0
the DT 0
association NN 0
between IN 0
ASD NNP 0
diagnosis NN 0
and CC 0
cost NN 0
, , 0
controlling VBG 0
for IN 0
child NN 0
gender NN 0
, , 0
age NN 0
, , 0
race/ethnicity NN 0
, , 0
insurance NN 0
status NN 0
, , 0
household JJ 0
income NN 0
, , 0
country NN 0
region NN 0
and CC 0
urban/rural JJ 0
classification NN 0
, , 0
and CC 0
non-ASD-related JJ 0
illnesses NNS 0
. . 0

RESULTS NNP 0
Children NNP 0
with IN 0
parent-reported JJ 0
ASD NNP 0
had VBD 0
higher JJR 0
levels NNS 0
of IN 0
health NN 0
care NN 0
office NN 0
visits NNS 0
and CC 0
prescription NN 0
drug NN 0
use NN 0
compared VBN 0
with IN 0
children NNS 0
without IN 0
ASD NNP 0
( ( 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
. . 0

A DT 0
greater JJR 0
proportion NN 0
of IN 0
children NNS 0
in IN 0
the DT 0
ASD NNP 0
group NN 0
used VBD 0
special JJ 0
educational JJ 0
services NNS 0
( ( 0
76 CD 0
% NN 0
vs. FW 0
7 CD 0
% NN 0
in IN 0
the DT 0
control NN 0
group NN 0
, , 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
. . 0

After IN 0
adjusting VBG 0
for IN 0
child JJ 0
demographic JJ 0
characteristics NNS 0
and CC 0
non-ASD-associated JJ 0
illnesses NNS 0
, , 0
ASD NNP 0
was VBD 0
associated VBN 0
with IN 0
$ $ 0
3020 CD 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
[ NNP 0
CI NNP 0
] NN 0
: : 0
$ $ 0
1017- CD 0
$ $ 0
4259 CD 0
) ) 0
higher JJR 0
health NN 0
care NN 0
costs NNS 0
and CC 0
$ $ 0
14,061 CD 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
: : 0
$ $ 0
4390- JJ 0
$ $ 0
24,302 CD 0
) ) 0
higher JJR 0
aggregate JJ 0
non-health NNS 0
care NN 0
costs NNS 0
, , 0
including VBG 0
$ $ 0
8610 CD 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
: : 0
$ $ 0
6595- JJ 0
$ $ 0
10,421 CD 0
) ) 0
higher JJR 0
school NN 0
costs NNS 0
. . 0

In IN 0
adjusted JJ 0
analyses NNS 0
, , 0
parents NNS 0
who WP 0
reported VBD 0
that IN 0
their PRP$ 0
child NN 0
had VBD 0
ASD NNP 0
did VBD 0
not RB 0
have VB 0
significantly RB 0
higher JJR 0
out-of-pocket NN 0
costs NNS 0
or CC 0
spend VB 0
more JJR 0
time NN 0
on IN 0
caregiving VBG 0
activities NNS 0
compared VBN 0
with IN 0
control NN 0
parents NNS 0
. . 0

CONCLUSIONS VB 0
The DT 0
economic JJ 0
burden NN 0
associated VBN 0
with IN 0
ASD NNP 0
is VBZ 0
substantial JJ 0
and CC 0
can MD 0
be VB 0
measured VBN 0
across IN 0
multiple JJ 0
sectors NNS 0
of IN 0
our PRP$ 0
society NN 0
. . 0

Previous JJ 0
analyses NNS 0
that WDT 0
focused VBD 0
on IN 0
health NN 0
care NN 0
underestimated VBD 0
this DT 0
economic JJ 0
burden NN 0
, , 0
particularly RB 0
for IN 0
school NN 0
systems NNS 0
. . 0

Amonafide NN 0
: : 0
An DT 0
active JJ 0
agent NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
previously RB 0
untreated VBN 0
advanced JJ 0
breast NN 0
cancer NN 0
-- : 0
a DT 0
cancer NN 0
and CC 0
leukemia NN 0
group NN 0
B NNP 0
study NN 0
( ( 0
CALGB NNP 0
8642 CD 0
) ) 0
. . 0

Amonafide NNP 0
is VBZ 0
a DT 0
new JJ 0
imide JJ 0
derivative NN 0
of IN 0
naphthalic JJ 0
acid NN 0
. . 0

The DT 0
drug NN 0
had VBD 0
demonstrated VBN 0
significant JJ 0
activity NN 0
in IN 0
preclinical JJ 0
studies NNS 0
and CC 0
some DT 0
activity NN 0
in IN 0
Phase NNP 0
I PRP 0
trials NNS 0
. . 0

The DT 0
drug NN 0
is VBZ 0
extensively RB 0
metabolized VBN 0
and CC 0
detected VBN 0
in IN 0
plasma NN 0
and CC 0
urine NN 0
. . 0

Its PRP$ 0
toxicity NN 0
has VBZ 0
previously RB 0
been VBN 0
correlated VBN 0
to TO 0
the DT 0
formation NN 0
of IN 0
an DT 0
active JJ 0
metabolite NN 0
, , 0
N-acetyl-amonafide NNP 0
. . 0

Amonafide NNP 0
was VBD 0
chosen VBN 0
for IN 0
inclusion NN 0
in IN 0
the DT 0
Cancer NNP 0
and CC 0
Leukemia NNP 0
Group NNP 0
B NNP 0
( ( 0
CALGB NNP 0
) ) 0
master NN 0
metastatic JJ 0
breast NN 0
cancer NN 0
protocol NN 0
. . 0

CALGB NNP 0
8642 CD 0
randomizes VBZ 0
previously RB 0
untreated VBN 0
metastatic JJ 0
breast NN 0
cancer NN 0
patients NNS 0
either CC 0
to TO 0
one CD 0
of IN 0
several JJ 0
Phase NNP 0
II NNP 0
agents NNS 0
given VBN 0
for IN 0
up IN 0
to TO 0
four CD 0
cycles NNS 0
and CC 0
then RB 0
followed VBN 0
by IN 0
standard JJ 0
cyclophosphamide-doxorubicin-5-fluorouracil NN 0
, , 0
or CC 0
to TO 0
immediate VB 0
treatment NN 0
with IN 0
standard JJ 0
cyclophosphamide-doxorubicin-5-fluorouracil NN 0
. . 0

The DT 0
end NN 0
point NN 0
of IN 0
CALGB NNP 0
8642 CD 0
is VBZ 0
to TO 0
assess VB 0
the DT 0
difference NN 0
in IN 0
survival NN 0
, , 0
toxicity NN 0
, , 0
and CC 0
overall JJ 0
response NN 0
when WRB 0
limited JJ 0
exposure NN 0
to TO 0
Phase NNP 0
II NNP 0
agents NNS 0
precedes VBZ 0
standard JJ 0
chemotherapy NN 0
. . 0

This DT 0
report NN 0
deals VBZ 0
only RB 0
with IN 0
amonafide RB 0
as IN 0
a DT 0
Phase NNP 0
II NNP 0
agent NN 0
. . 0

Comparisons NNS 0
with IN 0
the DT 0
cyclophosphamide-doxorubicin-5-fluorouracil JJ 0
arm NN 0
will MD 0
not RB 0
be VB 0
addressed VBN 0
. . 0

Patients NNS 0
had VBD 0
to TO 0
have VB 0
histologically RB 0
documented VBN 0
measurable JJ 0
breast NN 0
cancer NN 0
and CC 0
a DT 0
performance NN 0
status NN 0
of IN 0
0-1 NNP 0
. . 0

Patients NNS 0
could MD 0
not RB 0
have VB 0
had VBN 0
prior JJ 0
chemotherapy NN 0
for IN 0
metastatic JJ 0
disease NN 0
. . 0

Prior NNP 0
adjuvant JJ 0
chemotherapy NN 0
was VBD 0
permitted VBN 0
. . 0

Patients NNS 0
could MD 0
not RB 0
have VB 0
visceral JJ 0
crisis NN 0
. . 0

Amonafide NNP 0
was VBD 0
given VBN 0
at IN 0
300 CD 0
mg/m2/day JJ 0
i.v NN 0
. . 0

for IN 0
5 CD 0
days NNS 0
, , 0
and CC 0
repeated VBD 0
at IN 0
21-day JJ 0
intervals NNS 0
for IN 0
a DT 0
maximum NN 0
of IN 0
four CD 0
cycles NNS 0
. . 0

Escalation NN 0
and CC 0
reduction NN 0
in IN 0
dose NN 0
was VBD 0
mandated VBN 0
dependent NN 0
on IN 0
hematotoxicity NN 0
or CC 0
lack NN 0
thereof NN 0
. . 0

Toxicity NN 0
was VBD 0
primarily RB 0
hematological JJ 0
and CC 0
bimodal NN 0
: : 0
32 CD 0
% NN 0
had VBD 0
grade VBN 0
3 CD 0
or CC 0
4 CD 0
leukopenia NN 0
and CC 0
24 CD 0
% NN 0
had VBD 0
grade VBN 0
3 CD 0
or CC 0
4 CD 0
thrombocytopenia NN 0
; : 0
22 CD 0
% NN 0
had VBD 0
no DT 0
leukopenia NN 0
and CC 0
44 CD 0
% NN 0
had VBD 0
no DT 0
thrombocytopenia NN 0
. . 0

The DT 0
response NN 0
rate NN 0
was VBD 0
18 CD 0
% NN 0
, , 0
including VBG 0
one CD 0
complete JJ 0
response NN 0
. . 0

When WRB 0
response NN 0
was VBD 0
analyzed VBN 0
by IN 0
hematological JJ 0
toxicity NN 0
, , 0
there EX 0
was VBD 0
a DT 0
35.7 CD 0
% NN 0
response NN 0
if IN 0
patients NNS 0
had VBD 0
leukopenia VBN 0
grade NN 0
3/4 CD 0
( ( 0
versus IN 0
8.3 CD 0
% NN 0
, , 0
P NNP 0
= NNP 0
0.08 CD 0
) ) 0
. . 0

There EX 0
was VBD 0
a DT 0
50 CD 0
% NN 0
response NN 0
if IN 0
patients NNS 0
had VBD 0
thrombocytopenia VBN 0
grade NN 0
3/4 CD 0
( ( 0
versus IN 0
7.1 CD 0
% NN 0
, , 0
P NNP 0
= NNP 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

We PRP 0
conclude VBP 0
that DT 0
amonafide NN 0
is VBZ 0
somewhat RB 0
active JJ 0
in IN 0
previously RB 0
untreated VBN 0
breast NN 0
cancer NN 0
patients NNS 0
. . 0

There EX 0
may MD 0
be VB 0
a DT 0
steep JJ 0
dose-response NN 0
curve NN 0
, , 0
based VBN 0
on IN 0
the DT 0
significant JJ 0
correlation NN 0
between IN 0
myelosuppression NN 0
and CC 0
response NN 0
. . 0

Rates NNS 0
of IN 0
responses NNS 0
in IN 0
patients NNS 0
adequately RB 0
dosed VBN 0
( ( 0
i.e. FW 0
, , 0
with IN 0
significant JJ 0
hematotoxicity NN 0
) ) 0
with IN 0
amonafide NN 0
ranged VBD 0
from IN 0
35 CD 0
to TO 0
50 CD 0
% NN 0
. . 0

Further JJ 0
studies NNS 0
will MD 0
incorporate VB 0
individualized JJ 0
dosing NN 0
based VBN 0
on IN 0
pretreatment NN 0
acetylator NN 0
phenotyping NN 0
. . 0

In IN 0
school-aged JJ 1
children NNS 1
a DT 0
combination NN 0
of IN 0
galacto-oligosaccharides NNS 0
and CC 0
Lactobacillus NNP 0
GG NNP 0
increases VBZ 0
bifidobacteria RB 0
more JJR 0
than IN 0
Lactobacillus NNP 0
GG NNP 0
on IN 0
its PRP$ 0
own JJ 0
. . 0

The DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
compare VB 0
a DT 0
combination NN 0
of IN 0
Lactobacillus NNP 0
GG NNP 0
( ( 0
LGG NNP 0
) ) 0
and CC 0
galacto-oligosaccharides NNS 0
( ( 0
GOS NNP 0
) ) 0
with IN 0
LGG NNP 0
on IN 0
its PRP$ 0
own JJ 0
, , 0
and CC 0
their PRP$ 0
effects NNS 0
on IN 0
the DT 0
intestinal JJ 0
microbiota NN 0
in IN 0
school-aged JJ 0
children NNS 0
. . 0

The DT 0
randomized JJ 0
, , 0
double-blinded JJ 0
, , 0
crossover NN 0
study NN 0
comprised VBD 0
30 CD 3
healthy JJ 4
children NNS 0
. . 0

There EX 0
were VBD 0
two CD 0
3-week JJ 0
study NN 0
periods NNS 0
with IN 0
a DT 0
4-week JJ 0
wash-out JJ 0
period NN 0
in IN 0
between IN 0
. . 0

The DT 0
children NNS 0
ingested VBD 0
daily RB 0
65 CD 0
ml NN 0
of IN 0
milk-based JJ 0
fruit NN 0
juice NN 0
containing VBG 0
either CC 0
LGG NNP 0
alone RB 0
( ( 0
6.5 CD 0
x RB 0
10 CD 0
( ( 0
9 CD 0
) ) 0
CFU NNP 0
) ) 0
or CC 0
LGG NNP 0
plus CC 0
2 CD 0
g NN 0
of IN 0
GOS NNP 0
. . 0

Symptom NNP 0
diaries NNS 0
were VBD 0
filled VBN 0
during IN 0
the DT 0
study NN 0
periods NNS 0
. . 0

Fecal JJ 0
samples NNS 0
were VBD 0
collected VBN 0
at IN 0
the DT 0
beginning NN 0
and CC 0
end NN 0
of IN 0
both DT 0
study NN 0
periods NNS 0
. . 0

At IN 0
the DT 0
end NN 0
of IN 0
both DT 0
study NN 0
periods NNS 0
, , 0
the DT 0
amount NN 0
of IN 0
bifidobacteria NN 0
was VBD 0
significantly RB 0
greater JJR 0
after IN 0
the DT 0
ingestion NN 0
of IN 0
LGG NNP 0
+ NNP 0
GOS NNP 0
compared VBN 0
with IN 0
LGG NNP 0
alone RB 0
( ( 0
geometric JJ 0
mean VBP 0
9.33 CD 0
x $ 0
10 CD 0
( ( 0
9 CD 0
) ) 0
vs. FW 0
4.28 CD 0
x $ 0
10 CD 0
( ( 0
9 CD 0
) ) 0
CFU/g NNP 0
, , 0
p NN 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

No DT 0
significant JJ 0
differences NNS 0
were VBD 0
seen VBN 0
in IN 0
the DT 0
amount NN 0
of IN 0
lactobacilli NN 0
or CC 0
LGG NNP 0
, , 0
nor CC 0
did VBD 0
gastrointestinal JJ 0
symptoms NNS 0
, , 0
defecation NN 0
frequency NN 0
, , 0
consistency NN 0
of IN 0
stools NNS 0
or CC 0
ease NN 0
of IN 0
defecation NN 0
differ NN 0
between IN 0
the DT 0
two CD 0
study NN 0
periods NNS 0
. . 0

Ingestion NN 0
of IN 0
LGG NNP 0
combined VBD 0
with IN 0
2 CD 0
g NN 0
of IN 0
GOS NNP 0
increased VBD 0
the DT 0
bifidobacteria NN 0
more JJR 0
than IN 0
LGG NNP 0
on IN 0
its PRP$ 0
own JJ 0
and CC 0
thus RB 0
GOS NNP 0
clearly RB 0
has VBZ 0
a DT 0
prebiotic JJ 0
effect NN 0
in IN 0
children NNS 1
. . 0

The DT 0
children NNS 0
tolerated VBN 0
well RB 0
a DT 0
daily JJ 0
intake NN 0
of IN 0
2 CD 0
g NN 0
of IN 0
GOS NNP 0
. . 0

Trial JJ 0
design NN 0
challenges NNS 0
when WRB 0
combining VBG 0
medication NN 0
and CC 0
parent NN 0
training NN 0
in IN 0
children NNS 0
with IN 0
pervasive JJ 0
developmental NN 0
disorders NNS 0
. . 0

This DT 0
paper NN 0
presents VBZ 0
the DT 0
rationale NN 0
for IN 0
a DT 0
24-week JJ 0
, , 0
randomized JJ 0
trial NN 0
designed VBN 0
to TO 0
test VB 0
whether IN 0
risperidone NN 0
plus CC 0
structured JJ 0
parent NN 0
training NN 0
would MD 0
be VB 0
superior JJ 0
to TO 0
risperidone VB 0
only RB 0
on IN 0
measures NNS 0
of IN 0
noncompliance NN 0
, , 0
irritability NN 0
and CC 0
adaptive JJ 0
functioning NN 0
. . 0

In IN 0
this DT 0
model NN 0
, , 0
medication NN 0
reduces NNS 0
tantrums NNS 0
, , 0
aggression NN 0
and CC 0
self-injury NN 0
; : 0
parent NN 0
training NN 0
promotes NNS 0
improvement NN 0
in IN 0
noncompliance NN 0
and CC 0
adaptive JJ 0
functioning NN 0
. . 0

Thus RB 0
, , 0
medication NN 0
and CC 0
parent NN 0
training NN 0
target NN 0
related VBN 0
, , 0
but CC 0
separate JJ 0
, , 0
outcomes RB 0
. . 0

At IN 0
week NN 0
24 CD 0
, , 0
the DT 0
medication NN 0
was VBD 0
gradually RB 0
withdrawn VBN 0
to TO 0
determine VB 0
whether IN 0
subjects NNS 0
in IN 0
the DT 0
combined JJ 0
treatment NN 0
group NN 0
could MD 0
be VB 0
managed VBN 0
on IN 0
a DT 0
lower JJR 0
dose NN 0
or CC 0
off IN 0
medication NN 0
without IN 0
relapse NN 0
. . 0

Both DT 0
symptom JJ 0
reduction NN 0
and CC 0
functional JJ 0
improvement NN 0
are VBP 0
important JJ 0
clinical JJ 0
treatment NN 0
targets NNS 0
. . 0

Thus RB 0
, , 0
experimental JJ 0
evidence NN 0
on IN 0
the DT 0
beneficial JJ 0
effects NNS 0
of IN 0
combining VBG 0
pharmacotherapy NN 0
and CC 0
exportable JJ 0
behavioral JJ 0
interventions NNS 0
is VBZ 0
needed VBN 0
to TO 0
guide VB 0
clinical JJ 0
practice NN 0
. . 0

Randomized VBN 0
controlled VBD 0
study NN 0
of IN 0
chemoimmunotherapy NN 0
with IN 0
bestatin NN 0
of IN 0
acute JJ 0
nonlymphocytic JJ 0
leukemia NN 0
in IN 0
adults NNS 0
. . 0

A DT 0
new JJ 0
immunomodulating NN 0
agent NN 0
, , 0
bestatin NN 0
( ( 0
INN NNP 0
: : 0
Ubenimex NNP 0
has VBZ 0
low JJ 0
toxicity NN 0
even RB 0
after IN 0
long-term JJ 0
oral JJ 0
administration NN 0
and CC 0
has VBZ 0
significant JJ 0
modifications NNS 0
in IN 0
immunological JJ 0
response NN 0
. . 0

A DT 0
cooperative JJ 0
randomized NN 0
controlled VBD 0
study NN 0
of IN 0
bestatin NN 0
immunotherapy NN 0
in IN 0
combination NN 0
with IN 0
remission NN 0
maintenance NN 0
chemotherapy NN 0
for IN 0
adult NN 0
acute JJ 0
nonlymphocytic JJ 0
leukemia NN 0
( ( 0
ANLL NNP 0
) ) 0
was VBD 0
performed VBN 0
. . 0

After IN 0
induction NN 0
of IN 0
complete JJ 0
remission NN 0
, , 0
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
the DT 0
bestatin NN 0
group NN 0
( ( 0
30 CD 0
mg/bw NN 0
per IN 0
os NN 0
( ( 0
po NN 0
) ) 0
daily RB 0
) ) 0
and CC 0
the DT 0
control NN 0
group NN 0
. . 0

The DT 0
101 CD 0
eligible JJ 0
cases NNS 0
( ( 0
bestatin NN 0
: : 0
48 CD 0
, , 0
control NN 0
: : 0
53 CD 0
) ) 0
were VBD 0
analyzed VBN 0
; : 0
the DT 0
bestatin NN 0
group NN 0
achieved VBD 0
longer JJR 0
remission NN 0
than IN 0
the DT 0
control NN 0
group NN 0
and CC 0
a DT 0
statistically RB 0
significant JJ 0
longer JJR 0
survival NN 0
. . 0

Though IN 0
this DT 0
prolongation NN 0
of IN 0
remission NN 0
was VBD 0
not RB 0
significant JJ 0
in IN 0
the DT 0
bestatin NN 0
group NN 0
compared VBN 0
to TO 0
the DT 0
control NN 0
group NN 0
in IN 0
the DT 0
15-49 JJ 0
yr NN 0
age NN 0
group NN 0
, , 0
in IN 0
the DT 0
50-65 JJ 0
yr NN 0
age NN 0
group NN 0
it PRP 0
was VBD 0
significantly RB 0
longer JJR 0
. . 0

Bestatin NNP 0
is VBZ 0
shown VBN 0
to TO 0
be VB 0
a DT 0
clinically RB 0
useful JJ 0
drug NN 0
for IN 0
immunotherapy NN 0
of IN 0
adult NN 0
ANLL NNP 0
, , 0
since IN 0
it PRP 0
has VBZ 0
prolonged VBN 0
survival NN 0
and CC 0
remission NN 0
especially RB 0
in IN 0
elderly JJ 0
patients NNS 0
, , 0
with IN 0
few JJ 0
side-effects NNS 0
. . 0

Oral NNP 0
contraceptive NN 0
use NN 0
is VBZ 0
associated VBN 0
with IN 0
increased JJ 0
cardiovascular JJ 0
reactivity NN 0
in IN 0
nonsmokers NNS 0
. . 0

Women NNS 0
who WP 0
smoke VBD 0
and CC 0
take VB 0
oral JJ 0
contraceptives NNS 0
( ( 0
OCs NNP 0
) ) 0
have VBP 0
significantly RB 0
increased VBN 0
risk NN 0
of IN 0
cardiovascular JJ 0
disease NN 0
, , 0
but CC 0
the DT 0
exact JJ 0
mechanismsfor VBZ 0
the DT 0
increased VBN 0
risk NN 0
are VBP 0
not RB 0
known VBN 0
. . 0

Cardiovascular JJ 0
reactivity NN 0
to TO 0
psychological JJ 0
stress NN 0
may MD 0
be VB 0
one CD 0
mechanism NN 0
for IN 0
the DT 0
enhanced JJ 0
risk NN 0
, , 0
but CC 0
the DT 0
small JJ 0
number NN 0
of IN 0
studies NNS 0
examining VBG 0
whether IN 0
OC NNP 0
users NNS 0
who WP 0
smoke VBP 0
have VBP 0
greater JJR 0
reactivity NN 0
have VBP 0
produced VBN 0
mixed JJ 0
results NNS 0
. . 0

The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
examine VB 0
the DT 0
effect NN 0
of IN 0
chronic JJ 0
cigarette NN 0
smoking NN 0
, , 0
acute JJ 0
nicotine JJ 0
administration NN 0
, , 0
and CC 0
OC NNP 0
use VBP 0
on IN 0
cardiovascular NN 0
and CC 0
lipid JJ 0
reactivity NN 0
. . 0

Sixty NNP 0
healthy JJ 0
women NNS 0
, , 0
half NN 0
of IN 0
whom WP 0
had VBD 0
been VBN 0
using VBG 0
OCs NNP 0
for IN 0
at IN 0
least JJS 0
the DT 0
previous JJ 0
6 CD 0
months NNS 0
, , 0
participated VBN 0
in IN 0
the DT 0
study NN 0
. . 0

Approximately RB 0
two CD 0
thirds NNS 0
were VBD 0
smokers NNS 0
and CC 0
were VBD 0
randomized VBN 0
to TO 0
be VB 0
tested VBN 0
after IN 0
either DT 0
a DT 0
12-hr JJ 0
nicotine JJ 0
deprivation NN 0
or CC 0
administration NN 0
of IN 0
nicotine JJ 0
gum NN 0
. . 0

One CD 0
third WDT 0
were VBD 0
nonsmokers NNS 0
. . 0

Heart NNP 0
rate NN 0
, , 0
blood NN 0
pressure NN 0
, , 0
and CC 0
lipid JJ 0
measures NNS 0
were VBD 0
taken VBN 0
at IN 0
rest NN 0
, , 0
during IN 0
a DT 0
videotaped JJ 0
speech NN 0
task NN 0
, , 0
and CC 0
during IN 0
recovery NN 0
from IN 0
the DT 0
task NN 0
. . 0

Results NNS 0
indicated VBD 0
that IN 0
, , 0
among IN 0
OC NNP 0
nonusers NNS 0
, , 0
there EX 0
was VBD 0
no DT 0
effect NN 0
of IN 0
smoking VBG 0
status NN 0
or CC 0
nicotine JJ 0
administration NN 0
on IN 0
cardiovascular JJ 0
reactivity NN 0
. . 0

However RB 0
, , 0
among IN 0
OC NNP 0
users NNS 0
, , 0
nonsmokers NNS 0
had VBD 0
significantly RB 0
greater JJR 0
heart NN 0
rate NN 0
and CC 0
diastolic JJ 0
blood NN 0
pressure NN 0
reactivity NN 0
to TO 0
stress VB 0
. . 0

These DT 0
data NNS 0
show VBP 0
that IN 0
acute JJ 0
nicotine JJ 0
administration NN 0
, , 0
in IN 0
the DT 0
form NN 0
of IN 0
nicotine JJ 0
gum NN 0
, , 0
has VBZ 0
no DT 0
effect NN 0
on IN 0
cardiovascular NN 0
or CC 0
lipid JJ 0
stress NN 0
reactivity NN 0
in IN 0
women NNS 0
. . 0

However RB 0
OC NNP 0
use NN 0
among IN 0
nonsmoking JJ 0
women NNS 0
is VBZ 0
associated VBN 0
with IN 0
greater JJR 0
cardiovascular JJ 0
reactivity NN 0
to TO 0
stress VB 0
. . 0

Therapeutic JJ 0
effects NNS 0
of IN 0
combined JJ 0
treatment NN 0
using VBG 0
tetracycline-immobilized JJ 0
collagen NN 0
film NN 0
and CC 0
root NN 0
planing NN 0
in IN 0
periodontal JJ 0
furcation NN 0
pockets NNS 0
. . 0

46 CD 0
upper JJ 0
and CC 0
lower JJR 0
molars NNS 0
with IN 0
furcation NN 0
grade NN 0
II NNP 0
involvement NN 0
were VBD 0
selected VBN 0
from IN 0
16 CD 0
patients NNS 0
with IN 0
periodontal JJ 0
disease NN 0
. . 0

The DT 0
teeth NNS 0
were VBD 0
randomly RB 0
allocated VBN 0
to TO 0
the DT 0
following VBG 0
groups NNS 0
according VBG 0
to TO 0
treatment NN 0
; : 0
( ( 0
1 CD 0
) ) 0
4 CD 0
consecutive JJ 0
administrations NNS 0
of IN 0
tetracycline-immobilized JJ 0
cross-linked JJ 0
collagen NN 0
film NN 0
( ( 0
TC NNP 0
film NN 0
) ) 0
at IN 0
intervals NNS 0
of IN 0
1 CD 0
week NN 0
( ( 0
TC NNP 0
group NN 0
) ) 0
; : 0
( ( 0
2 CD 0
) ) 0
1 CD 0
root NN 0
planing VBG 0
treatment NN 0
( ( 0
RP NNP 0
group NN 0
) ) 0
; : 0
( ( 0
3 CD 0
) ) 0
combination NN 0
treatment NN 0
( ( 0
TC NNP 0
+ NNP 0
RP NNP 0
group NN 0
) ) 0
; : 0
( ( 0
4 CD 0
) ) 0
no DT 0
treatment NN 0
( ( 0
control VB 0
group NN 0
) ) 0
. . 0

The DT 0
therapeutic JJ 0
effects NNS 0
of IN 0
each DT 0
treatment NN 0
were VBD 0
compared VBN 0
both DT 0
clinically RB 0
and CC 0
microbiologically RB 0
. . 0

Records NNS 0
of IN 0
plaque NN 0
index NN 0
, , 0
gingival NN 0
index NN 0
, , 0
bleeding VBG 0
on IN 0
probing VBG 0
, , 0
probing VBG 0
depth NN 0
, , 0
probing VBG 0
attachment JJ 0
level NN 0
and CC 0
microscopic NN 0
counts NNS 0
were VBD 0
obtained VBN 0
at IN 0
0 CD 0
, , 0
4 CD 0
, , 0
6 CD 0
and CC 0
8 CD 0
weeks NNS 0
. . 0

The DT 0
results NNS 0
showed VBD 0
marked JJ 0
decreases NNS 0
in IN 0
probing VBG 0
depth NN 0
and CC 0
density NN 0
of IN 0
micro-organisms NN 0
in IN 0
both CC 0
the DT 0
RP NNP 0
and CC 0
TC NNP 0
+ NNP 0
RP NNP 0
groups NNS 0
. . 0

In IN 0
particular JJ 0
, , 0
the DT 0
TC NNP 0
+ NNP 0
RP NNP 0
group NN 0
was VBD 0
characterized VBN 0
by IN 0
a DT 0
decreased JJ 0
rate NN 0
of IN 0
bleeding VBG 0
on IN 0
pocket NN 0
probing NN 0
and CC 0
an DT 0
increased JJ 0
probing NN 0
attachment NN 0
gain NN 0
. . 0

The DT 0
above JJ 0
findings NNS 0
demonstrated VBD 0
that IN 0
root NN 0
planning NN 0
is VBZ 0
effective JJ 0
in IN 0
the DT 0
treatment NN 0
of IN 0
furcation NN 0
involvement NN 0
and CC 0
that IN 0
the DT 0
effects NNS 0
are VBP 0
enhanced VBN 0
by IN 0
the DT 0
local JJ 0
administration NN 0
of IN 0
TC NNP 0
films NNS 0
. . 0

Teacher DT 0
and CC 0
child JJ 0
predictors NNS 0
of IN 0
achieving VBG 0
IEP NNP 0
goals NNS 0
of IN 0
children NNS 0
with IN 0
autism NN 0
. . 0

It PRP 0
is VBZ 0
encouraging VBG 0
that IN 0
children NNS 0
with IN 0
autism NN 0
show VBP 0
a DT 0
strong JJ 0
response NN 0
to TO 0
early JJ 0
intervention NN 0
, , 0
yet RB 0
more JJR 0
research NN 0
is VBZ 0
needed VBN 0
for IN 0
understanding VBG 0
the DT 0
variability NN 0
in IN 0
responsiveness NN 0
to TO 0
specialized JJ 0
programs NNS 0
. . 0

Treatment NNP 0
predictor NN 0
variables NNS 0
from IN 0
47 CD 0
teachers NNS 0
and CC 0
children NNS 0
who WP 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
the DT 0
COMPASS NNP 0
intervention NN 0
( ( 0
Ruble JJ 0
et NN 0
al NN 0
. . 0

in IN 0
The DT 0
collaborative JJ 0
model NN 0
for IN 0
promoting VBG 0
competence NN 0
and CC 0
success NN 0
for IN 0
students NNS 0
with IN 0
ASD NNP 0
. . 0

Springer NNP 0
, , 0
New NNP 0
York NNP 0
, , 0
2012a CD 0
) ) 0
were VBD 0
analyzed VBN 0
. . 0

Predictors NNS 0
evaluated VBD 0
against IN 0
child NN 0
IEP NNP 0
goal NN 0
attainment NN 0
included VBD 0
child NN 0
, , 0
teacher NN 0
, , 0
intervention NN 0
practice NN 0
, , 0
and CC 0
implementation NN 0
practice NN 0
variables NNS 0
based VBN 0
on IN 0
an DT 0
implementation NN 0
science NN 0
framework NN 0
( ( 0
Dunst NNP 0
and CC 0
Trivette NNP 0
in IN 0
J NNP 0
Soc NNP 0
Sci NNP 0
8:143-148 CD 0
, , 0
2012 CD 0
) ) 0
. . 0

Findings NNS 0
revealed VBD 0
one CD 0
child NN 0
( ( 0
engagement NN 0
) ) 0
, , 0
one CD 0
teacher NN 0
( ( 0
exhaustion NN 0
) ) 0
, , 0
two CD 0
intervention NN 0
quality NN 0
( ( 0
IEP NNP 0
quality NN 0
for IN 0
targeted VBN 0
and CC 0
not RB 0
targeted JJ 0
elements NNS 0
) ) 0
, , 0
and CC 0
no DT 0
implementation NN 0
quality NN 0
variables NNS 0
accounted VBD 0
for IN 0
variance NN 0
in IN 0
child NN 0
outcomes NNS 0
when WRB 0
analyzed VBN 0
separately RB 0
. . 0

When WRB 0
the DT 0
four CD 0
significant JJ 0
variables NNS 0
were VBD 0
compared VBN 0
against IN 0
each DT 0
other JJ 0
in IN 0
a DT 0
single JJ 0
regression NN 0
analysis NN 0
, , 0
IEP NNP 0
quality NN 0
accounted VBD 0
for IN 0
one CD 0
quarter NN 0
of IN 0
the DT 0
variance NN 0
in IN 0
child NN 0
outcomes NNS 0
. . 0

Role NNP 0
of IN 0
angiotensin-converting JJ 0
enzyme NN 0
inhibitors NNS 0
in IN 0
early JJ 0
antihypertensive JJ 0
treatment NN 0
in IN 0
non-insulin JJ 0
dependent NN 0
diabetes VBZ 0
mellitus NN 0
. . 0

The DT 0
effect NN 0
of IN 0
captopril NN 0
monotherapy NN 0
on IN 0
blood NN 0
pressure NN 0
and CC 0
metabolism NN 0
was VBD 0
investigated VBN 0
in IN 0
a DT 0
placebo-controlled JJ 0
study NN 0
in IN 0
30 CD 0
non-insulin JJ 0
dependent NN 0
( ( 0
Type NNP 0
II NNP 0
) ) 0
diabetic JJ 0
subjects NNS 0
during IN 0
a DT 0
3-week JJ 0
observation NN 0
period NN 0
( ( 0
run-in/drug JJ 0
; : 0
placebo/wash-out NN 0
) ) 0
on IN 0
a DT 0
metabolic JJ 0
ward NN 0
. . 0

Captopril NNP 0
significantly RB 0
reduced VBD 0
both DT 0
systolic JJ 0
and CC 0
diastolic JJ 0
blood NN 0
pressure NN 0
( ( 0
154/90 CD 0
+/- JJ 0
5/2 CD 0
vs. FW 0
144/86 CD 0
+/- JJ 0
4/3 CD 0
mmHg NN 0
) ) 0
without IN 0
major JJ 0
side NN 0
effects NNS 0
. . 0

Mean JJ 0
run-in JJ 0
postprandial JJ 0
blood NN 0
glucose JJ 0
concentrations NNS 0
were VBD 0
also RB 0
reduced VBN 0
upon IN 0
ACE-inhibition NNP 0
( ( 0
9 CD 0
a.m. RB 0
: : 0
12.7 CD 0
+/- JJ 0
0.4 CD 0
vs. FW 0
11.1 CD 0
+/- JJ 0
0.4 CD 0
mmol/l NN 0
; : 0
1 CD 0
p.m. NN 0
: : 0
11.0 CD 0
+/- JJ 0
0.3 CD 0
vs. FW 0
8.9 CD 0
+/- JJ 0
0.3 CD 0
mmol/l NN 0
; : 0
P NNP 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
, , 0
while IN 0
blood NN 0
kinin NN 0
concentrations NNS 0
( ( 0
40.0 CD 0
+/- JJ 0
2.5 CD 0
pmol/l NN 0
) ) 0
were VBD 0
approximately RB 0
doubled VBN 0
( ( 0
108.8 CD 0
+/- JJ 0
23.5 CD 0
pmol/l NN 0
; : 0
P NNP 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
. . 0

Body NNP 0
mass NN 0
index NN 0
, , 0
fasting VBG 0
plasma JJ 0
insulin NN 0
, , 0
serum JJ 0
electrolyte NN 0
pattern NN 0
, , 0
uric JJ 0
acid NN 0
, , 0
white JJ 0
blood NN 0
count NN 0
, , 0
lipid JJ 0
profile NN 0
as RB 0
well RB 0
as IN 0
hepatic JJ 0
and CC 0
renal JJ 0
function NN 0
parameters NNS 0
remained VBD 0
unaltered JJ 0
throughout IN 0
the DT 0
observation NN 0
period NN 0
. . 0

The DT 0
data NNS 0
are VBP 0
in IN 0
line NN 0
with IN 0
recent JJ 0
experimental JJ 0
studies NNS 0
showing VBG 0
a DT 0
beneficial JJ 0
metabolic JJ 0
effect NN 0
of IN 0
captopril NN 0
in IN 0
Type NNP 0
II NNP 0
diabetes VBZ 0
. . 0

ACE NNP 0
inhibitors NNS 0
might MD 0
therefore VB 0
become JJ 0
first-line JJ 0
drugs NNS 0
in IN 0
early JJ 0
antihypertensive JJ 0
intervention NN 0
in IN 0
Type NNP 0
II NNP 0
diabetic JJ 0
patients NNS 0
. . 0

Influence NN 0
of IN 0
diets NNS 0
rich JJ 0
in IN 0
Maillard NNP 0
reaction NN 0
products NNS 0
on IN 0
calcium NN 0
bioavailability NN 0
. . 0

Assays NNS 0
in IN 0
male JJ 0
adolescents NNS 0
and CC 0
in IN 0
Caco-2 NNP 0
cells NNS 0
. . 0

The DT 0
effects NNS 0
of IN 0
the DT 0
high JJ 0
intake NN 0
of IN 0
Maillard NNP 0
reaction NN 0
products NNS 0
( ( 0
MRP NNP 0
) ) 0
on IN 0
calcium NN 0
availability NN 0
in IN 0
adolescents NNS 0
and CC 0
across IN 0
Caco-2 NNP 0
cell NN 0
monolayers NNS 0
were VBD 0
examined VBN 0
. . 0

In IN 0
a DT 0
2 CD 0
week NN 0
randomized VBN 0
two-period JJ 0
crossover NN 0
trial NN 0
, , 0
18 CD 0
male NN 0
adolescents NNS 0
consumed VBD 0
two CD 0
diets NNS 0
, , 0
named VBN 0
white JJ 0
diet NN 0
( ( 0
WD NNP 0
) ) 0
and CC 0
brown JJ 0
diet NN 0
( ( 0
BD NNP 0
) ) 0
, , 0
which WDT 0
were VBD 0
poor JJ 0
and CC 0
rich JJ 0
in IN 0
MRP NNP 0
, , 0
respectively RB 0
. . 0

A DT 0
3 CD 0
day NN 0
balance NN 0
was VBD 0
performed VBN 0
at IN 0
the DT 0
end NN 0
of IN 0
each DT 0
period NN 0
, , 0
and CC 0
fasting VBG 0
blood NN 0
samples NNS 0
were VBD 0
collected VBN 0
. . 0

Calcium NNP 0
solubility NN 0
and CC 0
absorption NN 0
across IN 0
Caco-2 NNP 0
cells NNS 0
were VBD 0
studied VBN 0
after IN 0
the DT 0
in IN 0
vitro JJ 0
digestion NN 0
of IN 0
the DT 0
diets NNS 0
. . 0

The DT 0
in IN 0
vitro NN 0
assay NN 0
showed VBD 0
similar JJ 0
solubility NN 0
after IN 0
the DT 0
in IN 0
vitro JJ 0
digestion NN 0
and CC 0
similar JJ 0
transport NN 0
across IN 0
Caco-2 NNP 0
cells NNS 0
. . 0

In IN 0
accordance NN 0
, , 0
calcium NN 0
bioavailability NN 0
in IN 0
adolescents NNS 0
did VBD 0
not RB 0
vary JJ 0
between IN 0
the DT 0
diets NNS 0
( ( 0
% NN 0
WD NNP 0
= VBZ 0
40.4 CD 0
+/- JJ 0
5.1 CD 0
, , 0
% NN 0
BD NNP 0
= VBZ 0
38.2 CD 0
+/- JJ 0
3.6 CD 0
) ) 0
. . 0

Serum NNP 0
and CC 0
urine JJ 0
biochemical JJ 0
parameters NNS 0
related VBN 0
to TO 0
calcium NN 0
status NN 0
and CC 0
bone NN 0
metabolism NN 0
remained VBD 0
unaltered JJ 0
. . 0

Only RB 0
deoxypyridinoline JJ 0
values NNS 0
were VBD 0
significantly RB 0
lower JJR 0
after IN 0
consumption NN 0
of IN 0
the DT 0
BD NNP 0
( ( 0
13.0 CD 0
+/- JJ 0
1.1 CD 0
compared VBN 0
to TO 0
18.3 CD 0
+/- JJ 0
2.1 CD 0
nM/Mm JJ 0
Cr NNP 0
in IN 0
the DT 0
WD NNP 0
) ) 0
, , 0
possibly RB 0
indicative JJ 0
of IN 0
less RBR 0
efficient JJ 0
bone NN 0
turnover NN 0
during IN 0
this DT 0
period NN 0
. . 0

As IN 0
calcium NN 0
acquired VBD 0
during IN 0
adolescence NN 0
is VBZ 0
essential JJ 0
to TO 0
maximize VB 0
peak JJ 0
bone NN 0
mass NN 0
and CC 0
to TO 0
prevent VB 0
osteoporosis NN 0
, , 0
possible JJ 0
long-term JJ 0
effects NNS 0
of IN 0
excessive JJ 0
MRP NNP 0
intake NN 0
during IN 0
this DT 0
period NN 0
warrant JJ 0
attention NN 0
. . 0

Fluoroscopic NNP 0
functional JJ 0
evaluation NN 0
of IN 0
bileaflet NN 0
prostheses NNS 0
: : 0
effect NN 0
of IN 0
different JJ 0
intraoperative JJ 0
valve NN 0
orientation NN 0
. . 0

Fluoroscopy NNP 0
is VBZ 0
a DT 0
reliable JJ 0
, , 0
easy JJ 0
, , 0
and CC 0
readily RB 0
available JJ 0
technique NN 0
to TO 0
follow-up JJ 0
prosthesis NN 0
functioning NN 0
after IN 0
heart NN 0
valve NN 0
surgery NN 0
. . 0

The DT 0
different JJ 0
orientation NN 0
given VBN 0
to TO 0
the DT 0
prosthesis NN 0
may MD 0
represent VB 0
a DT 0
limitation NN 0
of IN 0
the DT 0
technique NN 0
accounting NN 0
for IN 0
unsatisfactory JJ 0
results NNS 0
in IN 0
10 CD 0
% NN 0
to TO 0
40 CD 0
% NN 0
of IN 0
the DT 0
cases NNS 0
. . 0

The DT 0
aim NN 0
of IN 0
the DT 0
study NN 0
was VBD 0
to TO 0
evaluate VB 0
whether IN 0
and CC 0
to TO 0
what WP 0
extent VB 0
different JJ 0
intraoperative JJ 0
valve NN 0
orientation NN 0
influence NN 0
feasibility NN 0
and CC 0
accuracy NN 0
of IN 0
postoperative JJ 0
fluoroscopic JJ 0
evaluation NN 0
of IN 0
bileaflet NN 0
prostheses NNS 0
. . 0

We PRP 0
prospectively RB 0
evaluated VBD 0
90 CD 0
patients NNS 0
who WP 0
had VBD 0
aortic JJ 0
, , 0
mitral JJ 0
, , 0
and/or JJ 0
tricuspid JJ 0
valve FW 0
replacement NN 0
with IN 0
Sorin NNP 0
Bicarbon NNP 0
or CC 0
CarboMedics NNPS 0
bileaflet NN 0
prostheses NNS 0
. . 0

Fifty NNP 0
percent NN 0
of IN 0
the DT 0
patients NNS 0
in IN 0
each DT 0
group NN 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
prostheses NNS 0
oriented VBN 0
in IN 0
a DT 0
perpendicular NN 0
or CC 0
a DT 0
parallel JJ 0
position NN 0
with IN 0
respect NN 0
to TO 0
the DT 0
ventricular JJ 0
septum NN 0
. . 0

Fluoroscopic NNP 0
evaluation NN 0
was VBD 0
considered VBN 0
appropriate JJ 0
when WRB 0
the DT 0
prosthesis NN 0
' POS 0
tilting VBG 0
disk NN 0
projection NN 0
was VBD 0
obtained VBN 0
. . 0

The DT 0
valve NN 0
's POS 0
hemodynamic JJ 0
performance NN 0
was VBD 0
investigated VBN 0
through IN 0
Doppler NNP 0
study NN 0
. . 0

A DT 0
proper JJ 0
fluoroscopic NN 0
evaluation NN 0
was VBD 0
rapidly RB 0
( ( 0
15 CD 0
+/- JJ 0
5 CD 0
seconds NNS 0
) ) 0
achieved VBN 0
in IN 0
all DT 0
patients NNS 0
with IN 0
the DT 0
former JJ 0
orientation NN 0
, , 0
whereas IN 0
it PRP 0
was VBD 0
impossible JJ 0
to TO 0
obtain VB 0
it PRP 0
in IN 0
8 CD 0
of IN 0
20 CD 0
( ( 0
40 CD 0
% NN 0
) ) 0
, , 0
19 CD 0
of IN 0
20 CD 0
( ( 0
95 CD 0
% NN 0
) ) 0
, , 0
and CC 0
4 CD 0
of IN 0
5 CD 0
( ( 0
80 CD 0
% NN 0
) ) 0
of IN 0
patients NNS 0
with IN 0
the DT 0
latter JJ 0
orientation NN 0
. . 0

In IN 0
the DT 0
remaining VBG 0
patients NNS 0
extremely RB 0
angulated VBN 0
, , 0
uneasy JJ 0
projection NN 0
was VBD 0
often RB 0
required VBN 0
to TO 0
get VB 0
a DT 0
correct JJ 0
fluoroscopic NN 0
image NN 0
. . 0

The DT 0
Doppler NNP 0
study NN 0
showed VBD 0
a DT 0
similarly RB 0
favorable JJ 0
hemodynamic JJ 0
performance NN 0
regardless NN 0
of IN 0
valve JJ 0
orientation NN 0
. . 0

Prosthesis NNP 0
orientation NN 0
crucially RB 0
affects VBZ 0
the DT 0
rate NN 0
of IN 0
success NN 0
of IN 0
the DT 0
fluoroscopic JJ 0
evaluation NN 0
. . 0

The DT 0
orientation NN 0
perpendicular NN 0
to TO 0
the DT 0
ventricular JJ 0
septum NN 0
greatly RB 0
facilitates VBZ 0
the DT 0
postoperative JJ 0
feasibility NN 0
and CC 0
accuracy NN 0
of IN 0
fluoroscopy NN 0
, , 0
and CC 0
it PRP 0
is VBZ 0
not RB 0
detrimental JJ 0
to TO 0
the DT 0
valve NN 0
's POS 0
hemodynamic JJ 0
performance NN 0
. . 0

This DT 0
valve JJ 0
orientation NN 0
may MD 0
provide VB 0
a DT 0
better JJR 0
fluoroscopic NN 0
window NN 0
whenever WRB 0
a DT 0
valve NN 0
dysfunction NN 0
is VBZ 0
suspected VBN 0
. . 0

Why WRB 0
were VBD 0
the DT 0
results NNS 0
of IN 0
the DT 0
Heart NNP 0
Outcomes NNP 0
Prevention NNP 0
Evaluation NNP 0
( ( 0
HOPE NNP 0
) ) 0
trial NN 0
so IN 0
astounding VBG 0
? . 0
The DT 0
Heart NNP 0
Outcomes NNP 0
Prevention NNP 0
Evaluation NNP 0
( ( 0
HOPE NNP 0
) ) 0
study NN 0
was VBD 0
important JJ 0
because IN 0
it PRP 0
showed VBD 0
the DT 0
benefits NNS 0
of IN 0
ramipril NN 0
- : 0
an DT 0
angiotensin-converting JJ 0
enzyme NN 0
( ( 0
ACE NNP 0
) ) 0
inhibitor NN 0
- : 0
in IN 0
patients NNS 0
at IN 0
high JJ 0
risk NN 0
for IN 0
cardiovascular JJ 0
events NNS 0
. . 0

Treatment NN 0
with IN 0
ramipril NN 0
significantly RB 0
reduced VBD 0
the DT 0
rates NNS 0
of IN 0
death NN 0
, , 0
myocardial JJ 0
infarction NN 0
, , 0
stroke NN 0
, , 0
coronary JJ 0
revascularization NN 0
, , 0
cardiac JJ 0
arrest NN 0
and CC 0
heart NN 0
failure NN 0
, , 0
as RB 0
well RB 0
as IN 0
the DT 0
risk NN 0
of IN 0
diabetes-related JJ 0
complications NNS 0
and CC 0
of IN 0
diabetes NNS 0
itself PRP 0
. . 0

The DT 0
effects NNS 0
of IN 0
therapy NN 0
with IN 0
vitamin JJ 0
E NN 0
were VBD 0
also RB 0
evaluated VBN 0
, , 0
but CC 0
no DT 0
statistical JJ 0
benefits NNS 0
were VBD 0
shown VBN 0
. . 0

The DT 0
benefits NNS 0
of IN 0
ACE NNP 0
inhibitor NN 0
therapy NN 0
that WDT 0
were VBD 0
observed VBN 0
were VBD 0
likely JJ 0
due JJ 0
to TO 0
a DT 0
variety NN 0
of IN 0
mechanisms NNS 0
, , 0
not RB 0
just RB 0
a DT 0
reduction NN 0
in IN 0
blood NN 0
pressure NN 0
. . 0

Efficacy NN 0
of IN 0
intramuscular JJ 0
oxytetracycline NN 0
as IN 0
a DT 0
dry JJ 0
cow NN 0
treatment NN 0
for IN 0
Staphylococcus NNP 0
aureus NN 0
mastitis NN 0
. . 0

To TO 0
determine VB 0
the DT 0
efficacy NN 0
of IN 0
intramuscular JJ 0
oxytetracycline NN 0
as IN 0
a DT 0
supplemental JJ 0
dry JJ 0
cow NN 0
treatment NN 0
for IN 0
Staphylococcus NNP 0
aureus NN 0
mastitis NN 0
, , 0
37 CD 0
Holstein NNP 0
cows NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
two CD 0
treatment NN 0
groups NNS 0
: : 0
intracisternal JJ 0
infusion NN 0
with IN 0
a DT 0
commercial JJ 0
preparation NN 0
of IN 0
cephapirin JJ 0
benzathine NN 0
at IN 0
drying VBG 0
off RP 0
( ( 0
20 CD 0
cows NNS 0
) ) 0
and CC 0
infusion NN 0
with IN 0
cephapirin JJ 0
benzathine NN 0
at IN 0
drying VBG 0
off RP 0
and CC 0
intramuscular JJ 0
oxytetracycline NN 0
at IN 0
11 CD 0
mg/kg NNS 0
once RB 0
daily RB 0
on IN 0
d NN 0
7 CD 0
, , 0
8 CD 0
, , 0
9 CD 0
, , 0
and CC 0
10 CD 0
after IN 0
drying VBG 0
off RB 0
( ( 0
17 CD 0
cows NNS 0
) ) 0
. . 0

Milk NN 0
samples NNS 0
collected VBD 0
7 CD 0
, , 0
14 CD 0
, , 0
30 CD 0
, , 0
and CC 0
60 CD 0
d NN 0
after IN 0
calving VBG 0
were VBD 0
plated VBN 0
for IN 0
bacterial JJ 0
isolation NN 0
within IN 0
24 CD 0
h NN 0
after IN 0
collection NN 0
and CC 0
after IN 0
24 CD 0
to TO 0
72 CD 0
h NN 0
of IN 0
storage NN 0
at IN 0
-20 NNP 0
degrees NNS 0
C. NNP 0
Quarters NNS 0
were VBD 0
defined VBN 0
as IN 0
infected JJ 0
if IN 0
S. NNP 0
aureus NN 0
was VBD 0
isolated VBN 0
from IN 0
the DT 0
fresh JJ 0
and CC 0
frozen JJ 0
cultures NNS 0
from IN 0
any DT 0
one CD 0
sample NN 0
collected VBD 0
before IN 0
drying VBG 0
off RP 0
. . 0

An DT 0
infected JJ 0
quarter NN 0
was VBD 0
defined VBN 0
as IN 0
cured JJ 0
if IN 0
S. NNP 0
aureus NN 0
was VBD 0
not RB 0
isolated VBN 0
from IN 0
the DT 0
fresh JJ 0
or CC 0
frozen JJ 0
culture NN 0
from IN 0
milk NN 0
samples NNS 0
obtained VBD 0
following VBG 0
calving NN 0
. . 0

The DT 0
rate NN 0
of IN 0
cure NN 0
by IN 0
30 CD 0
d NN 0
after IN 0
calving VBG 0
for IN 0
systemic JJ 0
oxytetracycline NN 0
( ( 0
in IN 0
combination NN 0
with IN 0
cephapirin JJ 0
treatment NN 0
) ) 0
was VBD 0
29.4 CD 0
% NN 0
for IN 0
infected JJ 0
quarters NNS 0
and CC 0
29.4 CD 0
% NN 0
for IN 0
infected JJ 0
cows NNS 0
, , 0
compared VBN 0
with IN 0
27.5 CD 0
and CC 0
25.0 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
for IN 0
the DT 0
cephapirin NN 0
treatment NN 0
only RB 0
. . 0

Results NNS 0
including VBG 0
the DT 0
culture NN 0
at IN 0
60 CD 0
d NN 0
after IN 0
calving VBG 0
were VBD 0
21.2 CD 0
and CC 0
22.5 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
for IN 0
combination NN 0
therapy NN 0
and CC 0
cephapirin NN 0
therapy NN 0
only RB 0
. . 0

Systemic NNP 0
oxytetracycline NN 0
, , 0
in IN 0
combination NN 0
with IN 0
intramammary JJ 0
dry JJ 0
cow NN 0
treatment NN 0
, , 0
did VBD 0
not RB 0
improve VB 0
the DT 0
rate NN 0
of IN 0
cure NN 0
for IN 0
S. NNP 0
aureus JJ 0
mastitis NN 0
. . 0

Effects NNS 0
of IN 0
soy JJ 0
intake NN 0
on IN 0
sex NN 0
hormone NN 0
metabolism NN 0
in IN 0
premenopausal JJ 0
women NNS 0
. . 0

Studies NNS 0
suggest VBP 0
that IN 0
phytoestrogens NNS 0
in IN 0
soy JJ 0
products NNS 0
may MD 0
impart VB 0
hormonal JJ 0
effects NNS 0
that WDT 0
protect VBP 0
women NNS 0
against IN 0
breast NN 0
cancer NN 0
. . 0

Limited VBN 0
research NN 0
suggests VBZ 0
that IN 0
intake NN 0
of IN 0
soy NN 0
products NNS 0
high JJ 0
in IN 0
isoflavonoid JJ 0
phytoestrogens NNS 0
affects VBZ 0
sex NN 0
hormone NN 0
metabolism NN 0
, , 0
but CC 0
it PRP 0
is VBZ 0
unknown JJ 0
whether IN 0
phytoestrogens NNS 0
in IN 0
soy NNS 0
have VBP 0
any DT 0
effect NN 0
on IN 0
menstrual JJ 0
function NN 0
or CC 0
serum VB 0
sex NN 0
hormones NNS 0
in IN 0
women NNS 0
on IN 0
common JJ 0
hormone NN 0
therapies NNS 0
, , 0
such JJ 0
as IN 0
oral JJ 0
contraceptives NNS 0
( ( 0
OC NNP 0
) ) 0
. . 0

We PRP 0
studied VBD 0
the DT 0
effects NNS 0
of IN 0
soy NN 0
in IN 0
36 CD 0
premenopausal JJ 0
women NNS 0
, , 0
20 CD 0
of IN 0
whom WP 0
used VBD 0
OC NNP 0
. . 0

Subjects NNS 0
consumed VBD 0
their PRP$ 0
normal JJ 0
diet NNS 0
for IN 0
two CD 0
menstrual JJ 0
cycles NNS 0
and CC 0
added VBD 0
a DT 0
soy JJ 0
beverage NN 0
containing VBG 0
20 CD 0
g NN 0
of IN 0
protein NN 0
and CC 0
38 CD 0
mg NN 0
of IN 0
total JJ 0
isoflavones NNS 0
to TO 0
their PRP$ 0
usual JJ 0
diet NN 0
for IN 0
another DT 0
two CD 0
menstrual JJ 0
cycles NNS 0
. . 0

No DT 0
significant JJ 0
differences NNS 0
were VBD 0
observed VBN 0
in IN 0
serum NN 0
estrone NN 0
, , 0
estradiol NN 0
, , 0
sex NN 0
hormone-binding JJ 0
globulin NN 0
, , 0
dehydroepiandrosterone NN 0
sulfate NN 0
, , 0
prolactin NN 0
, , 0
or CC 0
progesterone NN 0
concentrations NNS 0
with IN 0
soy JJ 0
feeding NN 0
in IN 0
the DT 0
non-OC JJ 0
or CC 0
the DT 0
OC NNP 0
group NN 0
. . 0

No DT 0
changes NNS 0
in IN 0
menstrual JJ 0
cycle NN 0
length NN 0
or CC 0
the DT 0
urinary JJ 0
estrogen NN 0
metabolite NNS 0
ratio NN 0
of IN 0
2-hydroxyestrone CD 0
to TO 0
16 CD 0
alpha-hydroxyestrone NN 0
were VBD 0
seen VBN 0
with IN 0
soy JJ 0
feeding NN 0
in IN 0
the DT 0
non-OC JJ 0
or CC 0
the DT 0
OC NNP 0
group NN 0
. . 0

Levels NNP 0
of IN 0
urinary JJ 0
estrogen NN 0
metabolites NNS 0
were VBD 0
significantly RB 0
different JJ 0
between IN 0
the DT 0
non-OC JJ 0
and CC 0
the DT 0
OC NNP 0
group NN 0
. . 0

Thus RB 0
soy JJ 0
consumption NN 0
had VBD 0
no DT 0
significant JJ 0
effect NN 0
on IN 0
the DT 0
menstrual JJ 0
cycle NN 0
, , 0
serum JJ 0
sex NN 0
hormones NNS 0
, , 0
or CC 0
urinary JJ 0
estrogen NN 0
metabolite NN 0
ratio NN 0
in IN 0
premenopausal NN 0
OC NNP 0
or CC 0
non-OC JJ 0
users NNS 0
. . 0

Spotty JJ 0
calcification NN 0
as IN 0
a DT 0
marker NN 0
of IN 0
accelerated JJ 0
progression NN 0
of IN 0
coronary JJ 0
atherosclerosis NN 0
: : 0
insights NNS 0
from IN 0
serial JJ 0
intravascular JJ 0
ultrasound NN 0
. . 0

OBJECTIVES CC 0
The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
determine VB 0
atheroma JJ 0
progression NN 0
in IN 0
patients NNS 0
with IN 0
spotty JJ 0
calcification NN 0
. . 0

BACKGROUND NNP 0
Although IN 0
extensively RB 0
calcified VBN 0
atherosclerotic JJ 0
lesions NNS 0
have VBP 0
been VBN 0
proposed VBN 0
to TO 0
be VB 0
clinically RB 0
quiescent JJ 0
, , 0
the DT 0
presence NN 0
of IN 0
spotty JJ 0
calcification NN 0
within IN 0
plaque NN 0
has VBZ 0
been VBN 0
reported VBN 0
to TO 0
be VB 0
associated VBN 0
with IN 0
an DT 0
increased JJ 0
incidence NN 0
of IN 0
ischemic JJ 0
cardiovascular JJ 0
events NNS 0
. . 0

The DT 0
relationship NN 0
between IN 0
spotty JJ 0
calcification NN 0
and CC 0
disease NN 0
progression NN 0
has VBZ 0
not RB 0
been VBN 0
investigated VBN 0
. . 0

METHODS NNP 0
A NNP 0
total NN 0
of IN 0
1,347 CD 0
stable JJ 0
patients NNS 0
with IN 0
angiographic JJ 0
coronary JJ 0
artery NN 0
disease NN 0
underwent JJ 0
serial JJ 0
evaluation NN 0
of IN 0
atheroma JJ 0
burden NN 0
with IN 0
intravascular JJ 0
ultrasound NN 0
imaging NN 0
. . 0

Patients NNS 0
with IN 0
spotty JJ 0
calcification NN 0
were VBD 0
identified VBN 0
based VBN 0
on IN 0
the DT 0
presence NN 0
of IN 0
lesions NNS 0
( ( 0
1 CD 0
to TO 0
4 CD 0
mm NNS 0
in IN 0
length NN 0
) ) 0
containing VBG 0
an DT 0
arc NN 0
of IN 0
calcification NN 0
of IN 0
< $ 0
90? CD 0
. . 0

Clinical JJ 0
characteristics NNS 0
and CC 0
disease NN 0
progression NN 0
were VBD 0
compared VBN 0
between IN 0
patients NNS 0
with IN 0
spotty JJ 0
calcification NN 0
( ( 0
n JJ 0
= NNP 0
922 CD 0
) ) 0
and CC 0
those DT 0
with IN 0
no DT 0
calcification NN 0
( ( 0
n JJ 0
= NNP 0
425 CD 0
) ) 0
. . 0

RESULTS JJ 0
Patients NNS 0
with IN 0
spotty JJ 0
calcification NN 0
were VBD 0
older JJR 0
( ( 0
age NN 0
56 CD 0
years NNS 0
vs. IN 0
54 CD 0
years NNS 0
; : 0
p VBZ 0
= $ 0
0.001 CD 0
) ) 0
, , 0
more RBR 0
likely JJ 0
to TO 0
be VB 0
male JJ 0
( ( 0
68 CD 0
% NN 0
vs. FW 0
54 CD 0
% NN 0
; : 0
p CC 0
= VB 0
0.01 CD 0
) ) 0
, , 0
and CC 0
have VBP 0
a DT 0
history NN 0
of IN 0
diabetes NNS 0
mellitus NNS 0
( ( 0
30 CD 0
% NN 0
vs. FW 0
24 CD 0
% NN 0
; : 0
p CC 0
= VB 0
0.01 CD 0
) ) 0
and CC 0
myocardial JJ 0
infarction NN 0
( ( 0
28 CD 0
% NN 0
vs. FW 0
20 CD 0
% NN 0
; : 0
p CC 0
= VB 0
0.004 CD 0
) ) 0
, , 0
and CC 0
have VBP 0
lower JJR 0
on-treatment JJ 0
high-density NN 0
lipoprotein NN 0
cholesterol NN 0
levels NNS 0
( ( 0
48 CD 0
? . 0
16 CD 0
mg/dl NN 0
vs. FW 0
51 CD 0
? . 0
17 CD 0
mg/dl NN 0
; : 0
p CC 0
= VB 0
0.001 CD 0
) ) 0
. . 0

Patients NNS 0
with IN 0
spotty JJ 0
calcification NN 0
demonstrated VBD 0
a DT 0
greater JJR 0
percent JJ 0
atheroma NN 0
volume NN 0
( ( 0
PAV NNP 0
) ) 0
( ( 0
36.0 CD 0
? . 0
7.6 CD 0
% NN 0
vs. FW 0
29.0 CD 0
? . 0
8.5 CD 0
% NN 0
; : 0
p CC 0
< VB 0
0.001 CD 0
) ) 0
and CC 0
total JJ 0
atheroma NN 0
volume NN 0
( ( 0
174.6 CD 0
? . 0
71.9 CD 0
mm NN 0
( ( 0
3 CD 0
) ) 0
vs. FW 0
133.9 CD 0
? . 0
64.9 CD 0
mm NN 0
( ( 0
3 CD 0
) ) 0
; : 0
p CC 0
< VB 0
0.001 CD 0
) ) 0
. . 0

On IN 0
serial JJ 0
evaluation NN 0
, , 0
spotty JJ 0
calcification NN 0
was VBD 0
associated VBN 0
with IN 0
greater JJR 0
progression NN 0
of IN 0
PAV NNP 0
( ( 0
+0.43 NNP 0
? . 0
0.07 CD 0
% NN 0
vs. FW 0
+0.02 NNP 0
? . 0
0.11 CD 0
% NN 0
; : 0
p CC 0
= VB 0
0.002 CD 0
) ) 0
. . 0

Although IN 0
intensive JJ 0
low-density NN 0
lipoprotein NN 0
cholesterol NN 0
and CC 0
blood NN 0
pressure NN 0
lowering VBG 0
therapy NN 0
slowed VBD 0
disease JJ 0
progression NN 0
, , 0
these DT 0
efficacies NNS 0
were VBD 0
attenuated VBN 0
in IN 0
patients NNS 0
with IN 0
spotty JJ 0
calcification NN 0
. . 0

CONCLUSIONS VB 0
The DT 0
presence NN 0
of IN 0
spotty JJ 0
calcification NN 0
is VBZ 0
associated VBN 0
with IN 0
more RBR 0
extensive JJ 0
and CC 0
diffuse NN 0
coronary JJ 0
atherosclerosis NN 0
and CC 0
accelerated JJ 0
disease NN 0
progression NN 0
despite IN 0
use NN 0
of IN 0
medical JJ 0
therapies NNS 0
. . 0

[ JJ 0
Neoton NNP 0
and CC 0
thrombolytic JJ 0
therapy NN 0
of IN 0
myocardial JJ 0
infarction NN 0
] NNP 0
. . 0

AIM NNP 0
To TO 0
evaluate VB 0
neoton JJ 0
therapy NN 0
effects NNS 0
in IN 0
acute JJ 0
myocardial JJ 0
infarction NN 0
( ( 0
MI NNP 0
) ) 0
on IN 0
systolic JJ 0
function NN 0
of IN 0
the DT 0
left JJ 0
ventricle NN 0
, , 0
arrhythmia NN 0
and CC 0
clinical JJ 0
symptoms NNS 0
in IN 0
patients NNS 0
on IN 0
thrombolytic JJ 0
therapy NN 0
( ( 0
TLT NNP 0
) ) 0
. . 0

MATERIAL NNP 0
AND NNP 0
METHODS NNP 0
106 CD 0
males NNS 0
with IN 0
Q-MI NNP 0
entered VBD 0
the DT 0
study NN 0
. . 0

47 CD 0
received VBD 0
treatment NN 0
without IN 0
TLT NNP 0
and CC 0
neoton NN 0
, , 0
30 CD 0
patients NNS 0
received VBD 0
TLT NNP 0
with IN 0
streptokinase JJ 0
preparations NNS 0
, , 0
29 CD 0
patients NNS 0
were VBD 0
given VBN 0
streptokinase JJ 0
preparations NNS 0
and CC 0
neoton NN 0
. . 0

Left NNP 0
ventricular JJ 0
systolic JJ 0
function NN 0
was VBD 0
measured VBN 0
by IN 0
echocardiography NN 0
on IN 0
day NN 0
1 CD 0
, , 0
3 CD 0
, , 0
7 CD 0
, , 0
14 CD 0
, , 0
21 CD 0
and CC 0
28 CD 0
; : 0
arrhythmia NN 0
was VBD 0
analysed VBN 0
at IN 0
Holter NNP 0
monitoring VBG 0
in IN 0
day NN 0
1 CD 0
and CC 0
2 CD 0
of IN 0
MI NNP 0
. . 0

RESULTS NNP 0
TLT NNP 0
failed VBD 0
to TO 0
arrest VB 0
progression NN 0
of IN 0
left JJ 0
ventricular JJ 0
dilation NN 0
by IN 0
the DT 0
end NN 0
of IN 0
the DT 0
hospital NN 0
stay NN 0
. . 0

Patients NNS 0
given VBN 0
neoton NNS 0
in IN 0
acute JJ 0
period NN 0
of IN 0
MI NNP 0
had VBD 0
no DT 0
increase NN 0
in IN 0
the DT 0
end NN 0
systolic NN 0
and CC 0
diastolic JJ 0
volumes NNS 0
of IN 0
the DT 0
left JJ 0
ventricle NN 0
in IN 0
the DT 0
course NN 0
of IN 0
the DT 0
first JJ 0
months NNS 0
after IN 0
MI NNP 0
onset NN 0
. . 0

Antiarrhythmic NNP 0
action NN 0
of IN 0
neoton NN 0
manifested VBN 0
on IN 0
MI NNP 0
day NN 0
2 CD 0
. . 0

CONCLUSION NNP 0
Neoton NNP 0
given VBN 0
to TO 0
MI NNP 0
patients NNS 0
receiving VBG 0
TLT NNP 0
prevents NNS 0
progression NN 0
of IN 0
left JJ 0
ventricular JJ 0
systolic JJ 0
dysfunction NN 0
and CC 0
establishment NN 0
of IN 0
predictors NNS 0
of IN 0
unfavourable JJ 0
outcome NN 0
. . 0

Influence NN 0
of IN 0
lime NN 0
juice NN 0
on IN 0
the DT 0
severity NN 0
of IN 0
sickle NN 0
cell NN 0
anemia NN 0
. . 0

BACKGROUND NNP 0
AND CC 0
OBJECTIVES NNP 0
The DT 0
pain NN 0
in IN 0
sickle NN 0
cell NN 0
anemia NN 0
( ( 0
SCA NNP 0
) ) 0
is VBZ 0
often RB 0
triggered VBN 0
by IN 0
dehydration NN 0
, , 0
acidosis NN 0
, , 0
and CC 0
fever NN 0
that WDT 0
are VBP 0
usually RB 0
due JJ 0
to TO 0
malaria VB 0
. . 0

Intake NNP 0
of IN 0
lime JJ 0
juice NN 0
was VBD 0
recently RB 0
demonstrated VBN 0
to TO 0
facilitate VB 0
clearance NN 0
of IN 0
the DT 0
malaria NN 0
parasite NN 0
. . 0

It PRP 0
was VBD 0
therefore RB 0
sought VBN 0
to TO 0
determine VB 0
whether IN 0
regular JJ 0
intake NN 0
of IN 0
lime JJ 0
juice NN 0
will MD 0
ameliorate VB 0
crisis NN 0
, , 0
especially RB 0
recurrent JJ 0
bone NN 0
pain NN 0
. . 0

DESIGN NN 0
In IN 0
this DT 0
preliminary JJ 0
, , 0
open-labeled JJ 0
, , 0
randomized JJ 0
study NN 0
, , 0
the DT 0
effects NNS 0
of IN 0
lime JJ 0
juice NN 0
on IN 0
the DT 0
clinical JJ 0
and CC 0
some DT 0
laboratory JJ 0
characteristics NNS 0
of IN 0
children NNS 0
with IN 0
SCA NNP 0
were VBD 0
tested VBN 0
. . 0

RESULTS NNP 0
Among IN 0
the DT 0
113 CD 0
children NNS 0
with IN 0
SCA NNP 0
studied VBN 0
in IN 0
two CD 0
hospitals NNS 0
, , 0
the DT 0
58 CD 0
receiving NN 0
lime NN 0
treatment NN 0
had VBD 0
lower JJR 0
rates NNS 0
of IN 0
significant JJ 0
painful JJ 0
episodes NNS 0
than IN 0
the DT 0
55 CD 0
without IN 0
lime NN 0
( ( 0
37 CD 0
versus NN 0
83 CD 0
crises NNS 0
in IN 0
6 CD 0
months NNS 0
, , 0
and CC 0
0.64?0.11 CD 0
versus NN 0
1.51?0.34 CD 0
average JJ 0
rates NNS 0
per IN 0
child NN 0
, , 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

Also RB 0
, , 0
fewer JJR 0
subjects NNS 0
than IN 0
the DT 0
controls NNS 0
had VBD 0
significant JJ 0
painful JJ 0
episodes NNS 0
( ( 0
50.0 CD 0
% NN 0
versus IN 0
92.7 CD 0
% NN 0
) ) 0
; : 0
febrile JJ 0
illness NN 0
( ( 0
46.6 CD 0
% NN 0
versus IN 0
87.3 CD 0
% NN 0
) ) 0
and CC 0
admission NN 0
rate NN 0
( ( 0
3.4 CD 0
% NN 0
versus IN 0
34.5 CD 0
% NN 0
) ) 0
( ( 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

The DT 0
mean JJ 0
hematocrit NN 0
of IN 0
the DT 0
subjects NNS 0
( ( 0
26.23?2.03 CD 0
% NN 0
) ) 0
at IN 0
the DT 0
end NN 0
of IN 0
the DT 0
study NN 0
was VBD 0
also RB 0
higher JJR 0
, , 0
p JJ 0
< NN 0
0.001 CD 0
. . 0

However RB 0
, , 0
transfusion NN 0
rate NN 0
, , 0
presence NN 0
of IN 0
hepatomegaly NN 0
, , 0
splenomegaly NN 0
, , 0
and CC 0
jaundice NN 0
was VBD 0
similar JJ 0
. . 0

Treatment NN 0
with IN 0
lime NN 0
did VBD 0
not RB 0
cause VB 0
any DT 0
significant JJ 0
side-effect JJ 0
. . 0

CONCLUSIONS NNP 0
Regular NNP 0
intake NN 0
of IN 0
lime JJ 0
juice NN 0
may MD 0
be VB 0
of IN 0
great JJ 0
therapeutic JJ 0
and CC 0
nutritional JJ 0
relevance NN 0
in IN 0
children NNS 0
with IN 0
SCA NNP 0
. . 0

Comparison NNP 0
of IN 0
weakness NN 0
progression NN 0
in IN 0
inclusion NN 0
body NN 0
myositis NN 0
during IN 0
treatment NN 0
with IN 0
methotrexate NN 0
or CC 0
placebo NN 0
. . 0

We PRP 0
investigated VBD 0
whether IN 0
5 CD 0
to TO 0
20mg CD 0
per IN 0
week NN 0
oral JJ 0
methotrexate NN 0
could MD 0
slow VB 0
down RP 0
disease NN 0
progression NN 0
in IN 0
44 CD 0
patients NNS 0
with IN 0
inclusion NN 0
body NN 0
myositis NN 0
in IN 0
a DT 0
randomized JJ 0
double-blind JJ 0
placebo-controlled JJ 0
study NN 0
over IN 0
48 CD 0
weeks NNS 0
. . 0

Mean NNP 0
change NN 0
of IN 0
quantitative JJ 0
muscle NN 0
strength NN 0
testing VBG 0
sum NN 0
scores NNS 0
was VBD 0
the DT 0
primary JJ 0
study NN 0
outcome JJ 0
measure NN 0
. . 0

Quantitative JJ 0
muscle NN 0
strength NN 0
testing VBG 0
sum NN 0
scores NNS 0
declined VBD 0
in IN 0
both DT 0
treatment NN 0
groups NNS 0
, , 0
-0.2 CD 0
% NN 0
for IN 0
methotrexate NN 0
and CC 0
-3.4 CD 0
% NN 0
for IN 0
placebo NN 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
= NNP 0
-2.5 NNP 0
% NN 0
to TO 0
+9.1 CD 0
% NN 0
for IN 0
difference NN 0
) ) 0
. . 0

There EX 0
were VBD 0
also RB 0
no DT 0
differences NNS 0
in IN 0
manual JJ 0
muscle NN 0
testing VBG 0
sum JJ 0
scores NNS 0
, , 0
activity NN 0
scale NN 0
scores NNS 0
and CC 0
patients NNS 0
' POS 0
own JJ 0
assessments NNS 0
after IN 0
48 CD 0
weeks NNS 0
of IN 0
treatment NN 0
. . 0

Serum NNP 0
creatine JJ 0
kinase NN 0
activity NN 0
decreased VBN 0
significantly RB 0
in IN 0
the DT 0
methotrexate NN 0
group NN 0
. . 0

We PRP 0
conclude VBP 0
that IN 0
oral JJ 0
methotrexate NN 0
did VBD 0
not RB 0
slow VB 0
down RP 0
progression NN 0
of IN 0
muscle NN 0
weakness NN 0
but CC 0
decreased VBD 0
serum JJ 0
creatine JJ 0
kinase NN 0
activity NN 0
. . 0

Use NNP 0
of IN 0
hormonal JJ 0
contraceptives NNS 0
and CC 0
risk NN 0
of IN 0
HIV-1 NNP 0
transmission NN 0
: : 0
a DT 0
prospective JJ 0
cohort NN 0
study NN 0
. . 0

BACKGROUND NNP 0
Hormonal NNP 0
contraceptives NNS 0
are VBP 0
used VBN 0
widely RB 0
but CC 0
their PRP$ 0
effects NNS 0
on IN 0
HIV-1 NNP 0
risk NN 0
are VBP 0
unclear JJ 0
. . 0

We PRP 0
aimed VBD 0
to TO 0
assess VB 0
the DT 0
association NN 0
between IN 0
hormonal JJ 0
contraceptive NN 0
use NN 0
and CC 0
risk NN 0
of IN 0
HIV-1 NNP 0
acquisition NN 0
by IN 0
women NNS 0
and CC 0
HIV-1 JJ 0
transmission NN 0
from IN 0
HIV-1-infected JJ 0
women NNS 0
to TO 0
their PRP$ 0
male JJ 0
partners NNS 0
. . 0

METHODS NNP 0
In IN 0
this DT 0
prospective JJ 0
study NN 0
, , 0
we PRP 0
followed VBD 0
up RP 0
3790 CD 0
heterosexual JJ 0
HIV-1-serodiscordant JJ 0
couples NNS 0
participating VBG 0
in IN 0
two CD 0
longitudinal JJ 0
studies NNS 0
of IN 0
HIV-1 NNP 0
incidence NN 0
in IN 0
seven CD 0
African JJ 0
countries NNS 0
. . 0

Among IN 0
injectable JJ 0
and CC 0
oral JJ 0
hormonal JJ 0
contraceptive NN 0
users NNS 0
and CC 0
non-users NNS 0
, , 0
we PRP 0
compared VBN 0
rates NNS 0
of IN 0
HIV-1 NNP 0
acquisition NN 0
by IN 0
women NNS 0
and CC 0
HIV-1 JJ 0
transmission NN 0
from IN 0
women NNS 0
to TO 0
men NNS 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
measure NN 0
was VBD 0
HIV-1 JJ 0
seroconversion NN 0
. . 0

We PRP 0
used VBD 0
Cox NNP 0
proportional JJ 0
hazards NNS 0
regression NN 0
and CC 0
marginal JJ 0
structural JJ 0
modelling NN 0
to TO 0
assess VB 0
the DT 0
effect NN 0
of IN 0
contraceptive NN 0
use NN 0
on IN 0
HIV-1 NNP 0
risk NN 0
. . 0

FINDINGS NNP 0
Among IN 0
1314 CD 0
couples NNS 0
in IN 0
which WDT 0
the DT 0
HIV-1-seronegative JJ 0
partner NN 0
was VBD 0
female JJ 0
( ( 0
median JJ 0
follow-up NN 0
18?0 CD 0
[ JJ 0
IQR NNP 0
12?6-24?2 JJ 0
] NNP 0
months NNS 0
) ) 0
, , 0
rates NNS 0
of IN 0
HIV-1 NNP 0
acquisition NN 0
were VBD 0
6?61 CD 0
per IN 0
100 CD 0
person-years NNS 0
in IN 0
women NNS 0
who WP 0
used VBD 0
hormonal JJ 0
contraception NN 0
and CC 0
3?78 CD 0
per IN 0
100 CD 0
person-years NNS 0
in IN 0
those DT 0
who WP 0
did VBD 0
not RB 0
( ( 0
adjusted VBN 0
hazard RB 0
ratio JJ 0
1?98 CD 0
, , 0
95 CD 0
% NN 0
CI NNP 0
1?06-3?68 CD 0
, , 0
p=0?03 NN 0
) ) 0
. . 0

Among IN 0
2476 CD 0
couples NNS 0
in IN 0
which WDT 0
the DT 0
HIV-1-seronegative JJ 0
partner NN 0
was VBD 0
male JJ 0
( ( 0
median JJ 0
follow-up NN 0
18?7 CD 0
[ JJ 0
IQR NNP 0
12?8-24?2 JJ 0
] NNP 0
months NNS 0
) ) 0
, , 0
rates NNS 0
of IN 0
HIV-1 NNP 0
transmission NN 0
from IN 0
women NNS 0
to TO 0
men NNS 0
were VBD 0
2?61 CD 0
per IN 0
100 CD 0
person-years NNS 0
in IN 0
couples NNS 0
in IN 0
which WDT 0
women NNS 0
used VBD 0
hormonal JJ 0
contraception NN 0
and CC 0
1?51 CD 0
per IN 0
100 CD 0
person-years NNS 0
in IN 0
couples NNS 0
in IN 0
which WDT 0
women NNS 0
did VBD 0
not RB 0
use VB 0
hormonal JJ 0
contraception NN 0
( ( 0
adjusted VBN 0
hazard RB 0
ratio JJ 0
1?97 CD 0
, , 0
95 CD 0
% NN 0
CI NNP 0
1?12-3?45 CD 0
, , 0
p=0?02 NN 0
) ) 0
. . 0

Marginal JJ 0
structural JJ 0
model NN 0
analyses NNS 0
generated VBD 0
much RB 0
the DT 0
same JJ 0
results NNS 0
to TO 0
the DT 0
Cox NNP 0
proportional JJ 0
hazards NNS 0
regression NN 0
. . 0

INTERPRETATION NNP 0
Women NNP 0
should MD 0
be VB 0
counselled VBN 0
about IN 0
potentially RB 0
increased VBN 0
risk NN 0
of IN 0
HIV-1 NNP 0
acquisition NN 0
and CC 0
transmission NN 0
with IN 0
hormonal JJ 0
contraception NN 0
, , 0
especially RB 0
injectable JJ 0
methods NNS 0
, , 0
and CC 0
about IN 0
the DT 0
importance NN 0
of IN 0
dual JJ 0
protection NN 0
with IN 0
condoms NNS 0
to TO 0
decrease VB 0
HIV-1 NNP 0
risk NN 0
. . 0

Non-hormonal JJ 0
or CC 0
low-dose JJ 0
hormonal JJ 0
contraceptive NN 0
methods NNS 0
should MD 0
be VB 0
considered VBN 0
for IN 0
women NNS 0
with IN 0
or CC 0
at-risk JJ 0
for IN 0
HIV-1 NNP 0
. . 0

FUNDING NNP 0
US NNP 0
National NNP 0
Institutes NNP 0
of IN 0
Health NNP 0
and CC 0
the DT 0
Bill NNP 0
& CC 0
Melinda NNP 0
Gates NNP 0
Foundation NNP 0
. . 0

Changes NNS 0
in IN 0
the DT 0
fatty JJ 0
acid JJ 0
composition NN 0
of IN 0
the DT 0
plasma NN 0
lipid JJ 0
esters NNS 0
during IN 0
lipid-lowering JJ 0
treatment NN 0
with IN 0
diet JJ 0
, , 0
clofibrate NN 0
and CC 0
niceritrol NN 0
. . 0

Reduction NN 0
of IN 0
the DT 0
proportion NN 0
of IN 0
linoleate NN 0
by IN 0
clofibrate NN 0
but CC 0
not RB 0
by IN 0
niceritrol NN 0
. . 0

The DT 0
fatty JJ 0
acid JJ 0
composition NN 0
of IN 0
the DT 0
plasma NN 0
lipid JJ 0
esters NNS 0
has VBZ 0
been VBN 0
studied VBN 0
during IN 0
lipid-lowering JJ 0
treatment NN 0
of IN 0
95 CD 0
patients NNS 0
with IN 0
atherosclerotic JJ 0
disease NN 0
. . 0

During IN 0
the DT 0
first JJ 0
two CD 0
months NNS 0
of IN 0
the DT 0
trial NN 0
only RB 0
a DT 0
diet NN 0
was VBD 0
prescribed VBN 0
. . 0

During IN 0
the DT 0
ensuing VBG 0
two CD 0
months NNS 0
either CC 0
clofibrate NN 0
or CC 0
niceritrol NN 0
, , 0
a DT 0
nicotinic JJ 0
acid NN 0
ester NN 0
, , 0
was VBD 0
added VBN 0
in IN 0
a DT 0
randomized JJ 0
order NN 0
. . 0

During IN 0
the DT 0
last JJ 0
two CD 0
months NNS 0
the DT 0
second JJ 0
drug NN 0
was VBD 0
added VBN 0
. . 0

The DT 0
combined JJ 0
treatment NN 0
with IN 0
diet JJ 0
, , 0
clofibrate NN 0
and CC 0
niceritrol NN 0
caused VBN 0
highly RB 0
significant JJ 0
serum NN 0
lipid JJ 0
reductions NNS 0
. . 0

The DT 0
fatty JJ 0
acid JJ 0
composition NN 0
in IN 0
the DT 0
plasma NN 0
lipid JJ 0
esters NNS 0
was VBD 0
determined VBN 0
in IN 0
samples NNS 0
from IN 0
each DT 0
trial NN 0
period NN 0
to TO 0
measure VB 0
the DT 0
degree NN 0
of IN 0
dietary JJ 0
adherence NN 0
. . 0

During IN 0
dietary JJ 0
treatment NN 0
the DT 0
relative JJ 0
content NN 0
of IN 0
saturated JJ 0
and CC 0
monounsaturated VBD 0
fatty JJ 0
acids NNS 0
secreased VBD 0
and CC 0
the DT 0
polyunsaturated JJ 0
fatty JJ 0
acids NNS 0
increased VBD 0
with IN 0
an DT 0
increasing VBG 0
ratio NN 0
between IN 0
pulyunsaturated VBN 0
and CC 0
saturated VBN 0
fatty JJ 0
acids NNS 0
( ( 0
P/S NNP 0
ratio NN 0
) ) 0
in IN 0
the DT 0
cholesterol NN 0
esters NNS 0
and CC 0
triglycerides NNS 0
. . 0

Only RB 0
minor JJ 0
changes NNS 0
were VBD 0
seen VBN 0
in IN 0
the DT 0
phospholipids NNS 0
. . 0

The DT 0
changes NNS 0
caused VBN 0
by IN 0
the DT 0
diet NN 0
were VBD 0
partly RB 0
reversed VBN 0
by IN 0
clofibrate NN 0
while IN 0
niceritrol NN 0
did VBD 0
not RB 0
cause VB 0
any DT 0
major JJ 0
changes NNS 0
of IN 0
the DT 0
fatty JJ 0
acid JJ 0
composition NN 0
. . 0

Clofibrate NNP 0
treatment NN 0
coincided VBD 0
with IN 0
increasing VBG 0
amounts NNS 0
of IN 0
monounsaturated JJ 0
fatty JJ 0
acids NNS 0
, , 0
especially RB 0
oleate JJ 0
( ( 0
18 CD 0
: : 0
1 CD 0
) ) 0
, , 0
in IN 0
the DT 0
cholesterol NN 0
esters NNS 0
, , 0
triglycerides NNS 0
and CC 0
phospholipids NNS 0
while IN 0
there EX 0
were VBD 0
significant JJ 0
reductions NNS 0
of IN 0
the DT 0
content NN 0
of IN 0
linoleic NN 0
( ( 0
18 CD 0
: : 0
2 CD 0
) ) 0
acid NN 0
in IN 0
both CC 0
the DT 0
cholesterol NN 0
esters NNS 0
and CC 0
triglycerides NNS 0
. . 0

The DT 0
18 CD 0
: : 0
2/18 CD 0
: : 0
1 CD 0
ratio NN 0
decreased VBN 0
significantly RB 0
in IN 0
all PDT 0
the DT 0
lipid JJ 0
esters NNS 0
analyzed VBD 0
. . 0

However RB 0
, , 0
the DT 0
P/S NNP 0
ratio NN 0
was VBD 0
not RB 0
significantly RB 0
affected VBN 0
, , 0
partly RB 0
because IN 0
the DT 0
relative JJ 0
content NN 0
of IN 0
saturated JJ 0
fatty JJ 0
acids NNS 0
also RB 0
tended VBD 0
to TO 0
decrease VB 0
during IN 0
clofibrate JJ 0
treatment NN 0
. . 0

It PRP 0
is VBZ 0
concluded VBN 0
that IN 0
addition NN 0
of IN 0
clofibrate NN 0
treatment NN 0
to TO 0
patients NNS 0
who WP 0
are VBP 0
on IN 0
a DT 0
diet JJ 0
enriched VBN 0
with IN 0
polyunsaturated JJ 0
fats NNS 0
is VBZ 0
associated VBN 0
with IN 0
a DT 0
change NN 0
from IN 0
polyunsaturated VBN 0
to TO 0
monounsaturated VBN 0
fatty JJ 0
acids NNS 0
in IN 0
the DT 0
plasma NN 0
lipid JJ 0
esters NNS 0
but CC 0
does VBZ 0
not RB 0
significantly RB 0
effect NN 0
the DT 0
ratio NN 0
between IN 0
polyunsaturated VBN 0
and CC 0
saturated VBN 0
fatty JJ 0
acids NNS 0
. . 0

The DT 0
fatty JJ 0
acid NN 0
changes NNS 0
caused VBN 0
by IN 0
clofibrate NN 0
treatment NN 0
and CC 0
counteracted VBN 0
by IN 0
an DT 0
increased JJ 0
amount NN 0
of IN 0
polyunsaturated JJ 0
fat NN 0
in IN 0
the DT 0
diet NN 0
. . 0

Intrathecal JJ 0
morphine NN 0
suppresses NNS 0
NK NNP 0
cell NN 0
activity NN 0
following VBG 0
abdominal JJ 0
surgery NN 0
. . 0

PURPOSE VB 0
The DT 0
effects NNS 0
of IN 0
morphine NN 0
on IN 0
natural JJ 0
killer NN 0
( ( 0
NK NNP 0
) ) 0
cell NN 0
activity NN 0
were VBD 0
investigated VBN 0
in IN 0
patients NNS 0
who WP 0
underwent JJ 0
hysterectomy NN 0
. . 0

METHODS NNP 0
Forty NNP 0
patients NNS 0
were VBD 0
divided VBN 0
into IN 0
four CD 0
groups NNS 0
of IN 0
ten NN 0
. . 0

The DT 0
groups NNS 0
received VBD 0
intrathecal JJ 0
0.5 CD 0
mg NN 0
morphine NN 0
( ( 0
Group NNP 0
IT0.5 NNP 0
) ) 0
, , 0
intrathecal JJ 0
0.1 CD 0
mg NN 0
morphine NN 0
( ( 0
Group NNP 0
IT0.1 NNP 0
) ) 0
or CC 0
10 CD 0
mg NNS 0
morphine JJ 0
i.v NN 0
. . 0

( ( 0
Group NNP 0
IV NNP 0
) ) 0
. . 0

The DT 0
remaining VBG 0
ten JJ 0
patients NNS 0
served VBD 0
as IN 0
controls NNS 0
and CC 0
received VBN 0
inhalation NN 0
anesthesia NN 0
alone RB 0
( ( 0
Group NNP 0
C NNP 0
) ) 0
. . 0

Blood NN 0
samples NNS 0
were VBD 0
withdrawn VBN 0
before RB 0
and CC 0
two CD 0
hours NNS 0
after IN 0
surgery NN 0
and CC 0
on IN 0
postoperative JJ 0
days NNS 0
one CD 0
and CC 0
two CD 0
to TO 0
determine VB 0
the DT 0
blood NN 0
NK NNP 0
cell NN 0
activity NN 0
using VBG 0
a DT 0
chromium NN 0
release NN 0
assay VBP 0
with IN 0
K562 NNP 0
cells NNS 0
as IN 0
targets NNS 0
, , 0
plasma JJ 0
catecholamines NNS 0
and CC 0
cortisol NN 0
levels NNS 0
. . 0

The DT 0
postoperative JJ 0
pain NN 0
score NN 0
and CC 0
side NN 0
effects NNS 0
were VBD 0
studied VBN 0
in IN 0
the DT 0
four CD 0
groups NNS 0
. . 0

RESULTS NNP 0
In IN 0
Group NNP 0
IT0.5 NNP 0
, , 0
the DT 0
NK NNP 0
cell NN 0
activity NN 0
was VBD 0
lower JJR 0
on IN 0
postoperative JJ 0
day NN 0
1 CD 0
( ( 0
23.9 CD 0
+/- JJ 0
8.4 CD 0
% NN 0
) ) 0
than IN 0
the DT 0
baseline NN 0
level NN 0
( ( 0
45.7 CD 0
+/- JJ 0
13 CD 0
% NN 0
) ) 0
before IN 0
surgery NN 0
, , 0
and CC 0
recovered VBD 0
on IN 0
postoperative JJ 0
day NN 0
2 CD 0
. . 0

In IN 0
Groups NNP 0
IT0.1 NNP 0
, , 0
C NNP 0
and CC 0
IV NNP 0
, , 0
the DT 0
NK NNP 0
cell NN 0
activities NNS 0
showed VBD 0
no DT 0
significant JJ 0
changes NNS 0
. . 0

In IN 0
all DT 0
four CD 0
groups NNS 0
, , 0
neither CC 0
plasma JJ 0
adrenaline NN 0
nor CC 0
noradrenaline JJ 0
concentrations NNS 0
changed VBD 0
. . 0

In IN 0
all DT 0
four CD 0
groups NNS 0
, , 0
the DT 0
plasma NN 0
cortisol NN 0
levels NNS 0
increased VBN 0
after IN 0
surgery NN 0
, , 0
on IN 0
postoperative JJ 0
days NNS 0
1 CD 0
and CC 0
2 CD 0
. . 0

The DT 0
pain NN 0
score NN 0
was VBD 0
lower JJR 0
two CD 0
hours NNS 0
after IN 0
surgery NN 0
and CC 0
on IN 0
postoperative JJ 0
day NN 0
1 CD 0
in IN 0
Group NNP 0
IT0.5 NNP 0
than IN 0
in IN 0
the DT 0
other JJ 0
groups NNS 0
. . 0

CONCLUSION NNP 0
These DT 0
results NNS 0
suggest VBP 0
that IN 0
long-lasting JJ 0
analgesic JJ 0
effects NNS 0
of IN 0
intrathecal JJ 0
0.5 CD 0
mg JJ 0
morphine NN 0
suppress NN 0
the DT 0
immune JJ 0
response NN 0
following VBG 0
abdominal JJ 0
surgery NN 0
. . 0

Effect NN 0
of IN 0
indomethacin JJ 0
phonophoresis NN 0
on IN 0
the DT 0
relief NN 0
of IN 0
temporomandibular JJ 0
joint NN 0
pain NN 0
. . 0

The DT 0
pain-relieving JJ 0
effect NN 0
of IN 0
indomethacin JJ 0
phonophoresis NN 0
on IN 0
temporomandibular NN 0
( ( 0
TMJ NNP 0
) ) 0
joint NN 0
pain NN 0
was VBD 0
evaluated VBN 0
in IN 0
a DT 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
clinical JJ 0
trial NN 0
. . 0

Twenty NNP 0
subjects NNS 0
, , 0
who WP 0
have VBP 0
TMJ NNP 0
pain NN 0
, , 0
were VBD 0
included VBN 0
for IN 0
this DT 0
study NN 0
and CC 0
randomly RB 0
assigned VBN 0
to TO 0
either CC 0
the DT 0
experimental JJ 0
group NN 0
( ( 0
n JJ 0
= NNP 0
10 CD 0
) ) 0
or CC 0
the DT 0
control NN 0
group NN 0
( ( 0
n JJ 0
= NNP 0
10 CD 0
) ) 0
. . 0

Each DT 0
treatment NN 0
consisted VBN 0
of IN 0
the DT 0
application NN 0
of IN 0
ultrasound JJ 0
massage NN 0
( ( 0
1.0 CD 0
MHz NNP 0
, , 0
0.8 CD 0
to TO 0
1.5 CD 0
W/cm2 NNP 0
continuous JJ 0
output NN 0
) ) 0
for IN 0
15 CD 0
minutes NNS 0
to TO 0
the DT 0
painful JJ 0
temporomandibular JJ 0
joint NN 0
. . 0

As IN 0
a DT 0
conducting NN 0
medium NN 0
, , 0
1 CD 0
% NN 0
indomethacin JJ 0
cream NN 0
was VBD 0
used VBN 0
for IN 0
the DT 0
experimental JJ 0
group NN 0
and CC 0
placebo NN 0
cream NN 0
for IN 0
the DT 0
control NN 0
group NN 0
respectively RB 0
. . 0

Pre- JJ 0
and CC 0
post-treatment JJ 0
pain NN 0
levels NNS 0
and CC 0
pain NN 0
sensitivity NN 0
were VBD 0
assessed VBN 0
with IN 0
visual JJ 0
analogue NN 0
scales NNS 0
( ( 0
VAS NNP 0
) ) 0
and CC 0
pressure NN 0
pain NN 0
threshold NN 0
( ( 0
PPT NNP 0
) ) 0
. . 0

Mean NNP 0
data NNS 0
indicated VBD 0
that IN 0
post-treatment JJ 0
VAS NNP 0
was VBD 0
significantly RB 0
decreased VBN 0
and CC 0
post-treatment JJ 0
PPT NNP 0
was VBD 0
significantly RB 0
increased VBN 0
in IN 0
the DT 0
experimental JJ 0
group NN 0
, , 0
not RB 0
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

The DT 0
results NNS 0
of IN 0
this DT 0
study NN 0
suggest VBP 0
that IN 0
indomethacin JJ 0
phonophoresis NN 0
provides VBZ 0
significant JJ 0
pain NN 0
relieving VBG 0
effect NN 0
over IN 0
the DT 0
TMJ NNP 0
pain NN 0
. . 0

Systemic NNP 0
hemodynamic NN 0
, , 0
neurohormonal JJ 0
, , 0
and CC 0
renal JJ 0
effects NNS 0
of IN 0
a DT 0
steady-state JJ 0
infusion NN 0
of IN 0
human JJ 0
brain NN 0
natriuretic JJ 0
peptide NN 0
in IN 0
patients NNS 0
with IN 0
hemodynamically RB 0
decompensated VBN 0
heart NN 0
failure NN 0
. . 0

BACKGROUND NNP 0
Human NNP 0
brain NN 0
natriuretic JJ 0
peptide NN 0
( ( 0
hBNP NN 0
) ) 0
is VBZ 0
a DT 0
promising JJ 0
agent NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
decompensated JJ 0
cardiac JJ 0
failure NN 0
. . 0

However RB 0
, , 0
the DT 0
systemic JJ 0
hemodynamic NN 0
, , 0
neurohormonal JJ 0
, , 0
and CC 0
renal JJ 0
effects NNS 0
of IN 0
hBNP NNS 0
have VBP 0
been VBN 0
incompletely RB 0
studied VBN 0
in IN 0
human JJ 0
heart NN 0
failure NN 0
. . 0

METHODS NNP 0
AND CC 0
RESULTS NNP 0
The DT 0
effects NNS 0
of IN 0
a DT 0
continuous JJ 0
4-hour JJ 0
infusion NN 0
of IN 0
hBNP NN 0
were VBD 0
determined VBN 0
in IN 0
16 CD 0
decompensated JJ 0
heart NN 0
failure NN 0
patients NNS 0
in IN 0
an DT 0
invasive JJ 0
, , 0
randomized VBN 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
study NN 0
. . 0

Patients NNS 0
were VBD 0
evaluated VBN 0
during IN 0
three CD 0
4-hour JJ 0
study NN 0
periods NNS 0
: : 0
baseline NN 0
, , 0
treatment NN 0
( ( 0
placebo JJ 0
[ NNP 0
n NN 0
= VBD 0
4 CD 0
] NNP 0
versus NN 0
hBNP NN 0
0.025 CD 0
or CC 0
0.05 CD 0
microgram/kg/min NNS 0
[ JJ 0
n JJ 0
= NN 0
12 CD 0
] NN 0
) ) 0
, , 0
and CC 0
post-treatment NN 0
. . 0

Urinary JJ 0
volume NN 0
losses NNS 0
were VBD 0
replaced VBN 0
hourly RB 0
to TO 0
separate VB 0
the DT 0
vasodilatory NN 0
and CC 0
diuretic JJ 0
effects NNS 0
of IN 0
hBNP NN 0
. . 0

Two CD 0
patients NNS 0
in IN 0
the DT 0
hBNP NN 0
group NN 0
were VBD 0
excluded VBN 0
from IN 0
the DT 0
analysis NN 0
because IN 0
of IN 0
adverse JJ 0
events NNS 0
. . 0

hBNP NN 0
significantly RB 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
reduced VBD 0
right JJ 0
atrial JJ 0
pressure NN 0
and CC 0
pulmonary JJ 0
capillary JJ 0
wedge NN 0
pressure NN 0
by IN 0
approximately RB 0
30 CD 0
% NN 0
and CC 0
40 CD 0
% NN 0
, , 0
respectively RB 0
. . 0

hBNP NN 0
also RB 0
significantly RB 0
lowered VBN 0
systemic JJ 0
vascular JJ 0
resistance NN 0
from IN 0
1722 CD 0
+/- JJ 0
139 CD 0
to TO 0
1101 CD 0
+/- JJ 0
83 CD 0
dynes.s.cm-5 NN 0
( ( 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
. . 0

These DT 0
unloading JJ 0
effects NNS 0
of IN 0
hBNP NN 0
produced VBD 0
a DT 0
28 CD 0
% NN 0
increase NN 0
in IN 0
cardiac JJ 0
index NN 0
( ( 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
with IN 0
no DT 0
change NN 0
in IN 0
heart NN 0
rate NN 0
. . 0

Compared VBN 0
to TO 0
placebo VB 0
, , 0
hBNP VB 0
decreased VBN 0
plasma JJ 0
norepinephrine NN 0
and CC 0
aldosterone NN 0
. . 0

Renal JJ 0
hemodynamics NNS 0
were VBD 0
unaffected VBN 0
by IN 0
hBNP NN 0
; : 0
however RB 0
, , 0
most JJS 0
patients NNS 0
were VBD 0
resistant JJ 0
to TO 0
its PRP$ 0
natriuretic JJ 0
effect NN 0
. . 0

CONCLUSIONS NNP 0
1 CD 0
) ) 0
The DT 0
predominant JJ 0
hemodynamic JJ 0
effects NNS 0
of IN 0
hBNP NN 0
were VBD 0
a DT 0
decrease NN 0
in IN 0
cardiac JJ 0
preload NN 0
and CC 0
systemic JJ 0
vascular JJ 0
resistance NN 0
. . 0

2 CD 0
) ) 0
hBNP NN 0
also RB 0
improved VBD 0
cardiac JJ 0
output NN 0
without IN 0
increasing VBG 0
heart NN 0
rate NN 0
. . 0

3 CD 0
) ) 0
Plasma NNP 0
norepinephrine NN 0
and CC 0
aldosterone NN 0
levels NNS 0
decreased VBN 0
during IN 0
hBNP JJ 0
infusion NN 0
. . 0

4 CD 0
) ) 0
hBNP NN 0
is VBZ 0
pharmacologically RB 0
active JJ 0
and CC 0
has VBZ 0
potential VBN 0
in IN 0
the DT 0
therapy NN 0
for IN 0
decompensated JJ 0
heart NN 0
failure NN 0
. . 0

Once-daily RB 0
amoxicillin JJ 0
versus IN 0
twice-daily JJ 0
penicillin NN 0
V NNP 0
in IN 0
group NN 0
A NNP 0
beta-haemolytic JJ 0
streptococcal JJ 0
pharyngitis NN 0
. . 0

BACKGROUND NNP 0
Rheumatic NNP 0
fever NN 0
is VBZ 0
a DT 0
preventable JJ 0
chronic JJ 0
disease NN 0
preceded VBN 0
by IN 0
group NN 0
A NNP 0
beta-haemolytic JJ 0
streptococcal NN 0
( ( 0
GABHS NNP 0
) ) 0
pharyngitis NN 0
. . 0

OBJECTIVE UH 0
To TO 0
test VB 0
the DT 0
non-inferiority NN 0
of IN 0
once-daily JJ 0
( ( 0
QD NNP 0
) ) 0
oral JJ 0
amoxicillin NN 0
to TO 0
the DT 0
recommended VBN 0
twice-daily RB 0
( ( 0
BID NNP 0
) ) 0
oral JJ 0
penicillin NN 0
V NNP 0
in IN 0
GABHS NNP 0
pharyngitis NN 0
. . 0

METHODS NNP 0
This DT 0
was VBD 0
a DT 0
randomised JJ 0
non-inferiority JJ 0
trial NN 0
carried VBD 0
out RP 0
in IN 0
a DT 0
school-based JJ 0
clinic NN 0
in IN 0
New NNP 0
Zealand NNP 0
. . 0

Children NNP 0
presenting VBG 0
with IN 0
GABHS NNP 0
pharyngitis NN 0
were VBD 0
randomised VBN 0
to TO 0
oral JJ 0
amoxicillin NN 0
1500 CD 0
mg NN 0
QD NNP 0
( ( 0
or CC 0
750 CD 0
mg NN 0
if IN 0
bodyweight VBN 0
was VBD 0
< JJ 0
or=30 JJ 0
kg NN 0
) ) 0
or CC 0
to TO 0
oral JJ 0
penicillin NN 0
V NNP 0
500 CD 0
mg NN 0
BID NNP 0
( ( 0
or CC 0
250 CD 0
mg NN 0
if IN 0
bodyweight VBN 0
was VBD 0
< JJ 0
or=20 JJ 0
kg NN 0
) ) 0
for IN 0
10 CD 0
days NNS 0
. . 0

Observed VBN 0
medication NN 0
and CC 0
weekend NN 0
diary JJ 0
cards NNS 0
were VBD 0
used VBN 0
to TO 0
monitor VB 0
adherence NN 0
. . 0

OUTCOME NNP 0
Eradication NNP 0
of IN 0
GABHS NNP 0
, , 0
determined VBD 0
with IN 0
follow-up JJ 0
throat NN 0
cultures NNS 0
on IN 0
days NNS 0
3-6 CD 0
, , 0
12-16 CD 0
and CC 0
26-36 JJ 0
. . 0

GABHS NNP 0
isolates NNS 0
were VBD 0
serotyped VBN 0
to TO 0
distinguish VB 0
bacteriological JJ 0
treatment NN 0
failures NNS 0
( ( 0
and CC 0
relapses NNS 0
) ) 0
from IN 0
new JJ 0
acquisitions NNS 0
. . 0

Non-inferiority NN 0
was VBD 0
defined VBN 0
as IN 0
an DT 0
upper JJ 0
95 CD 0
% NN 0
confidence NN 0
limit NN 0
( ( 0
CL NNP 0
) ) 0
for IN 0
the DT 0
difference NN 0
in IN 0
success NN 0
of IN 0
eradication NN 0
in IN 0
the DT 0
amoxicillin NN 0
and CC 0
penicillin NN 0
V NNP 0
treatment NN 0
groups NNS 0
of IN 0
< NNP 0
or=10 FW 0
% NN 0
. . 0

RESULTS CC 0
353 CD 0
children NNS 0
with IN 0
positive JJ 0
throat NN 0
swabs NN 0
for IN 0
GABHS NNP 0
were VBD 0
randomised VBN 0
to TO 0
amoxicillin VB 0
( ( 0
n JJ 0
= NNP 0
177 CD 0
) ) 0
or CC 0
penicillin JJ 0
V NNP 0
( ( 0
n JJ 0
= NNP 0
176 CD 0
) ) 0
. . 0

The DT 0
upper JJ 0
95 CD 0
% NN 0
CL NNP 0
for IN 0
the DT 0
differences NNS 0
in IN 0
positive JJ 0
cultures NNS 0
between IN 0
the DT 0
antibiotics NNS 0
was VBD 0
4.9 CD 0
% NN 0
at IN 0
days NNS 0
3-6 CD 0
, , 0
6.5 CD 0
% NN 0
at IN 0
days NNS 0
12-16 CD 0
and CC 0
8.5 CD 0
% NN 0
at IN 0
days NNS 0
26-36 JJ 0
. . 0

Treatment NN 0
failures NNS 0
( ( 0
including VBG 0
relapses NNS 0
) ) 0
occurred VBD 0
at IN 0
each DT 0
visit NN 0
in IN 0
5.8 CD 0
% NN 0
, , 0
12.7 CD 0
% NN 0
and CC 0
10.7 CD 0
% NN 0
of IN 0
amoxicillin NN 0
recipients NNS 0
and CC 0
6.2 CD 0
% NN 0
, , 0
11.9 CD 0
% NN 0
and CC 0
11.3 CD 0
% NN 0
of IN 0
penicillin NN 0
V NNP 0
recipients NNS 0
, , 0
respectively RB 0
. . 0

No UH 0
significant JJ 0
differences NNS 0
in IN 0
resolution NN 0
of IN 0
symptoms NNS 0
were VBD 0
noted VBN 0
between IN 0
treatment NN 0
groups NNS 0
. . 0

One CD 0
case NN 0
of IN 0
unsubstantiated JJ 0
acute JJ 0
rheumatic JJ 0
fever NN 0
occurred VBD 0
after IN 0
7 CD 0
days NNS 0
of IN 0
amoxicillin NN 0
. . 0

CONCLUSION NN 0
In IN 0
this DT 0
adequately RB 0
powered VBN 0
study NN 0
, , 0
once-daily JJ 0
oral JJ 0
amoxicillin NN 0
is VBZ 0
not RB 0
inferior JJ 0
to TO 0
twice-daily JJ 0
penicillin NN 0
V NNP 0
for IN 0
the DT 0
treatment NN 0
and CC 0
eradication NN 0
of IN 0
GABHS NNP 0
in IN 0
children NNS 0
with IN 0
pharyngitis NN 0
. . 0

Psychological JJ 0
mediators NNS 0
of IN 0
bupropion NN 0
sustained-release NN 0
treatment NN 0
for IN 0
smoking VBG 0
cessation NN 0
. . 0

AIM IN 0
The DT 0
study NN 0
aimed VBN 0
to TO 0
test VB 0
simultaneously RB 0
our PRP$ 0
understanding NN 0
of IN 0
the DT 0
effects NNS 0
of IN 0
bupropion NN 0
sustained-release NN 0
( ( 0
SR NNP 0
) ) 0
treatment NN 0
on IN 0
putative JJ 0
mediators NNS 0
and CC 0
our PRP$ 0
understanding NN 0
of IN 0
determinants NNS 0
of IN 0
post-quit NN 0
abstinence NN 0
, , 0
including VBG 0
withdrawal NN 0
distress NN 0
, , 0
cigarette NN 0
craving NN 0
, , 0
positive JJ 0
affect NN 0
and CC 0
subjective JJ 0
reactions NNS 0
to TO 0
cigarettes NNS 0
smoked VBN 0
during IN 0
a DT 0
lapse NN 0
. . 0

The DT 0
specificity NN 0
of IN 0
bupropion NN 0
SR NNP 0
effects NNS 0
was VBD 0
also RB 0
tested VBN 0
in IN 0
exploratory JJ 0
analyses NNS 0
. . 0

DESIGN NNP 0
Data NNP 0
from IN 0
a DT 0
randomized VBN 0
, , 0
placebo-controlled JJ 0
clinical JJ 0
trial NN 0
of IN 0
bupropion NN 0
SR NNP 0
were VBD 0
submitted VBN 0
to TO 0
mediation NN 0
analyses NNS 0
. . 0

SETTING NN 0
Center NNP 0
for IN 0
Tobacco NNP 0
Research NNP 0
and CC 0
Intervention NNP 0
, , 0
Madison NNP 0
, , 0
WI NNP 0
, , 0
USA NNP 0
. . 0

PARTICIPANTS VB 0
A DT 0
total NN 0
of IN 0
403 CD 0
adult NN 0
, , 0
daily JJ 0
smokers NNS 0
without IN 0
contraindications NNS 0
to TO 0
bupropion VB 0
SR NNP 0
use NN 0
. . 0

INTERVENTION NN 0
Participants NNS 0
were VBD 0
assigned VBN 0
randomly RB 0
to TO 0
receive VB 0
a DT 0
9-week JJ 0
course NN 0
of IN 0
bupropion NN 0
SR NNP 0
or CC 0
placebo NN 0
pill NN 0
and CC 0
to TO 0
receive VB 0
eight CD 0
brief JJ 0
individual JJ 0
counseling NN 0
sessions NNS 0
or CC 0
no DT 0
counseling NN 0
. . 0

MEASUREMENTS NNP 0
Ecological NNP 0
momentary JJ 0
assessment NN 0
ratings NNS 0
of IN 0
smoking VBG 0
behavior NN 0
and CC 0
putative JJ 0
mediators NNS 0
were VBD 0
collected VBN 0
pre- JJ 0
and CC 0
post-quit NN 0
. . 0

FINDINGS NNP 0
Results NNP 0
of IN 0
structural JJ 0
equation NN 0
and CC 0
hierarchical JJ 0
linear JJ 0
models NNS 0
did VBD 0
not RB 0
support VB 0
the DT 0
hypothesis NN 0
that WDT 0
bupropion NN 0
SR NNP 0
treatment NN 0
improves VBZ 0
short-term JJ 0
abstinence NN 0
by IN 0
reducing VBG 0
withdrawal NN 0
distress NN 0
or CC 0
affecting VBG 0
the DT 0
subjective JJ 0
effects NNS 0
of IN 0
a DT 0
lapse NN 0
cigarette NN 0
, , 0
but CC 0
provided VBD 0
partial JJ 0
support NN 0
for IN 0
mediation NN 0
by IN 0
cigarette NN 0
craving VBG 0
reduction NN 0
and CC 0
enhanced VBD 0
positive JJ 0
affect NN 0
. . 0

Bupropion NNP 0
SR NNP 0
effects NNS 0
on IN 0
point-prevalence NN 0
abstinence NN 0
at IN 0
1 CD 0
month NN 0
post-quit NN 0
were VBD 0
also RB 0
mediated VBN 0
partially RB 0
by IN 0
enhanced JJ 0
motivation NN 0
to TO 0
quit VB 0
and CC 0
self-efficacy NN 0
. . 0

CONCLUSIONS NNP 0
Results NNP 0
provided VBD 0
some DT 0
support NN 0
for IN 0
models NNS 0
of IN 0
bupropion NN 0
SR NNP 0
treatment NN 0
and CC 0
relapse NN 0
and CC 0
suggested VBD 0
that IN 0
motivational JJ 0
processes NNS 0
may MD 0
partially RB 0
account VB 0
for IN 0
bupropion NN 0
SR NNP 0
efficacy NN 0
. . 0

Double-blind NNP 0
randomized JJ 0
evaluation NN 0
of IN 0
intercostal JJ 0
nerve NN 0
blocks NNS 0
as IN 0
an DT 0
adjuvant NN 0
to TO 0
subarachnoid VB 0
administered JJ 0
morphine NN 0
for IN 0
post-thoracotomy JJ 4
analgesia NN 4
. . 0

BACKGROUND NNP 0
AND NNP 0
OBJECTIVES NNP 0
Thoracotomy NNP 0
is VBZ 0
associated VBN 0
with IN 0
pain NN 0
and CC 0
compromised VBD 0
pulmonary JJ 0
function NN 0
. . 0

Intercostal NNP 0
nerve NN 0
blocks NNS 0
( ( 0
INB NNP 0
) ) 0
and CC 0
subarachnoid JJ 0
morphine NN 0
( ( 0
SM NNP 0
) ) 0
act NN 0
on IN 0
different JJ 0
portions NNS 0
of IN 0
the DT 0
pain NN 0
pathway RB 0
. . 0

Each DT 0
is VBZ 0
effective JJ 0
for IN 0
post-thoracotomy JJ 0
pain NN 0
relief NN 0
. . 0

The DT 0
combination NN 0
of IN 0
these DT 0
two CD 0
modalities NNS 0
in IN 0
relieving VBG 0
post-thoracotomy JJ 0
pain NN 0
and CC 0
improving VBG 0
postoperative JJ 0
pulmonary JJ 0
function NN 0
has VBZ 0
not RB 0
been VBN 0
investigated VBN 0
. . 0

METHODS NNP 0
In IN 0
a DT 0
double-blind NN 0
study NN 0
, , 0
20 CD 3
patients NNS 0
undergoing JJ 0
lateral JJ 4
thoracotomy NN 4
for IN 0
lung NN 4
resection NN 4
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
0.5 CD 0
mg NN 0
SM NNP 0
preoperatively RB 0
and CC 0
INB NNP 0
with IN 0
bupivacaine NN 0
( ( 0
INB+ NNP 0
) ) 0
prior RB 0
to TO 0
wound VB 0
closure NN 0
or CC 0
0.5 CD 0
mg NNS 0
SM NNP 0
with IN 0
INB NNP 0
using VBG 0
saline NN 0
( ( 0
INB- NNP 0
) ) 0
. . 0

Visual JJ 0
analog NN 0
scale NN 0
pain NN 0
scores NNS 0
at IN 0
rest NN 0
, , 0
with IN 0
cough NN 0
, , 0
and CC 0
with IN 0
movement NN 0
of IN 0
the DT 0
ipsilateral JJ 0
arm NN 0
, , 0
forced VBD 0
expiratory JJ 0
volume NN 0
in IN 0
1 CD 0
second JJ 0
( ( 0
FEV1 NNP 0
) ) 0
, , 0
and CC 0
forced VBD 0
vital JJ 0
capacity NN 0
( ( 0
FVC NNP 0
) ) 0
were VBD 0
measured VBN 0
at IN 0
4 CD 0
, , 0
24 CD 0
, , 0
48 CD 0
, , 0
and CC 0
72 CD 0
hours NNS 0
after IN 0
the DT 0
operation NN 0
. . 0

Opioid NNP 0
use NN 0
was VBD 0
measured VBN 0
during IN 0
the DT 0
initial JJ 0
24 CD 0
hours NNS 0
after IN 0
the DT 0
operation NN 0
. . 0

RESULTS NNP 0
At IN 0
4 CD 0
hours NNS 0
, , 0
the DT 0
INB+ NNP 0
group NN 0
demonstrated VBD 0
better JJR 0
FEV1 NNP 0
( ( 0
56.6 CD 0
% NN 0
vs. FW 0
40.4 CD 0
% NN 0
of IN 0
baseline NN 0
, , 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
and CC 0
FVC NNP 0
values NNS 0
( ( 0
54.6 CD 0
% NN 0
vs. FW 0
39.6 CD 0
% NN 0
of IN 0
baseline NN 0
, , 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
and CC 0
less RBR 0
resting VBG 0
and CC 0
cough JJ 0
pain NN 0
( ( 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
. . 0

However RB 0
, , 0
FEV1 NNP 0
continued VBD 0
to TO 0
decline VB 0
in IN 0
the DT 0
INB+ NNP 0
group NN 0
at IN 0
24 CD 0
hours NNS 0
to TO 0
lower JJR 0
than IN 0
the DT 0
INB- NNP 0
group NN 0
although IN 0
pain NN 0
scores NNS 0
were VBD 0
similar JJ 0
beyond IN 0
4 CD 0
hours NNS 0
. . 0

Opioid JJ 0
usage NN 0
during IN 0
the DT 0
first JJ 0
24 CD 0
hours NNS 0
was VBD 0
similar JJ 0
( ( 0
INB- NNP 0
, , 0
16.7 CD 0
mg NN 0
vs. FW 0
INB+ NNP 0
, , 0
13.2 CD 0
mg NN 0
, , 0
P NNP 0
= NNP 0
.7 NNP 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Although IN 0
postoperative JJ 0
INB NNP 0
provided VBD 0
modest JJ 0
improvements NNS 0
in IN 0
pain NN 0
and CC 0
pulmonary JJ 0
function NN 0
when WRB 0
used VBN 0
as IN 0
an DT 0
adjuvant NN 0
to TO 0
0.5 CD 0
mg NNS 0
SM NNP 0
for IN 0
post-thoracotomy JJ 0
analgesia NN 0
, , 0
the DT 0
benefits NNS 0
were VBD 0
transient JJ 0
. . 0

The DT 0
authors NNS 0
do VBP 0
not RB 0
recommend VB 0
adding VBG 0
INB NNP 0
for IN 0
patients NNS 0
undergoing JJ 0
lateral JJ 0
thoracotomy NN 0
who WP 0
receive VBP 0
0.5 CD 0
mg NN 0
SM NNP 0
. . 0

Quality NN 0
of IN 0
individual JJ 0
INR NNP 0
control NN 0
and CC 0
the DT 0
risk NN 0
of IN 0
stroke NN 0
and CC 0
bleeding VBG 0
events NNS 0
in IN 0
atrial JJ 0
fibrillation NN 0
patients NNS 0
: : 0
a DT 0
nested JJ 0
case NN 0
control NN 0
analysis NN 0
of IN 0
the DT 0
ACTIVE NNP 0
W NNP 0
study NN 0
. . 0

INTRODUCTION NNP 0
Time NNP 0
in IN 0
therapeutic JJ 0
range NN 0
( ( 0
TTR NNP 0
) ) 0
for IN 0
international JJ 0
normalized JJ 0
ratio NN 0
( ( 0
INR NNP 0
) ) 0
is VBZ 0
an DT 0
accepted JJ 0
quality NN 0
measure NN 0
of IN 0
anticoagulation NN 0
control NN 0
in IN 0
patient JJ 0
populations NNS 0
, , 0
but CC 0
its PRP$ 0
usefulness NN 0
for IN 0
predicting VBG 0
stroke NN 0
and CC 0
bleeding NN 0
in IN 0
individuals NNS 0
is VBZ 0
not RB 0
well RB 0
understood RB 0
. . 0

MATERIALS NNP 0
AND CC 0
METHODS NNP 0
In IN 0
a DT 0
nested JJ 0
case NN 0
control NN 0
analysis NN 0
among IN 0
ACTIVE NNP 0
W NNP 0
study NN 0
patients NNS 0
, , 0
cases NNS 0
with IN 0
stroke NN 0
and CC 0
cases NNS 0
with IN 0
bleeding NN 0
were VBD 0
separately RB 0
matched VBN 0
with IN 0
controls NNS 0
. . 0

Several JJ 0
anticoagulation NN 0
quality NN 0
measures NNS 0
were VBD 0
compared VBN 0
, , 0
overall JJ 0
and CC 0
in IN 0
a DT 0
time-dependent JJ 0
manner NN 0
. . 0

RESULTS CC 0
32 CD 0
cases NNS 0
with IN 0
ischemic JJ 0
stroke NN 0
and CC 0
234 CD 0
cases NNS 0
with IN 0
bleeding NN 0
in IN 0
the DT 0
analysis NN 0
were VBD 0
matched VBN 0
in IN 0
a DT 0
4:1 CD 0
ratio NN 0
to TO 0
122 CD 0
and CC 0
865 CD 0
controls NNS 0
, , 0
respectively RB 0
. . 0

Follow-up JJ 0
duration NN 0
was VBD 0
257?154days CD 0
for IN 0
the DT 0
stroke NN 0
analysis NN 0
and CC 0
222?146days CD 0
for IN 0
the DT 0
bleeding NN 0
analysis NN 0
. . 0

Compared VBN 0
with IN 0
their PRP$ 0
respective NN 0
controls NNS 0
, , 0
the DT 0
study NN 0
mean JJ 0
TTR NNP 0
of IN 0
both DT 0
stroke NN 0
cases NNS 0
( ( 0
53.9 CD 0
% NN 0
?25.1 NNP 0
vs VBZ 0
63.4 CD 0
% NN 0
?24.8 NN 0
; : 0
p=0.055 CC 0
) ) 0
and CC 0
bleeding VBG 0
cases NNS 0
( ( 0
56.2 CD 0
% NN 0
?25.4 NNP 0
vs VBZ 0
63.4 CD 0
% NN 0
?26.8 NN 0
; : 0
p CC 0
< VB 0
0.001 CD 0
) ) 0
was VBD 0
lower JJR 0
. . 0

Time NNP 0
below IN 0
range NN 0
for IN 0
stroke NN 0
and CC 0
time NN 0
above IN 0
range NN 0
for IN 0
bleeding VBG 0
were VBD 0
only RB 0
greater JJR 0
in IN 0
the DT 0
last JJ 0
month NN 0
leading VBG 0
up RP 0
to TO 0
the DT 0
event NN 0
, , 0
not RB 0
over IN 0
the DT 0
entire JJ 0
study NN 0
period NN 0
. . 0

Rather CC 0
, , 0
over IN 0
the DT 0
entire JJ 0
study NN 0
period NN 0
bleeding VBG 0
cases NNS 0
spent VBD 0
more JJR 0
time NN 0
below IN 0
range NN 0
than IN 0
controls NNS 0
( ( 0
26.8 CD 0
% NN 0
?25.9 NNP 0
vs VBZ 0
20.8 CD 0
% NN 0
?24.0 NN 0
; : 0
p=0.001 NN 0
) ) 0
. . 0

CONCLUSIONS NNP 0
TTR NNP 0
was VBD 0
lower JJR 0
in IN 0
individual JJ 0
AF NNP 0
patients NNS 0
with IN 0
stroke NN 0
or CC 0
bleeding NN 0
compared VBN 0
with IN 0
matched JJ 0
controls NNS 0
in IN 0
ACTIVE NNP 0
W. NNP 0
Maintaining VBG 0
a DT 0
high JJ 0
TTR NNP 0
, , 0
with IN 0
equal JJ 0
importance NN 0
to TO 0
avoid VB 0
low JJ 0
and CC 0
high JJ 0
INRs NNP 0
, , 0
is VBZ 0
a DT 0
relevant JJ 0
goal NN 0
of IN 0
individual JJ 0
patient NN 0
treatment NN 0
to TO 0
prevent VB 0
stroke NN 0
and CC 0
bleeding NN 0
. . 0

Oral JJ 0
ciprofloxacin NN 0
vs. FW 0
intramuscular JJ 0
ceftriaxone NN 0
as IN 0
empiric JJ 0
treatment NN 0
of IN 0
acute JJ 0
invasive JJ 0
diarrhea NN 0
in IN 0
children NNS 0
. . 0

BACKGROUND NNP 0
Acute NNP 0
invasive JJ 0
diarrhea NN 0
is VBZ 0
a DT 0
potentially RB 0
serious JJ 0
condition NN 0
in IN 0
children NNS 0
. . 0

Because IN 0
of IN 0
the DT 0
increasing VBG 0
resistance NN 0
of IN 0
enteric JJ 0
pathogens NNS 0
to TO 0
commonly RB 0
used JJ 0
oral JJ 0
antibiotics NNS 0
, , 0
intramuscular JJ 0
ceftriaxone NN 0
has VBZ 0
become VBN 0
the DT 0
routine JJ 0
drug NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
acute JJ 0
invasive JJ 0
diarrhea NN 0
requiring VBG 0
an DT 0
emergency NN 0
visit NN 0
in IN 0
southern JJ 0
Israel NNP 0
. . 0

The DT 0
inconvenience NN 0
of IN 0
this DT 0
parenteral JJ 0
regimen NNS 0
created VBD 0
an DT 0
increased VBN 0
need NN 0
for IN 0
oral JJ 0
pediatric JJ 0
formulations NNS 0
for IN 0
the DT 0
treatment NN 0
of IN 0
invasive JJ 0
diarrhea NN 0
. . 0

OBJECTIVES NNP 0
To TO 0
evaluate VB 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
a DT 0
suspension NN 0
formulation NN 0
of IN 0
ciprofloxacin NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
acute JJ 0
invasive JJ 0
diarrhea NN 0
in IN 0
infants NNS 0
and CC 0
children NNS 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
From NNP 0
July NNP 0
1996 CD 0
through IN 0
December NNP 0
1997 CD 0
, , 0
201 CD 0
evaluable JJ 0
children NNS 0
ages VBZ 0
6 CD 0
months NNS 0
to TO 0
10 CD 0
years NNS 0
( ( 0
35 CD 0
% NN 0
< CC 0
1 CD 0
year NN 0
; : 0
70 CD 0
% NN 0
< JJ 0
3 CD 0
years NNS 0
) ) 0
presenting VBG 0
with IN 0
acute JJ 0
invasive JJ 0
diarrhea NN 0
at IN 0
the DT 0
Pediatric NNP 0
Emergency NNP 0
Room NNP 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
either DT 0
ciprofloxacin NN 0
suspension NN 0
( ( 0
10 CD 0
mg/kg NN 0
twice RB 0
a DT 0
day NN 0
+ NNP 0
im NN 0
placebo NN 0
; : 0
n CC 0
= VB 0
95 CD 0
) ) 0
or CC 0
im VB 0
ceftriaxone NN 0
( ( 0
50 CD 0
mg/kg/day NN 0
+ NNP 0
placebo NN 0
suspension NN 0
; : 0
n CC 0
= VB 0
106 CD 0
) ) 0
for IN 0
3 CD 0
days NNS 0
in IN 0
a DT 0
double JJ 0
blind NN 0
manner NN 0
. . 0

Stool NNP 0
cultures NNS 0
for IN 0
Shigella NNP 0
, , 0
Salmonella NNP 0
, , 0
Campylobacter NNP 0
spp NN 0
. . 0

and CC 0
diarrheagenic JJ 0
Escherichia NNP 0
coli NNS 0
were VBD 0
obtained VBN 0
on IN 0
Days NNP 0
1 CD 0
, , 0
3 CD 0
, , 0
4 CD 0
to TO 0
5 CD 0
and CC 0
21 CD 0
+/- JJ 0
5 CD 0
. . 0

Clinical JJ 0
response NN 0
and CC 0
safety NN 0
were VBD 0
assessed VBN 0
on IN 0
Days NNP 0
1 CD 0
, , 0
2 CD 0
, , 0
3 CD 0
, , 0
4 CD 0
to TO 0
5 CD 0
and CC 0
21 CD 0
+/- JJ 0
5 CD 0
. . 0

RESULTS NNP 0
We PRP 0
isolated VBD 0
127 CD 0
pathogens NNS 0
from IN 0
121 CD 0
( ( 0
60 CD 0
% NN 0
) ) 0
patients NNS 0
: : 0
73 CD 0
( ( 0
57 CD 0
% NN 0
) ) 0
Shigella NNP 0
; : 0
23 CD 0
( ( 0
18 CD 0
% NN 0
) ) 0
Salmonella NNP 0
; : 0
18 CD 0
( ( 0
14 CD 0
% NN 0
) ) 0
E. NNP 0
coli NNS 0
; : 0
and CC 0
13 CD 0
( ( 0
10 CD 0
% NN 0
) ) 0
Campylobacter NNP 0
. . 0

Overall NNP 0
bacteriologic JJ 0
eradication NN 0
on IN 0
Day NNP 0
4 CD 0
to TO 0
5 CD 0
was VBD 0
99 CD 0
% NN 0
for IN 0
Shigella NNP 0
, , 0
77 CD 0
% NN 0
for IN 0
Salmonella NNP 0
and CC 0
77 CD 0
% NN 0
for IN 0
Campylobacter NNP 0
, , 0
with IN 0
no DT 0
difference NN 0
between IN 0
the DT 0
2 CD 0
groups NNS 0
. . 0

Clinical JJ 0
cure NN 0
or CC 0
improvement NN 0
was VBD 0
observed VBN 0
in IN 0
100 CD 0
and CC 0
99 CD 0
% NN 0
of IN 0
the DT 0
ciprofloxacin NN 0
and CC 0
ceftriaxone NN 0
groups NNS 0
, , 0
respectively RB 0
. . 0

Serum NNP 0
ciprofloxacin NN 0
values NNS 0
determined VBN 0
on IN 0
Day NNP 0
3 CD 0
of IN 0
the DT 0
treatment NN 0
were VBD 0
higher JJR 0
in IN 0
the DT 0
majority NN 0
of IN 0
patients NNS 0
than IN 0
were VBD 0
the DT 0
MIC50 NNP 0
and CC 0
MIC90 NNP 0
values NNS 0
for IN 0
the DT 0
Shigella NNP 0
and CC 0
Salmonella NNP 0
spp NN 0
. . 0

isolated VBN 0
. . 0

Possible JJ 0
drug-related JJ 0
adverse JJ 0
events NNS 0
occurred VBD 0
in IN 0
13 CD 0
patients NNS 0
[ JJ 0
ciprofloxacin NN 0
, , 0
8 CD 0
( ( 0
8 CD 0
% NN 0
) ) 0
; : 0
ceftriaxone NN 0
, , 0
5 CD 0
( ( 0
4.7 CD 0
% NN 0
) ) 0
] NN 0
and CC 0
were VBD 0
mild NNS 0
and CC 0
transient NN 0
. . 0

Joint JJ 0
examination NN 0
was VBD 0
normal JJ 0
during IN 0
and CC 0
after IN 0
completion NN 0
of IN 0
therapy NN 0
in IN 0
all DT 0
patients NNS 0
. . 0

CONCLUSION NNP 0
Oral NNP 0
ciprofloxacin NN 0
was VBD 0
as IN 0
safe JJ 0
and CC 0
effective JJ 0
as IN 0
intramuscular JJ 0
ceftriaxone NN 0
for IN 0
the DT 0
empiric JJ 0
treatment NN 0
of IN 0
acute JJ 0
invasive JJ 0
diarrhea NN 0
in IN 0
ambulatory JJ 0
pediatric JJ 0
patients NNS 0
requiring VBG 0
an DT 0
emergency NN 0
room NN 0
visit NN 0
. . 0

Effects NNS 0
of IN 0
mild JJ 0
physical JJ 0
exercise NN 0
on IN 0
serum NN 0
lipoproteins NNS 0
and CC 0
metabolites NNS 0
of IN 0
arachidonic JJ 0
acid NN 0
: : 0
a DT 0
controlled VBN 0
randomised JJ 0
trial NN 0
in IN 0
middle JJ 0
aged VBN 0
men NNS 0
. . 0

To TO 0
study VB 0
the DT 0
effects NNS 0
of IN 0
physical JJ 0
exercise NN 0
on IN 0
biochemical JJ 0
risk NN 0
factors NNS 0
for IN 0
ischaemic JJ 0
heart NN 0
disease NN 0
31 CD 0
healthy JJ 0
middle NNS 0
aged VBN 0
men NNS 0
undertook IN 0
regular JJ 0
physical JJ 0
exercise NN 0
for IN 0
two CD 0
months NNS 0
and CC 0
29 CD 0
served VBD 0
as IN 0
controls NNS 0
in IN 0
a DT 0
randomised JJ 0
trial NN 0
. . 0

In IN 0
the DT 0
men NNS 0
taking VBG 0
regular JJ 0
exercise NN 0
serum NN 0
cholesterol NN 0
concentrations NNS 0
increased VBD 0
26 CD 0
% NN 0
more JJR 0
in IN 0
the DT 0
high JJ 0
density NN 0
lipoprotein VBP 0
subfraction NN 0
two CD 0
( ( 0
HDL2 NNP 0
) ) 0
and CC 0
decreased VBD 0
31 CD 0
% NN 0
more JJR 0
in IN 0
the DT 0
subfraction NN 0
three CD 0
( ( 0
HDL3 NNP 0
) ) 0
and CC 0
9 CD 0
% NN 0
more JJR 0
in IN 0
the DT 0
low JJ 0
density NN 0
lipoprotein NN 0
fraction NN 0
than IN 0
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

A DT 0
tendency NN 0
towards NNS 0
increased VBD 0
plasma JJ 0
6-keto-prostaglandin JJ 0
F1 NNP 0
alpha NN 0
concentration NN 0
and CC 0
decreased VBD 0
serum NN 0
thromboxane NN 0
B2 NNP 0
concentration NN 0
was VBD 0
found VBN 0
during IN 0
the DT 0
period NN 0
of IN 0
regular JJ 0
exercise NN 0
, , 0
but CC 0
prostaglandin VBP 0
E2 NNP 0
concentrations NNS 0
remained VBD 0
unchanged JJ 0
. . 0

The DT 0
increase NN 0
in IN 0
plasma JJ 0
6-keto-prostaglandin JJ 0
F1 NNP 0
alpha NN 0
concentration NN 0
was VBD 0
associated VBN 0
with IN 0
an DT 0
increase NN 0
in IN 0
serum JJ 0
HDL2 NNP 0
cholesterol NN 0
concentration NN 0
in IN 0
the DT 0
group NN 0
taking VBG 0
regular JJ 0
exercise NN 0
. . 0

Our PRP$ 0
data NNS 0
suggest VBP 0
that IN 0
mild JJ 0
regular JJ 0
physical JJ 0
exercise NN 0
favourably RB 0
influences VBZ 0
cholesterol NN 0
distribution NN 0
in IN 0
serum NN 0
lipoproteins NNS 0
in IN 0
healthy JJ 0
middle NN 0
aged VBN 0
men NNS 0
and CC 0
may MD 0
have VB 0
beneficial JJ 0
effects NNS 0
on IN 0
circulating VBG 0
metabolites NNS 0
of IN 0
arachidonic JJ 0
acid NN 0
. . 0

Identifying VBG 0
patients NNS 0
at IN 0
high JJ 0
risk NN 0
for IN 0
neutropenic JJ 0
complications NNS 0
during IN 0
chemotherapy NN 0
for IN 0
metastatic JJ 0
breast NN 0
cancer NN 0
with IN 0
doxorubicin NN 0
or CC 0
pegylated VBN 0
liposomal JJ 0
doxorubicin NN 0
: : 0
the DT 0
development NN 0
of IN 0
a DT 0
prediction NN 0
model NN 0
. . 0

OBJECTIVE UH 0
To TO 0
develop VB 0
a DT 0
cycle-based JJ 0
risk NN 0
prediction NN 0
model NN 0
for IN 0
neutropenic JJ 0
complications NNS 0
( ( 0
NC NNP 0
) ) 0
during IN 0
chemotherapy NN 0
with IN 0
doxorubicin NN 0
( ( 0
DOX NNP 0
) ) 0
or CC 0
a DT 0
pegylated JJ 0
liposomal JJ 0
formulation NN 0
( ( 0
PLD NNP 0
) ) 0
for IN 0
patients NNS 0
with IN 0
metastatic JJ 0
breast NN 0
cancer NN 0
( ( 0
MBC NNP 0
) ) 0
. . 0

METHODS NNP 0
Data NNP 0
analyzed VBD 0
was VBD 0
from IN 0
a DT 0
phase NN 0
III NNP 0
, , 0
randomized VBD 0
clinical JJ 0
trial NN 0
of IN 0
DOX NNP 0
( ( 0
60 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
every DT 0
3 CD 0
weeks NNS 0
) ) 0
or CC 0
PLD NNP 0
( ( 0
50 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
every DT 0
4 CD 0
weeks NNS 0
) ) 0
for IN 0
the DT 0
first JJ 0
line NN 0
therapy NN 0
for IN 0
MBC NNP 0
( ( 0
n JJ 0
= NNP 0
509 CD 0
) ) 0
( ( 0
O'Brien NNP 0
et RB 0
al RB 0
, , 0
Ann NNP 0
Oncol NNP 0
. . 0

2004 CD 0
; : 0
15:440-449 JJ 0
) ) 0
. . 0

NC NNP 0
were VBD 0
defined VBN 0
as IN 0
an DT 0
absolute NN 0
neutrophil NN 0
count NN 0
< NNP 0
or CC 0
=1.5 NNP 0
x VBP 0
10 CD 0
( ( 0
9 CD 0
) ) 0
cells/L NN 0
( ( 0
ie JJ 0
, , 0
> JJ 0
or CC 0
=grade JJ 0
II NNP 0
) ) 0
before IN 0
the DT 0
next JJ 0
cycle NN 0
, , 0
febrile JJ 0
neutropenia NN 0
or CC 0
neutropenia NN 0
with IN 0
a DT 0
documented JJ 0
infection NN 0
. . 0

Patient NNP 0
and CC 0
hematologic JJ 0
factors NNS 0
potentially RB 0
associated VBN 0
with IN 0
NC NNP 0
were VBD 0
evaluated VBN 0
. . 0

Factors NNS 0
with IN 0
a DT 0
P NNP 0
value NN 0
of IN 0
< NNP 0
or CC 0
=0.25 NNP 0
within IN 0
a DT 0
cycle NN 0
were VBD 0
included VBN 0
in IN 0
a DT 0
generalized JJ 0
estimating NN 0
equations NNS 0
regression NN 0
model NN 0
. . 0

Using VBG 0
backward JJ 0
elimination NN 0
, , 0
we PRP 0
derived VBD 0
a DT 0
risk NN 0
scoring VBG 0
algorithm NN 0
( ( 0
range VB 0
0-63 NN 0
) ) 0
from IN 0
the DT 0
final JJ 0
reduced VBN 0
model NN 0
. . 0

RESULTS NNP 0
Risk NNP 0
factors NNS 0
retained VBD 0
in IN 0
the DT 0
model NN 0
included VBD 0
poor JJ 0
performance NN 0
status NN 0
, , 0
absolute VB 0
neutrophil JJ 0
count NN 0
< NN 0
or CC 0
=2.0 VB 0
x JJ 0
10 CD 0
( ( 0
9 CD 0
) ) 0
cells/L NN 0
in IN 0
the DT 0
previous JJ 0
cycle NN 0
, , 0
the DT 0
first JJ 0
cycle NN 0
of IN 0
chemotherapy NN 0
, , 0
DOX NNP 0
versus NN 0
PLD NNP 0
and CC 0
advanced JJ 0
age NN 0
. . 0

A DT 0
precycle NN 0
risk NN 0
score NN 0
from IN 0
> NN 0
or CC 0
=25 NN 0
to TO 0
< VB 0
40 CD 0
for IN 0
a DT 0
given VBN 0
patient NN 0
was VBD 0
identified VBN 0
as IN 0
being VBG 0
the DT 0
optimal JJ 0
threshold NN 0
for IN 0
sensitivity NN 0
( ( 0
58.0 CD 0
% NN 0
) ) 0
and CC 0
specificity NN 0
( ( 0
78.7 CD 0
% NN 0
) ) 0
. . 0

Patients NNS 0
with IN 0
a DT 0
score NN 0
at IN 0
or CC 0
beyond IN 0
this DT 0
threshold NN 0
would MD 0
be VB 0
considered VBN 0
at IN 0
high JJ 0
risk NN 0
for IN 0
developing VBG 0
NC NNP 0
in IN 0
later JJ 0
cycles NNS 0
. . 0

CONCLUSION NNP 0
The DT 0
use NN 0
of IN 0
this DT 0
model NN 0
may MD 0
enhance VB 0
patient NN 0
care NN 0
by IN 0
targeting VBG 0
preventative JJ 0
therapies NNS 0
( ( 0
eg NN 0
, , 0
granulocyte NN 0
colony NN 0
stimulating VBG 0
factor NN 0
or CC 0
PLD NNP 0
) ) 0
to TO 0
those DT 0
MBC NNP 0
patients NNS 0
most RBS 0
likely JJ 0
to TO 0
experience VB 0
NC NNP 0
during IN 0
anthracycline-based JJ 0
chemotherapy NN 0
. . 0

Assessment NN 0
of IN 0
acute JJ 0
bronchodilator NN 0
effects NNS 0
from IN 0
specific JJ 0
airway NN 0
resistance NN 0
changes NNS 0
in IN 0
stable JJ 0
COPD NNP 0
patients NNS 0
. . 0

BACKGROUND NNP 0
In IN 0
COPD NNP 0
patients NNS 0
, , 0
reversibility NN 0
is VBZ 0
currently RB 0
evaluated VBN 0
from IN 0
the DT 0
changes NNS 0
of IN 0
forced JJ 0
expiratory NN 0
volume NN 0
at IN 0
1s CD 0
( ( 0
?FEV1 NN 0
) ) 0
and CC 0
forced VBN 0
vital JJ 0
capacity NN 0
( ( 0
?FVC NNP 0
) ) 0
. . 0

By IN 0
lowering VBG 0
peripheral JJ 0
airway RB 0
smooth JJ 0
muscle NN 0
tone NN 0
, , 0
bronchodilators NNS 0
should MD 0
decrease VB 0
dynamic JJ 0
hyperinflation NN 0
, , 0
gas NN 0
trapping NN 0
, , 0
and CC 0
possibly RB 0
dyspnea VB 0
at IN 0
rest NN 0
. . 0

Hence NNP 0
, , 0
we PRP 0
hypothesize VBP 0
that IN 0
specific JJ 0
airway NN 0
resistance NN 0
changes NNS 0
( ( 0
?sRAW NN 0
) ) 0
should MD 0
better RBR 0
characterize VB 0
the DT 0
acute JJ 0
response NN 0
to TO 0
bronchodilators NNS 0
. . 0

METHODS NNP 0
On IN 0
two CD 0
days NNS 0
, , 0
60 CD 0
COPD NNP 0
patients NNS 0
underwent JJ 0
dyspnea JJ 0
evaluation NN 0
( ( 0
VAS NNP 0
score NN 0
) ) 0
and CC 0
pulmonary JJ 0
function NN 0
testing VBG 0
at IN 0
baseline NN 0
and CC 0
one CD 0
hour NN 0
after IN 0
placebo NN 0
or CC 0
300?g CD 0
indacaterol JJ 0
administration NN 0
. . 0

RESULTS NNP 0
Spirographic NNP 0
and CC 0
?sRAW-based JJ 0
criteria NNS 0
identified VBN 0
as IN 0
responders NNS 0
24 CD 0
and CC 0
45 CD 0
patients NNS 0
, , 0
respectively RB 0
. . 0

?sRAW NN 0
correlated VBD 0
with IN 0
changes NNS 0
of IN 0
intrathoracic NN 0
gas NN 0
volume NN 0
( ( 0
?ITGV NN 0
) ) 0
( ( 0
r=0.61 NN 0
; : 0
p CC 0
< VB 0
0.001 CD 0
) ) 0
, , 0
residual JJ 0
volume NN 0
( ( 0
?RV NN 0
) ) 0
( ( 0
r=0.60 NN 0
; : 0
p CC 0
< VB 0
0.001 CD 0
) ) 0
, , 0
?FVC NNP 0
( ( 0
r=0.44 NN 0
; : 0
p=0.001 NN 0
) ) 0
, , 0
and CC 0
?VAS NNP 0
( ( 0
r=0.73 NN 0
; : 0
p CC 0
< VB 0
0.001 CD 0
) ) 0
, , 0
while IN 0
?FEV1 NN 0
correlated VBD 0
only RB 0
with IN 0
?FVC NNP 0
( ( 0
r=0.34 NN 0
; : 0
p=0.008 NN 0
) ) 0
. . 0

Significant JJ 0
differences NNS 0
in IN 0
terms NNS 0
of IN 0
?ITGV NN 0
( ( 0
p=0.002 NN 0
) ) 0
, , 0
?RV NNP 0
( ( 0
p=0.023 NN 0
) ) 0
, , 0
and CC 0
?VAS NNP 0
( ( 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
occurred VBD 0
only RB 0
if IN 0
patients NNS 0
were VBD 0
stratified VBN 0
according VBG 0
to TO 0
?sRAW NNP 0
. . 0

CONCLUSIONS NNP 0
In IN 0
assessing VBG 0
the DT 0
acute JJ 0
functional JJ 0
effect NN 0
of IN 0
bronchodilators NNS 0
, , 0
?sRAW-based JJ 0
criterion NN 0
is VBZ 0
preferable JJ 0
to TO 0
FEV1-FVC-based JJ 0
criteria NNS 0
, , 0
being VBG 0
more RBR 0
closely RB 0
related VBN 0
to TO 0
bronchodilator-induced JJ 0
improvements NNS 0
of IN 0
lung NN 0
mechanics NNS 0
and CC 0
dyspnea NN 0
at IN 0
rest NN 0
. . 0

Effect NN 0
of IN 0
different JJ 0
rates NNS 0
of IN 0
infusion NN 0
of IN 0
propofol NN 0
for IN 0
induction NN 0
of IN 0
anaesthesia NN 0
in IN 0
elderly JJ 0
patients NNS 0
. . 0

The DT 0
effect NN 0
of IN 0
changing VBG 0
the DT 0
rate NN 0
of IN 0
infusion NN 0
of IN 0
propofol NN 0
for IN 0
induction NN 0
of IN 0
anaesthesia NN 0
was VBD 0
studied VBN 0
in IN 0
60 CD 0
elderly JJ 0
patients NNS 0
. . 0

Propofol NNP 0
was VBD 0
administered VBN 0
at IN 0
300 CD 0
, , 0
600 CD 0
or CC 0
1200 CD 0
ml JJ 0
h-1 JJ 0
until IN 0
loss NN 0
of IN 0
consciousness NN 0
( ( 0
as IN 0
judged VBN 0
by IN 0
loss NN 0
of IN 0
verbal JJ 0
contact NN 0
with IN 0
the DT 0
patient NN 0
) ) 0
had VBD 0
been VBN 0
achieved VBN 0
. . 0

The DT 0
duration NN 0
of IN 0
induction NN 0
was VBD 0
significantly RB 0
longer JJR 0
( ( 0
P NNP 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
with IN 0
the DT 0
slower JJR 0
infusion NN 0
rates NNS 0
( ( 0
104 CD 0
, , 0
68 CD 0
and CC 0
51 CD 0
s NN 0
) ) 0
, , 0
but CC 0
the DT 0
total JJ 0
dose NN 0
used VBN 0
was VBD 0
significantly RB 0
less JJR 0
( ( 0
P NNP 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
in IN 0
these DT 0
patients NNS 0
( ( 0
1.2 CD 0
, , 0
1.6 CD 0
and CC 0
2.5 CD 0
mg NN 0
kg-1 NN 0
, , 0
respectively RB 0
) ) 0
. . 0

The DT 0
decrease NN 0
in IN 0
systolic JJ 0
and CC 0
diastolic JJ 0
arterial JJ 0
pressure NN 0
was VBD 0
significantly RB 0
less RBR 0
in IN 0
the DT 0
300-ml JJ 0
h-1 JJ 0
group NN 0
at IN 0
the DT 0
end NN 0
of IN 0
induction NN 0
and CC 0
immediately RB 0
after IN 0
induction NN 0
( ( 0
P NNP 0
less JJR 0
than IN 0
0.01 CD 0
) ) 0
. . 0

The DT 0
incidence NN 0
of IN 0
apnoea NN 0
was VBD 0
also RB 0
significantly RB 0
less RBR 0
in IN 0
the DT 0
slower JJR 0
infusion NN 0
group NN 0
. . 0

Sedation NN 0
during IN 0
endoscopic NN 0
retrograde NN 0
cholangiopancreatography NN 0
: : 0
a DT 0
randomized NN 0
controlled VBN 0
study NN 0
of IN 0
patient-controlled JJ 0
propofol NN 0
sedation NN 0
and CC 0
that IN 0
given VBN 0
by IN 0
a DT 0
nurse JJ 0
anesthetist NN 0
. . 0

OBJECTIVE CC 0
Different JJ 0
regimens NNS 0
are VBP 0
used VBN 0
for IN 0
sedation NN 0
during IN 0
endoscopic NN 0
retrograde NN 0
cholangiopancreatography NN 0
( ( 0
ERCP NNP 0
) ) 0
. . 0

Our PRP$ 0
objectives NNS 0
were VBD 0
to TO 0
compare VB 0
safety NN 0
, , 0
ease NN 0
of IN 0
treatment NN 0
, , 0
recovery NN 0
, , 0
and CC 0
patients NNS 0
' POS 0
experiences NNS 0
using VBG 0
patient-controlled JJ 0
sedation NN 0
( ( 0
PCS NNP 0
) ) 0
with IN 0
propofol NN 0
, , 0
nurse JJ 0
anesthetist-controlled JJ 0
sedation NN 0
( ( 0
ACS NNP 0
) ) 0
, , 0
or CC 0
the DT 0
department NN 0
's POS 0
standard NN 0
of IN 0
care NN 0
, , 0
midazolam VB 0
given VBN 0
by IN 0
the DT 0
procedure NN 0
team NN 0
( ( 0
control VB 0
group NN 0
) ) 0
. . 0

MATERIAL NNP 0
AND CC 0
METHODS NNP 0
The DT 0
study NN 0
included VBD 0
281 CD 0
adults NNS 0
in IN 0
301 CD 0
procedures NNS 0
. . 0

The DT 0
PCS NNP 0
group NN 0
( ( 0
n JJ 0
= NNP 0
101 CD 0
) ) 0
delivered VBN 0
bolus JJ 0
doses NNS 0
of IN 0
5 CD 0
mg NN 0
of IN 0
propofol NN 0
according VBG 0
to TO 0
their PRP$ 0
need NN 0
for IN 0
sedation NN 0
. . 0

The DT 0
ACS NNP 0
group NN 0
( ( 0
n JJ 0
= NNP 0
100 CD 0
) ) 0
had VBD 0
2-8 JJ 0
mg/kg/h NN 0
of IN 0
propofol NN 0
infused VBN 0
, , 0
with IN 0
the DT 0
target NN 0
for IN 0
sedation NN 0
being VBG 0
level JJ 0
3 CD 0
of IN 0
the DT 0
Observer NNP 0
's POS 0
Assessment NNP 0
of IN 0
Alertness/Sedation NNP 0
( ( 0
OAA/S NNP 0
) ) 0
scale NN 0
. . 0

The DT 0
control NN 0
group NN 0
was VBD 0
given VBN 0
2-3 JJ 0
mg NN 0
of IN 0
midazolam NN 0
for IN 0
induction NN 0
and CC 0
additional JJ 0
1 CD 0
mg NN 0
if IN 0
required VBN 0
. . 0

RESULTS NNP 0
PCS NNP 0
and CC 0
ACS NNP 0
increased VBD 0
the DT 0
ease NN 0
of IN 0
the DT 0
procedure NN 0
and CC 0
reduced VBD 0
the DT 0
number NN 0
of IN 0
sedation NN 0
failures NNS 0
compared VBN 0
to TO 0
midazolam VB 0
sedation NN 0
( ( 0
ACS NNP 0
n RB 0
= VBZ 0
0 CD 0
; : 0
PCS NNP 0
n VBD 0
= JJ 0
4 CD 0
; : 0
midazolam NN 0
n IN 0
= $ 0
20 CD 0
) ) 0
. . 0

The DT 0
ACS NNP 0
group NN 0
had VBD 0
more RBR 0
deeply RB 0
sedated JJ 0
patients NNS 0
( ( 0
OAA/S NNP 0
level RB 0
2 CD 0
) ) 0
, , 0
desaturation NN 0
, , 0
and CC 0
obstructed VBD 0
airways NNS 0
than IN 0
the DT 0
PCS NNP 0
and CC 0
midazolam NN 0
groups NNS 0
. . 0

Time NN 0
to TO 0
full JJ 0
recovery NN 0
( ( 0
Aldrete NNP 0
score RB 0
?9 VBD 0
) ) 0
was VBD 0
shortest JJS 0
following VBG 0
PCS NNP 0
. . 0

PCS NNP 0
resulted VBD 0
in IN 0
the DT 0
least JJS 0
fatigue NN 0
and CC 0
pain NN 0
after IN 0
the DT 0
procedure NN 0
. . 0

Patients NNS 0
' POS 0
preference NN 0
for IN 0
PCS NNP 0
and CC 0
ACS NNP 0
was VBD 0
the DT 0
same JJ 0
. . 0

CONCLUSION NNP 0
PCS NNP 0
with IN 0
propofol NN 0
is VBZ 0
superior JJ 0
to TO 0
midazolam VB 0
and CC 0
comparable VB 0
to TO 0
ACS NNP 0
. . 0

PCS NNP 0
resulted VBD 0
in IN 0
a DT 0
rapid JJ 0
recovery NN 0
, , 0
fewer JJR 0
respiratory NN 0
events NNS 0
, , 0
and CC 0
was VBD 0
almost RB 0
as RB 0
effective JJ 0
as IN 0
ACS NNP 0
in IN 0
ensuring VBG 0
a DT 0
successful JJ 0
examination NN 0
. . 0

Randomized VBN 0
phase NN 0
II NNP 0
study NN 0
of IN 0
two CD 0
different JJ 0
schedules NNS 0
of IN 0
gemcitabine NN 0
and CC 0
oral JJ 0
S-1 NNP 0
in IN 0
chemo-na?ve JJ 0
patients NNS 0
with IN 0
advanced JJ 0
non-small JJ 0
cell NN 0
lung NN 0
cancer NN 0
. . 0

INTRODUCTION NNP 0
This DT 0
study NN 0
was VBD 0
conducted VBN 0
to TO 0
evaluate VB 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
and CC 0
to TO 0
compare VB 0
dosing VBG 0
schedules NNS 0
of IN 0
gemcitabine NN 0
combined VBN 0
with IN 0
S-1 NNP 0
in IN 0
chemo-na?ve JJ 0
non-small JJ 0
cell NN 0
lung NN 0
cancer NN 0
patients NNS 0
. . 0

METHODS NNP 0
Patients NNPS 0
with IN 0
chemo-na?ve JJ 0
stage NN 0
IIIB/IV NNP 0
non-small NN 0
cell NN 0
lung NN 0
cancer NN 0
were VBD 0
randomized VBN 0
into IN 0
two CD 0
treatment NN 0
arms NNS 0
. . 0

Patients NNS 0
were VBD 0
given VBN 0
oral JJ 0
S-1 NNP 0
( ( 0
60 CD 0
mg/m/d NN 0
, , 0
twice RB 0
a DT 0
day NN 0
) ) 0
from IN 0
days NNS 0
1 CD 0
to TO 0
14 CD 0
with IN 0
gemcitabine NN 0
( ( 0
1000 CD 0
mg/m/d NN 0
) ) 0
on IN 0
days NNS 0
1 CD 0
and CC 0
8 CD 0
( ( 0
arm VB 0
A NNP 0
) ) 0
or CC 0
on IN 0
days NNS 0
8 CD 0
and CC 0
15 CD 0
( ( 0
arm NN 0
B NNP 0
) ) 0
. . 0

This DT 0
cycle NN 0
was VBD 0
repeated VBN 0
every DT 0
21 CD 0
days NNS 0
. . 0

RESULTS VB 0
A DT 0
total NN 0
of IN 0
80 CD 0
patients NNS 0
were VBD 0
entered VBN 0
in IN 0
this DT 0
trial NN 0
. . 0

The DT 0
primary JJ 0
end NN 0
point NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
response NN 0
rate NN 0
. . 0

The DT 0
response NN 0
rates NNS 0
of IN 0
arm NN 0
A NNP 0
and CC 0
arm NN 0
B NNP 0
were VBD 0
22.0 CD 0
and CC 0
28.9 CD 0
% NN 0
, , 0
respectively RB 0
( ( 0
p JJ 0
= NNP 0
0.606 CD 0
) ) 0
. . 0

Median JJ 0
time NN 0
to TO 0
treatment NN 0
failure NN 0
in IN 0
arm NN 0
A NN 0
was VBD 0
3.6 CD 0
months NNS 0
and CC 0
4.8 CD 0
months NNS 0
in IN 0
arm NN 0
B NNP 0
. . 0

Median JJ 0
time NN 0
to TO 0
progression NN 0
in IN 0
arm NN 0
A NN 0
was VBD 0
4.1 CD 0
months NNS 0
and CC 0
5.5 CD 0
months NNS 0
in IN 0
arm NN 0
B NNP 0
. . 0

Median JJ 0
survival JJ 0
time NN 0
in IN 0
arm NN 0
A NN 0
and CC 0
arm NN 0
B NNP 0
was VBD 0
15.5 CD 0
months NNS 0
and CC 0
18.8 CD 0
months NNS 0
, , 0
respectively RB 0
. . 0

The DT 0
toxicity NN 0
profile NN 0
was VBD 0
relatively RB 0
mild JJ 0
and CC 0
did VBD 0
not RB 0
differ VB 0
very RB 0
much RB 0
between IN 0
two CD 0
arms NNS 0
. . 0

CONCLUSION VB 0
The DT 0
combination NN 0
of IN 0
gemcitabine NN 0
and CC 0
S-1 NNP 0
was VBD 0
determined VBN 0
to TO 0
be VB 0
feasible JJ 0
and CC 0
effective JJ 0
for IN 0
advanced JJ 0
non-small JJ 0
cell NN 0
lung NN 0
cancer NN 0
. . 0

We PRP 0
selected VBD 0
arm NN 0
B NNP 0
for IN 0
further JJ 0
studies NNS 0
because IN 0
of IN 0
its PRP$ 0
higher JJR 0
response NN 0
rate NN 0
and CC 0
survival NN 0
data NNS 0
. . 0

Visual JJ 0
and CC 0
kinesthetic JJ 0
locomotor NN 0
imagery NN 0
training NN 0
integrated VBN 0
with IN 0
auditory JJ 0
step NN 0
rhythm NN 0
for IN 0
walking VBG 0
performance NN 0
of IN 0
patients NNS 0
with IN 0
chronic JJ 0
stroke NN 0
. . 0

OBJECTIVE UH 0
To TO 0
compare VB 0
the DT 0
effect NN 0
of IN 0
visual JJ 0
and CC 0
kinesthetic JJ 0
locomotor NN 0
imagery NN 0
training NN 0
on IN 0
walking VBG 0
performance NN 0
and CC 0
to TO 0
determine VB 0
the DT 0
clinical JJ 0
feasibility NN 0
of IN 0
incorporating VBG 0
auditory JJ 0
step NN 0
rhythm NN 0
into IN 0
the DT 0
training NN 0
. . 0

DESIGN NNP 0
Randomized NNP 0
crossover NN 0
trial NN 0
. . 0

SETTING NNP 0
Laboratory NNP 0
of IN 0
a DT 0
Department NNP 0
of IN 0
Physical NNP 0
Therapy NNP 0
. . 0

SUBJECTS NNP 0
Fifteen NNP 0
subjects VBZ 0
with IN 0
post-stroke JJ 0
hemiparesis NN 0
. . 0

INTERVENTION NNP 0
Four NNP 0
locomotor NN 0
imagery NN 0
trainings NNS 0
on IN 0
walking VBG 0
performance NN 0
: : 0
visual JJ 0
locomotor NN 0
imagery NN 0
training NN 0
, , 0
kinesthetic JJ 0
locomotor NN 0
imagery NN 0
training NN 0
, , 0
visual JJ 0
locomotor NN 0
imagery NN 0
training NN 0
with IN 0
auditory JJ 0
step NN 0
rhythm NN 0
and CC 0
kinesthetic JJ 0
locomotor NN 0
imagery NN 0
training NN 0
with IN 0
auditory JJ 0
step NN 0
rhythm NN 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURES NNP 0
The DT 0
timed JJ 0
up-and-go JJ 0
test NN 0
and CC 0
electromyographic JJ 0
and CC 0
kinematic JJ 0
analyses NNS 0
of IN 0
the DT 0
affected JJ 0
lower JJR 0
limb NN 0
during IN 0
one CD 0
gait NN 0
cycle NN 0
. . 0

RESULTS NNP 0
After IN 0
the DT 0
interventions NNS 0
, , 0
significant JJ 0
differences NNS 0
were VBD 0
found VBN 0
in IN 0
the DT 0
timed JJ 0
up-and-go JJ 0
test NN 0
results NNS 0
between IN 0
the DT 0
visual JJ 0
locomotor NN 0
imagery NN 0
training NN 0
( ( 0
25.69 CD 0
? . 0
16.16 CD 0
to TO 0
23.97 CD 0
? . 0
14.30 CD 0
) ) 0
and CC 0
the DT 0
kinesthetic JJ 0
locomotor NN 0
imagery NN 0
training NN 0
with IN 0
auditory JJ 0
step NN 0
rhythm NN 0
( ( 0
22.68 CD 0
? . 0
12.35 CD 0
to TO 0
15.77 CD 0
? . 0
8.58 CD 0
) ) 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

During IN 0
the DT 0
swing NN 0
and CC 0
stance NN 0
phases NNS 0
, , 0
the DT 0
kinesthetic JJ 0
locomotor NN 0
imagery NN 0
training NN 0
exhibited VBN 0
significantly RB 0
increased VBN 0
activation NN 0
in IN 0
a DT 0
greater JJR 0
number NN 0
of IN 0
muscles NNS 0
and CC 0
increased VBD 0
angular JJ 0
displacement NN 0
of IN 0
the DT 0
knee NN 0
and CC 0
ankle NN 0
joints NNS 0
compared VBN 0
with IN 0
the DT 0
visual JJ 0
locomotor NN 0
imagery NN 0
training NN 0
, , 0
and CC 0
these DT 0
effects NNS 0
were VBD 0
more RBR 0
prominent JJ 0
when WRB 0
auditory JJ 0
step NN 0
rhythm NN 0
was VBD 0
integrated VBN 0
into IN 0
each DT 0
form NN 0
of IN 0
locomotor NN 0
imagery NN 0
training NN 0
. . 0

The DT 0
activation NN 0
of IN 0
the DT 0
hamstring NN 0
during IN 0
the DT 0
swing JJ 0
phase NN 0
and CC 0
the DT 0
gastrocnemius NN 0
during IN 0
the DT 0
stance NN 0
phase NN 0
, , 0
as RB 0
well RB 0
as IN 0
kinematic JJ 0
data NNS 0
of IN 0
the DT 0
knee NN 0
joint NN 0
, , 0
were VBD 0
significantly RB 0
different JJ 0
for IN 0
posttest JJS 0
values NNS 0
between IN 0
the DT 0
visual JJ 0
locomotor NN 0
imagery NN 0
training NN 0
and CC 0
the DT 0
kinesthetic JJ 0
locomotor NN 0
imagery NN 0
training NN 0
with IN 0
auditory JJ 0
step NN 0
rhythm NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

CONCLUSIONS VB 0
The DT 0
therapeutic JJ 0
effect NN 0
may MD 0
be VB 0
further RB 0
enhanced VBN 0
in IN 0
the DT 0
kinesthetic JJ 0
locomotor NN 0
imagery NN 0
training NN 0
than IN 0
in IN 0
the DT 0
visual JJ 0
locomotor NN 0
imagery NN 0
training NN 0
. . 0

The DT 0
auditory JJ 0
step NN 0
rhythm VBZ 0
together RB 0
with IN 0
the DT 0
locomotor NN 0
imagery NN 0
training NN 0
produces VBZ 0
a DT 0
greater JJR 0
positive JJ 0
effect NN 0
in IN 0
improving VBG 0
the DT 0
walking VBG 0
performance NN 0
of IN 0
patients NNS 0
with IN 0
post-stroke JJ 0
hemiparesis NN 0
. . 0

An DT 0
open-label JJ 0
extension NN 0
study NN 0
of IN 0
the DT 0
safety NN 0
and CC 0
efficacy NN 0
of IN 0
risperidone NN 0
in IN 0
children NNS 0
and CC 0
adolescents NNS 0
with IN 0
autistic JJ 0
disorder NN 0
. . 0

OBJECTIVE CC 0
The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
evaluate VB 0
the DT 0
long-term JJ 0
safety NN 0
and CC 0
efficacy NN 0
of IN 0
risperidone NN 0
in IN 0
treating VBG 0
irritability NN 0
and CC 0
related JJ 0
behaviors NNS 0
in IN 0
children NNS 0
and CC 0
adolescents NNS 0
with IN 0
autistic JJ 0
disorders NNS 0
. . 0

METHODS NNP 0
In IN 0
this DT 0
6 CD 0
month NN 0
( ( 0
26 CD 0
week NN 0
) ) 0
open-label NN 0
extension NN 0
( ( 0
OLE NNP 0
) ) 0
study NN 0
, , 0
patients NNS 0
( ( 0
5-17 JJ 0
years NNS 0
of IN 0
age NN 0
, , 0
who WP 0
completed VBD 0
the DT 0
previous JJ 0
fixed-dose JJ 0
, , 0
6 CD 0
week NN 0
, , 0
double-blind JJ 0
[ NNP 0
DB NNP 0
] NNP 0
phase NN 0
) ) 0
were VBD 0
flexibly RB 0
dosed VBN 0
with IN 0
risperidone NN 0
based VBN 0
on IN 0
body NN 0
weight NN 0
. . 0

The DT 0
maximum JJ 0
allowed VBD 0
dose NN 0
was VBD 0
1.25 CD 0
mg/day NN 0
for IN 0
those DT 0
weighing VBG 0
20 CD 0
to TO 0
< VB 0
45 CD 0
kg NN 0
, , 0
and CC 0
1.75 CD 0
mg/day NN 0
for IN 0
those DT 0
weighing VBG 0
? . 0
45 CD 0
kg NN 0
. . 0

The DT 0
study NN 0
primarily RB 0
assessed VBD 0
risperidone NN 0
's POS 0
safety NN 0
; : 0
efficacy NN 0
was VBD 0
assessed VBN 0
as IN 0
a DT 0
secondary JJ 0
end-point NN 0
. . 0

RESULTS VB 0
Fifty-six NNP 0
( ( 0
71 CD 0
% NN 0
) ) 0
out IN 0
of IN 0
79 CD 0
enrolled JJ 0
patients NNS 0
completed VBD 0
the DT 0
OLE NNP 0
; : 0
the DT 0
most RBS 0
common JJ 0
discontinuations NNS 0
were VBD 0
for IN 0
insufficient JJ 0
response NN 0
( ( 0
7 CD 0
[ RB 0
9 CD 0
% NN 0
] NN 0
) ) 0
or CC 0
adverse JJ 0
events NNS 0
( ( 0
AE NNP 0
) ) 0
( ( 0
5 CD 0
[ RB 0
6 CD 0
% NN 0
] NN 0
) ) 0
. . 0

The DT 0
most RBS 0
common JJ 0
( ( 0
? . 0
5 CD 0
% NN 0
frequency NN 0
in IN 0
the DT 0
total JJ 0
group NN 0
) ) 0
AEs NNP 0
were VBD 0
increased VBN 0
appetite RB 0
( ( 0
11 CD 0
% NN 0
[ JJ 0
n=9 JJ 0
] NN 0
) ) 0
; : 0
increased VBN 0
weight NN 0
and CC 0
vomiting NN 0
( ( 0
9 CD 0
% NN 0
[ JJ 0
n=7 JJ 0
] NNP 0
each DT 0
) ) 0
; : 0
sedation NN 0
, , 0
pyrexia NN 0
, , 0
and CC 0
upper JJ 0
respiratory NN 0
tract NN 0
infection NN 0
( ( 0
8 CD 0
% NN 0
[ JJ 0
n=6 JJ 0
] NNP 0
each DT 0
) ) 0
; : 0
nasopharyngitis NN 0
( ( 0
6 CD 0
% NN 0
[ JJ 0
n=5 JJ 0
] NN 0
) ) 0
; : 0
and CC 0
somnolence NN 0
and CC 0
fatigue NN 0
( ( 0
5 CD 0
% NN 0
[ JJ 0
n=4 JJ 0
] NNP 0
each DT 0
) ) 0
. . 0

Extrapyramidal JJ 0
AEs NNP 0
were VBD 0
reported VBN 0
in IN 0
6 CD 0
( ( 0
8 CD 0
% NN 0
) ) 0
patients NNS 0
. . 0

Increase NNP 0
in IN 0
mean JJ 0
weight NN 0
( ( 0
11-15 CD 0
% NN 0
) ) 0
and CC 0
body NN 0
mass NN 0
index NN 0
( ( 0
5-10 CD 0
% NN 0
) ) 0
occurred VBD 0
; : 0
one CD 0
patient NN 0
discontinued VBN 0
because IN 0
of IN 0
weight JJ 0
increase NN 0
. . 0

One CD 0
potentially RB 0
prolactin-related JJ 0
AE NNP 0
( ( 0
irregular JJ 0
menstruation NN 0
) ) 0
was VBD 0
reported VBN 0
. . 0

The DT 0
risperidone NN 0
high-dose JJ 0
group NN 0
had VBD 0
the DT 0
greatest JJS 0
mean JJ 0
improvement NN 0
in IN 0
sleep JJ 0
visual JJ 0
analog NN 0
scale NN 0
( ( 0
24.6 CD 0
) ) 0
. . 0

All DT 0
groups NNS 0
showed VBD 0
additional JJ 0
improvement NN 0
in IN 0
efficacy NN 0
scale JJ 0
scores NNS 0
during IN 0
the DT 0
OLE NNP 0
. . 0

CONCLUSIONS NNP 0
During IN 0
this DT 0
OLE NNP 0
, , 0
safety NN 0
findings NNS 0
with IN 0
risperidone NN 0
treatment NN 0
( ( 0
maximum JJ 0
weight-based JJ 0
dose NN 0
of IN 0
1.25 CD 0
mg/day NN 0
or CC 0
1.75 CD 0
mg/day NN 0
) ) 0
were VBD 0
consistent JJ 0
with IN 0
those DT 0
observed VBN 0
in IN 0
the DT 0
DB NNP 0
phase NN 0
, , 0
and CC 0
with IN 0
the DT 0
current JJ 0
safety NN 0
information NN 0
for IN 0
risperidone NN 0
in IN 0
autistic JJ 0
, , 0
psychiatric JJ 0
, , 0
and CC 0
behavioral JJ 0
disorders NNS 0
. . 0

Patients NNS 0
experienced VBD 0
some DT 0
additional JJ 0
improvement NN 0
in IN 0
irritability NN 0
and CC 0
related JJ 0
behaviors NNS 0
. . 0

CLINICAL JJ 0
TRIALS NNP 0
REGISTRY NNP 0
This DT 0
phase-4 JJ 0
study NN 0
is VBZ 0
registered VBN 0
at IN 0
ClinicalTrials.gov NNP 0
( ( 0
NCT00576732 NNP 0
) ) 0
. . 0

The DT 0
effects NNS 0
of IN 0
preoperative JJ 0
oral JJ 0
pregabalin NN 0
and CC 0
perioperative JJ 0
intravenous JJ 0
lidocaine NN 0
infusion NN 0
on IN 0
postoperative JJ 0
morphine NN 0
requirement NN 0
in IN 0
patients NNS 0
undergoing VBG 0
laparatomy NN 0
. . 0

OBJECTIVES NNP 0
To TO 0
evaluate VB 0
and CC 0
compare VB 0
the DT 0
effects NNS 0
of IN 0
preoperative JJ 0
oral JJ 0
pregabalin NN 0
and CC 0
perioperative JJ 0
intravenous JJ 0
lidocaine NN 0
infusion NN 0
on IN 0
postoperative JJ 0
morphine NN 0
requirement NN 0
, , 0
adverse JJ 0
effects NNS 0
, , 0
patients NNS 0
' POS 0
satisfaction NN 0
, , 0
mobilization NN 0
, , 0
time NN 0
to TO 0
first JJ 0
defecation NN 0
and CC 0
time NN 0
to TO 0
discharge VB 0
in IN 0
patients NNS 0
undergoing VBG 0
laparotomy NN 0
. . 0

METHODS NNP 0
Eighty NNP 0
patients NNS 0
( ( 0
18 CD 0
to TO 0
65 CD 0
years NNS 0
of IN 0
age NN 0
) ) 0
undergoing VBG 0
elective JJ 0
laparotomy NN 0
were VBD 0
randomly RB 0
divided VBN 0
into IN 0
four CD 0
groups NNS 0
( ( 0
n=20 JJ 0
in IN 0
each DT 0
group NN 0
) ) 0
: : 0
group NN 0
C NNP 0
, , 0
placebo NN 0
capsules NNS 0
and CC 0
normal JJ 0
saline JJ 0
infusion NN 0
perioperatively RB 0
( ( 0
control NN 0
) ) 0
; : 0
group NN 0
L NNP 0
, , 0
placebo NN 0
capsules NNS 0
and CC 0
lidocaine JJ 0
1 CD 0
mg?kg RB 0
intravenous JJ 0
bolus NN 0
dose NN 0
followed VBN 0
by IN 0
2 CD 0
mg?kg?h JJ 0
infusion NN 0
until IN 0
skin JJ 0
closure NN 0
; : 0
group NN 0
P NNP 0
, , 0
150 CD 0
mg JJ 0
oral JJ 0
pregabalin NN 0
and CC 0
normal JJ 0
saline JJ 0
infusion NN 0
perioperatively RB 0
; : 0
and CC 0
group NN 0
PL NNP 0
, , 0
150 CD 0
& CC 0
nbsp NN 0
; : 0
mg CC 0
oral JJ 0
pregabalin NN 0
and CC 0
lidocaine NN 0
2 CD 0
mg?kg?h NN 0
infusion NN 0
until IN 0
skin JJ 0
closure NN 0
. . 0

Hemodynamic NNP 0
parameters NNS 0
, , 0
visual JJ 0
analogue NN 0
scale NN 0
( ( 0
VAS NNP 0
) ) 0
scores VBZ 0
, , 0
analgesic JJ 0
consumption NN 0
, , 0
side NN 0
effects NNS 0
, , 0
time NN 0
to TO 0
mobilization VB 0
, , 0
time NN 0
to TO 0
first JJ 0
defecation NN 0
, , 0
time NN 0
to TO 0
discharge VB 0
and CC 0
patients NNS 0
' POS 0
satisfaction NN 0
were VBD 0
recorded VBN 0
. . 0

RESULTS NNP 0
VAS NNP 0
scores NNS 0
of IN 0
group NN 0
L NNP 0
, , 0
group NN 0
P NNP 0
and CC 0
group NN 0
PL NNP 0
were VBD 0
lower JJR 0
than IN 0
group NN 0
C NNP 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

Morphine NNP 0
consumption NN 0
of IN 0
group NN 0
P NNP 0
and CC 0
group NN 0
PL NNP 0
was VBD 0
lower JJR 0
than IN 0
group NN 0
C NNP 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

Incidence NN 0
of IN 0
nausea NN 0
in IN 0
group NN 0
C NNP 0
was VBD 0
higher JJR 0
than IN 0
group NN 0
L NNP 0
and CC 0
group NN 0
PL NNP 0
. . 0

Time NNP 0
to TO 0
first VB 0
defecation NN 0
and CC 0
mobilization NN 0
were VBD 0
shorter JJR 0
in IN 0
group NN 0
L NNP 0
and CC 0
group NN 0
PL NNP 0
compared VBN 0
with IN 0
group NN 0
C NNP 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
Preoperative NNP 0
oral JJ 0
pregabalin NN 0
and CC 0
perioperative JJ 0
intravenous JJ 0
lidocaine NN 0
infusion NN 0
decreased VBD 0
postoperative JJ 0
VAS NNP 0
scores NNS 0
. . 0

Preoperative JJ 0
oral JJ 0
pregabalin NN 0
decreased VBD 0
morphine JJ 0
requirement NN 0
and CC 0
perioperative JJ 0
intravenous JJ 0
lidocaine NN 0
infusion NN 0
hastened VBD 0
gastrointestinal JJ 0
motility NN 0
and CC 0
mobilization NN 0
, , 0
and CC 0
decreased VBD 0
the DT 0
incidence NN 0
of IN 0
nausea NN 0
in IN 0
patients NNS 0
undergoing VBG 0
laparotomy NN 0
. . 0

Therefore RB 0
, , 0
preoperative JJ 0
pregabalin NN 0
with IN 0
or CC 0
without IN 0
lidocaine JJ 0
provides VBZ 0
superior JJ 0
pain NN 0
relief NN 0
in IN 0
patients NNS 0
undergoing VBG 0
laparatomy NN 0
. . 0

[ RB 0
Clinical NNP 0
study NN 0
on IN 0
treatment NN 0
of IN 0
endometriosis-related JJ 0
infertility NN 0
patients NNS 0
by IN 0
laparoscopic NN 0
surgery NN 0
in IN 0
combination NN 0
of IN 0
quyu JJ 0
jiedu NN 0
recipe NN 0
] NNP 0
. . 0

OBJECTIVE NNP 0
To TO 0
study VB 0
the DT 0
clinical JJ 0
efficacy NN 0
of IN 0
the DT 0
laparoscopic NN 0
surgery NN 0
in IN 0
combination NN 0
of IN 0
Quyu NNP 0
Jiedu NNP 0
Recipe NNP 0
( ( 0
QYJDR NNP 0
) ) 0
on IN 0
endometriosis NN 0
( ( 0
EMs NNP 0
) ) 0
-related VBD 0
infertility NN 0
patients NNS 0
. . 0

METHODS NNP 0
130 CD 0
EMs-related JJ 0
infertility NN 0
patients NNS 0
of IN 0
blood NN 0
stasis NN 0
and CC 0
toxin NN 0
accumulation NN 0
syndrome NN 0
diagnosed VBD 0
and CC 0
treated VBN 0
by IN 0
laparoscopic NN 0
surgery NN 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
two CD 0
groups NNS 0
, , 0
i.e. FW 0
, , 0
the DT 0
test NN 0
group NN 0
( ( 0
75 CD 0
cases NNS 0
) ) 0
and CC 0
the DT 0
control NN 0
group NN 0
( ( 0
55 CD 0
cases NNS 0
) ) 0
. . 0

All DT 0
patients NNS 0
received VBD 0
routine JJ 0
progesterone NN 0
treatment NN 0
after IN 0
laparoscopic NN 0
surgery NN 0
. . 0

QYJDR NNP 0
was VBD 0
given VBN 0
to TO 0
patients NNS 0
in IN 0
the DT 0
test NN 0
group NN 0
after IN 0
laparoscopic NN 0
surgery NN 0
, , 0
lasting VBG 0
for IN 0
twelve JJ 0
months NNS 0
. . 0

The DT 0
pregnancy NN 0
rate NN 0
within IN 0
one CD 0
year NN 0
after IN 0
laparoscopic NN 0
surgery NN 0
were VBD 0
compared VBN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
. . 0

The DT 0
Chinese JJ 0
medicine NN 0
syndrome NN 0
integrals NNS 0
, , 0
serum JJ 0
endometrium NN 0
antibody NN 0
( ( 0
EMAb NNP 0
) ) 0
and CC 0
cancer NN 0
antigen NN 0
125 CD 0
( ( 0
CA125 NNP 0
) ) 0
levels NNS 0
were VBD 0
compared VBN 0
between IN 0
before RB 0
drug NN 0
therapy NN 0
and CC 0
three CD 0
months NNS 0
after IN 0
drug NN 0
therapy NN 0
. . 0

RESULTS VB 0
The DT 0
pregnancy NN 0
rate NN 0
within IN 0
one CD 0
year NN 0
after IN 0
laparoscopic NN 0
surgery NN 0
was VBD 0
higher RBR 0
in IN 0
the DT 0
test NN 0
group NN 0
than IN 0
in IN 0
the DT 0
control NN 0
group NN 0
[ VBD 0
61.33 CD 0
% NN 0
( ( 0
46/75 CD 0
) ) 0
vs FW 0
45.45 CD 0
% NN 0
( ( 0
25/55 CD 0
) ) 0
] NN 0
, , 0
showing VBG 0
significant JJ 0
difference NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

The DT 0
Chinese JJ 0
medicine NN 0
syndrome JJ 0
integral NN 0
was VBD 0
( ( 0
16.07 CD 0
+/- JJ 0
6.77 CD 0
) ) 0
score NN 0
and CC 0
( ( 0
7.25 CD 0
+/- JJ 0
3.27 CD 0
) ) 0
score NN 0
before IN 0
and CC 0
3 CD 0
months NNS 0
after IN 0
drug NN 0
therapy NN 0
in IN 0
the DT 0
test NN 0
group NN 0
, , 0
while IN 0
it PRP 0
was VBD 0
( ( 0
15.92 CD 0
+/- JJ 0
7.51 CD 0
) ) 0
score NN 0
and CC 0
( ( 0
12.73 CD 0
+/- JJ 0
6.12 CD 0
) ) 0
score NN 0
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

The DT 0
Chinese JJ 0
medicine NN 0
syndrome JJ 0
integral JJ 0
after IN 0
drug NN 0
therapy NN 0
was VBD 0
lower JJR 0
than IN 0
that DT 0
before IN 0
drug NN 0
therapy NN 0
in IN 0
the DT 0
same JJ 0
group NN 0
. . 0

Besides IN 0
, , 0
the DT 0
integral JJ 0
difference NN 0
between IN 0
before IN 0
and CC 0
after IN 0
drug NN 0
therapy NN 0
was VBD 0
higher RBR 0
in IN 0
the DT 0
test NN 0
group NN 0
than IN 0
in IN 0
the DT 0
control NN 0
group NN 0
[ NNP 0
( ( 0
9.12 CD 0
+/- JJ 0
6.16 CD 0
) ) 0
score NN 0
vs NN 0
( ( 0
3.48 CD 0
+/- JJ 0
2.06 CD 0
) ) 0
score NN 0
) ) 0
] NN 0
, , 0
showing VBG 0
statistical JJ 0
difference NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

After IN 0
three-month JJ 0
drug NN 0
therapy NN 0
, , 0
the DT 0
serum NN 0
EMAb NNP 0
negative JJ 0
conversion NN 0
rate NN 0
was VBD 0
obviously RB 0
higher JJR 0
in IN 0
the DT 0
test NN 0
group NN 0
than IN 0
in IN 0
the DT 0
control NN 0
group NN 0
( ( 0
44.44 CD 0
% NN 0
vs JJ 0
15.62 CD 0
% NN 0
) ) 0
, , 0
showing VBG 0
statistical JJ 0
difference NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

The DT 0
serum NN 0
CA125 NNP 0
level NN 0
was VBD 0
( ( 0
31.88 CD 0
+/- JJ 0
15.78 CD 0
) ) 0
U/mL NNP 0
before IN 0
drug NN 0
therapy NN 0
and CC 0
( ( 0
18.82 CD 0
+/- JJ 0
10.08 CD 0
) ) 0
U/mL NNP 0
three CD 0
months NNS 0
after IN 0
drug NN 0
therapy NN 0
in IN 0
the DT 0
test NN 0
group NN 0
, , 0
while IN 0
it PRP 0
was VBD 0
( ( 0
30.63 CD 0
+/- JJ 0
19.28 CD 0
) ) 0
U/mL NN 0
and CC 0
( ( 0
18.05 CD 0
+/- JJ 0
11.20 CD 0
) ) 0
U/mL NNP 0
respectively RB 0
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

It PRP 0
was VBD 0
lowered VBN 0
after IN 0
drug NN 0
therapy NN 0
in IN 0
the DT 0
two CD 0
groups NNS 0
with IN 0
statistical JJ 0
difference NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

There EX 0
was VBD 0
no DT 0
statistical JJ 0
difference NN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
after IN 0
drug NN 0
therapy NN 0
( ( 0
P NNP 0
> NNP 0
0.05 CD 0
) ) 0
. . 0

CONCLUSIONS VB 0
The DT 0
laparoscopic NN 0
surgery NN 0
in IN 0
combination NN 0
of IN 0
QYJDR NNP 0
could MD 0
effectively RB 0
improve VB 0
clinical JJ 0
symptoms NNS 0
of IN 0
EMs NNP 0
patients NNS 0
of IN 0
blood NN 0
stasis NN 0
and CC 0
toxin NN 0
accumulation NN 0
syndrome NN 0
, , 0
promote VBP 0
negative JJ 0
conversion NN 0
of IN 0
EMAb NNP 0
, , 0
lower JJR 0
serum NN 0
CA125 NNP 0
levels NNS 0
, , 0
and CC 0
elevate VB 0
the DT 0
clinical JJ 0
pregnancy NN 0
rate NN 0
. . 0

QYJDR NNP 0
is VBZ 0
an DT 0
effective JJ 0
formula NN 0
in IN 0
treatment NN 0
of IN 0
EMs-related JJ 0
infertility NN 0
. . 0

Sleep-anticipating JJ 0
effects NNS 0
of IN 0
melatonin NN 0
in IN 0
the DT 0
human JJ 0
brain NN 0
. . 0

Melatonin NNP 0
, , 0
the DT 0
hormone NN 0
produced VBN 0
nocturnally RB 0
by IN 0
the DT 0
pineal NN 0
gland NN 0
, , 0
is VBZ 0
an DT 0
endogenous JJ 0
regulator NN 0
of IN 0
the DT 0
sleep-wake JJ 0
cycle NN 0
. . 0

The DT 0
effects NNS 0
of IN 0
melatonin NN 0
on IN 0
brain NN 0
activities NNS 0
and CC 0
their PRP$ 0
relation NN 0
to TO 0
induction NN 0
of IN 0
sleepiness NN 0
were VBD 0
studied VBN 0
in IN 0
a DT 0
randomized JJ 0
, , 0
double-blind JJ 0
, , 0
placebo NN 0
controlled VBD 0
functional JJ 0
magnetic JJ 0
resonance NN 0
imaging NN 0
( ( 0
fMRI NN 0
) ) 0
study NN 0
. . 0

Melatonin NNP 0
, , 0
but CC 0
not RB 0
placebo VB 0
, , 0
reduced VBN 0
task-related JJ 0
activity NN 0
in IN 0
the DT 0
rostro-medial JJ 0
aspect NN 0
of IN 0
the DT 0
occipital JJ 0
cortex NN 0
during IN 0
a DT 0
visual-search JJ 0
task NN 0
and CC 0
in IN 0
the DT 0
auditory JJ 0
cortex NN 0
during IN 0
a DT 0
music NN 0
task NN 0
. . 0

These DT 0
effects NNS 0
correlated VBD 0
with IN 0
subjective JJ 0
measurements NNS 0
of IN 0
fatigue NN 0
. . 0

In IN 0
addition NN 0
, , 0
melatonin NN 0
enhanced VBD 0
the DT 0
activation NN 0
in IN 0
the DT 0
left NN 0
parahippocampus NN 0
in IN 0
an DT 0
autobiographic JJ 0
memory NN 0
task NN 0
. . 0

Results VB 0
demonstrate NN 0
that IN 0
melatonin NN 0
modulates NNS 0
brain NN 0
activity NN 0
in IN 0
a DT 0
manner NN 0
resembling VBG 0
actual JJ 0
sleep NN 0
although IN 0
subjects NNS 0
are VBP 0
fully RB 0
awake RB 0
. . 0

Furthermore RB 0
, , 0
the DT 0
fatigue NN 0
inducing VBG 0
effect NN 0
of IN 0
melatonin NN 0
on IN 0
brain NN 0
activity NN 0
is VBZ 0
essentially RB 0
different JJ 0
from IN 0
that DT 0
of IN 0
sleep JJ 0
deprivation NN 0
thus RB 0
revealing VBG 0
differences NNS 0
between IN 0
fatigues NNS 0
related VBN 0
to TO 0
the DT 0
circadian JJ 0
sleep NN 0
regulation NN 0
as IN 0
opposed VBN 0
to TO 0
increased VBN 0
homeostatic JJ 0
sleep NN 0
need NN 0
. . 0

Our PRP$ 0
findings NNS 0
highlight VBD 0
the DT 0
role NN 0
of IN 0
melatonin NN 0
in IN 0
priming VBG 0
sleep-associated JJ 0
brain NN 0
activation NN 0
patterns NNS 0
in IN 0
anticipation NN 0
of IN 0
sleep NN 0
. . 0

Adherence NN 0
to TO 0
lifestyle VB 0
recommendations NNS 0
by IN 0
patients NNS 0
with IN 0
depression NN 0
. . 0

INTRODUCTION NNP 0
There EX 0
is VBZ 0
an DT 0
increasing VBG 0
amount NN 0
of IN 0
evidence NN 0
showing VBG 0
that DT 0
physical JJ 0
activity NN 0
and CC 0
sun NN 0
exposure NN 0
are VBP 0
effective JJ 0
coadjuvant JJ 0
treatments NNS 0
for IN 0
patients NNS 0
with IN 0
mild JJ 0
to TO 0
moderate VB 0
depression NN 0
. . 0

However RB 0
, , 0
there EX 0
is VBZ 0
a DT 0
lack NN 0
of IN 0
information NN 0
regarding VBG 0
patient NN 0
's POS 0
adherence NN 0
to TO 0
these DT 0
recommendations NNS 0
in IN 0
daily JJ 0
clinical JJ 0
practice NN 0
. . 0

METHODS NNP 0
We PRP 0
conducted VBD 0
a DT 0
study NN 0
including VBG 0
15 CD 0
depressive JJ 0
patients NNS 0
who WP 0
had VBD 0
been VBN 0
under IN 0
antidepressant JJ 0
treatment NN 0
for IN 0
at IN 0
least JJS 0
one CD 0
month NN 0
. . 0

They PRP 0
wore VBD 0
a DT 0
wrist-watch-like JJ 0
actimetry NN 0
sensor NN 0
to TO 0
measure VB 0
physical JJ 0
activity NN 0
and CC 0
sun NN 0
exposure NN 0
24 CD 0
hours NNS 0
a DT 0
day NN 0
. . 0

After IN 0
one CD 0
week NN 0
of IN 0
baseline NN 0
assessment NN 0
, , 0
patients NNS 0
were VBD 0
randomised VBN 0
into IN 0
one CD 0
of IN 0
the DT 0
two CD 0
arms NNS 0
of IN 0
the DT 0
study NN 0
. . 0

Patients NNS 0
in IN 0
the DT 0
experimental JJ 0
group NN 0
received VBD 0
a DT 0
brief JJ 0
note NN 0
in IN 0
which WDT 0
they PRP 0
were VBD 0
explicitly RB 0
asked VBN 0
to TO 0
increase VB 0
both DT 0
their PRP$ 0
physical JJ 0
activity NN 0
level NN 0
and CC 0
time NN 0
of IN 0
sun NN 0
exposure NN 0
, , 0
while IN 0
control NN 0
group NN 0
patients NNS 0
did VBD 0
not RB 0
receive VB 0
these DT 0
explicit JJ 0
recommendations NNS 0
. . 0

RESULTS NNP 0
One CD 0
week NN 0
after IN 0
recommendations NNS 0
were VBD 0
delivered VBN 0
, , 0
only RB 0
patients NNS 0
in IN 0
the DT 0
experimental JJ 0
group NN 0
had VBD 0
increased VBN 0
time NN 0
of IN 0
sun NN 0
exposure NN 0
and CC 0
physical JJ 0
activity NN 0
( ( 0
25.8 CD 0
% NN 0
and CC 0
14.3 CD 0
% NN 0
, , 0
respectively RB 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Depressive JJ 0
patients NNS 0
are VBP 0
able JJ 0
to TO 0
follow VB 0
prescribed JJ 0
lifestyle JJ 0
recommendations NNS 0
in IN 0
the DT 0
short-term JJ 0
. . 0

Parent-implemented JJ 0
enhanced VBD 0
milieu NNS 0
teaching VBG 0
with IN 0
preschool JJ 0
children NNS 0
who WP 0
have VBP 0
intellectual JJ 0
disabilities NNS 0
. . 0

PURPOSE VB 0
The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
compare VB 0
the DT 0
effects NNS 0
of IN 0
enhanced JJ 0
milieu NN 0
teaching NN 0
( ( 0
EMT NNP 0
) ) 0
implemented VBN 0
by IN 0
parents NNS 0
and CC 0
therapists NNS 0
versus VBP 0
therapists VBZ 0
only RB 0
on IN 0
the DT 0
language NN 0
skills NNS 0
of IN 0
preschool NN 0
children NNS 0
with IN 0
intellectual JJ 0
disabilities NNS 0
( ( 0
IDs NNP 0
) ) 0
, , 0
including VBG 0
children NNS 0
with IN 0
Down NNP 0
syndrome NN 0
and CC 0
children NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorders NNS 0
. . 0

METHOD NNP 0
Seventy-seven JJ 0
children NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
2 CD 0
treatments NNS 0
( ( 0
parent NN 0
+ NNP 0
therapist NN 0
EMT NNP 0
or CC 0
therapist-only RB 0
EMT NNP 0
) ) 0
and CC 0
received VBD 0
36 CD 0
intervention NN 0
sessions NNS 0
. . 0

Children NNP 0
were VBD 0
assessed VBN 0
before RB 0
, , 0
immediately RB 0
after IN 0
, , 0
6 CD 0
months NNS 0
after IN 0
, , 0
and CC 0
12 CD 0
months NNS 0
after IN 0
intervention NN 0
. . 0

Separate JJ 0
linear JJ 0
regressions NNS 0
were VBD 0
conducted VBN 0
for IN 0
each DT 0
standardized JJ 0
and CC 0
observational JJ 0
measure NN 0
at IN 0
each DT 0
time NN 0
point NN 0
. . 0

RESULTS JJ 0
Parents NNS 0
in IN 0
the DT 0
parent NN 0
+ NNP 0
therapist NN 0
group NN 0
demonstrated VBD 0
greater JJR 0
use NN 0
of IN 0
EMT NNP 0
strategies NNS 0
at IN 0
home NN 0
than IN 0
untrained JJ 0
parents NNS 0
in IN 0
the DT 0
therapist-only JJ 0
group NN 0
, , 0
and CC 0
these DT 0
effects NNS 0
maintained VBD 0
over IN 0
time NN 0
. . 0

Effect JJ 0
sizes NN 0
for IN 0
observational JJ 0
measures NNS 0
ranged VBD 0
from IN 0
d NN 0
= $ 0
0.10 CD 0
to TO 0
d VB 0
= JJ 0
1.32 CD 0
favoring VBG 0
the DT 0
parent NN 0
+ NNP 0
therapist NN 0
group NN 0
, , 0
with IN 0
the DT 0
largest JJS 0
effect NN 0
sizes VBZ 0
found VBD 0
12 CD 0
months NNS 0
after IN 0
intervention NN 0
. . 0

CONCLUSION NNP 0
Findings NNS 0
from IN 0
this DT 0
study NN 0
indicate VBP 0
generally RB 0
that IN 0
there EX 0
are VBP 0
benefits NNS 0
to TO 0
training VBG 0
parents NNS 0
to TO 0
implement VB 0
naturalistic JJ 0
language NN 0
intervention NN 0
strategies NNS 0
with IN 0
preschool JJ 0
children NNS 0
who WP 0
have VBP 0
ID NNP 0
and CC 0
significant JJ 0
language NN 0
impairments NNS 0
. . 0

Reduced VBN 0
platelet NN 0
thromboxane NN 0
formation NN 0
after IN 0
long-term JJ 0
administration NN 0
of IN 0
a DT 0
dihydropyridine JJ 0
calcium NN 0
channel NN 0
blocker NN 0
: : 0
a DT 0
prospective JJ 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
study NN 0
with IN 0
nitrendipine NN 0
in IN 0
borderline JJ 0
hypertensive JJ 0
patients NNS 0
with IN 0
IDDM-type NNP 0
diabetes NNS 0
mellitus NN 0
. . 0

Twenty-nine JJ 0
IDDM NNP 0
patients NNS 0
with IN 0
borderline JJ 0
hypertension NN 0
were VBD 0
randomly RB 0
allocated VBN 0
to TO 0
placebo VB 0
or CC 0
nitrendipine VB 0
treatment NN 0
. . 0

Nitrendipine NNP 0
was VBD 0
given VBN 0
orally RB 0
at IN 0
a DT 0
dosage NN 0
of IN 0
20 CD 0
mg NNS 0
once RB 0
daily RB 0
over IN 0
4 CD 0
weeks NNS 0
. . 0

Stimulated VBN 0
platelet NN 0
thromboxane NN 0
formation NN 0
at IN 0
rest NN 0
and CC 0
after IN 0
standardized VBN 0
, , 0
non JJ 0
exhausting VBG 0
exercise NN 0
was VBD 0
measured VBN 0
by IN 0
standard JJ 0
methods NNS 0
. . 0

In IN 0
addition NN 0
, , 0
plasma NN 0
levels NNS 0
of IN 0
platelet NN 0
factor NN 0
4 CD 0
and CC 0
aggregation NN 0
responses NNS 0
to TO 0
collagen VB 0
and CC 0
ADP NNP 0
were VBD 0
determined VBN 0
. . 0

In IN 0
the DT 0
treatment NN 0
group NN 0
thromboxane NN 0
formation NN 0
after IN 0
stimulation NN 0
with IN 0
collagen NN 0
( ( 0
0.3 CD 0
and CC 0
1.0 CD 0
micrograms/ml NN 0
) ) 0
and CC 0
1 CD 0
mM NN 0
arachidonic JJ 0
acid NN 0
( ( 0
AA NNP 0
) ) 0
was VBD 0
reduced VBN 0
in IN 0
the DT 0
resting NN 0
state NN 0
. . 0

Exercise NN 0
induced JJ 0
change NN 0
of IN 0
thromboxane NN 0
synthesis NN 0
in IN 0
response NN 0
to TO 0
1.0 CD 0
micrograms/ml NNS 0
collagen NN 0
was VBD 0
significantly RB 0
lower JJR 0
as IN 0
compared VBN 0
to TO 0
placebo VB 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

In IN 0
parallel JJ 0
, , 0
PF4 NNP 0
plasma NN 0
levels NNS 0
were VBD 0
significantly RB 0
lowered VBN 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

Whole JJ 0
blood NN 0
aggregation NN 0
after IN 0
collagen NN 0
stimulation NN 0
( ( 0
1.0 CD 0
micrograms/ml NN 0
) ) 0
was VBD 0
reduced VBN 0
after IN 0
4 CD 0
weeks NNS 0
of IN 0
nitrendipine JJ 0
treatment NN 0
, , 0
but CC 0
ADP NNP 0
( ( 0
5 CD 0
microM NN 0
) ) 0
induced VBD 0
aggregation NN 0
was VBD 0
not RB 0
. . 0

These DT 0
effects NNS 0
of IN 0
nitrendipine NN 0
were VBD 0
not RB 0
seen VBN 0
in IN 0
platelet NN 0
rich JJ 0
plasma NN 0
. . 0

In IN 0
conclusion NN 0
long-term JJ 0
nitrendipine JJ 0
treatment NN 0
may MD 0
inhibit VB 0
collagen NN 0
dependent JJ 0
platelet NN 0
activation NN 0
in IN 0
the DT 0
blood NN 0
of IN 0
diabetic JJ 0
patients NNS 0
with IN 0
borderline JJ 0
hypertension NN 0
. . 0

Cancer NNP 0
information NN 0
and CC 0
anxiety NN 0
: : 0
applying VBG 0
the DT 0
extended JJ 0
parallel NN 0
process NN 0
model NN 0
. . 0

There EX 0
is VBZ 0
concern NN 0
that IN 0
public JJ 0
education NN 0
about IN 0
testicular JJ 0
cancer NN 0
( ( 0
TC NNP 0
) ) 0
may MD 0
cause VB 0
unnecessary JJ 0
anxiety NN 0
. . 0

Psychological JJ 0
theory NN 0
suggests VBZ 0
that IN 0
if IN 0
threat NN 0
( ( 0
eg JJ 0
, , 0
TC NNP 0
) ) 0
information NN 0
is VBZ 0
accompanied VBN 0
with IN 0
threat NN 0
control NN 0
strategies NNS 0
( ( 0
eg NN 0
, , 0
testicular JJ 0
self-examination NN 0
; : 0
TSE NNP 0
) ) 0
anxiety NN 0
is VBZ 0
less RBR 0
likely JJ 0
. . 0

Male JJ 0
students NNS 0
( ( 0
N=443 NNP 0
) ) 0
were VBD 0
randomized VBN 0
to TO 0
either VB 0
a DT 0
TC NNP 0
or CC 0
TC NNP 0
+TSE NNP 0
information NN 0
group NN 0
or CC 0
a DT 0
no DT 0
information NN 0
control NN 0
group NN 0
, , 0
and CC 0
assessed VBD 0
at IN 0
three CD 0
time NN 0
points NNS 0
. . 0

Anxiety NN 0
levels NNS 0
did VBD 0
not RB 0
differ VB 0
between IN 0
the DT 0
groups NNS 0
and CC 0
exposure NN 0
to TO 0
TC+TSE NNP 0
resulted VBD 0
in IN 0
greater JJR 0
perceived JJ 0
message NN 0
benefit NN 0
, , 0
increased VBN 0
intention NN 0
to TO 0
self-examine NN 0
and CC 0
lower JJR 0
message NN 0
denigration NN 0
. . 0

This DT 0
suggests VBZ 0
TC NNP 0
information NN 0
is VBZ 0
not RB 0
anxiogenic JJ 0
, , 0
but CC 0
inclusion NN 0
of IN 0
TSE NNP 0
information NN 0
may MD 0
improve VB 0
acceptance NN 0
of IN 0
disease NN 0
awareness NN 0
information NN 0
. . 0

Safety NN 0
, , 0
tolerability NN 0
, , 0
and CC 0
immunogenicity NN 0
after IN 0
1 CD 0
and CC 0
2 CD 0
doses NNS 0
of IN 0
zoster NN 0
vaccine NN 0
in IN 0
healthy JJ 0
adults NNS 0
?60 CD 0
years NNS 0
of IN 0
age NN 0
. . 0

BACKGROUND NNP 0
Incidence NNP 0
and CC 0
severity NN 0
of IN 0
herpes NNS 0
zoster NNP 0
( ( 0
HZ NNP 0
) ) 0
and CC 0
postherpetic JJ 0
neuralgia JJ 0
increase NN 0
with IN 0
age NN 0
, , 0
associated VBN 0
with IN 0
age-related JJ 0
decrease NN 0
in IN 0
immunity NN 0
to TO 0
varicella-zoster JJ 0
virus NN 0
( ( 0
VZV NNP 0
) ) 0
. . 0

One CD 0
dose NN 0
of IN 0
zoster NN 0
vaccine NN 0
( ( 0
ZV NNP 0
) ) 0
has VBZ 0
demonstrated VBN 0
substantial JJ 0
protection NN 0
against IN 0
HZ NNP 0
; : 0
this DT 0
study NN 0
examined VBD 0
impact NN 0
of IN 0
a DT 0
second JJ 0
dose NN 0
of IN 0
ZV NNP 0
. . 0

METHODS NNP 0
Randomized NNP 0
, , 0
double-blind NN 0
, , 0
multicenter NN 0
study NN 0
with IN 0
210 CD 0
subjects NNS 0
?60 CD 0
years NNS 0
old JJ 0
compared VBN 0
immunity NN 0
and CC 0
safety NN 0
profiles NNS 0
after IN 0
one CD 0
and CC 0
two CD 0
doses NNS 0
of IN 0
ZV NNP 0
, , 0
separated VBN 0
by IN 0
6 CD 0
weeks NNS 0
, , 0
vs. FW 0
placebo NN 0
. . 0

Immunogenicity NNP 0
was VBD 0
evaluated VBN 0
using VBG 0
VZV NNP 0
interferon-gamma JJ 0
( ( 0
IFN-? NNP 0
) ) 0
enzyme-linked JJ 0
immunospot NN 0
( ( 0
ELISPOT NNP 0
) ) 0
assay NN 0
and CC 0
VZV NNP 0
glycoprotein VBD 0
enzyme-linked JJ 0
immunosorbent NN 0
antibody NN 0
( ( 0
gpELISA NN 0
) ) 0
assay NN 0
. . 0

Adverse JJ 0
experiences NNS 0
( ( 0
AEs NNP 0
) ) 0
were VBD 0
recorded VBN 0
on IN 0
a DT 0
standardized JJ 0
Vaccination NNP 0
Report NNP 0
Card NNP 0
. . 0

RESULTS NNP 0
No NNP 0
serious JJ 0
vaccine-related JJ 0
AEs NNP 0
occurred VBD 0
. . 0

VZV NNP 0
IFN-? NNP 0
ELISPOT NNP 0
geometric JJ 0
mean NN 0
count NN 0
( ( 0
GMC NNP 0
) ) 0
of IN 0
spot-forming JJ 0
cells NNS 0
per IN 0
10 CD 0
( ( 0
6 CD 0
) ) 0
peripheral JJ 0
blood NN 0
mononuclear JJ 0
cells NNS 0
increased VBN 0
in IN 0
the DT 0
ZV NNP 0
group NN 0
from IN 0
16.9 CD 0
prevaccination NN 0
to TO 0
49.5 CD 0
and CC 0
32.8 CD 0
at IN 0
2 CD 0
and CC 0
6 CD 0
weeks NNS 0
postdose RB 0
1 CD 0
, , 0
respectively RB 0
. . 0

Two CD 0
weeks NNS 0
, , 0
6 CD 0
weeks NNS 0
and CC 0
6 CD 0
months NNS 0
postdose RB 0
2 CD 0
, , 0
GMC NNP 0
was VBD 0
44.3 CD 0
, , 0
42.9 CD 0
, , 0
and CC 0
36.5 CD 0
, , 0
respectively RB 0
. . 0

GMC NNP 0
in IN 0
the DT 0
placebo NN 0
group NN 0
did VBD 0
not RB 0
change NN 0
during IN 0
the DT 0
study NN 0
. . 0

The DT 0
peak JJ 0
ELISPOT NNP 0
response NN 0
occurred VBD 0
?2 NNP 0
weeks NNS 0
after IN 0
each DT 0
ZV NNP 0
dose NN 0
. . 0

The DT 0
gpELISA NN 0
geometric JJ 0
mean NN 0
titers NNS 0
( ( 0
GMTs NNP 0
) ) 0
in IN 0
the DT 0
ZV NNP 0
group NN 0
were VBD 0
higher JJR 0
than IN 0
in IN 0
the DT 0
placebo NN 0
group NN 0
at IN 0
6 CD 0
weeks NNS 0
after IN 0
each DT 0
dose NN 0
. . 0

Correlation NN 0
between IN 0
the DT 0
IFN-? NNP 0
ELISPOT NNP 0
and CC 0
gpELISA NN 0
assays NNS 0
was VBD 0
poor JJ 0
. . 0

CONCLUSIONS NNP 0
ZV NNP 0
was VBD 0
generally RB 0
well-tolerated JJ 0
and CC 0
immunogenic JJ 0
in IN 0
adults NNS 0
?60 CD 0
years NNS 0
old JJ 0
. . 0

A DT 0
second JJ 0
dose NN 0
of IN 0
ZV NNP 0
was VBD 0
generally RB 0
safe JJ 0
, , 0
but CC 0
did VBD 0
not RB 0
boost VB 0
VZV-specific NNP 0
immunity NN 0
beyond IN 0
levels NNS 0
achieved VBN 0
postdose RB 0
1 CD 0
. . 0

Compensation NN 0
in IN 0
intergroup JJ 0
relations NNS 0
: : 0
an DT 0
investigation NN 0
of IN 0
its PRP$ 0
structural JJ 0
and CC 0
strategic JJ 0
foundations NNS 0
. . 0

Recent JJ 0
work NN 0
in IN 0
intergroup JJ 0
relations NNS 0
stresses VBZ 0
the DT 0
role NN 0
of IN 0
two CD 0
fundamental JJ 0
dimensions NNS 0
, , 0
competence NN 0
and CC 0
warmth NN 0
, , 0
which WDT 0
organize VBP 0
the DT 0
perception NN 0
of IN 0
social JJ 0
groups NNS 0
. . 0

A DT 0
pattern NN 0
often RB 0
encountered VBN 0
in IN 0
people NNS 0
's POS 0
ratings NNS 0
is VBZ 0
one CD 0
of IN 0
compensation NN 0
in IN 0
that DT 0
a DT 0
group NN 0
that WDT 0
is VBZ 0
evaluated VBN 0
higher JJR 0
than IN 0
another DT 0
group NN 0
on IN 0
one CD 0
of IN 0
the DT 0
two CD 0
fundamental JJ 0
dimensions NNS 0
is VBZ 0
also RB 0
judged VBN 0
lower JJR 0
on IN 0
the DT 0
other JJ 0
fundamental JJ 0
dimension NN 0
. . 0

Based VBN 0
on IN 0
Social NNP 0
Identity NNP 0
Theory NNP 0
, , 0
the DT 0
present JJ 0
work NN 0
extends VBZ 0
previous JJ 0
research NN 0
on IN 0
compensation NN 0
by IN 0
examining VBG 0
boundary JJ 0
conditions NNS 0
as RB 0
well RB 0
as IN 0
underlying VBG 0
psychological JJ 0
processes NNS 0
. . 0

Two CD 0
studies NNS 0
involving VBG 0
experimental JJ 0
and CC 0
correlational JJ 0
evidence NN 0
, , 0
minimal JJ 0
and CC 0
real JJ 0
groups NNS 0
, , 0
and CC 0
different JJ 0
kinds NNS 0
of IN 0
conflict NN 0
, , 0
reveal NN 0
that IN 0
compensation NN 0
is VBZ 0
more RBR 0
likely JJ 0
when WRB 0
the DT 0
groups NNS 0
are VBP 0
in IN 0
asymmetrical JJ 0
relation NN 0
and CC 0
share NN 0
a DT 0
cooperative JJ 0
view NN 0
of IN 0
the DT 0
intergroup NN 0
setting NN 0
. . 0

Our PRP$ 0
data NNS 0
also RB 0
suggest VBP 0
that IN 0
, , 0
among IN 0
members NNS 0
of IN 0
low JJ 0
status NN 0
groups NNS 0
, , 0
compensation NN 0
is VBZ 0
associated VBN 0
with IN 0
social JJ 0
creativity NN 0
. . 0

In IN 0
contrast NN 0
, , 0
and CC 0
in IN 0
line NN 0
with IN 0
the DT 0
'noblesse NNP 0
oblige NN 0
' '' 0
effect NN 0
, , 0
members NNS 0
of IN 0
the DT 0
high JJ 0
status NN 0
group NN 0
would MD 0
seem VB 0
to TO 0
rely VB 0
on IN 0
compensation NN 0
as IN 0
a DT 0
means NN 0
to TO 0
appear VB 0
non-discriminatory JJ 0
. . 0

Serum NNP 0
biochemical JJ 0
characteristics NNS 0
of IN 0
Beluga NNP 0
, , 0
Huso NNP 0
huso NN 0
( ( 0
L. NNP 0
) ) 0
, , 0
in IN 0
response NN 0
to TO 0
blood NN 0
sampling NN 0
after IN 0
clove NN 0
powder NN 0
solution NN 0
exposure NN 0
. . 0

In IN 0
order NN 0
to TO 0
investigate VB 0
the DT 0
effect NN 0
of IN 0
anesthesia NN 0
on IN 0
serum NN 0
parameters NNS 0
, , 0
Beluga NNP 0
, , 0
Huso NNP 0
huso NN 0
( ( 0
L. NNP 0
) ) 0
were VBD 0
blood-sampled JJ 0
immediately RB 0
without IN 0
anesthesia NN 0
( ( 0
control NN 0
) ) 0
or CC 0
subjected VBN 0
to TO 0
following VBG 0
anesthesia JJ 0
procedure NN 0
: : 0
40 CD 0
, , 0
120 CD 0
, , 0
and CC 0
240 CD 0
s NN 0
exposure NN 0
to TO 0
3,000 CD 0
, , 0
700 CD 0
, , 0
and CC 0
500 CD 0
mg NN 0
l?? NN 0
clove NN 0
solution NN 0
, , 0
respectively RB 0
. . 0

Blood NN 0
samples NNS 0
were VBD 0
collected VBN 0
after IN 0
these DT 0
periods NNS 0
, , 0
when WRB 0
fish NN 0
were VBD 0
immobile JJ 0
and CC 0
reached VBD 0
stage NN 0
4 CD 0
anesthesia NN 0
. . 0

Results NNS 0
showed VBD 0
that IN 0
cortisol NN 0
and CC 0
glucose JJ 0
levels NNS 0
were VBD 0
significantly RB 0
high JJ 0
in IN 0
700 CD 0
and CC 0
500 CD 0
but CC 0
not RB 0
3,000 CD 0
mg NNS 0
l?? JJ 0
group NN 0
compared VBN 0
to TO 0
control VB 0
. . 0

Serum NNP 0
lactate NN 0
levels NNS 0
were VBD 0
significantly RB 0
high JJ 0
in IN 0
500 CD 0
mg NNS 0
l?? JJ 0
group NN 0
compared VBN 0
to TO 0
control VB 0
group NN 0
. . 0

Lactate NNP 0
levels NNS 0
were VBD 0
not RB 0
significantly RB 0
differed VBN 0
between IN 0
control NN 0
, , 0
3,000 CD 0
, , 0
and CC 0
700 CD 0
mg NN 0
l?? NN 0
groups NNS 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
serum NN 0
levels NNS 0
of IN 0
cholesterol NN 0
, , 0
total JJ 0
protein NN 0
, , 0
lactate JJ 0
dehydrogenase NN 0
, , 0
aspartate JJ 0
aminotransferase NN 0
, , 0
alanine JJ 0
aminotransferase NN 0
, , 0
Na? NNP 0
, , 0
Cl? NNP 0
, , 0
K? NNP 0
, , 0
and CC 0
Ca?? NNP 0
. . 0

Results NNP 0
suggest VBP 0
that IN 0
rapid JJ 0
anesthesia NN 0
with IN 0
higher JJR 0
dose NN 0
is VBZ 0
better JJR 0
than IN 0
slow JJ 0
anesthesia NN 0
with IN 0
lower JJR 0
dose NN 0
for IN 0
blood NN 0
sampling NN 0
in IN 0
Beluga NNP 0
. . 0

[ JJ 0
Effect NNP 0
of IN 0
branch NN 0
chain NN 0
amino NN 0
acid NN 0
enriched VBD 0
formula NN 0
on IN 0
postoperative JJ 0
fatigue NN 0
and CC 0
nutritional JJ 0
status NN 0
after IN 0
digestive JJ 0
surgery NN 0
] NN 0
. . 0

OBJECTIVE UH 0
To TO 0
evaluate VB 0
the DT 0
effect NN 0
of IN 0
branch NN 0
chain NN 0
amino NN 0
acid NN 0
( ( 0
BCAA NNP 0
) ) 0
enriched VBD 0
formula NN 0
on IN 0
nutritional JJ 0
status NN 0
and CC 0
postoperative JJ 0
fatigue NN 0
for IN 0
digestive JJ 0
surgery NN 0
patients NNS 0
. . 0

METHODS NNP 0
Forty NNP 0
patients NNS 0
who WP 0
underwent VBP 0
digestive JJ 0
surgery NN 0
were VBD 0
randomly RB 0
received VBN 0
parenteral JJ 0
nutrition NN 0
with IN 0
either DT 0
BCAA NNP 0
enriched VBD 0
( ( 0
study NN 0
group NN 0
, , 0
n=20 RB 0
) ) 0
or CC 0
routine JJ 0
amino NN 0
acid NN 0
( ( 0
control NN 0
group NN 0
, , 0
n=20 RB 0
) ) 0
for IN 0
seven CD 0
consecutive JJ 0
days NNS 0
. . 0

Nitrogen NNP 0
balance NN 0
, , 0
serum JJ 0
total NN 0
protein NN 0
, , 0
albumin NN 0
, , 0
prealbumin NN 0
, , 0
transferrin NN 0
, , 0
retinol NN 0
binding NN 0
protein NN 0
and CC 0
postoperative JJ 0
fatigue NN 0
score NN 0
were VBD 0
monitored VBN 0
during IN 0
the DT 0
postoperative JJ 0
period NN 0
. . 0

RESULTS VB 0
The DT 0
cumulative JJ 0
postoperative JJ 0
fatigue NN 0
scores NNS 0
were VBD 0
lower JJR 0
in IN 0
BCAA NNP 0
group NN 0
than IN 0
that DT 0
in IN 0
the DT 0
control NN 0
group NN 0
at IN 0
the DT 0
4th CD 0
, , 0
5th CD 0
and CC 0
7th CD 0
day NN 0
after IN 0
operation NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

Patients NNS 0
achieved VBD 0
positive JJ 0
nitrogen NN 0
balance NN 0
2 CD 0
days NNS 0
earlier RBR 0
in IN 0
the DT 0
study NN 0
group NN 0
than IN 0
that DT 0
in IN 0
the DT 0
control NN 0
group NN 0
, , 0
but CC 0
there EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
in IN 0
cumulative JJ 0
nitrogen NN 0
balance NN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
. . 0

There EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
in IN 0
elevation NN 0
of IN 0
serum JJ 0
total JJ 0
protein NN 0
, , 0
albumin NN 0
, , 0
prealbumin NN 0
, , 0
transferrin NN 0
at IN 0
the DT 0
7th CD 0
day NN 0
after IN 0
operation NN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
( ( 0
P NNP 0
> NNP 0
0.05 CD 0
) ) 0
, , 0
compared VBN 0
with IN 0
those DT 0
at IN 0
the DT 0
first JJ 0
day NN 0
after IN 0
operation NN 0
. . 0

The DT 0
serum JJ 0
level NN 0
of IN 0
retinol NN 0
binding VBG 0
protein NN 0
was VBD 0
higher JJR 0
in IN 0
BCAA-enriched NNP 0
group NN 0
than IN 0
that DT 0
in IN 0
the DT 0
control NN 0
group NN 0
( ( 0
P=0.004 NNP 0
) ) 0
. . 0

CONCLUSION NNP 0
TPN NNP 0
with IN 0
BCAA NNP 0
enriched VBD 0
formula NN 0
can MD 0
reduce VB 0
postoperative JJ 0
fatigue NN 0
score NN 0
and CC 0
improve VB 0
the DT 0
nutritional JJ 0
status NN 0
for IN 0
digestive JJ 0
surgery NN 0
patients NNS 0
. . 0

Effects NNS 0
of IN 0
individualized JJ 0
breast NN 0
cancer NN 0
risk NN 0
counseling NN 0
: : 0
a DT 0
randomized JJ 0
trial NN 0
. . 0

BACKGROUND NNP 0
Studies NNPS 0
have VBP 0
shown VBN 0
that IN 0
a DT 0
majority NN 0
of IN 0
women NNS 0
with IN 0
a DT 0
family NN 0
history NN 0
of IN 0
breast NN 0
cancer NN 0
have VBP 0
exaggerated VBN 0
perceptions NNS 0
of IN 0
their PRP$ 0
own JJ 0
risk NN 0
of IN 0
this DT 0
disease NN 0
and CC 0
experience NN 0
excessive JJ 0
anxiety NN 0
. . 0

In IN 0
response NN 0
to TO 0
the DT 0
need NN 0
to TO 0
communicate VB 0
more JJR 0
accurate JJ 0
risk NN 0
information NN 0
to TO 0
these DT 0
women NNS 0
, , 0
specialized JJ 0
programs NNS 0
for IN 0
breast NN 0
cancer NN 0
risk NN 0
counseling VBG 0
have VBP 0
been VBN 0
initiated VBN 0
in IN 0
medical JJ 0
centers NNS 0
across IN 0
the DT 0
United NNP 0
States NNPS 0
. . 0

PURPOSE VB 0
Our PRP$ 0
purpose NN 0
was VBD 0
1 CD 0
) ) 0
to TO 0
evaluate VB 0
the DT 0
impact NN 0
of IN 0
a DT 0
standardized JJ 0
protocol NN 0
for IN 0
individualized JJ 0
breast NN 0
cancer NN 0
risk NN 0
counseling VBG 0
on IN 0
comprehension NN 0
of IN 0
personal JJ 0
risk NN 0
among IN 0
first-degree JJ 0
relatives NNS 0
of IN 0
index NN 0
breast NN 0
cancer NN 0
patients NNS 0
and CC 0
2 CD 0
) ) 0
to TO 0
identify VB 0
women NNS 0
most RBS 0
and CC 0
least JJS 0
likely JJ 0
to TO 0
benefit VB 0
from IN 0
such JJ 0
counseling NN 0
. . 0

METHODS NNP 0
This DT 0
study NN 0
is VBZ 0
a DT 0
prospective JJ 0
randomized VBN 0
trial NN 0
comparing VBG 0
individualized VBN 0
breast NN 0
cancer NN 0
risk NN 0
counseling VBG 0
to TO 0
general JJ 0
health NN 0
counseling NN 0
( ( 0
control NN 0
) ) 0
. . 0

We PRP 0
studied VBD 0
200 CD 0
women NNS 0
aged VBN 0
35 CD 0
years NNS 0
and CC 0
older JJR 0
who WP 0
had VBD 0
a DT 0
family NN 0
history NN 0
of IN 0
breast NN 0
cancer NN 0
in IN 0
a DT 0
first-degree JJ 0
relative NN 0
. . 0

Women NNS 0
with IN 0
a DT 0
personal JJ 0
history NN 0
of IN 0
cancer NN 0
were VBD 0
excluded VBN 0
. . 0

Risk NNP 0
comprehension NN 0
was VBD 0
assessed VBN 0
as IN 0
the DT 0
concordance NN 0
between IN 0
perceived VBN 0
subjective JJ 0
lifetime NN 0
breast NN 0
cancer NN 0
risk NN 0
and CC 0
estimated VBN 0
objective JJ 0
lifetime NN 0
risk NN 0
. . 0

RESULTS VB 0
The DT 0
results NNS 0
of IN 0
logistic JJ 0
regression NN 0
analysis NN 0
showed VBD 0
that IN 0
women NNS 0
who WP 0
received VBD 0
risk NN 0
counseling NN 0
were VBD 0
significantly RB 0
more RBR 0
likely JJ 0
to TO 0
improve VB 0
their PRP$ 0
risk NN 0
comprehension NN 0
, , 0
compared VBN 0
with IN 0
women NNS 0
in IN 0
the DT 0
control NN 0
condition NN 0
( ( 0
odds NNS 0
ratio VBP 0
[ CD 0
OR NNP 0
] NNP 0
= VBZ 0
3.5 CD 0
; : 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
[ NNP 0
CI NNP 0
] NNP 0
= NNP 0
1.3-9.5 CD 0
; : 0
P NNP 0
= NNP 0
.01 NNP 0
) ) 0
. . 0

However RB 0
, , 0
in IN 0
both DT 0
groups NNS 0
, , 0
about RB 0
two CD 0
thirds NNS 0
of IN 0
women NNS 0
continued VBN 0
to TO 0
overestimate VB 0
their PRP$ 0
lifetime NN 0
risks NNS 0
substantially RB 0
following VBG 0
counseling VBG 0
. . 0

Examination NN 0
of IN 0
subjects NNS 0
by IN 0
treatment NN 0
interaction NN 0
effects NNS 0
indicated VBD 0
that IN 0
risk NN 0
counseling VBG 0
did VBD 0
not RB 0
produce VB 0
improved JJ 0
comprehension NN 0
among IN 0
the DT 0
large JJ 0
proportion NN 0
of IN 0
women NNS 0
who WP 0
had VBD 0
high JJ 0
levels NNS 0
of IN 0
anxious JJ 0
preoccupation NN 0
with IN 0
breast NN 0
cancer NN 0
at IN 0
base NN 0
line NN 0
( ( 0
P NNP 0
= NNP 0
.02 NNP 0
) ) 0
. . 0

In IN 0
addition NN 0
, , 0
white JJ 0
women NNS 0
were VBD 0
less RBR 0
likely JJ 0
to TO 0
benefit VB 0
than IN 0
African-American JJ 0
women NNS 0
( ( 0
OR NNP 0
= VBZ 0
0.34 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
= NNP 0
0.11-0.99 NN 0
; : 0
P NNP 0
= NNP 0
.05 NNP 0
) ) 0
. . 0

CONCLUSION NNP 0
Efforts NNPS 0
to TO 0
counsel NN 0
women NNS 0
about IN 0
their PRP$ 0
breast NN 0
cancer NN 0
risks NNS 0
are VBP 0
not RB 0
likely JJ 0
to TO 0
be VB 0
effective JJ 0
unless IN 0
their PRP$ 0
breast NN 0
cancer NN 0
anxieties NNS 0
are VBP 0
also RB 0
addressed VBN 0
. . 0

IMPLICATIONS NNP 0
Attention NNP 0
to TO 0
the DT 0
psychological JJ 0
aspects NNS 0
of IN 0
breast NN 0
cancer NN 0
risk NN 0
will MD 0
be VB 0
critical JJ 0
in IN 0
the DT 0
development NN 0
of IN 0
risk-counseling JJ 0
programs NNS 0
that WDT 0
incorporate VBP 0
testing VBG 0
for IN 0
the DT 0
recently RB 0
cloned VBN 0
breast NN 0
cancer NN 0
susceptibility NN 0
gene NN 0
, , 0
BRCA1 NNP 0
( ( 0
and CC 0
BRCA2 NNP 0
when WRB 0
that DT 0
gene NN 0
has VBZ 0
also RB 0
been VBN 0
cloned VBN 0
) ) 0
. . 0

Efficacy NN 0
and CC 0
safety NN 0
of IN 0
selamectin NN 0
against IN 0
fleas NNS 0
and CC 0
heartworms NNS 0
in IN 0
dogs NNS 0
and CC 0
cats NNS 0
presented VBD 0
as IN 0
veterinary JJ 0
patients NNS 0
in IN 0
North NNP 0
America NNP 0
. . 0

A NNP 0
series NN 0
of IN 0
randomized VBN 0
, , 0
controlled VBN 0
, , 0
masked VBD 0
field NN 0
studies NNS 0
was VBD 0
conducted VBN 0
to TO 0
assess VB 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
selamectin NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
flea NN 0
infestations NNS 0
on IN 0
dogs NNS 0
and CC 0
cats NNS 0
, , 0
and CC 0
in IN 0
the DT 0
prevention NN 0
of IN 0
heartworm NN 0
infection NN 0
in IN 0
dogs NNS 0
. . 0

In IN 0
addition NN 0
, , 0
observations NNS 0
were VBD 0
made VBN 0
on IN 0
the DT 0
beneficial JJ 0
effect NN 0
of IN 0
selamectin NN 0
treatment NN 0
on IN 0
dogs NNS 0
and CC 0
cats NNS 0
showing VBG 0
signs NNS 0
of IN 0
flea NN 0
allergy NN 0
dermatitis NN 0
( ( 0
FAD NNP 0
) ) 0
. . 0

In IN 0
all DT 0
studies NNS 0
selamectin VBP 0
was VBD 0
applied VBN 0
topically RB 0
, , 0
once RB 0
per IN 0
month NN 0
, , 0
in IN 0
unit NN 0
doses NNS 0
providing VBG 0
a DT 0
minimum JJ 0
dosage NN 0
of IN 0
6mgkg CD 0
( ( 0
-1 NN 0
) ) 0
. . 0

Dogs NNS 0
and CC 0
cats NNS 0
with IN 0
naturally RB 0
occurring VBG 0
flea NN 0
infestations NNS 0
, , 0
some DT 0
of IN 0
which WDT 0
also RB 0
had VBD 0
signs NNS 0
associated VBN 0
with IN 0
FAD NNP 0
, , 0
were VBD 0
assigned VBN 0
randomly RB 0
to TO 0
receive VB 0
three CD 0
months NNS 0
of IN 0
topical JJ 0
treatment NN 0
with IN 0
selamectin NN 0
( ( 0
220 CD 0
dogs NNS 0
, , 0
189 CD 0
cats NNS 0
) ) 0
or CC 0
a DT 0
positive-control JJ 0
product NN 0
( ( 0
dogs NNS 0
: : 0
fenthion NN 0
, , 0
n=81 RB 0
; : 0
cats NNS 0
: : 0
pyrethrins NNS 0
, , 0
n=66 NN 0
) ) 0
. . 0

Selamectin NNP 0
was VBD 0
administered VBN 0
on IN 0
days NNS 0
0 CD 0
, , 0
30 CD 0
, , 0
and CC 0
60 CD 0
. . 0

Day NNP 0
0 CD 0
was VBD 0
defined VBN 0
as IN 0
the DT 0
day NN 0
that IN 0
the DT 0
animal NN 0
first RB 0
received VBD 0
treatment NN 0
. . 0

Flea NN 0
burdens NNS 0
were VBD 0
assessed VBN 0
by IN 0
flea NN 0
comb NN 0
counts NNS 0
and CC 0
clinical JJ 0
evaluations NNS 0
of IN 0
FAD NNP 0
were VBD 0
performed VBN 0
before IN 0
treatment NN 0
, , 0
and CC 0
on IN 0
days NNS 0
14 CD 0
, , 0
30 CD 0
, , 0
60 CD 0
, , 0
and CC 0
90 CD 0
. . 0

On IN 0
days NNS 0
30 CD 0
, , 0
60 CD 0
, , 0
and CC 0
90 CD 0
, , 0
mean JJ 0
flea NN 0
counts NNS 0
in IN 0
selamectin-treated JJ 0
dogs NNS 0
were VBD 0
reduced VBN 0
by IN 0
92.1 CD 0
, , 0
99.0 CD 0
, , 0
and CC 0
99.8 CD 0
% NN 0
, , 0
and CC 0
mean JJ 0
flea NN 0
counts NNS 0
in IN 0
fenthion-treated JJ 0
dogs NNS 0
were VBD 0
reduced VBN 0
by IN 0
81.5 CD 0
, , 0
86.8 CD 0
, , 0
and CC 0
86.1 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
compared VBN 0
with IN 0
day NN 0
0 CD 0
counts NNS 0
. . 0

Also RB 0
, , 0
on IN 0
days NNS 0
30 CD 0
, , 0
60 CD 0
, , 0
and CC 0
90 CD 0
, , 0
mean JJ 0
flea NN 0
counts NNS 0
in IN 0
selamectin-treated JJ 0
cats NNS 0
were VBD 0
reduced VBN 0
by IN 0
92.5 CD 0
, , 0
98.3 CD 0
, , 0
and CC 0
99.3 CD 0
% NN 0
, , 0
and CC 0
mean JJ 0
flea NN 0
counts NNS 0
in IN 0
pyrethrin-treated JJ 0
cats NNS 0
were VBD 0
reduced VBN 0
by IN 0
66.4 CD 0
, , 0
73.9 CD 0
, , 0
and CC 0
81.3 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
compared VBN 0
with IN 0
day NN 0
0 CD 0
counts NNS 0
. . 0

Selamectin NNP 0
also RB 0
was VBD 0
beneficial JJ 0
in IN 0
alleviating VBG 0
signs NNS 0
in IN 0
dogs NNS 0
and CC 0
cats NNS 0
diagnosed VBD 0
clinically RB 0
with IN 0
FAD NNP 0
. . 0

A NNP 0
total NN 0
of IN 0
397 CD 0
dogs NNS 0
free JJ 0
of IN 0
adult NN 0
heartworm NN 0
infection NN 0
from IN 0
four CD 0
heartworm-endemic JJ 0
areas NNS 0
of IN 0
the DT 0
USA NNP 0
were VBD 0
allocated VBN 0
randomly RB 0
to TO 0
six CD 0
months NNS 0
of IN 0
treatment NN 0
with IN 0
selamectin NN 0
( ( 0
n=298 JJ 0
) ) 0
or CC 0
ivermectin NN 0
( ( 0
n=99 JJ 0
) ) 0
. . 0

Selamectin NNP 0
achieved VBD 0
a DT 0
heartworm JJ 0
prevention NN 0
rate NN 0
of IN 0
100 CD 0
% NN 0
, , 0
with IN 0
all DT 0
dogs NNS 0
testing VBG 0
negative JJ 0
for IN 0
microfilariae NN 0
and CC 0
adult NN 0
heartworm NN 0
antigen NN 0
on IN 0
days NNS 0
180 CD 0
and CC 0
300 CD 0
. . 0

Selamectin NNP 0
was VBD 0
administered VBN 0
to TO 0
a DT 0
total NN 0
of IN 0
673 CD 0
dogs NNS 0
and CC 0
347 CD 0
cats NNS 0
having VBG 0
an DT 0
age NN 0
range NN 0
of IN 0
6 CD 0
weeks NNS 0
to TO 0
19 CD 0
years NNS 0
( ( 0
3954 CD 0
doses NNS 0
) ) 0
. . 0

The DT 0
animals NNS 0
included VBD 0
19 CD 0
purebred VBD 0
or CC 0
crossbred JJ 0
Collies NNS 0
( ( 0
Bearded NNP 0
, , 0
Border NNP 0
, , 0
and CC 0
unspecified JJ 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
serious JJ 0
adverse JJ 0
events NNS 0
. . 0

Results NNS 0
of IN 0
these DT 0
studies NNS 0
indicated VBD 0
that IN 0
selamectin NN 0
was VBD 0
highly RB 0
effective JJ 0
in IN 0
the DT 0
control NN 0
of IN 0
flea NN 0
infestations NNS 0
in IN 0
dogs NNS 0
and CC 0
cats NNS 0
without IN 0
the DT 0
need NN 0
for IN 0
simultaneous JJ 0
treatment NN 0
of IN 0
the DT 0
environment NN 0
or CC 0
of IN 0
in-contact JJ 0
animals NNS 0
and CC 0
also RB 0
was VBD 0
beneficial JJ 0
in IN 0
alleviating VBG 0
signs NNS 0
associated VBN 0
with IN 0
FAD NNP 0
. . 0

Selamectin NNP 0
also RB 0
was VBD 0
100 CD 0
% NN 0
effective JJ 0
in IN 0
preventing VBG 0
the DT 0
development NN 0
of IN 0
canine NN 0
heartworms NNS 0
and CC 0
was VBD 0
safe JJ 0
for IN 0
topical JJ 0
use NN 0
in IN 0
dogs NNS 0
and CC 0
cats NNS 0
. . 0

A DT 0
selective JJ 0
angiotensin NN 0
receptor NN 0
antagonist NN 0
, , 0
Valsartan NNP 0
, , 0
produced VBD 0
regression NN 0
of IN 0
left JJ 0
ventricular JJ 0
hypertrophy NN 0
associated VBN 0
with IN 0
a DT 0
reduction NN 0
of IN 0
arterial JJ 0
stiffness NN 0
. . 0

We PRP 0
investigated VBD 0
whether IN 0
a DT 0
selective JJ 0
angiotensin NN 0
II NNP 0
receptor NN 0
blocker NN 0
( ( 0
ARB NNP 0
) ) 0
would MD 0
have VB 0
a DT 0
regressive JJ 0
effect NN 0
on IN 0
left NN 0
ventricular JJ 0
hypertrophy NN 0
( ( 0
LVH NNP 0
) ) 0
in IN 0
patients NNS 0
on IN 0
continuous JJ 0
ambulatory JJ 0
peritoneal JJ 0
dialysis NN 0
( ( 0
CAPD NNP 0
) ) 0
. . 0

In IN 0
a DT 0
double-blind NN 0
study NN 0
, , 0
24 CD 0
CAPD NNP 0
patients NNS 0
with IN 0
LVH NNP 0
[ NNP 0
left VBD 0
ventricular JJ 0
mass NN 0
index NN 0
( ( 0
LVMi NNP 0
) ) 0
> VBD 0
110 CD 0
g/m2 NN 0
for IN 0
women NNS 0
and CC 0
LVMi NNP 0
> NNP 0
137 CD 0
g/m2 NN 0
for IN 0
men NNS 0
] NNS 0
were VBD 0
randomized VBN 0
to TO 0
12 CD 0
months NNS 0
' POS 0
administration NN 0
of IN 0
either CC 0
the DT 0
ARB NNP 0
valsartan NN 0
( ( 0
n JJ 0
= NNP 0
14 CD 0
) ) 0
or CC 0
a DT 0
placebo NN 0
( ( 0
n JJ 0
= NNP 0
10 CD 0
) ) 0
. . 0

The DT 0
target NN 0
blood NN 0
pressure NN 0
( ( 0
BP NNP 0
) ) 0
was VBD 0
140/90 CD 0
mmHg NN 0
or CC 0
lower JJR 0
in IN 0
both DT 0
groups NNS 0
. . 0

The DT 0
following JJ 0
parameters NNS 0
were VBD 0
measured VBN 0
before RB 0
and CC 0
at IN 0
the DT 0
end NN 0
of IN 0
the DT 0
study NN 0
: : 0
aortic JJ 0
and CC 0
large-artery JJ 0
compliance NN 0
and CC 0
arterial JJ 0
wave NN 0
reflections NNS 0
[ VBP 0
pulse JJ 0
wave VBP 0
velocity NN 0
( ( 0
PWV NNP 0
) ) 0
and CC 0
augmentation NN 0
index NN 0
( ( 0
AI NNP 0
) ) 0
application NN 0
tonometry NN 0
] NNP 0
and CC 0
cardiac JJ 0
echocardiography NN 0
. . 0

Periodically RB 0
recorded VBN 0
were VBD 0
body JJ 0
weight NN 0
, , 0
BP NNP 0
( ( 0
mercury NN 0
sphygmomanometer NN 0
) ) 0
, , 0
serum JJ 0
creatinine NN 0
, , 0
electrolytes VBZ 0
, , 0
complete JJ 0
blood NN 0
cell NN 0
counts NNS 0
, , 0
urine JJ 0
volume NN 0
, , 0
drainage NN 0
volume NN 0
, , 0
and CC 0
weekly JJ 0
creatinine NN 0
clearance NN 0
. . 0

Two-way JJ 0
analysis NN 0
of IN 0
variance NN 0
for IN 0
repeated JJ 0
measurements NNS 0
was VBD 0
used VBN 0
for IN 0
statistical JJ 0
analysis NN 0
. . 0

Systolic NNP 0
and CC 0
diastolic JJ 0
BP NNP 0
were VBD 0
both DT 0
reduced VBN 0
in IN 0
patients NNS 0
treated VBN 0
with IN 0
ARB NNP 0
. . 0

The DT 0
LVMi NNP 0
was VBD 0
significantly RB 0
reduced VBN 0
in IN 0
patients NNS 0
treated VBN 0
with IN 0
ARB NNP 0
( ( 0
to TO 0
121 CD 0
+/- JJ 0
4 CD 0
from IN 0
145 CD 0
+/- JJ 0
5 CD 0
) ) 0
but CC 0
not RB 0
in IN 0
those DT 0
receiving VBG 0
placebo NN 0
( ( 0
to TO 0
137 CD 0
+/- JJ 0
3 CD 0
from IN 0
152 CD 0
+/- JJ 0
3 CD 0
, , 0
p NN 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

The DT 0
decrease NN 0
in IN 0
LVMi NNP 0
was VBD 0
associated VBN 0
with IN 0
a DT 0
reduction NN 0
in IN 0
PWV NNP 0
and CC 0
AI NNP 0
. . 0

In IN 0
CAPD NNP 0
patients NNS 0
with IN 0
LVH NNP 0
, , 0
ARB NNP 0
reduced VBD 0
LVMi NNP 0
in IN 0
association NN 0
with IN 0
alterations NNS 0
in IN 0
arterial JJ 0
hemodynamics NNS 0
. . 0

A DT 0
multi-component JJ 0
social JJ 0
skills NNS 0
intervention NN 0
for IN 0
children NNS 0
with IN 0
Asperger NNP 0
syndrome NN 0
: : 0
the DT 0
Junior NNP 0
Detective NNP 0
Training NNP 0
Program NNP 0
. . 0

BACKGROUND NNP 0
The DT 0
study NN 0
aimed VBN 0
to TO 0
investigate VB 0
the DT 0
effectiveness NN 0
of IN 0
a DT 0
new JJ 0
multi-component JJ 0
social JJ 0
skills NNS 0
intervention NN 0
for IN 0
children NNS 0
with IN 0
Asperger NNP 0
syndrome NN 0
( ( 0
AS IN 0
) ) 0
: : 0
The DT 0
Junior NNP 0
Detective NNP 0
Training NNP 0
Program NNP 0
. . 0

This DT 0
7-week JJ 0
program NN 0
included VBD 0
a DT 0
computer NN 0
game NN 0
, , 0
small JJ 0
group NN 0
sessions NNS 0
, , 0
parent NN 0
training NN 0
sessions NNS 0
and CC 0
teacher NN 0
handouts NNS 0
. . 0

METHOD NNP 0
Forty-nine JJ 0
children NNS 0
with IN 0
AS NNP 0
were VBD 0
recruited VBN 0
to TO 0
participate VB 0
and CC 0
randomly VB 0
assigned VBN 0
to TO 0
intervention NN 0
( ( 0
n JJ 0
= NNP 0
26 CD 0
) ) 0
or CC 0
wait-list JJ 0
control NN 0
( ( 0
n JJ 0
= NNP 0
23 CD 0
) ) 0
conditions NNS 0
. . 0

RESULTS NNP 0
Relative NNP 0
to TO 0
children NNS 0
in IN 0
the DT 0
wait-list JJ 0
group NN 0
, , 0
program NN 0
participants NNS 0
showed VBD 0
greater JJR 0
improvements NNS 0
in IN 0
social JJ 0
skills NNS 0
over IN 0
the DT 0
course NN 0
of IN 0
the DT 0
intervention NN 0
, , 0
as IN 0
indicated VBN 0
by IN 0
parent-report JJ 0
measures NNS 0
. . 0

Teacher-report NNP 0
data NNS 0
also RB 0
confirmed VBD 0
that IN 0
children NNS 0
receiving VBG 0
the DT 0
intervention NN 0
made VBD 0
significant JJ 0
improvements NNS 0
in IN 0
social JJ 0
functioning NN 0
from IN 0
pre- JJ 0
to TO 0
post-treatment JJ 0
. . 0

Treatment NNP 0
group NN 0
participants NNS 0
were VBD 0
better RBR 0
able JJ 0
to TO 0
suggest VB 0
appropriate JJ 0
emotion-management JJ 0
strategies NNS 0
for IN 0
story NN 0
characters NNS 0
at IN 0
post-intervention NN 0
than IN 0
at IN 0
pre-intervention NN 0
, , 0
whereas NNS 0
control VBP 0
participants NNS 0
were VBD 0
not RB 0
. . 0

However RB 0
, , 0
there EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
the DT 0
improvements NNS 0
made VBN 0
by IN 0
children NNS 0
in IN 0
the DT 0
intervention NN 0
and CC 0
control NN 0
conditions NNS 0
on IN 0
facial JJ 0
expression NN 0
and CC 0
body-posture NN 0
recognition NN 0
measures NNS 0
. . 0

Follow-up NNP 0
data NN 0
suggested VBD 0
that IN 0
treatment NN 0
gains NNS 0
were VBD 0
maintained VBN 0
by IN 0
children NNS 0
at IN 0
5-months JJ 0
post-intervention NN 0
. . 0

CONCLUSIONS VB 0
The DT 0
Junior NNP 0
Detective NNP 0
Training NNP 0
Program NNP 0
appeared VBD 0
to TO 0
be VB 0
effective JJ 0
in IN 0
enhancing VBG 0
the DT 0
social JJ 0
skills NNS 0
and CC 0
emotional JJ 0
understanding NN 0
of IN 0
children NNS 0
with IN 0
AS NNP 0
. . 0

Limitations NNS 0
and CC 0
suggestions NNS 0
for IN 0
future JJ 0
research NN 0
are VBP 0
discussed VBN 0
. . 0

Gastric NNP 0
dysrhythmia NN 0
in IN 0
infants NNS 0
with IN 0
gastrointestinal JJ 0
diseases NNS 0
measured VBN 0
by IN 0
epigastric JJ 0
impedance NN 0
. . 0

BACKGROUND NNP 0
Gastrointestinal NNP 0
symptoms NNS 0
have VBP 0
been VBN 0
reported VBN 0
in IN 0
association NN 0
with IN 0
myoelectrical JJ 0
dysrhythmia NN 0
, , 0
where WRB 0
different JJ 0
types NNS 0
of IN 0
gastric JJ 0
electrical JJ 0
activity NN 0
have VBP 0
been VBN 0
described VBN 0
. . 0

These DT 0
types NNS 0
of IN 0
gastric JJ 0
myoelectrical JJ 0
activity NN 0
and CC 0
dysrhythmia NN 0
can MD 0
be VB 0
measured VBN 0
by IN 0
electrogastrography NN 0
using VBG 0
cutaneous JJ 0
electrodes NNS 0
. . 0

Epigastric JJ 0
impedance NN 0
is VBZ 0
a DT 0
non-invasive JJ 0
method NN 0
used VBN 0
to TO 0
study VB 0
gastric JJ 0
emptying VBG 0
time NN 0
and CC 0
gastric JJ 0
phasic JJ 0
activity NN 0
. . 0

At IN 0
present JJ 0
no DT 0
study NN 0
of IN 0
gastric JJ 0
dysrhythmia NN 0
, , 0
measured VBN 0
with IN 0
epigastric JJ 0
impedance NN 0
, , 0
has VBZ 0
been VBN 0
presented VBN 0
, , 0
and CC 0
the DT 0
purpose NN 0
of IN 0
the DT 0
present JJ 0
study NN 0
was VBD 0
to TO 0
investigate VB 0
gastric JJ 0
rhythms NN 0
by IN 0
means NNS 0
of IN 0
impedance NN 0
gastrography NN 0
in IN 0
control NN 0
infants NNS 0
, , 0
compared VBN 0
to TO 0
infants NNS 0
with IN 0
different JJ 0
gastrointestinal JJ 0
diseases NNS 0
, , 0
before IN 0
and CC 0
after IN 0
treatment NN 0
of IN 0
their PRP$ 0
disease NN 0
. . 0

METHOD NNP 0
21 CD 0
patients NNS 0
( ( 0
age NN 0
0-2 CD 0
months NNS 0
) ) 0
and CC 0
40 CD 0
healthy JJ 0
infants NNS 0
( ( 0
age NN 0
0-2 CD 0
months NNS 0
) ) 0
were VBD 0
investigated VBN 0
. . 0

The DT 0
patients NNS 0
suffered VBD 0
from IN 0
partial JJ 0
or CC 0
total JJ 0
intestinal JJ 0
obstruction NN 0
, , 0
necrotizing VBG 0
enterocolitis NN 0
or CC 0
pyloric JJ 0
stenosis.All NN 0
infants NNS 0
were VBD 0
fasting VBG 0
and CC 0
studied VBN 0
during IN 0
periods NNS 0
of IN 0
at IN 0
least JJS 0
one CD 0
hour NN 0
. . 0

The DT 0
patients NNS 0
were VBD 0
examined VBN 0
in IN 0
the DT 0
acute NN 0
state NN 0
and CC 0
after IN 0
treatment NN 0
when WRB 0
possible JJ 0
. . 0

RESULTS VB 0
A DT 0
pathologic JJ 0
result NN 0
was VBD 0
found VBN 0
in IN 0
90 CD 0
% NN 0
of IN 0
the DT 0
patients NNS 0
. . 0

A DT 0
persistent JJ 0
phasic JJ 0
activity NN 0
pattern NN 0
was VBD 0
found VBN 0
in IN 0
19 CD 0
of IN 0
the DT 0
21 CD 0
patients NNS 0
, , 0
high JJ 0
frequency NN 0
phasic JJ 0
activity NN 0
in IN 0
11 CD 0
of IN 0
the DT 0
21 CD 0
patients NNS 0
. . 0

Short-term JJ 0
phasic JJ 0
activity NN 0
was VBD 0
only RB 0
found VBN 0
in IN 0
13 CD 0
out IN 0
of IN 0
40 CD 0
of IN 0
the DT 0
normal JJ 0
infants NNS 0
( ( 0
32.5 CD 0
% NN 0
) ) 0
. . 0

CONCLUSION NNP 0
Using NNP 0
epigastric JJ 0
impedance NN 0
we PRP 0
found VBD 0
that IN 0
infants NNS 0
with IN 0
partial JJ 0
or CC 0
total JJ 0
intestinal JJ 0
obstruction NN 0
had VBD 0
gastric JJ 0
phasic JJ 0
activity NN 0
, , 0
which WDT 0
was VBD 0
not RB 0
found VBN 0
in IN 0
the DT 0
control NN 0
infants NNS 0
. . 0

The DT 0
origin NN 0
of IN 0
the DT 0
gastric JJ 0
phasic JJ 0
activity NN 0
patterns NNS 0
is VBZ 0
unknown JJ 0
, , 0
but CC 0
they PRP 0
may MD 0
be VB 0
related VBN 0
to TO 0
electrical JJ 0
control NN 0
activity NN 0
. . 0

A DT 0
double-blind NN 0
, , 0
randomized VBN 0
, , 0
controlled VBN 0
, , 0
multicenter NN 0
safety NN 0
and CC 0
immunogenicity NN 0
study NN 0
of IN 0
a DT 0
refrigerator-stable JJ 0
formulation NN 0
of IN 0
Zostavax NNP 0
. . 0

The DT 0
vaccine NN 0
Zostavax NNP 0
has VBZ 0
been VBN 0
shown VBN 0
to TO 0
prevent VB 0
herpes NNS 0
zoster NNP 0
( ( 0
HZ NNP 0
) ) 0
and CC 0
postherpetic JJ 0
neuralgia NN 0
and CC 0
is VBZ 0
recommended VBN 0
for IN 0
individuals NNS 0
> CD 0
or CC 0
=60 CD 0
years NNS 0
of IN 0
age NN 0
. . 0

This DT 0
study NN 0
compared VBN 0
the DT 0
safety NN 0
and CC 0
the DT 0
immunogenicity NN 0
of IN 0
a DT 0
refrigerator-stable JJ 0
formulation NN 0
( ( 0
Zostavax NNP 0
refrigerated VBD 0
) ) 0
with IN 0
those DT 0
of IN 0
the DT 0
current JJ 0
formulation NN 0
( ( 0
Zostavax NNP 0
frozen RB 0
) ) 0
in IN 0
subjects NNS 0
> VBP 0
or CC 0
=50 CD 0
years NNS 0
of IN 0
age NN 0
. . 0

Subjects VBZ 0
with IN 0
a DT 0
negative JJ 0
history NN 0
for IN 0
HZ NNP 0
were VBD 0
randomized VBN 0
1:1 CD 0
to TO 0
receive VB 0
one CD 0
dose NN 0
of IN 0
either DT 0
formulation NN 0
. . 0

Enrollment NN 0
was VBD 0
stratified VBN 0
1:2 CD 0
by IN 0
age NN 0
( ( 0
50 CD 0
to TO 0
59 CD 0
years NNS 0
and CC 0
> NN 0
or CC 0
=60 CD 0
years NNS 0
) ) 0
. . 0

Safety NN 0
was VBD 0
evaluated VBN 0
for IN 0
28 CD 0
days NNS 0
postvaccination NN 0
. . 0

Varicella-zoster JJ 0
virus NN 0
( ( 0
VZV NNP 0
) ) 0
antibody NN 0
responses NNS 0
were VBD 0
measured VBN 0
by IN 0
a DT 0
glycoprotein JJ 0
enzyme-linked JJ 0
immunosorbent NN 0
assay NN 0
( ( 0
gpELISA NN 0
) ) 0
. . 0

The DT 0
primary JJ 0
endpoints NNS 0
were VBD 0
the DT 0
VZV NNP 0
antibody NN 0
geometric JJ 0
mean NN 0
titer NN 0
( ( 0
GMT NNP 0
; : 0
day NN 0
28 CD 0
) ) 0
, , 0
the DT 0
VZV NNP 0
antibody NN 0
geometric JJ 0
mean NN 0
rise NN 0
( ( 0
GMR NNP 0
; : 0
days NNS 0
1 CD 0
to TO 0
28 CD 0
) ) 0
, , 0
and CC 0
the DT 0
incidence NN 0
of IN 0
vaccine-related JJ 0
serious JJ 0
adverse JJ 0
experiences NNS 0
( ( 0
AEs NNP 0
) ) 0
over IN 0
28 CD 0
days NNS 0
. . 0

The DT 0
refrigerated JJ 0
( ( 0
n JJ 0
= NNP 0
182 CD 0
) ) 0
and CC 0
frozen JJ 0
( ( 0
n JJ 0
= NNP 0
185 CD 0
) ) 0
formulations NNS 0
induced VBD 0
similar JJ 0
GMTs NNP 0
( ( 0
727.4 CD 0
and CC 0
834.4 CD 0
gpELISA NN 0
units/ml NN 0
, , 0
respectively RB 0
) ) 0
; : 0
the DT 0
estimated VBN 0
GMT NNP 0
ratio NN 0
( ( 0
refrigerated VBN 0
formulation/frozen RB 0
formulation NN 0
) ) 0
was VBD 0
0.87 CD 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
, , 0
0.71 CD 0
to TO 0
1.07 CD 0
) ) 0
. . 0

The DT 0
GMRs NNPS 0
were VBD 0
2.6- JJ 0
and CC 0
2.9-fold JJ 0
, , 0
respectively RB 0
. . 0

No DT 0
vaccine-related JJ 0
serious JJ 0
AEs NNP 0
were VBD 0
reported VBN 0
in IN 0
either DT 0
group NN 0
, , 0
and CC 0
the DT 0
safety NN 0
profiles NNS 0
of IN 0
the DT 0
formulations NNS 0
were VBD 0
generally RB 0
similar JJ 0
. . 0

The DT 0
frequencies NNS 0
of IN 0
injection-site JJ 0
AEs NNP 0
during IN 0
follow-up JJ 0
were VBD 0
35.6 CD 0
% NN 0
and CC 0
46.4 CD 0
% NN 0
in IN 0
the DT 0
refrigerated JJ 0
and CC 0
the DT 0
frozen JJ 0
formulation NN 0
groups NNS 0
, , 0
respectively RB 0
, , 0
and CC 0
were VBD 0
generally RB 0
mild VBN 0
. . 0

The DT 0
frequencies NNS 0
of IN 0
systemic JJ 0
AEs NNP 0
were VBD 0
similar JJ 0
in IN 0
the DT 0
two CD 0
groups NNS 0
, , 0
and CC 0
those DT 0
of IN 0
vaccine-related JJ 0
AEs NNP 0
were VBD 0
approximately RB 0
6 CD 0
% NN 0
in IN 0
both DT 0
groups NNS 0
. . 0

The DT 0
refrigerator-stable JJ 0
formulation NN 0
of IN 0
Zostavax NNP 0
has VBZ 0
an DT 0
acceptable JJ 0
safety NN 0
profile NN 0
and CC 0
is VBZ 0
as RB 0
immunogenic JJ 0
as IN 0
the DT 0
frozen JJ 0
formulation NN 0
; : 0
thus RB 0
, , 0
the DT 0
vaccine NN 0
may MD 0
be VB 0
used VBN 0
in IN 0
clinical JJ 0
settings NNS 0
where WRB 0
freezer NN 0
availability NN 0
is VBZ 0
limited VBN 0
. . 0

Safety NN 0
and CC 0
preliminary JJ 0
immunogenicity NN 0
of IN 0
Cuban NNP 0
pneumococcal JJ 0
conjugate NN 0
vaccine NN 0
candidate NN 0
in IN 0
healthy JJ 0
children NNS 0
: : 0
a DT 0
randomized JJ 0
phase NN 0
I PRP 0
clinical JJ 0
trial NN 0
. . 0

A DT 0
new JJ 0
heptavalent NN 0
conjugate NN 0
vaccine NN 0
( ( 0
PCV7-TT NNP 0
) ) 0
is VBZ 0
under IN 0
development NN 0
in IN 0
Cuba NNP 0
. . 0

PCV7-TT NNP 0
contains VBZ 0
2 CD 0
?g NN 0
of IN 0
serotypes NNS 0
1 CD 0
, , 0
5 CD 0
, , 0
14 CD 0
, , 0
18C CD 0
, , 0
19F CD 0
, , 0
23F CD 0
and CC 0
4 CD 0
?g NN 0
of IN 0
6B CD 0
, , 0
each DT 0
one CD 0
conjugated VBN 0
to TO 0
tetanus VB 0
toxoid NN 0
( ( 0
TT NNP 0
) ) 0
. . 0

This DT 0
vaccine NN 0
was VBD 0
designed VBN 0
with IN 0
the DT 0
serotypes NNS 0
that WDT 0
cause VBP 0
most RBS 0
invasive JJ 0
pneumococcal JJ 0
diseases NNS 0
( ( 0
IPD NNP 0
) ) 0
worldwide NN 0
. . 0

In IN 0
the DT 0
present JJ 0
study NN 0
, , 0
we PRP 0
investigated VBD 0
the DT 0
safety NN 0
and CC 0
explored VBD 0
the DT 0
immunogenicity NN 0
of IN 0
PCV7-TT NNP 0
during IN 0
a DT 0
controlled VBN 0
, , 0
randomized VBN 0
and CC 0
double JJ 0
blind NN 0
clinical JJ 0
trial NN 0
phase NN 0
I PRP 0
in IN 0
4-5-year-old JJ 0
children NNS 0
. . 0

PCV7-TT NN 0
was VBD 0
well RB 0
tolerated JJ 0
and CC 0
as RB 0
safe JJ 0
as IN 0
Synflorix NNP 0
used VBD 0
as IN 0
control NN 0
vaccine NN 0
. . 0

Following VBG 0
a DT 0
single-dose JJ 0
vaccination NN 0
, , 0
all DT 0
individual JJ 0
serotypes NNS 0
included VBN 0
in IN 0
PCV7-TT NNP 0
induced VBD 0
statistically RB 0
significant JJ 0
increase NN 0
of IN 0
IgG NNP 0
GMC NNP 0
and CC 0
OPA NNP 0
GMT NNP 0
. . 0

These DT 0
are VBP 0
the DT 0
first JJ 0
clinical JJ 0
results NNS 0
of IN 0
PCV7-TT NNP 0
in IN 0
children NNS 0
and CC 0
they PRP 0
pave VBP 0
the DT 0
way NN 0
toward IN 0
next JJ 0
clinical JJ 0
trials NNS 0
in IN 0
children NNS 0
and CC 0
infants NNS 0
. . 0

This DT 0
clinical JJ 0
trial NN 0
was VBD 0
published VBN 0
in IN 0
the DT 0
Cuban NNP 0
Public NNP 0
Register NNP 0
of IN 0
Clinical NNP 0
Trials NNP 0
with IN 0
code NN 0
RPCEC00000173 NNP 0
. . 0

The DT 0
prophylactic JJ 0
effect NN 0
of IN 0
itraconazole JJ 0
capsules NNS 0
and CC 0
fluconazole JJ 0
capsules NNS 0
for IN 0
systemic JJ 0
fungal JJ 0
infections NNS 0
in IN 0
patients NNS 0
with IN 0
acute JJ 0
myeloid NN 0
leukemia NN 0
and CC 0
myelodysplastic JJ 0
syndromes NNS 0
: : 0
a DT 0
Japanese JJ 0
multicenter NN 0
randomized VBN 0
, , 0
controlled VBN 0
study NN 0
. . 0

We PRP 0
performed VBD 0
a DT 0
randomized VBN 0
, , 0
controlled VBN 0
study NN 0
comparing VBG 0
the DT 0
prophylactic JJ 0
effects NNS 0
of IN 0
capsule NN 0
forms NNS 0
of IN 0
fluconazole NN 0
( ( 0
n JJ 0
= NNP 0
110 CD 0
) ) 0
and CC 0
itraconazole JJ 0
( ( 0
n JJ 0
= NNP 0
108 CD 0
) ) 0
in IN 0
patients NNS 0
with IN 0
acute JJ 0
myeloid NN 0
leukemia NN 0
( ( 0
AML NNP 0
) ) 0
or CC 0
myelodysplastic JJ 0
syndromes NNS 0
( ( 0
MDS NNP 0
) ) 0
during IN 0
and CC 0
after IN 0
chemotherapy NN 0
. . 0

There EX 0
were VBD 0
4 CD 0
cases NNS 0
with IN 0
possible JJ 0
systemic JJ 0
fungal JJ 0
infection NN 0
in IN 0
the DT 0
itraconazole NN 0
group NN 0
, , 0
and CC 0
there EX 0
were VBD 0
8 CD 0
possible JJ 0
and CC 0
3 CD 0
probable JJ 0
cases NNS 0
in IN 0
the DT 0
fluconazole JJ 0
group NN 0
. . 0

Adverse JJ 0
events NNS 0
did VBD 0
not RB 0
significantly RB 0
differ VB 0
in IN 0
the DT 0
2 CD 0
groups NNS 0
. . 0

In IN 0
patients NNS 0
with IN 0
MDS NNP 0
or CC 0
in IN 0
the DT 0
remission-induction JJ 0
phase NN 0
of IN 0
chemotherapy NN 0
, , 0
the DT 0
numbers NNS 0
of IN 0
cases NNS 0
with IN 0
probable JJ 0
or CC 0
possible JJ 0
infections NNS 0
were VBD 0
lower JJR 0
in IN 0
the DT 0
itraconazole NN 0
group NN 0
than IN 0
in IN 0
the DT 0
fluconazole NN 0
group NN 0
, , 0
whereas IN 0
no DT 0
difference NN 0
was VBD 0
seen VBN 0
in IN 0
patients NNS 0
with IN 0
AML NNP 0
or CC 0
in IN 0
the DT 0
consolidation NN 0
phase NN 0
of IN 0
therapy NN 0
. . 0

In IN 0
patients NNS 0
with IN 0
neutrophil JJ 0
counts NNS 0
of IN 0
> $ 0
0.1 CD 0
x $ 0
10 CD 0
( ( 0
9 CD 0
) ) 0
/L NN 0
lasting VBG 0
for IN 0
more JJR 0
than IN 0
4 CD 0
weeks NNS 0
, , 0
the DT 0
frequency NN 0
of IN 0
infection NN 0
in IN 0
the DT 0
fluconazole JJ 0
group NN 0
( ( 0
5 CD 0
of IN 0
9 CD 0
patients NNS 0
) ) 0
was VBD 0
significantly RB 0
higher JJR 0
than IN 0
in IN 0
the DT 0
itraconazole JJ 0
group NN 0
( ( 0
0 CD 0
of IN 0
7 CD 0
patients NNS 0
; : 0
P NNP 0
= NNP 0
.03 NNP 0
) ) 0
. . 0

Our PRP$ 0
results NNS 0
suggest VBP 0
that IN 0
both DT 0
drugs NNS 0
were VBD 0
well RB 0
tolerated VBN 0
in IN 0
patients NNS 0
with IN 0
AML NNP 0
or CC 0
MDS NNP 0
who WP 0
received VBD 0
chemotherapy NN 0
and CC 0
that IN 0
the DT 0
efficacy NN 0
of IN 0
itraconazole NN 0
for IN 0
prophylaxis NN 0
against IN 0
systemic JJ 0
fungal JJ 0
disease NN 0
is VBZ 0
not RB 0
inferior JJ 0
to TO 0
that DT 0
of IN 0
fluconazole NN 0
. . 0

Comparison NNP 0
of IN 0
propofol NN 0
, , 0
droperidol NN 0
, , 0
and CC 0
metoclopramide NN 0
for IN 0
prophylaxis NN 0
of IN 0
postoperative JJ 0
nausea NN 0
and CC 0
vomiting NN 0
after IN 0
breast NN 0
cancer NN 0
surgery NN 0
: : 0
a DT 0
prospective JJ 0
, , 0
randomized VBN 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
study NN 0
in IN 0
Japanese JJ 0
patients NNS 0
. . 0

BACKGROUND NNP 0
Breast NNP 0
cancer NN 0
surgery NN 0
performed VBN 0
with IN 0
the DT 0
patient NN 0
under IN 0
general JJ 0
anesthesia NN 0
has VBZ 0
been VBN 0
associated VBN 0
with IN 0
a DT 0
relatively RB 0
high JJ 0
incidence NN 0
of IN 0
postoperative JJ 0
nausea NN 0
and CC 0
vomiting NN 0
( ( 0
PONV NNP 0
) ) 0
. . 0

Between $ 0
60 CD 0
% NN 0
and CC 0
80 CD 0
% NN 0
of IN 0
patients NNS 0
who WP 0
undergo VBP 0
mastectomy NNS 0
( ( 0
with IN 0
axillary JJ 0
dissection NN 0
) ) 0
experience NN 0
PONV NNP 0
. . 0

We PRP 0
previously RB 0
reported VBD 0
that IN 0
propofol NN 0
at IN 0
a DT 0
subhypnotic JJ 0
dose NN 0
of IN 0
0.5 CD 0
mg/kg NN 0
was VBD 0
more RBR 0
effective JJ 0
than IN 0
placebo NN 0
in IN 0
preventing VBG 0
PONV NNP 0
in IN 0
women NNS 0
who WP 0
undergo VBP 0
mastectomy NN 0
. . 0

OBJECTIVE CC 0
The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
compare VB 0
the DT 0
efficacy NN 0
of IN 0
a DT 0
subhypnotic JJ 0
dose NN 0
of IN 0
propofol NN 0
with IN 0
the DT 0
conventional JJ 0
antiemetics NNS 0
droperidol NN 0
and CC 0
metoclopramide NN 0
for IN 0
the DT 0
prophylaxis NN 0
of IN 0
PONV NNP 0
after IN 0
breast NN 0
cancer NN 0
surgery NN 0
in IN 0
Japanese JJ 0
patients NNS 0
. . 0

METHODS NNP 0
In IN 0
this DT 0
prospective JJ 0
, , 0
randomized VBN 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
study NN 0
, , 0
Japanese JJ 0
women NNS 0
were VBD 0
randomized VBN 0
to TO 0
1 CD 0
of IN 0
4 CD 0
groups NNS 0
to TO 0
receive VB 0
IV NNP 0
administration NN 0
of IN 0
propofol JJ 0
0.5 CD 0
mg/kg NN 0
, , 0
droperidol VBZ 0
20 CD 0
microg/kg NN 0
, , 0
metoclopramide RB 0
0.2 CD 0
mg/kg NN 0
, , 0
or CC 0
placebo NN 0
( ( 0
isotonic JJ 0
saline NN 0
) ) 0
immediately RB 0
after IN 0
skin JJ 0
suture NN 0
. . 0

A DT 0
standard JJ 0
general JJ 0
anesthetic JJ 0
technique NN 0
, , 0
including VBG 0
sevoflurane NN 0
and CC 0
air NN 0
in IN 0
oxygen NN 0
, , 0
was VBD 0
used VBN 0
. . 0

All DT 0
episodes NNS 0
of IN 0
PONV NNP 0
during IN 0
the DT 0
first JJ 0
24 CD 0
hours NNS 0
after IN 0
anesthesia JJ 0
administration NN 0
were VBD 0
recorded VBN 0
by IN 0
an DT 0
investigator NN 0
who WP 0
was VBD 0
blinded VBN 0
to TO 0
treatment NN 0
assignment NN 0
. . 0

The DT 0
investigator NN 0
questioned VBD 0
the DT 0
patients NNS 0
as IN 0
to TO 0
whether IN 0
they PRP 0
experienced VBD 0
extrapyramidal NN 0
symptoms NNS 0
. . 0

To TO 0
maintain VB 0
the DT 0
integrity NN 0
of IN 0
the DT 0
study NN 0
results NNS 0
, , 0
none NN 0
of IN 0
the DT 0
patients NNS 0
received VBD 0
preanesthetic JJ 0
medication NN 0
. . 0

RESULTS VB 0
A DT 0
total NN 0
of IN 0
100 CD 0
women NNS 0
( ( 0
mean JJ 0
[ NNP 0
SD NNP 0
] NNP 0
age NN 0
, , 0
52 CD 0
[ NN 0
7 CD 0
] CD 0
years NNS 0
; : 0
height VBD 0
, , 0
154 CD 0
[ NN 0
6 CD 0
] NNP 0
cm NN 0
; : 0
weight NN 0
, , 0
54 CD 0
[ NN 0
7 CD 0
] NNP 0
kg NN 0
) ) 0
were VBD 0
included VBN 0
in IN 0
the DT 0
study NN 0
. . 0

Each DT 0
study NN 0
group NN 0
comprised VBD 0
25 CD 0
patients NNS 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
between IN 0
treatment NN 0
groups NNS 0
with IN 0
regard NN 0
to TO 0
patient VB 0
demographics NNS 0
, , 0
surgery NN 0
type NN 0
, , 0
or CC 0
awakening VBG 0
time NN 0
. . 0

The DT 0
prevalences NNS 0
of IN 0
PONV NNP 0
0 CD 0
to TO 0
24 CD 0
hours NNS 0
after IN 0
anesthesia NN 0
were VBD 0
28 CD 0
% NN 0
with IN 0
propofol NN 0
( ( 0
P NNP 0
= NNP 0
0.005 CD 0
) ) 0
, , 0
32 CD 0
% NN 0
with IN 0
droperidol NN 0
( ( 0
P NNP 0
= NNP 0
0.011 CD 0
) ) 0
, , 0
and CC 0
60 CD 0
% NN 0
with IN 0
metoclopramide NN 0
( ( 0
P NNP 0
= NNP 0
NS NNP 0
) ) 0
, , 0
compared VBN 0
with IN 0
placebo NN 0
( ( 0
68 CD 0
% NN 0
) ) 0
. . 0

No DT 0
significant JJ 0
difference NN 0
in IN 0
the DT 0
prevalence NN 0
of IN 0
PONV NNP 0
was VBD 0
found VBN 0
between IN 0
patients NNS 0
receiving VBG 0
propofol NN 0
and CC 0
those DT 0
receiving VBG 0
droperidol NN 0
, , 0
and CC 0
propofol NN 0
and CC 0
droperidol NN 0
were VBD 0
associated VBN 0
with IN 0
significantly RB 0
lower JJR 0
prevalences NNS 0
of IN 0
PONV NNP 0
compared VBN 0
with IN 0
metoclopramide NN 0
( ( 0
P NNP 0
= NNP 0
0.022 CD 0
and CC 0
P NNP 0
= NNP 0
0.043 CD 0
, , 0
respectively RB 0
) ) 0
. . 0

Extrapyramidal NNP 0
symptoms NNS 0
were VBD 0
not RB 0
reported VBN 0
in IN 0
any DT 0
of IN 0
the DT 0
groups NNS 0
. . 0

CONCLUSIONS VB 0
The DT 0
prevalences NNS 0
of IN 0
PONV NNP 0
were VBD 0
not RB 0
significantly RB 0
different JJ 0
between IN 0
propofol NN 0
0.5 CD 0
mg/kg NN 0
and CC 0
droperidol NN 0
20 CD 0
microg/kg NN 0
0 CD 0
to TO 0
24 CD 0
hours NNS 0
after IN 0
anesthesia NN 0
in IN 0
this DT 0
small JJ 0
, , 0
select JJ 0
group NN 0
of IN 0
Japanese JJ 0
women NNS 0
who WP 0
underwent VBP 0
breast NN 0
cancer NN 0
surgery NN 0
. . 0

The DT 0
prevalences NNS 0
of IN 0
PONV NNP 0
were VBD 0
significantly RB 0
lower JJR 0
with IN 0
propofol NN 0
and CC 0
droperidol NN 0
compared VBN 0
with IN 0
metoclopramide JJ 0
0.2 CD 0
mg/kg NN 0
and CC 0
placebo NN 0
. . 0

Levobunolol NNP 0
compared VBN 0
with IN 0
timolol NN 0
: : 0
a DT 0
four-year JJ 0
study NN 0
. . 0

Fifty-one CD 0
patients NNS 0
with IN 0
raised VBN 0
intraocular JJ 0
pressure NN 0
( ( 0
IOP NNP 0
) ) 0
were VBD 0
treated VBN 0
for IN 0
up IN 0
to TO 0
four CD 0
years NNS 0
with IN 0
one CD 0
of IN 0
three CD 0
ophthalmic JJ 0
solutions NNS 0
: : 0
0.5 CD 0
% NN 0
levobunolol NN 0
, , 0
1 CD 0
% NN 0
levobunolol NN 0
, , 0
or CC 0
0.5 CD 0
% NN 0
timolol NN 0
. . 0

The DT 0
study NN 0
was VBD 0
conducted VBN 0
as IN 0
a DT 0
double-masked JJ 0
, , 0
randomised JJ 0
trial NN 0
in IN 0
which WDT 0
medications NNS 0
were VBD 0
administered VBN 0
twice RB 0
daily RB 0
to TO 0
both DT 0
eyes NNS 0
. . 0

Levobunolol NNP 0
and CC 0
timolol NN 0
were VBD 0
equally RB 0
effective JJ 0
in IN 0
reducing VBG 0
overall JJ 0
mean JJ 0
IOP NNP 0
; : 0
reductions NNS 0
were VBD 0
greater JJR 0
than IN 0
8.8 CD 0
mmHg NNS 0
in IN 0
all DT 0
three CD 0
treatment NN 0
groups NNS 0
. . 0

The DT 0
study NN 0
showed VBD 0
levobunolol NNS 0
to TO 0
be VB 0
as IN 0
safe JJ 0
and CC 0
effective JJ 0
as IN 0
timolol NN 0
in IN 0
the DT 0
long-term JJ 0
control NN 0
of IN 0
raised VBN 0
IOP NNP 0
. . 0

Goal NNP 0
attainment NN 0
scaling NN 0
as IN 0
an DT 0
outcome NN 0
measure NN 0
in IN 0
randomized VBN 0
controlled JJ 0
trials NNS 0
of IN 0
psychosocial JJ 0
interventions NNS 0
in IN 0
autism NN 0
. . 0

Goal NNP 0
attainment JJ 0
scaling NN 0
( ( 0
GAS NNP 0
) ) 0
holds VBZ 0
promise NN 0
as IN 0
an DT 0
idiographic JJ 0
approach NN 0
for IN 0
measuring VBG 0
outcomes NNS 0
of IN 0
psychosocial JJ 0
interventions NNS 0
in IN 0
community NN 0
settings NNS 0
. . 0

GAS NNP 0
has VBZ 0
been VBN 0
criticized VBN 0
for IN 0
untested JJ 0
assumptions NNS 0
of IN 0
scaling VBG 0
level NN 0
( ( 0
i.e. JJ 0
, , 0
interval JJ 0
or CC 0
ordinal JJ 0
) ) 0
, , 0
inter-individual JJ 0
equivalence NN 0
and CC 0
comparability NN 0
, , 0
and CC 0
reliability NN 0
of IN 0
coding VBG 0
across IN 0
different JJ 0
behavioral JJ 0
observation NN 0
methods NNS 0
. . 0

We PRP 0
tested VBD 0
assumptions NNS 0
of IN 0
equality NN 0
between IN 0
GAS NNP 0
descriptions NNS 0
for IN 0
outcome JJ 0
measurement NN 0
in IN 0
a DT 0
randomized JJ 0
trial NN 0
( ( 0
i.e. FW 0
, , 0
measurability NN 0
, , 0
equidistance NN 0
, , 0
level NN 0
of IN 0
difficulty NN 0
, , 0
comparability NN 0
of IN 0
behavior NN 0
samples NNS 0
collected VBN 0
from IN 0
teachers NNS 0
vs. FW 0
researchers NNS 0
and CC 0
live JJ 0
vs. FW 0
videotape NN 0
) ) 0
. . 0

Results NNP 0
suggest VBP 0
GAS NNP 0
descriptions NNS 0
can MD 0
be VB 0
evaluated VBN 0
for IN 0
equivalency NN 0
, , 0
that IN 0
teacher RB 0
collected VBN 0
behavior NN 0
samples NNS 0
are VBP 0
representative JJ 0
, , 0
and CC 0
that IN 0
varied JJ 0
sources NNS 0
of IN 0
behavior NN 0
samples NNS 0
can MD 0
be VB 0
reliably RB 0
coded VBN 0
. . 0

GAS NNP 0
is VBZ 0
a DT 0
promising JJ 0
measurement NN 0
approach NN 0
. . 0

Recommendations NNS 0
are VBP 0
provided VBN 0
to TO 0
ensure VB 0
methodological JJ 0
quality NN 0
. . 0

[ VB 0
The DT 0
sympatho-adrenergic JJ 0
stress NN 0
reaction NN 0
in IN 0
ear JJ 0
surgery NN 0
using VBG 0
various JJ 0
anesthesia JJ 0
technics NNS 0
] VBP 0
. . 0

The DT 0
aim NN 0
of IN 0
the DT 0
present JJ 0
study NN 0
was VBD 0
to TO 0
investigate VB 0
the DT 0
effects NNS 0
of IN 0
various JJ 0
anaesthetic JJ 0
procedures NNS 0
on IN 0
the DT 0
endocrine NN 0
stress NN 0
responses NNS 0
during IN 0
ear JJ 0
microsurgical JJ 0
operations NNS 0
. . 0

Simple JJ 0
mastoidectomies NNS 0
, , 0
radical JJ 0
mastoidectomies NNS 0
and CC 0
tympano NN 0
plastics NNS 0
were VBD 0
carried VBN 0
out IN 0
in IN 0
49 CD 0
patients NNS 0
under IN 0
the DT 0
following VBG 0
randomised VBD 0
anaesthetic JJ 0
procedures NNS 0
: : 0
Group NNP 0
1 CD 0
halothane NN 0
anaesthesia NN 0
and CC 0
retroauricular JJ 0
infiltration NN 0
anaesthesia NN 0
with IN 0
lidocaine NN 0
and CC 0
ornipressin NN 0
( ( 0
n JJ 0
= NNP 0
14 CD 0
) ) 0
, , 0
Group NNP 0
2 CD 0
fentanyl NN 0
anaesthesia NN 0
and CC 0
retroauricular JJ 0
anaesthesia NN 0
with IN 0
lidocaine NN 0
and CC 0
ornipressin NN 0
( ( 0
n JJ 0
= NNP 0
10 CD 0
) ) 0
, , 0
Group NNP 0
3 CD 0
fentanyl NN 0
anaesthesia NN 0
and CC 0
retroauricular JJ 0
infiltration NN 0
anaesthesia NN 0
with IN 0
lidocaine NN 0
and CC 0
epinephrine NN 0
( ( 0
n JJ 0
= NNP 0
14 CD 0
) ) 0
, , 0
and CC 0
Group NNP 0
4 CD 0
retroauricular JJ 0
infiltration NN 0
anaesthesia NN 0
with IN 0
prilocaine NN 0
and CC 0
epinephrine NN 0
( ( 0
n JJ 0
= NNP 0
14 CD 0
) ) 0
. . 0

The DT 0
plasma NN 0
levels NNS 0
of IN 0
epinephrine NN 0
, , 0
norepinephrine NN 0
, , 0
glucose NN 0
, , 0
lactate NN 0
and CC 0
free JJ 0
glycerol NN 0
were VBD 0
measured VBN 0
in IN 0
addition NN 0
to TO 0
mean VB 0
arterial JJ 0
pressure NN 0
( ( 0
MAP NNP 0
) ) 0
and CC 0
heart NN 0
rate NN 0
( ( 0
HR NNP 0
) ) 0
immediately RB 0
before IN 0
anaesthesia NN 0
, , 0
10 CD 0
minutes NNS 0
after IN 0
skin JJ 0
incision NN 0
, , 0
10 CD 0
minutes NNS 0
after IN 0
having VBG 0
started VBD 0
bone CD 0
drilling NN 0
, , 0
at IN 0
the DT 0
end NN 0
of IN 0
the DT 0
operation NN 0
and CC 0
3 CD 0
hours NNS 0
after IN 0
operation NN 0
. . 0

All DT 0
data NNS 0
were VBD 0
subjected VBN 0
to TO 0
covariance VB 0
analysis NN 0
including VBG 0
the DT 0
age NN 0
factor NN 0
. . 0

Plasma NNP 0
catecholamine JJ 0
concentrations NNS 0
remained VBD 0
within IN 0
the DT 0
normal JJ 0
range NN 0
during IN 0
the DT 0
investigation NN 0
in IN 0
patients NNS 0
subjected VBN 0
to TO 0
general JJ 0
anaesthesia NN 0
( ( 0
Groups NNP 0
1-3 CD 0
) ) 0
. . 0

Plasma NNP 0
catecholamines NNS 0
( ( 0
epinephrine NN 0
and CC 0
norepinephrine NN 0
) ) 0
increased VBD 0
significantly RB 0
in IN 0
Group NNP 0
4 CD 0
( ( 0
retroauricular JJ 0
infiltration NN 0
anaesthesia NN 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
group NN 0
variabilities VBZ 0
with IN 0
regard NN 0
to TO 0
MAP NNP 0
and CC 0
HR NNP 0
. . 0

The DT 0
plasma NN 0
levels NNS 0
of IN 0
epinephrine NN 0
and CC 0
norepinephrine JJ 0
demonstrate NN 0
a DT 0
direct JJ 0
response NN 0
to TO 0
stress NN 0
followed VBN 0
by IN 0
a DT 0
secondary JJ 0
change NN 0
in IN 0
glucose NN 0
, , 0
lactate NN 0
and CC 0
free JJ 0
glycerol NN 0
. . 0

The DT 0
beneficial JJ 0
effect NN 0
of IN 0
general JJ 0
anaesthesia NN 0
is VBZ 0
documented VBN 0
by IN 0
normal JJ 0
plasma NN 0
levels NNS 0
of IN 0
epinephrine NN 0
and CC 0
norepinephrine NN 0
throughout IN 0
the DT 0
operation NN 0
. . 0

( ( 0
ABSTRACT NNP 0
TRUNCATED NNP 0
AT NNP 0
250 CD 0
WORDS NNP 0
) ) 0
Teaching VBG 0
emotion NN 0
recognition NN 0
skills NNS 0
to TO 0
young JJ 0
children NNS 0
with IN 0
autism NN 0
: : 0
a DT 0
randomised JJ 0
controlled JJ 0
trial NN 0
of IN 0
an DT 0
emotion NN 0
training NN 0
programme NN 0
. . 0

BACKGROUND NNP 0
Children NNP 0
with IN 0
autism NN 0
have VBP 0
difficulties NNS 0
in IN 0
emotion NN 0
recognition NN 0
and CC 0
a DT 0
number NN 0
of IN 0
interventions NNS 0
have VBP 0
been VBN 0
designed VBN 0
to TO 0
target VB 0
these DT 0
problems NNS 0
. . 0

However RB 0
, , 0
few JJ 0
emotion NN 0
training NN 0
interventions NNS 0
have VBP 0
been VBN 0
trialled VBN 0
with IN 0
young JJ 0
children NNS 0
with IN 0
autism NN 0
and CC 0
co-morbid JJ 0
ID NNP 0
. . 0

This DT 0
study NN 0
aimed VBD 0
to TO 0
evaluate VB 0
the DT 0
efficacy NN 0
of IN 0
an DT 0
emotion NN 0
training NN 0
programme NN 0
for IN 0
a DT 0
group NN 0
of IN 0
young JJ 0
children NNS 0
with IN 0
autism NN 0
with IN 0
a DT 0
range NN 0
of IN 0
intellectual JJ 0
ability NN 0
. . 0

METHODS NNP 0
Participants NNPS 0
were VBD 0
55 CD 0
children NNS 0
with IN 0
autistic JJ 0
disorder NN 0
, , 0
aged VBN 0
4-7 CD 0
years NNS 0
( ( 0
FSIQ NNP 0
42-107 CD 0
) ) 0
. . 0

Children NNP 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
an DT 0
intervention NN 0
( ( 0
n JJ 0
= NNP 0
28 CD 0
) ) 0
or CC 0
control VB 0
group NN 0
( ( 0
n JJ 0
= NNP 0
27 CD 0
) ) 0
. . 0

Participants NNS 0
in IN 0
the DT 0
intervention NN 0
group NN 0
watched VBD 0
a DT 0
DVD NNP 0
designed VBN 0
to TO 0
teach VB 0
emotion NN 0
recognition NN 0
skills NNS 0
to TO 0
children NNS 0
with IN 0
autism NN 0
( ( 0
the DT 0
Transporters NNPS 0
) ) 0
, , 0
whereas IN 0
the DT 0
control NN 0
group NN 0
watched VBD 0
a DT 0
DVD NNP 0
of IN 0
Thomas NNP 0
the DT 0
Tank NNP 0
Engine NNP 0
. . 0

Participants NNS 0
were VBD 0
assessed VBN 0
on IN 0
their PRP$ 0
ability NN 0
to TO 0
complete VB 0
basic JJ 0
emotion NN 0
recognition NN 0
tasks NNS 0
, , 0
mindreading VBG 0
and CC 0
theory NN 0
of IN 0
mind NN 0
( ( 0
TOM NNP 0
) ) 0
tasks NNS 0
before IN 0
and CC 0
after IN 0
the DT 0
4-week JJ 0
intervention NN 0
period NN 0
, , 0
and CC 0
at IN 0
3-month JJ 0
follow-up NN 0
. . 0

RESULTS NNP 0
Analyses NNP 0
controlled VBD 0
for IN 0
the DT 0
effect NN 0
of IN 0
chronological JJ 0
age NN 0
, , 0
verbal JJ 0
intelligence NN 0
, , 0
gender NN 0
and CC 0
DVD NNP 0
viewing VBG 0
time NN 0
on IN 0
outcomes NNS 0
. . 0

Children NNP 0
in IN 0
the DT 0
intervention NN 0
group NN 0
showed VBD 0
improved JJ 0
performance NN 0
in IN 0
the DT 0
recognition NN 0
of IN 0
anger NN 0
compared VBN 0
with IN 0
the DT 0
control NN 0
group NN 0
, , 0
with IN 0
few JJ 0
improvements NNS 0
maintained VBD 0
at IN 0
3-month JJ 0
follow-up NN 0
. . 0

There EX 0
was VBD 0
no DT 0
generalisation NN 0
of IN 0
skills NNS 0
to TO 0
TOM NNP 0
or CC 0
social JJ 0
skills NNS 0
. . 0

CONCLUSIONS VB 0
The DT 0
Transporters NNP 0
programme NN 0
showed VBD 0
limited JJ 0
efficacy NN 0
in IN 0
teaching VBG 0
basic JJ 0
emotion NN 0
recognition NN 0
skills NNS 0
to TO 0
young JJ 0
children NNS 0
with IN 0
autism NN 0
with IN 0
a DT 0
lower JJR 0
range NN 0
of IN 0
cognitive JJ 0
ability NN 0
. . 0

Improvements NNS 0
were VBD 0
limited VBN 0
to TO 0
the DT 0
recognition NN 0
of IN 0
expressions NNS 0
of IN 0
anger NN 0
, , 0
with IN 0
poor JJ 0
maintenance NN 0
of IN 0
these DT 0
skills NNS 0
at IN 0
follow-up NN 0
. . 0

These DT 0
findings NNS 0
provide VBP 0
limited JJ 0
support NN 0
for IN 0
the DT 0
efficacy NN 0
of IN 0
the DT 0
Transporters NNP 0
programme NN 0
for IN 0
young JJ 0
children NNS 0
with IN 0
autism NN 0
of IN 0
a DT 0
lower JJR 0
cognitive JJ 0
range NN 0
. . 0

The DT 0
effect NN 0
of IN 0
four CD 0
different JJ 0
irrigation NN 0
systems NNS 0
in IN 0
the DT 0
removal NN 0
of IN 0
a DT 0
root JJ 0
canal JJ 0
sealer NN 0
. . 0

OBJECTIVES CC 0
The DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
compare VB 0
the DT 0
efficiency NN 0
of IN 0
sonic JJ 0
, , 0
ultrasonic JJ 0
, , 0
and CC 0
hydrodynamic JJ 0
devices NNS 0
in IN 0
the DT 0
removal NN 0
of IN 0
a DT 0
root JJ 0
canal JJ 0
sealer NN 0
from IN 0
the DT 0
surface NN 0
and CC 0
from IN 0
simulated JJ 0
irregularities NNS 0
of IN 0
root NN 0
canals NNS 0
. . 0

MATERIALS NNP 0
AND CC 0
METHODS NNP 0
Fifty-three NNP 0
root NN 0
canals NNS 0
with IN 0
two CD 0
standardized JJ 0
grooves NNS 0
in IN 0
the DT 0
apical JJ 0
and CC 0
coronal JJ 0
parts NNS 0
of IN 0
longitudinally RB 0
split VBN 0
roots NNS 0
were VBD 0
covered VBN 0
with IN 0
AH NNP 0
Plus NNP 0
root VBP 0
canal JJ 0
sealer NN 0
. . 0

Compared VBN 0
were VBD 0
the DT 0
effects NNS 0
of IN 0
( ( 0
control NN 0
) ) 0
syringe NN 0
irrigation NN 0
, , 0
( ( 0
1 CD 0
) ) 0
CanalBrush NN 0
, , 0
( ( 0
2 CD 0
) ) 0
passive NN 0
ultrasonic JJ 0
irrigation NN 0
, , 0
( ( 0
3 CD 0
) ) 0
EndoActivator NN 0
, , 0
and CC 0
( ( 0
4 CD 0
) ) 0
RinsEndo NN 0
on IN 0
the DT 0
removal NN 0
of IN 0
the DT 0
sealer NN 0
. . 0

The DT 0
specimens NNS 0
were VBD 0
divided VBN 0
into IN 0
four CD 0
groups NNS 0
( ( 0
N NNP 0
= NNP 0
12 CD 0
) ) 0
and CC 0
one CD 0
control NN 0
group NN 0
( ( 0
N NNP 0
= NNP 0
5 CD 0
) ) 0
via IN 0
randomization NN 0
. . 0

The DT 0
amount NN 0
of IN 0
remaining VBG 0
sealer NN 0
in IN 0
the DT 0
root NN 0
canal JJ 0
irregularities NNS 0
was VBD 0
evaluated VBN 0
under IN 0
a DT 0
microscope NN 0
using VBG 0
a DT 0
4-grade JJ 0
scoring NN 0
system NN 0
, , 0
whereas IN 0
the DT 0
remaining VBG 0
sealer NN 0
on IN 0
the DT 0
root NN 0
canal JJ 0
surface NN 0
was VBD 0
evaluated VBN 0
with IN 0
a DT 0
7-grade JJ 0
scoring NN 0
system NN 0
. . 0

RESULTS NNP 0
Passive NNP 0
ultrasonic JJ 0
irrigation NN 0
is VBZ 0
more RBR 0
effective JJ 0
than IN 0
the DT 0
other JJ 0
tested JJ 0
irrigation NN 0
systems NNS 0
or CC 0
syringe JJ 0
irrigation NN 0
in IN 0
removing VBG 0
sealer NN 0
from IN 0
root JJ 0
canal JJ 0
walls NNS 0
( ( 0
p JJ 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

None NN 0
of IN 0
the DT 0
techniques NNS 0
had VBD 0
a DT 0
significant JJ 0
effect NN 0
on IN 0
cleaning VBG 0
the DT 0
lateral JJ 0
grooves NNS 0
. . 0

CONCLUSIONS NNP 0
Within IN 0
the DT 0
limitations NNS 0
of IN 0
this DT 0
study NN 0
protocol VBZ 0
ultrasonic JJ 0
irrigation NN 0
shows VBZ 0
a DT 0
superior JJ 0
effect NN 0
on IN 0
sealer NN 0
removal NN 0
from IN 0
the DT 0
root NN 0
canal JJ 0
surface NN 0
during IN 0
endodontic JJ 0
retreatment NN 0
. . 0

Cleaning NN 0
of IN 0
lateral JJ 0
grooves NNS 0
seems VBZ 0
not RB 0
to TO 0
be VB 0
possible JJ 0
with IN 0
one CD 0
of IN 0
the DT 0
techniques NNS 0
investigated VBN 0
. . 0

CLINICAL JJ 0
RELEVANCE NNP 0
Incomplete NNP 0
removal NN 0
of IN 0
root JJ 0
canal JJ 0
sealer NN 0
during IN 0
re-treatment NN 0
may MD 0
cause VB 0
treatment NN 0
failure NN 0
. . 0

Passive NNP 0
Ultrasonic NNP 0
irrigation NN 0
seems VBZ 0
to TO 0
be VB 0
the DT 0
most RBS 0
effective JJ 0
system NN 0
to TO 0
remove VB 0
sealer NN 0
from IN 0
a DT 0
root NN 0
canal NN 0
. . 0

A DT 0
randomized JJ 0
comparison NN 0
of IN 0
alternative JJ 0
techniques NNS 0
to TO 0
achieve VB 0
coronary JJ 0
sinus NN 0
cannulation NN 0
during IN 0
biventricular JJ 0
implantation NN 0
procedures NNS 0
. . 0

INTRODUCTION NNP 0
Biventricular NNP 0
pacing VBG 0
system NN 0
implantation NN 0
is VBZ 0
a DT 0
time-consuming JJ 0
and CC 0
challenging JJ 0
procedure NN 0
. . 0

A DT 0
critical JJ 0
step NN 0
in IN 0
biventricular JJ 0
pacemaker NN 0
implantation NN 0
is VBZ 0
coronary JJ 0
sinus NN 0
( ( 0
CS NNP 0
) ) 0
cannulation NN 0
. . 0

CS NNP 0
cannulation NN 0
can MD 0
be VB 0
achieved VBN 0
either DT 0
using VBG 0
dedicated JJ 0
guiding NN 0
catheters NNS 0
( ( 0
guiding VBG 0
catheter NN 0
alone RB 0
positioning VBG 0
strategy NN 0
, , 0
GCA NNP 0
) ) 0
or CC 0
with IN 0
the DT 0
aid NN 0
of IN 0
an DT 0
electrophysiology NN 0
catheter NN 0
advanced VBD 0
inside IN 0
the DT 0
guiding NN 0
catheter NN 0
( ( 0
electrophysiology JJ 0
catheter NN 0
aided VBD 0
positioning VBG 0
strategy NN 0
, , 0
EPA NNP 0
) ) 0
. . 0

AIM NNP 0
OF IN 0
THE NNP 0
STUDY NNP 0
To TO 0
evaluate VB 0
whether IN 0
the DT 0
EPA NNP 0
technique NN 0
is VBZ 0
useful JJ 0
for IN 0
reducing VBG 0
CS NNP 0
cannulation NN 0
time NN 0
compared VBN 0
to TO 0
a DT 0
conventional JJ 0
GCA NNP 0
technique NN 0
. . 0

METHODS NNP 0
Thirty-four JJ 0
consecutive JJ 0
patients NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
the DT 0
GCA NNP 0
( ( 0
18 CD 0
patients NNS 0
) ) 0
or CC 0
EPA NNP 0
( ( 0
16 CD 0
patients NNS 0
) ) 0
CS NNP 0
cannulation NN 0
strategy NN 0
. . 0

RESULTS JJ 0
Time NNP 0
to TO 0
successful JJ 0
catheterization NN 0
of IN 0
CS NNP 0
was VBD 0
5.0 CD 0
+/- JJ 0
2.4 CD 0
min NN 0
in IN 0
the DT 0
EPA NNP 0
group NN 0
versus VBD 0
10.1 CD 0
+/- JJ 0
5.4 CD 0
min NN 0
in IN 0
the DT 0
GCA NNP 0
group NN 0
p VBD 0
= RB 0
0.004 CD 0
. . 0

Fluoroscopy NN 0
time NN 0
was VBD 0
4.6 CD 0
+/- JJ 0
2.3 CD 0
min NN 0
in IN 0
the DT 0
EPA NNP 0
group NN 0
versus VBD 0
9.2 CD 0
+/- JJ 0
4.9 CD 0
min NN 0
in IN 0
the DT 0
GCA NNP 0
group NN 0
p VBD 0
= RB 0
0.004 CD 0
. . 0

Total JJ 0
contrast NN 0
dye NN 0
volume NN 0
to TO 0
search NN 0
and CC 0
engage VB 0
the DT 0
CS NNP 0
ostium NN 0
was VBD 0
0.0 CD 0
ml NN 0
in IN 0
the DT 0
EPA NNP 0
group NN 0
versus VBD 0
14.3 CD 0
+/- JJ 0
3.4 CD 0
ml NN 0
in IN 0
the DT 0
GCA NNP 0
group NN 0
p VBD 0
< RB 0
0.001 CD 0
. . 0

CONCLUSIONS NNP 0
Cannulation NNP 0
of IN 0
CS NNP 0
with IN 0
the DT 0
adjunct NN 0
of IN 0
an DT 0
electrophysiology NN 0
catheter NN 0
to TO 0
dedicated VBN 0
delivery NN 0
systems NNS 0
significantly RB 0
reduces VBZ 0
procedural JJ 0
time NN 0
, , 0
fluoroscopy JJ 0
time NN 0
and CC 0
contrast NN 0
dye NN 0
volume NN 0
compared VBN 0
to TO 0
a DT 0
conventional JJ 0
strategy NN 0
. . 0

Prevention NN 0
of IN 0
spinal JJ 0
anesthesia-induced JJ 0
hypotension NN 0
in IN 0
the DT 0
elderly JJ 0
: : 0
comparison NN 0
between IN 0
preanesthetic JJ 0
administration NN 0
of IN 0
crystalloids NNS 0
, , 0
colloids NNS 0
, , 0
and CC 0
no DT 0
prehydration NN 0
. . 0

The DT 0
practice NN 0
of IN 0
routinely RB 0
prehydrating VBG 0
patients NNS 0
by IN 0
infusing VBG 0
a DT 0
crystalloid NN 0
or CC 0
colloid JJ 0
solution NN 0
( ( 0
up IN 0
to TO 0
1.0 CD 0
L/70 NNP 0
kg NN 0
) ) 0
for IN 0
prevention NN 0
of IN 0
spinal JJ 0
anesthesia-induced JJ 0
hypotension NN 0
has VBZ 0
been VBN 0
challenged VBN 0
recently RB 0
, , 0
after IN 0
several JJ 0
reports NNS 0
of IN 0
failure NN 0
to TO 0
demonstrate VB 0
its PRP$ 0
efficacy NN 0
in IN 0
young JJ 0
women NNS 0
. . 0

We PRP 0
compared VBN 0
the DT 0
incidence NN 0
and CC 0
frequency NN 0
of IN 0
hypotension NN 0
and CC 0
vasopressor NN 0
therapy NN 0
after IN 0
spinal JJ 0
anesthesia NN 0
and CC 0
no DT 0
prehydration NN 0
with IN 0
crystalloid NN 0
and CC 0
colloid JJ 0
prehydration NN 0
in IN 0
elderly JJ 0
patients NNS 0
. . 0

Eighty-five JJ 0
ASA NNP 0
grade NN 0
I PRP 0
or CC 0
II NNP 0
patients NNS 0
( ( 0
aged VBN 0
60-89 CD 0
yr NN 0
) ) 0
for IN 0
elective JJ 0
total JJ 0
hip NN 0
replacement NN 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
500 CD 0
mL NN 0
crystalloid JJ 0
solution NN 0
( ( 0
Hartmanns NNP 0
, , 0
n JJ 0
= NNP 0
29 CD 0
) ) 0
, , 0
500 CD 0
mL NN 0
colloid NN 0
( ( 0
Haemaccel NNP 0
, , 0
n JJ 0
= NNP 0
28 CD 0
) ) 0
, , 0
or CC 0
no DT 0
prehydration NN 0
( ( 0
n JJ 0
= NNP 0
28 CD 0
) ) 0
over IN 0
10 CD 0
min NNS 0
prior RB 0
to TO 0
spinal JJ 0
anesthesia NN 0
. . 0

Hypotension NNP 0
was VBD 0
defined VBN 0
as IN 0
a DT 0
30 CD 0
% NN 0
decrease NN 0
from IN 0
baseline JJ 0
systolic JJ 0
blood NN 0
pressure NN 0
( ( 0
BP NNP 0
) ) 0
or CC 0
systolic JJ 0
< $ 0
90 CD 0
mm NN 0
Hg NNP 0
, , 0
and CC 0
was VBD 0
treated VBN 0
with IN 0
ephedrine JJ 0
3-mg JJ 0
boluses NNS 0
. . 0

Although IN 0
absolute JJ 0
systolic JJ 0
BP NNP 0
readings NNS 0
were VBD 0
significantly RB 0
higher JJR 0
in IN 0
the DT 0
colloid NN 0
group NN 0
between IN 0
6 CD 0
and CC 0
30 CD 0
min NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
, , 0
the DT 0
incidence NN 0
of IN 0
hypotension NN 0
was VBD 0
not RB 0
significantly RB 0
different JJ 0
between IN 0
the DT 0
groups NNS 0
. . 0

The DT 0
incidence NN 0
of IN 0
ephedrine NN 0
use NN 0
, , 0
incidence NN 0
of IN 0
nausea/vomiting NN 0
, , 0
and CC 0
median JJ 0
total NN 0
dose NN 0
of IN 0
ephedrine NN 0
were VBD 0
similar JJ 0
in IN 0
all DT 0
groups NNS 0
. . 0

We PRP 0
conclude VBP 0
that DT 0
, , 0
in IN 0
elderly JJ 0
patients NNS 0
undergoing VBG 0
elective JJ 0
procedures NNS 0
, , 0
withholding VBG 0
prehydration NN 0
is VBZ 0
not RB 0
associated VBN 0
with IN 0
any DT 0
greater JJR 0
degree NN 0
of IN 0
hypotension NN 0
or CC 0
need NN 0
for IN 0
vasopressor NN 0
therapy NN 0
compared VBN 0
with IN 0
crystalloid NN 0
or CC 0
colloid JJ 0
prehydration NN 0
. . 0

[ RB 0
Clinical NNP 0
study NN 0
of IN 0
the DT 0
efficacy NN 0
of IN 0
and CC 0
tolerance NN 0
to TO 0
nimesulide VB 0
in IN 0
suppository JJ 0
formulation NN 0
in IN 0
pain-inflammatory JJ 0
pathologies NNS 0
of IN 0
the DT 0
ear NN 0
, , 0
nose RB 0
, , 0
and CC 0
throat NN 0
] NN 0
. . 0

The DT 0
efficacy NN 0
and CC 0
tolerability NN 0
of IN 0
a DT 0
new JJ 0
pharmaceutical JJ 0
form NN 0
of IN 0
the DT 0
non-steroid JJ 0
anti-inflammatory JJ 0
drug NN 0
. . 0

Nimesulide NNP 0
have VBP 0
been VBN 0
studied VBN 0
in IN 0
a DT 0
double JJ 0
blind NN 0
study NN 0
compared VBN 0
with IN 0
flurbiprofen NN 0
, , 0
in IN 0
98 CD 0
patients NNS 0
aged VBN 0
between IN 0
18 CD 0
and CC 0
75 CD 0
suffering VBG 0
from IN 0
pain-inflammatory JJ 0
pathologies NNS 0
of IN 0
ENT NNP 0
nature NN 0
. . 0

Both DT 0
drugs NNS 0
, , 0
administered VBN 0
in IN 0
a DT 0
dose NN 0
of IN 0
one CD 0
suppository NN 0
twice RB 0
a DT 0
day NN 0
for IN 0
7 CD 0
days NNS 0
, , 0
showed VBD 0
marked JJ 0
anti-inflammatory JJ 0
, , 0
analgesic JJ 0
and CC 0
antipyretic JJ 0
activity NN 0
and CC 0
produced VBD 0
a DT 0
significant JJ 0
, , 0
progressive JJ 0
improvement NN 0
in IN 0
the DT 0
typical JJ 0
symptoms NNS 0
of IN 0
the DT 0
inflammatory NN 0
state NN 0
up IN 0
to TO 0
their PRP$ 0
complete JJ 0
remission NN 0
. . 0

Nimesulide NNP 0
evidenced VBD 0
greater JJR 0
speed NN 0
and CC 0
duration NN 0
of IN 0
therapeutic JJ 0
action NN 0
. . 0

Assessment NN 0
on IN 0
the DT 0
effectiveness NN 0
and CC 0
tolerability NN 0
as IN 0
expressed VBN 0
separately RB 0
by IN 0
the DT 0
physician NN 0
and CC 0
patient NN 0
were VBD 0
positive JJ 0
in IN 0
almost RB 0
all DT 0
cases NNS 0
of IN 0
both DT 0
treatments NNS 0
. . 0

Intervention NN 0
to TO 0
lower VB 0
household NN 0
wood NN 0
smoke NN 0
exposure NN 0
in IN 0
Guatemala NNP 0
reduces NNS 0
ST-segment NNP 0
depression NN 0
on IN 0
electrocardiograms NNS 0
. . 0

BACKGROUND VB 0
A DT 0
large JJ 0
body NN 0
of IN 0
evidence NN 0
suggests VBZ 0
that IN 0
fine JJ 0
particulate NN 0
matter NN 0
( ( 0
PM NNP 0
) ) 0
air NN 0
pollution NN 0
is VBZ 0
a DT 0
cause NN 0
of IN 0
cardiovascular JJ 0
disease NN 0
, , 0
but CC 0
little JJ 0
is VBZ 0
known VBN 0
in IN 0
particular JJ 0
about IN 0
the DT 0
cardiovascular JJ 0
effects NNS 0
of IN 0
indoor JJ 0
air NN 0
pollution NN 0
from IN 0
household NN 0
use NN 0
of IN 0
solid JJ 0
fuels NNS 0
in IN 0
developing VBG 0
countries NNS 0
. . 0

RESPIRE NNP 0
( ( 0
Randomized NNP 0
Exposure NNP 0
Study NNP 0
of IN 0
Pollution NNP 0
Indoors NNP 0
and CC 0
Respiratory NNP 0
Effects NNP 0
) ) 0
was VBD 0
a DT 0
randomized JJ 0
trial NN 0
of IN 0
a DT 0
chimney NN 0
woodstove NN 0
that WDT 0
reduces VBZ 0
wood NN 0
smoke NN 0
exposure NN 0
. . 0

OBJECTIVES IN 0
We PRP 0
tested VBD 0
the DT 0
hypotheses NNS 0
that IN 0
the DT 0
stove NN 0
intervention NN 0
, , 0
compared VBN 0
with IN 0
open JJ 0
fire NN 0
use NN 0
, , 0
would MD 0
reduce VB 0
ST-segment NNP 0
depression NN 0
and CC 0
increase VB 0
heart NN 0
rate NN 0
variability NN 0
( ( 0
HRV NNP 0
) ) 0
. . 0

METHODS NNP 0
We PRP 0
used VBD 0
two CD 0
complementary JJ 0
study NN 0
designs NNS 0
: : 0
a DT 0
) ) 0
between-groups NN 0
comparisons NNS 0
based VBN 0
on IN 0
randomized JJ 0
stove NN 0
assignment NN 0
, , 0
and CC 0
b NN 0
) ) 0
before-and-after NN 0
comparisons NNS 0
within IN 0
control NN 0
subjects NNS 0
who WP 0
used VBD 0
open JJ 0
fires NNS 0
during IN 0
the DT 0
trial NN 0
and CC 0
received VBD 0
chimney NN 0
stoves NNS 0
after IN 0
the DT 0
trial NN 0
. . 0

Electrocardiogram NNP 0
sessions NNS 0
that WDT 0
lasted VBD 0
20 CD 0
hr NNS 0
were VBD 0
repeated VBN 0
up RP 0
to TO 0
three CD 0
times NNS 0
among IN 0
49 CD 0
intervention NN 0
and CC 0
70 CD 0
control NN 0
women NNS 0
38-84 CD 0
years NNS 0
of IN 0
age NN 0
, , 0
and CC 0
55 CD 0
control NN 0
subjects NNS 0
were VBD 0
also RB 0
assessed VBN 0
after IN 0
receiving VBG 0
stoves NNS 0
. . 0

HRV NNP 0
and CC 0
ST-segment JJ 0
values NNS 0
were VBD 0
assessed VBN 0
for IN 0
each DT 0
30-min JJ 0
period NN 0
. . 0

ST-segment JJ 0
depression NN 0
was VBD 0
defined VBN 0
as IN 0
an DT 0
average JJ 0
value NN 0
below IN 0
-1.00 NNP 0
mm NN 0
. . 0

Personal JJ 0
fine JJ 0
PM NNP 0
[ NNP 0
aerodynamic JJ 0
diameter NN 0
? . 0
2.5 CD 0
?m NN 0
( ( 0
PM?.? NNP 0
] NNP 0
exposures NNS 0
were VBD 0
measured VBN 0
for IN 0
24 CD 0
hr NN 0
before IN 0
each DT 0
electrocardiogram NN 0
. . 0

RESULTS NNP 0
PM?.? NNP 0
exposure NN 0
means NNS 0
were VBD 0
266 CD 0
and CC 0
102 CD 0
?g/m? NN 0
during IN 0
the DT 0
trial NN 0
period NN 0
in IN 0
the DT 0
control NN 0
and CC 0
intervention NN 0
groups NNS 0
, , 0
respectively RB 0
. . 0

During IN 0
the DT 0
trial NN 0
, , 0
the DT 0
stove NN 0
intervention NN 0
was VBD 0
associated VBN 0
with IN 0
an DT 0
odds NNS 0
ratio NN 0
of IN 0
0.26 CD 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
, , 0
0.08-0.90 NN 0
) ) 0
for IN 0
ST-segment JJ 0
depression NN 0
. . 0

We PRP 0
found VBD 0
similar JJ 0
associations NNS 0
with IN 0
the DT 0
before-and-after JJ 0
comparison NN 0
. . 0

The DT 0
intervention NN 0
was VBD 0
not RB 0
significantly RB 0
associated VBN 0
with IN 0
HRV NNP 0
. . 0

CONCLUSIONS NNP 0
The DT 0
stove NN 0
intervention NN 0
was VBD 0
associated VBN 0
with IN 0
reduced JJ 0
occurrence NN 0
of IN 0
nonspecific JJ 0
ST-segment JJ 0
depression NN 0
, , 0
suggesting VBG 0
that IN 0
household NN 0
wood NN 0
smoke NN 0
exposures NNS 0
affect VBP 0
ventricular JJ 0
repolarization NN 0
and CC 0
potentially RB 0
cardiovascular JJ 0
health NN 0
. . 0

Clinical JJ 0
performance NN 0
of IN 0
the DT 0
Reichert NNP 0
AT550 NNP 0
: : 0
a DT 0
new JJ 0
non-contact JJ 0
tonometer NN 0
. . 0

The DT 0
aim NN 0
of IN 0
the DT 0
present JJ 0
study NN 0
was VBD 0
to TO 0
assess VB 0
the DT 0
level NN 0
of IN 0
accuracy NN 0
for IN 0
measurements NNS 0
of IN 0
intra-ocular JJ 0
pressure NN 0
( ( 0
IOP NNP 0
) ) 0
obtained VBD 0
with IN 0
a DT 0
new JJ 0
non-contact JJ 0
tonometer NN 0
( ( 0
NCT NNP 0
) ) 0
the DT 0
Reichert NNP 0
AT550 NNP 0
. . 0

Measurements NNS 0
were VBD 0
compared VBN 0
against IN 0
those DT 0
obtained VBN 0
with IN 0
the DT 0
Reichert NNP 0
Xpert NNP 0
Plus NNP 0
, , 0
Goldmann NNP 0
applanation NN 0
tonometer NN 0
and CC 0
Perkins NNP 0
tonometer NN 0
. . 0

Thirty-five JJ 0
university NN 0
students NNS 0
were VBD 0
assessed VBN 0
with IN 0
the DT 0
four CD 0
tonometers NNS 0
in IN 0
a DT 0
randomised JJ 0
order NN 0
, , 0
with IN 0
non-contact JJ 0
tonometry NN 0
performed VBD 0
first RB 0
. . 0

Each DT 0
of IN 0
the DT 0
four CD 0
measurement NN 0
devices NNS 0
had VBD 0
its PRP$ 0
own JJ 0
trained JJ 0
clinical JJ 0
observer NN 0
. . 0

Plots NNP 0
of IN 0
differences NNS 0
of IN 0
IOP NNP 0
as IN 0
a DT 0
function NN 0
of IN 0
the DT 0
mean NN 0
for IN 0
each DT 0
pair NN 0
of IN 0
instruments NNS 0
were VBD 0
obtained VBN 0
. . 0

No DT 0
statistically RB 0
significant JJ 0
differences NNS 0
were VBD 0
found VBN 0
when WRB 0
comparing VBG 0
the DT 0
AT550 NNP 0
NCT NNP 0
with IN 0
contact JJ 0
applanation NN 0
tonometry NN 0
( ( 0
AT NNP 0
) ) 0
( ( 0
p JJ 0
> NNP 0
0.05 CD 0
) ) 0
, , 0
displaying VBG 0
the DT 0
closest JJS 0
level NN 0
of IN 0
agreement NN 0
( ( 0
as IN 0
represented VBN 0
by IN 0
the DT 0
lowest JJS 0
mean JJ 0
difference NN 0
and CC 0
the DT 0
narrowest JJS 0
confidence NN 0
interval NN 0
) ) 0
with IN 0
the DT 0
Goldmann NNP 0
tonometer NN 0
( ( 0
limits NNS 0
of IN 0
agreement NN 0
, , 0
0.12+/-2.17 NN 0
) ) 0
. . 0

In IN 0
conclusion NN 0
, , 0
readings NNS 0
of IN 0
IOP NNP 0
with IN 0
the DT 0
AT550 NNP 0
NCT NNP 0
are VBP 0
clinically RB 0
comparable JJ 0
with IN 0
those DT 0
obtained VBN 0
with IN 0
Goldmann NNP 0
tonometry NN 0
in IN 0
a DT 0
population NN 0
with IN 0
IOP NNP 0
within IN 0
the DT 0
normal JJ 0
range NN 0
. . 0

Effects NNS 0
of IN 0
guided JJ 0
imagery NN 0
with IN 0
relaxation NN 0
training NN 0
on IN 0
anxiety NN 0
and CC 0
quality NN 0
of IN 0
life NN 0
among IN 0
patients NNS 0
with IN 0
inflammatory JJ 0
bowel NN 0
disease NN 0
. . 0

BACKGROUND NNP 0
Inflammatory NNP 0
Bowel NNP 0
Disease NNP 0
( ( 0
IBD NNP 0
) ) 0
impacts VBZ 0
quality NN 0
of IN 0
life NN 0
( ( 0
QoL NNP 0
) ) 0
. . 0

Psychological JJ 0
factors NNS 0
influence VBP 0
the DT 0
course NN 0
of IN 0
the DT 0
disease NN 0
and CC 0
should MD 0
be VB 0
targeted VBN 0
for IN 0
intervention NN 0
. . 0

METHODS NNP 0
Our PRP$ 0
study NN 0
was VBD 0
a DT 0
prospective JJ 0
, , 0
randomised VBD 0
control NN 0
trial NN 0
. . 0

Fifty-six JJ 0
outpatients NNS 0
were VBD 0
randomly RB 0
chosen VBN 0
and CC 0
allocated VBN 0
to TO 0
a DT 0
treatment NN 0
group NN 0
or CC 0
a DT 0
waiting-list JJ 0
control NN 0
group NN 0
. . 0

Treatment NNP 0
group NN 0
patients NNS 0
attended VBD 0
three CD 0
relaxation-training JJ 0
sessions NNS 0
and CC 0
received VBD 0
an DT 0
audio JJ 0
disc NN 0
for IN 0
home NN 0
practice NN 0
. . 0

Evaluations NNS 0
performed VBD 0
pre JJ 0
and CC 0
post-treatment JJ 0
: : 0
state NN 0
anxiety NN 0
was VBD 0
assessed VBN 0
with IN 0
the DT 0
State-Trait NNP 0
Anxiety NNP 0
Inventory NNP 0
, , 0
QoL NNP 0
with IN 0
the DT 0
IBD NNP 0
Questionnaire NNP 0
. . 0

The DT 0
Visual NNP 0
Analogue NNP 0
Scale NNP 0
assessed VBD 0
pain NN 0
, , 0
depression NN 0
, , 0
stress NN 0
and CC 0
mood NN 0
. . 0

Patients NNS 0
completed VBD 0
a DT 0
symptom JJ 0
monitoring NN 0
diary NN 0
. . 0

The DT 0
control NN 0
group NN 0
's POS 0
symptoms NNS 0
were VBD 0
monitored VBN 0
without IN 0
study-related JJ 0
treatment NN 0
. . 0

RESULTS NNP 0
Thirty-nine JJ 0
subjects NNS 0
completed VBD 0
the DT 0
study NN 0
and CC 0
were VBD 0
included VBN 0
in IN 0
the DT 0
data NN 0
analysis NN 0
. . 0

Following VBG 0
the DT 0
relaxation-training JJ 0
intervention NN 0
, , 0
the DT 0
treatment NN 0
group NN 0
's POS 0
( ( 0
n JJ 0
= NNP 0
18 CD 0
) ) 0
measured VBN 0
results NNS 0
showed VBD 0
a DT 0
statistically RB 0
significant JJ 0
improvement NN 0
as IN 0
compared VBN 0
to TO 0
the DT 0
control NN 0
group NN 0
( ( 0
n JJ 0
= NNP 0
21 CD 0
) ) 0
( ( 0
time NN 0
by IN 0
treatment NN 0
interaction NN 0
) ) 0
: : 0
anxiety NN 0
levels NNS 0
decreased VBN 0
( ( 0
p JJ 0
< NNP 0
0.01 CD 0
) ) 0
, , 0
QoL NNP 0
and CC 0
mood NN 0
improved VBN 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
, , 0
while IN 0
levels NNS 0
of IN 0
pain NN 0
and CC 0
stress NN 0
decreased VBN 0
( ( 0
p JJ 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Findings NNP 0
indicate VBP 0
IBD NNP 0
patients NNS 0
may MD 0
benefit VB 0
from IN 0
relaxation NN 0
training NN 0
in IN 0
their PRP$ 0
holistic JJ 0
care NN 0
. . 0

New NNP 0
studies NNS 0
as RB 0
well RB 0
as IN 0
further JJ 0
investigation NN 0
of IN 0
the DT 0
subject NN 0
are VBP 0
warranted VBN 0
. . 0

Paternal NNP 0
RHD NNP 0
zygosity NN 0
determination NN 0
in IN 0
Tunisians NNS 0
: : 0
evaluation NN 0
of IN 0
three CD 0
molecular JJ 0
tests NNS 0
. . 0

BACKGROUND IN 0
The DT 0
choice NN 0
of IN 0
a DT 0
molecular JJ 0
test NN 0
for IN 0
first JJ 0
intention NN 0
determination NN 0
of IN 0
paternal JJ 0
RHD NNP 0
zygosity NN 0
, , 0
before IN 0
entering VBG 0
into IN 0
invasive JJ 0
diagnostics NNS 0
, , 0
is VBZ 0
important JJ 0
for IN 0
the DT 0
management NN 0
of IN 0
pregnancies NNS 0
at IN 0
risk NN 0
of IN 0
haemolytic JJ 0
disease NN 0
of IN 0
the DT 0
foetus NN 0
and CC 0
newborn RB 0
related VBN 0
to TO 0
anti-RhD JJ 0
. . 0

MATERIALS NNP 0
AND CC 0
METHODS NNP 0
RHD NNP 0
zygosity NN 0
was VBD 0
evaluated VBN 0
in IN 0
370 CD 0
RH:1 NNP 0
Tunisian JJ 0
donors NNS 0
by IN 0
polymerase NN 0
chain NN 0
reaction NN 0
- : 0
sequence-specific JJ 0
polymorphism NN 0
( ( 0
PCR-SSP NNP 0
) ) 0
analysis NN 0
and CC 0
polymerase NN 0
chain NN 0
reaction NN 0
- : 0
restriction NN 0
fragment NN 0
length NN 0
polymorphism NN 0
( ( 0
PCR-RFLP NNP 0
) ) 0
amplification NN 0
of IN 0
hybrid JJ 0
Rhesus NNP 0
box NN 0
and CC 0
by IN 0
real JJ 0
time NN 0
quantitative JJ 0
polymerase NN 0
chain NN 0
reaction NN 0
( ( 0
RQ-PCR NNP 0
) ) 0
specific NN 0
for IN 0
RHD NNP 0
exon VBD 0
5 CD 0
. . 0

To TO 0
evaluate VB 0
the DT 0
accuracy NN 0
of IN 0
molecular JJ 0
tests NNS 0
in IN 0
the DT 0
cases NNS 0
of IN 0
discordant JJ 0
results NNS 0
, , 0
the DT 0
ten JJ 0
exons NNS 0
of IN 0
RHD NNP 0
and CC 0
Rhesus NNP 0
boxes NNS 0
were VBD 0
amplified VBN 0
by IN 0
PCR NNP 0
and CC 0
sequenced VBN 0
. . 0

RESULTS NNP 0
Molecular JJ 0
investigations NNS 0
revealed VBD 0
that IN 0
our PRP$ 0
370 CD 0
donors NNS 0
comprise VBP 0
193 CD 0
dizygous JJ 0
and CC 0
145 CD 0
hemizygous JJ 0
individuals NNS 0
and CC 0
32 CD 0
subjects NNS 0
whose WP$ 0
zygosity NN 0
remains VBZ 0
unknown JJ 0
. . 0

Positive JJ 0
predictive JJ 0
values NNS 0
were VBD 0
higher JJR 0
than IN 0
99 CD 0
% NN 0
for IN 0
all PDT 0
the DT 0
methods NNS 0
, , 0
reaching VBG 0
100 CD 0
% NN 0
for IN 0
RQ-PCR NNP 0
. . 0

Negative NNP 0
predictive JJ 0
values NNS 0
were VBD 0
83.24 CD 0
% NN 0
, , 0
87.27 CD 0
% NN 0
and CC 0
98 CD 0
% NN 0
for IN 0
PCR-SSP NNP 0
, , 0
PCR-RFLP NNP 0
and CC 0
RQ-PCR NNP 0
respectively RB 0
. . 0

This DT 0
study NN 0
also RB 0
revealed VBD 0
19 CD 0
novel JJ 0
Rhesus NNP 0
box NN 0
polymorphisms NN 0
and CC 0
three CD 0
novel NN 0
RHD NNP 0
alleles NNS 0
: : 0
RHD NNP 0
( ( 0
Trp185Stop NNP 0
) ) 0
, , 0
RHD NNP 0
( ( 0
Ala176Thr NNP 0
) ) 0
and CC 0
RHD NNP 0
( ( 0
Ile342Ile NNP 0
) ) 0
. . 0

DISCUSSION NNP 0
RQ-PCR NNP 0
is VBZ 0
the DT 0
most RBS 0
convenient JJ 0
method NN 0
for IN 0
first JJ 0
intention NN 0
determination NN 0
of IN 0
paternal JJ 0
RHD NNP 0
zygosity NN 0
in IN 0
Tunisians NNPS 0
. . 0

However RB 0
, , 0
taking VBG 0
into IN 0
account NN 0
positive JJ 0
and CC 0
negative JJ 0
predictive NN 0
values NNS 0
, , 0
PCR-RFLP NNP 0
could MD 0
be VB 0
an DT 0
alternative JJ 0
despite IN 0
the DT 0
heterogeneity NN 0
of IN 0
Rhesus NNP 0
boxes NNS 0
and CC 0
the DT 0
complexity NN 0
of IN 0
RHD NNP 0
. . 0

Custom-fit NNP 0
minimally RB 0
invasive JJ 0
total JJ 0
knee NN 0
arthroplasty NN 0
: : 0
effect NN 0
on IN 0
blood NN 0
loss NN 0
and CC 0
early JJ 0
clinical JJ 0
outcomes NNS 0
. . 0

PURPOSE NNP 0
Recently NNP 0
, , 0
new JJ 0
custom-fit JJ 0
pin NN 0
guides NNS 0
in IN 0
total JJ 0
knee NN 0
arthroplasty NN 0
( ( 0
TKA NNP 0
) ) 0
have VBP 0
been VBN 0
introduced VBN 0
. . 0

Use NN 0
of IN 0
these DT 0
guides NNS 0
may MD 0
reduce VB 0
operating NN 0
time NN 0
. . 0

Use NN 0
of IN 0
the DT 0
guides NNS 0
combined VBN 0
with IN 0
the DT 0
absence NN 0
of IN 0
intramedullary JJ 0
alignment NN 0
jigs NNS 0
may MD 0
lead VB 0
to TO 0
reduced VB 0
blood NN 0
loss NN 0
and CC 0
improved VBN 0
early JJ 0
outcomes NNS 0
. . 0

Our PRP$ 0
aim NN 0
was VBD 0
to TO 0
evaluate VB 0
blood NN 0
loss NN 0
and CC 0
early JJ 0
clinical JJ 0
outcomes NNS 0
in IN 0
patients NNS 0
undergoing VBG 0
minimally RB 0
invasive JJ 0
TKA NNP 0
using VBG 0
custom-fit JJ 0
magnetic JJ 0
resonance NN 0
imaging NN 0
( ( 0
MRI NNP 0
) ) 0
-based VBD 0
pin NN 0
guides NNS 0
. . 0

METHODS NNP 0
A NNP 0
prospective JJ 0
study NN 0
in IN 0
80 CD 0
patients NNS 0
was VBD 0
carried VBN 0
out RP 0
. . 0

Patients NNS 0
were VBD 0
divided VBN 0
randomly RB 0
into IN 0
2 CD 0
equal JJ 0
groups NNS 0
. . 0

In IN 0
one CD 0
group NN 0
, , 0
intramedullary JJ 0
alignment NN 0
jigs NNS 0
were VBD 0
used VBN 0
. . 0

In IN 0
the DT 0
second JJ 0
group NN 0
, , 0
custom-fit JJ 0
MRI-based JJ 0
pin NN 0
guides NNS 0
were VBD 0
used VBN 0
. . 0

All DT 0
patients NNS 0
received VBD 0
the DT 0
same JJ 0
cemented VBD 0
posterior-stabilized JJ 0
implant NN 0
through IN 0
a DT 0
mini-midvastus JJ 0
approach NN 0
. . 0

The DT 0
volume NN 0
in IN 0
the DT 0
drain NN 0
bottles NNS 0
was VBD 0
recorded VBN 0
after IN 0
48 CD 0
h. JJ 0
Hb NNP 0
loss NN 0
was VBD 0
estimated VBN 0
by IN 0
subtracting VBG 0
the DT 0
postoperative NN 0
from IN 0
the DT 0
preoperative JJ 0
Hb NNP 0
level NN 0
. . 0

Transfusion NN 0
requirements NNS 0
and CC 0
surgical JJ 0
time NN 0
were VBD 0
recorded VBN 0
. . 0

Outcome JJ 0
measures NNS 0
were VBD 0
Knee NNP 0
Society NNP 0
Scores NNP 0
( ( 0
KSS NNP 0
) ) 0
, , 0
knee JJ 0
flexion NN 0
, , 0
knee VB 0
swelling VBG 0
and CC 0
pain NN 0
. . 0

RESULTS NNP 0
There EX 0
was VBD 0
lower JJR 0
mean JJ 0
drainage NN 0
of IN 0
blood NN 0
in IN 0
the DT 0
custom-fit JJ 0
group NN 0
( ( 0
391 CD 0
ml NN 0
vs. FW 0
603 CD 0
ml NN 0
; : 0
p CC 0
< VB 0
0.0001 CD 0
) ) 0
. . 0

There EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
estimated VBN 0
loss NN 0
of IN 0
Hb NNP 0
( ( 0
3.6 CD 0
g/dl NN 0
vs. FW 0
4.1 CD 0
g/dl NN 0
; : 0
n.s CC 0
. . 0

) ) 0
and CC 0
in IN 0
transfusion NN 0
requirements NNS 0
( ( 0
7.5 CD 0
% NN 0
vs. FW 0
10 CD 0
% NN 0
; : 0
n.s. CC 0
) ) 0
. . 0

Surgical JJ 0
time NN 0
was VBD 0
reduced VBN 0
in IN 0
the DT 0
custom-fit JJ 0
group NN 0
( ( 0
12 CD 0
min NN 0
less JJR 0
; : 0
p NN 0
= VBZ 0
0.001 CD 0
) ) 0
. . 0

KSS NNP 0
measured VBD 0
at IN 0
week NN 0
2 CD 0
, , 0
6 CD 0
and CC 0
12 CD 0
showed VBD 0
no DT 0
significant JJ 0
difference NN 0
between IN 0
groups NNS 0
. . 0

Knee NNP 0
flexion NN 0
measured VBN 0
on IN 0
days NNS 0
7 CD 0
, , 0
10 CD 0
and CC 0
at IN 0
week NN 0
6 CD 0
, , 0
12 CD 0
and CC 0
knee VB 0
swelling VBG 0
and CC 0
pain NN 0
measured VBN 0
on IN 0
days NNS 0
1 CD 0
, , 0
3 CD 0
, , 0
10 CD 0
and CC 0
at IN 0
week NN 0
6 CD 0
, , 0
12 CD 0
showed VBD 0
no DT 0
significant JJ 0
difference NN 0
between IN 0
groups NNS 0
. . 0

CONCLUSIONS NNP 0
Using VBG 0
custom-fit JJ 0
pin NN 0
guides NNS 0
reduces NNS 0
blood NN 0
drainage NN 0
, , 0
but CC 0
not RB 0
the DT 0
estimated VBN 0
Hb NNP 0
loss NN 0
in IN 0
minimally RB 0
invasive JJ 0
TKA NNP 0
and CC 0
does VBZ 0
not RB 0
affect VB 0
transfusion NN 0
rate NN 0
. . 0

Surgical JJ 0
time NN 0
is VBZ 0
reduced VBN 0
. . 0

There EX 0
is VBZ 0
no DT 0
effect NN 0
on IN 0
the DT 0
early JJ 0
clinical JJ 0
outcomes NNS 0
. . 0

LEVEL NN 0
OF IN 0
EVIDENCE NNP 0
Therapeutic NNP 0
study NN 0
, , 0
Level NNP 0
I PRP 0
. . 0

A DT 0
pooled JJ 0
analysis NN 0
of IN 0
eastern JJ 0
cooperative JJ 0
oncology NN 0
group NN 0
and CC 0
intergroup NN 0
trials NNS 0
of IN 0
adjuvant JJ 0
high-dose JJ 0
interferon NN 0
for IN 0
melanoma NN 0
. . 0

PURPOSE NNP 0
Nearly RB 0
2000 CD 0
patients NNS 0
with IN 0
stage NN 0
IIB NNP 0
and CC 0
III NNP 0
melanoma NNS 0
have VBP 0
participated VBN 0
in IN 0
four CD 0
multicenter NN 0
, , 0
randomized VBN 0
trials NNS 0
, , 0
conducted VBN 0
by IN 0
the DT 0
Eastern NNP 0
Cooperative NNP 0
Oncology NNP 0
Group NNP 0
and CC 0
the DT 0
Intergroup NNP 0
, , 0
investigating VBG 0
adjuvant JJ 0
high-dose JJ 0
IFN-alpha JJ 0
2b CD 0
therapy NN 0
. . 0

The DT 0
objectives NNS 0
of IN 0
this DT 0
study NN 0
were VBD 0
to TO 0
update VB 0
the DT 0
analyses NNS 0
of IN 0
each DT 0
individual JJ 0
trial NN 0
and CC 0
to TO 0
analyze VB 0
prognostic JJ 0
factors NNS 0
and CC 0
treatment NN 0
effects NNS 0
based VBN 0
on IN 0
pooled JJ 0
data NNS 0
. . 0

EXPERIMENTAL NNP 0
DESIGN NNP 0
Survival NNP 0
and CC 0
disease NN 0
status NN 0
were VBD 0
updated VBN 0
to TO 0
April NNP 0
2001 CD 0
. . 0

Analysis NN 0
of IN 0
prognostic JJ 0
factors NNS 0
using VBG 0
optimized JJ 0
statistical JJ 0
models NNS 0
was VBD 0
based VBN 0
on IN 0
data NNS 0
from IN 0
patients NNS 0
in IN 0
E1684 NNP 0
, , 0
E1690 NNP 0
, , 0
E1694 NNP 0
, , 0
and CC 0
E2696 NNP 0
. . 0

Analysis NN 0
of IN 0
treatment NN 0
effects NNS 0
versus VBP 0
observation NN 0
( ( 0
Obs NNP 0
) ) 0
was VBD 0
based VBN 0
on IN 0
data NNS 0
from IN 0
713 CD 0
patients NNS 0
randomized VBN 0
to TO 0
high-dose JJ 0
IFN-alpha JJ 0
2b CD 0
( ( 0
HDI NNP 0
) ) 0
or CC 0
Obs NNP 0
in IN 0
Trials NNP 0
E1684 NNP 0
and CC 0
E1690 NNP 0
. . 0

RESULTS NNP 0
Updated VBD 0
analysis NN 0
of IN 0
E1684 NNP 0
, , 0
E1690 NNP 0
, , 0
and CC 0
E1694 NNP 0
confirmed VBD 0
their PRP$ 0
original JJ 0
conclusions NNS 0
, , 0
now RB 0
at IN 0
median JJ 0
follow-up JJ 0
intervals NNS 0
of IN 0
2.1-12.6 JJ 0
years NNS 0
. . 0

Based VBN 0
on IN 0
two-sided JJ 0
univariate JJ 0
log-rank JJ 0
analysis NN 0
of IN 0
pooled VBN 0
data NNS 0
from IN 0
E1684 NNP 0
and CC 0
E1690 NNP 0
( ( 0
median JJ 0
follow-up NN 0
, , 0
7.2 CD 0
years NNS 0
) ) 0
, , 0
relapse-free JJ 0
survival NN 0
( ( 0
RFS NNP 0
) ) 0
-but VBZ 0
not RB 0
overall JJ 0
survival NN 0
( ( 0
OS NNP 0
) ) 0
-was VBP 0
significantly RB 0
prolonged VBN 0
( ( 0
two-sided JJ 0
log-rank NN 0
P NNP 0
value NN 0
= NNP 0
0.006 CD 0
) ) 0
for IN 0
patients NNS 0
treated VBN 0
with IN 0
HDI NNP 0
versus NN 0
Obs NNP 0
. . 0

Among IN 0
all DT 0
patients NNS 0
, , 0
prognostic JJ 0
factors NNS 0
that WDT 0
significantly RB 0
negatively RB 0
impacted JJ 0
RFS NNP 0
and CC 0
OS NNP 0
included VBD 0
ulceration NN 0
, , 0
recurrent JJ 0
disease NN 0
at IN 0
entry NN 0
, , 0
enrollment NN 0
in IN 0
E1684 NNP 0
, , 0
and CC 0
age NN 0
> VBP 0
49 CD 0
years NNS 0
. . 0

Multivariate NNP 0
statistical JJ 0
models NNS 0
adjusting VBG 0
for IN 0
these DT 0
factors NNS 0
confirmed VBD 0
the DT 0
statistically RB 0
significant JJ 0
RFS NNP 0
benefit NN 0
of IN 0
HDI NNP 0
versus NN 0
Obs NNP 0
but CC 0
did VBD 0
not RB 0
demonstrate VB 0
a DT 0
significant JJ 0
OS NNP 0
benefit NN 0
in IN 0
the DT 0
pooled JJ 0
populations NNS 0
. . 0

CONCLUSIONS NNP 0
In IN 0
patients NNS 0
with IN 0
high-risk JJ 0
resected JJ 0
melanoma NN 0
, , 0
HDI NNP 0
is VBZ 0
effective JJ 0
adjuvant JJ 0
therapy NN 0
with IN 0
strong JJ 0
evidence NN 0
for IN 0
improved JJ 0
RFS NNP 0
and CC 0
evidence NN 0
for IN 0
moderate JJ 0
improvement NN 0
in IN 0
OS NNP 0
based VBN 0
on IN 0
two CD 0
prospective JJ 0
randomized VBN 0
studies NNS 0
but CC 0
not RB 0
the DT 0
pooled JJ 0
analysis NN 0
. . 0

Analyses NNS 0
of IN 0
predictors NNS 0
of IN 0
relapse NN 0
and CC 0
response NN 0
are VBP 0
now RB 0
needed VBN 0
to TO 0
improve VB 0
the DT 0
therapeutic JJ 0
value NN 0
of IN 0
this DT 0
modality NN 0
. . 0

Group NNP 0
cognitive JJ 0
behavior NN 0
therapy NN 0
for IN 0
children NNS 0
with IN 0
high-functioning JJ 0
autism NN 0
spectrum NN 0
disorders NNS 0
and CC 0
anxiety NN 0
: : 0
a DT 0
randomized JJ 0
trial NN 0
. . 0

BACKGROUND NNP 0
Children NNP 0
with IN 0
high-functioning JJ 0
autism NN 0
spectrum NN 0
disorders NNS 0
( ( 0
ASD NNP 0
) ) 0
are VBP 0
at IN 0
high JJ 0
risk NN 0
for IN 0
developing VBG 0
significant JJ 0
anxiety NN 0
. . 0

Anxiety NN 0
can MD 0
adversely RB 0
impact VB 0
functioning VBG 0
across IN 0
school NN 0
, , 0
home NN 0
and CC 0
community NN 0
environments NNS 0
. . 0

Cognitive JJ 0
behavioral JJ 0
therapies NNS 0
( ( 0
CBT NNP 0
) ) 0
are VBP 0
frequently RB 0
used VBN 0
with IN 0
success NN 0
for IN 0
children NNS 0
with IN 0
anxiety NN 0
symptoms NNS 0
. . 0

Modified NNP 0
CBT NNP 0
interventions NNS 0
for IN 0
anxiety NN 0
in IN 0
children NNS 0
with IN 0
ASD NNP 0
have VBP 0
also RB 0
yielded VBN 0
promising JJ 0
results NNS 0
. . 0

METHODS NNP 0
Fifty NNP 0
children NNS 0
with IN 0
high-functioning JJ 0
ASD NNP 0
and CC 0
anxiety NN 0
were VBD 0
randomizedto JJ 0
group NN 0
CBT NNP 0
or CC 0
treatment-as-usual JJ 0
( ( 0
TAU NNP 0
) ) 0
for IN 0
12 CD 0
weeks NNS 0
. . 0

Independent NNP 0
clinical JJ 0
evaluators NNS 0
, , 0
blind NN 0
to TO 0
condition NN 0
, , 0
completed VBN 0
structured JJ 0
interviews NNS 0
( ( 0
Anxiety NNP 0
Disorders NNP 0
Interview NNP 0
Schedule NNP 0
? . 0
Parent NNP 0
Version NNP 0
; : 0
ADIS-P NNP 0
) ) 0
pre- NN 0
and CC 0
post-intervention NN 0
condition NN 0
. . 0

RESULTS NNP 0
Forty-seven JJ 0
children NNS 0
completed VBN 0
either CC 0
the DT 0
CBT NNP 0
or CC 0
TAU NNP 0
condition NN 0
. . 0

Results NNS 0
indicated VBD 0
markedly RB 0
better RBR 0
outcomes NNS 0
for IN 0
the DT 0
CBT NNP 0
group NN 0
. . 0

Significant JJ 0
differences NNS 0
by IN 0
group NN 0
were VBD 0
noted VBN 0
in IN 0
Clinician JJ 0
Severity NNP 0
Ratings NNP 0
, , 0
diagnostic JJ 0
status NN 0
, , 0
and CC 0
clinician JJ 0
ratings NNS 0
of IN 0
global JJ 0
improvement NN 0
. . 0

In IN 0
the DT 0
intent-to-treat JJ 0
sample NN 0
, , 0
10 CD 0
of IN 0
20 CD 0
children NNS 0
( ( 0
50 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
CBT NNP 0
group NN 0
had VBD 0
a DT 0
clinically RB 0
meaningful JJ 0
positive JJ 0
treatment NN 0
response NN 0
, , 0
compared VBN 0
to TO 0
2 CD 0
of IN 0
23 CD 0
children NNS 0
( ( 0
8.7 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
TAU NNP 0
group NN 0
. . 0

CONCLUSIONS NNP 0
Initial JJ 0
results NNS 0
from IN 0
this DT 0
randomized VBN 0
, , 0
designed VBN 0
treatment NN 0
study NN 0
suggest VBP 0
that IN 0
agroup NN 0
CBT NNP 0
intervention NN 0
specifically RB 0
developed VBD 0
for IN 0
children NNS 0
with IN 0
ASD NNP 0
may MD 0
be VB 0
effective JJ 0
in IN 0
decreasing VBG 0
anxiety NN 0
. . 0

Limitations NNS 0
of IN 0
this DT 0
study NN 0
include VBP 0
small JJ 0
sample JJ 0
size NN 0
, , 0
lack NN 0
of IN 0
an DT 0
attention NN 0
control NN 0
group NN 0
, , 0
and CC 0
use NN 0
of IN 0
outcome NN 0
measures NNS 0
normed VBN 0
with IN 0
typically RB 0
developing VBG 0
children NNS 0
Protection NN 0
of IN 0
man NN 0
from IN 0
natural JJ 0
infection NN 0
with IN 0
influenza JJ 0
A2 NNP 0
Hong NNP 0
Kong NNP 0
virus NN 0
by IN 0
amantadine NN 0
: : 0
a DT 0
controlled JJ 0
field NN 0
trial NN 0
. . 0

Prophylactic JJ 0
administration NN 0
of IN 0
amantadine NN 0
in IN 0
doses NNS 0
of IN 0
100 CD 0
mg. NN 0
twice RB 0
a DT 0
day NN 0
offered VBN 0
statistically RB 0
significant JJ 0
protection NN 0
against IN 0
influenza JJ 0
A2 NNP 0
infection NN 0
in IN 0
a DT 0
double-blind JJ 0
field NN 0
trial NN 0
involving VBG 0
391 CD 0
medical JJ 0
student NN 0
volunteers NNS 0
during IN 0
the DT 0
influenza JJ 0
A2 NNP 0
Hong NNP 0
Kong NNP 0
epidemic VBP 0
in IN 0
Helsinki NNP 0
in IN 0
the DT 0
winter NN 0
of IN 0
1969 CD 0
. . 0

Serologically RB 0
verified JJ 0
influenza NN 0
, , 0
as IN 0
measured VBN 0
by IN 0
complement JJ 0
fixation NN 0
and/or NN 0
haemagglutination NN 0
inhibition NN 0
, , 0
occurred VBD 0
in IN 0
27 CD 0
out IN 0
of IN 0
192 CD 0
students NNS 0
in IN 0
the DT 0
amantadine NN 0
group NN 0
against IN 0
57 CD 0
out IN 0
of IN 0
199 CD 0
in IN 0
the DT 0
placebo NN 0
group NN 0
, , 0
giving VBG 0
a DT 0
protection NN 0
rate NN 0
of IN 0
52 CD 0
% NN 0
. . 0

[ NN 0
Limbal NNP 0
epithelial NN 0
autograft NN 0
transplantation NN 0
in IN 0
treatment NN 0
of IN 0
pterygium NN 0
] NN 0
. . 0

OBJECTIVE UH 0
To TO 0
observe VB 0
the DT 0
therapeutic JJ 0
effects NNS 0
of IN 0
limbal JJ 0
epithelial JJ 0
autograft NN 0
transplantation NN 0
and CC 0
pterygium NN 0
excision NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
pterygium NN 0
. . 0

METHODS NNP 0
A NNP 0
prospective JJ 0
randomized VBN 0
paired-eye JJ 0
trial NN 0
was VBD 0
studied VBN 0
. . 0

There EX 0
were VBD 0
208 CD 0
patients NNS 0
( ( 0
229 CD 0
eyes NNS 0
) ) 0
with IN 0
initial JJ 0
pterygium NN 0
, , 0
and CC 0
they PRP 0
were VBD 0
allocated VBN 0
to TO 0
two CD 0
groups NNS 0
: : 0
excision NN 0
of IN 0
pterygium NN 0
with IN 0
limbal JJ 0
epithelial JJ 0
autograft NN 0
transplantation NN 0
surgery NN 0
( ( 0
A NNP 0
group NN 0
, , 0
106 CD 0
cases NNS 0
and CC 0
124 CD 0
eyes NNS 0
) ) 0
and CC 0
simple JJ 0
pterygium NN 0
excision NN 0
( ( 0
B NNP 0
group NN 0
, , 0
102 CD 0
cases NNS 0
and CC 0
105 CD 0
eyes NNS 0
) ) 0
. . 0

The DT 0
criteria NN 0
for IN 0
recovery NN 0
were VBD 0
corneal JJ 0
transparency NN 0
with IN 0
stable JJ 0
epithelial JJ 0
healing NN 0
and CC 0
no DT 0
abnormal JJ 0
proliferation NN 0
of IN 0
pterygium-like JJ 0
tissue NN 0
. . 0

The DT 0
post-operative JJ 0
follow-up JJ 0
periods NNS 0
ranged VBD 0
from IN 0
18 CD 0
approximately RB 0
28 CD 0
( ( 0
22.4 CD 0
+/- JJ 0
4.9 CD 0
) ) 0
months NNS 0
. . 0

RESULTS NNP 0
Some DT 0
of IN 0
the DT 0
patients NNS 0
lost VBD 0
follow-up JJ 0
. . 0

In IN 0
the DT 0
eyes NNS 0
followed VBD 0
up RB 0
, , 0
5 CD 0
of IN 0
11 CD 0
2 CD 0
eyes NNS 0
( ( 0
4.5 CD 0
% NN 0
) ) 0
in IN 0
A NNP 0
group NN 0
and CC 0
41 CD 0
of IN 0
96 CD 0
eyes NNS 0
( ( 0
42.7 CD 0
% NN 0
) ) 0
in IN 0
B NNP 0
group NN 0
were VBD 0
recurred VBN 0
, , 0
the DT 0
difference NN 0
being VBG 0
very RB 0
significant JJ 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
To TO 0
provide VB 0
a DT 0
new JJ 0
stem NN 0
cell NN 0
source NN 0
, , 0
limbal JJ 0
epithelial JJ 0
autograft NN 0
transplantation NN 0
, , 0
for IN 0
an DT 0
injured JJ 0
limb NN 0
us PRP 0
is VBZ 0
a DT 0
reasonable JJ 0
therapeutic JJ 0
method NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
pterygium NN 0
. . 0

Neural JJ 0
basis NN 0
of IN 0
self NN 0
and CC 0
other JJ 0
representation NN 0
in IN 0
autism NN 0
: : 0
an DT 0
FMRI NNP 0
study NN 0
of IN 0
self-face JJ 0
recognition NN 0
. . 0

BACKGROUND NNP 0
Autism NNP 0
is VBZ 0
a DT 0
developmental JJ 0
disorder NN 0
characterized VBN 0
by IN 0
decreased JJ 0
interest NN 0
and CC 0
engagement NN 0
in IN 0
social JJ 0
interactions NNS 0
and CC 0
by IN 0
enhanced JJ 0
self-focus NN 0
. . 0

While IN 0
previous JJ 0
theoretical JJ 0
approaches NNS 0
to TO 0
understanding VBG 0
autism NN 0
have VBP 0
emphasized VBN 0
social JJ 0
impairments NNS 0
and CC 0
altered VBD 0
interpersonal JJ 0
interactions NNS 0
, , 0
there EX 0
is VBZ 0
a DT 0
recent JJ 0
shift NN 0
towards NNS 0
understanding VBG 0
the DT 0
nature NN 0
of IN 0
the DT 0
representation NN 0
of IN 0
the DT 0
self NN 0
in IN 0
individuals NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorders NNS 0
( ( 0
ASD NNP 0
) ) 0
. . 0

Still RB 0
, , 0
the DT 0
neural JJ 0
mechanisms NNS 0
subserving VBG 0
self-representations NNS 0
in IN 0
ASD NNP 0
are VBP 0
relatively RB 0
unexplored JJ 0
. . 0

METHODOLOGY/PRINCIPAL NNP 0
FINDINGS NNP 0
We PRP 0
used VBD 0
event-related JJ 0
fMRI NN 0
to TO 0
investigate VB 0
brain NN 0
responsiveness NN 0
to TO 0
images NNS 0
of IN 0
the DT 0
subjects NNS 0
' POS 0
own JJ 0
face NN 0
and CC 0
to TO 0
faces VBZ 0
of IN 0
others NNS 0
. . 0

Children NNP 0
with IN 0
ASD NNP 0
and CC 0
typically RB 0
developing VBG 0
( ( 0
TD NNP 0
) ) 0
children NNS 0
viewed VBD 0
randomly RB 0
presented VBN 0
digital JJ 0
morphs NN 0
between IN 0
their PRP$ 0
own JJ 0
face NN 0
and CC 0
a DT 0
gender-matched JJ 0
other JJ 0
face NN 0
, , 0
and CC 0
made VBD 0
self/other JJR 0
judgments NNS 0
. . 0

Both DT 0
groups NNS 0
of IN 0
children NNS 0
activated VBD 0
a DT 0
right JJ 0
premotor/prefrontal NN 0
system NN 0
when WRB 0
identifying VBG 0
images NNS 0
containing VBG 0
a DT 0
greater JJR 0
percentage NN 0
of IN 0
the DT 0
self JJ 0
face NN 0
. . 0

However RB 0
, , 0
while IN 0
TD NNP 0
children NNS 0
showed VBD 0
activation NN 0
of IN 0
this DT 0
system NN 0
during IN 0
both DT 0
self- JJ 0
and CC 0
other-processing JJ 0
, , 0
children NNS 0
with IN 0
ASD NNP 0
only RB 0
recruited VBD 0
this DT 0
system NN 0
while IN 0
viewing VBG 0
images NNS 0
containing VBG 0
mostly RB 0
their PRP$ 0
own JJ 0
face NN 0
. . 0

CONCLUSIONS/SIGNIFICANCE VB 0
This DT 0
functional JJ 0
dissociation NN 0
between IN 0
the DT 0
representation NN 0
of IN 0
self NN 0
versus NN 0
others NNS 0
points NNS 0
to TO 0
a DT 0
potential JJ 0
neural JJ 0
substrate NN 0
for IN 0
the DT 0
characteristic JJ 0
self-focus NN 0
and CC 0
decreased VBN 0
social JJ 0
understanding NN 0
exhibited VBN 0
by IN 0
these DT 0
individuals NNS 0
, , 0
and CC 0
suggests VBZ 0
that IN 0
individuals NNS 0
with IN 0
ASD NNP 0
lack VBP 0
the DT 0
shared JJ 0
neural JJ 0
representations NNS 0
for IN 0
self NN 0
and CC 0
others NNS 0
that IN 0
TD NNP 0
children NNS 0
and CC 0
adults NNS 0
possess NN 0
and CC 0
may MD 0
use VB 0
to TO 0
understand VB 0
others NNS 0
. . 0

Insulin NNP 0
pump NN 0
therapy NN 0
started VBD 0
at IN 0
the DT 0
time NN 0
of IN 0
diagnosis NN 0
: : 0
effects NNS 0
on IN 0
glycemic JJ 0
control NN 0
and CC 0
pancreatic JJ 0
?-cell NN 0
function NN 0
in IN 0
type NN 0
1 CD 0
diabetes NNS 0
. . 0

BACKGROUND NNP 0
In IN 0
the DT 0
interest NN 0
of IN 0
preserving VBG 0
residual JJ 0
insulin NN 0
secretory NN 0
capacity NN 0
present NN 0
at IN 0
the DT 0
time NN 0
of IN 0
diagnosis NN 0
with IN 0
type JJ 0
1 CD 0
diabetes NNS 0
( ( 0
T1D NNP 0
) ) 0
, , 0
we PRP 0
compared VBN 0
the DT 0
efficacy NN 0
of IN 0
starting VBG 0
insulin JJ 0
pump NN 0
therapy NN 0
at IN 0
diagnosis NN 0
with IN 0
standard JJ 0
multiple JJ 0
daily JJ 0
insulin NN 0
injections NNS 0
( ( 0
MDIs NNP 0
) ) 0
. . 0

METHODS NNP 0
We PRP 0
conducted VBD 0
a DT 0
prospective JJ 0
, , 0
randomized VBN 0
, , 0
pilot JJ 0
trial NN 0
comparing VBG 0
MDI NNP 0
therapy NN 0
with IN 0
continuous JJ 0
subcutaneous JJ 0
insulin NN 0
therapy NN 0
( ( 0
pump JJ 0
therapy NN 0
) ) 0
in IN 0
24 CD 0
patients NNS 0
, , 0
8-18 CD 0
years NNS 0
old JJ 0
, , 0
with IN 0
newly RB 0
diagnosed VBN 0
T1D NNP 0
. . 0

Subjects NNS 0
were VBD 0
evaluated VBN 0
at IN 0
enrollment NN 0
and CC 0
1 CD 0
, , 0
3 CD 0
, , 0
6 CD 0
, , 0
9 CD 0
, , 0
and CC 0
12 CD 0
months NNS 0
after IN 0
initial JJ 0
diagnosis NN 0
of IN 0
T1D NNP 0
. . 0

Preservation NN 0
of IN 0
insulin NN 0
secretion NN 0
, , 0
measured VBN 0
by IN 0
mixed-meal-stimulated JJ 0
C-peptide JJ 0
secretion NN 0
, , 0
was VBD 0
compared VBN 0
after IN 0
6 CD 0
and CC 0
12 CD 0
months NNS 0
of IN 0
treatment NN 0
. . 0

Between-group JJ 0
differences NNS 0
in IN 0
glycosylated JJ 0
hemoglobin NN 0
( ( 0
HbA1c NNP 0
) ) 0
, , 0
continuous JJ 0
glucose NN 0
sensor NN 0
data NNS 0
, , 0
insulin NN 0
utilization NN 0
, , 0
anthropometric JJ 0
measures NNS 0
, , 0
and CC 0
patient JJ 0
satisfaction NN 0
with IN 0
therapy NN 0
were VBD 0
also RB 0
compared VBN 0
at IN 0
multiple JJ 0
time NN 0
points NNS 0
. . 0

RESULTS NNP 0
Initiation NNP 0
of IN 0
pump NN 0
therapy NN 0
within IN 0
1 CD 0
month NN 0
of IN 0
diagnosis NN 0
resulted VBD 0
in IN 0
consistently RB 0
higher JJR 0
mixed-meal JJ 0
tolerance NN 0
test-stimulated JJ 0
C-peptide JJ 0
values NNS 0
at IN 0
all DT 0
time NN 0
points NNS 0
, , 0
although IN 0
these DT 0
differences NNS 0
were VBD 0
not RB 0
statistically RB 0
significant JJ 0
. . 0

Nonetheless NNP 0
, , 0
improved JJ 0
glycemic JJ 0
control NN 0
was VBD 0
observed VBN 0
in IN 0
insulin JJ 0
pump-treated JJ 0
subjects NNS 0
( ( 0
more JJR 0
time NN 0
spent VBN 0
with IN 0
normoglycemia NN 0
, , 0
better JJR 0
mean JJ 0
HbA1c NNP 0
) ) 0
, , 0
and CC 0
pump-treated JJ 0
subjects NNS 0
reported VBN 0
comparatively RB 0
greater JJR 0
satisfaction NN 0
with IN 0
route NN 0
of IN 0
treatment NN 0
administration NN 0
. . 0

CONCLUSIONS NNP 0
Initiation NNP 0
of IN 0
insulin NN 0
pump NN 0
therapy NN 0
at IN 0
diagnosis NN 0
improved JJ 0
glycemic JJ 0
control NN 0
, , 0
was VBD 0
well RB 0
tolerated VBN 0
, , 0
and CC 0
contributed VBD 0
to TO 0
improved VBN 0
patient JJ 0
satisfaction NN 0
with IN 0
treatment NN 0
. . 0

This DT 0
study NN 0
also RB 0
suggests VBZ 0
that IN 0
earlier JJR 0
use NN 0
of IN 0
pump NN 0
therapy NN 0
might MD 0
help VB 0
to TO 0
preserve VB 0
residual JJ 0
?-cell NNP 0
function NN 0
, , 0
although IN 0
a DT 0
larger JJR 0
clinical JJ 0
trial NN 0
would MD 0
be VB 0
required VBN 0
to TO 0
confirm VB 0
this DT 0
. . 0

Feasibility NN 0
of IN 0
two CD 0
dose-dense JJ 0
FEC NNP 0
regimens VBZ 0
with IN 0
growth NN 0
factor NN 0
support NN 0
for IN 0
adjuvant JJ 0
therapy NN 0
in IN 0
patients NNS 0
with IN 0
early JJ 0
breast NN 0
cancer NN 0
: : 0
results NNS 0
from IN 0
a DT 0
randomised JJ 0
study NN 0
of IN 0
the DT 0
Central NNP 0
European NNP 0
Cooperative NNP 0
Oncology NNP 0
Group NNP 0
( ( 0
CECOG NNP 0
) ) 0
. . 0

Addition NN 0
of IN 0
epirubicin NN 0
to TO 0
adjuvant VB 0
chemotherapy NN 0
can MD 0
provide VB 0
important JJ 0
benefits NNS 0
for IN 0
patients NNS 0
with IN 0
early JJ 0
breast NN 0
cancer NN 0
, , 0
but CC 0
the DT 0
optimal JJ 0
dose NN 0
remains VBZ 0
unclear JJ 0
. . 0

Further JJ 0
improvements NNS 0
can MD 0
be VB 0
achieved VBN 0
with IN 0
dose-dense JJ 0
regimens NNS 0
, , 0
but CC 0
densification NN 0
of IN 0
fluorouracil/epirubicin/cyclophosphamide NN 0
( ( 0
FEC NNP 0
) ) 0
has VBZ 0
proved VBN 0
difficult JJ 0
, , 0
with IN 0
FEC NNP 0
( ( 0
60 CD 0
) ) 0
providing VBG 0
little JJ 0
benefit NN 0
over IN 0
standard JJ 0
chemotherapy NN 0
and CC 0
FEC NNP 0
( ( 0
100 CD 0
) ) 0
associated VBN 0
with IN 0
toxicity NN 0
. . 0

We PRP 0
investigated VBD 0
the DT 0
feasibility NN 0
of IN 0
two CD 0
intermediate JJ 0
dose-dense JJ 0
FEC NNP 0
regimens NNS 0
. . 0

Patients NNS 0
were VBD 0
randomised VBN 0
to TO 0
six CD 0
cycles NNS 0
of IN 0
FEC NNP 0
( ( 0
75 CD 0
) ) 0
or CC 0
FEC NNP 0
( ( 0
90 CD 0
) ) 0
, , 0
with IN 0
all DT 0
three CD 0
drugs NNS 0
given VBN 0
on IN 0
day NN 0
1 CD 0
of IN 0
each DT 0
14-day JJ 0
cycle NN 0
. . 0

Patients NNS 0
also RB 0
received VBD 0
pegfilgrastim JJ 0
6 CD 0
mg NN 0
as IN 0
a DT 0
single JJ 0
subcutaneous JJ 0
injection NN 0
on IN 0
day NN 0
2 CD 0
of IN 0
each DT 0
cycle NN 0
. . 0

The DT 0
primary JJ 0
efficacy NN 0
endpoint NN 0
was VBD 0
the DT 0
proportion NN 0
of IN 0
subjects NNS 0
receiving VBG 0
> NN 0
or CC 0
=85 CD 0
% NN 0
relative JJ 0
dose JJ 0
intensity NN 0
and CC 0
was VBD 0
achieved VBN 0
by IN 0
96 CD 0
% NN 0
and CC 0
88 CD 0
% NN 0
of IN 0
patients NNS 0
in IN 0
the DT 0
FEC NNP 0
( ( 0
75 CD 0
) ) 0
and CC 0
FEC NNP 0
( ( 0
90 CD 0
) ) 0
arms NNS 0
, , 0
respectively RB 0
. . 0

Of IN 0
147 CD 0
FEC NNP 0
( ( 0
75 CD 0
) ) 0
infusions NNS 0
, , 0
4.1 CD 0
% NN 0
were VBD 0
delayed VBN 0
, , 0
while IN 0
9.8 CD 0
% NN 0
of IN 0
143 CD 0
FEC NNP 0
( ( 0
90 CD 0
) ) 0
infusions NNS 0
were VBD 0
delayed VBN 0
. . 0

The DT 0
most RBS 0
common JJ 0
reasons NNS 0
for IN 0
delay NN 0
were VBD 0
adverse JJ 0
events NNS 0
and CC 0
personal/logistical JJ 0
reasons NNS 0
. . 0

One CD 0
dose JJ 0
reduction NN 0
occurred VBD 0
during IN 0
the DT 0
study NN 0
( ( 0
FEC NNP 0
( ( 0
90 CD 0
) ) 0
) ) 0
, , 0
related VBN 0
to TO 0
diarrhoea VB 0
. . 0

Grade VB 0
3-4 JJ 0
haematological JJ 0
toxicities NNS 0
were VBD 0
reported VBN 0
in IN 0
two CD 0
patients NNS 0
in IN 0
the DT 0
FEC NNP 0
( ( 0
90 CD 0
) ) 0
arm NN 0
. . 0

There EX 0
were VBD 0
no DT 0
incidences NNS 0
of IN 0
febrile JJ 0
neutropenia NN 0
during IN 0
the DT 0
study NN 0
. . 0

The DT 0
most RBS 0
common JJ 0
adverse JJ 0
events NNS 0
were VBD 0
increases NNS 0
in IN 0
liver NN 0
enzymes NNS 0
and CC 0
gastrointestinal JJ 0
events NNS 0
; : 0
no DT 0
event NN 0
resulted VBD 0
in IN 0
discontinuation NN 0
. . 0

Only RB 0
one CD 0
patient NN 0
( ( 0
FEC NNP 0
( ( 0
90 CD 0
) ) 0
) ) 0
experienced VBD 0
serious JJ 0
adverse JJ 0
events NNS 0
( ( 0
vomiting VBG 0
and CC 0
throat VB 0
oedema NN 0
) ) 0
. . 0

In IN 0
conclusion NN 0
, , 0
dose-dense JJ 0
FEC NNP 0
( ( 0
75 CD 0
) ) 0
and CC 0
FEC NNP 0
( ( 0
90 CD 0
) ) 0
are VBP 0
feasible JJ 0
with IN 0
pegfilgrastim JJ 0
support NN 0
. . 0

These DT 0
regimens NNS 0
are VBP 0
associated VBN 0
with IN 0
a DT 0
very RB 0
low JJ 0
risk NN 0
of IN 0
Grade NNP 0
3-4 JJ 0
toxicity NN 0
. . 0

A DT 0
New NNP 0
Interactive NNP 0
Screening NNP 0
Test NNP 0
for IN 0
Autism NNP 0
Spectrum NNP 0
Disorders NNP 0
in IN 0
Toddlers NNP 0
. . 0

OBJECTIVE NNP 0
To TO 0
develop VB 0
a DT 0
clinically RB 0
valid JJ 0
interactive JJ 0
level NN 0
2 CD 0
screening NN 0
assessment NN 0
for IN 0
autism NN 0
spectrum NN 0
disorders NNS 0
( ( 0
ASD NNP 0
) ) 0
in IN 0
toddlers NNS 0
that WDT 0
is VBZ 0
brief JJ 0
, , 0
easily RB 0
administered VBN 0
, , 0
and CC 0
scored VBN 0
by IN 0
clinicians NNS 0
. . 0

STUDY NNP 0
DESIGN NNP 0
We PRP 0
describe VBP 0
the DT 0
development NN 0
, , 0
training NN 0
, , 0
standardization NN 0
, , 0
and CC 0
validation NN 0
of IN 0
the DT 0
Rapid NNP 0
Interactive NNP 0
Screening NNP 0
Test NNP 0
for IN 0
Autism NNP 0
in IN 0
Toddlers NNP 0
( ( 0
RITA-T NNP 0
) ) 0
with IN 0
ASD-specific NNP 0
diagnostic JJ 0
instruments NNS 0
. . 0

The DT 0
RITA-T JJ 0
can MD 0
be VB 0
administered VBN 0
and CC 0
scored VBN 0
in IN 0
10 CD 0
minutes NNS 0
. . 0

We PRP 0
studied VBD 0
the DT 0
validity NN 0
of IN 0
the DT 0
RITA-T NNP 0
to TO 0
distinguish VB 0
between IN 0
toddlers NNS 0
with IN 0
ASD NNP 0
from IN 0
toddlers NNS 0
with IN 0
developmental JJ 0
delay NN 0
( ( 0
DD NNP 0
) ) 0
/non-ASD NN 0
in IN 0
an DT 0
early JJ 0
childhood NN 0
clinic NN 0
. . 0

We PRP 0
also RB 0
evaluated VBD 0
the DT 0
test NN 0
's POS 0
performance NN 0
in IN 0
toddlers NNS 0
with IN 0
no DT 0
developmental JJ 0
concerns NNS 0
. . 0

We PRP 0
identified VBD 0
a DT 0
cutoff NN 0
score NN 0
based VBN 0
on IN 0
sensitivity NN 0
, , 0
specificity NN 0
, , 0
and CC 0
positive JJ 0
predictive JJ 0
value NN 0
of IN 0
the DT 0
RITA-T NNP 0
that WDT 0
best JJS 0
differentiates NNS 0
between IN 0
ASD NNP 0
and CC 0
DD/non-ASD NNP 0
. . 0

RESULTS VB 0
A DT 0
total NN 0
of IN 0
61 CD 0
toddlers NNS 0
were VBD 0
enrolled VBN 0
. . 0

RITA-T JJ 0
scores NNS 0
were VBD 0
correlated VBN 0
with IN 0
ASD-specific NNP 0
diagnostic JJ 0
tools NNS 0
( ( 0
r VB 0
= RB 0
0.79 CD 0
; : 0
P NNP 0
< NNP 0
.01 NNP 0
) ) 0
and CC 0
ASD NNP 0
clinical JJ 0
diagnoses NNS 0
( ( 0
r VB 0
= RB 0
0.77 CD 0
; : 0
P NNP 0
< NNP 0
.01 NNP 0
) ) 0
. . 0

Mean JJ 0
scores NNS 0
were VBD 0
significantly RB 0
different JJ 0
in IN 0
subjects NNS 0
with IN 0
ASD NNP 0
, , 0
those DT 0
with IN 0
DD/non-ASD NNP 0
, , 0
and CC 0
those DT 0
with IN 0
no DT 0
developmental JJ 0
concerns NNS 0
( ( 0
20.8 CD 0
vs RB 0
13 CD 0
vs NN 0
10.6 CD 0
, , 0
respectively RB 0
; : 0
P NNP 0
< NNP 0
.0001 NNP 0
) ) 0
. . 0

At IN 0
a DT 0
cutoff NN 0
score NN 0
of IN 0
> $ 0
14 CD 0
, , 0
the DT 0
RITA-T NNP 0
had VBD 0
a DT 0
sensitivity NN 0
of IN 0
1.00 CD 0
, , 0
specificity NN 0
of IN 0
0.84 CD 0
, , 0
and CC 0
positive JJ 0
predictive JJ 0
value NN 0
of IN 0
0.88 CD 0
for IN 0
identifying VBG 0
ASD NNP 0
risk NN 0
in IN 0
a DT 0
high-risk JJ 0
group NN 0
. . 0

CONCLUSION VB 0
The DT 0
RITA-T NNP 0
is VBZ 0
a DT 0
promising JJ 0
new JJ 0
level NN 0
2 CD 0
interactive JJ 0
screening VBG 0
tool NN 0
for IN 0
improving VBG 0
the DT 0
early JJ 0
identification NN 0
of IN 0
ASD NNP 0
in IN 0
toddlers NNS 0
in IN 0
general JJ 0
pediatric NN 0
and CC 0
early JJ 0
intervention NN 0
settings NNS 0
and CC 0
allowing VBG 0
access NN 0
to TO 0
treatment NN 0
. . 0

Regional JJ 0
ventricular JJ 0
performance NN 0
and CC 0
exercise NN 0
training NN 0
in IN 0
children NNS 0
and CC 0
young JJ 0
adults NNS 0
after IN 0
repair NN 0
of IN 0
tetralogy NN 0
of IN 0
Fallot NN 0
: : 0
randomized VBN 0
controlled VBD 0
pilot NN 0
study NN 0
. . 0

BACKGROUND NNP 0
Public-health NNP 0
guidelines NNS 0
recommend VBP 0
patients NNS 0
with IN 0
congenital JJ 0
heart NN 0
disease NN 0
to TO 0
exercise VB 0
. . 0

Studies NNS 0
have VBP 0
shown VBN 0
that IN 0
patients NNS 0
with IN 0
congenital JJ 0
heart NN 0
disease NN 0
can MD 0
improve VB 0
physical JJ 0
exercise NN 0
capacity NN 0
. . 0

The DT 0
effect NN 0
of IN 0
training VBG 0
on IN 0
regional JJ 0
ventricular JJ 0
performance NN 0
has VBZ 0
hardly RB 0
been VBN 0
studied VBN 0
. . 0

We PRP 0
performed VBD 0
a DT 0
pilot NN 0
study NN 0
to TO 0
assess VB 0
whether IN 0
an DT 0
exercise NN 0
training NN 0
program NN 0
would MD 0
result VB 0
in IN 0
adverse JJ 0
changes NNS 0
of IN 0
regional JJ 0
ventricular JJ 0
performance NN 0
in IN 0
patients NNS 0
with IN 0
corrected JJ 0
tetralogy NN 0
of IN 0
Fallot NNP 0
. . 0

METHODS NNP 0
AND CC 0
RESULTS NNP 0
Multicenter NNP 0
prospective JJ 0
randomized VBN 0
controlled VBN 0
pilot NN 0
study NN 0
in IN 0
patients NNS 0
with IN 0
tetralogy NN 0
of IN 0
Fallot NNP 0
aged VBD 0
10 CD 0
to TO 0
25 CD 0
years NNS 0
. . 0

A DT 0
12-week JJ 0
standardized JJ 0
aerobic JJ 0
dynamic JJ 0
exercise NN 0
training NN 0
program NN 0
( ( 0
3 CD 0
one-hour JJ 0
sessions NNS 0
per IN 0
week NN 0
) ) 0
was VBD 0
used VBN 0
. . 0

Pre- JJ 0
and CC 0
post-training JJ 0
cardiopulmonary JJ 0
exercise NN 0
tests NNS 0
, , 0
MRI NNP 0
, , 0
and CC 0
echocardiography NN 0
, , 0
including VBG 0
tissue-Doppler NN 0
imaging NN 0
, , 0
were VBD 0
performed VBN 0
. . 0

Patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
the DT 0
exercise NN 0
group NN 0
( ( 0
n=28 JJ 0
) ) 0
or CC 0
control VB 0
group NN 0
( ( 0
n=20 RB 0
) ) 0
. . 0

One CD 0
patient NN 0
in IN 0
the DT 0
exercise NN 0
group NN 0
dropped VBD 0
out RP 0
. . 0

Change VB 0
in IN 0
tissue-Doppler NN 0
imaging NN 0
parameters NNS 0
was VBD 0
similar JJ 0
in IN 0
the DT 0
exercise NN 0
group NN 0
and CC 0
control NN 0
group NN 0
( ( 0
change NN 0
in IN 0
right JJ 0
ventricle NN 0
free JJ 0
wall NN 0
peak NN 0
velocity NN 0
E NNP 0
' POS 0
exercise NN 0
group NN 0
, , 0
0.8?2.6 CD 0
cm/s NN 0
; : 0
control NN 0
group NN 0
, , 0
0.9?4.1 CD 0
; : 0
peak JJ 0
velocity NN 0
A NNP 0
' POS 0
exercise NN 0
group NN 0
, , 0
0.4?2.4 CD 0
m/s NN 0
; : 0
control NN 0
group NN 0
4.6?18.1 CD 0
cm/s NN 0
) ) 0
. . 0

CONCLUSIONS VB 0
This DT 0
randomized VBN 0
controlled VBD 0
pilot NN 0
study NN 0
provides VBZ 0
preliminary JJ 0
data NNS 0
suggesting VBG 0
that IN 0
regional JJ 0
ventricular JJ 0
performance NN 0
is VBZ 0
well RB 0
maintained VBN 0
during IN 0
3-month JJ 0
aerobic JJ 0
dynamic JJ 0
exercise NN 0
training NN 0
in IN 0
children NNS 0
and CC 0
young JJ 0
adults NNS 0
with IN 0
repaired JJ 0
tetralogy NN 0
of IN 0
Fallot NNP 0
. . 0

This DT 0
information NN 0
might MD 0
help VB 0
patients NNS 0
adhere VB 0
to TO 0
current JJ 0
public-health NN 0
guidelines NNS 0
. . 0

CLINICAL JJ 0
TRIAL NNP 0
REGISTRATION NNP 0
URL NNP 0
: : 0
http// NN 0
: : 0
www.trialregister.nl NN 0
. . 0

Unique NNP 0
identifier NN 0
: : 0
NTR2731 NNP 0
. . 0

The DT 0
efficacy NN 0
of IN 0
prophylactic JJ 0
ondansetron NN 0
, , 0
droperidol NN 0
, , 0
perphenazine NN 0
, , 0
and CC 0
metoclopramide RB 0
in IN 0
the DT 0
prevention NN 0
of IN 0
nausea NN 0
and CC 0
vomiting NN 0
after IN 0
major JJ 0
gynecologic NN 0
surgery NN 0
. . 0

The DT 0
prophylactic JJ 0
antiemetic JJ 0
efficacy NN 0
of IN 0
intravenous JJ 0
( ( 0
i.v JJ 0
. . 0

) ) 0
ondansetron NN 0
, , 0
droperidol NN 0
, , 0
perphenazine NN 0
, , 0
and CC 0
metoclopramide NN 0
was VBD 0
evaluated VBN 0
in IN 0
a DT 0
prospective JJ 0
, , 0
double-blind JJ 0
study NN 0
of IN 0
360 CD 0
ASA NNP 0
physical JJ 0
status NN 0
I-III NNP 0
patients NNS 0
undergoing VBG 0
total JJ 0
abdominal JJ 0
hysterectomy NN 0
( ( 0
TAH NNP 0
) ) 0
. . 0

Subjects NNS 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
i.v. NN 0
, , 0
one CD 0
of IN 0
ondansetron NN 0
4 CD 0
mg NN 0
, , 0
droperidol VBZ 0
1.25 CD 0
mg NN 0
, , 0
perphenazine VBP 0
5 CD 0
mg NN 0
, , 0
metoclopramide RB 0
10 CD 0
mg NN 0
, , 0
or CC 0
placebo RB 0
prior JJ 0
to TO 0
induction NN 0
of IN 0
anesthesia NN 0
. . 0

Hypotension NNP 0
immediately RB 0
after IN 0
administration NN 0
of IN 0
metoclopramide NN 0
was VBD 0
observed VBN 0
in IN 0
two CD 0
patients NNS 0
and CC 0
four CD 0
patients NNS 0
given VBN 0
ondansetron RP 0
developed JJ 0
profound NN 0
systolic JJ 0
hypotension NN 0
at IN 0
induction NN 0
of IN 0
anesthesia NN 0
. . 0

Twenty-two JJ 0
percent NN 0
of IN 0
patients NNS 0
receiving VBG 0
droperidol NN 0
became VBD 0
sedated JJ 0
. . 0

Postoperatively RB 0
, , 0
patients NNS 0
developing VBG 0
severe JJ 0
nausea NN 0
, , 0
retching NN 0
, , 0
or CC 0
vomiting NN 0
, , 0
defined VBD 0
as IN 0
severe JJ 0
emetic JJ 0
sequelae NN 0
( ( 0
SES NNP 0
) ) 0
, , 0
were VBD 0
deemed VBN 0
to TO 0
have VB 0
failed VBN 0
antiemetic JJ 0
prophylaxis NN 0
and CC 0
received VBN 0
antiemetic JJ 0
rescue NN 0
. . 0

A DT 0
significantly RB 0
larger JJR 0
number NN 0
of IN 0
patients NNS 0
who WP 0
received VBD 0
i.v NN 0
. . 0

ondansetron NN 0
( ( 0
63 CD 0
% NN 0
) ) 0
, , 0
droperidol NN 0
( ( 0
76 CD 0
% NN 0
) ) 0
, , 0
and CC 0
perphenazine NN 0
( ( 0
70 CD 0
% NN 0
) ) 0
were VBD 0
free JJ 0
of IN 0
SES NNP 0
when WRB 0
compared VBN 0
to TO 0
placebo VB 0
( ( 0
43 CD 0
% NN 0
) ) 0
; : 0
P NNP 0
< VBD 0
0.05 CD 0
. . 0

Metoclopramide NNP 0
was VBD 0
ineffective JJ 0
. . 0

Although IN 0
ondansetron NN 0
, , 0
droperidol NN 0
, , 0
and CC 0
perphenazine NN 0
were VBD 0
effective JJ 0
in IN 0
providing VBG 0
antiemetic JJ 0
prophylaxis NN 0
, , 0
only RB 0
i.v NN 0
. . 0

perphenazine NN 0
was VBD 0
free JJ 0
of IN 0
side JJ 0
effects NNS 0
. . 0

Hence NNP 0
, , 0
we PRP 0
conclude VBP 0
that DT 0
perphenazine NN 0
is VBZ 0
the DT 0
best JJS 0
choice NN 0
for IN 0
antiemetic JJ 0
prophylaxis NN 0
after IN 0
TAH NNP 0
. . 0

The DT 0
course NN 0
of IN 0
depression NN 0
in IN 0
recent JJ 0
onset NN 0
rheumatoid NN 0
arthritis NN 0
: : 0
the DT 0
predictive JJ 0
role NN 0
of IN 0
disability NN 0
, , 0
illness JJ 0
perceptions NNS 0
, , 0
pain NN 0
and CC 0
coping NN 0
. . 0

BACKGROUND NNP 0
This DT 0
study NN 0
aimed VBD 0
to TO 0
investigate VB 0
the DT 0
course NN 0
of IN 0
depression NN 0
for IN 0
patients NNS 0
with IN 0
recently RB 0
diagnosed VBN 0
rheumatoid NN 0
arthritis NN 0
( ( 0
RA NNP 0
) ) 0
and CC 0
to TO 0
investigate VB 0
predictors NNS 0
of IN 0
depression NN 0
. . 0

METHODS NNP 0
Twenty-two JJ 0
patients NNS 0
with IN 0
a DT 0
history NN 0
of IN 0
recently RB 0
diagnosed VBN 0
RA NNP 0
of IN 0
less JJR 0
than IN 0
2 CD 0
years NNS 0
were VBD 0
assessed VBN 0
on IN 0
a DT 0
variety NN 0
of IN 0
clinical JJ 0
outcome NN 0
and CC 0
process NN 0
measures NNS 0
on IN 0
six CD 0
assessment JJ 0
occasions NNS 0
over IN 0
a DT 0
21-month JJ 0
period NN 0
. . 0

These DT 0
22 CD 0
patients NNS 0
constituted VBD 0
the DT 0
control NN 0
group NN 0
of IN 0
a DT 0
controlled VBN 0
trial NN 0
and CC 0
received VBN 0
standard JJ 0
outpatient NN 0
clinic JJ 0
treatment NN 0
during IN 0
follow-up JJ 0
. . 0

RESULTS JJ 0
Patients NNPS 0
became VBD 0
significantly RB 0
more RBR 0
depressed JJ 0
over IN 0
time NN 0
. . 0

A DT 0
set NN 0
of IN 0
five CD 0
factors NNS 0
were VBD 0
found VBN 0
to TO 0
consistently RB 0
predict VB 0
depression NN 0
at IN 0
the DT 0
following JJ 0
assessment NN 0
. . 0

These DT 0
were VBD 0
initial JJ 0
level NN 0
of IN 0
depression NN 0
, , 0
disability NN 0
, , 0
pain NN 0
, , 0
beliefs VB 0
about IN 0
the DT 0
consequences NNS 0
of IN 0
arthritis NN 0
and CC 0
coping VBG 0
strategies NNS 0
. . 0

CONCLUSIONS VB 0
The DT 0
results NNS 0
confirm VBP 0
the DT 0
importance NN 0
of IN 0
psychological JJ 0
factors NNS 0
in IN 0
early JJ 0
RA NNP 0
and CC 0
their PRP$ 0
relative JJ 0
independence NN 0
from IN 0
physical JJ 0
findings NNS 0
. . 0

This DT 0
is VBZ 0
the DT 0
first JJ 0
study NN 0
to TO 0
document VB 0
the DT 0
importance NN 0
of IN 0
illness JJ 0
perceptions NNS 0
in IN 0
recent JJ 0
onset NN 0
RA NNP 0
. . 0

Cryoprobe NNP 0
biopsy NN 0
increases VBZ 0
the DT 0
diagnostic JJ 0
yield NN 0
in IN 0
endobronchial JJ 0
tumor NN 0
lesions NNS 0
. . 0

OBJECTIVE NNP 0
Forceps NNP 0
biopsy NN 0
is VBZ 0
the DT 0
standard JJ 0
method NN 0
to TO 0
obtain VB 0
specimens NNS 0
in IN 0
endoscopically RB 0
visible JJ 0
lesions NNS 0
. . 0

It PRP 0
is VBZ 0
common JJ 0
to TO 0
combine VB 0
forceps NNS 0
biopsy VB 0
with IN 0
cytology NN 0
methods NNS 0
to TO 0
increase VB 0
the DT 0
diagnostic JJ 0
yield NN 0
. . 0

Although IN 0
the DT 0
flexible JJ 0
cryoprobe NN 0
has VBZ 0
been VBN 0
established VBN 0
for IN 0
bronchoscopic NN 0
interventions NNS 0
in IN 0
malignant JJ 0
stenosis NN 0
, , 0
the DT 0
obtained JJ 0
biopsies NNS 0
, , 0
called VBN 0
cryobiopsies NNS 0
, , 0
have VBP 0
not RB 0
been VBN 0
investigated VBN 0
in IN 0
a DT 0
large JJ 0
cohort NN 0
of IN 0
patients NNS 0
. . 0

The DT 0
aim NN 0
of IN 0
this DT 0
feasibility NN 0
study NN 0
was VBD 0
to TO 0
prospectively RB 0
evaluate VB 0
the DT 0
diagnostic JJ 0
yield NN 0
and CC 0
safety NN 0
of IN 0
cryobiopsy NN 0
and CC 0
forceps JJ 0
biopsy NN 0
. . 0

METHODS NNP 0
During IN 0
a DT 0
6-year JJ 0
period NN 0
, , 0
296 CD 0
patients NNS 0
with IN 0
visible JJ 0
endoluminal JJ 0
tumor NN 0
lesions NNS 0
were VBD 0
included VBN 0
in IN 0
the DT 0
study NN 0
at IN 0
the DT 0
bronchoscopy NN 0
unit NN 0
of IN 0
a DT 0
university NN 0
hospital NN 0
. . 0

In IN 0
the DT 0
first JJ 0
consecutively RB 0
conducted VBN 0
55 CD 0
cases NNS 0
, , 0
both DT 0
techniques NNS 0
, , 0
forceps NNS 0
biopsy NN 0
and CC 0
cryobiopsy NN 0
, , 0
were VBD 0
applied VBN 0
simultaneously RB 0
. . 0

Pathologic NNP 0
and CC 0
quantitative JJ 0
image NN 0
analyses NNS 0
were VBD 0
performed VBN 0
to TO 0
evaluate VB 0
the DT 0
size NN 0
and CC 0
quality NN 0
of IN 0
the DT 0
obtained VBN 0
specimens NNS 0
. . 0

We PRP 0
evaluated VBD 0
the DT 0
safety NN 0
and CC 0
diagnostic JJ 0
yield NN 0
to TO 0
describe VB 0
the DT 0
feasibility NN 0
of IN 0
cryobiopsy NN 0
. . 0

RESULTS NNP 0
Comparative JJ 0
analysis NN 0
of IN 0
the DT 0
first JJ 0
conducted VBN 0
and CC 0
randomly RB 0
assigned VBD 0
55 CD 0
cases NNS 0
revealed VBD 0
a DT 0
significantly RB 0
higher RBR 0
diagnostic JJ 0
yield NN 0
for IN 0
cryobiopsy NN 0
compared VBN 0
with IN 0
forceps NNS 0
biopsy NNS 0
( ( 0
89.1 CD 0
% NN 0
vs JJ 0
65.5 CD 0
% NN 0
, , 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
. . 0

In IN 0
this DT 0
cohort NN 0
, , 0
quantitative JJ 0
image NN 0
analysis NN 0
showed VBD 0
significantly RB 0
larger JJR 0
biopsies NNS 0
regarding VBG 0
size NN 0
and CC 0
artifact-free JJ 0
tissue NN 0
sections NNS 0
for IN 0
cryobiopsy NN 0
compared VBN 0
with IN 0
forceps NNS 0
biopsy NN 0
( ( 0
P NNP 0
< NNP 0
.0001 NNP 0
) ) 0
. . 0

The DT 0
overall JJ 0
diagnostic JJ 0
yield NN 0
of IN 0
cryobiopsy NN 0
was VBD 0
89.5 CD 0
% NN 0
. . 0

Mild NNP 0
bleeding VBG 0
occurred VBD 0
in IN 0
11 CD 0
cases NNS 0
( ( 0
3.7 CD 0
% NN 0
) ) 0
, , 0
moderate JJ 0
bleeding NN 0
occurred VBD 0
in IN 0
3 CD 0
cases NNS 0
( ( 0
1.0 CD 0
% NN 0
) ) 0
, , 0
and CC 0
severe JJ 0
bleeding NN 0
occurred VBD 0
in IN 0
1 CD 0
case NN 0
( ( 0
0.3 CD 0
% NN 0
) ) 0
. . 0

CONCLUSION NNP 0
Cryobiopsy NNP 0
is VBZ 0
safe JJ 0
and CC 0
increases VBZ 0
the DT 0
diagnostic JJ 0
yield NN 0
in IN 0
endobronchial JJ 0
tumor NN 0
lesions NNS 0
. . 0

The DT 0
method NN 0
also RB 0
is VBZ 0
feasible JJ 0
under IN 0
routine JJ 0
conditions NNS 0
. . 0

The DT 0
immediate JJ 0
efficacy NN 0
of IN 0
adjunctive JJ 0
doxycycline NN 0
in IN 0
treatment NN 0
of IN 0
localized VBN 0
juvenile NN 0
periodontitis NN 0
. . 0

A DT 0
randomized JJ 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
study NN 0
on IN 0
the DT 0
immediate JJ 0
clinical JJ 0
and CC 0
microbiological JJ 0
efficacy NN 0
of IN 0
doxycycline NN 0
( ( 0
100 CD 0
mg NN 0
for IN 0
14 CD 0
days NNS 0
) ) 0
was VBD 0
carried VBN 0
out IN 0
to TO 0
determine VB 0
the DT 0
benefit NN 0
of IN 0
adjunctive JJ 0
medication NN 0
in IN 0
16 CD 0
patients NNS 0
with IN 0
localized JJ 0
juvenile NN 0
periodontitis NN 0
. . 0

Measurements NNS 0
of IN 0
gingival NN 0
fluid NN 0
flow NN 0
, , 0
probing VBG 0
depths NNS 0
, , 0
bleeding VBG 0
on IN 0
probing VBG 0
and CC 0
suppuration NN 0
were VBD 0
determined VBN 0
at IN 0
2 CD 0
periodontal JJ 0
sites NNS 0
with IN 0
and CC 0
2 CD 0
without IN 0
radiographic JJ 0
attachment JJ 0
loss NN 0
, , 0
at IN 0
weeks NNS 0
0 CD 0
, , 0
1 CD 0
, , 0
3 CD 0
and CC 0
8 CD 0
. . 0

Subgingival JJ 0
bacterial JJ 0
samples NNS 0
were VBD 0
taken VBN 0
with IN 0
curettes NNS 0
from IN 0
the DT 0
same JJ 0
sites NNS 0
. . 0

Spirochaetes NNS 0
were VBD 0
searched VBN 0
for IN 0
by IN 0
dark-field JJ 0
microscopy NN 0
. . 0

Actinobacillus CC 0
actinomycetemcomitans NNS 0
, , 0
pigmented VBN 0
and CC 0
non-pigmented JJ 0
Bacteroides NNP 0
spp. NN 0
, , 0
Capnocytophaga NNP 0
, , 0
Fusobacterium NNP 0
and CC 0
Actinomyces NNP 0
spp NN 0
. . 0

were VBD 0
cultured VBN 0
on IN 0
various JJ 0
selective JJ 0
and CC 0
non-selective JJ 0
media NNS 0
. . 0

Bacterial JJ 0
species NNS 0
found VBN 0
at IN 0
least JJS 0
in IN 0
50 CD 0
% NN 0
of IN 0
the DT 0
patients NNS 0
and CC 0
comprising VBG 0
on IN 0
average JJ 0
5 CD 0
% NN 0
or CC 0
more JJR 0
of IN 0
the DT 0
cultivable JJ 0
flora NNS 0
were VBD 0
included VBN 0
in IN 0
the DT 0
analysis NN 0
. . 0

Neither CC 0
short-term JJ 0
clinical JJ 0
nor CC 0
microbiological JJ 0
efficacy NN 0
beyond IN 0
that DT 0
of IN 0
a DT 0
course NN 0
of IN 0
mechanical JJ 0
debridement NN 0
alone RB 0
was VBD 0
found VBN 0
by IN 0
using VBG 0
systemic JJ 0
medication NN 0
with IN 0
doxycycline NN 0
in IN 0
patients NNS 0
with IN 0
localized JJ 0
juvenile NN 0
periodontitis NN 0
. . 0

Bolus NNP 0
injection NN 0
of IN 0
contrast NN 0
agents NNS 0
with IN 0
various JJ 0
iodine JJ 0
concentrations NNS 0
and CC 0
delivery NN 0
rates NNS 0
for IN 0
intracranial JJ 0
three-dimensional JJ 0
CT NNP 0
angiography NN 0
: : 0
evaluation NN 0
of IN 0
intracranial JJ 0
arteriovenous JJ 0
contrast NN 0
using VBG 0
a DT 0
multidetector-row JJ 0
CT NNP 0
scanner NN 0
. . 0

PURPOSE NNP 0
We PRP 0
evaluated VBD 0
the DT 0
difference NN 0
in IN 0
computed JJ 0
tomography NN 0
( ( 0
CT NNP 0
) ) 0
attenuation NN 0
values NNS 0
of IN 0
the DT 0
intracranial JJ 0
arterial NN 0
and CC 0
venous JJ 0
systems NNS 0
among IN 0
the DT 0
various JJ 0
contrast NN 0
injection NN 0
protocols NNS 0
( ( 0
higher JJR 0
iodine NN 0
delivery NN 0
rate NN 0
or CC 0
higher JJR 0
concentration NN 0
of IN 0
the DT 0
agent NN 0
) ) 0
on IN 0
the DT 0
source NN 0
images NNS 0
of IN 0
intracranial JJ 0
three-dimensional JJ 0
CT NNP 0
angiography NN 0
( ( 0
3D-CTA JJ 0
) ) 0
using VBG 0
a DT 0
multidetector-row JJ 0
CT NNP 0
( ( 0
MDCT NNP 0
) ) 0
scanner NN 0
. . 0

MATERIALS NNP 0
AND CC 0
METHODS NNP 0
We PRP 0
used VBD 0
100 CD 0
ml NN 0
of IN 0
iopamidol JJ 0
300 CD 0
at IN 0
an DT 0
injection NN 0
rate NN 0
of IN 0
3.0 CD 0
ml/s NNS 0
, , 0
100 CD 0
ml NN 0
of IN 0
iopamidol JJ 0
300 CD 0
at IN 0
an DT 0
injection NN 0
rate NN 0
of IN 0
3.7 CD 0
ml/s NN 0
, , 0
and CC 0
80 CD 0
ml NN 0
of IN 0
iopamidol JJ 0
370 CD 0
at IN 0
an DT 0
injection NN 0
rate NN 0
of IN 0
3.0 CD 0
ml/s NN 0
. . 0

There EX 0
were VBD 0
10 CD 0
patients NNS 0
in IN 0
each DT 0
group NN 0
. . 0

Attenuation NNP 0
values NNS 0
of IN 0
the DT 0
bilateral JJ 0
internal JJ 0
carotid NN 0
arteries NNS 0
( ( 0
ICAs NNP 0
) ) 0
, , 0
basilar JJ 0
artery NN 0
trunk NN 0
, , 0
bilateral JJ 0
cavernous JJ 0
sinuses NNS 0
( ( 0
CSs NNP 0
) ) 0
, , 0
and CC 0
Galenic NNP 0
vein NNS 0
were VBD 0
measured VBN 0
quantitatively RB 0
on IN 0
the DT 0
axial JJ 0
CT NNP 0
angiographic JJ 0
source NN 0
images NNS 0
obtained VBN 0
by IN 0
four-channel JJ 0
MDCT NNP 0
. . 0

RESULTS NNP 0
Injection NNP 0
of IN 0
the DT 0
high-concentration NN 0
contrast NN 0
with IN 0
a DT 0
higher JJR 0
iodine-delivery JJ 0
rate NN 0
achieved VBN 0
good JJ 0
arteriovenous JJ 0
contrast NN 0
at IN 0
the DT 0
cavernous JJ 0
portion NN 0
. . 0

With IN 0
the DT 0
same JJ 0
rate NN 0
of IN 0
iodine NN 0
delivery NN 0
, , 0
injection NN 0
of IN 0
the DT 0
intermediate JJ 0
concentrate NN 0
agent NN 0
increased VBD 0
the DT 0
CT NNP 0
value NN 0
of IN 0
not RB 0
only RB 0
the DT 0
ICAs NNP 0
but CC 0
also RB 0
the DT 0
CSs NNP 0
. . 0

CONCLUSION NNP 0
High-concentration NNP 0
contrast NN 0
could MD 0
increase VB 0
ICA NNP 0
attenuation NN 0
without IN 0
intracavernous JJ 0
attenuation NN 0
gain NN 0
during IN 0
the DT 0
first-pass JJ 0
phase NN 0
. . 0

Virtual JJ 0
reality NN 0
hypnosis NN 0
for IN 0
pain NN 0
associated VBN 0
with IN 0
recovery NN 0
from IN 0
physical JJ 0
trauma NN 0
. . 0

Pain VB 0
following VBG 0
traumatic JJ 0
injuries NNS 0
is VBZ 0
common JJ 0
, , 0
can MD 0
impair VB 0
injury JJ 0
recovery NN 0
and CC 0
is VBZ 0
often RB 0
inadequately RB 0
treated VBN 0
. . 0

In IN 0
particular JJ 0
, , 0
the DT 0
role NN 0
of IN 0
adjunctive JJ 0
nonpharmacologic JJ 0
analgesic JJ 0
techniques NNS 0
is VBZ 0
unclear JJ 0
. . 0

The DT 0
authors NNS 0
report VBP 0
a DT 0
randomized VBN 0
, , 0
controlled VBD 0
study NN 0
of IN 0
21 CD 0
hospitalized JJ 0
trauma NN 0
patients NNS 0
to TO 0
assess VB 0
the DT 0
analgesic JJ 0
efficacy NN 0
of IN 0
virtual JJ 0
reality NN 0
hypnosis NN 0
( ( 0
VRH NNP 0
) ) 0
-hypnotic JJ 0
induction NN 0
and CC 0
analgesic JJ 0
suggestion NN 0
delivered VBN 0
by IN 0
customized JJ 0
virtual JJ 0
reality NN 0
( ( 0
VR NNP 0
) ) 0
hardware/software NN 0
. . 0

Subjective JJ 0
pain NN 0
ratings NNS 0
were VBD 0
obtained VBN 0
immediately RB 0
and CC 0
8 CD 0
hours NNS 0
after IN 0
VRH NNP 0
( ( 0
used VBN 0
as IN 0
an DT 0
adjunct NN 0
to TO 0
standard VB 0
analgesic JJ 0
care NN 0
) ) 0
and CC 0
compared VBN 0
to TO 0
both DT 0
adjunctive JJ 0
VR NNP 0
without IN 0
hypnosis NN 0
and CC 0
standard JJ 0
care NN 0
alone RB 0
. . 0

VRH JJ 0
patients NNS 0
reported VBD 0
less RBR 0
pain JJ 0
intensity NN 0
and CC 0
less JJR 0
pain NN 0
unpleasantness JJ 0
compared VBN 0
to TO 0
control VB 0
groups NNS 0
. . 0

These DT 0
preliminary JJ 0
findings NNS 0
suggest VBP 0
that IN 0
VRH NNP 0
analgesia NN 0
is VBZ 0
a DT 0
novel JJ 0
technology NN 0
worthy NN 0
of IN 0
further JJ 0
study NN 0
, , 0
both DT 0
to TO 0
improve VB 0
pain NN 0
management NN 0
and CC 0
to TO 0
increase VB 0
availability NN 0
of IN 0
hypnotic JJ 0
analgesia NN 0
to TO 0
populations NNS 0
without IN 0
access NN 0
to TO 0
therapist-provided JJ 0
hypnosis NN 0
and CC 0
suggestion NN 0
. . 0

Intermediate-term JJ 0
mortality NN 0
and CC 0
cardiac JJ 0
transplantation NN 0
in IN 0
infants NNS 0
with IN 0
single-ventricle JJ 0
lesions NNS 0
: : 0
risk NN 0
factors NNS 0
and CC 0
their PRP$ 0
interaction NN 0
with IN 0
shunt NN 0
type NN 0
. . 0

OBJECTIVE CC 0
The DT 0
study NN 0
objective NN 0
was VBD 0
to TO 0
identify VB 0
factors NNS 0
associated VBN 0
with IN 0
death NN 0
and CC 0
cardiac JJ 0
transplantation NN 0
in IN 0
infants NNS 0
undergoing VBG 0
the DT 0
Norwood NNP 0
procedure NN 0
and CC 0
to TO 0
determine VB 0
differences NNS 0
in IN 0
associations NNS 0
that WDT 0
might MD 0
favor VB 0
the DT 0
modified JJ 0
Blalock-Taussig NNP 0
shunt NN 0
or CC 0
a DT 0
right JJ 0
ventricle-to-pulmonary JJ 0
artery NN 0
shunt NN 0
. . 0

METHODS NNP 0
We PRP 0
used VBD 0
competing VBG 0
risks NNS 0
methodology NN 0
to TO 0
analyze VB 0
death NN 0
without IN 0
transplantation NN 0
, , 0
cardiac JJ 0
transplantation NN 0
, , 0
and CC 0
survival NN 0
without IN 0
transplantation NN 0
. . 0

Parametric NNP 0
time-to-event JJ 0
modeling NN 0
and CC 0
bootstrapping NN 0
were VBD 0
used VBN 0
to TO 0
identify VB 0
independent JJ 0
predictors NNS 0
. . 0

RESULTS NNP 0
Data NNP 0
from IN 0
549 CD 0
subjects NNS 0
( ( 0
follow-up JJ 0
, , 0
2.7 CD 0
? . 0
0.9 CD 0
years NNS 0
) ) 0
were VBD 0
analyzed VBN 0
. . 0

Mortality NNP 0
risk NN 0
was VBD 0
characterized VBN 0
by IN 0
early JJ 0
and CC 0
constant JJ 0
phases NNS 0
; : 0
transplant NN 0
was VBD 0
characterized VBN 0
by IN 0
only RB 0
a DT 0
constant JJ 0
phase NN 0
. . 0

Early JJ 0
phase NN 0
factors NNS 0
associated VBN 0
with IN 0
death NN 0
included VBD 0
lower JJR 0
socioeconomic JJ 0
status NN 0
( ( 0
P NNP 0
= NNP 0
.01 NNP 0
) ) 0
, , 0
obstructed VBD 0
pulmonary JJ 0
venous JJ 0
return NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
, , 0
smaller JJR 0
ascending VBG 0
aorta NN 0
( ( 0
P NNP 0
= NNP 0
.02 NNP 0
) ) 0
, , 0
and CC 0
anatomic JJ 0
subtype NN 0
. . 0

Constant JJ 0
phase NN 0
factors NNS 0
associated VBN 0
with IN 0
death NN 0
included VBD 0
genetic JJ 0
syndrome NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
and CC 0
lower JJR 0
gestational JJ 0
age NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

The DT 0
right JJ 0
ventricle-to-pulmonary JJ 0
artery NN 0
shunt NN 0
demonstrated VBD 0
better JJR 0
survival NN 0
in IN 0
the DT 0
51 CD 0
% NN 0
of IN 0
subjects NNS 0
who WP 0
were VBD 0
full JJ 0
term NN 0
with IN 0
aortic JJ 0
atresia NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

The DT 0
modified JJ 0
Blalock-Taussig NNP 0
shunt NN 0
was VBD 0
better RBR 0
among IN 0
the DT 0
4 CD 0
% NN 0
of IN 0
subjects NNS 0
who WP 0
were VBD 0
preterm VBN 0
with IN 0
a DT 0
patent NN 0
aortic JJ 0
valve NN 0
( ( 0
P NNP 0
= NNP 0
.003 NNP 0
) ) 0
. . 0

Lower JJR 0
pre-Norwood NN 0
right JJ 0
ventricular JJ 0
fractional JJ 0
area NN 0
change NN 0
, , 0
pre-Norwood NN 0
surgery NN 0
, , 0
and CC 0
anatomy VBZ 0
other JJ 0
than IN 0
hypoplastic JJ 0
left JJ 0
heart NN 0
syndrome NN 0
were VBD 0
independently RB 0
associated VBN 0
with IN 0
transplantation NN 0
( ( 0
all DT 0
P NNP 0
< NNP 0
.03 NNP 0
) ) 0
, , 0
but CC 0
shunt NN 0
type NN 0
was VBD 0
not RB 0
( ( 0
P NNP 0
= NNP 0
.43 NNP 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Independent NNP 0
risk NN 0
factors NNS 0
for IN 0
intermediate-term JJ 0
mortality NN 0
include VBP 0
lower JJR 0
socioeconomic JJ 0
status NN 0
, , 0
anatomy RB 0
, , 0
genetic JJ 0
syndrome NN 0
, , 0
and CC 0
lower JJR 0
gestational JJ 0
age NN 0
. . 0

Term JJ 0
infants NNS 0
with IN 0
aortic JJ 0
atresia NN 0
benefited VBD 0
from IN 0
a DT 0
right JJ 0
ventricle-to-pulmonary JJ 0
artery NN 0
shunt NN 0
, , 0
and CC 0
preterm JJ 0
infants NNS 0
with IN 0
a DT 0
patent NN 0
aortic JJ 0
valve NN 0
benefited VBD 0
from IN 0
a DT 0
modified VBN 0
Blalock-Taussig NNP 0
shunt NN 0
. . 0

Right NNP 0
ventricular JJ 0
function NN 0
and CC 0
anatomy NN 0
, , 0
but CC 0
not RB 0
shunt VB 0
type NN 0
, , 0
were VBD 0
associated VBN 0
with IN 0
transplantation NN 0
. . 0

Effects NNS 0
of IN 0
Saccharomyces NNP 0
boulardii NN 0
in IN 0
children NNS 0
with IN 0
acute JJ 0
diarrhoea NN 0
. . 0

AIM NNP 0
Certain NNP 0
probiotic JJ 0
agents NNS 0
, , 0
e.g NN 0
. . 0

Lactobacillus CC 0
GG NNP 0
, , 0
have VBP 0
shown VBN 0
efficacy NN 0
in IN 0
clinical JJ 0
trials NNS 0
for IN 0
the DT 0
treatment NN 0
of IN 0
acute JJ 0
childhood NN 0
diarrhoea NN 0
, , 0
but CC 0
few JJ 0
studies NNS 0
have VBP 0
examined VBN 0
the DT 0
effect NN 0
of IN 0
Saccharomyces NNP 0
boulardii NN 0
. . 0

We PRP 0
evaluated VBD 0
the DT 0
effect NN 0
of IN 0
S. NNP 0
boulardii NN 0
in IN 0
children NNS 0
with IN 0
acute JJ 0
diarrhoea NN 0
. . 0

METHODS NNP 0
Two CD 0
hundred VBD 0
children NNS 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
S. NNP 0
boulardii NN 0
in IN 0
a DT 0
granulated JJ 0
form NN 0
in IN 0
a DT 0
daily JJ 0
dose NN 0
of IN 0
250 CD 0
mg NN 0
( ( 0
S. NNP 0
boulardii NNP 0
group NN 0
) ) 0
or CC 0
placebo NN 0
( ( 0
placebo JJ 0
group NN 0
) ) 0
for IN 0
5 CD 0
d. JJ 0
Clinical NNP 0
and CC 0
demographic JJ 0
characteristics NNS 0
on IN 0
admission NN 0
were VBD 0
similar JJ 0
between IN 0
the DT 0
study NN 0
groups NNS 0
. . 0

RESULTS VB 0
The DT 0
medians NNS 0
of IN 0
the DT 0
average JJ 0
stool NN 0
frequency NN 0
after IN 0
the DT 0
second JJ 0
day NN 0
of IN 0
the DT 0
treatment NN 0
were VBD 0
significantly RB 0
lower JJR 0
in IN 0
the DT 0
S. NNP 0
boulardii NN 0
group NN 0
than IN 0
in IN 0
the DT 0
placebo NN 0
group NN 0
( ( 0
p JJ 0
= NNP 0
0.003 CD 0
) ) 0
. . 0

The DT 0
duration NN 0
of IN 0
diarrhoea NN 0
significantly RB 0
reduced VBN 0
in IN 0
the DT 0
S. NNP 0
boulardii NN 0
group NN 0
compared VBN 0
with IN 0
the DT 0
placebo NN 0
group NN 0
( ( 0
4.7 CD 0
vs RB 0
5.5 CD 0
d NN 0
, , 0
p JJ 0
= NNP 0
0.03 CD 0
) ) 0
. . 0

The DT 0
effect NN 0
of IN 0
S. NNP 0
boulardii NN 0
on IN 0
watery NN 0
diarrhoea NN 0
became VBD 0
apparent JJ 0
after IN 0
the DT 0
second JJ 0
day NN 0
of IN 0
the DT 0
treatment NN 0
. . 0

The DT 0
duration NN 0
of IN 0
hospital NN 0
stay NN 0
was VBD 0
shorter JJR 0
in IN 0
the DT 0
S. NNP 0
boulardii NN 0
group NN 0
than IN 0
in IN 0
the DT 0
placebo NN 0
group NN 0
( ( 0
2.9 CD 0
vs RB 0
3.9 CD 0
d NN 0
, , 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

Four CD 0
children NNS 0
from IN 0
the DT 0
placebo NN 0
group NN 0
versus VBD 0
only RB 0
one CD 0
child NN 0
from IN 0
the DT 0
S. NNP 0
boulardii NN 0
group NN 0
had VBD 0
persisting VBG 0
diarrhoea NN 0
. . 0

CONCLUSION VB 0
The DT 0
placebo-controlled JJ 0
study NN 0
suggested VBD 0
that IN 0
S. NNP 0
boulardii VBP 0
significantly RB 0
reduced VBN 0
the DT 0
duration NN 0
of IN 0
acute JJ 0
diarrhoea NN 0
and CC 0
the DT 0
duration NN 0
of IN 0
hospital NN 0
stay NN 0
. . 0

S. NNP 0
boulardii NN 0
seems VBZ 0
to TO 0
be VB 0
a DT 0
promising JJ 0
agent NN 0
for IN 0
the DT 0
amelioration NN 0
of IN 0
the DT 0
course NN 0
of IN 0
acute JJ 0
diarrhoea NN 0
in IN 0
children NNS 0
when WRB 0
used VBN 0
therapeutically RB 0
. . 0

Local JJ 0
immunotherapy NN 0
by IN 0
inhalation NN 0
of IN 0
a DT 0
powder NN 0
extract NN 0
in IN 0
asthma NN 0
due JJ 0
to TO 0
house NN 0
dust NN 0
mite NN 0
Dermatophagoides NNP 0
pteronyssinus NN 0
: : 0
a DT 0
double-blind JJ 0
comparison NN 0
with IN 0
parenteral JJ 0
immunotherapy NN 0
. . 0

To TO 0
verify VB 0
the DT 0
efficacy NN 0
and CC 0
the DT 0
tolerability NN 0
of IN 0
local JJ 0
immunotherapy NN 0
( ( 0
LI NNP 0
) ) 0
by IN 0
inhalation NN 0
of IN 0
a DT 0
powder NN 0
extract NN 0
of IN 0
house NN 0
dust NN 0
mite NN 0
( ( 0
HDM NNP 0
) ) 0
, , 0
in IN 0
comparison NN 0
with IN 0
parenteral JJ 0
immunotherapy NN 0
( ( 0
PI NNP 0
) ) 0
by IN 0
injection NN 0
, , 0
10 CD 0
patients NNS 0
with IN 0
asthma NNS 0
due JJ 0
to TO 0
HDM NNP 0
were VBD 0
studied VBN 0
in IN 0
a DT 0
blind JJ 0
fashion NN 0
. . 0

5 CD 0
patients NNS 0
( ( 0
Group NNP 0
A NNP 0
) ) 0
underwent NN 0
LI NNP 0
and CC 0
subcutaneous JJ 0
injections NNS 0
of IN 0
placebo NN 0
, , 0
5 CD 0
patients NNS 0
( ( 0
Group NNP 0
B NNP 0
) ) 0
underwent NN 0
PI NNP 0
and CC 0
inhalation NN 0
of IN 0
lactose NN 0
for IN 0
6 CD 0
months NNS 0
. . 0

In IN 0
both DT 0
groups NNS 0
each DT 0
inhalation NN 0
was VBD 0
preceded VBN 0
by IN 0
premedication NN 0
with IN 0
disodium NN 0
cromoglycate NN 0
( ( 0
DSCG NNP 0
) ) 0
( ( 0
40 CD 0
mg NN 0
) ) 0
. . 0

In IN 0
Group NNP 0
A NNP 0
a DT 0
significant JJ 0
decrease NN 0
in IN 0
symptoms NNS 0
score NN 0
and CC 0
in IN 0
peak JJ 0
expiratory NN 0
flow NN 0
( ( 0
PEF NNP 0
) ) 0
-derived VBD 0
parameters NNS 0
was VBD 0
observed VBN 0
already RB 0
after IN 0
3 CD 0
months NNS 0
of IN 0
treatment NN 0
, , 0
and CC 0
2 CD 0
patients NNS 0
lost VBD 0
the DT 0
late JJ 0
component NN 0
of IN 0
the DT 0
bronchial JJ 0
response NN 0
to TO 0
the DT 0
challenge NN 0
with IN 0
HDM NNP 0
. . 0

No NNP 0
significant JJ 0
variation NN 0
was VBD 0
found VBN 0
in IN 0
bronchial JJ 0
responsiveness NN 0
to TO 0
methacholine VB 0
and CC 0
ultrasonically RB 0
nebulized VBN 0
distilled JJ 0
water NN 0
( ( 0
UNDW NNP 0
) ) 0
and CC 0
in IN 0
immunologic JJ 0
humoral JJ 0
and CC 0
cellular JJ 0
parameters NNS 0
in IN 0
peripheral JJ 0
blood NN 0
after IN 0
treatment NN 0
in IN 0
either DT 0
group NN 0
. . 0

No DT 0
local JJ 0
important JJ 0
adverse JJ 0
reactions NNS 0
were VBD 0
observed VBN 0
in IN 0
Group NNP 0
A NNP 0
and CC 0
no DT 0
systemic JJ 0
side NN 0
effects NNS 0
were VBD 0
observed VBN 0
in IN 0
either DT 0
group NN 0
. . 0

We PRP 0
conclude VBP 0
that DT 0
LI NNP 0
is VBZ 0
as RB 0
effective JJ 0
as IN 0
PI NNP 0
, , 0
but CC 0
more RBR 0
rapid JJ 0
in IN 0
its PRP$ 0
action NN 0
, , 0
in IN 0
the DT 0
treatment NN 0
of IN 0
asthma NNS 0
due JJ 0
to TO 0
HDM NNP 0
. . 0

Moreover RB 0
, , 0
LI NNP 0
is VBZ 0
locally RB 0
well RB 0
tolerated VBN 0
, , 0
providing VBG 0
DSCG NNP 0
is VBZ 0
inhaled VBN 0
before IN 0
each DT 0
therapeutic JJ 0
inhalation NN 0
, , 0
and CC 0
does VBZ 0
not RB 0
induce VB 0
systemic JJ 0
side NN 0
effects NNS 0
. . 0

A DT 0
novel JJ 0
approach NN 0
to TO 0
the DT 0
use NN 0
of IN 0
subgingival JJ 0
controlled-release JJ 0
chlorhexidine NN 0
delivery NN 0
in IN 0
chronic JJ 0
periodontitis NN 0
: : 0
a DT 0
randomized JJ 0
clinical JJ 0
trial NN 0
. . 0

BACKGROUND IN 0
We PRP 0
aimed VBD 0
to TO 0
analyze VB 0
clinical JJ 0
, , 0
microbiologic JJ 0
, , 0
and CC 0
serologic JJ 0
effects NNS 0
of IN 0
chlorhexidine NN 0
( ( 0
CHX NNP 0
) ) 0
chips NNS 0
used VBN 0
as IN 0
a DT 0
subgingival JJ 0
controlled-release JJ 0
delivery NN 0
device NN 0
before IN 0
and CC 0
immediately RB 0
after IN 0
scaling VBG 0
and CC 0
root NN 0
planing NN 0
( ( 0
SRP NNP 0
) ) 0
. . 0

METHODS NNP 0
Twenty-four JJ 0
patients NNS 0
presenting VBG 0
with IN 0
?12 NNP 0
teeth NNS 0
with IN 0
probing VBG 0
depth NN 0
( ( 0
PD NNP 0
) ) 0
?5 VBP 0
mm NN 0
and CC 0
bleeding NN 0
on IN 0
probing VBG 0
were VBD 0
assigned VBN 0
in IN 0
test NN 0
or CC 0
control NN 0
groups NNS 0
. . 0

After IN 0
prophylaxis NN 0
, , 0
CHX NNP 0
chips NNS 0
( ( 0
test NN 0
) ) 0
or CC 0
placebo JJ 0
chips NNS 0
( ( 0
control NN 0
) ) 0
were VBD 0
placed VBN 0
in IN 0
pockets NNS 0
with IN 0
PD NNP 0
?5 NNP 0
mm NN 0
. . 0

Ten CD 0
days NNS 0
later RB 0
, , 0
SRP NNP 0
was VBD 0
performed VBN 0
in IN 0
all DT 0
teeth NNS 0
with IN 0
PD NNP 0
?4 NNP 0
mm NN 0
in IN 0
a DT 0
single JJ 0
appointment NN 0
. . 0

Immediately RB 0
after IN 0
SRP NNP 0
, , 0
new JJ 0
chips NNS 0
were VBD 0
inserted VBN 0
in IN 0
all DT 0
pockets NNS 0
with IN 0
PD NNP 0
?5 NNP 0
mm NN 0
. . 0

Parameters NNS 0
were VBD 0
assessed VBN 0
at IN 0
baseline NN 0
; : 0
beginning NN 0
of IN 0
SRP NNP 0
; : 0
and CC 0
1 CD 0
, , 0
3 CD 0
, , 0
and CC 0
6 CD 0
months NNS 0
after IN 0
treatment NN 0
. . 0

Subgingival JJ 0
samples NNS 0
were VBD 0
obtained VBN 0
at IN 0
baseline NN 0
; : 0
beginning NN 0
of IN 0
SRP NNP 0
; : 0
and CC 0
at IN 0
1 CD 0
month NN 0
after IN 0
treatment NN 0
. . 0

Periodontal JJ 0
pathogens NNS 0
Aggregatibacter NNP 0
actinomycetemcomitans NNS 0
, , 0
Porphyromonas NNP 0
gingivalis NN 0
, , 0
Prevotella NNP 0
intermedia NN 0
, , 0
Tannerella NNP 0
forsythia NN 0
, , 0
and CC 0
Treponema NNP 0
denticola NN 0
were VBD 0
analyzed VBN 0
. . 0

Serum NNP 0
levels NNS 0
of IN 0
high JJ 0
sensitive JJ 0
C-reactive JJ 0
and CC 0
lipopolysaccharide-binding JJ 0
proteins NNS 0
were VBD 0
measured VBN 0
. . 0

The DT 0
changes NNS 0
of IN 0
the DT 0
parameters NNS 0
between IN 0
and CC 0
within IN 0
the DT 0
groups NNS 0
were VBD 0
tested VBN 0
by IN 0
Mann-Whitney NNP 0
U NNP 0
test NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

RESULTS NNP 0
All NNP 0
clinical JJ 0
and CC 0
serologic JJ 0
parameters NNS 0
improved VBN 0
in IN 0
both DT 0
groups NNS 0
over IN 0
time NN 0
. . 0

There EX 0
was VBD 0
a DT 0
significant JJ 0
difference NN 0
in IN 0
clinical JJ 0
attachment NN 0
level NN 0
( ( 0
CAL NNP 0
) ) 0
gain NN 0
from IN 0
baseline NN 0
to TO 0
6 CD 0
months NNS 0
between IN 0
groups NNS 0
( ( 0
1.17 CD 0
mm NN 0
in IN 0
the DT 0
test NN 0
group NN 0
versus VBD 0
0.79 CD 0
mm NN 0
in IN 0
the DT 0
placebo NN 0
group NN 0
) ) 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

The DT 0
treatment NN 0
with IN 0
CHX NNP 0
chips NNS 0
showed VBD 0
a DT 0
greater JJR 0
reduction NN 0
of IN 0
the DT 0
microorganisms NN 0
of IN 0
the DT 0
red JJ 0
complex NN 0
after IN 0
1 CD 0
month NN 0
( ( 0
P NNP 0
= NNP 0
0.02 CD 0
) ) 0
. . 0

CONCLUSION VB 0
The DT 0
use NN 0
of IN 0
CHX NNP 0
chips NNS 0
before IN 0
and CC 0
immediately RB 0
after IN 0
SRP NNP 0
improved VBD 0
CAL NNP 0
and CC 0
reduced VBD 0
the DT 0
subgingival JJ 0
microorganisms NN 0
of IN 0
the DT 0
red JJ 0
complex NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
chronic JJ 0
periodontitis NN 0
. . 0

Sensory NNP 0
Adapted NNP 0
Dental NNP 0
Environments NNP 0
to TO 0
Enhance VB 0
Oral NNP 0
Care NNP 0
for IN 0
Children NNP 0
with IN 0
Autism NNP 0
Spectrum NNP 0
Disorders NNPS 0
: : 0
A DT 0
Randomized NNP 0
Controlled NNP 0
Pilot NNP 0
Study NNP 0
. . 0

This DT 0
pilot NN 0
and CC 0
feasibility NN 0
study NN 0
examined VBD 0
the DT 0
impact NN 0
of IN 0
a DT 0
sensory JJ 0
adapted JJ 0
dental NN 0
environment NN 0
( ( 0
SADE NNP 0
) ) 0
to TO 0
reduce VB 0
distress NN 0
, , 0
sensory JJ 0
discomfort NN 0
, , 0
and CC 0
perception NN 0
of IN 0
pain NN 0
during IN 0
oral JJ 0
prophylaxis NN 0
for IN 0
children NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorder NN 0
( ( 0
ASD NNP 0
) ) 0
. . 0

Participants NNS 0
were VBD 0
44 CD 0
children NNS 0
ages VBZ 0
6-12 NN 0
( ( 0
n JJ 0
= $ 0
22 CD 0
typical JJ 0
, , 0
n JJ 0
= FW 0
22 CD 0
ASD NNP 0
) ) 0
. . 0

In IN 0
an DT 0
experimental JJ 0
crossover NN 0
design NN 0
, , 0
each DT 0
participant JJ 0
underwent JJ 0
two CD 0
professional JJ 0
dental JJ 0
cleanings NNS 0
, , 0
one CD 0
in IN 0
a DT 0
regular JJ 0
dental NN 0
environment NN 0
( ( 0
RDE NNP 0
) ) 0
and CC 0
one CD 0
in IN 0
a DT 0
SADE NNP 0
, , 0
administered VBN 0
in IN 0
a DT 0
randomized JJ 0
and CC 0
counterbalanced JJ 0
order NN 0
3-4 JJ 0
months NNS 0
apart RB 0
. . 0

Outcomes NNP 0
included VBD 0
measures NNS 0
of IN 0
physiological JJ 0
anxiety NN 0
, , 0
behavioral JJ 0
distress NN 0
, , 0
pain NN 0
intensity NN 0
, , 0
and CC 0
sensory JJ 0
discomfort NN 0
. . 0

Both DT 0
groups NNS 0
exhibited VBD 0
decreased JJ 0
physiological JJ 0
anxiety NN 0
and CC 0
reported VBD 0
lower JJR 0
pain NN 0
and CC 0
sensory JJ 0
discomfort NN 0
in IN 0
the DT 0
SADE NNP 0
condition NN 0
compared VBN 0
to TO 0
RDE NNP 0
, , 0
indicating VBG 0
a DT 0
beneficial JJ 0
effect NN 0
of IN 0
the DT 0
SADE NNP 0
. . 0

Prospective JJ 0
study NN 0
of IN 0
short JJ 0
and CC 0
ultrashort JJ 0
regimens NNS 0
of IN 0
gonadotropin-releasing JJ 0
hormone NN 0
agonist NN 0
in IN 0
an DT 0
in IN 0
vitro JJ 0
fertilization NN 0
program NN 0
. . 0

OBJECTIVE NNP 0
To TO 0
assess VB 0
the DT 0
usefulness NN 0
of IN 0
the DT 0
ultrashort JJ 0
regimen NNS 0
of IN 0
gonadotropin-releasing JJ 0
hormone NN 0
agonist NN 0
( ( 0
GnRH-a NNP 0
) ) 0
in IN 0
ovulation NN 0
induction NN 0
in IN 0
an DT 0
in IN 0
vitro JJ 0
fertilization NN 0
( ( 0
IVF NNP 0
) ) 0
program NN 0
. . 0

DESIGN VB 0
A DT 0
prospective JJ 0
randomized VBN 0
trial NN 0
comparing VBG 0
short JJ 0
and CC 0
ultrashort JJ 0
regimens NNS 0
of IN 0
GnRH-a NNP 0
. . 0

SETTING NN 0
Aberdeen NNP 0
Assisted NNP 0
Reproduction NNP 0
Unit NNP 0
. . 0

PATIENTS NNP 0
Forty-eight JJ 0
patients NNS 0
having VBG 0
IVF NNP 0
for IN 0
the DT 0
first JJ 0
time NN 0
were VBD 0
randomized VBN 0
between IN 0
the DT 0
two CD 0
protocols NNS 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURES NNP 0
Response NNP 0
to TO 0
ovarian JJ 0
stimulation NN 0
and CC 0
occurrence NN 0
of IN 0
spontaneous JJ 0
luteinizing VBG 0
hormone NN 0
( ( 0
LH NNP 0
) ) 0
surges VBZ 0
. . 0

RESULTS NNP 0
In IN 0
ovulation NN 0
induction NN 0
, , 0
fertilization NN 0
, , 0
and CC 0
pregnancy NN 0
rates NNS 0
the DT 0
ultrashort JJ 0
regimen NNS 0
produces VBZ 0
results NNS 0
that WDT 0
were VBD 0
no DT 0
different JJ 0
to TO 0
the DT 0
short JJ 0
regimen NNS 0
but CC 0
it PRP 0
did VBD 0
not RB 0
always RB 0
prevent VB 0
an DT 0
LH NNP 0
surge NN 0
. . 0

CONCLUSION VB 0
The DT 0
ultrashort JJ 0
regimen NNS 0
can MD 0
be VB 0
a DT 0
useful JJ 0
alternative NN 0
for IN 0
ovarian JJ 0
stimulation NN 0
of IN 0
patients NNS 0
undergoing VBG 0
IVF NNP 0
. . 0

Atomoxetine NNP 0
in IN 0
autism NN 0
spectrum NN 0
disorder NN 0
: : 0
no DT 0
effects NNS 0
on IN 0
social JJ 0
functioning NN 0
; : 0
some DT 0
beneficial JJ 0
effects NNS 0
on IN 0
stereotyped JJ 0
behaviors NNS 0
, , 0
inappropriate JJ 0
speech NN 0
, , 0
and CC 0
fear NN 0
of IN 0
change NN 0
. . 0

UNLABELLED NNP 0
Abstract NNP 0
Objective NNP 0
: : 0
The DT 0
objective NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
investigate VB 0
the DT 0
short-term JJ 0
treatment NN 0
effects NNS 0
of IN 0
atomoxetine NN 0
on IN 0
autism NN 0
spectrum NN 0
disorder NN 0
( ( 0
ASD NNP 0
) ) 0
symptoms NNS 0
in IN 0
children NNS 0
and CC 0
adolescents NNS 0
with IN 0
both DT 0
ASD NNP 0
and CC 0
attention-deficit/hyperactivity JJ 0
disorder NN 0
( ( 0
ADHD NNP 0
) ) 0
. . 0

METHODS CC 0
A DT 0
total NN 0
of IN 0
97 CD 0
patients NNS 0
6-17 JJ 0
years NNS 0
of IN 0
age NN 0
, , 0
with IN 0
ASD NNP 0
and CC 0
ADHD NNP 0
, , 0
were VBD 0
treated VBN 0
with IN 0
1.2 CD 0
mg/kg/day NN 0
of IN 0
atomoxetine NN 0
during IN 0
an DT 0
8 CD 0
week NN 0
double-blind JJ 0
placebo-controlled JJ 0
period NN 0
. . 0

Here RB 0
, , 0
we PRP 0
investigated VBD 0
effects NNS 0
on IN 0
two CD 0
parent-based JJ 0
secondary JJ 0
outcome NN 0
measures NNS 0
, , 0
the DT 0
Aberrant NNP 0
Behavior NNP 0
Checklist NNP 0
( ( 0
ABC NNP 0
) ) 0
and CC 0
the DT 0
Children NNP 0
's POS 0
Social NNP 0
Behavior NNP 0
Questionnaire NNP 0
( ( 0
CSBQ NNP 0
) ) 0
. . 0

RESULTS NNP 0
After IN 0
8 CD 0
weeks NNS 0
of IN 0
double-blind JJ 0
treatment NN 0
, , 0
atomoxetine JJ 0
administration NN 0
was VBD 0
associated VBN 0
with IN 0
significant JJ 0
treatment NN 0
effects NNS 0
on IN 0
the DT 0
ABC NNP 0
subscales VBZ 0
Hyperactivity NNP 0
, , 0
Inappropriate NNP 0
Speech NNP 0
, , 0
and CC 0
Stereotypic NNP 0
Behavior NNP 0
, , 0
and CC 0
on IN 0
the DT 0
CSBQ NNP 0
subscale NN 0
Fear NNP 0
for IN 0
Changes NNP 0
. . 0

CONCLUSIONS NNP 0
Our PRP$ 0
study NN 0
results NNS 0
indicate VBP 0
no DT 0
beneficial JJ 0
effects NNS 0
of IN 0
atomoxetine NN 0
on IN 0
social JJ 0
functioning NN 0
. . 0

However RB 0
, , 0
atomoxetine NN 0
may MD 0
ameliorate VB 0
restricted VBN 0
and CC 0
stereotyped VBN 0
behaviors NNS 0
and CC 0
communication NN 0
. . 0

This DT 0
study NN 0
has VBZ 0
been VBN 0
registered VBN 0
in IN 0
ClinicalTrials.gov NNP 0
( ( 0
www.clinicaltrials.gov NN 0
) ) 0
under IN 0
registration NN 0
number NN 0
NCT00380692 NNP 0
. . 0

Rationale NNP 0
and CC 0
design NN 0
of IN 0
RE-LY NNP 0
: : 0
randomized JJ 0
evaluation NN 0
of IN 0
long-term JJ 0
anticoagulant JJ 0
therapy NN 0
, , 0
warfarin NN 0
, , 0
compared VBN 0
with IN 0
dabigatran NN 0
. . 0

Vitamin NNP 0
K NNP 0
antagonists NNS 0
( ( 0
VKAs NNP 0
) ) 0
are VBP 0
effective JJ 0
for IN 0
stroke NN 0
prevention NN 0
in IN 0
patients NNS 0
with IN 0
atrial JJ 4
fibrillation NN 4
( ( 0
AF NNP 4
) ) 0
but CC 0
are VBP 0
difficult JJ 0
to TO 0
use VB 0
. . 0

Dabigatran NNP 0
etexilate NN 0
is VBZ 0
a DT 0
prodrug NN 0
that WDT 0
is VBZ 0
rapidly RB 0
converted VBN 0
to TO 0
the DT 0
active JJ 0
direct JJ 0
thrombin NN 0
inhibitor NN 0
dabigatran NN 0
. . 0

It PRP 0
is VBZ 0
administered VBN 0
in IN 0
a DT 0
fixed JJ 0
dose NN 0
without IN 0
laboratory JJ 0
monitoring NN 0
and CC 0
is VBZ 0
being VBG 0
compared VBN 0
with IN 0
warfarin NN 0
( ( 0
international JJ 0
normalized VBN 0
ratio JJ 0
2-3 JJ 0
) ) 0
in IN 0
the DT 0
RE-LY JJ 0
trial NN 0
. . 0

Two CD 0
doses NNS 0
of IN 0
dabigatran NN 0
( ( 0
110 CD 0
and CC 0
150 CD 0
mg NNS 0
BID NNP 0
) ) 0
are VBP 0
being VBG 0
evaluated VBN 0
. . 0

RE-LY NNP 0
is VBZ 0
a DT 0
phase NN 0
3 CD 0
, , 0
prospective JJ 0
, , 0
randomized VBN 0
, , 0
open-label JJ 0
multinational NN 0
( ( 0
44 CD 0
countries NNS 0
) ) 0
trial NN 0
of IN 0
patients NNS 0
with IN 0
nonvalvular JJ 4
AF NNP 4
and CC 0
at IN 0
least JJS 0
1 CD 0
risk NN 0
factor NN 0
for IN 0
stroke NN 0
. . 0

Recruitment NNP 0
concluded VBD 0
with IN 0
a DT 0
total NN 0
of IN 0
18,113 CD 3
patients NNS 0
. . 0

Patients NNS 0
who WP 0
were VBD 0
VKA-naive NNP 0
and CC 0
experienced VBN 0
are VBP 0
included VBN 0
in IN 0
balanced JJ 0
proportions NNS 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
is VBZ 0
stroke VBN 0
( ( 0
including VBG 0
hemorrhagic NN 0
) ) 0
or CC 0
systemic JJ 0
embolism NN 0
. . 0

Safety NNP 0
outcomes NNS 0
are VBP 0
bleeding VBG 0
, , 0
liver JJ 0
function NN 0
abnormalities NNS 0
, , 0
and CC 0
other JJ 0
adverse JJ 0
events NNS 0
. . 0

Adjudication NN 0
of IN 0
end NN 0
points NNS 0
is VBZ 0
blinded VBN 0
to TO 0
drug NN 0
assignment NN 0
. . 0

The DT 0
trial NN 0
is VBZ 0
expected VBN 0
to TO 0
accrue VB 0
a DT 0
minimum NN 0
of IN 0
450 CD 0
events NNS 0
with IN 0
a DT 0
minimum JJ 0
1-year JJ 0
of IN 0
follow-up JJ 0
. . 0

RE-LY NN 0
is VBZ 0
the DT 0
largest JJS 0
AF NNP 0
stroke VBD 0
prevention NN 0
trial NN 0
yet RB 0
undertaken VBN 0
. . 0

It PRP 0
is VBZ 0
unique JJ 0
because IN 0
it PRP 0
includes VBZ 0
equal JJ 0
numbers NNS 0
of IN 0
VKA-experienced NNP 0
and CC 0
naive JJ 0
patients NNS 0
and CC 0
evaluates VBZ 0
2 CD 0
different JJ 0
dosages NNS 0
of IN 0
dabigatran NN 0
, , 0
which WDT 0
may MD 0
allow VB 0
tailoring NN 0
of IN 0
dosing VBG 0
to TO 0
individual JJ 0
patient NN 0
needs NNS 0
. . 0

The DT 0
worldwide JJ 0
site NN 0
distribution NN 0
and CC 0
broad JJ 0
range NN 0
of IN 0
stroke NN 0
risk NN 0
further RBR 0
increase VB 0
the DT 0
general JJ 0
applicability NN 0
of IN 0
the DT 0
trial NN 0
. . 0

Results NNS 0
are VBP 0
expected VBN 0
in IN 0
2009 CD 0
. . 0

Effect NN 0
of IN 0
simvastatin NN 0
on IN 0
hemostasis NN 0
in IN 0
patients NNS 0
with IN 0
isolated JJ 0
hypertriglyceridemia NN 0
. . 0

BACKGROUNDS/AIMS NNP 0
Elevated NNP 0
triglyceride NN 0
levels NNS 0
seem VBP 0
to TO 0
predispose VB 0
to TO 0
the DT 0
earlier JJR 0
development NN 0
and CC 0
accelerated JJ 0
progression NN 0
of IN 0
coronary JJ 0
artery NN 0
disease NN 0
. . 0

In IN 0
our PRP$ 0
study NN 0
, , 0
we PRP 0
assessed VBD 0
for IN 0
the DT 0
first JJ 0
time NN 0
whether IN 0
simvastatin JJ 0
treatment NN 0
affects NNS 0
coagulation NN 0
and CC 0
fibrinolysis NN 0
in IN 0
patients NNS 0
with IN 0
isolated JJ 0
hypertriglyceridemia NN 0
. . 0

METHODS NNP 0
The DT 0
study NN 0
included VBD 0
39 CD 0
patients NNS 0
with IN 0
elevated JJ 0
triglyceride NN 0
levels NNS 0
and CC 0
peripheral JJ 0
artery NN 0
sclerosis NN 0
, , 0
treated VBD 0
for IN 0
90 CD 0
days NNS 0
with IN 0
either DT 0
simvastatin NN 0
( ( 0
40 CD 0
mg NNS 0
daily RB 0
) ) 0
or CC 0
placebo NN 0
. . 0

Plasma NNP 0
lipids NNS 0
, , 0
glucose JJ 0
homeostasis NN 0
markers NNS 0
and CC 0
hemostasic JJ 0
variables NNS 0
were VBD 0
assessed VBN 0
at IN 0
baseline NN 0
and CC 0
after IN 0
treatment NN 0
. . 0

RESULTS NNP 0
Simvastatin NNP 0
, , 0
but CC 0
not RB 0
placebo VB 0
, , 0
administered VBN 0
to TO 0
these DT 0
patients NNS 0
reduced VBD 0
plasma JJ 0
levels/activity NN 0
of IN 0
fibrinogen NN 0
( ( 0
from IN 0
3.5 CD 0
? . 0
0.4 CD 0
to TO 0
2.8 CD 0
? . 0
0.3 CD 0
g/l NN 0
, , 0
p NN 0
< NNP 0
0.01 CD 0
) ) 0
, , 0
factor NN 0
VII NNP 0
( ( 0
from IN 0
144.2 CD 0
? . 0
16.9 CD 0
to TO 0
112.5 CD 0
? . 0
14.0 CD 0
% NN 0
, , 0
p NN 0
< NNP 0
0.01 CD 0
) ) 0
and CC 0
plasminogen JJ 0
activator NN 0
inhibitor-1 NN 0
( ( 0
from IN 0
76.9 CD 0
? . 0
13.5 CD 0
to TO 0
50.2 CD 0
? . 0
9.2 CD 0
ng/ml NN 0
, , 0
p NN 0
< NNP 0
0.001 CD 0
) ) 0
, , 0
without IN 0
a DT 0
significant JJ 0
reduction NN 0
in IN 0
von NN 0
Willebrand NNP 0
factor NN 0
levels NNS 0
, , 0
and CC 0
tended VBD 0
to TO 0
prolong VB 0
the DT 0
prothrombin NN 0
and CC 0
partial JJ 0
thromboplastin NN 0
times NNS 0
. . 0

CONCLUSION NNP 0
Our PRP$ 0
results NNS 0
suggest VBP 0
that IN 0
statin NN 0
treatment NN 0
produces VBZ 0
a DT 0
multidirectional JJ 0
effect NN 0
on IN 0
coagulation NN 0
and CC 0
fibrinolysis NN 0
in IN 0
patients NNS 0
with IN 0
isolated JJ 0
hypertriglyceridemia NN 0
and CC 0
that IN 0
this DT 0
treatment NN 0
may MD 0
bring VB 0
some DT 0
benefits NNS 0
to TO 0
patients NNS 0
with IN 0
elevated JJ 0
triglyceride NN 0
levels NNS 0
. . 0

Antioxidant JJ 0
supplementation NN 0
and CC 0
exercise-induced JJ 0
oxidative JJ 0
stress NN 0
in IN 0
the DT 0
60-year-old JJ 0
as IN 0
measured VBN 0
by IN 0
antipyrine NN 0
hydroxylates NNS 0
. . 0

The DT 0
effects NNS 0
of IN 0
12 CD 0
weeks NNS 0
of IN 0
antioxidant JJ 0
supplementation NN 0
on IN 0
exercise-induced JJ 0
oxidative JJ 0
stress NN 0
were VBD 0
investigated VBN 0
in IN 0
older JJR 0
adults NNS 0
( ( 0
60 CD 0
( ( 0
SE NNP 0
1 CD 0
) ) 0
years NNS 0
; : 0
BMI NNP 0
26 CD 0
( ( 0
SE NNP 0
1 CD 0
) ) 0
kg/m NN 0
( ( 0
2 CD 0
) ) 0
) ) 0
. . 0

Subjects NNS 0
were VBD 0
randomly RB 0
divided VBN 0
in IN 0
two CD 0
groups NNS 0
: : 0
supplementation NN 0
( ( 0
n JJ 0
11 CD 0
) ) 0
with IN 0
100 CD 0
mg NNS 0
dl-alpha-tocopheryl JJ 0
acetate NN 0
, , 0
200 CD 0
mg NN 0
ascorbic JJ 0
acid NN 0
, , 0
and CC 0
2 CD 0
mg NN 0
beta-carotene NN 0
, , 0
and CC 0
placebo NN 0
( ( 0
n JJ 0
9 CD 0
) ) 0
. . 0

Before IN 0
and CC 0
after IN 0
the DT 0
12 CD 0
week NN 0
supplementation NN 0
period NN 0
, , 0
subjects NNS 0
cycled VBD 0
for IN 0
45 CD 0
min NN 0
at IN 0
submaximal JJ 0
intensity NN 0
( ( 0
50 CD 0
% NN 0
maximal JJ 0
workload NN 0
capacity NN 0
) ) 0
. . 0

Antipyrine NNP 0
was VBD 0
used VBN 0
as IN 0
marker NN 0
for IN 0
oxidative JJ 0
stress NN 0
. . 0

Antipyrine NNP 0
reacts VBZ 0
quickly RB 0
with IN 0
hydroxyl JJ 0
radicals NNS 0
to TO 0
form VB 0
para- JJ 0
and CC 0
ortho-hydroxyantipyrine JJ 0
. . 0

The DT 0
latter JJ 0
metabolite NN 0
is VBZ 0
not RB 0
formed VBN 0
in IN 0
man NN 0
through IN 0
the DT 0
mono-oxygenase JJ 0
pathway NN 0
of IN 0
cytochrome JJ 0
P450 NNP 0
. . 0

Daily NNP 0
supplementation NN 0
significantly RB 0
increased VBD 0
plasma JJ 0
concentrations NNS 0
of IN 0
alpha-tocopherol NN 0
and CC 0
beta-carotene NN 0
in IN 0
the DT 0
supplemented VBN 0
group NN 0
( ( 0
Delta NNP 0
14.4 CD 0
( ( 0
SE NNP 0
3.2 CD 0
) ) 0
and CC 0
0.4 CD 0
( ( 0
se VB 0
0.1 CD 0
) ) 0
micromol/l NN 0
; : 0
P NNP 0
< VBZ 0
0.001 CD 0
and CC 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

No DT 0
significant JJ 0
differences NNS 0
, , 0
within IN 0
and CC 0
between IN 0
groups NNS 0
, , 0
were VBD 0
observed VBN 0
in IN 0
the DT 0
exercise-induced JJ 0
increase NN 0
in IN 0
the DT 0
ratios NNS 0
para- JJ 0
and CC 0
ortho-hydroxyantipyrine JJ 0
to TO 0
antipyrine VB 0
. . 0

In IN 0
addition NN 0
, , 0
supplementation NN 0
did VBD 0
not RB 0
affect VB 0
the DT 0
exercise-induced JJ 0
increase NN 0
in IN 0
thiobarbituric JJ 0
acid NN 0
reactive JJ 0
substances NNS 0
in IN 0
plasma NN 0
. . 0

In IN 0
conclusion NN 0
, , 0
in IN 0
60-year-old JJ 0
subjects NNS 0
antioxidant JJ 0
supplementation NN 0
had VBD 0
no DT 0
effect NN 0
on IN 0
the DT 0
exercise-induced JJ 0
increase NN 0
in IN 0
oxidative JJ 0
stress NN 0
as IN 0
measured VBN 0
by IN 0
free JJ 0
radical JJ 0
products NNS 0
of IN 0
antipyrine NN 0
. . 0

Conscious JJ 0
analgesia/sedation NN 0
with IN 0
remifentanil NN 0
and CC 0
propofol NN 0
versus NN 0
total JJ 0
intravenous JJ 0
anesthesia NN 0
with IN 0
fentanyl NN 0
, , 0
midazolam NN 0
, , 0
and CC 0
propofol NN 0
for IN 0
outpatient JJ 0
colonoscopy NN 0
. . 0

BACKGROUND NNP 0
This DT 0
study NN 0
tested VBD 0
the DT 0
hypothesis NN 0
that WDT 0
, , 0
for IN 0
colonoscopy NN 0
, , 0
analgesia/sedation NN 0
with IN 0
remifentanil NN 0
and CC 0
propofol NN 0
might MD 0
be VB 0
more RBR 0
effective JJ 0
compared VBN 0
with IN 0
anesthesia NN 0
by IN 0
intravenous JJ 0
administration NN 0
of IN 0
midazolam NN 0
, , 0
fentanyl NN 0
, , 0
and CC 0
propofol NN 0
. . 0

METHODS NNP 0
In IN 0
a DT 0
prospective JJ 0
, , 0
randomized JJ 0
trial NN 0
, , 0
100 CD 0
adult NN 0
patients NNS 0
received VBD 0
either RB 0
conscious JJ 0
analgesia/sedation NN 0
( ( 0
Sedation NNP 0
group NN 0
) ) 0
or CC 0
total JJ 0
intravenous JJ 0
anesthesia NN 0
( ( 0
TIVA NNP 0
group NN 0
) ) 0
. . 0

Analgesia/sedation NN 0
was VBD 0
achieved VBN 0
by IN 0
infusion NN 0
of IN 0
remifentanil NN 0
( ( 0
0.20 CD 0
to TO 0
0.25 CD 0
microg/kg/min NN 0
) ) 0
and CC 0
propofol NN 0
in IN 0
titrated JJ 0
doses NNS 0
. . 0

TIVA NNP 0
was VBD 0
induced VBN 0
by IN 0
intravenous JJ 0
administration NN 0
of IN 0
fentanyl NN 0
( ( 0
2 CD 0
microg/kg NN 0
) ) 0
, , 0
midazolam FW 0
( ( 0
0.05 CD 0
mg/kg NN 0
) ) 0
and CC 0
propofol NN 0
( ( 0
dosage NN 0
titrated VBN 0
) ) 0
. . 0

Cardiorespiratory JJ 0
parameters NNS 0
and CC 0
bispectral JJ 0
index NN 0
were VBD 0
monitored VBN 0
and CC 0
recorded VBN 0
. . 0

The DT 0
quality NN 0
of IN 0
the DT 0
analgesia NN 0
was VBD 0
assessed VBN 0
with IN 0
a DT 0
Numerical JJ 0
Pain NN 0
Rating NNP 0
Scale NNP 0
( ( 0
NRS NNP 0
) ) 0
; : 0
recovery NN 0
level NN 0
and CC 0
return NN 0
of IN 0
psychomotor NN 0
efficiency NN 0
were VBD 0
evaluated VBN 0
with IN 0
, , 0
respectively RB 0
, , 0
the DT 0
Aldrete NNP 0
scale NN 0
and CC 0
a DT 0
Modified NNP 0
Post NNP 0
Anesthesia NNP 0
Discharge NNP 0
Scoring NNP 0
( ( 0
MPADS NNP 0
) ) 0
system NN 0
. . 0

RESULTS VB 0
Both DT 0
groups NNS 0
of IN 0
50 CD 0
patients NNS 0
were VBD 0
comparable JJ 0
with IN 0
respect NN 0
to TO 0
demographic VB 0
data NNS 0
, , 0
initial JJ 0
parameters NNS 0
, , 0
and CC 0
duration NN 0
of IN 0
colonoscopy NN 0
. . 0

All DT 0
patients NNS 0
in IN 0
the DT 0
TIVA NNP 0
group NN 0
found VBD 0
the DT 0
colonoscopy NN 0
painless NN 0
( ( 0
NRS NNP 0
score RB 0
0 CD 0
) ) 0
. . 0

In IN 0
the DT 0
Sedation NNP 0
group NN 0
, , 0
the DT 0
average JJ 0
pain NN 0
intensity NN 0
score NN 0
was VBD 0
0.4 CD 0
( ( 0
0.8 CD 0
) ) 0
. . 0

There EX 0
was VBD 0
a DT 0
marked JJ 0
difference NN 0
between IN 0
the DT 0
Sedation NNP 0
and CC 0
TIVA NNP 0
groups NNS 0
with IN 0
respect NN 0
to TO 0
the DT 0
time NN 0
from IN 0
the DT 0
end NN 0
of IN 0
the DT 0
procedure NN 0
until IN 0
the DT 0
maximum JJ 0
MPADS NNP 0
score NN 0
was VBD 0
reached VBN 0
: : 0
respectively RB 0
, , 0
-6.9 NNP 0
( ( 0
4.0 CD 0
) ) 0
versus NN 0
25.7 CD 0
( ( 0
8.4 CD 0
) ) 0
minutes NNS 0
( ( 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

In IN 0
the DT 0
TIVA NNP 0
group NN 0
, , 0
changes NNS 0
in IN 0
mean JJ 0
arterial JJ 0
pressure NN 0
and CC 0
heart NN 0
rate NN 0
and CC 0
signs NNS 0
of IN 0
respiratory NN 0
depression NN 0
were VBD 0
significant JJ 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Combined NNP 0
administration NN 0
of IN 0
remifentanil NN 0
and CC 0
propofol NN 0
for IN 0
colonoscopy NN 0
provides VBZ 0
sufficient JJ 0
analgesia NN 0
, , 0
satisfactory JJ 0
hemodynamic JJ 0
stability NN 0
, , 0
minor JJ 0
respiratory NN 0
depression NN 0
, , 0
and CC 0
rapid JJ 0
recovery NN 0
, , 0
and CC 0
allows VBZ 0
patients NNS 0
to TO 0
be VB 0
discharged VBN 0
approximately RB 0
15 CD 0
minutes NNS 0
after IN 0
the DT 0
procedure NN 0
. . 0

Randomised VBN 0
trial NN 0
of IN 0
text NN 0
messaging NN 0
on IN 0
adherence NN 0
to TO 0
cardiovascular VB 0
preventive JJ 0
treatment NN 0
( ( 0
INTERACT NNP 0
trial NN 0
) ) 0
. . 0

BACKGROUND CC 0
About IN 0
one CD 0
third NN 0
of IN 0
patients NNS 0
prescribed VBN 0
blood JJ 0
pressure NN 0
or CC 0
lipid-lowering JJ 0
drugs NNS 0
for IN 0
the DT 0
prevention NN 0
of IN 0
coronary JJ 0
heart NN 0
disease NN 0
and CC 0
stroke NN 0
do VBP 0
not RB 0
take VB 0
their PRP$ 0
medication NN 0
as IN 0
prescribed JJ 0
. . 0

We PRP 0
conducted VBD 0
a DT 0
randomized JJ 0
trial NN 0
to TO 0
evaluate VB 0
text JJ 0
messaging NN 0
as IN 0
a DT 0
means NN 0
of IN 0
improving VBG 0
adherence NN 0
to TO 0
cardiovascular VB 0
disease NN 0
preventive JJ 0
treatment NN 0
. . 0

METHODS NNP 0
303 CD 0
patients NNS 0
taking VBG 0
blood NN 0
pressure NN 0
and/or IN 0
lipid-lowering JJ 0
medications NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
being VBG 0
sent VBN 0
text NN 0
messages NNS 0
( ( 0
Text NNP 0
group NN 0
, , 0
151 CD 0
) ) 0
or CC 0
not RB 0
being VBG 0
sent VBN 0
them PRP 0
( ( 0
No NNP 0
text NN 0
group NN 0
, , 0
152 CD 0
) ) 0
. . 0

Texts NNP 0
were VBD 0
sent VBN 0
daily RB 0
for IN 0
2 CD 0
weeks NNS 0
, , 0
alternate JJ 0
days NNS 0
for IN 0
2 CD 0
weeks NNS 0
and CC 0
weekly JJ 0
thereafter NN 0
for IN 0
22 CD 0
weeks NNS 0
( ( 0
6 CD 0
months NNS 0
overall JJ 0
) ) 0
, , 0
using VBG 0
an DT 0
automated VBN 0
computer NN 0
programme NN 0
. . 0

Patients NNS 0
were VBD 0
asked VBN 0
to TO 0
respond VB 0
on IN 0
whether IN 0
they PRP 0
had VBD 0
taken VBN 0
their PRP$ 0
medication NN 0
, , 0
whether IN 0
the DT 0
text NN 0
reminded VBD 0
them PRP 0
to TO 0
do VB 0
so RB 0
if IN 0
they PRP 0
had VBD 0
forgotten VBN 0
, , 0
and CC 0
if IN 0
they PRP 0
had VBD 0
not RB 0
taken VBN 0
their PRP$ 0
medication NN 0
to TO 0
determine VB 0
if IN 0
there EX 0
was VBD 0
a DT 0
reason NN 0
for IN 0
not RB 0
doing VBG 0
so RB 0
. . 0

At IN 0
6 CD 0
months NNS 0
, , 0
use NN 0
of IN 0
medication NN 0
was VBD 0
assessed VBN 0
. . 0

RESULTS NNP 0
Two CD 0
patients NNS 0
were VBD 0
lost VBN 0
to TO 0
follow-up NN 0
, , 0
providing VBG 0
data NNS 0
on IN 0
301 CD 0
for IN 0
analysis NN 0
. . 0

In IN 0
the DT 0
No NNP 0
text NN 0
group NN 0
38/151 CD 0
( ( 0
25 CD 0
% NN 0
) ) 0
took VBD 0
less JJR 0
than IN 0
80 CD 0
% NN 0
of IN 0
the DT 0
prescribed JJ 0
regimen NNS 0
( ( 0
ie NN 0
. . 0

stopped VBD 0
medication NN 0
completely RB 0
or CC 0
took VBD 0
it PRP 0
on IN 0
fewer JJR 0
than IN 0
22 CD 0
of IN 0
the DT 0
last JJ 0
28 CD 0
days NNS 0
of IN 0
follow-up NN 0
) ) 0
compared VBN 0
to TO 0
14/150 CD 0
patients NNS 0
( ( 0
9 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
Text NNP 0
group NN 0
- : 0
an DT 0
improvement NN 0
in IN 0
adherence NN 0
affecting VBG 0
16 CD 0
per IN 0
100 CD 0
patients NNS 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
7 CD 0
to TO 0
24 CD 0
) ) 0
, , 0
p JJ 0
< NN 0
0.001 CD 0
. . 0

The DT 0
texts NN 0
reminded VBD 0
98/151 CD 0
patients NNS 0
( ( 0
65 CD 0
% NN 0
) ) 0
to TO 0
take VB 0
medication NN 0
on IN 0
at IN 0
least JJS 0
one CD 0
occasion NN 0
and CC 0
lead NN 0
to TO 0
20/151 CD 0
( ( 0
13 CD 0
% NN 0
) ) 0
who WP 0
stopped VBD 0
taking VBG 0
medication NN 0
because IN 0
of IN 0
concern NN 0
over IN 0
efficacy NN 0
or CC 0
side-effects NNS 0
, , 0
resuming VBG 0
treatment NN 0
. . 0

CONCLUSIONS NNP 0
In IN 0
patients NNS 0
taking VBG 0
blood NN 0
pressure NN 0
or CC 0
lipid-lowering JJ 0
treatment NN 0
for IN 0
the DT 0
prevention NN 0
of IN 0
cardiovascular JJ 0
disease NN 0
, , 0
text NN 0
messaging NN 0
improved JJ 0
medication NN 0
adherence NN 0
compared VBN 0
with IN 0
no DT 0
text NN 0
messaging NN 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
Controlled-Trials.com NNP 0
ISRCTN74757601 NNP 0
. . 0

Lowering VBG 0
the DT 0
triglyceride/high-density NN 0
lipoprotein NN 0
cholesterol NN 0
ratio NN 0
is VBZ 0
associated VBN 0
with IN 0
the DT 0
beneficial JJ 0
impact NN 0
of IN 0
pioglitazone NN 0
on IN 0
progression NN 0
of IN 0
coronary JJ 0
atherosclerosis NN 0
in IN 0
diabetic JJ 0
patients NNS 0
: : 0
insights NNS 0
from IN 0
the DT 0
PERISCOPE NNP 0
( ( 0
Pioglitazone NNP 0
Effect NNP 0
on IN 0
Regression NNP 0
of IN 0
Intravascular NNP 0
Sonographic NNP 0
Coronary NNP 0
Obstruction NNP 0
Prospective NNP 0
Evaluation NNP 0
) ) 0
study NN 0
. . 0

OBJECTIVES CC 0
The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
determine VB 0
the DT 0
factors NNS 0
associated VBN 0
with IN 0
the DT 0
favorable JJ 0
effect NN 0
of IN 0
pioglitazone NN 0
on IN 0
atheroma JJ 0
progression NN 0
. . 0

BACKGROUND NNP 0
Diabetes NNP 0
mellitus NN 0
is VBZ 0
associated VBN 0
with IN 0
accelerated JJ 0
coronary JJ 0
atheroma NN 0
progression NN 0
. . 0

Pioglitazone NN 0
slowed VBD 0
progression NN 0
compared VBN 0
with IN 0
glimepiride NN 0
in IN 0
this DT 0
population NN 0
. . 0

METHODS NNP 0
In IN 0
all DT 0
, , 0
360 CD 0
diabetic JJ 0
patients NNS 0
with IN 0
coronary JJ 0
artery NN 0
disease NN 0
were VBD 0
treated VBN 0
with IN 0
pioglitazone NN 0
or CC 0
glimepiride NN 0
for IN 0
18 CD 0
months NNS 0
in IN 0
the DT 0
PERISCOPE NNP 0
( ( 0
Pioglitazone NNP 0
Effect NNP 0
on IN 0
Regression NNP 0
of IN 0
Intravascular NNP 0
Sonographic NNP 0
Coronary NNP 0
Obstruction NNP 0
Prospective NNP 0
Evaluation NNP 0
) ) 0
study NN 0
. . 0

Coronary NNP 0
atheroma NN 0
progression NN 0
was VBD 0
evaluated VBN 0
by IN 0
serial JJ 0
intravascular JJ 0
ultrasound NN 0
. . 0

The DT 0
relationship NN 0
between IN 0
changes NNS 0
in IN 0
biochemical JJ 0
parameters NNS 0
, , 0
percent JJ 0
atheroma NN 0
volume NN 0
, , 0
and CC 0
total JJ 0
atheroma NN 0
volume NN 0
was VBD 0
investigated VBN 0
. . 0

RESULTS JJ 0
Pioglitazone-treated JJ 0
patients NNS 0
demonstrated VBD 0
greater JJR 0
increases NNS 0
in IN 0
high-density NN 0
lipoprotein NN 0
cholesterol NN 0
( ( 0
HDL-C NNP 0
) ) 0
and CC 0
reductions NNS 0
in IN 0
glycated JJ 0
hemoglobin NN 0
, , 0
triglycerides NNS 0
, , 0
and CC 0
C-reactive JJ 0
protein NN 0
. . 0

Significant JJ 0
correlations NNS 0
were VBD 0
observed VBN 0
between IN 0
changes NNS 0
in IN 0
percent NN 0
atheroma NN 0
volume NN 0
and CC 0
triglycerides NNS 0
( ( 0
r VB 0
= RB 0
0.15 CD 0
, , 0
p NN 0
= NNP 0
0.04 CD 0
) ) 0
, , 0
triglyceride/HDL-C JJ 0
ratio NN 0
( ( 0
r JJ 0
= NN 0
0.16 CD 0
, , 0
p NN 0
= NNP 0
0.03 CD 0
) ) 0
, , 0
and CC 0
glycated VBD 0
hemoglobin NN 0
( ( 0
r JJ 0
= NN 0
0.16 CD 0
, , 0
p NN 0
= NNP 0
0.03 CD 0
) ) 0
with IN 0
pioglitazone NN 0
, , 0
and CC 0
changes NNS 0
in IN 0
low-density NN 0
lipoprotein NN 0
cholesterol NN 0
( ( 0
r JJ 0
= NNP 0
-0.15 NNP 0
, , 0
p NN 0
= NNP 0
0.05 CD 0
) ) 0
, , 0
apolipoprotein RB 0
B NNP 0
( ( 0
r NN 0
= NNP 0
-0.16 NNP 0
, , 0
p NN 0
= NNP 0
0.04 CD 0
) ) 0
, , 0
and CC 0
apolipoprotein RB 0
A-I NNP 0
( ( 0
r NN 0
= NNP 0
-0.20 NNP 0
, , 0
p NN 0
= NNP 0
0.01 CD 0
) ) 0
with IN 0
glimepiride NN 0
. . 0

Substantial JJ 0
atheroma JJ 0
regression NN 0
, , 0
compared VBN 0
to TO 0
progression NN 0
, , 0
was VBD 0
associated VBN 0
with IN 0
greater JJR 0
relative JJ 0
increases NNS 0
in IN 0
HDL-C NNP 0
( ( 0
14.2 CD 0
% NN 0
vs. FW 0
7.8 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.04 CD 0
) ) 0
, , 0
relative JJ 0
decreases NNS 0
in IN 0
triglycerides NNS 0
( ( 0
-13.3 CD 0
% NN 0
vs. FW 0
-1.9 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.045 CD 0
) ) 0
, , 0
triglyceride/HDL-C JJ 0
ratio NN 0
( ( 0
-22.5 NNP 0
vs. FW 0
-9.9 NNP 0
% NN 0
, , 0
p NN 0
= NNP 0
0.05 CD 0
) ) 0
, , 0
and CC 0
decrease NN 0
in IN 0
glycated JJ 0
hemoglobin NN 0
( ( 0
-0.6 CD 0
% NN 0
vs. FW 0
-0.3 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.01 CD 0
) ) 0
. . 0

Multivariable JJ 0
analysis NN 0
revealed VBD 0
that IN 0
pioglitazone-induced JJ 0
effects NNS 0
on IN 0
triglyceride/HDL-C NN 0
were VBD 0
associated VBN 0
with IN 0
changes NNS 0
in IN 0
percent NN 0
atheroma NN 0
volume NN 0
( ( 0
p JJ 0
= NNP 0
0.03 CD 0
) ) 0
and CC 0
total JJ 0
atheroma NN 0
volume NN 0
( ( 0
p JJ 0
= NNP 0
0.02 CD 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Favorable JJ 0
effects NNS 0
of IN 0
pioglitazone NN 0
on IN 0
the DT 0
triglyceride/HDL-C JJ 0
ratio NN 0
correlated VBN 0
with IN 0
delayed JJ 0
atheroma NN 0
progression NN 0
in IN 0
diabetic JJ 0
patients NNS 0
. . 0

This DT 0
finding NN 0
highlights VBZ 0
the DT 0
potential JJ 0
importance NN 0
of IN 0
targeting VBG 0
atherogenic JJ 0
dyslipidemia NN 0
in IN 0
diabetic JJ 0
patients NNS 0
with IN 0
coronary JJ 0
artery NN 0
disease NN 0
. . 0

Plasma NNP 0
AGE-peptides NNP 0
and CC 0
C-peptide NNP 0
in IN 0
early-stage JJ 0
diabetic JJ 0
nephropathy JJ 0
patients NNS 0
on IN 0
thiamine NN 0
and CC 0
pyridoxine NN 0
therapy NN 0
. . 0

AIM IN 0
The DT 0
aim NN 0
of IN 0
the DT 0
study NN 0
was VBD 0
to TO 0
evaluate VB 0
circulatory JJ 0
AGE-peptide JJ 0
levels NNS 0
in IN 0
diabetic JJ 0
nephropathy NN 0
and CC 0
to TO 0
observe VB 0
the DT 0
effects NNS 0
of IN 0
thiamine NN 0
( ( 0
vitamin JJ 0
B1 NNP 0
) ) 0
and CC 0
pyridoxine NN 0
( ( 0
vitamin JJ 0
B6 NNP 0
) ) 0
therapy NN 0
. . 0

METHODS NNP 0
Type NNP 0
2 CD 0
diabetic JJ 0
patients NNS 0
( ( 0
N.=57 NNP 0
) ) 0
were VBD 0
divided VBN 0
into IN 0
two CD 0
groups NNS 0
as IN 0
with IN 0
nephropathy JJ 0
( ( 0
N.=27 NNP 0
) ) 0
and CC 0
without IN 0
nephropathy JJ 0
( ( 0
N.=30 NNP 0
) ) 0
. . 0

Diabetic NNP 0
nephropathy JJ 0
patients NNS 0
were VBD 0
treated VBN 0
with IN 0
either DT 0
B6 NNP 0
( ( 0
N.=12 NNP 0
) ) 0
( ( 0
250 CD 0
mg/day NN 0
) ) 0
or CC 0
B1+B6 NNP 0
( ( 0
N.=15 NNP 0
) ) 0
( ( 0
250 CD 0
mg/day NN 0
, , 0
each DT 0
) ) 0
for IN 0
five CD 0
months NNS 0
. . 0

At IN 0
the DT 0
beginning NN 0
and CC 0
the DT 0
end NN 0
of IN 0
the DT 0
experimentation NN 0
period NN 0
, , 0
glucose NN 0
, , 0
HbA1c NNP 0
, , 0
triglyceride NN 0
, , 0
cholesterol NN 0
, , 0
insulin NN 0
, , 0
C-peptide NNP 0
, , 0
thiamine NN 0
pyrophosphate NN 0
, , 0
pyridoxal JJ 0
phosphate NN 0
and CC 0
AGE- NNP 0
peptides NNS 0
were VBD 0
measured VBN 0
. . 0

RESULTS JJ 0
AGE-peptides NNS 0
were VBD 0
higher JJR 0
in IN 0
the DT 0
diabetic JJ 0
group NN 0
with IN 0
nephropathy JJ 0
than IN 0
without IN 0
nephropathy JJ 0
( ( 0
P=0.005 NNP 0
) ) 0
. . 0

Within IN 0
five CD 0
months NNS 0
AGE-peptides NNS 0
increased VBD 0
in IN 0
the DT 0
diabetic JJ 0
group NN 0
without IN 0
nephropathy JJ 0
( ( 0
P=0.042 NNP 0
) ) 0
but CC 0
not RB 0
in IN 0
the DT 0
group NN 0
with IN 0
nephropathy JJ 0
treated VBN 0
either RB 0
with IN 0
B1+B6 NNP 0
or CC 0
B6 NNP 0
. . 0

In IN 0
B6 NNP 0
treated VBD 0
group NN 0
a DT 0
substantial JJ 0
decrease NN 0
was VBD 0
observed VBN 0
in IN 0
HbA1c NNP 0
( ( 0
P=0.033 NNP 0
) ) 0
. . 0

B1+B6 NNP 0
or CC 0
B6 NNP 0
treatment NN 0
both DT 0
caused VBD 0
an DT 0
increase NN 0
in IN 0
C-peptide NNP 0
( ( 0
P=0.006 NNP 0
, , 0
P=0.004 NNP 0
) ) 0
. . 0

CONCLUSION NNP 0
Among IN 0
the DT 0
parameters NNS 0
measured VBD 0
, , 0
plasma JJ 0
AGE-peptides NNP 0
was VBD 0
the DT 0
only JJ 0
parameter NN 0
found VBD 0
to TO 0
be VB 0
higher JJR 0
in IN 0
type NN 0
2 CD 0
diabetes NNS 0
mellitus JJ 0
patients NNS 0
with IN 0
nephropathy JJ 0
than IN 0
without IN 0
nephropathy JJ 0
. . 0

However RB 0
, , 0
patients NNS 0
with IN 0
nephropathy JJ 0
treated VBN 0
with IN 0
B1+B6 NNP 0
or CC 0
B6 NNP 0
did VBD 0
not RB 0
display VB 0
any DT 0
further JJ 0
increase NN 0
in IN 0
AGE-peptides NNP 0
within IN 0
five CD 0
months NNS 0
. . 0

Both DT 0
of IN 0
the DT 0
treatments NNS 0
caused VBD 0
an DT 0
increase NN 0
in IN 0
C-peptide NNP 0
. . 0

Distinct NNP 0
fast RB 0
and CC 0
slow VB 0
processes NNS 0
contribute VBP 0
to TO 0
the DT 0
selection NN 0
of IN 0
preferred JJ 0
step NN 0
frequency NN 0
during IN 0
human JJ 0
walking VBG 0
. . 0

Humans NNPS 0
spontaneously RB 0
select VB 0
a DT 0
step NN 0
frequency NN 0
that WDT 0
minimizes VBZ 0
the DT 0
energy NN 0
expenditure NN 0
of IN 0
walking VBG 0
. . 0

This DT 0
selection NN 0
might MD 0
be VB 0
embedded VBN 0
within IN 0
the DT 0
neural JJ 0
circuits NNS 0
that WDT 0
generate VBP 0
gait NNS 0
so RB 0
that IN 0
the DT 0
optimum NN 0
is VBZ 0
pre-programmed JJ 0
for IN 0
a DT 0
given VBN 0
walking VBG 0
speed NN 0
. . 0

Or CC 0
perhaps RB 0
step JJ 0
frequency NN 0
is VBZ 0
directly RB 0
optimized VBN 0
, , 0
based VBN 0
on IN 0
sensed JJ 0
feedback NN 0
of IN 0
energy NN 0
expenditure NN 0
. . 0

Direct JJ 0
optimization NN 0
is VBZ 0
expected VBN 0
to TO 0
be VB 0
slow JJ 0
due JJ 0
to TO 0
the DT 0
compounded JJ 0
effect NN 0
of IN 0
delays NNS 0
and CC 0
iteration NN 0
, , 0
whereas IN 0
a DT 0
pre-programmed JJ 0
mechanism NN 0
presumably RB 0
allows VBZ 0
for IN 0
faster JJR 0
step NN 0
frequency NN 0
selection NN 0
, , 0
albeit JJ 0
dependent NN 0
on IN 0
prior JJ 0
experience NN 0
. . 0

To TO 0
test VB 0
for IN 0
both DT 0
pre-programmed JJ 0
selection NN 0
and CC 0
direct JJ 0
optimization NN 0
, , 0
we PRP 0
applied VBD 0
perturbations NNS 0
to TO 0
treadmill VB 0
walking VBG 0
to TO 0
elicit VB 0
transient JJ 0
changes NNS 0
in IN 0
step NN 0
frequency NN 0
. . 0

We PRP 0
found VBD 0
that IN 0
human JJ 0
step NN 0
frequency NN 0
adjustments NNS 0
( ( 0
n JJ 0
= NNP 0
7 CD 0
) ) 0
occurred VBD 0
with IN 0
two CD 0
components NNS 0
, , 0
the DT 0
first JJ 0
dominating VBG 0
the DT 0
response NN 0
( ( 0
66 CD 0
? . 0
10 CD 0
% NN 0
of IN 0
total JJ 0
amplitude JJ 0
change NN 0
; : 0
mean VB 0
? . 0
SD NNP 0
) ) 0
and CC 0
occurring VBG 0
quite RB 0
quickly RB 0
( ( 0
1.44 CD 0
? . 0
1.14 CD 0
s NN 0
to TO 0
complete VB 0
95 CD 0
% NN 0
of IN 0
total JJ 0
change NN 0
) ) 0
. . 0

The DT 0
other JJ 0
component NN 0
was VBD 0
of IN 0
smaller JJR 0
amplitude NN 0
( ( 0
35 CD 0
? . 0
10 CD 0
% NN 0
of IN 0
total JJ 0
change NN 0
) ) 0
and CC 0
took VBD 0
tens NNS 0
of IN 0
seconds NNS 0
( ( 0
27.56 CD 0
? . 0
16.18 CD 0
s NN 0
for IN 0
95 CD 0
% NN 0
completion NN 0
) ) 0
. . 0

The DT 0
fast JJ 0
process NN 0
appeared VBD 0
to TO 0
be VB 0
too RB 0
fast JJ 0
for IN 0
direct JJ 0
optimization NN 0
and CC 0
more RBR 0
indicative JJ 0
of IN 0
a DT 0
pre-programmed JJ 0
response NN 0
. . 0

It PRP 0
also RB 0
persisted VBD 0
even RB 0
with IN 0
unusual JJ 0
closed-loop JJ 0
perturbations NNS 0
that WDT 0
conflicted VBD 0
with IN 0
prior JJ 0
experience NN 0
and CC 0
rendered VBD 0
the DT 0
response NN 0
energetically RB 0
suboptimal JJ 0
. . 0

The DT 0
slow JJ 0
process NN 0
was VBD 0
more RBR 0
consistent JJ 0
with IN 0
the DT 0
timing NN 0
expected VBN 0
for IN 0
direct JJ 0
optimization NN 0
. . 0

Our PRP$ 0
interpretation NN 0
of IN 0
these DT 0
results NNS 0
is VBZ 0
that IN 0
humans NNS 0
may MD 0
rely VB 0
heavily RB 0
on IN 0
pre-programmed JJ 0
gaits NNS 0
to TO 0
rapidly RB 0
select VB 0
their PRP$ 0
preferred JJ 0
step NN 0
frequency NN 0
and CC 0
then RB 0
gradually RB 0
fine-tune JJ 0
that IN 0
selection NN 0
with IN 0
direct JJ 0
optimization NN 0
. . 0

[ JJ 0
Effect NNP 0
of IN 0
transcranial JJ 0
electrostimulation NN 0
on IN 0
clinical JJ 0
and CC 0
laboratory JJ 0
characteristics NNS 0
in IN 0
patients NNS 0
with IN 0
gastric JJ 0
ulcer JJ 0
] NN 0
. . 0

The DT 0
study NN 0
included VBD 0
100 CD 0
patients NNS 0
with IN 0
gastric JJ 0
ulcer NNS 0
aged VBN 0
from IN 0
16 CD 0
to TO 0
60 CD 0
years NNS 0
. . 0

In IN 0
58 CD 0
patients NNS 0
, , 0
traditional JJ 0
treatment NN 0
was VBD 0
supplemented VBN 0
by IN 0
transcranial JJ 0
electrotherapy NN 0
using VBG 0
a DT 0
TRANSAIR-02 JJ 0
apparatus NN 0
. . 0

Laboratory NNP 0
studies NNS 0
included VBD 0
measurements NNS 0
of IN 0
lactoferrin NN 0
( ( 0
LF NNP 0
) ) 0
and CC 0
tumour JJ 0
necrosis NN 0
factor-alpha NN 0
( ( 0
TNF-alpha NNP 0
) ) 0
, , 0
besides VBZ 0
standard JJ 0
analyses NNS 0
. . 0

Combined VBN 0
treatment NN 0
( ( 0
traditional JJ 0
therapy NN 0
plus CC 0
electrostimulation NN 0
) ) 0
resulted VBD 0
in IN 0
a DT 0
significant JJ 0
reduction NN 0
in IN 0
duration NN 0
of IN 0
the DT 0
main JJ 0
symptoms NNS 0
of IN 0
the DT 0
gastric JJ 0
ulcer NN 0
depending VBG 0
on IN 0
the DT 0
severity NN 0
of IN 0
ulceration NN 0
process NN 0
, , 0
patients NNS 0
' POS 0
age NN 0
and CC 0
sex NN 0
. . 0

Moreover RB 0
, , 0
it PRP 0
facilitated VBD 0
ulcer JJ 0
scarring NN 0
and CC 0
had VBD 0
beneficial JJ 0
effect NN 0
on IN 0
dynamics NNS 0
of IN 0
serum NN 0
LF NNP 0
and CC 0
TNF-alpha NNP 0
levels NNS 0
. . 0

To TO 0
compare VB 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
nifedipine NN 0
sustained VBN 0
release NN 0
with IN 0
Ginkgo NNP 0
biloba NN 0
extract NN 0
to TO 0
treat VB 0
patients NNS 0
with IN 0
primary JJ 0
Raynaud NNP 0
's POS 0
phenomenon NN 0
in IN 0
South NNP 0
Korea NNP 0
; : 0
Korean NNP 0
Raynaud NNP 0
study NN 0
( ( 0
KOARA NNP 0
study NN 0
) ) 0
. . 0

This DT 0
study NN 0
examined VBD 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
nifedipine NN 0
sustained VBN 0
release NN 0
( ( 0
nifedipine JJ 0
SR NNP 0
) ) 0
compared VBN 0
with IN 0
Ginkgo NNP 0
biloba NN 0
extract NN 0
as IN 0
treatment NN 0
for IN 0
primary JJ 0
Raynaud NNP 0
's POS 0
phenomenon NN 0
( ( 0
RP NNP 0
) ) 0
in IN 0
Korea NNP 0
. . 0

Primary NNP 0
RP NNP 0
were VBD 0
screened VBN 0
and CC 0
assigned VBN 0
to TO 0
either CC 0
the DT 0
nifedipine JJ 0
SR NNP 0
group NN 0
( ( 0
Group NNP 0
N NNP 0
) ) 0
or CC 0
the DT 0
Ginkgo NNP 0
biloba NN 0
extract NN 0
group NN 0
( ( 0
Group NNP 0
G NNP 0
) ) 0
in IN 0
the DT 0
ratio NN 0
of IN 0
2:1 CD 0
. . 0

After IN 0
a DT 0
run-in JJ 0
period NN 0
of IN 0
2 CD 0
weeks NNS 0
, , 0
patients NNS 0
received VBD 0
treatment NN 0
for IN 0
8 CD 0
weeks NNS 0
. . 0

We PRP 0
observed VBD 0
the DT 0
percent NN 0
improvement NN 0
of IN 0
the DT 0
RP NNP 0
attack NN 0
rate NN 0
between IN 0
before IN 0
and CC 0
after IN 0
the DT 0
8-week JJ 0
treatment NN 0
. . 0

Ninety-three JJ 0
subjects NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
. . 0

The DT 0
percent NN 0
improvement NN 0
in IN 0
Group NNP 0
N NNP 0
was VBD 0
50.1 CD 0
% NN 0
at IN 0
8 CD 0
weeks NNS 0
after IN 0
treatment NN 0
, , 0
while IN 0
it PRP 0
was VBD 0
31.0 CD 0
% NN 0
in IN 0
Group NNP 0
G NNP 0
( ( 0
p JJ 0
= NNP 0
0.03 CD 0
) ) 0
. . 0

No DT 0
serious JJ 0
adverse JJ 0
events NNS 0
occurred VBD 0
, , 0
and CC 0
almost RB 0
adverse JJ 0
events NNS 0
were VBD 0
mild JJ 0
and CC 0
improved VBN 0
without IN 0
specific JJ 0
treatment NN 0
. . 0

nifedipine JJ 0
SR NNP 0
was VBD 0
more RBR 0
effective JJ 0
than IN 0
Ginkgo NNP 0
biloba NN 0
extract NN 0
for IN 0
treatment NN 0
of IN 0
primary JJ 0
RP NNP 0
in IN 0
Korean JJ 0
patients NNS 0
. . 0

Both DT 0
drugs NNS 0
were VBD 0
tolerable JJ 0
with IN 0
primary JJ 0
RP NNP 0
patients NNS 0
. . 0

Effects NNS 0
of IN 0
tryptophan JJ 0
depletion NN 0
in IN 0
drug-free JJ 0
adults NNS 0
with IN 0
autistic JJ 0
disorder NN 0
. . 0

BACKGROUND IN 0
The DT 0
primary JJ 0
objective NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
investigate VB 0
the DT 0
behavioral JJ 0
and CC 0
biochemical JJ 0
responses NNS 0
to TO 0
acute VB 0
tryptophan JJ 0
depletion NN 0
in IN 0
drug-free JJ 0
adult NN 0
patients NNS 0
with IN 0
autistic JJ 0
disorder NN 0
. . 0

METHODS NNP 0
Twenty NNP 0
drug-free JJ 0
adults NNS 0
with IN 0
autistic JJ 0
disorder NN 0
( ( 0
16 CD 0
men NNS 0
and CC 0
4 CD 0
women NNS 0
) ) 0
( ( 0
mean JJ 0
[ NNP 0
+/- NN 0
SD NNP 0
] NNP 0
age NN 0
, , 0
30.5 CD 0
+/- JJ 0
8.5 CD 0
years NNS 0
) ) 0
underwent JJ 0
short-term JJ 0
tryptophan NN 0
depletion NN 0
in IN 0
a DT 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
, , 0
randomized JJ 0
crossover NN 0
design NN 0
. . 0

Patients NNS 0
received VBD 0
a DT 0
24-hour JJ 0
, , 0
low-tryptophan JJ 0
diet NN 0
followed VBD 0
the DT 0
next JJ 0
morning NN 0
by IN 0
an DT 0
amino NN 0
acid NN 0
drink NN 0
. . 0

Behavioral JJ 0
ratings NNS 0
were VBD 0
obtained VBN 0
on IN 0
the DT 0
morning NN 0
of IN 0
the DT 0
amino NN 0
acid NN 0
drink NN 0
( ( 0
baseline NN 0
) ) 0
and CC 0
180 CD 0
, , 0
300 CD 0
, , 0
and CC 0
420 CD 0
minutes NNS 0
after IN 0
the DT 0
drink NN 0
. . 0

Plasma NNP 0
free JJ 0
and CC 0
total JJ 0
tryptophan NN 0
levels NNS 0
were VBD 0
obtained VBN 0
at IN 0
baseline NN 0
and CC 0
5 CD 0
hours NNS 0
after IN 0
the DT 0
drink NN 0
. . 0

The DT 0
active JJ 0
and CC 0
sham JJ 0
testing NN 0
sessions NNS 0
were VBD 0
separated VBN 0
by IN 0
7 CD 0
days NNS 0
. . 0

RESULTS NNP 0
Eleven NNP 0
( ( 0
65 CD 0
% NN 0
) ) 0
of IN 0
the DT 0
17 CD 0
patients NNS 0
who WP 0
completed VBD 0
both DT 0
test NN 0
days NNS 0
showed VBD 0
a DT 0
significant JJ 0
global JJ 0
worsening NN 0
of IN 0
behavioral JJ 0
symptoms NNS 0
with IN 0
short-term JJ 0
tryptophan NN 0
depletion NN 0
, , 0
but CC 0
none NN 0
of IN 0
the DT 0
17 CD 0
patients NNS 0
showed VBD 0
any DT 0
significant JJ 0
change NN 0
in IN 0
clinical JJ 0
status NN 0
from IN 0
baseline NN 0
after IN 0
sham JJ 0
depletion NN 0
( ( 0
P NNP 0
= NNP 0
.001 NNP 0
) ) 0
. . 0

Tryptophan NNP 0
depletion NN 0
led VBD 0
to TO 0
a DT 0
significant JJ 0
increase NN 0
in IN 0
behaviors NNS 0
such JJ 0
as IN 0
whirling NN 0
, , 0
flapping NN 0
, , 0
pacing NN 0
, , 0
banging NN 0
and CC 0
hitting VBG 0
self NN 0
, , 0
rocking NN 0
, , 0
and CC 0
toe NN 0
walking NN 0
( ( 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
. . 0

In IN 0
addition NN 0
, , 0
patients NNS 0
were VBD 0
significantly RB 0
less JJR 0
calm JJ 0
and CC 0
happy JJ 0
and CC 0
more RBR 0
anxious JJ 0
. . 0

No DT 0
significant JJ 0
change NN 0
was VBD 0
observed VBN 0
in IN 0
social JJ 0
relatedness NN 0
or CC 0
repetitive JJ 0
thoughts NNS 0
and CC 0
behavior NN 0
. . 0

Plasma NNP 0
total JJ 0
and CC 0
free JJ 0
tryptophan NN 0
levels NNS 0
were VBD 0
reduced VBN 0
86 CD 0
% NN 0
and CC 0
69 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
5 CD 0
hours NNS 0
after IN 0
the DT 0
tryptophan-deficient JJ 0
amino NN 0
acid NN 0
drink NN 0
. . 0

Patients NNS 0
who WP 0
had VBD 0
a DT 0
significant JJ 0
global JJ 0
exacerbation NN 0
of IN 0
symptoms NNS 0
had VBD 0
significantly RB 0
higher JJR 0
baseline NN 0
plasma IN 0
total JJ 0
tryptophan NN 0
levels NNS 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
and CC 0
Autism NNP 0
Behavior NNP 0
Checklist NNP 0
scores NNS 0
( ( 0
P NNP 0
= NNP 0
.005 NNP 0
) ) 0
than IN 0
did VBD 0
patients NNS 0
who WP 0
showed VBD 0
no DT 0
significant JJ 0
change NN 0
in IN 0
symptoms NNS 0
after IN 0
tryptophan JJ 0
depletion NN 0
. . 0

CONCLUSIONS VB 0
The DT 0
results NNS 0
of IN 0
this DT 0
study NN 0
are VBP 0
consistent JJ 0
with IN 0
previous JJ 0
research NN 0
that WDT 0
has VBZ 0
implicated VBN 0
a DT 0
dysregulation NN 0
in IN 0
serotonin JJ 0
function NN 0
in IN 0
some DT 0
patients NNS 0
with IN 0
autism NN 0
. . 0

These DT 0
data NNS 0
suggest VBP 0
that IN 0
the DT 0
short-term JJ 0
reduction NN 0
of IN 0
serotonin NN 0
precursor NN 0
availability NN 0
may MD 0
exacerbate VB 0
some DT 0
symptoms NNS 0
characteristic JJ 0
of IN 0
autism NN 0
in IN 0
some DT 0
patients NNS 0
. . 0

Continued JJ 0
investigation NN 0
into IN 0
the DT 0
role NN 0
of IN 0
serotonin NN 0
in IN 0
the DT 0
pathogenesis NN 0
and CC 0
treatment NN 0
of IN 0
autistic JJ 0
disorder NN 0
is VBZ 0
warranted VBN 0
. . 0

[ JJ 0
Effect NNP 0
of IN 0
liu NN 0
wei NN 0
di NN 0
huang NN 0
or CC 0
jin NN 0
gui NN 0
shen NN 0
qi JJ 0
decoction NN 0
as IN 0
on IN 0
adjuvant JJ 0
treatment NN 0
in IN 0
small JJ 0
cell NN 0
lung NN 0
cancer NN 0
] NNP 0
. . 0

Eighty-three JJ 0
patients NNS 0
with IN 0
small JJ 0
cell NN 0
lung NN 0
cancer NN 0
were VBD 0
randomized VBN 0
with IN 0
or CC 0
without IN 0
using VBG 0
a DT 0
traditional JJ 0
Chinese JJ 0
Kidney-tonifying NNP 0
decoction NN 0
( ( 0
Liu NNP 0
Wei NNP 0
Di NNP 0
Huang NNP 0
or CC 0
Jin NNP 0
Gui NNP 0
Shen NNP 0
Qi NNP 0
medicinal JJ 0
decoction NN 0
) ) 0
in IN 0
chemotherapy NN 0
or CC 0
radiotherapy NN 0
courses NNS 0
. . 0

74 CD 0
patients NNS 0
were VBD 0
availble JJ 0
to TO 0
be VB 0
analysis NN 0
. . 0

The DT 0
two CD 0
treatment NN 0
groups NNS 0
were VBD 0
well-matched JJ 0
in IN 0
age NN 0
, , 0
sex NN 0
, , 0
stage NN 0
and CC 0
performance NN 0
status NN 0
. . 0

There EX 0
was VBD 0
a DT 0
statistically RB 0
significant JJ 0
difference NN 0
in IN 0
response NN 0
rate NN 0
and CC 0
the DT 0
median JJ 0
survival NN 0
between IN 0
two CD 0
groups NNS 0
. . 0

The DT 0
overall JJ 0
response NN 0
rate NN 0
( ( 0
CR+PR NNP 0
) ) 0
was VBD 0
91.5 CD 0
% NN 0
for IN 0
Chinese JJ 0
herb NN 0
group NN 0
and CC 0
46.9 CD 0
% NN 0
for IN 0
control NN 0
group NN 0
( ( 0
P NNP 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
. . 0

The DT 0
median JJ 0
survival NN 0
was VBD 0
16 CD 0
months NNS 0
for IN 0
the DT 0
traditional JJ 0
Chinese JJ 0
Kidney-tonifying NNP 0
decoction NN 0
group NN 0
, , 0
and CC 0
10 CD 0
months NNS 0
for IN 0
the DT 0
control NN 0
group NN 0
( ( 0
P NNP 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
. . 0

Survival JJ 0
curve NN 0
( ( 0
Kaplan-meire NNP 0
's POS 0
) ) 0
of IN 0
the DT 0
Chinese NNP 0
herb NN 0
group NN 0
was VBD 0
better JJR 0
than IN 0
that DT 0
of IN 0
the DT 0
control NN 0
group NN 0
. . 0

10 CD 0
patients NNS 0
of IN 0
Chinese JJ 0
herb NN 0
group NN 0
was VBD 0
alive JJ 0
beyond IN 0
more JJR 0
than IN 0
2 CD 0
years NNS 0
. . 0

Until IN 0
now RB 0
, , 0
4 CD 0
patients NNS 0
in IN 0
the DT 0
Chinese JJ 0
herb NN 0
group NN 0
, , 0
one CD 0
in IN 0
the DT 0
control NN 0
group NN 0
are VBP 0
still RB 0
enjoying VBG 0
their PRP$ 0
disease-free JJ 0
life NN 0
for IN 0
more JJR 0
than IN 0
7 CD 0
years NNS 0
. . 0

Hematologic NNP 0
toxicities NNS 0
were VBD 0
observed VBN 0
much RB 0
frequently RB 0
in IN 0
the DT 0
patients NNS 0
of IN 0
the DT 0
control NN 0
group NN 0
( ( 0
P NNP 0
less JJR 0
than IN 0
0.005 CD 0
and CC 0
0.01/WBC CD 0
and CC 0
BPC NNP 0
) ) 0
. . 0

Results NNS 0
of IN 0
animal JJ 0
experiments NNS 0
with IN 0
the DT 0
same JJ 0
traditional JJ 0
medicinal JJ 0
decoctions NNS 0
as IN 0
used VBN 0
in IN 0
clinic NN 0
have VBP 0
showed VBN 0
immuno-enhancement JJ 0
activities NNS 0
. . 0

These DT 0
results NNS 0
have VBP 0
showed VBN 0
that IN 0
the DT 0
traditional JJ 0
Chinese JJ 0
Kidney-tonifying NNP 0
decoction NN 0
may MD 0
enhance VB 0
non-specific JJ 0
immunology NN 0
activities NNS 0
and CC 0
may MD 0
be VB 0
much JJ 0
useful JJ 0
for IN 0
solid JJ 0
cancer NN 0
patients NNS 0
as IN 0
an DT 0
adjuvant JJ 0
treatment NN 0
. . 0

Role NNP 0
of IN 0
posterior JJ 0
tibial JJ 0
nerve NN 0
stimulation NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
refractory JJ 0
monosymptomatic JJ 0
nocturnal JJ 0
enuresis NN 0
: : 0
a DT 0
pilot NN 0
study NN 0
. . 0

PURPOSE NNP 0
We PRP 0
evaluated VBD 0
the DT 0
early JJ 0
clinical JJ 0
and CC 0
urodynamic JJ 0
results NNS 0
of IN 0
posterior JJ 0
tibial JJ 0
nerve NN 0
stimulation NN 0
in IN 0
patients NNS 0
with IN 0
refractory JJ 4
monosymptomatic JJ 4
nocturnal JJ 4
enuresis NN 4
. . 0

MATERIALS NNP 0
AND CC 0
METHODS NNP 0
We PRP 0
randomly VBP 0
assigned VBD 0
28 CD 3
patients NNS 0
with IN 0
refractory JJ 0
monosymptomatic JJ 0
nocturnal JJ 0
enuresis NN 0
to TO 0
2 CD 0
equal JJ 0
groups NNS 0
. . 0

Group NNP 0
1 CD 0
received VBD 0
a DT 0
weekly JJ 0
session NN 0
of IN 0
posterior JJ 0
tibial JJ 0
nerve NN 0
stimulation NN 0
for IN 0
12 CD 0
weeks NNS 0
and CC 0
group NN 0
2 CD 0
was VBD 0
the DT 0
placebo NN 0
group NN 0
. . 0

Evaluation NN 0
was VBD 0
performed VBN 0
in IN 0
each DT 0
group NN 0
at IN 0
baseline NN 0
and CC 0
after IN 0
posterior JJ 0
tibial JJ 0
nerve NN 0
stimulation NN 0
to TO 0
compare VB 0
clinical JJ 0
and CC 0
urodynamic JJ 0
findings NNS 0
. . 0

Another DT 0
clinical JJ 0
assessment NN 0
was VBD 0
done VBN 0
3 CD 0
months NNS 0
after IN 0
the DT 0
first JJ 0
followup NN 0
. . 0

RESULTS VB 0
The DT 0
2 CD 0
groups NNS 0
were VBD 0
comparable JJ 0
in IN 0
baseline JJ 0
clinical JJ 0
and CC 0
urodynamic JJ 0
data NNS 0
. . 0

Overall NNP 0
, , 0
13 CD 0
patients NNS 0
( ( 0
46.4 CD 0
% NN 0
) ) 0
had VBD 0
detrusor VBN 0
overactivity NN 0
and CC 0
14 CD 0
( ( 0
50 CD 0
% NN 0
) ) 0
had VBD 0
decreased VBN 0
bladder NN 0
capacity NN 0
. . 0

After IN 0
treatment NN 0
11 CD 0
group NN 0
1 CD 0
patients NNS 0
( ( 0
78.6 CD 0
% NN 0
) ) 0
had VBD 0
a DT 0
partial JJ 0
or CC 0
full JJ 0
response NN 0
to TO 0
posterior VB 0
tibial JJ 0
nerve NN 0
stimulation NN 0
but CC 0
only RB 0
2 CD 0
( ( 0
14.3 CD 0
% NN 0
) ) 0
in IN 0
group NN 0
2 CD 0
had VBD 0
a DT 0
partial JJ 0
response NN 0
( ( 0
p JJ 0
= NNP 0
0.002 CD 0
) ) 0
. . 0

Also RB 0
, , 0
the DT 0
average JJ 0
number NN 0
of IN 0
wet JJ 0
nights NNS 0
in IN 0
group NN 0
1 CD 0
was VBD 0
significantly RB 0
lower JJR 0
than IN 0
at IN 0
baseline NN 0
( ( 0
p JJ 0
= NNP 0
0.002 CD 0
) ) 0
. . 0

All DT 0
urodynamic JJ 0
parameters NNS 0
significantly RB 0
improved VBN 0
in IN 0
group NN 0
1 CD 0
. . 0

In IN 0
contrast NN 0
, , 0
the DT 0
number NN 0
of IN 0
wet JJ 0
nights NNS 0
and CC 0
urodynamic JJ 0
parameters NNS 0
did VBD 0
not RB 0
change VB 0
significantly RB 0
in IN 0
group NN 0
2 CD 0
. . 0

At IN 0
3-month JJ 0
followup NN 0
the DT 0
number NN 0
of IN 0
patients NNS 0
with IN 0
a DT 0
partial JJ 0
or CC 0
full JJ 0
response NN 0
in IN 0
group NN 0
1 CD 0
had VBD 0
decreased VBN 0
from IN 0
11 CD 0
( ( 0
78.6 CD 0
% NN 0
) ) 0
to TO 0
6 CD 0
( ( 0
42.9 CD 0
% NN 0
) ) 0
. . 0

No DT 0
change NN 0
was VBD 0
evident JJ 0
in IN 0
group NN 0
2 CD 0
. . 0

CONCLUSIONS NNP 0
Posterior NNP 0
tibial JJ 0
nerve NN 0
stimulation NN 0
can MD 0
be VB 0
a DT 0
viable JJ 0
treatment NN 0
option NN 0
in IN 0
some DT 0
patients NNS 0
with IN 0
refractory JJ 0
monosymptomatic JJ 0
nocturnal JJ 0
enuresis NN 0
. . 0

However RB 0
, , 0
deterioration NN 0
in IN 0
some DT 0
responders NNS 0
with IN 0
time NN 0
suggests VBZ 0
the DT 0
need NN 0
for IN 0
maintenance NN 0
protocols NNS 0
. . 0

A DT 0
randomized JJ 0
double-blind JJ 0
placebo-controlled JJ 0
cross-over JJ 0
trial NN 0
of IN 0
the DT 0
impact NN 0
on IN 0
quality NN 0
of IN 0
life NN 0
of IN 0
continuing VBG 0
dexamethasone JJ 0
beyond IN 0
24 CD 0
h NN 0
following VBG 0
adjuvant JJ 0
chemotherapy NN 0
for IN 0
breast NN 0
cancer NN 0
. . 0

Uncertainty NN 0
remains VBZ 0
about IN 0
the DT 0
optimal JJ 0
anti-emetic JJ 0
regimen NNS 0
for IN 0
control NN 0
of IN 0
delayed JJ 0
nausea NN 0
and CC 0
vomiting NN 0
after IN 0
adjuvant JJ 0
chemotherapy NN 0
for IN 0
breast NN 0
cancer NN 0
. . 0

Many JJ 0
patients NNS 0
receive VBP 0
dexamethasone NN 0
but CC 0
complain NN 0
of IN 0
insomnia NN 0
, , 0
anxiety/agitation NN 0
, , 0
and CC 0
indigestion NN 0
. . 0

The DT 0
aim NN 0
was VBD 0
to TO 0
determine VB 0
if IN 0
patients NNS 0
receiving VBG 0
chemotherapy NN 0
for IN 0
breast NN 0
cancer NN 0
prefer VBP 0
treatment NN 0
with IN 0
dexamethasone NN 0
or CC 0
placebo NN 0
for IN 0
prophylaxis NN 0
against IN 0
delayed VBN 0
nausea NN 0
and CC 0
vomiting NN 0
, , 0
and CC 0
to TO 0
compare VB 0
quality NN 0
of IN 0
life NN 0
( ( 0
QOL NNP 0
) ) 0
between IN 0
the DT 0
two CD 0
treatments NNS 0
. . 0

In IN 0
this DT 0
randomized JJ 0
, , 0
double-blind JJ 0
, , 0
cross-over JJ 0
trial NN 0
, , 0
we PRP 0
compared VBN 0
oral JJ 0
dexamethasone NN 0
( ( 0
4 CD 0
mg NN 0
twice RB 0
daily RB 0
for IN 0
2 CD 0
days NNS 0
) ) 0
versus VBP 0
placebo NN 0
for IN 0
chemotherapy-na?ve JJ 0
patients NNS 0
with IN 0
breast JJ 0
cancer NN 0
. . 0

All DT 0
patients NNS 0
received VBD 0
intravenous JJ 0
granisetron NN 0
and CC 0
dexamethasone NN 0
pre-chemotherapy NN 0
and CC 0
oral JJ 0
granisetron NN 0
on IN 0
day NN 0
2 CD 0
. . 0

Primary JJ 0
endpoints NNS 0
were VBD 0
: : 0
( ( 0
i NN 0
) ) 0
patient NN 0
preference NN 0
; : 0
( ( 0
ii NN 0
) ) 0
difference NN 0
between IN 0
cycles NNS 0
in IN 0
change NN 0
of IN 0
QOL NNP 0
from IN 0
days NNS 0
1 CD 0
to TO 0
8 CD 0
. . 0

Median JJ 0
age NN 0
of IN 0
the DT 0
94 CD 0
women NNS 0
was VBD 0
51 CD 0
years NNS 0
( ( 0
range VB 0
27-76 JJ 0
) ) 0
: : 0
79 CD 0
received VBD 0
fluorouracil/epirubicin/cyclophosphamide NN 0
and CC 0
15 CD 0
received VBD 0
doxorubicin/cyclophosphamide NN 0
. . 0

Thirteen JJ 0
withdrew VBD 0
pre-cycle JJ 0
2 CD 0
with IN 0
no DT 0
differences NNS 0
between IN 0
arms NNS 0
. . 0

Of IN 0
80 CD 0
patients NNS 0
stating VBG 0
a DT 0
preference NN 0
, , 0
31 CD 0
preferred JJ 0
placebo NN 0
( ( 0
39 CD 0
% NN 0
, , 0
95 CD 0
% NN 0
CI NNP 0
: : 0
28-50 CD 0
% NN 0
) ) 0
and CC 0
37 CD 0
( ( 0
46 CD 0
% NN 0
, , 0
95 CD 0
% NN 0
CI NNP 0
: : 0
35-58 CD 0
% NN 0
) ) 0
preferred VBD 0
dexamethasone NN 0
; : 0
12 CD 0
had VBD 0
no DT 0
preference NN 0
. . 0

There EX 0
were VBD 0
no DT 0
differences NNS 0
in IN 0
intensity NN 0
of IN 0
vomiting VBG 0
, , 0
nausea NN 0
, , 0
or CC 0
time NN 0
to TO 0
onset VB 0
of IN 0
vomiting VBG 0
. . 0

There EX 0
was VBD 0
greater JJR 0
decrease NN 0
in IN 0
global JJ 0
QOL NNP 0
( ( 0
p JJ 0
= NNP 0
0.06 CD 0
) ) 0
when WRB 0
patients NNS 0
received VBD 0
dexamethasone NN 0
. . 0

No DT 0
other JJ 0
symptom/QOL NN 0
domains NNS 0
differed VBD 0
significantly RB 0
. . 0

In IN 0
conclusion NN 0
, , 0
no DT 0
significant JJ 0
difference NN 0
was VBD 0
found VBN 0
in IN 0
patient JJ 0
preference NN 0
, , 0
QOL NNP 0
, , 0
or CC 0
symptoms NNS 0
regardless RB 0
of IN 0
whether IN 0
dexamethasone NN 0
or CC 0
placebo NN 0
was VBD 0
used VBN 0
after IN 0
adjuvant JJ 0
chemotherapy NN 0
. . 0

RESPECT-PTSD JJ 0
: : 0
re-engineering JJ 0
systems NNS 0
for IN 0
the DT 0
primary JJ 0
care NN 0
treatment NN 0
of IN 0
PTSD NNP 0
, , 0
a DT 0
randomized VBN 0
controlled VBN 0
trial NN 0
. . 0

BACKGROUND NNP 0
Although IN 0
collaborative JJ 0
care NN 0
is VBZ 0
effective JJ 0
for IN 0
treating VBG 0
depression NN 0
and CC 0
other JJ 0
mental JJ 0
disorders NNS 0
in IN 0
primary JJ 0
care NN 0
, , 0
there EX 0
have VBP 0
been VBN 0
no DT 0
randomized JJ 0
trials NNS 0
of IN 0
collaborative JJ 0
care NN 0
specifically RB 0
for IN 0
patients NNS 0
with IN 0
Posttraumatic NNP 0
stress NN 0
disorder NN 0
( ( 0
PTSD NNP 0
) ) 0
. . 0

OBJECTIVE UH 0
To TO 0
compare VB 0
a DT 0
collaborative JJ 0
approach NN 0
, , 0
the DT 0
Three NNP 0
Component NNP 0
Model NNP 0
( ( 0
3CM CD 0
) ) 0
, , 0
with IN 0
usual JJ 0
care NN 0
for IN 0
treating VBG 0
PTSD NNP 0
in IN 0
primary JJ 0
care NN 0
. . 0

DESIGN VB 0
The DT 0
study NN 0
was VBD 0
a DT 0
two-arm JJ 0
, , 0
parallel JJ 0
randomized VBD 0
clinical JJ 0
trial NN 0
. . 0

PTSD JJ 0
patients NNS 0
were VBD 0
recruited VBN 0
from IN 0
five CD 0
primary JJ 0
care NN 0
clinics NNS 0
at IN 0
four CD 0
Veterans NNS 0
Affairs NNP 0
healthcare NN 0
facilities NNS 0
and CC 0
randomized VBN 0
to TO 0
receive VB 0
usual JJ 0
care NN 0
or CC 0
usual JJ 0
care NN 0
plus CC 0
3CM CD 0
. . 0

Blinded VBN 0
assessors NNS 0
collected VBD 0
data NNS 0
at IN 0
baseline NN 0
and CC 0
3-month JJ 0
and CC 0
6-month JJ 0
follow-up NN 0
. . 0

PARTICIPANTS JJ 0
Participants NNS 0
were VBD 0
195 CD 0
Veterans NNPS 0
. . 0

Their PRP$ 0
average JJ 0
age NN 0
was VBD 0
45 CD 0
years NNS 0
, , 0
91 CD 0
% NN 0
were VBD 0
male JJ 0
, , 0
58 CD 0
% NN 0
were VBD 0
white JJ 0
, , 0
40 CD 0
% NN 0
served VBN 0
in IN 0
Iraq NNP 0
or CC 0
Afghanistan NNP 0
, , 0
and CC 0
42 CD 0
% NN 0
served VBD 0
in IN 0
Vietnam NNP 0
. . 0

INTERVENTION NNP 0
All NNP 0
participants NNS 0
received VBD 0
usual JJ 0
care NN 0
. . 0

Participants NNS 0
assigned VBD 0
to TO 0
3CM CD 0
also RB 0
received VBD 0
telephone NN 0
care NN 0
management NN 0
. . 0

Care NN 0
managers NNS 0
received VBD 0
supervision NN 0
from IN 0
a DT 0
psychiatrist NN 0
. . 0

MAIN NNP 0
MEASURES NNP 0
PTSD NNP 0
symptom NN 0
severity NN 0
was VBD 0
the DT 0
primary JJ 0
outcome NN 0
. . 0

Depression NNP 0
, , 0
functioning NN 0
, , 0
perceived VBD 0
quality NN 0
of IN 0
care NN 0
, , 0
utilization NN 0
, , 0
and CC 0
costs NNS 0
were VBD 0
secondary JJ 0
outcomes NNS 0
. . 0

KEY JJ 0
RESULTS NNP 0
There EX 0
were VBD 0
no DT 0
differences NNS 0
between IN 0
3CM CD 0
and CC 0
usual JJ 0
care NN 0
in IN 0
symptoms NNS 0
or CC 0
functioning VBG 0
. . 0

Participants NNS 0
assigned VBD 0
to TO 0
3CM CD 0
were VBD 0
more RBR 0
likely JJ 0
to TO 0
have VB 0
a DT 0
mental JJ 0
health NN 0
visit NN 0
, , 0
fill VB 0
an DT 0
antidepressant JJ 0
prescription NN 0
, , 0
and CC 0
have VBP 0
adequate VBN 0
antidepressant JJ 0
refills NNS 0
. . 0

3CM CD 0
participants NNS 0
also RB 0
had VBD 0
more RBR 0
mental JJ 0
health NN 0
visits NNS 0
and CC 0
higher JJR 0
outpatient NN 0
pharmacy NN 0
costs NNS 0
. . 0

CONCLUSIONS NNP 0
Results NNP 0
suggest VBP 0
the DT 0
need NN 0
for IN 0
careful JJ 0
examination NN 0
of IN 0
the DT 0
way NN 0
that IN 0
collaborative JJ 0
care NN 0
models NNS 0
are VBP 0
implemented VBN 0
for IN 0
treating VBG 0
PTSD NNP 0
, , 0
and CC 0
for IN 0
additional JJ 0
supports NNS 0
to TO 0
encourage VB 0
primary JJ 0
care NN 0
providers NNS 0
to TO 0
manage VB 0
PTSD NNP 0
. . 0

Preschoolers NNS 0
acquire VB 0
general JJ 0
knowledge NN 0
by IN 0
sharing VBG 0
in IN 0
pretense NN 0
. . 0

Children NNP 0
acquire VB 0
general JJ 0
knowledge NN 0
about IN 0
many JJ 0
kinds NNS 0
of IN 0
things NNS 0
, , 0
but CC 0
there EX 0
are VBP 0
few JJ 0
known VBN 0
means NNS 0
by IN 0
which WDT 0
this DT 0
knowledge NN 0
is VBZ 0
acquired VBN 0
. . 0

In IN 0
this DT 0
article NN 0
, , 0
it PRP 0
is VBZ 0
proposed VBN 0
that IN 0
children NNS 0
acquire VB 0
generic JJ 0
knowledge NN 0
by IN 0
sharing VBG 0
in IN 0
pretend JJ 0
play NN 0
. . 0

In IN 0
Experiment JJ 0
1 CD 0
, , 0
twenty-two JJ 0
3- JJ 0
to TO 0
4-year-olds NNS 0
watched VBN 0
pretense NN 0
in IN 0
which WDT 0
a DT 0
puppet NN 0
represented VBD 0
a DT 0
nerp NN 0
( ( 0
an DT 0
unfamiliar JJ 0
kind NN 0
of IN 0
animal NN 0
) ) 0
. . 0

For IN 0
instance NN 0
, , 0
in IN 0
one CD 0
scenario NN 0
, , 0
the DT 0
nerp JJ 0
ate NN 0
and CC 0
disliked VBD 0
a DT 0
carrot NN 0
. . 0

When WRB 0
subsequently RB 0
asked VBD 0
generic JJ 0
questions NNS 0
about IN 0
real JJ 0
nerps NNS 0
, , 0
children NNS 0
's POS 0
responses NNS 0
suggested VBD 0
that IN 0
they PRP 0
had VBD 0
learned VBN 0
general JJ 0
facts NNS 0
( ( 0
e.g. NN 0
, , 0
nerps RB 0
dislike JJ 0
carrots NNS 0
) ) 0
. . 0

In IN 0
Experiment JJ 0
2 CD 0
, , 0
thirty-two JJ 0
4- JJ 0
to TO 0
5-year-olds NNS 0
learned VBN 0
from IN 0
scenarios NNS 0
lacking VBG 0
pretend JJ 0
speech NN 0
or CC 0
sound JJ 0
effects NNS 0
. . 0

The DT 0
findings NNS 0
reveal VBP 0
a DT 0
long JJ 0
overlooked JJ 0
means NNS 0
by IN 0
which WDT 0
children NNS 0
can MD 0
acquire VB 0
generic JJ 0
knowledge NN 0
. . 0

The DT 0
safety NN 0
of IN 0
whey JJ 0
protein NN 0
concentrate NN 0
derived VBN 0
from IN 0
the DT 0
milk NN 0
of IN 0
cows NNS 0
immunized VBN 0
against IN 0
Clostridium NNP 0
difficile NN 0
. . 0

A DT 0
whey JJ 0
protein NN 0
concentrate NN 0
prepared VBN 0
from IN 0
the DT 0
milk NN 0
of IN 0
cows NNS 0
that WDT 0
have VBP 0
been VBN 0
immunized VBN 0
against IN 0
Clostridium NNP 0
difficile NN 0
( ( 0
C. NNP 0
difficile NN 0
) ) 0
and CC 0
its PRP$ 0
toxins NNS 0
, , 0
toxin NN 0
A NNP 0
and CC 0
toxin NN 0
B NNP 0
, , 0
is VBZ 0
produced VBN 0
for IN 0
use NN 0
as IN 0
a DT 0
medical JJ 0
food NN 0
for IN 0
the DT 0
dietary JJ 0
management NN 0
of IN 0
patients NNS 0
with IN 0
C. NNP 0
difficile-associated JJ 0
diarrhea NN 0
( ( 0
CDAD NNP 0
) ) 0
to TO 0
prevent VB 0
a DT 0
relapse NN 0
of IN 0
the DT 0
infection NN 0
. . 0

The DT 0
safety NN 0
of IN 0
anti-C. JJ 0
difficile NN 0
whey NN 0
protein VBP 0
concentrate NN 0
( ( 0
anti-CD JJ 0
WPC NNP 0
) ) 0
is VBZ 0
supported VBN 0
by IN 0
analytical JJ 0
data NNS 0
comparing VBG 0
the DT 0
composition NN 0
of IN 0
raw JJ 0
milk NN 0
from IN 0
immunized JJ 0
cows NNS 0
versus VBP 0
that IN 0
from IN 0
non-immunized JJ 0
cows NNS 0
, , 0
and CC 0
the DT 0
composition NN 0
of IN 0
anti-CD JJ 0
WPC NNP 0
versus NN 0
that IN 0
of IN 0
regular JJ 0
whey NN 0
protein NN 0
concentrate NN 0
. . 0

Additionally RB 0
, , 0
a DT 0
prospective JJ 0
clinical JJ 0
study NN 0
was VBD 0
conducted VBN 0
in IN 0
77 CD 0
patients NNS 0
with IN 0
CDAD NNP 0
to TO 0
demonstrate VB 0
the DT 0
safety NN 0
of IN 0
consuming VBG 0
anti-CD JJ 0
WPC NNP 0
to TO 0
prevent VB 0
relapse NN 0
of IN 0
the DT 0
infection NN 0
. . 0

This DT 0
study NN 0
, , 0
which WDT 0
included VBD 0
adverse JJ 0
event NN 0
monitoring NN 0
, , 0
physical JJ 0
examinations NNS 0
, , 0
and CC 0
extensive JJ 0
hematological NN 0
and CC 0
biochemical JJ 0
assessments NNS 0
, , 0
showed VBD 0
that IN 0
anti-CD JJ 0
WPC NNP 0
is VBZ 0
safe JJ 0
to TO 0
consume VB 0
by IN 0
patients NNS 0
with IN 0
CDAD NNP 0
. . 0

The DT 0
available JJ 0
analytical JJ 0
and CC 0
clinical JJ 0
evidence NN 0
demonstrate NN 0
that IN 0
anti-CD JJ 0
WPC NNP 0
is VBZ 0
safe JJ 0
for IN 0
use NN 0
by IN 0
individuals NNS 0
with IN 0
CDAD NNP 0
, , 0
under IN 0
the DT 0
described JJ 0
conditions NNS 0
of IN 0
use NN 0
. . 0

A DT 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
study NN 0
of IN 0
fluvoxamine NN 0
in IN 0
adults NNS 0
with IN 0
autistic JJ 0
disorder NN 0
. . 0

BACKGROUND NNP 0
Autistic NNP 0
disorder NN 0
is VBZ 0
characterized VBN 0
by IN 0
a DT 0
fundamental JJ 0
disturbance NN 0
in IN 0
social JJ 0
interaction NN 0
, , 0
impairments NNS 0
in IN 0
communication NN 0
, , 0
and CC 0
a DT 0
markedly RB 0
restricted JJ 0
repertoire NN 0
of IN 0
activities NNS 0
and CC 0
interests NNS 0
. . 0

Abnormalities NNS 0
in IN 0
the DT 0
serotonin NN 0
neurotransmitter NN 0
system NN 0
have VBP 0
been VBN 0
identified VBN 0
in IN 0
some DT 0
persons NNS 0
with IN 0
autism NN 0
. . 0

No DT 0
consistently RB 0
effective JJ 0
and CC 0
safe JJ 0
drugs NNS 0
have VBP 0
been VBN 0
developed VBN 0
for IN 0
treating VBG 0
the DT 0
symptoms NNS 0
of IN 0
autism NN 0
. . 0

METHODS NNP 0
Thirty NNP 0
adults NNS 0
with IN 0
autistic JJ 0
disorder NN 0
completed VBD 0
a DT 0
12-week JJ 0
double-blind NN 0
, , 0
placebo-controlled JJ 0
trial NN 0
of IN 0
the DT 0
potent NN 0
and CC 0
selective JJ 0
serotonin NN 0
uptake JJ 0
inhibitor NN 0
fluvoxamine NN 0
maleate NN 0
. . 0

Behavioral JJ 0
ratings NNS 0
were VBD 0
obtained VBN 0
at IN 0
baseline NN 0
and CC 0
after IN 0
4 CD 0
, , 0
8 CD 0
, , 0
and CC 0
12 CD 0
weeks NNS 0
of IN 0
treatment NN 0
. . 0

RESULTS NNP 0
Eight NNP 0
( ( 0
53 CD 0
% NN 0
) ) 0
of IN 0
15 CD 0
patients NNS 0
in IN 0
the DT 0
fluvoxamine-treated JJ 0
group NN 0
were VBD 0
categorized VBN 0
as IN 0
responders NNS 0
compared VBN 0
with IN 0
none NN 0
of IN 0
15 CD 0
in IN 0
the DT 0
placebo NN 0
group NN 0
( ( 0
P NNP 0
= NNP 0
.001 NNP 0
) ) 0
. . 0

Fluvoxamine NNP 0
was VBD 0
superior JJ 0
to TO 0
placebo VB 0
in IN 0
reducing VBG 0
repetitive JJ 0
thoughts NNS 0
and CC 0
behavior NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
, , 0
maladaptive JJ 0
behavior NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
, , 0
and CC 0
aggression NN 0
( ( 0
P NNP 0
< NNP 0
.03 NNP 0
) ) 0
, , 0
and CC 0
in IN 0
improving VBG 0
some DT 0
aspects NNS 0
of IN 0
social JJ 0
relatedness NN 0
( ( 0
P NNP 0
< NNP 0
.04 NNP 0
) ) 0
, , 0
especially RB 0
language NN 0
usage NN 0
( ( 0
P NNP 0
< NNP 0
.008 NNP 0
) ) 0
. . 0

Treatment JJ 0
response NN 0
was VBD 0
not RB 0
correlated VBN 0
with IN 0
age NN 0
level NN 0
of IN 0
autistic JJ 0
behavior NN 0
, , 0
or CC 0
full-scale JJ 0
IQ NNP 0
. . 0

Other JJ 0
than IN 0
mild JJ 0
sedation NN 0
and CC 0
nausea NN 0
in IN 0
a DT 0
few JJ 0
patients NNS 0
, , 0
fluvoxamine NN 0
was VBD 0
well RB 0
tolerated VBN 0
. . 0

No DT 0
dyskinesias NN 0
, , 0
adverse JJ 0
cardiovascular JJ 0
events NNS 0
, , 0
or CC 0
seizures NNS 0
occurred VBD 0
. . 0

CONCLUSIONS NNP 0
Fluvoxamine NNP 0
is VBZ 0
more RBR 0
effective JJ 0
than IN 0
placebo NN 0
in IN 0
the DT 0
short-term JJ 0
treatment NN 0
of IN 0
the DT 0
symptoms NNS 0
of IN 0
autistic JJ 0
disorder NN 0
in IN 0
adults NNS 0
. . 0

Controlled JJ 0
studies NNS 0
of IN 0
fluvoxamine NN 0
and CC 0
other JJ 0
potent NN 0
and CC 0
selective JJ 0
serotonin NN 0
uptake JJ 0
inhibitors NNS 0
seem VBP 0
warranted VBN 0
in IN 0
children NNS 0
and CC 0
adolescents NNS 0
with IN 0
autism NN 0
. . 0

A DT 0
randomized VBN 0
controlled VBN 0
study NN 0
of IN 0
a DT 0
social JJ 0
skills NNS 0
training VBG 0
for IN 0
preadolescent JJ 0
children NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorders NNS 0
: : 0
generalization NN 0
of IN 0
skills NNS 0
by IN 0
training VBG 0
parents NNS 0
and CC 0
teachers NNS 0
? . 0
BACKGROUND NNP 0
Social NNP 0
skills NNS 0
training VBG 0
( ( 0
SST NNP 0
) ) 0
is VBZ 0
a DT 0
common JJ 0
intervention NN 0
for IN 0
children NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorders NNS 0
( ( 0
ASDs NNP 0
) ) 0
to TO 0
improve VB 0
their PRP$ 0
social JJ 0
and CC 0
communication NN 0
skills NNS 0
. . 0

Despite IN 0
the DT 0
fact NN 0
that IN 0
SSTs NNP 0
are VBP 0
often RB 0
applied VBN 0
in IN 0
clinical JJ 0
practice NN 0
, , 0
the DT 0
evidence NN 0
for IN 0
the DT 0
effectiveness NN 0
of IN 0
these DT 0
trainings NNS 0
for IN 0
children NNS 0
with IN 0
ASD NNP 0
is VBZ 0
inconclusive JJ 0
. . 0

Moreover RB 0
, , 0
long JJ 0
term NN 0
outcome NN 0
and CC 0
generalization NN 0
of IN 0
learned JJ 0
skills NNS 0
are VBP 0
little JJ 0
evaluated JJ 0
. . 0

Additionally RB 0
, , 0
there EX 0
is VBZ 0
no DT 0
research NN 0
on IN 0
the DT 0
influence NN 0
of IN 0
involvement NN 0
of IN 0
parents NNS 0
and CC 0
teachers NNS 0
on IN 0
effectiveness NN 0
of IN 0
SST NNP 0
and CC 0
on IN 0
the DT 0
generalization NN 0
of IN 0
learned VBN 0
social JJ 0
skills NNS 0
to TO 0
daily JJ 0
life NN 0
. . 0

We PRP 0
expect VBP 0
parent NN 0
and CC 0
teacher NN 0
involvement NN 0
in IN 0
SST NNP 0
to TO 0
enhance VB 0
treatment NN 0
efficacy NN 0
and CC 0
to TO 0
facilitate VB 0
generalization NN 0
of IN 0
learned JJ 0
skills NNS 0
to TO 0
daily JJ 0
life NN 0
. . 0

METHOD/DESIGN NNP 0
In IN 0
a DT 0
randomized NN 0
controlled VBN 0
trial NN 0
( ( 0
RCT NNP 0
) ) 0
with IN 0
three CD 0
conditions NNS 0
, , 0
120 CD 0
participants NNS 0
with IN 0
ASD NNP 0
at IN 0
the DT 0
end NN 0
of IN 0
primary JJ 0
school NN 0
( ( 0
10-12 CD 0
years NNS 0
of IN 0
calendar NN 0
age NN 0
) ) 0
have VBP 0
been VBN 0
randomized VBN 0
to TO 0
SST NNP 0
, , 0
SST-PTI NNP 0
( ( 0
SST NNP 0
with IN 0
Parent NNP 0
& CC 0
Teacher NNP 0
Involvement NNP 0
) ) 0
, , 0
or CC 0
care-as-usual JJ 0
. . 0

The DT 0
SST NNP 0
consists VBZ 0
of IN 0
18 CD 0
group NN 0
sessions NNS 0
of IN 0
1.5 CD 0
hours NNS 0
for IN 0
the DT 0
children NNS 0
. . 0

In IN 0
the DT 0
SST-PTI JJ 0
condition NN 0
, , 0
parents NNS 0
additionally RB 0
participate VBP 0
in IN 0
8 CD 0
parent NN 0
sessions NNS 0
and CC 0
parents NNS 0
and CC 0
teachers NNS 0
are VBP 0
actively RB 0
involved VBN 0
in IN 0
homework NN 0
assignments NNS 0
. . 0

Assessment NNP 0
takes VBZ 0
place NN 0
at IN 0
three CD 0
moments NNS 0
: : 0
before RB 0
and CC 0
immediately RB 0
after IN 0
the DT 0
intervention NN 0
period NN 0
and CC 0
at IN 0
6 CD 0
months NNS 0
follow-up RB 0
. . 0

Primary JJ 0
outcome NN 0
is VBZ 0
socialization NN 0
, , 0
as IN 0
an DT 0
aspect NN 0
of IN 0
adaptive JJ 0
functioning NN 0
. . 0

Secondary JJ 0
outcomes NNS 0
focus VBP 0
on IN 0
specific JJ 0
social JJ 0
skills NNS 0
children NNS 0
learn VBP 0
during IN 0
SST NNP 0
and CC 0
on IN 0
more JJR 0
general JJ 0
social JJ 0
skills NNS 0
pertaining VBG 0
to TO 0
home NN 0
and CC 0
community NN 0
settings NNS 0
from IN 0
a DT 0
multi-informant JJ 0
perspective NN 0
. . 0

Additionally RB 0
, , 0
possible JJ 0
predictors NNS 0
of IN 0
treatment NN 0
outcome NN 0
will MD 0
be VB 0
assessed VBN 0
. . 0

DISCUSSION VB 0
The DT 0
current JJ 0
study NN 0
is VBZ 0
an DT 0
RCT NNP 0
study NN 0
evaluating VBG 0
SST NNP 0
in IN 0
a DT 0
large JJ 0
sample NN 0
of IN 0
Dutch NNP 0
children NNS 0
with IN 0
ASD NNP 0
in IN 0
a DT 0
specific JJ 0
age NN 0
range NN 0
( ( 0
10-12 CD 0
years NNS 0
) ) 0
. . 0

Strengths NNP 0
of IN 0
the DT 0
study NN 0
are VBP 0
the DT 0
use NN 0
of IN 0
one CD 0
manualized VBN 0
protocol NN 0
, , 0
application NN 0
of IN 0
standardized JJ 0
and CC 0
internationally RB 0
used VBD 0
rating NN 0
instruments NNS 0
, , 0
use NN 0
of IN 0
multiple JJ 0
raters NNS 0
, , 0
investigation NN 0
of IN 0
generalization NN 0
of IN 0
learned JJ 0
skills NNS 0
to TO 0
daily JJ 0
life NN 0
, , 0
and CC 0
the DT 0
evaluation NN 0
of IN 0
efficacy NN 0
in IN 0
the DT 0
longer JJR 0
term NN 0
by IN 0
follow-up JJ 0
measures NNS 0
at IN 0
6 CD 0
months NNS 0
after IN 0
the DT 0
end NN 0
of IN 0
training NN 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
NTR2405 NNP 0
. . 0

Data NNP 0
mining NN 0
the DT 0
ScanBrit NNP 0
study NN 0
of IN 0
a DT 0
gluten- JJ 0
and CC 0
casein-free JJ 0
dietary JJ 0
intervention NN 0
for IN 0
children NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorders NNS 0
: : 0
behavioural JJ 0
and CC 0
psychometric JJ 0
measures NNS 0
of IN 0
dietary JJ 0
response NN 0
. . 0

We PRP 0
previously RB 0
reported VBD 0
results NNS 0
based VBN 0
on IN 0
the DT 0
examination NN 0
of IN 0
a DT 0
gluten- JJ 0
and CC 0
casein-free JJ 0
diet NN 0
as IN 0
an DT 0
intervention NN 0
for IN 0
children NNS 0
diagnosed VBN 0
with IN 0
an DT 0
autism NN 0
spectrum NN 0
disorder NN 0
as IN 0
part NN 0
of IN 0
the DT 0
ScanBrit NNP 0
collaboration NN 0
. . 0

Analysis NN 0
based VBN 0
on IN 0
grouped JJ 0
results NNS 0
indicated VBD 0
several JJ 0
significant JJ 0
differences NNS 0
between IN 0
dietary JJ 0
and CC 0
non-dietary JJ 0
participants NNS 0
across IN 0
various JJ 0
core NN 0
and CC 0
peripheral JJ 0
areas NNS 0
of IN 0
functioning VBG 0
. . 0

Results NNP 0
also RB 0
indicated VBD 0
some DT 0
disparity NN 0
in IN 0
individual JJ 0
responses NNS 0
to TO 0
dietary JJ 0
modification NN 0
potentially RB 0
indicative JJ 0
of IN 0
responder NN 0
and CC 0
non-responder JJ 0
differences NNS 0
. . 0

Further JJ 0
examination NN 0
of IN 0
the DT 0
behavioural JJ 0
and CC 0
psychometric JJ 0
data NNS 0
garnered VBN 0
from IN 0
participants NNS 0
was VBD 0
undertaken VBN 0
, , 0
with IN 0
a DT 0
view NN 0
to TO 0
determining VBG 0
potential JJ 0
factors NNS 0
pertinent VBP 0
to TO 0
response NN 0
to TO 0
dietary JJ 0
intervention NN 0
. . 0

Participants NNS 0
with IN 0
clinically RB 0
significant JJ 0
scores NNS 0
indicative JJ 0
of IN 0
inattention NN 0
and CC 0
hyperactivity NN 0
behaviours NNS 0
and CC 0
who WP 0
had VBD 0
a DT 0
significant JJ 0
positive JJ 0
changes NNS 0
to TO 0
said VBD 0
scores NNS 0
were VBD 0
defined VBN 0
as IN 0
responders NNS 0
to TO 0
the DT 0
dietary JJ 0
intervention NN 0
. . 0

Analyses NNS 0
indicated VBD 0
several JJ 0
factors NNS 0
to TO 0
be VB 0
potentially RB 0
pertinent JJ 0
to TO 0
a DT 0
positive JJ 0
response NN 0
to TO 0
dietary JJ 0
intervention NN 0
in IN 0
terms NNS 0
of IN 0
symptom NN 0
presentation NN 0
. . 0

Chronological JJ 0
age NN 0
was VBD 0
found VBN 0
to TO 0
be VB 0
the DT 0
strongest JJS 0
predictor NN 0
of IN 0
response NN 0
, , 0
where WRB 0
those DT 0
participants NNS 0
aged VBD 0
between IN 0
7 CD 0
and CC 0
9 CD 0
years NNS 0
seemed VBD 0
to TO 0
derive VB 0
most JJS 0
benefit NN 0
from IN 0
dietary JJ 0
intervention NN 0
. . 0

Further CC 0
analysis NN 0
based VBN 0
on IN 0
the DT 0
criteria NNS 0
for IN 0
original JJ 0
study NN 0
inclusion NN 0
on IN 0
the DT 0
presence NN 0
of IN 0
the DT 0
urine JJ 0
compound NN 0
, , 0
trans-indolyl-3-acryloylglycine NN 0
may MD 0
also RB 0
merit VB 0
further JJ 0
investigation NN 0
. . 0

These DT 0
preliminary JJ 0
observations NNS 0
on IN 0
potential JJ 0
best JJS 0
responder NN 0
characteristics NNS 0
to TO 0
a DT 0
gluten- JJ 0
and CC 0
casein-free JJ 0
diet NN 0
for IN 0
children NNS 0
with IN 0
autism NN 0
require VBP 0
independent JJ 0
replication NN 0
. . 0

Development NNP 0
of IN 0
renal JJ 0
disease NN 0
in IN 0
people NNS 0
at IN 0
high JJ 0
cardiovascular JJ 0
risk NN 0
: : 0
results NNS 0
of IN 0
the DT 0
HOPE NNP 0
randomized VBD 0
study NN 0
. . 0

In IN 0
people NNS 0
with IN 0
diabetes NNS 0
, , 0
renal JJ 0
disease NN 0
tends VBZ 0
to TO 0
progress VB 0
from IN 0
microalbuminuria NN 0
to TO 0
clinical JJ 0
proteinuria NN 0
to TO 0
renal JJ 0
insufficiency NN 0
. . 0

Little JJ 0
evidence NN 0
has VBZ 0
been VBN 0
published VBN 0
for IN 0
the DT 0
nondiabetic JJ 0
population NN 0
. . 0

This DT 0
study NN 0
retrospectively RB 0
analyzed VBD 0
changes NNS 0
of IN 0
proteinuria NN 0
over IN 0
4.5 CD 0
yr NNS 0
in IN 0
the DT 0
HOPE NNP 0
( ( 0
Heart NNP 0
Outcomes NNP 0
and CC 0
Prevention NNP 0
Evaluation NNP 0
) ) 0
study NN 0
, , 0
which WDT 0
compared VBN 0
ramipril NN 0
's POS 0
effects NNS 0
to TO 0
placebo VB 0
in IN 0
9297 CD 0
participants NNS 0
, , 0
including VBG 0
3577 CD 0
with IN 0
diabetes NNS 0
and CC 0
1956 CD 0
with IN 0
microalbuminuria NN 0
. . 0

This DT 0
report NN 0
is VBZ 0
restricted VBN 0
to TO 0
7674 CD 0
participants NNS 0
with IN 0
albuminuria NNS 0
data NNS 0
at IN 0
baseline NN 0
and CC 0
at IN 0
follow-up JJ 0
. . 0

Inclusion NN 0
criteria NNS 0
were VBD 0
known VBN 0
vascular JJ 0
disease NN 0
or CC 0
diabetes VBZ 0
plus CC 0
one CD 0
other JJ 0
cardiovascular JJ 0
risk NN 0
factor NN 0
, , 0
exclusion NN 0
criteria NNS 0
included VBD 0
heart NN 0
failure NN 0
or CC 0
known VBN 0
impaired JJ 0
left VBD 0
ventricular JJ 0
function NN 0
, , 0
dipstick-positive JJ 0
proteinuria NN 0
( ( 0
> JJ 0
1+ CD 0
) ) 0
, , 0
and CC 0
serum JJ 0
creatinine NN 0
> $ 0
2.3 CD 0
mg/dl NN 0
( ( 0
200 CD 0
microM NN 0
) ) 0
. . 0

Baseline NNP 0
microalbuminuria NN 0
predicted VBD 0
subsequent JJ 0
clinical JJ 0
proteinuria NN 0
for IN 0
the DT 0
study NN 0
participants NNS 0
overall JJ 0
( ( 0
adjusted VBN 0
odds NNS 0
ratio VBP 0
[ CD 0
OR NNP 0
] NNP 0
, , 0
17.5 CD 0
; : 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
[ NNP 0
CI NNP 0
] NNP 0
, , 0
12.6 CD 0
to TO 0
24.4 CD 0
) ) 0
, , 0
in IN 0
participants NNS 0
without IN 0
diabetes NNS 0
( ( 0
OR NNP 0
, , 0
16.7 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
8.6 CD 0
to TO 0
32.4 CD 0
) ) 0
, , 0
and CC 0
in IN 0
participants NNS 0
with IN 0
diabetes NNS 0
( ( 0
OR NNP 0
, , 0
18.2 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
12.4 CD 0
to TO 0
26.7 CD 0
) ) 0
. . 0

Any DT 0
progression NN 0
of IN 0
albuminuria NNS 0
( ( 0
defined VBN 0
as IN 0
new JJ 0
microalbuminuria NNS 0
or CC 0
new JJ 0
clinical JJ 0
proteinuria NN 0
) ) 0
occurred VBD 0
in IN 0
1859 CD 0
participants NNS 0
; : 0
1542 CD 0
developed VBD 0
new JJ 0
microalbuminuria NNS 0
, , 0
and CC 0
317 CD 0
participants NNS 0
developed VBD 0
clinical JJ 0
proteinuria NN 0
. . 0

Ramipril NNP 0
reduced VBD 0
the DT 0
risk NN 0
for IN 0
any DT 0
progression NN 0
( ( 0
OR NNP 0
, , 0
0.87 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
0.78 CD 0
to TO 0
0.97 CD 0
; : 0
P NNP 0
= NNP 0
0.0146 CD 0
) ) 0
. . 0

People NNS 0
without IN 0
and CC 0
with IN 0
diabetes NNS 0
who WP 0
are VBP 0
at IN 0
high JJ 0
risk NN 0
for IN 0
cardiovascular JJ 0
disease NN 0
are VBP 0
also RB 0
at IN 0
risk NN 0
for IN 0
a DT 0
progressive JJ 0
rise NN 0
in IN 0
albuminuria NN 0
. . 0

Microalbuminuria NNP 0
itself PRP 0
predicts VBZ 0
clinical JJ 0
proteinuria NNS 0
in IN 0
nondiabetic JJ 0
and CC 0
in IN 0
diabetic JJ 0
people NNS 0
. . 0

Ramipril JJ 0
prevents NNS 0
or CC 0
delays VBZ 0
the DT 0
progression NN 0
of IN 0
albuminuria NN 0
. . 0

[ JJ 0
Impact NNP 0
of IN 0
CCND1 NNP 0
A870G NNP 0
polymorphism NN 0
on IN 0
acute JJ 0
adverse JJ 0
events NNS 0
in IN 0
postoperative JJ 0
rectal JJ 0
cancer NN 0
patients NNS 0
treated VBN 0
with IN 0
adjuvant JJ 0
concurrent NN 0
chemoradiotherapy NN 0
] NNP 0
. . 0

OBJECTIVE CC 0
The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
investigate VB 0
the DT 0
association NN 0
between IN 0
single JJ 0
nucleotide JJ 0
polymorphism NN 0
( ( 0
SNP NNP 0
) ) 0
of IN 0
CCND1 NNP 0
A870G NNP 0
and CC 0
acute JJ 0
adverse JJ 0
events NNS 0
( ( 0
AEs NNP 0
) ) 0
in IN 0
postoperative JJ 0
rectal JJ 0
cancer NN 0
patients NNS 0
who WP 0
received VBD 0
capecitabine-based JJ 0
postoperative JJ 0
chemoradiotherapy NN 0
( ( 0
CRT NNP 0
) ) 0
. . 0

METHODS NNP 0
Four CD 0
hundred VBD 0
patients NNS 0
with IN 0
stage NN 0
II NNP 0
and CC 0
III NNP 0
rectal JJ 0
cancer NN 0
received VBD 0
postoperative JJ 0
CRT NNP 0
of IN 0
capecitabine NN 0
with IN 0
or CC 0
without IN 0
oxaliplatin NNS 0
were VBD 0
accumulated VBN 0
and CC 0
prostectively RB 0
studied VBN 0
in IN 0
this DT 0
study NN 0
. . 0

The DT 0
patients NNS 0
were VBD 0
randomly RB 0
divided VBN 0
into IN 0
two CD 0
groups NNS 0
. . 0

Two CD 0
hundred CD 0
and CC 0
twenty-eight JJ 0
patients NNS 0
were VBD 0
treated VBN 0
with IN 0
concurrent JJ 0
capecitabine NN 0
and CC 0
radiotherapy NN 0
( ( 0
Cap-CRT NNP 0
) ) 0
, , 0
and CC 0
172 CD 0
patients NNS 0
were VBD 0
treated VBN 0
with IN 0
capecitabine NN 0
and CC 0
oxaliplatin JJ 0
plus CC 0
radiotherapy JJ 0
( ( 0
Cap-Oxa-CRT NNP 0
) ) 0
. . 0

Adverse JJ 0
events NNS 0
were VBD 0
graded VBN 0
according VBG 0
to TO 0
the DT 0
Common NNP 0
Terminology NNP 0
Criteria NNP 0
for IN 0
Adverse NNP 0
Events NNP 0
, , 0
v. NN 0
3.0 CD 0
( ( 0
CTCAE NNP 0
v3.0 NN 0
) ) 0
. . 0

The DT 0
genotype NN 0
of IN 0
CCND1 NNP 0
A870G NNP 0
in IN 0
the DT 0
patients NNS 0
was VBD 0
detected VBN 0
by IN 0
polymerase NN 0
chain NN 0
reaction-based JJ 0
restriction NN 0
fragment NN 0
length NN 0
polymorphism NN 0
( ( 0
PCR-RFLP NNP 0
) ) 0
analysis NN 0
. . 0

The DT 0
associations NNS 0
between IN 0
the DT 0
SNP NNP 0
and CC 0
acute JJ 0
AEs NNP 0
were VBD 0
indicated VBN 0
by IN 0
odds NNS 0
ratios NNS 0
( ( 0
ORs NNP 0
) ) 0
and CC 0
95 CD 0
% NN 0
confidence NN 0
intervals NNS 0
( ( 0
CIs NNP 0
) ) 0
, , 0
which WDT 0
were VBD 0
computed VBN 0
with IN 0
logistic JJ 0
regression NN 0
model NN 0
. . 0

RESULTS VB 0
A DT 0
total NN 0
of IN 0
136 CD 0
patients NNS 0
presented VBN 0
severe JJ 0
AEs NNP 0
. . 0

Among IN 0
them PRP 0
the DT 0
frequencies NNS 0
of IN 0
the DT 0
three CD 0
genotypes NNS 0
GG NNP 0
, , 0
GA NNP 0
and CC 0
AA NNP 0
were VBD 0
16.9 CD 0
% NN 0
, , 0
50.7 CD 0
% NN 0
and CC 0
32.4 CD 0
% NN 0
, , 0
compared VBN 0
with IN 0
24.6 CD 0
% NN 0
, , 0
48.1 CD 0
% NN 0
and CC 0
27.3 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
among IN 0
the DT 0
patients NNS 0
without IN 0
severe JJ 0
AEs NNP 0
. . 0

Diarrhea NNP 0
was VBD 0
the DT 0
most RBS 0
common JJ 0
AE NNP 0
, , 0
and CC 0
severe JJ 0
diarrhea NN 0
occurred VBD 0
in IN 0
109 CD 0
patients NNS 0
. . 0

The DT 0
frequencies NNS 0
of IN 0
the DT 0
three CD 0
genotypes NNS 0
GG NNP 0
, , 0
GA NNP 0
and CC 0
AA NNP 0
were VBD 0
15.6 CD 0
% NN 0
, , 0
47.7 CD 0
% NN 0
and CC 0
36.7 CD 0
% NN 0
among IN 0
these DT 0
patients NNS 0
, , 0
compared VBN 0
with IN 0
24.4 CD 0
% NN 0
, , 0
49.5 CD 0
% NN 0
and CC 0
26.1 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
among IN 0
patients NNS 0
without IN 0
severe JJ 0
diarrhea NN 0
. . 0

Multivariate NNP 0
logistic JJ 0
regression NN 0
analysis NN 0
showed VBD 0
a DT 0
1.66-fold JJ 0
increased JJ 0
risk NN 0
for IN 0
severe JJ 0
diarrhea NN 0
in IN 0
patients NNS 0
with IN 0
AA NNP 0
genotype NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
1.03 CD 0
- : 0
2.67 CD 0
, , 0
P NNP 0
= NNP 0
0.038 CD 0
) ) 0
compared VBN 0
with IN 0
the DT 0
cases NNS 0
with IN 0
GG NNP 0
or CC 0
GA NNP 0
genotypes NNS 0
. . 0

Stratified VBN 0
analysis NN 0
showed VBD 0
that IN 0
in IN 0
the DT 0
Cap-Oxa-CRT NNP 0
group NN 0
, , 0
patients NNS 0
with IN 0
AA NNP 0
genotype NN 0
showed VBD 0
a DT 0
2.34-fold JJ 0
increased JJ 0
risk NN 0
for IN 0
severe JJ 0
diarrhea NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
1.16 CD 0
- : 0
4.76 CD 0
, , 0
P NNP 0
= NNP 0
0.018 CD 0
) ) 0
compared VBN 0
with IN 0
those DT 0
with IN 0
GG NNP 0
or CC 0
GA NNP 0
genotypes NNS 0
, , 0
but CC 0
in IN 0
the DT 0
Cap-CRT NNP 0
group NN 0
, , 0
the DT 0
SNP NNP 0
was VBD 0
not RB 0
associated VBN 0
with IN 0
the DT 0
risk NN 0
of IN 0
severe JJ 0
diarrhea NN 0
. . 0

CONCLUSIONS VB 0
The DT 0
genetic JJ 0
polymorphism NN 0
of IN 0
CCND1 NNP 0
A870G NNP 0
might MD 0
be VB 0
a DT 0
potential JJ 0
biomarker NN 0
for IN 0
predicting VBG 0
acute JJ 0
AEs NNP 0
in IN 0
postoperative JJ 0
stage NN 0
II NNP 0
and CC 0
III NNP 0
rectal JJ 0
cancer NN 0
patients NNS 0
treated VBN 0
with IN 0
adjuvant JJ 0
concurrent JJ 0
chemoradiotherapy NN 0
of IN 0
capecitabine NN 0
and CC 0
oxaliplatin NN 0
. . 0

Language NNP 0
outcome NN 0
in IN 0
autism NN 0
: : 0
randomized JJ 0
comparison NN 0
of IN 0
joint JJ 0
attention NN 0
and CC 0
play NN 0
interventions NNS 0
. . 0

This DT 0
study NN 0
reports VBZ 0
results NNS 0
of IN 0
a DT 0
randomized VBN 0
controlled VBN 0
trial NN 0
aimed VBN 0
at IN 0
joint JJ 0
attention NN 0
( ( 0
JA NNP 0
) ) 0
and CC 0
symbolic JJ 0
play NN 0
( ( 0
SP NNP 0
) ) 0
in IN 0
preschool NN 0
children NNS 0
with IN 0
autism NN 0
, , 0
with IN 0
prediction NN 0
to TO 0
language NN 0
outcome RB 0
12 CD 0
months NNS 0
later RB 0
. . 0

Participants NNS 0
were VBD 0
58 CD 0
children NNS 0
( ( 0
46 CD 0
boys NNS 0
) ) 0
with IN 0
autism NN 0
between IN 0
3 CD 0
and CC 0
4 CD 0
years NNS 0
of IN 0
age NN 0
. . 0

Children NNP 0
were VBD 0
randomized VBN 0
to TO 0
a DT 0
JA NNP 0
intervention NN 0
, , 0
an DT 0
SP NNP 0
intervention NN 0
, , 0
or CC 0
control NN 0
group NN 0
. . 0

Interventions NNS 0
were VBD 0
conducted VBN 0
30 CD 0
min JJ 0
daily JJ 0
for IN 0
5-6 JJ 0
weeks NNS 0
. . 0

Assessments NNS 0
of IN 0
JA NNP 0
skills NNS 0
, , 0
SP NNP 0
skills NNS 0
, , 0
mother-child JJ 0
interactions NNS 0
, , 0
and CC 0
language NN 0
development NN 0
were VBD 0
collected VBN 0
at IN 0
4 CD 0
time NN 0
points NNS 0
: : 0
pre- NN 0
and CC 0
postintervention NN 0
and CC 0
6 CD 0
and CC 0
12 CD 0
months NNS 0
postintervention NN 0
by IN 0
independent JJ 0
testers NNS 0
. . 0

Results NNS 0
indicate VBP 0
that IN 0
expressive JJ 0
language NN 0
gains NNS 0
were VBD 0
greater JJR 0
for IN 0
both DT 0
treatment NN 0
groups NNS 0
compared VBN 0
with IN 0
the DT 0
control NN 0
group NN 0
, , 0
and CC 0
results NNS 0
could MD 0
not RB 0
be VB 0
explained VBN 0
by IN 0
differences NNS 0
in IN 0
other JJ 0
interventions NNS 0
in IN 0
which WDT 0
children NNS 0
participated VBD 0
. . 0

For IN 0
children NNS 0
beginning VBG 0
treatment NN 0
with IN 0
the DT 0
lowest JJS 0
language NN 0
levels NNS 0
, , 0
the DT 0
JA NNP 0
intervention NN 0
improved VBD 0
language NN 0
outcome NN 0
significantly RB 0
more RBR 0
than IN 0
did VBD 0
the DT 0
SP NNP 0
or CC 0
control VB 0
interventions NNS 0
. . 0

These DT 0
findings NNS 0
suggest VBP 0
clinically RB 0
significant JJ 0
benefits NNS 0
of IN 0
actively RB 0
treating VBG 0
JA NNP 0
and CC 0
SP NNP 0
skills NNS 0
in IN 0
young JJ 0
children NNS 0
with IN 0
autism NN 0
. . 0

[ JJ 0
Antazoline/tetryzoline NNP 0
eyedrops NNS 0
in IN 0
comparison NN 0
with IN 0
levocabastine JJ 0
eyedrops NNS 0
in IN 0
acute JJ 0
allergic JJ 0
conjunctivitis NN 0
] NNP 0
. . 0

BACKGROUND NNP 0
Allergic NNP 0
conjunctivitis NN 0
is VBZ 0
one CD 0
of IN 0
the DT 0
most RBS 0
frequent JJ 0
allergic JJ 0
diseases NNS 0
of IN 0
the DT 0
anterior JJ 0
eye NN 0
segment NN 0
. . 0

METHODS NNP 0
This DT 0
multicentre NN 0
, , 0
clinical JJ 0
trial NN 0
was VBD 0
an DT 0
investigation NN 0
to TO 0
compare VB 0
the DT 0
antiallergic JJ 0
efficacy NN 0
, , 0
local JJ 0
tolerance NN 0
and CC 0
safety NN 0
of IN 0
Antazolin/Tetryzolin NNP 0
eye NN 0
drops NNS 0
and CC 0
Levocabastine NNP 0
eye NN 0
drops NNS 0
. . 0

69 CD 0
patients NNS 0
were VBD 0
treated VBN 0
over IN 0
a DT 0
2 CD 0
weeks NNS 0
course NN 0
of IN 0
therapy NN 0
. . 0

The DT 0
subjective JJ 0
and CC 0
objective JJ 0
ocular NN 0
symptoms NNS 0
were VBD 0
documented VBN 0
over IN 0
the DT 0
treatment NN 0
period NN 0
. . 0

RESULTS NNP 0
Both NNP 0
eye NN 0
drops NNS 0
reduced VBD 0
subjective JJ 0
and CC 0
objective JJ 0
ocular NN 0
symptoms NNS 0
effective JJ 0
. . 0

The DT 0
difference NN 0
between IN 0
the DT 0
treatments NNS 0
( ( 0
p JJ 0
= NNP 0
0.0395 CD 0
) ) 0
was VBD 0
the DT 0
faster JJ 0
onset NN 0
of IN 0
action NN 0
of IN 0
Antazolin/Tetryzolin NNP 0
30 CD 0
minutes NNS 0
after IN 0
administration NN 0
of IN 0
the DT 0
first JJ 0
drop NN 0
of IN 0
trial NN 0
medication NN 0
. . 0

CONCLUSION VB 0
A DT 0
fast JJ 0
and CC 0
effective JJ 0
onset NN 0
of IN 0
action NN 0
is VBZ 0
of IN 0
high JJ 0
clinical JJ 0
relevance NN 0
. . 0

Therefore IN 0
the DT 0
benefits NNS 0
of IN 0
using VBG 0
Antazolin/Tetryzolin NNP 0
eye NN 0
drops NN 0
was VBD 0
clearly RB 0
outweigh JJ 0
. . 0

[ JJ 0
Postural NNP 0
biofeedback NN 0
and CC 0
locomotion NN 0
reeducation NN 0
in IN 0
stroke NN 0
patients NNS 0
] VBP 0
. . 0

AIMS NNP 0
To TO 0
compare VB 0
, , 0
in IN 0
post-acute JJ 0
hemiparetic JJ 0
patients NNS 0
, , 0
gait NN 0
improvement NN 0
after IN 0
conventional JJ 0
physical JJ 0
therapy NN 0
alone RB 0
or CC 0
with IN 0
a DT 0
specialised JJ 0
balance NN 0
retraining VBG 0
program NN 0
. . 0

PATIENTS VB 0
Twenty-six JJ 0
patients NNS 0
within IN 0
3 CD 0
months NNS 0
of IN 0
onset NN 0
of IN 0
stroke NN 0
were VBD 0
randomised VBN 0
to TO 0
receive VB 0
physical JJ 0
therapy NN 0
( ( 0
control VB 0
group NN 0
) ) 0
or CC 0
therapy NN 0
and CC 0
retraining NN 0
( ( 0
experimental JJ 0
group NN 0
) ) 0
, , 0
most JJS 0
of IN 0
the DT 0
patients NNS 0
in IN 0
both DT 0
groups NNS 0
with IN 0
left JJ 0
hemiplegia NN 0
. . 0

The DT 0
experimental JJ 0
group NN 0
was VBD 0
significantly RB 0
older JJR 0
than IN 0
the DT 0
control NN 0
group NN 0
. . 0

METHOD NNP 0
Thirteen NNP 0
patients NNS 0
received VBD 0
early JJ 0
conventional JJ 0
therapy NN 0
, , 0
and CC 0
13 CD 0
received VBD 0
therapy NN 0
combined VBN 0
with IN 0
standing VBG 0
balance NN 0
training NN 0
by IN 0
biofeedback NN 0
( ( 0
BPM NNP 0
Monitor NNP 0
) ) 0
. . 0

Clinical JJ 0
measures NNS 0
were VBD 0
collected VBN 0
at IN 0
entry NN 0
( ( 0
J0 NNP 0
) ) 0
, , 0
once RB 0
when WRB 0
subjects NNS 0
began VBD 0
to TO 0
walk VB 0
( ( 0
JM NNP 0
) ) 0
and CC 0
30 CD 0
days NNS 0
later RB 0
( ( 0
JM NNP 0
+ NNP 0
30 CD 0
) ) 0
. . 0

Gait NNP 0
spatiotemporal JJ 0
parameters NNS 0
were VBD 0
collected VBN 0
by IN 0
use NN 0
of IN 0
the DT 0
Vicon NNP 0
system NN 0
at IN 0
JM NNP 0
and CC 0
JM NNP 0
+ NNP 0
30 CD 0
. . 0

RESULTS VB 0
Whatever IN 0
the DT 0
method NN 0
of IN 0
rehabilitation NN 0
, , 0
the DT 0
clinical JJ 0
scores NNS 0
improved VBN 0
significantly RB 0
between IN 0
J0 NNP 0
and CC 0
JM NNP 0
+ NNP 0
30 CD 0
, , 0
except IN 0
for IN 0
spasticity NN 0
. . 0

The DT 0
time NN 0
between IN 0
stroke NN 0
and CC 0
the DT 0
beginning NN 0
of IN 0
walking NN 0
was VBD 0
not RB 0
significantly RB 0
different JJ 0
between IN 0
both DT 0
groups NNS 0
. . 0

Gait NNP 0
velocity NN 0
increased VBD 0
significantly RB 0
between IN 0
JM NNP 0
and CC 0
JM NNP 0
+ NNP 0
30 CD 0
in IN 0
both DT 0
groups NNS 0
, , 0
with IN 0
no DT 0
difference NN 0
between IN 0
groups NNS 0
. . 0

The DT 0
walking NN 0
pattern NN 0
was VBD 0
improved VBN 0
for IN 0
both DT 0
groups NNS 0
, , 0
with IN 0
a DT 0
significant JJ 0
increase NN 0
of IN 0
the DT 0
duration NN 0
of IN 0
the DT 0
paretic JJ 0
limb NN 0
single JJ 0
stance NN 0
. . 0

The DT 0
experimental JJ 0
group NN 0
significantly RB 0
improved VBD 0
the DT 0
duration NN 0
of IN 0
the DT 0
reception NN 0
double JJ 0
stance NN 0
on IN 0
the DT 0
paretic JJ 0
limb NN 0
between IN 0
JM NNP 0
and CC 0
JM NNP 0
+ NNP 0
30 CD 0
compared VBN 0
with IN 0
the DT 0
control NN 0
group NN 0
( ( 0
P NNP 0
= NNP 0
0.03 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
Both NNP 0
groups NNS 0
demonstrated VBD 0
improvement NN 0
in IN 0
the DT 0
rehabilitation NN 0
unit NN 0
. . 0

The DT 0
benefits NNS 0
of IN 0
visual JJ 0
biofeedback NN 0
by IN 0
forceplate NN 0
system NN 0
training VBG 0
suggest JJ 0
particular JJ 0
improvement NN 0
of IN 0
anticipation NN 0
equilibrium NN 0
with IN 0
conventional JJ 0
therapy NN 0
. . 0

Low JJ 0
doses NNS 0
of IN 0
ketazolam NN 0
in IN 0
anxiety NN 0
: : 0
a DT 0
double-blind NN 0
, , 0
placebo-controlled JJ 0
study NN 0
. . 0

A DT 0
multicenter NN 0
, , 0
double-blind JJ 0
, , 0
between-patient JJ 0
trial NN 0
comparing VBG 0
two CD 0
doses NNS 0
of IN 0
ketazolam NN 0
( ( 0
15 CD 0
and CC 0
30 CD 0
mg NN 0
) ) 0
with IN 0
placebo NN 0
, , 0
each DT 0
given VBN 0
once RB 0
daily JJ 0
, , 0
in IN 0
the DT 0
evening NN 0
, , 0
to TO 0
92 CD 0
outpatients NNS 0
affected VBN 0
by IN 0
generalized JJ 0
anxiety NN 0
disorders NNS 0
for IN 0
at IN 0
least JJS 0
1 CD 0
month NN 0
, , 0
was VBD 0
carried VBN 0
out RP 0
. . 0

After IN 0
1-week JJ 0
washout NN 0
period NN 0
47 CD 0
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
ketazolam VB 0
15 CD 0
mg NN 0
, , 0
and CC 0
45 CD 0
to TO 0
placebo VB 0
for IN 0
15 CD 0
days NNS 0
( ( 0
first JJ 0
period NN 0
) ) 0
. . 0

At IN 0
the DT 0
end NN 0
of IN 0
this DT 0
period NN 0
, , 0
if IN 0
the DT 0
patient NN 0
experienced VBD 0
a DT 0
decrease NN 0
on IN 0
the DT 0
total JJ 0
Hamilton NNP 0
Anxiety NNP 0
Rating NNP 0
Scale NNP 0
( ( 0
HAM-A NNP 0
) ) 0
of IN 0
at IN 0
least JJS 0
25 CD 0
% NN 0
of IN 0
basal NN 0
value NN 0
, , 0
the DT 0
treatment NN 0
was VBD 0
kept VBN 0
unchanged JJ 0
for IN 0
a DT 0
further JJ 0
15 CD 0
days NNS 0
, , 0
otherwise RB 0
15 CD 0
mg NN 0
of IN 0
ketazolam NNS 0
were VBD 0
added VBN 0
to TO 0
the DT 0
previous JJ 0
treatment NN 0
( ( 0
second JJ 0
period NN 0
) ) 0
. . 0

Anxiety NN 0
was VBD 0
rated VBN 0
after IN 0
2 CD 0
and CC 0
4 CD 0
weeks NNS 0
with IN 0
the DT 0
Italian JJ 0
HAM-A NNP 0
scale NN 0
and CC 0
with IN 0
a DT 0
4-point JJ 0
scale NN 0
( ( 0
patient NN 0
's POS 0
assessment NN 0
) ) 0
. . 0

Seventy-eight JJ 0
patients NNS 0
completed VBD 0
the DT 0
first JJ 0
period NN 0
and CC 0
75 CD 0
the DT 0
whole NN 0
study NN 0
. . 0

During IN 0
the DT 0
first JJ 0
period NN 0
the DT 0
percentage NN 0
of IN 0
responders NNS 0
was VBD 0
almost RB 0
identical JJ 0
in IN 0
both DT 0
treatment NN 0
groups NNS 0
, , 0
but CC 0
during IN 0
the DT 0
second JJ 0
period NN 0
a DT 0
further JJ 0
slight NN 0
improvement NN 0
was VBD 0
observed VBN 0
in IN 0
the DT 0
early JJ 0
placebo NN 0
responders NNS 0
, , 0
while IN 0
the DT 0
HAM-A NNP 0
score NN 0
of IN 0
patients NNS 0
on IN 0
ketazolam NNS 0
continued VBN 0
to TO 0
improve VB 0
significantly RB 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.01 CD 0
) ) 0
throughout IN 0
the DT 0
study NN 0
. . 0

Likewise VB 0
a DT 0
significant JJ 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
difference NN 0
between IN 0
treatments NNS 0
was VBD 0
observed VBN 0
, , 0
on IN 0
the DT 0
4-point JJ 0
scale NN 0
, , 0
in IN 0
the DT 0
population NN 0
as IN 0
a DT 0
whole NN 0
( ( 0
end NN 0
of IN 0
first JJ 0
period NN 0
) ) 0
as RB 0
well RB 0
as IN 0
in IN 0
responder NN 0
patients NNS 0
( ( 0
end JJ 0
second JJ 0
period NN 0
) ) 0
. . 0

Tolerability NN 0
was VBD 0
good JJ 0
, , 0
except IN 0
in IN 0
1 CD 0
patient NN 0
on IN 0
placebo NN 0
, , 0
who WP 0
was VBD 0
withdrawn VBN 0
from IN 0
the DT 0
study NN 0
because IN 0
of IN 0
severe JJ 0
headache NN 0
. . 0

Bacteremia NNP 0
due JJ 0
to TO 0
Bacteroides NNP 0
fragilis NN 0
after IN 0
elective JJ 0
appendectomy NN 0
in IN 0
renal JJ 0
transplant NN 0
recipients NNS 0
. . 0

Bacteremia NNP 0
caused VBN 0
by IN 0
Bacteroides NNP 0
fragilis NN 0
occurred VBD 0
in IN 0
four CD 0
of IN 0
75 CD 0
children NNS 0
after IN 0
renal JJ 0
transplantation NN 0
, , 0
and CC 0
B. NNP 0
fragilis NN 0
was VBD 0
the DT 0
most RBS 0
common JJ 0
cause NN 0
of IN 0
postoperative JJ 0
bacteremia NN 0
. . 0

Bacteroides NNP 0
bacteremia NN 0
was VBD 0
significantly RB 0
associated VBN 0
with IN 0
performance NN 0
of IN 0
elective JJ 0
appendectomy NN 0
at IN 0
the DT 0
time NN 0
of IN 0
transplantation NN 0
( ( 0
P NNP 0
less JJR 0
than IN 0
0.01 CD 0
) ) 0
and CC 0
with IN 0
profound JJ 0
lymphocytopenia NN 0
( ( 0
P NNP 0
= NNP 0
0.01 CD 0
) ) 0
. . 0

No DT 0
patient NN 0
received VBD 0
antibiotics NNS 0
at IN 0
the DT 0
time NN 0
of IN 0
surgery NN 0
or CC 0
prior RB 0
to TO 0
the DT 0
first JJ 0
positive JJ 0
blood NN 0
culture NN 0
, , 0
yet RB 0
B. NNP 0
fragilis NN 0
was VBD 0
the DT 0
single JJ 0
organism NN 0
isolated VBN 0
from IN 0
blood NN 0
and CC 0
abscesses NNS 0
in IN 0
these DT 0
patients NNS 0
. . 0

A DT 0
role NN 0
for IN 0
lymphocytes NNS 0
in IN 0
containment NN 0
of IN 0
B. NNP 0
fragilis NN 0
has VBZ 0
not RB 0
been VBN 0
suggested VBN 0
previously RB 0
, , 0
although IN 0
unexplained JJ 0
occurrence NN 0
of IN 0
bacteroides NNS 0
bacteremia VBP 0
in IN 0
immunocompromised JJ 0
patients NNS 0
has VBZ 0
occasionally RB 0
been VBN 0
reported VBN 0
. . 0

Lymphocytes VBZ 0
themselves PRP 0
may MD 0
be VB 0
important JJ 0
in IN 0
this DT 0
host-bacterium JJ 0
interaction NN 0
, , 0
or CC 0
lymphocytopenia NN 0
may MD 0
be VB 0
the DT 0
marker NN 0
for IN 0
a DT 0
more RBR 0
generalized JJ 0
deficiency NN 0
in IN 0
host NN 0
defenses NNS 0
. . 0

A DT 0
double-blind NN 0
, , 0
randomized VBN 0
, , 0
controlled VBN 0
, , 0
multicenter NN 0
study NN 0
to TO 0
assess VB 0
the DT 0
safety NN 0
and CC 0
cardiovascular JJ 0
effects NNS 0
of IN 0
skeletal JJ 0
myoblast NN 0
implantation NN 0
by IN 0
catheter NN 0
delivery NN 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 0
heart NN 0
failure NN 0
after IN 0
myocardial JJ 0
infarction NN 0
. . 0

BACKGROUND NNP 0
We PRP 0
sought VBD 0
to TO 0
determine VB 0
the DT 0
safety NN 0
and CC 0
preliminary JJ 0
efficacy NN 0
of IN 0
transcatheter NN 0
intramyocardial JJ 0
administration NN 0
of IN 0
myoblasts NNS 0
in IN 0
patients NNS 0
with IN 0
heart NN 0
failure NN 0
( ( 0
HF NNP 0
) ) 0
. . 0

METHODS NNP 0
MARVEL NNP 0
is VBZ 0
a DT 0
randomized JJ 0
placebo-controlled JJ 0
trial NN 0
of IN 0
image-guided JJ 0
, , 0
catheter-based JJ 0
intramyocardial JJ 0
injection NN 0
of IN 0
placebo NN 0
or CC 0
myoblasts NNS 0
( ( 0
400 CD 0
or CC 0
800 CD 0
million CD 0
) ) 0
in IN 0
patients NNS 0
with IN 0
class NN 0
II NNP 0
to TO 0
IV NNP 0
HF NNP 0
and CC 0
ejection NN 0
fraction NN 0
< VBD 0
35 CD 0
% NN 0
. . 0

Primary JJ 0
end NN 0
points NNS 0
were VBD 0
frequency NN 0
of IN 0
serious JJ 0
adverse JJ 0
events NNS 0
( ( 0
safety NN 0
) ) 0
and CC 0
changes NNS 0
in IN 0
6-minute JJ 0
walk NN 0
test NN 0
and CC 0
Minnesota NNP 0
Living NNP 0
With IN 0
HF NNP 0
score NN 0
( ( 0
efficacy NN 0
) ) 0
. . 0

Of IN 0
330 CD 0
patients NNS 0
intended VBN 0
for IN 0
enrollment NN 0
, , 0
23 CD 0
were VBD 0
randomized VBN 0
( ( 0
MARVEL-1 NNP 0
) ) 0
before IN 0
stopping VBG 0
the DT 0
study NN 0
for IN 0
financial JJ 0
reasons NNS 0
. . 0

RESULTS NNP 0
At IN 0
6 CD 0
months NNS 0
, , 0
similar JJ 0
numbers NNS 0
of IN 0
events NNS 0
occurred VBN 0
in IN 0
each DT 0
group NN 0
: : 0
8 CD 0
( ( 0
placebo NN 0
) ) 0
, , 0
7 CD 0
( ( 0
low JJ 0
dose NN 0
) ) 0
, , 0
and CC 0
8 CD 0
( ( 0
high JJ 0
dose NN 0
) ) 0
, , 0
without IN 0
deaths NNS 0
. . 0

Ventricular JJ 0
tachycardia NN 0
responsive NN 0
to TO 0
amiodarone VB 0
was VBD 0
more RBR 0
frequent JJ 0
in IN 0
myoblast-treated JJ 0
patients NNS 0
: : 0
1 CD 0
( ( 0
placebo NN 0
) ) 0
, , 0
3 CD 0
( ( 0
low JJ 0
dose NN 0
) ) 0
, , 0
and CC 0
4 CD 0
( ( 0
high JJ 0
dose NN 0
) ) 0
. . 0

A DT 0
trend NN 0
toward IN 0
improvement NN 0
in IN 0
functional JJ 0
capacity NN 0
was VBD 0
noted VBN 0
in IN 0
myoblast-treated JJ 0
groups NNS 0
( ( 0
?6-minute JJ 0
walk NN 0
test NN 0
of IN 0
-3.6 NNP 0
vs FW 0
+95.6 NNP 0
vs FW 0
+85.5 NNP 0
m FW 0
[ NNP 0
placebo NN 0
vs NN 0
low JJ 0
dose NN 0
vs NN 0
high JJ 0
dose NN 0
; : 0
P NNP 0
= NNP 0
.50 NNP 0
] NNP 0
) ) 0
without IN 0
significant JJ 0
changes NNS 0
in IN 0
Minnesota NNP 0
Living NNP 0
With IN 0
HF NNP 0
scores NNS 0
. . 0

CONCLUSIONS NNP 0
In IN 0
HF NNP 0
patients NNS 0
with IN 0
chronic JJ 0
postinfarction NN 0
cardiomyopathy NN 0
, , 0
transcatheter JJ 0
administration NN 0
of IN 0
myoblasts NNS 0
in IN 0
doses NNS 0
of IN 0
400 CD 0
to TO 0
800 CD 0
million CD 0
cells NNS 0
is VBZ 0
feasible JJ 0
and CC 0
may MD 0
lead VB 0
to TO 0
important JJ 0
clinical JJ 0
benefits NNS 0
. . 0

Ventricular JJ 0
tachycardia NN 0
may MD 0
be VB 0
provoked VBN 0
by IN 0
myoblast JJ 0
injection NN 0
but CC 0
appears VBZ 0
to TO 0
be VB 0
a DT 0
transient NN 0
and CC 0
treatable JJ 0
problem NN 0
. . 0

A DT 0
large-scale JJ 0
outcome JJ 0
trial NN 0
of IN 0
myoblast JJ 0
administration NN 0
in IN 0
HF NNP 0
patients NNS 0
with IN 0
postinfarction NN 0
cardiomyopathy NN 0
is VBZ 0
feasible JJ 0
and CC 0
warranted VBD 0
. . 0

Superior JJ 0
visual JJ 0
search NN 0
in IN 0
adults NNS 0
with IN 0
autism NN 0
. . 0

Recent JJ 0
studies NNS 0
have VBP 0
suggested VBN 0
that IN 0
children NNS 0
with IN 0
autism NN 0
perform NN 0
better RBR 0
than IN 0
matched VBN 0
controls NNS 0
on IN 0
visual JJ 0
search NN 0
tasks NNS 0
and CC 0
that IN 0
this DT 0
stems VBZ 0
from IN 0
a DT 0
superior JJ 0
visual JJ 0
discrimination NN 0
ability NN 0
. . 0

This DT 0
study NN 0
assessed VBD 0
whether IN 0
these DT 0
findings NNS 0
generalize VBP 0
from IN 0
children NNS 0
to TO 0
adults NNS 0
with IN 0
autism NN 0
. . 0

Experiments NNS 0
1 CD 0
and CC 0
2 CD 0
showed VBD 0
that IN 0
, , 0
like IN 0
children NNS 0
, , 0
adults NNS 0
with IN 0
autism NN 0
were VBD 0
superior JJ 0
to TO 0
controls NNS 0
at IN 0
searching VBG 0
for IN 0
targets NNS 0
. . 0

Experiment NN 0
3 CD 0
showed VBD 0
that IN 0
increases NNS 0
in IN 0
target-distractor JJ 0
similarity NN 0
slowed VBD 0
the DT 0
visual JJ 0
search NN 0
performance NN 0
of IN 0
the DT 0
control NN 0
group NN 0
significantly RB 0
more RBR 0
than IN 0
that DT 0
of IN 0
the DT 0
autism NN 0
group NN 0
, , 0
suggesting VBG 0
that IN 0
the DT 0
adults NNS 0
with IN 0
autism NN 0
have VBP 0
a DT 0
superior JJ 0
visual JJ 0
discrimination NN 0
ability NN 0
. . 0

Thus RB 0
, , 0
these DT 0
experiments NNS 0
replicate VBP 0
in IN 0
adults NNS 0
previous JJ 0
findings NNS 0
in IN 0
children NNS 0
with IN 0
autism NN 0
. . 0

Superior NNP 0
unique JJ 0
item NN 0
detection NN 0
in IN 0
adults NNS 0
with IN 0
autism NN 0
, , 0
stemming VBG 0
from IN 0
enhanced VBN 0
discrimination NN 0
, , 0
is VBZ 0
discussed VBN 0
in IN 0
the DT 0
light NN 0
of IN 0
the DT 0
possible JJ 0
role NN 0
of IN 0
stimulus JJ 0
processing NN 0
disturbances NNS 0
in IN 0
the DT 0
disorder NN 0
in IN 0
general JJ 0
. . 0

Inverse JJ 0
Effect NNP 0
of IN 0
Fluoxetine NNP 0
on IN 0
Medial NNP 0
Prefrontal NNP 0
Cortex NNP 0
Activation NNP 0
During IN 0
Reward NNP 0
Reversal NNP 0
in IN 0
ADHD NNP 0
and CC 0
Autism NNP 0
. . 0

Attention NNP 0
deficit NN 0
hyperactivity NN 0
disorder NN 0
( ( 0
ADHD NNP 0
) ) 0
and CC 0
autism NN 0
spectrum NN 0
disorder NN 0
( ( 0
ASD NNP 0
) ) 0
share NN 0
brain NN 0
function NN 0
abnormalities NNS 0
during IN 0
cognitive JJ 0
flexibility NN 0
. . 0

Serotonin NNP 0
is VBZ 0
involved VBN 0
in IN 0
both DT 0
disorders NNS 0
, , 0
and CC 0
selective JJ 0
serotonin NN 0
reuptake NN 0
inhibitors NNS 0
( ( 0
SSRIs NNP 0
) ) 0
can MD 0
modulate VB 0
cognitive JJ 0
flexibility NN 0
and CC 0
improve VB 0
behavior NN 0
in IN 0
both DT 0
disorders NNS 0
. . 0

Thus RB 0
, , 0
this DT 0
study NN 0
investigates VBZ 0
shared VBN 0
and CC 0
disorder-specific JJ 0
brain NN 0
dysfunctions NNS 0
in IN 0
these DT 0
2 CD 0
disorders NNS 0
during IN 0
reward NN 0
reversal NN 0
, , 0
and CC 0
the DT 0
acute JJ 0
effects NNS 0
of IN 0
an DT 0
SSRI NNP 0
on IN 0
these DT 0
. . 0

Age-matched JJ 0
boys NNS 0
with IN 0
ADHD NNP 0
( ( 0
15 CD 0
) ) 0
, , 0
ASD NNP 0
( ( 0
18 CD 0
) ) 0
, , 0
and CC 0
controls NNS 0
( ( 0
21 CD 0
) ) 0
were VBD 0
compared VBN 0
with IN 0
functional JJ 0
magnetic JJ 0
resonance NN 0
imaging NN 0
( ( 0
fMRI JJ 0
) ) 0
during IN 0
a DT 0
reversal NN 0
task NN 0
. . 0

Patients NNS 0
were VBD 0
scanned VBN 0
twice RB 0
, , 0
under IN 0
either DT 0
an DT 0
acute NN 0
dose NN 0
of IN 0
Fluoxetine NNP 0
or CC 0
placebo NN 0
in IN 0
a DT 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
randomized JJ 0
design NN 0
. . 0

Repeated-measures JJ 0
analyses NNS 0
within IN 0
patients NNS 0
assessed JJ 0
drug NN 0
effects NNS 0
. . 0

Patients NNS 0
under IN 0
each DT 0
drug NN 0
condition NN 0
were VBD 0
compared VBN 0
with IN 0
controls NNS 0
to TO 0
assess VB 0
normalization NN 0
effects NNS 0
. . 0

fMRI NN 0
data NNS 0
showed VBD 0
that IN 0
, , 0
under IN 0
placebo NN 0
, , 0
ASD NNP 0
boys VBZ 0
underactivated JJ 0
medial JJ 0
prefrontal NN 0
cortex NN 0
( ( 0
mPFC NN 0
) ) 0
, , 0
compared VBN 0
with IN 0
control NN 0
and CC 0
ADHD NNP 0
boys NNS 0
. . 0

Both DT 0
patient JJ 0
groups NNS 0
shared VBD 0
decreased JJ 0
precuneus NN 0
activation NN 0
. . 0

Under IN 0
Fluoxetine NNP 0
, , 0
mPFC JJ 0
activation NN 0
was VBD 0
up-regulated JJ 0
and CC 0
normalized VBN 0
in IN 0
ASD NNP 0
boys NNS 0
relative VBP 0
to TO 0
controls NNS 0
, , 0
but CC 0
down-regulated JJ 0
in IN 0
ADHD NNP 0
boys NNS 0
relative VBP 0
to TO 0
placebo VB 0
, , 0
which WDT 0
was VBD 0
concomitant NN 0
with IN 0
worse JJR 0
task NN 0
performance NN 0
in IN 0
ADHD NNP 0
. . 0

Fluoxetine NNP 0
therefore NN 0
has VBZ 0
inverse JJ 0
effects NNS 0
on IN 0
mPFC JJ 0
activation NN 0
in IN 0
ASD NNP 0
and CC 0
ADHD NNP 0
during IN 0
reversal NN 0
learning NN 0
, , 0
suggesting VBG 0
dissociated VBN 0
underlying JJ 0
serotonin NN 0
abnormalities NNS 0
. . 0

Epidemiology NN 0
of IN 0
stroke NN 0
. . 0

Importance NN 0
of IN 0
preventive JJ 0
pharmacological JJ 0
strategies NNS 0
in IN 0
elderly JJ 0
patients NNS 0
and CC 0
associated JJ 0
costs NNS 0
. . 0

Stroke NNP 0
is VBZ 0
a DT 0
major JJ 0
cause NN 0
of IN 0
death NN 0
and CC 0
disability NN 0
in IN 0
developed JJ 0
countries NNS 0
. . 0

The DT 0
incidence NN 0
of IN 0
stroke NN 0
increases NNS 0
exponentially RB 0
with IN 0
age NN 0
, , 0
yet RB 0
, , 0
traditionally RB 0
, , 0
many JJ 0
medical JJ 0
practitioners NNS 0
have VBP 0
been VBN 0
reluctant JJ 0
to TO 0
treat VB 0
hypertension NN 0
in IN 0
older JJR 0
patients NNS 0
. . 0

Since IN 0
1991 CD 0
, , 0
the DT 0
results NNS 0
of IN 0
3 CD 0
major JJ 0
trials NNS 0
-- : 0
the DT 0
British JJ 0
Medical NNP 0
Research NNP 0
Council NNP 0
( ( 0
MRC NNP 0
) ) 0
trial NN 0
of IN 0
treatment NN 0
in IN 0
older JJR 0
adults NNS 0
, , 0
the DT 0
Swedish JJ 0
Trial NNP 0
in IN 0
Old NNP 0
Patients NNPS 0
with IN 0
Hypertension NNP 0
( ( 0
STOP-Hypertension NNP 0
) ) 0
and CC 0
the DT 0
Systolic NNP 0
Hypertension NNP 0
in IN 0
the DT 0
Elderly JJ 0
Program NNP 0
( ( 0
SHEP NNP 0
) ) 0
-- : 0
have VBP 0
conclusively RB 0
established VBN 0
the DT 0
benefits NNS 0
of IN 0
treating VBG 0
older JJR 0
patients NNS 0
( ( 0
> JJ 0
60 CD 0
years NNS 0
) ) 0
with IN 0
both DT 0
diastolic JJ 0
and CC 0
isolated JJ 0
systolic JJ 0
hypertension NN 0
. . 0

International NNP 0
guidelines NNS 0
for IN 0
the DT 0
management NN 0
of IN 0
hypertension NN 0
-- : 0
including VBG 0
the DT 0
Fifth NNP 0
Report NNP 0
of IN 0
the DT 0
Joint NNP 0
National NNP 0
Committee NNP 0
, , 0
the DT 0
1993 CD 0
report NN 0
of IN 0
the DT 0
World NNP 0
Health NNP 0
Organization NNP 0
and CC 0
the DT 0
International NNP 0
Society NNP 0
of IN 0
Hypertension NNP 0
and CC 0
the DT 0
second JJ 0
report NN 0
of IN 0
the DT 0
British JJ 0
Hypertension NNP 0
Society NNP 0
Working NNP 0
Party NNP 0
-- : 0
have VBP 0
all DT 0
been VBN 0
modified VBN 0
to TO 0
reflect VB 0
the DT 0
emerging VBG 0
evidence NN 0
concerning VBG 0
the DT 0
benefits NNS 0
of IN 0
treating VBG 0
older JJR 0
patients NNS 0
. . 0

Cost-effectiveness JJ 0
data NNS 0
are VBP 0
similarly RB 0
in IN 0
accord NN 0
with IN 0
giving VBG 0
high JJ 0
priority NN 0
to TO 0
the DT 0
treatment NN 0
of IN 0
older JJR 0
individuals NNS 0
with IN 0
hypertension NN 0
. . 0

Subjective JJ 0
and CC 0
objective JJ 0
levels NNS 0
of IN 0
physical JJ 0
activity NN 0
and CC 0
their PRP$ 0
association NN 0
with IN 0
cardiorespiratory NN 0
fitness NN 0
in IN 0
rheumatoid JJ 0
arthritis NN 0
patients NNS 0
. . 0

INTRODUCTION NNP 0
The DT 0
aims NNS 0
of IN 0
the DT 0
present JJ 0
study NN 0
were VBD 0
: : 0
( ( 0
a DT 0
) ) 0
to TO 0
examine VB 0
the DT 0
agreement NN 0
between IN 0
subjective JJ 0
( ( 0
assessed JJ 0
via IN 0
the DT 0
International NNP 0
Physical NNP 0
Activity NNP 0
Questionnaire NNP 0
; : 0
IPAQ NNP 0
) ) 0
and CC 0
objective JJ 0
( ( 0
accelerometry NN 0
; : 0
GT3X NNP 0
) ) 0
physical JJ 0
activity NN 0
( ( 0
PA NNP 0
) ) 0
levels NNS 0
in IN 0
patients NNS 0
with IN 0
rheumatoid JJ 0
arthritis NN 0
( ( 0
RA NNP 0
) ) 0
, , 0
and CC 0
( ( 0
b NN 0
) ) 0
to TO 0
evaluate VB 0
the DT 0
associations NNS 0
of IN 0
RA NNP 0
patients NNS 0
' POS 0
subjective JJ 0
and CC 0
objective JJ 0
PA NNP 0
to TO 0
their PRP$ 0
scores NNS 0
on IN 0
the DT 0
maximal JJ 0
oxygen NN 0
uptake JJ 0
test NN 0
( ( 0
VO2max NNP 0
) ) 0
. . 0

METHODS PDT 0
The DT 0
participants NNS 0
wore VBD 0
the DT 0
GT3X NNP 0
for IN 0
seven CD 0
days NNS 0
before IN 0
completing VBG 0
the DT 0
IPAQ NNP 0
and CC 0
VO2max NNP 0
test NN 0
. . 0

The DT 0
Bland-Altman NNP 0
plot NN 0
was VBD 0
used VBN 0
to TO 0
illustrate VB 0
the DT 0
agreement NN 0
between IN 0
the DT 0
objective NN 0
and CC 0
subjective JJ 0
PA NNP 0
data NN 0
, , 0
and CC 0
the DT 0
Wilcoxon NNP 0
test NN 0
was VBD 0
employed VBN 0
to TO 0
examine VB 0
the DT 0
differences NNS 0
. . 0

The DT 0
association NN 0
between IN 0
the DT 0
PA NNP 0
measurement NN 0
and CC 0
VO2max NNP 0
test NN 0
was VBD 0
examined VBN 0
via IN 0
the DT 0
correlations NNS 0
and CC 0
the DT 0
magnitude NN 0
was VBD 0
presented VBN 0
by IN 0
the DT 0
Steiger NNP 0
's POS 0
Z NNP 0
value NN 0
. . 0

RESULTS NNP 0
Sixty-eight JJ 0
RA NNP 0
patients NNS 0
( ( 0
age=55?13 JJ 0
years NNS 0
, , 0
body NN 0
mass NN 0
index NN 0
: : 0
27.8?5.4 CD 0
kg/m2 NN 0
, , 0
median NN 0
of IN 0
disease NN 0
duration=5 NN 0
( ( 0
2-8 JJ 0
) ) 0
yrs NN 0
) ) 0
were VBD 0
recruited VBN 0
. . 0

Smaller NNP 0
differences NNS 0
between IN 0
the DT 0
subjective JJ 0
and CC 0
objective JJ 0
measures NNS 0
were VBD 0
found VBN 0
when WRB 0
PA NNP 0
was VBD 0
assessed VBN 0
at IN 0
the DT 0
moderate JJ 0
level NN 0
. . 0

Wilcoxon NNP 0
tests NNS 0
revealed VBD 0
that IN 0
patients NNS 0
reported VBD 0
less JJR 0
time NN 0
spent VBN 0
engaged VBN 0
in IN 0
sedentary JJ 0
behaviours NNS 0
( ( 0
Z=-6.80 NNP 0
, , 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
and CC 0
light JJ 0
PA NNP 0
( ( 0
Z=-6.89 NNP 0
, , 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
and CC 0
more JJR 0
moderate JJ 0
PA NNP 0
( ( 0
Z=-6.26 NNP 0
, , 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
than IN 0
was VBD 0
objectively RB 0
indicated VBN 0
. . 0

Significant NNP 0
positive JJ 0
correlations NNS 0
were VBD 0
revealed VBN 0
between IN 0
VO2max NNP 0
with IN 0
all DT 0
PA NNP 0
levels NNS 0
derived VBN 0
from IN 0
accelerometry NN 0
( ( 0
light JJ 0
PA NNP 0
rho=.35 NN 0
, , 0
P NNP 0
< NNP 0
.01 NNP 0
; : 0
moderate JJ 0
PA NNP 0
rho=.34 NN 0
, , 0
P=.01 NNP 0
; : 0
moderate JJ 0
and CC 0
vigorous JJ 0
PA NNP 0
, , 0
( ( 0
MVPA NNP 0
) ) 0
rho=.33 NN 0
, , 0
P=.01 NNP 0
) ) 0
, , 0
and CC 0
a DT 0
negative JJ 0
association NN 0
to TO 0
sedentary JJ 0
time NN 0
( ( 0
ST NNP 0
) ) 0
emerged VBD 0
( ( 0
rho=-.27 JJ 0
, , 0
P=.04 NNP 0
) ) 0
. . 0

IPAQ-reported JJ 0
moderate JJ 0
PA NNP 0
and CC 0
MVPA NNP 0
positively RB 0
correlated VBD 0
with IN 0
maxV02 NN 0
( ( 0
rho=.25 NN 0
, , 0
P=.01 NNP 0
, , 0
rho=.27 NN 0
, , 0
P=.01 NNP 0
, , 0
respectively RB 0
) ) 0
. . 0

Differences NNS 0
between IN 0
the DT 0
magnitude NN 0
of IN 0
correlations NNS 0
between IN 0
the DT 0
IPAQ-VO2 NNP 0
max NN 0
and CC 0
GT3X-VO2 NNP 0
max NN 0
were VBD 0
only RB 0
significant JJ 0
for IN 0
ST NNP 0
( ( 0
Z=3.43 NNP 0
, , 0
P NNP 0
< NNP 0
.01 NNP 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Via NNP 0
responses VBZ 0
to TO 0
the DT 0
IPAQ NNP 0
, , 0
RA NNP 0
patients NNS 0
reported VBD 0
that IN 0
they PRP 0
were VBD 0
less JJR 0
sedentary JJ 0
and CC 0
engaged VBN 0
in IN 0
more RBR 0
higher JJR 0
intensity NN 0
PA NNP 0
than IN 0
what WP 0
was VBD 0
objectively RB 0
assessed VBN 0
. . 0

Accelerometry NNP 0
data NNS 0
correlated VBD 0
with IN 0
VO2max NNP 0
at IN 0
all DT 0
PA NNP 0
levels NNS 0
. . 0

Only RB 0
subjective JJ 0
moderate NN 0
and CC 0
MPVA NNP 0
correlated VBD 0
with IN 0
VO2max NNP 0
. . 0

Findings NNS 0
suggest VBP 0
that IN 0
self-reported JJ 0
PA NNP 0
and CC 0
ST NNP 0
should MD 0
be VB 0
interpreted VBN 0
with IN 0
caution NN 0
in IN 0
people NNS 0
with IN 0
RA NNP 0
and CC 0
complemented VBN 0
with IN 0
accelerometry NN 0
when WRB 0
possible JJ 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
Trial NNP 0
registration NN 0
: : 0
ClinicalTrials.gov NNP 0
ISRCTN04121489 NNP 0
. . 0

Registered VBD 0
5 CD 0
September NNP 0
2012 CD 0
. . 0

Measurement NN 0
of IN 0
transfer NN 0
factor NN 0
during IN 0
constant JJ 0
exhalation NN 0
. . 0

BACKGROUND NNP 0
Transfer NNP 0
factor NN 0
of IN 0
the DT 0
lung NN 0
for IN 0
carbon NN 0
monoxide NN 0
( ( 0
TLCO NNP 0
) ) 0
was VBD 0
measured VBN 0
by IN 0
a DT 0
new JJ 0
method NN 0
based VBN 0
on IN 0
analysis NN 0
of IN 0
the DT 0
ratio NN 0
of IN 0
the DT 0
concentrations NNS 0
of IN 0
carbon NN 0
monoxide NN 0
to TO 0
an DT 0
inert NN 0
gas NN 0
( ( 0
methane NN 0
) ) 0
relative NN 0
to TO 0
lung NN 0
volume NN 0
during IN 0
a DT 0
constant JJ 0
exhalation NN 0
. . 0

Since IN 0
this DT 0
new JJ 0
technique NN 0
is VBZ 0
based VBN 0
solely RB 0
upon JJ 0
exhalation NN 0
, , 0
anomalies NNS 0
associated VBN 0
with IN 0
inspiration NN 0
and CC 0
breath NN 0
holding VBG 0
do VBP 0
not RB 0
affect VB 0
results NNS 0
. . 0

Additionally RB 0
, , 0
because IN 0
prolonged JJ 0
breath NN 0
holding NN 0
is VBZ 0
not RB 0
required VBN 0
, , 0
measurements NNS 0
can MD 0
readily RB 0
be VB 0
made VBN 0
in IN 0
dyspnoeic JJ 4
patients NNS 0
. . 0

METHODS NNP 0
Exhalation NNP 0
TLCO NNP 0
( ( 0
TLCO NNP 0
, , 0
ex NN 0
) ) 0
was VBD 0
compared VBN 0
with IN 0
the DT 0
standard NN 0
( ( 0
Jones NNP 0
and CC 0
Meade NNP 0
) ) 0
10 CD 0
second JJ 0
breath NN 0
holding VBG 0
TLCO NNP 0
( ( 0
TLCO NNP 0
, , 0
bh NN 0
) ) 0
in IN 0
100 CD 3
consecutive JJ 0
patients NNS 0
. . 0

Patients NNS 0
did VBD 0
not RB 0
practise VB 0
the DT 0
exhalation NN 0
manoeuvre NN 0
prior RB 0
to TO 0
testing VBG 0
. . 0

RESULTS VB 0
The DT 0
comparative JJ 0
results NNS 0
were VBD 0
very RB 0
close RB 0
; : 0
mean JJ 0
difference NN 0
( ( 0
bias JJ 0
) ) 0
+/- JJ 0
standard JJ 0
deviation NN 0
( ( 0
precision NN 0
) ) 0
was VBD 0
0.05 CD 0
( ( 0
0.84 CD 0
) ) 0
mmol/min/kPa NN 0
. . 0

The DT 0
relation NN 0
was VBD 0
equally RB 0
strong JJ 0
in IN 0
patients NNS 0
with IN 0
severe JJ 4
pulmonary JJ 4
disease NN 4
; : 0
for IN 0
patients NNS 0
with IN 0
FEV1 NNP 0
< $ 0
1.51 CD 0
the DT 0
mean NN 0
difference NN 0
was VBD 0
0.21 CD 0
( ( 0
0.80 CD 0
) ) 0
mmol/min/kPa NN 0
. . 0

CONCLUSIONS NNP 0
Since IN 0
the DT 0
results NNS 0
were VBD 0
essentially RB 0
identical JJ 0
between IN 0
the DT 0
techniques NNS 0
, , 0
it PRP 0
seems VBZ 0
that IN 0
comparable JJ 0
pathophysiological JJ 0
factors NNS 0
affect VBP 0
TLCO NNP 0
during IN 0
breath NN 0
holding NN 0
and CC 0
constant JJ 0
exhalation NN 0
. . 0

Constant JJ 0
exhalation NN 0
may MD 0
therefore RB 0
be VB 0
a DT 0
useful JJ 0
alternative NN 0
to TO 0
the DT 0
breath NN 0
holding NN 0
technique NN 0
for IN 0
clinical JJ 0
measurement NN 0
of IN 0
TLCO NNP 0
. . 0

[ JJ 0
Effects NNS 0
of IN 0
auditory JJ 0
integrative JJ 0
training NN 0
on IN 0
autistic JJ 0
children NNS 0
] VBP 0
. . 0

OBJECTIVE NNP 0
To TO 0
explore VB 0
the DT 0
short-term JJ 0
treatment NN 0
effect NN 0
of IN 0
the DT 0
auditory JJ 0
integrative JJ 0
training NN 0
on IN 0
autistic JJ 0
children NNS 0
and CC 0
provide VB 0
them PRP 0
with IN 0
clinical JJ 0
support NN 0
for IN 0
rehabilitative JJ 0
treatment NN 0
. . 0

METHODS NNP 0
A NNP 0
total NN 0
of IN 0
81 CD 0
cases NNS 0
of IN 0
autistic JJ 0
children NNS 0
were VBD 0
selected VBN 0
through IN 0
the DT 0
standard NN 0
of IN 0
DSM-4 NNP 0
and CC 0
clinical JJ 0
case NN 0
study NN 0
was VBD 0
used VBN 0
. . 0

They PRP 0
were VBD 0
divided VBN 0
randomly RB 0
into IN 0
experimental JJ 0
group NN 0
and CC 0
control VB 0
one CD 0
, , 0
and CC 0
respectively RB 0
received VBD 0
auditory JJ 0
integrative JJ 0
training NN 0
and CC 0
no DT 0
training NN 0
based VBN 0
on IN 0
the DT 0
multiple JJ 0
therapies NNS 0
. . 0

The DT 0
patients NNS 0
were VBD 0
investigated VBN 0
using VBG 0
clinical JJ 0
manifestation NN 0
and CC 0
Autism NNP 0
Behavior NNP 0
Checklist NNP 0
( ( 0
ABC NNP 0
) ) 0
and CC 0
intelligence NN 0
quotient NN 0
( ( 0
IQ NNP 0
) ) 0
before IN 0
and CC 0
after IN 0
six CD 0
months NNS 0
of IN 0
treatment NN 0
. . 0

The DT 0
effect NN 0
was VBD 0
evaluated VBN 0
through IN 0
the DT 0
changes NNS 0
of IN 0
clinical JJ 0
manifestations NNS 0
and CC 0
scores NNS 0
of IN 0
ABC NNP 0
and CC 0
IQ NNP 0
. . 0

The DT 0
changes NNS 0
of IN 0
scores NNS 0
of IN 0
IQ NNP 0
were VBD 0
determined VBN 0
with IN 0
Gesell NNP 0
and CC 0
WPPSI NNP 0
or CC 0
WISC-R NNP 0
. . 0

RESULTS NNP 0
Compared VBD 0
with IN 0
40 CD 0
patients NNS 0
of IN 0
the DT 0
control NN 0
group NN 0
after IN 0
the DT 0
six CD 0
months NNS 0
of IN 0
the DT 0
auditory JJ 0
integrative JJ 0
training NN 0
, , 0
41 CD 0
of IN 0
the DT 0
experimental JJ 0
group NN 0
had VBD 0
greatly RB 0
improved VBN 0
in IN 0
many JJ 0
aspects NNS 0
, , 0
such JJ 0
as IN 0
the DT 0
disorders NNS 0
of IN 0
their PRP$ 0
language NN 0
, , 0
social JJ 0
interactions NNS 0
and CC 0
typical JJ 0
behavior NN 0
symptoms NNS 0
while IN 0
they PRP 0
had VBD 0
not RB 0
changed VBN 0
in IN 0
their PRP$ 0
abnormal JJ 0
behaviors NNS 0
. . 0

The DT 0
scores NNS 0
of IN 0
IQ NNP 0
or CC 0
DQ NNP 0
had VBD 0
increased VBN 0
and CC 0
scores NNS 0
of IN 0
ABC NNP 0
had VBD 0
dropped VBN 0
. . 0

The DT 0
differences NNS 0
between IN 0
the DT 0
two CD 0
groups NNS 0
were VBD 0
greatly RB 0
significant JJ 0
in IN 0
statistics NNS 0
( ( 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

The DT 0
decreasing VBG 0
level NN 0
of IN 0
both DT 0
ABC NNP 0
scores NNS 0
and CC 0
the DT 0
increasing VBG 0
level NN 0
of IN 0
the DT 0
IQ NNP 0
scores NNS 0
were VBD 0
negatively RB 0
correlated VBN 0
with IN 0
age NN 0
, , 0
and CC 0
the DT 0
decreasing VBG 0
level NN 0
of IN 0
ABC NNP 0
scores NNS 0
was VBD 0
in IN 0
line NN 0
regression NN 0
( ( 0
positive JJ 0
correlation NN 0
) ) 0
with IN 0
base NN 0
IQ NNP 0
. . 0

CONCLUSION NNP 0
The DT 0
treatment NN 0
of IN 0
auditory JJ 0
integrative JJ 0
training NN 0
( ( 0
AIT NNP 0
) ) 0
could MD 0
greatly RB 0
improve VB 0
on IN 0
language NN 0
disorders NNS 0
, , 0
the DT 0
difficulties NNS 0
of IN 0
social JJ 0
interactions NNS 0
, , 0
typical JJ 0
behavior NN 0
symptoms NNS 0
and CC 0
developmental JJ 0
levels NNS 0
, , 0
therefore IN 0
it PRP 0
is VBZ 0
positive JJ 0
to TO 0
the DT 0
autistic JJ 0
children NNS 0
in IN 0
its PRP$ 0
short-term JJ 0
treatment NN 0
effect NN 0
. . 0

Time-varying JJ 0
smoking NN 0
abstinence NN 0
predicts VBZ 0
lower JJR 0
depressive JJ 0
symptoms NNS 0
following VBG 0
smoking VBG 0
cessation NN 0
treatment NN 0
. . 0

INTRODUCTION NNP 0
The DT 0
question NN 0
of IN 0
whether IN 0
abstinence NN 0
during IN 0
the DT 0
months NNS 0
following VBG 0
a DT 0
planned VBN 0
quit NN 0
attempt NN 0
exacerbates VBZ 0
or CC 0
improves VBZ 0
depressive JJ 0
symptoms NNS 0
is VBZ 0
an DT 0
important JJ 0
clinical JJ 0
issue NN 0
. . 0

Extant NNP 0
research NN 0
has VBZ 0
primarily RB 0
modeled VBN 0
between-person JJ 0
covariation NN 0
between IN 0
postquit NN 0
abstinence NN 0
and CC 0
depressive JJ 0
symptom NN 0
trajectories NNS 0
. . 0

However RB 0
, , 0
this DT 0
approach NN 0
can MD 0
not RB 0
account VB 0
for IN 0
potential JJ 0
third JJ 0
variables NNS 0
between IN 0
participants NNS 0
that WDT 0
may MD 0
affect VB 0
both DT 0
smoking NN 0
and CC 0
depression NN 0
. . 0

Accordingly RB 0
, , 0
the DT 0
current JJ 0
study NN 0
examined VBD 0
within-person JJ 0
covariation NN 0
between IN 0
time-varying JJ 0
abstinence NN 0
and CC 0
depressive JJ 0
symptom NN 0
in IN 0
a DT 0
multilevel NN 0
model NN 0
( ( 0
MLM NNP 0
) ) 0
, , 0
which WDT 0
allowed VBD 0
for IN 0
transitions NNS 0
between IN 0
smoking VBG 0
statuses NNS 0
within IN 0
a DT 0
participant NN 0
. . 0

METHODS JJ 0
Participants NNS 0
were VBD 0
236 CD 0
heavy JJ 0
drinking NN 0
smokers NNS 0
in IN 0
a DT 0
randomized JJ 0
clinical JJ 0
trial NN 0
testing VBG 0
the DT 0
efficacy NN 0
of IN 0
incorporating VBG 0
brief JJ 0
alcohol NN 0
intervention NN 0
into IN 0
smoking VBG 0
cessation NN 0
treatment NN 0
. . 0

Depressive NNP 0
symptoms NNS 0
and CC 0
biochemically RB 0
verified JJ 0
abstinence NN 0
were VBD 0
assessed VBN 0
1 CD 0
week NN 0
prior RB 0
to TO 0
and CC 0
2 CD 0
, , 0
8 CD 0
, , 0
16 CD 0
, , 0
and CC 0
26 CD 0
weeks NNS 0
after IN 0
quit NN 0
date NN 0
. . 0

RESULTS NNP 0
MLMs NNP 0
indicated VBD 0
a DT 0
slight JJ 0
increase NN 0
in IN 0
depressive JJ 0
symptoms NNS 0
over IN 0
time NN 0
in IN 0
the DT 0
sample NN 0
as IN 0
a DT 0
whole NN 0
. . 0

However RB 0
, , 0
there EX 0
was VBD 0
an DT 0
inverse JJ 0
relation NN 0
between IN 0
time-varying JJ 0
abstinence NN 0
( ( 0
vs. IN 0
smoking NN 0
) ) 0
and CC 0
concurrent JJ 0
level NN 0
of IN 0
depressive JJ 0
symptoms NNS 0
, , 0
indicating VBG 0
that IN 0
transitions NNS 0
from IN 0
smoking VBG 0
to TO 0
abstinence VB 0
within IN 0
individuals NNS 0
were VBD 0
associated VBN 0
with IN 0
reductions NNS 0
in IN 0
depressive JJ 0
symptoms NNS 0
. . 0

CONCLUSIONS NNP 0
During IN 0
the DT 0
first JJ 0
6 CD 0
months NNS 0
following VBG 0
a DT 0
planned VBN 0
quit NN 0
attempt NN 0
, , 0
being VBG 0
abstinent NN 0
in IN 0
a DT 0
particular JJ 0
week NN 0
appears VBZ 0
to TO 0
be VB 0
associated VBN 0
with IN 0
lower JJR 0
levels NNS 0
of IN 0
concurrent NN 0
depressive NN 0
symptoms NNS 0
. . 0

These DT 0
results NNS 0
are VBP 0
not RB 0
concordant JJ 0
with IN 0
the DT 0
view NN 0
that IN 0
intentional JJ 0
smoking NN 0
abstinence NN 0
exacerbates VBZ 0
depressive JJ 0
symptoms NNS 0
. . 0

Efforts NNS 0
to TO 0
promote VB 0
smoking VBG 0
cessation NN 0
should MD 0
highlight VB 0
that IN 0
individuals NNS 0
are VBP 0
likely JJ 0
to TO 0
feel VB 0
more RBR 0
rather RB 0
than IN 0
less JJR 0
psychologically RB 0
healthy JJ 0
when WRB 0
they PRP 0
successfully RB 0
quit VBP 0
smoking NN 0
. . 0

Effect NN 0
of IN 0
treatment NN 0
with IN 0
paromomycin NN 0
on IN 0
endotoxemia NN 0
in IN 0
patients NNS 0
with IN 0
alcoholic JJ 0
liver NN 0
disease NN 0
-- : 0
a DT 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
trial NN 0
. . 0

The DT 0
results NNS 0
of IN 0
experimental JJ 0
and CC 0
clinical JJ 0
studies NNS 0
support VBP 0
the DT 0
hypothesis NN 0
that IN 0
gut-derived JJ 0
endotoxins NNS 0
might MD 0
be VB 0
of IN 0
relevance NN 0
for IN 0
the DT 0
development NN 0
and CC 0
course NN 0
of IN 0
alcoholic JJ 0
liver NN 0
disease NN 0
. . 0

The DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
test VB 0
the DT 0
effect NN 0
of IN 0
a DT 0
nonabsorbable JJ 0
, , 0
broad-spectrum JJ 0
antibiotic NN 0
on IN 0
endotoxemia NN 0
in IN 0
patients NNS 0
with IN 0
alcoholic JJ 0
liver NN 0
disease NN 0
. . 0

Fifty JJ 0
patients NNS 0
with IN 0
alcoholic JJ 0
liver NN 0
disease NN 0
( ( 0
27 CD 0
with IN 0
cirrhosis NN 0
, , 0
23 CD 0
without IN 0
cirrhosis NN 0
) ) 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
either DT 0
paromomycin NN 0
sulfate NN 0
( ( 0
3 CD 0
x RB 0
1 CD 0
g/day NN 0
) ) 0
or CC 0
placebo NN 0
in IN 0
a DT 0
double-blind JJ 0
fashion NN 0
for IN 0
at IN 0
least JJS 0
3 CD 0
weeks NNS 0
, , 0
and CC 0
if IN 0
possible JJ 0
4 CD 0
weeks NNS 0
. . 0

Endotoxin NNP 0
concentration NN 0
, , 0
liver JJ 0
function NN 0
tests NNS 0
, , 0
and CC 0
other JJ 0
laboratory NN 0
parameters NNS 0
were VBD 0
determined VBN 0
in IN 0
weekly JJ 0
intervals NNS 0
. . 0

Endotoxin NNP 0
concentration NN 0
was VBD 0
also RB 0
determined VBN 0
in IN 0
15 CD 0
healthy JJ 0
controls NNS 0
. . 0

Groups NNP 0
receiving VBG 0
paromomycin NN 0
or CC 0
placebo NN 0
were VBD 0
similar JJ 0
for IN 0
clinical JJ 0
and CC 0
biological JJ 0
items NNS 0
collected VBN 0
initially RB 0
. . 0

Mean JJ 0
initial JJ 0
endotoxin NN 0
concentrations NNS 0
were VBD 0
significantly RB 0
elevated VBN 0
in IN 0
both DT 0
groups NNS 0
( ( 0
mean JJ 0
+/- JJ 0
SEM NNP 0
; : 0
paromomycin NN 0
, , 0
16.7 CD 0
+/- JJ 0
5.3 CD 0
pg/ml NN 0
; : 0
placebo NN 0
, , 0
17.5 CD 0
+/- JJ 0
6.9 CD 0
pg/ml NN 0
; : 0
healthy JJ 0
controls NNS 0
, , 0
2.3 CD 0
+/- JJ 0
0.4 CD 0
pg/ml NN 0
) ) 0
. . 0

Although IN 0
the DT 0
mean JJ 0
endotoxin NN 0
concentration NN 0
was VBD 0
lower JJR 0
in IN 0
the DT 0
verum NN 0
group NN 0
after IN 0
1 CD 0
week NN 0
( ( 0
paromomycin NN 0
, , 0
8.0 CD 0
+/- JJ 0
1.9 CD 0
pg/ml NN 0
; : 0
placebo NN 0
, , 0
14.6 CD 0
+/- JJ 0
3.5 CD 0
pg/ml NN 0
; : 0
p CC 0
> VB 0
0.05 CD 0
) ) 0
, , 0
paromomycin JJ 0
treatment NN 0
had VBD 0
no DT 0
significant JJ 0
effect NN 0
on IN 0
endotoxin NN 0
concentration NN 0
or CC 0
liver JJ 0
function NN 0
tests NNS 0
during IN 0
the DT 0
4-week JJ 0
period NN 0
. . 0

The DT 0
beneficial JJ 0
effect NN 0
of IN 0
paromomycin NN 0
treatment NN 0
on IN 0
endotoxemia NN 0
in IN 0
cirrhotics NNS 0
reported VBN 0
in IN 0
earlier JJR 0
studies NNS 0
could MD 0
not RB 0
be VB 0
reproduced VBN 0
under IN 0
the DT 0
conditions NNS 0
of IN 0
this DT 0
trial NN 0
in IN 0
patients NNS 0
with IN 0
alcoholic JJ 0
liver NN 0
disease NN 0
. . 0

Economic JJ 0
evaluation NN 0
of IN 0
aquatic JJ 0
exercise NN 0
for IN 0
persons NNS 0
with IN 0
osteoarthritis NN 0
. . 0

OBJECTIVES NNP 0
To TO 0
estimate VB 0
cost NN 0
and CC 0
outcomes NNS 0
of IN 0
the DT 0
Arthritis NNP 0
Foundation NNP 0
aquatic JJ 0
exercise NN 0
classes NNS 0
from IN 0
the DT 0
societal JJ 0
perspective NN 0
. . 0

DESIGN NNP 0
Randomized NNP 0
trial NN 0
of IN 0
20-week JJ 0
aquatic JJ 0
classes NNS 0
. . 0

Cost NN 0
per IN 0
quality-adjusted JJ 0
life NN 0
year NN 0
( ( 0
QALY NNP 0
) ) 0
gained VBD 0
was VBD 0
estimated VBN 0
using VBG 0
trial NN 0
data NNS 0
. . 0

Sample NNP 0
size NN 0
was VBD 0
based VBN 0
on IN 0
80 CD 0
% NN 0
power NN 0
to TO 0
reject VB 0
the DT 0
null JJ 0
hypothesis NN 0
that IN 0
the DT 0
cost/QALY NN 0
gained VBD 0
would MD 0
not RB 0
exceed VB 0
$ $ 0
50,000 CD 0
. . 0

SUBJECTS NNP 0
AND NNP 0
METHODS NNP 0
Recruited VBD 0
249 CD 0
adults NNS 0
from IN 0
Washington NNP 0
State NNP 0
aged VBD 0
55 CD 0
to TO 0
75 CD 0
with IN 0
a DT 0
doctor-confirmed JJ 0
diagnosis NN 0
of IN 0
osteoarthritis NN 0
to TO 0
participate VB 0
in IN 0
aquatic JJ 0
classes NNS 0
. . 0

The DT 0
Quality NN 0
of IN 0
Well-Being NNP 0
Scale NNP 0
( ( 0
QWB NNP 0
) ) 0
and CC 0
Current NNP 0
Health NNP 0
Desirability NNP 0
Rating NNP 0
( ( 0
CHDR NNP 0
) ) 0
were VBD 0
used VBN 0
for IN 0
economic JJ 0
evaluation NN 0
, , 0
supplemented VBN 0
by IN 0
the DT 0
arthritis-specific JJ 0
Health NNP 0
Assessment NNP 0
Questionnaire NNP 0
( ( 0
HAQ NNP 0
) ) 0
, , 0
Center NNP 0
for IN 0
Epidemiologic NNP 0
Studies-Depression NNP 0
Scale NNP 0
( ( 0
CES-D NNP 0
) ) 0
, , 0
and CC 0
Perceived NNP 0
Quality NNP 0
of IN 0
Life NNP 0
Scale NNP 0
( ( 0
PQOL NNP 0
) ) 0
collected VBD 0
at IN 0
baseline NN 0
and CC 0
postclass NN 0
. . 0

Outcome NNP 0
results NNS 0
applied VBD 0
to TO 0
life NN 0
expectancy NN 0
tables NNS 0
were VBD 0
used VBN 0
to TO 0
estimate VB 0
QALYs NNP 0
. . 0

Use NNP 0
of IN 0
health NN 0
care NN 0
facilities NNS 0
was VBD 0
assessed VBN 0
from IN 0
diaries/questionnaires NNS 0
and CC 0
Medicare NNP 0
reimbursement NN 0
rates NNS 0
used VBD 0
to TO 0
estimate VB 0
costs NNS 0
. . 0

Nonparametric NNP 0
bootstrap NN 0
sampling NN 0
of IN 0
costs/QALY NN 0
ratios NNS 0
established VBD 0
the DT 0
95 CD 0
% NN 0
CI NNP 0
around IN 0
the DT 0
estimates NNS 0
. . 0

RESULTS NNP 0
Aquatic JJ 0
exercisers NNS 0
reported VBD 0
equal JJ 0
( ( 0
QWB NNP 0
) ) 0
or CC 0
better JJR 0
( ( 0
CHDR NNP 0
, , 0
HAQ NNP 0
, , 0
PQOL NNP 0
) ) 0
health-related JJ 0
quality NN 0
of IN 0
life NN 0
compared VBN 0
with IN 0
controls NNS 0
. . 0

Outcomes NNS 0
improved VBN 0
with IN 0
regular JJ 0
class NN 0
attendance NN 0
. . 0

Costs/QALY NNP 0
gained VBD 0
discounted VBN 0
at IN 0
3 CD 0
% NN 0
were VBD 0
$ $ 0
205,186 CD 0
using VBG 0
the DT 0
QWB NNP 0
and CC 0
$ $ 0
32,643 CD 0
using VBG 0
the DT 0
CHRD NNP 0
. . 0

CONCLUSION NNP 0
Aquatic NNP 0
exercise NN 0
exceeded VBD 0
$ $ 0
50,000 CD 0
per IN 0
QALY NN 0
gained VBN 0
using VBG 0
the DT 0
community-weighted JJ 0
outcome NN 0
but CC 0
fell VBD 0
below IN 0
this DT 0
arbitrary JJ 0
budget NN 0
constraint NN 0
when WRB 0
using VBG 0
the DT 0
participant-weighted JJ 0
measure NN 0
. . 0

Confidence NN 0
intervals NNS 0
around IN 0
these DT 0
ratios NNS 0
suggested VBD 0
wide JJ 0
variability NN 0
of IN 0
cost NN 0
effectiveness NN 0
of IN 0
aquatic JJ 0
exercise NN 0
. . 0

[ VB 0
The DT 0
effect NN 0
of IN 0
ionic JJ 0
and CC 0
nonionic JJ 0
x-ray JJ 0
contrast NN 0
media NNS 0
on IN 0
myocardial JJ 0
perfusion NN 0
and CC 0
myocardial JJ 0
function NN 0
] NN 0
. . 0

The DT 0
influence NN 0
of IN 0
injections NNS 0
of IN 0
Amidotrizoate NNP 0
and CC 0
Iopromide NNP 0
into IN 0
the DT 0
left JJ 0
coronary JJ 0
artery NN 0
on IN 0
global JJ 0
myocardial JJ 0
perfusion NN 0
and CC 0
function NN 0
( ( 0
pressures NNS 0
in IN 0
the DT 0
left JJ 0
ventricle NN 0
, , 0
heart NN 0
rate NN 0
) ) 0
as RB 0
well RB 0
as IN 0
excitation NN 0
formation NN 0
and CC 0
transmission NN 0
was VBD 0
studied VBN 0
in IN 0
16 CD 0
patients NNS 0
with IN 0
ischaemic JJ 0
heart NN 0
disease NN 0
. . 0

No DT 0
statistically RB 0
significant JJ 0
differences NNS 0
in IN 0
myocardial JJ 0
perfusion NN 0
measured VBN 0
were VBD 0
found VBN 0
with IN 0
xenon-133 JJ 0
in IN 0
this DT 0
small JJ 0
group NN 0
between IN 0
rest NN 0
and CC 0
dipyridamole JJ 0
load NN 0
for IN 0
ionic JJ 0
and CC 0
non-ionic JJ 0
contrast NN 0
media NNS 0
. . 0

[ NN 0
Improving VBG 0
wound IN 0
healing VBG 0
after IN 0
nose JJ 0
surgery NN 0
by IN 0
combined JJ 0
administration NN 0
of IN 0
xylometazoline NNP 0
and CC 0
dexpanthenol JJ 0
] NNP 0
. . 0

BACKGROUND NNP 0
The DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
the DT 0
examination NN 0
of IN 0
efficacy NN 0
and CC 0
tolerability NN 0
of IN 0
an DT 0
application-form NN 0
of IN 0
the DT 0
new JJ 0
combination NN 0
of IN 0
Xylometazoline NN 0
with IN 0
Dexpanthenol NNP 0
( ( 0
Nasic NNP 0
) ) 0
versus FW 0
Xylometazoline NNP 0
alone RB 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
Randomized NNP 0
verum NN 0
controlled VBD 0
parallel-group-comparison NN 0
of IN 0
two CD 0
weeks NNS 0
treatment NN 0
of IN 0
a DT 0
nasal-spray JJ 0
. . 0

61 CD 0
inpatients NNS 0
with IN 0
the DT 0
diagnosis NN 0
Rhinitis NNP 0
following VBG 0
nasal JJ 0
operation NN 0
were VBD 0
included VBN 0
in IN 0
this DT 0
study NN 0
and CC 0
30 CD 0
patients NNS 0
were VBD 0
treated VBN 0
with IN 0
verum NN 0
and CC 0
placebo NN 0
each DT 0
. . 0

The DT 0
assessment NN 0
of IN 0
nasal-breathing-resistance NN 0
according VBG 0
to TO 0
scores NNS 0
was VBD 0
defined VBN 0
as IN 0
target-parameter NN 0
. . 0

Confirmatory NNP 0
statistical JJ 0
analysis NN 0
was VBD 0
carried VBN 0
out RP 0
according VBG 0
to TO 0
Wilcoxon-Mann-Whitney-U JJ 0
two-sided JJ 0
at IN 0
alpha JJ 0
< NN 0
or CC 0
= $ 0
0.05 CD 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURE NNP 0
The DT 0
superiority NN 0
of IN 0
the DT 0
combination NN 0
of IN 0
Xylometazoline-Dexpanthenol JJ 0
nasal-spray JJ 0
versus NN 0
Xylometazoline NNP 0
nasal NN 0
spray NN 0
could MD 0
be VB 0
proven VBN 0
for IN 0
the DT 0
target-parameter NN 0
as IN 0
clinically RB 0
relevant JJ 0
and CC 0
statistically RB 0
significant JJ 0
. . 0

The DT 0
clinically RB 0
proven JJ 0
efficacy NN 0
is VBZ 0
emphasized VBN 0
by IN 0
good JJ 0
tolerability NN 0
of IN 0
both DT 0
treatments NNS 0
. . 0

Due NNP 0
to TO 0
easy VB 0
handling NN 0
of IN 0
the DT 0
nasal-spray JJ 0
a DT 0
good JJ 0
compliance NN 0
was VBD 0
confirmed VBN 0
. . 0

CONCLUSION NNP 0
Distinct NNP 0
improvement NN 0
of IN 0
symptoms NNS 0
in IN 0
patients NNS 0
following VBG 0
nasal JJ 0
operations NNS 0
underlines VBP 0
the DT 0
efficacy NN 0
of IN 0
both DT 0
medications NNS 0
. . 0

With IN 0
respect NN 0
to TO 0
the DT 0
tolerability NN 0
therapy NN 0
with IN 0
the DT 0
combination NN 0
is VBZ 0
more RBR 0
beneficial JJ 0
in IN 0
comparison NN 0
to TO 0
the DT 0
alternative JJ 0
therapy NN 0
. . 0

The DT 0
result NN 0
of IN 0
this DT 0
controlled VBN 0
clinical JJ 0
study NN 0
confirms VBZ 0
that IN 0
the DT 0
combination NN 0
Xylometazoline-Dexpanthenol NNP 0
is VBZ 0
an DT 0
enlargement NN 0
and CC 0
improvement NN 0
of IN 0
effective JJ 0
medicinal JJ 0
treatment NN 0
of IN 0
rhinitis NN 0
following VBG 0
nasal JJ 0
operation NN 0
in IN 0
comparison NN 0
to TO 0
therapy VB 0
with IN 0
Xylometazoline NNP 0
alone RB 0
. . 0

The DT 0
effects NNS 0
of IN 0
sevoflurane NN 0
and CC 0
isoflurane NN 0
on IN 0
recovery NN 0
from IN 0
outpatient JJ 0
surgery NN 0
. . 0

This DT 0
randomized JJ 0
, , 0
open-label JJ 0
study NN 0
compared VBN 0
the DT 0
investigational JJ 0
inhalational JJ 0
anesthetic JJ 0
sevoflurane NN 0
with IN 0
isoflurane NN 0
in IN 0
47 CD 0
healthy JJ 0
women NNS 0
undergoing VBG 0
elective JJ 0
ambulatory NN 0
surgery NN 0
. . 0

The DT 0
women NNS 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
either DT 0
sevoflurane NN 0
or CC 0
isoflurane NN 0
in IN 0
60 CD 0
% NN 0
nitrous JJ 0
oxide-oxygen NN 0
. . 0

Induction NN 0
with IN 0
thiopental JJ 0
3-6 JJ 0
mg/kg NN 0
was VBD 0
followed VBN 0
by IN 0
vecuronium NN 0
0.1 CD 0
mg/kg NN 0
and CC 0
fentanyl JJ 0
0-200 JJ 0
micrograms NNS 0
. . 0

Duration NN 0
of IN 0
anesthesia NN 0
, , 0
time NN 0
to TO 0
emergence VB 0
, , 0
orientation NN 0
, , 0
length NN 0
of IN 0
stay NN 0
in IN 0
the DT 0
surgical JJ 0
unit NN 0
, , 0
and CC 0
hospital JJ 0
discharge NN 0
were VBD 0
recorded VBN 0
. . 0

The DT 0
emergence NN 0
, , 0
length NN 0
of IN 0
stay NN 0
, , 0
and CC 0
discharge NN 0
times NNS 0
after IN 0
discontinuation NN 0
of IN 0
sevoflurane NN 0
were VBD 0
9.7 CD 0
+/- JJ 0
0.7 CD 0
, , 0
120.6 CD 0
+/- JJ 0
8.0 CD 0
, , 0
and CC 0
244 CD 0
+/- JJ 0
15 CD 0
minutes NNS 0
, , 0
respectively RB 0
, , 0
and CC 0
for IN 0
isoflurane NN 0
were VBD 0
11.9 CD 0
+/- JJ 0
1.4 CD 0
, , 0
106.8 CD 0
+/- JJ 0
7.1 CD 0
, , 0
and CC 0
282 CD 0
+/- JJ 0
24 CD 0
minutes NNS 0
, , 0
respectively RB 0
( ( 0
NS NNP 0
) ) 0
. . 0

The DT 0
isoflurane NN 0
group NN 0
had VBD 0
a DT 0
higher JJR 0
frequency NN 0
of IN 0
postoperative JJ 0
cough NN 0
. . 0

At IN 0
the DT 0
end NN 0
of IN 0
surgery NN 0
, , 0
the DT 0
sevoflurane NN 0
group NN 0
received VBD 0
a DT 0
deeper JJR 0
level NN 0
of IN 0
anesthesia NN 0
( ( 0
minimum JJ 0
alveolar JJ 0
concentration NN 0
1.5 CD 0
vs NN 0
1.3 CD 0
) ) 0
, , 0
however RB 0
, , 0
these DT 0
patients NNS 0
were VBD 0
oriented VBN 0
earlier RB 0
( ( 0
13.6 CD 0
+/- JJ 0
1.1 CD 0
min NN 0
vs NN 0
17.0 CD 0
+/- JJ 0
1.5 CD 0
min NN 0
isoflurane NN 0
; : 0
p CC 0
= VB 0
0.02 CD 0
) ) 0
after IN 0
discontinuation NN 0
of IN 0
anesthesia NN 0
, , 0
although IN 0
this DT 0
difference NN 0
is VBZ 0
of IN 0
little JJ 0
clinical JJ 0
significance NN 0
. . 0

Phase NNP 0
III NNP 0
study NN 0
of IN 0
two CD 0
different JJ 0
dosing VBG 0
schedules NNS 0
of IN 0
erythropoietin NN 0
in IN 0
anemic JJ 0
patients NNS 0
with IN 0
cancer NN 0
. . 0

PURPOSE NNP 0
To TO 0
compare VB 0
maintenance NN 0
epoetin NN 0
alfa NN 0
administered VBD 0
once RB 0
every DT 0
3 CD 0
weeks NNS 0
with IN 0
continued JJ 0
weekly JJ 0
epoetin NN 0
alfa NN 0
for IN 0
patients NNS 0
with IN 0
cancer-associated JJ 0
anemia NN 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
Eligible JJ 0
patients NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
at IN 0
enrollment NN 0
to TO 0
receive VB 0
three CD 0
weekly JJ 0
doses NNS 0
of IN 0
epoetin NN 0
alfa NN 0
40,000 CD 0
U NNP 0
subcutaneously RB 0
( ( 0
SC NNP 0
) ) 0
, , 0
followed VBN 0
by IN 0
either DT 0
standard JJ 0
weekly JJ 0
epoetin NN 0
alfa NN 0
( ( 0
40K CD 0
arm NN 0
) ) 0
or CC 0
120,000 CD 0
U NNP 0
of IN 0
epoetin NN 0
alfa NN 0
( ( 0
120K CD 0
arm NN 0
) ) 0
SC NNP 0
every DT 0
3 CD 0
weeks NNS 0
for IN 0
18 CD 0
additional JJ 0
weeks NNS 0
. . 0

RESULTS NNP 0
Three CD 0
hundred VBD 0
sixty-five JJ 0
patients NNS 0
were VBD 0
enrolled VBN 0
. . 0

One CD 0
hundred VBD 0
eighty-three JJ 0
patients NNS 0
were VBD 0
assigned VBN 0
to TO 0
the DT 0
40K CD 0
arm NN 0
, , 0
and CC 0
182 CD 0
were VBD 0
assigned VBN 0
to TO 0
the DT 0
120K CD 0
arm NN 0
. . 0

There EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
the DT 0
proportion NN 0
of IN 0
patients NNS 0
requiring VBG 0
transfusions NNS 0
during IN 0
the DT 0
study NN 0
( ( 0
23 CD 0
% NN 0
in IN 0
40K CD 0
arm NN 0
and CC 0
18 CD 0
% NN 0
in IN 0
120K CD 0
arm NN 0
, , 0
P NNP 0
= NNP 0
.22 NNP 0
) ) 0
or CC 0
specifically RB 0
during IN 0
the DT 0
maintenance NN 0
phase NN 0
( ( 0
13 CD 0
% NN 0
in IN 0
40K CD 0
arm NN 0
v NN 0
15 CD 0
% NN 0
in IN 0
120K CD 0
arm NN 0
, , 0
P NNP 0
= NNP 0
.58 NNP 0
) ) 0
. . 0

Patients NNS 0
randomly RB 0
assigned VBN 0
to TO 0
the DT 0
40K CD 0
arm NN 0
were VBD 0
more RBR 0
likely JJ 0
to TO 0
have VB 0
a DT 0
> NN 0
or CC 0
= VB 0
2 CD 0
or CC 0
> CD 0
or CC 0
= VB 0
3 CD 0
g/dL NN 0
hemoglobin NN 0
( ( 0
Hb NNP 0
) ) 0
increment NN 0
, , 0
were VBD 0
more RBR 0
likely JJ 0
to TO 0
have VB 0
a DT 0
drug NN 0
dose RB 0
held VBD 0
because IN 0
of IN 0
high JJ 0
Hb NNP 0
, , 0
and CC 0
had VBD 0
higher JJR 0
mean JJ 0
end-of-study JJ 0
Hb NNP 0
levels NNS 0
. . 0

Toxicities NNS 0
, , 0
including VBG 0
thromboembolism NN 0
, , 0
and CC 0
overall JJ 0
survival NN 0
were VBD 0
similar JJ 0
. . 0

Patients NNS 0
in IN 0
the DT 0
40K CD 0
arm NN 0
had VBD 0
a DT 0
higher JJR 0
global JJ 0
quality NN 0
of IN 0
life NN 0
( ( 0
QOL NNP 0
) ) 0
at IN 0
baseline NN 0
for IN 0
unclear JJ 0
reasons NNS 0
, , 0
whereas JJ 0
patients NNS 0
in IN 0
the DT 0
120K CD 0
arm NN 0
had VBD 0
a DT 0
greater JJR 0
global JJ 0
QOL NNP 0
improvement NN 0
during IN 0
the DT 0
study NN 0
, , 0
so IN 0
end-of-study JJ 0
QOL NNP 0
was VBD 0
equivalent JJ 0
. . 0

CONCLUSION NN 0
After IN 0
three CD 0
weekly JJ 0
doses NNS 0
of IN 0
epoetin NN 0
alfa NN 0
40,000 CD 0
U NNP 0
, , 0
a DT 0
dose NN 0
of IN 0
120,000 CD 0
U NNS 0
can MD 0
be VB 0
administered VBN 0
safely RB 0
once RB 0
every DT 0
3 CD 0
weeks NNS 0
without IN 0
increasing VBG 0
transfusion NN 0
needs NNS 0
or CC 0
sacrificing VBG 0
QOL NNP 0
. . 0

The DT 0
Hb NNP 0
increment NN 0
is VBZ 0
somewhat RB 0
greater JJR 0
with IN 0
continued JJ 0
weekly JJ 0
epoetin NN 0
alfa NN 0
. . 0

Lack NNP 0
of IN 0
blinding VBG 0
as IN 0
a DT 0
result NN 0
of IN 0
different JJ 0
treatment NN 0
schedules NNS 0
may MD 0
have VB 0
confounded VBN 0
results NNS 0
. . 0

Necessary NNP 0
but CC 0
not RB 0
sufficient JJ 0
: : 0
the DT 0
effect NN 0
of IN 0
screening NN 0
and CC 0
feedback NN 0
on IN 0
outcomes NNS 0
of IN 0
primary JJ 0
care NN 0
patients NNS 0
with IN 0
untreated JJ 0
anxiety NN 0
. . 0

OBJECTIVE UH 0
To TO 0
consider VB 0
the DT 0
impact NN 0
on IN 0
primary JJ 0
care NN 0
patient JJ 0
outcomes NNS 0
of IN 0
using VBG 0
both DT 0
a DT 0
screener NN 0
to TO 0
determine VB 0
elevated VBN 0
anxiety NN 0
levels NNS 0
among IN 0
patients NNS 0
with IN 0
previously RB 0
undetected VBN 0
anxiety NN 0
and CC 0
a DT 0
physician JJ 0
intervention NN 0
to TO 0
inform VB 0
physicians NNS 0
of IN 0
their PRP$ 0
patients NNS 0
' POS 0
conditions NNS 0
. . 0

DESIGN NNP 0
Participating VBG 0
physicians NNS 0
were VBD 0
randomized VBN 0
to TO 0
either CC 0
the DT 0
demonstration NN 0
or CC 0
the DT 0
control NN 0
arm NN 0
, , 0
and CC 0
patients NNS 0
were VBD 0
assigned VBN 0
to TO 0
a DT 0
study NN 0
arm NN 0
based VBN 0
on IN 0
the DT 0
randomization NN 0
of IN 0
their PRP$ 0
physicians NNS 0
. . 0

The DT 0
patients NNS 0
were VBD 0
followed VBN 0
for IN 0
change NN 0
in IN 0
outcome JJ 0
measures NNS 0
during IN 0
the DT 0
five-month JJ 0
study NN 0
period NN 0
. . 0

SETTING VB 0
A DT 0
mixed-model JJ 0
health NN 0
maintenance NN 0
organization NN 0
serving VBG 0
approximately RB 0
110,000 CD 0
enrollees NNS 0
in IN 0
central JJ 0
Colorado NNP 0
. . 0

PATIENTS/PARTICIPANTS NNP 0
573 CD 0
patients NNS 0
who WP 0
had VBD 0
unrecognized VBN 0
and CC 0
untreated JJ 0
anxiety NN 0
identified VBN 0
from IN 0
the DT 0
approximately RB 0
8,000 CD 0
patients NNS 0
who WP 0
completed VBD 0
the DT 0
waiting VBG 0
room NN 0
screening NN 0
questionnaire NN 0
. . 0

INTERVENTIONS VBZ 0
A DT 0
physician JJ 0
intervention NN 0
served VBD 0
the DT 0
dual JJ 0
function NN 0
of IN 0
1 CD 0
) ) 0
providing VBG 0
an DT 0
educational JJ 0
demonstration NN 0
of IN 0
anxiety NN 0
in IN 0
the DT 0
primary JJ 0
care NN 0
setting VBG 0
and CC 0
2 CD 0
) ) 0
providing VBG 0
a DT 0
reporting NN 0
system NN 0
for IN 0
summarizing VBG 0
the DT 0
anxiety NN 0
symptom NN 0
levels NNS 0
and CC 0
functioning VBG 0
status NN 0
of IN 0
the DT 0
patients NNS 0
enrolled VBN 0
in IN 0
the DT 0
study NN 0
. . 0

MEASUREMENTS NNP 0
AND CC 0
MAIN NNP 0
RESULTS NNP 0
Patient NNP 0
outcomes NNS 0
were VBD 0
measured VBN 0
as IN 0
changes NNS 0
in IN 0
global JJ 0
anxiety NN 0
scores NNS 0
, , 0
functioning VBG 0
and CC 0
well-being JJ 0
, , 0
and CC 0
patients NNS 0
' POS 0
reports NNS 0
of IN 0
global JJ 0
improvements NNS 0
. . 0

CONCLUSIONS VB 0
The DT 0
findings NNS 0
indicate VBP 0
that IN 0
this DT 0
method NN 0
of IN 0
reporting VBG 0
symptoms NNS 0
and CC 0
functioning VBG 0
status NN 0
to TO 0
primary VB 0
care NN 0
physicians NNS 0
did VBD 0
not RB 0
significantly RB 0
change VBP 0
patient JJ 0
outcomes NNS 0
. . 0

Improvement NN 0
in IN 0
outcomes NNS 0
appeared VBD 0
to TO 0
be VB 0
more RBR 0
closely RB 0
associated VBN 0
with IN 0
the DT 0
patient NN 0
's POS 0
severity NN 0
of IN 0
psychological JJ 0
distress NN 0
. . 0

Social NNP 0
skills NNS 0
improvement NN 0
in IN 0
children NNS 0
with IN 0
high-functioning JJ 0
autism NN 0
: : 0
a DT 0
pilot NN 0
randomized VBN 0
controlled VBN 0
trial NN 0
. . 0

High-functioning JJ 0
autism NN 0
( ( 0
HFA NNP 0
) ) 0
is VBZ 0
characterized VBN 0
by IN 0
persistent JJ 0
impairment NN 0
in IN 0
social JJ 0
interaction NN 0
despite IN 0
the DT 0
absence NN 0
of IN 0
mental JJ 0
retardation NN 0
. . 0

Although IN 0
an DT 0
increasing VBG 0
number NN 0
of IN 0
group-based JJ 0
programs NNS 0
for IN 0
the DT 0
improvement NN 0
of IN 0
social JJ 0
skills NNS 0
have VBP 0
been VBN 0
described VBN 0
, , 0
randomized VBN 0
controlled VBN 0
trials NNS 0
are VBP 0
needed VBN 0
to TO 0
evaluate VB 0
their PRP$ 0
efficacy NN 0
. . 0

To TO 0
compare VB 0
the DT 0
effect NN 0
of IN 0
a DT 0
Social NNP 0
Skills NNP 0
Training NNP 0
Group-based JJ 0
Program NNP 0
( ( 0
SST-GP NNP 0
) ) 0
and CC 0
a DT 0
Leisure NN 0
Activities VBZ 0
Group-based JJ 0
Program NNP 0
( ( 0
LA-GP NNP 0
) ) 0
on IN 0
the DT 0
perception NN 0
of IN 0
facial JJ 0
emotions NNS 0
and CC 0
quality NN 0
of IN 0
life NN 0
( ( 0
QoL NNP 0
) ) 0
in IN 0
young JJ 0
people NNS 0
with IN 0
HFA NNP 0
. . 0

Eligible JJ 0
patients NNS 0
were VBD 0
children NNS 0
and CC 0
adolescents NNS 0
with IN 0
HFA NNP 0
. . 0

Participants NNS 0
were VBD 0
randomized VBN 0
to TO 0
the DT 0
SST NNP 0
or CC 0
LA NNP 0
group NN 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
was VBD 0
defined VBN 0
as IN 0
an DT 0
improvement NN 0
of IN 0
2 CD 0
points NNS 0
in IN 0
error NN 0
rates NNS 0
for IN 0
facial JJ 0
emotion NN 0
labeling NN 0
( ( 0
DANVA2 NNP 0
) ) 0
from IN 0
baseline NN 0
. . 0

After IN 0
the DT 0
6-month JJ 0
training NN 0
period NN 0
, , 0
the DT 0
SST NNP 0
Group NNP 0
made VBD 0
fewer JJR 0
errors NNS 0
in IN 0
labeling VBG 0
anger NN 0
on IN 0
adult NN 0
faces VBZ 0
, , 0
whereas JJ 0
error NN 0
rates NNS 0
in IN 0
the DT 0
LA NNP 0
Group NNP 0
remained VBD 0
stable JJ 0
. . 0

Progress NN 0
in IN 0
the DT 0
ability NN 0
to TO 0
recognize VB 0
anger NN 0
in IN 0
the DT 0
SST NNP 0
Group NNP 0
was VBD 0
due JJ 0
to TO 0
better JJR 0
recognition NN 0
of IN 0
low JJ 0
intensity NN 0
stimuli NN 0
on IN 0
adult NN 0
faces VBZ 0
. . 0

QoL NNP 0
increased VBD 0
in IN 0
the DT 0
SST NNP 0
Group NNP 0
in IN 0
the DT 0
dimension NN 0
of IN 0
school NN 0
environment NN 0
, , 0
as IN 0
a DT 0
marker NN 0
of IN 0
the DT 0
transfer NN 0
of IN 0
skills NNS 0
acquired VBN 0
in IN 0
the DT 0
treatment NN 0
setting VBG 0
to TO 0
their PRP$ 0
use NN 0
in IN 0
the DT 0
community NN 0
. . 0

The DT 0
SST-GP NNP 0
had VBD 0
higher JJR 0
efficacy NN 0
than IN 0
the DT 0
LA-GP NNP 0
. . 0

Data NNP 0
justify NN 0
replication NN 0
using VBG 0
larger JJR 0
samples NNS 0
. . 0

A DT 0
physiotherapy NN 0
service NN 0
to TO 0
an DT 0
emergency NN 0
extended VBD 0
care NN 0
unit NN 0
does VBZ 0
not RB 0
decrease VB 0
admission NN 0
rates NNS 0
to TO 0
hospital VB 0
: : 0
a DT 0
randomised JJ 0
trial NN 0
. . 0

BACKGROUND NNP 0
One CD 0
of IN 0
the DT 0
reasons NNS 0
physiotherapy NN 0
services NNS 0
are VBP 0
provided VBN 0
to TO 0
emergency NN 0
departments NNS 0
( ( 0
EDs NNP 0
) ) 0
and CC 0
emergency NN 0
extended VBN 0
care NN 0
units NNS 0
( ( 0
EECUs NNP 0
) ) 0
is VBZ 0
to TO 0
review VB 0
patients NNS 0
' POS 0
mobility NN 0
to TO 0
ensure VB 0
they PRP 0
are VBP 0
safe JJ 0
to TO 0
be VB 0
discharged VBN 0
home NN 0
. . 0

AIM NNP 0
To TO 0
investigate VB 0
whether IN 0
a DT 0
physiotherapy NN 0
service NN 0
to TO 0
an DT 0
EECU NNP 0
altered VBD 0
the DT 0
rate NN 0
of IN 0
hospital NN 0
admission NN 0
, , 0
rate NN 0
of IN 0
re-presentation NN 0
to TO 0
the DT 0
ED NNP 0
, , 0
visits VBZ 0
to TO 0
community NN 0
healthcare NN 0
practitioners NNS 0
, , 0
return NN 0
to TO 0
usual JJ 0
work/home/leisure NN 0
activities NNS 0
and CC 0
patient JJ 0
satisfaction NN 0
. . 0

METHODS NNP 0
A DT 0
randomised JJ 0
trial NN 0
with IN 0
concealed JJ 0
allocation NN 0
, , 0
assessor NN 0
blinding NN 0
and CC 0
intention-to-treat JJ 0
analysis NN 0
was VBD 0
undertaken VBN 0
in IN 0
an DT 0
EECU NNP 0
. . 0

The DT 0
sample NN 0
comprised VBD 0
186 CD 0
patients NNS 0
( ( 0
mean JJ 0
age NN 0
70 CD 0
years NNS 0
, , 0
123 CD 0
( ( 0
66 CD 0
% NN 0
) ) 0
female NN 0
patients NNS 0
, , 0
130 CD 0
( ( 0
70 CD 0
% NN 0
) ) 0
trauma NN 0
) ) 0
who WP 0
were VBD 0
referred VBN 0
for IN 0
physiotherapy NN 0
assessment/intervention NN 0
. . 0

Referral JJ 0
occurred VBD 0
at IN 0
any DT 0
stage NN 0
of IN 0
the DT 0
patients NNS 0
' POS 0
EECU NNP 0
admission NN 0
. . 0

All DT 0
participants NNS 0
received VBD 0
medical/nursing VBG 0
care NN 0
as IN 0
required VBN 0
. . 0

The DT 0
physiotherapy NN 0
group NN 0
also RB 0
received VBD 0
physiotherapy JJ 0
assessment/intervention NN 0
. . 0

RESULTS VB 0
The DT 0
physiotherapy NN 0
group NN 0
had VBD 0
a DT 0
4 CD 0
% NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
-18 CD 0
% NN 0
to TO 0
9 CD 0
% NN 0
) ) 0
lower JJR 0
rate NN 0
of IN 0
admission NN 0
to TO 0
hospital NN 0
than IN 0
the DT 0
control NN 0
group NN 0
and CC 0
a DT 0
4 CD 0
% NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
-6 NNP 0
% NN 0
to TO 0
13 CD 0
% NN 0
) ) 0
higher JJR 0
rate NN 0
of IN 0
re-presentation NN 0
to TO 0
the DT 0
ED NNP 0
, , 0
which WDT 0
were VBD 0
statistically RB 0
non-significant JJ 0
( ( 0
p?0.45 NN 0
) ) 0
. . 0

Differences NNS 0
between IN 0
groups NNS 0
for IN 0
use NN 0
of IN 0
community NN 0
healthcare NN 0
resources NNS 0
, , 0
return NN 0
to TO 0
usual JJ 0
work/home/leisure NN 0
activities NNS 0
and CC 0
satisfaction NN 0
with IN 0
their PRP$ 0
EECU NNP 0
care NN 0
were VBD 0
small JJ 0
and CC 0
not RB 0
significant JJ 0
. . 0

CONCLUSION VB 0
A NNP 0
physiotherapy NN 0
service NN 0
for IN 0
EECU NNP 0
patients NNS 0
, , 0
as IN 0
provided VBN 0
in IN 0
this DT 0
study NN 0
, , 0
did VBD 0
not RB 0
reduce VB 0
the DT 0
rate NN 0
of IN 0
hospital NN 0
admission NN 0
, , 0
rate NN 0
of IN 0
re-presentation NN 0
to TO 0
the DT 0
ED NNP 0
, , 0
use NN 0
of IN 0
community NN 0
healthcare NN 0
resources NNS 0
, , 0
or CC 0
improve VB 0
the DT 0
rate NN 0
of IN 0
return NN 0
to TO 0
usual JJ 0
work/home/leisure NN 0
activities NNS 0
or CC 0
patient JJ 0
satisfaction NN 0
. . 0

Trial JJ 0
registration NN 0
number NN 0
ANZCTRN12609000106235 NNP 0
. . 0

A DT 0
randomised VBN 0
controlled VBN 0
trial NN 0
of IN 0
personalised JJ 0
decision NN 0
support NN 0
delivered VBD 0
via IN 0
the DT 0
internet NN 0
for IN 0
bowel NN 0
cancer NN 0
screening VBG 0
with IN 0
a DT 0
faecal JJ 0
occult NN 0
blood NN 0
test NN 0
: : 0
the DT 0
effects NNS 0
of IN 0
tailoring NN 0
of IN 0
messages NNS 0
according VBG 0
to TO 0
social JJ 0
cognitive JJ 0
variables NNS 0
on IN 0
participation NN 0
. . 0

BACKGROUND NNP 0
In IN 0
Australia NNP 0
, , 0
bowel NN 0
cancer NN 0
screening VBG 0
participation NN 0
using VBG 0
faecal JJ 0
occult NN 0
blood NN 0
testing NN 0
( ( 0
FOBT NNP 0
) ) 0
is VBZ 0
low JJ 0
. . 0

Decision NN 0
support NN 0
tailored VBD 0
to TO 0
psychological JJ 0
predictors NNS 0
of IN 0
participation NN 0
may MD 0
increase VB 0
screening VBG 0
. . 0

The DT 0
study NN 0
compared VBN 0
tailored VBD 0
computerised JJ 0
decision NN 0
support NN 0
to TO 0
non-tailored JJ 0
computer NN 0
or CC 0
paper NN 0
information NN 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
was VBD 0
FOBT NNP 0
return NN 0
within IN 0
12 CD 0
weeks NNS 0
. . 0

Additional JJ 0
analyses NNS 0
were VBD 0
conducted VBN 0
on IN 0
movement NN 0
in IN 0
decision NN 0
to TO 0
screen NN 0
and CC 0
change NN 0
on IN 0
psychological JJ 0
variables NNS 0
. . 0

METHODS NNP 0
A NNP 0
parallel NN 0
, , 0
randomised VBD 0
controlled VBN 0
, , 0
trial NN 0
invited VBD 0
25,511 CD 0
people NNS 0
aged VBN 0
50-74 JJ 0
years NNS 0
to TO 0
complete VB 0
an DT 0
eligibility NN 0
questionnaire NN 0
. . 0

Eligible JJ 0
respondents NNS 0
( ( 0
n JJ 0
= NNP 0
3,408 CD 0
) ) 0
were VBD 0
assigned VBN 0
to TO 0
Tailored NNP 0
Personalised VBD 0
Decision NNP 0
Support NNP 0
( ( 0
TPDS NNP 0
) ) 0
, , 0
Non-Tailored JJ 0
PDS NNP 0
( ( 0
NTPDS NNP 0
) ) 0
, , 0
or CC 0
Control NNP 0
( ( 0
CG NNP 0
) ) 0
( ( 0
intention-to-treat JJ 0
, , 0
ITT NNP 0
sample NN 0
) ) 0
. . 0

TPDS NNP 0
and CC 0
NTPDS NNP 0
groups NNS 0
completed VBD 0
an DT 0
on-line JJ 0
baseline NN 0
survey NN 0
( ( 0
BS NNP 0
) ) 0
and CC 0
accessed VBN 0
generic JJ 0
information NN 0
. . 0

The DT 0
TPDS NNP 0
group NN 0
additionally RB 0
received VBD 0
a DT 0
tailored VBN 0
intervention NN 0
. . 0

CG JJ 0
participants NNS 0
completed VBD 0
a DT 0
paper NN 0
BS NNP 0
only RB 0
. . 0

Those DT 0
completing VBG 0
the DT 0
BS NNP 0
( ( 0
n JJ 0
= NN 0
2270 CD 0
) ) 0
were VBD 0
mailed VBN 0
an DT 0
FOBT NNP 0
and CC 0
requested VBN 0
to TO 0
complete VB 0
an DT 0
endpoint NN 0
survey NN 0
( ( 0
ES NNP 0
) ) 0
that IN 0
re-measured JJ 0
BS NNP 0
variables NNS 0
( ( 0
per-protocol NN 0
, , 0
PP NNP 0
sample NN 0
) ) 0
. . 0

RESULTS NNP 0
FOBT NNP 0
return NN 0
: : 0
In IN 0
the DT 0
ITT NNP 0
sample NN 0
, , 0
there EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
between IN 0
any DT 0
group NN 0
( ( 0
? . 0
( ( 0
2 CD 0
) ) 0
( ( 0
2 CD 0
) ) 0
= NN 0
2.57 CD 0
, , 0
p NN 0
= NNP 0
.26 NNP 0
; : 0
TPDS NNP 0
, , 0
32.5 CD 0
% NN 0
; : 0
NTPDS NNP 0
, , 0
33 CD 0
% NN 0
; : 0
and CC 0
CG NNP 0
, , 0
34.5 CD 0
% NN 0
) ) 0
. . 0

In IN 0
the DT 0
PP NNP 0
sample NN 0
, , 0
FOBT NNP 0
return NN 0
in IN 0
the DT 0
internet NN 0
groups NNS 0
was VBD 0
significantly RB 0
higher JJR 0
than IN 0
the DT 0
paper NN 0
group NN 0
( ( 0
? . 0
( ( 0
2 CD 0
) ) 0
( ( 0
2 CD 0
) ) 0
= NN 0
17.01 CD 0
, , 0
p NN 0
< NNP 0
.001 NNP 0
; : 0
TPDS NNP 0
, , 0
80 CD 0
% NN 0
; : 0
NTPDS NNP 0
, , 0
83 CD 0
% NN 0
; : 0
and CC 0
CG NNP 0
, , 0
74 CD 0
% NN 0
) ) 0
. . 0

FOBT NNP 0
completion NN 0
by IN 0
TPDS NNP 0
and CC 0
NTPDS NNP 0
did VBD 0
not RB 0
differ VB 0
( ( 0
? . 0
( ( 0
2 CD 0
) ) 0
( ( 0
1 CD 0
) ) 0
= NN 0
2.23 CD 0
, , 0
p NN 0
= NNP 0
.13 NNP 0
) ) 0
. . 0

Age NNP 0
was VBD 0
positively RB 0
associated VBN 0
with IN 0
kit JJ 0
return NN 0
. . 0

Decision NN 0
to TO 0
screen NN 0
: : 0
2227/2270 CD 0
of IN 0
the DT 0
PP NNP 0
sample NN 0
provided VBD 0
complete JJ 0
BS NNP 0
data NN 0
. . 0

Participants NNS 0
not RB 0
wanting VBG 0
to TO 0
screen VB 0
at IN 0
baseline NN 0
( ( 0
1083/2227 CD 0
) ) 0
and CC 0
allocated VBN 0
to TO 0
TPDS NNP 0
and CC 0
NTPDS NNP 0
were VBD 0
significantly RB 0
more RBR 0
likely JJ 0
to TO 0
decide VB 0
to TO 0
screen VB 0
and CC 0
return VB 0
an DT 0
FOBT NNP 0
than IN 0
those DT 0
assigned VBN 0
to TO 0
the DT 0
CG NNP 0
. . 0

FOBT NNP 0
return NN 0
by IN 0
TPDS NNP 0
and CC 0
NTPDS NNP 0
did VBD 0
not RB 0
differ VB 0
from IN 0
one CD 0
another DT 0
( ( 0
OR NNP 0
= VBZ 0
1.16 CD 0
, , 0
p NN 0
= NNP 0
.42 NNP 0
) ) 0
. . 0

Change NN 0
on IN 0
psychosocial JJ 0
predictors NNS 0
: : 0
Analysis NN 0
of IN 0
change NN 0
indicated VBD 0
that IN 0
salience NN 0
and CC 0
coherence NN 0
of IN 0
screening VBG 0
and CC 0
self-efficacy NN 0
were VBD 0
improved VBN 0
and CC 0
faecal JJ 0
aversion NN 0
decreased VBN 0
by IN 0
tailored JJ 0
messaging NN 0
. . 0

CONCLUSIONS NNP 0
Online NNP 0
information NN 0
resources NNS 0
may MD 0
have VB 0
a DT 0
role NN 0
in IN 0
encouraging VBG 0
internet-enabled JJ 0
people NNS 0
who WP 0
are VBP 0
uncommitted VBN 0
to TO 0
screening VBG 0
to TO 0
change VB 0
their PRP$ 0
attitudes NNS 0
, , 0
perceptions NNS 0
and CC 0
behaviour NN 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
Australian NNP 0
New NNP 0
Zealand NNP 0
Clinical NNP 0
Trials NNP 0
Registry NNP 0
ACTRN12610000095066 NNP 0
. . 0

Long-term JJ 0
survival NN 0
in IN 0
a DT 0
phase NN 0
III NNP 0
, , 0
randomised VBD 0
study NN 0
of IN 0
topotecan JJ 0
versus NN 0
paclitaxel NN 0
in IN 0
advanced JJ 0
epithelial JJ 0
ovarian JJ 0
carcinoma NN 0
. . 0

BACKGROUND IN 0
We PRP 0
have VBP 0
continued VBN 0
to TO 0
monitor VB 0
the DT 0
survival NN 0
of IN 0
patients NNS 0
randomised VBN 0
in IN 0
a DT 0
previously RB 0
reported VBN 0
multicentre JJ 0
phase NN 0
III NNP 0
study NN 0
of IN 0
topotecan JJ 0
versus NN 0
paclitaxel NN 0
in IN 0
patients NNS 0
with IN 0
advanced JJ 0
epithelial JJ 0
ovarian JJ 0
cancer NN 0
who WP 0
had VBD 0
failed VBN 0
one CD 0
prior JJ 0
platinum-based JJ 0
regimen NNS 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
Patients NNPS 0
with IN 0
bidimensionally RB 0
measurable JJ 0
disease NN 0
were VBD 0
randomised VBN 0
to TO 0
topotecan VB 0
( ( 0
1.5 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
/day NN 0
for IN 0
5 CD 0
days NNS 0
) ) 0
or CC 0
paclitaxel NN 0
( ( 0
175 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
/day NN 0
as IN 0
a DT 0
3-h JJ 0
infusion NN 0
) ) 0
every DT 0
21 CD 0
days NNS 0
. . 0

Patients NNS 0
were VBD 0
eligible JJ 0
for IN 0
treatment NN 0
with IN 0
the DT 0
alternate NN 0
therapy NN 0
at IN 0
third JJ 0
line NN 0
. . 0

The DT 0
European JJ 0
Organisation NNP 0
for IN 0
Research NNP 0
and CC 0
Treatment NNP 0
of IN 0
Cancer NNP 0
Quality NNP 0
of IN 0
Life NNP 0
( ( 0
EORTC NNP 0
QOL NNP 0
) ) 0
-C30 VBP 0
questionnaire NN 0
was VBD 0
also RB 0
used VBN 0
to TO 0
measure VB 0
eight CD 0
symptoms NNS 0
at IN 0
baseline NN 0
and CC 0
during IN 0
each DT 0
course NN 0
( ( 0
pain NN 0
, , 0
anorexia NN 0
, , 0
diarrhoea NN 0
, , 0
fatigue NN 0
, , 0
nausea NN 0
and CC 0
vomiting NN 0
, , 0
dyspnea NN 0
, , 0
constipation NN 0
and CC 0
insomnia NN 0
) ) 0
. . 0

RESULTS VB 0
A DT 0
total NN 0
of IN 0
226 CD 0
patients NNS 0
were VBD 0
evaluable JJ 0
for IN 0
response NN 0
. . 0

Demographic JJ 0
characteristics NNS 0
were VBD 0
similar JJ 0
in IN 0
both DT 0
treatment NN 0
groups NNS 0
, , 0
as IN 0
were VBD 0
results NNS 0
of IN 0
the DT 0
EORTC NNP 0
QOL-30 NNP 0
questionnaire NN 0
. . 0

For IN 0
the DT 0
topotecan JJ 0
group NN 0
, , 0
median JJ 0
time NN 0
to TO 0
progression NN 0
was VBD 0
18.9 CD 0
weeks NNS 0
( ( 0
range NN 0
< RB 0
1 CD 0
to TO 0
92.6+ CD 0
weeks NNS 0
; : 0
25 CD 0
% NN 0
censored VBN 0
) ) 0
, , 0
and CC 0
, , 0
for IN 0
paclitaxel NN 0
, , 0
14.7 CD 0
weeks NNS 0
( ( 0
range NN 0
< RB 0
1 CD 0
to TO 0
137.3+ CD 0
weeks NNS 0
; : 0
12.3 CD 0
% NN 0
censored VBN 0
) ) 0
; : 0
P NNP 0
= VBD 0
0.076 CD 0
. . 0

At IN 0
4 CD 0
years NNS 0
post-randomisation NN 0
, , 0
median JJ 0
survival NN 0
in IN 0
the DT 0
topotecan JJ 0
group NN 0
was VBD 0
63.0 CD 0
weeks NNS 0
( ( 0
range NN 0
< RB 0
1 CD 0
to TO 0
238.4+ CD 0
weeks NNS 0
; : 0
20.5 CD 0
% NN 0
censored VBN 0
) ) 0
and CC 0
, , 0
for IN 0
paclitaxel NN 0
, , 0
53.0 CD 0
weeks NNS 0
( ( 0
range NN 0
< RB 0
1 CD 0
to TO 0
226.3+ CD 0
weeks NNS 0
; : 0
12.3 CD 0
% NN 0
censored VBN 0
) ) 0
; : 0
P NNP 0
= VBD 0
0.44 CD 0
. . 0

CONCLUSION NNP 0
Topotecan NNP 0
continues VBZ 0
to TO 0
demonstrate VB 0
comparable JJ 0
efficacy NN 0
and CC 0
survival NN 0
to TO 0
paclitaxel VB 0
with IN 0
manageable JJ 0
and CC 0
non-cumulative JJ 0
haematological JJ 0
toxicity NN 0
. . 0

Non-haematological JJ 0
toxicity NN 0
was VBD 0
generally RB 0
mild VBN 0
for IN 0
both DT 0
groups NNS 0
. . 0

The DT 0
long-term JJ 0
survival NN 0
rate NN 0
indicates VBZ 0
substantial JJ 0
therapeutic JJ 0
benefit NN 0
for IN 0
this DT 0
group NN 0
of IN 0
patients NNS 0
receiving VBG 0
topotecan JJ 0
at IN 0
relapse NN 0
of IN 0
ovarian JJ 0
cancer NN 0
. . 0

Experimental JJ 0
hyaline NN 0
membrane NN 0
disease NN 0
in IN 0
the DT 0
premature NN 0
monkey NN 0
: : 0
effects NNS 0
of IN 0
antenatal JJ 0
dexamethasone NN 0
. . 0

A DT 0
blind NN 0
, , 0
randomized VBN 0
trial NN 0
of IN 0
antenatal JJ 0
glucocorticoid NN 0
treatment NN 0
was VBD 0
conducted VBN 0
using VBG 0
the DT 0
premature NN 0
monkey NN 0
( ( 0
Macaca NNP 0
nemestrina RB 0
) ) 0
model NN 0
of IN 0
hyaline JJ 0
membrane NN 0
disease NN 0
( ( 0
HMD NNP 0
) ) 0
. . 0

Twelve NNP 0
dams VBZ 0
received VBN 0
dexamethasone NN 0
( ( 0
2 CD 0
mg/dose NN 0
) ) 0
72 CD 0
, , 0
48 CD 0
, , 0
and CC 0
24 CD 0
h NN 0
before IN 0
abdominal JJ 0
delivery NN 0
at IN 0
135 CD 0
+/- JJ 0
1 CD 0
days NNS 0
of IN 0
gestation NN 0
. . 0

Twelve VB 0
control NN 0
animals NNS 0
received VBD 0
saline JJ 0
. . 0

Infants NNS 0
of IN 0
dexamethasone-treated JJ 0
dams NNS 0
had VBD 0
significantly RB 0
lower JJR 0
incidence NN 0
and CC 0
severity NN 0
of IN 0
HMD NNP 0
than IN 0
did VBD 0
infants NNS 0
of IN 0
control NN 0
animals NNS 0
( ( 0
50 CD 0
versus RB 0
92 CD 0
% NN 0
, , 0
p NN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
. . 0

Improvement JJ 0
with IN 0
treatment NN 0
was VBD 0
markedly RB 0
greater JJR 0
for IN 0
males NNS 0
than IN 0
for IN 0
females NNS 0
. . 0

Differences NNS 0
in IN 0
volume-pressure JJ 0
behavior NN 0
of IN 0
the DT 0
excised JJ 0
lungs NNS 0
included VBD 0
greater JJR 0
distensibility NN 0
in IN 0
the DT 0
infants NNS 0
from IN 0
dexamethasone-treated JJ 0
dams NNS 0
( ( 0
20.6 CD 0
+/- JJ 0
7.1 CD 0
ml/g NN 0
dry JJ 0
lung NN 0
versus IN 0
14.7 CD 0
+/- JJ 0
6.1 CD 0
, , 0
p NN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
and CC 0
enhanced JJ 0
deflation NN 0
stability NN 0
with IN 0
treatment NN 0
. . 0

Accelerated JJ 0
production NN 0
of IN 0
surface NN 0
active JJ 0
material NN 0
( ( 0
SAM NNP 0
) ) 0
phospholipids NNS 0
in IN 0
infants NNS 0
from IN 0
dexamethasone-treated JJ 0
dams NNS 0
was VBD 0
indicated VBN 0
by IN 0
increases NNS 0
in IN 0
total JJ 0
lung NN 0
phospholipid NN 0
( ( 0
84.5 CD 0
+/- JJ 0
8.1 CD 0
mg/g NN 0
dry JJ 0
lung NN 0
versus IN 0
75.1 CD 0
+/- JJ 0
9.9 CD 0
, , 0
p NN 0
less JJR 0
than IN 0
0.025 CD 0
) ) 0
, , 0
alveolar JJ 0
lavage NN 0
fluid NN 0
phospholipid NN 0
( ( 0
5.65 CD 0
+/- JJ 0
3.33 CD 0
mg/g NN 0
dry JJ 0
lung NN 0
versus IN 0
3.01 CD 0
+/- JJ 0
1.84 CD 0
, , 0
p NN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
, , 0
and CC 0
alveolar JJ 0
lavage NN 0
fluid NN 0
disaturated VBN 0
phosphatidylcholine NN 0
( ( 0
DPC NNP 0
) ) 0
( ( 0
2.47 CD 0
+/- JJ 0
1.84 CD 0
mg/g NN 0
dry JJ 0
lung NN 0
versus IN 0
1.06 CD 0
+/- JJ 0
1.05 CD 0
, , 0
p NN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
. . 0

Incorporation NN 0
of IN 0
14C-palmitate JJ 0
into IN 0
lung NN 0
lipid NN 0
was VBD 0
not RB 0
influenced VBN 0
by IN 0
dexamethasone NN 0
, , 0
but CC 0
a DT 0
significantly RB 0
greater JJR 0
portion NN 0
of IN 0
the DT 0
label NN 0
appeared VBD 0
in IN 0
the DT 0
DPC NNP 0
fraction NN 0
with IN 0
treatment NN 0
. . 0

Antenatal NNP 0
dexamethasone NN 0
treatment NN 0
was VBD 0
successful JJ 0
in IN 0
reducing VBG 0
the DT 0
incidence NN 0
and CC 0
severity NN 0
of IN 0
experimental JJ 0
HMD NNP 0
in IN 0
this DT 0
animal JJ 0
model NN 0
; : 0
the DT 0
beneficial JJ 0
effects NNS 0
of IN 0
treatment NN 0
were VBD 0
associated VBN 0
with IN 0
accelerated JJ 0
maturation NN 0
of IN 0
fetal JJ 0
pulmonary JJ 0
functions NNS 0
, , 0
including VBG 0
, , 0
but CC 0
not RB 0
limited JJ 0
to TO 0
, , 0
synthetic JJ 0
metabolism NN 0
of IN 0
SAM NNP 0
phospholipid NN 0
. . 0

Training VBG 0
referential JJ 0
communicative JJ 0
skills NNS 0
to TO 0
individuals NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorder NN 0
: : 0
a DT 0
pilot NN 0
study NN 0
. . 0

The DT 0
present JJ 0
study NN 0
reports VBZ 0
the DT 0
effects NNS 0
of IN 0
referential JJ 0
communication NN 0
training NN 0
in IN 0
individuals NNS 0
formally RB 0
diagnosed VBN 0
with IN 0
autism NN 0
spectrum NN 0
disorder NN 0
( ( 0
ASD NNP 0
) ) 0
. . 0

Participants NNS 0
were VBD 0
20 CD 0
children NNS 0
with IN 0
ASD NNP 0
( ( 0
M NNP 0
age NN 0
= VBD 0
14.3 CD 0
yr. NN 0
, , 0
SD NNP 0
= NNP 0
4.2 CD 0
; : 0
6 CD 0
girls NNS 0
, , 0
14 CD 0
boys NNS 0
) ) 0
in IN 0
the DT 0
role NN 0
of IN 0
speakers NNS 0
and CC 0
20 CD 0
control NN 0
children NNS 0
, , 0
who WP 0
acted VBD 0
as IN 0
listeners NNS 0
. . 0

They PRP 0
were VBD 0
all DT 0
enrolled VBN 0
in IN 0
mainstream JJ 0
compulsory NN 0
education NN 0
. . 0

Inclusion/exclusion NNP 0
criteria NNS 0
were VBD 0
defined VBN 0
according VBG 0
to TO 0
the DT 0
clinical JJ 0
diagnosis NN 0
of IN 0
ASD NNP 0
, , 0
the DT 0
presence NN 0
or CC 0
absence NN 0
of IN 0
additional JJ 0
or CC 0
associated JJ 0
disability NN 0
, , 0
previous JJ 0
training NN 0
in IN 0
referential JJ 0
communication NN 0
, , 0
and CC 0
any DT 0
drug NN 0
treatment NN 0
. . 0

Speakers NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
one CD 0
of IN 0
two CD 0
groups NNS 0
( ( 0
trained JJ 0
vs NN 0
untrained VBD 0
) ) 0
. . 0

Linguistic JJ 0
age NN 0
, , 0
cognitive JJ 0
level NN 0
and CC 0
autistic JJ 0
symptoms NNS 0
were VBD 0
analyzed VBN 0
, , 0
respectively RB 0
, , 0
with IN 0
the DT 0
Peabody NNP 0
Picture NNP 0
Vocabulary NNP 0
Test NNP 0
( ( 0
PPVT NNP 0
) ) 0
, , 0
the DT 0
Wechsler NNP 0
Intelligence NNP 0
Scale NNP 0
( ( 0
WISC-R NNP 0
or CC 0
WAIS-III NNP 0
) ) 0
, , 0
and CC 0
the DT 0
Autistic NNP 0
Behavior NNP 0
Checklist NNP 0
( ( 0
ABC NNP 0
) ) 0
. . 0

Communicative JJ 0
abilities NNS 0
were VBD 0
analyzed VBN 0
through IN 0
two CD 0
indexes NNS 0
related VBN 0
to TO 0
message VB 0
complexity NN 0
and CC 0
self-regulation NN 0
. . 0

The DT 0
trained JJ 0
group NN 0
was VBD 0
trained VBN 0
in IN 0
referential JJ 0
communication NN 0
tasks NNS 0
( ( 0
task NN 0
analysis NN 0
, , 0
role NN 0
taking NN 0
, , 0
and CC 0
task JJ 0
evaluation NN 0
) ) 0
, , 0
while IN 0
the DT 0
untrained JJ 0
group NN 0
took VBD 0
part NN 0
in IN 0
a DT 0
communicative JJ 0
game NN 0
but CC 0
without IN 0
any DT 0
specific JJ 0
communicative JJ 0
training NN 0
. . 0

The DT 0
results NNS 0
showed VBD 0
that IN 0
the DT 0
complexity NN 0
of IN 0
emitted JJ 0
messages NNS 0
had VBD 0
improved VBN 0
statistically RB 0
significantly RB 0
in IN 0
the DT 0
trained JJ 0
group NN 0
as IN 0
an DT 0
effect NN 0
of IN 0
training NN 0
. . 0

Ecological JJ 0
referential JJ 0
communication NN 0
is VBZ 0
shown VBN 0
to TO 0
be VB 0
an DT 0
appropriate JJ 0
paradigm NN 0
for IN 0
studying VBG 0
the DT 0
communicative JJ 0
process NN 0
and CC 0
its PRP$ 0
products NNS 0
and CC 0
could MD 0
be VB 0
used VBN 0
to TO 0
develop VB 0
and CC 0
implement VB 0
a DT 0
training NN 0
program NN 0
focused VBN 0
on IN 0
those DT 0
skills NNS 0
in IN 0
which WDT 0
individuals NNS 0
with IN 0
ASD NNP 0
are VBP 0
most RBS 0
deficient JJ 0
. . 0

Effect NN 0
of IN 0
antipyretic JJ 0
drugs NNS 0
in IN 0
children NNS 0
with IN 0
malaria NN 0
. . 0

A DT 0
comparison NN 0
of IN 0
different JJ 0
antipyretics NNS 0
in IN 0
children NNS 0
with IN 0
malaria NN 0
showed VBD 0
a DT 0
small JJ 0
effect NN 0
of IN 0
naproxen NN 0
, , 0
but CC 0
not RB 0
of IN 0
metamizol NN 0
, , 0
on IN 0
the DT 0
reduction NN 0
of IN 0
fever NN 0
peaks NNS 0
. . 0

Antipyretic JJ 0
treatment NN 0
had VBD 0
no DT 0
effect NN 0
on IN 0
fever NN 0
clearance NN 0
and CC 0
therefore NN 0
should MD 0
be VB 0
used VBN 0
cautiously RB 0
in IN 0
the DT 0
treatment NN 0
of IN 0
malaria NN 0
. . 0

Additive JJ 0
IOP-reducing JJ 0
effect NN 0
of IN 0
latanoprost NN 0
in IN 0
patients NNS 0
insufficiently RB 0
controlled VBN 0
on IN 0
timolol NN 0
. . 0

PURPOSE NNP 0
To TO 0
evaluate VB 0
the DT 0
effect NN 0
on IN 0
intraocular JJ 0
pressure NN 0
( ( 0
IOP NNP 0
) ) 0
of IN 0
switching VBG 0
from IN 0
timolol NN 0
to TO 0
latanoprost VB 0
or CC 0
adding VBG 0
latanoprost NN 0
to TO 0
timolol VB 0
in IN 0
patients NNS 0
with IN 0
open JJ 0
angle NN 0
glaucoma NN 0
or CC 0
ocular JJ 0
hypertension NN 0
where WRB 0
IOP NNP 0
is VBZ 0
not RB 0
adequately RB 0
controlled VBN 0
with IN 0
timolol NN 0
. . 0

METHODS NNP 0
This DT 0
was VBD 0
a DT 0
6-week JJ 0
, , 0
double-masked JJ 0
, , 0
randomised VBD 0
multi-centre NN 0
study NN 0
. . 0

53 CD 0
patients NNS 0
with IN 0
primary JJ 0
open JJ 0
angle NN 0
glaucoma NN 0
, , 0
capsular JJ 0
glaucoma NN 0
, , 0
or CC 0
ocular JJ 0
hypertension NN 0
with IN 0
an DT 0
IOP NNP 0
of IN 0
at IN 0
least JJS 0
21 CD 0
mmHg NN 0
on IN 0
current JJ 0
therapy NN 0
were VBD 0
recruited VBN 0
. . 0

After IN 0
a DT 0
run-in JJ 0
period NN 0
of IN 0
at IN 0
least JJS 0
2 CD 0
weeks NNS 0
on IN 0
timolol NN 0
, , 0
5 CD 0
mg/ml NN 0
twice RB 0
daily RB 0
, , 0
patients NNS 0
were VBD 0
randomised VBN 0
to TO 0
one CD 0
of IN 0
three CD 0
groups NNS 0
. . 0

One CD 0
group NN 0
continued VBD 0
on IN 0
timolol NN 0
, , 0
one CD 0
switched VBN 0
from IN 0
timolol NN 0
to TO 0
latanoprost VB 0
, , 0
50 CD 0
microg/ml NN 0
once RB 0
daily JJ 0
, , 0
and CC 0
a DT 0
third JJ 0
group NN 0
received VBD 0
latanoprost RB 0
in IN 0
addition NN 0
to TO 0
timolol VB 0
. . 0

The DT 0
efficacy NN 0
was VBD 0
evaluated VBN 0
by IN 0
comparing VBG 0
IOP NNP 0
at IN 0
9 CD 0
AM NNP 0
at IN 0
baseline NN 0
and CC 0
after IN 0
6 CD 0
weeks NNS 0
of IN 0
treatment NN 0
. . 0

RESULTS NNP 0
IOP NNP 0
at IN 0
baseline NN 0
and CC 0
after IN 0
6 CD 0
weeks NNS 0
of IN 0
treatment NN 0
( ( 0
mean JJ 0
+/- NNP 0
SEM NNP 0
) ) 0
were VBD 0
24.2 CD 0
+/- JJ 0
0.9 CD 0
and CC 0
23.8 CD 0
+/- JJ 0
1.0 CD 0
mmHg NN 0
( ( 0
n JJ 0
= NNP 0
16 CD 0
) ) 0
for IN 0
patients NNS 0
continuing VBG 0
on IN 0
timolol NN 0
, , 0
26.3 CD 0
+/- JJ 0
1.2 CD 0
and CC 0
19.6 CD 0
+/- JJ 0
1.1 CD 0
mmHg NN 0
( ( 0
n JJ 0
= NNP 0
17 CD 0
) ) 0
for IN 0
patients NNS 0
switching VBG 0
to TO 0
latanoprost VB 0
, , 0
and CC 0
23.2 CD 0
+/- JJ 0
1.0 CD 0
and CC 0
17.5 CD 0
+/- JJ 0
0.8 CD 0
mmHg NN 0
( ( 0
n JJ 0
= NNP 0
17 CD 0
) ) 0
for IN 0
patients NNS 0
with IN 0
combined JJ 0
treatment NN 0
. . 0

Adding VBG 0
latanoprost NN 0
to TO 0
timolol VB 0
reduced VBN 0
IOP NNP 0
with IN 0
5.9 CD 0
+/- JJ 0
0.9 CD 0
mmHg NN 0
( ( 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
and CC 0
switching VBG 0
from IN 0
timolol NN 0
to TO 0
latanoprost VB 0
reduced VBN 0
IOP NNP 0
with IN 0
5.0 CD 0
+/- JJ 0
0.9 CD 0
mmHg NN 0
( ( 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
, , 0
which WDT 0
caused VBD 0
in IN 0
each DT 0
group NN 0
a DT 0
significant JJ 0
IOP NNP 0
reduction NN 0
of IN 0
about RB 0
25 CD 0
% NN 0
. . 0

CONCLUSIONS VB 0
The DT 0
effect NN 0
of IN 0
latanoprost NN 0
was VBD 0
additive JJ 0
to TO 0
that DT 0
of IN 0
timolol NN 0
, , 0
and CC 0
a DT 0
good JJ 0
effect NN 0
on IN 0
IOP NNP 0
reduction NN 0
was VBD 0
also RB 0
achieved VBN 0
by IN 0
switching VBG 0
from IN 0
timolol NN 0
to TO 0
latanoprost VB 0
, , 0
suggesting VBG 0
that IN 0
a DT 0
switch NN 0
in IN 0
many JJ 0
patients NNS 0
is VBZ 0
an DT 0
effective JJ 0
alternative NN 0
to TO 0
combination NN 0
treatment NN 0
. . 0

Chronic NNP 0
vasodilator NN 0
therapy NN 0
with IN 0
flosequinan NN 0
in IN 0
congestive JJ 0
heart NN 0
failure NN 0
. . 0

This DT 0
study NN 0
was VBD 0
conducted VBN 0
to TO 0
determine VB 0
the DT 0
long-term JJ 0
effect NN 0
of IN 0
flosequinan NN 0
, , 0
a DT 0
new JJ 0
orally RB 0
administered VBN 0
arterial JJ 0
and CC 0
venous JJ 0
dilator NN 0
, , 0
on IN 0
the DT 0
clinical JJ 0
course NN 0
of IN 0
patients NNS 0
with IN 0
moderate JJ 0
to TO 0
severe VB 0
congestive JJ 0
heart NN 0
failure NN 0
. . 0

Seventeen JJ 0
patients NNS 0
on IN 0
chronic JJ 0
digitalis NN 0
and CC 0
diuretic JJ 0
therapy NN 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
either DT 0
flosequinan NN 0
( ( 0
n JJ 0
= NNP 0
9 CD 0
) ) 0
or CC 0
placebo NN 0
( ( 0
n JJ 0
= NNP 0
8 CD 0
) ) 0
in IN 0
a DT 0
double-blind JJ 0
fashion NN 0
. . 0

Changes NNS 0
in IN 0
symptomatology NN 0
, , 0
exercise NN 0
performance NN 0
, , 0
and CC 0
left VBD 0
ventricular JJ 0
function NN 0
were VBD 0
assessed VBN 0
serially RB 0
during IN 0
the DT 0
two-month JJ 0
treatment NN 0
period NN 0
. . 0

During IN 0
the DT 0
course NN 0
of IN 0
therapy NN 0
, , 0
a DT 0
modest JJ 0
improvement NN 0
in IN 0
the DT 0
symptom NN 0
scores NNS 0
and CC 0
functional JJ 0
classification NN 0
of IN 0
the DT 0
flosequinan-treated JJ 0
patients NNS 0
was VBD 0
observed VBN 0
. . 0

Flosequinan NNP 0
evoked VBD 0
a DT 0
significant JJ 0
increase NN 0
in IN 0
maximal JJ 0
exercise NN 0
capacity NN 0
. . 0

While IN 0
long-term JJ 0
flosequinan JJ 0
administration NN 0
also RB 0
effected VBD 0
a DT 0
progressive JJ 0
increase NN 0
in IN 0
resting VBG 0
heart NN 0
rate NN 0
, , 0
it PRP 0
did VBD 0
not RB 0
consistently RB 0
improve VB 0
indices NNS 0
of IN 0
left JJ 0
ventricular JJ 0
systolic JJ 0
function NN 0
. . 0

The DT 0
addition NN 0
of IN 0
chronic JJ 0
vasodilator NN 0
therapy NN 0
with IN 0
flosequinan NN 0
to TO 0
standard VB 0
digitalis-diuretic JJ 0
regimens NNS 0
is VBZ 0
capable JJ 0
of IN 0
inducing VBG 0
clinical JJ 0
improvement NN 0
in IN 0
patients NNS 0
with IN 0
moderate JJ 0
to TO 0
severe VB 0
chronic JJ 0
heart NN 0
failure NN 0
. . 0

Trials NNS 0
involving VBG 0
larger JJR 0
patient JJ 0
populations NNS 0
will MD 0
be VB 0
necessary JJ 0
to TO 0
confirm VB 0
the DT 0
results NNS 0
of IN 0
this DT 0
preliminary JJ 0
study NN 0
and CC 0
to TO 0
determine VB 0
the DT 0
extent NN 0
of IN 0
clinical JJ 0
improvement NN 0
, , 0
subpopulations NNS 0
benefited VBD 0
, , 0
role NN 0
in IN 0
heart NN 0
failure NN 0
therapeutics NNS 0
, , 0
and CC 0
so RB 0
forth JJ 0
. . 0

Rapid JJ 0
tightening NN 0
of IN 0
blood NN 0
glucose NN 0
control NN 0
leads VBZ 0
to TO 0
transient VB 0
deterioration NN 0
of IN 0
retinopathy NN 0
in IN 0
insulin NN 0
dependent NN 0
diabetes VBZ 0
mellitus NNS 0
: : 0
the DT 0
Oslo NNP 0
study NN 0
. . 0

In IN 0
a DT 0
study NN 0
of IN 0
retinopathy NN 0
during IN 0
one CD 0
year NN 0
of IN 0
tight JJ 0
blood NN 0
glucose VB 0
control NN 0
45 CD 0
type NN 0
I PRP 0
( ( 0
insulin JJ 0
dependent NN 0
) ) 0
diabetics NNS 0
without IN 0
proliferative JJ 0
retinopathy NN 0
were VBD 0
randomised VBN 0
to TO 0
receive VB 0
either RB 0
continuous JJ 0
subcutaneous JJ 0
insulin NN 0
infusion NN 0
, , 0
multiple JJ 0
insulin NN 0
injections NNS 0
, , 0
or CC 0
conventional JJ 0
insulin NN 0
treatment NN 0
( ( 0
controls NNS 0
) ) 0
. . 0

Near IN 0
normoglycaemia NN 0
was VBD 0
achieved VBN 0
with IN 0
continuous JJ 0
infusion NN 0
and CC 0
multiple JJ 0
injections NNS 0
but CC 0
not RB 0
with IN 0
conventional JJ 0
treatment NN 0
. . 0

Blind NNP 0
evaluation NN 0
of IN 0
fluorescein JJ 0
angiograms NNS 0
performed VBD 0
three CD 0
monthly JJ 0
showed VBD 0
progression NN 0
of IN 0
retinopathy NN 0
in IN 0
the DT 0
control NN 0
group NN 0
, , 0
transient JJ 0
deterioration NN 0
in IN 0
the DT 0
continuous JJ 0
infusion NN 0
group NN 0
, , 0
and CC 0
no DT 0
change NN 0
in IN 0
the DT 0
multiple JJ 0
injection NN 0
group NN 0
. . 0

Half PDT 0
the DT 0
patients NNS 0
receiving VBG 0
continuous JJ 0
infusion NN 0
and CC 0
multiple JJ 0
injections NNS 0
developed VBD 0
retinal JJ 0
cotton NN 0
wool NN 0
spots NNS 0
after IN 0
three CD 0
to TO 0
six CD 0
months NNS 0
. . 0

These DT 0
changes NNS 0
regressed VBD 0
in IN 0
all DT 0
but CC 0
four CD 0
patients NNS 0
after IN 0
12 CD 0
months NNS 0
. . 0

Control NNP 0
patients NNS 0
did VBD 0
not RB 0
develop VB 0
cotton NN 0
wool NN 0
spots NNS 0
. . 0

Patients NNS 0
who WP 0
developed VBD 0
cotton NN 0
wool NN 0
spots NNS 0
are VBP 0
characterised VBN 0
by IN 0
a DT 0
larger JJR 0
decrement NN 0
in IN 0
glycosylated JJ 0
haemoglobin NN 0
and CC 0
blood NN 0
glucose NN 0
values NNS 0
, , 0
more RBR 0
frequent JJ 0
episodes NNS 0
of IN 0
hypoglycaemia NN 0
, , 0
a DT 0
longer JJR 0
duration NN 0
of IN 0
diabetes NNS 0
, , 0
and CC 0
more RBR 0
severe JJ 0
retinopathy NN 0
at IN 0
onset NN 0
. . 0

A DT 0
large JJ 0
and CC 0
rapid JJ 0
fall NN 0
in IN 0
blood NN 0
glucose JJ 0
concentration NN 0
may MD 0
promote VB 0
transient JJ 0
deterioration NN 0
of IN 0
diabetic JJ 0
retinopathy NN 0
. . 0

Salmeterol NNP 0
plus CC 0
fluticasone JJ 0
propionate NN 0
versus IN 0
fluticasone NN 0
propionate NN 0
plus CC 0
montelukast NN 0
: : 0
a DT 0
randomised JJ 0
controlled VBN 0
trial NN 0
investigating VBG 0
the DT 0
effects NNS 0
on IN 0
airway JJ 0
inflammation NN 0
in IN 0
asthma NN 0
. . 0

BACKGROUND NNP 0
Few NNP 0
studies NNS 0
have VBP 0
compared VBN 0
treatment NN 0
strategies NNS 0
in IN 0
patients NNS 0
with IN 0
asthma JJ 0
poorly RB 0
controlled VBN 0
on IN 0
low JJ 0
dose NN 0
inhaled JJ 0
corticosteroids NNS 0
, , 0
and CC 0
little JJ 0
is VBZ 0
known VBN 0
about IN 0
the DT 0
effects NNS 0
of IN 0
different JJ 0
treatments NNS 0
on IN 0
airway JJ 0
inflammation NN 0
. . 0

In IN 0
this DT 0
double-blind NN 0
, , 0
placebo-controlled JJ 0
, , 0
parallel JJ 0
group NN 0
study NN 0
, , 0
we PRP 0
compared VBN 0
the DT 0
effects NNS 0
of IN 0
salmeterol NN 0
plus CC 0
fluticasone NN 0
propionate NN 0
( ( 0
FP NNP 0
) ) 0
( ( 0
Seretide NNP 0
; : 0
SFC NNP 0
) ) 0
and CC 0
FP NNP 0
plus CC 0
montelukast NN 0
( ( 0
FP/M NNP 0
) ) 0
on IN 0
sputum NN 0
inflammatory NN 0
markers NNS 0
, , 0
airway RB 0
responsiveness NN 0
, , 0
lung NN 0
function NN 0
, , 0
and CC 0
symptoms NNS 0
in IN 0
adult NN 0
asthmatics NNS 0
. . 0

METHODS NNP 0
Sixty-six JJ 0
subjects NNS 0
were VBD 0
randomised VBN 0
to TO 0
SFC NNP 0
or CC 0
FP/M NNP 0
for IN 0
12 CD 0
weeks NNS 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
was VBD 0
changes NNS 0
in IN 0
neutrophil NN 0
, , 0
eosinophil NN 0
, , 0
macrophage NN 0
, , 0
lymphocyte NN 0
, , 0
and CC 0
epithelial JJ 0
cell NN 0
levels NNS 0
in IN 0
induced JJ 0
sputum NN 0
. . 0

Additional NNP 0
outcomes NNS 0
included VBD 0
the DT 0
change NN 0
in IN 0
other JJ 0
sputum JJ 0
markers NNS 0
of IN 0
airway JJ 0
inflammation NN 0
, , 0
airway RB 0
responsiveness NN 0
, , 0
symptom NN 0
control NN 0
, , 0
and CC 0
lung NN 0
function NN 0
. . 0

RESULTS NNP 0
Both NNP 0
treatments NNS 0
had VBD 0
no DT 0
significant JJ 0
effect NN 0
on IN 0
induced JJ 0
sputum NN 0
inflammatory NN 0
cells NNS 0
, , 0
although IN 0
there EX 0
was VBD 0
a DT 0
trend NN 0
for IN 0
a DT 0
reduction NN 0
in IN 0
sputum NN 0
eosinophils NNS 0
. . 0

Both DT 0
treatments NNS 0
significantly RB 0
improved VBN 0
airway RB 0
responsiveness NN 0
, , 0
whereas WP 0
SFC NNP 0
generally RB 0
led VBD 0
to TO 0
greater JJR 0
improvements NNS 0
in IN 0
symptom JJ 0
control NN 0
and CC 0
lung NN 0
function NN 0
than IN 0
FP/M NNP 0
. . 0

FP/M NNP 0
led VBD 0
to TO 0
significantly RB 0
greater JJR 0
reductions NNS 0
in IN 0
sputum NN 0
cysteinyl NN 0
leukotrienes NNS 0
than IN 0
SFC NNP 0
( ( 0
treatment NN 0
ratio NN 0
1.80 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
1.09 CD 0
, , 0
2.94 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
Both DT 0
treatments NNS 0
led VBD 0
to TO 0
similar JJ 0
control NN 0
of IN 0
eosinophilic JJ 0
airway NN 0
inflammation NN 0
, , 0
although IN 0
PEF NNP 0
and CC 0
symptom VB 0
control NN 0
were VBD 0
better JJR 0
with IN 0
SFC NNP 0
. . 0

STUDY NNP 0
NUMBER NNP 0
: : 0
SAM40030 NNP 0
( ( 0
SOLTA NNP 0
) ) 0
. . 0

Is VBZ 0
a DT 0
2-week JJ 0
duration NN 0
sufficient NN 0
for IN 0
stenting VBG 0
in IN 0
endopyelotomy NN 0
? . 0
PURPOSE NNP 0
Internal NNP 0
stenting NN 0
is VBZ 0
an DT 0
integral JJ 0
part NN 0
of IN 0
endopyelotomy NN 0
. . 0

Studies NNS 0
in IN 0
animals NNS 0
show VBP 0
good JJ 0
healing NN 0
after IN 0
1 CD 0
to TO 0
2 CD 0
weeks NNS 0
of IN 0
ureterotomy JJ 0
. . 0

Inherent JJ 0
stent NN 0
related VBN 0
problems NNS 0
warrant VBP 0
a DT 0
minimum JJ 0
possible JJ 0
duration NN 0
of IN 0
stenting VBG 0
without IN 0
compromising VBG 0
the DT 0
results NNS 0
of IN 0
endopyelotomy JJ 0
. . 0

We PRP 0
performed VBD 0
a DT 0
prospective JJ 0
randomized VBN 0
trial NN 0
to TO 0
evaluate VB 0
the DT 0
optimum JJ 0
duration NN 0
of IN 0
stenting VBG 0
after IN 0
endopyelotomy NN 0
. . 0

MATERIALS NNP 0
AND NNP 0
METHODS NNP 0
A NNP 0
total NN 0
of IN 0
57 CD 0
consecutive JJ 0
patients NNS 0
with IN 0
primary JJ 0
ureteropelvic JJ 0
junction NN 0
obstruction NN 0
were VBD 0
randomized VBN 0
to TO 0
undergo VB 0
7/14Fr CD 0
internal JJ 0
endopyelotomy NN 0
stent JJ 0
placement NN 0
for IN 0
2 CD 0
( ( 0
group NN 0
1 CD 0
) ) 0
and CC 0
4 CD 0
( ( 0
group NN 0
2 CD 0
) ) 0
weeks NNS 0
. . 0

A DT 0
symptom NN 0
based VBN 0
questionnaire NN 0
was VBD 0
administered VBN 0
to TO 0
all DT 0
patients NNS 0
at IN 0
stent JJ 0
removal NN 0
. . 0

Followup NNP 0
was VBD 0
done VBN 0
with IN 0
diuretic JJ 0
scanning NN 0
at IN 0
3 CD 0
, , 0
6 CD 0
, , 0
9 CD 0
and CC 0
12 CD 0
months NNS 0
and CC 0
then RB 0
yearly RB 0
, , 0
and CC 0
thereafter RB 0
with IN 0
diuretic JJ 0
renography NN 0
. . 0

RESULTS NNP 0
In IN 0
each DT 0
group NN 0
26 CD 0
patients NNS 0
were VBD 0
available JJ 0
for IN 0
evaluation NN 0
. . 0

The DT 0
2 CD 0
groups NNS 0
were VBD 0
comparable JJ 0
in IN 0
terms NNS 0
of IN 0
age NN 0
, , 0
sex NN 0
, , 0
symptoms NNS 0
and CC 0
ipsilateral JJ 0
glomerular JJ 0
filtration NN 0
rate NN 0
. . 0

Mean NNP 0
followup NN 0
was VBD 0
22.3 CD 0
( ( 0
range NN 0
12 CD 0
to TO 0
36 CD 0
) ) 0
and CC 0
21.3 CD 0
months NNS 0
( ( 0
range VB 0
12 CD 0
to TO 0
35 CD 0
) ) 0
in IN 0
groups NNS 0
1 CD 0
and CC 0
2 CD 0
, , 0
respectively RB 0
. . 0

At IN 0
the DT 0
end NN 0
of IN 0
1 CD 0
year NN 0
24 CD 0
group NN 0
1 CD 0
( ( 0
92.3 CD 0
% NN 0
) ) 0
and CC 0
23 CD 0
group NN 0
2 CD 0
( ( 0
90.3 CD 0
% NN 0
) ) 0
patients NNS 0
had VBD 0
an DT 0
improved JJ 0
drainage NN 0
pattern NN 0
. . 0

This DT 0
difference NN 0
was VBD 0
not RB 0
significant JJ 0
. . 0

Stent NNP 0
related JJ 0
symptoms NNS 0
were VBD 0
present JJ 0
in IN 0
a DT 0
good JJ 0
proportion NN 0
of IN 0
patients NNS 0
in IN 0
groups NNS 0
1 CD 0
and CC 0
2 CD 0
but CC 0
there EX 0
was VBD 0
a DT 0
significant JJ 0
difference NN 0
in IN 0
the DT 0
incidence NN 0
of IN 0
urinary JJ 0
tract NN 0
infections NNS 0
( ( 0
11.5 CD 0
% NN 0
versus IN 0
38.1 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.04 CD 0
) ) 0
. . 0

Of IN 0
the DT 0
group NN 0
2 CD 0
patients NNS 0
64 CD 0
% NN 0
preferred JJ 0
2 CD 0
weeks NNS 0
of IN 0
stenting VBG 0
. . 0

CONCLUSIONS NNP 0
Two CD 0
weeks NNS 0
seems VBZ 0
to TO 0
be VB 0
a DT 0
sufficient JJ 0
duration NN 0
to TO 0
allow VB 0
functional JJ 0
restoration NN 0
across IN 0
the DT 0
ureteropelvic JJ 0
junction NN 0
after IN 0
endopyelotomy NN 0
and CC 0
decrease NN 0
stent NN 0
related JJ 0
complications NNS 0
. . 0

Comparison NNP 0
of IN 0
budesonide JJ 0
Turbuhaler NNP 0
with IN 0
budesonide JJ 0
aqua NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
seasonal JJ 0
allergic JJ 0
rhinitis NN 0
. . 0

Rhinocort NNP 0
Study NNP 0
Group NNP 0
. . 0

OBJECTIVE NNP 0
To TO 0
compare VB 0
the DT 0
effect NN 0
of IN 0
budesonide NN 0
Turbuhaler NNP 0
400 CD 0
microg/day NN 0
with IN 0
budesonide JJ 0
aqua NN 0
256 CD 0
microg/day NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
seasonal JJ 0
allergic JJ 0
rhinitis NN 0
( ( 0
SAR NNP 0
) ) 0
. . 0

Secondarily RB 0
to TO 0
ascertain VB 0
patients NNS 0
' POS 0
preferences NNS 0
for IN 0
the DT 0
two CD 0
nasal JJ 0
devices NNS 0
and CC 0
to TO 0
assess VB 0
quality NN 0
of IN 0
life NN 0
. . 0

DESIGN NNP 0
Randomized NNP 0
, , 0
multicentre NN 0
, , 0
double-blind JJ 0
, , 0
double- JJ 0
dummy NN 0
, , 0
parallel JJ 0
groups NNS 0
study NN 0
. . 0

SETTING NNP 0
Private NNP 0
practices NNS 0
and CC 0
hospital NN 0
clinics NNS 0
in IN 0
Ontario NNP 0
, , 0
Quebec NNP 0
and CC 0
Manitoba NNP 0
. . 0

POPULATION NNP 0
Two CD 0
hundred VBD 0
and CC 0
eighty-four JJ 0
out-patients NNS 0
with IN 0
SAR NNP 0
, , 0
who WP 0
were VBD 0
symptomatic JJ 0
during IN 0
the DT 0
ragweed NN 0
season NN 0
, , 0
volunteered VBD 0
for IN 0
enrolment NN 0
( ( 0
243 CD 0
randomized VBN 0
) ) 0
. . 0

RESULTS JJ 0
Mean JJ 0
daily JJ 0
nasal NN 0
symptom NN 0
scores NNS 0
were VBD 0
significantly RB 0
reduced VBN 0
with IN 0
treatment NN 0
. . 0

There EX 0
were VBD 0
no DT 0
statistically RB 0
significant JJ 0
changes NNS 0
from IN 0
baseline NN 0
for IN 0
eye NN 0
symptoms NNS 0
. . 0

Most JJS 0
patients NNS 0
( ( 0
more JJR 0
than IN 0
80 CD 0
% NN 0
) ) 0
achieved VBN 0
substantial JJ 0
control NN 0
of IN 0
their PRP$ 0
symptoms NNS 0
with IN 0
budesonide NN 0
. . 0

The DT 0
most RBS 0
common JJ 0
nasal NN 0
and CC 0
non-nasal JJ 0
adverse JJ 0
events NNS 0
for IN 0
both DT 0
groups NNS 0
were VBD 0
epistaxis JJ 0
and CC 0
headache NN 0
. . 0

Turbuhaler NNP 0
was VBD 0
easier JJR 0
to TO 0
use VB 0
and CC 0
more RBR 0
convenient JJ 0
to TO 0
carry VB 0
, , 0
had VBD 0
less JJR 0
of IN 0
an DT 0
unpleasant JJ 0
taste NN 0
, , 0
and CC 0
caused VBD 0
less JJR 0
nasal JJ 0
irritation NN 0
than IN 0
the DT 0
aqua JJ 0
spray NN 0
. . 0

More JJR 0
than IN 0
twice RB 0
as IN 0
many JJ 0
patients NNS 0
preferred JJ 0
Turbuhaler NNP 0
to TO 0
the DT 0
aqua NN 0
spray NN 0
( ( 0
69 CD 0
% NN 0
versus IN 0
31 CD 0
% NN 0
) ) 0
. . 0

Improvement NN 0
in IN 0
quality NN 0
of IN 0
life NN 0
from IN 0
baseline NN 0
to TO 0
clinic VB 0
visits NNS 0
was VBD 0
statistically RB 0
significant JJ 0
in IN 0
both DT 0
groups NNS 0
. . 0

CONCLUSION NNP 0
Once RB 0
daily JJ 0
use NN 0
of IN 0
256 CD 0
mg NN 0
of IN 0
budesonide NN 0
aqua NN 0
and CC 0
400 CD 0
mg NN 0
of IN 0
budesonide NN 0
Turbuhaler NNP 0
are VBP 0
equally RB 0
safe JJ 0
and CC 0
efficacious JJ 0
in IN 0
the DT 0
treatment NN 0
of IN 0
SAR NNP 0
. . 0

Patients NNS 0
preferred VBD 0
the DT 0
budesonide NN 0
powder NN 0
formulation NN 0
delivered VBD 0
via IN 0
Turbuhaler NNP 0
two CD 0
to TO 0
one CD 0
over IN 0
the DT 0
aqua JJ 0
formulation NN 0
. . 0

A DT 0
comparison NN 0
of IN 0
continuous JJ 0
femoral JJ 0
nerve NN 0
block NN 0
( ( 0
CFNB NNP 0
) ) 0
and CC 0
continuous JJ 0
epidural JJ 0
infusion NN 0
( ( 0
CEI NNP 0
) ) 0
in IN 0
postoperative JJ 0
analgesia NN 0
and CC 0
knee NN 0
rehabilitation NN 0
after IN 0
total JJ 0
knee NN 0
arthroplasty NN 0
( ( 0
TKA NNP 0
) ) 0
. . 0

BACKGROUND NNP 0
Postoperative NNP 0
epidural JJ 0
analgesia NN 0
( ( 0
EA NNP 0
) ) 0
and CC 0
femoral JJ 0
nerve NN 0
block NN 0
( ( 0
FNB NNP 0
) ) 0
provided VBD 0
effective JJ 0
pain NN 0
relief NN 0
However RB 0
, , 0
EA NNP 0
has VBZ 0
common JJ 0
side NN 0
effects NNS 0
such JJ 0
as IN 0
nausea NN 0
, , 0
vomiting VBG 0
, , 0
pruritus NN 0
, , 0
dizziness NN 0
, , 0
and CC 0
hypotension NN 0
. . 0

Some DT 0
investigations NNS 0
found VBD 0
that IN 0
those DT 0
side JJ 0
effects NNS 0
were VBD 0
less RBR 0
in IN 0
FNB NNP 0
than IN 0
in IN 0
EA NNP 0
. . 0

However RB 0
the DT 0
analgesic JJ 0
equivalent NN 0
of IN 0
both DT 0
techniques NNS 0
have VBP 0
not RB 0
been VBN 0
confirmed VBN 0
. . 0

OBJECTIVE IN 0
The DT 0
authors NNS 0
compared VBN 0
continuous JJ 0
epidural JJ 0
infusion NN 0
( ( 0
CEI NNP 0
) ) 0
with IN 0
continuous JJ 0
femoral JJ 0
nerve NN 0
block NN 0
( ( 0
CFNB NNP 0
) ) 0
regarding VBG 0
the DT 0
postoperative JJ 0
analgesic JJ 0
efficacy NN 0
, , 0
side NN 0
effects NNS 0
, , 0
postoperative JJ 0
knee NN 0
rehabilitation NN 0
, , 0
and CC 0
hospital JJ 0
length NN 0
of IN 0
stay NN 0
( ( 0
LOS NNP 0
) ) 0
. . 0

MATERIAL NNP 0
AND NNP 0
METHOD NNP 0
In IN 0
this DT 0
prospective JJ 0
, , 0
randomized VBN 0
controlled VBD 0
study NN 0
, , 0
61 CD 0
ASA NNP 0
physical JJ 0
status NN 0
I-III NNP 0
patients NNS 0
scheduled VBN 0
for IN 0
elective JJ 0
unilateral JJ 0
total NN 0
knee NN 0
arthroplasty NN 0
( ( 0
TKA NNP 0
) ) 0
under IN 0
spinal JJ 0
anesthesia NN 0
( ( 0
SA NNP 0
) ) 0
participated VBD 0
. . 0

The DT 0
patients NNS 0
were VBD 0
allocated VBN 0
into IN 0
two CD 0
groups NNS 0
. . 0

In IN 0
the DT 0
ward NN 0
, , 0
patients NNS 0
in IN 0
Group NNP 0
I PRP 0
( ( 0
CEI NNP 0
) ) 0
were VBD 0
maintained VBN 0
by IN 0
continuous JJ 0
infusion NN 0
of IN 0
0.125 CD 0
% NN 0
levobupivacaine NN 0
with IN 0
morphine JJ 0
0.0125 CD 0
mg/ml NN 0
( ( 0
4 CD 0
ml/hr NN 0
) ) 0
, , 0
Group NNP 0
II NNP 0
( ( 0
CFNB NNP 0
) ) 0
were VBD 0
maintained VBN 0
by IN 0
0.125 CD 0
% NN 0
levobupivacaine NN 0
( ( 0
8 CD 0
ml/hr NN 0
) ) 0
. . 0

RESULTS JJ 0
Patients NNPS 0
in IN 0
the DT 0
CFNB NNP 0
group NN 0
, , 0
the DT 0
VAS NNP 0
scores NNS 0
at IN 0
PO6-12 NNP 0
hr NN 0
and CC 0
tramadol NN 0
IV NNP 0
requirement NN 0
were VBD 0
significantly RB 0
greater JJR 0
than IN 0
the DT 0
CEI NNP 0
group NN 0
( ( 0
VAS NNP 0
: : 0
PO6 NNP 0
hr VBD 0
p-value JJ 0
= NN 0
0.001 CD 0
, , 0
PO12 NNP 0
hr VBD 0
p-value JJ 0
= NNP 0
0.004 CD 0
) ) 0
. . 0

Patients NNS 0
in IN 0
the DT 0
CEI NNP 0
group NN 0
experienced VBD 0
dizziness NN 0
, , 0
pruritus NN 0
, , 0
and CC 0
PONV NNP 0
more JJR 0
than IN 0
the DT 0
CFNB NNP 0
group NN 0
significantly RB 0
. . 0

Patient JJ 0
satisfaction NN 0
was VBD 0
greater JJR 0
with IN 0
the DT 0
CFNB NNP 0
group NN 0
although IN 0
postoperative JJ 0
knee NN 0
rehabilitation NN 0
and CC 0
the DT 0
hospital NN 0
LOS NNP 0
were VBD 0
not RB 0
different JJ 0
. . 0

CONCLUSION NNP 0
CFNB NNP 0
represents VBZ 0
the DT 0
optimal JJ 0
analgesia NN 0
with IN 0
fewer JJR 0
side NN 0
effects NNS 0
and CC 0
greater JJR 0
patient NN 0
, , 0
satisfaction NN 0
. . 0

The DT 0
rehabilitation NN 0
indices NNS 0
and CC 0
duration NN 0
of IN 0
hospital NN 0
stay NN 0
are VBP 0
comparable JJ 0
in IN 0
both DT 0
groups NNS 0
. . 0

Raising VBG 0
high-density NN 0
lipoprotein NN 0
in IN 0
humans NNS 0
through IN 0
inhibition NN 0
of IN 0
cholesteryl NN 0
ester NN 0
transfer NN 0
protein NN 0
: : 0
an DT 0
initial JJ 0
multidose NN 0
study NN 0
of IN 0
torcetrapib NN 0
. . 0

OBJECTIVE CC 0
The DT 0
ability NN 0
of IN 0
the DT 0
potent NN 0
cholesteryl NN 0
ester NN 0
transfer NN 0
protein NN 0
( ( 0
CETP NNP 0
) ) 0
inhibitor NN 0
torcetrapib NN 0
( ( 0
CP-529,414 NNP 0
) ) 0
to TO 0
raise VB 0
high-density NN 0
lipoprotein NN 0
cholesterol NN 0
( ( 0
HDL-C NNP 0
) ) 0
levels NNS 0
in IN 0
healthy JJ 0
young JJ 0
subjects NNS 0
was VBD 0
tested VBN 0
in IN 0
this DT 0
initial JJ 0
phase NN 0
1 CD 0
multidose NN 0
study NN 0
. . 0

METHODS NNP 0
AND CC 0
RESULTS NNP 0
Five NNP 0
groups NNS 0
of IN 0
8 CD 0
subjects NNS 0
each DT 0
were VBD 0
randomized VBN 0
to TO 0
placebo VB 0
( ( 0
n=2 NN 0
) ) 0
or CC 0
torcetrapib NN 0
( ( 0
n=6 JJ 0
) ) 0
at IN 0
10 CD 0
, , 0
30 CD 0
, , 0
60 CD 0
, , 0
and CC 0
120 CD 0
mg NNS 0
daily RB 0
and CC 0
120 CD 0
mg NN 0
twice RB 0
daily RB 0
for IN 0
14 CD 0
days NNS 0
. . 0

Torcetrapib NN 0
was VBD 0
well RB 0
tolerated VBN 0
, , 0
with IN 0
all DT 0
treated JJ 0
subjects NNS 0
completing VBG 0
the DT 0
study NN 0
. . 0

The DT 0
correlation NN 0
of IN 0
plasma JJ 0
drug NN 0
levels NNS 0
with IN 0
inhibition NN 0
( ( 0
EC50=43 NNP 0
nM RB 0
) ) 0
was VBD 0
as IN 0
expected VBN 0
based VBN 0
on IN 0
in IN 0
vitro JJ 0
potency NN 0
( ( 0
IC50 NNP 0
approximately RB 0
50 CD 0
nM NNS 0
) ) 0
, , 0
and CC 0
increases VBZ 0
in IN 0
CETP NNP 0
mass NN 0
were VBD 0
consistent JJ 0
with IN 0
the DT 0
proposed VBN 0
mechanism NN 0
of IN 0
inhibition NN 0
. . 0

CETP NNP 0
inhibition NN 0
increased VBD 0
with IN 0
escalating VBG 0
dose NN 0
, , 0
leading VBG 0
to TO 0
elevations NNS 0
of IN 0
HDL-C NNP 0
of IN 0
16 CD 0
% NN 0
to TO 0
91 CD 0
% NN 0
. . 0

Total JJ 0
plasma JJ 0
cholesterol NN 0
did VBD 0
not RB 0
change VB 0
significantly RB 0
because IN 0
of IN 0
a DT 0
reduction NN 0
in IN 0
nonHDL-C JJ 0
, , 0
including VBG 0
a DT 0
21 CD 0
% NN 0
to TO 0
42 CD 0
% NN 0
lowering NN 0
of IN 0
low-density NN 0
lipoprotein NN 0
cholesterol NN 0
at IN 0
the DT 0
higher JJR 0
doses NNS 0
. . 0

Apolipoprotein NNP 0
A-I NNP 0
and CC 0
E NNP 0
were VBD 0
elevated VBN 0
27 CD 0
% NN 0
and CC 0
66 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
and CC 0
apoB NN 0
was VBD 0
reduced VBN 0
26 CD 0
% NN 0
with IN 0
120 CD 0
mg NNS 0
twice RB 0
daily RB 0
. . 0

Cholesteryl NNP 0
ester NN 0
content NN 0
decreased VBN 0
and CC 0
triglyceride VB 0
increased VBN 0
in IN 0
the DT 0
nonHDL JJ 0
plasma NN 0
fraction NN 0
, , 0
with IN 0
contrasting VBG 0
changes NNS 0
occurring VBG 0
in IN 0
HDL NNP 0
. . 0

CONCLUSIONS NNP 0
These DT 0
effects NNS 0
of IN 0
CETP NNP 0
inhibition NN 0
resemble VBP 0
those DT 0
observed VBN 0
in IN 0
partial JJ 0
CETP NNP 0
deficiency NN 0
. . 0

This DT 0
work NN 0
serves VBZ 0
as IN 0
a DT 0
prelude NN 0
to TO 0
further JJ 0
studies NNS 0
in IN 0
subjects NNS 0
with IN 0
low JJ 0
HDL NNP 0
, , 0
or CC 0
combinations NNS 0
of IN 0
dyslipidemia NN 0
, , 0
in IN 0
assessing VBG 0
the DT 0
role NN 0
of IN 0
CETP NNP 0
in IN 0
atherosclerosis NN 0
. . 0

[ IN 0
The DT 0
chemotherapy NN 0
of IN 0
advanced JJ 0
breast NN 0
cancer NN 0
. . 0

A DT 0
report NN 0
on IN 0
the DT 0
first JJ 0
600 CD 0
cases NNS 0
in IN 0
a DT 0
cooperative JJ 0
programme NN 0
to TO 0
carry VB 0
out RP 0
a DT 0
systematic JJ 0
study NN 0
( ( 0
1974-1977 JJ 0
) ) 0
( ( 0
author NN 0
's POS 0
transl NN 0
) ) 0
] NN 0
. . 0

The DT 0
authors NNS 0
explain VBP 0
the DT 0
objectives NNS 0
and CC 0
the DT 0
structure NN 0
of IN 0
a DT 0
programme NN 0
evolved VBN 0
for IN 0
the DT 0
methodic JJ 0
study NN 0
of IN 0
advanced JJ 0
breast NN 0
cancers NNS 0
which WDT 0
they PRP 0
have VBP 0
worked VBN 0
out RP 0
and CC 0
carried VBD 0
out RP 0
in IN 0
cooperation NN 0
with IN 0
the DT 0
departments NNS 0
of IN 0
medicine NN 0
in IN 0
eight CD 0
French JJ 0
anticancer NN 0
centres NNS 0
. . 0

They PRP 0
analyse VBP 0
the DT 0
initial JJ 0
phases NNS 0
, , 0
which WDT 0
correspond NN 0
to TO 0
the DT 0
three CD 0
first JJ 0
years NNS 0
of IN 0
work NN 0
. . 0

They PRP 0
give VBP 0
the DT 0
state NN 0
of IN 0
the DT 0
results NNS 0
that WDT 0
have VBP 0
been VBN 0
obtained VBN 0
in IN 0
603 CD 0
patients NNS 0
using VBG 0
three CD 0
protocols NNS 0
for IN 0
treatment NN 0
. . 0

These DT 0
consisted VBN 0
of IN 0
the DT 0
administration NN 0
in IN 0
interrupted JJ 0
doses NNS 0
of IN 0
chemotherapy NN 0
which WDT 0
consisted VBD 0
of IN 0
vincristine NN 0
associated VBN 0
for IN 0
the DT 0
one CD 0
part NN 0
with IN 0
cyclophosphamide NN 0
and CC 0
5-fluoro-uracil JJ 0
and CC 0
on IN 0
the DT 0
other JJ 0
hand NN 0
with IN 0
doxorubicine NN 0
or/and NN 0
with IN 0
methotrexate NN 0
. . 0

From IN 0
this DT 0
study NN 0
there RB 0
emerged VBD 0
the DT 0
value NN 0
of IN 0
combined JJ 0
therapy NN 0
using VBG 0
doxorubicine NN 0
as IN 0
much JJ 0
because IN 0
of IN 0
the DT 0
frequency NN 0
with IN 0
which WDT 0
results NNS 0
better JJR 0
than IN 0
50 CD 0
% NN 0
were VBD 0
obtained VBN 0
( ( 0
in IN 0
a DT 0
randomised JJ 0
trial NN 0
) ) 0
as IN 0
by IN 0
their PRP$ 0
quality NN 0
, , 0
which WDT 0
was VBD 0
made VBN 0
clear JJ 0
in IN 0
an DT 0
important JJ 0
series NN 0
of IN 0
240 CD 0
cases NNS 0
. . 0

They PRP 0
point VBP 0
out RP 0
the DT 0
conditions NNS 0
required VBN 0
to TO 0
initiate VB 0
the DT 0
place NN 0
of IN 0
such PDT 0
a DT 0
scheme NN 0
in IN 0
all DT 0
complex JJ 0
therapy NN 0
which WDT 0
aims VBZ 0
as RB 0
much JJ 0
at IN 0
palliation NN 0
as IN 0
at IN 0
cure NN 0
, , 0
and CC 0
point VB 0
out RP 0
how WRB 0
important JJ 0
it PRP 0
is VBZ 0
to TO 0
be VB 0
methodical JJ 0
in IN 0
the DT 0
application NN 0
of IN 0
chemotherapy NN 0
in IN 0
order NN 0
to TO 0
ensure VB 0
its PRP$ 0
development NN 0
as IN 0
an DT 0
anticancer NN 0
therapy NN 0
. . 0

The DT 0
role NN 0
of IN 0
somatostatin NN 0
( ( 0
octreotide JJ 0
) ) 0
in IN 0
the DT 0
regulation NN 0
of IN 0
melatonin JJ 0
secretion NN 0
in IN 0
healthy JJ 0
volunteers NNS 0
and CC 0
in IN 0
patients NNS 0
with IN 0
primary JJ 0
hypothyroidism NN 0
. . 0

Somatostatin NNP 0
has VBZ 0
been VBN 0
found VBN 0
in IN 0
the DT 0
pineal JJ 0
gland NN 0
of IN 0
several JJ 0
animal JJ 0
species NNS 0
, , 0
which WDT 0
suggests VBZ 0
that IN 0
it PRP 0
may MD 0
be VB 0
involved VBN 0
in IN 0
the DT 0
regulation NN 0
of IN 0
melatonin JJ 0
secretion NN 0
. . 0

Whether NNP 0
somatostatin NN 0
has VBZ 0
regulatory JJ 0
influence NN 0
on IN 0
melatonin NN 0
secretion NN 0
in IN 0
man NN 0
has VBZ 0
never RB 0
been VBN 0
unequivocally RB 0
shown VBN 0
. . 0

We PRP 0
studied VBD 0
the DT 0
nocturnal JJ 0
melatonin NN 0
secretion NN 0
in IN 0
8 CD 0
healthy JJ 0
volunteers NNS 0
, , 0
and CC 0
6 CD 0
women NNS 0
with IN 0
untreated JJ 0
primary JJ 0
hypothyroidism NN 0
, , 0
a DT 0
disease NN 0
state NN 0
that WDT 0
is VBZ 0
associated VBN 0
with IN 0
increased JJ 0
nocturnal JJ 0
secretion NN 0
of IN 0
melatonin NN 0
. . 0

The DT 0
participants NNS 0
were VBD 0
given VBN 0
subcutaneous JJ 0
injections NNS 0
at IN 0
18:00 CD 0
h NN 0
and CC 0
23:00 CD 0
h NN 0
of IN 0
either DT 0
saline NN 0
or CC 0
octreotide NN 0
( ( 0
Sandostatin NNP 0
; : 0
each DT 0
injection NN 0
50 CD 0
microg NN 0
) ) 0
. . 0

During IN 0
the DT 0
nights NNS 0
when WRB 0
the DT 0
healthy JJ 0
volunteers NNS 0
were VBD 0
given VBN 0
octreotide RB 0
, , 0
melatonin JJ 0
secretion NN 0
was VBD 0
similar JJ 0
to TO 0
that DT 0
recorded VBN 0
during IN 0
administration NN 0
of IN 0
saline NN 0
. . 0

Also RB 0
the DT 0
urinary JJ 0
excretion NN 0
of IN 0
melatonin NN 0
was VBD 0
of IN 0
similar JJ 0
magnitude NN 0
at IN 0
these DT 0
two CD 0
occasions NNS 0
. . 0

By IN 0
contrast NN 0
, , 0
the DT 0
GH NNP 0
secretion NN 0
was VBD 0
significantly RB 0
lower JJR 0
the DT 0
nights NNS 0
the DT 0
healthy JJ 0
controls NNS 0
were VBD 0
given VBN 0
octreotide RB 0
( ( 0
GH NNP 0
AUC NNP 0
22.6+/-5.4 JJ 0
mU/l NN 0
x NNP 0
h NN 0
during IN 0
octreotide JJ 0
and CC 0
126.6+/-21.9 JJ 0
mU/l NN 0
x NNP 0
h NN 0
during IN 0
saline NN 0
; : 0
p CC 0
< VB 0
0.01 CD 0
) ) 0
. . 0

The DT 0
patients NNS 0
with IN 0
hypothyroidism NN 0
also RB 0
showed VBD 0
similar JJ 0
nocturnal JJ 0
melatonin NN 0
secretion NN 0
during IN 0
octreotide NN 0
and CC 0
saline NN 0
. . 0

Urinary JJ 0
excretion NN 0
of IN 0
melatonin NN 0
also RB 0
remained VBD 0
unchanged JJ 0
, , 0
as IN 0
did VBD 0
GH NNP 0
secretion NN 0
. . 0

The DT 0
total JJ 0
nocturnal JJ 0
secretion NN 0
of IN 0
TSH NNP 0
was VBD 0
, , 0
however RB 0
, , 0
significantly RB 0
reduced VBN 0
by IN 0
octreotide NN 0
( ( 0
TSH NNP 0
AUC NNP 0
562+/-136 JJ 0
mU/l NN 0
x NNP 0
h NN 0
during IN 0
octreotide JJ 0
and CC 0
851+/-185 JJ 0
mU/l NN 0
x NNP 0
h NN 0
during IN 0
saline NN 0
; : 0
p CC 0
< VB 0
0.05 CD 0
) ) 0
, , 0
thus RB 0
suggesting VBG 0
that IN 0
100 CD 0
microg NN 0
of IN 0
octreotide NN 0
should MD 0
be VB 0
sufficient JJ 0
to TO 0
inhibit VB 0
also RB 0
the DT 0
pinealocytes NNS 0
if IN 0
their PRP$ 0
function NN 0
were VBD 0
regulated VBN 0
by IN 0
somatostatin NN 0
. . 0

Since IN 0
exogenous JJ 0
somatostatin NN 0
-- : 0
in IN 0
the DT 0
form NN 0
of IN 0
octreotide NN 0
-- : 0
fails VBZ 0
to TO 0
influence VB 0
nocturnal JJ 0
secretion NN 0
and CC 0
urinary JJ 0
excretion NN 0
of IN 0
melatonin NN 0
in IN 0
normal JJ 0
subjects NNS 0
and CC 0
in IN 0
patients NNS 0
with IN 0
primary JJ 0
hypothyroidism NN 0
, , 0
it PRP 0
is VBZ 0
reasonable JJ 0
to TO 0
assume VB 0
that DT 0
endogenous JJ 0
somatostatin NN 0
may MD 0
not RB 0
be VB 0
an DT 0
important JJ 0
regulator NN 0
of IN 0
melatonin JJ 0
secretion NN 0
in IN 0
man NN 0
. . 0

Randomized VBN 0
controlled JJ 0
trial NN 0
of IN 0
acupuncture NN 0
versus NN 0
sham JJ 0
acupuncture NN 0
in IN 0
autism NN 0
spectrum NN 0
disorder NN 0
. . 0

OBJECTIVE IN 0
We PRP 0
aim VBP 0
to TO 0
study VB 0
the DT 0
efficacy NN 0
of IN 0
acupuncture NN 0
versus NN 0
sham JJ 0
acupuncture NN 0
in IN 0
children NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorder NN 0
. . 0

METHODS VB 0
A DT 0
single-blind JJ 0
randomized VBN 0
control NN 0
trial NN 0
was VBD 0
conducted VBN 0
in IN 0
50 CD 0
children NNS 0
. . 0

These DT 0
children NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
the DT 0
treatment NN 0
group NN 0
with IN 0
tongue JJ 0
acupuncture NN 0
( ( 0
40 CD 0
sessions NNS 0
over IN 0
8 CD 0
weeks NNS 0
) ) 0
or CC 0
the DT 0
control NN 0
group NN 0
( ( 0
sham JJ 0
tongue NN 0
acupuncture NN 0
to TO 0
nonacupoints NNS 0
in IN 0
the DT 0
tongue NN 0
) ) 0
. . 0

RESULTS NNP 0
There EX 0
was VBD 0
improvement NN 0
in IN 0
both CC 0
the DT 0
treatment NN 0
and CC 0
control NN 0
groups NNS 0
in IN 0
all DT 0
assessed JJ 0
measures NNS 0
but CC 0
more JJR 0
so RB 0
in IN 0
the DT 0
treatment NN 0
than IN 0
in IN 0
the DT 0
control NN 0
group NN 0
: : 0
( ( 0
1 CD 0
) ) 0
eye-hand NN 0
coordination NN 0
, , 0
performance NN 0
, , 0
and CC 0
practical JJ 0
reasoning NN 0
of IN 0
Griffiths NNP 0
Mental NNP 0
Developmental NNP 0
Scale NNP 0
; : 0
( ( 0
2 CD 0
) ) 0
sensory-motor NN 0
, , 0
social JJ 0
, , 0
affectual JJ 0
, , 0
language NN 0
, , 0
and CC 0
total JJ 0
score NN 0
of IN 0
Ritvo-Freeman NNP 0
Real NNP 0
Life NNP 0
Scale NNP 0
; : 0
( ( 0
3 CD 0
) ) 0
Comprehension NN 0
Language NNP 0
age NN 0
in IN 0
the DT 0
Reynell NNP 0
Language NNP 0
Developmental NNP 0
Scale NNP 0
; : 0
and CC 0
( ( 0
4 CD 0
) ) 0
Total NN 0
Score NNP 0
and CC 0
Mental NNP 0
Age NNP 0
in IN 0
Symbolic NNP 0
Play NNP 0
Test NNP 0
. . 0

The DT 0
only JJ 0
statistically RB 0
significant JJ 0
improvement NN 0
in IN 0
the DT 0
treatment NN 0
as IN 0
compared VBN 0
to TO 0
the DT 0
control NN 0
group NN 0
was VBD 0
seen VBN 0
in IN 0
self-care JJ 0
and CC 0
cognition NN 0
domains NNS 0
of IN 0
the DT 0
Functional NNP 0
Independence NNP 0
Measure NN 0
for IN 0
children NNS 0
. . 0

CONCLUSIONS NNP 0
We PRP 0
had VBD 0
demonstrated VBN 0
that IN 0
a DT 0
short JJ 0
course NN 0
of IN 0
acupuncture NN 0
had VBD 0
efficacy NN 0
in IN 0
improving VBG 0
various JJ 0
developmental JJ 0
and CC 0
behavioral JJ 0
aspects NNS 0
of IN 0
children NNS 0
with IN 0
autism NN 0
. . 0

The DT 0
long-term JJ 0
efficacy NN 0
in IN 0
functional JJ 0
gain NN 0
needs NNS 0
to TO 0
be VB 0
further RB 0
explored VBN 0
. . 0

The DT 0
effect NN 0
of IN 0
cognitive-behavioral JJ 0
therapy NN 0
versus NN 0
treatment NN 0
as IN 0
usual JJ 0
for IN 0
anxiety NN 0
in IN 0
children NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorders NNS 0
: : 0
a DT 0
randomized NN 0
, , 0
controlled VBN 0
trial NN 0
. . 0

OBJECTIVE UH 0
To TO 0
examine VB 0
the DT 0
efficacy NN 0
of IN 0
a DT 0
modular JJ 0
cognitive-behavioral JJ 0
therapy NN 0
( ( 0
CBT NNP 0
) ) 0
protocol VBP 0
relative JJ 0
to TO 0
treatment NN 0
as IN 0
usual JJ 0
( ( 0
TAU NNP 0
) ) 0
among IN 0
children NNS 0
with IN 0
high-functioning JJ 0
autism NN 0
spectrum NN 0
disorders NNS 0
( ( 0
ASD NNP 0
) ) 0
and CC 0
clinically RB 0
significant JJ 0
anxiety NN 0
. . 0

METHOD NNP 0
A NNP 0
total NN 0
of IN 0
45 CD 0
children NNS 0
( ( 0
7-11 CD 0
years NNS 0
of IN 0
age NN 0
) ) 0
with IN 0
high-functioning JJ 0
ASD NNP 0
and CC 0
clinically RB 0
significant JJ 0
anxiety NN 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
16 CD 0
sessions NNS 0
of IN 0
weekly JJ 0
CBT NNP 0
or CC 0
TAU NNP 0
for IN 0
an DT 0
equivalent JJ 0
duration NN 0
. . 0

After IN 0
screening VBG 0
, , 0
assessments NNS 0
were VBD 0
conducted VBN 0
at IN 0
baseline NN 0
, , 0
post-treatment JJ 0
, , 0
and CC 0
3-month JJ 0
follow-up NN 0
. . 0

Raters NNPS 0
were VBD 0
blind RB 0
to TO 0
treatment NN 0
condition NN 0
. . 0

RESULTS NNP 0
Youth NNP 0
receiving VBG 0
CBT NNP 0
showed VBD 0
substantial JJ 0
improvement NN 0
relative NN 0
to TO 0
TAU VB 0
on IN 0
primary JJ 0
anxiety NN 0
outcomes NNS 0
. . 0

Of IN 0
24 CD 0
children NNS 0
randomized VBN 0
to TO 0
the DT 0
CBT NNP 0
arm NN 0
, , 0
18 CD 0
( ( 0
75 CD 0
% NN 0
) ) 0
were VBD 0
treatment NN 0
responders NNS 0
, , 0
versus IN 0
only RB 0
3 CD 0
of IN 0
21 CD 0
children NNS 0
( ( 0
14 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
TAU NNP 0
arm NN 0
. . 0

Gains NNS 0
were VBD 0
generally RB 0
maintained VBN 0
at IN 0
3-month JJ 0
follow-up NN 0
for IN 0
CBT NNP 0
responders NNS 0
. . 0

CONCLUSIONS NNP 0
Relative NNP 0
to TO 0
usual JJ 0
care NN 0
, , 0
CBT NNP 0
adapted VBD 0
for IN 0
anxious JJ 0
youth NN 0
with IN 0
high-functioning JJ 0
ASD NNP 0
demonstrates VBZ 0
large JJ 0
effects NNS 0
in IN 0
reducing VBG 0
anxiety NN 0
symptoms NNS 0
. . 0

This DT 0
study NN 0
contributes VBZ 0
to TO 0
the DT 0
growing VBG 0
literature NN 0
supporting VBG 0
adapted VBN 0
CBT NNP 0
approaches NNS 0
for IN 0
treating VBG 0
anxiety NN 0
in IN 0
youth NN 0
with IN 0
ASD NNP 0
. . 0

[ JJ 0
Double-blind NNP 0
placebo-controlled JJ 0
study NN 0
of IN 0
the DT 0
effectiveness NN 0
and CC 0
tolerability NN 0
of IN 0
10 CD 0
and CC 0
30 CD 0
mg NN 0
ketorolac NN 0
tromethamine NN 0
suppositories NNS 0
in IN 0
post-cholecystectomy JJ 0
pain NN 0
] NN 0
. . 0

OBJECTIVE UH 0
To TO 0
evaluate VB 0
the DT 0
efficacy NN 0
and CC 0
tolerability NN 0
of IN 0
ketorolac NN 0
tromethamine NN 0
10 CD 0
mg NN 0
and CC 0
30 CD 0
mg NN 0
suppositories NNS 0
in IN 0
comparison NN 0
to TO 0
placebo VB 0
, , 0
after IN 0
single JJ 0
dose JJ 0
administration NN 0
in IN 0
patients NNS 0
suffering VBG 0
from IN 0
post-operative JJ 0
pain NN 0
after IN 0
cholecystectomy NN 0
. . 0

DESIGN NNP 0
Double-blind NNP 0
, , 0
randomized VBD 0
, , 0
controlled VBD 0
study NN 0
. . 0

SETTING NNP 0
Anaesthesia NNP 0
Service NNP 0
. . 0

PATIENTS NNP 0
99 CD 0
patients NNS 0
with IN 0
severe JJ 0
pain NN 0
following VBG 0
surgery NN 0
. . 0

INTERVENTIONS NNP 0
Cholecystectomy NNP 0
. . 0

MEASUREMENTS NNP 0
AND CC 0
MAIN NNP 0
RESULTS NNP 0
The DT 0
analgesia JJ 0
activity NN 0
of IN 0
ketorolac NN 0
tromethamine NN 0
10 CD 0
mg NN 0
and CC 0
30 CD 0
mg NN 0
suppositories NNS 0
were VBD 0
evaluated VBN 0
after IN 0
single JJ 0
dose JJ 0
administration NN 0
by IN 0
assessing VBG 0
pain NN 0
intensity NN 0
and CC 0
pain NN 0
relief NN 0
using VBG 0
a DT 0
4 CD 0
point NN 0
scale NN 0
( ( 0
VRS NNP 0
) ) 0
. . 0

At IN 0
the DT 0
end NN 0
of IN 0
the DT 0
treatment NN 0
period NN 0
overall JJ 0
assessment NN 0
of IN 0
safety NN 0
and CC 0
efficacy NN 0
were VBD 0
recorded VBN 0
by IN 0
physician JJ 0
and CC 0
patient JJ 0
. . 0

The DT 0
results NNS 0
show VBP 0
that IN 0
in IN 0
both DT 0
active JJ 0
groups NNS 0
after IN 0
30 CD 0
' POS 0
and CC 0
until IN 0
4 CD 0
hours NNS 0
, , 0
pain VBP 0
intensity NN 0
decreased VBN 0
significantly RB 0
with IN 0
respect NN 0
to TO 0
the DT 0
baseline NN 0
. . 0

However RB 0
a DT 0
statistically RB 0
significant JJ 0
difference NN 0
between IN 0
groups NNS 0
of IN 0
p NN 0
< NN 0
0.02 CD 0
, , 0
p NN 0
< VBD 0
0.01 CD 0
and CC 0
p VB 0
< JJ 0
0.05 CD 0
was VBD 0
found VBN 0
in IN 0
favour NN 0
of IN 0
the DT 0
30 CD 0
mg NN 0
dose NN 0
respectively RB 0
at IN 0
30 CD 0
' '' 0
, , 0
6 CD 0
and CC 0
8 CD 0
hours NNS 0
after IN 0
administration NN 0
. . 0

All PDT 0
the DT 0
patients NNS 0
treated VBN 0
with IN 0
placebo JJ 0
suppositories NNS 0
required VBN 0
another DT 0
rescue NN 0
analgesic JJ 0
drug NN 0
and CC 0
withdrew NN 0
from IN 0
the DT 0
trial NN 0
. . 0

Three CD 0
patients NNS 0
complained VBD 0
adverse JJ 0
events NNS 0
not RB 0
related VBN 0
to TO 0
treatment NN 0
: : 0
two CD 0
on IN 0
placebo NN 0
and CC 0
one CD 0
on IN 0
ketorolac NN 0
10 CD 0
mg NN 0
. . 0

The DT 0
systemic JJ 0
and CC 0
local JJ 0
tolerability NN 0
of IN 0
the DT 0
drug NN 0
was VBD 0
good JJ 0
. . 0

CONCLUSIONS VB 0
This DT 0
study NN 0
shows VBZ 0
that IN 0
ketorolac $ 0
30 CD 0
mg NN 0
suppositories NNS 0
are VBP 0
effective JJ 0
in IN 0
clinical JJ 0
conditions NNS 0
, , 0
such JJ 0
as IN 0
after IN 0
surgery NN 0
, , 0
in IN 0
which WDT 0
pain NN 0
control NN 0
must MD 0
be VB 0
achieved VBN 0
within IN 0
the DT 0
shortest JJ 0
time NN 0
interval NN 0
and CC 0
maintained VBD 0
or CC 0
improved VBN 0
by IN 0
means NNS 0
of IN 0
a DT 0
single JJ 0
route NN 0
of IN 0
administration NN 0
. . 0

Effects NNS 0
of IN 0
low-dose JJ 0
aspirin NN 0
on IN 0
clinic NN 0
and CC 0
ambulatory JJ 0
blood NN 0
pressure NN 0
in IN 0
treated JJ 0
hypertensive JJ 0
patients NNS 0
. . 0

Collaborative NNP 0
Group NNP 0
of IN 0
the DT 0
Primary NNP 0
Prevention NNP 0
Project NNP 0
( ( 0
PPP NNP 0
) ) 0
-- : 0
Hypertension NNP 0
study NN 0
. . 0

Nonsteroidal NNP 0
antiinflammatory JJ 0
drugs NNS 0
may MD 0
affect VB 0
blood NN 0
pressure NN 0
( ( 0
BP NNP 0
) ) 0
control NN 0
in IN 0
hypertensive JJ 0
patients NNS 0
receiving VBG 0
drug NN 0
treatment NN 0
, , 0
but CC 0
data NNS 0
on IN 0
the DT 0
effects NNS 0
of IN 0
low-dose JJ 0
aspirin NNS 0
are VBP 0
scanty RB 0
. . 0

This DT 0
study NN 0
assessed VBD 0
the DT 0
effects NNS 0
of IN 0
chronic JJ 0
treatment NN 0
with IN 0
low JJ 0
doses NNS 0
of IN 0
aspirin NN 0
( ( 0
100 CD 0
mg/day NN 0
) ) 0
on IN 0
clinic NN 0
and CC 0
ambulatory JJ 0
systolic NN 0
( ( 0
SBP NNP 0
) ) 0
and CC 0
diastolic JJ 0
( ( 0
DBP NNP 0
) ) 0
BP NNP 0
in IN 0
hypertensives NNS 0
on IN 0
chronic NN 0
, , 0
stable JJ 0
antihypertensive JJ 0
therapy NN 0
. . 0

The DT 0
study NN 0
was VBD 0
conducted VBN 0
in IN 0
the DT 0
framework NN 0
of IN 0
the DT 0
Primary NNP 0
Prevention NNP 0
Project NNP 0
( ( 0
PPP NNP 0
) ) 0
, , 0
a DT 0
randomized VBN 0
, , 0
controlled VBN 0
factorial JJ 0
trial NN 0
on IN 0
the DT 0
preventive JJ 0
effect NN 0
of IN 0
aspirin NN 0
or CC 0
vitamin NN 0
E NN 0
in IN 0
people NNS 0
with IN 0
one CD 0
or CC 0
more JJR 0
cardiovascular JJ 0
risk NN 0
factors NNS 0
. . 0

Fifteen NNP 0
Italian JJ 0
hypertension NN 0
units NNS 0
studied VBD 0
142 CD 0
hypertensive JJ 0
patients NNS 0
( ( 0
76 CD 0
men NNS 0
, , 0
66 CD 0
women NNS 0
; : 0
mean JJ 0
age NN 0
59 CD 0
+/- JJ 0
5.9 CD 0
years NNS 0
) ) 0
treated VBD 0
with IN 0
different JJ 0
antihypertensive JJ 0
drugs NNS 0
: : 0
71 CD 0
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
aspirin VB 0
and CC 0
71 CD 0
served VBD 0
as IN 0
controls NNS 0
. . 0

All DT 0
patients NNS 0
underwent VBD 0
a DT 0
clinic JJ 0
BP NNP 0
evaluation NN 0
with IN 0
an DT 0
automatic JJ 0
sphygmomanometer NN 0
and CC 0
a DT 0
24-h JJ 0
ambulatory NN 0
BP NNP 0
monitoring NN 0
, , 0
at IN 0
baseline NN 0
and CC 0
after IN 0
3 CD 0
months NNS 0
of IN 0
aspirin JJ 0
treatment NN 0
. . 0

At IN 0
the DT 0
end NN 0
of IN 0
the DT 0
study NN 0
the DT 0
changes NNS 0
in IN 0
clinic JJ 0
SBP NNP 0
and CC 0
DBP NNP 0
were VBD 0
not RB 0
statistically RB 0
different JJ 0
in IN 0
treated JJ 0
and CC 0
untreated JJ 0
subjects NNS 0
. . 0

Ambulatory NNP 0
SBP NNP 0
and CC 0
DBP NNP 0
after IN 0
3 CD 0
months NNS 0
of IN 0
aspirin JJ 0
treatment NN 0
were VBD 0
similar JJ 0
to TO 0
baseline VB 0
: : 0
deltaSBP NN 0
-0.5 NN 0
mmHg NN 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
intervals NNS 0
[ VBP 0
CI NNP 0
] NN 0
from IN 0
-1.9 NN 0
to TO 0
+2.9 VB 0
mm JJ 0
Hg NNP 0
) ) 0
and CC 0
deltaDBP JJ 0
-1.1 NNP 0
mm NN 0
Hg NNP 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
from IN 0
-2.5 NNP 0
to TO 0
+0.3 VB 0
mm JJ 0
Hg NNP 0
) ) 0
. . 0

The DT 0
pattern NN 0
was VBD 0
similar JJ 0
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

No DT 0
interaction NN 0
was VBD 0
found VBN 0
between IN 0
aspirin NN 0
and CC 0
the DT 0
most RBS 0
used JJ 0
antihypertensive JJ 0
drug NN 0
classes NNS 0
( ( 0
angiotensin IN 0
converting VBG 0
enzyme JJ 0
inhibitors NNS 0
and CC 0
calcium NN 0
antagonists NNS 0
) ) 0
. . 0

Despite IN 0
the DT 0
relatively RB 0
small JJ 0
sample NN 0
size NN 0
our PRP$ 0
results NNS 0
seem VBP 0
to TO 0
exclude VB 0
any DT 0
significant JJ 0
influence NN 0
of IN 0
low-dose JJ 0
aspirin NN 0
on IN 0
BP NNP 0
control NN 0
in IN 0
hypertensives NNS 0
under IN 0
treatment NN 0
. . 0

A DT 0
pilot NN 0
study NN 0
on IN 0
the DT 0
effect NN 0
of IN 0
progressive JJ 0
muscle NN 0
relaxation NN 0
training NN 0
of IN 0
patients NNS 0
after IN 0
stoma NN 0
surgery NN 0
. . 0

Eighteen JJ 0
patients NNS 0
who WP 0
had VBD 0
undergone JJ 0
stoma NN 0
surgery NN 0
were VBD 0
assessed VBN 0
with IN 0
respect NN 0
to TO 0
their PRP$ 0
anxiety NN 0
level NN 0
and CC 0
self-reported JJ 0
quality NN 0
of IN 0
life NN 0
( ( 0
QoL NNP 0
) ) 0
on IN 0
three CD 0
occasions NNS 0
; : 0
namely RB 0
, , 0
immediately RB 0
after IN 0
surgery NN 0
, , 0
5 CD 0
weeks NNS 0
after IN 0
surgery NN 0
, , 0
and CC 0
10 CD 0
weeks NNS 0
after IN 0
surgery NN 0
. . 0

The DT 0
patients NNS 0
were VBD 0
randomised VBN 0
into IN 0
a DT 0
control NN 0
group NN 0
( ( 0
n JJ 0
= NNP 0
10 CD 0
) ) 0
and CC 0
an DT 0
experimental JJ 0
group NN 0
( ( 0
n JJ 0
= NNP 0
8 CD 0
) ) 0
. . 0

A DT 0
20-min JJ 0
set NN 0
of IN 0
audiotaped JJ 0
instructions NNS 0
on IN 0
progressive JJ 0
muscle NN 0
relaxation NN 0
training NN 0
( ( 0
PMRT NNP 0
) ) 0
was VBD 0
given VBN 0
to TO 0
the DT 0
patients NNS 0
in IN 0
the DT 0
experimental JJ 0
group NN 0
for IN 0
home NN 0
practice NN 0
. . 0

Assessment NNP 0
instructions NNS 0
included VBD 0
the DT 0
Chinese JJ 0
State-Trait NNP 0
Anxiety NNP 0
Inventory NNP 0
( ( 0
C-STAI NNP 0
) ) 0
, , 0
the DT 0
Quality NN 0
of IN 0
Life NNP 0
Index NNP 0
for IN 0
Colostomy NNP 0
( ( 0
QoL-Colostomy NNP 0
) ) 0
and CC 0
the DT 0
Hong NNP 0
Kong NNP 0
Chinese JJ 0
version NN 0
of IN 0
the DT 0
World NNP 0
Health NNP 0
Organisation NNP 0
Quality NNP 0
of IN 0
Life NNP 0
Scale NNP 0
( ( 0
WHOQoL NNP 0
) ) 0
. . 0

Results NNS 0
indicated VBD 0
that IN 0
there EX 0
was VBD 0
a DT 0
significant JJ 0
decrease NN 0
in IN 0
both DT 0
the DT 0
C-STAI NNP 0
score NN 0
( ( 0
F NNP 0
= NNP 0
4.66 CD 0
, , 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
and CC 0
the DT 0
WHOQoL NNP 0
score NN 0
( ( 0
F NNP 0
= NNP 0
4.74 CD 0
, , 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
in IN 0
the DT 0
experimental JJ 0
group NN 0
. . 0

Among IN 0
the DT 0
domains NNS 0
of IN 0
WHOQoL NNP 0
, , 0
a DT 0
significant JJ 0
difference NN 0
was VBD 0
shown VBN 0
in IN 0
physical JJ 0
health/independence NN 0
and CC 0
general JJ 0
perception NN 0
of IN 0
QoL NNP 0
, , 0
with IN 0
the DT 0
experimental JJ 0
group NN 0
demonstrating VBG 0
better JJR 0
functioning NN 0
. . 0

For IN 0
the DT 0
QoL-Colostomy NNP 0
, , 0
however RB 0
, , 0
there EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
between IN 0
the DT 0
control NN 0
and CC 0
experimental JJ 0
groups NNS 0
. . 0

The DT 0
results NNS 0
suggest VBP 0
that IN 0
the DT 0
use NN 0
of IN 0
PMRT NNP 0
could MD 0
enhance VB 0
quality NN 0
of IN 0
life NN 0
and CC 0
decrease NN 0
state NN 0
anxiety NN 0
in IN 0
patients NNS 0
after IN 0
stoma NN 0
surgery NN 0
. . 0

A DT 0
controlled VBN 0
study NN 0
of IN 0
psychiatric JJ 0
hospital NN 0
versus NN 0
community NN 0
treatment NN 0
- : 0
the DT 0
effect NN 0
on IN 0
relatives NNS 0
. . 0

One CD 0
hundred CD 0
and CC 0
twenty JJ 0
patients NNS 0
presenting VBG 0
at IN 0
Macquarie NNP 0
Hospital NNP 0
for IN 0
admission NN 0
were VBD 0
randomly RB 0
allocated VBN 0
into IN 0
two CD 0
groups NNS 0
. . 0

The DT 0
control NN 0
group NN 0
patients NNS 0
received VBD 0
standard JJ 0
hospital NN 0
care NN 0
and CC 0
follow-up NN 0
. . 0

The DT 0
project NN 0
group NN 0
patients NNS 0
were VBD 0
not RB 0
admitted VBN 0
if IN 0
this DT 0
could MD 0
be VB 0
avoided VBN 0
; : 0
instead RB 0
they PRP 0
were VBD 0
taken VBN 0
back RB 0
to TO 0
the DT 0
community NN 0
by IN 0
the DT 0
project NN 0
team NN 0
who WP 0
provided VBD 0
them PRP 0
and CC 0
their PRP$ 0
relatives NNS 0
with IN 0
comprehensive JJ 0
, , 0
assertive JJ 0
and CC 0
prolonged JJ 0
follow-up JJ 0
treatment NN 0
backed VBN 0
by IN 0
a DT 0
24-hour JJ 0
crisis NN 0
service NN 0
. . 0

The DT 0
majority NN 0
( ( 0
63 CD 0
% NN 0
) ) 0
of IN 0
the DT 0
project NN 0
group NN 0
had VBD 0
no DT 0
admission NN 0
during IN 0
the DT 0
10 CD 0
month NN 0
study NN 0
period NN 0
. . 0

Initially RB 0
, , 0
the DT 0
burden NN 0
on IN 0
the DT 0
relatives NNS 0
of IN 0
the DT 0
project NN 0
group NN 0
was VBD 0
higher JJR 0
, , 0
but CC 0
by IN 0
one CD 0
month NN 0
it PRP 0
was VBD 0
somewhat RB 0
lower JJR 0
and CC 0
by IN 0
four CD 0
months NNS 0
it PRP 0
was VBD 0
significantly RB 0
lower JJR 0
than IN 0
the DT 0
burden NN 0
on IN 0
the DT 0
control NN 0
group NN 0
relatives VBZ 0
. . 0

Relatives NNS 0
of IN 0
the DT 0
project NN 0
group NN 0
patients NNS 0
were VBD 0
significantly RB 0
more RBR 0
satisfied JJ 0
with IN 0
the DT 0
treatment NN 0
than IN 0
control NN 0
group NN 0
relatives VBZ 0
. . 0

It PRP 0
is VBZ 0
clearly RB 0
feasible JJ 0
to TO 0
treat VB 0
most JJS 0
psychiatric JJ 0
patients NNS 0
in IN 0
the DT 0
community NN 0
without IN 0
increasing VBG 0
the DT 0
burden NN 0
on IN 0
their PRP$ 0
relatives NNS 0
. . 0

Double-blind NNP 0
comparison NN 0
of IN 0
doxepin NN 0
versus NN 0
bupropion NN 0
in IN 0
outpatients NNS 0
with IN 0
a DT 0
major JJ 0
depressive JJ 0
disorder NN 0
. . 0

A DT 0
double-blind NN 0
controlled VBN 0
study NN 0
comparing VBG 0
the DT 0
effects NNS 0
of IN 0
bupropion NN 0
to TO 0
doxepin VB 0
in IN 0
outpatients NNS 0
with IN 0
primary JJ 0
depression NN 0
was VBD 0
conducted VBN 0
to TO 0
evaluate VB 0
efficacy NN 0
and CC 0
safety NN 0
differences NNS 0
between IN 0
the DT 0
two CD 0
drugs NNS 0
. . 0

Following VBG 0
a DT 0
7-day JJ 0
placebo NN 0
washout NN 0
period NN 0
, , 0
patients NNS 0
could MD 0
be VB 0
treated VBN 0
for IN 0
up RB 0
to TO 0
13 CD 0
weeks NNS 0
on IN 0
either DT 0
treatment NN 0
. . 0

Antidepressant JJ 0
response NN 0
was VBD 0
assessed VBN 0
by IN 0
the DT 0
Hamilton NNP 0
Depression NNP 0
and CC 0
Anxiety NNP 0
Scales NNP 0
, , 0
Clinical NNP 0
Global NNP 0
Severity NNP 0
and CC 0
Improvement NNP 0
Ratings NNP 0
, , 0
and CC 0
the DT 0
Zung NNP 0
Self-Rating NNP 0
Depression NNP 0
Scale NNP 0
. . 0

Comparable JJ 0
efficacy NN 0
between IN 0
the DT 0
compounds NNS 0
was VBD 0
found VBN 0
across IN 0
the DT 0
13-week JJ 0
study NN 0
. . 0

Doxepin NNP 0
differed VBD 0
from IN 0
bupropion NN 0
mainly RB 0
on IN 0
the DT 0
sleep JJ 0
factor NN 0
of IN 0
the DT 0
Hamilton NNP 0
Depression NNP 0
Scale NNP 0
, , 0
with IN 0
doxepin NN 0
improving VBG 0
sleep NN 0
to TO 0
a DT 0
greater JJR 0
extent NN 0
than IN 0
bupropion NN 0
. . 0

Doxepin NNP 0
produced VBD 0
a DT 0
greater JJR 0
incidence NN 0
of IN 0
anticholinergic JJ 0
side NN 0
effects NNS 0
, , 0
including VBG 0
dry JJ 0
mouth NN 0
, , 0
constipation NN 0
, , 0
sleepiness NN 0
, , 0
and CC 0
tiredness NN 0
, , 0
in IN 0
comparison NN 0
to TO 0
bupropion NN 0
. . 0

Also RB 0
, , 0
increased VBD 0
appetite NN 0
and CC 0
weight JJ 0
gain NN 0
were VBD 0
consistent JJ 0
side NN 0
effects NNS 0
of IN 0
doxepin NN 0
relative NN 0
to TO 0
bupropion NN 0
. . 0

Clinical JJ 0
effects NNS 0
of IN 0
root NN 0
instrumentation NN 0
using VBG 0
conventional JJ 0
steel NN 0
or CC 0
non-tooth JJ 0
substance NN 0
removing VBG 0
plastic NN 0
curettes NNS 0
during IN 0
supportive JJ 0
periodontal JJ 0
therapy NN 0
( ( 0
SPT NNP 0
) ) 0
. . 0

Although IN 0
root NN 0
instrumentation NN 0
has VBZ 0
been VBN 0
accepted VBN 0
as IN 0
the DT 0
most RBS 0
important JJ 0
cause-related JJ 0
treatment NN 0
of IN 0
periodontal JJ 0
diseases NNS 0
, , 0
repeated VBD 0
scaling NN 0
and CC 0
root NN 0
planing NN 0
may MD 0
over VB 0
time NN 0
result NN 0
in IN 0
substantive JJ 0
loss NN 0
of IN 0
tooth JJ 0
substance NN 0
and CC 0
increased JJ 0
sensitivity NN 0
of IN 0
the DT 0
teeth NN 0
. . 0

In IN 0
an DT 0
effort NN 0
to TO 0
minimize VB 0
these DT 0
side JJ 0
effects NNS 0
of IN 0
therapy NN 0
, , 0
non-root JJ 0
substance NN 0
removing VBG 0
curettes NNS 0
have VBP 0
been VBN 0
developed VBN 0
. . 0

However RB 0
, , 0
the DT 0
clinical JJ 0
effects NNS 0
of IN 0
such JJ 0
plastic NN 0
curettes NNS 0
with IN 0
regard NN 0
to TO 0
the DT 0
control NN 0
of IN 0
the DT 0
periodontal JJ 0
infection NN 0
has VBZ 0
not RB 0
yet RB 0
been VBN 0
established VBN 0
. . 0

The DT 0
aims NNS 0
of IN 0
this DT 0
study NN 0
were VBD 0
, , 0
therefore RB 0
, , 0
to TO 0
compare VB 0
the DT 0
effects NNS 0
of IN 0
root NN 0
instrumentation NN 0
using VBG 0
plastic NN 0
curettes NNS 0
( ( 0
Universal NNP 0
Perio NNP 0
Soft NNP 0
Scaler NNP 0
, , 0
Hawe-Neos NNP 0
Dental NNP 0
, , 0
Bioggio NNP 0
, , 0
TI NNP 0
, , 0
Switzerland NNP 0
) ) 0
versus VBP 0
conventional JJ 0
steel NN 0
curettes NNS 0
on IN 0
the DT 0
periodontal JJ 0
conditions NNS 0
during IN 0
supportive JJ 0
periodontal JJ 0
therapy NN 0
. . 0

40 CD 0
subjects NNS 0
participated VBN 0
in IN 0
this DT 0
parallel NN 0
, , 0
randomized VBN 0
, , 0
double JJ 0
blind NN 0
, , 0
prospective JJ 0
longitudinal JJ 0
clinical JJ 0
study NN 0
following VBG 0
active JJ 0
peridontal JJ 0
therapy NN 0
. . 0

20 CD 0
subjects NNS 0
served VBD 0
as IN 0
a DT 0
control NN 0
group NN 0
and CC 0
were VBD 0
treated VBN 0
with IN 0
conventional JJ 0
steel NN 0
curettes NNS 0
during IN 0
a DT 0
supportive JJ 0
periodontal NN 0
care NN 0
visit NN 0
( ( 0
SPT NNP 0
) ) 0
. . 0

The DT 0
other JJ 0
20 CD 0
subjects NNS 0
, , 0
the DT 0
experimental JJ 0
group NN 0
, , 0
were VBD 0
treated VBN 0
using VBG 0
plastic NN 0
curettes NNS 0
during IN 0
a DT 0
similar JJ 0
SPT NNP 0
visit NN 0
. . 0

Clinical JJ 0
parameters NNS 0
, , 0
such JJ 0
as IN 0
bleeding VBG 0
on IN 0
probing VBG 0
( ( 0
BOP NNP 0
) ) 0
and CC 0
probing VBG 0
pocket NN 0
depth NN 0
( ( 0
PPD NNP 0
) ) 0
, , 0
were VBD 0
assessed VBN 0
at IN 0
baseline NN 0
and CC 0
3-6 JJ 0
months NNS 0
later RB 0
at IN 0
the DT 0
next JJ 0
regular JJ 0
SPT NNP 0
visit NN 0
. . 0

In IN 0
addition NN 0
, , 0
the DT 0
BOP NNP 0
percentage NN 0
was VBD 0
determined VBN 0
10 CD 0
days NNS 0
following VBG 0
baseline NN 0
. . 0

The DT 0
results NNS 0
showed VBD 0
that IN 0
there EX 0
were VBD 0
no DT 0
statistically RB 0
significant JJ 0
differences NNS 0
between IN 0
the DT 0
2 CD 0
treatment NN 0
modalities NNS 0
regarding VBG 0
BOP NNP 0
and CC 0
PPD NNP 0
at IN 0
any DT 0
observation NN 0
time NN 0
. . 0

Both DT 0
treatments NNS 0
were VBD 0
effective JJ 0
in IN 0
reducing VBG 0
the DT 0
BOP NNP 0
percentage NN 0
which WDT 0
ranged VBD 0
from IN 0
17-42 CD 0
% NN 0
at IN 0
baseline NN 0
by IN 0
about IN 0
40 CD 0
% NN 0
after IN 0
10 CD 0
days NNS 0
( ( 0
mean JJ 0
BOP NNP 0
baseline NN 0
: : 0
26 CD 0
% NN 0
, , 0
mean JJ 0
BOP NNP 0
after IN 0
10 CD 0
days NNS 0
: : 0
16 CD 0
% NN 0
) ) 0
. . 0

This DT 0
clinical JJ 0
study NN 0
suggests VBZ 0
that IN 0
non-root JJ 0
substance NN 0
removing VBG 0
curettes NNS 0
may MD 0
be VB 0
valuable JJ 0
instruments NNS 0
for IN 0
periodontally RB 0
treated JJ 0
patients NNS 0
during IN 0
maintenance NN 0
care NN 0
, , 0
thus RB 0
minimizing VBG 0
trauma NN 0
on IN 0
the DT 0
hard JJ 0
structures NNS 0
of IN 0
the DT 0
teeth NN 0
. . 0

Remote NNP 0
ischaemic JJ 0
conditioning NN 0
before IN 0
hospital JJ 0
admission NN 0
, , 0
as IN 0
a DT 0
complement NN 0
to TO 0
angioplasty VB 0
, , 0
and CC 0
effect NN 0
on IN 0
myocardial JJ 0
salvage NN 0
in IN 0
patients NNS 0
with IN 0
acute JJ 0
myocardial JJ 0
infarction NN 0
: : 0
a DT 0
randomised JJ 0
trial NN 0
. . 0

BACKGROUND NNP 0
Remote NNP 0
ischaemic JJ 0
preconditioning NN 0
attenuates NNS 0
cardiac JJ 0
injury NN 0
at IN 0
elective JJ 0
surgery NN 0
and CC 0
angioplasty NN 0
. . 0

We PRP 0
tested VBD 0
the DT 0
hypothesis NN 0
that WDT 0
remote VBP 0
ischaemic JJ 0
conditioning NN 0
during IN 0
evolving VBG 0
ST-elevation NNP 0
myocardial JJ 0
infarction NN 0
, , 0
and CC 0
done VBN 0
before IN 0
primary JJ 0
percutaneous JJ 0
coronary JJ 0
intervention NN 0
, , 0
increases VBZ 0
myocardial JJ 0
salvage NN 0
. . 0

METHODS NNP 0
333 CD 0
consecutive JJ 0
adult NN 0
patients NNS 0
with IN 0
a DT 0
suspected VBN 0
first JJ 0
acute JJ 0
myocardial JJ 0
infarction NN 0
were VBD 0
randomly RB 0
assigned VBN 0
in IN 0
a DT 0
1:1 CD 0
ratio NN 0
by IN 0
computerised JJ 0
block NN 0
randomisation NN 0
to TO 0
receive VB 0
primary JJ 0
percutaneous JJ 0
coronary JJ 0
intervention NN 0
with IN 0
( ( 0
n=166 JJ 0
patients NNS 0
) ) 0
versus NN 0
without IN 0
( ( 0
n=167 NN 0
) ) 0
remote VBP 0
conditioning VBG 0
( ( 0
intermittent JJ 0
arm NN 0
ischaemia NN 0
through IN 0
four CD 0
cycles NNS 0
of IN 0
5-min JJ 0
inflation NN 0
and CC 0
5-min JJ 0
deflation NN 0
of IN 0
a DT 0
blood-pressure JJ 0
cuff NN 0
) ) 0
. . 0

Allocation NN 0
was VBD 0
concealed VBN 0
with IN 0
opaque NN 0
sealed VBN 0
envelopes NNS 0
. . 0

Patients NNS 0
received VBD 0
remote JJ 0
conditioning NN 0
during IN 0
transport NN 0
to TO 0
hospital NN 0
, , 0
and CC 0
primary JJ 0
percutaneous JJ 0
coronary JJ 0
intervention NN 0
in IN 0
hospital NN 0
. . 0

The DT 0
primary JJ 0
endpoint NN 0
was VBD 0
myocardial JJ 0
salvage NN 0
index NN 0
at IN 0
30 CD 0
days NNS 0
after IN 0
primary JJ 0
percutaneous JJ 0
coronary JJ 0
intervention NN 0
, , 0
measured VBN 0
by IN 0
myocardial JJ 0
perfusion NN 0
imaging NN 0
as IN 0
the DT 0
proportion NN 0
of IN 0
the DT 0
area NN 0
at IN 0
risk NN 0
salvaged VBN 0
by IN 0
treatment NN 0
; : 0
analysis NN 0
was VBD 0
per IN 0
protocol NN 0
. . 0

This DT 0
study NN 0
is VBZ 0
registered VBN 0
with IN 0
ClinicalTrials.gov NNP 0
, , 0
number NN 0
NCT00435266 NNP 0
. . 0

FINDINGS NNP 0
82 CD 0
patients NNS 0
were VBD 0
excluded VBN 0
on IN 0
arrival NN 0
at IN 0
hospital NN 0
because IN 0
they PRP 0
did VBD 0
not RB 0
meet VB 0
inclusion NN 0
criteria NNS 0
, , 0
32 CD 0
were VBD 0
lost VBN 0
to TO 0
follow-up NN 0
, , 0
and CC 0
77 CD 0
did VBD 0
not RB 0
complete VB 0
the DT 0
follow-up JJ 0
with IN 0
data NNS 0
for IN 0
salvage NN 0
index NN 0
. . 0

Median JJ 0
salvage NN 0
index NN 0
was VBD 0
0.75 CD 0
( ( 0
IQR NNP 0
0.50-0.93 CD 0
, , 0
n=73 NN 0
) ) 0
in IN 0
the DT 0
remote JJ 0
conditioning NN 0
group NN 0
versus VBD 0
0.55 CD 0
( ( 0
0.35-0.88 CD 0
, , 0
n=69 NN 0
) ) 0
in IN 0
the DT 0
control NN 0
group NN 0
, , 0
with IN 0
median JJ 0
difference NN 0
of IN 0
0.10 CD 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
0.01-0.22 CD 0
; : 0
p=0.0333 NN 0
) ) 0
; : 0
mean JJ 0
salvage NN 0
index NN 0
was VBD 0
0.69 CD 0
( ( 0
SD NNP 0
0.27 CD 0
) ) 0
versus NN 0
0.57 CD 0
( ( 0
0.26 CD 0
) ) 0
, , 0
with IN 0
mean JJ 0
difference NN 0
of IN 0
0.12 CD 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
0.01-0.21 CD 0
; : 0
p=0.0333 NN 0
) ) 0
. . 0

Major JJ 0
adverse JJ 0
coronary JJ 0
events NNS 0
were VBD 0
death NN 0
( ( 0
n=3 JJ 0
per IN 0
group NN 0
) ) 0
, , 0
reinfarction NN 0
( ( 0
n=1 JJ 0
per IN 0
group NN 0
) ) 0
, , 0
and CC 0
heart NN 0
failure NN 0
( ( 0
n=3 JJ 0
per IN 0
group NN 0
) ) 0
. . 0

INTERPRETATION NNP 0
Remote NNP 0
ischaemic JJ 0
conditioning NN 0
before IN 0
hospital JJ 0
admission NN 0
increases VBZ 0
myocardial JJ 0
salvage NN 0
, , 0
and CC 0
has VBZ 0
a DT 0
favourable JJ 0
safety NN 0
profile NN 0
. . 0

Our PRP$ 0
findings NNS 0
merit VBP 0
a DT 0
larger JJR 0
trial NN 0
to TO 0
establish VB 0
the DT 0
effect NN 0
of IN 0
remote JJ 0
conditioning NN 0
on IN 0
clinical JJ 0
outcomes NNS 0
. . 0

FUNDING NN 0
Fondation NNP 0
Leducq NNP 0
. . 0

Vibrotactile NNP 0
-- : 0
auditory JJ 0
interactions NNS 0
are VBP 0
post-perceptual JJ 0
. . 0

Vibrotactile NNP 0
stimuli NN 0
can MD 0
elicit VB 0
compelling VBG 0
auditory JJ 0
sensations NNS 0
, , 0
even RB 0
when WRB 0
sound NN 0
energy NN 0
levels NNS 0
are VBP 0
minimal JJ 0
and CC 0
undetectable JJ 0
. . 0

It PRP 0
has VBZ 0
previously RB 0
been VBN 0
shown VBN 0
that IN 0
subjects NNS 0
judge VBP 0
auditory JJ 0
tones NNS 0
embedded VBN 0
in IN 0
white JJ 0
noise NN 0
to TO 0
be VB 0
louder VBN 0
when WRB 0
they PRP 0
are VBP 0
accompanied VBN 0
by IN 0
a DT 0
vibrotactile JJ 0
stimulus NN 0
of IN 0
the DT 0
same JJ 0
frequency NN 0
. . 0

A DT 0
first JJ 0
experiment NN 0
replicated VBN 0
this DT 0
result NN 0
at IN 0
four CD 0
different JJ 0
levels NNS 0
of IN 0
auditory JJ 0
stimulation NN 0
( ( 0
no DT 0
tone NN 0
, , 0
tone NN 0
at IN 0
detection NN 0
threshold NN 0
, , 0
tone NN 0
at IN 0
5 CD 0
dB NNS 0
above IN 0
threshold NN 0
, , 0
and CC 0
tone NN 0
at IN 0
10 CD 0
dB NNS 0
above IN 0
threshold NN 0
) ) 0
. . 0

The DT 0
presence NN 0
of IN 0
a DT 0
vibrotactile JJ 0
stimulus NN 0
induced VBD 0
an DT 0
increase NN 0
in IN 0
the DT 0
perceived JJ 0
loudness NN 0
of IN 0
auditory NN 0
tones NNS 0
at IN 0
three CD 0
of IN 0
the DT 0
four CD 0
values NNS 0
in IN 0
this DT 0
range NN 0
. . 0

In IN 0
two CD 0
further JJ 0
experiments NNS 0
, , 0
a DT 0
2-interval JJ 0
forced-choice JJ 0
procedure NN 0
was VBD 0
used VBN 0
to TO 0
assess VB 0
the DT 0
nature NN 0
of IN 0
this DT 0
cross-modal JJ 0
interaction NN 0
. . 0

Subjects NNS 0
were VBD 0
biased VBN 0
when WRB 0
vibrotaction NN 0
was VBD 0
applied VBN 0
in IN 0
one CD 0
interval NN 0
, , 0
but CC 0
applying VBG 0
vibrotaction NN 0
in IN 0
both DT 0
intervals NNS 0
produced VBD 0
performance NN 0
comparable JJ 0
to TO 0
conditions NNS 0
without IN 0
vibrotactile NN 0
stimuli NN 0
. . 0

This DT 0
demonstrates VBZ 0
that IN 0
vibrotaction NN 0
is VBZ 0
sometimes RB 0
ignored VBN 0
when WRB 0
judging VBG 0
the DT 0
presence NN 0
of IN 0
an DT 0
auditory JJ 0
tone NN 0
. . 0

Hence NNP 0
the DT 0
interaction NN 0
between IN 0
vibrotaction NN 0
and CC 0
audition NN 0
does VBZ 0
not RB 0
appear VB 0
to TO 0
occur VB 0
at IN 0
an DT 0
early JJ 0
perceptual JJ 0
level NN 0
. . 0

Analysis NN 0
of IN 0
prevention NN 0
program NN 0
effectiveness NN 0
with IN 0
clustered VBN 0
data NNS 0
using VBG 0
generalized JJ 0
estimating NN 0
equations NNS 0
. . 0

Experimental JJ 0
studies NNS 0
of IN 0
prevention NN 0
programs NNS 0
often RB 0
randomize VBP 0
clusters NNS 0
of IN 0
individuals NNS 0
rather RB 0
than IN 0
individuals NNS 0
to TO 0
treatment NN 0
conditions NNS 0
. . 0

When WRB 0
the DT 0
correlation NN 0
among IN 0
individuals NNS 0
within IN 0
clusters NNS 0
is VBZ 0
not RB 0
accounted VBN 0
for IN 0
in IN 0
statistical JJ 0
analysis NN 0
, , 0
the DT 0
standard JJ 0
errors NNS 0
are VBP 0
biased VBN 0
, , 0
potentially RB 0
resulting VBG 0
in IN 0
misleading VBG 0
conclusions NNS 0
about IN 0
the DT 0
significance NN 0
of IN 0
treatment NN 0
effects NNS 0
. . 0

This DT 0
study NN 0
demonstrates VBZ 0
the DT 0
generalized JJ 0
estimating NN 0
equations NNS 0
( ( 0
GEE NNP 0
) ) 0
method NN 0
, , 0
focusing VBG 0
specifically RB 0
on IN 0
the DT 0
GEE-independent NNP 0
method NN 0
, , 0
to TO 0
control VB 0
for IN 0
within-cluster JJ 0
correlation NN 0
in IN 0
regression NN 0
models NNS 0
with IN 0
either DT 0
continuous JJ 0
or CC 0
binary JJ 0
outcomes NNS 0
. . 0

The DT 0
GEE-independent JJ 0
method NN 0
yields NNS 0
consistent JJ 0
and CC 0
robust JJ 0
variance NN 0
estimates NNS 0
. . 0

Data NNS 0
from IN 0
project NN 0
DARE NNP 0
, , 0
a DT 0
youth NN 0
substance NN 0
abuse NN 0
prevention NN 0
program NN 0
, , 0
are VBP 0
used VBN 0
for IN 0
illustration NN 0
. . 0

Methodology NNP 0
of IN 0
serial JJ 0
ECG NNP 0
classification NN 0
using VBG 0
an DT 0
adaptation NN 0
of IN 0
the DT 0
NOVACODE NNP 0
for IN 0
Q NNP 0
wave VBP 0
myocardial JJ 0
infarction NN 0
in IN 0
the DT 0
Bypass NNP 0
Angioplasty NNP 0
Revascularization NNP 0
Investigation NNP 0
( ( 0
BARI NNP 0
) ) 0
. . 0

Serial JJ 0
electrocardiographic JJ 0
( ( 0
ECG NNP 0
) ) 0
changes NNS 0
are VBP 0
a DT 0
critical JJ 0
component NN 0
of IN 0
the DT 0
diagnostic JJ 0
algorithm NN 0
for IN 0
classification NN 0
of IN 0
myocardial JJ 0
ischemic JJ 0
events NNS 0
in IN 0
large-scale JJ 0
clinical JJ 0
trials NNS 0
. . 0

This DT 0
study NN 0
describes VBZ 0
a DT 0
computerized JJ 0
serial JJ 0
ECG NNP 0
classification NN 0
program NN 0
developed VBN 0
at IN 0
the DT 0
St. NNP 0
Louis NNP 0
University NNP 0
Core NNP 0
ECG NNP 0
Laboratory NNP 0
for IN 0
use NN 0
in IN 0
the DT 0
Bypass NNP 0
Angioplasty NNP 0
Revascularization NNP 0
Investigation NNP 0
( ( 0
BARI NNP 0
) ) 0
trial NN 0
, , 0
in IN 0
which WDT 0
patients NNS 0
with IN 0
multivessel JJ 0
coronary JJ 0
artery NN 0
disease NN 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
either DT 0
coronary JJ 0
artery NN 0
bypass NN 0
grafting NN 0
or CC 0
percutaneous JJ 0
transluminal JJ 0
coronary JJ 0
angioplasty NN 0
. . 0

The DT 0
St. NNP 0
Louis NNP 0
University NNP 0
program NN 0
detects NNS 0
and CC 0
codes VBZ 0
serial JJ 0
changes NNS 0
in IN 0
Q NNP 0
, , 0
ST NNP 0
, , 0
and CC 0
T NNP 0
wave VBP 0
items NNS 0
according VBG 0
to TO 0
Minnesota NNP 0
code NN 0
( ( 0
MC NNP 0
) ) 0
criteria VBP 0
using VBG 0
a DT 0
modified JJ 0
NOVACODE NNP 0
hierarchical JJ 0
classification NN 0
system NN 0
. . 0

Measurements NNS 0
using VBG 0
a DT 0
seven-power NN 0
calibrated VBN 0
coding NN 0
loupe NN 0
are VBP 0
used VBN 0
to TO 0
generate VB 0
the DT 0
MC NNP 0
from IN 0
a DT 0
customized JJ 0
software NN 0
program NN 0
. . 0

Significant NNP 0
minor VBD 0
or CC 0
major JJ 0
changes NNS 0
are VBP 0
detected VBN 0
by IN 0
the DT 0
serial JJ 0
comparison NN 0
program NN 0
and CC 0
referred VBD 0
to TO 0
a DT 0
physician JJ 0
coder NN 0
for IN 0
verification NN 0
. . 0

Serial JJ 0
comparison NN 0
coding NN 0
rules NNS 0
are VBP 0
used VBN 0
to TO 0
adjust VB 0
for IN 0
weaknesses NNS 0
in IN 0
the DT 0
standard JJ 0
MC NNP 0
classification NN 0
system NN 0
resulting VBG 0
from IN 0
instability NN 0
at IN 0
decision NN 0
boundaries NNS 0
. . 0

Of IN 0
4,244 CD 0
BARI NNP 0
randomized VBN 0
and CC 0
registry NN 0
study NN 0
participants NNS 0
with IN 0
follow-up JJ 0
ECGs NNP 0
received VBD 0
at IN 0
the DT 0
Core NNP 0
ECG NNP 0
Laboratory NNP 0
as IN 0
of IN 0
March NNP 0
1995 CD 0
, , 0
a DT 0
grade NN 0
2 CD 0
MC NNP 0
Q NNP 0
wave VBP 0
progression NN 0
was VBD 0
noted VBN 0
in IN 0
568 CD 0
participants NNS 0
( ( 0
13.4 CD 0
% NN 0
) ) 0
using VBG 0
MC NNP 0
criteria NNS 0
alone RB 0
, , 0
as IN 0
compared VBN 0
with IN 0
367 CD 0
( ( 0
8.6 CD 0
% NN 0
) ) 0
after IN 0
the DT 0
St. NNP 0
Louis NNP 0
University NNP 0
coding NN 0
rules NNS 0
were VBD 0
applied VBN 0
. . 0

The DT 0
incidence NN 0
of IN 0
grade NN 0
1 CD 0
MC NNP 0
Q NNP 0
wave VBP 0
progressions NNS 0
was VBD 0
16.4 CD 0
% NN 0
( ( 0
697/4,244 CD 0
) ) 0
versus NN 0
6.1 CD 0
% NN 0
( ( 0
259/4,244 CD 0
) ) 0
when WRB 0
the DT 0
St. NNP 0
Louis NNP 0
University NNP 0
program NN 0
was VBD 0
applied VBN 0
. . 0

Intraobserver NNP 0
variability NN 0
for IN 0
grade NN 0
2 CD 0
Q NNP 0
wave VBP 0
progression NN 0
codes NNS 0
determined VBD 0
from IN 0
a DT 0
sample NN 0
of IN 0
812 CD 0
serial NN 0
. . 0

Salbutamol NNP 0
or CC 0
mist NN 0
in IN 0
acute JJ 0
bronchiolitis NN 0
. . 0

BACKGROUND IN 0
The DT 0
role NN 0
of IN 0
bronchodilators NNS 0
in IN 0
the DT 0
treatment NN 0
of IN 0
bronchiolitis NN 0
remains VBZ 0
controversial JJ 0
. . 0

METHODS VB 0
A DT 0
double-blind NN 0
, , 0
placebo NN 0
controlled VBD 0
trial NN 0
was VBD 0
performed VBN 0
to TO 0
evaluate VB 0
the DT 0
clinical JJ 0
response NN 0
to TO 0
nebulized VBN 0
salbutamol NN 0
. . 0

One CD 0
hundred CD 0
and CC 0
fifty-six JJ 0
infants NNS 0
aged VBN 0
between IN 0
7 CD 0
weeks NNS 0
and CC 0
24 CD 0
months NNS 0
who WP 0
had VBD 0
had VBN 0
an DT 0
episode NN 0
of IN 0
wheezing NN 0
and CC 0
other JJ 0
signs NNS 0
and CC 0
symptoms NNS 0
of IN 0
bronchiolitis NN 0
were VBD 0
randomized VBN 0
to TO 0
three CD 0
groups NNS 0
as IN 0
follows VBZ 0
: : 0
( ( 0
i NN 0
) ) 0
nebulized VBD 0
salbutamol NN 0
was VBD 0
administered VBN 0
to TO 0
52 CD 0
patients NNS 0
in IN 0
group NN 0
I PRP 0
at IN 0
a DT 0
dose NN 0
of IN 0
0.15 CD 0
mg/kg NNS 0
in IN 0
2 CD 0
mL JJ 0
saline NN 0
; : 0
( ( 0
ii NN 0
) ) 0
saline NN 0
was VBD 0
nebulized VBN 0
to TO 0
52 CD 0
patients NNS 0
in IN 0
group NN 0
II NNP 0
and CC 0
( ( 0
iii NN 0
) ) 0
in IN 0
group NN 0
III NNP 0
52 CD 0
patients NNS 0
received JJ 0
mist NN 0
in IN 0
a DT 0
tent NN 0
. . 0

All DT 0
three CD 0
groups NNS 0
were VBD 0
administered VBN 0
oxygen NN 0
during IN 0
the DT 0
procedures NNS 0
. . 0

Treatment NNP 0
was VBD 0
repeated VBN 0
with IN 0
the DT 0
same JJ 0
agent NN 0
after IN 0
30 CD 0
min NN 0
if IN 0
the DT 0
respiratory NN 0
score NN 0
was VBD 0
5 CD 0
or CC 0
more JJR 0
. . 0

Respiratory JJ 0
rate NN 0
, , 0
heart NN 0
rate NN 0
, , 0
oxygen NN 0
saturation NN 0
and CC 0
presence NN 0
of IN 0
cyanosis NN 0
, , 0
wheezing VBG 0
, , 0
retractions NNS 0
were VBD 0
recorded VBN 0
before IN 0
and CC 0
after IN 0
each DT 0
treatment NN 0
. . 0

RESULTS VB 0
The DT 0
decrease NN 0
in IN 0
the DT 0
respiratory NN 0
score NN 0
was VBD 0
5.2 CD 0
+/- JJ 0
1.8 CD 0
, , 0
0.82 CD 0
+/- JJ 0
2.4 CD 0
and CC 0
1.7 CD 0
+/- JJ 0
1.3 CD 0
in IN 0
group NN 0
I PRP 0
, , 0
II NNP 0
and CC 0
III NNP 0
, , 0
respectively RB 0
. . 0

The DT 0
decrease NN 0
in IN 0
group NN 0
I PRP 0
was VBD 0
significantly RB 0
higher JJR 0
than IN 0
in IN 0
the DT 0
other JJ 0
groups NNS 0
. . 0

Heart NNP 0
rate NN 0
was VBD 0
similar JJ 0
between IN 0
groups NNS 0
. . 0

Oxygen NNP 0
saturation NN 0
decreased VBD 0
in IN 0
group NN 0
I PRP 0
without IN 0
reaching VBG 0
statistical JJ 0
significance NN 0
. . 0

CONCLUSIONS NNP 0
Salbutamol NNP 0
was VBD 0
shown VBN 0
to TO 0
be VB 0
effective JJ 0
and CC 0
safe JJ 0
in IN 0
the DT 0
treatment NN 0
of IN 0
acute JJ 0
bronchiolitis NN 0
. . 0

Intervention NN 0
pilot NN 0
for IN 0
parents NNS 0
of IN 0
children NNS 0
with IN 0
autistic JJ 0
spectrum NN 0
disorder NN 0
. . 0

Parents NNS 0
of IN 0
children NNS 0
who WP 0
receive VBP 0
the DT 0
diagnosis NN 0
of IN 0
autistic JJ 0
spectrum NN 0
disorder NN 0
( ( 0
ASD NNP 0
) ) 0
experience NN 0
a DT 0
situational JJ 0
crisis NN 0
related VBN 0
to TO 0
receiving VBG 0
the DT 0
diagnosis NN 0
, , 0
which WDT 0
causes VBZ 0
feelings NNS 0
of IN 0
distress NN 0
and CC 0
urgency NN 0
to TO 0
access NN 0
services NNS 0
for IN 0
the DT 0
affected JJ 0
child NN 0
. . 0

This DT 0
paper NN 0
describes VBZ 0
a DT 0
randomized JJ 0
trial NN 0
( ( 0
n JJ 0
= NNP 0
31 CD 0
) ) 0
that WDT 0
was VBD 0
conducted VBN 0
at IN 0
a DT 0
regional JJ 0
diagnostic JJ 0
center NN 0
of IN 0
a DT 0
large JJ 0
metropolitan JJ 0
children NNS 0
's POS 0
hospital NN 0
to TO 0
( ( 0
a DT 0
) ) 0
refine NN 0
a DT 0
nursing NN 0
intervention NN 0
designed VBN 0
for IN 0
parents NNS 0
of IN 0
children NNS 0
with IN 0
ASD NNP 0
and CC 0
( ( 0
b NN 0
) ) 0
to TO 0
identify VB 0
methodological JJ 0
revisions NNS 0
for IN 0
a DT 0
larger JJR 0
study NN 0
. . 0

A DT 0
secondary JJ 0
purpose NN 0
was VBD 0
to TO 0
test VB 0
the DT 0
effects NNS 0
of IN 0
a DT 0
post-diagnosis JJ 0
nursing NN 0
intervention NN 0
on IN 0
parents NNS 0
' POS 0
reports NNS 0
of IN 0
stress NN 0
, , 0
impact NN 0
of IN 0
event NN 0
( ( 0
diagnosis NN 0
) ) 0
, , 0
and CC 0
use NN 0
of IN 0
services NNS 0
after IN 0
a DT 0
child NN 0
is VBZ 0
newly RB 0
diagnosed VBN 0
with IN 0
ASD NNP 0
. . 0

The DT 0
intervention NN 0
consisted VBD 0
of IN 0
usual JJ 0
care NN 0
plus CC 0
3 CD 0
hours NNS 0
contact NN 0
with IN 0
a DT 0
pediatric JJ 0
nurse NN 0
practitioner NN 0
( ( 0
PNP NNP 0
) ) 0
for IN 0
counseling NN 0
, , 0
instruction NN 0
, , 0
and CC 0
assistance NN 0
with IN 0
implementation NN 0
of IN 0
the DT 0
recommended VBN 0
treatment NN 0
plan NN 0
. . 0

The DT 0
control NN 0
group NN 0
received VBD 0
only RB 0
the DT 0
usual JJ 0
care NN 0
post-diagnosis NN 0
, , 0
which WDT 0
consisted VBD 0
of IN 0
a DT 0
1-hour JJ 0
consultation NN 0
session NN 0
to TO 0
receive VB 0
the DT 0
results NNS 0
of IN 0
diagnostic JJ 0
tests NNS 0
and CC 0
a DT 0
written VBN 0
copy NN 0
of IN 0
the DT 0
recommended VBN 0
treatment NN 0
plan NN 0
provided VBN 0
by IN 0
a DT 0
developmental JJ 0
pediatrician JJ 0
and/or NN 0
PNP NNP 0
. . 0

Between NNP 0
group NN 0
differences NNS 0
in IN 0
measures NNS 0
of IN 0
impact NN 0
of IN 0
event NN 0
and CC 0
perceived VBD 0
stress NN 0
were VBD 0
not RB 0
statistically RB 0
significant JJ 0
. . 0

This DT 0
was VBD 0
attributed VBN 0
to TO 0
a DT 0
small JJ 0
sample NN 0
size NN 0
. . 0

A NNP 0
larger JJR 0
study NN 0
is VBZ 0
feasible JJ 0
and CC 0
recommended VBD 0
with IN 0
an DT 0
expanded JJ 0
nursing NN 0
intervention NN 0
and CC 0
a DT 0
significantly RB 0
larger JJR 0
sample NN 0
recruited VBD 0
from IN 0
an DT 0
additional JJ 0
recruitment NN 0
site NN 0
. . 0

Nurses NNS 0
working VBG 0
with IN 0
this DT 0
special JJ 0
population NN 0
must MD 0
recognize VB 0
that IN 0
parents NNS 0
have VBP 0
information NN 0
and CC 0
counseling NN 0
needs NNS 0
that WDT 0
begin VBP 0
after IN 0
they PRP 0
receive VBP 0
the DT 0
diagnosis NN 0
of IN 0
ASD NNP 0
for IN 0
their PRP$ 0
child NN 0
and CC 0
can MD 0
address VB 0
these DT 0
needs NNS 0
with IN 0
a DT 0
standardized JJ 0
nursing NN 0
intervention NN 0
. . 0

[ RB 0
Intravenous JJ 0
treatment NN 0
of IN 0
postpartum NN 0
anemia NN 0
with IN 0
trivalent JJ 0
ferrum NN 0
preparation NN 0
] NNP 0
. . 0

AIM NNP 0
OF IN 0
THE NNP 0
STUDY NNP 0
To TO 0
assess VB 0
the DT 0
effectivity NN 0
and CC 0
safeness NN 0
of IN 0
intravenous JJ 0
treatment NN 0
of IN 0
pospartal JJ 0
anemia NN 0
with IN 0
trivalent JJ 0
ferrum NN 0
preparation NN 0
. . 0

TYPE NNP 0
OF IN 0
THE NNP 0
STUDY NNP 0
Prospective NNP 0
randomized VBD 0
study NN 0
. . 0

SETTING NNP 0
Department NNP 0
of IN 0
Obstetric NNP 0
and CC 0
Gynecology NNP 0
2nd CD 0
Medical NNP 0
Faculty NNP 0
Charles NNP 0
University NNP 0
and CC 0
Teaching NNP 0
Hospital NNP 0
Motol NNP 0
, , 0
Prague NNP 0
, , 0
and CC 0
Department NNP 0
of IN 0
Obstetric NNP 0
and CC 0
Gynecology NNP 0
1st CD 0
Medical NNP 0
Faculty NNP 0
and CC 0
Teaching NNP 0
Hospital NNP 0
Bulovka NNP 0
, , 0
Prague NNP 0
. . 0

METHODS NNP 0
500 CD 0
mg NN 0
of IN 0
sacharose JJ 0
ferric JJ 0
oxide NN 0
( ( 0
Venofer NNP 0
) ) 0
was VBD 0
intravenously RB 0
administered VBN 0
in IN 0
two CD 0
days NNS 0
regimen NNS 0
to TO 0
50 CD 0
women NNS 0
with IN 0
clinical JJ 0
and CC 0
lab JJ 0
signs NNS 0
of IN 0
postpartal JJ 0
anemia NN 0
. . 0

The DT 0
effect NN 0
of IN 0
administered JJ 0
drug NN 0
was VBD 0
determined VBN 0
by IN 0
comparsion NN 0
of IN 0
values NNS 0
of IN 0
red JJ 0
blood NN 0
count NN 0
recovered VBD 0
before IN 0
the DT 0
treatment NN 0
, , 0
2nd CD 0
or CC 0
3rd CD 0
day NN 0
post NN 0
administration NN 0
and CC 0
two CD 0
weeks NNS 0
later RB 0
. . 0

The DT 0
serum NN 0
values NNS 0
of IN 0
soluble JJ 0
transferrin NN 0
receptors NNS 0
and CC 0
ferritin NNS 0
were VBD 0
observed VBN 0
as IN 0
markers NNS 0
of IN 0
iron NN 0
cell NN 0
saturation NN 0
and CC 0
body NN 0
iron NN 0
reserves NNS 0
, , 0
too RB 0
. . 0

Integral JJ 0
part NN 0
of IN 0
the DT 0
study NN 0
was VBD 0
the DT 0
monitoring NN 0
of IN 0
adverse JJ 0
events NNS 0
during IN 0
the DT 0
treatment NN 0
. . 0

RESULTS NNP 0
Venofer NNP 0
came VBD 0
in IN 0
sight NN 0
as IN 0
effective JJ 0
drug NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
pospartal JJ 0
anemia NN 0
and CC 0
could MD 0
become VB 0
as IN 0
the DT 0
alternative NN 0
to TO 0
blood VB 0
transfusion NN 0
in IN 0
mid-severe JJ 0
cases NNS 0
. . 0

It PRP 0
should MD 0
be VB 0
emphasized VBN 0
that IN 0
we PRP 0
have VBP 0
not RB 0
encountered VBN 0
any DT 0
serious JJ 0
adverse JJ 0
event NN 0
with IN 0
intravenous JJ 0
trivalent NN 0
saccharose VBD 0
ferric JJ 0
oxide JJ 0
treatment NN 0
. . 0

Phase NNP 0
III NNP 0
study NN 0
of IN 0
concurrent JJ 0
chemoradiotherapy NN 0
versus NN 0
radiotherapy NN 0
alone RB 0
for IN 0
advanced JJ 0
nasopharyngeal JJ 0
carcinoma NN 0
: : 0
positive JJ 0
effect NN 0
on IN 0
overall JJ 0
and CC 0
progression-free JJ 0
survival NN 0
. . 0

PURPOSE NNP 0
Nasopharyngeal NNP 0
carcinoma NN 0
( ( 0
NPC NNP 0
) ) 0
is VBZ 0
a DT 0
radiosensitive JJ 0
and CC 0
chemosensitive JJ 0
tumor NN 0
. . 0

This DT 0
randomized JJ 0
phase NN 0
III NNP 0
trial NN 0
compared VBN 0
concurrent JJ 0
chemoradiotherapy NN 0
( ( 0
CCRT NNP 0
) ) 0
versus NN 0
radiotherapy NN 0
( ( 0
RT NNP 0
) ) 0
alone RB 0
in IN 0
patients NNS 0
with IN 0
advanced JJ 0
NPC NNP 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
From NNP 0
December NNP 0
1993 CD 0
to TO 0
April NNP 0
1999 CD 0
, , 0
284 CD 0
patients NNS 0
with IN 0
1992 CD 0
American NNP 0
Joint NNP 0
Committee NNP 0
on IN 0
Cancer NNP 0
stage NN 0
III NNP 0
to TO 0
IV NNP 0
( ( 0
M0 NNP 0
) ) 0
NPC NNP 0
were VBD 0
randomly RB 0
allocated VBN 0
into IN 0
two CD 0
arms NNS 0
. . 0

Similar JJ 0
dosage NN 0
and CC 0
fractionation NN 0
of IN 0
RT NNP 0
was VBD 0
administered VBN 0
in IN 0
both DT 0
arms NNS 0
. . 0

The DT 0
investigational JJ 0
arm NN 0
received VBD 0
two CD 0
cycles NNS 0
of IN 0
concurrent JJ 0
chemotherapy NN 0
with IN 0
cisplatin NN 0
20 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
/d NN 0
plus CC 0
fluorouracil JJ 0
400 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
/d NN 0
by IN 0
96-hour CD 0
continuous JJ 0
infusion NN 0
during IN 0
the DT 0
weeks NNS 0
1 CD 0
and CC 0
5 CD 0
of IN 0
RT NNP 0
. . 0

Survival NNP 0
analysis NN 0
was VBD 0
estimated VBN 0
by IN 0
the DT 0
Kaplan-Meier NNP 0
method NN 0
and CC 0
compared VBN 0
by IN 0
the DT 0
log-rank JJ 0
test NN 0
. . 0

RESULTS NNP 0
Baseline NNP 0
patient JJ 0
characteristics NNS 0
were VBD 0
comparable JJ 0
in IN 0
both DT 0
arms NNS 0
. . 0

After IN 0
a DT 0
median JJ 0
follow-up NN 0
of IN 0
65 CD 0
months NNS 0
, , 0
26.2 CD 0
% NN 0
( ( 0
37 CD 0
of IN 0
141 CD 0
) ) 0
and CC 0
46.2 CD 0
% NN 0
( ( 0
66 CD 0
of IN 0
143 CD 0
) ) 0
of IN 0
patients NNS 0
developed JJ 0
tumor NN 0
relapse NN 0
in IN 0
the DT 0
CCRT NNP 0
and CC 0
RT-alone NNP 0
groups NNS 0
, , 0
respectively RB 0
. . 0

The DT 0
5-year JJ 0
overall JJ 0
survival NN 0
rates NNS 0
were VBD 0
72.3 CD 0
% NN 0
for IN 0
the DT 0
CCRT NNP 0
arm NN 0
and CC 0
54.2 CD 0
% NN 0
for IN 0
the DT 0
RT-only JJ 0
arm NN 0
( ( 0
P NNP 0
=.0022 NNP 0
) ) 0
. . 0

The DT 0
5-year JJ 0
progression-free JJ 0
survival NN 0
rates NNS 0
were VBD 0
71.6 CD 0
% NN 0
for IN 0
the DT 0
CCRT NNP 0
group NN 0
compared VBN 0
with IN 0
53.0 CD 0
% NN 0
for IN 0
the DT 0
RT-only JJ 0
group NN 0
( ( 0
P NNP 0
=.0012 NNP 0
) ) 0
. . 0

Although IN 0
significantly RB 0
more JJR 0
toxicity NN 0
was VBD 0
noted VBN 0
in IN 0
the DT 0
CCRT NNP 0
arm NN 0
, , 0
including VBG 0
leukopenia NN 0
and CC 0
emesis NN 0
, , 0
compliance NN 0
with IN 0
the DT 0
combined JJ 0
treatment NN 0
was VBD 0
good JJ 0
. . 0

The DT 0
second JJ 0
cycle NN 0
of IN 0
concurrent JJ 0
chemotherapy NN 0
was VBD 0
refused VBN 0
by IN 0
nine CD 0
patients NNS 0
and CC 0
was VBD 0
delayed VBN 0
for IN 0
> NN 0
or CC 0
= $ 0
1 CD 0
week NN 0
for IN 0
another DT 0
nine CD 0
patients NNS 0
. . 0

There EX 0
were VBD 0
no DT 0
treatment-related JJ 0
deaths NNS 0
in IN 0
either DT 0
arm NN 0
. . 0

CONCLUSION NN 0
We PRP 0
conclude VBP 0
that DT 0
CCRT NNP 0
is VBZ 0
superior JJ 0
to TO 0
RT VB 0
alone RB 0
for IN 0
patients NNS 0
with IN 0
advanced JJ 0
NPC NNP 0
in IN 0
endemic JJ 0
areas NNS 0
. . 0

Recurrent JJ 0
epithelial JJ 0
ovarian JJ 0
carcinoma NN 0
: : 0
a DT 0
randomized JJ 0
phase NN 0
III NNP 0
study NN 0
of IN 0
pegylated VBN 0
liposomal JJ 0
doxorubicin NN 0
versus NN 0
topotecan JJ 0
. . 0

PURPOSE NNP 0
To TO 0
compare VB 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
pegylated JJ 0
liposomal JJ 0
doxorubicin NN 0
( ( 0
PLD NNP 0
) ) 0
and CC 0
topotecan JJ 0
in IN 0
patients NNS 0
with IN 0
epithelial JJ 0
ovarian JJ 0
carcinoma NN 0
that WDT 0
recurred VBD 0
after IN 0
or CC 0
did VBD 0
n't RB 0
respond VB 0
to TO 0
first-line JJ 0
, , 0
platinum-based JJ 0
chemotherapy NN 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
Patients NNPS 0
with IN 0
measurable JJ 0
and CC 0
assessable JJ 0
disease NN 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
either DT 0
PLD NNP 0
50 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
as IN 0
a DT 0
1-hour JJ 0
infusion NN 0
every DT 0
4 CD 0
weeks NNS 0
or CC 0
topotecan JJ 0
1.5 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
/d NN 0
for IN 0
5 CD 0
consecutive JJ 0
days NNS 0
every DT 0
3 CD 0
weeks NNS 0
. . 0

Patients NNS 0
were VBD 0
stratified VBN 0
prospectively RB 0
for IN 0
platinum NN 0
sensitivity NN 0
and CC 0
for IN 0
the DT 0
presence NN 0
or CC 0
absence NN 0
of IN 0
bulky JJ 0
disease NN 0
. . 0

RESULTS VB 0
A DT 0
total NN 0
of IN 0
474 CD 0
patients NNS 0
were VBD 0
treated VBN 0
( ( 0
239 CD 0
PLD NNP 0
and CC 0
235 CD 0
topotecan JJ 0
) ) 0
. . 0

They PRP 0
comprised VBD 0
the DT 0
intent-to-treat JJ 0
population NN 0
. . 0

The DT 0
overall JJ 0
progression-free JJ 0
survival NN 0
rates NNS 0
were VBD 0
similar JJ 0
between IN 0
the DT 0
two CD 0
arms NNS 0
( ( 0
P NNP 0
=.095 NNP 0
) ) 0
. . 0

The DT 0
overall JJ 0
response NN 0
rates NNS 0
for IN 0
PLD NNP 0
and CC 0
topotecan JJ 0
were VBD 0
19.7 CD 0
% NN 0
and CC 0
17.0 CD 0
% NN 0
, , 0
respectively RB 0
( ( 0
P NNP 0
=.390 NNP 0
) ) 0
. . 0

Median JJ 0
overall JJ 0
survival NN 0
times NNS 0
were VBD 0
60 CD 0
weeks NNS 0
for IN 0
PLD NNP 0
and CC 0
56.7 CD 0
weeks NNS 0
for IN 0
topotecan JJ 0
. . 0

Data NNP 0
analyzed VBD 0
in IN 0
platinum-sensitive JJ 0
patients NNS 0
demonstrated VBD 0
a DT 0
statistically RB 0
significant JJ 0
benefit NN 0
from IN 0
PLD NNP 0
for IN 0
progression-free JJ 0
survival NN 0
( ( 0
P NNP 0
=.037 NNP 0
) ) 0
, , 0
with IN 0
medians NNS 0
of IN 0
28.9 CD 0
for IN 0
PLD NNP 0
versus FW 0
23.3 CD 0
weeks NNS 0
for IN 0
topotecan JJ 0
. . 0

For IN 0
overall JJ 0
survival NN 0
, , 0
PLD NNP 0
was VBD 0
significantly RB 0
superior JJ 0
to TO 0
topotecan VB 0
( ( 0
P NNP 0
=.008 NNP 0
) ) 0
, , 0
with IN 0
a DT 0
median NN 0
of IN 0
108 CD 0
weeks NNS 0
versus RB 0
71.1 CD 0
weeks NNS 0
. . 0

The DT 0
platinum-refractory JJ 0
subgroup NN 0
demonstrated VBD 0
a DT 0
nonstatistically RB 0
significant JJ 0
survival JJ 0
trend NN 0
in IN 0
favor NN 0
of IN 0
topotecan JJ 0
( ( 0
P NNP 0
=.455 NNP 0
) ) 0
. . 0

Severe JJ 0
hematologic JJ 0
toxicity NN 0
was VBD 0
more RBR 0
common JJ 0
with IN 0
topotecan JJ 0
and CC 0
was VBD 0
more RBR 0
likely JJ 0
to TO 0
be VB 0
associated VBN 0
with IN 0
dosage NN 0
modification NN 0
, , 0
or CC 0
growth NN 0
factor NN 0
or CC 0
blood NN 0
product NN 0
utilization NN 0
. . 0

CONCLUSION VB 0
The DT 0
comparable JJ 0
efficacy NN 0
, , 0
favorable JJ 0
safety NN 0
profile NN 0
, , 0
and CC 0
convenient NN 0
dosing VBG 0
support NN 0
the DT 0
role NN 0
of IN 0
PLD NNP 0
as IN 0
a DT 0
valuable JJ 0
treatment NN 0
option NN 0
in IN 0
this DT 0
patient JJ 0
population NN 0
. . 0

The DT 0
treatment NN 0
of IN 0
asthma NN 0
in IN 0
adults NNS 0
using VBG 0
sodium NN 0
cromoglycate NN 0
pressurized VBN 0
aerosol NN 0
: : 0
a DT 0
double-blind NN 0
controlled VBN 0
trial NN 0
. . 0

Sodium NN 0
cromoglycate NN 0
formulated VBN 0
as IN 0
a DT 0
pressurized JJ 0
aerosol NN 0
( ( 0
2 CD 0
mg RB 0
4-times JJ 0
daily JJ 0
) ) 0
and CC 0
placebo NN 0
were VBD 0
compared VBN 0
in IN 0
31 CD 0
adult NN 0
asthmatic JJ 0
patients NNS 0
in IN 0
a DT 0
double-blind JJ 0
crossover NN 0
trial NN 0
lasting VBG 0
12 CD 0
weeks NNS 0
. . 0

Sodium NNP 0
cromoglycate NN 0
was VBD 0
superior JJ 0
to TO 0
placebo VB 0
in IN 0
improving VBG 0
breathlessness NN 0
at IN 0
rest NN 0
( ( 0
p IN 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
, , 0
breathlessness NN 0
on IN 0
exertion NN 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
and CC 0
the DT 0
quality NN 0
of IN 0
sleep NN 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
, , 0
and CC 0
also RB 0
in IN 0
improving VBG 0
the DT 0
morning NN 0
peak NN 0
expiratory NN 0
flow NN 0
rate NN 0
value NN 0
( ( 0
p IN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
. . 0

Both CC 0
the DT 0
patients NNS 0
' POS 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
and CC 0
the DT 0
clinicians NNS 0
' POS 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.01 CD 0
) ) 0
treatment NN 0
opinions NNS 0
, , 0
and CC 0
their PRP$ 0
treatment NN 0
preferences NNS 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
, , 0
favoured VBD 0
sodium NN 0
cromoglycate NN 0
. . 0

Moreover RB 0
, , 0
usage NN 0
of IN 0
bronchodilators NNS 0
( ( 0
theophylline NN 0
and CC 0
aerosol JJ 0
beta-stimulants NNS 0
combined VBN 0
) ) 0
declined VBD 0
significantly RB 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
during IN 0
sodium NN 0
cromoglycate NN 0
treatment NN 0
compared VBN 0
to TO 0
placebo VB 0
. . 0

No DT 0
side-effects NNS 0
were VBD 0
reported VBN 0
. . 0

The DT 0
results NNS 0
of IN 0
this DT 0
study NN 0
show NN 0
that IN 0
sodium NN 0
cromoglycate NN 0
delivered VBN 0
by IN 0
pressurized JJ 0
aerosol NN 0
was VBD 0
significantly RB 0
superior JJ 0
to TO 0
placebo VB 0
, , 0
not RB 0
only RB 0
in IN 0
improving VBG 0
asthmatic JJ 0
symptoms NNS 0
, , 0
but CC 0
also RB 0
in IN 0
reducing VBG 0
the DT 0
amount NN 0
of IN 0
concomitant JJ 0
bronchodilator NN 0
therapy NN 0
required VBN 0
. . 0

The DT 0
effect NN 0
of IN 0
weight NN 0
training NN 0
on IN 0
bone JJ 0
mineral JJ 0
density NN 0
and CC 0
bone NN 0
turnover NN 0
in IN 0
postmenopausal JJ 0
breast NN 0
cancer NN 0
survivors NNS 0
with IN 0
bone JJ 0
loss NN 0
: : 0
a DT 0
24-month JJ 0
randomized NN 0
controlled VBD 0
trial NN 0
. . 0

SUMMARY VB 0
This DT 0
study NN 0
examined VBD 0
whether IN 0
24 CD 0
months NNS 0
of IN 0
weight JJ 0
training NN 0
exercises NNS 0
enhanced VBD 0
the DT 0
effectiveness NN 0
of IN 0
risedronate NN 0
, , 0
calcium NN 0
, , 0
and CC 0
vitamin NN 0
D NNP 0
in IN 0
maintaining VBG 0
or CC 0
improving VBG 0
bone JJ 0
mineral JJ 0
density NN 0
( ( 0
BMD NNP 0
) ) 0
in IN 0
223 CD 0
postmenopausal NN 0
breast NN 0
cancer NN 0
survivors NNS 0
. . 0

Subjects NNS 0
who WP 0
were VBD 0
> NNP 0
or CC 0
=50 CD 0
% NN 0
adherent NN 0
to TO 0
exercise VB 0
had VBN 0
no DT 0
improvement NN 0
in IN 0
BMD NNP 0
but CC 0
were VBD 0
less RBR 0
likely JJ 0
to TO 0
lose VB 0
BMD NNP 0
. . 0

INTRODUCTION NNP 0
This DT 0
study NN 0
examined VBD 0
whether IN 0
( ( 0
1 CD 0
) ) 0
postmenopausal NN 0
breast NN 0
cancer NN 0
survivors NNS 0
( ( 0
BCS NNP 0
) ) 0
with IN 0
bone NN 0
loss NN 0
taking VBG 0
24 CD 0
months NNS 0
of IN 0
risedronate NN 0
, , 0
calcium NN 0
, , 0
and CC 0
vitamin NN 0
D NNP 0
had VBD 0
increased VBN 0
bone RB 0
mineral JJ 0
density NN 0
( ( 0
BMD NNP 0
) ) 0
at IN 0
the DT 0
total JJ 0
hip NN 0
, , 0
femoral JJ 0
neck NN 0
, , 0
L1-L4 NNP 0
spine NN 0
, , 0
total JJ 0
radius NN 0
and CC 0
33 CD 0
% NN 0
radius NN 0
, , 0
and CC 0
decreased VBD 0
bone NN 0
turnover NN 0
; : 0
( ( 0
2 CD 0
) ) 0
subjects NNS 0
who WP 0
also RB 0
participated VBD 0
in IN 0
strength/weight JJ 0
training NN 0
( ( 0
ST NNP 0
) ) 0
exercises NNS 0
had VBD 0
greater JJR 0
increases NNS 0
in IN 0
BMD NNP 0
and CC 0
greater JJR 0
decreases NNS 0
in IN 0
bone NN 0
turnover NN 0
; : 0
and CC 0
( ( 0
3 CD 0
) ) 0
subjects NNS 0
who WP 0
also RB 0
exercised VBD 0
were VBD 0
more RBR 0
likely JJ 0
to TO 0
preserve VB 0
( ( 0
at IN 0
least JJS 0
maintain NN 0
) ) 0
BMD NNP 0
. . 0

METHODS NNP 0
Postmenopausal NNP 0
BCS NNP 0
( ( 0
223 CD 0
) ) 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
exercise VB 0
plus JJ 0
medication NN 0
or CC 0
medication NN 0
only RB 0
groups NNS 0
. . 0

Both DT 0
groups NNS 0
received VBD 0
24 CD 0
months NNS 0
of IN 0
1,200 CD 0
mg NN 0
of IN 0
calcium NN 0
and CC 0
400 CD 0
IU NNP 0
of IN 0
vitamin NNP 0
D NNP 0
daily RB 0
and CC 0
35 CD 0
mg NN 0
of IN 0
risedronate JJ 0
weekly JJ 0
, , 0
and CC 0
the DT 0
exercise NN 0
group NN 0
additionally RB 0
had VBD 0
ST NNP 0
exercises NNS 0
twice RB 0
weekly RB 0
. . 0

RESULTS NNP 0
After IN 0
24 CD 0
months NNS 0
, , 0
women NNS 0
who WP 0
took VBD 0
medications NNS 0
without IN 0
exercising VBG 0
had VBD 0
significant JJ 0
improvements NNS 0
in IN 0
BMD NNP 0
at IN 0
the DT 0
total JJ 0
hip NN 0
( ( 0
+1.81 CD 0
% NN 0
) ) 0
and CC 0
spine NN 0
( ( 0
+2.85 CD 0
% NN 0
) ) 0
and CC 0
significant JJ 0
decreases NNS 0
in IN 0
Alkphase NNP 0
B NNP 0
( ( 0
-8.7 NNP 0
% NN 0
) ) 0
and CC 0
serum JJ 0
NTx NNP 0
( ( 0
-16.7 NNP 0
% NN 0
) ) 0
. . 0

Women NNS 0
who WP 0
also RB 0
exercised VBD 0
had VBD 0
additional JJ 0
increases NNS 0
in IN 0
BMD NNP 0
at IN 0
the DT 0
femoral JJ 0
neck NN 0
( ( 0
+0.29 CD 0
% NN 0
) ) 0
, , 0
total JJ 0
hip NN 0
( ( 0
+0.34 CD 0
% NN 0
) ) 0
, , 0
spine NN 0
( ( 0
+0.23 CD 0
% NN 0
) ) 0
, , 0
total JJ 0
radius NN 0
( ( 0
+0.30 CD 0
% NN 0
) ) 0
, , 0
and CC 0
additional JJ 0
decreases NNS 0
in IN 0
Alkphase NNP 0
B NNP 0
( ( 0
-2.4 NNP 0
% NN 0
) ) 0
and CC 0
Serum NNP 0
NTx NNP 0
( ( 0
-6.5 NNP 0
% NN 0
) ) 0
. . 0

Additional JJ 0
changes NNS 0
in IN 0
BMD NNP 0
and CC 0
bone NN 0
turnover NN 0
with IN 0
exercise NN 0
were VBD 0
not RB 0
significant JJ 0
. . 0

Subjects NNS 0
who WP 0
were VBD 0
> NNP 0
or CC 0
=50 CD 0
% NN 0
adherent NN 0
to TO 0
exercise VB 0
were VBD 0
less RBR 0
likely JJ 0
to TO 0
lose VB 0
BMD NNP 0
at IN 0
the DT 0
total JJ 0
hip NN 0
( ( 0
chi-square JJ 0
[ NN 0
1 CD 0
] NNP 0
= NNP 0
4.66 CD 0
, , 0
p NN 0
= NNP 0
0.03 CD 0
) ) 0
and CC 0
femoral JJ 0
neck NN 0
( ( 0
chi-square JJ 0
[ NN 0
1 CD 0
] NNP 0
= NNP 0
4.63 CD 0
, , 0
p NN 0
= NNP 0
0.03 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
Strength/weight NNP 0
training NN 0
exercises NNS 0
may MD 0
prevent VB 0
loss NN 0
of IN 0
BMD NNP 0
in IN 0
postmenopausal NN 0
BCS NNP 0
at IN 0
risk NN 0
for IN 0
bone NN 0
loss NN 0
. . 0

EORTC NNP 0
protocols NNS 0
in IN 0
prostatic JJ 0
cancer NN 0
. . 0

An DT 0
interim JJ 0
report NN 0
. . 0

Two CD 0
parallel JJ 0
prospective JJ 0
randomized VBN 0
studies NNS 0
have VBP 0
been VBN 0
undertaken VBN 0
by IN 0
the DT 0
EORTC NNP 0
Urological NNP 0
Group NNP 0
in IN 0
previously RB 0
untreated JJ 0
patients NNS 0
with IN 0
prostatic JJ 0
cancer NN 0
in IN 0
order NN 0
to TO 0
compare VB 0
low JJ 0
dose JJ 0
Stilboestrol NNP 0
versus NN 0
Cyproterone NNP 0
acetate NN 0
versus NN 0
Medroxyprogesterone NNP 0
acetate NN 0
in IN 0
the DT 0
first JJ 0
trial NN 0
, , 0
and CC 0
Stilboestrol NNP 0
versus VBP 0
Estracyt NNP 0
in IN 0
the DT 0
second JJ 0
trial NN 0
. . 0

Although IN 0
the DT 0
follow JJ 0
up NN 0
is VBZ 0
still RB 0
short JJ 0
, , 0
no DT 0
superiority NN 0
of IN 0
the DT 0
other JJ 0
drugs NNS 0
over IN 0
Stilboestrol NNP 0
had VBD 0
appeared VBN 0
so RB 0
far RB 0
with IN 0
regard NN 0
to TO 0
either DT 0
objective JJ 0
response NN 0
or CC 0
significant JJ 0
side NN 0
effects NNS 0
apart RB 0
from IN 0
gynaecomastia NN 0
. . 0

In IN 0
the DT 0
third JJ 0
trial NN 0
, , 0
patients NNS 0
with IN 0
advanced JJ 0
disease NN 0
no RB 0
longer RBR 0
responsive VB 0
to TO 0
hormonal JJ 0
treatment NN 0
were VBD 0
randomized VBN 0
to TO 0
either DT 0
Adriamycin NNP 0
or CC 0
Procarbazine NNP 0
. . 0

Toxicity NN 0
and CC 0
early JJ 0
death NN 0
were VBD 0
particularly RB 0
frequent JJ 0
in IN 0
Procarbazine NNP 0
treated VBD 0
patients NNS 0
, , 0
whereas NNS 0
most JJS 0
patients NNS 0
progressed VBN 0
in IN 0
both DT 0
treatment NN 0
groups NNS 0
. . 0

Prediction NN 0
of IN 0
creatinine JJ 0
clearance NN 0
from IN 0
serum JJ 0
creatinine NN 0
in IN 0
patients NNS 0
with IN 0
rheumatoid JJ 0
arthritis NN 0
: : 0
comparison NN 0
of IN 0
six CD 0
formulae NNS 0
and CC 0
one CD 0
nomogram NN 0
. . 0

The DT 0
estimation NN 0
of IN 0
glomerular JJ 0
filtration NN 0
rate NN 0
is VBZ 0
important JJ 0
for IN 0
the DT 0
medical JJ 0
treatment NN 0
of IN 0
patients NNS 0
with IN 0
rheumatoid JJ 0
arthritis NN 0
( ( 0
RA NNP 0
) ) 0
. . 0

However RB 0
, , 0
the DT 0
determination NN 0
of IN 0
endogenous JJ 0
creatinine JJ 0
clearance NN 0
( ( 0
Clcr NNP 0
) ) 0
from IN 0
a DT 0
24-h JJ 0
urine JJ 0
collection NN 0
is VBZ 0
an DT 0
unreliable JJ 0
and CC 0
time-consuming JJ 0
procedure NN 0
. . 0

We PRP 0
therefore RB 0
tested VBD 0
the DT 0
accuracy NN 0
of IN 0
six CD 0
equations NNS 0
and CC 0
one CD 0
nomogram NN 0
for IN 0
the DT 0
prediction NN 0
of IN 0
Clcr NNP 0
from IN 0
serum JJ 0
creatinine NN 0
( ( 0
Scr NNP 0
) ) 0
in IN 0
38 CD 0
patients NNS 0
with IN 0
RA NNP 0
and CC 0
20 CD 0
controls NNS 0
. . 0

A DT 0
positive JJ 0
correlation NN 0
was VBD 0
found VBN 0
for IN 0
all DT 0
methods NNS 0
in IN 0
the DT 0
controls NNS 0
( ( 0
r VB 0
= NNP 0
0.83-0.94 NN 0
) ) 0
and CC 0
RA NNP 0
patients NNS 0
( ( 0
r JJ 0
= NNP 0
0.51-0.69 NN 0
) ) 0
. . 0

The DT 0
methods NNS 0
did VBD 0
not RB 0
overestimate VB 0
Clcr NNP 0
in IN 0
RA NNP 0
. . 0

In IN 0
the DT 0
RA NNP 0
group NN 0
the DT 0
simple JJ 0
formula NN 0
published VBN 0
by IN 0
Cockcroft NNP 0
[ NNP 0
Clcr NNP 0
= NNP 0
( ( 0
( ( 0
140 CD 0
- : 0
age NN 0
) ) 0
x VBZ 0
body NN 0
weight NN 0
) ) 0
/ NN 0
( ( 0
72 CD 0
x NNP 0
Scr NNP 0
) ) 0
, , 0
x $ 0
0.85 CD 0
for IN 0
females NNS 0
] VBP 0
showed VBD 0
the DT 0
best JJS 0
correlation NN 0
with IN 0
the DT 0
measured VBN 0
Clcr NNP 0
. . 0

In IN 0
RA NNP 0
the DT 0
Cockroft NNP 0
formula NN 0
can MD 0
reliably RB 0
be VB 0
used VBN 0
to TO 0
predict VB 0
Clcr NNP 0
from IN 0
Scr NNP 0
. . 0

[ JJ 0
Efficacy NNP 0
of IN 0
paliperidone NN 0
extended-release JJ 0
tablets NNS 0
in IN 0
the DT 0
improvement NN 0
of IN 0
social JJ 0
functions NNS 0
in IN 0
schizophrenics NNS 0
: : 0
a DT 0
randomized NN 0
and CC 0
controlled VBD 0
study NN 0
] NN 0
. . 0

OBJECTIVE UH 0
To TO 0
explore VB 0
the DT 0
efficacy NN 0
of IN 0
paliperidone NN 0
extended-release JJ 0
tablets NNS 0
in IN 0
the DT 0
improvement NN 0
of IN 0
social JJ 0
functions NNS 0
in IN 0
schizophrenics NNS 0
. . 0

METHODS NNP 0
A NNP 0
total NN 0
of IN 0
81 CD 0
schizophrenics NNS 0
were VBD 0
randomly RB 0
divided VBN 0
into IN 0
study NN 0
group NN 0
with IN 0
paliperidone NN 0
extended-release JJ 0
tablets NNS 0
and CC 0
control NN 0
group NN 0
with IN 0
risperidone NN 0
for IN 0
a DT 0
12-week JJ 0
treatment NN 0
. . 0

They PRP 0
were VBD 0
assessed VBN 0
and CC 0
analyzed VBN 0
by IN 0
positive JJ 0
and CC 0
negative JJ 0
symptoms NNS 0
scales NNS 0
( ( 0
PANSS NNP 0
) ) 0
, , 0
social JJ 0
disability NN 0
screening VBG 0
schedule NN 0
( ( 0
SDSS NNP 0
) ) 0
and CC 0
treatment NN 0
emergent NN 0
symptom NN 0
scale NN 0
( ( 0
TESS NNP 0
) ) 0
at IN 0
baseline NN 0
, , 0
6 CD 0
( ( 0
th NN 0
) ) 0
weekend NN 0
and CC 0
12 CD 0
( ( 0
th NN 0
) ) 0
weekend NN 0
. . 0

RESULTS NNP 0
In IN 0
study NN 0
group NN 0
, , 0
the DT 0
factors NNS 0
and CC 0
total JJ 0
scores NNS 0
of IN 0
PANSS NNP 0
in IN 0
the DT 0
12 CD 0
( ( 0
th NN 0
) ) 0
weekend NN 0
of IN 0
treatment NN 0
[ NNP 0
( ( 0
12.0 CD 0
? . 0
2.8 CD 0
) ) 0
, , 0
( ( 0
12.1 CD 0
? . 0
3.6 CD 0
) ) 0
, , 0
( ( 0
26.2 CD 0
? . 0
5.0 CD 0
) ) 0
, , 0
( ( 0
50.2 CD 0
? . 0
8.7 CD 0
) ) 0
] NN 0
were VBD 0
all DT 0
significantly RB 0
lower JJR 0
than IN 0
those DT 0
at IN 0
baseline JJ 0
[ NNP 0
( ( 0
24.7 CD 0
? . 0
5.3 CD 0
) ) 0
, , 0
( ( 0
23.8 CD 0
? . 0
3.6 CD 0
) ) 0
, , 0
( ( 0
45.0 CD 0
? . 0
2.9 CD 0
) ) 0
, , 0
( ( 0
93.5 CD 0
? . 0
6.8 CD 0
) ) 0
] NN 0
( ( 0
t JJ 0
= NNP 0
9.60-16.78 CD 0
, , 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

In IN 0
study NN 0
group NN 0
, , 0
the DT 0
positive JJ 0
factor NN 0
, , 0
negative JJ 0
factor NN 0
and CC 0
total JJ 0
scores NNS 0
of IN 0
PANSS NNP 0
in IN 0
the DT 0
12 CD 0
( ( 0
th NN 0
) ) 0
weekend NN 0
of IN 0
treatment NN 0
[ NNP 0
( ( 0
12.0 CD 0
? . 0
2.8 CD 0
) ) 0
, , 0
( ( 0
12.1 CD 0
? . 0
3.6 CD 0
) ) 0
, , 0
( ( 0
50.2 CD 0
? . 0
8.7 CD 0
) ) 0
] NN 0
were VBD 0
all DT 0
significantly RB 0
lower JJR 0
than IN 0
those DT 0
in IN 0
the DT 0
6 CD 0
( ( 0
th NN 0
) ) 0
weekend NN 0
of IN 0
treatment NN 0
[ NNP 0
( ( 0
14.2 CD 0
? . 0
1.8 CD 0
) ) 0
, , 0
( ( 0
14.6 CD 0
? . 0
2.4 CD 0
) ) 0
, , 0
( ( 0
56.5 CD 0
? . 0
6.4 CD 0
) ) 0
] NN 0
( ( 0
t JJ 0
= NNP 0
2.58-4.26 CD 0
, , 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

In IN 0
the DT 0
12 CD 0
( ( 0
th NN 0
) ) 0
weekend NN 0
of IN 0
treatment NN 0
, , 0
the DT 0
factors NNS 0
and CC 0
total JJ 0
scores NNS 0
of IN 0
PANSS NNP 0
in IN 0
study NN 0
group NN 0
[ NNP 0
( ( 0
12.0 CD 0
? . 0
2.8 CD 0
) ) 0
, , 0
( ( 0
12.1 CD 0
? . 0
3.6 CD 0
) ) 0
, , 0
( ( 0
26.2 CD 0
? . 0
5.0 CD 0
) ) 0
, , 0
( ( 0
50.2 CD 0
? . 0
8.7 CD 0
) ) 0
] NN 0
were VBD 0
all DT 0
significantly RB 0
lower JJR 0
than IN 0
those DT 0
in IN 0
control NN 0
group NN 0
[ NNP 0
( ( 0
16.9 CD 0
? . 0
4.9 CD 0
) ) 0
, , 0
( ( 0
18.7 CD 0
? . 0
5.3 CD 0
) ) 0
, , 0
( ( 0
32.5 CD 0
? . 0
5.1 CD 0
) ) 0
, , 0
( ( 0
68.1 CD 0
? . 0
13.0 CD 0
) ) 0
] NN 0
( ( 0
t JJ 0
= NNP 0
-4.28 NNP 0
-- : 0
5.67 CD 0
, , 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

In IN 0
study NN 0
group NN 0
, , 0
the DT 0
total JJ 0
scores NNS 0
of IN 0
SDSS NNP 0
in IN 0
the DT 0
12 CD 0
( ( 0
th NN 0
) ) 0
weekend NN 0
of IN 0
treatment NN 0
( ( 0
5.93 CD 0
? . 0
2.78 CD 0
) ) 0
were VBD 0
significantly RB 0
lower JJR 0
than IN 0
those DT 0
at IN 0
baseline NN 0
( ( 0
13.9 CD 0
? . 0
3.4 CD 0
) ) 0
( ( 0
t JJ 0
= NN 0
10.83 CD 0
, , 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

In IN 0
study NN 0
group NN 0
, , 0
the DT 0
total JJ 0
scores NNS 0
of IN 0
SDSS NNP 0
in IN 0
the DT 0
12 CD 0
( ( 0
th NN 0
) ) 0
weekend NN 0
of IN 0
treatment NN 0
( ( 0
5.9 CD 0
? . 0
2.8 CD 0
) ) 0
were VBD 0
significantly RB 0
lower JJR 0
than IN 0
those DT 0
in IN 0
the DT 0
6 CD 0
( ( 0
th NN 0
) ) 0
weekend NN 0
of IN 0
treatment NN 0
( ( 0
7.6 CD 0
? . 0
2.9 CD 0
) ) 0
( ( 0
t JJ 0
= NN 0
5.21 CD 0
, , 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

But CC 0
there EX 0
was VBD 0
no DT 0
significant JJ 0
improvement NN 0
in IN 0
control NN 0
group NN 0
( ( 0
t JJ 0
= NN 0
1.88 CD 0
, , 0
P NNP 0
> NNP 0
0.05 CD 0
) ) 0
. . 0

In IN 0
the DT 0
12 CD 0
( ( 0
th NN 0
) ) 0
weekend NN 0
of IN 0
treatment NN 0
, , 0
the DT 0
total JJ 0
scores NNS 0
of IN 0
SDSS NNP 0
in IN 0
study NN 0
group NN 0
( ( 0
5.9 CD 0
? . 0
2.8 CD 0
) ) 0
were VBD 0
significantly RB 0
lower JJR 0
than IN 0
those DT 0
in IN 0
control NN 0
group NN 0
( ( 0
8.8 CD 0
? . 0
2.9 CD 0
) ) 0
( ( 0
t JJ 0
= NNP 0
-4.49 NNP 0
, , 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

No UH 0
severe JJ 0
adverse JJ 0
effect NN 0
was VBD 0
reported VBN 0
in IN 0
either DT 0
group NN 0
. . 0

CONCLUSION NNP 0
Paliperidone NNP 0
extended-release JJ 0
tablets NNS 0
are VBP 0
effective JJ 0
to TO 0
improve VB 0
social JJ 0
functions NNS 0
and CC 0
psychiatric JJ 0
symptoms NNS 0
of IN 0
schizophrenics NNS 0
. . 0

Youth NN 0
with IN 0
autism NN 0
spectrum NN 0
disorder NN 0
comprehend NN 0
lexicalized VBN 0
and CC 0
novel JJ 0
primary JJ 0
conceptual JJ 0
metaphors NNS 0
. . 0

Individuals NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorder NN 0
( ( 0
ASD NNP 0
) ) 0
have VBP 0
difficulty NN 0
comprehending VBG 0
metaphors NNS 0
. . 0

However RB 0
, , 0
no DT 0
study NN 0
to TO 0
date NN 0
has VBZ 0
examined VBN 0
whether IN 0
or CC 0
not RB 0
they PRP 0
understand VBP 0
conceptual JJ 0
metaphors NNS 0
( ( 0
i.e NN 0
. . 0

mappings NNS 0
between IN 0
conceptual JJ 0
structures NNS 0
) ) 0
, , 0
which WDT 0
could MD 0
be VB 0
the DT 0
building NN 0
blocks NNS 0
of IN 0
metaphoric JJ 0
thinking NN 0
and CC 0
understanding NN 0
. . 0

We PRP 0
investigated VBD 0
whether IN 0
13 CD 0
participants NNS 0
with IN 0
ASD NNP 0
( ( 0
age NN 0
7 CD 0
; : 0
03-22 CD 0
; : 0
03 CD 0
) ) 0
and CC 0
13 CD 0
age-matched JJ 0
typically RB 0
developing VBG 0
( ( 0
TD NNP 0
) ) 0
controls NNS 0
could MD 0
comprehend VB 0
lexicalized JJ 0
conceptual JJ 0
metaphors NNS 0
( ( 0
e.g. NN 0
, , 0
Susan NNP 0
is VBZ 0
a DT 0
warm JJ 0
person NN 0
) ) 0
and CC 0
novel JJ 0
ones NNS 0
( ( 0
e.g. NN 0
, , 0
Susan NNP 0
is VBZ 0
a DT 0
toasty JJ 0
person NN 0
) ) 0
. . 0

Individuals NNS 0
with IN 0
ASD NNP 0
performed VBD 0
at IN 0
greater JJR 0
than IN 0
chance NN 0
levels NNS 0
on IN 0
both DT 0
metaphor NN 0
types NNS 0
, , 0
although IN 0
their PRP$ 0
performance NN 0
was VBD 0
lower JJR 0
than IN 0
TD CD 0
participants NNS 0
. . 0

We PRP 0
discuss VBP 0
the DT 0
theoretical JJ 0
relevance NN 0
of IN 0
these DT 0
findings NNS 0
and CC 0
educational JJ 0
implications NNS 0
. . 0

Ascaris NNP 0
and CC 0
growth NN 0
rates NNS 0
: : 0
a DT 0
randomized JJ 0
trial NN 0
of IN 0
treatment NN 0
. . 0

Three CD 0
hundred VBD 0
forty-one NN 0
Tanzanian JJ 0
preschool NN 0
children NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
levamisole VB 0
or CC 0
placebo VB 0
treatment NN 0
given VBN 0
at IN 0
three-month JJ 0
intervals NNS 0
. . 0

Weights NNS 0
and CC 0
heights NNS 0
were VBD 0
measured VBN 0
at IN 0
the DT 0
tri-monthly JJ 0
treatment NN 0
visits NNS 0
for IN 0
a DT 0
period NN 0
of IN 0
one CD 0
year NN 0
. . 0

Among IN 0
the DT 0
273 CD 0
children NNS 0
who WP 0
were VBD 0
seen VBN 0
and CC 0
weighed VBN 0
at IN 0
the DT 0
one-year JJ 0
follow-up JJ 0
visit NN 0
, , 0
the DT 0
rate NN 0
of IN 0
weight NN 0
gain NN 0
was VBD 0
8 CD 0
per IN 0
cent NN 0
greater JJR 0
for IN 0
those DT 0
receiving VBG 0
levamisole JJR 0
than IN 0
for IN 0
placebo-treated JJ 0
controls NNS 0
( ( 0
p JJ 0
= NNP 0
.06 NNP 0
) ) 0
. . 0

In IN 0
78 CD 0
children NNS 0
known VBN 0
to TO 0
be VB 0
infected VBN 0
with IN 0
Ascaris NNP 0
at IN 0
baseline NN 0
, , 0
the DT 0
rate NN 0
of IN 0
weight NN 0
gain NN 0
was VBD 0
21 CD 0
per IN 0
cent NN 0
greater JJR 0
in IN 0
children NNS 0
treated VBN 0
with IN 0
levamisole NN 0
than IN 0
in IN 0
those DT 0
receiving VBG 0
placebo NN 0
( ( 0
p JJ 0
= NNP 0
.03 NNP 0
) ) 0
. . 0

The DT 0
rate NN 0
of IN 0
height NN 0
gain NN 0
was VBD 0
no DT 0
different JJ 0
for IN 0
treatment NN 0
and CC 0
placebo NN 0
groups NNS 0
. . 0

Effect NN 0
of IN 0
duloxetine NN 0
on IN 0
pain NN 0
, , 0
function NN 0
, , 0
and CC 0
quality NN 0
of IN 0
life NN 0
among IN 0
patients NNS 0
with IN 0
chemotherapy-induced JJ 0
painful JJ 0
peripheral JJ 0
neuropathy NN 0
: : 0
a DT 0
randomized JJ 0
clinical JJ 0
trial NN 0
. . 0

IMPORTANCE NNP 0
There EX 0
are VBP 0
no DT 0
known JJ 0
effective JJ 0
treatments NNS 0
for IN 0
painful JJ 0
chemotherapy-induced JJ 0
peripheral JJ 0
neuropathy NN 0
. . 0

OBJECTIVE UH 0
To TO 0
determine VB 0
the DT 0
effect NN 0
of IN 0
duloxetine NN 0
, , 0
60 CD 0
mg JJ 0
daily RB 0
, , 0
on IN 0
average JJ 0
pain NN 0
severity NN 0
. . 0

DESIGN NNP 0
, , 0
SETTING NNP 0
, , 0
AND NNP 0
PATIENTS NNP 0
Randomized NNP 0
, , 0
double-blind NN 0
, , 0
placebo-controlled JJ 0
crossover NN 0
trial NN 0
at IN 0
8 CD 0
National NNP 0
Cancer NNP 0
Institute NNP 0
( ( 0
NCI NNP 0
) ) 0
-funded VBD 0
cooperative JJ 0
research NN 0
networks NNS 0
that WDT 0
enrolled VBD 0
231 CD 0
patients NNS 0
who WP 0
were VBD 0
25 CD 0
years NNS 0
or CC 0
older JJR 0
being VBG 0
treated VBN 0
at IN 0
community NN 0
and CC 0
academic JJ 0
settings NNS 0
between IN 0
April NNP 0
2008 CD 0
and CC 0
March NNP 0
2011 CD 0
. . 0

Study NNP 0
follow-up NN 0
was VBD 0
completed VBN 0
July NNP 0
2012 CD 0
. . 0

Stratified VBN 0
by IN 0
chemotherapeutic JJ 0
drug NN 0
and CC 0
comorbid NN 0
pain NN 0
risk NN 0
, , 0
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
either DT 0
duloxetine NN 0
followed VBN 0
by IN 0
placebo NN 0
or CC 0
placebo NN 0
followed VBN 0
by IN 0
duloxetine NN 0
. . 0

Eligibility NN 0
required VBD 0
that IN 0
patients NNS 0
have VBP 0
grade VBN 0
1 CD 0
or CC 0
higher JJR 0
sensory NN 0
neuropathy JJ 0
according VBG 0
to TO 0
the DT 0
NCI NNP 0
Common NNP 0
Terminology NNP 0
Criteria NNP 0
for IN 0
Adverse NNP 0
Events NNS 0
and CC 0
at IN 0
least JJS 0
4 CD 0
on IN 0
a DT 0
scale NN 0
of IN 0
0 CD 0
to TO 0
10 CD 0
, , 0
representing VBG 0
average JJ 0
chemotherapy-induced JJ 0
pain NN 0
, , 0
after IN 0
paclitaxel NN 0
, , 0
other JJ 0
taxane NN 0
, , 0
or CC 0
oxaliplatin JJ 0
treatment NN 0
. . 0

INTERVENTIONS VBZ 0
The DT 0
initial JJ 0
treatment NN 0
consisted VBN 0
of IN 0
taking VBG 0
1 CD 0
capsule JJ 0
daily RB 0
of IN 0
either CC 0
30 CD 0
mg NN 0
of IN 0
duloxetine NN 0
or CC 0
placebo NN 0
for IN 0
the DT 0
first JJ 0
week NN 0
and CC 0
2 CD 0
capsules NNS 0
of IN 0
either DT 0
30 CD 0
mg NN 0
of IN 0
duloxetine NN 0
or CC 0
placebo JJ 0
daily JJ 0
for IN 0
4 CD 0
additional JJ 0
weeks NNS 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURES NNP 0
The DT 0
primary JJ 0
hypothesis NN 0
was VBD 0
that IN 0
duloxetine NN 0
would MD 0
be VB 0
more RBR 0
effective JJ 0
than IN 0
placebo NN 0
in IN 0
decreasing VBG 0
chemotherapy-induced JJ 0
peripheral JJ 0
neuropathic JJ 0
pain NN 0
. . 0

Pain NNP 0
severity NN 0
was VBD 0
assessed VBN 0
using VBG 0
the DT 0
Brief JJ 0
Pain NNP 0
Inventory-Short NNP 0
Form NNP 0
average NN 0
pain NN 0
item NN 0
with IN 0
0 CD 0
representing VBG 0
no DT 0
pain NN 0
and CC 0
10 CD 0
representing VBG 0
as RB 0
bad JJ 0
as IN 0
can MD 0
be VB 0
imagined VBN 0
. . 0

RESULTS JJ 0
Individuals NNS 0
receiving VBG 0
duloxetine NN 0
as IN 0
their PRP$ 0
initial JJ 0
5-week JJ 0
treatment NN 0
reported VBD 0
a DT 0
mean JJ 0
decrease NN 0
in IN 0
average JJ 0
pain NN 0
of IN 0
1.06 CD 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
0.72-1.40 NNP 0
) ) 0
vs VBZ 0
0.34 CD 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
0.01-0.66 NNP 0
) ) 0
among IN 0
those DT 0
who WP 0
received VBD 0
placebo NN 0
( ( 0
P NNP 0
= NNP 0
.003 NNP 0
; : 0
effect NN 0
size NN 0
, , 0
0.513 CD 0
) ) 0
. . 0

The DT 0
observed JJ 0
mean JJ 0
difference NN 0
in IN 0
the DT 0
average JJ 0
pain NN 0
score NN 0
between IN 0
duloxetine NN 0
and CC 0
placebo NN 0
was VBD 0
0.73 CD 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
0.26-1.20 NN 0
) ) 0
. . 0

Fifty-nine JJ 0
percent NN 0
of IN 0
those DT 0
initially RB 0
receiving VBG 0
duloxetine NN 0
vs FW 0
38 CD 0
% NN 0
of IN 0
those DT 0
initially RB 0
receiving VBG 0
placebo NN 0
reported VBD 0
decreased JJ 0
pain NN 0
of IN 0
any DT 0
amount NN 0
. . 0

CONCLUSION NNP 0
AND CC 0
RELEVANCE NNP 0
Among IN 0
patients NNS 0
with IN 0
painful JJ 0
chemotherapy-induced JJ 0
peripheral JJ 0
neuropathy NN 0
, , 0
the DT 0
use NN 0
of IN 0
duloxetine NN 0
compared VBN 0
with IN 0
placebo NN 0
for IN 0
5 CD 0
weeks NNS 0
resulted VBD 0
in IN 0
a DT 0
greater JJR 0
reduction NN 0
in IN 0
pain NN 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
clinicaltrials.gov NN 0
Identifier NNP 0
: : 0
NCT00489411 NN 0
. . 0

Effectiveness NN 0
of IN 0
hygienic-dietary JJ 0
recommendations NNS 0
as IN 0
enhancers NNS 0
of IN 0
antidepressant JJ 0
treatment NN 0
in IN 0
patients NNS 0
with IN 0
depression NN 0
: : 0
study NN 0
protocol NN 0
of IN 0
a DT 0
randomized VBN 0
controlled VBN 0
trial NN 0
. . 0

BACKGROUND NNP 0
In IN 0
recent JJ 0
years NNS 0
some DT 0
studies NNS 0
have VBP 0
been VBN 0
published VBN 0
supporting VBG 0
the DT 0
efficacy NN 0
of IN 0
light JJ 0
exposure NN 0
, , 0
physical JJ 0
activity NN 0
, , 0
sleep VB 0
control NN 0
and CC 0
a DT 0
Mediterranean NNP 0
diet JJ 0
pattern NN 0
on IN 0
the DT 0
improvement NN 0
or CC 0
prevention NN 0
of IN 0
depression NN 0
. . 0

However RB 0
, , 0
to TO 0
our PRP$ 0
knowledge NN 0
, , 0
there EX 0
have VBP 0
been VBN 0
no DT 0
studies NNS 0
using VBG 0
all PDT 0
these DT 0
measures NNS 0
together RB 0
as IN 0
an DT 0
adjuvant JJ 0
antidepressant NN 0
strategy NN 0
. . 0

METHODS NNP 0
Multicenter NNP 0
, , 0
randomized VBD 0
, , 0
controlled VBN 0
, , 0
two CD 0
arm-parallel JJ 0
, , 0
clinical JJ 0
trial NN 0
. . 0

Eighty NNP 0
depressed VBD 0
patients NNS 0
undergoing VBG 0
standard JJ 0
antidepressant JJ 0
treatment NN 0
will MD 0
be VB 0
advised VBN 0
to TO 0
follow VB 0
four CD 0
additional JJ 0
hygienic-dietary JJ 0
recommendations NNS 0
about IN 0
exercise NN 0
, , 0
diet JJ 0
, , 0
sunlight JJ 0
exposure NN 0
and CC 0
sleep NN 0
. . 0

Outcome NNP 0
measures NNS 0
will MD 0
be VB 0
assessed VBN 0
before IN 0
and CC 0
after IN 0
the DT 0
6 CD 0
month NN 0
intervention NN 0
period NN 0
. . 0

DISCUSSION NNP 0
We PRP 0
expect VBP 0
the DT 0
patients NNS 0
in IN 0
the DT 0
active JJ 0
recommendations NNS 0
group NN 0
to TO 0
experience VB 0
a DT 0
greater JJR 0
improvement NN 0
in IN 0
their PRP$ 0
depressive NN 0
symptoms NNS 0
. . 0

If IN 0
so RB 0
, , 0
this DT 0
would MD 0
be VB 0
a DT 0
great JJ 0
support NN 0
for IN 0
doctors NNS 0
who WP 0
might MD 0
systematically RB 0
recommend VB 0
these DT 0
simple JJ 0
and CC 0
costless JJ 0
measures NNS 0
, , 0
especially RB 0
in IN 0
primary JJ 0
care NN 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
ISRCTN59506583 NNP 0
. . 0

The DT 0
effect NN 0
of IN 0
two CD 0
types NNS 0
of IN 0
teacher NN 0
training NN 0
on IN 0
implementation NN 0
of IN 0
Smart NNP 0
Choices NNPS 0
: : 0
a DT 0
tobacco NN 0
prevention NN 0
curriculum NN 0
. . 0

This DT 0
study NN 0
examined VBD 0
the DT 0
implementation NN 0
phase NN 0
of IN 0
a DT 0
four-year JJ 0
research NN 0
project NN 0
to TO 0
test VB 0
the DT 0
effectiveness NN 0
of IN 0
strategies NNS 0
to TO 0
increase VB 0
diffusion NN 0
of IN 0
Smart NNP 0
Choices NNP 0
, , 0
a DT 0
school-based JJ 0
tobacco NN 0
prevention NN 0
program NN 0
. . 0

The DT 0
impact NN 0
on IN 0
curriculum JJ 0
implementation NN 0
of IN 0
two CD 0
approaches NNS 0
to TO 0
teacher VB 0
training NN 0
are VBP 0
compared VBN 0
. . 0

School JJ 0
districts NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
a DT 0
live JJ 0
workshop NN 0
training NN 0
or CC 0
video NN 0
training NN 0
condition NN 0
. . 0

The DT 0
outcome NN 0
of IN 0
the DT 0
evaluation NN 0
was VBD 0
teachers NNS 0
' POS 0
implementation NN 0
of IN 0
Smart NNP 0
Choices NNP 0
. . 0

Results NNP 0
show VBP 0
a DT 0
lower JJR 0
proportion NN 0
of IN 0
video-trained JJ 0
teachers NNS 0
implemented VBD 0
the DT 0
curriculum NN 0
, , 0
but CC 0
overall JJ 0
completeness NN 0
and CC 0
fidelity NN 0
of IN 0
implementation NN 0
for IN 0
those DT 0
teachers NNS 0
who WP 0
did VBD 0
teach VB 0
the DT 0
curriculum NN 0
were VBD 0
comparable JJ 0
for IN 0
the DT 0
two CD 0
groups NNS 0
. . 0

Video-trained JJ 0
teachers NNS 0
, , 0
however RB 0
, , 0
were VBD 0
less RBR 0
likely JJ 0
to TO 0
use VB 0
brainstorming NN 0
and CC 0
student NN 0
presentations/role NN 0
plays NNS 0
, , 0
two CD 0
of IN 0
the DT 0
methods NNS 0
prescribed VBN 0
by IN 0
the DT 0
curriculum NN 0
. . 0

Implications NNS 0
of IN 0
the DT 0
results NNS 0
for IN 0
teacher JJ 0
training NN 0
are VBP 0
discussed VBN 0
. . 0

Effect NN 0
of IN 0
rosuvastatin NN 0
monotherapy NN 0
or CC 0
in IN 0
combination NN 0
with IN 0
fenofibrate NN 0
or CC 0
?-3 JJ 0
fatty JJ 0
acids NNS 0
on IN 0
lipoprotein JJ 0
subfraction NN 0
profile NN 0
in IN 0
patients NNS 0
with IN 0
mixed JJ 0
dyslipidaemia NN 0
and CC 0
metabolic JJ 0
syndrome NN 0
. . 0

BACKGROUND NNP 0
Raised VBD 0
triglycerides NNS 0
( ( 0
TG NNP 0
) ) 0
, , 0
decreased VBD 0
high-density NN 0
lipoprotein NN 0
cholesterol NN 0
( ( 0
HDL-C NNP 0
) ) 0
levels NNS 0
and CC 0
a DT 0
predominance NN 0
of IN 0
small JJ 0
dense NN 0
low JJ 0
density NN 0
lipoproteins NNS 0
( ( 0
sdLDL NN 0
) ) 0
are VBP 0
characteristics NNS 0
of IN 0
the DT 0
metabolic JJ 0
syndrome NN 0
( ( 0
MetS NNP 0
) ) 0
. . 0

OBJECTIVE UH 0
To TO 0
compare VB 0
the DT 0
effect NN 0
of IN 0
high-dose JJ 0
rosuvastatin NN 0
monotherapy NN 0
with IN 0
moderate JJ 0
dosing NN 0
combined VBN 0
with IN 0
fenofibrate NN 0
or CC 0
?-3 JJ 0
fatty JJ 0
acids NNS 0
on IN 0
the DT 0
lipoprotein JJ 0
subfraction NN 0
profile NN 0
in IN 0
patients NNS 0
with IN 0
mixed JJ 0
dyslipidaemia NN 0
and CC 0
MetS NNP 0
. . 0

METHODS NNP 0
We PRP 0
previously RB 0
randomised VBD 0
patients NNS 0
with IN 0
low-density JJ 0
lipoprotein NNS 0
cholesterol NN 0
( ( 0
LDL-C NNP 0
) ) 0
> VBZ 0
160 CD 0
and CC 0
TG NNP 0
> NNP 0
200 CD 0
mg/dl NN 0
to TO 0
rosuvastatin VB 0
monotherapy NN 0
40 CD 0
mg/day NN 0
( ( 0
R NNP 0
group NN 0
, , 0
n RB 0
= VBZ 0
30 CD 0
) ) 0
or CC 0
rosuvastatin $ 0
10 CD 0
mg/day NN 0
combined VBN 0
with IN 0
fenofibrate JJ 0
200 CD 0
mg/day NN 0
( ( 0
RF NNP 0
group NN 0
, , 0
n RB 0
= VBZ 0
30 CD 0
) ) 0
or CC 0
?-3 JJ 0
fatty JJ 0
acids NNS 0
2 CD 0
g/day NN 0
( ( 0
R? NNP 0
group NN 0
, , 0
n RB 0
= VBZ 0
30 CD 0
) ) 0
. . 0

In IN 0
the DT 0
present JJ 0
study NN 0
, , 0
only RB 0
patients NNS 0
with IN 0
MetS NNP 0
were VBD 0
included VBN 0
( ( 0
24 CD 0
, , 0
23 CD 0
and CC 0
24 CD 0
in IN 0
the DT 0
R NNP 0
, , 0
RF NNP 0
and CC 0
R? NNP 0
groups NNS 0
respectively RB 0
) ) 0
. . 0

At IN 0
baseline NN 0
and CC 0
after IN 0
12 CD 0
weeks NNS 0
of IN 0
treatment NN 0
, , 0
the DT 0
lipoprotein JJ 0
subfraction NN 0
profile NN 0
was VBD 0
determined VBN 0
by IN 0
polyacrylamide JJ 0
3 CD 0
% NN 0
gel JJ 0
electrophoresis NN 0
. . 0

RESULTS VB 0
The DT 0
mean JJ 0
LDL NNP 0
size NN 0
was VBD 0
significantly RB 0
increased VBN 0
in IN 0
all DT 0
groups NNS 0
. . 0

This DT 0
change NN 0
was VBD 0
more RBR 0
prominent JJ 0
with IN 0
RF NNP 0
than IN 0
with IN 0
other JJ 0
treatments NNS 0
in IN 0
parallel JJ 0
with IN 0
its PRP$ 0
greater JJR 0
hypotriglyceridemic JJ 0
capacity NN 0
( ( 0
p JJ 0
< $ 0
0.05 CD 0
compared VBN 0
with IN 0
R NNP 0
and CC 0
R? NNP 0
) ) 0
. . 0

A DT 0
decrease NN 0
in IN 0
insulin NN 0
resistance NN 0
by IN 0
RF NNP 0
was VBD 0
also RB 0
noted VBN 0
. . 0

Only RB 0
RF NNP 0
significantly RB 0
raised VBD 0
HDL-C NNP 0
levels NNS 0
( ( 0
by IN 0
7.7 CD 0
% NN 0
, , 0
p NN 0
< NNP 0
0.05 CD 0
) ) 0
by IN 0
increasing VBG 0
the DT 0
cholesterol NN 0
of IN 0
small JJ 0
HDL NNP 0
particles NNS 0
. . 0

The DT 0
cholesterol NN 0
of IN 0
larger JJR 0
HDL NNP 0
subclasses NNS 0
was VBD 0
significantly RB 0
increased VBN 0
by IN 0
R NNP 0
and CC 0
R? NNP 0
. . 0

CONCLUSIONS NNP 0
All NNP 0
regimens VBZ 0
increased VBN 0
mean JJ 0
LDL NNP 0
size NN 0
; : 0
RF NNP 0
was VBD 0
the DT 0
most RBS 0
effective JJ 0
. . 0

A DT 0
differential JJ 0
effect NN 0
of IN 0
treatments NNS 0
was VBD 0
noted VBN 0
on IN 0
the DT 0
HDL NNP 0
subfraction NN 0
profile NN 0
. . 0

Effect NN 0
of IN 0
the DT 0
essential JJ 0
oils NNS 0
of IN 0
garlic NN 0
and CC 0
onion NN 0
on IN 0
alimentary JJ 0
hyperlipemia NN 0
. . 0

SUMMARY VB 0
The DT 0
effect NN 0
of IN 0
garlic NN 0
and CC 0
onion NN 0
on IN 0
alimentary JJ 0
hyperlipemia NN 0
, , 0
induced VBN 0
by IN 0
feeding VBG 0
100 CD 0
g JJ 0
butter NN 0
, , 0
has VBZ 0
been VBN 0
studied VBN 0
in IN 0
10 CD 0
healthy JJ 0
subjects NNS 0
. . 0

The DT 0
freshly RB 0
extracted JJ 0
juice NN 0
of IN 0
50 CD 0
g NN 0
of IN 0
garlic NN 0
or CC 0
onion NN 0
, , 0
as RB 0
well RB 0
as IN 0
an DT 0
equivalent JJ 0
amount NN 0
of IN 0
their PRP$ 0
ether-extracted JJ 0
essential JJ 0
oils NNS 0
, , 0
was VBD 0
administered VBN 0
randomly RB 0
on IN 0
four CD 0
different JJ 0
days NNS 0
during IN 0
a DT 0
one-week JJ 0
period NN 0
. . 0

Garlic NNP 0
and CC 0
onion NN 0
have VBP 0
a DT 0
significant JJ 0
protective JJ 0
action NN 0
against IN 0
fat-induced JJ 0
increases NNS 0
in IN 0
serum NN 0
cholesterol NN 0
and CC 0
plasma NN 0
fibrinogen NN 0
and CC 0
decreases NNS 0
in IN 0
coagulation NN 0
time NN 0
and CC 0
fibrinolytic JJ 0
activity NN 0
. . 0

The DT 0
essential JJ 0
oil NN 0
fraction NN 0
, , 0
which WDT 0
contains VBZ 0
all PDT 0
the DT 0
taste NN 0
and CC 0
odour NN 0
, , 0
exactly RB 0
duplicated VBD 0
the DT 0
beneficial JJ 0
effects NNS 0
of IN 0
whole JJ 0
garlic NN 0
and CC 0
onion NN 0
. . 0

It PRP 0
is VBZ 0
, , 0
therefore RB 0
, , 0
concluded VBD 0
that IN 0
the DT 0
active JJ 0
principle NN 0
of IN 0
garlic JJ 0
and CC 0
onion NN 0
is VBZ 0
the DT 0
essential JJ 0
oil NN 0
, , 0
which WDT 0
chemically RB 0
is VBZ 0
a DT 0
combination NN 0
of IN 0
sulphur-containing JJ 0
compounds NNS 0
, , 0
mainly RB 0
allyl VBZ 0
propyl JJ 0
disulphide NN 0
and CC 0
diallyl JJ 0
disulphide NN 0
. . 0

Effects NNS 0
of IN 0
cuff NN 0
inflation NN 0
on IN 0
self-recorded JJ 0
blood NN 0
pressure NN 0
. . 0

Changes NNS 0
in IN 0
continuously RB 0
recorded VBN 0
'Finapres NNS 0
' POS 0
finger NN 0
blood NN 0
pressure NN 0
in IN 0
ten JJ 0
normotensive JJ 0
and CC 0
seven CD 0
hypertensive JJ 0
subjects NNS 0
induced VBN 0
by IN 0
self-inflation NN 0
of IN 0
the DT 0
cuff NN 0
or CC 0
just RB 0
wearing VBG 0
the DT 0
inflated JJ 0
cuff NN 0
were VBD 0
studied VBN 0
. . 0

Inflating VBG 0
the DT 0
cuff NN 0
caused VBD 0
an DT 0
instantaneous JJ 0
rise NN 0
in IN 0
systolic JJ 0
blood NN 0
pressure NN 0
of IN 0
13 CD 0
and CC 0
12 CD 0
mm NN 0
Hg NNP 0
( ( 0
hypertensive JJ 0
and CC 0
normotensive JJ 0
subjects NNS 0
, , 0
respectively RB 0
) ) 0
. . 0

Wearing VBG 0
the DT 0
inflated JJ 0
cuff NN 0
did VBD 0
not RB 0
change VB 0
blood NN 0
pressure NN 0
. . 0

Thus VB 0
the DT 0
rise NN 0
in IN 0
pressure NN 0
was VBD 0
related VBN 0
to TO 0
the DT 0
muscular JJ 0
activity NN 0
required VBN 0
for IN 0
cuff NN 0
inflation NN 0
. . 0

Systolic NNP 0
blood NN 0
pressure NN 0
took VBD 0
on IN 0
average JJ 0
7 CD 0
s NN 0
and CC 0
at IN 0
most JJS 0
21 CD 0
s NN 0
to TO 0
return VB 0
to TO 0
baseline VB 0
level NN 0
after IN 0
stopping VBG 0
cuff NN 0
inflation NN 0
. . 0

Since IN 0
first JJ 0
Korotkoff NNP 0
sounds NNS 0
may MD 0
already RB 0
be VB 0
heard VBN 0
after IN 0
10-15 JJ 0
s NN 0
when WRB 0
following VBG 0
recommended VBD 0
procedures NNS 0
, , 0
self-recorded JJ 0
systolic JJ 0
blood NN 0
pressure NN 0
may MD 0
be VB 0
recorded VBN 0
as IN 0
too RB 0
high JJ 0
when WRB 0
subjects NNS 0
inflate VBP 0
their PRP$ 0
cuff NN 0
at IN 0
too RB 0
low JJ 0
a DT 0
pressure NN 0
or CC 0
deflate VB 0
it PRP 0
too RB 0
fast RB 0
. . 0

Inhaled VBN 0
fluticasone NN 0
reduces NNS 0
sputum VBP 0
inflammatory JJ 0
indices NNS 0
in IN 0
severe JJ 0
bronchiectasis NN 0
. . 0

Although IN 0
corticosteroid JJ 0
therapy NN 0
might MD 0
be VB 0
clinically RB 0
beneficial JJ 0
for IN 0
bronchiectasis NN 0
, , 0
very RB 0
little JJ 0
is VBZ 0
known VBN 0
of IN 0
its PRP$ 0
effects NNS 0
on IN 0
the DT 0
inflammatory NN 0
and CC 0
infective JJ 0
markers NNS 0
in IN 0
bronchiectasis NN 0
. . 0

We PRP 0
have VBP 0
therefore RB 0
performed VBN 0
a DT 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
study NN 0
to TO 0
evaluate VB 0
the DT 0
effects NNS 0
of IN 0
a DT 0
4-wk JJ 0
administration NN 0
of IN 0
inhaled JJ 0
fluticasone NN 0
in IN 0
bronchiectasis NN 0
. . 0

Twenty-four CD 0
patients NNS 0
( ( 0
12 CD 0
female NN 0
; : 0
mean JJ 0
age NN 0
51 CD 0
yr NN 0
) ) 0
were VBD 0
randomized VBN 0
into IN 0
receiving VBG 0
either CC 0
inhaled JJ 0
fluticasone NN 0
( ( 0
500 CD 0
microgram NN 0
twice RB 0
daily RB 0
) ) 0
via IN 0
the DT 0
Accuhaler NNP 0
device NN 0
( ( 0
n JJ 0
= NNP 0
12 CD 0
) ) 0
or CC 0
placebo NN 0
. . 0

At IN 0
each DT 0
visit NN 0
, , 0
spirometry NN 0
, , 0
24-h JJ 0
sputum NN 0
volume NN 0
, , 0
sputum NN 0
leukocyte NN 0
density NN 0
, , 0
bacterial JJ 0
densities NNS 0
, , 0
and CC 0
concentrations NNS 0
of IN 0
interleukin NN 0
( ( 0
IL NNP 0
) ) 0
-1beta NN 0
, , 0
IL-8 NNP 0
, , 0
tumor NN 0
necrosis NN 0
factor-alpha JJ 0
( ( 0
TNF-alpha NNP 0
) ) 0
, , 0
and CC 0
leukotriene JJ 0
B4 NNP 0
( ( 0
LTB4 NNP 0
) ) 0
were VBD 0
determined VBN 0
. . 0

There EX 0
was VBD 0
a DT 0
significant JJ 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
decrease NN 0
in IN 0
sputum NN 0
leukocyte NN 0
density NN 0
and CC 0
IL-1beta NNP 0
, , 0
IL-8 NNP 0
, , 0
and CC 0
LTB4 NNP 0
after IN 0
fluticasone NN 0
treatment NN 0
. . 0

The DT 0
fluticasone NN 0
group NN 0
had VBD 0
one CD 0
and CC 0
the DT 0
placebo NN 0
group NN 0
three CD 0
episodes NNS 0
of IN 0
exacerbation NN 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
changes NNS 0
in IN 0
spirometry NN 0
( ( 0
p JJ 0
> NNP 0
0.05 CD 0
) ) 0
or CC 0
any DT 0
reported JJ 0
adverse JJ 0
reactions NNS 0
in IN 0
either DT 0
group NN 0
. . 0

The DT 0
results NNS 0
of IN 0
this DT 0
study NN 0
show VB 0
that IN 0
high-dose JJ 0
fluticasone NN 0
is VBZ 0
effective JJ 0
in IN 0
reducing VBG 0
the DT 0
sputum NN 0
inflammatory NN 0
indices NNS 0
in IN 0
bronchiectasis NN 0
. . 0

Large-scale JJ 0
and CC 0
long-term JJ 0
studies NNS 0
are VBP 0
indicated VBN 0
to TO 0
evaluate VB 0
the DT 0
effects NNS 0
of IN 0
inhaled JJ 0
steroid JJ 0
therapy NN 0
on IN 0
the DT 0
inflammatory JJ 0
components NNS 0
in IN 0
bronchiectasis NN 0
. . 0

Review NN 0
of IN 0
the DT 0
Multicenter NNP 0
Trial NNP 0
Committee NNP 0
report NN 0
: : 0
a DT 0
prospective JJ 0
, , 0
randomized VBN 0
study NN 0
on IN 0
the DT 0
prophylaxis NN 0
of IN 0
postoperative JJ 0
deep JJ 0
venous JJ 0
thrombosis NN 0
. . 0

The DT 0
etiology NN 0
of IN 0
postoperative JJ 0
deep JJ 0
venous JJ 0
thrombosis NN 0
( ( 0
DVT NNP 0
) ) 0
is VBZ 0
thought VBN 0
to TO 0
be VB 0
due JJ 0
to TO 0
a DT 0
combination NN 0
of IN 0
factors NNS 0
including VBG 0
stasis NN 0
, , 0
a DT 0
hypercoagulable JJ 0
state NN 0
and CC 0
venous JJ 0
endothelial JJ 0
damage NN 0
. . 0

Methods NNS 0
of IN 0
prophylaxis NN 0
are VBP 0
directed VBN 0
toward IN 0
correcting VBG 0
one CD 0
or CC 0
more JJR 0
of IN 0
these DT 0
pathologic JJ 0
events NNS 0
. . 0

Methods NNS 0
counteracting VBG 0
more JJR 0
than IN 0
one CD 0
of IN 0
these DT 0
factors NNS 0
can MD 0
be VB 0
expected VBN 0
to TO 0
be VB 0
even RB 0
more RBR 0
effective JJ 0
. . 0

The DT 0
combination NN 0
of IN 0
dihydroergotamine NN 0
( ( 0
DHE NNP 0
) ) 0
and CC 0
heparin NN 0
was VBD 0
anticipated VBN 0
to TO 0
minimize VB 0
stasis NN 0
and CC 0
the DT 0
hypercoagulable JJ 0
state NN 0
respectively RB 0
. . 0

Based VBN 0
upon IN 0
current JJ 0
experimental JJ 0
evidence NN 0
and CC 0
current JJ 0
theory NN 0
, , 0
an DT 0
additional JJ 0
benefit NN 0
might MD 0
include VB 0
minimizing VBG 0
venous JJ 0
endothelial JJ 0
injury NN 0
by IN 0
controlling VBG 0
venomotor NN 0
tone NN 0
. . 0

A DT 0
prospective JJ 0
, , 0
randomized VBN 0
, , 0
double-blind JJ 0
, , 0
multicenter JJ 0
trial NN 0
was VBD 0
designed VBN 0
and CC 0
performed VBN 0
in IN 0
the DT 0
United NNP 0
States NNPS 0
evaluating VBG 0
the DT 0
prophylactic JJ 0
efficacy NN 0
of IN 0
DHE NNP 0
0.5 CD 0
mg NN 0
plus CC 0
heparin JJ 0
5000 CD 0
U NNP 0
, , 0
DHE NNP 0
0.5 CD 0
mg NN 0
plus CC 0
heparin JJ 0
2500 CD 0
U NNP 0
, , 0
heparin NN 0
5000 CD 0
U NNP 0
, , 0
and CC 0
DHE NNP 0
0.5 CD 0
mg NN 0
versus NN 0
placebo NN 0
. . 0

General NNP 0
surgical JJ 0
patients NNS 0
including VBG 0
those DT 0
undergoing JJ 0
noncardiac JJ 0
thoracic NN 0
and CC 0
pelvic JJ 0
operations NNS 0
who WP 0
were VBD 0
identified VBN 0
at IN 0
moderate JJ 0
to TO 0
high JJ 0
risk NN 0
for IN 0
postop JJ 0
DVT NNP 0
were VBD 0
included VBN 0
. . 0

Study NNP 0
medications NNS 0
were VBD 0
injected VBN 0
subcutaneously RB 0
two CD 0
hours NNS 0
preoperatively RB 0
and CC 0
every DT 0
12 CD 0
hours NNS 0
postoperatively RB 0
for IN 0
5-7 JJ 0
days NNS 0
or CC 0
until IN 0
the DT 0
125I-fibrinogen-uptake JJ 0
test NN 0
( ( 0
RFUT NNP 0
) ) 0
became VBD 0
positive JJ 0
. . 0

Eight NNP 0
hundred VBD 0
and CC 0
eighty JJ 0
eight CD 0
patients NNS 0
were VBD 0
entered VBN 0
into IN 0
this DT 0
trial NN 0
and CC 0
744 CD 0
( ( 0
85 CD 0
% NN 0
) ) 0
completed VBD 0
the DT 0
study NN 0
. . 0

Results NNP 0
showed VBD 0
a DT 0
statistically RB 0
significant JJ 0
benefit NN 0
from IN 0
DHE/Hep NNP 0
5000 CD 0
compared VBN 0
to TO 0
placebo VB 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.01 CD 0
) ) 0
and CC 0
compared VBN 0
to TO 0
other JJ 0
active JJ 0
agents NNS 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
. . 0

None NN 0
of IN 0
the DT 0
other JJ 0
active JJ 0
agents NNS 0
showed VBD 0
a DT 0
statistically RB 0
significant JJ 0
prophylactic JJ 0
benefit NN 0
. . 0

( ( 0
ABSTRACT NNP 0
TRUNCATED NNP 0
AT NNP 0
250 CD 0
WORDS NNP 0
) ) 0
Inference-Based JJ 0
Approach NNP 0
versus NN 0
Cognitive NNP 0
Behavioral NNP 0
Therapy NNP 0
in IN 0
the DT 0
Treatment NNP 0
of IN 0
Obsessive-Compulsive NNP 0
Disorder NNP 0
with IN 0
Poor NNP 0
Insight NNP 0
: : 0
A DT 0
24-Session JJ 0
Randomized NNP 0
Controlled NNP 0
Trial NNP 0
. . 0

OBJECTIVE NNP 0
Obsessive-compulsive JJ 0
disorder NN 0
( ( 0
OCD NNP 0
) ) 0
with IN 0
poor JJ 0
insight NN 0
has VBZ 0
severe JJ 0
consequences NNS 0
for IN 0
patients NNS 0
; : 0
nonetheless RB 0
, , 0
no DT 0
randomized VBN 0
controlled VBN 0
trial NN 0
has VBZ 0
ever RB 0
been VBN 0
performed VBN 0
to TO 0
evaluate VB 0
the DT 0
effectiveness NN 0
of IN 0
any DT 0
treatment NN 0
specifically RB 0
for IN 0
poor-insight JJ 0
OCD NNP 0
. . 0

A DT 0
new JJ 0
psychotherapy NN 0
for IN 0
OCD NNP 0
, , 0
the DT 0
inference-based JJ 0
approach NN 0
( ( 0
IBA NNP 0
) ) 0
, , 0
targets NNS 0
insight VBP 0
in IN 0
OCD NNP 0
by IN 0
strengthening VBG 0
normal JJ 0
sensory-driven JJ 0
reality NN 0
testing VBG 0
. . 0

The DT 0
goal NN 0
of IN 0
the DT 0
present JJ 0
study NN 0
is VBZ 0
to TO 0
compare VB 0
the DT 0
effectiveness NN 0
of IN 0
this DT 0
new JJ 0
treatment NN 0
to TO 0
the DT 0
effectiveness NN 0
of IN 0
cognitive JJ 0
behavior NN 0
therapy NN 0
( ( 0
CBT NNP 0
) ) 0
for IN 0
patients NNS 0
with IN 0
OCD NNP 0
with IN 0
poor JJ 0
insight NN 0
. . 0

METHOD NNP 0
A NNP 0
randomized VBD 0
controlled JJ 0
trial NN 0
was VBD 0
conducted VBN 0
, , 0
in IN 0
which WDT 0
90 CD 0
patients NNS 0
with IN 0
OCD NNP 0
with IN 0
poor JJ 0
insight NN 0
received VBD 0
either RB 0
24 CD 0
CBT NNP 0
sessions NNS 0
or CC 0
24 CD 0
IBA JJ 0
sessions NNS 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
measure NN 0
was VBD 0
the DT 0
Yale-Brown JJ 0
Obsessive NNP 0
Compulsive NNP 0
Scale NNP 0
( ( 0
YBOCS NNP 0
) ) 0
. . 0

Secondary JJ 0
outcome NN 0
measures NNS 0
were VBD 0
level NN 0
of IN 0
insight NN 0
, , 0
anxiety NN 0
and CC 0
depressive JJ 0
symptoms NNS 0
, , 0
and CC 0
quality NN 0
of IN 0
life NN 0
. . 0

Mixed-effects NNS 0
models NNS 0
were VBD 0
used VBN 0
to TO 0
determine VB 0
the DT 0
treatment NN 0
effect NN 0
. . 0

RESULTS NN 0
In IN 0
both DT 0
conditions NNS 0
, , 0
a DT 0
significant JJ 0
OCD NNP 0
symptom NN 0
reduction NN 0
was VBD 0
reached VBN 0
, , 0
but CC 0
no DT 0
condition NN 0
effects NNS 0
were VBD 0
established VBN 0
. . 0

Post NNP 0
hoc NN 0
, , 0
in IN 0
a DT 0
small JJ 0
subgroup NN 0
of IN 0
patients NNS 0
with IN 0
the DT 0
worst JJS 0
insight NN 0
( ( 0
n JJ 0
= NNP 0
23 CD 0
) ) 0
, , 0
it PRP 0
was VBD 0
found VBN 0
that IN 0
the DT 0
patients NNS 0
treated VBN 0
with IN 0
the DT 0
IBA NNP 0
reached VBD 0
a DT 0
significantly RB 0
higher JJR 0
OCD NNP 0
symptom VBZ 0
reduction NN 0
than IN 0
the DT 0
patients NNS 0
treated VBN 0
with IN 0
CBT NNP 0
[ NNP 0
estimated VBD 0
marginal JJ 0
mean NN 0
= NNP 0
-7.77 NNP 0
, , 0
t NN 0
( ( 0
219.45 CD 0
) ) 0
= NN 0
-2.4 NN 0
, , 0
p NN 0
= VBD 0
0.017 CD 0
] NN 0
. . 0

CONCLUSION NNP 0
Patients NNPS 0
with IN 0
OCD NNP 0
with IN 0
poor JJ 0
insight JJ 0
improve VB 0
significantly RB 0
after IN 0
psychological JJ 0
treatment NN 0
. . 0

The DT 0
results NNS 0
of IN 0
this DT 0
study NN 0
suggest VBP 0
that IN 0
both DT 0
CBT NNP 0
and CC 0
the DT 0
IBA NNP 0
are VBP 0
effective JJ 0
treatments NNS 0
for IN 0
OCD NNP 0
with IN 0
poor JJ 0
insight NN 0
. . 0

The DT 0
IBA NNP 0
might MD 0
be VB 0
more RBR 0
promising JJ 0
than IN 0
CBT NNP 0
for IN 0
patients NNS 0
with IN 0
more RBR 0
extreme JJ 0
poor JJ 0
insight NN 0
. . 0

Anti-emetic JJ 0
efficacy NN 0
of IN 0
prophylactic JJ 0
granisetron NNS 0
compared VBN 0
with IN 0
perphenazine NN 0
for IN 0
the DT 0
prevention NN 0
of IN 0
post-operative JJ 0
vomiting NN 0
in IN 0
children NNS 0
. . 0

We PRP 0
have VBP 0
compared VBN 0
the DT 0
efficacy NN 0
of IN 0
granisetron NN 0
with IN 0
perphenazine NN 0
in IN 0
the DT 0
prevention NN 0
of IN 0
vomiting VBG 0
after IN 0
tonsillectomy NN 0
with IN 0
or CC 0
without IN 0
adenoidectomy NN 0
in IN 0
children NNS 0
. . 0

In IN 0
a DT 0
prospective JJ 0
, , 0
randomized VBN 0
, , 0
double-blind JJ 0
study NN 0
, , 0
90 CD 0
paediatric JJ 0
patients NNS 0
, , 0
ASA NNP 0
I PRP 0
, , 0
aged VBN 0
4-10 CD 0
years NNS 0
, , 0
received VBD 0
granisetron NN 0
40 CD 0
mg JJ 0
kg-1 NN 0
or CC 0
perphenazine VB 0
70 CD 0
mg JJ 0
kg-1 NN 0
( ( 0
n JJ 0
= RB 0
45 CD 0
each DT 0
) ) 0
intravenously RB 0
immediately RB 0
after IN 0
an DT 0
inhalation NN 0
induction NN 0
of IN 0
anaesthesia NN 0
. . 0

A DT 0
standard JJ 0
general JJ 0
anaesthetic JJ 0
technique NN 0
was VBD 0
employed VBN 0
throughout IN 0
. . 0

A DT 0
complete JJ 0
response NN 0
, , 0
defined VBD 0
as IN 0
no DT 0
emesis NN 0
with IN 0
no DT 0
need NN 0
for IN 0
another DT 0
rescue NN 0
antiemetic JJ 0
, , 0
during IN 0
the DT 0
first JJ 0
3 CD 0
h NN 0
( ( 0
0-3 JJ 0
h NN 0
) ) 0
after IN 0
anesthesia NN 0
was VBD 0
87 CD 0
% NN 0
with IN 0
granisetron NN 0
and CC 0
78 CD 0
% NN 0
with IN 0
perphenazine NN 0
( ( 0
P NNP 0
= NNP 0
0.204 CD 0
) ) 0
. . 0

The DT 0
corresponding JJ 0
incidence NN 0
during IN 0
the DT 0
next JJ 0
21 CD 0
h NN 0
( ( 0
3-24 JJ 0
h NN 0
) ) 0
after IN 0
anaesthesia NN 0
was VBD 0
87 CD 0
% NN 0
and CC 0
62 CD 0
% NN 0
( ( 0
P NNP 0
= NNP 0
0.007 CD 0
) ) 0
. . 0

No UH 0
clinically RB 0
serious JJ 0
adverse JJ 0
events NNS 0
were VBD 0
observed VBN 0
in IN 0
any DT 0
of IN 0
the DT 0
groups NNS 0
. . 0

We PRP 0
conclude VBP 0
that DT 0
granisetron NN 0
is VBZ 0
a DT 0
better JJR 0
anti-emetic JJ 0
than IN 0
perphenazine NN 0
for IN 0
the DT 0
long-term JJ 0
prevention NN 0
of IN 0
post-operative JJ 0
vomiting NN 0
in IN 0
children NNS 0
undergoing VBG 0
general JJ 0
anaesthesia NN 0
for IN 0
tonsillectomy NN 0
. . 0

Cophenylcaine NNP 0
spray NN 0
vs. FW 0
placebo NN 0
in IN 0
flexible JJ 0
nasendoscopy NN 0
: : 0
a DT 0
prospective JJ 0
double-blind NN 0
randomised VBD 0
controlled VBN 0
trial NN 0
. . 0

Practices NNS 0
vary VBP 0
across IN 0
the DT 0
UK NNP 0
on IN 0
the DT 0
use NN 0
of IN 0
topical JJ 0
preparation NN 0
prior RB 0
to TO 0
flexible JJ 0
fibreoptic JJ 0
nasendoscopy NN 0
. . 0

In IN 0
this DT 0
double-blind NN 0
study NN 0
, , 0
we PRP 0
randomised VBD 0
98 CD 0
patients NNS 0
to TO 0
receive VB 0
cophenylcaine NN 0
or CC 0
placebo NN 0
nasal JJ 0
spray NN 0
before IN 0
flexible JJ 0
nasendoscopy NN 0
. . 0

A DT 0
visual JJ 0
analogue NN 0
scale NN 0
( ( 0
1-100 JJ 0
) ) 0
was VBD 0
used VBN 0
to TO 0
record VB 0
pain NN 0
, , 0
unpleasantness NN 0
of IN 0
taste NN 0
and CC 0
overall JJ 0
discomfort NN 0
experienced VBD 0
. . 0

Overall JJ 0
, , 0
the DT 0
procedure NN 0
was VBD 0
associated VBN 0
with IN 0
minimal JJ 0
pain NN 0
and CC 0
discomfort NN 0
in IN 0
both DT 0
groups NNS 0
. . 0

There EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
in IN 0
pain NN 0
or CC 0
overall JJ 0
discomfort NN 0
experienced VBD 0
between IN 0
the DT 0
two CD 0
groups NNS 0
; : 0
however RB 0
, , 0
the DT 0
sensation NN 0
of IN 0
bad JJ 0
taste NN 0
was VBD 0
significantly RB 0
worse JJR 0
in IN 0
the DT 0
cophenylcaine NN 0
group NN 0
. . 0

In IN 0
linear JJ 0
regression NN 0
, , 0
factors NNS 0
that WDT 0
predicted VBD 0
the DT 0
overall JJ 0
unpleasantness NN 0
of IN 0
the DT 0
experience NN 0
were VBD 0
primarily RB 0
pain VBN 0
experienced JJ 0
and CC 0
secondarily JJ 0
unpleasantness NN 0
of IN 0
taste NN 0
. . 0

We PRP 0
conclude VBP 0
that IN 0
the DT 0
routine JJ 0
use NN 0
of IN 0
cophenylcaine NN 0
for IN 0
nasal JJ 0
preparation NN 0
is VBZ 0
not RB 0
justified VBN 0
before IN 0
flexible JJ 0
nasendoscopy NN 0
. . 0

Learning VBG 0
about IN 0
the DT 0
equal JJ 0
sign NN 0
: : 0
does VBZ 0
comparing VBG 0
with IN 0
inequality NN 0
symbols NNS 0
help VB 0
? . 0
This DT 0
study NN 0
investigated VBD 0
whether IN 0
instruction NN 0
that WDT 0
involves VBZ 0
comparing VBG 0
the DT 0
equal JJ 0
sign NN 0
with IN 0
other JJ 0
relational JJ 0
symbols NNS 0
is VBZ 0
more RBR 0
effective JJ 0
at IN 0
imparting VBG 0
a DT 0
relational JJ 0
interpretation NN 0
of IN 0
the DT 0
equal JJ 0
sign NN 0
than IN 0
instruction NN 0
about IN 0
the DT 0
equal JJ 0
sign NN 0
alone RB 0
. . 0

Third- JJ 1
and CC 1
fourth-grade JJ 1
students NNS 1
in IN 0
a DT 0
comparing NN 0
symbols NNS 0
group NN 0
learned VBD 0
about IN 0
the DT 0
greater JJR 0
than IN 0
, , 0
less JJR 0
than IN 0
, , 0
and CC 0
equal JJ 0
signs NNS 0
and CC 0
had VBD 0
the DT 0
opportunity NN 0
to TO 0
compare VB 0
the DT 0
inequality NN 0
symbols VBZ 0
with IN 0
the DT 0
equal JJ 0
sign NN 0
. . 0

Students NNS 0
in IN 0
an DT 0
equal JJ 0
sign NN 0
group NN 0
learned VBD 0
about IN 0
the DT 0
equal JJ 0
sign NN 0
only RB 0
. . 0

A NNP 0
third JJ 0
group NN 0
of IN 0
students NNS 0
served VBD 0
as IN 0
a DT 0
control NN 0
group NN 0
. . 0

Three CD 0
aspects NNS 0
of IN 0
students NNS 0
' POS 0
knowledge NN 0
were VBD 0
assessed VBN 0
before IN 0
and CC 0
after IN 0
the DT 0
lesson NN 0
: : 0
( ( 0
a DT 0
) ) 0
conceptual JJ 0
understanding NN 0
of IN 0
the DT 0
equal JJ 0
sign NN 0
, , 0
( ( 0
b NN 0
) ) 0
equation NN 0
encoding NN 0
, , 0
and CC 0
( ( 0
c NN 0
) ) 0
problem NN 0
solving VBG 0
. . 0

Students NNS 0
in IN 0
the DT 0
comparing NN 0
symbols NNS 0
group NN 0
showed VBD 0
greater JJR 0
gains NNS 0
in IN 0
conceptual JJ 0
understanding NN 0
from IN 0
pretest NN 0
to TO 0
posttest VB 0
than IN 0
students NNS 0
in IN 0
the DT 0
other JJ 0
two CD 0
groups NNS 0
, , 0
and CC 0
students NNS 0
in IN 0
the DT 0
comparing NN 0
symbols NNS 0
group NN 0
also RB 0
scored VBD 0
higher JJR 0
on IN 0
a DT 0
posttest NN 0
that WDT 0
assessed VBD 0
knowledge NN 0
about IN 0
inequality NN 0
symbols NNS 0
and CC 0
inequality NN 0
problem NN 0
solving VBG 0
. . 0

Thus RB 0
, , 0
they PRP 0
learned VBD 0
about IN 0
three CD 0
symbols NNS 0
in IN 0
the DT 0
same JJ 0
amount NN 0
of IN 0
time NN 0
as IN 0
other JJ 0
students NNS 0
learned VBD 0
about IN 0
the DT 0
equal JJ 0
sign NN 0
alone RB 0
or CC 0
not RB 0
at IN 0
all DT 0
. . 0

Therefore NNP 0
, , 0
an DT 0
instructional JJ 0
approach NN 0
involving VBG 0
comparison NN 0
can MD 0
be VB 0
an DT 0
effective JJ 0
tool NN 0
for IN 0
learning VBG 0
about IN 0
concepts NNS 0
in IN 0
mathematics NNS 0
. . 0

Once-daily RB 0
MMX NNP 0
( ( 0
? . 0
) ) 0
mesalamine NN 0
for IN 0
endoscopic JJ 0
maintenance NN 0
of IN 0
remission NN 0
of IN 0
ulcerative JJ 0
colitis NN 0
. . 0

OBJECTIVES NNP 0
Treatment NNP 0
with IN 0
mesalamine NN 0
to TO 0
maintain VB 0
endoscopic JJ 0
remission NN 0
( ( 0
mucosal JJ 0
healing VBG 0
) ) 0
of IN 0
ulcerative JJ 0
colitis NN 0
( ( 0
UC NNP 0
) ) 0
has VBZ 0
been VBN 0
shown VBN 0
to TO 0
reduce VB 0
the DT 0
risk NN 0
of IN 0
relapse NN 0
and CC 0
is VBZ 0
the DT 0
recommended JJ 0
first-line JJ 0
maintenance NN 0
therapy NN 0
. . 0

To TO 0
improve VB 0
treatment NN 0
adherence NN 0
, , 0
a DT 0
mesalamine NN 0
formulation NN 0
that WDT 0
can MD 0
be VB 0
administered VBN 0
once-daily RB 0
, , 0
MMX NNP 0
( ( 0
? . 0
) ) 0
mesalamine NN 0
( ( 0
Lialda NNP 0
; : 0
Shire NNP 0
Pharmaceuticals NNP 0
LLC NNP 0
, , 0
Wayne NNP 0
, , 0
PA NNP 0
) ) 0
, , 0
was VBD 0
developed VBN 0
. . 0

This DT 0
study NN 0
was VBD 0
conducted VBN 0
to TO 0
determine VB 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
once-daily JJ 0
MMX NNP 0
mesalamine NN 0
compared VBN 0
with IN 0
twice-daily JJ 0
delayed-release JJ 0
mesalamine NN 0
( ( 0
Asacol NNP 0
; : 0
Warner NNP 0
Chilcott NNP 0
, , 0
Dublin NNP 0
, , 0
Ireland NNP 0
) ) 0
for IN 0
maintaining VBG 0
endoscopic JJ 0
remission NN 0
in IN 0
patients NNS 0
with IN 0
UC NNP 0
. . 0

METHODS NNP 0
A NNP 0
multicenter NN 0
, , 0
randomized VBN 0
, , 0
double-blind JJ 0
, , 0
6-month JJ 0
, , 0
active-control JJ 0
trial NN 0
was VBD 0
conducted VBN 0
to TO 0
assess VB 0
the DT 0
non-inferiority NN 0
of IN 0
once-daily JJ 0
MMX NNP 0
mesalamine NN 0
2.4 CD 0
g/day NN 0
compared VBN 0
with IN 0
twice-daily JJ 0
delayed-release JJ 0
mesalamine NN 0
at IN 0
a DT 0
total JJ 0
daily JJ 0
dose NN 0
of IN 0
1.6 CD 0
g/day NN 0
in IN 0
patients NNS 0
with IN 0
UC NNP 0
in IN 0
endoscopic JJ 0
remission NN 0
. . 0

The DT 0
primary JJ 0
end NN 0
point NN 0
was VBD 0
maintenance NN 0
of IN 0
endoscopic JJ 0
remission NN 0
at IN 0
month NN 0
6 CD 0
in IN 0
the DT 0
per-protocol NN 0
( ( 0
PP NNP 0
) ) 0
population NN 0
. . 0

RESULTS NNP 0
Overall NNP 0
, , 0
826 CD 0
patients NNS 0
were VBD 0
randomized VBN 0
and CC 0
dosed VBN 0
. . 0

The DT 0
primary JJ 0
objective JJ 0
( ( 0
non-inferiority NN 0
) ) 0
was VBD 0
met VBN 0
. . 0

At IN 0
month NN 0
6 CD 0
, , 0
83.7 CD 0
and CC 0
77.8 CD 0
% NN 0
of IN 0
patients NNS 0
receiving VBG 0
MMX NNP 0
mesalamine NN 0
in IN 0
the DT 0
PP NNP 0
and CC 0
intent-to-treat NN 0
( ( 0
ITT NNP 0
) ) 0
populations NNS 0
, , 0
respectively RB 0
, , 0
had VBD 0
maintained VBN 0
endoscopic JJ 0
remission NN 0
compared VBN 0
with IN 0
81.5 CD 0
% NN 0
( ( 0
PP NNP 0
) ) 0
and CC 0
76.9 CD 0
% NN 0
( ( 0
ITT NNP 0
) ) 0
of IN 0
patients NNS 0
receiving VBG 0
delayed-release JJ 0
mesalamine NN 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
for IN 0
difference NN 0
: : 0
-3.9 CD 0
% NN 0
, , 0
8.1 CD 0
% NN 0
( ( 0
PP NNP 0
) ) 0
; : 0
-5.0 CD 0
% NN 0
, , 0
6.9 CD 0
% NN 0
( ( 0
ITT NNP 0
) ) 0
) ) 0
. . 0

Time NN 0
to TO 0
relapse VB 0
was VBD 0
not RB 0
significantly RB 0
different JJ 0
between IN 0
the DT 0
two CD 0
treatment NN 0
groups NNS 0
( ( 0
log-rank JJ 0
test NN 0
, , 0
P=0.5116 NNP 0
( ( 0
PP NNP 0
) ) 0
; : 0
P=0.5455 NNP 0
( ( 0
ITT NNP 0
) ) 0
) ) 0
. . 0

The DT 0
proportion NN 0
of IN 0
patients NNS 0
with IN 0
adverse JJ 0
events NNS 0
was VBD 0
37.1 CD 0
and CC 0
36.0 CD 0
% NN 0
in IN 0
patients NNS 0
receiving VBG 0
MMX NNP 0
mesalamine NN 0
and CC 0
delayed-release JJ 0
mesalamine NN 0
, , 0
respectively RB 0
. . 0

CONCLUSIONS NNP 0
Once-daily JJ 0
dosing NN 0
of IN 0
MMX NNP 0
mesalamine NN 0
2.4 CD 0
g/day NN 0
was VBD 0
shown VBN 0
to TO 0
be VB 0
well RB 0
tolerated VBN 0
and CC 0
non-inferior JJ 0
to TO 0
twice-daily JJ 0
dosing VBG 0
with IN 0
delayed-release JJ 0
mesalamine NN 0
1.6 CD 0
g/day NN 0
for IN 0
maintenance NN 0
of IN 0
endoscopic JJ 0
remission NN 0
in IN 0
patients NNS 0
with IN 0
UC NNP 0
. . 0

The DT 0
effect NN 0
of IN 0
person-centred JJ 0
dementia NN 0
care NN 0
to TO 0
prevent VB 0
agitation NN 0
and CC 0
other JJ 0
neuropsychiatric JJ 0
symptoms NNS 0
and CC 0
enhance JJ 0
quality NN 0
of IN 0
life NN 0
in IN 0
nursing NN 4
home NN 4
patients NNS 4
: : 0
a DT 0
10-month JJ 0
randomized NN 0
controlled VBD 0
trial NN 0
. . 0

AIMS IN 0
We PRP 0
examined VBD 0
whether IN 0
Dementia NNP 0
Care NNP 0
Mapping NNP 0
( ( 0
DCM NNP 0
) ) 0
or CC 0
the DT 0
VIPS NNP 0
practice NN 0
model NN 0
( ( 0
VPM NNP 0
) ) 0
is VBZ 0
more RBR 0
effective JJ 0
than IN 0
education NN 0
of IN 0
the DT 0
nursing NN 0
home NN 0
staff NN 0
about IN 0
dementia NN 0
( ( 0
control VB 0
group NN 0
) ) 0
in IN 0
reducing VBG 0
agitation NN 0
and CC 0
other JJ 0
neuropsychiatric JJ 0
symptoms NNS 0
as RB 0
well RB 0
as IN 0
in IN 0
enhancing VBG 0
the DT 0
quality NN 0
of IN 0
life NN 0
among IN 0
nursing JJ 0
home NN 0
patients NNS 0
. . 0

METHODS VB 0
A DT 0
10-month JJ 0
three-armed JJ 0
cluster-randomized JJ 0
controlled VBN 0
trial NN 0
compared VBN 0
DCM NNP 0
and CC 0
VPM NNP 0
with IN 0
control NN 0
. . 0

Of IN 0
624 CD 3
nursing NN 0
home NN 0
patients NNS 0
with IN 0
dementia NN 4
, , 0
446 CD 3
completed VBD 0
follow-up JJ 0
assessments NNS 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
was VBD 0
the DT 0
change NN 0
on IN 0
the DT 0
Brief JJ 0
Agitation NNP 0
Rating NNP 0
Scale NNP 0
( ( 0
BARS NNP 0
) ) 0
. . 0

Secondary JJ 0
outcomes NNS 0
were VBD 0
changes NNS 0
on IN 0
the DT 0
10-item JJ 0
version NN 0
of IN 0
the DT 0
Neuropsychiatric NNP 0
Inventory NNP 0
Questionnaire NNP 0
( ( 0
NPI-Q NNP 0
) ) 0
, , 0
the DT 0
Cornell NNP 0
Scale NNP 0
for IN 0
Depression NNP 0
in IN 0
Dementia NNP 0
( ( 0
CSDD NNP 0
) ) 0
and CC 0
the DT 0
Quality NN 0
of IN 0
Life NNP 0
in IN 0
Late-Stage NNP 0
Dementia NNP 0
( ( 0
QUALID NNP 0
) ) 0
scale NN 0
. . 0

RESULTS NNP 0
Changes NNP 0
in IN 0
the DT 0
BARS NNP 0
score NN 0
did VBD 0
not RB 0
differ VB 0
significantly RB 0
between IN 0
the DT 0
DCM NNP 0
and CC 0
the DT 0
control NN 0
group NN 0
or CC 0
between IN 0
the DT 0
VPM NNP 0
and CC 0
the DT 0
control NN 0
group NN 0
after IN 0
10 CD 0
months NNS 0
. . 0

Positive JJ 0
differences NNS 0
were VBD 0
found VBN 0
for IN 0
changes NNS 0
in IN 0
the DT 0
secondary JJ 0
outcomes NNS 0
: : 0
the DT 0
NPI-Q NNP 0
sum NN 0
score NN 0
as RB 0
well RB 0
as IN 0
the DT 0
subscales NNS 0
NPI-Q NNP 0
agitation NN 0
and CC 0
NPI-Q JJ 0
psychosis NN 0
were VBD 0
in IN 0
favour NN 0
of IN 0
both DT 0
interventions NNS 0
versus VBP 0
control NN 0
, , 0
the DT 0
QUALID NNP 0
score NN 0
was VBD 0
in IN 0
favour NN 0
of IN 0
DCM NNP 0
versus NN 0
control NN 0
and CC 0
the DT 0
CSDD NNP 0
score NN 0
was VBD 0
in IN 0
favour NN 0
of IN 0
VPM NNP 0
versus NN 0
control NN 0
. . 0

CONCLUSIONS NNP 0
This DT 0
study NN 0
failed VBD 0
to TO 0
find VB 0
a DT 0
significant JJ 0
effect NN 0
of IN 0
both DT 0
interventions NNS 0
on IN 0
the DT 0
primary JJ 0
outcome NN 0
. . 0

Positive JJ 0
effects NNS 0
on IN 0
the DT 0
secondary JJ 0
outcomes NNS 0
indicate VBP 0
that IN 0
the DT 0
methods NNS 0
merit VBP 0
further JJ 0
investigation NN 0
. . 0

Comparison NNP 0
of IN 0
rectal JJ 0
midazolam NN 0
and CC 0
diazepam NN 0
for IN 0
premedication NN 0
in IN 0
pediatric JJ 1
dental JJ 4
patients NNS 4
. . 0

Rectally RB 0
administered VBN 0
midazolam NN 0
( ( 0
0.35 CD 0
mg/kg NN 0
) ) 0
and CC 0
diazepam NN 0
( ( 0
0.70 CD 0
mg/kg NN 0
) ) 0
were VBD 0
compared VBN 0
with IN 0
each DT 0
other JJ 0
and CC 0
with IN 0
placebo NN 0
for IN 0
preanesthetic JJ 0
medication NN 0
in IN 0
children NNS 1
undergoing VBG 0
dental JJ 4
extractions NNS 4
. . 0

All DT 0
rectal JJ 0
medications NNS 0
were VBD 0
very RB 0
well RB 0
accepted VBN 0
, , 0
but CC 0
mask JJ 0
acceptance NN 0
, , 0
improvement NN 0
in IN 0
anxiety NN 0
, , 0
and CC 0
sedation NN 0
were VBD 0
best RBS 0
in IN 0
the DT 0
midazolam NN 0
group NN 0
. . 0

Improvement NNP 0
in IN 0
anxiety NN 0
and CC 0
sedation NN 0
were VBD 0
significantly RB 0
better RBR 0
in IN 0
the DT 0
two CD 0
drug NN 0
groups NNS 0
than IN 0
in IN 0
those DT 0
patients NNS 0
who WP 0
had VBD 0
received VBN 0
placebo NN 0
. . 0

Thirty NNP 0
minutes NNS 0
after IN 0
rectal JJ 0
administration NN 0
of IN 0
midazolam NNS 0
, , 0
patients NNS 0
showed VBD 0
a DT 0
decrease NN 0
in IN 0
both DT 0
systolic JJ 0
and CC 0
diastolic JJ 0
blood NN 0
pressure NN 0
and CC 0
heart NN 0
rate NN 0
. . 0

Although IN 0
these DT 0
decreases NNS 0
differed VBD 0
significantly RB 0
from IN 0
the DT 0
premedication NN 0
values NNS 0
, , 0
they PRP 0
were VBD 0
probably RB 0
of IN 0
little JJ 0
clinical JJ 0
importance NN 0
. . 0

Only RB 0
minor JJ 0
adverse JJ 0
effects NNS 0
were VBD 0
observed VBN 0
in IN 0
this DT 0
study NN 0
. . 0

Overall NNP 0
rectally RB 0
administered VBD 0
midazolam NNS 0
appeared VBD 0
to TO 0
be VB 0
somewhat RB 0
more RBR 0
efficacious JJ 0
than IN 0
diazepam NN 0
. . 0

Efficacy NN 0
of IN 0
patient JJ 0
education NN 0
and CC 0
supervised VBD 0
exercise NN 0
vs NN 0
patient JJ 0
education NN 0
alone RB 0
in IN 0
patients NNS 0
with IN 0
hip JJ 4
osteoarthritis NN 4
: : 0
a DT 0
single JJ 0
blind NN 0
randomized VBD 0
clinical JJ 0
trial NN 0
. . 0

OBJECTIVE UH 0
To TO 0
compare VB 0
the DT 0
efficacy NN 0
of IN 0
patient JJ 0
education NN 0
and CC 0
supervised VBD 0
exercise NN 0
with IN 0
that DT 0
of IN 0
patient JJ 0
education NN 0
alone RB 0
for IN 0
the DT 0
management NN 0
of IN 0
pain NN 0
in IN 0
patients NNS 0
with IN 0
hip NN 0
osteoarthritis NN 0
( ( 0
OA NNP 4
) ) 0
. . 0

DESIGN NNP 0
Single NNP 0
blind IN 0
randomized JJ 0
clinical JJ 0
trial NN 0
. . 0

SETTING NNP 0
Recruitment NNP 0
of IN 0
patients NNS 0
from IN 0
hospitals NNS 0
, , 0
primary JJ 0
health NN 0
care NN 0
and CC 0
advertisement NN 0
, , 0
Oslo NNP 0
, , 0
Norway NNP 0
. . 0

PARTICIPANTS NNP 0
109 CD 3
patients NNS 0
with IN 0
radiographic JJ 0
and CC 0
symptomatic JJ 0
hip NN 0
OA NNP 0
with IN 0
mild NN 0
to TO 0
moderate VB 0
symptoms NNS 0
. . 0

INTERVENTIONS NNP 0
Patient NNP 0
education NN 0
( ( 0
PE NNP 0
) ) 0
. . 0

Patient JJ 0
education NN 0
and CC 0
supervised VBN 0
exercise NN 0
( ( 0
PE+SE NNP 0
) ) 0
. . 0

PRIMARY NNP 0
OUTCOME NNP 0
MEASURE NNP 0
The DT 0
pain NN 0
subscale NN 0
of IN 0
the DT 0
Western NNP 0
Ontario NNP 0
and CC 0
McMaster NNP 0
Universities NNP 0
Osteoarthritis NNP 0
Index NNP 0
( ( 0
WOMAC NNP 0
pain NN 0
) ) 0
. . 0

RESULTS NNP 0
No NNP 0
significant JJ 0
between IN 0
group NN 0
differences NNS 0
were VBD 0
found VBN 0
for IN 0
WOMAC NNP 0
pain NN 0
over IN 0
the DT 0
16-month JJ 0
follow-up NN 0
. . 0

Significant JJ 0
improvements NNS 0
were VBD 0
found VBN 0
for IN 0
the DT 0
secondary JJ 0
outcome NN 0
WOMAC NNP 0
physical JJ 0
function NN 0
( ( 0
P=0.011 NNP 0
) ) 0
in IN 0
the DT 0
group NN 0
receiving VBG 0
PE+SE NNP 0
compared VBN 0
to TO 0
the DT 0
group NN 0
receiving VBG 0
PE NNP 0
only RB 0
. . 0

No DT 0
significant JJ 0
differences NNS 0
were VBD 0
found VBN 0
for IN 0
WOMAC NNP 0
stiffness NN 0
, , 0
the DT 0
SF-36 JJ 0
subscales NNS 0
or CC 0
the DT 0
activity NN 0
scale NN 0
. . 0

The DT 0
effect NN 0
sizes VBZ 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
) ) 0
for IN 0
WOMAC NNP 0
pain NN 0
were VBD 0
-0.26 NNP 0
( ( 0
0.11 CD 0
, , 0
-0.64 NN 0
) ) 0
, , 0
-0.35 NNP 0
( ( 0
0.07 CD 0
, , 0
-0.77 NN 0
) ) 0
, , 0
and CC 0
-0.30 NNP 0
( ( 0
0.15 CD 0
, , 0
-0.75 NN 0
) ) 0
, , 0
and CC 0
for IN 0
WOMAC NNP 0
physical JJ 0
function NN 0
-0.29 NNP 0
( ( 0
0.09 CD 0
, , 0
-0.67 NN 0
) ) 0
, , 0
-0.48 NNP 0
( ( 0
-0.06 NNP 0
, , 0
-0.91 NNP 0
) ) 0
, , 0
and CC 0
-0.47 NNP 0
( ( 0
-0.02 NNP 0
, , 0
-0.93 NNP 0
) ) 0
at IN 0
4 CD 0
, , 0
10 CD 0
and CC 0
16 CD 0
months NNS 0
, , 0
respectively RB 0
, , 0
in IN 0
favor NN 0
of IN 0
the DT 0
group NN 0
receiving VBG 0
both DT 0
PE NNP 0
and CC 0
SE NNP 0
. . 0

All DT 0
patients NNS 0
attended VBD 0
the DT 0
three-session JJ 0
PE NNP 0
program NN 0
, , 0
and CC 0
75 CD 0
% NN 0
performed VBN 0
?16 JJ 0
sessions NNS 0
of IN 0
the DT 0
12-week JJ 0
SE NNP 0
program NN 0
. . 0

CONCLUSION NNP 0
The DT 0
study NN 0
could MD 0
not RB 0
demonstrate VB 0
a DT 0
significant JJ 0
difference NN 0
in IN 0
pain NN 0
reduction NN 0
over IN 0
time NN 0
between IN 0
PE+SE NNP 0
vs NNP 0
PE NNP 0
alone RB 0
. . 0

Adding VBG 0
SE NNP 0
to TO 0
PE NNP 0
may MD 0
improve VB 0
physical JJ 0
function NN 0
, , 0
but CC 0
the DT 0
magnitude NN 0
of IN 0
possible JJ 0
benefit NN 0
is VBZ 0
unknown JJ 0
as IN 0
the DT 0
95 CD 0
% NN 0
confidence NN 0
intervals NNS 0
around IN 0
the DT 0
mean JJ 0
difference NN 0
were VBD 0
wide JJ 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
Clinical NNP 0
Trials NNP 0
NCT00319423 NNP 0
. . 0

[ JJ 0
Usage NN 0
of IN 0
titanoreine NN 0
after IN 0
procedure NN 4
for IN 4
prolapse NN 4
and CC 4
hemorrhoids NNS 4
] NNP 0
. . 0

OBJECTIVE NNP 0
To TO 0
evaluate VB 0
the DT 0
effect NN 0
of IN 0
titanoreine NN 0
on IN 0
early JJ 0
postoperative NN 0
symptoms NNS 0
after IN 0
procedure NN 0
for IN 0
prolapse NN 0
and CC 0
hemorrhoids NNS 0
( ( 0
PPH NNP 0
) ) 0
. . 0

METHODS NNP 0
From IN 0
November NNP 0
2002 CD 0
to TO 0
July NNP 0
2003 CD 0
, , 0
80 CD 3
patients NNS 0
who WP 0
received VBD 0
PPH NNP 0
were VBD 0
randomly RB 0
divided VBN 0
in IN 0
to TO 0
titanoreine VB 0
group NN 0
( ( 0
n=42 CC 0
) ) 0
and CC 0
control VB 0
group NN 0
without IN 0
titanoreine NN 0
( ( 0
n=38 JJ 0
) ) 0
. . 0

Symptom JJ 0
relief NN 0
was VBD 0
recorded VBN 0
24 CD 0
hours NNS 0
, , 0
6 CD 0
days NNS 0
and CC 0
12 CD 0
days NNS 0
after IN 0
PPH NNP 0
, , 0
urine JJ 0
retention NN 0
24h CD 0
after IN 0
PPH NNP 0
, , 0
first RB 0
stool JJ 0
time NN 0
, , 0
wound IN 0
healing VBG 0
time NN 0
, , 0
mean JJ 0
hospital NN 0
stay NN 0
were VBD 0
also RB 0
recorded VBN 0
. . 0

RESULTS VB 0
The DT 0
score NN 0
of IN 0
symptom NN 0
was VBD 0
lower JJR 0
in IN 0
titanoreine NN 0
group NN 0
( ( 0
4.4 CD 0
) ) 0
than IN 0
that DT 0
in IN 0
the DT 0
control NN 0
group NN 0
( ( 0
6.1 CD 0
) ) 0
24 CD 0
hours NNS 0
after IN 0
PPH NNP 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
, , 0
but CC 0
no DT 0
significant JJ 0
difference NN 0
in IN 0
symptom NN 0
grade NN 0
was VBD 0
found VBN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
6 CD 0
days NNS 0
and CC 0
12 CD 0
days NNS 0
after IN 0
PPH NNP 0
( ( 0
P NNP 0
> NNP 0
0.05 CD 0
) ) 0
. . 0

Decrements NNS 0
of IN 0
symptom NN 0
grade NN 0
were VBD 0
lower JJR 0
in IN 0
titanoreine NN 0
group NN 0
than IN 0
those DT 0
of IN 0
control NN 0
group NN 0
at IN 0
any DT 0
point NN 0
after IN 0
PPH NNP 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

There EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
in IN 0
urine JJ 0
retention NN 0
rate NN 0
and CC 0
mean JJ 0
hospital NN 0
stay NN 0
between IN 0
two CD 0
groups NNS 0
( ( 0
P NNP 0
> NNP 0
0.05 CD 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Titanoreine NNP 0
can MD 0
effectively RB 0
relieve VB 0
the DT 0
early JJ 0
postoperative NN 0
symptoms NNS 0
after IN 0
PPH NNP 0
. . 0

Midazolam NNP 0
vs NN 0
ondansetron NN 0
for IN 0
preventing VBG 0
postoperative JJ 0
nausea NN 0
and CC 0
vomiting NN 0
: : 0
a DT 0
randomised JJ 0
controlled VBN 0
trial NN 0
. . 0

We PRP 0
compared VBN 0
the DT 0
prophylactic JJ 0
anti-emetic JJ 0
efficacy NN 0
of IN 0
midazolam NN 0
and CC 0
ondansetron NN 0
in IN 0
90 CD 3
patients NNS 0
scheduled VBN 0
for IN 0
minor JJ 4
gynaecological JJ 4
( ( 0
hysteroscopy NN 4
) ) 0
or CC 0
urological JJ 4
( ( 0
ureteroscopy JJ 4
) ) 0
procedures NNS 0
planned VBN 0
to TO 0
last JJ 0
1-2 JJ 0
h NN 0
under IN 0
sevoflurane NN 0
anaesthesia NN 0
with IN 0
spontaneous JJ 0
ventilation NN 0
of IN 0
the DT 0
lungs NNS 0
via IN 0
a DT 0
laryngeal JJ 0
mask NN 0
airway NN 0
. . 0

Midazolam NNP 0
2 CD 0
mg NN 0
or CC 0
ondansetron $ 0
4 CD 0
mg NN 0
were VBD 0
administered VBN 0
intravenously RB 0
30 CD 0
min NN 0
before IN 0
the DT 0
end NN 0
of IN 0
surgery NN 0
. . 0

The DT 0
proportions NNS 0
of IN 0
patients NNS 0
who WP 0
experienced VBD 0
postoperative JJ 4
nausea NN 4
and CC 0
vomiting NN 4
in IN 0
the DT 0
first JJ 0
24 CD 0
h NN 0
( ( 0
30 CD 0
% NN 0
and CC 0
27 CD 0
% NN 0
for IN 0
the DT 0
midazolam NN 0
and CC 0
ondansetron NN 0
groups NNS 0
, , 0
respectively RB 0
) ) 0
were VBD 0
similar JJ 0
in IN 0
the DT 0
two CD 0
groups NNS 0
. . 0

The DT 0
incidence NN 0
of IN 0
postoperative JJ 0
nausea NN 0
and CC 0
vomiting NN 0
was VBD 0
significantly RB 0
smaller JJR 0
in IN 0
both DT 0
groups NNS 0
than IN 0
predicted VBN 0
according VBG 0
to TO 0
the DT 0
patients NNS 0
' POS 0
underlying JJ 0
risks NNS 0
( ( 0
midazolam JJ 0
group NN 0
: : 0
p NN 0
= VBZ 0
0.018 CD 0
; : 0
ondansetron VBN 0
group NN 0
: : 0
p NN 0
= VBZ 0
0.017 CD 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
average JJ 0
sedation NN 0
scores NNS 0
or CC 0
pain NN 0
scores NNS 0
. . 0

Treatment NNP 0
using VBG 0
ondansetron NN 0
for IN 0
anti-emetic JJ 0
prophylaxis NN 0
did VBD 0
not RB 0
provide VB 0
a DT 0
superior JJ 0
benefit NN 0
compared VBN 0
to TO 0
midazolam VB 0
in IN 0
the DT 0
present JJ 0
study NN 0
. . 0

A DT 0
comparison NN 0
of IN 0
intermittent JJ 0
vaginal JJ 0
administration NN 0
of IN 0
misoprostol NN 0
with IN 0
continuous JJ 0
dinoprostone NN 0
for IN 0
cervical JJ 0
ripening NN 0
and CC 0
labor NN 0
induction NN 0
. . 0

OBJECTIVE CC 0
Our PRP$ 0
purpose NN 0
was VBD 0
to TO 0
compare VB 0
the DT 0
effect NN 0
of IN 0
vaginal JJ 0
administration NN 0
of IN 0
misoprostol NN 0
( ( 0
Cytotec NNP 0
) ) 0
with IN 0
that DT 0
of IN 0
dinoprostone NN 0
( ( 0
Cervidil NNP 0
) ) 0
on IN 0
cervical JJ 0
ripening NN 0
and CC 0
labor NN 0
induction NN 0
. . 0

STUDY NNP 0
DESIGN NNP 0
Two CD 3
hundred VBD 3
patients NNS 0
with IN 0
indications NNS 0
for IN 0
induction NN 4
of IN 4
labor NN 4
and CC 0
unfavorable JJ 4
cervical JJ 4
examinations NNS 4
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
vaginally RB 0
administered VBN 0
misoprostol NN 0
( ( 0
prostaglandin JJ 0
E1 NNP 0
) ) 0
or CC 0
the DT 0
dinoprostone NN 0
( ( 0
prostaglandin JJ 0
E2 NNP 0
) ) 0
vaginal NN 0
insert NN 0
. . 0

Twenty-five JJ 0
microgram JJ 0
tablets NNS 0
of IN 0
misoprostol NN 0
were VBD 0
placed VBN 0
in IN 0
the DT 0
posterior JJ 0
vaginal JJ 0
fornix NN 0
every DT 0
4 CD 0
hours NNS 0
for IN 0
a DT 0
maximum NN 0
of IN 0
six CD 0
doses NNS 0
. . 0

Additional NNP 0
misoprostol NN 0
was VBD 0
not RB 0
given VBN 0
after IN 0
either DT 0
spontaneous JJ 0
rupture NN 0
of IN 0
membranes NNS 0
, , 0
adequate JJ 0
cervical JJ 0
ripening NN 0
( ( 0
Bishop NNP 0
score NN 0
of IN 0
> NN 0
or CC 0
= VB 0
8 CD 0
or CC 0
cervical JJ 0
dilatation NN 0
of IN 0
> NN 0
or CC 0
= $ 0
3 CD 0
cm NN 0
) ) 0
, , 0
or CC 0
beginning NN 0
of IN 0
active JJ 0
labor NN 0
. . 0

The DT 0
vaginal JJ 0
insert NN 0
, , 0
Cervidil NNP 0
, , 0
containing VBG 0
10 CD 0
mg NN 0
of IN 0
dinoprostone NN 0
in IN 0
a DT 0
timed-release JJ 0
preparation NN 0
was VBD 0
placed VBN 0
in IN 0
the DT 0
posterior JJ 0
vaginal JJ 0
formix NN 0
for IN 0
a DT 0
maximum JJ 0
period NN 0
of IN 0
24 CD 0
hours NNS 0
. . 0

The DT 0
vaginal JJ 0
insert NN 0
was VBD 0
removed VBN 0
for IN 0
spontaneous JJ 0
rupture NN 0
of IN 0
membranes NNS 0
, , 0
entry NN 0
into IN 0
active JJ 0
labor NN 0
, , 0
adequate JJ 0
cervical JJ 0
ripening NN 0
, , 0
or CC 0
abnormality NN 0
of IN 0
uterine JJ 0
contractile NN 0
pattern NN 0
or CC 0
fetal JJ 0
cardiac JJ 0
activity NN 0
. . 0

RESULTS NN 0
Of IN 0
the DT 0
200 CD 3
patients NNS 0
enrolled VBD 0
, , 0
99 CD 3
were VBD 0
randomized VBN 0
to TO 0
misoprostol VB 0
and CC 0
101 CD 3
to TO 0
dinoprostone VB 0
. . 0

The DT 0
average JJ 0
interval NN 0
from IN 0
start NN 0
of IN 0
induction NN 0
to TO 0
vaginal JJ 0
delivery NN 0
was VBD 0
1 CD 0
hour NN 0
shorter NN 0
in IN 0
the DT 0
misoprostol NN 0
group NN 0
( ( 0
1296.7 CD 0
+/- JJ 0
722.1 CD 0
minutes NNS 0
) ) 0
than IN 0
in IN 0
the DT 0
dinoprostone NN 0
group NN 0
( ( 0
1360.0 CD 0
+/- JJ 0
792.0 CD 0
minutes NNS 0
) ) 0
, , 0
but CC 0
this DT 0
difference NN 0
was VBD 0
not RB 0
statistically RB 0
significant JJ 0
( ( 0
p JJ 0
= NNP 0
0.97 CD 0
) ) 0
. . 0

Oxytocin NNP 0
augmentation NN 0
of IN 0
labor NN 0
was VBD 0
used VBN 0
in IN 0
50 CD 0
( ( 0
50.5 CD 0
% NN 0
) ) 0
misoprostol-treated JJ 0
patients NNS 0
and CC 0
43 CD 0
( ( 0
43.5 CD 0
% NN 0
) ) 0
dinoprostone-treated JJ 0
patients NNS 0
( ( 0
relative JJ 0
risk NN 0
1.14 CD 0
, , 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
0.86 CD 0
to TO 0
1.51 CD 0
, , 0
p NN 0
= NNP 0
0.35 CD 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
between IN 0
routes NNS 0
of IN 0
delivery NN 0
with IN 0
misoprostol NN 0
or CC 0
dinoprostone NN 0
. . 0

Overall NNP 0
, , 0
38 CD 3
patients NNS 0
( ( 0
19.3 CD 0
% NN 0
) ) 0
had VBD 0
cesarean JJ 0
deliveries NNS 0
. . 0

There EX 0
was VBD 0
a DT 0
significantly RB 0
lower JJR 0
prevalence NN 0
of IN 0
tachysystole NN 0
( ( 0
six CD 0
or CC 0
more JJR 0
uterine JJ 0
contractions NNS 0
in IN 0
a DT 0
10-minute JJ 0
window NN 0
for IN 0
two CD 0
consecutive JJ 0
10-minute JJ 0
periods NNS 0
) ) 0
in IN 0
the DT 0
misoprostol NN 0
group NN 0
( ( 0
7.1 CD 0
% NN 0
) ) 0
than IN 0
in IN 0
the DT 0
dinoprostone NN 0
group NN 0
( ( 0
18.4 CD 0
% NN 0
) ) 0
( ( 0
relative JJ 0
risk NN 0
0.52 CD 0
, , 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
0.31 CD 0
to TO 0
0.89 CD 0
, , 0
p NN 0
= NNP 0
0.02 CD 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
frequency NN 0
of IN 0
uterine JJ 0
hyperstimulation NN 0
or CC 0
hypertonus NN 0
. . 0

Abnormal NNP 0
fetal JJ 0
heart NN 0
rate NN 0
tracings NNS 0
were VBD 0
found VBN 0
in IN 0
23 CD 0
( ( 0
23.2 CD 0
% NN 0
) ) 0
of IN 0
misoprostol-treated JJ 0
patients NNS 0
and CC 0
35 CD 0
( ( 0
35.7 CD 0
% NN 0
) ) 0
of IN 0
dinoprostone-treated JJ 0
patients NNS 0
( ( 0
relative JJ 0
risk NN 0
0.73 CD 0
, , 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
0.52 CD 0
to TO 0
1.01 CD 0
, , 0
p NN 0
= NNP 0
0.0546 CD 0
) ) 0
. . 0

No DT 0
significant JJ 0
differences NNS 0
were VBD 0
found VBN 0
in IN 0
meconium NN 0
passage NN 0
, , 0
1- JJ 0
or CC 0
5-minute JJ 0
Apgar NNP 0
scores NNS 0
< VBP 0
7 CD 0
, , 0
neonatal JJ 0
resuscitations NNS 0
, , 0
or CC 0
admissions NNS 0
to TO 0
the DT 0
neonatal JJ 0
intensive JJ 0
care NN 0
unit NN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
. . 0

CONCLUSIONS NNP 0
Vaginally NNP 0
administered VBD 0
misoprostol NN 0
is VBZ 0
as RB 0
effective JJ 0
as IN 0
dinoprostone NN 0
for IN 0
cervical JJ 0
ripening NN 0
and CC 0
the DT 0
induction NN 0
of IN 0
labor NN 0
. . 0

Mean JJ 0
time NN 0
intervals NNS 0
to TO 0
delivery NN 0
, , 0
need NN 0
for IN 0
oxytocin JJ 0
augmentation NN 0
, , 0
and CC 0
routes NNS 0
of IN 0
delivery NN 0
were VBD 0
similar JJ 0
between IN 0
the DT 0
two CD 0
groups NNS 0
. . 0

Incidence NN 0
of IN 0
uterine JJ 0
tachysystole NN 0
with IN 0
misoprostol NN 0
every DT 0
4 CD 0
hours NNS 0
was VBD 0
significantly RB 0
less JJR 0
than IN 0
with IN 0
dinoprostone NN 0
. . 0

Efficacy NN 0
of IN 0
physiotherapy JJ 0
management NN 0
of IN 0
knee NN 4
joint JJ 4
osteoarthritis NN 4
: : 0
a DT 0
randomised JJ 0
, , 0
double JJ 0
blind NN 0
, , 0
placebo NN 0
controlled VBD 0
trial NN 0
. . 0

OBJECTIVE NN 0
To TO 0
determine VB 0
whether IN 0
a DT 0
multimodal JJ 0
physiotherapy NN 0
programme NN 0
including VBG 0
taping VBG 0
, , 0
exercises NNS 0
, , 0
and CC 0
massage NN 0
is VBZ 0
effective JJ 0
for IN 0
knee NN 4
osteoarthritis NN 4
, , 0
and CC 0
if IN 0
benefits NNS 0
can MD 0
be VB 0
maintained VBN 0
with IN 0
self JJ 0
management NN 0
. . 0

METHODS NNP 0
Randomised VBD 0
, , 0
double JJ 0
blind NN 0
, , 0
placebo NN 0
controlled VBD 0
trial NN 0
; : 0
140 CD 3
community NN 0
volunteers NNS 0
with IN 0
knee NN 4
osteoarthritis NN 4
participated VBD 0
and CC 0
119 CD 3
completed VBD 0
the DT 0
trial NN 0
. . 0

Physiotherapy NNP 0
and CC 0
placebo JJ 0
interventions NNS 0
were VBD 0
applied VBN 0
by IN 0
10 CD 0
physiotherapists NNS 0
in IN 0
private JJ 0
practices NNS 0
for IN 0
12 CD 0
weeks NNS 0
. . 0

Physiotherapy NNP 0
included VBD 0
exercise NN 0
, , 0
massage NN 0
, , 0
taping VBG 0
, , 0
and CC 0
mobilisation NN 0
, , 0
followed VBN 0
by IN 0
12 CD 0
weeks NNS 0
of IN 0
self JJ 0
management NN 0
. . 0

Placebo NNP 0
was VBD 0
sham VBN 0
ultrasound JJ 0
and CC 0
light JJ 0
application NN 0
of IN 0
a DT 0
non-therapeutic JJ 0
gel NN 0
, , 0
followed VBN 0
by IN 0
no DT 0
treatment NN 0
. . 0

Primary JJ 0
outcomes NNS 0
were VBD 0
pain RB 0
measured VBN 0
by IN 0
visual JJ 0
analogue NN 0
scale NN 0
and CC 0
patient JJ 0
global JJ 0
change NN 0
. . 0

Secondary JJ 0
measures NNS 0
included VBD 0
WOMAC NNP 0
, , 0
knee NN 0
pain NN 0
scale NN 0
, , 0
SF-36 NNP 0
, , 0
assessment NN 0
of IN 0
quality NN 0
of IN 0
life NN 0
index NN 0
, , 0
quadriceps JJ 0
strength NN 0
, , 0
and CC 0
balance NN 0
test NN 0
. . 0

RESULTS NNP 0
Using VBG 0
an DT 0
intention NN 0
to TO 0
treat VB 0
analysis NN 0
, , 0
physiotherapy NN 0
and CC 0
placebo NN 0
groups NNS 0
showed VBD 0
similar JJ 0
pain NN 0
reductions NNS 0
at IN 0
12 CD 0
weeks NNS 0
: : 0
-2.2 NN 0
cm NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
-2.6 NNP 0
to TO 0
-1.7 VB 0
) ) 0
and CC 0
-2.0 $ 0
cm NN 0
( ( 0
-2.5 UH 0
to TO 0
-1.5 VB 0
) ) 0
, , 0
respectively RB 0
. . 0

At IN 0
24 CD 0
weeks NNS 0
, , 0
pain NN 0
remained VBD 0
reduced VBN 0
from IN 0
baseline NN 0
in IN 0
both DT 0
groups NNS 0
: : 0
-2.1 NN 0
( ( 0
-2.6 UH 0
to TO 0
-1.6 VB 0
) ) 0
and CC 0
-1.6 NNP 0
( ( 0
-2.2 UH 0
to TO 0
-1.0 VB 0
) ) 0
, , 0
respectively RB 0
. . 0

Global JJ 0
improvement NN 0
was VBD 0
reported VBN 0
by IN 0
70 CD 0
% NN 0
of IN 0
physiotherapy NN 0
participants NNS 0
( ( 0
51/73 CD 0
) ) 0
at IN 0
12 CD 0
weeks NNS 0
and CC 0
by IN 0
59 CD 0
% NN 0
( ( 0
43/73 CD 0
) ) 0
at IN 0
24 CD 0
weeks NNS 0
. . 0

Similarly RB 0
, , 0
global JJ 0
improvement NN 0
was VBD 0
reported VBN 0
by IN 0
72 CD 0
% NN 0
of IN 0
placebo NN 0
participants NNS 0
( ( 0
48/67 CD 0
) ) 0
at IN 0
12 CD 0
weeks NNS 0
and CC 0
by IN 0
49 CD 0
% NN 0
( ( 0
33/67 CD 0
) ) 0
at IN 0
24 CD 0
weeks NNS 0
( ( 0
all DT 0
p VBP 0
> $ 0
0.05 CD 0
) ) 0
. . 0

CONCLUSIONS VB 0
The DT 0
physiotherapy NN 0
programme NN 0
tested VBN 0
in IN 0
this DT 0
trial NN 0
was VBD 0
no DT 0
more RBR 0
effective JJ 0
than IN 0
regular JJ 0
contact NN 0
with IN 0
a DT 0
therapist NN 0
at IN 0
reducing VBG 0
pain NN 0
and CC 0
disability NN 0
. . 0

Docosahexaenoic NNP 0
acid-rich JJ 0
fish JJ 0
oil NN 0
modulates VBZ 0
the DT 0
cerebral JJ 0
hemodynamic JJ 0
response NN 0
to TO 0
cognitive JJ 0
tasks NNS 0
in IN 0
healthy JJ 4
young JJ 1
adults NNS 1
. . 0

A DT 0
number NN 0
of IN 0
recent JJ 0
studies NNS 0
have VBP 0
assessed VBN 0
the DT 0
impact NN 0
of IN 0
dietary JJ 0
omega-3 JJ 0
polyunsaturated VBN 0
fatty JJ 0
acids NNS 0
( ( 0
n-3 JJ 0
PUFAs NNP 0
) ) 0
on IN 0
behavioral JJ 0
outcomes NNS 0
; : 0
however RB 0
, , 0
very RB 0
little JJ 0
attention NN 0
has VBZ 0
been VBN 0
given VBN 0
to TO 0
their PRP$ 0
impact NN 0
upon IN 0
brain NN 0
function NN 0
in IN 0
physiological JJ 0
terms NNS 0
. . 0

Sixty-five JJ 3
healthy JJ 4
adults NNS 1
aged VBD 0
18-29yrs JJ 1
took VBD 0
part NN 0
in IN 0
this DT 0
double-blind NN 0
, , 0
placebo-controlled JJ 0
study NN 0
assessing VBG 0
the DT 0
effects NNS 0
of IN 0
12 CD 0
weeks NNS 0
daily RB 0
dietary JJ 0
supplementation NN 0
with IN 0
docosahexaenoic JJ 0
acid-rich JJ 0
fish JJ 0
oil NN 0
( ( 0
1g CD 0
, , 0
2g CD 0
) ) 0
or CC 0
placebo NN 0
( ( 0
olive JJ 0
oil NN 0
) ) 0
. . 0

Relative JJ 0
changes NNS 0
in IN 0
the DT 0
concentration NN 0
of IN 0
oxyhemoglobin NN 0
and CC 0
deoxyhemoglobin NN 0
were VBD 0
assessed VBN 0
in IN 0
the DT 0
prefrontal JJ 0
cortex NN 0
using VBG 0
near-infrared JJ 0
spectroscopy NN 0
during IN 0
performance NN 0
of IN 0
nine CD 0
computerized JJ 0
cognitive JJ 0
tasks NNS 0
. . 0

Supplementation NN 0
with IN 0
both DT 0
doses NNS 0
of IN 0
fish JJ 0
oil NN 0
, , 0
in IN 0
comparison NN 0
with IN 0
placebo NN 0
, , 0
resulted VBD 0
in IN 0
significantly RB 0
increased JJ 0
concentrations NNS 0
of IN 0
oxyhemoglobin NN 0
and CC 0
total JJ 0
levels NNS 0
of IN 0
hemoglobin NN 0
, , 0
indicative JJ 0
of IN 0
increased JJ 0
cerebral JJ 0
blood NN 0
flow NN 0
, , 0
during IN 0
the DT 0
cognitive JJ 0
tasks NNS 0
. . 0

Changes NNS 0
in IN 0
hemodynamic JJ 0
response NN 0
to TO 0
tasks NNS 0
were VBD 0
not RB 0
accompanied VBN 0
by IN 0
consistent JJ 0
changes NNS 0
in IN 0
cognitive JJ 0
performance NN 0
. . 0

Predictors NNS 0
of IN 0
postdischarge NN 0
outcomes NNS 0
from IN 0
information NN 0
acquired VBN 0
shortly RB 0
after IN 0
admission NN 0
for IN 0
acute JJ 4
heart NN 4
failure NN 4
: : 0
a DT 0
report NN 0
from IN 0
the DT 0
Placebo-Controlled NNP 0
Randomized NNP 0
Study NNP 0
of IN 0
the DT 0
Selective NNP 0
A1 NNP 0
Adenosine NNP 0
Receptor NNP 0
Antagonist NNP 0
Rolofylline NNP 0
for IN 0
Patients NNP 0
Hospitalized NNP 0
With IN 0
Acute NNP 4
Decompensated NNP 4
Heart NNP 4
Failure NNP 4
and CC 0
Volume NN 4
Overload NNP 4
to TO 0
Assess NNP 0
Treatment NNP 0
Effect NNP 0
on IN 0
Congestion NNP 0
and CC 0
Renal NNP 0
Function NNP 0
( ( 0
PROTECT NNP 0
) ) 0
Study NNP 0
. . 0

BACKGROUND NNP 0
Acute NNP 4
heart NN 4
failure NN 4
is VBZ 0
a DT 0
common JJ 0
reason NN 0
for IN 0
admission NN 0
, , 0
and CC 0
outcome NN 0
is VBZ 0
often RB 0
poor JJ 0
. . 0

Improved VBN 0
prognostic JJ 0
risk NN 0
stratification NN 0
may MD 0
assist VB 0
in IN 0
the DT 0
design NN 0
of IN 0
future JJ 0
trials NNS 0
and CC 0
in IN 0
patient JJ 0
management NN 0
. . 0

Using VBG 0
data NNS 0
from IN 0
a DT 0
large JJ 0
randomized JJ 0
trial NN 0
, , 0
we PRP 0
explored VBD 0
the DT 0
prognostic JJ 0
value NN 0
of IN 0
clinical JJ 0
variables NNS 0
, , 0
measured VBN 0
at IN 0
hospital JJ 0
admission NN 0
for IN 0
acute JJ 0
heart NN 0
failure NN 0
, , 0
to TO 0
determine VB 0
whether IN 0
a DT 0
few JJ 0
selected VBN 0
variables NNS 0
were VBD 0
inferior JJ 0
to TO 0
an DT 0
extended VBN 0
data NN 0
set NN 0
. . 0

METHODS NNP 0
AND CC 0
RESULTS NNP 0
The DT 0
prognostic JJ 0
model NN 0
included VBD 0
37 CD 0
clinical JJ 0
characteristics NNS 0
collected VBN 0
at IN 0
baseline NN 0
in IN 0
PROTECT NNP 0
, , 0
a DT 0
study NN 0
comparing VBG 0
rolofylline NN 0
and CC 0
placebo NN 0
in IN 0
2033 CD 3
patients NNS 0
admitted VBN 0
with IN 0
acute JJ 4
heart NN 4
failure NN 4
. . 0

Prespecified VBN 0
outcomes NNS 0
at IN 0
30 CD 0
days NNS 0
were VBD 0
death NN 0
or CC 0
rehospitalization NN 0
for IN 0
any DT 0
reason NN 0
; : 0
death NN 0
or CC 0
rehospitalization NN 0
for IN 0
cardiovascular NN 0
or CC 0
renal JJ 0
reasons NNS 0
; : 0
and CC 0
, , 0
at IN 0
both DT 0
30 CD 0
and CC 0
180 CD 0
days NNS 0
, , 0
all-cause JJ 0
mortality NN 0
. . 0

No DT 0
variable JJ 0
had VBD 0
a DT 0
c-index NN 0
> NN 0
0.70 CD 0
, , 0
and CC 0
few JJ 0
had VBD 0
values NNS 0
> $ 0
0.60 CD 0
; : 0
c-indices NNS 0
were VBD 0
lower JJR 0
for IN 0
composite JJ 0
outcomes NNS 0
than IN 0
for IN 0
mortality NN 0
. . 0

Blood NNP 0
urea NN 0
was VBD 0
generally RB 0
the DT 0
strongest JJS 0
single JJ 0
predictor NN 0
. . 0

Eighteen NNP 0
variables NNS 0
contributed VBD 0
independent JJ 0
prognostic JJ 0
information NN 0
, , 0
but CC 0
a DT 0
reduced JJ 0
model NN 0
using VBG 0
only RB 0
8 CD 0
items NNS 0
( ( 0
age NN 0
, , 0
previous JJ 0
heart NN 0
failure NN 0
hospitalization NN 0
, , 0
peripheral JJ 0
edema NN 0
, , 0
systolic JJ 0
blood NN 0
pressure NN 0
, , 0
serum NN 0
sodium NN 0
, , 0
urea JJ 0
, , 0
creatinine NN 0
, , 0
and CC 0
albumin NN 0
) ) 0
performed VBD 0
similarly RB 0
. . 0

For IN 0
prediction NN 0
of IN 0
all-cause JJ 0
mortality NN 0
at IN 0
180 CD 0
days NNS 0
, , 0
the DT 0
model NN 0
c-index NN 0
using VBG 0
all DT 0
variables NNS 0
was VBD 0
0.72 CD 0
and CC 0
for IN 0
the DT 0
simplified JJ 0
model NN 0
, , 0
also RB 0
0.72 CD 0
. . 0

CONCLUSIONS VB 0
A NNP 0
few JJ 0
simple JJ 0
clinical JJ 0
variables NNS 0
measured VBN 0
on IN 0
admission NN 0
in IN 0
patients NNS 0
with IN 0
acute JJ 4
heart NN 4
failure NN 4
predict VBP 0
a DT 0
variety NN 0
of IN 0
adverse JJ 0
outcomes NNS 0
with IN 0
accuracy NN 0
similar JJ 0
to TO 0
more RBR 0
complex JJ 0
models NNS 0
. . 0

However RB 0
, , 0
predictive JJ 0
models NNS 0
were VBD 0
of IN 0
only RB 0
moderate JJ 0
accuracy NN 0
, , 0
especially RB 0
for IN 0
outcomes NNS 0
that WDT 0
included VBD 0
nonfatal JJ 0
events NNS 0
. . 0

Better NNP 0
methods NNS 0
of IN 0
risk NN 0
stratification NN 0
are VBP 0
required VBN 0
. . 0

CLINICAL JJ 0
TRIAL NNP 0
REGISTRATION NNP 0
URL NNP 0
: : 0
http NN 0
: : 0
//www.clinicaltrials.gov NN 0
. . 0

Unique JJ 0
identifiers NNS 0
: : 0
NCT00328692 NNP 0
and CC 0
NCT00354458 NNP 0
. . 0

The DT 0
problem NN 0
of IN 0
measurement NN 0
error NN 0
in IN 0
multisite JJ 0
clinical JJ 0
trials NNS 0
. . 0

The DT 0
implementation NN 0
of IN 0
a DT 0
multisite NN 0
, , 0
randomized VBN 0
, , 0
clinical JJ 0
psychopharmacologic JJ 0
trial NN 0
involves VBZ 0
a DT 0
substantial JJ 0
investment NN 0
of IN 0
time NN 0
and CC 0
effort NN 0
on IN 0
the DT 0
part NN 0
of IN 0
all DT 0
participants NNS 0
. . 0

Because IN 0
of IN 0
their PRP$ 0
complexity NN 0
, , 0
such JJ 0
clinical JJ 0
trials NNS 0
present JJ 0
unique JJ 0
methodological JJ 0
and CC 0
design NN 0
challenges NNS 0
. . 0

Indeed RB 0
, , 0
it PRP 0
is VBZ 0
not RB 0
uncommon JJ 0
for IN 0
such JJ 0
studies NNS 0
to TO 0
conclude VB 0
with IN 0
uninterpretable JJ 0
results NNS 0
, , 0
due JJ 0
in IN 0
part NN 0
to TO 0
such JJ 0
methodological JJ 0
pitfalls NNS 0
. . 0

It PRP 0
has VBZ 0
been VBN 0
suggested VBN 0
that IN 0
clarification NN 0
of IN 0
such JJ 0
methodologic JJ 0
dilemmas NN 0
is VBZ 0
one CD 0
of IN 0
the DT 0
most RBS 0
important JJ 0
challenges NNS 0
facing VBG 0
the DT 0
future NN 0
of IN 0
industry-sponsored JJ 0
psychopharmacologic JJ 0
drug NN 0
development NN 0
. . 0

Among IN 0
the DT 0
many JJ 0
factors NNS 0
that WDT 0
may MD 0
contribute VB 0
to TO 0
problematic JJ 0
clinical JJ 0
trial NN 0
results NNS 0
, , 0
error NN 0
in IN 0
measuring VBG 0
the DT 0
phenomena NN 0
being VBG 0
studied VBN 0
is VBZ 0
of IN 0
particular JJ 0
concern NN 0
. . 0

In IN 0
this DT 0
article NN 0
, , 0
we PRP 0
describe VBP 0
the DT 0
outcome NN 0
of IN 0
an DT 0
intensive JJ 0
series NN 0
of IN 0
interrater JJ 0
reliability NN 0
training NN 0
sessions NNS 0
for IN 0
the DT 0
17-item JJ 0
Hamilton NNP 0
Depression NNP 0
Rating NNP 0
Scale NNP 0
conducted VBD 0
at IN 0
the DT 0
start NN 0
of IN 0
a DT 0
Phase NNP 0
II NNP 0
multisite RB 0
clinical JJ 0
drug NN 0
trial NN 0
. . 0

The DT 0
data NN 0
underscore IN 0
the DT 0
magnitude NN 0
of IN 0
error NN 0
present NN 0
in IN 0
such JJ 0
a DT 0
test NN 0
setting NN 0
and CC 0
provide VB 0
preliminary JJ 0
evidence NN 0
for IN 0
the DT 0
potential JJ 0
effect NN 0
of IN 0
this DT 0
problem NN 0
on IN 0
the DT 0
detection NN 0
of IN 0
clinical JJ 0
change NN 0
. . 0

Lack NN 0
of IN 0
effect NN 0
of IN 0
food NN 0
on IN 0
the DT 0
steady JJ 0
state NN 0
pharmacokinetics NNS 0
of IN 0
BMS-181101 NNP 0
, , 0
an DT 0
antidepressant NN 0
, , 0
in IN 0
healthy JJ 4
subjects NNS 0
. . 0

The DT 0
effect NN 0
of IN 0
food NN 0
on IN 0
the DT 0
pharmacokinetics NNS 0
of IN 0
BMS-181101 NNP 0
, , 0
a DT 0
new JJ 0
anti-depressant JJ 0
under IN 0
development NN 0
, , 0
was VBD 0
investigated VBN 0
in IN 0
12 CD 3
healthy JJ 4
male NN 2
volunteers NNS 0
at IN 0
steady JJ 0
state NN 0
. . 0

Each DT 0
subject NN 0
received VBD 0
a DT 0
15 CD 0
mg JJ 0
oral JJ 0
dose NN 0
of IN 0
BMS-181101 NNP 0
twice NN 0
a DT 0
day NN 0
( ( 0
q JJ 0
12 CD 0
h NN 0
) ) 0
for IN 0
11 CD 0
days NNS 0
and CC 0
a DT 0
morning NN 0
dose NN 0
of IN 0
BMS-181101 NNP 0
on IN 0
day NN 0
12 CD 0
. . 0

Six CD 3
subjects NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
BMS-181101 NNP 0
under IN 0
fasted VBN 0
conditions NNS 0
from IN 0
days NNS 0
1 CD 0
to TO 0
6 CD 0
and CC 0
then RB 0
crossed VBD 0
over IN 0
to TO 0
fed VB 0
conditions NNS 0
from IN 0
days NNS 0
7 CD 0
to TO 0
12 CD 0
. . 0

The DT 0
other JJ 0
six CD 3
subjects NNS 0
received VBD 0
the DT 0
reverse NN 0
conditions NNS 0
, , 0
fed VBN 0
for IN 0
days NNS 0
1-6 CD 0
and CC 0
fasted VBN 0
for IN 0
days NNS 0
7-12 CD 0
. . 0

Serial JJ 0
blood NN 0
samples NNS 0
were VBD 0
collected VBN 0
up RB 0
to TO 0
12 CD 0
h NNS 0
on IN 0
days NNS 0
6 CD 0
and CC 0
12 CD 0
following VBG 0
the DT 0
administration NN 0
of IN 0
the DT 0
morning NN 0
dose NN 0
. . 0

In IN 0
addition NN 0
, , 0
trough IN 0
blood NN 0
samples NNS 0
were VBD 0
collected VBN 0
on IN 0
days NNS 0
4 CD 0
, , 0
5 CD 0
, , 0
10 CD 0
, , 0
and CC 0
11 CD 0
prior RB 0
to TO 0
the DT 0
morning NN 0
dose NN 0
. . 0

Plasma NNP 0
samples NNS 0
were VBD 0
analyzed VBN 0
for IN 0
intact JJ 0
BMS-181101 NNP 0
using VBG 0
a DT 0
validated JJ 0
high-performance NN 0
liquid NN 0
chromatography NN 0
method NN 0
with IN 0
an DT 0
electrochemical JJ 0
detector NN 0
. . 0

BMS-181101 NNP 0
was VBD 0
well RB 0
tolerated VBN 0
both DT 0
with IN 0
and CC 0
without IN 0
ingestion NN 0
of IN 0
food NN 0
. . 0

The DT 0
statistical JJ 0
evaluation NN 0
of IN 0
the DT 0
Cmin NNP 0
values NNS 0
indicated VBD 0
that IN 0
steady JJ 0
state NN 0
of IN 0
BMS-181101 NNP 0
was VBD 0
achieved VBN 0
by IN 0
the DT 0
fourth JJ 0
day NN 0
of IN 0
dosing VBG 0
regardless NN 0
of IN 0
whether IN 0
the DT 0
subject NN 0
was VBD 0
fasted VBN 0
or CC 0
fed VBN 0
. . 0

When WRB 0
BMS-181101 NNP 0
was VBD 0
administered VBN 0
with IN 0
food NN 0
, , 0
Cmax NNP 0
was VBD 0
reduced VBN 0
by IN 0
about IN 0
25 CD 0
% NN 0
and CC 0
tmax NN 0
was VBD 0
prolonged VBN 0
by IN 0
1 CD 0
h. NN 0
However RB 0
, , 0
AUCtau NNP 0
, , 0
t1/2 NN 0
, , 0
and CC 0
time NN 0
to TO 0
attain VB 0
steady JJ 0
state NN 0
of IN 0
BMS-181101 NNP 0
were VBD 0
not RB 0
altered VBN 0
by IN 0
ingestion NN 0
of IN 0
food NN 0
. . 0

In IN 0
summary JJ 0
, , 0
BMS-181101 NNP 0
can MD 0
be VB 0
given VBN 0
with IN 0
food NN 0
without IN 0
adversely RB 0
impacting VBG 0
the DT 0
safety NN 0
or CC 0
pharmacokinetic JJ 0
profiles NNS 0
of IN 0
the DT 0
drug NN 0
. . 0

Codeine/acetaminophen NNP 0
and CC 0
hydrocodone/acetaminophen JJ 0
combination NN 0
tablets NNS 0
for IN 0
the DT 0
management NN 0
of IN 0
chronic JJ 4
cancer NN 4
pain NN 4
in IN 0
adults NNS 1
: : 0
a DT 0
23-day JJ 0
, , 0
prospective JJ 0
, , 0
double-blind JJ 0
, , 0
randomized VBN 0
, , 0
parallel-group JJ 0
study NN 0
. . 0

BACKGROUND NNP 0
Analgesics NNPS 0
are VBP 0
an DT 0
essential JJ 0
component NN 0
of IN 0
the DT 0
treatment NN 0
of IN 0
cancer-associated JJ 0
pain NN 0
. . 0

Pharmacologic NNP 0
treatment NN 0
is VBZ 0
usually RB 0
begun VBN 0
with IN 0
nonopioid JJ 0
analgesics NNS 0
, , 0
most JJS 0
frequently RB 0
acetaminophen VBP 0
. . 0

If IN 0
pain JJ 0
relief NN 0
is VBZ 0
not RB 0
achieved VBN 0
, , 0
the DT 0
so-called JJ 0
weak JJ 0
opioids NNS 0
, , 0
such JJ 0
as IN 0
codeine NN 0
and CC 0
hydrocodone NN 0
, , 0
may MD 0
be VB 0
used VBN 0
in IN 0
combination NN 0
with IN 0
acetaminophen NN 0
. . 0

Adverse JJ 0
effects NNS 0
( ( 0
AEs NNP 0
) ) 0
of IN 0
the DT 0
opioids NNS 0
include VBP 0
constipation NN 0
, , 0
somnolence NN 0
, , 0
nausea NN 0
, , 0
and CC 0
vomiting VBG 0
. . 0

Based VBN 0
on IN 0
the DT 0
results NNS 0
of IN 0
a DT 0
literature NN 0
search NN 0
, , 0
data NNS 0
comparing VBG 0
the DT 0
effects NNS 0
of IN 0
the DT 0
opioids NNS 0
are VBP 0
lacking VBG 0
. . 0

OBJECTIVE CC 0
The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
compare VB 0
the DT 0
analgesic JJ 0
efficacy NN 0
and CC 0
tolerability NN 0
of IN 0
codeine NN 0
phosphate NN 0
versus IN 0
hydrocodone NN 0
bitartrate NN 0
in IN 0
combination NN 0
with IN 0
acetaminophen NN 0
in IN 0
the DT 0
relief NN 0
of IN 0
cancer-related JJ 0
pain NN 0
. . 0

METHODS NNP 0
This DT 0
23-day JJ 0
, , 0
prospective JJ 0
, , 0
double-blind JJ 0
, , 0
randomized VBN 0
, , 0
parallel-group JJ 0
study NN 0
was VBD 0
conducted VBN 0
at IN 0
3 CD 0
Colombian JJ 0
centers NNS 0
: : 0
University NNP 0
Libre NNP 0
, , 0
Social NNP 0
Security NNP 0
Institute NNP 0
, , 0
and CC 0
General NNP 0
Hospital NNP 0
of IN 0
Medell?n NNP 0
, , 0
Cali NNP 0
, , 0
Colombia NNP 0
. . 0

Outpatients NNS 0
with IN 0
cancer NN 0
were VBD 0
eligible JJ 0
for IN 0
the DT 0
study NN 0
if IN 0
they PRP 0
were VBD 0
aged VBN 0
> JJ 0
-18 CD 0
years NNS 0
and CC 0
had VBD 0
chronic VBN 0
( ( 0
duration NN 0
, , 0
> NNP 0
/= VBZ 0
3 CD 0
months NNS 0
) ) 0
moderate VBP 0
to TO 0
severe VB 0
cancer-related JJ 0
pain NN 0
( ( 0
score NN 0
on IN 0
10-cm JJ 0
visual JJ 0
analog NN 0
scale NN 0
[ NNP 0
VAS NNP 0
] NNP 0
, , 0
> VBD 0
3 CD 0
cm NN 0
[ NN 0
moderate JJ 0
] NN 0
; : 0
score NN 0
on IN 0
a DT 0
4-point JJ 0
verbal JJ 0
pain-intensity NN 0
scale NN 0
, , 0
> VBZ 0
1 CD 0
[ NN 0
moderate JJ 0
] NN 0
) ) 0
. . 0

Eligible JJ 0
patients NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
1 CD 0
tablet NN 0
of IN 0
codeine/acetaminophen NN 0
( ( 0
C/A NNP 0
) ) 0
30/500 CD 0
mg NN 0
or CC 0
hydrocodone/acetaminophen NN 0
( ( 0
H/A NNP 0
) ) 0
5/500 CD 0
mg NN 0
PO NNP 0
q4h NN 0
( ( 0
total JJ 0
daily JJ 0
doses NNS 0
, , 0
150/2500 CD 0
and CC 0
25/2500 CD 0
mg NN 0
, , 0
respectively RB 0
) ) 0
for IN 0
23 CD 0
days NNS 0
. . 0

In IN 0
both DT 0
groups NNS 0
, , 0
if IN 0
pain JJ 0
intensity NN 0
was VBD 0
rated VBN 0
as IN 0
> JJ 0
3 CD 0
on IN 0
the DT 0
VAS NNP 0
at IN 0
week NN 0
1 CD 0
or CC 0
2 CD 0
, , 0
the DT 0
dosage NN 0
was VBD 0
doubled VBN 0
. . 0

The DT 0
primary JJ 0
end NN 0
point NN 0
was VBD 0
the DT 0
proportion NN 0
of IN 0
patients NNS 0
who WP 0
achieved VBD 0
pain NN 0
relief NN 0
( ( 0
defined VBN 0
as IN 0
a DT 0
score NN 0
of IN 0
> $ 0
1 CD 0
on IN 0
a DT 0
5-point JJ 0
verbal NN 0
rating NN 0
scale NN 0
[ NNP 0
VRS NNP 0
] NNP 0
( ( 0
0 CD 0
= NNP 0
none NN 0
; : 0
1 CD 0
= IN 0
a DT 0
little JJ 0
; : 0
2 CD 0
= IN 0
some DT 0
; : 0
3 CD 0
= IN 0
a DT 0
lot NN 0
; : 0
and CC 0
4 CD 0
= NNP 0
complete JJ 0
) ) 0
on IN 0
study NN 0
days NNS 0
1 CD 0
and CC 0
2 CD 0
and CC 0
weeks NNS 0
1 CD 0
, , 0
2 CD 0
, , 0
and CC 0
3 CD 0
. . 0

The DT 0
secondary JJ 0
end NN 0
point NN 0
was VBD 0
the DT 0
proportion NN 0
of IN 0
patients NNS 0
in IN 0
whom WP 0
pain NN 0
was VBD 0
decreased VBN 0
( ( 0
VAS NNP 0
score RB 0
, , 0
< NNP 0
- : 0
3 CD 0
cm NN 0
) ) 0
. . 0

AEs $ 0
were VBD 0
self-reported VBN 0
on IN 0
a DT 0
4-point JJ 0
VRS NNP 0
( ( 0
0 CD 0
= NNP 0
absent NN 0
; : 0
1 CD 0
= NNP 0
mild NN 0
; : 0
2 CD 0
= NN 0
moderate NN 0
; : 0
and CC 0
3 CD 0
= NNP 0
severe RB 0
) ) 0
. . 0

RESULTS NNP 0
Of IN 0
the DT 0
121 CD 0
patients NNS 0
who WP 0
participated VBD 0
, , 0
59 CD 0
received VBD 0
C/A NNP 0
and CC 0
62 CD 0
received VBD 0
H/A NNP 0
. . 0

Of IN 0
the DT 0
total JJ 0
number NN 0
of IN 0
cases NNS 0
, , 0
59 CD 0
% NN 0
were VBD 0
aged VBN 0
60 CD 0
to TO 0
89 CD 0
years NNS 0
, , 0
and CC 0
55 CD 0
% NN 0
were VBD 0
men NNS 0
. . 0

At IN 0
baseline NN 0
, , 0
88 CD 0
% NN 0
of IN 0
the DT 0
patients NNS 0
described VBD 0
their PRP$ 0
pain NN 0
intensity NN 0
as IN 0
moderate JJ 0
; : 0
12 CD 0
% NN 0
, , 0
severe JJ 0
. . 0

Of IN 0
the DT 0
patients NNS 0
who WP 0
received VBD 0
C/A NNP 0
, , 0
58 CD 0
% NN 0
responded VBD 0
to TO 0
the DT 0
initial JJ 0
dosage NN 0
of IN 0
150/2500 CD 0
mg/d NN 0
, , 0
and CC 0
8 CD 0
% NN 0
of IN 0
the DT 0
patients NNS 0
responded VBD 0
to TO 0
the DT 0
double JJ 0
dosage NN 0
; : 0
34 CD 0
% NN 0
did VBD 0
not RB 0
experience VB 0
pain NN 0
relief NN 0
. . 0

In IN 0
patients NNS 0
with IN 0
H/A NNP 0
, , 0
pain NN 0
was VBD 0
reported VBN 0
as IN 0
absent NN 0
or CC 0
mild NN 0
in IN 0
56 CD 0
% NN 0
of IN 0
patients NNS 0
at IN 0
the DT 0
starting VBG 0
dosage NN 0
of IN 0
25/2500 CD 0
mg/d NN 0
; : 0
an DT 0
additional JJ 0
15 CD 0
% NN 0
of IN 0
the DT 0
patients NNS 0
responded VBD 0
to TO 0
the DT 0
double JJ 0
dosage NN 0
; : 0
the DT 0
remaining VBG 0
29 CD 0
% NN 0
of IN 0
patients NNS 0
did VBD 0
not RB 0
experience VB 0
any DT 0
pain NN 0
relief NN 0
. . 0

None NN 0
of IN 0
the DT 0
between-group JJ 0
differences NNS 0
in IN 0
response NN 0
rates NNS 0
were VBD 0
significant JJ 0
. . 0

The DT 0
most RBS 0
common JJ 0
AEs NNP 0
in IN 0
the DT 0
C/A NNP 0
and CC 0
H/A NNP 0
groups NNS 0
were VBD 0
constipation NN 0
( ( 0
36 CD 0
% NN 0
and CC 0
29 CD 0
% NN 0
, , 0
respectively RB 0
) ) 0
, , 0
dizziness NN 0
( ( 0
24 CD 0
% NN 0
and CC 0
19 CD 0
% NN 0
) ) 0
, , 0
vomiting VBG 0
( ( 0
24 CD 0
% NN 0
and CC 0
16 CD 0
% NN 0
) ) 0
, , 0
and CC 0
dry JJ 0
mouth NN 0
( ( 0
15 CD 0
% NN 0
and CC 0
18 CD 0
% NN 0
) ) 0
, , 0
with IN 0
no DT 0
significant JJ 0
differences NNS 0
between IN 0
groups NNS 0
. . 0

CONCLUSION NNP 0
In IN 0
this DT 0
study NN 0
, , 0
efficacy NN 0
and CC 0
tolerability NN 0
were VBD 0
comparable JJ 0
between IN 0
C/A NNP 0
and CC 0
H/A NNP 0
over IN 0
23 CD 0
days NNS 0
of IN 0
treatment NN 0
in IN 0
these DT 0
patients NNS 0
with IN 0
moderate JJ 0
or CC 0
severe JJ 0
, , 0
chronic JJ 0
, , 0
cancer-related JJ 0
pain NN 0
. . 0

Relationship NN 0
between IN 0
baseline NN 0
blood NN 0
pressure NN 0
parameters NNS 0
( ( 0
including VBG 0
mean JJ 0
pressure NN 0
, , 0
pulse JJ 0
pressure NN 0
, , 0
and CC 0
variability NN 0
) ) 0
and CC 0
early JJ 0
outcome NN 0
after IN 0
stroke NN 4
: : 0
data NN 0
from IN 0
the DT 0
Tinzaparin NNP 0
in IN 0
Acute NNP 4
Ischaemic NNP 4
Stroke NNP 4
Trial NNP 0
( ( 0
TAIST NNP 0
) ) 0
. . 0

BACKGROUND NNP 0
AND NNP 0
PURPOSE NNP 0
High NNP 4
blood NN 4
pressure NN 4
( ( 0
BP NNP 0
) ) 0
in IN 0
acute JJ 4
stroke NN 4
is VBZ 0
associated VBN 0
independently RB 0
with IN 0
a DT 0
poor JJ 0
outcome NN 0
. . 0

Recent JJ 0
evidence NN 0
suggests VBZ 0
that IN 0
other JJ 0
hemodynamic JJ 0
parameters NNS 0
may MD 0
also RB 0
be VB 0
associated VBN 0
with IN 0
outcomes NNS 0
following VBG 0
stroke NN 0
. . 0

METHODS NNP 0
The DT 0
relationship NN 0
between IN 0
baseline NN 0
BP NNP 0
, , 0
heart NN 0
rate NN 0
, , 0
and CC 0
other JJ 0
hemodynamic JJ 0
parameters NNS 0
, , 0
and CC 0
early RB 0
outcomes NNS 0
were VBD 0
assessed VBN 0
using VBG 0
data NNS 0
from IN 0
TAIST NNP 0
trial NN 0
. . 0

RESULTS NNP 0
Death NNP 0
or CC 0
neurological JJ 0
deterioration NN 0
at IN 0
day NN 0
10 CD 0
was VBD 0
associated VBN 0
, , 0
both DT 0
in IN 0
unadjusted JJ 0
and CC 0
adjusted JJ 0
analyses NNS 0
, , 0
with IN 0
systolic JJ 0
BP NNP 0
( ( 0
adjusted VBN 0
OR NNP 0
, , 0
1.02 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
1.01-1.03 JJ 0
) ) 0
, , 0
mean JJ 0
arterial JJ 0
pressure NN 0
( ( 0
OR NNP 0
, , 0
1.02 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
1.01-1.04 JJ 0
) ) 0
, , 0
pulse JJ 0
pressure NN 0
( ( 0
OR NNP 0
, , 0
1.02 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
1.01-1.03 JJ 0
) ) 0
, , 0
and CC 0
BP NNP 0
variability NN 0
( ( 0
OR NNP 0
, , 0
1.03 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
1.01-1.05 JJ 0
) ) 0
. . 0

Similar JJ 0
relationships NNS 0
were VBD 0
noted VBN 0
for IN 0
deterioration NN 0
alone RB 0
, , 0
and CC 0
recurrent JJ 0
stroke NN 0
. . 0

CONCLUSIONS NNP 0
Early JJ 0
death NN 0
or CC 0
neurologic JJ 0
deterioration NN 0
, , 0
deterioration NN 0
, , 0
and CC 0
recurrent JJ 0
stroke NN 0
are VBP 0
associated VBN 0
independently RB 0
with IN 0
high JJ 0
systolic JJ 0
BP NNP 0
, , 0
mean JJ 0
arterial JJ 0
pressure NN 0
, , 0
pulse JJ 0
pressure NN 0
, , 0
and CC 0
BP NNP 0
variability NN 0
. . 0

These DT 0
measures NNS 0
offer VBP 0
potential JJ 0
therapeutic JJ 0
targets NNS 0
for IN 0
improving VBG 0
early JJ 0
outcome NN 0
after IN 0
acute JJ 4
ischemic JJ 4
stroke NN 4
. . 0

Relation NN 0
of IN 0
total JJ 0
homocysteine NN 0
and CC 0
lipid JJ 0
levels NNS 0
in IN 0
children NNS 1
to TO 0
premature VB 0
cardiovascular JJ 0
death NN 0
in IN 0
male JJ 2
relatives NNS 0
. . 0

We PRP 0
assessed VBD 0
the DT 0
relative JJ 0
importance NN 0
of IN 0
lipid JJ 0
, , 0
apo JJ 0
B NNP 0
, , 0
lipoprotein NN 0
( ( 0
a DT 0
) ) 0
[ NN 0
Lp NNP 0
( ( 0
a DT 0
) ) 0
] NN 0
, , 0
and CC 0
total JJ 0
homocysteine NN 0
( ( 0
tHcy NN 0
) ) 0
levels NNS 0
in IN 0
children NNS 1
in IN 0
relation NN 0
to TO 0
premature VB 0
cardiovascular JJ 0
disease NN 0
in IN 0
family NN 0
members NNS 0
. . 0

Parents NNS 0
of IN 0
381 CD 3
girls NNS 2
and CC 0
375 CD 3
boys NNS 2
age NN 0
8-12 JJ 1
y NN 0
completed VBN 0
family NN 0
history NN 0
questionnaires NNS 0
. . 0

Nonfasting VBG 0
serum JJ 0
lipid JJ 0
and CC 0
lipoproteins NNS 0
and CC 0
plasma NN 0
tHcy NN 0
and CC 0
cysteine NN 0
levels NNS 0
were VBD 0
measured VBN 0
in IN 0
the DT 0
children NNS 0
. . 0

Serum NNP 0
folate NN 0
and CC 0
vitamin NN 0
B12 NNP 0
levels NNS 0
were VBD 0
determined VBN 0
in IN 0
a DT 0
random JJ 0
subsample NN 0
of IN 0
23 CD 0
% NN 0
of IN 0
the DT 0
children NNS 0
, , 0
who WP 0
participated VBD 0
in IN 0
a DT 0
food NN 0
frequency NN 0
interview NN 0
. . 0

Children NNP 0
whose WP$ 0
parents NNS 0
reported VBD 0
hypercholesterolemia NN 0
had VBD 0
higher JJR 0
total JJ 0
and CC 0
non-HDL JJ 0
cholesterol NN 0
and CC 0
apo NN 0
B NNP 0
levels NNS 0
than IN 0
the DT 0
rest NN 0
, , 0
but CC 0
these DT 0
levels NNS 0
were VBD 0
not RB 0
associated VBN 0
with IN 0
cardiovascular JJ 0
disease NN 0
. . 0

tHcy NN 0
levels NNS 0
were VBD 0
similar JJ 0
in IN 0
girls NNS 0
and CC 0
boys NNS 0
. . 0

tHcy NN 0
was VBD 0
higher RBR 0
in IN 0
children NNS 1
whose WP$ 0
father NN 0
, , 0
grandfather NN 0
, , 0
or CC 0
uncle NN 0
died VBN 0
at IN 0
age NN 0
< NN 0
or CC 0
= $ 0
55 CD 0
y NN 0
of IN 0
myocardial JJ 0
infarction NN 0
or CC 0
sudden JJ 0
cardiac JJ 0
arrest NN 0
( ( 0
n JJ 0
= NNP 0
42 CD 0
) ) 0
than IN 0
in IN 0
control NN 0
children NNS 0
[ VBP 0
5.92 CD 0
mumol/L NN 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
[ NNP 0
CI NNP 0
] NNP 0
of IN 0
5.47-6.36 NNP 0
) ) 0
versus NN 0
5.25 CD 0
mumol/L NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
5.16-5.34 JJ 0
) ) 0
] NN 0
, , 0
also RB 0
after IN 0
adjustment NN 0
for IN 0
socioeconomic JJ 0
group NN 0
. . 0

Intake NNP 0
and CC 0
serum NN 0
levels NNS 0
of IN 0
vitamin NN 0
B12 NNP 0
and CC 0
folate NN 0
were VBD 0
within IN 0
recommended VBN 0
or CC 0
reference NN 0
ranges NNS 0
. . 0

In IN 0
a DT 0
stepwise NN 0
multiple JJ 0
regression NN 0
analysis NN 0
, , 0
serum NN 0
folate NN 0
( ( 0
negative JJ 0
correlation NN 0
) ) 0
, , 0
plasma JJ 0
creatinine NN 0
, , 0
and CC 0
sugar RB 0
intake VB 0
as IN 0
percent NN 0
of IN 0
dietary JJ 0
energy NN 0
( ( 0
positive JJ 0
correlations NNS 0
) ) 0
were VBD 0
significantly RB 0
associated VBN 0
with IN 0
tHcy NN 0
( ( 0
multiple JJ 0
r NN 0
= NN 0
0.44 CD 0
, , 0
adjusted VBN 0
r2 NN 0
= VBZ 0
18 CD 0
% NN 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
5-30 JJ 0
% NN 0
) ) 0
. . 0

Our PRP$ 0
data NNS 0
show VBP 0
that IN 0
a DT 0
modest JJ 0
elevation NN 0
in IN 0
tHcy NN 0
in IN 0
children NNS 0
was VBD 0
related VBN 0
to TO 0
premature VB 0
cardiovascular JJ 0
death NN 0
in IN 0
their PRP$ 0
male NN 0
relatives NNS 0
and CC 0
may MD 0
partly RB 0
account VB 0
for IN 0
the DT 0
contribution NN 0
of IN 0
family NN 0
history NN 0
to TO 0
risk NN 0
of IN 0
cardiovascular JJ 0
disease NN 0
. . 0

tHcy NN 0
may MD 0
be VB 0
modifiable JJ 0
through IN 0
the DT 0
diet NN 0
, , 0
even RB 0
in IN 0
children NNS 0
with IN 0
apparently RB 0
adequate JJ 0
vitamin JJ 0
nutriture NN 0
. . 0

Three-year JJ 0
clinical JJ 0
outcome NN 0
after IN 0
primary JJ 0
stenting NN 0
of IN 0
totally RB 0
occluded JJ 0
native JJ 0
coronary JJ 0
arteries NNS 0
: : 0
a DT 0
randomized JJ 0
comparison NN 0
of IN 0
bare-metal JJ 0
stent JJ 0
implantation NN 0
with IN 0
sirolimus-eluting JJ 0
stent NN 0
implantation NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
total JJ 4
coronary JJ 4
occlusions NNS 4
( ( 0
Primary JJ 0
Stenting NNP 0
of IN 0
Totally NNP 0
Occluded NNP 0
Native NNP 0
Coronary NNP 0
Arteries NNP 0
[ NNP 0
PRISON NNP 0
] NNP 0
II NNP 0
study NN 0
) ) 0
. . 0

BACKGROUND IN 0
The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
examine VB 0
the DT 0
3-year JJ 0
clinical JJ 0
outcome NN 0
in IN 0
patients NNS 0
enrolled VBN 0
in IN 0
the DT 0
Primary NNP 0
Stenting NNP 0
of IN 0
Totally NNP 0
Occluded NNP 0
Native NNP 0
Coronary NNP 0
Arteries NNP 0
II NNP 0
study NN 0
. . 0

METHODS NNP 0
Patients NNPS 0
with IN 0
totally RB 4
occluded JJ 4
coronary JJ 4
arteries NNS 4
randomized VBN 0
to TO 0
either DT 0
sirolimus-eluting JJ 0
Cypher NNP 0
stents NNS 0
( ( 0
SESs NNP 0
) ) 0
( ( 0
Cordis NNP 0
, , 0
a DT 0
Johnson NNP 0
& CC 0
Joshson NNP 0
Company NNP 0
, , 0
Miami NNP 0
Lakes NNP 0
, , 0
FL NNP 0
) ) 0
( ( 0
100 CD 3
patients NNS 0
) ) 0
or CC 0
bare-metal JJ 0
BxVelocity NNP 0
stents NNS 0
( ( 0
BMSs NNP 0
) ) 0
( ( 0
Cordis NNP 0
) ) 0
( ( 0
100 CD 3
patients NNS 0
) ) 0
were VBD 0
followed VBN 0
clinically RB 0
for IN 0
3 CD 0
years NNS 0
. . 0

RESULTS NNP 0
Between NNP 0
1 CD 0
and CC 0
3 CD 0
years NNS 0
, , 0
there EX 0
were VBD 0
infrequent JJ 0
additional JJ 0
clinical JJ 0
events NNS 0
that WDT 0
were VBD 0
equally RB 0
distributed VBN 0
between IN 0
the DT 0
SES NNP 0
and CC 0
the DT 0
BMS NNP 0
group NN 0
. . 0

After IN 0
3 CD 0
years NNS 0
, , 0
target NN 0
lesion NN 0
revascularization NN 0
was VBD 0
7 CD 0
% NN 0
in IN 0
the DT 0
SES NNP 0
group NN 0
versus VBD 0
27 CD 0
% NN 0
in IN 0
the DT 0
BMS NNP 0
group NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
; : 0
and CC 0
target VB 0
vessel JJ 0
revascularization NN 0
was VBD 0
seen VBN 0
in IN 0
11 CD 0
% NN 0
in IN 0
the DT 0
SES NNP 0
group NN 0
versus VBD 0
30 CD 0
% NN 0
in IN 0
the DT 0
BMS NNP 0
group NN 0
( ( 0
P NNP 0
= NNP 0
.002 NNP 0
) ) 0
. . 0

Major JJ 0
adverse JJ 0
cardiac NN 0
events NNS 0
were VBD 0
noted VBN 0
in IN 0
10 CD 0
% NN 0
of IN 0
the DT 0
SES NNP 0
group NN 0
versus VBD 0
34 CD 0
% NN 0
in IN 0
the DT 0
BMS NNP 0
group NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
statistically RB 0
significant JJ 0
differences NNS 0
in IN 0
death NN 0
, , 0
myocardial JJ 0
infarction NN 0
, , 0
and CC 0
stent JJ 0
thrombosis NN 0
according VBG 0
to TO 0
the DT 0
Academic NNP 0
Research NNP 0
Consortium NNP 0
criteria NNS 0
between IN 0
the DT 0
2 CD 0
groups NNS 0
. . 0

CONCLUSIONS NNP 0
Clinical NNP 0
outcome VBD 0
up RB 0
to TO 0
3 CD 0
years NNS 0
after IN 0
implantation NN 0
of IN 0
SESs NNP 0
for IN 0
total JJ 0
coronary JJ 0
occlusions NNS 0
continues VBZ 0
to TO 0
demonstrate VB 0
a DT 0
significant JJ 0
reduction NN 0
in IN 0
adverse JJ 0
clinical JJ 0
events NNS 0
compared VBN 0
with IN 0
BMSs NNP 0
without IN 0
the DT 0
evidence NN 0
for IN 0
either DT 0
disproportionate NN 0
late JJ 0
restenosis NN 0
or CC 0
late JJ 0
stent JJ 0
thrombosis NN 0
. . 0

Lactobacillus NNP 0
plantarum NN 0
CECT7315 NNP 0
and CC 0
CECT7316 NNP 0
stimulate VBP 0
immunoglobulin NN 0
production NN 0
after IN 0
influenza JJ 4
vaccination NN 4
in IN 0
elderly JJ 1
. . 0

OBJECTIVE IN 0
The DT 0
effectiveness NN 0
of IN 0
influenza JJ 0
vaccination NN 0
in IN 0
preventing VBG 0
illness NN 0
is VBZ 0
lower RBR 0
in IN 0
the DT 0
elderly JJ 0
; : 0
this DT 0
is VBZ 0
why WRB 0
the DT 0
ability NN 0
of IN 0
Lactobacillus NNP 0
plantarum NN 0
CECT NNP 0
7315/7316 CD 0
to TO 0
stimulate VB 0
the DT 0
response NN 0
to TO 0
influenza VB 4
vaccination NN 4
in IN 0
elderly JJ 1
was VBD 0
evaluated VBN 0
. . 0

RESEARCH NNP 0
METHODS NNP 0
AND NNP 0
PROCEDURES NNP 0
A NNP 0
randomized JJ 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
human JJ 0
trial NN 0
including VBG 0
60 CD 3
institutionalized JJ 0
volunteers NNS 0
aged VBN 0
65-85 CD 1
years NNS 0
was VBD 0
performed VBN 0
. . 0

All PDT 0
the DT 0
volunteers NNS 0
were VBD 0
vaccinated VBN 0
with IN 0
a DT 0
trivalent JJ 0
influenza NN 0
vaccine NN 0
( ( 0
A/Wisconsin/67/2005 NNP 0
NYMC NNP 0
X-161B NNP 0
( ( 0
H3N2 NNP 0
) ) 0
, , 0
A/Solomon NNP 0
Islands/3/2006 NNP 0
( ( 0
H1N1 NNP 0
) ) 0
and CC 0
B/Malaysia/2506/2004 NNP 0
) ) 0
for IN 0
the DT 0
Spanish JJ 0
vaccine NN 0
campaign NN 0
2006/2007 CD 0
. . 0

The DT 0
consumption NN 0
of IN 0
the DT 0
probiotic JJ 0
began VBD 0
between IN 0
three CD 0
and CC 0
four CD 0
months NNS 0
after IN 0
the DT 0
vaccination NN 0
. . 0

Volunteers NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
one CD 0
of IN 0
three CD 0
following VBG 0
groups NNS 0
: : 0
group NN 0
A NNP 0
( ( 0
receiving VBG 0
5*10 CD 0
( ( 0
9 CD 0
) ) 0
cfu/day NN 0
of IN 0
L. NNP 0
plantarum NN 0
CECT NNP 0
7315/7316 CD 0
in IN 0
20 CD 0
g NN 0
powdered VBD 0
skim JJ 0
milk NN 0
) ) 0
, , 0
group NN 0
B NNP 0
( ( 0
receiving VBG 0
5*10 CD 0
( ( 0
8 CD 0
) ) 0
cfu/day NN 0
of IN 0
L. NNP 0
plantarum NN 0
CECT NNP 0
7315/7316 CD 0
in IN 0
20 CD 0
g NN 0
powdered VBD 0
skim JJ 0
milk NN 0
) ) 0
and CC 0
group NN 0
C NNP 0
or CC 0
placebo NN 0
( ( 0
20 CD 0
g NN 0
powered VBN 0
skim JJ 0
milk NN 0
) ) 0
. . 0

The DT 0
participants NNS 0
consumed VBD 0
the DT 0
probiotic JJ 0
during IN 0
3 CD 0
months NNS 0
. . 0

RESULTS VB 0
The DT 0
consumption NN 0
of IN 0
L. NNP 0
plantarum NN 0
CECT NNP 0
7315/7316 CD 0
during IN 0
3 CD 0
months NNS 0
after IN 0
influenza JJ 0
vaccination NN 0
increased VBD 0
the DT 0
levels NNS 0
of IN 0
influenza-specific JJ 0
IgA NNP 0
and CC 0
IgG NNP 0
antibodies NNS 0
. . 0

Moreover RB 0
, , 0
a DT 0
trend NN 0
towards IN 0
an DT 0
increase NN 0
in IN 0
influenza-specific JJ 0
IgM NNP 0
antibodies NNS 0
was VBD 0
also RB 0
observed VBN 0
. . 0

CONCLUSION NNP 0
L. NNP 0
plantarum NN 0
CECT7315/7316 NNP 0
has VBZ 0
an DT 0
immunostimulating JJ 0
effect NN 0
and CC 0
could MD 0
be VB 0
used VBN 0
to TO 0
improve VB 0
the DT 0
response NN 0
to TO 0
influenza VB 0
vaccination NN 0
in IN 0
elderly JJ 0
. . 0

Transurethral JJ 4
prostate NN 4
resection NN 4
and CC 0
bleeding NN 0
: : 0
a DT 0
randomized JJ 0
, , 0
placebo NN 0
controlled VBD 0
trial NN 0
of IN 0
role NN 0
of IN 0
finasteride NN 0
for IN 0
decreasing VBG 0
operative JJ 0
blood NN 0
loss NN 0
. . 0

PURPOSE NNP 0
Bleeding NNP 0
associated VBN 0
with IN 0
transurethral JJ 0
prostate NN 0
resection NN 0
can MD 0
often RB 0
be VB 0
significant JJ 0
and CC 0
lead JJ 0
to TO 0
increased VBN 0
morbidity NN 0
and CC 0
occasionally RB 0
mortality NN 0
. . 0

It PRP 0
has VBZ 0
been VBN 0
shown VBN 0
that IN 0
finasteride NN 0
decreases VBZ 0
bleeding VBG 0
in IN 0
patients NNS 0
with IN 0
hematuria NNS 4
of IN 0
prostatic JJ 0
origin NN 0
. . 0

We PRP 0
hypothesized VBD 0
that IN 0
bleeding VBG 0
in IN 0
patients NNS 0
undergoing JJ 0
transurethral JJ 4
prostate NN 4
resection NN 4
could MD 0
be VB 0
decreased VBN 0
by IN 0
giving VBG 0
finasteride NN 0
for IN 0
2 CD 0
weeks NNS 0
before RB 0
surgery NN 0
. . 0

MATERIALS NNP 0
AND NNP 0
METHODS NNP 0
A NNP 0
total JJ 0
70 CD 3
patients NNS 0
scheduled VBN 0
to TO 0
undergo VB 0
elective JJ 4
transurethral JJ 4
prostate NN 4
resection NN 4
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
5 CD 0
mg. NNS 0
finasteride JJ 0
daily RB 0
or CC 0
placebo VB 0
for IN 0
2 CD 0
weeks NNS 0
before RB 0
surgery NN 0
. . 0

Serum NNP 0
hemoglobin NN 0
was VBD 0
measured VBN 0
before IN 0
and CC 0
after IN 0
surgery NN 0
, , 0
and CC 0
the DT 0
following JJ 0
day NN 0
. . 0

The DT 0
volume NN 0
of IN 0
irrigation NN 0
fluid NN 0
used VBN 0
and CC 0
its PRP$ 0
hemoglobin JJ 0
concentration NN 0
as RB 0
well RB 0
as IN 0
resected VBN 0
prostate NN 0
weight NN 0
were VBD 0
recorded VBN 0
. . 0

RESULTS NNP 0
Of IN 0
the DT 0
68 CD 3
patients NNS 0
who WP 0
underwent JJ 0
transurethral JJ 4
prostate NN 4
resection NN 4
2 CD 0
were VBD 0
withdrawn VBN 0
before RB 0
surgery NN 0
, , 0
and CC 0
so RB 0
32 CD 0
received VBD 0
finasteride NN 0
and CC 0
36 CD 0
received VBD 0
placebo NN 0
. . 0

There EX 0
was VBD 0
significantly RB 0
less JJR 0
mean JJ 0
blood NN 0
loss NN 0
in IN 0
irrigation NN 0
fluid NN 0
in IN 0
the DT 0
finasteride NN 0
group NN 0
than IN 0
in IN 0
the DT 0
control NN 0
group NN 0
( ( 0
43.6 CD 0
versus NN 0
69.3 CD 0
gm NN 0
. . 0

hemoglobin NN 0
, , 0
p NN 0
= NNP 0
0.011 CD 0
) ) 0
. . 0

The DT 0
mean JJ 0
difference NN 0
was VBD 0
more RBR 0
significant JJ 0
when WRB 0
blood NN 0
loss NN 0
per IN 0
gm NN 0
. . 0

resected JJ 0
prostate NN 0
was VBD 0
calculated VBN 0
( ( 0
2.65 CD 0
versus NN 0
4.65 CD 0
gm NN 0
. . 0

hemoglobin NN 0
per IN 0
gm NN 0
. . 0

prostate NN 0
, , 0
p NN 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

CONCLUSIONS VB 0
This DT 0
study NN 0
shows VBZ 0
that IN 0
finasteride NN 0
given VBN 0
for IN 0
2 CD 0
weeks NNS 0
preoperatively RB 0
decreases VBZ 0
bleeding VBG 0
in IN 0
patients NNS 0
undergoing JJ 0
transurethral JJ 4
prostate NN 4
resection NN 4
. . 0

Further NNP 0
study NN 0
is VBZ 0
required VBN 0
to TO 0
determine VB 0
the DT 0
optimal JJ 0
timing NN 0
and CC 0
dose JJ 0
duration NN 0
to TO 0
minimize VB 0
blood NN 0
loss NN 0
and CC 0
identify VB 0
how WRB 0
relevant JJ 0
such JJ 0
a DT 0
decrease NN 0
in IN 0
bleeding NN 0
is VBZ 0
in IN 0
clinical JJ 0
practice NN 0
. . 0

Effect NN 0
of IN 0
aliskiren NN 0
on IN 0
proteinuria NNS 0
in IN 0
non-diabetic JJ 4
chronic JJ 4
kidney NN 4
disease NN 4
: : 0
a DT 0
double-blind NN 0
, , 0
crossover NN 0
, , 0
randomised VBN 0
, , 0
controlled VBN 0
trial NN 0
. . 0

AIM NNP 0
To TO 0
evaluate VB 0
the DT 0
proteinuria-lowering JJ 0
effect NN 0
of IN 0
a DT 0
renin NN 0
inhibitor NN 0
( ( 0
aliskiren NN 0
) ) 0
, , 0
compared VBN 0
to TO 0
placebo VB 0
and CC 0
to TO 0
an DT 0
angiotensin-converting JJ 0
enzyme NN 0
inhibitor NN 0
( ( 0
perindopril NN 0
) ) 0
, , 0
in IN 0
patients NNS 0
with IN 0
non-diabetic JJ 0
chronic JJ 0
kidney NN 0
disease NN 0
. . 0

METHODS NNP 0
A DT 0
randomised JJ 0
, , 0
double-blind JJ 0
, , 0
crossover JJ 0
trial NN 0
was VBD 0
performed VBN 0
in IN 0
14 CD 0
patients NNS 0
with IN 0
nondiabetic JJ 0
chronic JJ 0
kidney NN 0
disease NN 0
with IN 0
24-h JJ 0
mean JJ 0
proteinuria NN 0
of IN 0
2.01 CD 0
g NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
1.36?2.66 CD 0
) ) 0
and CC 0
estimated VBN 0
creatinine JJ 0
clearance NN 0
of IN 0
93?6.8 CD 0
ml/min NN 0
. . 0

The DT 0
study NN 0
consisted VBD 0
of IN 0
five CD 0
treatment NN 0
periods NNS 0
. . 0

The DT 0
patients NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
aliskiren NNS 0
( ( 0
150 CD 0
mg NN 0
) ) 0
, , 0
aliskiren RB 0
( ( 0
300 CD 0
mg NN 0
) ) 0
, , 0
perindopril NN 0
( ( 0
5 CD 0
mg NN 0
) ) 0
, , 0
perindopril NN 0
( ( 0
10 CD 0
mg NN 0
) ) 0
or CC 0
placebo NN 0
. . 0

RESULTS NNP 0
Aliskiren NNP 0
and CC 0
perindopril NN 0
reduced VBN 0
proteinuria NN 0
. . 0

These DT 0
effects NNS 0
were VBD 0
dose-dependent JJ 0
. . 0

Furthermore CD 0
, , 0
24-h JJ 0
proteinuria NN 0
was VBD 0
reduced VBN 0
by IN 0
23 CD 0
% NN 0
( ( 0
mean JJ 0
95 CD 0
% NN 0
CI NNP 0
; : 0
2?44 CD 0
) ) 0
by IN 0
treatment NN 0
with IN 0
aliskiren NNS 0
( ( 0
150 CD 0
mg NN 0
) ) 0
, , 0
by IN 0
36 CD 0
% NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
17?55 CD 0
; : 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
with IN 0
aliskiren NN 0
( ( 0
300 CD 0
mg NN 0
) ) 0
, , 0
by IN 0
7.1 CD 0
% NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
11?26 CD 0
) ) 0
with IN 0
perindopril NN 0
( ( 0
5 CD 0
mg NN 0
) ) 0
and CC 0
by IN 0
25 CD 0
% NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
11?39 CD 0
; : 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
with IN 0
perindopril NN 0
( ( 0
10 CD 0
mg NN 0
) ) 0
, , 0
compared VBN 0
to TO 0
placebo VB 0
. . 0

No DT 0
significant JJ 0
difference NN 0
was VBD 0
found VBN 0
between IN 0
the DT 0
effects NNS 0
of IN 0
aliskiren NNS 0
and CC 0
perindopril NN 0
. . 0

CONCLUSIONS NNP 0
Aliskiren NNP 0
significantly RB 0
reduced VBD 0
proteinuria NNS 0
. . 0

The DT 0
antiproteinuric JJ 0
effect NN 0
is VBZ 0
probably RB 0
similar JJ 0
to TO 0
that DT 0
of IN 0
perindopril NN 0
, , 0
for IN 0
equivalent JJ 0
hypotensive JJ 0
dosages NNS 0
. . 0

The DT 0
renin JJ 0
inhibitor NN 0
provides VBZ 0
a DT 0
promising JJ 0
alternative JJ 0
approach NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
patients NNS 0
with IN 0
chronic JJ 0
proteinuric JJ 0
non-diabetic JJ 0
kidney NN 0
disease NN 0
. . 0

Enhanced NNP 0
small JJ 0
group NN 0
instruction NN 0
using VBG 0
choral JJ 0
responding NN 0
and CC 0
student NN 0
interaction NN 0
for IN 0
children NNS 0
with IN 0
autism NN 4
and CC 0
developmental JJ 4
disabilities NNS 4
. . 0

The DT 0
use NN 0
of IN 0
effective JJ 0
instructional JJ 0
strategies NNS 0
in IN 0
small JJ 0
groups NNS 0
was VBD 0
investigated VBN 0
to TO 0
determine VB 0
learning JJ 0
effects NNS 0
for IN 0
24 CD 3
elementary JJ 1
age NN 1
students NNS 0
with IN 0
autism NN 4
and CC 0
developmental JJ 4
disabilities NNS 4
. . 0

Effective JJ 0
strategies NNS 0
included VBD 0
( ( 0
a DT 0
) ) 0
the DT 0
use NN 0
of IN 0
choral JJ 0
responding NN 0
; : 0
( ( 0
b NN 0
) ) 0
the DT 0
use NN 0
of IN 0
student-to-student JJ 0
responding NN 0
; : 0
( ( 0
c NN 0
) ) 0
the DT 0
rotation NN 0
of IN 0
materials NNS 0
every DT 0
5 CD 0
minutes NNS 0
during IN 0
the DT 0
30-minute JJ 0
group NN 0
while IN 0
teaching VBG 0
2 CD 0
to TO 0
3 CD 0
concepts NNS 0
; : 0
and CC 0
( ( 0
d NN 0
) ) 0
the DT 0
use NN 0
of IN 0
random NN 0
, , 0
unpredictable JJ 0
trials NNS 0
for IN 0
student NN 0
responding VBG 0
. . 0

Thirty-minute JJ 0
language NN 0
groups NNS 0
were VBD 0
targeted VBN 0
to TO 0
teach VB 0
receptive JJ 0
and CC 0
expressive JJ 0
skills NNS 0
using VBG 0
pictures NNS 0
and CC 0
common JJ 0
objects NNS 0
across IN 0
five CD 0
categories NNS 0
( ( 0
e.g. NN 0
, , 0
household NN 0
items NNS 0
, , 0
foods NNS 0
) ) 0
. . 0

Results JJ 0
showed VBD 0
increased JJ 0
opportunities NNS 0
to TO 0
respond VB 0
, , 0
increased JJ 0
levels NNS 0
of IN 0
responding VBG 0
and CC 0
academic JJ 0
engagement NN 0
, , 0
higher JJR 0
gains NNS 0
on IN 0
weekly JJ 0
criterion-referenced JJ 0
pre- NN 0
and CC 0
posttests NNS 0
, , 0
and CC 0
decreased VBD 0
passive JJ 0
and CC 0
inappropriate JJ 0
student NN 0
behavior NN 0
during IN 0
interventions NNS 0
. . 0

Oral NNP 0
health NN 0
impacts NNS 0
on IN 0
daily JJ 0
living NN 0
related VBN 0
to TO 0
four CD 0
different JJ 0
treatment NN 0
protocols NNS 0
for IN 0
chronic JJ 4
periodontitis NN 4
. . 0

BACKGROUND IN 0
The DT 0
aims NNS 0
of IN 0
this DT 0
study NN 0
were VBD 0
to TO 0
evaluate VB 0
the DT 0
oral JJ 0
health NN 0
impacts NNS 0
perceived VBN 0
by IN 0
patients NNS 0
submitted VBN 0
to TO 0
different JJ 0
treatments NNS 0
of IN 0
chronic JJ 4
periodontitis NN 4
and CC 0
their PRP$ 0
association NN 0
with IN 0
clinical JJ 0
parameters NNS 0
. . 0

METHODS NNP 0
Sixty NNP 3
patients NNS 0
were VBD 0
assigned VBN 0
to TO 0
one CD 0
of IN 0
the DT 0
following JJ 0
therapeutic JJ 0
groups NNS 0
: : 0
control NN 0
, , 0
treated VBN 0
with IN 0
full-mouth JJ 0
scaling NN 0
and CC 0
root NN 0
planing NN 0
( ( 0
SRP NNP 0
) ) 0
; : 0
test $ 0
1 CD 0
, , 0
treated VBN 0
with IN 0
SRP NNP 0
and CC 0
400 CD 0
mg NNS 0
systemically RB 0
administered VBN 0
metronidazole NN 0
( ( 0
MET NNP 0
) ) 0
three CD 0
times NNS 0
per IN 0
day NN 0
for IN 0
10 CD 0
days NNS 0
; : 0
test JJS 0
2 CD 0
, , 0
treated VBN 0
with IN 0
SRP NNP 0
and CC 0
professional JJ 0
supragingival NN 0
plaque NN 0
removal NN 0
( ( 0
PP NNP 0
) ) 0
every DT 0
week NN 0
for IN 0
3 CD 0
months NNS 0
; : 0
and CC 0
test VB 0
3 CD 0
, , 0
treated VBN 0
with IN 0
SRP NNP 0
and CC 0
MET NNP 0
plus CC 0
PP NNP 0
. . 0

Clinical NNP 0
periodontal JJ 0
measurements NNS 0
and CC 0
data NNS 0
regarding VBG 0
patients NNS 0
' POS 0
oral JJ 0
health NN 0
impacts NNS 0
( ( 0
perceived VBN 0
impacts NNS 0
on IN 0
bleeding VBG 0
gums NNS 0
, , 0
gingival JJ 0
recession NN 0
, , 0
sensitivity NN 0
to TO 0
cold VB 0
, , 0
packing VBG 0
foods NNS 0
, , 0
aesthetics NNS 0
, , 0
bad JJ 0
breath NN 0
, , 0
and CC 0
tooth DT 0
mobility NN 0
) ) 0
were VBD 0
collected VBN 0
at IN 0
baseline NN 0
and CC 0
3 CD 0
months NNS 0
after IN 0
therapy NN 0
. . 0

RESULTS NNP 0
All NNP 0
groups NNS 0
presented VBD 0
significant JJ 0
improvement NN 0
in IN 0
oral JJ 0
health NN 0
perceived VBD 0
impacts NNS 0
. . 0

There EX 0
was VBD 0
no DT 0
statistically RB 0
significant JJ 0
difference NN 0
in IN 0
the DT 0
improvement NN 0
of IN 0
oral JJ 0
health NN 0
impacts NNS 0
among IN 0
groups NNS 0
subjected VBN 0
to TO 0
different JJ 0
treatments NNS 0
. . 0

The DT 0
clinical JJ 0
data NNS 0
of IN 0
percentage NN 0
of IN 0
deep JJ 0
probing VBG 0
depth NN 0
, , 0
deep JJ 0
clinical JJ 0
attachment NN 0
level NN 0
, , 0
and CC 0
bleeding VBG 0
on IN 0
probing VBG 0
were VBD 0
found VBN 0
to TO 0
be VB 0
correlated VBN 0
significantly RB 0
with IN 0
oral JJ 0
health NN 0
impacts NNS 0
. . 0

CONCLUSIONS NNP 0
Periodontal NNP 0
treatment NN 0
leads VBZ 0
to TO 0
a DT 0
significant JJ 0
reduction NN 0
of IN 0
self-perceived JJ 0
impacts NNS 0
regardless RB 0
of IN 0
the DT 0
non-surgical JJ 0
treatment NN 0
protocol NN 0
employed VBN 0
. . 0

Most JJS 0
of IN 0
the DT 0
clinical JJ 0
data NNS 0
were VBD 0
associated VBN 0
with IN 0
oral JJ 0
health NN 0
impacts NNS 0
. . 0

Observer NNP 0
variation NN 0
in IN 0
the DT 0
assessment NN 0
of IN 0
outcome NN 0
in IN 0
traumatic JJ 0
brain NN 0
injury NN 0
: : 0
experience NN 0
from IN 0
a DT 0
multicenter NN 0
, , 0
international JJ 0
randomized VBD 0
clinical JJ 0
trial NN 0
. . 0

OBJECTIVE NNP 0
Accurate NNP 0
and CC 0
consistent JJ 0
outcome NN 0
assessment NN 0
is VBZ 0
essential JJ 0
to TO 0
randomized VB 0
clinical JJ 0
trials NNS 0
. . 0

We PRP 0
aimed VBD 0
to TO 0
explore VB 0
observer JJ 0
variation NN 0
in IN 0
the DT 0
assessment NN 0
of IN 0
outcome NN 0
in IN 0
a DT 0
recently RB 0
completed VBN 0
trial NN 0
of IN 0
dexanabinol NN 0
in IN 0
head JJ 4
injury NN 4
and CC 0
to TO 0
consider VB 0
steps NNS 0
to TO 0
reduce VB 0
such JJ 0
variation NN 0
. . 0

METHODS NNP 0
Eight NNP 3
hundred VBD 3
sixty-one JJ 3
patients NNS 0
with IN 0
severe JJ 4
traumatic JJ 4
brain NN 4
injury NN 4
who WP 0
were VBD 0
admitted VBN 0
to TO 0
86 CD 0
centers NNS 0
were VBD 0
included VBN 0
in IN 0
a DT 0
multicenter NN 0
, , 0
placebo-controlled JJ 0
, , 0
Phase NNP 0
III NNP 0
trial NN 0
. . 0

Outcome NNP 0
was VBD 0
assessed VBN 0
at IN 0
3 CD 0
and CC 0
6 CD 0
months NNS 0
postinjury NN 0
using VBG 0
the DT 0
extended JJ 0
Glasgow NNP 0
Outcome NNP 0
Scale NNP 0
; : 0
standardized VBD 0
assessment NN 0
was VBD 0
facilitated VBN 0
by IN 0
the DT 0
use NN 0
of IN 0
a DT 0
structured JJ 0
interview NN 0
. . 0

Before IN 0
initiation NN 0
of IN 0
trial NN 0
centers NNS 0
, , 0
outcome JJ 0
ratings NNS 0
were VBD 0
obtained VBN 0
for IN 0
sample JJ 0
cases NNS 0
to TO 0
establish VB 0
initial JJ 0
levels NNS 0
of IN 0
agreement NN 0
. . 0

Training NN 0
sessions NNS 0
in IN 0
outcome JJ 0
assessment NN 0
were VBD 0
held VBN 0
, , 0
and CC 0
problems NNS 0
in IN 0
assigning VBG 0
outcome NN 0
were VBD 0
investigated VBN 0
. . 0

During IN 0
the DT 0
trial NN 0
, , 0
a DT 0
process NN 0
of IN 0
central JJ 0
review NN 0
was VBD 0
established VBN 0
to TO 0
monitor VB 0
performance NN 0
. . 0

Interobserver NNP 0
variation NN 0
was VBD 0
analyzed VBN 0
using VBG 0
the DT 0
kappa NN 0
statistic JJ 0
. . 0

RESULTS NNP 0
Substantial NNP 0
observer JJ 0
variation NN 0
was VBD 0
found VBN 0
in IN 0
the DT 0
rating NN 0
of IN 0
sample JJ 0
cases NNS 0
( ( 0
weighted JJ 0
kappa NN 0
, , 0
0.72 CD 0
; : 0
confidence NN 0
interval NN 0
, , 0
0.68-0.75 JJ 0
) ) 0
and CC 0
in IN 0
assigning VBG 0
outcome NN 0
based VBN 0
on IN 0
completed VBN 0
structured JJ 0
interviews NNS 0
( ( 0
weighted JJ 0
kappa NN 0
, , 0
0.61 CD 0
; : 0
confidence NN 0
interval NN 0
, , 0
0.57-0.64 JJ 0
) ) 0
. . 0

In IN 0
the DT 0
early JJ 0
stages NNS 0
of IN 0
the DT 0
trial NN 0
, , 0
a DT 0
relatively RB 0
large JJ 0
number NN 0
of IN 0
discrepancies NNS 0
( ( 0
29-37 CD 0
% NN 0
) ) 0
were VBD 0
identified VBN 0
on IN 0
central JJ 0
review NN 0
. . 0

This DT 0
number NN 0
declined VBD 0
as IN 0
the DT 0
trial NN 0
progressed VBD 0
and CC 0
coincided VBD 0
with IN 0
investigator NN 0
training NN 0
and CC 0
feedback NN 0
from IN 0
central JJ 0
review NN 0
. . 0

Centers NNS 0
with IN 0
higher JJR 0
enrollment NN 0
rates NNS 0
showed VBD 0
better JJR 0
performance NN 0
. . 0

CONCLUSION NNP 0
Observer NNP 0
variation NN 0
in IN 0
outcome JJ 0
assessment NN 0
is VBZ 0
a DT 0
significant JJ 0
problem NN 0
for IN 0
head NN 0
injury NN 0
trials NNS 0
. . 0

Consistency NN 0
can MD 0
be VB 0
improved VBN 0
by IN 0
standardizing VBG 0
procedures NNS 0
, , 0
training VBG 0
assessors NNS 0
, , 0
and CC 0
monitoring VBG 0
the DT 0
quality NN 0
of IN 0
assessments NNS 0
and CC 0
providing VBG 0
feedback NN 0
to TO 0
interviewers NNS 0
. . 0

1999 CD 0
WHO/ISH NNP 0
Guidelines NNP 0
applied VBD 0
to TO 0
a DT 0
1999 CD 0
MONICA NNP 0
sample NN 0
from IN 0
northern JJ 0
Sweden NNP 0
. . 0

BACKGROUND NNP 0
Treating NNP 0
hypertension NN 0
with IN 0
drugs NNS 0
is VBZ 0
so RB 0
far RB 0
the DT 0
most RBS 0
cost-effective JJ 0
way NN 0
to TO 0
reduce VB 0
this DT 0
important JJ 0
risk NN 0
factor NN 0
for IN 0
cardiovascular JJ 0
disease NN 0
( ( 0
CVD NNP 0
) ) 0
. . 0

It PRP 0
is VBZ 0
, , 0
however RB 0
, , 0
important JJ 0
to TO 0
determine VB 0
absolute NN 0
risk NN 0
, , 0
and CC 0
thereby RB 0
estimate VB 0
indication NN 0
for IN 0
drug NN 0
treatment NN 0
, , 0
in IN 0
order NN 0
to TO 0
maintain VB 0
a DT 0
cost-effective JJ 0
drug NN 0
treatment NN 0
. . 0

WHO/ISH NNP 0
Hypertension NNP 0
Guidelines NNP 0
from IN 0
1999 CD 0
propose NN 0
a DT 0
risk NN 0
stratification NN 0
for IN 0
estimating VBG 0
absolute NN 0
risk NN 0
for IN 0
CVD NNP 0
based VBN 0
on IN 0
blood NN 0
pressure NN 0
and CC 0
additional JJ 0
risk NN 0
factors NNS 0
, , 0
target NN 0
organ JJ 0
damage NN 0
( ( 0
TOD NNP 0
) ) 0
and CC 0
CVD NNP 0
. . 0

OBJECTIVES NNP 0
We PRP 0
studied VBD 0
the DT 0
consequences NNS 0
of IN 0
applying VBG 0
the DT 0
recent JJ 0
WHO/ISH NNP 0
risk NN 0
stratification NN 0
scheme NN 0
to TO 0
a DT 0
MONICA NNP 0
sample NN 0
of IN 0
6000 CD 3
subjects NNS 0
from IN 0
a DT 0
geographically RB 0
defined VBN 0
population NN 0
in IN 0
northern JJ 0
Sweden NNP 0
, , 0
regarding VBG 0
indications NNS 0
for IN 0
treatment NN 0
, , 0
target VB 0
blood NN 0
pressure NN 0
and CC 0
risk NN 0
distribution NN 0
. . 0

METHODS NNP 0
We PRP 0
have VBP 0
risk-classified JJ 0
each DT 0
of IN 0
these DT 0
patients NNS 0
using VBG 0
a DT 0
computer NN 0
program NN 0
, , 0
according VBG 0
to TO 0
the DT 0
WHO/ISH NNP 0
scheme NN 0
. . 0

Data NNP 0
on IN 0
TOD NNP 0
were VBD 0
not RB 0
available JJ 0
. . 0

RESULTS NNP 0
In IN 0
all DT 0
, , 0
917 CD 0
( ( 0
15 CD 0
% NN 0
) ) 0
had VBD 0
drug-treated JJ 4
hypertension NN 4
. . 0

Three-quarters NNS 0
( ( 0
n JJ 0
= NNP 0
737 CD 0
) ) 0
were VBD 0
inadequately RB 0
treated VBN 0
, , 0
with IN 0
blood NN 0
pressure NN 0
levels NNS 0
at IN 0
or CC 0
above VB 0
140 CD 0
or CC 0
90 CD 0
mmHg NN 0
. . 0

1773 CD 0
( ( 0
30 CD 0
% NN 0
of IN 0
5997 CD 0
) ) 0
untreated JJ 4
subjects NNS 0
had VBD 0
a DT 0
blood NN 0
pressure NN 0
of IN 0
140/90 CD 0
or CC 0
above RB 0
; : 0
16 CD 0
% NN 0
in IN 0
the DT 0
low- JJ 0
, , 0
62 CD 0
% NN 0
in IN 0
the DT 0
medium- NN 0
, , 0
8 CD 0
% NN 0
in IN 0
the DT 0
high- NN 0
, , 0
and CC 0
14 CD 0
% NN 0
in IN 0
the DT 0
very-high-risk JJ 0
group NN 0
. . 0

The DT 0
corresponding JJ 0
risk-group JJ 0
pattern NN 0
for IN 0
the DT 0
inadequately RB 0
treated JJ 0
hypertensives NNS 0
( ( 0
n JJ 0
= NNP 0
737 CD 0
) ) 0
was VBD 0
5.5 CD 0
, , 0
48.3 CD 0
, , 0
11.1 CD 0
and CC 0
35.2 CD 0
% NN 0
, , 0
respectively RB 0
. . 0

If IN 0
we PRP 0
shifted VBD 0
the DT 0
target NN 0
blood NN 0
pressure NN 0
from IN 0
below IN 0
140/90 CD 0
to TO 0
below VB 0
130/85 CD 0
for IN 0
drug-treated JJ 0
subjects NNS 0
under IN 0
60 CD 0
( ( 0
n JJ 0
= NNP 0
278 CD 0
) ) 0
the DT 0
number NN 0
of IN 0
inadequately RB 0
treated JJ 0
subjects NNS 0
increased VBN 0
by IN 0
34 CD 0
( ( 0
12.2 CD 0
% NN 0
of IN 0
278 CD 0
) ) 0
; : 0
14 CD 0
in IN 0
the DT 0
low-risk JJ 0
group NN 0
, , 0
15 CD 0
in IN 0
the DT 0
medium-risk JJ 0
group NN 0
, , 0
and CC 0
only RB 0
five CD 0
in IN 0
the DT 0
high- JJ 0
or CC 0
very-high-risk JJ 0
groups NNS 0
. . 0

CONCLUSIONS NNP 0
Only RB 0
one-fifth NN 0
of IN 0
the DT 0
drug-treated JJ 0
hypertensives NNS 0
were VBD 0
well RB 0
controlled VBN 0
. . 0

Moreover RB 0
, , 0
the DT 0
incidence NN 0
of IN 0
newly RB 0
detected VBN 0
blood NN 0
pressure NN 0
elevation NN 0
was VBD 0
high JJ 0
. . 0

The DT 0
majority NN 0
of IN 0
younger JJR 0
subjects NNS 0
with IN 0
high JJ 0
blood NN 0
pressure NN 0
had VBD 0
low JJ 0
risk NN 0
, , 0
but CC 0
in IN 0
those DT 0
aged VBN 0
45-54 CD 1
this DT 0
had VBD 0
already RB 0
risen VBN 0
to TO 0
a DT 0
medium NN 0
risk NN 0
. . 0

Changing VBG 0
the DT 0
target NN 0
blood NN 0
pressure NN 0
to TO 0
below IN 0
130/85 CD 0
, , 0
for IN 0
subjects NNS 0
aged VBN 1
below IN 1
60 CD 1
, , 0
as IN 0
recommended VBN 0
by IN 0
WHO/ISH NNP 0
, , 0
affects VBZ 0
predominantly RB 0
low- JJ 0
and CC 0
medium-risk JJ 0
groups NNS 0
. . 0

Direct JJ 0
trocar NN 0
insertion NN 0
vs. FW 0
Verres NNP 0
needle FW 0
use NN 0
for IN 0
laparoscopic JJ 4
sterilization NN 4
. . 0

A DT 0
randomized JJ 0
, , 0
prospective JJ 0
trial NN 0
was VBD 0
designed VBN 0
to TO 0
compare VB 0
direct JJ 0
trocar NN 0
insertion NN 0
with IN 0
prior JJ 0
peritoneal JJ 0
insufflation NN 0
with IN 0
a DT 0
Verres NNP 0
needle NN 0
for IN 0
laparoscopic NN 4
tubal JJ 4
sterilization NN 4
. . 0

Direct JJ 0
trocar NN 0
insertion NN 0
resulted VBD 0
in IN 0
fewer JJR 0
instrument NN 0
insertions NNS 0
( ( 0
21.8 CD 0
% NN 0
vs. FW 0
7.8 CD 0
% NN 0
) ) 0
and CC 0
use NN 0
of IN 0
smaller JJR 0
volumes NNS 0
of IN 0
CO2 NNP 0
( ( 0
2.67 CD 0
vs. FW 0
2.32 CD 0
L NNP 0
) ) 0
. . 0

Direct JJ 0
trocar NN 0
use NN 0
resulted VBD 0
in IN 0
a DT 0
decrease NN 0
in IN 0
operating NN 0
time NN 0
from IN 0
9 CD 0
minutes NNS 0
, , 0
40 CD 0
seconds NNS 0
in IN 0
the DT 0
needle JJ 0
group NN 0
to TO 0
7 CD 0
minutes NNS 0
, , 0
30 CD 0
seconds NNS 0
in IN 0
the DT 0
trocar NN 0
group NN 0
. . 0

Minor NNP 0
omental JJ 4
injuries NNS 4
occurred VBD 0
in IN 0
a DT 0
small JJ 0
percentage NN 0
of IN 0
each DT 0
group NN 0
, , 0
while IN 0
serious JJ 0
complications NNS 0
occurred VBD 0
once RB 0
in IN 0
each DT 0
group NN 0
. . 0

Pilot NNP 0
study NN 0
of IN 0
imiquimod JJ 0
5 CD 0
% NN 0
cream NN 0
as IN 0
adjunctive JJ 0
therapy NN 0
to TO 0
curettage VB 0
and CC 0
electrodesiccation NN 0
for IN 0
nodular JJ 4
basal NN 4
cell NN 4
carcinoma NN 4
. . 0

BACKGROUND NNP 0
Curettage NNP 0
and CC 0
electrodesiccation NN 0
( ( 0
C NNP 0
& CC 0
D NNP 0
) ) 0
is VBZ 0
a DT 0
widely RB 0
used VBN 0
method NN 0
to TO 0
treat VB 0
nodular JJ 4
basal NN 4
cell NN 4
carcinoma NN 4
( ( 0
BCC NNP 4
) ) 0
. . 0

However RB 0
, , 0
residual JJ 0
tumor NN 0
is VBZ 0
present JJ 0
immediately RB 0
after IN 0
the DT 0
procedure NN 0
in IN 0
approximately RB 0
20 CD 0
to TO 0
40 CD 0
% NN 0
of IN 0
cases NNS 0
. . 0

Imiquimod NNP 0
, , 0
a DT 0
topical JJ 0
immune NN 0
response NN 0
modifier NN 0
that WDT 0
targets VBZ 0
Toll-like NNP 0
receptor NN 0
7 CD 0
, , 0
is VBZ 0
currently RB 0
approved VBN 0
for IN 0
superficial JJ 0
BCC NNP 0
. . 0

OBJECTIVE NNP 0
In IN 0
a DT 0
double-blind JJ 0
, , 0
vehicle-controlled JJ 0
study NN 0
, , 0
the DT 0
administration NN 0
of IN 0
imiquimod NN 0
after IN 0
C NNP 0
& CC 0
D NNP 0
was VBD 0
investigated VBN 0
to TO 0
determine VB 0
if IN 0
the DT 0
combination NN 0
regimen NNS 0
would MD 0
reduce VB 0
the DT 0
frequency NN 0
of IN 0
residual JJ 0
tumor NN 0
compared VBN 0
with IN 0
C NNP 0
& CC 0
D NNP 0
alone RB 0
in IN 0
patients NNS 0
with IN 0
nodular JJ 4
BCC NNP 4
. . 0

METHODS NNP 0
Twenty NNP 3
patients NNS 0
received VBD 0
three CD 0
cycles NNS 0
of IN 0
C NNP 0
& CC 0
D NNP 0
followed VBN 0
by IN 0
imiquimod JJ 0
5 CD 0
% NN 0
or CC 0
vehicle NN 0
cream NN 0
once RB 0
daily JJ 0
for IN 0
1 CD 0
month NN 0
as IN 0
adjunctive JJ 0
therapy NN 0
. . 0

The DT 0
primary JJ 0
end NN 0
point NN 0
was VBD 0
the DT 0
frequency NN 0
of IN 0
residual JJ 0
tumor NN 0
. . 0

The DT 0
secondary JJ 0
end NN 0
points NNS 0
included VBD 0
the DT 0
time NN 0
to TO 0
heal VB 0
and CC 0
cosmetic JJ 0
appearance NN 0
. . 0

RESULTS NNP 0
Twenty NNP 3
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
the DT 0
imiquimod NN 0
( ( 0
n JJ 0
= NNP 0
10 CD 3
) ) 0
or CC 0
vehicle NN 0
( ( 0
n JJ 0
= NNP 0
10 CD 3
) ) 0
treatment NN 0
group NN 0
. . 0

At IN 0
8 CD 0
weeks NNS 0
, , 0
the DT 0
proportion NN 0
of IN 0
patients NNS 0
with IN 0
residual JJ 0
tumor NN 0
was VBD 0
substantially RB 0
decreased VBN 0
with IN 0
imiquimod JJ 0
therapy NN 0
( ( 0
10 CD 0
% NN 0
) ) 0
compared VBN 0
with IN 0
vehicle NN 0
( ( 0
40 CD 0
% NN 0
) ) 0
. . 0

Wounds VBZ 0
in IN 0
the DT 0
vehicle NN 0
group NN 0
healed VBD 0
more RBR 0
quickly RB 0
than IN 0
those DT 0
in IN 0
the DT 0
imiquimod NN 0
group NN 0
, , 0
although IN 0
by IN 0
8 CD 0
weeks NNS 0
, , 0
all DT 0
excision NN 0
sites NNS 0
were VBD 0
healed VBN 0
. . 0

The DT 0
majority NN 0
of IN 0
scars NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
were VBD 0
atrophic JJ 0
and CC 0
hypopigmented VBD 0
, , 0
whereas IN 0
most JJS 0
scars NNS 0
in IN 0
the DT 0
imiquimod NN 0
group NN 0
were VBD 0
flat JJ 0
and CC 0
slightly RB 0
pink VBP 0
. . 0

CONCLUSION NNP 0
Imiquimod NNP 0
5 CD 0
% NN 0
cream NN 0
once RB 0
daily JJ 0
for IN 0
1 CD 0
month NN 0
as IN 0
adjunctive JJ 0
therapy NN 0
after IN 0
C NNP 0
& CC 0
D NNP 0
substantially RB 0
reduced VBD 0
the DT 0
frequency NN 0
of IN 0
residual JJ 0
tumor NN 0
and CC 0
improved VBD 0
the DT 0
cosmetic JJ 0
appearance NN 0
compared VBN 0
with IN 0
C NNP 0
& CC 0
D NNP 0
alone RB 0
. . 0

These DT 0
preliminary JJ 0
results NNS 0
suggest VBP 0
that IN 0
further JJ 0
studies NNS 0
to TO 0
investigate VB 0
imiquimod JJ 0
adjunctive JJ 0
therapy NN 0
are VBP 0
warranted VBN 0
. . 0

Olanzapine NNP 0
versus NN 0
haloperidol NN 0
in IN 0
children NNS 1
with IN 0
autistic JJ 4
disorder NN 4
: : 0
an DT 0
open JJ 0
pilot NN 0
study NN 0
. . 0

OBJECTIVES NNP 0
Conventional NNP 0
neuroleptics NNS 0
ameliorate VBP 0
symptoms NNS 0
in IN 0
children NNS 1
with IN 0
autistic JJ 4
disorder NN 4
; : 0
however RB 0
, , 0
they PRP 0
are VBP 0
known VBN 0
to TO 0
cause VB 0
dyskinesias NN 0
. . 0

Atypical JJ 0
neuroleptics NNS 0
, , 0
including VBG 0
olanzapine NN 0
, , 0
may MD 0
have VB 0
less JJR 0
risk NN 0
for IN 0
dyskinesia NN 0
, , 0
but CC 0
their PRP$ 0
efficacy NN 0
in IN 0
autistic JJ 0
disorder NN 0
is VBZ 0
not RB 0
established VBN 0
. . 0

This DT 0
study NN 0
was VBD 0
designed VBN 0
to TO 0
investigate VB 0
the DT 0
safety NN 0
and CC 0
effectiveness NN 0
of IN 0
open-label JJ 0
olanzapine NN 0
as IN 0
a DT 0
treatment NN 0
for IN 0
children NNS 1
with IN 0
autistic JJ 4
disorder NN 4
by IN 0
using VBG 0
haloperidol NN 0
as IN 0
a DT 0
standard JJ 0
comparator NN 0
treatment NN 0
. . 0

METHOD NNP 0
In IN 0
a DT 0
parallel JJ 0
groups NNS 0
design NN 0
, , 0
12 CD 3
children NNS 1
with IN 0
DSM-IV NNP 4
autistic JJ 4
disorder NN 4
( ( 0
mean JJ 0
age NN 0
7.8+/-2.1 CD 1
years NNS 0
) ) 0
were VBD 0
randomized VBN 0
to TO 0
6 CD 0
weeks NNS 0
of IN 0
open JJ 0
treatment NN 0
with IN 0
olanzapine NN 0
or CC 0
haloperidol NN 0
. . 0

Mean NNP 0
final JJ 0
dosages NNS 0
were VBD 0
7.9+/-2.5 JJ 0
mg/day NN 0
for IN 0
olanzapine NN 0
and CC 0
1.4+/-0.7 JJ 0
mg/day NN 0
for IN 0
haloperidol NN 0
. . 0

Outcome NNP 0
measures NNS 0
included VBD 0
the DT 0
Clinical NNP 0
Global NNP 0
Impressions NNP 0
( ( 0
CGI NNP 0
) ) 0
and CC 0
the DT 0
Children NNP 0
's POS 0
Psychiatric NNP 0
Rating NNP 0
Scale NNP 0
( ( 0
CPRS NNP 0
) ) 0
. . 0

RESULTS NNP 0
Both NNP 0
groups NNS 0
had VBD 0
symptom VBN 0
reduction NN 0
. . 0

Five CD 0
of IN 0
six CD 0
in IN 0
the DT 0
olanzapine NN 0
group NN 0
and CC 0
three CD 0
of IN 0
six CD 0
in IN 0
the DT 0
haloperidol NN 0
group NN 0
were VBD 0
rated VBN 0
as IN 0
responders NNS 0
according VBG 0
to TO 0
the DT 0
CGI NNP 0
Improvement NNP 0
item NN 0
. . 0

Subjects NNS 0
showed VBD 0
improvement NN 0
on IN 0
the DT 0
CPRS NNP 0
Autism NNP 0
Factor NNP 0
( ( 0
F1,9 NNP 0
= NNP 0
24.4 CD 0
, , 0
p NN 0
= NNP 0
.0008 NNP 0
) ) 0
. . 0

Side JJ 0
effects NNS 0
included VBD 0
drowsiness NN 0
and CC 0
weight JJ 0
gain NN 0
. . 0

CONCLUSIONS VB 0
The DT 0
findings NNS 0
suggest VBP 0
that IN 0
olanzapine NN 0
is VBZ 0
a DT 0
promising JJ 0
treatment NN 0
for IN 0
children NNS 1
with IN 0
autistic JJ 4
disorder NN 4
. . 0

Further JJ 0
placebo-controlled JJ 0
and CC 0
long-term JJ 0
studies NNS 0
of IN 0
olanzapine NN 0
in IN 0
autistic JJ 0
disorder NN 0
are VBP 0
required VBN 0
. . 0

Double-blind NNP 0
, , 0
placebo-controlled JJ 0
trial NN 0
of IN 0
risperidone NN 0
plus CC 0
amantadine NN 0
in IN 0
children NNS 1
with IN 0
autism NN 4
: : 0
a DT 0
10-week JJ 0
randomized NN 0
study NN 0
. . 0

OBJECTIVE NNP 0
This DT 0
study NN 0
aimed VBD 0
to TO 0
investigate VB 0
the DT 0
effect NN 0
of IN 0
adding VBG 0
amantadine NN 0
to TO 0
risperidone VB 0
for IN 0
treatment NN 0
of IN 0
autism NN 0
. . 0

METHODS NNP 0
Forty NNP 3
outpatients NNS 0
aged VBD 0
4 CD 1
to12 NN 1
years NNS 0
, , 0
who WP 0
were VBD 0
diagnosed VBN 0
with IN 0
autism NN 4
spectrum NN 4
disorders NNS 4
based VBN 0
on IN 0
the DT 0
Diagnostic NNP 0
and CC 0
Statistical NNP 0
Manual NNP 0
of IN 0
Mental NNP 0
Disorders NNP 0
, , 0
Fourth NNP 0
Edition NNP 0
, , 0
Text NNP 0
Revision NNP 0
criteria NNS 0
, , 0
were VBD 0
assigned VBN 0
to TO 0
this DT 0
double-blind JJ 0
clinical JJ 0
trial NN 0
. . 0

The DT 0
subjects NNS 0
were VBD 0
divided VBN 0
randomly RB 0
into IN 0
2 CD 0
groups NNS 0
. . 0

One CD 0
group NN 0
received VBD 0
risperidone JJ 0
plus CC 0
amantadine JJ 0
, , 0
and CC 0
the DT 0
other JJ 0
group NN 0
received VBD 0
risperidone JJ 0
plus CC 0
placebo NN 0
. . 0

The DT 0
dose NN 0
of IN 0
risperidone NN 0
was VBD 0
titrated VBN 0
between IN 0
1 CD 0
and CC 0
2.0 CD 0
mg/d NN 0
, , 0
and CC 0
the DT 0
dose NN 0
of IN 0
amantadine NN 0
was VBD 0
100 CD 0
or CC 0
150 CD 0
mg/d NNS 0
for IN 0
patients NNS 0
less JJR 0
than IN 0
30 CD 0
kg NN 0
or CC 0
more JJR 0
than IN 0
30 CD 0
kg NNS 0
, , 0
respectively RB 0
. . 0

The DT 0
patients NNS 0
were VBD 0
assessed VBN 0
using VBG 0
the DT 0
Aberrant NNP 0
Behavioral NNP 0
Checklist-Community NNP 0
( ( 0
ABC-C NNP 0
) ) 0
and CC 0
adverse JJ 0
effects NNS 0
checklist NN 0
as RB 0
well RB 0
as IN 0
clinical JJ 0
global JJ 0
impression-improvement NN 0
( ( 0
CGI-I NNP 0
) ) 0
at2 VBZ 0
checkpoints NNS 0
of IN 0
5-week JJ 0
intervals NNS 0
after IN 0
the DT 0
baseline NN 0
. . 0

Informed NNP 0
consentwas NN 0
obtained VBN 0
from IN 0
the DT 0
parents NNS 0
of IN 0
each DT 0
participant NN 0
. . 0

RESULTS NNP 0
Among IN 0
ABC-C NNP 0
subscales NNS 0
, , 0
Hyperactivity NNP 0
and CC 0
Irritability NNP 0
showed VBD 0
significantly RB 0
greater JJR 0
reduction NN 0
in IN 0
the DT 0
amantadine NN 0
group NN 0
than IN 0
the DT 0
placebo NN 0
group NN 0
. . 0

There EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
in IN 0
adverse JJ 0
effects NNS 0
between IN 0
the DT 0
2 CD 0
groups NNS 0
. . 0

The DT 0
CGI-I JJ 0
scores NNS 0
show VBP 0
significant JJ 0
improvement NN 0
in IN 0
the DT 0
amantadine NN 0
group NN 0
compared VBN 0
to TO 0
the DT 0
placebo NN 0
group NN 0
. . 0

CONCLUSIONS VB 0
The DT 0
present JJ 0
study NN 0
suggests VBZ 0
that IN 0
amantadine NN 0
may MD 0
be VB 0
a DT 0
potential JJ 0
adjunctive JJ 0
treatment NN 0
strategy NN 0
for IN 0
autism NN 0
and CC 0
it PRP 0
was VBD 0
generally RB 0
well RB 0
tolerated VBN 0
. . 0

Effect NN 0
of IN 0
a DT 0
multi-faceted JJ 0
intervention NN 0
on IN 0
gingival JJ 0
health NN 0
among IN 0
adults NNS 1
with IN 0
systemic JJ 4
sclerosis NN 4
. . 0

OBJECTIVES NNP 0
To TO 0
evaluate VB 0
the DT 0
effect NN 0
of IN 0
adaptive JJ 0
oral JJ 0
hygiene NN 0
devices NNS 0
and CC 0
orofacial JJ 0
exercise NN 0
to TO 0
improve VB 0
gingival JJ 0
health NN 0
among IN 0
adults NNS 1
with IN 0
systemic JJ 4
sclerosis NN 4
( ( 0
SSc NNP 4
) ) 0
. . 0

METHODS NNP 0
Forty-eight JJ 3
patients NNS 0
with IN 0
SSc NNP 4
were VBD 0
assigned VBN 0
randomly RB 0
to TO 0
the DT 0
multifaceted VBN 0
oral JJ 0
health NN 0
intervention NN 0
or CC 0
usual JJ 0
dental JJ 0
care NN 0
control NN 0
group NN 0
. . 0

Participants NNS 0
in IN 0
the DT 0
intervention NN 0
group NN 0
received VBD 0
a DT 0
rechargeable JJ 0
, , 0
powered JJ 0
Oral-B? NNP 0
oscillating-rotating-pulsating NN 0
toothbrush NN 0
and CC 0
a DT 0
Reach? NNP 0
Access? NNP 0
Flosser NNP 0
that WDT 0
has VBZ 0
a DT 0
toothbrush-like JJ 0
handle NN 0
. . 0

For IN 0
those DT 0
with IN 0
an DT 0
oral JJ 0
aperture NN 0
of IN 0
less JJR 0
than IN 0
40 CD 0
mm NN 0
, , 0
orofacial JJ 0
exercises NNS 0
were VBD 0
taught VBN 0
. . 0

Participants NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
were VBD 0
each DT 0
given VBN 0
a DT 0
manual JJ 0
toothbrush NN 0
and CC 0
dental JJ 0
floss NN 0
. . 0

Participants NNS 0
in IN 0
both DT 0
groups NNS 0
received VBD 0
instructions NNS 0
and CC 0
demonstration NN 0
on IN 0
the DT 0
use NN 0
of IN 0
the DT 0
devices NNS 0
, , 0
and CC 0
were VBD 0
requested VBN 0
to TO 0
perform VB 0
the DT 0
respective JJ 0
intervention NN 0
twice RB 0
a DT 0
day NN 0
for IN 0
6 CD 0
months NNS 0
. . 0

Evaluations NNS 0
were VBD 0
at IN 0
baseline NN 0
, , 0
3- JJ 0
, , 0
and CC 0
6-months NNS 0
. . 0

The DT 0
main JJ 0
outcome NN 0
was VBD 0
gingival JJ 0
index NN 0
( ( 0
GI NNP 0
) ) 0
, , 0
an DT 0
indicator NN 0
of IN 0
gingival JJ 0
inflammation NN 0
. . 0

RESULTS NNP 0
Both NNP 0
groups NNS 0
showed VBD 0
significant JJ 0
reduction NN 0
in IN 0
GI NNP 0
scores NNS 0
at IN 0
6 CD 0
months NNS 0
( ( 0
ps JJ 0
< NNP 0
0.005 CD 0
) ) 0
. . 0

Reduction NN 0
in IN 0
GI NNP 0
scores NNS 0
of IN 0
the DT 0
intervention NN 0
group NN 0
at IN 0
6 CD 0
months NNS 0
was VBD 0
20.8 CD 0
% NN 0
which WDT 0
is VBZ 0
considered VBN 0
to TO 0
be VB 0
clinically RB 0
significant JJ 0
. . 0

Compared VBN 0
to TO 0
the DT 0
control NN 0
group NN 0
, , 0
the DT 0
intervention NN 0
group NN 0
showed VBD 0
a DT 0
significant JJ 0
and CC 0
larger JJR 0
reduction NN 0
in IN 0
GI NNP 0
score NN 0
by IN 0
8 CD 0
% NN 0
at IN 0
6 CD 0
months NNS 0
( ( 0
p=0.0007 NN 0
) ) 0
. . 0

CONCLUSIONS JJ 0
Results NNP 0
support NN 0
the DT 0
use NN 0
of IN 0
adaptive JJ 0
devices NNS 0
and CC 0
orofacial JJ 0
exercise NN 0
to TO 0
improve VB 0
gingival NN 0
health NN 0
in IN 0
adults NNS 0
with IN 0
SSc NNP 0
when WRB 0
compared VBN 0
to TO 0
use VB 0
of IN 0
manual JJ 0
toothbrushing NN 0
and CC 0
finger-held JJ 0
flossing NN 0
. . 0

Recommending VBG 0
and CC 0
educating VBG 0
patients NNS 0
with IN 0
SSc NNP 0
to TO 0
use VB 0
adaptive JJ 0
devices NNS 0
to TO 0
clean VB 0
the DT 0
tooth NN 0
surfaces NNS 0
looks VBZ 0
promising VBG 0
for IN 0
long-term JJ 0
oral JJ 0
health NN 0
improvement NN 0
. . 0

Effects NNS 0
of IN 0
self-directed JJ 0
stress NN 0
management NN 0
training NN 0
and CC 0
home-based JJ 0
exercise NN 0
on IN 0
stress NN 0
management NN 0
skills NNS 0
in IN 0
cancer NN 4
patients NNS 0
receiving VBG 0
chemotherapy NN 4
. . 0

Although IN 0
exercise NN 0
may MD 0
be VB 0
used VBN 0
by IN 0
some DT 0
to TO 0
decrease VB 0
distress NN 0
, , 0
little JJ 0
is VBZ 0
known VBN 0
about IN 0
how WRB 0
it PRP 0
may MD 0
contribute VB 0
to TO 0
stress VB 0
management NN 0
( ( 0
SM NNP 0
) ) 0
among IN 0
patients NNS 0
receiving VBG 0
chemotherapy NN 0
. . 0

We PRP 0
evaluated VBD 0
whether IN 0
exercise NN 0
separately RB 0
or CC 0
in IN 0
combination NN 0
with IN 0
SM NNP 0
training NN 0
is VBZ 0
effective JJ 0
at IN 0
increasing VBG 0
perceived JJ 0
ability NN 0
to TO 0
manage VB 0
stress NN 0
. . 0

Patients NNS 0
receiving VBG 0
chemotherapy NN 0
( ( 0
N NNP 0
= NNP 0
391 CD 3
) ) 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
usual JJ 0
care NN 0
only RB 0
( ( 0
UCO NNP 0
) ) 0
, , 0
SM NNP 0
, , 0
exercise NN 0
( ( 0
EX NNP 0
) ) 0
, , 0
or CC 0
stress JJ 0
management NN 0
and CC 0
exercise NN 0
( ( 0
SMEX NNP 0
) ) 0
. . 0

They PRP 0
completed VBD 0
the DT 0
Measure NN 0
of IN 0
Current NNP 0
Status NNP 0
prior RB 0
to TO 0
receiving VBG 0
chemotherapy NN 0
and CC 0
12 CD 0
weeks NNS 0
after IN 0
the DT 0
first JJ 0
infusion NN 0
. . 0

We PRP 0
hypothesized VBD 0
that IN 0
participants NNS 0
randomized VBN 0
to TO 0
an DT 0
intervention NN 0
condition NN 0
would MD 0
report VB 0
improvements NNS 0
in IN 0
relaxation NN 0
, , 0
awareness NN 0
of IN 0
tension NN 0
, , 0
getting VBG 0
needs NNS 0
met VBD 0
and CC 0
coping VBG 0
confidence NN 0
compared VBN 0
with IN 0
those DT 0
receiving VBG 0
UCO NNP 0
. . 0

Results NNP 0
indicated VBD 0
significant JJ 0
group-by-time JJ 0
interactions NNS 0
for IN 0
the DT 0
following NN 0
: : 0
relaxation NN 0
( ( 0
UCO NNP 0
versus NN 0
SM NNP 0
, , 0
p NN 0
= NNP 0
0.008 CD 0
) ) 0
, , 0
awareness NN 0
of IN 0
tension NN 0
( ( 0
UCO NNP 0
versus NN 0
SMEX NNP 0
, , 0
p NN 0
= VBD 0
0.029 CD 0
and CC 0
UCO NNP 0
versus NN 0
EX NNP 0
, , 0
p NN 0
< NNP 0
0.001 CD 0
) ) 0
, , 0
getting VBG 0
needs NNS 0
met VBD 0
( ( 0
UCO NNP 0
versus NN 0
SMEX NNP 0
, , 0
p NN 0
= NNP 0
0.020 CD 0
) ) 0
and CC 0
Measure NN 0
of IN 0
Current NNP 0
Status NNP 0
total NN 0
score NN 0
( ( 0
UCO NNP 0
versus NN 0
SMEX NNP 0
, , 0
p NN 0
= VBD 0
0.007 CD 0
and CC 0
UCO NNP 0
versus NN 0
EX NNP 0
, , 0
p NN 0
= NNP 0
0.016 CD 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
group-by-time JJ 0
interactions NNS 0
for IN 0
coping VBG 0
confidence NN 0
( ( 0
p-values JJ 0
> NNP 0
0.05 CD 0
) ) 0
. . 0

This DT 0
study NN 0
provides VBZ 0
support NN 0
for IN 0
including VBG 0
an DT 0
exercise NN 0
component NN 0
in IN 0
SM NNP 0
interventions NNS 0
for IN 0
cancer NN 0
patients NNS 0
receiving VBG 0
chemotherapy NN 0
( ( 0
clinicaltrials.gov JJ 0
identifier NN 0
: : 0
NCT00740038 NNP 0
) ) 0
. . 0

Intra-articular JJ 0
hyaluronic JJ 0
acid NN 0
compared VBN 0
to TO 0
exercise VB 0
therapy NN 0
in IN 0
osteoarthritis NN 4
of IN 0
the DT 0
ankle NN 4
. . 0

A DT 0
prospective JJ 0
randomized VBN 0
trial NN 0
with IN 0
long-term JJ 0
follow-up NN 0
. . 0

OBJECTIVE CC 0
The DT 0
goal NN 0
of IN 0
this DT 0
study NN 0
has VBZ 0
been VBN 0
to TO 0
determine VB 0
whether IN 0
hyaluronic JJ 0
acid NN 0
( ( 0
HA NNP 0
) ) 0
or CC 0
exercise NN 0
therapy NN 0
can MD 0
improve VB 0
functional JJ 0
parameters NNS 0
in IN 0
patients NNS 0
with IN 0
osteoarthritis NN 0
( ( 0
OA NNP 4
) ) 0
of IN 0
the DT 0
ankle NN 0
. . 0

METHODS NNP 0
In IN 0
a DT 0
prospective JJ 0
clinical JJ 0
trial NN 0
, , 0
43 CD 0
ankles NNS 0
( ( 0
30 CD 3
patients NNS 0
) ) 0
with IN 0
radiographic JJ 0
Kellgren NNP 0
Lawrence NNP 0
grade VBD 0
III NNP 0
OA NNP 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
three CD 0
intra-articular JJ 0
HA NNP 0
injections NNS 0
, , 0
with IN 0
one-week JJ 0
interval NN 0
of IN 0
or CC 0
exercise NN 0
therapy NN 0
for IN 0
six CD 0
weeks NNS 0
. . 0

Patients NNS 0
were VBD 0
evaluated VBN 0
by IN 0
the DT 0
American JJ 0
Orthopaedic NNP 0
Foot NNP 0
and CC 0
Ankle NNP 0
Society NNP 0
( ( 0
AOFAS NNP 0
) ) 0
Ankle-Hindfoot NNP 0
Scale NNP 0
and CC 0
followed-up NN 0
after IN 0
12 CD 0
months NNS 0
. . 0

RESULTS NNP 0
Total JJ 0
AOFAS NNP 0
Ankle-Hindfoot NNP 0
score NN 0
of IN 0
OA NNP 0
patients NNS 0
has VBZ 0
improved VBN 0
in IN 0
both DT 0
groups NNS 0
, , 0
varying VBG 0
from IN 0
61.6+/-16.8 JJ 0
to TO 0
90.1+/-9.7 JJ 0
with IN 0
HA NNP 0
treatment NN 0
and CC 0
from IN 0
72.1+/-16.6 JJ 0
to TO 0
87.5+/-17.5 JJ 0
using VBG 0
exercise NN 0
therapy NN 0
at IN 0
the DT 0
end NN 0
of IN 0
the DT 0
trial NN 0
( ( 0
p JJ 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
statistically RB 0
significant JJ 0
differences NNS 0
between IN 0
the DT 0
groups NNS 0
. . 0

CONCLUSION NNP 0
This DT 0
prospective JJ 0
randomized VBN 0
trial NN 0
confirmed VBD 0
that IN 0
, , 0
both DT 0
HA NNP 0
injections NNS 0
and CC 0
exercise NN 0
therapy NN 0
provide VBP 0
functional JJ 0
improvement NN 0
. . 0

However RB 0
, , 0
larger JJR 0
trials NNS 0
with IN 0
longer JJR 0
follow-up NN 0
are VBP 0
necessary JJ 0
for IN 0
more RBR 0
definite JJ 0
conclusions NNS 0
. . 0

Cytokine NN 0
levels NNS 0
and CC 0
systemic JJ 0
toxicity NN 0
in IN 0
patients NNS 0
undergoing VBG 0
isolated JJ 4
limb NN 4
perfusion NN 4
with IN 0
high-dose JJ 0
tumor NN 0
necrosis NN 0
factor NN 0
, , 0
interferon NN 0
gamma NN 0
, , 0
and CC 0
melphalan NN 0
. . 0

PURPOSE NNP 0
Isolated NNP 0
limb NN 0
perfusion NN 0
( ( 0
ILP NNP 0
) ) 0
with IN 0
tumor NN 0
necrosis NN 0
factor NN 0
( ( 0
TNF NNP 0
) ) 0
, , 0
interferon JJ 0
gamma NN 0
, , 0
and CC 0
melphalan NN 0
( ( 0
M NNP 0
) ) 0
has VBZ 0
been VBN 0
reported VBN 0
to TO 0
result VB 0
in IN 0
high JJ 0
response NN 0
rates NNS 0
for IN 0
extremity NN 0
melanoma NN 0
and CC 0
sarcoma NN 0
. . 0

We PRP 0
have VBP 0
evaluated VBN 0
the DT 0
relationship NN 0
of IN 0
systemic JJ 0
TNF NNP 0
exposure NN 0
to TO 0
induction NN 0
of IN 0
several JJ 0
secondary JJ 0
mediators NNS 0
and CC 0
incidence NN 0
of IN 0
systemic JJ 0
toxicity NN 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
Nineteen NNP 3
patients NNS 0
with IN 0
extremity NN 4
melanoma NN 4
( ( 0
n JJ 0
= NNP 0
16 CD 3
) ) 0
or CC 0
sarcoma NN 4
( ( 0
n JJ 0
= NNP 0
3 CD 3
) ) 0
, , 0
underwent JJ 0
90-minute JJ 0
ILP NNP 0
with IN 0
TNF-alpha NNP 0
, , 0
interferon NN 0
gamma NN 0
( ( 0
0.2 CD 0
mg NN 0
) ) 0
, , 0
and CC 0
M NNP 0
( ( 0
10 CD 0
to TO 0
13 CD 0
mg/L NN 0
of IN 0
limb NN 0
volume NN 0
) ) 0
( ( 0
TNF/IFN/M NNP 0
) ) 0
( ( 0
n JJ 0
= NNP 0
12 CD 0
) ) 0
, , 0
or CC 0
M NNP 0
alone RB 0
( ( 0
n JJ 0
= NNP 0
7 CD 0
) ) 0
. . 0

Continuous JJ 0
intraoperative JJ 0
monitoring NN 0
( ( 0
CIM NNP 0
) ) 0
for IN 0
systemic JJ 0
leak NN 0
from IN 0
the DT 0
perfusion NN 0
circuit NN 0
was VBD 0
performed VBN 0
using VBG 0
radioactive JJ 0
iodine-131 JJ 0
albumin NN 0
. . 0

Cytokine NN 0
levels NNS 0
in IN 0
the DT 0
perfusate NN 0
and CC 0
systemic JJ 0
circulation NN 0
during IN 0
and CC 0
after IN 0
ILP NNP 0
were VBD 0
measured VBN 0
by IN 0
enzyme-linked JJ 0
immunosorbent NN 0
assay NN 0
. . 0

RESULTS NNP 0
Systemic NNP 0
leaks VBZ 0
> CD 0
or CC 0
= VB 0
1 CD 0
% NN 0
from IN 0
the DT 0
perfusion NN 0
circuit NN 0
occurred VBD 0
in IN 0
six CD 0
patients NNS 0
who WP 0
received VBD 0
TNF/IFN/M NNP 0
and CC 0
in IN 0
four CD 0
who WP 0
received VBD 0
M NNP 0
alone RB 0
. . 0

Hypotension NNP 0
that IN 0
required VBD 0
vasopressor NN 0
support NN 0
occurred VBD 0
in IN 0
six CD 0
of IN 0
six CD 0
patients NNS 0
with IN 0
evidence NN 0
of IN 0
a DT 0
leak NN 0
( ( 0
> CD 0
or CC 0
= VB 0
1 CD 0
% NN 0
) ) 0
and CC 0
zero CD 0
of IN 0
six CD 0
patients NNS 0
without IN 0
a DT 0
leak NN 0
( ( 0
< JJ 0
1 CD 0
% NN 0
) ) 0
. . 0

These DT 0
six CD 0
patients NNS 0
had VBD 0
significantly RB 0
higher JJR 0
peak JJ 0
systemic JJ 0
TNF NNP 0
levels NNS 0
during IN 0
and CC 0
after IN 0
perfusion NN 0
than IN 0
patients NNS 0
without IN 0
a DT 0
leak NN 0
( ( 0
2.8 CD 0
and CC 0
8.2 CD 0
ng/mL JJ 0
v NN 0
0.7 CD 0
and CC 0
2.0 CD 0
ng/mL NN 0
, , 0
respectively RB 0
; : 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
. . 0

All PDT 0
patients NNS 0
who WP 0
received VBD 0
TNF/IFN/M NNP 0
had VBD 0
significantly RB 0
greater JJR 0
increases NNS 0
in IN 0
systemic JJ 0
interleukin-6 JJ 0
( ( 0
IL-6 NNP 0
) ) 0
levels NNS 0
than IN 0
in IN 0
patients NNS 0
with IN 0
M NNP 0
alone RB 0
( ( 0
12,395 CD 0
+/- JJ 0
10,374 CD 0
pg/mL NN 0
v NN 0
79.4 CD 0
+/- JJ 0
7.2 CD 0
pg/mL NN 0
, , 0
respectively RB 0
; : 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

Intracellular JJ 0
adhesion NN 0
molecule NN 0
( ( 0
ICAM NNP 0
) ) 0
, , 0
IL-8 NNP 0
, , 0
and CC 0
TNF-R JJ 0
levels NNS 0
were VBD 0
also RB 0
increased VBN 0
after IN 0
ILP NNP 0
with IN 0
TNF/IFN/M NNP 0
. . 0

CONCLUSION NNP 0
ILP NNP 0
with IN 0
TNF/IFN/M NNP 0
can MD 0
be VB 0
safely RB 0
performed VBN 0
, , 0
as IN 0
I131 NNP 0
albumin VBP 0
provides VBZ 0
a DT 0
sensitive JJ 0
measure NN 0
of IN 0
systemic JJ 0
leakage NN 0
from IN 0
the DT 0
perfusion NN 0
circuit NN 0
. . 0

Patients NNS 0
with IN 0
a DT 0
measured JJ 0
leak NN 0
of IN 0
> NN 0
or CC 0
= VB 0
1 CD 0
% NN 0
develop NN 0
mild NN 0
and CC 0
transient JJ 0
postoperative JJ 0
hypotension NN 0
with IN 0
significantly RB 0
higher JJR 0
systemic JJ 0
TNF NNP 0
levels NNS 0
and CC 0
lower JJR 0
perfusate NN 0
TNF NNP 0
levels NNS 0
than IN 0
in IN 0
patients NNS 0
without IN 0
leaks NNS 0
. . 0

The DT 0
influence NN 0
of IN 0
dietary JJ 0
fibre NN 0
source NN 0
and CC 0
gender NN 0
on IN 0
the DT 0
postprandial JJ 0
glucose NN 0
and CC 0
lipid JJ 0
response NN 0
in IN 0
healthy JJ 4
subjects NNS 0
. . 0

BACKGROUND NNP 0
Consumption NNP 0
of IN 0
soluble JJ 0
dietary JJ 0
fibre NN 0
is VBZ 0
correlated VBN 0
with IN 0
decreased JJ 0
postprandial JJ 0
glucose NN 0
and CC 0
insulin NN 0
responses NNS 0
and CC 0
hence NN 0
has VBZ 0
beneficial JJ 0
effects NNS 0
on IN 0
the DT 0
metabolic JJ 0
syndrome NN 0
. . 0

AIM NNP 0
OF IN 0
THE NNP 0
STUDY NNP 0
To TO 0
investigate VB 0
the DT 0
effects NNS 0
on IN 0
postprandial JJ 0
glucose NN 0
, , 0
insulin NN 0
and CC 0
triglyceride JJ 0
concentrations NNS 0
of IN 0
meals NNS 0
enriched VBN 0
with IN 0
soluble JJ 0
dietary JJ 0
fibres NNS 0
from IN 0
oats NNS 0
, , 0
rye NN 0
bran NN 0
, , 0
sugar JJ 0
beet NN 0
fibre NN 0
or CC 0
a DT 0
mixture NN 0
of IN 0
these DT 0
three CD 0
fibres NNS 0
. . 0

METHODS NNP 0
Thirteen NNP 3
healthy JJ 0
human JJ 0
volunteers NNS 0
( ( 0
6 CD 2
men NNS 2
and CC 2
7 CD 2
women NNS 2
, , 0
aged VBN 0
20-28 CD 1
years NNS 0
) ) 0
were VBD 0
included VBN 0
in IN 0
the DT 0
study NN 0
. . 0

The DT 0
subjects NNS 0
came VBD 0
to TO 0
the DT 0
study NN 0
centre NN 0
once RB 0
a DT 0
week NN 0
after IN 0
an DT 0
overnight JJ 0
fast NN 0
to TO 0
ingest VB 0
test NN 0
meals NNS 0
and CC 0
a DT 0
control NN 0
meal NN 0
in IN 0
random JJ 0
order NN 0
. . 0

The DT 0
meals NNS 0
contained VBD 0
either CC 0
oat JJ 0
powder NN 0
( ( 0
62 CD 0
g NN 0
, , 0
of IN 0
which WDT 0
2.7 CD 0
soluble JJ 0
fibre NN 0
) ) 0
, , 0
rye NN 0
bran NN 0
( ( 0
31 CD 0
g NN 0
, , 0
of IN 0
which WDT 0
1.7 CD 0
g NN 0
soluble JJ 0
fibre NN 0
) ) 0
, , 0
sugar JJ 0
beet NN 0
fibre NN 0
( ( 0
19 CD 0
g NN 0
, , 0
of IN 0
which WDT 0
5 CD 0
g NN 0
soluble JJ 0
fibre NN 0
) ) 0
, , 0
a DT 0
mixture NN 0
of IN 0
these DT 0
three CD 0
fibres NNS 0
( ( 0
74 CD 0
g NN 0
, , 0
of IN 0
which WDT 0
1.7 CD 0
g NN 0
soluble JJ 0
fibre NN 0
from IN 0
each DT 0
source NN 0
, , 0
giving VBG 0
5 CD 0
g NN 0
soluble JJ 0
fibre NN 0
) ) 0
or CC 0
no DT 0
added JJ 0
fibre NN 0
( ( 0
control NN 0
) ) 0
and CC 0
were VBD 0
all DT 0
adjusted VBN 0
to TO 0
contain VB 0
the DT 0
same JJ 0
total JJ 0
amount NN 0
of IN 0
available JJ 0
carbohydrates NNS 0
. . 0

Blood NN 0
samples NNS 0
were VBD 0
drawn VBN 0
before RB 0
and CC 0
every DT 0
30 CD 0
min NN 0
up RB 0
to TO 0
180 CD 0
min NN 0
after IN 0
the DT 0
meals NNS 0
. . 0

RESULTS NNP 0
Meals NNP 0
with IN 0
rye NN 0
bran NN 0
gave VBD 0
a DT 0
lower JJR 0
postprandial JJ 0
glucose NN 0
peak NN 0
when WRB 0
compared VBN 0
with IN 0
the DT 0
control NN 0
meal NN 0
, , 0
and CC 0
this DT 0
effect NN 0
was VBD 0
more RBR 0
pronounced JJ 0
in IN 0
women NNS 0
compared VBN 0
to TO 0
men NNS 0
. . 0

Oat NNP 0
powder NN 0
, , 0
containing VBG 0
a DT 0
low JJ 0
amount NN 0
of IN 0
total JJ 0
fibre NN 0
and CC 0
a DT 0
high JJ 0
amount NN 0
of IN 0
carbohydrates NNS 0
in IN 0
liquid NN 0
matrix NN 0
, , 0
gave VBD 0
a DT 0
higher JJR 0
incremental JJ 0
glucose JJ 0
peak NN 0
concentration NN 0
compared VBN 0
to TO 0
rye VB 0
bran NN 0
and CC 0
sugar NN 0
beet NN 0
fibre NN 0
and CC 0
higher JJR 0
insulin NN 0
incremental JJ 0
area NN 0
under IN 0
curve NN 0
compared VBN 0
to TO 0
control VB 0
. . 0

The DT 0
oat NN 0
powder NN 0
also RB 0
influenced VBD 0
the DT 0
effects NNS 0
of IN 0
the DT 0
mixed JJ 0
meal NN 0
, , 0
diminishing VBG 0
the DT 0
glucose-lowering JJ 0
effects NNS 0
. . 0

Postprandial NNP 0
triglyceride NN 0
levels NNS 0
tended VBD 0
to TO 0
be VB 0
higher JJR 0
after IN 0
all DT 0
fibre-rich JJ 0
meals NNS 0
, , 0
but CC 0
only RB 0
significant JJ 0
for IN 0
oat NN 0
powder NN 0
and CC 0
the DT 0
mixed JJ 0
meal NN 0
when WRB 0
compared VBN 0
with IN 0
the DT 0
control NN 0
meal NN 0
. . 0

CONCLUSIONS NNP 0
Postprandial NNP 0
glucose NN 0
, , 0
insulin NN 0
and CC 0
triglyceride JJ 0
concentrations NNS 0
are VBP 0
influenced VBN 0
by IN 0
dietary JJ 0
fibre-rich JJ 0
meals NNS 0
, , 0
depending VBG 0
on IN 0
fibre NN 0
source NN 0
, , 0
dose NN 0
of IN 0
soluble JJ 0
and CC 0
total JJ 0
fibre NN 0
and CC 0
possibly RB 0
gender NN 0
. . 0

Using VBG 0
baby NN 0
books NNS 0
to TO 0
increase VB 0
new JJ 4
mothers NNS 4
' POS 0
safety NN 0
practices NNS 0
. . 0

OBJECTIVE NN 0
To TO 0
determine VB 0
whether IN 0
educational JJ 0
baby NN 0
books NNS 0
are VBP 0
an DT 0
effective JJ 0
method NN 0
for IN 0
increasing VBG 0
low-income JJ 0
, , 0
first-time JJ 0
mothers NNS 0
' POS 0
safety NN 0
practices NNS 0
during IN 0
their PRP$ 0
child NN 0
's POS 0
first JJ 0
18 CD 0
months NNS 0
. . 0

METHODS NNP 0
Primiparous JJ 4
women NNS 2
( ( 0
n JJ 0
= NNP 0
167 CD 3
) ) 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
1 CD 0
of IN 0
3 CD 0
groups NNS 0
: : 0
an DT 0
educational JJ 0
book NN 0
group NN 0
, , 0
a DT 0
noneducational JJ 0
book NN 0
group NN 0
, , 0
or CC 0
a DT 0
no-book JJ 0
group NN 0
. . 0

Home NNP 0
visits NNS 0
and CC 0
interviews NNS 0
measured VBN 0
safety NN 0
practices NNS 0
when WRB 0
women NNS 0
were VBD 0
in IN 0
their PRP$ 0
third JJ 0
trimester NN 0
of IN 0
pregnancy NN 0
( ( 0
baseline NN 0
) ) 0
and CC 0
when WRB 0
their PRP$ 0
children NNS 0
were VBD 0
2 CD 0
, , 0
4 CD 0
, , 0
6 CD 0
, , 0
9 CD 0
, , 0
12 CD 0
, , 0
and CC 0
18 CD 0
months NNS 0
of IN 0
age NN 0
. . 0

RESULTS NNP 0
Women NNP 0
in IN 0
the DT 0
educational JJ 0
book NN 0
group NN 0
had VBD 0
fewer JJR 0
risks NNS 0
in IN 0
their PRP$ 0
homes NNS 0
and CC 0
exercised VBD 0
more JJR 0
safety NN 0
practices NNS 0
than IN 0
the DT 0
no-book JJ 0
group NN 0
( ( 0
- : 0
20 CD 0
% NN 0
risk NN 0
reduction NN 0
; : 0
effect NN 0
size NN 0
= NNP 0
-.30 NNP 0
) ) 0
. . 0

When WRB 0
the DT 0
safety NN 0
practices NNS 0
involved VBN 0
little JJ 0
time NN 0
or CC 0
expense NN 0
( ( 0
eg UH 0
, , 0
putting VBG 0
away RB 0
sharp JJ 0
objects NNS 0
) ) 0
, , 0
the DT 0
educational JJ 0
book NN 0
group NN 0
was VBD 0
significantly RB 0
more RBR 0
likely JJ 0
to TO 0
engage VB 0
in IN 0
these DT 0
behaviors NNS 0
than IN 0
the DT 0
no-book JJ 0
group NN 0
( ( 0
40 CD 0
% NN 0
higher JJR 0
practices NNS 0
; : 0
effect NN 0
size NN 0
= NNP 0
0.19 CD 0
) ) 0
or CC 0
noneducational JJ 0
book NN 0
group NN 0
( ( 0
27 CD 0
% NN 0
higher JJR 0
practices NNS 0
; : 0
effect NN 0
size NN 0
= NNP 0
0.13 CD 0
) ) 0
. . 0

However RB 0
, , 0
no DT 0
differences NNS 0
were VBD 0
found VBN 0
between IN 0
groups NNS 0
for IN 0
behaviors NNS 0
that WDT 0
required VBD 0
high JJ 0
effort NN 0
in IN 0
time NN 0
, , 0
money NN 0
, , 0
or CC 0
hassle NN 0
( ( 0
eg JJ 0
, , 0
installing VBG 0
latches NNS 0
on IN 0
cabinets NNS 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Educational NNP 0
baby NN 0
books NNS 0
appear VBP 0
to TO 0
be VB 0
an DT 0
easy JJ 0
and CC 0
low-cost JJ 0
way NN 0
to TO 0
increase VB 0
the DT 0
safety NN 0
practices NNS 0
of IN 0
new JJ 0
mothers NNS 0
, , 0
especially RB 0
if IN 0
the DT 0
practices NNS 0
involve VBP 0
little JJ 0
to TO 0
no DT 0
time NN 0
, , 0
money NN 0
, , 0
or CC 0
hassle NN 0
. . 0

The DT 0
effect NN 0
of IN 0
acupressure NN 0
at IN 0
the DT 0
extra JJ 0
1 CD 0
point NN 0
on IN 0
subjective JJ 0
and CC 0
autonomic JJ 0
responses NNS 0
to TO 0
needle VB 0
insertion NN 0
. . 0

BACKGROUND NNP 0
Premedication NNP 0
with IN 0
sedatives NNS 0
can MD 0
decrease VB 0
the DT 0
discomfort NN 0
associated VBN 0
with IN 0
invasive JJ 0
anesthetic JJ 0
procedures NNS 0
. . 0

Some DT 0
researchers NNS 0
have VBP 0
shown VBN 0
that IN 0
acupressure NN 0
on IN 0
the DT 0
acupuncture NN 0
extra JJ 0
1 CD 0
point NN 0
is VBZ 0
effective JJ 0
for IN 0
sedation NN 0
. . 0

We PRP 0
investigated VBD 0
whether IN 0
acupressure NN 0
on IN 0
the DT 0
extra JJ 0
1 CD 0
point NN 0
could MD 0
alleviate VB 0
the DT 0
pain NN 0
of IN 0
needle JJ 0
insertion NN 0
. . 0

METHODS NNP 0
We PRP 0
investigated VBD 0
the DT 0
effect NN 0
of IN 0
acupressure NN 0
at IN 0
the DT 0
extra JJ 0
1 CD 0
point NN 0
or CC 0
a DT 0
sham JJ 0
point NN 0
on IN 0
needle JJ 0
insertion NN 0
using VBG 0
verbal JJ 0
rating NN 0
scale NN 0
( ( 0
VRS NNP 0
) ) 0
pain NN 0
scores NNS 0
and CC 0
heart NN 0
rate NN 0
variability NN 0
( ( 0
HRV NNP 0
) ) 0
. . 0

Twenty-two NNP 3
healthy JJ 4
female NN 2
volunteers NNS 0
were VBD 0
randomly RB 0
allocated VBN 0
to TO 0
two CD 0
groups NNS 0
: : 0
the DT 0
extra JJ 0
1 CD 0
group NN 0
received VBD 0
acupressure NN 0
at IN 0
the DT 0
extra JJ 0
1 CD 0
point NN 0
, , 0
and CC 0
the DT 0
sham NN 0
group NN 0
received VBD 0
acupressure NN 0
at IN 0
a DT 0
sham JJ 0
point NN 0
. . 0

After IN 0
starting VBG 0
the DT 0
electrocardiogram NN 0
record NN 0
, , 0
a DT 0
27-gauge JJ 0
needle NN 0
was VBD 0
inserted VBN 0
into IN 0
the DT 0
skin NN 0
of IN 0
a DT 0
forearm NN 0
. . 0

Thereafter NNP 0
, , 0
another DT 0
needle NN 0
was VBD 0
inserted VBN 0
into IN 0
the DT 0
skin NN 0
of IN 0
the DT 0
other JJ 0
forearm NN 0
during IN 0
acupressure NN 0
. . 0

RESULTS JJ 0
Acupressure NN 0
at IN 0
the DT 0
extra JJ 0
1 CD 0
point NN 0
significantly RB 0
reduced VBD 0
the DT 0
VRS NNP 0
, , 0
but CC 0
acupressure NN 0
at IN 0
the DT 0
sham NN 0
increased VBD 0
the DT 0
VRS NNP 0
. . 0

Acupressure NN 0
at IN 0
the DT 0
extra JJ 0
1 CD 0
significantly RB 0
reduced VBD 0
the DT 0
low JJ 0
frequency/high JJ 0
frequency NN 0
ratio NN 0
of IN 0
HRV NNP 0
responding VBG 0
to TO 0
needle DT 0
insertion NN 0
. . 0

CONCLUSIONS JJ 0
Acupressure NN 0
at IN 0
the DT 0
extra JJ 0
1 CD 0
point NN 0
significantly RB 0
reduced VBD 0
needle JJ 0
insertion NN 0
pain NN 0
compared VBN 0
with IN 0
acupressure NN 0
at IN 0
the DT 0
sham NN 0
point NN 0
. . 0

Also RB 0
, , 0
acupressure NN 0
at IN 0
the DT 0
extra JJ 0
1 CD 0
point NN 0
significantly RB 0
reduced VBD 0
the DT 0
low JJ 0
frequency/high JJ 0
frequency NN 0
ratio NN 0
of IN 0
HRV NNP 0
responding VBG 0
to TO 0
needle VB 0
insertion NN 0
, , 0
which WDT 0
implies VBZ 0
a DT 0
reduction NN 0
in IN 0
sympathetic JJ 0
nervous JJ 0
system NN 0
activity NN 0
. . 0

Efficacy NN 0
of IN 0
amantadine NN 0
on IN 0
quality NN 0
of IN 0
life NN 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 4
hepatitis NN 4
C NNP 4
treated VBD 0
with IN 0
interferon-alpha JJ 0
and CC 0
ribavirin NN 0
: : 0
results NNS 0
from IN 0
a DT 0
randomized VBN 0
, , 0
placebo-controlled JJ 0
, , 0
double-blind JJ 0
trial NN 0
. . 0

AIM VB 0
The DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
investigate VB 0
whether IN 0
amantadine JJ 0
reduces NNS 0
deterioration NN 0
of IN 0
quality NN 0
of IN 0
life NN 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 0
hepatitis NN 0
C NNP 0
during IN 0
and CC 0
after IN 0
treatment NN 0
with IN 0
interferon-alpha JJ 0
( ( 0
IFN-alpha NNP 0
) ) 0
and CC 0
ribavirin NN 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
In IN 0
this DT 0
randomized VBN 0
, , 0
prospective JJ 0
, , 0
placebo-controlled JJ 0
, , 0
multicenter JJ 0
trial NN 0
, , 0
previously RB 0
untreated JJ 0
patients NNS 0
with IN 0
chronic JJ 4
hepatitis NN 4
C NNP 4
were VBD 0
treated VBN 0
with IN 0
IFN-alpha NNP 0
plus CC 0
ribavirin JJ 0
[ NN 0
17 CD 0
] NN 0
and CC 0
randomized VBN 0
for IN 0
treatment NN 0
with IN 0
amantadine NN 0
( ( 0
200 CD 0
mg/day NN 0
, , 0
orally RB 0
, , 0
n=136 NN 0
) ) 0
or CC 0
placebo NN 0
( ( 0
n=131 JJ 0
) ) 0
. . 0

Quality NN 0
of IN 0
life NN 0
was VBD 0
assessed VBN 0
with IN 0
the DT 0
'Profile NN 0
of IN 0
Mood NNP 0
States NNPS 0
' POS 0
scale NN 0
and CC 0
the DT 0
'Everyday JJ 0
Life NNP 0
' POS 0
questionnaire NN 0
at IN 0
baseline NN 0
, , 0
treatment NN 0
week NN 0
( ( 0
TW NNP 0
) ) 0
8 CD 0
, , 0
TW24 NNP 0
, , 0
TW48 NNP 0
, , 0
and CC 0
at IN 0
follow-up JJ 0
. . 0

RESULTS VB 0
Early JJ 0
during IN 0
treatment NN 0
at IN 0
TW8 NNP 0
, , 0
quality NN 0
of IN 0
life NN 0
was VBD 0
not RB 0
different JJ 0
between IN 0
patients NNS 0
in IN 0
the DT 0
control NN 0
and CC 0
the DT 0
amantadine NN 0
group NN 0
. . 0

At IN 0
TW24 NNP 0
, , 0
the DT 0
control NN 0
group NN 0
but CC 0
not RB 0
the DT 0
amantadine NN 0
group NN 0
, , 0
however RB 0
, , 0
showed VBD 0
significant JJ 0
deterioration NN 0
of IN 0
the DT 0
modalities NNS 0
depression NN 0
, , 0
fatigue NN 0
, , 0
and CC 0
vigor NN 0
compared VBN 0
with IN 0
baseline NN 0
. . 0

Especially RB 0
, , 0
nonresponders NNS 0
in IN 0
the DT 0
amantadine NN 0
group NN 0
showed VBD 0
significantly RB 0
lower JJR 0
deterioration NN 0
of IN 0
depression NN 0
, , 0
anger NN 0
, , 0
mind NN 0
function NN 0
, , 0
everyday JJ 0
life NN 0
, , 0
and CC 0
zest JJS 0
for IN 0
life NN 0
than IN 0
those DT 0
in IN 0
the DT 0
placebo NN 0
group NN 0
. . 0

After IN 0
treatment NN 0
, , 0
the DT 0
beneficial JJ 0
effects NNS 0
of IN 0
amantadine NN 0
disappeared VBN 0
. . 0

CONCLUSION VB 0
The DT 0
addition NN 0
of IN 0
amantadine NN 0
to TO 0
IFN-alpha NNP 0
plus CC 0
ribavirin JJ 0
combination NN 0
therapy NN 0
may MD 0
reduce VB 0
deterioration NN 0
of IN 0
depression NN 0
, , 0
fatigue NN 0
, , 0
and CC 0
vigor NN 0
during IN 0
treatment NN 0
but CC 0
does VBZ 0
not RB 0
affect JJ 0
quality NN 0
of IN 0
life NN 0
after IN 0
treatment NN 0
. . 0

Simvastatin NNP 0
reduces VBZ 0
sympathetic JJ 0
outflow NN 0
and CC 0
augments NNS 0
endothelium-independent JJ 0
dilation NN 0
in IN 0
non-hyperlipidaemic JJ 4
primary JJ 4
hypertension NN 4
. . 0

OBJECTIVES NNP 0
Previous JJ 0
reports NNS 0
, , 0
involving VBG 0
hypercholesterolaemic JJ 0
hypertensive JJ 0
subjects NNS 0
, , 0
that IN 0
statins VBZ 0
reduce VB 0
muscle NN 0
sympathetic JJ 0
nerve NN 0
activity NN 0
( ( 0
MSNA NNP 0
) ) 0
did VBD 0
not RB 0
investigate VB 0
potential JJ 0
neural JJ 0
sites NNS 0
of IN 0
such JJ 0
sympathoinhibition NN 0
or CC 0
determine VB 0
its PRP$ 0
consequences NNS 0
for IN 0
endothelial JJ 0
function NN 0
or CC 0
insulin NN 0
resistance NN 0
. . 0

This DT 0
study NN 0
of IN 0
hypertensive JJ 4
subjects NNS 4
with IN 4
lower JJR 4
plasma NN 4
cholesterol NN 4
tested VBD 0
the DT 0
hypotheses NNS 0
that WDT 0
lipophilic JJ 0
simvastatin NN 0
would MD 0
attenuate VB 0
resting VBG 0
sympathoexcitation NN 0
and CC 0
augment NN 0
baroreflex JJ 0
modulation NN 0
of IN 0
MSNA NNP 0
and CC 0
heart NN 0
rate NN 0
( ( 0
HR NNP 0
) ) 0
, , 0
flow-mediated JJ 0
vasodilation NN 0
and CC 0
insulin NN 0
sensitivity NN 0
. . 0

DESIGN NNP 0
Prospective NNP 0
, , 0
randomised VBD 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
crossover NN 0
study NN 0
. . 0

SETTING NNP 0
Academic NNP 0
hospital-based JJ 0
study NN 0
. . 0

PATIENTS NNP 0
Fourteen JJ 0
non-hyperlipidaemic JJ 0
primary JJ 0
hypertensive JJ 0
subjects NNS 0
( ( 0
10 CD 0
men NNS 0
; : 0
overall JJ 0
mean?SD NN 0
age NN 0
58?12 CD 0
years NNS 0
) ) 0
. . 0

INTERVENTIONS NNP 0
Four NNP 0
weeks NNS 0
of IN 0
simvastatin NN 0
( ( 0
80 CD 0
mg/day NN 0
) ) 0
or CC 0
placebo NN 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURES NNP 0
Resting NNP 0
blood NN 0
pressure NN 0
( ( 0
BP NNP 0
) ) 0
, , 0
HR NNP 0
, , 0
MSNA NNP 0
, , 0
spontaneous JJ 0
arterial JJ 0
baroreflex NN 0
MSNA NNP 0
and CC 0
HR NNP 0
modulation NN 0
, , 0
endothelium-dependent JJ 0
and CC 0
endothelium-independent JJ 0
vasodilation NN 0
, , 0
and CC 0
the DT 0
homoeostatic JJ 0
model NN 0
assessment NN 0
of IN 0
insulin NN 0
resistance NN 0
( ( 0
HOMA-IR NNP 0
) ) 0
. . 0

RESULTS NNP 0
Simvastatin NNP 0
lowered VBD 0
MSNA NNP 0
burst JJ 0
frequency NN 0
( ( 0
from IN 0
32?12 CD 0
to TO 0
25?9 CD 0
bursts/min NN 0
) ) 0
and CC 0
MSNA NNP 0
burst NN 0
incidence NN 0
( ( 0
from IN 0
55?23 CD 0
% NN 0
to TO 0
43?17 CD 0
% NN 0
; : 0
all DT 0
p VBP 0
< $ 0
0.01 CD 0
) ) 0
without IN 0
affecting VBG 0
BP NNP 0
, , 0
HR NNP 0
, , 0
baroreflex JJ 0
modulation NN 0
of IN 0
either DT 0
MSNA NNP 0
or CC 0
HR NNP 0
, , 0
or CC 0
HR NNP 0
variability NN 0
( ( 0
all DT 0
p VBP 0
> $ 0
0.05 CD 0
) ) 0
. . 0

Plasma NNP 0
glucose NN 0
, , 0
insulin NN 0
, , 0
HOMA-IR NNP 0
and CC 0
endothelium-dependent JJ 0
vasodilation NN 0
( ( 0
all DT 0
p VBP 0
> $ 0
0.05 CD 0
) ) 0
were VBD 0
unchanged JJ 0
, , 0
whereas JJ 0
endothelium-independent JJ 0
vasodilation NN 0
increased VBD 0
( ( 0
7.1?3.8 CD 0
% NN 0
to TO 0
9.7?3.9 CD 0
% NN 0
, , 0
n=13 RB 0
; : 0
p VB 0
< $ 0
0.01 CD 0
) ) 0
. . 0

The DT 0
fall NN 0
in IN 0
MSNA NNP 0
was VBD 0
unrelated JJ 0
to TO 0
the DT 0
decrease NN 0
in IN 0
low-density NN 0
lipoprotein NN 0
cholesterol NN 0
( ( 0
r=0.41 NN 0
, , 0
p=0.14 NN 0
) ) 0
. . 0

CONCLUSIONS NNP 0
These DT 0
findings NNS 0
are VBP 0
consistent JJ 0
with IN 0
the DT 0
concept NN 0
that IN 0
, , 0
in IN 0
non-hyperlipidaemic JJ 0
subjects NNS 0
with IN 0
primary JJ 0
hypertension NN 0
, , 0
simvastatin JJ 0
causes VBZ 0
a DT 0
cholesterol-independent JJ 0
reduction NN 0
in IN 0
an DT 0
elevated JJ 0
central JJ 0
set-point NN 0
for IN 0
MSNA NNP 0
, , 0
without IN 0
affecting VBG 0
arterial JJ 0
baroreflex JJ 0
modulation NN 0
of IN 0
either DT 0
MSNA NNP 0
or CC 0
HR NNP 0
. . 0

There EX 0
may MD 0
be VB 0
less JJR 0
neurogenic JJ 0
constraint NN 0
on IN 0
endothelium-independent JJ 0
vasodilation NN 0
as IN 0
a DT 0
consequence NN 0
. . 0

Paricalcitol NNP 0
capsule NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
secondary JJ 4
hyperparathyroidism NN 4
in IN 0
stages NNS 4
3 CD 4
and CC 4
4 CD 4
CKD NNP 4
. . 0

BACKGROUND NNP 0
The DT 0
safety NN 0
and CC 0
efficacy NN 0
of IN 0
paricalcitol NN 0
injection NN 0
have VBP 0
been VBN 0
well RB 0
established VBN 0
for IN 0
the DT 0
prevention NN 0
and CC 0
treatment NN 0
of IN 0
secondary JJ 0
hyperparathyroidism NN 0
( ( 0
SHPT NNP 4
) ) 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 4
kidney NN 4
disease NN 4
( ( 0
CKD NNP 4
) ) 0
stage NN 4
5 CD 4
. . 0

The DT 0
capsule JJ 0
form NN 0
of IN 0
paricalcitol NN 0
was VBD 0
developed VBN 0
to TO 0
provide VB 0
a DT 0
convenient JJ 0
dosage NN 0
form NN 0
for IN 0
patients NNS 0
with IN 0
stages NNS 0
3 CD 0
and CC 0
4 CD 0
CKD NNP 0
. . 0

METHODS NNP 0
Three NNP 0
randomized VBD 0
, , 0
placebo-controlled JJ 0
, , 0
phase-3 JJ 0
trials NNS 0
were VBD 0
conducted VBN 0
in IN 0
patients NNS 0
with IN 0
stages NNS 0
3 CD 0
and CC 0
4 CD 0
CKD NNP 0
with IN 0
SHPT NNP 0
. . 0

Enrollment NNP 0
criteria NNS 0
included VBD 0
an DT 0
estimated VBN 0
glomerular JJ 0
filtration NN 0
rate NN 0
between IN 0
15 CD 0
and CC 0
60 CD 0
mL/min/1.73 NN 0
m2 NN 0
( ( 0
0.25 CD 0
and CC 0
1.00 CD 0
mL/s/1.73 NNS 0
m2 NN 0
) ) 0
, , 0
an DT 0
average NN 0
of IN 0
2 CD 0
consecutive JJ 0
intact JJ 0
parathyroid NN 0
hormone NN 0
( ( 0
iPTH NN 0
) ) 0
levels NNS 0
greater JJR 0
than IN 0
150 CD 0
pg/mL NN 0
( ( 0
ng/L JJ 0
) ) 0
, , 0
2 CD 0
consecutive JJ 0
serum NN 0
calcium NN 0
levels NNS 0
between IN 0
8.0 CD 0
and CC 0
10.0 CD 0
mg/dL NN 0
( ( 0
2.00 CD 0
and CC 0
2.50 CD 0
mmol/L NN 0
) ) 0
, , 0
and CC 0
2 CD 0
consecutive JJ 0
serum NN 0
phosphorus NN 0
levels NNS 0
of IN 0
5.2 CD 0
mg/dL NN 0
or CC 0
less JJR 0
( ( 0
< NN 0
or CC 0
= $ 0
1.68 CD 0
mmol/L NN 0
) ) 0
. . 0

Two CD 0
studies NNS 0
used VBD 0
a DT 0
thrice-weekly JJ 0
dosing NN 0
regimen NNS 0
and CC 0
1 CD 0
study NN 0
used VBD 0
a DT 0
once-daily JJ 0
dosing NN 0
regimen NNS 0
for IN 0
24 CD 0
weeks NNS 0
. . 0

Dosing NNP 0
was VBD 0
based VBN 0
on IN 0
serum NN 0
iPTH NN 0
, , 0
calcium NN 0
, , 0
and CC 0
phosphorus NN 0
levels NNS 0
. . 0

The DT 0
primary JJ 0
efficacy JJ 0
end NN 0
point NN 0
is VBZ 0
2 CD 0
consecutive JJ 0
decreases NNS 0
in IN 0
iPTH NN 0
levels NNS 0
greater JJR 0
than IN 0
30 CD 0
% NN 0
from IN 0
baseline NN 0
. . 0

RESULTS NNP 0
Two CD 3
hundred VBD 3
twenty NN 3
patients NNS 0
participated VBD 0
( ( 0
n JJ 0
= NN 0
107 CD 3
, , 0
paricalcitol NN 0
; : 0
n CC 0
= $ 0
113 CD 3
, , 0
placebo NN 0
) ) 0
. . 0

At IN 0
least JJS 0
2 CD 0
consecutive JJ 0
decreases NNS 0
in IN 0
iPTH JJ 0
levels NNS 0
of IN 0
30 CD 0
% NN 0
or CC 0
greater JJR 0
from IN 0
baseline NN 0
occurred VBN 0
in IN 0
91 CD 0
% NN 0
of IN 0
paricalcitol JJ 0
versus FW 0
13 CD 0
% NN 0
of IN 0
placebo NN 0
patients NNS 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

Incidences NNS 0
of IN 0
hypercalcemia NN 0
, , 0
hyperphosphatemia NN 0
, , 0
and CC 0
elevated VBD 0
calcium-phosphorus JJ 0
product NN 0
levels NNS 0
were VBD 0
not RB 0
significantly RB 0
different JJ 0
between IN 0
groups NNS 0
. . 0

Similarly RB 0
, , 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
urinary JJ 0
calcium NN 0
and CC 0
phosphorus JJ 0
excretion NN 0
or CC 0
deterioration NN 0
in IN 0
kidney NN 0
function NN 0
were VBD 0
detected VBN 0
in IN 0
patients NNS 0
administered VBN 0
paricalcitol NNS 0
compared VBN 0
with IN 0
placebo NN 0
. . 0

CONCLUSION NNP 0
Paricalcitol NNP 0
capsule NN 0
was VBD 0
well RB 0
tolerated VBN 0
and CC 0
effectively RB 0
decreased VBN 0
iPTH NN 0
levels NNS 0
with IN 0
minimal JJ 0
or CC 0
no DT 0
impact NN 0
on IN 0
calcium NN 0
levels NNS 0
, , 0
phosphorus NN 0
balance NN 0
, , 0
and CC 0
kidney NN 0
function NN 0
in IN 0
patients NNS 0
with IN 0
stages NNS 0
3 CD 0
and CC 0
4 CD 0
CKD NNP 0
. . 0

Cognitive-behavioural JJ 0
stress NN 0
management NN 0
with IN 0
HIV-positive JJ 4
homosexual JJ 0
men NNS 2
: : 0
mechanisms NNS 0
of IN 0
sustained JJ 0
reductions NNS 0
in IN 0
depressive JJ 0
symptoms NNS 0
. . 0

BACKGROUND IN 0
We PRP 0
examined VBD 0
the DT 0
sustained JJ 0
efficacy NN 0
of IN 0
a DT 0
group-based JJ 0
cognitive-behavioural JJ 0
stress NN 0
management NN 0
( ( 0
CBSM NNP 0
) ) 0
intervention NN 0
in IN 0
comparison NN 0
to TO 0
a DT 0
modified VBN 0
wait-list NN 0
control NN 0
condition NN 0
on IN 0
measures NNS 0
of IN 0
mood NN 0
, , 0
coping VBG 0
and CC 0
social JJ 0
support NN 0
in IN 0
mildly RB 0
symptomatic JJ 0
HIV-positive JJ 4
homosexual JJ 4
and CC 0
bisexual JJ 4
men NNS 2
. . 0

Participants NNS 0
were VBD 0
recruited VBN 0
largely RB 0
during IN 0
the DT 0
era NN 0
prior RB 0
to TO 0
highly RB 0
active JJ 0
antiretroviral JJ 0
therapy NN 0
( ( 0
HAART NNP 0
; : 0
1992-1997 JJ 0
) ) 0
. . 0

METHODS NNP 0
Men NNPS 0
were VBD 0
randomized VBN 0
to TO 0
either VB 0
a DT 0
10-week JJ 0
, , 0
group-based JJ 0
CBSM NNP 0
intervention NN 0
( ( 0
n JJ 0
= NNP 0
83 CD 0
) ) 0
or CC 0
a DT 0
psychoeducational JJ 0
seminar NN 0
group NN 0
( ( 0
n JJ 0
= NNP 0
46 CD 3
) ) 0
. . 0

All DT 0
participants NNS 0
completed VBD 0
a DT 0
battery NN 0
of IN 0
psychosocial JJ 0
questionnaires NNS 0
administered VBN 0
by IN 0
a DT 0
research NN 0
assistant NN 0
at IN 0
baseline NN 0
, , 0
immediately RB 0
following VBG 0
the DT 0
10-week JJ 0
CBSM NNP 0
intervention NN 0
period NN 0
, , 0
and CC 0
at IN 0
a DT 0
6-month JJ 0
follow-up NN 0
. . 0

RESULTS NNP 0
Men NNP 0
in IN 0
the DT 0
CBSM NNP 0
group NN 0
maintained VBD 0
previously RB 0
observed VBN 0
effects NNS 0
on IN 0
depressive NN 0
symptoms NNS 0
and CC 0
perceived VBD 0
social JJ 0
support NN 0
. . 0

These DT 0
sustained JJ 0
effects NNS 0
of IN 0
CBSM NNP 0
on IN 0
depressive JJ 0
symptoms NNS 0
were VBD 0
mediated VBN 0
by IN 0
10-week JJ 0
increases NNS 0
in IN 0
cognitive JJ 0
coping NN 0
( ( 0
i.e JJ 0
. . 0

positive JJ 0
reframing NN 0
) ) 0
. . 0

DISCUSSION NNP 0
CBSM NNP 0
appears VBZ 0
to TO 0
be VB 0
a DT 0
potentially RB 0
efficacious JJ 0
treatment NN 0
that WDT 0
reduces VBZ 0
and CC 0
maintains NNS 0
lower JJR 0
levels NNS 0
of IN 0
depressive NN 0
symptoms NNS 0
and CC 0
enhances VBZ 0
social JJ 0
support NN 0
in IN 0
HIV-positive JJ 0
homosexual JJ 0
and CC 0
bisexual JJ 0
men NNS 0
. . 0

In IN 0
particular JJ 0
, , 0
changes NNS 0
in IN 0
positive JJ 0
reframing NN 0
during IN 0
the DT 0
10-week JJ 0
intervention NN 0
period NN 0
remain VBP 0
a DT 0
crucial JJ 0
factor NN 0
contributing VBG 0
to TO 0
sustained VBN 0
reductions NNS 0
in IN 0
depressive JJ 0
symptoms NNS 0
. . 0

Moist NN 0
Exposed VBD 0
Burn NNP 0
Ointment NNP 0
( ( 0
MEBO NNP 0
) ) 0
in IN 0
partial JJ 4
thickness NN 4
burns NNS 4
- : 0
a DT 0
randomized JJ 0
, , 0
comparative JJ 0
open JJ 0
mono-center NN 0
study NN 0
on IN 0
the DT 0
efficacy NN 0
of IN 0
dermaheal NN 0
( ( 0
MEBO NNP 0
) ) 0
ointment NN 0
on IN 0
thermal JJ 4
2nd CD 4
degree NN 4
burns NNS 4
compared VBN 0
to TO 0
conventional JJ 0
therapy NN 0
. . 0

OBJECTIVE NNP 0
Wound NNP 0
healing NN 0
in IN 0
burn NN 0
wounds NNS 0
presents VBZ 0
a DT 0
challenge NN 0
in IN 0
healthcare NN 0
, , 0
and CC 0
there EX 0
is VBZ 0
still RB 0
a DT 0
lack NN 0
of IN 0
alternatives NNS 0
in IN 0
topical JJ 0
burn NN 0
wound NN 0
treatments NNS 0
. . 0

- : 0
The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
evaluate VB 0
the DT 0
efficacy NN 0
of IN 0
a DT 0
new JJ 0
therapeutic JJ 0
ointment NN 0
( ( 0
MEBO NNP 0
) ) 0
in IN 0
the DT 0
treatment NN 0
of IN 0
partial JJ 4
thickness NN 4
burns NNS 4
. . 0

METHODS NNP 0
40 CD 3
patients NNS 0
received VBD 0
either RB 0
topical JJ 0
treatment NN 0
with IN 0
Moist NNP 0
Exposed VBD 0
Burn NNP 0
Ointment NNP 0
( ( 0
MEBO NNP 0
) ) 0
or CC 0
standard JJ 0
Flammazine NNP 0
treatment NN 0
. . 0

All DT 0
patients NNS 0
suffered VBD 0
from IN 0
partial-thickness JJ 0
burn NN 0
injuries NNS 0
( ( 0
< VB 0
20 CD 0
% NN 0
TBSA NNP 0
) ) 0
. . 0

Wounds NNS 0
were VBD 0
evaluated VBN 0
for IN 0
60 CD 0
up RB 0
to TO 0
days NNS 0
regarding VBG 0
wound NN 0
healing NN 0
, , 0
water NN 0
loss NN 0
, , 0
inflammation NN 0
, , 0
and CC 0
pain NN 0
alleviation NN 0
. . 0

RESULTS NNP 0
For IN 0
transepidermal JJ 0
water NN 0
loss NN 0
, , 0
there EX 0
was VBD 0
a DT 0
difference NN 0
of IN 0
2.3 CD 0
gr/m2/h NN 0
between IN 0
MEBO NNP 0
, , 0
and CC 0
Flammazine NNP 0
, , 0
favoring VBG 0
MEBO NNP 0
. . 0

However RB 0
, , 0
this DT 0
difference NN 0
was VBD 0
not RB 0
statistically RB 0
significant JJ 0
( ( 0
p=0.78 NN 0
) ) 0
. . 0

For IN 0
all DT 0
secondary JJ 0
efficacy NN 0
parameter NN 0
results NNS 0
were VBD 0
similar JJ 0
. . 0

- : 0
CONCLUSIONS NN 0
This DT 0
study NN 0
showed VBD 0
that IN 0
MEBO NNP 0
ointment NN 0
for IN 0
topical JJ 0
treatment NN 0
of IN 0
burn NN 0
injuries NNS 0
presents VBZ 0
an DT 0
attractive JJ 0
alternative NN 0
for IN 0
the DT 0
topical JJ 0
treatment NN 0
of IN 0
limited JJ 4
partial JJ 4
thickness NN 4
thermal JJ 4
burns NNS 4
. . 0

Comparison NNP 0
of IN 0
antihypertensives NNS 0
after IN 0
coronary JJ 0
artery NN 0
surgery NN 0
. . 0

Hypertension NN 0
following VBG 0
coronary JJ 4
artery JJ 4
bypass NN 4
grafting NN 4
is VBZ 0
a DT 0
common JJ 0
problem NN 0
that WDT 0
may MD 0
result VB 0
in IN 0
postoperative JJ 0
myocardial JJ 0
infraction NN 0
or CC 0
bleeding NN 0
, , 0
Hemodynamic NNP 0
effects NNS 0
were VBD 0
compared VBN 0
in IN 0
45 CD 3
hypertensive JJ 4
coronary JJ 4
bypass NN 4
patients NNS 0
randomized VBN 0
to TO 0
receive VB 0
either DT 0
diltiazem NN 0
, , 0
nitroglycerin NN 0
, , 0
or CC 0
sodium NN 0
nitroprusside RB 0
. . 0

Diltiazem NNP 0
was VBD 0
administered VBN 0
as IN 0
an DT 0
intravenous JJ 0
bolus NN 0
of IN 0
0.3 CD 0
mg.kg-1 NN 0
within IN 0
5 CD 0
min NN 0
, , 0
followed VBN 0
by IN 0
infusion NN 0
of IN 0
0.1-0.8 JJ 0
mg.kg-1.h-1 NN 0
in IN 0
group NN 0
1 CD 0
. . 0

Nitroglycerin NNP 0
was VBD 0
infused VBN 0
at IN 0
a DT 0
rate NN 0
of IN 0
1-3 JJ 0
microg.kg.h-1 NN 0
in IN 0
group NN 0
2 CD 0
, , 0
and CC 0
sodium NN 0
nitroprusside NN 0
was VBD 0
given VBN 0
at IN 0
a DT 0
rate NN 0
of IN 0
1-3 JJ 0
microg.kg-1.min-1 NN 0
in IN 0
group NN 0
3 CD 0
. . 0

Hemodynamic JJ 0
measurements NNS 0
were VBD 0
carried VBN 0
out RP 0
before IN 0
infusion NN 0
( ( 0
T1 NNP 0
) ) 0
and CC 0
at IN 0
30 CD 0
min NN 0
( ( 0
T2 NNP 0
) ) 0
, , 0
2 CD 0
h NN 0
( ( 0
T3 NNP 0
) ) 0
, , 0
and CC 0
12 CD 0
h NN 0
( ( 0
T4 NNP 0
) ) 0
after IN 0
initiation NN 0
of IN 0
treatment NN 0
in IN 0
the DT 0
intensive JJ 0
care NN 0
unit NN 0
. . 0

Mean NNP 0
arterial JJ 0
pressure NN 0
decreased VBN 0
significantly RB 0
in IN 0
all DT 0
groups NNS 0
. . 0

There EX 0
were VBD 0
no DT 0
differences NNS 0
among IN 0
groups NNS 0
at IN 0
T1 NNP 0
and CC 0
T2 NNP 0
. . 0

At IN 0
T3 NNP 0
, , 0
heart NN 0
rate NN 0
in IN 0
group NN 0
2 CD 0
was VBD 0
significantly RB 0
higher JJR 0
than IN 0
group NN 0
1 CD 0
. . 0

At IN 0
T3 NNP 0
and CC 0
T4 NNP 0
, , 0
the DT 0
double JJ 0
product NN 0
was VBD 0
highest JJS 0
in IN 0
group NN 0
3 CD 0
( ( 0
group NN 0
1 CD 0
vs. NN 0
3 CD 0
, , 0
p NN 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

These DT 0
results NNS 0
suggest VBP 0
that IN 0
the DT 0
hemodynamic JJ 0
effects NNS 0
of IN 0
the DT 0
3 CD 0
drugs NNS 0
are VBP 0
similar JJ 0
within IN 0
the DT 0
first JJ 0
30 CD 0
min NN 0
. . 0

However RB 0
, , 0
after IN 0
30 CD 0
min NN 0
, , 0
diltiazem NN 0
affords NNS 0
better RBR 0
myocardial JJ 0
performance NN 0
and CC 0
more RBR 0
effective JJ 0
control NN 0
of IN 0
hypertension NN 0
. . 0

Effectiveness NN 0
and CC 0
safety NN 0
of IN 0
the DT 0
Levitan NNP 0
FPS NNP 0
Scope? NNP 0
for IN 0
tracheal JJ 0
intubation NN 0
under IN 0
general JJ 0
anesthesia NN 0
with IN 0
a DT 0
simulated JJ 0
difficult JJ 0
airway NN 0
. . 0

PURPOSE NNP 0
Studies NNP 0
show VBP 0
that IN 0
the DT 0
Levitan NNP 0
FPS NNP 0
( ( 0
first JJ 0
pass NN 0
success NN 0
) ) 0
Scope? NNP 0
( ( 0
LFS NNP 0
) ) 0
is VBZ 0
analogous JJ 0
to TO 0
a DT 0
bougie NN 0
in IN 0
simulated JJ 0
difficult JJ 0
airways NNS 0
with IN 0
comparable JJ 0
tracheal JJ 0
intubation NN 0
success NN 0
rates NNS 0
. . 0

In IN 0
this DT 0
study NN 0
, , 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
tracheal JJ 0
intubation NN 0
with IN 0
the DT 0
LFS NNP 0
was VBD 0
compared VBN 0
with IN 0
that DT 0
of IN 0
the DT 0
Macintosh NNP 0
laryngoscope NN 0
utilizing VBG 0
manual JJ 0
in-line JJ 0
stabilization NN 0
( ( 0
MILS NNP 0
) ) 0
to TO 0
simulate VB 0
difficult JJ 0
airways NNS 0
. . 0

METHODS NNP 0
Ninety-four JJ 0
subjects NNS 0
successfully RB 0
completed VBD 0
the DT 0
trial NN 0
. . 0

Manual JJ 0
in-line JJ 0
stabilization NN 0
of IN 0
the DT 0
cervical JJ 0
spine NN 0
was VBD 0
applied VBN 0
and CC 0
the DT 0
initial JJ 0
laryngoscopy NN 0
was VBD 0
performed VBN 0
using VBG 0
either CC 0
the DT 0
Macintosh NNP 0
or CC 0
the DT 0
LFS NNP 0
in IN 0
conjunction NN 0
with IN 0
the DT 0
Macintosh NNP 0
. . 0

Following VBG 0
the DT 0
initial JJ 0
grading NN 0
, , 0
a DT 0
second JJ 0
laryngoscopy NN 0
was VBD 0
repeated VBN 0
using VBG 0
the DT 0
second JJ 0
randomized JJ 0
technique NN 0
. . 0

Cormack-Lehane NNP 0
grades NNS 0
, , 0
percentage NN 0
of IN 0
glottic JJ 0
opening NN 0
( ( 0
POGO NNP 0
) ) 0
scores VBZ 0
, , 0
time NN 0
to TO 0
intubate VB 0
, , 0
number NN 0
of IN 0
intubation NN 0
attempts NNS 0
, , 0
and CC 0
the DT 0
use NN 0
of IN 0
alternate NN 0
techniques NNS 0
were VBD 0
recorded VBN 0
. . 0

The DT 0
anesthesiologist NN 0
rated VBD 0
the DT 0
subjective JJ 0
difficulty NN 0
in IN 0
using VBG 0
each DT 0
technique NN 0
with IN 0
a DT 0
numeric JJ 0
rating NN 0
scale NN 0
and CC 0
a DT 0
visual JJ 0
rating NN 0
scale NN 0
. . 0

RESULTS NNP 0
There EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
in IN 0
the DT 0
primary JJ 0
outcome NN 0
good JJ 0
laryngoscopic NN 0
views NNS 0
( ( 0
Cormack-Lehane NNP 0
grade VBD 0
1 CD 0
and CC 0
2 CD 0
) ) 0
compared VBN 0
with IN 0
poor JJ 0
laryngoscopic JJ 0
views NNS 0
( ( 0
Cormack-Lehane NNP 0
grade VBD 0
3 CD 0
and CC 0
4 CD 0
) ) 0
between IN 0
the DT 0
LFS NNP 0
and CC 0
the DT 0
Macintosh NNP 0
. . 0

There EX 0
were VBD 0
higher JJR 0
POGO NNP 0
scores NNS 0
with IN 0
the DT 0
LFS NNP 0
compared VBN 0
with IN 0
the DT 0
Macintosh NNP 0
( ( 0
80 CD 0
% NN 0
vs JJ 0
20 CD 0
% NN 0
, , 0
respectively RB 0
; : 0
P NNP 0
< NNP 0
0.0001 CD 0
) ) 0
, , 0
but CC 0
this DT 0
did VBD 0
not RB 0
translate VB 0
to TO 0
easier JJR 0
intubations NNS 0
, , 0
as IN 0
documented VBN 0
by IN 0
the DT 0
need NN 0
for IN 0
an DT 0
alternate JJ 0
intubation NN 0
technique NN 0
or CC 0
time NN 0
to TO 0
intubate VB 0
( ( 0
< JJ 0
30 CD 0
and CC 0
< $ 0
60 CD 0
sec NN 0
, , 0
respectively RB 0
) ) 0
. . 0

The DT 0
incidence NN 0
of IN 0
mucosal NN 0
trauma NN 0
, , 0
sore RB 0
throat NN 0
, , 0
and CC 0
hemodynamic JJ 0
responses NNS 0
did VBD 0
not RB 0
differ VB 0
significantly RB 0
between IN 0
the DT 0
two CD 0
techniques NNS 0
. . 0

CONCLUSION VB 0
The DT 0
LFS NNP 0
in IN 0
conjunction NN 0
with IN 0
the DT 0
Macintosh NNP 0
laryngoscope NN 0
does VBZ 0
not RB 0
improve VB 0
the DT 0
efficacy NN 0
or CC 0
safety NN 0
of IN 0
tracheal JJ 0
intubation NN 0
in IN 0
a DT 0
simulated JJ 0
difficult JJ 0
airway NN 0
. . 0

Human NNP 0
recombinant JJ 0
GM-CSF NNP 0
in IN 0
allogeneic JJ 0
bone NN 0
marrow NN 0
transplantation NN 0
for IN 0
leukaemia NN 0
: : 0
double-blind JJ 0
placebo NN 0
controlled VBN 0
trial NN 0
. . 0

A DT 0
double-blind NN 0
randomised VBN 0
trial NN 0
compared VBN 0
20 CD 3
patients NNS 0
with IN 0
leukaemia JJ 4
receiving VBG 0
human JJ 0
recombinant JJ 0
granulocyte NN 0
macrophage NN 0
colony NN 0
stimulating VBG 0
factor NN 0
( ( 0
GM NNP 0
CSF NNP 0
) ) 0
, , 0
with IN 0
20 CD 3
patients NNS 0
receiving VBG 0
placebo NN 0
for IN 0
14 CD 0
days NNS 0
after IN 0
allogeneic JJ 0
matched VBD 0
sibling VBG 0
bone NN 0
marrow NN 0
transplantation NN 0
. . 0

The DT 0
median JJ 0
neutrophil NN 0
count NN 0
at IN 0
14 CD 0
days NNS 0
was VBD 0
significantly RB 0
higher JJR 0
in IN 0
the DT 0
GM NNP 0
CSF NNP 0
group NN 0
( ( 0
1.90 CD 0
vs. FW 0
0.46 CD 0
x $ 0
10 CD 0
( ( 0
9 CD 0
) ) 0
/l NN 0
) ) 0
. . 0

The DT 0
duration NN 0
of IN 0
hospital NN 0
stay NN 0
, , 0
the DT 0
number NN 0
of IN 0
antibiotic JJ 0
days NNS 0
, , 0
and CC 0
the DT 0
number NN 0
of IN 0
fever JJ 0
days NNS 0
was VBD 0
the DT 0
same JJ 0
for IN 0
both DT 0
patient JJ 0
groups NNS 0
. . 0

The DT 0
lymphocyte NN 0
count NN 0
was VBD 0
significantly RB 0
higher JJR 0
in IN 0
the DT 0
GM-CSF NNP 0
group NN 0
than IN 0
in IN 0
the DT 0
placebo NN 0
group NN 0
between IN 0
days NNS 0
10 CD 0
and CC 0
15 CD 0
after IN 0
transplantation NN 0
. . 0

The DT 0
GM-CSF NNP 0
group NN 0
had VBD 0
lower JJR 0
haemoglobin NN 0
concentrations NNS 0
and CC 0
platelets NNS 0
counts NNS 0
, , 0
and CC 0
higher JJR 0
plasma NN 0
urea JJ 0
creatinine NN 0
and CC 0
bilirubin NN 0
, , 0
than IN 0
the DT 0
placebo NN 0
group NN 0
. . 0

There EX 0
was VBD 0
no DT 0
evidence NN 0
that IN 0
GM NNP 0
CSF NNP 0
was VBD 0
associated VBN 0
with IN 0
a DT 0
greater JJR 0
incidence NN 0
of IN 0
leukaemic JJ 0
relapse NN 0
. . 0

Gamma-hydroxybutyric JJ 0
acid NN 0
versus NN 0
clomethiazole NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
alcohol NN 4
withdrawal NN 4
syndrome NN 4
in IN 0
a DT 0
medical JJ 0
intensive JJ 0
care NN 0
unit NN 0
: : 0
an DT 0
open JJ 0
, , 0
single-center JJ 0
randomized VBN 0
study NN 0
. . 0

BACKGROUND NNP 0
Clomethiazole NNP 0
( ( 0
CLO NNP 0
) ) 0
has VBZ 0
been VBN 0
shown VBN 0
to TO 0
be VB 0
effective JJ 0
in IN 0
treating VBG 0
alcohol NN 4
withdrawal NN 4
syndrome NN 4
( ( 0
AWS NNP 4
) ) 0
. . 0

Gamma-Hydroxybutyric JJ 0
acid NN 0
( ( 0
GHB NNP 0
) ) 0
has VBZ 0
also RB 0
been VBN 0
introduced VBN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
alcoholic JJ 0
patients NNS 0
and CC 0
is VBZ 0
effective JJ 0
in IN 0
surgical JJ 0
intensive JJ 0
care NN 0
unit NN 0
( ( 0
ICU NNP 0
) ) 0
patients NNS 0
in IN 0
preventing VBG 0
and CC 0
treating VBG 0
AWS NNP 0
. . 0

There EX 0
are VBP 0
no DT 0
comparative JJ 0
studies NNS 0
between IN 0
CLO NNP 0
and CC 0
GHB NNP 0
in IN 0
a DT 0
medical JJ 0
ICU NNP 0
setting NN 0
. . 0

METHODS NNP 0
Twenty-six NNP 3
alcoholic JJ 0
patients NNS 0
with IN 0
severe JJ 0
AWS NNP 0
and CC 0
concomitant JJ 0
medical JJ 0
diseases NNS 0
were VBD 0
randomally RB 0
enrolled VBN 0
in IN 0
the DT 0
study NN 0
. . 0

CLO NNP 0
was VBD 0
given VBN 0
orally RB 0
to TO 0
12 CD 0
patients NNS 0
in IN 0
a DT 0
dosage NN 0
of IN 0
250 CD 0
mg NN 0
every DT 0
4 CD 0
hours NNS 0
as IN 0
a DT 0
liquid NN 0
; : 0
GHB NNP 0
( ( 0
initially RB 0
30 CD 0
mg/kg NNS 0
body NN 0
weight NN 0
( ( 0
BW NNP 0
) ) 0
followed VBN 0
by IN 0
15 CD 0
mg/kg NNS 0
BW NNP 0
) ) 0
was VBD 0
administered VBN 0
intravenously RB 0
to TO 0
14 CD 0
patients NNS 0
. . 0

Four CD 0
major JJ 0
AWS NNP 0
symptoms NNS 0
( ( 0
tremor NN 0
, , 0
sweating VBG 0
, , 0
nausea NN 0
, , 0
restlessness NN 0
) ) 0
were VBD 0
scored VBN 0
, , 0
and CC 0
the DT 0
administration NN 0
of IN 0
additional JJ 0
medication NN 0
was VBD 0
registered VBN 0
. . 0

RESULTS NNP 0
GHB NNP 0
was VBD 0
more RBR 0
effective JJ 0
in IN 0
treating VBG 0
AWS NNP 0
symptoms NNS 0
. . 0

In IN 0
the DT 0
GHB NNP 0
group NN 0
, , 0
AWS NNP 0
score NN 0
dropped VBD 0
from IN 0
6.6 CD 0
+/- JJ 0
2.6 CD 0
to TO 0
1.8 CD 0
+/- JJ 0
2.1 CD 0
( ( 0
p JJ 0
< NNP 0
.01 NNP 0
) ) 0
, , 0
while IN 0
in IN 0
the DT 0
CLO NNP 0
group NN 0
, , 0
the DT 0
score NN 0
dropped VBD 0
from IN 0
6 CD 0
+/- JJ 0
2.5 CD 0
to TO 0
4.1 CD 0
+/- JJ 0
2.4 CD 0
( ( 0
n. JJ 0
s. NN 0
) ) 0
. . 0

Differences NNS 0
between IN 0
groups NNS 0
were VBD 0
significant JJ 0
( ( 0
p JJ 0
=.021 NN 0
, , 0
two-way JJ 0
ANOVA NNP 0
) ) 0
. . 0

The DT 0
treatment NN 0
did VBD 0
not RB 0
alter VB 0
outcome NN 0
or CC 0
the DT 0
duration NN 0
of IN 0
ICU NNP 0
stay NN 0
. . 0

No DT 0
serious JJ 0
side NN 0
effects NNS 0
were VBD 0
detected VBN 0
. . 0

CONCLUSION NNP 0
GHB NNP 0
effectively RB 0
controls VBZ 0
AWS NNP 0
symptoms NNS 0
in IN 0
medical JJ 0
ICU NNP 0
patients NNS 0
. . 0

The DT 0
rapid JJ 0
initial JJ 0
treatment NN 0
response NN 0
of IN 0
GHB NNP 0
in IN 0
contrast NN 0
to TO 0
CLO NNP 0
has VBZ 0
no DT 0
influence NN 0
on IN 0
duration NN 0
of IN 0
patient NN 0
withdrawal NN 0
. . 0

The DT 0
development NN 0
of IN 0
a DT 0
web- JJ 0
and CC 0
a DT 0
print-based JJ 0
decision NN 0
aid NN 0
for IN 0
prostate NN 4
cancer NN 4
screening VBG 0
. . 0

BACKGROUND NNP 0
Whether NNP 0
early JJ 0
detection NN 0
and CC 0
treatment NN 0
of IN 0
prostate NN 0
cancer NN 0
( ( 0
PCa NNP 0
) ) 0
will MD 0
reduce VB 0
disease-related JJ 0
mortality NN 0
remains VBZ 0
uncertain JJ 0
. . 0

As IN 0
a DT 0
result NN 0
, , 0
tools NNS 0
are VBP 0
needed VBN 0
to TO 0
facilitate VB 0
informed JJ 0
decision NN 0
making NN 0
. . 0

While IN 0
there EX 0
have VBP 0
been VBN 0
several JJ 0
decision NN 0
aids NNS 0
( ( 0
DAs NNP 0
) ) 0
developed VBD 0
and CC 0
tested VBD 0
, , 0
very RB 0
few JJ 0
have VBP 0
included VBN 0
an DT 0
exercise NN 0
to TO 0
help VB 0
men NNS 0
clarify VB 0
their PRP$ 0
values NNS 0
and CC 0
preferences NNS 0
about IN 0
PCa NNP 0
screening NN 0
. . 0

Further NNP 0
, , 0
only RB 0
one CD 0
DA NNP 0
has VBZ 0
utilized VBN 0
an DT 0
interactive JJ 0
web-based JJ 0
format NN 0
, , 0
which WDT 0
allows VBZ 0
for IN 0
an DT 0
expansion NN 0
and CC 0
customization NN 0
of IN 0
the DT 0
material NN 0
. . 0

We PRP 0
describe VBP 0
the DT 0
development NN 0
of IN 0
two CD 0
DAs NNP 0
, , 0
a DT 0
booklet NN 0
and CC 0
an DT 0
interactive JJ 0
website NN 0
, , 0
each DT 0
with IN 0
a DT 0
values NNS 0
clarification NN 0
component NN 0
and CC 0
designed VBN 0
for IN 0
use NN 0
in IN 0
diverse JJ 0
settings NNS 0
. . 0

METHODS NNP 0
We PRP 0
conducted VBD 0
two CD 0
feasibility NN 0
studies NNS 0
to TO 0
assess VB 0
men NNS 2
's POS 2
( ( 0
45-70 CD 1
years NNS 0
) ) 0
Internet NNP 0
access NN 0
and CC 0
their PRP$ 0
willingness NN 0
to TO 0
use VB 0
a DT 0
web- JJ 0
vs. FW 0
a DT 0
print-based JJ 0
tool NN 0
. . 0

The DT 0
booklet NN 0
was VBD 0
adapted VBN 0
from IN 0
two CD 0
previous JJ 0
versions NNS 0
evaluated VBN 0
in IN 0
randomized VBN 0
controlled JJ 0
trials NNS 0
( ( 0
RCTs NNP 0
) ) 0
and CC 0
the DT 0
website NN 0
was VBD 0
created VBN 0
to TO 0
closely RB 0
match VB 0
the DT 0
content NN 0
of IN 0
the DT 0
revised JJ 0
booklet NN 0
. . 0

Usability NNP 0
testing NN 0
was VBD 0
conducted VBN 0
to TO 0
obtain VB 0
feedback NN 0
regarding VBG 0
draft JJ 0
versions NNS 0
of IN 0
the DT 0
materials NNS 0
. . 0

The DT 0
tools NNS 0
were VBD 0
also RB 0
reviewed VBN 0
by IN 0
a DT 0
plain NN 0
language NN 0
expert NN 0
and CC 0
the DT 0
interdisciplinary JJ 0
research NN 0
team NN 0
. . 0

Feedback NN 0
on IN 0
the DT 0
content NN 0
and CC 0
presentation NN 0
led VBD 0
to TO 0
iterative JJ 0
modifications NNS 0
of IN 0
the DT 0
tools NNS 0
. . 0

RESULTS VB 0
The DT 0
feasibility NN 0
studies NNS 0
confirmed VBD 0
that IN 0
the DT 0
Internet NNP 0
was VBD 0
a DT 0
viable JJ 0
medium NN 0
, , 0
as IN 0
the DT 0
majority NN 0
of IN 0
men NNS 0
used VBN 0
a DT 0
computer NN 0
, , 0
had VBD 0
access NN 0
to TO 0
the DT 0
Internet NNP 0
, , 0
and CC 0
Internet NNP 0
use NN 0
increased VBD 0
over IN 0
time NN 0
. . 0

Feedback NN 0
from IN 0
the DT 0
usability NN 0
testing VBG 0
on IN 0
the DT 0
length NN 0
, , 0
presentation NN 0
, , 0
and CC 0
content NN 0
of IN 0
the DT 0
materials NNS 0
was VBD 0
incorporated VBN 0
into IN 0
the DT 0
final JJ 0
versions NNS 0
of IN 0
the DT 0
booklet NN 0
and CC 0
website NN 0
. . 0

Both CC 0
the DT 0
feasibility NN 0
studies NNS 0
and CC 0
the DT 0
usability NN 0
testing VBG 0
highlighted VBD 0
the DT 0
need NN 0
to TO 0
address VB 0
men NNS 0
's POS 0
informed VBN 0
decision NN 0
making VBG 0
regarding VBG 0
screening NN 0
. . 0

CONCLUSIONS NNP 0
Informed NNP 0
decision NN 0
making VBG 0
for IN 0
PCa NNP 0
screening NN 0
is VBZ 0
crucial JJ 0
at IN 0
present JJ 0
and CC 0
may MD 0
be VB 0
important JJ 0
for IN 0
some DT 0
time NN 0
, , 0
particularly RB 0
if IN 0
a DT 0
definitive JJ 0
recommendation NN 0
either DT 0
for IN 0
or CC 0
against IN 0
screening VBG 0
does VBZ 0
not RB 0
emerge VB 0
from IN 0
ongoing VBG 0
prostate NN 0
cancer NN 0
screening VBG 0
trials NNS 0
. . 0

We PRP 0
have VBP 0
detailed VBN 0
our PRP$ 0
efforts NNS 0
at IN 0
developing VBG 0
print- JJ 0
and CC 0
web-based JJ 0
DAs NNP 0
to TO 0
assist VB 0
men NNS 0
in IN 0
determining VBG 0
how WRB 0
to TO 0
best VB 0
meet VB 0
their PRP$ 0
PCa NNP 0
screening NN 0
preferences NNS 0
. . 0

Following VBG 0
completion NN 0
of IN 0
our PRP$ 0
ongoing JJ 0
RCT NNP 0
designed VBN 0
to TO 0
test VB 0
these DT 0
materials NNS 0
, , 0
our PRP$ 0
goal NN 0
will MD 0
be VB 0
to TO 0
develop VB 0
a DT 0
dissemination NN 0
project NN 0
for IN 0
the DT 0
more RBR 0
effective JJ 0
tool NN 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
NCT00623090 NNP 0
. . 0

Niacin NNP 0
revisited VBD 0
. . 0

A DT 0
randomized JJ 0
, , 0
controlled JJ 0
trial NN 0
of IN 0
wax-matrix JJ 0
sustained-release JJ 0
niacin NN 0
in IN 0
hypercholesterolemia NN 4
. . 0

Two CD 3
hundred VBD 3
one CD 3
male NN 2
and CC 2
female JJ 2
subjects NNS 0
, , 0
aged VBD 0
20 CD 1
to TO 1
70 CD 1
years NNS 0
, , 0
with IN 0
elevated VBN 4
low-density NN 4
lipoprotein NN 4
cholesterol NN 0
values NNS 0
( ( 0
in IN 0
the DT 0
75th CD 4
to TO 4
95th CD 4
percentiles NNS 4
) ) 0
, , 0
participated VBN 0
in IN 0
a DT 0
randomized NN 0
, , 0
controlled VBN 0
, , 0
double-blind NN 0
study NN 0
using VBG 0
a DT 0
new JJ 0
form NN 0
of IN 0
niacin NN 0
( ( 0
Enduracin NNP 0
) ) 0
, , 0
which WDT 0
employs VBZ 0
a DT 0
wax-matrix JJ 0
vehicle NN 0
for IN 0
sustained JJ 0
release NN 0
. . 0

Four CD 0
niacin JJ 0
treatment NN 0
groups NNS 0
( ( 0
daily JJ 0
doses NNS 0
of IN 0
2000 CD 0
, , 0
1500 CD 0
, , 0
1250 CD 0
, , 0
and CC 0
1000 CD 0
mg NN 0
) ) 0
were VBD 0
compared VBN 0
with IN 0
placebo- JJ 0
and CC 0
diet-treated JJ 0
controls NNS 0
to TO 0
determine VB 0
side-effect JJ 0
profile NN 0
and CC 0
optimal JJ 0
range NN 0
of IN 0
efficacy NN 0
. . 0

The DT 0
groups NNS 0
given VBN 0
2000 CD 0
and CC 0
1500 CD 0
mg NN 0
demonstrated VBD 0
significant JJ 0
reductions NNS 0
in IN 0
values NNS 0
of IN 0
low-density NN 0
lipoprotein NN 0
cholesterol NN 0
( ( 0
-26 CD 0
% NN 0
and CC 0
-19.3 CD 0
% NN 0
, , 0
respectively RB 0
) ) 0
, , 0
total JJ 0
cholesterol NN 0
( ( 0
-18.4 CD 0
% NN 0
and CC 0
-13.3 NNP 0
% NN 0
) ) 0
, , 0
and CC 0
total JJ 0
cholesterol-high-density NN 0
lipoprotein NN 0
cholesterol NN 0
ratio NN 0
( ( 0
-20.4 CD 0
% NN 0
and CC 0
-19.4 CD 0
% NN 0
) ) 0
when WRB 0
compared VBN 0
with IN 0
diet- JJ 0
and CC 0
placebo-treated JJ 0
controls NNS 0
. . 0

Smaller NN 0
improvements NNS 0
were VBD 0
seen VBN 0
in IN 0
high-density NN 0
lipoprotein NN 0
cholesterol NN 0
and CC 0
triglyceride NN 0
levels NNS 0
. . 0

Blood NNP 0
chemistry NN 0
monitoring NN 0
indicated VBD 0
that DT 0
reduction NN 0
in IN 0
low-density NN 0
lipoprotein NN 0
cholesterol NN 0
level NN 0
strongly RB 0
correlated VBN 0
with IN 0
an DT 0
increase NN 0
in IN 0
baseline JJ 0
levels NNS 0
of IN 0
some DT 0
enzymes NNS 0
for IN 0
niacin-treated JJ 0
subjects NNS 0
. . 0

The DT 0
improved JJ 0
side-effect JJ 0
profile NN 0
of IN 0
the DT 0
wax-matrix JJ 0
form NN 0
of IN 0
niacin NN 0
was VBD 0
particularly RB 0
notable JJ 0
. . 0

The DT 0
dropout NN 0
rate NN 0
due JJ 0
to TO 0
side VB 0
effects NNS 0
was VBD 0
only RB 0
3.4 CD 0
% NN 0
and CC 0
was VBD 0
coupled VBN 0
with IN 0
good JJ 0
medication NN 0
compliance NN 0
. . 0

Hip NNP 0
protectors NNS 0
improve VBP 0
falls VBZ 0
self-efficacy NN 0
. . 0

OBJECTIVES NNP 0
To TO 0
investigate VB 0
the DT 0
effect NN 0
of IN 0
use NN 0
of IN 0
external JJ 0
hip NN 0
protectors NNS 0
on IN 0
subjects NNS 0
' POS 0
fear NN 0
of IN 0
falling VBG 0
and CC 0
falls VBZ 0
self-efficacy NN 0
( ( 0
belief NN 0
in IN 0
their PRP$ 0
own JJ 0
ability NN 0
to TO 0
avoid VB 0
falling VBG 0
) ) 0
. . 0

DESIGN NNP 0
Randomized NNP 0
controlled VBD 0
trial NN 0
. . 0

SETTING CC 0
Aged-care JJ 1
health NN 0
services NNS 0
in IN 0
Sydney NNP 0
, , 0
Australia NNP 0
. . 0

PARTICIPANTS NNP 0
131 CD 3
women NNS 2
aged VBN 0
75 CD 1
years NNS 1
or CC 1
older JJR 1
, , 0
who WP 0
had VBD 0
two CD 0
or CC 0
more JJR 0
falls NNS 4
or CC 0
one CD 0
fall NN 4
requiring VBG 4
hospital JJ 4
admission NN 4
in IN 0
the DT 0
previous JJ 0
year NN 0
and CC 0
who WP 0
live VBP 0
at IN 0
home NN 0
. . 0

Sixty-one JJ 3
subjects NNS 0
were VBD 0
in IN 0
the DT 0
intervention NN 0
group NN 0
and CC 0
70 CD 3
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

INTERVENTION NNP 0
Use NNP 0
of IN 0
external JJ 0
hip NN 0
protectors NNS 0
and CC 0
encouragement NN 0
to TO 0
use VB 0
the DT 0
protectors NNS 0
by IN 0
an DT 0
adherence NN 0
nurse NN 0
. . 0

MEASUREMENTS CC 0
At IN 0
the DT 0
time NN 0
of IN 0
enrolment NN 0
into IN 0
a DT 0
wider NN 0
study NN 0
examining VBG 0
the DT 0
effect NN 0
of IN 0
hip NN 0
protectors NNS 0
on IN 0
hip NN 0
fractures NNS 0
, , 0
participants NNS 0
recruited VBD 0
at IN 0
home NN 0
completed VBD 0
an DT 0
assessment NN 0
of IN 0
fear NN 0
of IN 0
falling VBG 0
and CC 0
falls VBZ 0
efficacy NN 0
as IN 0
measured VBN 0
by IN 0
the DT 0
Falls NNP 0
Efficacy NNP 0
Scale NNP 0
and CC 0
the DT 0
Modified NNP 0
Falls NNP 0
Efficacy NNP 0
Scale NNP 0
. . 0

At IN 0
4-month JJ 0
follow-up NN 0
, , 0
these DT 0
scales NNS 0
were VBD 0
readministered VBN 0
by IN 0
an DT 0
observer NN 0
who WP 0
was VBD 0
not RB 0
aware JJ 0
of IN 0
the DT 0
allocation NN 0
of IN 0
the DT 0
participant NN 0
to TO 0
intervention NN 0
or CC 0
control NN 0
groups NNS 0
. . 0

RESULTS NNP 0
Fear NNP 0
of IN 0
falling VBG 0
and CC 0
falls VBZ 0
self-efficacy NN 0
, , 0
as IN 0
measured VBN 0
by IN 0
the DT 0
Falls NNP 0
Efficacy NNP 0
and CC 0
Modified NNP 0
Falls NNP 0
Efficacy NNP 0
Scales NNP 0
, , 0
were VBD 0
similar JJ 0
at IN 0
baseline NN 0
in IN 0
both DT 0
groups NNS 0
. . 0

Fear NN 0
of IN 0
falling VBG 0
was VBD 0
present JJ 0
at IN 0
follow-up NN 0
in IN 0
43 CD 0
% NN 0
of IN 0
subjects NNS 0
using VBG 0
hip NN 0
protectors NNS 0
and CC 0
57 CD 0
% NN 0
of IN 0
the DT 0
control NN 0
group NN 0
( ( 0
chi2 JJ 0
= NN 0
2.58 CD 0
, , 0
P NNP 0
= NNP 0
0.11 CD 0
) ) 0
. . 0

Hip NNP 0
protector NN 0
users NNS 0
had VBD 0
greater JJR 0
improvement NN 0
in IN 0
falls VBZ 0
self-efficacy NN 0
at IN 0
follow-up JJ 0
as IN 0
measured VBN 0
by IN 0
the DT 0
Falls NNP 0
Efficacy NNP 0
Scale NNP 0
( ( 0
t JJ 0
= NN 0
2.44 CD 0
, , 0
P NNP 0
= NNP 0
0.016 CD 0
) ) 0
and CC 0
the DT 0
Modified NNP 0
Falls NNP 0
Efficacy NNP 0
Scale NNP 0
( ( 0
t JJ 0
= NN 0
2.08 CD 0
, , 0
P NNP 0
= NNP 0
0.039 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
Hip NNP 0
protectors NNS 0
improve VBP 0
falls VBZ 0
self-efficacy NN 0
. . 0

As IN 0
users NNS 0
of IN 0
hip NN 0
protectors NNS 0
feel VBP 0
more RBR 0
confident JJ 0
that IN 0
they PRP 0
can MD 0
complete VB 0
tasks NNS 0
safely RB 0
, , 0
they PRP 0
may MD 0
become VB 0
more RBR 0
physically RB 0
active JJ 0
and CC 0
require VB 0
less JJR 0
assistance NN 0
with IN 0
activities NNS 0
of IN 0
daily JJ 0
living NN 0
. . 0

Timing VBG 0
for IN 0
delivering VBG 0
individualized JJ 0
patient JJ 0
education NN 0
intervention NN 0
to TO 0
Coronary NNP 4
Artery NNP 4
Bypass NNP 4
Graft NNP 4
patients NNS 0
: : 0
An DT 0
RCT NNP 0
. . 0

BACKGROUND NNP 0
The DT 0
primary JJ 0
focus NN 0
of IN 0
this DT 0
study NN 0
is VBZ 0
on IN 0
the DT 0
timing NN 0
of IN 0
the DT 0
delivery NN 0
of IN 0
education NN 0
to TO 0
patients NNS 0
who WP 0
had VBD 0
CABG NNP 4
surgery NN 4
. . 0

AIM NNP 0
To TO 0
determine VB 0
the DT 0
efficacy NN 0
of IN 0
an DT 0
individualized JJ 0
telephone NN 0
patient JJ 0
education NN 0
intervention NN 0
, , 0
delivered VBN 0
at IN 0
two CD 0
different JJ 0
points NNS 0
in IN 0
time NN 0
( ( 0
1-2 JJ 0
days NNS 0
pre-discharge JJ 0
versus JJ 0
1-2 JJ 0
days NNS 0
post-discharge NN 0
) ) 0
in IN 0
enhancing VBG 0
the DT 0
CABG NNP 4
patient NN 0
's POS 0
knowledge NN 0
of IN 0
self-care JJ 0
behaviours NNS 0
, , 0
performance NN 0
of IN 0
self-care JJ 0
behaviours NNS 0
, , 0
and CC 0
symptom JJ 0
frequency NN 0
. . 0

METHOD NNP 0
A NNP 0
randomized VBD 0
clinical JJ 0
trial NN 0
that WDT 0
included VBD 0
a DT 0
convenience NN 0
sample NN 0
of IN 0
first JJ 0
time NN 0
CABG NNP 4
patients NNS 0
. . 0

Individuals NNS 0
who WP 0
received VBD 0
education NN 0
pre-discharge NN 0
were VBD 0
compared VBN 0
to TO 0
individuals NNS 0
who WP 0
received VBD 0
education NN 0
post-discharge NN 0
on IN 0
the DT 0
outcomes NNS 0
. . 0

RESULTS NNP 0
Results NNP 0
indicated VBD 0
no DT 0
statistically RB 0
significant JJ 0
difference NN 0
in IN 0
outcomes NNS 0
between IN 0
the DT 0
two CD 0
time NN 0
points NNS 0
. . 0

As NNP 0
well RB 0
, , 0
anxiety NN 0
levels NNS 0
were VBD 0
found VBN 0
to TO 0
be VB 0
significantly RB 0
higher JJR 0
in IN 0
the DT 0
pre-discharge NN 0
group NN 0
than IN 0
the DT 0
post-discharge JJ 0
group NN 0
. . 0

CONCLUSIONS VB 0
The DT 0
individualized JJ 0
nature NN 0
of IN 0
the DT 0
educational JJ 0
intervention NN 0
may MD 0
have VB 0
accounted VBN 0
for IN 0
non-significant JJ 0
findings NNS 0
reported VBN 0
in IN 0
outcomes NNS 0
between IN 0
the DT 0
two CD 0
time NN 0
points NNS 0
. . 0

PRACTICE NNP 0
IMPLICATIONS NNP 0
Nurses NNP 0
may MD 0
consider VB 0
assessing VBG 0
anxiety NN 0
levels NNS 0
prior RB 0
to TO 0
delivery NN 0
of IN 0
educational JJ 0
interventions NNS 0
, , 0
implement JJ 0
interventions NNS 0
aimed VBN 0
at IN 0
reducing VBG 0
anxiety NN 0
levels NNS 0
, , 0
and CC 0
provide VB 0
individualized JJ 0
teaching NN 0
. . 0

Randomized NNP 0
comparison NN 0
of IN 0
interferon NN 0
alpha NN 0
and CC 0
hydroxyurea NN 0
with IN 0
hydroxyurea JJ 0
monotherapy NN 0
in IN 0
chronic JJ 0
myeloid NN 0
leukemia NN 0
( ( 0
CML-study NNP 0
II NNP 0
) ) 0
: : 0
prolongation NN 0
of IN 0
survival NN 0
by IN 0
the DT 0
combination NN 0
of IN 0
interferon NN 0
alpha NN 0
and CC 0
hydroxyurea NN 0
. . 0

The DT 0
optimum JJ 0
treatment NN 0
conditions NNS 0
of IN 0
interferon NN 0
( ( 0
IFN NNP 0
) ) 0
alpha VBP 0
therapy NN 0
in IN 0
chronic JJ 0
myeloid NN 0
leukemia NN 0
( ( 0
CML NNP 0
) ) 0
are VBP 0
still RB 0
controversial JJ 0
. . 0

To TO 0
evaluate VB 0
the DT 0
role NN 0
of IN 0
hydroxyurea NN 0
( ( 0
HU NNP 0
) ) 0
for IN 0
the DT 0
outcome NN 0
of IN 0
IFN NNP 0
therapy NN 0
, , 0
we PRP 0
conducted VBD 0
a DT 0
randomized JJ 0
trial NN 0
to TO 0
compare VB 0
the DT 0
combination NN 0
of IN 0
IFN NNP 0
and CC 0
HU NNP 0
vs VBP 0
HU NNP 0
monotherapy NN 0
( ( 0
CML-study NNP 0
II NNP 0
) ) 0
. . 0

From IN 0
February NNP 0
1991 CD 0
to TO 0
December NNP 0
1994 CD 0
, , 0
376 CD 3
patients NNS 0
with IN 0
newly RB 0
diagnosed VBN 0
CML NNP 4
in IN 0
chronic JJ 4
phase NN 4
were VBD 0
randomized VBN 0
. . 0

In IN 0
all DT 0
, , 0
340 CD 3
patients NNS 0
were VBD 0
Ph/BCR-ABL NNP 4
positive JJ 0
and CC 0
evaluable JJ 0
. . 0

Randomization NN 0
was VBD 0
unbalanced JJ 0
1:2 CD 0
in IN 0
favor NN 0
of IN 0
the DT 0
combination NN 0
therapy NN 0
, , 0
since IN 0
study NN 0
conditions NNS 0
were VBD 0
identical JJ 0
to TO 0
the DT 0
previous JJ 0
CML-study NNP 0
I PRP 0
and CC 0
it PRP 0
had VBD 0
been VBN 0
planned VBN 0
in IN 0
advance NN 0
to TO 0
add VB 0
the DT 0
HU NNP 0
patients NNS 0
of IN 0
study NN 0
I PRP 0
( ( 0
n=194 RB 0
) ) 0
to TO 0
the DT 0
HU NNP 0
control NN 0
group NN 0
. . 0

Therefore RB 0
, , 0
a DT 0
total NN 0
of IN 0
534 CD 3
patients NNS 0
were VBD 0
evaluable JJ 0
( ( 0
226 CD 3
patients NNS 0
with IN 0
IFN/HU NNP 0
and CC 0
308 CD 3
patients NNS 0
with IN 0
HU NNP 0
) ) 0
. . 0

Analyses NNS 0
were VBD 0
according VBG 0
to TO 0
intention-to-treat NN 0
. . 0

Median JJ 0
observation NN 0
time NN 0
of IN 0
nontransplanted JJ 0
living NN 0
patients NNS 0
was VBD 0
7.6 CD 0
years NNS 0
( ( 0
7.9 CD 0
years NNS 0
for IN 0
IFN/HU NNP 0
and CC 0
7.3 CD 0
years NNS 0
for IN 0
HU NNP 0
) ) 0
. . 0

The DT 0
risk NN 0
profile NN 0
( ( 0
new JJ 0
CML NNP 0
score NN 0
) ) 0
was VBD 0
available JJ 0
for IN 0
532 CD 0
patients NNS 0
: : 0
200 CD 0
patients NNS 0
( ( 0
38 CD 0
% NN 0
) ) 0
were VBD 0
low JJ 0
, , 0
239 CD 0
patients NNS 0
( ( 0
45 CD 0
% NN 0
) ) 0
intermediate NN 0
, , 0
and CC 0
93 CD 0
patients NNS 0
( ( 0
17 CD 0
% NN 0
) ) 0
high JJ 0
risk NN 0
. . 0

Complete NNP 0
hematologic JJ 0
response NN 0
rates NNS 0
were VBD 0
higher JJR 0
in IN 0
IFN/HU-treated JJ 0
patients NNS 0
( ( 0
59 CD 0
vs RB 0
32 CD 0
% NN 0
) ) 0
. . 0

Of IN 0
169 CD 0
evaluable JJ 0
IFN/HU-treated JJ 0
patients NNS 0
( ( 0
75 CD 0
% NN 0
) ) 0
, , 0
104 CD 0
patients NNS 0
( ( 0
62 CD 0
% NN 0
) ) 0
achieved VBD 0
a DT 0
cytogenetic JJ 0
response NN 0
that WDT 0
was VBD 0
complete JJ 0
in IN 0
12 CD 0
% NN 0
( ( 0
n=21 JJ 0
) ) 0
, , 0
major JJ 0
in IN 0
14 CD 0
% NN 0
( ( 0
n=24 JJ 0
) ) 0
, , 0
and CC 0
at IN 0
least JJS 0
minimal JJ 0
in IN 0
35 CD 0
% NN 0
( ( 0
n=59 JJ 0
) ) 0
. . 0

Of IN 0
the DT 0
534 CD 3
patients NNS 0
, , 0
105 CD 0
( ( 0
20 CD 0
% NN 0
) ) 0
underwent NN 0
allogeneic JJ 0
stem NN 0
cell NN 0
transplantation NN 0
in IN 0
first JJ 0
chronic JJ 0
phase NN 0
. . 0

In IN 0
the DT 0
low-risk JJ 0
group NN 0
, , 0
65 CD 0
of IN 0
200 CD 0
patients NNS 0
were VBD 0
transplanted VBN 0
( ( 0
33 CD 0
% NN 0
) ) 0
, , 0
30 CD 0
( ( 0
13 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
intermediate-risk JJ 0
group NN 0
, , 0
and CC 0
nine CD 0
( ( 0
10 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
high-risk JJ 0
group NN 0
. . 0

Duration NN 0
of IN 0
chronic JJ 0
phase NN 0
was VBD 0
55 CD 0
months NNS 0
for IN 0
IFN/HU NNP 0
and CC 0
41 CD 0
months NNS 0
for IN 0
HU NNP 0
( ( 0
P NNP 0
< NNP 0
0.0001 CD 0
) ) 0
. . 0

Median JJ 0
survival NN 0
was VBD 0
64 CD 0
months NNS 0
for IN 0
IFN/HU NNP 0
and CC 0
53 CD 0
months NNS 0
for IN 0
HU-treated JJ 0
patients NNS 0
( ( 0
P=0.0063 NNP 0
) ) 0
. . 0

We PRP 0
conclude VBP 0
that DT 0
IFN NNP 0
in IN 0
combination NN 0
with IN 0
HU NNP 0
achieves VBZ 0
a DT 0
significant JJ 0
long-term JJ 0
survival NN 0
advantage NN 0
over IN 0
HU NNP 0
monotherapy NN 0
. . 0

In IN 0
view NN 0
of IN 0
the DT 0
data NNS 0
of IN 0
CML-study NNP 0
I PRP 0
, , 0
these DT 0
results NNS 0
suggest VBP 0
that IN 0
IFN/HU NNP 0
is VBZ 0
also RB 0
superior JJ 0
to TO 0
IFN NNP 0
alone RB 0
. . 0

HU NNP 0
should MD 0
be VB 0
combined VBN 0
with IN 0
IFN NNP 0
in IN 0
IFN-based JJ 0
therapies NNS 0
and CC 0
for IN 0
comparisons NNS 0
with IN 0
new JJ 0
therapies NNS 0
. . 0

Short- JJ 0
and CC 0
long-term JJ 0
effects NNS 0
of IN 0
tactile JJ 0
massage NN 0
on IN 0
salivary JJ 0
cortisol NN 0
concentrations NNS 0
in IN 0
Parkinson NNP 4
's POS 4
disease NN 4
: : 0
a DT 0
randomised JJ 0
controlled VBN 0
pilot NN 0
study NN 0
. . 0

BACKGROUND NNP 0
Parkinson NNP 0
's POS 0
disease NN 0
( ( 0
PD NNP 0
) ) 0
is VBZ 0
a DT 0
chronic JJ 0
neurodegenerative JJ 0
disorder NN 0
with IN 0
limited JJ 0
knowledge NN 0
about IN 0
the DT 0
normal JJ 0
function NN 0
and CC 0
effects NNS 0
of IN 0
non-pharmacological JJ 0
therapies NNS 0
on IN 0
the DT 0
hypothalamic-pituitary-adrenal JJ 0
( ( 0
HPA NNP 0
) ) 0
axis NN 0
. . 0

The DT 0
aim NN 0
of IN 0
the DT 0
study NN 0
was VBD 0
to TO 0
analyse VB 0
the DT 0
basal NN 0
diurnal JJ 0
and CC 0
total JJ 0
secretion NN 0
of IN 0
salivary JJ 0
cortisol NN 0
in IN 0
short- JJ 0
and CC 0
long-term JJ 0
aspects NNS 0
of IN 0
tactile JJ 0
massage NN 0
( ( 0
TM NNP 0
) ) 0
. . 0

METHODS NNP 0
DESIGN NNP 0
Prospective NNP 0
, , 0
Controlled NNP 0
and CC 0
Randomised VBD 0
Multicentre NNP 0
Trial NNP 0
. . 0

SETTING NN 0
AND JJ 0
INTERVENTIONS NNP 0
Forty-five NNP 3
women NNS 2
and CC 2
men NNS 2
, , 0
aged VBN 0
50-79 CD 1
years NNS 0
, , 0
were VBD 0
recruited VBN 0
. . 0

Twenty-nine NN 3
of IN 0
them PRP 0
were VBD 0
blindly RB 0
randomised VBN 0
to TO 0
tactile VB 0
massage NN 0
( ( 0
TM NNP 0
) ) 0
and CC 0
16 CD 3
of IN 0
them PRP 0
to TO 0
the DT 0
control NN 0
group NN 0
, , 0
rest NN 0
to TO 0
music NN 0
( ( 0
RTM NNP 0
) ) 0
. . 0

Ten CD 0
interventions NNS 0
were VBD 0
given VBN 0
during IN 0
8 CD 0
weeks NNS 0
followed VBN 0
by IN 0
a DT 0
26 CD 0
weeks NNS 0
of IN 0
follow JJ 0
up RB 0
. . 0

Salivary JJ 0
cortisol NN 0
was VBD 0
collected VBN 0
at IN 0
8 CD 0
am VBP 0
, , 0
1 CD 0
pm NN 0
, , 0
8 CD 0
pm NN 0
, , 0
and CC 0
8 CD 0
am VBP 0
the DT 0
next JJ 0
day NN 0
, , 0
on IN 0
five CD 0
occasions NNS 0
. . 0

With IN 0
the DT 0
first JJ 0
and CC 0
eighth JJ 0
interventions NNS 0
, , 0
it PRP 0
was VBD 0
collected VBN 0
immediately RB 0
before IN 0
and CC 0
after IN 0
intervention NN 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURES NNP 0
The DT 0
primary JJ 0
aim NN 0
was VBD 0
to TO 0
assess VB 0
and CC 0
compare VB 0
cortisol JJ 0
concentrations NNS 0
before IN 0
and CC 0
immediately RB 0
after IN 0
intervention NN 0
and CC 0
also RB 0
during IN 0
the DT 0
follow-up JJ 0
period NN 0
. . 0

The DT 0
secondary JJ 0
aim NN 0
was VBD 0
to TO 0
assess VB 0
the DT 0
impact NN 0
of IN 0
age NN 0
, , 0
gender NN 0
, , 0
body NN 0
mass NN 0
index NN 0
( ( 0
BMI NNP 0
) ) 0
, , 0
duration NN 0
and CC 0
severity NN 0
of IN 0
PD NNP 0
, , 0
effects NNS 0
of IN 0
interventional JJ 0
time-point NN 0
of IN 0
the DT 0
day NN 0
, , 0
and CC 0
levodopa JJ 0
doses NNS 0
on IN 0
cortisol JJ 0
concentration NN 0
. . 0

RESULTS VB 0
The DT 0
median JJ 0
cortisol NN 0
concentrations NNS 0
for IN 0
all DT 0
participants NNS 0
were VBD 0
16.0 CD 0
, , 0
5.8 CD 0
, , 0
2.8 CD 0
, , 0
and CC 0
14.0 CD 0
nmol/L NN 0
at IN 0
baseline NN 0
, , 0
later RB 0
reproduced VBD 0
four CD 0
times NNS 0
without IN 0
significant JJ 0
differences NNS 0
. . 0

Cortisol NNP 0
concentrations NNS 0
decreased VBD 0
significantly RB 0
after IN 0
TM NNP 0
intervention NN 0
but CC 0
no DT 0
change NN 0
in IN 0
diurnal JJ 0
salivary JJ 0
cortisol NN 0
pattern NN 0
was VBD 0
found VBN 0
. . 0

The DT 0
findings NNS 0
of IN 0
reduced JJ 0
salivary JJ 0
cortisol NN 0
concentrations NNS 0
immediately RB 0
after IN 0
the DT 0
interventions NNS 0
are VBP 0
in IN 0
agreement NN 0
with IN 0
previous JJ 0
studies NNS 0
. . 0

However RB 0
, , 0
there EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
between IN 0
the DT 0
TM NNP 0
and CC 0
control NN 0
groups NNS 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
correlations NNS 0
between IN 0
cortisol JJ 0
concentrations NNS 0
and CC 0
age NN 0
, , 0
gender NN 0
, , 0
BMI NNP 0
, , 0
time-point NN 0
for IN 0
intervention NN 0
, , 0
time NN 0
interval NN 0
between IN 0
anti-parkinson JJ 0
pharmacy NN 0
intake NN 0
and CC 0
sampling NN 0
, , 0
levodopa NN 0
doses NNS 0
, , 0
duration NN 0
, , 0
or CC 0
severity NN 0
of IN 0
PD NNP 0
. . 0

CONCLUSIONS NNP 0
Diurnal NNP 0
salivary JJ 0
cortisol NN 0
rhythm NN 0
was VBD 0
normal JJ 0
. . 0

Salivary JJ 0
cortisol NN 0
concentrations NNS 0
were VBD 0
significantly RB 0
reduced VBN 0
after IN 0
the DT 0
TM NNP 0
intervention NN 0
and CC 0
after IN 0
RTM NNP 0
, , 0
but CC 0
there EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
between IN 0
the DT 0
groups NNS 0
and CC 0
no DT 0
sustained JJ 0
long-term JJ 0
effect NN 0
. . 0

No CC 0
associations NNS 0
were VBD 0
seen VBN 0
between IN 0
salivary JJ 0
cortisol NN 0
concentration NN 0
and CC 0
clinical JJ 0
and/or NN 0
pharmacological JJ 0
characteristics NNS 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
ClinicalTrial.gov NNP 0
, , 0
NCT01734876 NNP 0
and CC 0
FoU NNP 0
Sweden NNP 0
108881 CD 0
. . 0

Does VBZ 0
the DT 0
result NN 0
of IN 0
completion NN 0
axillary JJ 0
lymph NN 0
node NN 0
dissection NN 0
influence NN 0
the DT 0
recommendation NN 0
for IN 0
adjuvant JJ 0
treatment NN 0
in IN 0
sentinel JJ 4
lymph JJ 4
node-positive JJ 4
patients NNS 0
? . 0
OBJECTIVE IN 0
The DT 0
Hungarian NNP 0
National NNP 0
Institute NNP 0
of IN 0
Oncology NNP 0
has VBZ 0
just RB 0
closed VBN 0
a DT 0
single-center JJ 0
randomized JJ 0
clinical JJ 0
study NN 0
. . 0

The DT 0
Optimal NNP 0
Treatment NNP 0
of IN 0
the DT 0
Axilla-Surgery NNP 0
or CC 0
Radiotherapy NNP 0
( ( 0
OTOASOR NNP 0
) ) 0
trial NN 0
compares VBZ 0
completion NN 0
axillary JJ 0
lymph NN 0
node NN 0
dissection NN 0
( ( 0
cALND NN 0
) ) 0
with IN 0
regional JJ 0
nodal JJ 0
irradiation NN 0
( ( 0
RNI NNP 0
) ) 0
in IN 0
patients NNS 0
with IN 0
sentinel JJ 4
lymph JJ 4
node-positive JJ 4
( ( 4
SLN+ NNP 4
) ) 4
primary VBP 4
invasive JJ 4
breast NN 4
cancer NN 4
. . 0

In IN 0
the DT 0
investigational JJ 0
treatment NN 0
arm NN 0
, , 0
patients NNS 0
received VBD 0
50 CD 0
Gy NNP 0
RNI NNP 0
instead RB 0
of IN 0
cALND NN 0
. . 0

In IN 0
these DT 0
patients NNS 0
we PRP 0
had VBD 0
information NN 0
only RB 0
about IN 0
the DT 0
sentinel NN 0
lymph NN 0
node NN 0
( ( 0
SLN NNP 0
) ) 0
status NN 0
, , 0
but CC 0
the DT 0
further JJ 0
axillary JJ 0
nodal JJ 0
involvement NN 0
remained VBD 0
unknown JJ 0
. . 0

The DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
investigate VB 0
whether IN 0
the DT 0
result NN 0
of IN 0
cALND NN 0
influenced VBD 0
the DT 0
recommendation NN 0
for IN 0
adjuvant JJ 0
treatment NN 0
in IN 0
patients NNS 0
with IN 0
SLN+ NNP 4
breast NN 4
cancer NN 4
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
Patients NNPS 0
with IN 0
SLN+ NNP 4
primary JJ 4
breast NN 4
cancer NN 4
were VBD 0
randomized VBN 0
for IN 0
cALND NN 0
( ( 0
arm NN 0
A NNP 0
, , 0
standard JJ 0
treatment NN 0
) ) 0
or CC 0
RNI NNP 0
( ( 0
arm NN 0
B NNP 0
, , 0
investigational JJ 0
treatment NN 0
) ) 0
. . 0

Adjuvant JJ 0
systemic JJ 0
treatments NNS 0
were VBD 0
given VBN 0
according VBG 0
to TO 0
the DT 0
standard JJ 0
institutional JJ 0
protocol NN 0
, , 0
and CC 0
patients NNS 0
were VBD 0
followed VBN 0
according VBG 0
to TO 0
the DT 0
actual JJ 0
institutional JJ 0
guidelines NNS 0
. . 0

RESULTS NNP 0
Between NNP 0
August NNP 0
2002 CD 0
and CC 0
June NNP 0
2009 CD 0
, , 0
474 CD 3
SLN+ NN 4
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
cALND VB 0
( ( 0
arm NN 0
A NNP 0
, , 0
standard JJ 0
treatment NN 0
= JJ 0
244 CD 0
patients NNS 0
) ) 0
or CC 0
RNI NNP 0
( ( 0
arm NN 0
B NNP 0
, , 0
investigational JJ 0
treatment NN 0
= VBD 0
230 CD 0
patients NNS 0
) ) 0
. . 0

The DT 0
2 CD 0
arms NNS 0
were VBD 0
well RB 0
balanced VBN 0
according VBG 0
to TO 0
the DT 0
majority NN 0
of IN 0
main JJ 0
prognostic JJ 0
factors NNS 0
. . 0

However RB 0
, , 0
more JJR 0
patients NNS 0
were VBD 0
premenopausal JJ 4
( ( 0
34 CD 0
% NN 0
vs. FW 0
27 CD 0
% NN 0
; : 0
P NNP 0
= NNP 0
.095 NNP 0
) ) 0
and CC 0
had VBD 0
pT2-3 NN 0
tumors NNS 0
( ( 0
57 CD 0
% NN 0
vs. FW 0
40 CD 0
% NN 0
; : 0
P NNP 0
= NNP 0
.003 NNP 0
) ) 0
in IN 0
the DT 0
completion NN 0
axillary JJ 0
lymph NN 0
node NN 0
dissection NN 0
( ( 0
ALND NNP 0
) ) 0
arm NN 0
. . 0

On IN 0
the DT 0
other JJ 0
hand NN 0
, , 0
there EX 0
were VBD 0
more JJR 0
patients NNS 0
with IN 0
known JJ 0
human JJ 0
epidermal JJ 0
growth NN 0
factor NN 0
receptor NN 0
type VBD 0
2 CD 0
positive JJ 0
tumor NN 0
( ( 0
12 CD 0
% NN 0
vs. FW 0
17 CD 0
% NN 0
, , 0
P NNP 0
= NNP 0
.066 NNP 0
) ) 0
in IN 0
the DT 0
RNI NNP 0
arm NN 0
. . 0

In IN 0
the DT 0
ALND NNP 0
and CC 0
RNI NNP 0
arms NNS 0
, , 0
78 CD 0
% NN 0
( ( 0
190/244 CD 0
) ) 0
and CC 0
69 CD 0
% NN 0
( ( 0
159/230 CD 0
) ) 0
, , 0
respectively RB 0
, , 0
received VBD 0
chemotherapy NN 0
( ( 0
P NNP 0
= NNP 0
.020 NNP 0
) ) 0
. . 0

Endocrine NNP 0
therapy NN 0
was VBD 0
administered VBN 0
in IN 0
87 CD 0
% NN 0
( ( 0
213/244 CD 0
) ) 0
of IN 0
the DT 0
patients NNS 0
in IN 0
the DT 0
ALND NNP 0
arm NN 0
and CC 0
89 CD 0
% NN 0
( ( 0
204/230 CD 0
) ) 0
of IN 0
the DT 0
patients NNS 0
in IN 0
the DT 0
RNI NNP 0
arm NN 0
( ( 0
P NNP 0
= NNP 0
.372 NNP 0
) ) 0
. . 0

Six CD 0
patients NNS 0
( ( 0
2.5 CD 0
% NN 0
) ) 0
on IN 0
arm NN 0
A NN 0
and CC 0
13 CD 0
patients NNS 0
( ( 0
5.7 CD 0
% NN 0
) ) 0
on IN 0
arm NN 0
B NNP 0
received VBD 0
adjuvant JJ 0
trastuzumab NN 0
treatment NN 0
( ( 0
P NNP 0
= NNP 0
not RB 0
significant JJ 0
) ) 0
. . 0

Subgroup NNP 0
analyses VBZ 0
explored VBD 0
that IN 0
more RBR 0
frequent JJ 0
administration NN 0
of IN 0
adjuvant JJ 0
chemotherapy NN 0
in IN 0
arm NN 0
A NN 0
was VBD 0
associated VBN 0
with IN 0
the DT 0
higher JJR 0
percentage NN 0
of IN 0
premenopausal NN 0
patients NNS 0
and CC 0
patients NNS 0
with IN 0
larger JJR 0
( ( 4
pT2-3 NN 4
) ) 4
tumors NNS 4
. . 0

CONCLUSIONS VB 0
The DT 0
result NN 0
of IN 0
cALND NN 0
after IN 0
positive JJ 0
SLN NNP 0
biopsy NN 0
seems VBZ 0
to TO 0
have VB 0
no DT 0
major JJ 0
impact NN 0
on IN 0
the DT 0
administration NN 0
of IN 0
adjuvant JJ 0
systemic JJ 0
therapy NN 0
. . 0

Pilot NNP 0
study NN 0
of IN 0
Panax NNP 0
quinquefolius NN 0
( ( 0
American NNP 0
ginseng NN 0
) ) 0
to TO 0
improve VB 0
cancer-related JJ 4
fatigue NN 4
: : 0
a DT 0
randomized JJ 0
, , 0
double-blind JJ 0
, , 0
dose-finding JJ 0
evaluation NN 0
: : 0
NCCTG NNP 0
trial NN 0
N03CA NNP 0
. . 0

PURPOSE NNP 0
This DT 0
pilot NN 0
trial NN 0
sought VBD 0
to TO 0
investigate VB 0
whether IN 0
any DT 0
of IN 0
three CD 0
doses NNS 0
of IN 0
American JJ 0
ginseng NN 0
( ( 0
Panax NNP 0
quinquefolius RB 0
) ) 0
might MD 0
help VB 0
cancer-related JJ 4
fatigue NN 4
. . 0

A DT 0
secondary JJ 0
aim NN 0
was VBD 0
to TO 0
evaluate VB 0
toxicity NN 0
. . 0

METHODS NNP 0
Eligible JJ 0
adults NNS 1
with IN 0
cancer NN 4
were VBD 0
randomized VBN 0
in IN 0
a DT 0
double-blind JJ 0
manner NN 0
, , 0
to TO 0
receive VB 0
American JJ 0
ginseng NN 0
in IN 0
doses NNS 0
of IN 0
750 CD 0
, , 0
1,000 CD 0
, , 0
or CC 0
2,000 CD 0
mg/day NN 0
or CC 0
placebo VB 0
given VBN 0
in IN 0
twice JJ 0
daily JJ 0
dosing NN 0
over IN 0
8 CD 0
weeks NNS 0
. . 0

Outcome NNP 0
measures NNS 0
included VBD 0
the DT 0
Brief NNP 0
Fatigue NNP 0
Inventory NNP 0
, , 0
vitality NN 0
subscale NN 0
of IN 0
the DT 0
Medical NNP 0
Outcome NNP 0
Scale NNP 0
Short NNP 0
Form-36 NNP 0
( ( 0
SF-36 NNP 0
) ) 0
, , 0
and CC 0
the DT 0
Global NNP 0
Impression NNP 0
of IN 0
Benefit NNP 0
Scale NNP 0
at IN 0
4 CD 0
and CC 0
8 CD 0
weeks NNS 0
. . 0

RESULTS NNP 0
Two CD 3
hundred VBD 3
ninety NN 3
patients NNS 0
were VBD 0
accrued VBN 0
to TO 0
this DT 0
trial NN 0
. . 0

Nonsignificant JJ 0
trends NNS 0
for IN 0
all DT 0
outcomes NNS 0
were VBD 0
seen VBN 0
in IN 0
favor NN 0
of IN 0
the DT 0
1,000- JJ 0
and CC 0
2,000-mg/day JJ 0
doses NNS 0
of IN 0
American JJ 0
ginseng NN 0
. . 0

Area NNP 0
under IN 0
the DT 0
curve NN 0
analysis NN 0
of IN 0
activity NN 0
interference NN 0
from IN 0
the DT 0
Brief NNP 0
Fatigue NNP 0
Inventory NNP 0
was VBD 0
460-467 JJ 0
in IN 0
the DT 0
placebo NN 0
group NN 0
and CC 0
750 CD 0
mg/day NN 0
group NN 0
versus VBD 0
480-551 CD 0
in IN 0
the DT 0
1,000- JJ 0
and CC 0
2,000-mg/day JJ 0
arms NNS 0
, , 0
respectively RB 0
. . 0

Change NN 0
from IN 0
baseline NN 0
in IN 0
the DT 0
vitality NN 0
subscale NN 0
of IN 0
the DT 0
SF-36 NNP 0
was VBD 0
7.3-7.8 JJ 0
in IN 0
the DT 0
placebo NN 0
and CC 0
the DT 0
750-mg/day JJ 0
arm NN 0
, , 0
versus NN 0
10.5-14.6 JJ 0
in IN 0
the DT 0
1,000- JJ 0
and CC 0
2,000-mg/day JJ 0
arms NNS 0
. . 0

Over NNP 0
twice RB 0
as RB 0
many JJ 0
patients NNS 0
on IN 0
ginseng NN 0
perceived VBD 0
a DT 0
benefit NN 0
and CC 0
were VBD 0
satisfied VBN 0
with IN 0
treatment NN 0
over IN 0
those DT 0
on IN 0
placebo NN 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
any DT 0
measured JJ 0
toxicities NNS 0
between IN 0
any DT 0
of IN 0
the DT 0
arms NNS 0
. . 0

CONCLUSION NN 0
There EX 0
appears VBZ 0
to TO 0
be VB 0
some DT 0
activity NN 0
and CC 0
tolerable JJ 0
toxicity NN 0
at IN 0
1,000-2,000 CD 0
mg/day JJ 0
doses NNS 0
of IN 0
American JJ 0
ginseng NN 0
with IN 0
regard NN 0
to TO 0
cancer-related JJ 0
fatigue NN 0
. . 0

Thus NNP 0
, , 0
further JJ 0
study NN 0
of IN 0
American NNP 0
ginseng NN 0
is VBZ 0
warranted VBN 0
. . 0

Pegfilgrastim NN 0
for IN 0
peripheral JJ 0
CD34+ NNP 0
mobilization NN 0
in IN 0
patients NNS 0
with IN 0
solid JJ 4
tumours NNS 4
. . 0

The DT 0
efficacy NN 0
of IN 0
pegfilgrastim+/-chemotherapy NN 0
for IN 0
mobilizing VBG 0
stem NN 0
cells NNS 0
in IN 0
patients NNS 0
with IN 0
solid JJ 4
tumours NN 4
was VBD 0
assessed VBN 0
. . 0

In IN 0
cycle NN 0
0 CD 0
, , 0
a DT 0
14-day JJ 0
prechemotherapy NN 0
cycle NN 0
, , 0
patients NNS 0
( ( 0
N=61 NNP 3
) ) 0
were VBD 0
randomized VBN 0
open-label NN 0
to TO 0
single JJ 0
doses NNS 0
of IN 0
pegfilgrastim NN 0
( ( 0
6 CD 0
, , 0
12 CD 0
or CC 0
18 CD 0
mg NN 0
) ) 0
on IN 0
day NN 0
1 CD 0
, , 0
or CC 0
daily RB 0
filgrastim NNS 0
( ( 0
10 CD 0
microg/kg NN 0
) ) 0
for IN 0
< NN 0
or CC 0
=7 JJ 0
days NNS 0
. . 0

Mean JJ 0
peak JJ 0
peripheral JJ 0
CD34+ NNP 0
cell NN 0
counts NNS 0
increased VBD 0
with IN 0
pegfilgrastim NN 0
dose NN 0
, , 0
but CC 0
were VBD 0
significantly RB 0
higher JJR 0
than IN 0
filgrastim JJR 0
only RB 0
at IN 0
the DT 0
18 CD 0
mg NN 0
dose NN 0
( ( 0
10.17 CD 0
vs RB 0
4.96 CD 0
x JJ 0
10 CD 0
( ( 0
4 CD 0
) ) 0
/ml NN 0
; : 0
P=0.014 NNP 0
) ) 0
. . 0

In IN 0
the DT 0
clinically NN 0
relevant JJ 0
period NN 0
of IN 0
days NNS 0
3-7 CD 0
, , 0
both DT 0
12 CD 0
and CC 0
18 CD 0
mg NN 0
pegfilgrastim NN 0
doses NNS 0
produced VBD 0
significantly RB 0
higher JJR 0
peak NN 0
CD34+ NNP 0
counts VBZ 0
( ( 0
8.18 CD 0
and CC 0
9.96 CD 0
vs NN 0
4.51 CD 0
x NN 0
10 CD 0
( ( 0
4 CD 0
) ) 0
/ml NN 0
for IN 0
filgrastim NN 0
; : 0
P=0.034 NNP 0
and CC 0
0.006 CD 0
) ) 0
. . 0

In IN 0
cycle NN 0
1 CD 0
, , 0
patients NNS 0
received VBD 0
carboplatin/paclitaxel NNS 0
on IN 0
day NN 0
1 CD 0
, , 0
followed VBD 0
from IN 0
day NN 0
2 CD 0
by IN 0
pegfilgrastim JJ 0
6-18 JJ 0
mg NN 0
or CC 0
daily JJ 0
filgrastim NN 0
( ( 0
5 CD 0
microg/kg/day NN 0
for IN 0
< NN 0
or CC 0
=14 NNP 0
days NNS 0
) ) 0
as IN 0
per IN 0
randomization NN 0
in IN 0
cycle NN 0
0 CD 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
mean JJ 0
peak NN 0
CD34+ NNP 0
count NN 0
between IN 0
pegfilgrastim NN 0
and CC 0
filgrastim NN 0
, , 0
but CC 0
there EX 0
was VBD 0
an DT 0
advantage NN 0
for IN 0
pegfilgrastim NN 0
18 CD 0
mg NN 0
in IN 0
the DT 0
relevant JJ 0
period NN 0
of IN 0
days NNS 0
7-12 NNP 0
( ( 0
3.14 CD 0
vs RB 0
1.19 CD 0
x JJ 0
10 CD 0
( ( 0
4 CD 0
) ) 0
/ml NN 0
; : 0
P=0.043 NNP 0
) ) 0
. . 0

A DT 0
single JJ 0
pegfilgrastim NN 0
dose NN 0
( ( 0
> CD 0
or CC 0
=6 VB 0
mg NN 0
) ) 0
could MD 0
be VB 0
substituted VBN 0
for IN 0
daily JJ 0
filgrastim NN 0
in IN 0
cytokine-only JJ 0
peripheral JJ 0
CD34+ NNP 0
cell NN 0
mobilization NN 0
. . 0

Treatment NN 0
with IN 0
metformin NN 0
of IN 0
non-diabetic JJ 4
men NNS 2
with IN 0
hypertension NN 4
, , 0
hypertriglyceridaemia NN 4
and CC 0
central JJ 4
fat JJ 4
distribution NN 4
: : 0
the DT 0
BIGPRO NNP 0
1.2 CD 0
trial NN 0
. . 0

BACKGROUND NNP 0
In IN 0
the DT 0
BIGPRO NNP 0
1 CD 0
trial NN 0
, , 0
one CD 0
year NN 0
of IN 0
treatment NN 0
with IN 0
metformin NN 0
in IN 0
non-diabetic JJ 4
obese JJ 4
subjects NNS 0
with IN 0
a DT 0
central JJ 4
fat JJ 4
distribution NN 4
had VBD 0
no DT 0
significant JJ 0
effect NN 0
on IN 0
fasting VBG 0
plasma JJ 0
triglyceride JJ 0
concentration NN 0
or CC 0
on IN 0
blood NN 0
pressure NN 0
despite IN 0
a DT 0
decrease NN 0
in IN 0
weight NN 0
, , 0
fasting VBG 0
plasma JJ 0
insulin NN 0
and CC 0
glucose JJ 0
concentrations NNS 0
. . 0

To TO 0
re-evaluate VB 0
the DT 0
effect NN 0
of IN 0
metformin NN 0
on IN 0
fasting VBG 0
triglyceride JJ 0
concentration NN 0
and CC 0
on IN 0
blood NN 0
pressure NN 0
, , 0
the DT 0
BIGPRO NNP 0
1.2 CD 0
trial NN 0
included VBD 0
non-diabetic JJ 4
men NNS 2
( ( 0
n=168 NN 3
) ) 0
with IN 0
a DT 0
fasting VBG 0
plasma NN 0
triglyceride JJ 0
concentration NN 0
> NN 4
or CC 4
=1.7 NN 4
and CC 4
< NN 4
or CC 4
=6.5 NN 4
mmol/l NN 4
, , 0
high JJ 4
blood NN 4
pressure NN 4
( ( 0
systolic JJ 0
> NN 0
or CC 0
=140 NN 0
and CC 0
< NN 0
or CC 0
=180 VB 0
and/or JJ 0
diastolic JJ 0
> NN 0
or CC 0
=90 NN 0
and CC 0
< NN 0
or CC 0
=105 NN 0
mmHg NN 0
, , 0
or CC 0
treatment NN 0
for IN 0
hypertension NN 4
) ) 0
and CC 0
a DT 0
waist-to-hip JJ 4
ratio NN 4
> NN 4
or CC 4
=0.95 NN 4
. . 4

METHODS NNP 0
A DT 0
randomised JJ 0
double-blind JJ 0
trial NN 0
comparing VBG 0
metformin NN 0
treatment NN 0
( ( 0
850 CD 0
mg RB 0
bid NN 0
) ) 0
with IN 0
placebo NN 0
. . 0

RESULTS NNP 0
Metformin NNP 0
had VBD 0
no DT 0
significant JJ 0
effect NN 0
either DT 0
on IN 0
blood NN 0
pressure NN 0
or CC 0
plasma NN 0
triglyceride JJ 0
concentration NN 0
. . 0

In IN 0
comparison NN 0
with IN 0
the DT 0
placebo NN 0
group NN 0
, , 0
fasting VBG 0
plasma JJ 0
insulin NN 0
( ( 0
p JJ 0
< NNP 0
0.04 CD 0
) ) 0
, , 0
total JJ 0
cholesterol NN 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
and CC 0
Apo NNP 0
B NNP 0
( ( 0
p JJ 0
< NNP 0
0.008 CD 0
) ) 0
concentrations NNS 0
decreased VBD 0
more RBR 0
in IN 0
the DT 0
metformin NN 0
group NN 0
in IN 0
the DT 0
BIGPRO NNP 0
1 CD 0
. . 0

2 CD 0
trial NN 0
, , 0
confirming VBG 0
most JJS 0
of IN 0
the DT 0
previous JJ 0
results NNS 0
of IN 0
the DT 0
BIGPRO NNP 0
1 CD 0
trial NN 0
. . 0

Tissue NNP 0
plasminogen NN 0
activator NN 0
antigen NN 0
concentration NN 0
decreased VBN 0
significantly RB 0
( ( 0
p JJ 0
< NNP 0
0.01 CD 0
) ) 0
only RB 0
in IN 0
the DT 0
metformin NN 0
group NN 0
, , 0
but CC 0
this DT 0
was VBD 0
not RB 0
significantly RB 0
different JJ 0
from IN 0
the DT 0
placebo NN 0
group NN 0
( ( 0
p JJ 0
< NNP 0
0.12 CD 0
) ) 0
; : 0
further RB 0
, , 0
there EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
the DT 0
change NN 0
in IN 0
plasminogen NN 0
activator NN 0
inhibitor NN 0
1 CD 0
. . 0

CONCLUSIONS VB 0
The DT 0
consistency NN 0
of IN 0
the DT 0
two CD 0
BIGPRO NNP 0
trials NNS 0
supports VBZ 0
the DT 0
conclusion NN 0
that IN 0
metformin VBZ 0
affects NNS 0
several JJ 0
cardiovascular JJ 0
risk NN 0
factors NNS 0
favourably RB 0
in IN 0
non-diabetic JJ 4
subjects NNS 0
with IN 0
a DT 0
central JJ 4
fat JJ 4
distribution NN 4
. . 0

Impact NN 0
of IN 0
a DT 0
single JJ 0
intravenous JJ 0
administration NN 0
of IN 0
nicorandil JJ 0
before IN 0
reperfusion NN 0
in IN 0
patients NNS 0
with IN 0
ST-segment-elevation NNP 4
myocardial JJ 4
infarction NN 4
. . 0

BACKGROUND NNP 0
Intravenous NNP 0
nicorandil NN 0
, , 0
a DT 0
hybrid JJ 0
compound NN 0
of IN 0
ATP-sensitive JJ 0
potassium NN 0
channel NN 0
opener NN 0
and CC 0
nitric JJ 0
oxide NN 0
donor NN 0
, , 0
has VBZ 0
been VBN 0
reported VBN 0
to TO 0
ameliorate VB 0
early JJ 0
functional NN 0
and CC 0
clinical JJ 0
problems NNS 0
in IN 0
patients NNS 0
with IN 0
acute JJ 0
myocardial JJ 0
infarction NN 0
. . 0

However RB 0
, , 0
its PRP$ 0
effects NNS 0
on IN 0
the DT 0
late JJ 0
phase NN 0
remain VBP 0
unclear JJ 0
. . 0

METHODS NNP 0
AND CC 0
RESULTS NNP 0
This DT 0
follow-up JJ 0
study NN 0
to TO 0
5 CD 0
years NNS 0
of IN 0
a DT 0
randomized JJ 0
, , 0
double-blinded JJ 0
trial NN 0
was VBD 0
conducted VBN 0
among IN 0
368 CD 3
patients NNS 0
with IN 0
first JJ 0
ST-segment-elevation NNP 0
myocardial JJ 0
infarction NN 0
undergoing VBG 0
percutaneous JJ 4
coronary JJ 4
intervention NN 4
( ( 0
PCI NNP 4
) ) 0
. . 0

They PRP 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
12 CD 0
mg NN 0
of IN 0
nicorandil NN 0
or CC 0
a DT 0
placebo NN 0
intravenously RB 0
just RB 0
before IN 0
reperfusion NN 0
. . 0

We PRP 0
analyzed VBD 0
incidence NN 0
of IN 0
cardiovascular JJ 0
death NN 0
or CC 0
rehospitalization NN 0
for IN 0
congestive JJ 0
heart NN 0
failure NN 0
after IN 0
PCI NNP 0
as RB 0
well RB 0
as IN 0
various JJ 0
aspects NNS 0
of IN 0
epicardial JJ 0
flow NN 0
and CC 0
microvascular JJ 0
function NN 0
. . 0

Mean JJ 0
follow-up NN 0
was VBD 0
2.4 CD 0
years NNS 0
( ( 0
SD NNP 0
, , 0
1.4 CD 0
) ) 0
. . 0

A DT 0
total NN 0
of IN 0
12 CD 0
( ( 0
6.5 CD 0
% NN 0
) ) 0
patients NNS 0
receiving VBG 0
nicorandil JJ 0
and CC 0
30 CD 0
( ( 0
16.4 CD 0
% NN 0
) ) 0
receiving NN 0
placebo NN 0
had VBD 0
cardiovascular JJ 0
death NN 0
or CC 0
hospital NN 0
admission NN 0
for IN 0
congestive JJ 0
heart NN 0
failure NN 0
( ( 0
hazard JJ 0
ratio NN 0
, , 0
0.39 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
0.20 CD 0
to TO 0
0.76 CD 0
; : 0
P=0.0058 NNP 0
) ) 0
. . 0

Postprocedural NNP 0
TIMI NNP 0
3 CD 0
flow NN 0
was VBD 0
obtained VBN 0
in IN 0
89.7 CD 0
% NN 0
of IN 0
the DT 0
nicorandil JJ 0
group NN 0
and CC 0
in IN 0
81.4 CD 0
% NN 0
of IN 0
the DT 0
placebo NN 0
( ( 0
hazard JJ 0
ratio NN 0
, , 0
1.99 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
1.09 CD 0
to TO 0
3.65 CD 0
; : 0
P=0.025 NNP 0
) ) 0
. . 0

Corrected VBN 0
TIMI NNP 0
frame NN 0
count NN 0
was VBD 0
furthermore RB 0
lower JJR 0
in IN 0
the DT 0
nicorandil NN 0
group NN 0
( ( 0
21.0+/-9.1 JJ 0
versus NN 0
25.1+/-14.1 CD 0
; : 0
P=0.0009 NNP 0
) ) 0
. . 0

ST-segment JJ 0
resolution NN 0
> VBD 0
50 CD 0
% NN 0
was VBD 0
observed VBN 0
in IN 0
79.5 CD 0
% NN 0
and CC 0
61.2 CD 0
% NN 0
of IN 0
the DT 0
nicorandil NN 0
and CC 0
placebo NN 0
groups NNS 0
, , 0
respectively RB 0
( ( 0
hazard JJ 0
ratio NN 0
, , 0
2.45 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
1.54 CD 0
to TO 0
3.90 CD 0
; : 0
P=0.0002 NNP 0
) ) 0
. . 0

CONCLUSIONS VB 0
The DT 0
addition NN 0
of IN 0
intravenous JJ 0
nicorandil NNS 0
to TO 0
PCI NNP 0
leads VBZ 0
to TO 0
beneficial JJ 0
clinical JJ 0
outcomes NNS 0
and CC 0
prevents NNS 0
cardiovascular JJ 0
events NNS 0
of IN 0
long JJ 0
duration NN 0
and CC 0
death NN 0
in IN 0
patients NNS 0
with IN 0
ST-segment-elevation NNP 0
myocardial JJ 0
infarction NN 0
. . 0

Genotyping VBG 0
of IN 0
CYP21 NNP 0
, , 0
linked VBD 0
chromosome NN 0
6p CD 0
markers NNS 0
, , 0
and CC 0
a DT 0
sex-specific JJ 0
gene NN 0
in IN 0
neonatal JJ 1
screening NN 0
for IN 0
congenital JJ 4
adrenal JJ 4
hyperplasia NN 4
. . 0

We PRP 0
investigated VBD 0
the DT 0
feasibility NN 0
and CC 0
diagnostic JJ 0
utility NN 0
of IN 0
genotyping VBG 0
9 CD 0
CYP21 NNP 0
mutations NNS 0
, , 0
linked VBD 0
chromosome NN 0
6p CD 0
markers NNS 0
, , 0
and CC 0
a DT 0
dimorphic JJ 0
X-Y JJ 0
marker NN 0
from IN 0
neonatal JJ 1
screening NN 0
samples NNS 0
. . 0

Blood-impregnated JJ 0
filter NN 0
papers NNS 0
( ( 0
Guthrie NNP 0
cards NNS 0
) ) 0
from IN 0
603 CD 3
randomly RB 0
chosen VBN 0
New NNP 0
Zealand NNP 0
neonates NNS 1
were VBD 0
genotyped VBN 0
blind IN 0
to TO 0
17-hydroxyprogesterone CD 0
( ( 0
17-OHP CD 0
) ) 0
levels NNS 0
. . 0

Another DT 0
50 CD 3
samples NNS 0
from IN 0
Swiss NNP 0
and CC 0
North NNP 0
American JJ 0
infants NNS 0
with IN 0
correlative JJ 0
hormonal JJ 0
data NNS 0
were VBD 0
also RB 0
genotyped VBN 0
. . 0

DNA NN 0
was VBD 0
extracted VBN 0
, , 0
and CC 0
gene-specific JJ 0
PCR NNP 0
was VBD 0
performed VBN 0
. . 0

CYP21 NNP 0
PCR NNP 0
products NNS 0
were VBD 0
subjected VBN 0
to TO 0
ligase VB 0
detection NN 0
reaction NN 0
, , 0
simultaneously RB 0
analyzing VBG 0
9 CD 0
CYP21 NNP 0
mutations NNS 0
; : 0
PCR NNP 0
products NNS 0
of IN 0
other JJ 0
genes NNS 0
were VBD 0
subjected VBN 0
to TO 0
direct VB 0
gel JJ 0
analysis NN 0
. . 0

CYP21 NNP 0
genotyping VBG 0
indicated VBD 0
a DT 0
heterozygote NN 0
rate NN 0
of IN 0
2.8 CD 0
% NN 0
for IN 0
classic JJ 0
mutations NNS 0
( ( 0
excluding VBG 0
CYP21 NNP 0
deletions NNS 0
) ) 0
, , 0
and CC 0
2.0 CD 0
% NN 0
for IN 0
nonclassic JJ 0
mutations NNS 0
in IN 0
New NNP 0
Zealanders NNP 0
. . 0

Ten CD 0
full-term JJ 0
affected JJ 0
neonates NNS 0
showed VBD 0
a DT 0
wide JJ 0
range NN 0
of IN 0
17-OHP JJ 0
levels NNS 0
( ( 0
15-1400 JJ 0
nmol/L NN 0
) ) 0
. . 0

Sick NNP 0
or CC 0
preterm JJ 0
infants NNS 0
or CC 0
infants NNS 0
screened VBN 0
on IN 0
the DT 0
first JJ 0
day NN 0
of IN 0
life NN 0
with IN 0
high JJ 0
17-OHP JJ 0
proved VBN 0
genetically RB 0
unaffected JJ 0
. . 0

Genetic JJ 0
linkage NN 0
disequilibrium NN 0
was VBD 0
found VBN 0
between IN 0
two CD 0
CYP21 NNP 0
mutations NNS 0
and CC 0
chromosome NN 0
6p CD 0
markers NNS 0
. . 0

Guthrie NNP 0
cards NNS 0
can MD 0
be VB 0
used VBN 0
to TO 0
accurately RB 0
genotype VB 0
CYP21 NNP 0
and CC 0
other JJ 0
relevant JJ 0
markers NNS 0
, , 0
potentially RB 0
enhancing VBG 0
the DT 0
specificity NN 0
and CC 0
sensitivity NN 0
of IN 0
congenital JJ 0
adrenal JJ 0
hyperplasia NN 0
screening NN 0
. . 0

CYP21 NNP 0
heterozygote JJ 0
frequency NN 0
for IN 0
classic JJ 0
mutations NNS 0
is VBZ 0
higher JJR 0
than IN 0
expected VBN 0
based VBN 0
on IN 0
genotype NN 0
compared VBN 0
with IN 0
that DT 0
predicted VBN 0
by IN 0
hormonal JJ 0
newborn JJ 1
screening NN 0
. . 0

Laser NNP 0
conization NN 0
versus NN 0
cold JJ 0
knife NN 0
conization NN 0
. . 0

This DT 0
prospective JJ 0
, , 0
randomized VBN 0
study NN 0
compares VBZ 0
, , 0
for IN 0
the DT 0
first JJ 0
time NN 0
, , 0
measured VBN 0
blood NN 0
loss NN 0
at IN 0
conization NN 0
and CC 0
within IN 0
24 CD 0
hours NNS 0
after IN 0
using VBG 0
either CC 0
the DT 0
cold JJ 0
knife NN 0
technique NN 0
or CC 0
the DT 0
carbon NN 0
dioxide NN 0
laser NN 0
scalpel NN 0
. . 0

One CD 3
hundred CD 3
and CC 3
ten VB 3
consecutive JJ 0
patients NNS 0
were VBD 0
evaluated VBN 0
. . 0

The DT 0
median JJ 0
blood NN 0
loss NN 0
in IN 0
the DT 0
laser NN 0
group NN 0
of IN 0
55 CD 0
patients NNS 0
was VBD 0
4.6 CD 0
milliliters NNS 0
at IN 0
, , 0
and CC 0
within IN 0
, , 0
24 CD 0
hours NNS 0
after IN 0
operation NN 0
compared VBN 0
with IN 0
30.1 CD 0
milliliters NNS 0
in IN 0
the DT 0
cold JJ 0
knife NN 0
group NN 0
of IN 0
55 CD 0
patients NNS 0
. . 0

More RBR 0
important JJ 0
, , 0
however RB 0
, , 0
is VBZ 0
that IN 0
the DT 0
corresponding JJ 0
figures NNS 0
for IN 0
the DT 0
range NN 0
of IN 0
bleeding VBG 0
were VBD 0
0.4 CD 0
to TO 0
155.4 CD 0
milliliters NNS 0
and CC 0
5.6 CD 0
to TO 0
1,570.9 CD 0
milliliters NNS 0
, , 0
respectively RB 0
. . 0

The DT 0
incidence NN 0
rate NN 0
for IN 0
bleeding VBG 0
complications NNS 0
requiring VBG 0
surgical JJ 0
intervention NN 0
was VBD 0
1.8 CD 0
per IN 0
cet NN 0
for IN 0
the DT 0
laser NN 0
group NN 0
and CC 0
14.6 CD 0
per IN 0
cent NN 0
for IN 0
the DT 0
cold JJ 0
knife NN 0
group NN 0
. . 0

This DT 0
difference NN 0
was VBD 0
statistically RB 0
significant JJ 0
, , 0
p RB 0
less JJR 0
than IN 0
0.015 CD 0
-- : 0
Fischer NNP 0
's POS 0
exact JJ 0
test NN 0
. . 0

Conization NN 0
for IN 0
treatment NN 0
of IN 0
premalignant JJ 4
changes NNS 4
of IN 4
the DT 4
cervix NN 4
uteri NN 4
will MD 0
probably RB 0
remain VB 0
the DT 0
treatment NN 0
of IN 0
choice NN 0
for IN 0
some DT 0
time NN 0
to TO 0
come VB 0
. . 0

It PRP 0
is VBZ 0
our PRP$ 0
opinion NN 0
that IN 0
, , 0
in IN 0
the DT 0
future NN 0
, , 0
laser JJR 0
conization NN 0
will MD 0
replace VB 0
cold JJ 0
knife NN 0
conization NN 0
. . 0

Margarines NNS 0
fortified VBN 0
with IN 0
?-linolenic JJ 0
acid NN 0
, , 0
eicosapentaenoic JJ 0
acid NN 0
, , 0
or CC 0
docosahexaenoic JJ 0
acid NN 0
alter IN 0
the DT 0
fatty JJ 0
acid JJ 0
composition NN 0
of IN 0
erythrocytes NNS 0
but CC 0
do VBP 0
not RB 0
affect VB 0
the DT 0
antioxidant JJ 0
status NN 0
of IN 0
healthy JJ 0
adults NNS 0
. . 0

We PRP 0
aimed VBD 0
to TO 0
investigate VB 0
the DT 0
effects NNS 0
of IN 0
increased JJ 0
intake NN 0
of IN 0
?-linolenic JJ 0
acid NN 0
( ( 0
ALA NNP 0
) ) 0
, , 0
EPA NNP 0
, , 0
or CC 0
DHA NNP 0
incorporated VBN 0
into IN 0
a DT 0
food NN 0
matrix NN 0
on IN 0
the DT 0
fatty JJ 0
acid JJ 0
composition NN 0
of IN 0
erythrocytes NNS 0
and CC 0
on IN 0
biomarkers NNS 0
of IN 0
oxidant/antioxidant JJ 0
status NN 0
. . 0

To TO 0
this DT 0
end NN 0
, , 0
a DT 0
controlled VBN 0
dietary NN 0
study NN 0
was VBD 0
conducted VBN 0
in IN 0
74 CD 0
healthy JJ 0
men NNS 0
and CC 0
women NNS 0
. . 0

The DT 0
participants NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
1 CD 0
of IN 0
3 CD 0
interventions NNS 0
in IN 0
which WDT 0
margarines NNS 0
fortified VBD 0
with IN 0
either DT 0
10 CD 0
weight NN 0
percent NN 0
ALA NNP 0
, , 0
EPA NNP 0
, , 0
or CC 0
DHA NNP 0
ethyl VBP 0
esters NNS 0
replaced VBD 0
their PRP$ 0
normal JJ 0
spread NN 0
for IN 0
6 CD 0
wk NN 0
. . 0

The DT 0
total JJ 0
intakes NNS 0
of IN 0
ALA NNP 0
, , 0
EPA NNP 0
, , 0
and CC 0
DHA NNP 0
were VBD 0
4.4 CD 0
, , 0
2.2 CD 0
, , 0
and CC 0
2.3 CD 0
g/d NN 0
, , 0
respectively RB 0
. . 0

Consuming VBG 0
EPA NNP 0
increased VBD 0
the DT 0
erythrocyte JJ 0
proportion NN 0
of IN 0
EPA NNP 0
( ( 0
394 CD 0
% NN 0
) ) 0
and CC 0
the DT 0
omega-3 JJ 0
index NN 0
( ( 0
sum NN 0
of IN 0
EPA NNP 0
and CC 0
DHA NNP 0
, , 0
38 CD 0
% NN 0
) ) 0
. . 0

Consumption NN 0
of IN 0
DHA NNP 0
increased VBD 0
erythrocyte JJ 0
DHA NNP 0
( ( 0
91 CD 0
% NN 0
) ) 0
, , 0
the DT 0
omega-3 JJ 0
index NN 0
( ( 0
98 CD 0
% NN 0
) ) 0
, , 0
and CC 0
EPA NNP 0
( ( 0
137 CD 0
% NN 0
) ) 0
. . 0

The DT 0
omega-3 JJ 0
index NN 0
increased VBD 0
to TO 0
a DT 0
significantly RB 0
greater JJR 0
extent NN 0
in IN 0
the DT 0
DHA NNP 0
group NN 0
than IN 0
in IN 0
the DT 0
EPA NNP 0
group NN 0
. . 0

ALA NNP 0
did VBD 0
not RB 0
increase VB 0
erythrocyte NN 0
EPA NNP 0
or CC 0
the DT 0
omega-3 JJ 0
index NN 0
. . 0

We PRP 0
found VBD 0
no DT 0
change NN 0
in IN 0
plasma NN 0
uric JJ 0
acid NN 0
or CC 0
antioxidant JJ 0
capacity NN 0
in IN 0
any DT 0
of IN 0
the DT 0
groups NNS 0
. . 0

Plasma NNP 0
malondialdehyde NN 0
( ( 0
MDA NNP 0
) ) 0
increased VBD 0
with IN 0
the DT 0
EPA NNP 0
and CC 0
DHA NNP 0
interventions NNS 0
. . 0

All DT 0
3 CD 0
interventions NNS 0
decreased VBD 0
erythrocyte JJ 0
linoleic NN 0
acid NN 0
hydroperoxides NNS 0
but CC 0
did VBD 0
not RB 0
affect VB 0
their PRP$ 0
MDA NNP 0
concentrations NNS 0
. . 0

In IN 0
conclusion NN 0
, , 0
the DT 0
intake NN 0
of IN 0
both DT 0
isolated JJ 0
EPA NNP 0
and CC 0
DHA NNP 0
incorporated VBD 0
into IN 0
margarine NN 0
resulted VBN 0
in IN 0
an DT 0
enhanced JJ 0
incorporation NN 0
of IN 0
EPA NNP 0
and CC 0
DHA NNP 0
into IN 0
erythrocytes NNS 0
. . 0

Our PRP$ 0
findings NNS 0
indicate VBP 0
that IN 0
DHA NNP 0
is VBZ 0
quantitatively RB 0
superior JJ 0
to TO 0
EPA NNP 0
in IN 0
view NN 0
of IN 0
the DT 0
EPA+DHA NNP 0
tissue NN 0
incorporation NN 0
and CC 0
also RB 0
that IN 0
4 CD 0
g/d NN 0
ALA NNP 0
is VBZ 0
not RB 0
sufficient JJ 0
to TO 0
increase VB 0
the DT 0
omega-3 JJ 0
index NN 0
over IN 0
a DT 0
6-wk JJ 0
period NN 0
. . 0

Immunological JJ 0
changes NNS 0
after IN 0
minimally RB 0
invasive JJ 0
or CC 0
conventional JJ 0
esophageal JJ 0
resection NN 0
for IN 0
cancer NN 4
: : 0
a DT 0
randomized JJ 0
trial NN 0
. . 0

BACKGROUND VB 0
This DT 0
study NN 0
was VBD 0
performed VBN 0
as IN 0
a DT 0
substudy NN 0
analysis NN 0
of IN 0
a DT 0
randomized JJ 0
trial NN 0
comparing VBG 0
conventional JJ 0
open JJ 0
esophagectomy NN 0
[ NNP 0
open JJ 0
surgical JJ 0
technique NN 0
( ( 0
OE NNP 0
) ) 0
] NN 0
by IN 0
thoracotomy NN 0
and CC 0
laparotomy NN 0
with IN 0
minimally RB 0
invasive JJ 0
esophagectomy NN 0
[ NNP 0
minimally RB 0
invasive JJ 0
procedure NN 0
( ( 0
MIE NNP 0
) ) 0
] NN 0
by IN 0
thoracoscopy NN 0
and CC 0
laparoscopy NN 0
. . 0

This DT 0
additional JJ 0
analysis NN 0
focuses VBZ 0
on IN 0
the DT 0
immunological JJ 0
changes NNS 0
and CC 0
surgical JJ 0
stress NN 0
response NN 0
in IN 0
these DT 0
two CD 0
randomized VBD 0
groups NNS 0
of IN 0
a DT 0
single JJ 0
center NN 0
. . 0

METHODS NNP 0
Patients NNPS 0
with IN 0
a DT 0
resectable JJ 4
esophageal NN 4
cancer NN 4
were VBD 0
randomized VBN 0
to TO 0
OE NNP 0
( ( 0
n JJ 0
= NNP 0
13 CD 3
) ) 0
or CC 0
MIE NNP 0
( ( 0
n JJ 0
= NNP 0
14 CD 3
) ) 0
. . 0

All DT 0
patients NNS 0
received VBD 0
neoadjuvant JJ 0
chemoradiotherapy NN 0
. . 0

The DT 0
immunological JJ 0
response NN 0
was VBD 0
measured VBN 0
by IN 0
means NNS 0
of IN 0
leukocyte NN 0
counts NNS 0
, , 0
HLA-DR NNP 0
expression NN 0
on IN 0
monocytes NNS 0
, , 0
the DT 0
acute-phase JJ 0
response NN 0
by IN 0
means NNS 0
of IN 0
C-reactive JJ 0
protein NN 0
( ( 0
CRP NNP 0
) ) 0
, , 0
interleukin-6 JJ 0
( ( 0
IL-6 NNP 0
) ) 0
, , 0
and CC 0
interleukin-8 JJ 0
( ( 0
IL-8 NNP 0
) ) 0
, , 0
and CC 0
the DT 0
stress NN 0
response NN 0
was VBD 0
measured VBN 0
by IN 0
cortisol NN 0
, , 0
growth NN 0
hormone NN 0
, , 0
and CC 0
prolactin NN 0
. . 0

All DT 0
parameters NNS 0
were VBD 0
determined VBN 0
at IN 0
baseline NN 0
( ( 0
preoperatively RB 0
) ) 0
and CC 0
24 CD 0
, , 0
72 CD 0
, , 0
96 CD 0
, , 0
and CC 0
168 CD 0
h NN 0
postoperatively RB 0
. . 0

RESULTS NNP 0
Significant JJ 0
differences NNS 0
between IN 0
the DT 0
two CD 0
groups NNS 0
were VBD 0
seen VBN 0
in IN 0
favor NN 0
of IN 0
the DT 0
MIE NNP 0
group NN 0
with IN 0
regard NN 0
to TO 0
leukocyte VB 0
counts NNS 0
, , 0
IL-8 NNP 0
, , 0
and CC 0
prolactin NN 0
at IN 0
168 CD 0
h NN 0
( ( 0
1 CD 0
week NN 0
) ) 0
postoperatively RB 0
. . 0

For IN 0
HLA-DR NNP 0
expression NN 0
, , 0
IL-6 NNP 0
, , 0
and CC 0
CRP NNP 0
levels NNS 0
, , 0
there EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
between IN 0
the DT 0
two CD 0
groups NNS 0
, , 0
although IN 0
there EX 0
was VBD 0
a DT 0
clear JJ 0
rise NN 0
in IN 0
levels NNS 0
upon IN 0
operation NN 0
in IN 0
both DT 0
groups NNS 0
. . 0

CONCLUSION NNP 0
In IN 0
this DT 0
substudy NN 0
of IN 0
a DT 0
randomized JJ 0
trial NN 0
comparing VBG 0
minimally RB 0
invasive JJ 0
and CC 0
conventional JJ 0
open JJ 0
esophagectomies NNS 0
for IN 0
cancer NN 0
, , 0
significantly RB 0
better RBR 0
preserved VBN 0
leukocyte JJ 0
counts NNS 0
and CC 0
IL-8 JJ 0
levels NNS 0
were VBD 0
observed VBN 0
in IN 0
the DT 0
MIE NNP 0
group NN 0
compared VBN 0
to TO 0
the DT 0
open JJ 0
group NN 0
. . 0

Both DT 0
findings NNS 0
can MD 0
be VB 0
related VBN 0
to TO 0
fewer JJR 0
respiratory NN 0
infections NNS 0
found VBD 0
postoperatively RB 0
in IN 0
the DT 0
MIE NNP 0
group NN 0
. . 0

Moreover RB 0
, , 0
significant JJ 0
differences NNS 0
in IN 0
the DT 0
prolactin NN 0
levels NNS 0
at IN 0
168 CD 0
h NN 0
after IN 0
surgery NN 0
imply NN 0
that IN 0
the DT 0
stress NN 0
response NN 0
is VBZ 0
better RBR 0
preserved VBN 0
in IN 0
the DT 0
MIE NNP 0
group NN 0
. . 0

These DT 0
findings NNS 0
indicate VBP 0
that IN 0
less JJR 0
surgical JJ 0
trauma NN 0
could MD 0
lead VB 0
to TO 0
better JJR 0
preserved VBN 0
acute-phase NN 0
and CC 0
stress NN 0
responses NNS 0
and CC 0
fewer JJR 0
clinical JJ 0
manifestations NNS 0
of IN 0
respiratory JJ 0
infections NNS 0
. . 0

Pedantic JJ 0
speaking NN 0
style NN 0
differentiates VBZ 0
Asperger NNP 0
syndrome NN 0
from IN 0
high-functioning JJ 0
autism NN 0
. . 0

Asperger NNP 0
syndrome NN 0
( ( 0
AS IN 0
) ) 0
is VBZ 0
a DT 0
pervasive JJ 0
developmental NN 0
disorder NN 0
recently RB 0
introduced VBD 0
as IN 0
a DT 0
new JJ 0
diagnostic JJ 0
category NN 0
in IN 0
the DT 0
ICD-10 NNP 0
and CC 0
the DT 0
DSM-IV NNP 0
. . 0

Along IN 0
with IN 0
motor NN 0
clumsiness NN 0
, , 0
pedantic JJ 0
speech NN 0
has VBZ 0
been VBN 0
proposed VBN 0
as IN 0
a DT 0
clinical JJ 0
feature NN 0
of IN 0
AS NNP 0
. . 0

However RB 0
, , 0
few JJ 0
attempts NNS 0
have VBP 0
been VBN 0
made VBN 0
to TO 0
define VB 0
and CC 0
measure VB 0
this DT 0
symptom NN 0
. . 0

We PRP 0
studied VBD 0
17 CD 3
patients NNS 0
with IN 0
AS NNP 4
( ( 0
ICD-10 NNP 0
; : 0
14 CD 3
male NN 2
, , 0
3 CD 3
female NN 2
; : 0
mean JJ 0
age NN 0
16.4 CD 1
years NNS 0
, , 0
mean JJ 0
full-scale JJ 0
IQ NNP 0
97 CD 0
) ) 0
and CC 0
compared VBN 0
them PRP 0
with IN 0
a DT 0
control NN 0
group NN 0
of IN 0
13 CD 3
patients NNS 0
with IN 0
normal-intelligence JJ 4
autism NN 4
or CC 0
high-functioning JJ 4
autism NN 4
( ( 0
HFA NNP 4
) ) 0
( ( 0
ICD-10/DSM-III-R NNP 0
; : 0
12 CD 3
male NN 2
, , 0
1 CD 3
female NN 2
; : 0
mean JJ 0
age NN 0
15.5 CD 1
years NNS 0
, , 0
mean JJ 0
full-scale JJ 0
IQ NNP 0
81.2 CD 0
) ) 0
. . 0

An DT 0
operational JJ 0
definition NN 0
of IN 0
pedantic JJ 0
speech NN 0
was VBD 0
formulated VBN 0
and CC 0
a DT 0
rating NN 0
scale NN 0
devised VBD 0
. . 0

13 CD 0
( ( 0
76 CD 0
% NN 0
) ) 0
of IN 0
the DT 0
AS NNP 4
patients NNS 0
were VBD 0
rated VBN 0
as IN 0
pedantic JJ 0
compared VBN 0
to TO 0
4 CD 0
( ( 0
31 CD 0
% NN 0
) ) 0
of IN 0
the DT 0
HFA NNP 4
group NN 0
( ( 0
chi JJ 0
2 CD 0
= JJ 0
6.3 CD 0
; : 0
p NN 0
= NNP 0
.01 NNP 0
) ) 0
. . 0

Results VB 0
suggest JJS 0
that IN 0
pedantic JJ 0
speech NN 0
is VBZ 0
common JJ 0
in IN 0
AS NNP 0
and CC 0
may MD 0
help VB 0
differentiate VB 0
AS IN 0
from IN 0
high-functioning JJ 0
autism NN 0
. . 0

The DT 0
effects NNS 0
of IN 0
physical JJ 0
and CC 0
emotional JJ 0
status NN 0
on IN 0
adherence NN 0
to TO 0
a DT 0
low-fat JJ 0
dietary JJ 0
pattern NN 0
in IN 0
the DT 0
Women NNP 0
's POS 0
Health NNP 0
Initiative NNP 0
. . 0

OBJECTIVE NNP 0
To TO 0
examine VB 0
whether IN 0
the DT 0
effects NNS 0
of IN 0
physical JJ 0
and CC 0
emotional JJ 0
status NN 0
on IN 0
adherance NN 0
to TO 0
a DT 0
low-fat JJ 0
( ( 0
20 CD 0
% NN 0
energy NN 0
) ) 0
dietary JJ 0
pattern NN 0
are VBP 0
mediated VBN 0
by IN 0
participation NN 0
in IN 0
an DT 0
intervention NN 0
program NN 0
( ( 0
attending VBG 0
sessions NNS 0
and CC 0
self-monitoring NN 0
) ) 0
. . 0

DESIGN VB 0
The DT 0
Baron NNP 0
and CC 0
Kenny NNP 0
mediator NN 0
model NN 0
, , 0
a DT 0
series NN 0
of IN 0
4 CD 0
regression NN 0
analyses NNS 0
, , 0
was VBD 0
used VBN 0
to TO 0
evaluate VB 0
whether IN 0
: : 0
a DT 0
) ) 0
physical JJ 0
and CC 0
emotional JJ 0
status NN 0
predicted VBD 0
program NN 0
participation NN 0
, , 0
b NN 0
) ) 0
program NN 0
participation NN 0
predicted VBD 0
dietary JJ 0
adherence NN 0
, , 0
c NN 0
) ) 0
physical JJ 0
and CC 0
emotional JJ 0
status NN 0
factors NNS 0
predicted VBD 0
dietary JJ 0
adherence NN 0
, , 0
and CC 0
, , 0
ultimately RB 0
d NN 0
) ) 0
the DT 0
effects NNS 0
of IN 0
physical JJ 0
and CC 0
emotional JJ 0
status NN 0
on IN 0
dietary JJ 0
adherence NN 0
were VBD 0
mediated VBN 0
by IN 0
program NN 0
participation NN 0
. . 0

SUBJECTS/SETTING NNP 0
Data NNP 0
from IN 0
13,277 CD 3
postmenopausal JJ 4
women NNS 2
randomly RB 0
assigned VBN 0
to TO 0
the DT 0
low-fat JJ 0
intervention NN 0
arm NN 0
of IN 0
the DT 0
Women NNP 0
's POS 0
Health NNP 0
Initiative NNP 0
Dietary NNP 0
Modification NNP 0
Trial NNP 0
. . 0

INTERVENTION NNP 0
The DT 0
nutrition NN 0
goals NNS 0
for IN 0
women NNS 0
randomly RB 0
assigned VBN 0
to TO 0
the DT 0
low-fat JJ 0
intervention NN 0
were VBD 0
to TO 0
reduce VB 0
total JJ 0
fat JJ 0
intake NN 0
to TO 0
20 CD 0
% NN 0
or CC 0
less JJR 0
of IN 0
energy NN 0
from IN 0
fat JJ 0
and CC 0
to TO 0
consume VB 0
5 CD 0
or CC 0
more JJR 0
fruit/vegetable JJ 0
servings NNS 0
daily RB 0
and CC 0
6 CD 0
or CC 0
more JJR 0
grain JJ 0
servings NNS 0
daily RB 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURES NNP 0
Year NNP 0
1 CD 0
program NN 0
participation NN 0
( ( 0
degree NN 0
of IN 0
attending VBG 0
group NN 0
sessions NNS 0
and CC 0
submitting VBG 0
fat JJ 0
scores NNS 0
) ) 0
and CC 0
adherence NN 0
to TO 0
the DT 0
low-fat JJ 0
dietary JJ 0
pattern NN 0
( ( 0
percent JJ 0
energy NN 0
from IN 0
fat NN 0
) ) 0
as IN 0
predicted VBN 0
by IN 0
baseline JJ 0
physical JJ 0
and CC 0
emotional JJ 0
status NN 0
( ( 0
eight CD 0
SF-36 NNP 0
Health NNP 0
Survey NNP 0
subscales VBZ 0
) ) 0
. . 0

RESULTS NNP 0
Participating VBG 0
in IN 0
the DT 0
dietary JJ 0
intervention NN 0
program NN 0
reduced VBN 0
( ( 0
mediated VBN 0
) ) 0
the DT 0
negative JJ 0
effect NN 0
of IN 0
poorer JJR 0
mental JJ 0
health NN 0
on IN 0
dietary JJ 0
adherence NN 0
by IN 0
15 CD 0
% NN 0
. . 0

Additional JJ 0
findings NNS 0
included VBD 0
that IN 0
a DT 0
10 CD 0
% NN 0
increase NN 0
in IN 0
physical JJ 0
functioning NN 0
increased VBD 0
session NN 0
attendance NN 0
by IN 0
0.4 CD 0
% NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
and CC 0
a DT 0
10 CD 0
% NN 0
increase NN 0
in IN 0
mental JJ 0
health NN 0
predicted VBD 0
a DT 0
decrease NN 0
in IN 0
percent NN 0
energy NN 0
from IN 0
fat NN 0
of IN 0
0.3 CD 0
% NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

Program NNP 0
participation NN 0
had VBD 0
a DT 0
marked JJ 0
effect NN 0
on IN 0
dietary JJ 0
adherence NN 0
: : 0
a DT 0
10 CD 0
% NN 0
increase NN 0
in IN 0
session NN 0
attendance NN 0
predicted VBD 0
a DT 0
1.2 CD 0
% NN 0
decrease NN 0
in IN 0
percent NN 0
energy NN 0
from IN 0
fat JJ 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

APPLICATIONS/CONCLUSIONS NNP 0
Understanding NNP 0
and CC 0
using VBG 0
instruments NNS 0
to TO 0
assess VB 0
the DT 0
physical JJ 0
and CC 0
emotional JJ 0
status NN 0
of IN 0
a DT 0
target NN 0
population NN 0
will MD 0
help VB 0
dietetic JJ 0
professionals NNS 0
promote VBP 0
healthful JJ 0
dietary JJ 0
change NN 0
and CC 0
maintenance NN 0
. . 0

Warfarin NNP 0
for IN 0
atrial JJ 4
fibrillation NN 4
. . 0

The DT 0
patient NN 0
's POS 0
perspective NN 0
. . 0

OBJECTIVE UH 0
To TO 0
determine VB 0
the DT 0
minimal JJ 0
clinically RB 0
important JJ 0
difference NN 0
( ( 0
MCID NNP 0
) ) 0
of IN 0
warfarin NN 0
therapy NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
nonvalvular JJ 4
atrial JJ 4
fibrillation NN 4
from IN 0
the DT 0
perspective NN 0
of IN 0
patients NNS 0
using VBG 0
2 CD 0
different JJ 0
elicitation NN 0
methods NNS 0
. . 0

DESIGN NNP 0
All DT 0
patients NNS 0
completed VBD 0
2 CD 0
face-to-face JJ 0
interviews NNS 0
, , 0
which WDT 0
were VBD 0
2 CD 0
weeks NNS 0
apart RB 0
. . 0

For IN 0
each DT 0
interview NN 0
, , 0
they PRP 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
1 CD 0
of IN 0
2 CD 0
elicitation NN 0
methods NNS 0
: : 0
ping-ponging NN 0
or CC 0
starting VBG 0
at IN 0
the DT 0
known JJ 0
efficacy NN 0
. . 0

SETTING CC 0
The DT 0
practices NNS 0
of IN 0
2 CD 0
university-affiliated JJ 0
family NN 0
medicine NN 0
centers NNS 0
( ( 0
8 CD 0
physicians NNS 0
each DT 0
) ) 0
, , 0
14 CD 0
community-based JJ 0
family NN 0
physicians NNS 0
, , 0
and CC 0
2 CD 0
cardiologists NNS 0
. . 0

PATIENTS VB 0
Sixty-four JJ 3
patients NNS 0
with IN 0
nonvalvular JJ 4
atrial JJ 4
fibrillation NN 4
who WP 0
were VBD 0
initiated VBN 0
with IN 0
warfarin JJ 0
therapy NN 0
at IN 0
least JJS 0
3 CD 0
months NNS 0
before IN 0
the DT 0
study NN 0
. . 0

INTERVENTION NNP 0
During IN 0
each DT 0
interview NN 0
, , 0
the DT 0
patients NNS 0
' POS 0
MCIDs NNP 0
were VBD 0
determined VBN 0
by IN 0
using VBG 0
( ( 0
1 CD 0
) ) 0
a DT 0
pictorial JJ 0
flip NN 0
chart NN 0
to TO 0
describe VB 0
atrial JJ 0
fibrillation NN 0
; : 0
the DT 0
consequences NNS 0
of IN 0
a DT 0
minor JJ 0
stroke NN 0
, , 0
a DT 0
major JJ 0
stroke NN 0
, , 0
and CC 0
a DT 0
major JJ 0
bleeding NN 0
episode NN 0
; : 0
the DT 0
chance NN 0
of IN 0
stroke NN 0
if IN 0
not RB 0
taking VBG 0
warfarin NN 0
; : 0
the DT 0
chance NN 0
of IN 0
a DT 0
major JJ 0
bleeding NN 0
episode NN 0
if IN 0
taking VBG 0
warfarin NN 0
; : 0
examples NNS 0
of IN 0
the DT 0
inconvenience NN 0
, , 0
minor JJ 0
side NN 0
effects NNS 0
, , 0
and CC 0
costs NNS 0
of IN 0
warfarin JJ 0
therapy NN 0
; : 0
and CC 0
then RB 0
( ( 0
2 CD 0
) ) 0
1 CD 0
of IN 0
the DT 0
2 CD 0
elicitation NN 0
methods NNS 0
to TO 0
determine VB 0
their PRP$ 0
MCIDs NNP 0
( ( 0
the DT 0
smallest JJS 0
reduction NN 0
in IN 0
stroke NN 0
risk NN 0
at IN 0
which WDT 0
the DT 0
patients NNS 0
were VBD 0
willing JJ 0
to TO 0
take VB 0
warfarin NN 0
) ) 0
. . 0

Patients NNS 0
' POS 0
knowledge NN 0
of IN 0
their PRP$ 0
stroke NN 0
risk NN 0
, , 0
acceptability NN 0
of IN 0
the DT 0
interview NN 0
process NN 0
, , 0
and CC 0
factors NNS 0
determining VBG 0
their PRP$ 0
preferences NNS 0
were VBD 0
also RB 0
assessed VBN 0
. . 0

MAIN NNP 0
RESULTS NNP 0
Given NNP 0
a DT 0
baseline NN 0
risk NN 0
of IN 0
having VBG 0
a DT 0
stroke NN 0
in IN 0
the DT 0
next JJ 0
2 CD 0
years NNS 0
, , 0
if IN 0
not RB 0
taking VBG 0
warfarin NN 0
, , 0
of IN 0
10 CD 0
of IN 0
100 CD 0
, , 0
the DT 0
mean JJ 0
MCID NNP 0
was VBD 0
2.01 CD 0
of IN 0
100 CD 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
, , 0
1.60-2.42 JJ 0
) ) 0
. . 0

Fifty-two JJ 0
percent NN 0
of IN 0
the DT 0
patients NNS 0
would MD 0
take VB 0
warfarin NN 0
for IN 0
an DT 0
absolute JJ 0
decrease NN 0
in IN 0
stroke NN 0
risk NN 0
of IN 0
1 CD 0
% NN 0
over IN 0
2 CD 0
years NNS 0
. . 0

Before IN 0
eliciting VBG 0
their PRP$ 0
MCIDs NNP 0
, , 0
patients NNS 0
showed VBD 0
poor JJ 0
knowledge NN 0
of IN 0
their PRP$ 0
stroke NN 0
risk NN 0
, , 0
which WDT 0
improved VBD 0
afterward RB 0
. . 0

The DT 0
interview NN 0
process NN 0
was VBD 0
well RB 0
accepted VBN 0
by IN 0
the DT 0
patients NNS 0
. . 0

The DT 0
MCID NNP 0
using VBG 0
the DT 0
ping-ponging JJ 0
elicitation NN 0
method NN 0
was VBD 0
1.015 CD 0
of IN 0
100 CD 0
smaller JJR 0
compared VBN 0
with IN 0
use NN 0
of IN 0
the DT 0
starting NN 0
at IN 0
the DT 0
known JJ 0
efficacy NN 0
method NN 0
( ( 0
P NNP 0
= NNP 0
.01 NNP 0
) ) 0
. . 0

CONCLUSIONS NN 0
We PRP 0
were VBD 0
able JJ 0
to TO 0
determine VB 0
the DT 0
MCID NNP 0
of IN 0
warfarin NN 0
therapy NN 0
for IN 0
the DT 0
prevention NN 0
of IN 0
stroke NN 0
from IN 0
the DT 0
perspective NN 0
of IN 0
patients NNS 0
with IN 0
nonvalvular JJ 4
atrial JJ 4
fibrillation NN 4
. . 0

Their PRP$ 0
MCIDs NNPS 0
were VBD 0
much RB 0
smaller JJR 0
than IN 0
those DT 0
that WDT 0
have VBP 0
been VBN 0
implied VBN 0
by IN 0
some DT 0
experts NNS 0
and CC 0
clinicians NNS 0
. . 0

The DT 0
interview NN 0
process NN 0
, , 0
using VBG 0
the DT 0
flip JJ 0
chart NN 0
approach NN 0
, , 0
appeared VBD 0
to TO 0
improve VB 0
the DT 0
patients NNS 0
' POS 0
knowledge NN 0
of IN 0
their PRP$ 0
disease NN 0
and CC 0
its PRP$ 0
consequences NNS 0
and CC 0
treatment NN 0
. . 0

The DT 0
method NN 0
used VBN 0
to TO 0
elicit VB 0
the DT 0
patients NNS 0
' POS 0
MCIDs NNP 0
can MD 0
have VB 0
a DT 0
clinically RB 0
important JJ 0
effect NN 0
on IN 0
patient NN 0
responses NNS 0
. . 0

The DT 0
method NN 0
used VBN 0
in IN 0
our PRP$ 0
study NN 0
can MD 0
be VB 0
generalized VBN 0
to TO 0
other JJ 0
conditions NNS 0
and CC 0
, , 0
thus RB 0
, , 0
could MD 0
be VB 0
helpful JJ 0
in IN 0
3 CD 0
ways NNS 0
: : 0
( ( 0
1 CD 0
) ) 0
from IN 0
a DT 0
clinical JJ 0
decision-making NN 0
perspective NN 0
, , 0
it PRP 0
could MD 0
facilitate VB 0
patient-physician JJ 0
communication NN 0
; : 0
( ( 0
2 CD 0
) ) 0
it PRP 0
could MD 0
clarify VB 0
the DT 0
patient NN 0
perspective NN 0
when WRB 0
interpreting VBG 0
the DT 0
results NNS 0
of IN 0
previously RB 0
completed VBN 0
trials NNS 0
; : 0
and CC 0
( ( 0
3 CD 0
) ) 0
it PRP 0
could MD 0
be VB 0
used VBN 0
to TO 0
derive VB 0
more RBR 0
clinically RB 0
relevant JJ 0
sample NN 0
sizes NNS 0
for IN 0
randomized JJ 0
treatment NN 0
trials NNS 0
. . 0

[ JJ 0
Effect NNP 0
of IN 0
Yufeining VBG 0
on IN 0
induced JJ 0
sputum JJ 0
interleukin-8 NN 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 4
obstructive JJ 4
pulmonary JJ 4
disease NN 4
at IN 0
the DT 0
stable JJ 0
phase NN 0
] NNP 0
. . 0

OBJECTIVE NNP 0
To TO 0
evaluate VB 0
the DT 0
effect NN 0
of IN 0
Yufeining NNP 0
, , 0
a DT 0
traditional JJ 0
Chinese JJ 0
medicine NN 0
, , 0
on IN 0
induced JJ 0
sputum NN 0
interleukin-8 JJ 0
( ( 0
IL-8 NNP 0
) ) 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 0
obstructive JJ 0
pulmonary JJ 0
disease NN 0
( ( 0
COPD NNP 4
) ) 0
at IN 0
the DT 0
stable JJ 4
phase NN 4
. . 0

METHODS NNP 0
Thirty-six JJ 3
patients NNS 0
with IN 0
COPD NNP 4
were VBD 0
divided VBN 0
into IN 0
trial NN 0
group NN 0
( ( 0
18 CD 0
cases NNS 0
) ) 0
and CC 0
control NN 0
group NN 0
( ( 0
18 CD 0
cases NNS 0
) ) 0
randomly RB 0
. . 0

The DT 0
trial NN 0
group NN 0
was VBD 0
treated VBN 0
with IN 0
Yufeining VBG 0
pills NNS 0
taken VBN 0
orally RB 0
for IN 0
half PDT 0
a DT 0
year NN 0
; : 0
the DT 0
control NN 0
group NN 0
was VBD 0
not RB 0
given VBN 0
any DT 0
medicine NN 0
. . 0

Routine NNP 0
lung NN 0
function NN 0
was VBD 0
recorded VBN 0
before IN 0
and CC 0
after IN 0
treatment NN 0
. . 0

Total JJ 0
cell NN 0
count NN 0
( ( 0
TCC NNP 0
) ) 0
, , 0
differential JJ 0
cell NN 0
counts NNS 0
( ( 0
DCCs NNP 0
) ) 0
and CC 0
IL-8 NNP 0
in IN 0
induced JJ 0
sputum NN 0
were VBD 0
determined VBN 0
at IN 0
the DT 0
baseline NN 0
and CC 0
6 CD 0
months NNS 0
later RB 0
. . 0

RESULTS VB 0
The DT 0
indices NNS 0
of IN 0
lung NN 0
function NN 0
improved VBD 0
significantly RB 0
after IN 0
6 CD 0
months NNS 0
' POS 0
treatment NN 0
in IN 0
trial NN 0
group NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
; : 0
TCC NNP 0
and CC 0
absolute JJ 0
neutrophil NN 0
count NN 0
decreased VBD 0
significantly RB 0
compared VBN 0
with IN 0
baseline NN 0
in IN 0
the DT 0
trial NN 0
group NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
; : 0
Sputum NNP 0
IL-8 NNP 0
concentration NN 0
dropped VBD 0
significantly RB 0
after IN 0
6 CD 0
months NNS 0
' POS 0
treatment NN 0
, , 0
from IN 0
a DT 0
mean NN 0
of IN 0
5.216 CD 0
+/- JJ 0
2.914 CD 0
microg/L NN 0
to TO 0
4.222 CD 0
+/- JJ 0
2.140 CD 0
microg/L NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

There EX 0
were VBD 0
insignificant JJ 0
changes NNS 0
in IN 0
the DT 0
parameters NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
between IN 0
baseline NN 0
and CC 0
6 CD 0
months NNS 0
later RB 0
. . 0

CONCLUSION NNP 0
Yufeining NNP 0
could MD 0
improve VB 0
lung NN 0
function NN 0
, , 0
decrease NN 0
sputum NN 0
TCC NNP 0
, , 0
absolute JJ 0
neutrophil NN 0
count NN 0
and CC 0
IL-8 NNP 0
concentration NN 0
, , 0
and CC 0
relieve VB 0
airway NN 0
inflammation NN 0
in IN 0
patients NNS 0
with IN 0
COPD NNP 0
in IN 0
the DT 0
stable JJ 0
phase NN 0
. . 0

Psychological JJ 0
well-being NN 0
correlates NNS 0
with IN 0
free JJ 0
thyroxine NN 0
but CC 0
not RB 0
free JJ 0
3,5,3'-triiodothyronine JJ 0
levels NNS 0
in IN 0
patients NNS 0
on IN 0
thyroid JJ 4
hormone NN 4
replacement NN 4
. . 0

CONTEXT NNP 0
AND NNP 0
OBJECTIVE NNP 0
An DT 0
association NN 0
between IN 0
mood NN 0
disorders NNS 0
and CC 0
overt JJ 0
thyroid JJ 0
dysfunction NN 0
is VBZ 0
well RB 0
established VBN 0
, , 0
but CC 0
there EX 0
are VBP 0
few JJ 0
data NNS 0
on IN 0
the DT 0
potential NN 0
for IN 0
thyroid JJ 0
hormone NN 0
levels NNS 0
closer RBR 0
to TO 0
the DT 0
reference NN 0
range NN 0
to TO 0
correlate VB 0
with IN 0
psychological JJ 0
well-being NN 0
. . 0

DESIGN NNP 0
, , 0
SETTING NNP 0
, , 0
AND NNP 0
PATIENTS NNP 0
We PRP 0
analyzed VBD 0
the DT 0
relationship NN 0
between IN 0
psychological JJ 0
well-being NN 0
and CC 0
free JJ 0
T NNP 0
( ( 0
4 CD 0
) ) 0
( ( 0
fT4 NN 0
) ) 0
, , 0
free JJ 0
T NNP 0
( ( 0
3 CD 0
) ) 0
( ( 0
fT3 NN 0
) ) 0
, , 0
TSH NNP 0
, , 0
and CC 0
total JJ 0
rT NN 0
( ( 0
3 CD 0
) ) 0
in IN 0
697 CD 3
patients NNS 0
on IN 0
thyroid JJ 0
hormone NN 0
replacement NN 0
therapy NN 0
at IN 0
entry NN 0
to TO 0
a DT 0
randomized VBN 0
, , 0
controlled VBD 0
trial NN 0
of IN 0
combined JJ 0
T NNP 0
( ( 0
4 CD 0
) ) 0
and CC 0
T NNP 0
( ( 0
3 CD 0
) ) 0
replacement NN 0
therapy NN 0
. . 0

All DT 0
patients NNS 0
were VBD 0
on IN 0
100 CD 0
mug NN 0
or CC 0
more JJR 0
T NNP 0
( ( 0
4 CD 0
) ) 0
. . 0

INTERVENTIONS NNP 0
AND CC 0
MAIN NNP 0
OUTCOME NNP 0
MEASURES NNP 0
Psychological NNP 0
well-being NN 0
was VBD 0
assessed VBN 0
with IN 0
General NNP 0
Health NNP 0
Questionnaire-12 NNP 0
( ( 0
GHQ-12 NNP 0
) ) 0
, , 0
Thyroid NNP 0
Symptom NNP 0
Questionnaire NNP 0
, , 0
and CC 0
Hospital NNP 0
Anxiety NNP 0
and CC 0
Depression NNP 0
Scale NNP 0
. . 0

RESULTS NNP 0
fT NN 0
( ( 0
4 CD 0
) ) 0
and CC 0
TSH NNP 0
showed VBD 0
a DT 0
strong JJ 0
correlation NN 0
with IN 0
GHQ-12 NNP 0
scores NNS 0
( ( 0
fT4 SYM 0
- : 0
b NN 0
: : 0
-0.16 NN 0
, , 0
P NNP 0
= NNP 0
0.005 CD 0
; : 0
TSH NNP 0
- : 0
b NN 0
: : 0
0.663 CD 0
, , 0
P NNP 0
= NNP 0
0.04 CD 0
) ) 0
. . 0

No UH 0
correlations NNS 0
were VBD 0
seen VBN 0
between IN 0
the DT 0
GHQ NNP 0
scores NNS 0
and CC 0
fT3 NN 0
( ( 0
b NN 0
: : 0
0.318 CD 0
, , 0
P NNP 0
= NNP 0
0.275 CD 0
) ) 0
, , 0
rT NN 0
( ( 0
3 CD 0
) ) 0
( ( 0
b NN 0
: : 0
0.095 CD 0
, , 0
P NNP 0
= NNP 0
0.95 CD 0
) ) 0
, , 0
rT NN 0
( ( 0
3 CD 0
) ) 0
to TO 0
fT4 VB 0
ratio NN 0
( ( 0
b NN 0
: : 0
71.83 CD 0
, , 0
P NNP 0
= NNP 0
0.09 CD 0
) ) 0
or CC 0
fT3 VBN 0
to TO 0
rT VB 0
( ( 0
3 CD 0
) ) 0
ratio NN 0
( ( 0
b NN 0
: : 0
0.05 CD 0
, , 0
P NNP 0
= NNP 0
0.32 CD 0
) ) 0
. . 0

The DT 0
correlations NNS 0
remained VBD 0
when WRB 0
the DT 0
data NN 0
set NN 0
was VBD 0
limited VBN 0
to TO 0
patients NNS 0
with IN 0
TSH NNP 0
in IN 0
the DT 0
range NN 0
0.3-4.0 JJ 0
mIU/liter NN 0
. . 0

Similar JJ 0
correlations NNS 0
were VBD 0
seen VBN 0
with IN 0
the DT 0
Thyroid NNP 0
Symptom NNP 0
Questionnaire NNP 0
, , 0
although IN 0
not RB 0
with IN 0
the DT 0
Hospital NNP 0
Anxiety NNP 0
and CC 0
Depression NNP 0
Scale NNP 0
scores NNS 0
. . 0

CONCLUSIONS NNP 0
Differences NNPS 0
in IN 0
fT4 NN 0
and CC 0
TSH NNP 0
concentration NN 0
, , 0
even RB 0
within IN 0
the DT 0
reference NN 0
range NN 0
, , 0
may MD 0
be VB 0
a DT 0
determinant NN 0
of IN 0
psychological JJ 0
well-being NN 0
in IN 0
treated JJ 0
hypothyroid NN 4
patients NNS 0
although IN 0
not RB 0
necessarily RB 0
with IN 0
symptoms NNS 0
typical JJ 0
of IN 0
anxiety NN 0
or CC 0
depression NN 0
. . 0

Short-term JJ 0
studies NNS 0
on IN 0
the DT 0
use NN 0
of IN 0
glycerol NN 0
as IN 0
an DT 0
osmotic JJ 0
agent NN 0
in IN 0
continuous JJ 4
ambulatory JJ 4
peritoneal JJ 4
dialysis NN 4
( ( 0
CAPD NNP 4
) ) 0
. . 0

The DT 0
use NN 0
of IN 0
glycerol NN 0
as IN 0
an DT 0
osmotic JJ 0
agent NN 0
in IN 0
two CD 0
different JJ 0
concentrations NNS 0
( ( 0
92 CD 0
mmol/l NN 0
and CC 0
272 CD 0
mmol/l NN 0
) ) 0
in IN 0
peritoneal JJ 0
dialysis NN 0
fluid NN 0
was VBD 0
investigated VBN 0
over IN 0
3 CD 0
days NNS 0
in IN 0
six CD 3
patients NNS 0
on IN 0
continuous JJ 4
ambulatory JJ 4
peritoneal JJ 4
dialysis NN 4
and CC 0
compared VBN 0
with IN 0
two CD 0
concentrations NNS 0
of IN 0
glucose NN 0
( ( 0
76 CD 0
mmol/l NN 0
and CC 0
215 CD 0
mmol/l NN 0
) ) 0
in IN 0
the DT 0
same JJ 0
patients NNS 0
. . 0

The DT 0
calorific JJ 0
value NN 0
of IN 0
the DT 0
absorbed JJ 0
osmotic JJ 0
agent NN 0
was VBD 0
lower JJR 0
, , 0
by IN 0
19 CD 0
% NN 0
with IN 0
isotonic JJ 0
and CC 0
22 CD 0
% NN 0
with IN 0
hypertonic JJ 0
solutions NNS 0
, , 0
when WRB 0
glycerol NN 0
was VBD 0
used VBN 0
in IN 0
place NN 0
of IN 0
glucose NN 0
. . 0

However RB 0
, , 0
glycerol NN 0
provided VBD 0
significantly RB 0
lower JJR 0
total JJ 0
ultrafiltration NN 0
than IN 0
glucose NN 0
at IN 0
each DT 0
concentration NN 0
, , 0
despite IN 0
a DT 0
higher JJR 0
initial JJ 0
osmotic JJ 0
pressure NN 0
of IN 0
the DT 0
glycerol-based JJ 0
solutions NNS 0
. . 0

Thus RB 0
, , 0
the DT 0
higher JJR 0
concentration NN 0
of IN 0
glycerol NN 0
required VBN 0
to TO 0
provide VB 0
equal JJ 0
ultrafiltration NN 0
may MD 0
offset VB 0
any DT 0
calorific JJ 0
advantage NN 0
. . 0

Equilibration NN 0
of IN 0
creatinine NN 0
and CC 0
urea NN 0
was VBD 0
slower JJR 0
and CC 0
creatinine JJ 0
clearance NN 0
lower RBR 0
with IN 0
glycerol NN 0
. . 0

Solutions NNS 0
containing VBG 0
glycerol NN 0
were VBD 0
initially RB 0
less JJR 0
acid JJ 0
( ( 0
pH JJ 0
6.5 CD 0
) ) 0
than IN 0
those DT 0
containing VBG 0
glucose NN 0
( ( 0
pH JJ 0
5.1 CD 0
) ) 0
. . 0

Blood NNP 0
glycerol NN 0
levels NNS 0
, , 0
which WDT 0
were VBD 0
in IN 0
the DT 0
physiological JJ 0
range NN 0
with IN 0
glucose NN 0
as IN 0
the DT 0
osmotic JJ 0
agent NN 0
, , 0
reached VBD 0
a DT 0
peak JJ 0
80-fold JJ 0
greater JJR 0
at IN 0
4.3 CD 0
+/- JJ 0
0.8 CD 0
mmol/l NN 0
during IN 0
dialysis NN 0
with IN 0
fluid NN 0
containing VBG 0
glycerol NN 0
at IN 0
272 CD 0
mmol/l NN 0
and CC 0
eightfold VB 0
higher JJR 0
at IN 0
0.42 CD 0
+/- JJ 0
0.09 CD 0
mmol/l NN 0
with IN 0
glycerol NN 0
at IN 0
92 CD 0
mmol/l NN 0
. . 0

There EX 0
was VBD 0
no DT 0
evidence NN 0
of IN 0
haemolysis NN 0
or CC 0
other JJ 0
toxic JJ 0
effect NN 0
despite IN 0
these DT 0
levels NNS 0
. . 0

The DT 0
rise NN 0
in IN 0
blood NN 0
glucose NN 0
and CC 0
insulin NN 0
noted VBD 0
during IN 0
the DT 0
use NN 0
of IN 0
glucose-based JJ 0
solutions NNS 0
was VBD 0
not RB 0
found VBN 0
with IN 0
glycerol NN 0
. . 0

Circulating NNP 0
levels NNS 0
of IN 0
lactate NN 0
, , 0
pyruvate NN 0
, , 0
alanine NN 0
, , 0
non-esterified JJ 0
fatty JJ 0
acids NNS 0
and CC 0
the DT 0
ketone NN 0
bodies NNS 0
were VBD 0
similar JJ 0
with IN 0
the DT 0
two CD 0
agents NNS 0
. . 0

Although IN 0
these DT 0
short-term JJ 0
studies NNS 0
have VBP 0
shown VBN 0
no DT 0
conclusive JJ 0
advantage NN 0
of IN 0
glycerol NN 0
over IN 0
glucose JJ 0
, , 0
long-term JJ 0
effects NNS 0
of IN 0
glycerol NN 0
, , 0
particularly RB 0
on IN 0
circulating VBG 0
lipid JJ 0
levels NNS 0
, , 0
will MD 0
determine VB 0
its PRP$ 0
future JJ 0
role NN 0
as IN 0
an DT 0
osmotic JJ 0
agent NN 0
in IN 0
continuous JJ 0
ambulatory JJ 4
peritoneal JJ 4
dialysis NN 4
. . 0

Perioperative JJ 0
myocardial JJ 0
infarctions NNS 0
are VBP 0
common JJ 0
and CC 0
often RB 0
unrecognized JJ 0
in IN 0
patients NNS 0
undergoing VBG 0
hip JJ 4
fracture NN 4
surgery NN 4
. . 0

BACKGROUND IN 0
The DT 0
aim NN 0
of IN 0
this DT 0
prospective JJ 0
cohort NN 0
study NN 0
was VBD 0
to TO 0
assess VB 0
the DT 0
incidence NN 0
and CC 0
characteristics NNS 0
of IN 0
acute JJ 0
myocardial JJ 0
infarction NN 0
in IN 0
patients NNS 0
undergoing JJ 0
surgery NN 4
for IN 0
acute JJ 4
hip NN 4
fracture NN 4
. . 0

METHODS NNP 0
A NNP 0
consecutive JJ 0
cohort NN 0
of IN 0
patients NNS 0
( ( 0
n JJ 0
= NN 0
200 CD 3
, , 0
68 CD 3
men NNS 2
) ) 0
referred VBD 0
to TO 0
acute VB 4
surgical JJ 4
correction NN 0
of IN 0
hip NN 4
fracture NN 4
was VBD 0
studied VBN 0
. . 0

Troponin NNP 0
T NNP 0
( ( 0
TnT NNP 0
) ) 0
measurements NNS 0
and CC 0
electrocardiographic JJ 0
( ( 0
ECG NNP 0
) ) 0
recordings NNS 0
were VBD 0
performed VBN 0
at IN 0
admission NN 0
, , 0
before IN 0
operation NN 0
, , 0
and CC 0
on IN 0
the DT 0
first JJ 0
and CC 0
2nd CD 0
postoperative JJ 0
days NNS 0
, , 0
which WDT 0
were VBD 0
used VBN 0
for IN 0
diagnosis NN 0
. . 0

RESULTS VB 0
The DT 0
age NN 0
of IN 0
the DT 0
patients NNS 0
ranged VBD 0
from IN 0
32 CD 1
to TO 1
98 CD 1
years NNS 0
( ( 0
mean NN 0
, , 0
80.8 CD 1
years NNS 1
) ) 0
, , 0
and CC 0
65 CD 3
patients NNS 0
had VBD 0
a DT 0
history NN 0
of IN 0
coronary JJ 4
artery NN 4
disease NN 4
. . 0

A DT 0
significant JJ 0
rise NN 0
in IN 0
TnT NNP 0
as IN 0
a DT 0
sign NN 0
of IN 0
myocardial JJ 0
infarction NN 0
was VBD 0
observed VBN 0
in IN 0
71 CD 0
patients NNS 0
( ( 0
35.5 CD 0
% NN 0
) ) 0
, , 0
and CC 0
25 CD 0
of IN 0
them PRP 0
had VBD 0
a DT 0
TnT NNP 0
elevation NN 0
exceeding VBG 0
five CD 0
times NNS 0
the DT 0
upper JJ 0
normal JJ 0
limit NN 0
. . 0

TnT NNP 0
elevation NN 0
was VBD 0
observed VBN 0
in IN 0
36 CD 0
patients NNS 0
( ( 0
51 CD 0
% NN 0
) ) 0
already RB 0
before RB 0
surgery NN 0
. . 0

Seven CD 0
patients NNS 0
( ( 0
10 CD 0
% NN 0
) ) 0
had VBD 0
ST NNP 0
elevation NN 0
myocardial JJ 0
infarction NN 0
, , 0
23 CD 0
patients NNS 0
( ( 0
32 CD 0
% NN 0
) ) 0
had VBD 0
new JJ 0
ST NNP 0
depressions NNS 0
, , 0
and CC 0
21 CD 0
patients NNS 0
( ( 0
30 CD 0
% NN 0
) ) 0
had VBD 0
no DT 0
new JJ 0
ST NNP 0
segment NN 0
changes NNS 0
in IN 0
the DT 0
serial JJ 0
electrocardiographic JJ 0
recordings NNS 0
. . 0

In IN 0
40 CD 0
patients NNS 0
( ( 0
56 CD 0
% NN 0
) ) 0
, , 0
the DT 0
perioperative JJ 0
myocardial JJ 0
infarction NN 0
was VBD 0
the DT 0
first JJ 0
manifestation NN 0
of IN 0
coronary JJ 0
artery NN 0
disease NN 0
. . 0

Multivariate NNP 0
logistic JJ 0
regression NN 0
revealed VBD 0
that IN 0
old JJ 0
age NN 0
( ( 0
odds NNS 0
ratio VBP 0
[ CD 0
OR NNP 0
] NNP 0
, , 0
1.06 CD 0
; : 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
[ NNP 0
CI NNP 0
] NNP 0
, , 0
1.02-1.10 JJ 0
; : 0
p VB 0
= $ 0
0.002 CD 0
) ) 0
, , 0
earlier JJR 0
revascularization NN 0
( ( 0
OR NNP 0
, , 0
3.29 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
1.12-9.73 CD 0
; : 0
p CC 0
= VB 0
0.03 CD 0
) ) 0
, , 0
and CC 0
heart NN 0
failure NN 0
( ( 0
OR NNP 0
, , 0
2.42 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
1.04-5.61 CD 0
; : 0
p CC 0
= VB 0
0.04 CD 0
) ) 0
were VBD 0
independent JJ 0
predictors NNS 0
of IN 0
TnT NNP 0
elevation NN 0
. . 0

Majority NNP 0
of IN 0
myocardial JJ 0
infarctions NNS 0
were VBD 0
asymptomatic JJ 0
or CC 0
unrecognized JJ 0
. . 0

Evidence-based JJ 0
medications NNS 0
of IN 0
myocardial JJ 0
infarction NN 0
were VBD 0
seldom RB 0
started VBN 0
and CC 0
cardiologist NN 0
was VBD 0
consulted VBN 0
in IN 0
12 CD 0
patients NNS 0
( ( 0
16.9 CD 0
% NN 0
) ) 0
. . 0

CONCLUSION JJ 0
Patients NNS 0
with IN 0
hip JJ 0
fracture NN 0
often RB 0
develop VBZ 0
asymptomatic JJ 0
and CC 0
clinically RB 0
unrecognized JJ 0
perioperative JJ 0
myocardial JJ 0
infarctions NNS 0
. . 0

Earlier JJR 0
diagnosis NN 0
and CC 0
appropriate JJ 0
treatment NN 0
of IN 0
cardiac JJ 0
infarction NN 0
may MD 0
improve VB 0
survival NN 0
of IN 0
hip NN 0
fracture NN 0
patients NNS 0
. . 0

LEVEL NNP 0
OF IN 0
EVIDENCE NNP 0
Epidemiologic NNP 0
study NN 0
, , 0
level NN 0
III NNP 0
. . 0

Optimization NN 0
of IN 0
acid JJ 0
suppression NN 0
for IN 0
patients NNS 0
with IN 0
peptic JJ 4
ulcer NN 4
bleeding NN 4
: : 0
an DT 0
intragastric JJ 0
pH-metry NN 0
study NN 0
with IN 0
omeprazole NN 0
. . 0

OBJECTIVE UH 0
To TO 0
study VB 0
whether IN 0
an DT 0
intravenous JJ 0
infusion NN 0
dose NN 0
of IN 0
omeprazole NN 0
( ( 0
80 CD 0
mg NN 0
+ VBD 0
8 CD 0
mg/h NN 0
) ) 0
during IN 0
24 CD 0
h NNS 0
can MD 0
be VB 0
subsequently RB 0
reduced VBN 0
with IN 0
maintained JJ 0
effect NN 0
. . 0

Second NNP 0
, , 0
to TO 0
study VB 0
the DT 0
effect NN 0
of IN 0
oral JJ 0
omeprazole JJ 0
20 CD 0
mg NN 0
given VBN 0
once RB 0
or CC 0
twice RB 0
daily RB 0
up IN 0
to TO 0
day NN 0
10 CD 0
, , 0
after IN 0
cessation NN 0
of IN 0
a DT 0
3-day JJ 0
intravenous JJ 0
infusion NN 0
( ( 0
80 CD 0
mg NN 0
+ VBD 0
8 CD 0
mg/h NN 0
) ) 0
. . 0

DESIGN NNP 0
Prospective NNP 0
, , 0
randomized VBD 0
, , 0
partly RB 0
blinded VBD 0
study NN 0
. . 0

METHODS NNP 0
Twelve NNP 3
Helicobacter NNP 4
pylori NN 4
( ( 4
+ NNP 4
) ) 4
patients NNS 4
and CC 0
12 CD 3
H. NNP 4
pylori NN 4
( ( 4
- : 4
) ) 4
subjects NNS 0
were VBD 0
included VBN 0
. . 0

In IN 0
part NN 0
I PRP 0
the DT 0
patients NNS 0
received VBD 0
omeprazole JJ 0
, , 0
80 CD 0
mg NN 0
+ VBD 0
8 CD 0
mg/h NN 0
, , 0
during IN 0
24 CD 0
h NN 0
followed VBN 0
by IN 0
8 CD 0
, , 0
4 CD 0
or CC 0
2 CD 0
mg/h NN 0
. . 0

In IN 0
part NN 0
II NNP 0
the DT 0
subjects NNS 0
received VBD 0
80 CD 0
mg NNS 0
+ VBD 0
8 CD 0
mg/h NN 0
during IN 0
3 CD 0
days NNS 0
followed VBN 0
by IN 0
20 CD 0
mg NNS 0
omeprazole JJ 0
orally RB 0
, , 0
once RB 0
or CC 0
twice JJ 0
daily JJ 0
until IN 0
day NN 0
10 CD 0
. . 0

Intragastric NNP 0
pH NN 0
was VBD 0
measured VBN 0
. . 0

RESULTS NNP 0
All NNP 0
H. NNP 0
pylori FW 0
( ( 0
+ NN 0
) ) 0
patients NNS 0
showed VBD 0
a DT 0
rapid JJ 0
increase NN 0
of IN 0
intragastric JJ 0
pH NN 0
with IN 0
a DT 0
mean JJ 0
intragastric JJ 0
pH NN 0
of IN 0
6.7 CD 0
during IN 0
the DT 0
second JJ 0
half NN 0
of IN 0
the DT 0
first JJ 0
day NN 0
. . 0

After IN 0
the DT 0
subsequent JJ 0
dose NN 0
reduction NN 0
, , 0
the DT 0
mean JJ 0
pH NN 0
decreased VBD 0
to TO 0
6.1-6.2 JJ 0
. . 0

Patients NNPS 0
continuing VBG 0
on IN 0
8 CD 0
mg/h NN 0
showed VBD 0
the DT 0
best JJS 0
results NNS 0
. . 0

Likewise NNP 0
, , 0
all DT 0
H. NNP 0
pylori NN 0
( ( 0
- : 0
) ) 0
subjects VBZ 0
showed VBD 0
a DT 0
rapid JJ 0
and CC 0
sustained JJ 0
reduction NN 0
of IN 0
intragastric JJ 0
acidity NN 0
during IN 0
the DT 0
infusion NN 0
. . 0

Subsequent NNP 0
dose JJ 0
reduction NN 0
to TO 0
20 CD 0
mg NNS 0
once RB 0
daily RB 0
led VBN 0
to TO 0
a DT 0
stable JJ 0
fraction NN 0
of IN 0
time NN 0
with IN 0
pH JJ 0
> JJ 0
3 CD 0
of IN 0
72 CD 0
% NN 0
. . 0

CONCLUSIONS NNP 0
Omeprazole NNP 0
given VBN 0
as IN 0
a DT 0
continuous JJ 0
infusion NN 0
of IN 0
80 CD 0
mg NNS 0
+ VBD 0
8 CD 0
mg/h NN 0
for IN 0
72 CD 0
h NN 0
followed VBN 0
by IN 0
omeprazole JJ 0
20 CD 0
mg NN 0
once RB 0
daily RB 0
raised VBD 0
the DT 0
intragastric JJ 0
pH NN 0
to TO 0
and CC 0
above JJ 0
levels NNS 0
alleged VBN 0
to TO 0
allow VB 0
haemostasis NN 0
in IN 0
patients NNS 0
with IN 0
peptic JJ 4
ulcer NN 4
bleeding NN 4
and CC 0
subsequent JJ 0
healing NN 0
of IN 0
the DT 0
ulcer NN 0
. . 0

A DT 0
pilot NN 0
study NN 0
of IN 0
extended JJ 0
duration NN 0
peginterferon NN 0
alfa-2a NN 0
for IN 0
patients NNS 0
with IN 0
hepatitis NN 4
B NNP 4
e VBZ 4
antigen-negative JJ 4
chronic JJ 4
hepatitis NN 4
B NNP 4
. . 0

OBJECTIVES NNP 0
Forty-eight JJ 0
weeks NNS 0
of IN 0
peginterferon NN 0
alfa-2a NN 0
is VBZ 0
the DT 0
approved JJ 0
regimen NNS 0
for IN 0
chronic JJ 4
hepatitis NN 4
B NNP 4
( ( 0
CHB NNP 4
) ) 0
. . 0

Standard NNP 0
interferon NN 0
is VBZ 0
more RBR 0
effective JJ 0
for IN 0
hepatitis NN 0
B NNP 0
e NN 0
antigen NN 0
( ( 0
HBeAg NNP 0
) ) 0
-negative VBP 0
CHB NNP 0
when WRB 0
given VBN 0
for IN 0
longer JJR 0
than IN 0
1 CD 0
yr NN 0
. . 0

This DT 0
study NN 0
evaluated VBD 0
peginterferon JJ 0
alfa-2a NN 0
for IN 0
60 CD 0
wk NN 0
, , 0
alone RB 0
or CC 0
in IN 0
combination NN 0
with IN 0
lamivudine NN 0
. . 0

METHODS NNP 0
Thirteen NNP 3
patients NNS 0
with IN 0
HBeAg-negative JJ 0
CHB NNP 0
received VBD 0
peginterferon JJ 0
alfa-2a JJ 0
( ( 0
180 CD 0
microg/week NN 0
) ) 0
for IN 0
60 CD 0
wk NN 0
or CC 0
peginterferon VB 0
alfa-2a JJ 0
( ( 0
180 CD 0
microg/week NN 0
) ) 0
for IN 0
12 CD 0
wk NN 0
followed VBN 0
by IN 0
48 CD 0
wk NN 0
of IN 0
peginterferon NN 0
alfa-2a JJ 0
plus CC 0
lamivudine JJ 0
. . 0

The DT 0
primary JJ 0
end NN 0
point NN 0
, , 0
sustained VBD 0
virologic JJ 0
response NN 0
( ( 0
SVR NNP 0
) ) 0
, , 0
was VBD 0
defined VBN 0
as IN 0
a DT 0
reduction NN 0
in IN 0
hepatitis NN 0
B NNP 0
virus NN 0
deoxyribonucleic NN 0
acid NN 0
( ( 0
HBV NNP 0
DNA NNP 0
) ) 0
of IN 0
> NNP 0
or=2 FW 0
log10 NN 0
copies/mL NN 0
and CC 0
HBV NNP 0
DNA NNP 0
< VBD 0
20,000 CD 0
copies/mL NN 0
at IN 0
24 CD 0
wk NN 0
of IN 0
follow-up NN 0
( ( 0
week NN 0
84 CD 0
) ) 0
. . 0

Hepatitis $ 0
B NNP 0
surface NN 0
antigen NN 0
( ( 0
HBsAg NNP 0
) ) 0
concentrations NNS 0
were VBD 0
analyzed VBN 0
and CC 0
compared VBN 0
to TO 0
changes NNS 0
in IN 0
HBV NNP 0
DNA NNP 0
. . 0

RESULTS NNP 0
SVR NNP 0
was VBD 0
achieved VBN 0
by IN 0
9/13 CD 0
patients NNS 0
( ( 0
69 CD 0
% NN 0
) ) 0
. . 0

At IN 0
week NN 0
84 CD 0
, , 0
HBV NNP 0
DNA NNP 0
was VBD 0
undetectable JJ 0
by IN 0
polymerase NN 0
chain NN 0
reaction NN 0
in IN 0
5/13 CD 0
( ( 0
38 CD 0
% NN 0
) ) 0
patients NNS 0
, , 0
and CC 0
3 CD 0
additional JJ 0
patients NNS 0
had VBD 0
a DT 0
sustained VBN 0
2-3 CD 0
log NN 0
reduction NN 0
in IN 0
HBV NNP 0
DNA NNP 0
. . 0

Five CD 0
patients NNS 0
demonstrated VBD 0
a DT 0
> JJ 0
90 CD 0
% NN 0
decrease NN 0
in IN 0
HBsAg NNP 0
concentration NN 0
at IN 0
week NN 0
60 CD 0
, , 0
including VBG 0
3 CD 0
with IN 0
undetectable JJ 0
HBV NNP 0
DNA NNP 0
at IN 0
week NN 0
84 CD 0
and CC 0
a DT 0
fourth JJ 0
who WP 0
met VBD 0
criteria NNS 0
for IN 0
SVR NNP 0
. . 0

CONCLUSIONS NNP 0
Sixty NNP 0
weeks NNS 0
of IN 0
peginterferon NN 0
alfa-2a NN 0
with IN 0
or CC 0
without IN 0
lamivudine JJ 0
resulted VBN 0
in IN 0
a DT 0
higher JJR 0
rate NN 0
of IN 0
SVR NNP 0
compared VBN 0
to TO 0
historical JJ 0
controls NNS 0
with IN 0
HBeAg-negative JJ 4
CHB NNP 4
treated VBD 0
with IN 0
48 CD 0
wk NN 0
of IN 0
pegylated JJ 0
interferon NN 0
. . 0

Larger JJR 0
studies NNS 0
are VBP 0
necessary JJ 0
to TO 0
assess VB 0
if IN 0
longer JJR 0
duration NN 0
therapy NN 0
is VBZ 0
more RBR 0
effective JJ 0
than IN 0
the DT 0
standard JJ 0
regimen NNS 0
and CC 0
results NNS 0
in IN 0
a DT 0
greater JJR 0
decline NN 0
in IN 0
HBsAg NNP 0
concentration NN 0
. . 0

The DT 0
dipeptidyl JJ 0
peptidase-4 JJ 0
inhibitor NN 0
PHX1149 NNP 0
improves VBZ 0
blood NN 0
glucose NN 0
control NN 0
in IN 0
patients NNS 0
with IN 0
type JJ 4
2 CD 4
diabetes NNS 4
mellitus RB 4
. . 0

AIM NNP 0
To TO 0
determine VB 0
the DT 0
efficacy NN 0
and CC 0
tolerability NN 0
of IN 0
PHX1149 NNP 0
, , 0
a DT 0
novel JJ 0
dipeptidyl NN 0
peptidase-4 NN 0
( ( 0
DPP4 NNP 0
) ) 0
inhibitor NN 0
, , 0
in IN 0
patients NNS 0
with IN 0
type JJ 4
2 CD 4
diabetes NNS 4
. . 0

METHODS NNP 0
This DT 0
is VBZ 0
a DT 0
multicentre NN 0
, , 0
randomized VBN 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
, , 0
4-week JJ 0
study NN 0
in IN 0
patients NNS 0
with IN 0
type JJ 0
2 CD 0
diabetes NNS 0
with IN 0
suboptimal JJ 0
metabolic JJ 0
control NN 0
. . 0

Patients NNS 0
with IN 0
a DT 0
baseline NN 0
haemoglobin NN 0
A NNP 0
( ( 0
1c CD 0
) ) 0
( ( 0
HbA NNP 0
( ( 0
1c CD 0
) ) 0
) ) 0
of IN 0
7.3 CD 0
to TO 0
11.0 CD 0
% NN 0
were VBD 0
randomized VBN 0
1 CD 0
: : 0
1 CD 0
: : 0
1 CD 0
: : 0
1 CD 0
to TO 0
receive VB 0
once-daily JJ 0
oral JJ 0
therapy NN 0
with IN 0
either DT 0
PHX1149 NNP 0
( ( 0
100 CD 0
, , 0
200 CD 0
or CC 0
400 CD 0
mg NN 0
) ) 0
or CC 0
placebo NN 0
; : 0
patients NNS 0
were VBD 0
on IN 0
a DT 0
constant JJ 0
background NN 0
therapy NN 0
of IN 0
either DT 0
metformin NN 0
alone RB 0
or CC 0
metformin JJ 0
plus CC 0
a DT 0
glitazone NN 0
. . 0

RESULTS NNP 0
Treatment NNP 0
with IN 0
100 CD 0
, , 0
200 CD 0
or CC 0
400 CD 0
mg NN 0
of IN 0
PHX1149 NNP 0
significantly RB 0
decreased VBD 0
postprandial JJ 0
glucose JJ 0
area NN 0
under IN 0
the DT 0
curve NN 0
AUC NNP 0
( ( 0
0-2 JJ 0
h NN 0
) ) 0
by IN 0
approximately RB 0
20 CD 0
% NN 0
( ( 0
+0.11 JJ 0
+/- JJ 0
0.50 CD 0
, , 0
-2.08 VBD 0
+/- JJ 0
0.51 CD 0
, , 0
-1.73 VBD 0
+/- JJ 0
0.49 CD 0
and CC 0
-1.88 VB 0
+/- JJ 0
0.48 CD 0
mmol/l NN 0
x NN 0
h NN 0
, , 0
respectively RB 0
, , 0
for IN 0
placebo NN 0
and CC 0
100 CD 0
, , 0
200 CD 0
and CC 0
400 CD 0
mg NN 0
( ( 0
p JJ 0
= NN 0
0.002 CD 0
, , 0
0.008 CD 0
and CC 0
0.004 CD 0
vs. FW 0
placebo NN 0
) ) 0
. . 0

Postprandial JJ 0
AUC NNP 0
( ( 0
0-2 JJ 0
h NN 0
) ) 0
of IN 0
intact JJ 0
glucagon-like JJ 0
peptide-1 NN 0
, , 0
the DT 0
principal JJ 0
mediator NN 0
of IN 0
the DT 0
biological JJ 0
effects NNS 0
of IN 0
DPP4 NNP 0
inhibitors NNS 0
, , 0
was VBD 0
increased VBN 0
by IN 0
3.90 CD 0
+/- JJ 0
2.83 CD 0
, , 0
11.63 CD 0
+/- JJ 0
2.86 CD 0
, , 0
16.42 CD 0
+/- JJ 0
2.72 CD 0
and CC 0
15.75 CD 0
+/- JJ 0
2.71 CD 0
pmol/l NN 0
x NN 0
h NN 0
, , 0
respectively RB 0
, , 0
for IN 0
placebo NN 0
and CC 0
100 CD 0
, , 0
200 CD 0
and CC 0
400 CD 0
mg NN 0
( ( 0
p JJ 0
= NN 0
0.053 CD 0
, , 0
0.001 CD 0
and CC 0
0.002 CD 0
vs. FW 0
placebo NN 0
) ) 0
. . 0

Mean JJ 0
HbA NNP 0
( ( 0
1c CD 0
) ) 0
was VBD 0
lower JJR 0
in IN 0
all DT 0
dose JJ 0
groups NNS 0
; : 0
the DT 0
placebo-corrected JJ 0
change NN 0
in IN 0
the DT 0
groups NNS 0
receiving VBG 0
400 CD 0
mg JJ 0
PHX1149 NNP 0
was VBD 0
-0.28 VBN 0
% NN 0
( ( 0
p JJ 0
= NNP 0
0.02 CD 0
) ) 0
. . 0

DPP4 NNP 0
inhibition NN 0
on IN 0
day NN 0
28 CD 0
was VBD 0
53 CD 0
, , 0
73 CD 0
and CC 0
78 CD 0
% NN 0
at IN 0
24 CD 0
h NN 0
postdose NN 0
in IN 0
the DT 0
groups NNS 0
receiving VBG 0
100 CD 0
, , 0
200 CD 0
and CC 0
400 CD 0
mg NN 0
PHX1149 NNP 0
, , 0
respectively RB 0
. . 0

There EX 0
were VBD 0
no DT 0
differences NNS 0
in IN 0
adverse JJ 0
events NNS 0
between IN 0
PHX1149-treated NNP 0
and CC 0
placebo JJ 0
subjects NNS 0
. . 0

CONCLUSIONS NNP 0
Addition NNP 0
of IN 0
the DT 0
DPP4 NNP 0
inhibitor NN 0
PHX1149 NNP 0
to TO 0
a DT 0
stable JJ 0
regimen NN 0
of IN 0
metformin NN 0
or CC 0
metformin NN 0
plus CC 0
a DT 0
glitazone NN 0
in IN 0
patients NNS 0
with IN 0
type JJ 0
2 CD 0
diabetes NNS 0
was VBD 0
well RB 0
tolerated VBN 0
and CC 0
improved VBN 0
blood NN 0
glucose NN 0
control NN 0
. . 0

Mechanisms NNP 0
underlying VBG 0
the DT 0
lack NN 0
of IN 0
effect NN 0
of IN 0
implantable JJ 0
cardioverter-defibrillator JJ 0
therapy NN 0
on IN 0
mortality NN 0
in IN 0
high-risk JJ 0
patients NNS 0
with IN 0
recent JJ 0
myocardial JJ 4
infarction NN 4
: : 0
insights NNS 0
from IN 0
the DT 0
Defibrillation NNP 0
in IN 0
Acute NNP 0
Myocardial NNP 0
Infarction NNP 0
Trial NNP 0
( ( 0
DINAMIT NNP 0
) ) 0
. . 0

BACKGROUND NNP 0
although IN 0
implantable JJ 0
cardioverter-defibrillators NNS 0
( ( 0
ICDs NNP 0
) ) 0
lower JJR 0
mortality NN 0
in IN 0
stable JJ 0
patients NNS 0
with IN 0
low JJ 4
ejection NN 4
fraction NN 4
late RB 0
after IN 0
myocardial JJ 0
infarction NN 0
, , 0
randomized VBN 0
trials NNS 0
of IN 0
ICD NNP 0
versus FW 0
control NN 0
subjects NNS 0
implanted VBD 0
early RB 0
after IN 0
myocardial JJ 0
infarction NN 0
do VBP 0
not RB 0
show VB 0
mortality NN 0
benefit NN 0
. . 0

Our PRP$ 0
objective NN 0
was VBD 0
to TO 0
investigate VB 0
possible JJ 0
mechanisms NNS 0
underlying VBG 0
the DT 0
lack NN 0
of IN 0
mortality NN 0
benefit NN 0
in IN 0
the DT 0
Defibrillation NNP 0
in IN 0
Acute NNP 0
Myocardial NNP 0
Infarction NNP 0
Trial NNP 0
( ( 0
DINAMIT NNP 0
) ) 0
. . 0

METHODS NNP 0
AND CC 0
RESULTS NNP 0
this DT 0
is VBZ 0
a DT 0
secondary JJ 0
analysis NN 0
of IN 0
the DT 0
prospective JJ 0
randomized JJ 0
clinical JJ 0
trial NN 0
. . 0

Outpatients NNS 0
with IN 0
recent JJ 0
( ( 0
6 CD 0
to TO 0
40 CD 0
days NNS 0
) ) 0
acute VBP 4
myocardial JJ 4
infarction NN 4
, , 0
left VBD 4
ventricular JJ 4
dysfunction NN 4
( ( 4
ejection JJ 4
fraction NN 4
< VBD 4
35 CD 4
% NN 4
) ) 0
, , 0
and CC 0
low JJ 4
heart NN 4
rate NN 4
variability NN 4
were VBD 0
randomized VBN 0
to TO 0
ICD NNP 0
( ( 0
n=311 NN 0
) ) 0
or CC 0
to TO 0
standard VB 0
medical JJ 0
therapy NN 0
( ( 0
n=342 JJ 0
) ) 0
. . 0

In IN 0
a DT 0
competing-risks JJ 0
analysis NN 0
, , 0
those DT 0
factors NNS 0
that WDT 0
increased VBD 0
the DT 0
risk NN 0
of IN 0
arrhythmic JJ 0
death NN 0
also RB 0
increased VBD 0
the DT 0
risk NN 0
of IN 0
nonarrhythmic JJ 0
deaths NNS 0
. . 0

After IN 0
adjustment NN 0
for IN 0
these DT 0
factors NNS 0
, , 0
receiving VBG 0
an DT 0
ICD NNP 0
was VBD 0
associated VBN 0
with IN 0
a DT 0
decreased JJ 0
risk NN 0
of IN 0
arrhythmic JJ 0
death NN 0
( ( 0
hazard JJ 0
ratio NN 0
, , 0
0.33 CD 0
; : 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
, , 0
0.15 CD 0
to TO 0
0.71 CD 0
) ) 0
but CC 0
an DT 0
increase NN 0
in IN 0
nonarrhythmic JJ 0
death NN 0
( ( 0
hazard JJ 0
ratio NN 0
, , 0
1.70 CD 0
; : 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
, , 0
1.00 CD 0
to TO 0
2.80 CD 0
) ) 0
. . 0

In IN 0
an DT 0
adjusted JJ 0
time-dependent JJ 0
analysis NN 0
, , 0
patients NNS 0
receiving VBG 0
an DT 0
ICD NNP 0
and CC 0
having VBG 0
appropriate JJ 0
ICD NNP 0
therapy NN 0
had VBD 0
a DT 0
15.1 CD 0
% NN 0
yearly RB 0
hazard NN 0
of IN 0
mortality NN 0
compared VBN 0
with IN 0
5.2 CD 0
% NN 0
in IN 0
ICD NNP 4
patients NNS 0
with IN 0
no DT 0
appropriate JJ 0
therapy NN 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

The DT 0
reduction NN 0
in IN 0
sudden JJ 0
death NN 0
in IN 0
ICD NNP 4
patients NNS 0
was VBD 0
completely RB 0
offset VBN 0
by IN 0
increased JJ 0
nonarrhythmic JJ 0
deaths NNS 0
, , 0
which WDT 0
were VBD 0
greatest JJS 0
in IN 0
patients NNS 0
receiving VBG 0
ICD NNP 0
shock NN 0
therapy NN 0
( ( 0
hazard JJ 0
ratio NN 0
, , 0
6.0 CD 0
; : 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
, , 0
2.8 CD 0
to TO 0
12.7 CD 0
) ) 0
. . 0

CONCLUSIONS NNP 0
in IN 0
patients NNS 0
receiving VBG 0
ICDs NNP 4
early RB 0
after IN 0
myocardial JJ 4
infarction NN 4
, , 0
those DT 0
factors NNS 0
that WDT 0
are VBP 0
associated VBN 0
with IN 0
arrhythmia NN 0
requiring VBG 0
ICD NNP 0
therapy NN 0
are VBP 0
also RB 0
associated VBN 0
with IN 0
a DT 0
high JJ 0
risk NN 0
of IN 0
nonsudden JJ 0
death NN 0
, , 0
negating VBG 0
the DT 0
benefit NN 0
of IN 0
ICDs NNP 0
in IN 0
this DT 0
setting NN 0
. . 0

QT/QTc NNP 0
study NN 0
conducted VBD 0
in IN 0
Japanese JJ 0
adult NN 1
healthy JJ 4
subjects NNS 0
: : 0
a DT 0
novel JJ 0
xanthine NN 0
oxidase NN 0
inhibitor NN 0
topiroxostat NN 0
was VBD 0
not RB 0
associated VBN 0
with IN 0
QT NNP 0
prolongation NN 0
. . 0

A DT 0
QT/QTc NNP 0
study NN 0
was VBD 0
conducted VBN 0
in IN 0
compliance NN 0
with IN 0
ICH NNP 0
E14 NNP 0
guideline NN 0
to TO 0
evaluate VB 0
the DT 0
effects NNS 0
of IN 0
a DT 0
new JJ 0
xanthine JJ 0
oxidase NN 0
inhibitor NN 0
topiroxostat NN 0
in IN 0
Japanese JJ 0
healthy JJ 4
subjects NNS 4
. . 0

Forty-eight JJ 3
Japanese JJ 0
healthy JJ 4
subjects NNS 4
( ( 0
males NNS 2
24 CD 3
; : 0
females NNS 2
24 CD 3
) ) 0
received VBD 0
a DT 0
single JJ 0
oral JJ 0
dose NN 0
of IN 0
topiroxostat NN 0
( ( 0
60 CD 0
or CC 0
180 CD 0
mg NN 0
) ) 0
, , 0
moxifloxacin FW 0
( ( 0
400 CD 0
mg NN 0
) ) 0
or CC 0
placebo NN 0
in IN 0
a DT 0
single-center JJ 0
, , 0
double-blind JJ 0
, , 0
four-period JJ 0
crossover NN 0
design NN 0
. . 0

Fridericia NNP 0
's POS 0
formula NN 0
( ( 0
QTcF NNP 0
= NNP 0
QT/RR NNP 0
( ( 0
0.33 CD 0
) ) 0
) ) 0
was VBD 0
used VBN 0
as IN 0
a DT 0
primary JJ 0
method NN 0
for IN 0
QT-interval JJ 0
correction NN 0
. . 0

The DT 0
mean JJ 0
QTcF NNP 0
was VBD 0
prolonged VBN 0
by IN 0
moxifloxacin NN 0
, , 0
of IN 0
which WDT 0
largest JJS 0
time-matched JJ 0
difference NN 0
from IN 0
placebo JJ 0
administration NN 0
was VBD 0
13.6 CD 0
milliseconds NNS 0
with IN 0
90 CD 0
% NN 0
confidence NN 0
interval NN 0
( ( 0
CI NNP 0
) ) 0
of IN 0
11.2 CD 0
and CC 0
15.9 CD 0
milliseconds NNS 0
at IN 0
4 CD 0
hours NNS 0
post-dose JJ 0
. . 0

The DT 0
mean JJ 0
QTcF NNP 0
was VBD 0
hardly RB 0
affected VBN 0
by IN 0
either DT 0
dose NN 0
of IN 0
topiroxostat NN 0
, , 0
of IN 0
which WDT 0
largest JJS 0
time-matched JJ 0
difference NN 0
from IN 0
placebo JJ 0
administration NN 0
was VBD 0
2.9 CD 0
milliseconds NNS 0
with IN 0
90 CD 0
% NN 0
CI NNP 0
of IN 0
0.6 CD 0
and CC 0
5.3 CD 0
milliseconds NNS 0
at IN 0
4 CD 0
hours NNS 0
post-dose JJ 0
for IN 0
60 CD 0
mg NN 0
, , 0
and CC 0
2.3 CD 0
milliseconds NNS 0
with IN 0
90 CD 0
% NN 0
CI NNP 0
of IN 0
0 CD 0
and CC 0
4.7 CD 0
milliseconds NNS 0
at IN 0
1 CD 0
hour NN 0
post-dose NN 0
for IN 0
180 CD 0
mg NN 0
. . 0

The DT 0
results NNS 0
were VBD 0
essentially RB 0
the DT 0
same JJ 0
in IN 0
the DT 0
sex NN 0
subgroup NN 0
analysis NN 0
. . 0

Moxifloxacin NNP 0
can MD 0
be VB 0
used VBN 0
as IN 0
a DT 0
positive JJ 0
control NN 0
for IN 0
QT/QTc NNP 0
studies NNS 0
in IN 0
Japanese JJ 0
subjects NNS 0
; : 0
and CC 0
topiroxostat VB 0
may MD 0
not RB 0
cause VB 0
QT-interval JJ 0
prolongation NN 0
in IN 0
males NNS 0
as RB 0
well RB 0
as IN 0
females NNS 0
. . 0

Prophylactic JJ 0
vs NN 0
therapeutic JJ 0
blood NN 0
patch NN 0
for IN 0
obstetric JJ 4
patients NNS 0
with IN 0
accidental JJ 4
dural JJ 4
puncture NN 4
-- : 0
a DT 0
randomised JJ 0
controlled VBN 0
trial NN 0
. . 0

Epidural JJ 0
blood NN 0
patch NN 0
is VBZ 0
a DT 0
standard JJ 0
treatment NN 0
for IN 0
obstetric JJ 4
patients NNS 0
experiencing VBG 0
a DT 0
severe JJ 4
post-dural JJ 4
puncture NN 4
headache NN 4
. . 0

Patients NNS 0
who WP 0
sustained VBD 0
an DT 0
accidental JJ 4
dural JJ 4
puncture NN 4
during IN 0
establishment NN 0
of IN 0
epidural JJ 4
analgesia NN 4
during IN 0
labour NN 4
or CC 0
at IN 0
caesarean JJ 4
delivery NN 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
a DT 0
prophylactic JJ 0
epidural JJ 0
blood NN 0
patch NN 0
or CC 0
conservative JJ 0
treatment NN 0
with IN 0
a DT 0
therapeutic JJ 0
epidural JJ 0
blood NN 0
patch NN 0
if IN 0
required VBN 0
. . 0

Eleven NNP 3
of IN 0
60 CD 3
( ( 0
18.3 CD 0
% NN 0
) ) 0
patients NNS 0
in IN 0
the DT 0
prophylactic JJ 0
epidural JJ 0
blood NN 0
patch NN 0
group NN 0
developed VBD 0
a DT 0
post-dural JJ 0
puncture NN 0
headache NN 0
compared VBN 0
with IN 0
39 CD 3
of IN 0
49 CD 3
( ( 0
79.6 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
therapeutic JJ 0
epidural JJ 0
blood NN 0
patch NN 0
group NN 0
( ( 0
p JJ 0
< NNP 0
0.0001 CD 0
) ) 0
. . 0

A DT 0
blood NN 0
patch NN 0
was VBD 0
performed VBN 0
in IN 0
36 CD 0
( ( 0
73.4 CD 0
% NN 0
) ) 0
of IN 0
patients NNS 0
in IN 0
the DT 0
therapeutic JJ 0
group NN 0
. . 0

The DT 0
number NN 0
of IN 0
patients NNS 0
who WP 0
needed VBD 0
a DT 0
second JJ 0
blood NN 0
patch NN 0
did VBD 0
not RB 0
differ VB 0
significantly RB 0
between IN 0
the DT 0
two CD 0
groups NNS 0
: : 0
6 CD 0
( ( 0
10.0 CD 0
% NN 0
) ) 0
for IN 0
prophylactic JJ 0
epidural JJ 0
blood NN 0
patch NN 0
and CC 0
4 CD 0
( ( 0
11.1 CD 0
% NN 0
) ) 0
for IN 0
therapeutic JJ 0
epidural JJ 0
blood NN 0
patch NN 0
. . 0

We PRP 0
conclude VBP 0
that IN 0
prophylactic JJ 0
epidural JJ 0
blood NN 0
patch NN 0
is VBZ 0
an DT 0
effective JJ 0
method NN 0
to TO 0
reduce VB 0
the DT 0
development NN 0
of IN 0
post-dural JJ 0
puncture NN 0
headache NN 0
in IN 0
obstetric JJ 4
patients NNS 0
. . 0

Family RB 0
education NN 0
for IN 0
people NNS 0
with IN 0
schizophrenia NN 4
in IN 0
Beijing NNP 0
, , 0
China NNP 0
: : 0
randomised VBD 0
controlled JJ 0
trial NN 0
. . 0

BACKGROUND NNP 0
Much NNP 0
of IN 0
China NNP 0
lacks VBZ 0
well-developed JJ 0
services NNS 0
for IN 0
people NNS 0
with IN 0
schizophrenia NN 0
and CC 0
their PRP$ 0
families NNS 0
, , 0
and CC 0
most JJS 0
of IN 0
the DT 0
existing VBG 0
services NNS 0
focus NN 0
on IN 0
hospitals NNS 0
. . 0

There EX 0
is VBZ 0
a DT 0
need NN 0
for IN 0
culturally RB 0
sensitive JJ 0
family NN 0
treatments NNS 0
offered VBN 0
by IN 0
nurses NNS 0
. . 0

AIMS NNP 0
To TO 0
conduct VB 0
a DT 0
longitudinal JJ 0
experimental NN 0
study NN 0
examining VBG 0
the DT 0
effect NN 0
of IN 0
patient NN 0
and CC 0
family NN 0
education NN 0
in IN 0
a DT 0
sample NN 0
of IN 0
Chinese JJ 0
people NNS 0
with IN 0
schizophrenia NN 0
. . 0

METHOD NNP 0
A NNP 0
randomised VBD 0
controlled VBN 0
trial NN 0
was VBD 0
conducted VBN 0
in IN 0
a DT 0
large JJ 0
hospital NN 0
with IN 0
a DT 0
was VBD 0
conducted VBN 0
in IN 0
a DT 0
large JJ 0
hospital NN 0
with IN 0
a DT 0
sample NN 0
of IN 0
101 CD 3
patients NNS 0
with IN 0
schizophrenia NN 0
and CC 0
their PRP$ 0
families NNS 0
. . 0

Data NNS 0
were VBD 0
collected VBN 0
at IN 0
admission NN 0
and CC 0
at IN 0
discharge NN 0
, , 0
and CC 0
then RB 0
at IN 0
3 CD 0
and CC 0
9 CD 0
months NNS 0
after IN 0
discharge NN 0
. . 0

The DT 0
intervention NN 0
group NN 0
received VBD 0
family NN 0
education NN 0
, , 0
and CC 0
data NNS 0
on IN 0
their PRP$ 0
knowledge NN 0
about IN 0
schizophrenia NN 0
, , 0
symptoms NNS 0
, , 0
functioning VBG 0
, , 0
psychosocial JJ 0
behaviour NN 0
, , 0
relapse NN 0
and CC 0
medication NN 0
adherence NN 0
were VBD 0
collected VBN 0
and CC 0
compared VBN 0
with IN 0
the DT 0
control NN 0
group NN 0
. . 0

RESULTS NNP 0
There EX 0
was VBD 0
a DT 0
significant JJ 0
improvement NN 0
in IN 0
knowledge NN 0
about IN 0
schizophrenia NN 0
in IN 0
the DT 0
experimental JJ 0
group NN 0
and CC 0
a DT 0
significant JJ 0
difference NN 0
in IN 0
symptom JJ 0
scores NNS 0
and CC 0
functioning VBG 0
at IN 0
9 CD 0
months NNS 0
after IN 0
discharge NN 0
. . 0

Patients NNS 0
who WP 0
were VBD 0
nonadherent JJ 0
to TO 0
medication NN 0
regimens NNS 0
were VBD 0
more RBR 0
likely JJ 0
to TO 0
relapse VB 0
. . 0

CONCLUSIONS NNP 0
Family NNP 0
education NN 0
on IN 0
schizophrenia NN 0
by IN 0
nurses NNS 0
in IN 0
China NNP 0
was VBD 0
effective JJ 0
in IN 0
improving VBG 0
knowledge NN 0
and CC 0
promoting VBG 0
improvement NN 0
in IN 0
patients NNS 0
' POS 0
symptoms NNS 0
. . 0

Rehabilitation NN 0
of IN 0
therapy-related JJ 0
cognitive JJ 0
deficits NNS 0
in IN 0
patients NNS 0
after IN 0
hematopoietic JJ 4
stem NN 4
cell NN 4
transplantation NN 4
. . 0

Neuropsychological JJ 0
deficits NNS 0
are VBP 0
potential JJ 0
side NN 0
effects NNS 0
of IN 0
hematopoietic JJ 0
stem NN 0
cell NN 0
therapy NN 0
( ( 0
HSCT NNP 0
) ) 0
. . 0

Systematic JJ 0
data NNS 0
on IN 0
the DT 0
long-term JJ 0
course NN 0
of IN 0
and CC 0
therapeutic JJ 0
options NNS 0
for IN 0
these DT 0
consequences NNS 0
are VBP 0
limited VBN 0
. . 0

One CD 3
hundred VBD 3
fifty-seven JJ 3
patients NNS 0
were VBD 0
screened VBN 0
for IN 0
cognitive JJ 4
deficits NNS 4
following VBG 0
HSCT NNP 0
for IN 0
malignant JJ 4
diseases NNS 4
at IN 0
an DT 0
in-patient JJ 0
oncologic NN 0
rehabilitation NN 0
clinic NN 0
. . 0

Patients NNS 0
showing VBG 0
evidence NN 0
of IN 0
impairment NN 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
one CD 0
of IN 0
two CD 0
training VBG 0
groups NNS 0
: : 0
individualized VBN 0
PC-supported JJ 0
training NN 0
or CC 0
neuropsychological JJ 0
group NN 0
therapy NN 0
. . 0

The DT 0
control NN 0
group NN 0
consisted VBD 0
of IN 0
patients NNS 0
who WP 0
received VBD 0
no DT 0
specific JJ 0
training NN 0
. . 0

During IN 0
in-patient JJ 0
rehabilitation NN 0
, , 0
the DT 0
results NNS 0
of IN 0
a DT 0
comprehensive JJ 0
neuropsychological JJ 0
test NN 0
battery NN 0
improved VBD 0
significantly RB 0
in IN 0
all DT 0
three CD 0
groups NNS 0
, , 0
and CC 0
no DT 0
specific JJ 0
intervention NN 0
effects NNS 0
were VBD 0
identified VBN 0
. . 0

Neuropsychological JJ 0
deficits NNS 0
were VBD 0
still RB 0
evident JJ 0
in IN 0
a DT 0
subgroup NN 0
of IN 0
patients NNS 0
6 CD 0
months NNS 0
later RB 0
. . 0

Correlation NN 0
between IN 0
neuropsychological JJ 0
testing NN 0
and CC 0
patients NNS 0
' POS 0
self-evaluation NN 0
of IN 0
cognitive JJ 0
functioning NN 0
in IN 0
daily JJ 0
life NN 0
was VBD 0
generally RB 0
low JJ 0
. . 0

Sustained VBN 0
attention NN 0
and CC 0
verbal-semantic JJ 0
memory NN 0
played VBD 0
the DT 0
main JJ 0
role NN 0
for IN 0
self-appraisal JJ 0
and CC 0
in IN 0
the DT 0
designation NN 0
as IN 0
'neuropsychologically RB 0
impaired VBN 0
' '' 0
. . 0

In IN 0
conclusion NN 0
, , 0
a DT 0
substantial JJ 0
number NN 0
of IN 0
patients NNS 0
revealed JJ 0
evidence NN 0
of IN 0
cognitive JJ 0
deficits NNS 0
a DT 0
long JJ 0
time NN 0
after IN 0
HSCT NNP 0
. . 0

There EX 0
is VBZ 0
a DT 0
need NN 0
for IN 0
more JJR 0
studies NNS 0
and CC 0
for IN 0
the DT 0
development NN 0
of IN 0
differentiated JJ 0
rehabilitative JJ 0
measures NNS 0
for IN 0
such JJ 0
therapeutic JJ 0
consequences NNS 0
. . 0

Shorter NNP 0
treatment NN 0
for IN 0
vaginal JJ 4
candidosis NN 4
: : 0
comparison NN 0
between IN 0
single-dose JJ 0
oral JJ 0
fluconazole NN 0
and CC 0
three-day JJ 0
treatment NN 0
with IN 0
local JJ 0
miconazole NN 0
. . 0

Fluconazole NNP 0
is VBZ 0
an DT 0
effective JJ 0
, , 0
simple JJ 0
and CC 0
safe JJ 0
, , 0
although IN 0
slightly RB 0
expensive JJ 0
, , 0
agent NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
vaginal JJ 4
candidosis NN 4
. . 0

Single-dose JJ 0
fluconazole NN 0
( ( 0
150 CD 0
mg NN 0
) ) 0
administered VBD 0
orally RB 0
in IN 0
capsule NN 0
form NN 0
was VBD 0
compared VBN 0
with IN 0
three-day JJ 0
local JJ 0
treatment NN 0
with IN 0
miconazole JJ 0
pessaries NNS 0
in IN 0
the DT 0
treatment NN 0
of IN 0
vaginal JJ 4
candidosis NN 4
in IN 0
a DT 0
randomized JJ 0
study NN 0
in IN 0
Finland NNP 0
. . 0

Cure NN 0
rates NNS 0
were VBD 0
good JJ 0
( ( 0
> JJ 0
80 CD 0
% NN 0
) ) 0
in IN 0
randomized VBN 0
patient NN 0
groups NNS 0
assessed VBD 0
both DT 0
clinically RB 0
and CC 0
by IN 0
the DT 0
results NNS 0
of IN 0
yeast JJ 0
cultures NNS 0
. . 0

Oral JJ 0
administration NN 0
was VBD 0
preferred VBN 0
to TO 0
local JJ 0
therapy NN 0
by IN 0
patients NNS 0
in IN 0
both DT 0
the DT 0
miconazole NN 0
and CC 0
fluconazole JJ 0
groups NNS 0
. . 0

For IN 0
the DT 0
time NN 0
being VBG 0
, , 0
fluconazole NN 0
is VBZ 0
not RB 0
recommended VBN 0
for IN 0
use NN 0
during IN 0
pregnancy NN 0
or CC 0
lactation NN 0
. . 0

Use NNP 0
and CC 0
limitations NNS 0
of IN 0
Holter NNP 0
electrocardiography NN 0
in IN 0
assessing VBG 0
drug NN 0
therapy NN 0
of IN 0
myocardial JJ 4
ischemia NN 4
during IN 0
the DT 0
peri-PTCA JJ 4
period NN 0
. . 0

Incidence NN 0
and CC 0
pattern NN 0
of IN 0
myocardial JJ 0
ischemia NN 0
during IN 0
the DT 0
peri-PTCA JJ 4
( ( 0
percutaneous JJ 4
transluminal JJ 4
coronary JJ 4
angioplasty NN 4
) ) 0
period NN 0
and CC 0
the DT 0
possible JJ 0
role NN 0
of IN 0
continuous JJ 0
intravenous JJ 0
isosorbide NN 0
dinitrate NN 0
in IN 0
its PRP$ 0
prevention NN 0
were VBD 0
examined VBN 0
prospectively RB 0
in IN 0
30 CD 3
patients NNS 0
. . 0

Holter NNP 0
electrocardiographic JJ 0
monitoring NN 0
was VBD 0
performed VBN 0
for IN 0
21 CD 0
+/- JJ 0
3 CD 0
h NN 0
before IN 0
PTCA NNP 0
and CC 0
continued VBN 0
during IN 0
and CC 0
for IN 0
41 CD 0
+/- JJ 0
8 CD 0
h NN 0
after IN 0
the DT 0
procedure NN 0
. . 0

Before IN 0
PTCA NNP 0
, , 0
19 CD 0
ischemic JJ 0
episodes NNS 0
were VBD 0
present JJ 0
in IN 0
10 CD 0
( ( 0
33 CD 0
% NN 0
) ) 0
of IN 0
30 CD 3
patients NNS 0
. . 0

PTCA NNP 0
produced VBD 0
an DT 0
abrupt JJ 0
decrease NN 0
in IN 0
number NN 0
( ( 0
p JJ 0
= NNP 0
0.015 CD 0
) ) 0
and CC 0
duration NN 0
( ( 0
p JJ 0
= NNP 0
0.03 CD 0
) ) 0
of IN 0
spontaneous JJ 0
ischemic JJ 0
episodes NNS 0
. . 0

The DT 0
rarity NN 0
of IN 0
recurrent JJ 0
myocardial JJ 0
ischemic JJ 0
events NNS 0
by IN 0
Holter NNP 0
monitoring NN 0
after IN 0
PTCA NNP 0
negated VBD 0
any DT 0
attempt NN 0
at IN 0
assessing VBG 0
the DT 0
efficacy NN 0
of IN 0
intravenous JJ 0
isosorbide JJ 0
dinitrate NN 0
in IN 0
their PRP$ 0
prevention NN 0
. . 0

Holter NNP 0
monitoring NN 0
could MD 0
not RB 0
be VB 0
used VBN 0
as IN 0
an DT 0
early JJ 0
predictor NN 0
of IN 0
late JJ 0
coronary JJ 0
restenosis NN 0
. . 0

Effects NNS 0
of IN 0
tonabersat NN 0
on IN 0
migraine NN 4
with IN 4
aura NN 4
: : 0
a DT 0
randomised JJ 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
crossover NN 0
study NN 0
. . 0

BACKGROUND NNP 0
Migraine NNP 0
with IN 0
aura NN 0
is VBZ 0
thought VBN 0
likely RB 0
to TO 0
be VB 0
caused VBN 0
by IN 0
cortical JJ 0
spreading VBG 0
depression NN 0
( ( 0
CSD NNP 0
) ) 0
. . 0

Tonabersat NNP 0
inhibits VBZ 0
CSD NNP 0
, , 0
and CC 0
we PRP 0
therefore RB 0
investigated VBD 0
whether IN 0
tonabersat NN 0
has VBZ 0
a DT 0
preventive JJ 0
effect NN 0
in IN 0
migraine NN 0
with IN 0
aura NN 0
. . 0

METHODS NNP 0
In IN 0
this DT 0
randomised JJ 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
crossover NN 0
trial NN 0
, , 0
40 CD 0
mg NN 0
tonabersat NN 0
once IN 0
daily JJ 0
was VBD 0
compared VBN 0
with IN 0
matched JJ 0
placebo NN 0
in IN 0
patients NNS 0
who WP 0
had VBD 0
at IN 0
least JJS 0
one CD 4
aura NN 4
attack NN 4
per IN 4
month NN 4
during IN 0
the DT 0
past JJ 0
3 CD 0
months NNS 0
. . 0

Randomisation NN 0
was VBD 0
by IN 0
computer-generated JJ 0
list NN 0
. . 0

Patients NNS 0
kept VBD 0
a DT 0
detailed JJ 0
diary NN 0
to TO 0
enable VB 0
objective JJ 0
diagnosis NN 0
of IN 0
each DT 0
attack NN 0
as IN 0
migraine NN 0
with IN 0
aura NN 0
, , 0
migraine NN 0
without IN 0
aura NN 0
, , 0
or CC 0
other JJ 0
type NN 0
of IN 0
headache NN 0
. . 0

Primary JJ 0
endpoints NNS 0
were VBD 0
a DT 0
reduction NN 0
in IN 0
aura NN 0
attacks NNS 0
with IN 0
or CC 0
without IN 0
headache NN 0
and CC 0
a DT 0
reduction NN 0
in IN 0
migraine JJ 0
headache NN 0
days NNS 0
with IN 0
or CC 0
without IN 0
an DT 0
aura NN 0
. . 0

Analysis NN 0
was VBD 0
per IN 0
protocol NN 0
. . 0

This DT 0
trial NN 0
is VBZ 0
registered VBN 0
, , 0
number NN 0
NCT00332007 NNP 0
. . 0

FINDINGS NNP 0
39 CD 3
patients NNS 0
were VBD 0
included VBN 0
in IN 0
the DT 0
study NN 0
, , 0
of IN 0
whom WP 0
31 CD 3
were VBD 0
included VBN 0
in IN 0
the DT 0
statistical JJ 0
analysis NN 0
of IN 0
efficacy NN 0
. . 0

Median JJ 0
( ( 0
IQR NNP 0
) ) 0
attacks NNS 0
of IN 0
aura NN 0
were VBD 0
reduced VBN 0
from IN 0
3.2 CD 0
( ( 0
1.0-5.0 JJ 0
) ) 0
per IN 0
12 CD 0
weeks NNS 0
on IN 0
placebo NN 0
to TO 0
1.0 CD 0
( ( 0
0-3.0 CD 0
) ) 0
on IN 0
tonabersat NN 0
( ( 0
p=0.01 NN 0
) ) 0
, , 0
whereas VBP 0
the DT 0
other JJ 0
primary JJ 0
outcome JJ 0
measure NN 0
, , 0
median JJ 0
migraine NN 0
headache NN 0
days NNS 0
with IN 0
or CC 0
without IN 0
aura NN 0
, , 0
was VBD 0
not RB 0
significantly RB 0
different JJ 0
between IN 0
placebo NN 0
and CC 0
tonabersat NN 0
groups NNS 0
( ( 0
3.0 CD 0
days NNS 0
in IN 0
each DT 0
group NN 0
; : 0
p=0.09 NN 0
) ) 0
. . 0

Tonabersat NNP 0
was VBD 0
well RB 0
tolerated VBN 0
but CC 0
overall JJ 0
had VBD 0
more RBR 0
side-effects NNS 0
than IN 0
placebo NN 0
. . 0

INTERPRETATION NNP 0
Tonabersat NNP 0
showed VBD 0
a DT 0
preventive JJ 0
effect NN 0
on IN 0
attacks NNS 0
of IN 0
migraine NN 0
aura NN 0
but CC 0
no DT 0
efficacy NN 0
on IN 0
non-aura JJ 0
attacks NNS 0
, , 0
in IN 0
keeping VBG 0
with IN 0
its PRP$ 0
known JJ 0
inhibitory JJ 0
effect NN 0
on IN 0
CSD NNP 0
. . 0

The DT 0
results NNS 0
support VBD 0
the DT 0
theory NN 0
that IN 0
auras NNS 0
are VBP 0
caused VBN 0
by IN 0
CSD NNP 0
and CC 0
that IN 0
this DT 0
phenomenon NN 0
is VBZ 0
not RB 0
involved VBN 0
in IN 0
attacks NNS 0
without IN 0
aura NN 0
. . 0

FUNDING NN 0
Minster NNP 0
Pharmaceuticals NNP 0
; : 0
Lundbeck NNP 0
Foundation NNP 0
. . 0

Efficacy NN 0
of IN 0
nebulized JJ 0
flunisolide NN 0
combined VBN 0
with IN 0
salbutamol NN 0
and CC 0
ipratropium NN 0
bromide NN 0
in IN 0
stable JJ 0
patients NNS 0
with IN 0
moderate-to-severe JJ 0
chronic JJ 4
obstructive JJ 4
pulmonary JJ 4
disease NN 4
. . 0

BACKGROUND IN 0
The DT 0
efficacy NN 0
of IN 0
nebulized JJ 0
corticosteroids NNS 0
in IN 0
the DT 0
prevention NN 0
of IN 0
exacerbation NN 0
of IN 0
chronic JJ 0
obstructive JJ 0
pulmonary JJ 0
disease NN 0
( ( 0
COPD NNP 4
) ) 0
has VBZ 0
been VBN 0
poorly RB 0
studied VBN 0
. . 0

OBJECTIVE UH 0
To TO 0
evaluate VB 0
the DT 0
efficacy NN 0
and CC 0
tolerability NN 0
of IN 0
nebulized JJ 0
flunisolide NN 0
( ( 0
1 CD 0
mg NN 0
) ) 0
+ VBZ 0
salbutamol/ipratropium JJ 0
bromide NN 0
( ( 0
1,875/375 CD 0
microg NN 0
) ) 0
b.i.d NN 0
. . 0

in IN 0
comparison NN 0
with IN 0
placebo NN 0
+ NNP 0
salbutamol/ipratropium NN 0
bromide NN 0
. . 0

METHODS NNP 0
This DT 0
was VBD 0
a DT 0
randomized JJ 0
, , 0
parallel-group JJ 0
, , 0
double-blind JJ 0
study NN 0
on IN 0
114 CD 3
patients NNS 0
with IN 0
COPD NNP 4
of IN 0
moderate-to-severe JJ 0
degree NN 0
. . 0

The DT 0
main JJ 0
outcome NN 0
was VBD 0
the DT 0
frequency NN 0
of IN 0
severe JJ 0
exacerbations NNS 0
over IN 0
a DT 0
6-month JJ 0
period NN 0
. . 0

Before IN 0
and CC 0
after IN 0
treatment NN 0
, , 0
respiratory NN 0
symptoms NNS 0
, , 0
forced VBD 0
expiratory JJ 0
volume NN 0
in IN 0
1 CD 0
s NN 0
( ( 0
FEV NNP 0
( ( 0
1 CD 0
) ) 0
) ) 0
, , 0
shuttle JJ 0
walking VBG 0
test NN 0
distance NN 0
and CC 0
St. NNP 0
George NNP 0
's POS 0
Respiratory NNP 0
Questionnaire NNP 0
scores NNS 0
were VBD 0
evaluated VBN 0
. . 0

RESULTS VB 0
The DT 0
total JJ 0
number NN 0
of IN 0
exacerbations NNS 0
was VBD 0
slightly RB 0
lower JJR 0
in IN 0
the DT 0
flunisolide NN 0
group NN 0
compared VBN 0
to TO 0
the DT 0
placebo NN 0
group NN 0
( ( 0
19 CD 0
vs. FW 0
34 CD 0
, , 0
p NN 0
= NNP 0
0.054 CD 0
) ) 0
; : 0
the DT 0
number NN 0
of IN 0
patients NNS 0
experiencing VBG 0
at IN 0
least JJS 0
one CD 0
exacerbation NN 0
during IN 0
the DT 0
study NN 0
was VBD 0
also RB 0
decreased VBN 0
( ( 0
16 CD 0
vs. FW 0
26 CD 0
, , 0
p NN 0
= NNP 0
0.059 CD 0
) ) 0
. . 0

In IN 0
particular JJ 0
, , 0
type JJ 0
3 CD 0
Anthonisens NNP 0
's POS 0
exacerbations NNS 0
were VBD 0
significantly RB 0
reduced VBN 0
by IN 0
flunisolide NN 0
( ( 0
p JJ 0
= NNP 0
0.044 CD 0
) ) 0
. . 0

In IN 0
the DT 0
placebo NN 0
group NN 0
, , 0
scores NNS 0
were VBD 0
higher JJR 0
than IN 0
in IN 0
the DT 0
flunisolide JJ 0
group NN 0
but CC 0
nonsignificant NN 0
for IN 0
dyspnea NN 0
, , 0
cough NN 0
, , 0
sputum NN 0
amount NN 0
and CC 0
purulence NN 0
. . 0

FEV NNP 0
( ( 0
1 CD 0
) ) 0
was VBD 0
significantly RB 0
increased VBN 0
compared VBN 0
to TO 0
baseline VB 0
in IN 0
both DT 0
groups NNS 0
, , 0
and CC 0
the DT 0
area NN 0
under IN 0
the DT 0
FEV NNP 0
( ( 0
1 CD 0
) ) 0
-time NN 0
curve NN 0
during IN 0
the DT 0
6-month JJ 0
period NN 0
was VBD 0
significantly RB 0
greater JJR 0
in IN 0
the DT 0
flunisolide NN 0
group NN 0
( ( 0
5.2 CD 0
+/- JJ 0
10.6 CD 0
vs. FW 0
2.1 CD 0
+/- JJ 0
5.0 CD 0
, , 0
flunisolide RB 0
vs. FW 0
placebo NN 0
, , 0
respectively RB 0
; : 0
p VB 0
= $ 0
0.047 CD 0
) ) 0
. . 0

For IN 0
shuttle JJ 0
walking VBG 0
test NN 0
distance NN 0
and CC 0
scores NNS 0
of IN 0
the DT 0
St. NNP 0
George NNP 0
's POS 0
Respiratory NNP 0
Questionnaire NNP 0
, , 0
no DT 0
significant JJ 0
difference NN 0
between IN 0
the DT 0
baseline NN 0
evaluation NN 0
and CC 0
the DT 0
end NN 0
of IN 0
the DT 0
study NN 0
was VBD 0
observed VBN 0
in IN 0
both DT 0
groups NNS 0
. . 0

CONCLUSIONS NNP 0
Nebulized NNP 0
flunisolide NN 0
is VBZ 0
a DT 0
good JJ 0
alternative NN 0
to TO 0
other JJ 0
inhaled JJ 0
corticosteroids NNS 0
when WRB 0
added VBN 0
to TO 0
nebulized JJ 0
salbutamol/ipratropium NN 0
bromide NN 0
in IN 0
the DT 0
long-term JJ 0
treatment NN 0
of IN 0
moderate-to-severe JJ 4
COPD NNP 4
patients NNS 0
. . 0

The DT 0
influence NN 0
of IN 0
rTMS NN 0
over IN 0
the DT 0
left JJ 0
dorsolateral JJ 0
prefrontal JJ 0
cortex NN 0
on IN 0
Stroop NNP 0
task NN 0
performance NN 0
. . 0

Several JJ 0
studies NNS 0
have VBP 0
demonstrated VBN 0
that IN 0
repetitive JJ 0
transcranial JJ 0
magnetic JJ 0
stimulation NN 0
( ( 0
rTMS NN 0
) ) 0
can MD 0
improve VB 0
cognitive JJ 0
processing NN 0
. . 0

Neuroimaging VBG 0
studies NNS 0
have VBP 0
shown VBN 0
the DT 0
engagement NN 0
of IN 0
the DT 0
left JJ 0
dorsolateral JJ 0
prefrontal NN 0
cortex NN 0
( ( 0
DLPFC NNP 0
) ) 0
in IN 0
executive NN 0
functioning NN 0
, , 0
and CC 0
more RBR 0
specifically RB 0
during IN 0
selective JJ 0
attention NN 0
. . 0

In IN 0
the DT 0
present JJ 0
study NN 0
, , 0
the DT 0
influence NN 0
of IN 0
high-frequency NN 0
rTMS NN 0
over IN 0
the DT 0
left JJ 0
DLPFC NNP 0
on IN 0
Stroop NNP 0
task NN 0
performance NN 0
in IN 0
healthy JJ 4
female NN 2
volunteers NNS 0
was VBD 0
investigated VBN 0
. . 0

As IN 0
expected VBN 0
, , 0
reaction NN 0
time NN 0
on IN 0
both CC 0
the DT 0
incongruent NN 0
and CC 0
congruent NN 0
trials NNS 0
decreased VBD 0
significantly RB 0
after IN 0
stimulation NN 0
, , 0
and CC 0
there EX 0
was VBD 0
no DT 0
difference NN 0
with IN 0
regard NN 0
to TO 0
the DT 0
Stroop NNP 0
interference NN 0
effect NN 0
. . 0

Mood NNP 0
remained VBD 0
unchanged JJ 0
after IN 0
rTMS NN 0
. . 0

Such PDT 0
a DT 0
pattern NN 0
is VBZ 0
consistent JJ 0
with IN 0
the DT 0
role NN 0
of IN 0
the DT 0
left NN 0
DLPFC NNP 0
in IN 0
implementing VBG 0
top-down JJ 0
attentional JJ 0
control NN 0
. . 0

A DT 0
comparative JJ 0
study NN 0
of IN 0
methyldopa NN 0
and CC 0
labetalol NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
hypertension NN 4
. . 0

1 CD 0
Twenty CD 3
patients NNS 0
with IN 0
essential JJ 4
hypertension NN 4
completed VBD 0
a DT 0
double-blind JJ 0
, , 0
dose-tritrated JJ 0
, , 0
cross-over JJ 0
comparison NN 0
of IN 0
methyldopa NN 0
and CC 0
labetalol NN 0
. . 0

2 CD 0
Average JJ 0
lying VBG 0
BPs NNP 0
( ( 0
systolic/diastolic JJ 0
) ) 0
were VBD 0
reduced VBN 0
by IN 0
28/15 CD 0
mmHg NNS 0
with IN 0
methyldopa NN 0
and CC 0
by IN 0
23/15 CD 0
mmHg NNS 0
with IN 0
labetalol NN 0
. . 0

3 CD 0
Average JJ 0
standing VBG 0
BPs NNP 0
( ( 0
systolic/diastolic JJ 0
) ) 0
were VBD 0
reduced VBN 0
by IN 0
29/14 CD 0
mmHg NNS 0
with IN 0
methyldopa NN 0
and CC 0
by IN 0
29/15 CD 0
mmHg NNS 0
with IN 0
labetalol NN 0
. . 0

4 CD 0
Both DT 0
lying NN 0
and CC 0
standing VBG 0
heart NN 0
rates NNS 0
were VBD 0
reduced VBN 0
with IN 0
labetalol NN 0
. . 0

5 CD 0
It PRP 0
is VBZ 0
concluded VBN 0
that IN 0
the DT 0
antihypertensive JJ 0
properties NNS 0
of IN 0
labetalol NN 0
and CC 0
methyldopa NN 0
are VBP 0
similar JJ 0
but CC 0
that IN 0
larger JJR 0
patient NN 0
populations NNS 0
are VBP 0
needed VBN 0
to TO 0
study VB 0
the DT 0
relative JJ 0
incidence NN 0
of IN 0
subjective JJ 0
adverse JJ 0
effects NNS 0
. . 0

Effects NNS 0
of IN 0
alfuzosin NN 0
10 CD 0
mg NN 0
once RB 0
daily RB 0
on IN 0
sexual JJ 0
function NN 0
in IN 0
men NNS 2
treated VBN 0
for IN 0
symptomatic JJ 4
benign NN 4
prostatic JJ 4
hyperplasia NN 4
. . 0

We PRP 0
evaluated VBD 0
the DT 0
effects NNS 0
of IN 0
extended-release JJ 0
alfuzosin NN 0
HCl NNP 0
10 CD 0
mg NN 0
once RB 0
daily JJ 0
( ( 0
q.d JJ 0
. . 0

) ) 0
on IN 0
sexual JJ 0
function NN 0
in IN 0
men NNS 0
with IN 0
lower JJR 4
urinary JJ 4
tract NN 4
symptoms NNS 4
associated VBN 0
with IN 0
benign JJ 4
prostatic JJ 4
hyperplasia NN 4
( ( 0
BPH NNP 4
) ) 0
. . 0

In IN 0
a DT 0
randomized JJ 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
study NN 0
of IN 0
men NNS 0
aged VBN 0
> NN 1
or CC 1
= $ 1
50 CD 1
years NNS 0
, , 0
after IN 0
a DT 0
28-day JJ 0
placebo NN 0
run-in JJ 0
period NN 0
, , 0
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
alfuzosin NN 0
10 CD 0
mg NN 0
q.d NN 0
. . 0

or CC 0
matching VBG 0
placebo NN 0
for IN 0
28 CD 0
days NNS 0
. . 0

The DT 0
mean JJ 0
change NN 0
from IN 0
baseline NN 0
( ( 0
day NN 0
1 CD 0
) ) 0
in IN 0
sexual JJ 0
function NN 0
on IN 0
day NN 0
29 CD 0
was VBD 0
assessed VBN 0
using VBG 0
the DT 0
Danish JJ 0
Prostate NNP 0
Symptom NNP 0
Score NNP 0
Sex NNP 0
( ( 0
DAN-PSSsex NNP 0
) ) 0
questionnaire NN 0
. . 0

A DT 0
total NN 0
of IN 0
372 CD 3
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
alfuzosin NN 0
( ( 0
n=186 JJ 0
) ) 0
or CC 0
placebo NN 0
( ( 0
n=186 JJ 0
) ) 0
, , 0
with IN 0
355 CD 3
completing VBG 0
the DT 0
study NN 0
. . 0

At IN 0
baseline NN 0
, , 0
64 CD 0
% NN 0
of IN 0
the DT 0
patients NNS 0
reported VBD 0
erectile JJ 4
dysfunction NN 4
( ( 0
ED NNP 4
) ) 0
and CC 0
63 CD 0
% NN 0
reported VBD 0
ejaculatory JJ 4
dysfunction NN 4
( ( 0
EjD NNP 4
) ) 0
. . 0

For IN 0
the DT 0
320 CD 0
patients NNS 0
who WP 0
completed VBD 0
the DT 0
DAN-PSSsex NNP 0
, , 0
alfuzosin NN 0
treatment NN 0
was VBD 0
associated VBN 0
with IN 0
a DT 0
significant JJ 0
improvement NN 0
in IN 0
the DT 0
mean JJ 0
change NN 0
from IN 0
baseline NN 0
in IN 0
erectile JJ 0
function NN 0
on IN 0
day NN 0
29 CD 0
compared VBN 0
with IN 0
placebo NN 0
( ( 0
P=0.02 NNP 0
) ) 0
. . 0

No DT 0
significant JJ 0
difference NN 0
was VBD 0
observed VBN 0
between IN 0
the DT 0
two CD 0
treatment NN 0
groups NNS 0
in IN 0
the DT 0
mean JJ 0
change NN 0
from IN 0
baseline NN 0
in IN 0
ejaculatory JJ 0
function NN 0
on IN 0
day NN 0
29 CD 0
. . 0

For IN 0
patients NNS 0
with IN 0
ED NNP 0
at IN 0
baseline NN 0
, , 0
a DT 0
marginal JJ 0
improvement NN 0
in IN 0
erectile JJ 0
function NN 0
was VBD 0
demonstrated VBN 0
with IN 0
alfuzosin NN 0
treatment NN 0
( ( 0
P=0.09 NNP 0
vs NNP 0
placebo NN 0
) ) 0
. . 0

For IN 0
patients NNS 0
with IN 0
EjD NNP 0
at IN 0
baseline NN 0
, , 0
the DT 0
mean JJ 0
change NN 0
from IN 0
baseline NN 0
in IN 0
ejaculatory JJ 0
function NN 0
with IN 0
alfuzosin NN 0
was VBD 0
comparable JJ 0
to TO 0
that DT 0
with IN 0
placebo NN 0
. . 0

Dizziness NNP 0
was VBD 0
the DT 0
most RBS 0
common JJ 0
adverse JJ 0
event NN 0
with IN 0
alfuzosin NN 0
treatment NN 0
( ( 0
5 CD 0
vs RB 0
0 CD 0
% NN 0
with IN 0
placebo NN 0
) ) 0
, , 0
with IN 0
other JJ 0
adverse JJ 0
events NNS 0
reported VBN 0
with IN 0
comparable JJ 0
frequency NN 0
in IN 0
both DT 0
treatment NN 0
groups NNS 0
. . 0

After IN 0
1 CD 0
month NN 0
of IN 0
treatment NN 0
, , 0
alfuzosin RB 0
10 CD 0
mg NN 0
q.d NN 0
. . 0

significantly RB 0
improved VBN 0
erectile JJ 0
function NN 0
in IN 0
men NNS 0
with IN 0
lower JJR 0
urinary JJ 0
tract NN 0
symptoms/ NN 0
benign JJ 0
prostatic JJ 0
hypertrophy NN 0
and CC 0
had VBD 0
no DT 0
adverse JJ 0
effect NN 0
on IN 0
ejaculatory NN 0
function NN 0
. . 0

The DT 0
costs NNS 0
and CC 0
effects NNS 0
of IN 0
a DT 0
nutritional JJ 0
education NN 0
program NN 0
following VBG 0
work-site JJ 0
cholesterol NN 0
screening NN 0
. . 0

OBJECTIVES CC 0
The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
assess VB 0
the DT 0
costs NNS 0
and CC 0
impact NN 0
of IN 0
a DT 0
nutrition JJ 0
education NN 0
program NN 0
following VBG 0
a DT 0
cholesterol NN 0
screening NN 0
. . 0

METHODS NNP 0
Forty NNP 3
work-sites NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
one CD 0
of IN 0
two CD 0
educational JJ 0
interventions NNS 0
: : 0
a DT 0
usual JJ 0
intervention NN 0
of IN 0
5 CD 0
minutes NNS 0
of IN 0
counseling NN 0
, , 0
or CC 0
a DT 0
special JJ 0
intervention NN 0
of IN 0
2 CD 0
hours NNS 0
of IN 0
behaviorally RB 0
based VBN 0
education NN 0
on IN 0
dietary JJ 0
changes NNS 0
to TO 0
lower VB 0
serum NN 0
cholesterol NN 0
. . 0

Costs NNS 0
were VBD 0
monitored VBN 0
, , 0
and CC 0
cholesterol NN 0
levels NNS 0
were VBD 0
retested VBN 0
6 CD 0
and CC 0
12 CD 0
months NNS 0
later RB 0
. . 0

RESULTS VB 0
The DT 0
total JJ 0
per-person JJ 0
cost NN 0
for IN 0
screening VBG 0
and CC 0
the DT 0
educational JJ 0
intervention NN 0
was VBD 0
about IN 0
$ $ 0
50 CD 0
. . 0

Cholesterol NN 0
levels NNS 0
differed VBD 0
little RB 0
between IN 0
the DT 0
two CD 0
intervention NN 0
groups NNS 0
6 CD 0
months NNS 0
after IN 0
screening VBG 0
, , 0
but CC 0
after IN 0
12 CD 0
months NNS 0
those DT 0
in IN 0
the DT 0
special JJ 0
intervention NN 0
worksites NNS 0
showed VBD 0
a DT 0
6.5 CD 0
% NN 0
drop NN 0
in IN 0
cholesterol NN 0
, , 0
whereas IN 0
those DT 0
at IN 0
the DT 0
usual JJ 0
intervention NN 0
worksites NNS 0
showed VBD 0
a DT 0
drop NN 0
of IN 0
only RB 0
3.0 CD 0
% NN 0
. . 0

Hence NNP 0
a DT 0
3.5 CD 0
% NN 0
cholesterol NN 0
reduction NN 0
was VBD 0
attributable JJ 0
to TO 0
the DT 0
special JJ 0
intervention NN 0
. . 0

CONCLUSIONS VB 0
A NNP 0
behaviorally RB 0
based VBN 0
nutrition JJ 0
education NN 0
program NN 0
following VBG 0
cholesterol NN 0
screening VBG 0
can MD 0
have VB 0
a DT 0
meaningful JJ 0
impact NN 0
on IN 0
long-term JJ 0
cholesterol NN 0
levels NNS 0
at IN 0
a DT 0
low JJ 0
cost NN 0
. . 0

Nutrition NNP 0
education NN 0
in IN 0
work-sites NNS 0
may MD 0
therefore RB 0
be VB 0
a DT 0
useful JJ 0
way NN 0
to TO 0
lower VB 0
the DT 0
risk NN 0
of IN 0
heart NN 0
disease NN 0
in IN 0
communities NNS 0
. . 0

How WRB 0
to TO 0
establish VB 0
equivalence NN 0
when WRB 0
data NNS 0
are VBP 0
censored VBN 0
: : 0
a DT 0
randomized JJ 0
trial NN 0
of IN 0
treatments NNS 0
for IN 0
B NNP 4
non-Hodgkin JJ 4
lymphoma NN 4
. . 0

Interest NN 0
in IN 0
equivalence NN 0
trials NNS 0
has VBZ 0
been VBN 0
increasing VBG 0
for IN 0
many JJ 0
years NNS 0
, , 0
though IN 0
the DT 0
methodology NN 0
which WDT 0
has VBZ 0
been VBN 0
developed VBN 0
for IN 0
such JJ 0
trials NNS 0
is VBZ 0
mainly RB 0
for IN 0
uncensored JJ 0
data NNS 0
. . 0

In IN 0
cancer NN 0
research NN 0
we PRP 0
are VBP 0
more RBR 0
often RB 0
concerned VBN 0
with IN 0
survival NN 0
. . 0

In IN 0
an DT 0
efficacy NN 0
trial NN 0
, , 0
the DT 0
null JJ 0
hypothesis NN 0
specifies NNS 0
equality NN 0
of IN 0
the DT 0
two CD 0
survival JJ 0
distributions NNS 0
, , 0
but CC 0
in IN 0
an DT 0
equivalence NN 0
trial NN 0
, , 0
a DT 0
null JJ 0
hypothesis NN 0
of IN 0
inequivalence NN 0
H0 NNP 0
has VBZ 0
to TO 0
be VB 0
tested VBN 0
. . 0

The DT 0
usual JJ 0
logrank NN 0
test NN 0
has VBZ 0
to TO 0
be VB 0
modified VBN 0
to TO 0
test VB 0
whether IN 0
the DT 0
true JJ 0
value NN 0
r NN 0
of IN 0
the DT 0
ratio NN 0
of IN 0
hazard NN 0
rates NNS 0
in IN 0
two CD 0
treatment NN 0
groups NNS 0
is VBZ 0
at IN 0
least JJS 0
equal JJ 0
to TO 0
a DT 0
limit NN 0
value NN 0
r0 NN 0
. . 0

If IN 0
prognostic JJ 0
factors NNS 0
have VBP 0
to TO 0
be VB 0
taken VBN 0
into IN 0
account NN 0
, , 0
the DT 0
Cox NNP 0
model NN 0
provides VBZ 0
tests NNS 0
of IN 0
Ho NNP 0
, , 0
and CC 0
a DT 0
useful JJ 0
confidence NN 0
interval NN 0
for IN 0
the DT 0
adjusted JJ 0
relative JJ 0
derived VBN 0
from IN 0
the DT 0
regression NN 0
parameter NN 0
for IN 0
the DT 0
treatment NN 0
indicator NN 0
. . 0

An DT 0
equivalence NN 0
trial NN 0
of IN 0
maintenance NN 0
therapy NN 0
was VBD 0
carried VBN 0
out RP 0
in IN 0
children NNS 1
with IN 0
B NNP 4
non-Hodgkin JJ 4
lymphoma NN 4
, , 0
and CC 0
serves VBZ 0
as IN 0
an DT 0
illustration NN 0
. . 0

The DT 0
effect NN 0
of IN 0
body NN 0
positioning VBG 0
upon IN 0
maximal JJ 0
oxygenation NN 0
of IN 0
patients NNS 0
with IN 0
unilateral JJ 4
lung NN 4
pathology NN 4
. . 0

A DT 0
quasi-experimental JJ 0
, , 0
repeated-measures JJ 0
cross-over NN 0
design NN 0
study NN 0
on IN 0
the DT 0
effect NN 0
of IN 0
body NN 0
position NN 0
on IN 0
oxygenation NN 0
( ( 0
SaO2 NNP 0
) ) 0
blood NN 0
pressure NN 0
, , 0
respiration NN 0
and CC 0
pulse NN 0
in IN 0
patients NNS 0
with IN 0
unilateral JJ 4
lung NN 4
pathology NN 4
was VBD 0
conducted VBN 0
. . 0

Previous JJ 0
research NN 0
strongly RB 0
suggests VBZ 0
that IN 0
positioning VBG 0
with IN 0
the DT 0
healthy JJ 0
( ( 0
unaffected JJ 0
) ) 0
lung NN 0
in IN 0
the DT 0
dependent JJ 0
lateral NN 0
( ( 0
down RP 0
) ) 0
position NN 0
is VBZ 0
related VBN 0
to TO 0
improved VBN 0
oxygenation NN 0
, , 0
but CC 0
knowledge VBP 0
about IN 0
whether IN 0
this DT 0
effect NN 0
is VBZ 0
maintained VBN 0
over IN 0
time NN 0
is VBZ 0
lacking VBG 0
. . 0

The DT 0
purpose NN 0
of IN 0
this DT 0
investigation NN 0
was VBD 0
to TO 0
determine VB 0
: : 0
( ( 0
1 CD 0
) ) 0
Is VBZ 0
positioning VBG 0
with IN 0
the DT 0
unaffected JJ 0
lung NN 0
in IN 0
the DT 0
dependent JJ 0
lateral JJ 0
position NN 0
related VBN 0
to TO 0
increased VBN 0
arterial JJ 0
blood NN 0
saturation NN 0
levels NNS 0
and CC 0
decreased VBD 0
blood NN 0
pressure NN 0
, , 0
pulse NN 0
and CC 0
respiration NN 0
? . 0
( ( 0
2 CD 0
) ) 0
What WP 0
is VBZ 0
the DT 0
relationship NN 0
between IN 0
the DT 0
dependent JJ 0
variables NNS 0
-- : 0
oxygenation NN 0
saturation NN 0
levels NNS 0
, , 0
blood NN 0
pressure NN 0
, , 0
pulse NN 0
and CC 0
respiration NN 0
-- : 0
and CC 0
the DT 0
independent JJ 0
variables NNS 0
-- : 0
body NN 0
position NN 0
and CC 0
time NN 0
in IN 0
the DT 0
position NN 0
? . 0
Thirty-nine JJ 3
patients NNS 0
with IN 0
unilateral JJ 4
lung NN 4
pathology NN 4
were VBD 0
positioned VBN 0
on IN 0
their PRP$ 0
sides NNS 0
with IN 0
the DT 0
unaffected JJ 0
lung NN 0
down RP 0
, , 0
on IN 0
their PRP$ 0
sides NNS 0
with IN 0
the DT 0
affected JJ 0
lung NN 0
down RB 0
, , 0
and CC 0
also RB 0
in IN 0
semi-Fowler NN 0
's POS 0
position NN 0
. . 0

Arterial NNP 0
( ( 0
SaO2 NNP 0
) ) 0
blood NN 0
saturation NN 0
and CC 0
vital JJ 0
signs NNS 0
were VBD 0
measured VBN 0
at IN 0
baseline NN 0
0 CD 0
, , 0
15 CD 0
and CC 0
30 CD 0
minutes NNS 0
. . 0

There EX 0
was VBD 0
no DT 0
statistically RB 0
significant JJ 0
relationship NN 0
between IN 0
oxygenation NN 0
level NN 0
or CC 0
systolic JJ 0
blood NN 0
pressure NN 0
. . 0

Diastolic NNP 0
blood NN 0
pressure NN 0
, , 0
respiration NN 0
and CC 0
pulse NN 0
did VBD 0
vary JJ 0
significantly RB 0
with IN 0
position NN 0
. . 0

0.1 CD 0
% NN 0
bupivacaine NN 0
does VBZ 0
not RB 0
reduce VB 0
the DT 0
requirement NN 0
for IN 0
epidural JJ 0
fentanyl NN 0
infusion NN 0
after IN 0
major JJ 4
abdominal JJ 4
surgery NN 4
. . 0

BACKGROUND NNP 0
AND NNP 0
OBJECTIVES NNP 0
Although IN 0
local JJ 0
anesthesia NN 0
has VBZ 0
been VBN 0
demonstrated VBN 0
to TO 0
potentiate VB 0
spinal JJ 0
morphine NN 0
analgesia NN 0
in IN 0
animal JJ 0
studies NNS 0
, , 0
results NNS 0
comparing VBG 0
epidural JJ 0
local JJ 0
anesthesia/opioid NN 0
mixtures NNS 0
with IN 0
opioid JJ 0
alone NN 0
are VBP 0
contradictory JJ 0
in IN 0
clinical JJ 0
studies NNS 0
. . 0

The DT 0
hypothesis NN 0
was VBD 0
that IN 0
, , 0
although IN 0
the DT 0
concentration NN 0
of IN 0
bupivacaine NN 0
( ( 0
0.1 CD 0
% NN 0
) ) 0
was VBD 0
low JJ 0
to TO 0
minimize VB 0
its PRP$ 0
adverse JJ 0
effects NNS 0
, , 0
if IN 0
the DT 0
infusion NN 0
rate NN 0
of IN 0
a DT 0
fentanyl/bupivacaine JJ 0
solution NN 0
was VBD 0
closely RB 0
adjusted VBN 0
according VBG 0
to TO 0
need NN 0
, , 0
the DT 0
presence NN 0
bupivacaine NN 0
would MD 0
reduce VB 0
the DT 0
requirement NN 0
for IN 0
epidural JJ 0
fentanyl NN 0
. . 0

METHODS NNP 0
Forty NNP 3
patients NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
either DT 0
fentanyl NN 0
( ( 0
10 CD 0
micrograms/mL NN 0
) ) 0
or CC 0
a DT 0
fentanyl/bupivacaine NN 0
( ( 0
0.1 CD 0
% NN 0
) ) 0
mixture NN 0
epidurally RB 0
corresponding VBG 0
to TO 0
the DT 0
dermatome NN 0
of IN 0
the DT 0
surgical JJ 0
incision NN 0
in IN 0
a DT 0
double-blind JJ 0
fashion NN 0
for IN 0
the DT 0
first JJ 0
18 CD 0
hours NNS 0
after IN 0
major JJ 4
abdominal JJ 4
surgery NN 4
. . 0

The DT 0
infusion NN 0
was VBD 0
titrated VBN 0
for IN 0
each DT 0
patient NN 0
to TO 0
the DT 0
rate NN 0
required VBN 0
for IN 0
pain NN 0
relief NN 0
during IN 0
forced VBN 0
inspiration NN 0
( ( 0
pain NN 0
score NN 0
< NN 0
or CC 0
= $ 0
2 CD 0
, , 0
maximum JJ 0
10 CD 0
) ) 0
. . 0

Pain NN 0
scores NNS 0
, , 0
the DT 0
fentanyl JJ 0
doses NNS 0
required VBN 0
, , 0
plasma JJ 0
concentrations NNS 0
of IN 0
fentanyl NN 0
at IN 0
18 CD 0
hours NNS 0
, , 0
and CC 0
the DT 0
incidence NN 0
and CC 0
severity NN 0
of IN 0
adverse JJ 0
effects NNS 0
were VBD 0
recorded VBN 0
. . 0

RESULTS JJ 0
Patients NNPS 0
reported VBD 0
similar JJ 0
median JJ 0
pain NN 0
scores NNS 0
and CC 0
were VBD 0
equally RB 0
satisfied VBN 0
with IN 0
pain NN 0
relief NN 0
in IN 0
both DT 0
groups NNS 0
. . 0

The DT 0
mean NN 0
required VBN 0
post-operative JJ 0
fentanyl JJ 0
infusion NN 0
rate NN 0
( ( 0
57.7 CD 0
+/- JJ 0
19.5 CD 0
micrograms/h NN 0
) ) 0
and CC 0
the DT 0
plasma NN 0
concentrations NNS 0
( ( 0
0.84 CD 0
+/- JJ 0
0.36 CD 0
ng/mL NN 0
) ) 0
in IN 0
the DT 0
fentanyl NN 0
group NN 0
were VBD 0
comparable JJ 0
to TO 0
the DT 0
infusion NN 0
rate NN 0
( ( 0
54.4 CD 0
+/- JJ 0
19.2 CD 0
micrograms/h NN 0
) ) 0
and CC 0
the DT 0
plasma NN 0
concentrations NNS 0
( ( 0
0.86 CD 0
+/- JJ 0
0.36 CD 0
ng/mL NN 0
) ) 0
in IN 0
the DT 0
fentanyl/bupivacaine NN 0
group NN 0
. . 0

Respiratory NNP 0
and CC 0
cardiovascular JJ 0
functions NNS 0
were VBD 0
preserved VBN 0
, , 0
and CC 0
the DT 0
incidence NN 0
of IN 0
nausea NN 0
, , 0
pruritus NN 0
, , 0
and CC 0
periods NNS 0
of IN 0
drowsiness NN 0
or CC 0
sleep NN 0
were VBD 0
similar JJ 0
in IN 0
both DT 0
groups NNS 0
. . 0

CONCLUSIONS NNP 0
In IN 0
low JJ 0
concentrations NNS 0
( ( 0
0.1 CD 0
% NN 0
) ) 0
, , 0
bupivacaine NN 0
did VBD 0
not RB 0
reduce VB 0
the DT 0
titrated JJ 0
dose NN 0
of IN 0
epidural JJ 0
fentanyl NN 0
required VBN 0
for IN 0
adequate JJ 0
pain NN 0
relief NN 0
during IN 0
forced VBN 0
inspiration NN 0
after IN 0
major JJ 0
abdominal JJ 0
surgery NN 0
. . 0

The DT 0
incidence NN 0
and CC 0
severity NN 0
of IN 0
adverse JJ 0
effects NNS 0
were VBD 0
also RB 0
comparable JJ 0
whether IN 0
or CC 0
not RB 0
low-dose JJ 0
bupivacaine NN 0
infusion NN 0
was VBD 0
used VBN 0
. . 0

Norfloxacin NNP 0
modulates VBZ 0
the DT 0
inflammatory JJ 0
response NN 0
and CC 0
directly RB 0
affects VBZ 0
neutrophils NNS 0
in IN 0
patients NNS 0
with IN 0
decompensated JJ 4
cirrhosis NN 4
. . 0

BACKGROUND NNP 0
& CC 0
AIMS NNP 0
Patients NNPS 0
with IN 0
cirrhosis NN 4
undergoing VBG 0
selective JJ 0
intestinal JJ 0
decontamination NN 0
with IN 0
norfloxacin JJ 0
show NN 0
a DT 0
reduction NN 0
in IN 0
serum JJ 0
cytokine NN 0
levels NNS 0
, , 0
probably RB 0
because IN 0
of IN 0
a DT 0
combined JJ 0
effect NN 0
of IN 0
norfloxacin NN 0
on IN 0
bowel NN 0
flora NNS 0
and CC 0
neutrophils NNS 0
. . 0

METHODS NNP 0
Thirty-one CD 3
patients NNS 0
with IN 0
cirrhosis NN 0
receiving VBG 0
norfloxacin NN 0
( ( 0
400 CD 0
mg/day NN 0
) ) 0
were VBD 0
included VBN 0
. . 0

Blood NNP 0
samples NNS 0
were VBD 0
collected VBN 0
at IN 0
0.5-4 JJ 0
hours NNS 0
( ( 0
peak JJ 0
samples NNS 0
group NN 0
, , 0
n RB 0
= VBZ 0
47 CD 0
) ) 0
and CC 0
at IN 0
22-24 JJ 0
hours NNS 0
( ( 0
trough IN 0
samples NNS 0
group NN 0
, , 0
n RB 0
= VBZ 0
84 CD 0
) ) 0
after IN 0
dose NN 0
. . 0

Fifty-nine JJ 0
ascitic JJ 0
fluid NN 0
samples NNS 0
were VBD 0
obtained VBN 0
. . 0

Single NNP 0
doses NNS 0
of IN 0
norfloxacin NN 0
and CC 0
trimethoprim/sulfamethoxazole NN 0
were VBD 0
administered VBN 0
to TO 0
13 CD 0
and CC 0
5 CD 0
patients NNS 0
, , 0
respectively RB 0
, , 0
( ( 0
temporal JJ 0
profile NN 0
group NN 0
) ) 0
and CC 0
samples NNS 0
were VBD 0
collected VBN 0
at IN 0
0 CD 0
, , 0
0.5 CD 0
, , 0
1 CD 0
, , 0
1.5 CD 0
, , 0
2 CD 0
, , 0
4 CD 0
, , 0
and CC 0
24 CD 0
hours NNS 0
. . 0

Norfloxacin NNP 0
, , 0
trimethoprim/sulfamethoxazole NN 0
, , 0
cytokines NNS 0
, , 0
nitric JJ 0
oxide NN 0
, , 0
expression NN 0
levels NNS 0
of IN 0
nuclear JJ 0
factor NN 0
( ( 0
NF NNP 0
) ) 0
-kappaB NN 0
and CC 0
inhibitor NN 0
of IN 0
NF-kappaB NNP 0
( ( 0
IkB-alpha NNP 0
) ) 0
, , 0
neutrophil JJ 0
oxidative JJ 0
burst NN 0
, , 0
and CC 0
rate NN 0
of IN 0
apoptotic JJ 0
events NNS 0
were VBD 0
determined VBN 0
. . 0

RESULTS NNP 0
All NNP 0
samples NNS 0
were VBD 0
bacterial JJ 0
DNA NNP 0
negative NN 0
and CC 0
had VBD 0
no DT 0
significant JJ 0
levels NNS 0
of IN 0
lipopolysaccharide NN 0
. . 0

Serum NNP 0
and CC 0
ascitic JJ 0
levels NNS 0
of IN 0
tumor NN 0
necrosis NN 0
factor-alpha JJ 0
, , 0
interferon-gamma JJ 0
, , 0
interleukin-12 JJ 0
, , 0
and CC 0
nitric JJ 0
oxide NN 0
were VBD 0
significantly RB 0
lower JJR 0
in IN 0
peak NN 0
than IN 0
in IN 0
trough JJ 0
samples NNS 0
. . 0

A DT 0
correlation NN 0
was VBD 0
present JJ 0
between IN 0
serum NN 0
norfloxacins NNS 0
concentrations NNS 0
and CC 0
tumor NN 0
necrosis NN 0
factor-alpha NN 0
( ( 0
r JJ 0
= NNP 0
-0.68 NNP 0
; : 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
, , 0
interferon-gamma JJ 0
( ( 0
r JJ 0
= NNP 0
-0.66 NNP 0
; : 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
, , 0
interleukin-12 JJ 0
( ( 0
r JJ 0
= NNP 0
-0.66 NNP 0
; : 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
, , 0
and CC 0
nitric JJ 0
oxide NN 0
( ( 0
r JJ 0
= NNP 0
-0.68 NNP 0
; : 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

Serum NNP 0
norfloxacin NN 0
's POS 0
highest JJS 0
concentrations NNS 0
( ( 0
1 CD 0
+/- JJ 0
0.5 CD 0
microg/mL NN 0
) ) 0
were VBD 0
achieved VBN 0
at IN 0
1-2 JJ 0
hours NNS 0
and CC 0
concurred VBN 0
in IN 0
time NN 0
with IN 0
the DT 0
lower JJR 0
levels NNS 0
of IN 0
cytokines NNS 0
and CC 0
nitric JJ 0
oxide NN 0
. . 0

Intracellular NNP 0
norfloxacin NN 0
's POS 0
highest JJS 0
levels NNS 0
( ( 0
2 CD 0
+/- JJ 0
1 CD 0
microg/mL/10 NN 0
( ( 0
7 CD 0
) ) 0
cells NNS 0
) ) 0
were VBD 0
observed VBN 0
at IN 0
2 CD 0
hours NNS 0
and CC 0
concurred VBN 0
with IN 0
a DT 0
lower JJR 0
NF-kappaB JJ 0
expression NN 0
, , 0
a DT 0
reduced JJ 0
anion NN 0
superoxide NN 0
generation NN 0
, , 0
and CC 0
apoptotic JJ 0
rate NN 0
in IN 0
response NN 0
to TO 0
phorbol VB 0
myristate JJ 0
acetate NN 0
. . 0

Trimethoprim/sulfamethoxazole NNP 0
did VBD 0
not RB 0
significantly RB 0
modulate VB 0
cytokine JJ 0
expression NN 0
. . 0

CONCLUSIONS NNP 0
Norfloxacin NNP 0
but CC 0
not RB 0
trimethoprim/sulfamethoxazole JJ 0
modulates NNS 0
inflammatory JJ 0
response NN 0
and CC 0
directly RB 0
affects VBZ 0
neutrophils NNS 0
in IN 0
patients NNS 0
with IN 0
cirrhosis NN 4
. . 0

The DT 0
effectiveness NN 0
of IN 0
physical JJ 0
activity NN 0
monitoring NN 0
and CC 0
distance NN 0
counselling NN 0
in IN 0
an DT 0
occupational JJ 0
health NN 0
setting NN 0
-- : 0
a DT 0
research NN 0
protocol NN 0
for IN 0
a DT 0
randomised JJ 0
controlled VBN 0
trial NN 0
( ( 0
CoAct NNP 0
) ) 0
. . 0

BACKGROUND IN 0
The DT 0
CoAct NNP 0
( ( 0
Cocreating NNP 0
Activity NNP 0
) ) 0
study NN 0
is VBZ 0
investigating VBG 0
a DT 0
novel JJ 0
lifestyle JJ 0
intervention NN 0
, , 0
aimed VBN 0
at IN 0
the DT 0
working VBG 4
population NN 4
, , 0
with IN 0
daily JJ 0
activity NN 0
monitoring NN 0
and CC 0
distance NN 0
counselling NN 0
via IN 0
telephone NN 0
and CC 0
secure NN 0
web NN 0
messages NNS 0
. . 0

The DT 0
main JJ 0
purpose NN 0
of IN 0
this DT 0
study NN 0
is VBZ 0
to TO 0
evaluate VB 0
the DT 0
effectiveness NN 0
of IN 0
lifestyle JJ 0
counselling VBG 0
on IN 0
the DT 0
level NN 0
of IN 0
physical JJ 0
activity NN 0
in IN 0
an DT 0
occupational JJ 0
health NN 0
setting NN 0
. . 0

The DT 0
purposes NNS 0
include VBP 0
also RB 0
analysing VBG 0
the DT 0
potential JJ 0
effects NNS 0
of IN 0
changes NNS 0
in IN 0
physical JJ 0
activity NN 0
on IN 0
productivity NN 0
at IN 0
work NN 0
and CC 0
sickness JJ 0
absence NN 0
, , 0
and CC 0
healthcare NN 0
costs NNS 0
. . 0

This DT 0
article NN 0
describes VBZ 0
the DT 0
design NN 0
of IN 0
the DT 0
study NN 0
and CC 0
the DT 0
participant NN 0
flow NN 0
until IN 0
and CC 0
including VBG 0
randomization NN 0
. . 0

METHODS/DESIGN NNP 0
CoAct NNP 0
is VBZ 0
a DT 0
randomised JJ 0
controlled VBN 0
trial NN 0
with IN 0
two CD 0
arms NNS 0
: : 0
a DT 0
control NN 0
group NN 0
and CC 0
intervention NN 0
group NN 0
with IN 0
daily JJ 0
activity NN 0
monitoring NN 0
and CC 0
distance NN 0
counselling NN 0
. . 0

The DT 0
intervention NN 0
focuses VBZ 0
on IN 0
lifestyle JJ 0
modification NN 0
and CC 0
takes VBZ 0
12 CD 0
months NNS 0
. . 0

The DT 0
study NN 0
population NN 0
consists VBZ 0
of IN 0
volunteers NNS 0
from IN 0
1100 CD 3
eligible JJ 0
employees NNS 0
of IN 0
a DT 0
Finnish JJ 0
insurance NN 0
company NN 0
. . 0

The DT 0
primary JJ 0
outcomes NNS 0
of IN 0
this DT 0
study NN 0
are VBP 0
change NN 0
in IN 0
physical JJ 0
activity NN 0
measured VBN 0
in IN 0
MET NNP 0
minutes NNS 0
per IN 0
week NN 0
, , 0
work NN 0
productivity NN 0
and CC 0
sickness NN 0
absence NN 0
, , 0
and CC 0
healthcare JJ 0
utilisation NN 0
. . 0

Secondary JJ 0
outcomes NNS 0
include VBP 0
various JJ 0
physiological JJ 0
measures NNS 0
. . 0

Cost-effectiveness JJ 0
analysis NN 0
will MD 0
also RB 0
be VB 0
performed VBN 0
. . 0

The DT 0
outcomes NNS 0
will MD 0
be VB 0
measured VBN 0
by IN 0
questionnaires NNS 0
at IN 0
baseline NN 0
, , 0
after IN 0
6 CD 0
, , 0
12 CD 0
, , 0
and CC 0
24 CD 0
months NNS 0
, , 0
and CC 0
sickness JJ 0
absence NN 0
will MD 0
be VB 0
obtained VBN 0
from IN 0
the DT 0
employer NN 0
's POS 0
registers NNS 0
. . 0

DISCUSSION NNP 0
No NNP 0
trials NNS 0
are VBP 0
yet RB 0
available JJ 0
that WDT 0
have VBP 0
evaluated VBN 0
the DT 0
effectiveness NN 0
of IN 0
daily JJ 0
physical JJ 0
activity NN 0
monitoring NN 0
and CC 0
distance NN 0
counselling NN 0
in IN 0
an DT 0
occupational JJ 0
health NN 0
setting NN 0
over IN 0
a DT 0
12 CD 0
month NN 0
period NN 0
and CC 0
no DT 0
data NN 0
on IN 0
cost-effectiveness NN 0
of IN 0
such JJ 0
intervention NN 0
are VBP 0
available JJ 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
ClinicalTrials.gov NNP 0
identifier NN 0
: : 0
NCT00994565 NNP 0
. . 0

Ilioinguinal-iliohypogastric JJ 0
nerve NN 0
block NN 0
within IN 0
travenous JJ 0
dexketoprofen NN 0
improves VBZ 0
postoperative JJ 0
analgesia NN 0
in IN 0
abdominal JJ 4
hysterectomies NNS 4
. . 0

BACKGROUND NNP 0
AND NNP 0
OBJECTIVE NNP 0
In IN 0
this DT 0
study NN 0
, , 0
our PRP$ 0
aim NN 0
was VBD 0
to TO 0
evaluate VB 0
the DT 0
effects NNS 0
of IN 0
intravenous JJ 0
dexketoprofen NNS 0
trometamol VBP 0
with IN 0
ilioinguinal JJ 0
and CC 0
iliohypogastric JJ 0
nerve NN 0
block NN 0
on IN 0
analgesic JJ 0
quality NN 0
and CC 0
morphine NN 0
consumption NN 0
after IN 0
total JJ 4
abdominal JJ 4
hysterectomy NN 4
operations NNS 0
. . 0

METHODS NNP 0
We PRP 0
conducted VBD 0
this DT 0
randomized VBN 0
controlled VBD 0
clinical JJ 0
study NN 0
on IN 0
61 CD 3
patients NNS 0
. . 0

The DT 0
study NN 0
was VBD 0
conducted VBN 0
in IN 0
the DT 0
operation NN 0
room NN 0
, , 0
post-anesthesia JJ 0
care NN 0
unit NN 0
, , 0
and CC 0
inpatient JJ 0
clinic NN 0
. . 0

We PRP 0
randomly RB 0
grouped VBD 0
the DT 0
61 CD 0
patients NNS 0
into IN 0
control NN 0
group NN 0
( ( 0
group NN 0
C NNP 0
) ) 0
, , 0
block NN 0
group NN 0
( ( 0
group NN 0
B NNP 0
) ) 0
and CC 0
dexketoprofen-block JJ 0
group NN 0
( ( 0
group NN 0
DB NNP 0
) ) 0
. . 0

Before IN 0
the DT 0
skin NN 0
incision NN 0
performed VBD 0
after IN 0
anesthesia JJ 0
induction NN 0
, , 0
we PRP 0
performed VBD 0
ilioinguinal JJ 0
iliohypogastric JJ 0
block NN 0
( ( 0
group NN 0
C NNP 0
given VBN 0
saline NN 0
and CC 0
group NN 0
P NNP 0
and CC 0
DB NNP 0
given VBN 0
levobupivacaine NN 0
) ) 0
. . 0

In IN 0
contrast NN 0
to TO 0
group NN 0
C NNP 0
and CC 0
B NNP 0
, , 0
group NN 0
DB NNP 0
was VBD 0
given VBN 0
dexketoprofen RB 0
. . 0

We PRP 0
administered VBD 0
morphine JJ 0
analgesia NN 0
to TO 0
all DT 0
patients NNS 0
by IN 0
patient-controlled JJ 0
analgesia NN 0
( ( 0
PCA NNP 0
) ) 0
during IN 0
the DT 0
postoperative JJ 0
24 CD 0
hours NNS 0
. . 0

We PRP 0
recorded VBD 0
Visual NNP 0
Analogue NNP 0
Scale NNP 0
( ( 0
VAS NNP 0
) ) 0
, , 0
satisfaction NN 0
scores NNS 0
, , 0
morphine NN 0
consumption NN 0
and CC 0
side NN 0
effects NNS 0
during IN 0
postoperative JJ 0
24 CD 0
hours NNS 0
. . 0

RESULTS NNP 0
We PRP 0
found VBD 0
the DT 0
DB NNP 0
group?s NN 0
VAS NNP 0
scores VBZ 0
to TO 0
be VB 0
lower JJR 0
than IN 0
the DT 0
control NN 0
group NN 0
and CC 0
block NN 0
group?s NN 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
values NNS 0
at IN 0
postoperative JJ 0
1st CD 0
, , 0
2nd CD 0
, , 0
6th CD 0
and CC 0
12th CD 0
hours NNS 0
. . 0

VAS NNP 0
scores NNS 0
of IN 0
group NN 0
C NNP 0
were VBD 0
higher JJR 0
than IN 0
of IN 0
group NN 0
B NNP 0
at IN 0
postoperative JJ 0
fi NN 0
rst VBD 0
2 CD 0
hours NNS 0
. . 0

Time NNP 0
to TO 0
fi VB 0
rst JJ 0
PCA NNP 0
demand NN 0
was VBD 0
longer RBR 0
, , 0
morphine JJ 0
consumption NN 0
values NNS 0
were VBD 0
lower JJR 0
and CC 0
satisfaction NN 0
scores NNS 0
were VBD 0
higher JJR 0
in IN 0
group NN 0
DB NNP 0
than IN 0
in IN 0
the DT 0
other JJ 0
two CD 0
groups NNS 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Ilioinguinal-iliohypogastric JJ 0
nerve NN 0
block NN 0
with IN 0
IV NNP 0
dexketoprofen NN 0
increases NNS 0
patient JJ 0
satisfaction NN 0
by IN 0
decreasing VBG 0
opioid JJ 0
consumption NN 0
, , 0
increasing VBG 0
patient JJ 0
satisfaction NN 0
, , 0
which WDT 0
suggests VBZ 0
that IN 0
dexketoprofen NN 0
trometamol NN 0
is VBZ 0
an DT 0
effective JJ 0
non-steroidal JJ 0
anti-inflammatory JJ 0
analgesic NN 0
in IN 0
postoperative JJ 0
analgesia NN 0
. . 0

Iron NNP 0
in IN 0
relation NN 0
to TO 0
gastric JJ 4
cancer NN 4
in IN 0
the DT 0
Alpha-tocopherol NNP 0
, , 0
Beta-carotene NNP 0
Cancer NNP 0
Prevention NNP 0
Study NNP 0
. . 0

BACKGROUND NNP 0
Iron NNP 0
is VBZ 0
an DT 0
essential JJ 0
micronutrient NN 0
that WDT 0
can MD 0
have VB 0
carcinogenic JJ 0
effects NNS 0
when WRB 0
at IN 0
high JJ 0
or CC 0
low JJ 0
concentrations NNS 0
. . 0

Previous JJ 0
studies NNS 0
of IN 0
iron NN 0
in IN 0
relation NN 0
to TO 0
gastric JJ 0
cancer NN 0
have VBP 0
not RB 0
assessed VBN 0
subtype-specific JJ 0
relationships NNS 0
. . 0

We PRP 0
used VBD 0
the DT 0
prospective JJ 0
Alpha-Tocopherol NNP 0
, , 0
Beta-Carotene NNP 0
( ( 0
ATBC NNP 0
) ) 0
Cancer NNP 0
Prevention NNP 0
Study NNP 0
to TO 0
assess VB 0
whether IN 0
iron NN 0
metrics NNS 0
were VBD 0
associated VBN 0
with IN 0
gastric JJ 4
cardia NN 4
cancer NN 4
( ( 0
GCC NNP 4
) ) 0
and CC 0
gastric JJ 4
noncardia NN 4
cancer NN 4
( ( 0
GNCC NNP 4
) ) 0
. . 0

METHODS NNP 0
We PRP 0
selected VBD 0
341 CD 3
incident JJ 0
gastric JJ 0
cancer NN 0
cases NNS 0
( ( 0
86 CD 0
cardia NN 0
, , 0
172 CD 0
noncardia NN 0
, , 0
and CC 0
83 CD 0
nonspecified VBN 0
) ) 0
, , 0
accrued VBN 0
during IN 0
22 CD 0
years NNS 0
of IN 0
follow-up NN 0
, , 0
and CC 0
341 CD 3
individually RB 0
matched VBN 0
controls NNS 0
. . 0

We PRP 0
measured VBD 0
prediagnostic JJ 0
serum NN 0
iron NN 0
, , 0
ferritin NN 0
, , 0
unsaturated JJ 0
iron NN 0
binding NN 0
capacity NN 0
, , 0
and CC 0
C-reactive JJ 0
protein NN 0
. . 0

Total JJ 0
iron-binding JJ 0
capacity NN 0
( ( 0
TIBC NNP 0
) ) 0
and CC 0
transferrin JJ 0
saturation NN 0
were VBD 0
estimated VBN 0
from IN 0
these DT 0
metrics NNS 0
. . 0

Dietary NNP 0
iron NN 0
exposures NNS 0
were VBD 0
estimated VBN 0
from IN 0
a DT 0
food NN 0
frequency NN 0
questionnaire NN 0
. . 0

Multivariable JJ 0
logistic JJ 0
regression NN 0
was VBD 0
used VBN 0
for IN 0
analysis NN 0
. . 0

RESULTS NNP 0
Serum NNP 0
iron NN 0
metrics NNS 0
were VBD 0
not RB 0
associated VBN 0
with IN 0
GCC NNP 0
, , 0
except IN 0
for IN 0
a DT 0
potential JJ 0
n NN 0
-shaped VBD 0
relationship NN 0
with IN 0
TIBC NNP 0
( ( 0
global JJ 0
P NNP 0
= NNP 0
0.038 CD 0
) ) 0
. . 0

GNCC NNP 0
was VBD 0
inversely RB 0
associated VBN 0
with IN 0
serum NN 0
ferritin NN 0
( ( 0
global JJ 0
P NNP 0
= NNP 0
0.024 CD 0
) ) 0
, , 0
serum JJ 0
iron NN 0
( ( 0
global JJ 0
P NNP 0
= NNP 0
0.060 CD 0
) ) 0
and CC 0
, , 0
possibly RB 0
, , 0
transferrin JJ 0
saturation NN 0
. . 0

TIBC NNP 0
appeared VBD 0
to TO 0
share NN 0
a DT 0
u NN 0
-shaped VBD 0
relationship NN 0
with IN 0
GNCC NNP 0
( ( 0
global JJ 0
P NNP 0
= NNP 0
0.033 CD 0
) ) 0
. . 0

Dietary NNP 0
iron NN 0
exposures NNS 0
were VBD 0
not RB 0
associated VBN 0
with IN 0
either DT 0
subsite NN 0
. . 0

Adjustment NN 0
for IN 0
Helicobacter NNP 0
pylori NN 0
and CC 0
gastric JJ 0
atrophy NN 0
had VBD 0
little JJ 0
effect NN 0
on IN 0
observed JJ 0
associations NNS 0
. . 0

CONCLUSIONS NNP 0
We PRP 0
found VBD 0
little JJ 0
evidence NN 0
for IN 0
the DT 0
involvement NN 0
of IN 0
iron NN 0
exposure NN 0
in IN 0
the DT 0
pathogenesis NN 0
of IN 0
GCC NNP 0
. . 0

GNCC NNP 0
was VBD 0
associated VBN 0
with IN 0
an DT 0
iron NN 0
profile NN 0
similar JJ 0
to TO 0
that DT 0
of IN 0
iron NN 0
deficiency NN 0
. . 0

IMPACT NNP 0
Our PRP$ 0
findings NNS 0
indicate VBP 0
that IN 0
inverse JJ 0
associations NNS 0
between IN 0
iron NN 0
metrics NNS 0
and CC 0
gastric JJ 0
cancer NN 0
are VBP 0
driven VBN 0
by IN 0
associations NNS 0
with IN 0
GNCC NNP 0
. . 0

Further NNP 0
elucidation NN 0
of IN 0
potential JJ 0
mechanisms NN 0
is VBZ 0
warranted VBN 0
. . 0

Psychoeducational NNP 0
group NN 0
intervention NN 0
for IN 0
wives NNS 2
of IN 0
men NNS 2
with IN 0
prostate NN 4
cancer NN 4
. . 0

OBJECTIVE CC 0
The DT 0
effects NNS 0
of IN 0
a DT 0
6-week JJ 0
psychoeducational JJ 0
group NN 0
intervention NN 0
on IN 0
the DT 0
distress NN 0
, , 0
coping NN 0
, , 0
personal JJ 0
growth NN 0
, , 0
and CC 0
marital JJ 0
communication NN 0
of IN 0
wives NNS 2
of IN 0
men NNS 2
diagnosed VBN 0
with IN 0
prostate JJ 4
cancer NN 4
were VBD 0
evaluated VBN 0
using VBG 0
a DT 0
randomized JJ 0
clinical JJ 0
trial NN 0
. . 0

METHODS NNP 0
Sixty NNP 3
wives NNS 2
completed VBD 0
measures NNS 0
prior RB 0
to TO 0
random VB 0
assignment NN 0
to TO 0
either VB 0
the DT 0
psychoeducational JJ 0
group NN 0
intervention NN 0
or CC 0
a DT 0
no-treatment JJ 0
control NN 0
group NN 0
, , 0
and CC 0
1 CD 0
month NN 0
after IN 0
completion NN 0
of IN 0
the DT 0
group NN 0
. . 0

RESULTS NNP 0
No NNP 0
differences NNS 0
with IN 0
regard NN 0
to TO 0
wives NNS 0
' POS 0
general JJ 0
distress NN 0
or CC 0
cancer-specific JJ 0
distress NN 0
were VBD 0
noted VBN 0
. . 0

In IN 0
comparison NN 0
with IN 0
the DT 0
control NN 0
group NN 0
, , 0
participants NNS 0
receiving VBG 0
the DT 0
intervention NN 0
perceived VBD 0
that IN 0
having VBG 0
a DT 0
spouse NN 0
with IN 0
prostate NN 0
cancer NN 0
had VBD 0
made VBN 0
positive JJ 0
contributions NNS 0
to TO 0
their PRP$ 0
lives NNS 0
, , 0
reported VBD 0
gains NNS 0
in IN 0
the DT 0
use NN 0
of IN 0
positive JJ 0
reappraisal NN 0
coping VBG 0
and CC 0
reductions NNS 0
in IN 0
denial JJ 0
coping NN 0
. . 0

CONCLUSION NNP 0
Although IN 0
the DT 0
psychoeducational JJ 0
intervention NN 0
did VBD 0
not RB 0
result VB 0
in IN 0
changes NNS 0
in IN 0
psychological JJ 0
distress NN 0
, , 0
improvements NNS 0
in IN 0
adaptive JJ 0
coping NN 0
and CC 0
indicators NNS 0
of IN 0
psychological JJ 0
growth NN 0
were VBD 0
found VBN 0
. . 0

The DT 0
utility NN 0
of IN 0
group NN 0
interventions NNS 0
for IN 0
spouses NNS 2
of IN 0
men NNS 2
with IN 0
prostate NN 4
cancer NN 4
is VBZ 0
discussed VBN 0
. . 0

Effect NN 0
of IN 0
motivational JJ 0
music NN 0
on IN 0
lactate NN 0
levels NNS 0
during IN 0
recovery NN 0
from IN 0
intense JJ 0
exercise NN 0
. . 0

The DT 0
effects NNS 0
of IN 0
music NN 0
played VBN 0
during IN 0
an DT 0
exercise NN 0
task NN 0
on IN 0
athletic JJ 0
performance NN 0
have VBP 0
been VBN 0
previously RB 0
studied VBN 0
. . 0

Yet CC 0
, , 0
these DT 0
results NNS 0
are VBP 0
not RB 0
applicable JJ 0
for IN 0
competitive JJ 0
athletes NNS 0
, , 0
who WP 0
can MD 0
use VB 0
music NN 0
only RB 0
during IN 0
warm-up NN 0
or CC 0
recovery NN 0
from IN 0
exercise NN 0
. . 0

Therefore RB 0
, , 0
the DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
determine VB 0
the DT 0
effect NN 0
of IN 0
motivational JJ 0
music NN 0
( ( 0
music NN 0
that WDT 0
stimulates VBZ 0
or CC 0
inspires VBZ 0
physical JJ 0
activity NN 0
) ) 0
during IN 0
recovery NN 0
from IN 0
intense JJ 0
exercise NN 0
, , 0
on IN 0
activity NN 0
pattern NN 0
, , 0
rate NN 0
of IN 0
perceived VBN 0
exertion NN 0
( ( 0
RPE NNP 0
) ) 0
, , 0
and CC 0
blood NN 0
lactate NN 0
concentration NN 0
. . 0

Twenty NNP 0
young JJ 0
, , 0
active JJ 0
men NNS 0
( ( 0
mean JJ 0
age NN 0
26.2 CD 0
? . 0
2.1 CD 0
years NNS 0
) ) 0
performed VBD 0
a DT 0
6-minute JJ 0
run NN 0
at IN 0
peak NN 0
oxygen NN 0
consumption NN 0
speed NN 0
( ( 0
predetermined VBN 0
from IN 0
the DT 0
VO NNP 0
( ( 0
2 CD 0
) ) 0
max FW 0
test NN 0
) ) 0
. . 0

The DT 0
mean JJ 0
heart NN 0
rate NN 0
( ( 0
HR NNP 0
) ) 0
, , 0
RPE NNP 0
, , 0
number NN 0
of IN 0
steps NNS 0
( ( 0
determined VBN 0
by IN 0
step NN 0
counter NN 0
) ) 0
, , 0
and CC 0
blood NN 0
lactate NN 0
concentrations NNS 0
were VBD 0
determined VBN 0
at IN 0
3 CD 0
, , 0
6 CD 0
, , 0
9 CD 0
, , 0
12 CD 0
, , 0
and CC 0
15 CD 0
minutes NNS 0
during IN 0
the DT 0
recovery NN 0
from IN 0
the DT 0
exercise NN 0
, , 0
with IN 0
and CC 0
without IN 0
motivational JJ 0
music NN 0
( ( 0
2 CD 0
separate JJ 0
sessions NNS 0
, , 0
at IN 0
random JJ 0
order NN 0
) ) 0
. . 0

There EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
the DT 0
mean JJ 0
HR NNP 0
during IN 0
the DT 0
recovery NN 0
with IN 0
and CC 0
without IN 0
music NN 0
. . 0

Listening VBG 0
to TO 0
motivational JJ 0
music NN 0
during IN 0
the DT 0
recovery NN 0
was VBD 0
associated VBN 0
with IN 0
increased JJ 0
voluntary JJ 0
activity NN 0
of IN 0
the DT 0
participants NNS 0
, , 0
determined VBN 0
by IN 0
increased JJ 0
number NN 0
of IN 0
steps NNS 0
( ( 0
499.4 CD 0
? . 0
220.1 CD 0
vs. IN 0
413.2 CD 0
? . 0
150.6 CD 0
steps NNS 0
, , 0
with IN 0
and CC 0
without IN 0
music NN 0
, , 0
respectively RB 0
; : 0
p VB 0
? . 0
0.05 CD 0
) ) 0
. . 0

The DT 0
increased JJ 0
number NN 0
of IN 0
steps NNS 0
during IN 0
the DT 0
recovery NN 0
was VBD 0
accompanied VBN 0
by IN 0
a DT 0
significantly RB 0
greater JJR 0
decrease NN 0
in IN 0
blood NN 0
lactate NN 0
concentration NN 0
percentage NN 0
( ( 0
28.1 CD 0
? . 0
12.2 CD 0
vs. IN 0
22.8 CD 0
? . 0
10.9 CD 0
% NN 0
, , 0
with IN 0
and CC 0
without IN 0
music NN 0
, , 0
respectively RB 0
, , 0
p VB 0
? . 0
0.05 CD 0
) ) 0
. . 0

This DT 0
was VBD 0
associated VBN 0
with IN 0
a DT 0
greater JJR 0
decrease NN 0
in IN 0
RPE NNP 0
( ( 0
77.7 CD 0
? . 0
14.4 CD 0
vs. IN 0
73.1 CD 0
? . 0
14.7 CD 0
% NN 0
with IN 0
and CC 0
without IN 0
music NN 0
, , 0
respectively RB 0
; : 0
p VB 0
? . 0
0.05 CD 0
) ) 0
. . 0

Our PRP$ 0
results NNS 0
suggest VBP 0
that IN 0
listening VBG 0
to TO 0
motivational JJ 0
music NN 0
during IN 0
nonstructured JJ 0
recovery NN 0
from IN 0
intense JJ 0
exercise NN 0
leads VBZ 0
to TO 0
increased VBN 0
activity NN 0
, , 0
faster JJR 0
lactate JJ 0
clearance NN 0
, , 0
and CC 0
reduced VBD 0
RPE NNP 0
and CC 0
therefore RB 0
may MD 0
be VB 0
used VBN 0
by IN 0
athletes NNS 0
in IN 0
their PRP$ 0
effort NN 0
to TO 0
enhance VB 0
recovery NN 0
. . 0

Acute JJ 0
effects NNS 0
of IN 0
decaffeinated JJ 0
coffee NN 0
and CC 0
the DT 0
major JJ 0
coffee NN 0
components NNS 0
chlorogenic JJ 0
acid NN 0
and CC 0
trigonelline NN 0
on IN 0
glucose JJ 4
tolerance NN 4
. . 0

OBJECTIVE NNP 0
Coffee NNP 0
consumption NN 0
has VBZ 0
been VBN 0
associated VBN 0
with IN 0
lower JJR 0
risk NN 0
of IN 0
type NN 4
2 CD 4
diabetes NNS 4
. . 0

We PRP 0
evaluated VBD 0
the DT 0
acute JJ 0
effects NNS 0
of IN 0
decaffeinated JJ 0
coffee NN 0
and CC 0
the DT 0
major JJ 0
coffee NN 0
components NNS 0
chlorogenic JJ 0
acid NN 0
and CC 0
trigonelline NN 0
on IN 0
glucose JJ 0
tolerance NN 0
. . 0

RESEARCH NNP 0
DESIGN NNP 0
AND NNP 0
METHODS NNP 0
We PRP 0
conducted VBD 0
a DT 0
randomized VBN 0
crossover NN 0
trial NN 0
of IN 0
the DT 0
effects NNS 0
of IN 0
12 CD 0
g NN 0
decaffeinated VBD 0
coffee NN 0
, , 0
1 CD 0
g NN 0
chlorogenic JJ 0
acid NN 0
, , 0
500 CD 0
mg NN 0
trigonelline NN 0
, , 0
and CC 0
placebo NN 0
( ( 0
1 CD 0
g NN 0
mannitol NN 0
) ) 0
on IN 0
glucose NN 0
and CC 0
insulin NN 0
concentrations NNS 0
during IN 0
a DT 0
2-h JJ 0
oral JJ 0
glucose NN 0
tolerance NN 0
test NN 0
( ( 0
OGTT NNP 0
) ) 0
in IN 0
15 CD 3
overweight JJ 4
men NNS 2
. . 0

RESULTS NNP 0
Chlorogenic NNP 0
acid NN 0
and CC 0
trigonelline NN 0
ingestion NN 0
significantly RB 0
reduced VBN 0
glucose NN 0
( ( 0
-0.7 JJ 0
mmol/l NN 0
, , 0
P NNP 0
= NNP 0
0.007 CD 0
, , 0
and CC 0
-0.5 NNP 0
mmol/l NN 0
, , 0
P NNP 0
= NNP 0
0.024 CD 0
, , 0
respectively RB 0
) ) 0
and CC 0
insulin NN 0
( ( 0
-73 JJ 0
pmol/l NN 0
, , 0
P NNP 0
= NNP 0
0.038 CD 0
, , 0
and CC 0
-117 NNP 0
pmol/l NN 0
, , 0
P NNP 0
= NNP 0
0.007 CD 0
) ) 0
concentrations NNS 0
15 CD 0
min NN 0
following VBG 0
an DT 0
OGTT NNP 0
compared VBN 0
with IN 0
placebo NN 0
. . 0

None NN 0
of IN 0
the DT 0
treatments NNS 0
affected VBD 0
insulin NN 0
or CC 0
glucose JJ 0
area NN 0
under IN 0
the DT 0
curve NN 0
values NNS 0
during IN 0
the DT 0
OGTT NNP 0
compared VBN 0
with IN 0
placebo NN 0
. . 0

CONCLUSIONS NNP 0
Chlorogenic NNP 0
acid NN 0
and CC 0
trigonelline NN 0
reduced VBD 0
early JJ 0
glucose NN 0
and CC 0
insulin NN 0
responses NNS 0
during IN 0
an DT 0
OGTT NNP 0
. . 0

Albendazole JJ 0
trial NN 0
at IN 0
15 CD 0
or CC 0
30 CD 0
mg/kg/day NN 0
for IN 0
subarachnoid NN 4
and CC 0
intraventricular JJ 4
cysticercosis NN 4
. . 0

Thirty-six JJ 3
patients NNS 0
with IN 0
subarachnoid JJ 4
and CC 0
intraventricular JJ 4
cysticercosis NN 4
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
albendazole NN 0
at IN 0
15 CD 0
or CC 0
30 CD 0
mg/kg/day JJ 0
plus CC 0
dexamethasone NN 0
for IN 0
8 CD 0
days NNS 0
. . 0

Results NNS 0
favored VBD 0
a DT 0
higher JJR 0
dose NN 0
, , 0
with IN 0
larger JJR 0
cyst NN 0
reduction NN 0
on IN 0
MRI NNP 0
at IN 0
90 CD 0
and CC 0
180 CD 0
days NNS 0
and CC 0
higher JJR 0
albendazole JJ 0
sulfoxide NN 0
levels NNS 0
in IN 0
plasma NN 0
. . 0

An DT 0
albendazole JJ 0
course NN 0
at IN 0
30 CD 0
mg/kg/day NN 0
combined VBN 0
with IN 0
corticosteroids NNS 0
is VBZ 0
safe JJ 0
and CC 0
more RBR 0
effective JJ 0
than IN 0
the DT 0
usual JJ 0
dose NN 0
. . 0

A DT 0
single JJ 0
treatment NN 0
was VBD 0
insufficient JJ 0
in IN 0
intraventricular JJ 0
and CC 0
giant JJ 0
cysts NNS 0
. . 0

Pre-bent JJ 0
instruments NNS 0
used VBN 0
in IN 0
single-port JJ 0
laparoscopic NN 0
surgery NN 0
versus IN 0
conventional JJ 0
laparoscopic NN 0
surgery NN 0
: : 0
comparative JJ 0
study NN 0
of IN 0
performance NN 0
in IN 0
a DT 0
dry JJ 0
lab NN 0
. . 0

BACKGROUND NNP 0
Different NNP 0
types NNS 0
of IN 0
single-incision NN 0
laparoscopic NN 0
surgery NN 0
( ( 0
SILS NNP 0
) ) 0
have VBP 0
become VBN 0
increasingly RB 0
popular JJ 0
. . 0

Although IN 0
SILS NNP 0
is VBZ 0
technically RB 0
even RB 0
more RBR 0
challenging JJ 0
than IN 0
conventional JJ 0
laparoscopy NN 0
, , 0
published VBN 0
data NNS 0
of IN 0
first JJ 0
clinical JJ 0
series NN 0
seem VBP 0
to TO 0
demonstrate VB 0
the DT 0
feasibility NN 0
of IN 0
these DT 0
approaches NNS 0
. . 0

Various JJ 0
attempts NNS 0
have VBP 0
been VBN 0
made VBN 0
to TO 0
overcome VB 0
restrictions NNS 0
due JJ 0
to TO 0
loss NN 0
of IN 0
triangulation NN 0
in IN 0
SILS NNP 0
by IN 0
specially RB 0
designed VBN 0
SILS-specific JJ 0
instruments NNS 0
. . 0

This DT 0
study NN 0
involving VBG 0
novices NNS 0
in IN 0
a DT 0
dry JJ 0
lab NN 0
compared VBN 0
task NN 0
performances NNS 0
between IN 0
conventional JJ 0
laparoscopic NN 0
surgery NN 0
( ( 0
CLS NNP 0
) ) 0
and CC 0
single-port JJ 0
laparoscopic NN 0
surgery NN 0
( ( 0
SPLS NNP 0
) ) 0
using VBG 0
newly RB 0
designed VBN 0
pre-bent JJ 0
instruments NNS 0
. . 0

METHODS NNP 0
In IN 0
this DT 0
study NN 0
, , 0
90 CD 3
medical JJ 4
students NNS 0
without IN 0
previous JJ 0
experience NN 0
in IN 0
laparoscopic NN 0
techniques NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
undergo VB 0
one CD 0
of IN 0
three CD 0
procedures NNS 0
: : 0
CLS NNP 0
, , 0
SPLS NNP 0
using VBG 0
two CD 0
pre-bent JJ 0
instruments NNS 0
( ( 0
SPLS-pp NNP 0
) ) 0
, , 0
or CC 0
SPLS NNP 0
using VBG 0
one CD 0
pre-bent NN 0
and CC 0
one CD 0
straight NN 0
laparoscopic NN 0
instrument NN 0
( ( 0
SPLS-ps NNP 0
) ) 0
. . 0

In IN 0
the DT 0
dry JJ 0
lab NN 0
, , 0
the DT 0
participants NNS 0
performed VBD 0
four CD 0
typical JJ 0
laparoscopic NN 0
tasks NNS 0
of IN 0
increasing VBG 0
difficulty NN 0
. . 0

Evaluation NNP 0
included VBD 0
performance NN 0
times NNS 0
or CC 0
number NN 0
of IN 0
completed VBN 0
tasks NNS 0
within IN 0
a DT 0
given VBN 0
time NN 0
frame NN 0
. . 0

All DT 0
performances NNS 0
were VBD 0
videotaped VBN 0
and CC 0
evaluated VBN 0
for IN 0
unsuccessful JJ 0
attempts NNS 0
and CC 0
unwanted JJ 0
interactions NNS 0
of IN 0
instruments NNS 0
. . 0

Using VBG 0
subjective JJ 0
questionnaires NNS 0
, , 0
the DT 0
participants NNS 0
rated VBN 0
difficulties NNS 0
with IN 0
two-dimensional JJ 0
vision NN 0
and CC 0
coordination NN 0
of IN 0
instruments NNS 0
. . 0

RESULTS NNP 0
Task NNP 0
performances NNS 0
were VBD 0
significantly RB 0
better RBR 0
in IN 0
the DT 0
CLS NNP 0
group NN 0
than IN 0
in IN 0
either DT 0
SPLS NNP 0
group NN 0
. . 0

The DT 0
SPLS-ps NNP 0
group NN 0
showed VBD 0
a DT 0
tendency NN 0
toward IN 0
better JJR 0
performances NNS 0
than IN 0
the DT 0
SPLS-pp NNP 0
group NN 0
, , 0
but CC 0
the DT 0
difference NN 0
was VBD 0
not RB 0
significant JJ 0
. . 0

Video NNP 0
sequences NNS 0
and CC 0
participants` NN 0
questionnaires NNS 0
showed VBD 0
instrument JJ 0
interaction NN 0
as IN 0
the DT 0
major JJ 0
problem NN 0
in IN 0
the DT 0
single-incision NN 0
surgery NN 0
groups NNS 0
. . 0

CONCLUSIONS NNP 0
Although IN 0
SILS NNP 0
is VBZ 0
feasible JJ 0
, , 0
as IN 0
shown VBN 0
in IN 0
clinical JJ 0
series NN 0
published VBN 0
by IN 0
laparoscopically RB 0
experienced JJ 0
experts NNS 0
, , 0
SILS NNP 0
techniques NNS 0
are VBP 0
demanding VBG 0
due JJ 0
to TO 0
restrictions NNS 0
that IN 0
come VBP 0
with IN 0
the DT 0
loss NN 0
of IN 0
triangulation NN 0
. . 0

These DT 0
can MD 0
be VB 0
compensated VBN 0
only RB 0
partially RB 0
by IN 0
currently RB 0
available JJ 0
SILS-designed JJ 0
instruments NNS 0
. . 0

The DT 0
future NN 0
of IN 0
SILS NNP 0
depends VBZ 0
on IN 0
further JJ 0
improvements NNS 0
in IN 0
the DT 0
available JJ 0
equipment NN 0
or CC 0
the DT 0
development NN 0
of IN 0
new JJ 0
approaches NNS 0
such JJ 0
as IN 0
needlescopically RB 0
assisted VBN 0
or CC 0
robotically RB 0
assisted JJ 0
procedures NNS 0
. . 0

A DT 0
description NN 0
of IN 0
the DT 0
clinical JJ 0
characteristics NNS 0
at IN 0
baseline NN 0
of IN 0
patients NNS 0
recruited VBN 0
into IN 0
the DT 0
Carvedilol NNP 0
or CC 0
Metoprolol NNP 0
European JJ 0
Trial NNP 0
( ( 0
COMET NNP 0
) ) 0
. . 0

BACKGROUND NNP 0
& CC 0
AIMS NNP 0
The DT 0
COMET NNP 0
trial NN 0
was VBD 0
a DT 0
prospective JJ 0
, , 0
double-blind JJ 0
, , 0
randomised JJ 0
trial NN 0
comparing VBG 0
carvedilol NN 0
, , 0
a DT 0
comprehensive JJ 0
adrenergic NN 0
receptor NN 0
antagonist NN 0
, , 0
with IN 0
metoprolol NN 0
, , 0
a DT 0
beta-1-selective JJ 0
agent NN 0
in IN 0
patients NNS 0
with IN 0
heart NN 4
failure NN 4
and CC 0
left VBD 4
ventricular JJ 4
systolic JJ 4
dysfunction NN 4
. . 0

The DT 0
trial NN 0
showed VBD 0
a DT 0
reduction NN 0
in IN 0
mortality NN 0
with IN 0
carvedilol NN 0
that WDT 0
was VBD 0
consistent JJ 0
across IN 0
subgroups NNS 0
. . 0

The DT 0
purpose NN 0
of IN 0
this DT 0
report NN 0
is VBZ 0
to TO 0
describe VB 0
in IN 0
greater JJR 0
detail NN 0
the DT 0
heterogeneity NN 0
of IN 0
this DT 0
population NN 0
at IN 0
baseline NN 0
with IN 0
particular JJ 0
reference NN 0
to TO 0
the DT 0
impact NN 0
of IN 0
symptomatic JJ 0
severity NN 0
, , 0
age NN 0
and CC 0
gender NN 0
on IN 0
patient JJ 0
characteristics NNS 0
. . 0

METHODS NNP 0
A NNP 0
descriptive JJ 0
report NN 0
using VBG 0
data NNS 0
entered VBN 0
in IN 0
the DT 0
COMET NNP 0
study NN 0
data-base NN 0
. . 0

RESULTS VB 0
The DT 0
characteristics NNS 0
of IN 0
the DT 0
population NN 0
studied VBN 0
were VBD 0
similar JJ 0
to TO 0
those DT 0
reported VBN 0
in IN 0
previous JJ 0
trials NNS 0
of IN 0
beta-blockers NNS 0
. . 0

Almost NNP 0
all DT 0
patients NNS 0
were VBD 0
receiving VBG 0
diuretics NNS 0
and CC 0
ACE NNP 0
inhibitors NNS 0
with IN 0
few JJ 0
patients NNS 0
taking VBG 0
angiotensin JJ 0
receptor NN 0
blockers NNS 0
. . 0

As IN 0
expected VBN 0
, , 0
older JJR 0
patients NNS 0
had VBD 0
more RBR 0
co-morbidity JJ 0
. . 0

Older JJR 0
patients NNS 0
and CC 0
women NNS 0
reported VBD 0
worse JJR 0
symptoms NNS 0
and CC 0
poorer JJR 0
well-being JJ 0
despite IN 0
similar JJ 0
ventricular JJ 0
dimensions NNS 0
and CC 0
systolic JJ 0
dysfunction NN 0
. . 0

NT-proBNP NNP 0
was VBD 0
higher RBR 0
in IN 0
patients NNS 0
with IN 0
more RBR 0
severe JJ 0
symptoms NNS 0
and CC 0
older JJR 0
patients NNS 0
but CC 0
not RB 0
in IN 0
women NNS 0
, , 0
although IN 0
differences NNS 0
in IN 0
NT-proBNP NNP 0
may MD 0
have VB 0
been VBN 0
confounded VBN 0
by IN 0
differences NNS 0
in IN 0
renal JJ 0
function NN 0
. . 0

CONCLUSION NNP 0
Age NNP 0
and CC 0
gender NN 0
, , 0
as RB 0
well RB 0
as IN 0
the DT 0
severity NN 0
of IN 0
cardiac JJ 0
dysfunction NN 0
, , 0
appear VBP 0
to TO 0
have VB 0
an DT 0
important JJ 0
effect NN 0
on IN 0
the DT 0
severity NN 0
of IN 0
heart NN 0
failure NN 0
symptoms NNS 0
and CC 0
patient JJ 0
'well-being NN 0
' POS 0
. . 0

This DT 0
could MD 0
have VB 0
important JJ 0
implications NNS 0
for IN 0
the DT 0
relationship NN 0
between IN 0
symptoms NNS 0
and CC 0
prognosis NN 0
and CC 0
therefore RB 0
the DT 0
way NN 0
in IN 0
which WDT 0
patients NNS 0
are VBP 0
selected VBN 0
for IN 0
clinical JJ 0
trials NNS 0
and CC 0
the DT 0
goals NNS 0
of IN 0
treatment NN 0
. . 0

This DT 0
will MD 0
be VB 0
the DT 0
subject NN 0
of IN 0
further JJ 0
analyses NNS 0
. . 0

A DT 0
prospective JJ 0
, , 0
double-blind JJ 0
, , 0
randomized VBN 0
, , 0
controlled VBD 0
clinical JJ 0
trial NN 0
comparing VBG 0
standard NN 0
wound NN 0
care NN 0
with IN 0
adjunctive JJ 0
hyperbaric JJ 0
oxygen NN 0
therapy NN 0
( ( 0
HBOT NNP 0
) ) 0
to TO 0
standard VB 0
wound NN 0
care NN 0
only RB 0
for IN 0
the DT 0
treatment NN 0
of IN 0
chronic JJ 4
, , 0
non-healing JJ 4
ulcers NNS 4
of IN 0
the DT 0
lower JJR 4
limb NN 4
in IN 0
patients NNS 0
with IN 0
diabetes NNS 4
mellitus NNS 4
: : 0
a DT 0
study NN 0
protocol NN 0
. . 0

BACKGROUND NNP 0
It PRP 0
has VBZ 0
been VBN 0
suggested VBN 0
that IN 0
the DT 0
use NN 0
of IN 0
adjunctive JJ 0
hyperbaric JJ 0
oxygen NN 0
therapy NN 0
improves VBZ 0
the DT 0
healing NN 0
of IN 0
diabetic JJ 0
foot NN 0
ulcers NNS 0
, , 0
and CC 0
decreases VBZ 0
the DT 0
risk NN 0
of IN 0
lower JJR 0
extremity NN 0
amputations NNS 0
. . 0

A DT 0
limited JJ 0
number NN 0
of IN 0
studies NNS 0
have VBP 0
used VBN 0
a DT 0
double JJ 0
blind NN 0
approach NN 0
to TO 0
evaluate VB 0
the DT 0
efficacy NN 0
of IN 0
hyperbaric JJ 0
oxygen NN 0
therapy NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
diabetic JJ 4
ulcers NNS 4
. . 0

The DT 0
primary JJ 0
aim NN 0
of IN 0
this DT 0
study NN 0
is VBZ 0
to TO 0
assess VB 0
the DT 0
efficacy NN 0
of IN 0
hyperbaric JJ 0
oxygen NN 0
therapy NN 0
plus CC 0
standard NN 0
wound NN 0
care NN 0
compared VBN 0
with IN 0
standard NN 0
wound NN 0
care NN 0
alone RB 0
in IN 0
preventing VBG 0
the DT 0
need NN 0
for IN 0
major JJ 0
amputation NN 0
in IN 0
patients NNS 0
with IN 0
diabetes NNS 0
mellitus NNS 0
and CC 0
chronic JJ 4
ulcers NNS 4
of IN 0
the DT 0
lower JJR 4
limb NN 4
. . 0

METHODS/DESIGN NNP 0
One CD 3
hundred CD 3
and CC 3
eighteen JJ 3
( ( 0
59 CD 3
patients NNS 0
per IN 0
arm NN 0
) ) 0
patients NNS 0
with IN 0
non-healing JJ 4
diabetic JJ 4
ulcers NNS 4
of IN 0
the DT 0
lower JJR 4
limb NN 4
, , 0
referred VBD 0
to TO 0
the DT 0
Judy NNP 0
Dan NNP 0
Research NNP 0
and CC 0
Treatment NNP 0
Centre NNP 0
are VBP 0
being VBG 0
recruited VBN 0
if IN 0
they PRP 0
are VBP 0
at IN 0
least JJS 0
18 CD 1
years NNS 0
of IN 0
age NN 0
, , 0
have VBP 0
either DT 0
Type NNP 4
1 CD 4
or CC 4
2 CD 4
diabetes NNS 4
with IN 0
a DT 0
Wagner NNP 0
grading NN 0
of IN 0
foot NN 0
lesions NNS 0
2 CD 0
, , 0
3 CD 0
or CC 0
4 CD 0
on IN 0
lower JJR 0
limb NN 0
not RB 0
healing VBG 0
for IN 0
at IN 0
least JJS 0
4 CD 0
weeks NNS 0
. . 0

Patients NNS 0
receive JJ 0
hyperbaric JJ 0
oxygen NN 0
therapy NN 0
every DT 0
day NN 0
for IN 0
6 CD 0
weeks NNS 0
during IN 0
the DT 0
treatment NN 0
phase NN 0
and CC 0
are VBP 0
provided VBN 0
ongoing VBG 0
wound NN 0
care NN 0
and CC 0
weekly JJ 0
assessments NNS 0
. . 0

Patients NNS 0
are VBP 0
required VBN 0
to TO 0
return VB 0
to TO 0
the DT 0
study NN 0
centre NN 0
every DT 0
week NN 0
for IN 0
an DT 0
additional JJ 0
6 CD 0
weeks NNS 0
of IN 0
follow-up NN 0
for IN 0
wound JJ 0
evaluation NN 0
and CC 0
management NN 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
is VBZ 0
freedom RB 0
from IN 0
having VBG 0
, , 0
or CC 0
meeting VBG 0
the DT 0
criteria NN 0
for IN 0
, , 0
a DT 0
major JJ 0
amputation NN 0
( ( 0
below IN 0
knee NN 0
amputation NN 0
, , 0
or CC 0
metatarsal VB 0
level NN 0
) ) 0
up RB 0
to TO 0
12 CD 0
weeks NNS 0
after IN 0
randomization NN 0
. . 0

The DT 0
decision NN 0
to TO 0
amputate VB 0
is VBZ 0
made VBN 0
by IN 0
a DT 0
vascular JJ 0
surgeon NN 0
. . 0

Other JJ 0
outcomes NNS 0
include VBP 0
wound IN 0
healing NN 0
, , 0
effectiveness NN 0
, , 0
safety NN 0
, , 0
healthcare JJ 0
resource NN 0
utilization NN 0
, , 0
quality NN 0
of IN 0
life NN 0
, , 0
and CC 0
cost-effectiveness NN 0
. . 0

The DT 0
study NN 0
will MD 0
run VB 0
for IN 0
a DT 0
total NN 0
of IN 0
about IN 0
3 CD 0
years NNS 0
. . 0

DISCUSSION VB 0
The DT 0
results NNS 0
of IN 0
this DT 0
study NN 0
will MD 0
provide VB 0
detailed JJ 0
information NN 0
on IN 0
the DT 0
efficacy NN 0
of IN 0
hyperbaric JJ 0
oxygen NN 0
therapy NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
non-healing JJ 0
ulcers NNS 0
of IN 0
the DT 0
lower JJR 0
limb NN 0
. . 0

This DT 0
will MD 0
be VB 0
the DT 0
first JJ 0
double-blind JJ 0
randomized VBN 0
controlled JJ 0
trial NN 0
for IN 0
this DT 0
health NN 0
technology NN 0
which WDT 0
evaluates VBZ 0
the DT 0
efficacy NN 0
of IN 0
hyperbaric JJ 0
oxygen NN 0
therapy NN 0
in IN 0
prevention NN 0
of IN 0
amputations NNS 0
in IN 0
diabetic JJ 0
patients NNS 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
ClinicalTrials.gov NNP 0
Identifier NNP 0
: : 0
NCT00621608 NN 0
. . 0

Brief JJ 0
report NN 0
: : 0
imitation NN 0
effects NNS 0
on IN 0
children NNS 1
with IN 0
autism NN 4
. . 0

Twenty NNP 3
children NNS 1
with IN 0
autism NN 4
( ( 0
mean JJ 0
age NN 0
, , 0
5 CD 1
years NNS 1
) ) 0
were VBD 0
recruited VBN 0
for IN 0
the DT 0
study NN 0
from IN 0
a DT 0
school NN 0
for IN 0
children NNS 1
with IN 0
autism NN 4
. . 0

The DT 0
children NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
an DT 0
imitation NN 0
( ( 0
n JJ 0
= NNP 0
10 CD 3
) ) 0
or CC 0
contingently RB 0
responsive JJ 0
( ( 0
n JJ 0
= NNP 0
10 CD 3
) ) 0
interaction NN 0
group NN 0
based VBN 0
on IN 0
a DT 0
stratification NN 0
table NN 0
for IN 0
gender NN 0
and CC 0
developmental NN 0
and CC 0
chronological JJ 0
age NN 0
. . 0

The DT 0
sessions NNS 0
consisted VBD 0
of IN 0
four CD 0
phases NNS 0
, , 0
with IN 0
each DT 0
phase NN 0
lasting VBG 0
3 CD 0
minutes NNS 0
. . 0

In IN 0
the DT 0
first JJ 0
phase NN 0
, , 0
the DT 0
child NN 0
walked VBD 0
into IN 0
a DT 0
room NN 0
that WDT 0
was VBD 0
furnished VBN 0
with IN 0
a DT 0
sofa NN 0
, , 0
a DT 0
table NN 0
, , 0
chairs NNS 0
, , 0
and CC 0
two CD 0
sets NNS 0
of IN 0
identical JJ 0
toys NN 0
. . 0

An DT 0
adult NN 0
was VBD 0
in IN 0
the DT 0
room NN 0
sitting VBG 0
very RB 0
still RB 0
like IN 0
a DT 0
statue NN 0
( ( 0
first JJ 0
still-face JJ 0
condition NN 0
) ) 0
. . 0

In IN 0
the DT 0
second JJ 0
phase NN 0
, , 0
the DT 0
adult NN 0
either RB 0
imitated VBD 0
the DT 0
child NN 0
or CC 0
was VBD 0
contingently RB 0
responsive JJ 0
to TO 0
the DT 0
child NN 0
. . 0

In IN 0
the DT 0
third JJ 0
phase NN 0
, , 0
the DT 0
adult NN 0
sat VBD 0
still RB 0
again RB 0
( ( 0
second JJ 0
still-face JJ 0
condition NN 0
) ) 0
, , 0
and CC 0
in IN 0
the DT 0
fourth JJ 0
phase NN 0
, , 0
the DT 0
adult NN 0
engaged VBN 0
in IN 0
a DT 0
spontaneous JJ 0
interaction NN 0
. . 0

During IN 0
the DT 0
third JJ 0
phase NN 0
( ( 0
the DT 0
second JJ 0
still-face JJ 0
condition NN 0
) ) 0
, , 0
the DT 0
children NNS 0
in IN 0
the DT 0
imitation NN 0
group NN 0
spent VBD 0
less JJR 0
time NN 0
in IN 0
gross JJ 0
motor NN 0
activity NN 0
and CC 0
more JJR 0
time NN 0
touching VBG 0
the DT 0
adult NN 0
, , 0
as IN 0
if IN 0
attempting VBG 0
to TO 0
initiate VB 0
an DT 0
interaction NN 0
. . 0

The DT 0
contingency NN 0
condition NN 0
appeared VBD 0
to TO 0
be VB 0
a DT 0
more RBR 0
effective JJ 0
way NN 0
to TO 0
facilitate VB 0
a DT 0
distal JJ 0
social JJ 0
behavior NN 0
( ( 0
attention NN 0
) ) 0
, , 0
whereas IN 0
the DT 0
imitative JJ 0
condition NN 0
was VBD 0
a DT 0
more RBR 0
effective JJ 0
way NN 0
to TO 0
facilitate VB 0
a DT 0
proximal JJ 0
social JJ 0
behavior NN 0
( ( 0
touching VBG 0
) ) 0
. . 0

Glibenclamide NNP 0
vs NN 0
gliclazide NN 0
in IN 0
reducing VBG 0
oxidative JJ 0
stress NN 0
in IN 0
patients NNS 0
of IN 0
noninsulin JJ 4
dependent JJ 4
diabetes VBZ 4
mellitus NN 4
-- : 0
a DT 0
double JJ 0
blind NN 0
randomized VBN 0
study NN 0
. . 0

OBJECTIVE NNP 0
Parameters NNPS 0
of IN 0
oxidative JJ 0
stress NN 0
were VBD 0
quantitated VBN 0
in IN 0
50 CD 3
patients NNS 0
with IN 0
type JJ 4
2 CD 4
diabetes NNS 4
mellitus VBP 4
in IN 4
uncontrolled JJ 4
state NN 4
and CC 0
after IN 0
control NN 0
using VBG 0
oral JJ 0
glibenclamide NN 0
or CC 0
gliclazide NN 0
. . 0

The DT 0
estimates NNS 0
were VBD 0
further RB 0
compared VBN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
irrespective JJ 0
of IN 0
drug NN 0
used VBN 0
to TO 0
evaluate VB 0
the DT 0
difference NN 0
, , 0
if IN 0
any DT 0
. . 0

METHODS NNP 0
The DT 0
study NN 0
was VBD 0
a DT 0
double JJ 0
blind NN 0
, , 0
uncontrolled JJ 0
, , 0
noncrossover RB 0
and CC 0
randomized JJ 0
trial NN 0
. . 0

Fifty JJ 3
patients NNS 0
of IN 0
uncontrolled JJ 4
type NN 4
2 CD 4
diabetes NNS 4
were VBD 0
divided VBN 0
in IN 0
to TO 0
two CD 0
groups NNS 0
. . 0

Group NNP 0
I PRP 0
( ( 0
25 CD 0
patients NNS 0
) ) 0
received VBD 0
capsule NN 0
A NNP 0
( ( 0
glibenclamide NN 0
) ) 0
while IN 0
Group NNP 0
II NNP 0
( ( 0
25 CD 0
patients NNS 0
) ) 0
received VBD 0
capsule NN 0
B NNP 0
( ( 0
gliclazide NN 0
) ) 0
. . 0

The DT 0
parameters NNS 0
studied VBN 0
were VBD 0
Superoxide NNP 0
dismutase NN 0
( ( 0
SOD NNP 0
) ) 0
, , 0
malonyl-dialdehyde JJ 0
( ( 0
MDA NNP 0
) ) 0
and CC 0
reduced VBN 0
glutathione NN 0
( ( 0
GSH NNP 0
) ) 0
. . 0

They PRP 0
were VBD 0
done VBN 0
at IN 0
( ( 0
a DT 0
) ) 0
uncontrolled JJ 0
stage NN 0
( ( 0
FBS NNP 0
-- : 0
165 CD 0
+/- JJ 0
16.7 CD 0
mg/dl NN 0
, , 0
PP NNP 0
-- : 0
240 CD 0
+/- JJ 0
30.1 CD 0
mg/dl NN 0
and CC 0
HbA1 NNP 0
-- : 0
10.5 CD 0
+/- JJ 0
0.9 CD 0
% NN 0
in IN 0
group NN 0
I PRP 0
and CC 0
FBS NNP 0
-- : 0
150 CD 0
+/- JJ 0
15.8 CD 0
mg/dl NN 0
, , 0
PP NNP 0
-- : 0
246 CD 0
+/- JJ 0
29.1 CD 0
mg/dl NN 0
HbA1 NNP 0
10.6 CD 0
+/- JJ 0
0.8 CD 0
% NN 0
in IN 0
group NN 0
II NNP 0
) ) 0
and CC 0
during IN 0
controlled VBN 0
stage NN 0
at IN 0
12 CD 0
weeks NNS 0
( ( 0
FBS NNP 0
-- : 0
120 CD 0
+/- JJ 0
18.5 CD 0
mg/dl NN 0
, , 0
PP NNP 0
-- : 0
180 CD 0
+/- JJ 0
19.1 CD 0
mg/dl NN 0
and CC 0
HbA1 NNP 0
-- : 0
8.4 CD 0
+/- JJ 0
0.29 CD 0
% NN 0
in IN 0
group NN 0
I PRP 0
and CC 0
FBS NNP 0
-- : 0
118 CD 0
+/- JJ 0
17.6 CD 0
mg/dl NN 0
, , 0
PP NNP 0
-- : 0
176 CD 0
+/- JJ 0
20.1 CD 0
mg/dl NN 0
and CC 0
HbA1 NNP 0
-- : 0
8.5 CD 0
+/- JJ 0
0.39 CD 0
% NN 0
in IN 0
group NN 0
II NNP 0
patients NNS 0
) ) 0
. . 0

RESULTS VB 0
The DT 0
significantly RB 0
raised VBN 0
levels NNS 0
of IN 0
MDA NNP 0
and CC 0
SOD NNP 0
, , 0
and CC 0
decreased JJ 0
levels NNS 0
of IN 0
reduced VBN 0
glutathione NN 0
( ( 0
GSH NNP 0
) ) 0
during IN 0
uncontrolled JJ 0
stage NN 0
of IN 0
diabetes NNS 0
indicated VBD 0
free JJ 0
radical JJ 0
stress NN 0
induced VBD 0
lipid JJ 0
peroxidation NN 0
. . 0

The DT 0
significant JJ 0
fall NN 0
of IN 0
MDA NNP 0
and CC 0
SOD NNP 0
and CC 0
increased VBD 0
levels NNS 0
of IN 0
GSH NNP 0
in IN 0
blood NN 0
in IN 0
both DT 0
groups NNS 0
after IN 0
control NN 0
revealed VBD 0
beneficial JJ 0
effects NNS 0
of IN 0
glycemic JJ 0
control NN 0
on IN 0
oxidative JJ 0
stress NN 0
. . 0

The DT 0
levels NNS 0
were VBD 0
not RB 0
normalized VBN 0
and CC 0
stayed VBD 0
higher JJR 0
than IN 0
those DT 0
in IN 0
controls NNS 0
. . 0

On IN 0
intergroup JJ 0
comparison NN 0
; : 0
the DT 0
control NN 0
of IN 0
diabetes NNS 0
with IN 0
gliclazide NN 0
( ( 0
group NN 0
II NNP 0
) ) 0
showed VBD 0
improvement NN 0
in IN 0
oxidative JJ 0
stress NN 0
( ( 0
MDA NNP 0
, , 0
GSH NNP 0
) ) 0
better JJR 0
( ( 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
than IN 0
glibenclamide NN 0
( ( 0
group NN 0
I PRP 0
) ) 0
. . 0

CONCLUSION NNP 0
Oxidative NNP 0
stress NN 0
in IN 0
uncontrolled JJ 0
diabetes NNS 0
is VBZ 0
decreased VBN 0
with IN 0
glycemic JJ 0
control NN 0
. . 0

The DT 0
control NN 0
of IN 0
diabetes NNS 0
with IN 0
gliclazide NN 0
reduced VBN 0
oxidative JJ 0
stress NN 0
more JJR 0
than IN 0
glibenclamide NN 0
, , 0
indicating VBG 0
higher JJR 0
antioxidant JJ 0
properties NNS 0
of IN 0
gliclazide NN 0
. . 0

Normalization NN 0
of IN 0
oxidative JJ 0
stress NN 0
was VBD 0
not RB 0
achieved VBN 0
. . 0

Further JJ 0
studies NNS 0
are VBP 0
required VBN 0
to TO 0
see VB 0
long-term JJ 0
effect NN 0
of IN 0
drug NN 0
therapy NN 0
in IN 0
combating VBG 0
oxidative JJ 0
stress NN 0
after IN 0
achieving VBG 0
acceptable JJ 0
control NN 0
of IN 0
diabetes NNS 0
. . 0

Induction NNP 0
chemotherapy NN 0
in IN 0
head NN 4
and CC 4
neck NN 4
cancer NN 4
: : 0
results NNS 0
of IN 0
a DT 0
phase NN 0
III NNP 0
trial NN 0
. . 0

Between IN 0
December NNP 0
1982 CD 0
and CC 0
October NNP 0
1986 CD 0
, , 0
131 CD 3
patients NNS 0
with IN 0
stage JJ 4
II-III-IV NNP 4
squamous JJ 4
cell NN 4
carcinoma NN 4
of IN 0
the DT 0
oropharynx NN 4
or CC 0
oral JJ 4
cavity NN 4
were VBD 0
randomized VBN 0
to TO 0
induction VB 0
chemotherapy NN 0
, , 0
consisting VBG 0
of IN 0
bleomycin NN 0
( ( 0
10 CD 0
mg/m2/day NN 0
in IN 0
continuous JJ 0
infusion NN 0
from IN 0
day NN 0
1 CD 0
to TO 0
day NN 0
5 CD 0
) ) 0
, , 0
methotrexate NN 0
( ( 0
120 CD 0
mg/m2 NN 0
on IN 0
day NN 0
2 CD 0
) ) 0
followed VBN 0
by IN 0
folinic JJ 0
acid NN 0
, , 0
5-fluorouracil JJ 0
( ( 0
5 CD 0
FU NNP 0
) ) 0
( ( 0
600 CD 0
mg/m2 NN 0
on IN 0
day NN 0
2 CD 0
) ) 0
, , 0
and CC 0
cisplatin NN 0
( ( 0
120 CD 0
mg/m2 NN 0
on IN 0
day NN 0
4 CD 0
) ) 0
every DT 0
4 CD 0
weeks NNS 0
for IN 0
a DT 0
total NN 0
of IN 0
three CD 0
cycles NNS 0
followed VBN 0
by IN 0
definitive JJ 0
locoregional JJ 0
treatment NN 0
versus IN 0
locoregional JJ 0
treatment NN 0
alone RB 0
. . 0

The DT 0
modalities NNS 0
of IN 0
definitive JJ 0
treatment NN 0
( ( 0
radiotherapy JJ 0
+/- JJ 0
surgery NN 0
) ) 0
were VBD 0
chosen VBN 0
prior RB 0
to TO 0
randomization NN 0
. . 0

A DT 0
total NN 0
of IN 0
116 CD 3
patients NNS 0
were VBD 0
evaluable JJ 0
. . 0

Of IN 0
55 CD 0
patients NNS 0
in IN 0
the DT 0
chemotherapy NN 0
arm NN 0
, , 0
four CD 0
( ( 0
7 CD 0
% NN 0
) ) 0
had VBD 0
a DT 0
complete JJ 0
response NN 0
( ( 0
CR NNP 0
) ) 0
and CC 0
23 CD 0
( ( 0
42 CD 0
% NN 0
) ) 0
a DT 0
partial JJ 0
response NN 0
( ( 0
PR NNP 0
) ) 0
following VBG 0
the DT 0
induction NN 0
regimen NNS 0
. . 0

At IN 0
the DT 0
completion NN 0
of IN 0
locoregional JJ 0
treatment NN 0
, , 0
76 CD 0
% NN 0
( ( 0
42 CD 0
of IN 0
55 CD 0
) ) 0
of IN 0
patients NNS 0
in IN 0
the DT 0
experimental JJ 0
group NN 0
were VBD 0
in IN 0
CR NNP 0
compared VBN 0
to TO 0
89 CD 0
% NN 0
( ( 0
54 CD 0
of IN 0
61 CD 0
) ) 0
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

There EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
survival NN 0
, , 0
cause-specific JJ 0
survival NN 0
, , 0
and CC 0
pattern NN 0
of IN 0
relapse NN 0
between IN 0
both DT 0
groups NNS 0
. . 0

The DT 0
median JJ 0
survival NN 0
was VBD 0
22 CD 0
months NNS 0
in IN 0
the DT 0
chemotherapy NN 0
group NN 0
and CC 0
29 CD 0
months NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

Responders NNS 0
to TO 0
chemotherapy VB 0
did VBD 0
not RB 0
fare VB 0
better JJR 0
than IN 0
nonresponders NNS 0
. . 0

Chemotherapy-related JJ 0
toxicities NNS 0
were VBD 0
few JJ 0
and CC 0
most JJS 0
of IN 0
them PRP 0
related VBN 0
to TO 0
cisplatin VB 0
which WDT 0
was VBD 0
reduced VBN 0
to TO 0
100 CD 0
mg/m2 NN 0
for IN 0
35 CD 0
patients NNS 0
. . 0

There EX 0
were VBD 0
no DT 0
treatment-related JJ 0
deaths NNS 0
and CC 0
, , 0
in IN 0
the DT 0
experimental JJ 0
arm NN 0
of IN 0
the DT 0
trial NN 0
, , 0
no DT 0
increased VBN 0
morbidity NN 0
from IN 0
locoregional JJ 0
treatment NN 0
. . 0

This DT 0
induction NN 0
regimen NN 0
does VBZ 0
not RB 0
offer VB 0
any DT 0
advantages NNS 0
over IN 0
standard JJ 0
treatment NN 0
. . 0

Immunologic NNP 0
response NN 0
after IN 0
laparoscopic NN 0
colon NN 4
cancer NN 4
operation NN 0
within IN 0
an DT 0
enhanced JJ 0
recovery NN 0
program NN 0
. . 0

OBJECTIVE NN 0
It PRP 0
has VBZ 0
been VBN 0
demonstrated VBN 0
that IN 0
colon NN 0
operation NN 0
combined VBN 0
with IN 0
fast-track NN 0
( ( 0
FT NNP 0
) ) 0
surgery NN 0
and CC 0
laparoscopic NN 0
technique NN 0
can MD 0
shorten VB 0
the DT 0
length NN 0
of IN 0
hospital NN 0
stay NN 0
, , 0
accelerate JJ 0
recovery NN 0
of IN 0
intestinal JJ 0
function NN 0
, , 0
and CC 0
reduce VB 0
the DT 0
occurrence NN 0
of IN 0
post-operative JJ 0
complications NNS 0
. . 0

However RB 0
, , 0
there EX 0
are VBP 0
no DT 0
reports NNS 0
regarding VBG 0
the DT 0
combined JJ 0
effects NNS 0
of IN 0
FT NNP 0
colon NN 0
operation NN 0
and CC 0
laparoscopic NN 0
technique NN 0
on IN 0
humoral JJ 0
inflammatory NN 0
cellular JJ 0
immunity NN 0
. . 0

METHODS NNP 0
This DT 0
was VBD 0
a DT 0
prospective JJ 0
, , 0
controlled VBD 0
study NN 0
. . 0

One CD 3
hundred VBD 3
sixty-three JJ 3
colon NN 4
cancer NN 4
patients NNS 0
underwent VBD 0
the DT 0
traditional JJ 0
protocol NN 0
and CC 0
open JJ 0
operation NN 0
( ( 0
traditional JJ 0
open JJ 0
group NN 0
, , 0
n=42 RB 3
) ) 0
, , 0
the DT 0
traditional JJ 0
protocol NN 0
and CC 0
laparoscopic NN 0
operation NN 0
( ( 0
traditional JJ 0
laparoscopic NN 0
group NN 0
, , 0
n=40 RB 3
) ) 0
, , 0
the DT 0
FT NNP 0
protocol NN 0
and CC 0
open JJ 0
operation NN 0
( ( 0
FT NNP 0
open JJ 0
group NN 0
, , 0
n=41 RB 3
) ) 0
, , 0
or CC 0
the DT 0
FT NNP 0
protocol NN 0
and CC 0
laparoscopic NN 0
operation NN 0
( ( 0
FT NNP 0
laparoscopic NN 0
group NN 0
, , 0
n=40 RB 3
) ) 0
. . 0

Blood NN 0
samples NNS 0
were VBD 0
taken VBN 0
prior RB 0
to TO 0
operation NN 0
as RB 0
well RB 0
as IN 0
on IN 0
days NNS 0
1 CD 0
, , 0
3 CD 0
, , 0
and CC 0
5 CD 0
after IN 0
operation NN 0
. . 0

The DT 0
number NN 0
of IN 0
lymphocyte JJ 0
subpopulations NNS 0
was VBD 0
determined VBN 0
by IN 0
flow JJ 0
cytometry NN 0
, , 0
and CC 0
serum VB 0
interleukin-6 JJ 0
and CC 0
C-reactive JJ 0
protein NN 0
levels NNS 0
were VBD 0
measured VBN 0
. . 0

Post-operative JJ 0
hospital NN 0
stay NN 0
, , 0
post-operative JJ 0
morbidity NN 0
, , 0
readmission NN 0
rate NN 0
, , 0
and CC 0
in-hospital JJ 0
mortality NN 0
were VBD 0
recorded VBN 0
. . 0

RESULTS NNP 0
Compared VBD 0
with IN 0
open JJ 0
operation NN 0
, , 0
laparoscopic JJ 0
colon NN 0
operation NN 0
effectively RB 0
inhibited VBD 0
the DT 0
release NN 0
of IN 0
post-operative JJ 0
inflammatory JJ 0
factors NNS 0
and CC 0
yielded VBD 0
good JJ 0
protection NN 0
via IN 0
post-operative JJ 0
cell NN 0
immunity NN 0
. . 0

FT NNP 0
surgery NN 0
had VBD 0
a DT 0
better RBR 0
protective JJ 0
role NN 0
with IN 0
respect NN 0
to TO 0
the DT 0
post-operative JJ 0
immune NN 0
system NN 0
compared VBN 0
with IN 0
traditional JJ 0
peri-operative JJ 0
care NN 0
. . 0

Inflammatory JJ 0
reactions NNS 0
, , 0
based VBN 0
on IN 0
interleukin-6 JJ 0
and CC 0
C-reactive JJ 0
protein NN 0
levels NNS 0
, , 0
were VBD 0
less JJR 0
intense JJ 0
following VBG 0
FT NNP 0
laparoscopic NN 0
operation NN 0
compared VBN 0
to TO 0
FT NNP 0
open JJ 0
operation NN 0
; : 0
however RB 0
, , 0
there EX 0
were VBD 0
no DT 0
differences NNS 0
in IN 0
specific JJ 0
immunity NN 0
( ( 0
CD3+ NNP 0
and CC 0
CD4+ NNP 0
counts NNS 0
, , 0
and CC 0
the DT 0
CD4+/CD8+ NNP 0
ratio NN 0
) ) 0
during IN 0
these DT 0
two CD 0
types NNS 0
of IN 0
surgical JJ 0
procedures NNS 0
. . 0

Post-operative JJ 0
hospital NN 0
stay NN 0
in IN 0
patients NNS 0
randomized VBN 0
to TO 0
the DT 0
FT NNP 0
laparoscopic NN 0
group NN 0
was VBD 0
significantly RB 0
shorter JJR 0
than IN 0
in IN 0
the DT 0
other JJ 0
three CD 0
treatment NN 0
groups NNS 0
( ( 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

Post-operative JJ 0
complications NNS 0
in IN 0
patients NNS 0
who WP 0
underwent VBP 0
FT NNP 0
laparoscopic NN 0
treatment NN 0
were VBD 0
less JJR 0
than IN 0
in IN 0
the DT 0
other JJ 0
three CD 0
treatment NN 0
groups NNS 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
between IN 0
the DT 0
four CD 0
treatment NN 0
groups NNS 0
regarding VBG 0
readmission NN 0
rate NN 0
and CC 0
in-hospital JJ 0
mortality NN 0
. . 0

CONCLUSIONS VB 0
The DT 0
laparoscopic NN 0
technique NN 0
and CC 0
FT NNP 0
surgery NN 0
rehabilitation NN 0
program NN 0
effectively RB 0
inhibited VBD 0
release NN 0
of IN 0
post-operative JJ 0
inflammatory JJ 0
factors NNS 0
with IN 0
a DT 0
reduction NN 0
in IN 0
peri-operative JJ 0
trauma NN 0
and CC 0
stress NN 0
, , 0
which WDT 0
together RB 0
played VBD 0
a DT 0
protective JJ 0
role NN 0
on IN 0
the DT 0
post-operative JJ 0
immune NN 0
system NN 0
. . 0

Combining VBG 0
two CD 0
treatment NN 0
measures NNS 0
during IN 0
colon NN 0
operation NN 0
produced VBD 0
better RBR 0
protective JJ 0
effects NNS 0
via IN 0
the DT 0
immune JJ 0
system NN 0
. . 0

The DT 0
beneficial JJ 0
clinical JJ 0
effects NNS 0
support NN 0
that IN 0
the DT 0
better-preserved JJ 0
post-operative JJ 0
immune NN 0
system NN 0
may MD 0
also RB 0
contribute VB 0
to TO 0
the DT 0
improvement NN 0
of IN 0
post-operative JJ 0
results NNS 0
in IN 0
FT NNP 0
laparoscopic NN 0
patients NNS 0
. . 0

Late JJ 0
patient-reported JJ 0
toxicity NN 0
after IN 0
preoperative JJ 0
radiotherapy NN 0
or CC 0
chemoradiotherapy NN 0
in IN 0
nonresectable JJ 4
rectal JJ 4
cancer NN 4
: : 0
results NNS 0
from IN 0
a DT 0
randomized JJ 0
Phase NNP 0
III NNP 0
study NN 0
. . 0

PURPOSE NNP 0
Preoperative NNP 0
chemoradiotherapy NN 0
( ( 0
CRT NNP 0
) ) 0
is VBZ 0
superior JJ 0
to TO 0
radiotherapy VB 0
( ( 0
RT NNP 0
) ) 0
in IN 0
locally RB 4
advanced JJ 4
rectal JJ 4
cancer NN 4
, , 0
but CC 0
the DT 0
survival JJ 0
gain NN 0
is VBZ 0
limited JJ 0
. . 0

Late JJ 0
toxicity NN 0
is VBZ 0
, , 0
therefore RB 0
, , 0
important JJ 0
. . 0

The DT 0
aim NN 0
was VBD 0
to TO 0
compare VB 0
late JJ 0
bowel NN 0
, , 0
urinary JJ 0
, , 0
and CC 0
sexual JJ 0
functions NNS 0
after IN 0
CRT NNP 0
or CC 0
RT NNP 0
. . 0

METHODS NNP 0
AND CC 0
MATERIALS NNP 0
Patients NNP 0
( ( 0
N NNP 0
= NNP 0
207 CD 0
) ) 0
with IN 0
nonresectable JJ 0
rectal JJ 0
cancer NN 0
were VBD 0
randomized VBN 0
to TO 0
preoperative VB 0
CRT NNP 0
or CC 0
RT NNP 0
( ( 0
2 CD 0
Gy NNP 0
? . 0
25 CD 0
? . 0
5-fluorouracil/leucovorin JJ 0
) ) 0
. . 0

Extended VBN 0
surgery NN 0
was VBD 0
often RB 0
required VBN 0
. . 0

Self-reported JJ 0
late JJ 0
toxicity NN 0
was VBD 0
scored VBN 0
according VBG 0
to TO 0
the DT 0
LENT NNP 0
SOMA NNP 0
criteria NNS 0
in IN 0
a DT 0
structured JJ 0
telephone NN 0
interview NN 0
and CC 0
with IN 0
questionnaires NNS 0
European JJ 0
Organisation NNP 0
for IN 0
Research NNP 0
and CC 0
Treatment NNP 0
of IN 0
Cancer NNP 0
( ( 0
EORTC NNP 0
) ) 0
Quality NN 0
of IN 0
Life NNP 0
Questionnaire NNP 0
( ( 0
QLQ-C30 NNP 0
) ) 0
, , 0
International NNP 0
Index NNP 0
of IN 0
Erectile NNP 0
Function NNP 0
( ( 0
IIEF NNP 0
) ) 0
, , 0
and CC 0
sexual JJ 0
function-vaginal JJ 0
changes NNS 0
questionnaire VBP 0
( ( 0
SVQ NNP 0
) ) 0
. . 0

RESULTS NNP 0
Of IN 0
the DT 0
105 CD 0
patients NNS 0
alive JJ 0
in IN 0
Norway NNP 0
and CC 0
Sweden NNP 0
after IN 0
4 CD 0
to TO 0
12 CD 0
years NNS 0
of IN 0
follow-up NN 0
, , 0
78 CD 0
( ( 0
74 CD 0
% NN 0
) ) 0
responded VBD 0
. . 0

More JJR 0
patients NNS 0
in IN 0
the DT 0
CRT NNP 0
group NN 0
had VBD 0
received VBN 0
a DT 0
stoma NN 0
( ( 0
73 CD 0
% NN 0
vs. FW 0
52 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.09 CD 0
) ) 0
. . 0

Most JJS 0
patients NNS 0
without IN 0
a DT 0
stoma NN 0
( ( 0
7 CD 0
of IN 0
12 CD 0
in IN 0
CRT NNP 0
group NN 0
and CC 0
9 CD 0
of IN 0
16 CD 0
in IN 0
RT NNP 0
group NN 0
) ) 0
had VBD 0
incontinence NN 0
for IN 0
liquid NN 0
stools NNS 0
or CC 0
gas NN 0
. . 0

No DT 0
stoma NN 0
and CC 0
good JJ 0
anal JJ 0
function NN 0
were VBD 0
seen VBN 0
in IN 0
5 CD 0
patients NNS 0
( ( 0
11 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
CRT NNP 0
group NN 0
and CC 0
in IN 0
11 CD 0
( ( 0
30 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
RT NNP 0
group NN 0
( ( 0
p JJ 0
= NNP 0
0.046 CD 0
) ) 0
. . 0

Of IN 0
44 CD 0
patients NNS 0
in IN 0
the DT 0
CRT NNP 0
group NN 0
, , 0
12 CD 0
( ( 0
28 CD 0
% NN 0
) ) 0
had VBD 0
had VBN 0
bowel VBN 0
obstruction NN 0
compared VBN 0
with IN 0
5 CD 0
of IN 0
33 CD 0
( ( 0
15 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
RT NNP 0
group NN 0
( ( 0
p JJ 0
= NNP 0
0.27 CD 0
) ) 0
. . 0

One-quarter NN 0
of IN 0
the DT 0
patients NNS 0
reported VBD 0
urinary JJ 0
incontinence NN 0
. . 0

The DT 0
majority NN 0
of IN 0
men NNS 0
had VBD 0
severe JJ 0
erectile JJ 0
dysfunction NN 0
. . 0

Few JJ 0
women NNS 0
reported VBD 0
sexual JJ 0
activity NN 0
during IN 0
the DT 0
previous JJ 0
month NN 0
. . 0

However RB 0
, , 0
the DT 0
majority NN 0
did VBD 0
not RB 0
have VB 0
concerns NNS 0
about IN 0
their PRP$ 0
sex NN 0
life NN 0
. . 0

CONCLUSIONS NNP 0
Fecal NNP 0
incontinence NN 0
and CC 0
erectile JJ 0
dysfunction NN 0
are VBP 0
frequent JJ 0
after IN 0
combined JJ 0
treatment NN 0
for IN 0
locally RB 0
advanced JJ 0
rectal JJ 0
cancer NN 0
. . 0

There EX 0
was VBD 0
a DT 0
clear JJ 0
tendency NN 0
for IN 0
the DT 0
problems NNS 0
to TO 0
be VB 0
more JJR 0
common JJ 0
after IN 0
CRT NNP 0
than IN 0
after IN 0
RT NNP 0
. . 0

Somatostatin NNP 0
and CC 0
ranitidine NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
non-variceal JJ 4
upper JJ 4
gastrointestinal JJ 4
bleeding NN 4
: : 0
a DT 0
prospective JJ 0
, , 0
randomized VBN 0
, , 0
double-blind NN 0
, , 0
controlled VBN 0
study NN 0
. . 0

BACKGROUND/AIMS IN 0
The DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
compare VB 0
the DT 0
efficacy NN 0
of IN 0
somatostatin NN 0
vs. FW 0
ranitidine NN 0
in IN 0
controlling VBG 0
acute JJ 4
non-variceal JJ 4
gastrointestinal JJ 4
bleeding NN 4
. . 0

METHODOLOGY NNP 0
A NNP 0
total NN 0
of IN 0
48 CD 3
patients NNS 0
with IN 0
acute JJ 4
upper JJ 4
gastrointestinal NN 4
bleeding NN 4
due JJ 0
to TO 0
duodenal JJ 4
or CC 4
gastric JJ 4
ulcer NN 4
were VBD 0
divided VBN 0
into IN 0
2 CD 0
groups NNS 0
. . 0

Group NNP 0
I PRP 0
consisted VBD 0
of IN 0
15 CD 3
patients NNS 0
with IN 0
Forrest NNP 0
IB NNP 0
and CC 0
Group NNP 0
II NNP 0
consisted VBD 0
of IN 0
30 CD 3
patients NNS 0
with IN 0
Forrest NNP 0
II NNP 0
. . 0

Two CD 0
regimens NNS 0
were VBD 0
randomly RB 0
allocated VBN 0
to TO 0
all DT 0
patients NNS 0
within IN 0
half PDT 0
an DT 0
hour NN 0
after IN 0
the DT 0
endoscopic JJ 0
procedure NN 0
: : 0
1 CD 0
) ) 0
somatostatin-UCB NN 0
250 CD 0
mcg NN 0
i.v NN 0
. . 0

bolus CC 0
followed VBN 0
by IN 0
continuous JJ 0
i.v NN 0
. . 0

infusion NN 0
at IN 0
a DT 0
rate NN 0
of IN 0
6 CD 0
mg/d NN 0
for IN 0
72 CD 0
h NN 0
, , 0
or CC 0
2 CD 0
) ) 0
ranitidine NN 0
300 CD 0
mg/d NN 0
by IN 0
continuous JJ 0
i.v NN 0
. . 0

infusion NN 0
for IN 0
72 CD 0
h. JJ 0
RESULTS NNP 0
In IN 0
Group NNP 0
I PRP 0
, , 0
although IN 0
mean JJ 0
blood NN 0
transfusion NN 0
requirements NNS 0
( ( 0
no DT 0
. . 0

of IN 0
units NNS 0
) ) 0
were VBD 0
lower JJR 0
in IN 0
patients NNS 0
treated VBN 0
with IN 0
somatostatin NN 0
than IN 0
in IN 0
those DT 0
treated VBN 0
with IN 0
ranitidine NN 0
, , 0
this DT 0
was VBD 0
not RB 0
statistically RB 0
significant JJ 0
( ( 0
mean JJ 0
+/- JJ 0
SD NN 0
: : 0
2.56 CD 0
+/- JJ 0
3.05 CD 0
vs. FW 0
5.17 CD 0
+/- JJ 0
4.96 CD 0
, , 0
respectively RB 0
; : 0
P NNP 0
> NNP 0
0.05 CD 0
) ) 0
; : 0
the DT 0
time NN 0
of IN 0
bleeding VBG 0
stop NN 0
was VBD 0
shorter RBR 0
in IN 0
the DT 0
somatostatin NN 0
group NN 0
than IN 0
in IN 0
the DT 0
ranitidine NN 0
group NN 0
( ( 0
mean JJ 0
+/- JJ 0
SD NN 0
: : 0
3.24 CD 0
+/- JJ 0
2.45 CD 0
vs. FW 0
11.25 CD 0
+/- JJ 0
11.63 CD 0
, , 0
respectively RB 0
; : 0
P NNP 0
= NNP 0
0.0383 CD 0
) ) 0
. . 0

The DT 0
rebleeding NN 0
and CC 0
the DT 0
mortality NN 0
rates NNS 0
did VBD 0
not RB 0
differ VB 0
between IN 0
the DT 0
treatment NN 0
groups NNS 0
in IN 0
both DT 0
Group NNP 0
I PRP 0
and CC 0
Group NNP 0
II NNP 0
. . 0

CONCLUSIONS NNP 0
Somatostatin NNP 0
is VBZ 0
more RBR 0
effective JJ 0
than IN 0
ranitidine NN 0
in IN 0
controlling VBG 0
acute JJ 0
non-variceal JJ 0
gastrointestinal JJ 0
bleeding NN 0
in IN 0
patients NNS 0
with IN 0
Forrest NNP 0
IB NNP 0
bleeding NN 0
activity NN 0
. . 0

Somatostatin NNP 0
has VBZ 0
no DT 0
additional JJ 0
benefit NN 0
in IN 0
those DT 0
with IN 0
Forrest NNP 0
II NNP 0
bleeding NN 0
activity NN 0
. . 0

Effect NN 0
of IN 0
acute NN 0
exercise NN 0
on IN 0
executive NN 0
function NN 0
in IN 0
children NNS 1
with IN 0
attention NN 4
deficit NN 4
hyperactivity NN 4
disorder NN 4
. . 0

This DT 0
study NN 0
was VBD 0
conducted VBN 0
to TO 0
determine VB 0
the DT 0
effect NN 0
of IN 0
acute NN 0
aerobic JJ 0
exercise NN 0
on IN 0
executive NN 0
function NN 0
in IN 0
children NNS 1
with IN 0
attention NN 4
deficit NN 4
hyperactivity NN 4
disorder NN 4
( ( 0
ADHD NNP 4
) ) 0
. . 0

Forty NNP 3
children NNS 1
with IN 0
ADHD NNP 4
were VBD 0
randomly RB 0
assigned VBN 0
into IN 0
exercise NN 0
or CC 0
control NN 0
groups NNS 0
. . 0

Participants NNS 0
in IN 0
the DT 0
exercise NN 0
group NN 0
performed VBD 0
a DT 0
moderate JJ 0
intensity NN 0
aerobic JJ 0
exercise NN 0
for IN 0
30 CD 0
min NN 0
, , 0
whereas IN 0
the DT 0
control NN 0
group NN 0
watched VBD 0
a DT 0
running/exercise-related JJ 0
video NN 0
. . 0

Neuropsychological JJ 0
tasks NNS 0
, , 0
the DT 0
Stroop NNP 0
Test NNP 0
and CC 0
the DT 0
Wisconsin NNP 0
Card NNP 0
Sorting NNP 0
Test NNP 0
( ( 0
WCST NNP 0
) ) 0
, , 0
were VBD 0
assessed VBN 0
before IN 0
and CC 0
after IN 0
each DT 0
treatment NN 0
. . 0

The DT 0
results NNS 0
indicated VBD 0
that IN 0
acute JJ 0
exercise NN 0
facilitated VBN 0
performance NN 0
in IN 0
the DT 0
Stroop NNP 0
Test NNP 0
, , 0
particularly RB 0
in IN 0
the DT 0
Stroop NNP 0
Color-Word NNP 0
condition NN 0
. . 0

Additionally RB 0
, , 0
children NNS 0
in IN 0
the DT 0
exercise NN 0
group NN 0
demonstrated VBD 0
improvement NN 0
in IN 0
specific JJ 0
WCST NNP 0
performances NNS 0
in IN 0
Non-perseverative JJ 0
Errors NNS 0
and CC 0
Categories NNP 0
Completed NNP 0
, , 0
whereas VBZ 0
no DT 0
influences NNS 0
were VBD 0
found VBN 0
in IN 0
those DT 0
performances NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

Tentative JJ 0
explanations NNS 0
for IN 0
the DT 0
exercise NN 0
effect NN 0
postulate NN 0
that WDT 0
exercise NN 0
allocates VBZ 0
attention NN 0
resources NNS 0
, , 0
influences VBZ 0
the DT 0
dorsolateral JJ 0
prefrontal NN 0
cortex NN 0
, , 0
and CC 0
is VBZ 0
implicated VBN 0
in IN 0
exercise-induced JJ 0
dopamine NN 0
release NN 0
. . 0

These DT 0
findings NNS 0
are VBP 0
promising VBG 0
and CC 0
additional JJ 0
investigations NNS 0
to TO 0
explore VB 0
the DT 0
efficacy NN 0
of IN 0
exercise NN 0
on IN 0
executive NN 0
function NN 0
in IN 0
children NNS 0
with IN 0
ADHD NNP 0
are VBP 0
encouraged VBN 0
. . 0

Similar JJ 0
effects NNS 0
of IN 0
rofecoxib NN 0
and CC 0
indomethacin NN 0
on IN 0
the DT 0
incidence NN 0
of IN 0
heterotopic NN 0
ossification NN 0
after IN 0
hip NN 4
arthroplasty NN 4
. . 0

BACKGROUND NNP 0
Although IN 0
indomethacin NN 0
is VBZ 0
effective JJ 0
in IN 0
preventing VBG 0
heterotopic NN 0
ossification NN 0
( ( 0
HO NNP 0
) ) 0
after IN 0
primary JJ 4
total JJ 4
hip NN 4
arthroplasty NN 4
, , 0
side NN 0
effects NNS 0
are VBP 0
frequently RB 0
observed VBN 0
. . 0

In IN 0
the DT 0
last JJ 0
decade NN 0
a DT 0
new JJ 0
class NN 0
of IN 0
drugs NNS 0
-- : 0
the DT 0
COX-2 NNP 0
selective JJ 0
nonsteroidal JJ 0
anti-inflammatory JJ 0
drugs NNS 0
-- : 0
has VBZ 0
been VBN 0
developed VBN 0
. . 0

To TO 0
investigate VB 0
the DT 0
effect NN 0
of IN 0
these DT 0
COX-2 NNP 0
selective NN 0
NSAIDs NNP 0
on IN 0
heterotopic NN 0
ossification NN 0
( ( 0
HO NNP 0
) ) 0
after IN 0
primary JJ 0
total JJ 0
hip NN 0
arthroplasty NN 0
( ( 0
THA NNP 0
) ) 0
, , 0
we PRP 0
conducted VBD 0
a DT 0
randomized VBN 0
controlled VBN 0
trial NN 0
using VBG 0
either CC 0
indomethacin NN 0
or CC 0
rofecoxib NN 0
for IN 0
7 CD 0
days NNS 0
. . 0

METHODS NNP 0
186 CD 3
patients NNS 0
received VBD 0
either RB 0
indomethacin JJ 0
3 CD 0
times NNS 0
daily RB 0
, , 0
or CC 0
rofecoxib VB 0
twice RB 0
, , 0
and CC 0
1 CD 0
placebo NN 0
, , 0
daily RB 0
for IN 0
7 CD 0
days NNS 0
. . 0

HO NNP 0
was VBD 0
graded VBN 0
according VBG 0
to TO 0
the DT 0
1-year JJ 0
postoperative NN 0
radiographs NN 0
according VBG 0
to TO 0
the DT 0
Brooker NNP 0
classification NN 0
. . 0

RESULTS NNP 0
12 CD 0
of IN 0
the DT 0
186 CD 0
patients NNS 0
included VBD 0
discontinued VBN 0
their PRP$ 0
medication NN 0
before IN 0
the DT 0
end NN 0
of IN 0
the DT 0
trial NN 0
due JJ 0
to TO 0
side VB 0
effects NNS 0
. . 0

The DT 0
remaining VBG 0
174 CD 3
patients NNS 0
were VBD 0
included VBN 0
in IN 0
the DT 0
analysis NN 0
. . 0

In IN 0
the DT 0
indomethacin NN 0
group NN 0
( ( 0
n JJ 0
= NNP 0
89 CD 3
) ) 0
, , 0
77 CD 0
patients NNS 0
( ( 0
87 CD 0
% NN 0
) ) 0
showed VBD 0
no DT 0
HO NNP 0
, , 0
9 CD 0
showed VBD 0
HO NNP 0
of IN 0
grade NN 0
1 CD 0
and CC 0
3 CD 0
showed VBD 0
HO NNP 0
of IN 0
grade NN 0
2 CD 0
according VBG 0
to TO 0
the DT 0
Brooker NNP 0
classification NN 0
. . 0

In IN 0
the DT 0
rofecoxib NN 0
group NN 0
( ( 0
n JJ 0
= NNP 0
85 CD 3
) ) 0
73 CD 0
patients NNS 0
( ( 0
86 CD 0
% NN 0
) ) 0
showed VBD 0
no DT 0
ossification NN 0
, , 0
9 CD 0
showed VBD 0
grade NN 0
1 CD 0
, , 0
and CC 0
3 CD 0
showed VBD 0
grade JJ 0
2 CD 0
. . 0

INTERPRETATION VB 0
The DT 0
prophylactic JJ 0
effect NN 0
of IN 0
rofecoxib NN 0
for IN 0
7 CD 0
days NNS 0
in IN 0
preventing VBG 0
heterotopic NN 0
ossification NN 0
after IN 0
primary JJ 0
total JJ 0
hip NN 0
arthroplasty NN 0
is VBZ 0
comparable JJ 0
to TO 0
the DT 0
effect NN 0
of IN 0
indomethacin NN 0
given VBN 0
for IN 0
7 CD 0
days NNS 0
. . 0

These DT 0
results NNS 0
indicate VBP 0
that IN 0
the DT 0
development NN 0
of IN 0
HO NNP 0
follows VBZ 0
a DT 0
COX-2 JJ 0
pathway NN 0
. . 0

Arthroscopic NNP 0
rotator NN 0
cuff NN 0
repair NN 0
with IN 0
and CC 0
without IN 0
acromioplasty NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
full-thickness JJ 4
rotator NN 4
cuff NN 4
tears NNS 4
: : 0
a DT 0
multicenter NN 0
, , 0
randomized VBN 0
controlled VBN 0
trial NN 0
. . 0

BACKGROUND VB 0
The DT 0
primary JJ 0
objective NN 0
of IN 0
this DT 0
prospective JJ 0
randomized NN 0
controlled VBD 0
trial NN 0
was VBD 0
to TO 0
compare VB 0
functional JJ 0
and CC 0
quality-of-life JJ 0
indices NNS 0
and CC 0
rates NNS 0
of IN 0
revision NN 0
surgery NN 0
in IN 0
arthroscopic NN 0
rotator NN 0
cuff NN 0
repair NN 0
with IN 0
and CC 0
without IN 0
acromioplasty JJ 0
. . 0

METHODS NNP 0
Eighty-six JJ 3
patients NNS 0
consented VBN 0
and CC 0
were VBD 0
randomly RB 0
assigned VBN 0
intraoperatively RB 0
to TO 0
one CD 0
of IN 0
two CD 0
study NN 0
groups NNS 0
, , 0
and CC 0
sixty-eight NN 3
of IN 0
them PRP 0
completed VBD 0
the DT 0
study NN 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
was VBD 0
the DT 0
Western JJ 0
Ontario NNP 0
Rotator NNP 0
Cuff NNP 0
( ( 0
WORC NNP 0
) ) 0
index NN 0
. . 0

Secondary JJ 0
outcome NN 0
measures NNS 0
included VBD 0
the DT 0
American JJ 0
Shoulder NNP 0
and CC 0
Elbow NNP 0
Surgeons NNP 0
( ( 0
ASES NNP 0
) ) 0
shoulder NN 0
assessment JJ 0
form NN 0
and CC 0
a DT 0
count NN 0
of IN 0
revisions NNS 0
required VBN 0
in IN 0
each DT 0
group NN 0
. . 0

Outcome NNP 0
measures NNS 0
were VBD 0
completed VBN 0
preoperatively RB 0
and CC 0
at IN 0
three CD 0
, , 0
six CD 0
, , 0
twelve NN 0
, , 0
eighteen NN 0
, , 0
and CC 0
twenty-four JJ 0
months NNS 0
after IN 0
surgery NN 0
. . 0

RESULTS NNP 0
WORC NNP 0
and CC 0
ASES NNP 0
scores VBZ 0
improved VBN 0
significantly RB 0
in IN 0
each DT 0
group NN 0
over IN 0
time NN 0
( ( 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
differences NNS 0
in IN 0
WORC NNP 0
or CC 0
ASES NNP 0
scores NNS 0
between IN 0
the DT 0
groups NNS 0
that WDT 0
had VBD 0
arthroscopic VBN 0
cuff JJ 0
repair NN 0
with IN 0
or CC 0
without IN 0
acromioplasty JJ 0
at IN 0
any DT 0
time NN 0
point NN 0
. . 0

There EX 0
were VBD 0
no DT 0
differences NNS 0
in IN 0
scores NNS 0
on IN 0
the DT 0
basis NN 0
of IN 0
acromion NN 0
type NN 0
, , 0
nor CC 0
were VBD 0
any DT 0
interaction NN 0
effects NNS 0
identified VBN 0
between IN 0
group NN 0
and CC 0
acromion NN 0
type NN 0
. . 0

Four CD 0
participants NNS 0
( ( 0
9 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
group NN 0
that WDT 0
had VBD 0
arthroscopic VBN 0
cuff JJ 0
repair NN 0
alone RB 0
, , 0
one CD 0
with IN 0
a DT 0
Type-2 JJ 0
and CC 0
three CD 0
with IN 0
a DT 0
Type-3 JJ 0
acromion NN 0
, , 0
required VBN 0
additional JJ 0
surgery NN 0
by IN 0
the DT 0
twenty-four-month JJ 0
time NN 0
point NN 0
. . 0

The DT 0
number NN 0
of IN 0
patients NNS 0
who WP 0
required VBD 0
additional JJ 0
surgery NN 0
was VBD 0
greater JJR 0
( ( 0
p JJ 0
= NNP 0
0.05 CD 0
) ) 0
in IN 0
the DT 0
group NN 0
that WDT 0
had VBD 0
arthroscopic VBN 0
cuff JJ 0
repair NN 0
alone RB 0
than IN 0
in IN 0
the DT 0
group NN 0
that WDT 0
had VBD 0
arthroscopic VBN 0
cuff JJ 0
repair NN 0
and CC 0
acromioplasty NN 0
. . 0

CONCLUSIONS NNP 0
Our PRP$ 0
findings NNS 0
are VBP 0
consistent JJ 0
with IN 0
previous JJ 0
research NN 0
reports NNS 0
in IN 0
which WDT 0
there EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
functional JJ 0
and CC 0
quality-of-life JJ 0
indices NNS 0
for IN 0
patients NNS 0
who WP 0
had VBD 0
rotator NN 0
cuff NN 0
repair NN 0
with IN 0
or CC 0
without IN 0
acromioplasty JJ 0
. . 0

The DT 0
higher JJR 0
reoperation NN 0
rate NN 0
was VBD 0
found VBN 0
in IN 0
the DT 0
group NN 0
without IN 0
acromioplasty NN 0
. . 0

Further CC 0
study NN 0
that WDT 0
includes VBZ 0
follow-up JJ 0
imaging NN 0
and CC 0
patient-reported JJ 0
outcomes NNS 0
over IN 0
a DT 0
greater JJR 0
follow-up JJ 0
period NN 0
is VBZ 0
needed VBN 0
. . 0

[ JJ 0
Dose-reduced NNP 0
antihypertensive JJ 0
agents NNS 0
-- : 0
use NN 0
in IN 0
complex JJ 0
nonmedicamentous JJ 0
therapy NN 0
of IN 0
hypertension NN 0
] NNP 0
. . 0

In IN 0
order NN 0
to TO 0
estimate VB 0
the DT 0
influence NN 0
of IN 0
a DT 0
non-medicamentous JJ 0
therapy NN 0
( ( 0
CNT NNP 0
) ) 0
on IN 0
the DT 0
consumption NN 0
of IN 0
medicaments NNS 0
and CC 0
coronary JJ 0
risk NN 0
in IN 0
high JJ 0
blood NN 0
pressure NN 0
73 CD 3
hypertensives NNS 4
of IN 0
a DT 0
medicamentously RB 0
stabilized VBN 0
CNT-group NNP 0
were VBD 0
examined VBN 0
in IN 0
comparison NN 0
to TO 0
a DT 0
group NN 0
of IN 0
the DT 0
same JJ 0
size NN 0
of IN 0
patients NNS 0
with IN 0
hypertension NN 4
who WP 0
were VBD 0
managed VBN 0
exclusively RB 0
medicamentously RB 0
for IN 0
behaviour NN 0
of IN 0
blood NN 0
pressure NN 0
, , 0
need NN 0
of IN 0
antihypertensive JJ 0
drugs NNS 0
and CC 0
changes NNS 0
of IN 0
hypertension-associated JJ 0
risk NN 0
factors NNS 0
. . 0

After IN 0
an DT 0
exactly RB 0
controlled VBN 0
6-month JJ 0
treatment NN 0
hypertensives NNS 4
with IN 0
additionally RB 0
recommended VBN 0
far-reaching NN 0
CNT NNP 0
showed VBD 0
an DT 0
economization NN 0
of IN 0
medicaments NNS 0
by IN 0
scarcely RB 0
the DT 0
half NN 0
in IN 0
comparison NN 0
to TO 0
the DT 0
reference NN 0
group NN 0
. . 0

By IN 0
means NNS 0
of IN 0
suitable JJ 0
control NN 0
methods VBZ 0
a DT 0
causal JJ 0
non-medicamentously RB 0
conditioned JJ 0
decrease NN 0
of IN 0
blood NN 0
pressure NN 0
could MD 0
be VB 0
excluded VBN 0
. . 0

A DT 0
different JJ 0
need NN 0
of IN 0
antihypertensive JJ 0
drugs NNS 0
was VBD 0
simulated VBN 0
by IN 0
the DT 0
exacter JJ 0
intake NN 0
of IN 0
medicaments NNS 0
in IN 0
the DT 0
index-patients NNS 0
. . 0

Notwithstanding VBG 0
the DT 0
metabolic JJ 0
effects NNS 0
of IN 0
the DT 0
additional JJ 0
therapy NN 0
have VBP 0
induced VBN 0
a DT 0
positive JJ 0
change NN 0
of IN 0
atherogenic JJ 0
lipids NNS 0
. . 0

The DT 0
examinations NNS 0
indicate VBP 0
in IN 0
general JJ 0
the DT 0
difficulty NN 0
of IN 0
the DT 0
judgement NN 0
of IN 0
efficacy NN 0
of IN 0
non-medicamentous JJ 0
therapeutic JJ 0
measures NNS 0
in IN 0
connection NN 0
with IN 0
a DT 0
rational JJ 0
dose-reduced JJ 0
long-term JJ 0
therapy NN 0
with IN 0
antihypertensive JJ 0
drugs NNS 0
. . 0

Treatment NN 0
of IN 0
adults NNS 1
with IN 0
acute JJ 4
lymphoblastic JJ 4
leukemia NN 4
: : 0
do VB 0
the DT 0
specifics NNS 0
of IN 0
the DT 0
regimen NNS 0
matter NN 0
? . 0
: : 0
Results NNS 0
from IN 0
a DT 0
prospective JJ 0
randomized VBN 0
trial NN 0
. . 0

BACKGROUND NNP 0
Induction NNP 0
therapy NN 0
for IN 0
adults NNS 1
with IN 0
acute JJ 4
lymphoblastic JJ 4
leukemia NN 4
( ( 0
ALL DT 4
) ) 0
is VBZ 0
similar JJ 0
across IN 0
essentially RB 0
all DT 0
regimens NNS 0
, , 0
comprised VBN 0
of IN 0
vincristine NN 0
, , 0
corticosteroids NNS 0
, , 0
and CC 0
anthracyclines NNS 0
intensified VBN 0
with IN 0
cyclophosphamide NN 0
, , 0
asparaginase NN 0
, , 0
or CC 0
both DT 0
. . 0

Given VBN 0
the DT 0
lack NN 0
of IN 0
randomized VBN 0
data NNS 0
, , 0
to TO 0
date NN 0
, , 0
no DT 0
regimen NN 0
has VBZ 0
emerged VBN 0
as IN 0
standard NN 0
. . 0

The DT 0
authors NNS 0
previously RB 0
evaluated VBD 0
cytarabine JJ 0
3 CD 0
g/m NN 0
( ( 0
2 CD 0
) ) 0
daily RB 0
for IN 0
5 CD 0
days NNS 0
with IN 0
mitoxantrone NN 0
80 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
( ( 0
the DT 0
ALL-2 NNP 0
regimen NNS 0
) ) 0
as IN 0
a DT 0
novel JJ 0
induction NN 0
regimen NNS 0
. . 0

Compared VBN 0
with IN 0
historic JJ 0
controls NNS 0
, , 0
the DT 0
ALL-2 NNP 0
regimen NN 0
was VBD 0
superior JJ 0
in IN 0
terms NNS 0
of IN 0
incidence NN 0
of IN 0
complete JJ 0
remission NN 0
, , 0
failure NN 0
with IN 0
resistant JJ 0
disease NN 0
, , 0
and CC 0
activity NN 0
in IN 0
patients NNS 0
with IN 0
Philadelphia NNP 4
chromosome NN 4
( ( 4
Ph NNP 4
) ) 4
-positive VBP 4
ALL NNP 0
. . 0

METHODS NNP 0
The DT 0
authors NNS 0
conducted VBD 0
a DT 0
multicenter NN 0
, , 0
prospective JJ 0
, , 0
randomized JJ 0
trial NN 0
of IN 0
the DT 0
ALL-2 NNP 0
regimen NNS 0
compared VBN 0
with IN 0
a DT 0
standard JJ 0
4-drug JJ 0
induction NN 0
( ( 0
the DT 0
L-20 NNP 0
regimen NNS 0
) ) 0
. . 0

Patients NNS 0
also RB 0
received VBD 0
consolidation NN 0
, , 0
maintenance NN 0
therapy NN 0
, , 0
and CC 0
central JJ 0
nervous JJ 0
system NN 0
prophylaxis NN 0
. . 0

The DT 0
trial NN 0
accrued VBD 0
patients NNS 0
from IN 0
August NNP 0
1996 CD 0
to TO 0
October NNP 0
2004 CD 0
. . 0

RESULTS VB 0
The DT 0
median JJ 0
follow-up NN 0
for IN 0
survivors NNS 0
was VBD 0
7 CD 0
years NNS 0
, , 0
and CC 0
the DT 0
median JJ 0
patient NN 0
age NN 0
was VBD 0
43 CD 1
years NNS 0
. . 0

Responses NNS 0
were VBD 0
evaluated VBN 0
in IN 0
164 CD 3
patients NNS 0
. . 0

The DT 0
treatment NN 0
arms NNS 0
were VBD 0
balanced VBN 0
in IN 0
terms NNS 0
of IN 0
pretreatment NN 0
characteristics NNS 0
. . 0

The DT 0
frequency NN 0
of IN 0
complete JJ 0
remission NN 0
for IN 0
the DT 0
ALL-2 NNP 0
regimen NNS 0
versus IN 0
the DT 0
L-20 JJ 0
regimen NN 0
was VBD 0
83 CD 0
% NN 0
versus IN 0
71 CD 0
% NN 0
( ( 0
P NNP 0
= NNP 0
.06 NNP 0
) ) 0
. . 0

More JJR 0
patients NNS 0
on IN 0
the DT 0
L-20 NNP 0
arm NN 0
failed VBD 0
with IN 0
resistant JJ 0
disease NN 0
( ( 0
21 CD 0
% NN 0
vs JJ 0
8 CD 0
% NN 0
; : 0
P NNP 0
= NNP 0
.02 NNP 0
) ) 0
. . 0

Induction NNP 0
deaths NNS 0
were VBD 0
comparable JJ 0
at IN 0
9 CD 0
% NN 0
( ( 0
ALL-2 NNP 0
) ) 0
versus VBD 0
7 CD 0
% NN 0
( ( 0
L-20 NNP 0
) ) 0
. . 0

The DT 0
median JJ 0
survival NN 0
was VBD 0
similar JJ 0
; : 0
and CC 0
, , 0
at IN 0
5 CD 0
years NNS 0
, , 0
the DT 0
survival NN 0
rate NN 0
was VBD 0
33 CD 0
% NN 0
alive JJ 0
on IN 0
the DT 0
ALL-2 NNP 0
arm NN 0
versus NN 0
27 CD 0
% NN 0
on IN 0
the DT 0
L-20 NNP 0
. . 0

CONCLUSIONS NNP 0
Despite IN 0
superior JJ 0
results NNS 0
of IN 0
induction NN 0
therapy NN 0
with IN 0
the DT 0
ALL-2 NNP 0
regimen NNS 0
, , 0
this DT 0
treatment NN 0
did VBD 0
not RB 0
improve VB 0
long-term JJ 0
outcomes NNS 0
. . 0

When WRB 0
coupled VBN 0
to TO 0
the DT 0
reported VBN 0
experience NN 0
of IN 0
other JJ 0
studies NNS 0
in IN 0
adults NNS 0
with IN 0
ALL NNP 0
, , 0
the DT 0
results NNS 0
of IN 0
this DT 0
randomized VBN 0
trial NN 0
raise NN 0
the DT 0
possibility NN 0
that WDT 0
ultimate JJ 0
outcomes NNS 0
in IN 0
adult NN 0
ALL NNP 0
may MD 0
be VB 0
independent JJ 0
of IN 0
the DT 0
specific JJ 0
regimen NNS 0
chosen VBN 0
. . 0

Cancer NN 0
2013 CD 0
. . 0

? . 0
2012 CD 0
American JJ 0
Cancer NNP 0
Society NNP 0
. . 0

A DT 0
randomized VBN 0
controlled VBN 0
trial NN 0
to TO 0
improve VB 0
colon NN 0
cancer NN 0
screening VBG 0
in IN 0
rural JJ 4
family NN 4
medicine NN 0
: : 0
an DT 0
Iowa NNP 0
Research NNP 0
Network NNP 0
( ( 0
IRENE NNP 0
) ) 0
study NN 0
. . 0

BACKGROUND NNP 0
Many JJ 0
adults NNS 0
have VBP 0
not RB 0
been VBN 0
screened VBN 0
for IN 0
colon NN 0
cancer NN 0
, , 0
a DT 0
potentially RB 0
preventable JJ 0
cause NN 0
of IN 0
death NN 0
. . 0

METHODS NNP 0
This DT 0
was VBD 0
a DT 0
randomized VBN 0
controlled VBN 0
trial NN 0
conducted VBN 0
between IN 0
December NNP 0
2008 CD 0
and CC 0
April NNP 0
2011 CD 0
to TO 0
improve VB 0
CRC NNP 0
screening VBG 0
in IN 0
16 CD 0
rural JJ 0
family NN 0
physician NN 0
offices NNS 0
. . 0

Subjects NNS 4
due JJ 0
for IN 0
CRC NNP 4
screening VBG 4
were VBD 0
randomized VBN 0
within IN 0
each DT 0
practice NN 0
to TO 0
1 CD 0
of IN 0
4 CD 0
groups NNS 0
: : 0
( ( 0
1 CD 0
) ) 0
usual JJ 0
care NN 0
; : 0
( ( 0
2 CD 0
) ) 0
physician JJ 0
chart NN 0
reminder NN 0
; : 0
( ( 0
3 CD 0
) ) 0
physician JJ 0
chart NN 0
reminder NN 0
, , 0
mailed VBN 0
education NN 0
, , 0
CRC NNP 0
reminder NN 0
magnet NN 0
, , 0
and CC 0
fecal JJ 0
immunochemical JJ 0
test NN 0
( ( 0
FIT NNP 0
) ) 0
( ( 0
mailed JJ 0
education/FIT NN 0
) ) 0
; : 0
or CC 0
( ( 0
4 CD 0
) ) 0
all PDT 0
the DT 0
preceding VBG 0
plus CC 0
a DT 0
structured JJ 0
telephone NN 0
call NN 0
to TO 0
the DT 0
patient NN 0
from IN 0
project JJ 0
staff NN 0
to TO 0
provide VB 0
education NN 0
, , 0
assess JJ 0
interest NN 0
in IN 0
screening VBG 0
, , 0
explain VB 0
the DT 0
screening NN 0
tests NNS 0
, , 0
and CC 0
address JJ 0
barriers NNS 0
( ( 0
mailed VBN 0
education/FIT RB 0
plus CC 0
phone NN 0
call NN 0
) ) 0
. . 0

The DT 0
main JJ 0
outcome NN 0
was VBD 0
completion NN 0
of IN 0
any DT 0
CRC NNP 0
screening NN 0
. . 0

RESULTS VB 0
This DT 0
study NN 0
enrolled VBD 0
743 CD 3
patients NNS 0
. . 0

CRC NNP 0
screening NN 0
was VBD 0
completed VBN 0
by IN 0
17.8 CD 0
% NN 0
in IN 0
the DT 0
usual JJ 0
care NN 0
group NN 0
, , 0
20.5 CD 0
% NN 0
in IN 0
the DT 0
chart NN 0
reminder NN 0
group NN 0
, , 0
56.5 CD 0
% NN 0
in IN 0
the DT 0
mailed JJ 0
education/FIT NN 0
group NN 0
, , 0
and CC 0
57.2 CD 0
% NN 0
in IN 0
the DT 0
mailed JJ 0
education/FIT NN 0
plus CC 0
phone NN 0
call NN 0
group NN 0
. . 0

We PRP 0
found VBD 0
no DT 0
effect NN 0
from IN 0
the DT 0
chart NN 0
reminder NN 0
compared VBN 0
with IN 0
usual JJ 0
care NN 0
( ( 0
odds NNS 0
ratio VBP 0
[ CD 0
OR NNP 0
] NNP 0
, , 0
1.2 CD 0
; : 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
[ NNP 0
CI NNP 0
] NNP 0
, , 0
0.7-2.0 NNP 0
) ) 0
; : 0
and CC 0
a DT 0
beneficial JJ 0
effect NN 0
from IN 0
the DT 0
mailed VBN 0
education/FIT NN 0
( ( 0
OR NNP 0
, , 0
6.0 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
3.7-9.6 JJ 0
) ) 0
and CC 0
the DT 0
mailed JJ 0
education/FIT NN 0
plus CC 0
phone NN 0
call NN 0
( ( 0
OR NNP 0
, , 0
6.2 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
3.8-9.9 JJ 0
) ) 0
. . 0

Both DT 0
FIT NNP 0
and CC 0
colonoscopy JJ 0
rates NNS 0
increased VBD 0
significantly RB 0
in IN 0
both DT 0
mailed JJ 0
education NN 0
groups NNS 0
. . 0

CONCLUSION NNP 0
CRC NNP 0
screening VBG 0
rates NNS 0
increased VBD 0
significantly RB 0
among IN 0
patients NNS 0
who WP 0
were VBD 0
overdue JJ 0
for IN 0
screening VBG 0
after IN 0
they PRP 0
received VBD 0
mailed VBD 0
educational JJ 0
materials NNS 0
and CC 0
a DT 0
FIT NNP 0
. . 0

The DT 0
addition NN 0
of IN 0
a DT 0
phone NN 0
call NN 0
did VBD 0
not RB 0
further JJ 0
increase NN 0
screening VBG 0
rates NNS 0
. . 0

Allogeneic NNP 0
marrow NN 0
transplantation NN 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 4
myeloid NN 4
leukemia NN 4
in IN 0
the DT 0
chronic JJ 4
phase NN 4
: : 0
a DT 0
randomized JJ 0
trial NN 0
of IN 0
two CD 0
irradiation NN 0
regimens NNS 0
. . 0

A DT 0
randomized JJ 0
trial NN 0
was VBD 0
performed VBN 0
to TO 0
compare VB 0
two CD 0
regimens NNS 0
of IN 0
total JJ 0
body NN 0
irradiation NN 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 4
myeloid NN 4
leukemia NN 4
treated VBN 0
by IN 0
allogeneic JJ 4
marrow NN 4
transplantation NN 4
while IN 0
in IN 0
the DT 0
chronic JJ 4
phase NN 4
. . 0

All DT 0
patients NNS 0
received VBD 0
cyclophosphamide JJ 0
120 CD 0
mg/kg NN 0
followed VBN 0
by IN 0
total JJ 0
body NN 0
irradiation NN 0
and CC 0
marrow NN 0
from IN 0
HLA-identical JJ 0
siblings NNS 0
. . 0

Cyclosporine NNP 0
and CC 0
methotrexate NN 0
were VBD 0
used VBN 0
for IN 0
prophylaxis NN 0
against IN 0
acute JJ 0
graft-versus-host JJ 0
disease NN 0
. . 0

Fifty-seven JJ 3
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
2.0 CD 0
Gy NNP 0
fractions NNS 0
of IN 0
irradiation NN 0
daily NN 0
for IN 0
6 CD 0
days NNS 0
and CC 0
59 CD 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
2.25 CD 0
Gy NNP 0
fractions NNS 0
daily RB 0
for IN 0
7 CD 0
days NNS 0
. . 0

The DT 0
probabilities NNS 0
of IN 0
relapse NN 0
at IN 0
4 CD 0
years NNS 0
were VBD 0
0.25 CD 0
for IN 0
the DT 0
12.0 CD 0
Gy NNP 0
group NN 0
and CC 0
0.00 CD 0
for IN 0
the DT 0
15.75 CD 0
Gy NNP 0
group NN 0
( ( 0
P NNP 0
= NNP 0
.008 NNP 0
) ) 0
. . 0

The DT 0
actuarial JJ 0
probabilities NNS 0
of IN 0
survival NN 0
and CC 0
relapse-free JJ 0
survival NN 0
at IN 0
4 CD 0
years NNS 0
were VBD 0
0.60 CD 0
and CC 0
0.58 CD 0
among IN 0
the DT 0
patients NNS 0
who WP 0
received VBD 0
12.0 CD 0
Gy NNP 0
compared VBN 0
with IN 0
0.66 CD 0
and CC 0
0.66 CD 0
for IN 0
those DT 0
who WP 0
received VBD 0
15.75 CD 0
Gy NNP 0
. . 0

The DT 0
4-year JJ 0
probabilities NNS 0
of IN 0
transplant-related JJ 0
mortality NN 0
were VBD 0
0.24 CD 0
and CC 0
0.34 CD 0
respectively RB 0
( ( 0
P NNP 0
= NNP 0
.13 NNP 0
) ) 0
while IN 0
the DT 0
probability NN 0
of IN 0
moderate JJ 0
to TO 0
severe VB 0
acute JJ 0
graft-versus-host JJ 0
disease NN 0
was VBD 0
0.33 CD 0
for IN 0
the DT 0
12.0 CD 0
Gy NNP 0
group NN 0
and CC 0
0.44 CD 0
for IN 0
the DT 0
15.75 CD 0
Gy NNP 0
group NN 0
( ( 0
P NNP 0
= NNP 0
.15 NNP 0
) ) 0
. . 0

The DT 0
lower JJR 0
relapse NN 0
probability NN 0
in IN 0
the DT 0
patients NNS 0
receiving VBG 0
the DT 0
higher JJR 0
dose NN 0
of IN 0
total JJ 0
body NN 0
irradiation NN 0
did VBD 0
not RB 0
result VB 0
in IN 0
improved JJ 0
survival NN 0
because IN 0
mortality NN 0
from IN 0
causes VBZ 0
other JJ 0
than IN 0
relapse NN 0
was VBD 0
increased VBN 0
. . 0

Validity NNP 0
and CC 0
reliability NN 0
assessment NN 0
of IN 0
the DT 0
Siriraj NNP 0
Asthma NNP 4
Control NNP 0
Questionnaire NNP 0
. . 0

OBJECTIVE CC 0
The DT 0
present JJ 0
study NN 0
assessed VBD 0
the DT 0
validity NN 0
and CC 0
reliability NN 0
of IN 0
the DT 0
Siriraj NNP 0
Asthma NNP 0
Control NNP 0
Questionnaire NNP 0
in IN 0
Asthma NNP 0
Clinic NNP 0
, , 0
Siriraj NNP 0
Hospital NNP 0
. . 0

MATERIAL NNP 0
AND CC 0
METHOD NNP 0
The DT 0
data NN 0
of IN 0
the DT 0
questionnaire NN 0
responses NNS 0
and CC 0
spirometric JJ 0
results NNS 0
from IN 0
20 CD 3
randomized JJ 0
asthmatic JJ 4
patients NNS 0
in IN 0
the DT 0
clinic NN 0
including VBG 0
the DT 0
record NN 0
of IN 0
3 CD 0
visits NNS 0
for IN 0
each DT 0
subject NN 0
. . 0

The DT 0
validation NN 0
was VBD 0
performed VBN 0
by IN 0
Kruskal-Wallis NNP 0
test NN 0
comparing VBG 0
the DT 0
scores NNS 0
with IN 0
the DT 0
level NN 0
of IN 0
asthma NNS 0
control NN 0
determined VBN 0
by IN 0
physicians NNS 0
according VBG 0
to TO 0
GINA NNP 0
guideline NN 0
. . 0

Internal NNP 0
consistency NN 0
reliability NN 0
was VBD 0
analyzed VBN 0
by IN 0
Cronbach NNP 0
's POS 0
alpha NN 0
. . 0

RESULTS NNP 0
Sixty NNP 0
questionnaires VBZ 0
from IN 0
20 CD 0
patients NNS 0
with IN 0
age NN 0
29-73 CD 1
years NNS 0
were VBD 0
analyzed VBN 0
. . 0

There EX 0
were VBD 0
40 CD 0
controlled VBN 0
, , 0
7 CD 0
partly RB 0
controlled VBN 0
and CC 0
13 CD 0
uncontrolled JJ 0
visits NNS 0
. . 0

The DT 0
scores NNS 0
from IN 0
5-items JJ 0
questionnaires NNS 0
and CC 0
6-items JJ 0
clinical JJ 0
score NN 0
were VBD 0
significantly RB 0
associated VBN 0
with IN 0
the DT 0
physician-diagnosed JJ 0
groups NNS 0
( ( 0
i.e. FW 0
, , 0
controlled VBD 0
, , 0
partly RB 0
controlled VBN 0
and CC 0
uncontrolled JJ 0
groups NNS 0
) ) 0
. . 0

Median JJ 0
scores NNS 0
( ( 0
min NN 0
, , 0
max NN 0
) ) 0
were VBD 0
0 CD 0
( ( 0
0 CD 0
, , 0
5 CD 0
) ) 0
, , 0
2 CD 0
( ( 0
0 CD 0
, , 0
6 CD 0
) ) 0
, , 0
4 CD 0
( ( 0
0 CD 0
, , 0
12 CD 0
) ) 0
respectively RB 0
, , 0
( ( 0
5-items CD 0
, , 0
p VBZ 0
< NNP 0
0.001 CD 0
) ) 0
and CC 0
2 CD 0
( ( 0
0 CD 0
, , 0
7 CD 0
) ) 0
, , 0
3 CD 0
( ( 0
1 CD 0
, , 0
7 CD 0
) ) 0
, , 0
6 CD 0
( ( 0
2,15 CD 0
) ) 0
respectively RB 0
, , 0
( ( 0
6-items CD 0
, , 0
p VBZ 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

Internal NNP 0
consistency NN 0
reliability NN 0
of IN 0
both DT 0
5-items JJ 0
questionnaire NN 0
and CC 0
6-items JJ 0
clinical JJ 0
score NN 0
were VBD 0
within IN 0
the DT 0
acceptable JJ 0
range NN 0
( ( 0
0.829 CD 0
and CC 0
0.708 CD 0
respectively RB 0
) ) 0
. . 0

5-items JJ 0
questionnaire NN 0
is VBZ 0
more RBR 0
associated JJ 0
with IN 0
the DT 0
physician NN 0
diagnosed VBN 0
group NN 0
and CC 0
more JJR 0
consistent JJ 0
than IN 0
6-items JJ 0
clinical JJ 0
score NN 0
. . 0

Further JJ 0
analysis NN 0
revealed VBD 0
cutoff NN 0
point NN 0
at IN 0
2.5 CD 0
to TO 0
separate VB 0
uncontrolled JJ 0
from IN 0
controlled VBN 0
or CC 0
partly RB 0
controlled VBN 0
patient NN 0
with IN 0
sensitivity NN 0
76.9 CD 0
% NN 0
and CC 0
specificity NN 0
89.4 CD 0
% NN 0
and CC 0
cutoff NN 0
point NN 0
at IN 0
1.5 CD 0
to TO 0
separate VB 0
uncontrolled JJ 0
or CC 0
partly RB 0
controlled VBN 0
from IN 0
controlled VBN 0
patient NN 0
with IN 0
sensitivity NN 0
70.0 CD 0
% NN 0
and CC 0
specificity NN 0
85.0 CD 0
% NN 0
. . 0

CONCLUSION NNP 0
The DT 0
validity NN 0
and CC 0
reliability NN 0
of IN 0
Siriraj NNP 0
Asthma NNP 0
Control NNP 0
Questionnaire NNP 0
is VBZ 0
acceptable JJ 0
and CC 0
might MD 0
be VB 0
used VBN 0
in IN 0
the DT 0
clinical JJ 0
practice NN 0
and CC 0
research NN 0
in IN 0
Thai NNP 0
asthmatic JJ 4
patients NNS 0
. . 0

Attenuation NN 0
of IN 0
hemodynamic JJ 0
responses NNS 0
to TO 0
laryngoscopy VB 0
and CC 0
tracheal VB 0
intubation NN 0
during IN 0
rapid JJ 0
sequence NN 0
induction NN 0
: : 0
remifentanil NN 0
vs. FW 0
lidocaine NN 0
with IN 0
esmolol NN 0
. . 0

AIM NNP 0
This DT 0
study NN 0
was VBD 0
designed VBN 0
to TO 0
compare VB 0
the DT 0
effectiveness NN 0
of IN 0
remifentanil NN 0
vs. FW 0
a DT 0
lidocaine-esmolol JJ 0
combination NN 0
in IN 0
blunting VBG 0
the DT 0
hemodynamic JJ 0
response NN 0
to TO 0
laryngoscopy VB 0
and CC 0
intubation NN 0
during IN 0
rapid JJ 0
sequence NN 0
induction NN 0
using VBG 0
thiopental JJ 0
and CC 0
rocuronium NN 0
in IN 0
normotensive JJ 4
patients NNS 0
. . 0

METHODS NNP 0
Sixty-six JJ 3
patients NNS 0
with IN 0
American JJ 0
Society NNP 0
of IN 0
Anesthesiologists NNP 0
( ( 4
ASA NNP 4
) ) 4
physical JJ 4
status NN 4
class NN 4
I PRP 4
who WP 0
required VBD 0
tracheal JJ 4
intubation NN 4
for IN 0
elective JJ 0
surgery NN 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
one CD 0
of IN 0
two CD 0
groups NNS 0
. . 0

Group NNP 0
R NNP 0
received VBD 0
0.9 CD 0
% NN 0
saline NN 0
10 CD 0
ml NN 0
and CC 0
remifentanil VB 0
1 CD 0
microg/kg NN 0
. . 0

Group NNP 0
LE NNP 0
received VBD 0
lidocaine JJ 0
1.5 CD 0
mg/kg NN 0
and CC 0
esmolol $ 0
1.0 CD 0
mg/kg NN 0
. . 0

Anesthesia NNP 0
was VBD 0
induced VBN 0
with IN 0
thiopental JJ 0
sodium NN 0
5 CD 0
mg/kg NN 0
, , 0
followed VBN 0
by IN 0
rocuronium NN 0
1.0 CD 0
mg/kg NN 0
. . 0

Mean NNP 0
arterial JJ 0
pressure NN 0
and CC 0
heart NN 0
rate NN 0
were VBD 0
recorded VBN 0
at IN 0
baseline NN 0
, , 0
after IN 0
induction NN 0
, , 0
immediately RB 0
after IN 0
intubation NN 0
and CC 0
every DT 0
minute NN 0
for IN 0
five CD 0
minutes NNS 0
after IN 0
intubation NN 0
. . 0

RESULTS NNP 0
Changes NNP 0
in IN 0
mean JJ 0
arterial JJ 0
pressure NN 0
over IN 0
time NN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
were VBD 0
significantly RB 0
different JJ 0
( ( 0
P NNP 0
< NNP 0
0.0001 CD 0
) ) 0
. . 0

The DT 0
maximum JJ 0
pressor NN 0
response NN 0
was VBD 0
observed VBN 0
immediately RB 0
after IN 0
intubation NN 0
, , 0
at IN 0
which WDT 0
time NN 0
the DT 0
mean JJ 0
arterial JJ 0
pressure NN 0
change NN 0
from IN 0
baseline NN 0
in IN 0
group NN 0
LE NNP 0
( ( 0
29.7 CD 0
% NN 0
) ) 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
[ NNP 0
CI NNP 0
] NN 0
: : 0
116.1 CD 0
, , 0
121.9 CD 0
) ) 0
was VBD 0
higher JJR 0
than IN 0
that DT 0
in IN 0
group NN 0
R NNP 0
( ( 0
4.4 CD 0
% NN 0
) ) 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
: : 0
92.9 CD 0
, , 0
98.5 CD 0
) ) 0
( ( 0
P NNP 0
< NNP 0
0.0001 CD 0
) ) 0
. . 0

Two CD 0
patients NNS 0
in IN 0
group NN 0
R NNP 0
and CC 0
15 CD 0
patients NNS 0
in IN 0
group NN 0
LE NNP 0
developed VBD 0
hypertension NN 0
( ( 0
odds NNS 0
ratio VBP 0
[ CD 0
OR NNP 0
] NN 0
: : 0
0.064 CD 0
) ) 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

Changes NNS 0
in IN 0
heart NN 0
rate NN 0
over IN 0
time NN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
were VBD 0
not RB 0
significantly RB 0
different JJ 0
( ( 0
P=0.465 NNP 0
) ) 0
. . 0

CONCLUSION VB 0
The DT 0
results NNS 0
of IN 0
this DT 0
study NN 0
show NN 0
that IN 0
remifentanil VBZ 0
1 CD 0
mg/kg NN 0
is VBZ 0
more RBR 0
effective JJ 0
than IN 0
the DT 0
combination NN 0
of IN 0
lidocaine JJ 0
1.5 CD 0
mg/kg NN 0
and CC 0
esmolol $ 0
1 CD 0
mg/kg NN 0
for IN 0
attenuating VBG 0
the DT 0
hemodynamic JJ 0
responses NNS 0
to TO 0
rapid JJ 0
sequence NN 0
intubation NN 0
. . 0

Evaluation NN 0
of IN 0
reducing VBG 0
postoperative JJ 0
hip NN 0
precautions NNS 0
in IN 0
total JJ 4
hip JJ 4
replacement NN 4
: : 0
a DT 0
randomized JJ 0
prospective JJ 0
study NN 0
. . 0

Currently NNP 0
, , 0
many JJ 0
rehabilitation NN 0
protocols NNS 0
for IN 0
total JJ 0
hip NN 0
replacements NNS 0
( ( 0
THRs NNP 0
) ) 0
include VBP 0
activity NN 0
restrictions NNS 0
to TO 0
prevent VB 0
postoperative JJ 0
dislocation NN 0
. . 0

There EX 0
is VBZ 0
increasing VBG 0
demand NN 0
for IN 0
more RBR 0
efficient JJ 0
and CC 0
safe JJ 0
rehabilitation NN 0
protocols NNS 0
. . 0

This DT 0
randomized JJ 0
prospective JJ 0
study NN 0
evaluates VBZ 0
the DT 0
need NN 0
for IN 0
hip NN 0
restrictions NNS 0
following VBG 0
a DT 0
modified JJ 0
anterolateral JJ 0
procedure NN 0
. . 0

From IN 0
2004 CD 0
to TO 0
2008 CD 0
, , 0
81 CD 3
patients NNS 0
seeking VBG 0
elective JJ 0
THRs NNP 0
were VBD 0
randomly RB 0
assigned VBN 0
into IN 0
a DT 0
standard JJ 0
rehabilitation NN 0
group NN 0
or CC 0
an DT 0
early JJ 0
rehabilitation NN 0
group NN 0
. . 0

The DT 0
standard JJ 0
group NN 0
included VBD 0
restrictions NNS 0
to TO 0
avoid VB 0
hip NN 0
flexion NN 0
> VBD 0
90 CD 0
degrees NNS 0
and CC 0
avoidance NN 0
of IN 0
riding VBG 0
in IN 0
a DT 0
car NN 0
for IN 0
the DT 0
first JJ 0
postoperative JJ 0
month NN 0
. . 0

The DT 0
early JJ 0
group NN 0
had VBD 0
no DT 0
flexion NN 0
or CC 0
car NN 0
riding NN 0
restrictions NNS 0
. . 0

Forty-three JJ 3
patients NNS 0
were VBD 0
in IN 0
the DT 0
standard JJ 0
group NN 0
and CC 0
38 CD 3
patients NNS 0
were VBD 0
in IN 0
the DT 0
early JJ 0
group NN 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
demographic JJ 0
differences NNS 0
between IN 0
the DT 0
2 CD 0
groups NNS 0
. . 0

All DT 0
patients NNS 0
completed VBD 0
the DT 0
Short JJ 0
Form NNP 0
12-question JJ 0
Health NNP 0
Survey NNP 0
and CC 0
Harris NNP 0
Hip NNP 0
Score NNP 0
preoperatively RB 0
and CC 0
at IN 0
4 CD 0
weeks NNS 0
, , 0
1 CD 0
month NN 0
, , 0
3 CD 0
months NNS 0
, , 0
and CC 0
1 CD 0
year NN 0
postoperatively RB 0
. . 0

The DT 0
time-points NNS 0
at IN 0
which WDT 0
the DT 0
patient NN 0
first RB 0
drove VBD 0
and CC 0
ambulated VBD 0
with IN 0
a DT 0
cane NN 0
, , 0
without IN 0
a DT 0
cane NN 0
, , 0
and CC 0
without IN 0
a DT 0
limp NN 0
were VBD 0
also RB 0
collected VBN 0
. . 0

No DT 0
incidents NNS 0
of IN 0
dislocation NN 0
occurred VBD 0
. . 0

Patients NNS 0
in IN 0
the DT 0
early JJ 0
group NN 0
were VBD 0
faster JJR 0
to TO 0
ambulate VB 0
with IN 0
only RB 0
a DT 0
cane NN 0
( ( 0
P=.03 NNP 0
) ) 0
, , 0
without IN 0
a DT 0
cane NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
, , 0
and CC 0
without IN 0
a DT 0
limp NN 0
( ( 0
P=.003 NNP 0
) ) 0
. . 0

They PRP 0
also RB 0
drove VBD 0
earlier RBR 0
( ( 0
P=.02 NNP 0
) ) 0
. . 0

Pace NN 0
of IN 0
recovery NN 0
was VBD 0
the DT 0
only JJ 0
significant JJ 0
difference NN 0
between IN 0
the DT 0
2 CD 0
groups NNS 0
. . 0

The DT 0
early JJ 0
rehabilitation NN 0
protocol NN 0
increases VBZ 0
the DT 0
pace NN 0
of IN 0
recovery NN 0
compared VBN 0
to TO 0
a DT 0
pathway NN 0
with IN 0
hip NN 0
precautions NNS 0
without IN 0
increasing VBG 0
complications NNS 0
. . 0

A DT 0
pilot NN 0
study NN 0
of IN 0
a DT 0
low-tilt JJ 0
biphasic JJ 0
waveform NN 0
for IN 0
transvenous JJ 0
cardioversion NN 0
of IN 0
atrial JJ 4
fibrillation NN 4
: : 0
improved VBN 0
efficacy NN 0
compared VBN 0
with IN 0
conventional JJ 0
capacitor-based JJ 0
waveforms NNS 0
in IN 0
patients NNS 0
. . 0

BACKGROUND NNP 0
The DT 0
optimal JJ 0
waveform NN 0
tilt NN 0
for IN 0
defibrillation NN 0
is VBZ 0
not RB 0
known VBN 0
. . 0

Most JJS 0
modern JJ 0
defibrillators NNS 0
used VBN 0
for IN 0
the DT 0
cardioversion NN 0
of IN 0
atrial JJ 0
fibrillation NN 0
( ( 0
AF NNP 0
) ) 0
employ VBD 0
high-tilt JJ 0
, , 0
capacitor-based JJ 0
biphasic JJ 0
waveforms NNS 0
. . 0

METHODS NNP 0
We PRP 0
have VBP 0
developed VBN 0
a DT 0
low-tilt JJ 0
biphasic JJ 0
waveform NN 0
for IN 0
defibrillation NN 0
. . 0

This DT 0
low-tilt JJ 0
waveform NN 0
was VBD 0
compared VBN 0
with IN 0
a DT 0
conventional JJ 0
waveform NN 0
of IN 0
equivalent JJ 0
duration NN 0
and CC 0
voltage NN 0
in IN 0
patients NNS 0
with IN 0
AF NNP 0
. . 0

Patients NNS 0
with IN 0
persistent JJ 4
AF NNP 4
or CC 0
AF NNP 4
induced VBD 4
during IN 0
a DT 0
routine JJ 0
electrophysiology NN 4
study NN 4
( ( 0
EPS NNP 0
) ) 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
either RB 0
the DT 0
low-tilt JJ 0
waveform NN 0
or CC 0
a DT 0
conventional JJ 0
waveform NN 0
. . 0

Defibrillation NNP 0
electrodes NNS 0
were VBD 0
positioned VBN 0
in IN 0
the DT 0
right JJ 0
atrial JJ 0
appendage NN 0
and CC 0
distal JJ 0
coronary JJ 0
sinus NN 0
. . 0

Phase VB 0
1 CD 0
peak JJ 0
voltage NN 0
was VBD 0
increased VBN 0
in IN 0
a DT 0
stepwise NN 0
progression NN 0
from IN 0
50 CD 0
V NNP 0
to TO 0
300V CD 0
. . 0

Shock NNP 0
success NN 0
was VBD 0
defined VBN 0
as IN 0
return NN 0
of IN 0
sinus NN 0
rhythm NN 0
for IN 0
> NNP 0
/=30 NNP 0
seconds NNS 0
. . 0

RESULTS VB 0
The DT 0
low-tilt JJ 0
waveform NN 0
produced VBN 0
successful JJ 0
termination NN 0
of IN 0
persistent JJ 0
AF NNP 0
at IN 0
a DT 0
mean JJ 0
voltage NN 0
of IN 0
223 CD 0
V NNP 0
( ( 0
8.2 CD 0
J NNP 0
) ) 0
versus VBD 0
270 CD 0
V NNP 0
( ( 0
6.7 CD 0
J NNP 0
) ) 0
with IN 0
the DT 0
conventional JJ 0
waveform NN 0
( ( 0
P NNP 0
= VBZ 0
0.002 CD 0
for IN 0
voltage NN 0
, , 0
P NNP 0
= NNP 0
ns NN 0
for IN 0
energy NN 0
) ) 0
. . 0

In IN 0
patients NNS 0
with IN 0
induced JJ 0
AF NNP 0
the DT 0
mean JJ 0
voltage NN 0
for IN 0
the DT 0
low-tilt JJ 0
waveform NN 0
was VBD 0
91V CD 0
( ( 0
1.6 CD 0
J NNP 0
) ) 0
and CC 0
for IN 0
the DT 0
conventional JJ 0
waveform NN 0
was VBD 0
158 CD 0
V NNP 0
( ( 0
2.0 CD 0
J NNP 0
) ) 0
( ( 0
P NNP 0
= VBZ 0
0.005 CD 0
for IN 0
voltage NN 0
, , 0
P NNP 0
= NNP 0
ns NN 0
for IN 0
energy NN 0
) ) 0
. . 0

The DT 0
waveform NN 0
was VBD 0
much RB 0
more RBR 0
successful JJ 0
at IN 0
very RB 0
low JJ 0
voltages NNS 0
( ( 0
less JJR 0
than IN 0
or CC 0
equal JJ 0
to TO 0
100 CD 0
V NNP 0
) ) 0
compared VBN 0
with IN 0
the DT 0
conventional JJ 0
waveform NN 0
( ( 0
Novel NNP 0
: : 0
82 CD 0
% NN 0
vs JJ 0
Conventional NNP 0
22 CD 0
% NN 0
, , 0
P NNP 0
= NNP 0
0.008 CD 0
) ) 0
. . 0

CONCLUSION VB 0
The DT 0
low-tilt JJ 0
biphasic JJ 0
waveform NN 0
was VBD 0
more RBR 0
successful JJ 0
for IN 0
the DT 0
internal JJ 0
cardioversion NN 0
of IN 0
both DT 0
persistent JJ 0
and CC 0
induced JJ 0
AF NNP 0
in IN 0
patients NNS 0
( ( 0
in IN 0
terms NNS 0
of IN 0
leading VBG 0
edge NN 0
voltage NN 0
) ) 0
. . 0

Randomized VBN 0
controlled VBD 0
trial NN 0
to TO 0
compare VB 0
the DT 0
early JJ 0
and CC 0
mid-term JJ 0
results NNS 0
of IN 0
stapled JJ 0
versus NN 0
open JJ 0
hemorrhoidectomy NN 4
. . 0

BACKGROUND VB 0
The DT 0
new JJ 0
technique NN 0
of IN 0
circular JJ 0
stapler NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
hemorrhoids NNS 4
has VBZ 0
shown VBN 0
early JJ 0
promise NN 0
in IN 0
terms NNS 0
of IN 0
minimal NN 0
or CC 0
no DT 0
postoperative JJ 0
pain NN 0
, , 0
early JJ 0
discharge NN 0
from IN 0
hospital NN 0
, , 0
and CC 0
quick JJ 0
return NN 0
to TO 0
work VB 0
. . 0

This DT 0
study NN 0
was VBD 0
designed VBN 0
to TO 0
compare VB 0
stapled VBN 0
technique NN 0
with IN 0
the DT 0
well-accepted JJ 0
conventional JJ 0
Milligan NNP 0
Morgan NNP 0
hemorrhoidectomy NN 0
. . 0

METHODS NNP 0
After IN 0
fulfilling VBG 0
the DT 0
selection NN 0
criteria NNS 0
, , 0
84 CD 3
patients NNS 0
were VBD 0
randomly RB 0
allocated VBN 0
to TO 0
the DT 0
stapled VBN 0
( ( 0
n JJ 0
= NNP 0
42 CD 3
) ) 0
or CC 0
open JJ 0
group NN 0
( ( 0
n JJ 0
= NNP 0
42 CD 3
) ) 0
. . 0

All DT 0
patients NNS 0
were VBD 0
operated VBN 0
on IN 0
under IN 0
spinal JJ 0
anesthesia NN 0
. . 0

The DT 0
2 CD 0
techniques NNS 0
were VBD 0
evaluated VBN 0
with IN 0
respect NN 0
to TO 0
the DT 0
operative JJ 0
time NN 0
, , 0
pain NN 0
scores NNS 0
, , 0
complications NNS 0
, , 0
day NN 0
of IN 0
discharge NN 0
, , 0
return NN 0
to TO 0
work VB 0
, , 0
and CC 0
level NN 0
of IN 0
satisfaction NN 0
. . 0

RESULTS VB 0
The DT 0
mean JJ 0
age NN 0
of IN 0
patients NNS 0
was VBD 0
46.02 CD 1
years NNS 0
( ( 0
SD NNP 0
, , 0
12.33 CD 0
) ) 0
in IN 0
the DT 0
stapled JJ 0
group NN 0
and CC 0
48.64 CD 1
years NNS 0
( ( 0
14.57 CD 0
) ) 0
in IN 0
the DT 0
open JJ 0
group NN 0
. . 0

Grade NNP 4
III NNP 4
or CC 4
IV NNP 4
hemorrhoids NNS 4
were VBD 0
more JJR 0
common JJ 0
in IN 0
men NNS 0
( ( 0
ie NN 0
, , 0
80.9 CD 0
% NN 0
and CC 0
85.7 CD 0
% NN 0
in IN 0
the DT 0
stapled JJ 0
and CC 0
open JJ 0
group NN 0
, , 0
respectively RB 0
) ) 0
. . 0

The DT 0
mean JJ 0
operative JJ 0
time NN 0
was VBD 0
shorter RBR 0
in IN 0
the DT 0
stapled JJ 0
group NN 0
24.28 CD 0
minutes NNS 0
( ( 0
4.25 CD 0
) ) 0
versus NN 0
45.21 CD 0
minutes NNS 0
( ( 0
5.36 CD 0
) ) 0
in IN 0
the DT 0
Milligan-Morgan NNP 0
group NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

The DT 0
blood NN 0
loss NN 0
, , 0
pain NN 0
scores NNS 0
and CC 0
requirement NN 0
of IN 0
analgesics NNS 0
was VBD 0
significantly RB 0
less RBR 0
in IN 0
the DT 0
stapled JJ 0
group NN 0
. . 0

Mean NNP 0
hospital NN 0
stay NN 0
was VBD 0
1.24 CD 0
days NNS 0
( ( 0
0.62 CD 0
) ) 0
and CC 0
2.76 CD 0
days NNS 0
( ( 0
1.01 CD 0
) ) 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
in IN 0
the DT 0
stapled JJ 0
and CC 0
open JJ 0
group NN 0
, , 0
respectively RB 0
. . 0

The DT 0
patients NNS 0
in IN 0
the DT 0
stapled JJ 0
group NN 0
returned VBD 0
to TO 0
work VB 0
or CC 0
routine VB 0
activities NNS 0
earlier RBR 0
( ( 0
ie NN 0
, , 0
within IN 0
8.12 CD 0
days NNS 0
[ RB 0
2.48 CD 0
] NN 0
) ) 0
as IN 0
compared VBN 0
with IN 0
17.62 CD 0
( ( 0
5.59 CD 0
) ) 0
in IN 0
the DT 0
open JJ 0
group NN 0
. . 0

Only RB 0
88.1 CD 0
% NN 0
of IN 0
patients NNS 0
were VBD 0
satisfied VBN 0
by IN 0
the DT 0
open JJ 0
method NN 0
compared VBN 0
with IN 0
97.6 CD 0
% NN 0
after IN 0
the DT 0
stapled JJ 0
technique NN 0
. . 0

The DT 0
median JJ 0
follow-up JJ 0
period NN 0
was VBD 0
11 CD 0
months NNS 0
with IN 0
a DT 0
maximum JJ 0
follow-up NN 0
of IN 0
19 CD 0
months NNS 0
( ( 0
range VB 0
2-19 JJ 0
months NNS 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Stapled NNP 0
hemorrhoidectomy NN 0
is VBZ 0
a DT 0
safe JJ 0
and CC 0
effective JJ 0
day-care JJ 0
procedure NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
grade NN 4
III NNP 4
and CC 4
grade VBD 4
IV NNP 4
hemorrhoids NNS 4
. . 0

It PRP 0
ensures VBZ 0
lesser RBR 0
postoperative JJ 0
pain NN 0
, , 0
early JJ 0
discharge NN 0
, , 0
less JJR 0
time NN 0
off IN 0
work NN 0
, , 0
complications NNS 0
similar JJ 0
to TO 0
the DT 0
open JJ 0
technique NN 0
, , 0
and CC 0
in IN 0
the DT 0
end NN 0
a DT 0
more RBR 0
satisfied JJ 0
patient NN 0
with IN 0
no DT 0
perianal JJ 0
wound NN 0
. . 0

However RB 0
, , 0
more RBR 0
such JJ 0
randomized JJ 0
trials NNS 0
are VBP 0
essential JJ 0
to TO 0
deny VB 0
any DT 0
long-term JJ 0
complication NN 0
. . 0

The DT 0
effect NN 0
of IN 0
magnesium NN 0
added VBN 0
to TO 0
levobupivacaine VB 0
for IN 0
femoral JJ 0
nerve NN 0
block NN 0
on IN 0
postoperative JJ 0
analgesia NN 0
in IN 0
patients NNS 0
undergoing VBG 0
ACL NNP 4
reconstruction NN 4
. . 0

PURPOSE VB 0
The DT 0
aim NN 0
of IN 0
this DT 0
prospective JJ 0
randomised VBD 0
double-blind NN 0
study NN 0
is VBZ 0
to TO 0
investigate VB 0
the DT 0
effect NN 0
of IN 0
magnesium NN 0
added VBN 0
to TO 0
local JJ 0
anaesthetics NNS 0
on IN 0
postoperative JJ 0
VAS NNP 0
scores NNS 0
, , 0
total JJ 0
opioid JJ 0
consumption NN 0
, , 0
time NN 0
to TO 0
first JJ 0
mobilisation NN 0
, , 0
patient JJ 0
satisfaction NN 0
and CC 0
rescue NN 0
analgesic JJ 0
requirements NNS 0
in IN 0
arthroscopic JJ 0
ACL NNP 0
reconstruction NN 0
surgery NN 0
. . 0

METHODS NNP 0
A NNP 0
total NN 0
of IN 0
107 CD 3
American JJ 0
Society NNP 0
of IN 0
Anaesthesiologists NNP 0
physical JJ 0
status NN 0
grade NN 0
I PRP 0
and CC 0
II NNP 0
patients NNS 0
between IN 0
18 CD 1
and CC 1
65 CD 1
years NNS 0
of IN 0
age NN 0
who WP 0
were VBD 0
scheduled VBN 0
to TO 0
undergo VB 0
elective JJ 4
anterior JJ 4
crucial JJ 4
ligament NN 4
( ( 4
ACL NNP 4
) ) 4
reconstruction NN 4
with IN 0
hamstring VBG 0
autografts NNS 0
were VBD 0
enrolled VBN 0
in IN 0
the DT 0
study NN 0
. . 0

The DT 0
patients NNS 0
were VBD 0
randomly RB 0
allocated VBN 0
to TO 0
Groups NNP 0
L NNP 0
( ( 0
n JJ 0
= NNP 0
51 CD 0
) ) 0
and CC 0
LM NNP 0
( ( 0
n JJ 0
= NNP 0
56 CD 0
) ) 0
using VBG 0
the DT 0
closed-envelope NN 0
method NN 0
. . 0

Group NNP 0
LM NNP 0
was VBD 0
administered VBN 0
19 CD 0
ml NN 0
of IN 0
0.25 CD 0
% NN 0
levobupivacaine NN 0
and CC 0
1 CD 0
ml NN 0
of IN 0
15 CD 0
% NN 0
magnesium NN 0
sulphate NN 0
, , 0
while IN 0
Group NNP 0
L NNP 0
was VBD 0
administered VBN 0
20 CD 0
ml NN 0
of IN 0
0.25 CD 0
% NN 0
levobupivacaine NN 0
for IN 0
femoral JJ 0
blockade NN 0
. . 0

General NNP 0
anaesthesia NN 0
was VBD 0
administered VBN 0
using VBG 0
laryngeal JJ 0
airway RB 0
masks NNS 0
following VBG 0
neural JJ 0
blockade NN 0
in IN 0
both DT 0
groups NNS 0
. . 0

The DT 0
patients NNS 0
were VBD 0
evaluated VBN 0
for IN 0
heart NN 0
rate NN 0
and CC 0
mean VB 0
arterial JJ 0
pressure NN 0
, , 0
oxygen NN 0
saturation NN 0
, , 0
visual JJ 0
analogue NN 0
score NN 0
( ( 0
VAS NNP 0
) ) 0
, , 0
verbal JJ 0
rating NN 0
scale NN 0
( ( 0
VRS NNP 0
) ) 0
, , 0
rescue NN 0
analgesic JJ 0
requirements NNS 0
, , 0
total JJ 0
opioid JJ 0
consumption NN 0
, , 0
side NN 0
effects NNS 0
and CC 0
time NN 0
to TO 0
first JJ 0
mobilisation NN 0
at IN 0
the DT 0
1st CD 0
, , 0
2nd CD 0
, , 0
4th CD 0
, , 0
6th CD 0
, , 0
12th CD 0
and CC 0
24th CD 0
hours NNS 0
postoperatively RB 0
. . 0

RESULTS NNP 0
There EX 0
was VBD 0
no DT 0
statistically RB 0
significant JJ 0
difference NN 0
in IN 0
terms NNS 0
of IN 0
demographic JJ 0
data NNS 0
, , 0
mean JJ 0
arterial JJ 0
pressure NN 0
, , 0
heart NN 0
rate NN 0
or CC 0
oxygen NN 0
saturation NN 0
between IN 0
groups NNS 0
. . 0

The DT 0
area NN 0
under IN 0
the DT 0
curve NN 0
VAS NNP 0
and CC 0
VRS NNP 0
scores NNS 0
were VBD 0
lower JJR 0
at IN 0
4 CD 0
, , 0
6 CD 0
, , 0
12 CD 0
and CC 0
24 CD 0
h NN 0
in IN 0
Group NNP 0
LM NNP 0
( ( 0
p JJ 0
= NN 0
0.001 CD 0
, , 0
p NN 0
= VBD 0
0.016 CD 0
, , 0
respectively RB 0
) ) 0
. . 0

The DT 0
rescue NN 0
analgesic JJ 0
requirement NN 0
and CC 0
the DT 0
total JJ 0
opioid JJ 0
consumption NN 0
were VBD 0
significantly RB 0
lower JJR 0
in IN 0
Group NNP 0
LM NNP 0
( ( 0
p JJ 0
= NN 0
0.015 CD 0
, , 0
p NN 0
= VBD 0
0.019 CD 0
, , 0
respectively RB 0
) ) 0
. . 0

The DT 0
time NN 0
to TO 0
first JJ 0
mobilisation NN 0
and CC 0
the DT 0
Likert NNP 0
score NN 0
( ( 0
completely RB 0
comfortable JJ 0
; : 0
quite RB 0
comfortable JJ 0
; : 0
slight JJ 0
discomfort NN 0
; : 0
painful JJ 0
; : 0
very RB 0
painful JJ 0
) ) 0
were VBD 0
higher JJR 0
, , 0
and CC 0
the DT 0
block NN 0
onset VBD 0
time NN 0
was VBD 0
lower JJR 0
in IN 0
Group NNP 0
LM NNP 0
( ( 0
p JJ 0
= NN 0
0.014 CD 0
and CC 0
p VB 0
= JJ 0
0.012 CD 0
, , 0
respectively RB 0
) ) 0
. . 0

There EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
terms NNS 0
of IN 0
side NN 0
effects NNS 0
. . 0

CONCLUSIONS VB 0
The DT 0
addition NN 0
of IN 0
magnesium NN 0
to TO 0
levobupivacaine VB 0
prolongs NNS 0
the DT 0
sensory NN 0
and CC 0
motor NN 0
block NN 0
duration NN 0
without IN 0
increasing VBG 0
side NN 0
effects NNS 0
, , 0
enhances VBZ 0
the DT 0
quality NN 0
of IN 0
postoperative JJ 0
analgesia NN 0
and CC 0
increases VBZ 0
patient JJ 0
satisfaction NN 0
; : 0
however RB 0
, , 0
the DT 0
addition NN 0
of IN 0
magnesium NN 0
delays VBZ 0
the DT 0
time NN 0
to TO 0
first JJ 0
mobilisation NN 0
and CC 0
decreases VBZ 0
rescue NN 0
analgesic JJ 0
requirements NNS 0
. . 0

Comparative JJ 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
twice JJ 0
daily JJ 0
fluticasone NN 0
propionate NN 0
powder NN 0
versus NN 0
placebo NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
moderate JJ 4
asthma NN 4
. . 0

BACKGROUND NNP 0
Fluticasone NNP 0
propionate NN 0
, , 0
an DT 0
inhaled JJ 0
corticosteroid NN 0
with IN 0
negligible JJ 0
systemic JJ 0
bioavailability NN 0
via IN 0
the DT 0
oral JJ 0
route NN 0
, , 0
is VBZ 0
efficacious JJ 0
in IN 0
the DT 0
treatment NN 0
of IN 0
asthma NN 4
when WRB 0
administered VBN 0
via IN 0
metered-dose JJ 0
inhaler NN 0
. . 0

OBJECTIVE UH 0
To TO 0
evaluate VB 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
inhaled JJ 0
fluticasone NN 0
propionate NN 0
powder NN 0
in IN 0
patients NNS 0
with IN 0
moderate JJ 4
asthma NNS 4
previously RB 0
treated VBN 0
with IN 0
an DT 0
inhaled JJ 0
corticosteroid NN 0
. . 0

METHODS NNP 0
This DT 0
was VBD 0
a DT 0
randomized JJ 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
, , 0
parallel-group JJ 0
, , 0
multicenter NN 0
study NN 0
of IN 0
342 CD 3
adolescent NN 1
and CC 0
adult NN 1
patients NNS 0
with IN 0
moderate JJ 4
asthma NNS 4
[ RB 0
forced VBD 0
expiratory JJ 0
volume NN 0
in IN 0
1 CD 0
second JJ 0
( ( 0
FEV1 NNP 0
) ) 0
between IN 0
50 CD 0
% NN 0
and CC 0
80 CD 0
% NN 0
of IN 0
predicted JJ 0
] NNP 0
treated VBD 0
previously RB 0
by IN 0
beclomethasone NN 0
dipropionate NN 0
or CC 0
triamcinolone NN 0
acetonide RB 0
. . 0

Patients NNS 0
received VBD 0
fluticasone JJ 0
propionate NN 0
powder NN 0
50 CD 0
micrograms NNS 0
, , 0
100 CD 0
micrograms NNS 0
, , 0
250 CD 0
micrograms NNS 0
, , 0
or CC 0
placebo NN 0
via IN 0
a DT 0
breath-actuated JJ 0
inhalation NN 0
device NN 0
, , 0
the DT 0
Diskhaler NNP 0
, , 0
twice RB 0
daily RB 0
for IN 0
12 CD 0
weeks NNS 0
. . 0

RESULTS JJ 0
Patients NNPS 0
in IN 0
the DT 0
fluticasone NN 0
propionate NN 0
groups NNS 0
experienced VBD 0
a DT 0
mean JJ 0
increase NN 0
from IN 0
baseline NN 0
to TO 0
endpoint VB 0
in IN 0
FEV1 NNP 0
ranging VBG 0
from IN 0
0.43 CD 0
L NNP 0
to TO 0
0.47 CD 0
L. NNP 0
Patients NNPS 0
in IN 0
the DT 0
placebo NN 0
group NN 0
experienced VBD 0
a DT 0
mean JJ 0
decrease NN 0
from IN 0
baseline NN 0
of IN 0
0.22 CD 0
L NNP 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

The DT 0
probability NN 0
of IN 0
patients NNS 0
remaining VBG 0
in IN 0
the DT 0
study NN 0
over IN 0
time NN 0
without IN 0
developing VBG 0
signs NNS 0
of IN 0
exacerbating VBG 0
asthma NN 0
was VBD 0
significantly RB 0
greater JJR 0
in IN 0
the DT 0
fluticasone NN 0
propionate NN 0
groups NNS 0
than IN 0
in IN 0
the DT 0
placebo NN 0
group NN 0
( ( 0
P NNP 0
= NNP 0
.001 NNP 0
) ) 0
. . 0

Asthma NNP 0
symptom NN 0
scores NNS 0
, , 0
supplemental JJ 0
rescue NN 0
albuterol NN 0
use NN 0
, , 0
and CC 0
number NN 0
of IN 0
nighttime JJ 0
awakenings NNS 0
due JJ 0
to TO 0
asthma VB 0
requiring VBG 0
treatment NN 0
also RB 0
improved VBN 0
significantly RB 0
with IN 0
all DT 0
fluticasone NN 0
propionate NN 0
treatment NN 0
regimens NNS 0
compared VBN 0
with IN 0
placebo NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
statistically RB 0
significant JJ 0
differences NNS 0
at IN 0
endpoint NN 0
among IN 0
the DT 0
three CD 0
fluticasone NN 0
propionate NN 0
groups NNS 0
. . 0

No DT 0
serious JJ 0
drug-related JJ 0
adverse JJ 0
events NNS 0
occurred VBD 0
. . 0

CONCLUSIONS NNP 0
Fluticasone NNP 0
propionate NN 0
powder NN 0
( ( 0
50 CD 0
, , 0
100 CD 0
, , 0
and CC 0
250 CD 0
micrograms NNS 0
) ) 0
was VBD 0
well-tolerated JJ 0
and CC 0
significantly RB 0
improved VBN 0
lung NN 0
function NN 0
in IN 0
patients NNS 0
with IN 0
moderate JJ 4
asthma NNS 4
. . 0

Sunbathing VBG 0
and CC 0
sunbed VBN 0
use NN 0
related VBN 0
to TO 0
self-image NN 0
in IN 0
a DT 0
randomized JJ 0
sample NN 0
of IN 0
Swedish JJ 0
adolescents NNS 1
. . 0

In IN 0
1996 CD 0
a DT 0
randomized JJ 0
sample NN 0
of IN 0
4,020 CD 3
Swedish JJ 0
adolescents NNS 1
from IN 0
three CD 0
birth NN 0
cohorts NNS 0
were VBD 0
sent VBN 0
a DT 0
questionnaire NN 0
consisting NN 0
of IN 0
50 CD 0
items NNS 0
concerning VBG 0
habitual JJ 0
sun-related JJ 0
behaviours NNS 0
and CC 0
attitudes NNS 0
, , 0
knowledge NN 0
about IN 0
melanoma NN 0
, , 0
risk NN 0
perception NN 0
and CC 0
self-image NN 0
. . 0

A DT 0
total NN 0
of IN 0
2,615 CD 3
questionnaires NNS 0
were VBD 0
returned VBN 0
. . 0

Girls NNP 2
sunbathed VBD 0
and CC 0
used VBD 0
sunbeds NNS 0
more RBR 0
than IN 0
boys NNS 2
at IN 0
all DT 0
ages NNS 0
. . 0

Sunbathing VBG 0
and CC 0
sunbed VBN 0
use NN 0
increased VBN 0
with IN 0
age NN 0
. . 0

Boys NNS 0
who WP 0
were VBD 0
most RBS 0
satisfied JJ 0
and CC 0
girls NNS 0
least JJS 0
satisfied JJ 0
with IN 0
themselves PRP 0
sunbathed VBD 0
most JJS 0
. . 0

Those DT 0
who WP 0
were VBD 0
least JJS 0
satisfied JJ 0
with IN 0
themselves PRP 0
used VBD 0
sunbeds NNS 0
most RBS 0
frequently RB 0
. . 0

Girls NNP 0
reported VBD 0
a DT 0
higher JJR 0
perceived JJ 0
susceptibility NN 0
to TO 0
melanoma VB 0
than IN 0
did VBD 0
boys VB 0
. . 0

The DT 0
perception NN 0
of IN 0
susceptibility NN 0
increased VBN 0
with IN 0
age NN 0
. . 0

Those DT 0
who WP 0
were VBD 0
least JJS 0
satisfied JJ 0
with IN 0
themselves PRP 0
reported VBD 0
feeling VBG 0
most RBS 0
susceptible JJ 0
. . 0

The DT 0
overall JJ 0
main JJ 0
reason NN 0
for IN 0
sunbathing NN 0
was VBD 0
appearance NN 0
, , 0
both DT 0
for IN 0
own JJ 0
sunbathing NN 0
, , 0
and CC 0
to TO 0
an DT 0
even RB 0
higher JJR 0
degree NN 0
, , 0
as IN 0
a DT 0
supposed JJ 0
reason NN 0
for IN 0
other JJ 0
adolescents NNS 0
' POS 0
behaviour NN 0
, , 0
and CC 0
was VBD 0
reported VBN 0
most JJS 0
frequently RB 0
by IN 0
girls NNS 0
and CC 0
the DT 0
older JJR 0
age NN 0
groups NNS 0
. . 0

The DT 0
second JJ 0
most RBS 0
'important JJ 0
' POS 0
reason NN 0
for IN 0
sunbathing NN 0
was VBD 0
'feeling VBG 0
warm JJ 0
and CC 0
comfortable JJ 0
' '' 0
. . 0

Preventive JJ 0
programmes NNS 0
aimed VBN 0
at IN 0
a DT 0
change NN 0
of IN 0
sun NN 0
related VBN 0
behaviours NNS 0
among IN 0
Swedish JJ 0
adolescents NNS 0
have VBP 0
to TO 0
be VB 0
tailored VBN 0
to TO 0
the DT 0
climate NN 0
and CC 0
cultural JJ 0
conditions NNS 0
and CC 0
must MD 0
take VB 0
into IN 0
account NN 0
that IN 0
having VBG 0
a DT 0
tan NN 0
, , 0
and CC 0
the DT 0
warmth NN 0
of IN 0
the DT 0
sun NN 0
, , 0
are VBP 0
highly RB 0
valued VBN 0
by IN 0
most JJS 0
adolescents NNS 0
. . 0

Comparison NNP 0
of IN 0
thiopentone/guaifenesin NN 0
, , 0
ketamine/guaifenesin NN 0
and CC 0
ketamine/midazolam NN 0
for IN 0
the DT 0
induction NN 0
of IN 0
horses NNS 0
to TO 0
be VB 0
anaesthetised VBN 4
with IN 0
isoflurane NN 0
. . 0

Forty-eight JJ 3
horses NNS 0
subjected VBN 0
to TO 0
elective VB 4
surgery NN 4
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
three CD 3
groups NNS 0
of IN 0
16 CD 3
horses NNS 0
. . 0

After IN 0
premedication NN 0
with IN 0
0.1 CD 0
mg/kg NNS 0
acepromazine VBP 0
intramuscularly RB 0
and CC 0
0.6 CD 0
mg/kg NNS 0
xylazine JJ 0
intravenously RB 0
, , 0
anaesthesia NN 0
was VBD 0
induced VBN 0
either RB 0
with IN 0
2 CD 0
g NNS 0
thiopentone NN 0
in IN 0
500 CD 0
ml NN 0
of IN 0
a DT 0
10 CD 0
per IN 0
cent NN 0
guaifenesin NN 0
solution NN 0
, , 0
given VBN 0
intravenously RB 0
at IN 0
a DT 0
dose NN 0
of IN 0
1 CD 0
ml/kg NNS 0
( ( 0
group NN 0
TG NNP 0
) ) 0
, , 0
or CC 0
with IN 0
100 CD 0
mg/kg NNS 0
guaifenesin NN 0
and CC 0
2.2 CD 0
mg/kg NN 0
ketamine NN 0
given VBN 0
intravenously RB 0
( ( 0
group NN 0
KG NNP 0
) ) 0
, , 0
or CC 0
with IN 0
0.06 CD 0
mg/kg NNS 0
midazolam NN 0
, , 0
and CC 0
2.2 CD 0
mg/kg NN 0
ketamine NN 0
given VBN 0
intravenously RB 0
( ( 0
group NN 0
KM NNP 0
) ) 0
. . 0

Anaesthesia NNP 0
was VBD 0
maintained VBN 0
with IN 0
isoflurane NN 0
. . 0

The DT 0
mean NN 0
( ( 0
sd NN 0
) ) 0
end NN 0
tidal JJ 0
isoflurane NN 0
concentration NN 0
( ( 0
per IN 0
cent NN 0
) ) 0
needed VBD 0
to TO 0
maintain VB 0
a DT 0
light JJ 0
surgical JJ 0
anaesthesia NN 0
( ( 0
stage NN 0
III NNP 0
, , 0
plane NN 0
2 CD 0
) ) 0
was VBD 0
significantly RB 0
lower JJR 0
in IN 0
group NN 0
KM NNP 0
( ( 0
0.91 CD 0
[ RB 0
0.03 CD 0
] NN 0
) ) 0
than IN 0
in IN 0
groups NNS 0
TG NNP 0
( ( 0
1.11 CD 0
[ RB 0
0.03 CD 0
] NN 0
) ) 0
and CC 0
KG NNP 0
( ( 0
1.14 CD 0
[ RB 0
0.03 CD 0
] NN 0
) ) 0
. . 0

The DT 0
mean NN 0
( ( 0
sd NN 0
) ) 0
arterial JJ 0
pressure NN 0
( ( 0
mmHg NN 0
) ) 0
was VBD 0
significantly RB 0
lower JJR 0
in IN 0
group NN 0
KG NNP 0
( ( 0
67.4 CD 0
[ RB 0
2.07 CD 0
] NN 0
) ) 0
than IN 0
in IN 0
groups NNS 0
TC NNP 0
( ( 0
75.6 CD 0
[ RB 0
2.23 CD 0
] NN 0
) ) 0
and CC 0
KM NNP 0
( ( 0
81.0 CD 0
[ RB 0
2.16 CD 0
] NN 0
) ) 0
. . 0

There EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
the DT 0
logarithm NN 0
of IN 0
the DT 0
heart NN 0
rate NN 0
, , 0
recovery NN 0
time NN 0
or CC 0
quality NN 0
of IN 0
recovery NN 0
between IN 0
the DT 0
three CD 0
induction NN 0
groups NNS 0
. . 0

However RB 0
, , 0
pronounced VBD 0
ataxia NN 0
was VBD 0
observed VBN 0
in IN 0
the DT 0
horses NNS 0
of IN 0
group NN 0
KM NNP 0
, , 0
especially RB 0
after IN 0
periods NNS 0
of IN 0
anaesthesia NN 0
lasting VBG 0
less JJR 0
than IN 0
75 CD 0
minutes NNS 0
. . 0

Can MD 0
a DT 0
home-visit JJ 0
invitation NN 0
increase NN 0
Pap NNP 0
smear JJ 0
screening NN 0
in IN 0
Samliem NNP 0
, , 0
Khon NNP 0
Kaen NNP 0
, , 0
Thailand NNP 0
? . 0
Our PRP$ 0
objective NN 0
was VBD 0
to TO 0
assess VB 0
the DT 0
efficiency NN 0
of IN 0
a DT 0
home-visit JJ 0
invitation NN 0
aimed VBN 0
to TO 0
increase VB 0
uptake NN 0
of IN 0
cervical JJ 4
cancer NN 4
screening VBG 4
in IN 0
women NNS 2
between IN 0
35 CD 1
and CC 1
60 CD 1
years NNS 0
of IN 0
age NN 0
. . 0

From NN 0
May NNP 0
, , 0
2006 CD 0
, , 0
we PRP 0
conducted VBD 0
a DT 0
quasi-randomized JJ 0
trial NN 0
to TO 0
determine VB 0
if IN 0
an DT 0
in-home JJ 0
education NN 0
and CC 0
invitation NN 0
intervention NN 0
would MD 0
increase VB 0
uptake NN 0
of IN 0
cervical JJ 0
cancer NN 0
screening VBG 0
. . 0

We PRP 0
randomly RB 0
recruited VBD 0
304 CD 3
women NNS 0
from IN 0
the DT 0
Samliem NNP 0
inner-city NN 0
community NN 0
, , 0
Khon NNP 0
Kaen NNP 0
, , 0
Northeast NNP 0
Thailand NNP 0
, , 0
and CC 0
assigned VBD 0
participants NNS 0
to TO 0
either VB 0
the DT 0
intervention NN 0
or CC 0
control VB 0
zone NN 0
. . 0

Baseline NNP 0
screening VBG 0
coverage NN 0
interviews NNS 0
were VBD 0
then RB 0
performed VBN 0
: : 0
58 CD 0
of IN 0
158 CD 3
women NNS 0
in IN 0
the DT 0
intervention NN 0
zone NN 0
and CC 0
46 CD 0
of IN 0
146 CD 3
in IN 0
the DT 0
control NN 0
zone NN 0
were VBD 0
excluded VBN 0
from IN 0
the DT 0
study NN 0
because IN 0
of IN 0
having VBG 0
had VBD 0
a DT 0
Pap NNP 0
smear NN 0
within IN 0
5 CD 0
years NNS 0
, , 0
but CC 0
these DT 0
were VBD 0
included VBN 0
in IN 0
the DT 0
final JJ 0
analysis NN 0
. . 0

First NNP 0
, , 0
100 CD 0
women NNS 0
in IN 0
the DT 0
intervention NN 0
group NN 0
were VBD 0
visited VBN 0
in IN 0
their PRP$ 0
homes NNS 0
by IN 0
one CD 0
of IN 0
the DT 0
researchers NNS 0
, , 0
who WP 0
provided VBD 0
culturally-sensitive JJ 0
health NN 0
education NN 0
that WDT 0
emphasized VBD 0
the DT 0
need NN 0
for IN 0
screening VBG 0
. . 0

Four CD 0
months NNS 0
later RB 0
, , 0
post-intervention NN 0
, , 0
screening-coverage JJ 0
interviews NNS 0
were VBD 0
again RB 0
performed VBN 0
in IN 0
both DT 0
groups NNS 0
, , 0
in IN 0
combination NN 0
with IN 0
the DT 0
same JJ 0
health NN 0
education NN 0
for IN 0
100 CD 0
women NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
for IN 0
a DT 0
comparison NN 0
. . 0

There EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
the DT 0
baseline NN 0
Pap NNP 0
smear JJ 0
screening-coverage NN 0
rate NN 0
in IN 0
the DT 0
intervention NN 0
vs. FW 0
control NN 0
zones NNS 0
( ( 0
36.7 CD 0
vs. FW 0
31.5 CD 0
% NN 0
, , 0
p=0.339 NN 0
) ) 0
. . 0

One CD 0
hundred JJ 0
women NNS 0
in IN 0
the DT 0
intervention NN 0
group NN 0
completed VBD 0
the DT 0
intervention NN 0
interviews NNS 0
and CC 0
after IN 0
four CD 0
months NNS 0
, , 0
100 CD 0
women NNS 0
in IN 0
the DT 0
intervention NN 0
group NN 0
and CC 0
100 CD 0
in IN 0
the DT 0
control NN 0
group NN 0
also RB 0
completed VBD 0
the DT 0
post-intervention NN 0
interviews NNS 0
. . 0

The DT 0
increased JJ 0
screening-coverage NN 0
rate NN 0
in IN 0
the DT 0
intervention NN 0
zone NN 0
was VBD 0
similar JJ 0
to TO 0
that DT 0
of IN 0
the DT 0
control NN 0
zone NN 0
( ( 0
43.6 CD 0
vs. FW 0
34.9 CD 0
% NN 0
, , 0
p=0.119 NN 0
) ) 0
; : 0
however RB 0
, , 0
there EX 0
was VBD 0
a DT 0
borderline NN 0
significant JJ 0
increase NN 0
in IN 0
the DT 0
intervention NN 0
zone NN 0
compared VBN 0
with IN 0
baseline NN 0
( ( 0
36.7 CD 0
to TO 0
43.6 CD 0
% NN 0
, , 0
p=0.070 NN 0
) ) 0
. . 0

Therefore NNP 0
, , 0
home NN 0
visit NN 0
education NN 0
and CC 0
invitation NN 0
intervention NN 0
produced VBD 0
only RB 0
a DT 0
nominal JJ 0
effect NN 0
on IN 0
increasing VBG 0
Pap NNP 0
smear JJ 0
coverage NN 0
within IN 0
a DT 0
4-month JJ 0
study NN 0
period NN 0
. . 0

Nitrous JJ 0
oxide JJ 0
diffusion NN 0
into IN 0
tracheal JJ 0
tube JJ 0
cuffs NNS 0
-- : 0
efficacy NN 0
of IN 0
a DT 0
new JJ 0
prototype NN 0
cuff NN 0
pressure NN 0
release NN 0
valve NN 0
. . 0

BACKGROUND IN 0
The DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
evaluate VB 0
the DT 0
performance NN 0
of IN 0
a DT 0
new JJ 0
cuff NN 0
pressure NN 0
release NN 0
valve NN 0
( ( 0
CPRV NNP 0
) ) 0
, , 0
in IN 0
which WDT 0
the DT 0
release NN 0
pressure NN 0
can MD 0
be VB 0
adjusted VBN 0
from IN 0
10 CD 0
to TO 0
25 CD 0
cmH2O NNS 0
, , 0
particularly RB 0
intended VBN 0
to TO 0
control VB 0
pressure NN 0
in IN 0
paediatric JJ 1
cuffed NN 4
tracheal NN 4
tubes NNS 4
and CC 0
to TO 0
avoid VB 0
cuff NN 0
hyperinflation NN 0
caused VBN 0
by IN 0
N2O NNP 0
diffusion NN 0
. . 0

METHODS NNP 0
In IN 0
vitro NN 0
: : 0
the DT 0
PRV NNP 0
was VBD 0
set VBN 0
to TO 0
10 CD 0
, , 0
15 CD 0
, , 0
20 CD 0
or CC 0
25 CD 0
cmH2O JJ 0
release NN 0
pressure NN 0
and CC 0
connected VBN 0
to TO 0
a DT 0
cuffed NN 0
tube NN 0
placed VBD 0
into IN 0
a DT 0
box NN 0
flushed VBN 0
with IN 0
66 CD 0
% NN 0
N2O NNP 0
in IN 0
O2 NNP 0
. . 0

The DT 0
cuff NN 0
pressure NN 0
was VBD 0
monitored VBN 0
with IN 0
and CC 0
without IN 0
CPRV NNP 0
for IN 0
60 CD 0
min NN 0
. . 0

Experiments NNS 0
were VBD 0
performed VBN 0
four CD 0
times NNS 0
using VBG 0
two CD 0
different JJ 0
CPRVs NNP 0
. . 0

In IN 0
vivo NN 0
: : 0
with IN 0
Institutional NNP 0
Review NNP 0
Board NNP 0
approval NN 0
, , 0
CPRV NNP 0
was VBD 0
studied VBN 0
in IN 0
50 CD 3
children NNS 1
undergoing VBG 0
general JJ 4
anaesthesia NN 4
with IN 4
tracheal JJ 4
intubation NN 4
and CC 0
standardized JJ 4
anaesthesia NN 4
technique NN 4
( ( 0
including VBG 0
66 CD 0
% NN 0
N2O NNP 0
in IN 0
O2 NNP 0
) ) 0
and CC 0
ventilator JJ 4
settings NNS 4
. . 0

Patients NNS 0
were VBD 0
randomized VBN 0
into IN 0
two CD 0
groups NNS 0
( ( 0
with IN 0
and CC 0
without IN 0
CPRV NNP 0
) ) 0
. . 0

The DT 0
cuff JJ 0
pressure NN 0
baseline NN 0
was VBD 0
20 CD 0
cmH2O NN 0
and CC 0
CPRV NNP 0
was VBD 0
set VBN 0
to TO 0
25 CD 0
cmH2O NN 0
. . 0

If IN 0
the DT 0
cuff NN 0
pressure NN 0
exceeded VBD 0
25 CD 0
cmH2O NN 0
, , 0
it PRP 0
was VBD 0
manually RB 0
released VBN 0
to TO 0
20 CD 0
cmH2O NN 0
. . 0

The DT 0
numbers NNS 0
of IN 0
deflations NNS 0
in IN 0
both DT 0
groups NNS 0
were VBD 0
noted VBN 0
and CC 0
compared VBN 0
by IN 0
Mann-Whitney NNP 0
U-test NNP 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

RESULTS NNP 0
In IN 0
vitro NN 0
: : 0
the DT 0
cuff NN 0
pressure NN 0
exceeded VBD 0
50 CD 0
cmH2O NN 0
after IN 0
60 CD 0
min NN 0
without IN 0
CPRV NNP 0
, , 0
but CC 0
did VBD 0
not RB 0
exceed VB 0
the DT 0
settings NNS 0
with IN 0
CPRV NNP 0
. . 0

In IN 0
vivo NN 0
: : 0
there EX 0
was VBD 0
no DT 0
need NN 0
to TO 0
manually RB 0
deflate VB 0
the DT 0
cuff NN 0
in IN 0
the DT 0
CPRV NNP 0
group NN 0
but CC 0
, , 0
in IN 0
every DT 0
patient NN 0
in IN 0
the DT 0
control NN 0
group NN 0
, , 0
three CD 0
( ( 0
two CD 0
to TO 0
seven CD 0
) ) 0
deflating VBG 0
manoeuvres NNS 0
were VBD 0
required VBN 0
within IN 0
the DT 0
first JJ 0
hour NN 0
of IN 0
anaesthesia NN 0
( ( 0
P NNP 0
< NNP 0
0.0001 CD 0
) ) 0
. . 0

CONCLUSION VB 0
The DT 0
CPRV NNP 0
allows VBZ 0
reliable JJ 0
cuff NN 0
pressure NN 0
release NN 0
at IN 0
various JJ 0
pressure NN 0
levels NNS 0
and CC 0
reliably RB 0
prevents NNS 0
cuff JJ 0
pressure NN 0
increases NNS 0
caused VBN 0
by IN 0
N2O NNP 0
. . 0

Effect NN 0
of IN 0
upper JJ 0
arm NN 0
brachial NN 0
basilic NN 0
and CC 0
prosthetic JJ 0
forearm NN 0
arteriovenous JJ 0
fistula NN 0
on IN 0
left JJ 0
ventricular JJ 0
hypertrophy NN 0
. . 0

BACKGROUND NNP 0
Creation NNP 0
of IN 0
an DT 0
arteriovenous JJ 0
fistula NN 0
( ( 0
AVF NNP 0
) ) 0
may MD 0
increase VB 0
left VBD 0
ventricular JJ 0
hypertrophy NN 0
in IN 0
the DT 0
hemodialysis NN 4
population NN 0
. . 0

Aim NNP 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
compare VB 0
the DT 0
effects NNS 0
of IN 0
a DT 0
brachial-basilic JJ 0
( ( 0
BB NNP 0
) ) 0
AVF NNP 0
and CC 0
the DT 0
prosthetic JJ 0
brachial-antecubital JJ 0
forearm NN 0
loop NN 0
access NN 0
( ( 0
PTFE NNP 0
) ) 0
on IN 0
cardiac JJ 0
performance NN 0
. . 0

METHODS JJ 0
Patients NNPS 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
BB-AVF NNP 0
or CC 0
prosthetic JJ 0
brachial-antecubital JJ 0
forearm NN 0
loop NN 0
access NN 0
. . 0

Before IN 0
and CC 0
three CD 0
months NNS 0
after IN 0
AVF NNP 0
creation NN 0
patients NNS 0
underwent VBD 0
an DT 0
echocardiographic JJ 0
examination NN 0
. . 0

Mann-Whitney JJ 0
U-test NNP 0
was VBD 0
used VBN 0
to TO 0
compare VB 0
relative JJ 0
increase NN 0
between IN 0
the DT 0
measured JJ 0
cardiac JJ 0
parameters NNS 0
for IN 0
the DT 0
two CD 0
groups NNS 0
. . 0

RESULTS NNP 0
Twenty-seven JJ 3
patients NNS 0
participated VBN 0
in IN 0
the DT 0
study NN 0
. . 0

The DT 0
relative JJ 0
increase NN 0
in IN 0
left JJ 0
ventricular JJ 0
parameters NNS 0
was VBD 0
not RB 0
significantly RB 0
different JJ 0
between IN 0
the DT 0
two CD 0
groups NNS 0
. . 0

Only RB 0
left VBD 0
ventricular JJ 0
end-diastolic JJ 0
diameter NN 0
tended VBD 0
to TO 0
be VB 0
of IN 0
significance NN 0
. . 0

Mean NNP 0
blood NN 0
flow NN 0
through IN 0
the DT 0
brachial JJ 0
artery NN 0
was VBD 0
1680+/-156 JJ 0
and CC 0
1450+/-221 JJ 0
mL/min NNS 0
three CD 0
months NNS 0
after IN 0
surgery NN 0
for IN 0
the DT 0
PTFE NNP 0
and CC 0
the DT 0
BB-AVF NNP 0
group NN 0
, , 0
respectively RB 0
. . 0

CONCLUSION NN 0
After IN 0
three CD 0
months NNS 0
of IN 0
follow-up NN 0
, , 0
changes NNS 0
in IN 0
cardiac JJ 0
structure NN 0
were VBD 0
comparable JJ 0
between IN 0
patients NNS 0
with IN 0
BB NNP 4
and CC 0
PTFE NNP 4
AVFs NNP 4
. . 0

Also RB 0
access NN 0
flow NN 0
was VBD 0
comparable JJ 0
at IN 0
this DT 0
time NN 0
. . 0

In IN 0
general JJ 0
, , 0
the DT 0
effects NNS 0
of IN 0
creation NN 0
of IN 0
a DT 0
fistula NN 0
on IN 0
LV NNP 0
structure NN 0
were VBD 0
limited VBN 0
. . 0

Longer RBR 0
follow VB 0
up RP 0
time NN 0
may MD 0
be VB 0
needed VBN 0
to TO 0
explore VB 0
the DT 0
long JJ 0
term NN 0
effects NNS 0
of IN 0
different JJ 0
vascular JJ 0
accesses NNS 0
on IN 0
cardiac JJ 0
function NN 0
. . 0

Contingency NNP 0
management NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
antipsychotic-induced JJ 0
weight JJ 0
gain NN 0
: : 0
a DT 0
randomized VBN 0
controlled VBN 0
pilot NN 0
study NN 0
. . 0

OBJECTIVE NNP 0
Weight NNP 0
gain NN 0
is VBZ 0
common JJ 0
for IN 0
individuals NNS 0
with IN 0
serious JJ 4
mental JJ 4
illness NN 4
( ( 0
SMI NNP 4
) ) 0
receiving VBG 0
antipsychotic JJ 0
drug NN 0
therapy NN 0
. . 0

Contingency NNP 0
management NN 0
( ( 0
CM NNP 0
) ) 0
is VBZ 0
a DT 0
behavioral JJ 0
intervention NN 0
that IN 0
rewards NNS 0
positive JJ 0
performance NN 0
and CC 0
has VBZ 0
demonstrated VBN 0
effectiveness NN 0
in IN 0
reducing VBG 0
drug NN 0
use NN 0
in IN 0
SMI NNP 0
populations NNS 0
. . 0

This DT 0
study NN 0
evaluated VBD 0
the DT 0
feasibility NN 0
of IN 0
using VBG 0
CM NNP 0
to TO 0
promote VB 0
weight JJ 0
loss NN 0
in IN 0
individuals NNS 0
with IN 0
SMI NNP 0
over IN 0
8 CD 0
weeks NNS 0
. . 0

METHOD NNP 0
30 CD 0
individuals NNS 0
( ( 0
BMI NNP 0
? . 0
28 CD 0
kg/m NN 0
( ( 0
2 CD 0
) ) 0
) ) 0
were VBD 0
randomized VBN 0
to TO 0
one CD 0
of IN 0
three CD 0
conditions NNS 0
: : 0
i NN 0
) ) 0
The DT 0
combination NN 0
of IN 0
a DT 0
standardized JJ 0
lifestyle NN 0
modification NN 0
( ( 0
LM NNP 0
) ) 0
program NN 0
for IN 0
individuals NNS 0
with IN 0
SMI NNP 0
and CC 0
payment NN 0
for IN 0
group NN 0
attendance NN 0
( ( 0
CM NNP 0
( ( 0
attendance NN 0
) ) 0
) ) 0
, , 0
ii NN 0
) ) 0
The DT 0
combination NN 0
of IN 0
LM NNP 0
and CC 0
payment NN 0
for IN 0
weight JJ 0
loss NN 0
( ( 0
CM NNP 0
( ( 0
weight NN 0
) ) 0
) ) 0
, , 0
and CC 0
iii NN 0
) ) 0
waitlist NN 0
control NN 0
( ( 0
CON NNP 0
) ) 0
. . 0

After IN 0
the DT 0
waitlist JJ 0
period NN 0
, , 0
those DT 0
participants NNS 0
joined VBD 0
a DT 0
LM NNP 0
group NN 0
and CC 0
received VBD 0
payment NN 0
for IN 0
behavioral JJ 0
change NN 0
( ( 0
CM NNP 0
( ( 0
behavior NN 0
) ) 0
) ) 0
. . 0

RESULTS JJ 0
Subjects NNPS 0
in IN 0
the DT 0
CM NNP 0
( ( 0
attendance NN 0
) ) 0
and CC 0
in IN 0
the DT 0
CM NNP 0
( ( 0
weight NN 0
) ) 0
group NN 0
lost VBD 0
a DT 0
mean NN 0
of IN 0
1.16 CD 0
kg NNS 0
and CC 0
1.23 CD 0
kg NN 0
, , 0
respectively RB 0
, , 0
while IN 0
subjects NNS 0
in IN 0
the DT 0
CON NNP 0
gained VBD 0
a DT 0
mean NN 0
of IN 0
0.68 CD 0
kg NNS 0
. . 0

Subjects NNS 0
receiving VBG 0
CM NNP 0
( ( 0
behavior NN 0
) ) 0
, , 0
lost VBD 0
a DT 0
mean NN 0
of IN 0
2.54 CD 0
kg NNS 0
, , 0
which WDT 0
was VBD 0
a DT 0
significant JJ 0
weight NN 0
loss NN 0
compared VBN 0
to TO 0
the DT 0
control NN 0
period NN 0
. . 0

CONCLUSION NNP 0
LM NNP 0
supplemented VBD 0
with IN 0
CM NNP 0
may MD 0
facilitate VB 0
weight NN 0
loss NN 0
in IN 0
patients NNS 0
taking VBG 0
antipsychotic JJ 0
medications NNS 0
; : 0
financial JJ 0
reimbursement NN 0
for IN 0
behavioral JJ 0
change NN 0
may MD 0
be VB 0
particularly RB 0
effective JJ 0
in IN 0
this DT 0
population NN 0
. . 0

[ JJ 0
Clinical NNP 0
observation NN 0
on IN 0
different JJ 0
acupuncture NN 0
and CC 0
moxibustion NN 0
therapies NNS 0
for IN 0
treatment NN 0
of IN 0
postsurgical JJ 4
gastroparesis NN 4
syndrome NN 4
] NNP 0
. . 0

OBJECTIVE NNP 0
To TO 0
optimize VB 0
therapy NN 0
of IN 0
acupuncture NN 0
and CC 0
moxibustion NN 0
for IN 0
postsurgical JJ 0
gastroparesis NN 0
syndrome NN 0
( ( 0
PGS NNP 4
) ) 0
. . 0

METHODS NNP 0
Forty-one JJ 3
cases NNS 0
of IN 0
PGS NNP 0
were VBD 0
randomly RB 0
divided VBN 0
into IN 0
3 CD 0
groups NNS 0
in IN 0
order NN 0
of IN 0
visiting VBG 0
. . 0

Group NNP 0
A NNP 0
( ( 0
n JJ 0
= NNP 0
17 CD 3
) ) 0
were VBD 0
treated VBN 0
by IN 0
warming VBG 0
needle JJ 0
moxibustion NN 0
, , 0
group NN 0
B NNP 0
( ( 0
n JJ 0
= NNP 0
12 CD 3
) ) 0
by IN 0
acupuncture NN 0
plus CC 0
auricular JJ 0
point NN 0
sticking NN 0
, , 0
and CC 0
group NN 0
C NNP 0
( ( 0
n JJ 0
= NNP 0
12 CD 3
) ) 0
by IN 0
routine JJ 0
acupuncture NN 0
. . 0

Changes NNS 0
of IN 0
gastric JJ 0
drainage NN 0
volume NN 0
, , 0
therapeutic JJ 0
times NNS 0
and CC 0
cured JJ 0
rate NN 0
were VBD 0
investigated VBN 0
in IN 0
the DT 0
3 CD 0
groups NNS 0
. . 0

RESULTS NNP 0
All PDT 0
the DT 0
3 CD 0
therapeutic JJ 0
methods NNS 0
could MD 0
significantly RB 0
decrease VB 0
gastric JJ 0
drainage NN 0
volume NN 0
. . 0

The DT 0
cured JJ 0
rate NN 0
was VBD 0
100.0 CD 0
% NN 0
and CC 0
the DT 0
therapeutic JJ 0
times NNS 0
was VBD 0
( ( 0
7.24 CD 0
+/- JJ 0
3.87 CD 0
) ) 0
in IN 0
the DT 0
group NN 0
A NNP 0
, , 0
66.7 CD 0
% NN 0
, , 0
( ( 0
9.83 CD 0
+/- JJ 0
4.60 CD 0
) ) 0
times NNS 0
in IN 0
the DT 0
group NN 0
B NNP 0
and CC 0
75.0 CD 0
% NN 0
, , 0
( ( 0
15.25 CD 0
+/- JJ 0
3.81 CD 0
) ) 0
times NNS 0
in IN 0
the DT 0
group NN 0
C NNP 0
, , 0
with IN 0
significant JJ 0
differences NNS 0
in IN 0
the DT 0
cured JJ 0
rate NN 0
and CC 0
the DT 0
therapeutic JJ 0
times NNS 0
among IN 0
the DT 0
3 CD 0
groups NNS 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
, , 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
The DT 0
warming VBG 0
needle JJ 0
moxibustion NN 0
is VBZ 0
the DT 0
best JJS 0
method NN 0
for IN 0
PGS NNP 0
, , 0
with IN 0
less RBR 0
therapeutic JJ 0
times NNS 0
, , 0
high JJ 0
cured VBN 0
rate NN 0
and CC 0
rapid JJ 0
effect NN 0
. . 0

Action NNP 0
observation NN 0
treatment NN 0
improves VBZ 0
recovery NN 0
of IN 0
postsurgical JJ 4
orthopedic JJ 4
patients NNS 4
: : 0
evidence NN 0
for IN 0
a DT 0
top-down JJ 0
effect NN 0
? . 0
OBJECTIVE UH 0
To TO 0
assess VB 0
whether IN 0
action NN 0
observation NN 0
treatment NN 0
( ( 0
AOT NNP 0
) ) 0
may MD 0
also RB 0
improve VB 0
motor NN 0
recovery NN 0
in IN 0
postsurgical JJ 4
orthopedic JJ 4
patients NNS 0
, , 0
in IN 0
addition NN 0
to TO 0
conventional JJ 0
physiotherapy NN 0
. . 0

DESIGN NNP 0
Randomized NNP 0
controlled VBD 0
trial NN 0
. . 0

SETTING NNP 0
Department NNP 0
of IN 0
rehabilitation NN 0
. . 0

PARTICIPANTS JJ 0
Patients NNPS 0
( ( 0
N=60 NNP 3
) ) 0
admitted VBD 0
to TO 0
our PRP$ 0
department NN 0
postorthopedic NN 0
surgery NN 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
either VB 0
a DT 0
case NN 0
( ( 0
n=30 NN 0
) ) 0
or CC 0
control NN 0
( ( 0
n=30 JJ 0
) ) 0
group NN 0
. . 0

Exclusion NN 0
criteria NNS 0
were VBD 0
age NN 0
18 CD 1
years NNS 1
or CC 1
younger JJR 1
and CC 1
90 CD 1
years NNS 1
or CC 1
older JJR 1
, , 0
Mini-Mental JJ 0
State NNP 0
Examination NNP 0
score NN 0
of IN 0
21 CD 0
of IN 0
30 CD 0
or CC 0
lower JJR 0
, , 0
no DT 0
ambulating VBG 0
order NN 0
, , 0
advanced JJ 0
vision NN 0
impairment NN 0
, , 0
malignancy NN 0
, , 0
pneumonia NN 0
, , 0
or CC 0
heart NN 0
failure NN 0
. . 0

INTERVENTIONS NNP 0
All NNP 0
participants NNS 0
underwent JJ 0
conventional JJ 0
physiotherapy NN 0
. . 0

In IN 0
addition NN 0
, , 0
patients NNS 0
in IN 0
the DT 0
case NN 0
group NN 0
were VBD 0
asked VBN 0
to TO 0
observe VB 0
video JJ 0
clips NNS 0
showing VBG 0
daily JJ 0
actions NNS 0
and CC 0
to TO 0
imitate VB 0
them PRP 0
afterward RB 0
. . 0

Patients NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
were VBD 0
asked VBN 0
to TO 0
observe VB 0
video JJ 0
clips NNS 0
with IN 0
no DT 0
motor NN 0
content NN 0
and CC 0
to TO 0
execute VB 0
the DT 0
same JJ 0
actions NNS 0
as IN 0
patients NNS 0
in IN 0
the DT 0
case NN 0
group NN 0
afterward RB 0
. . 0

Participants NNS 0
were VBD 0
scored VBN 0
on IN 0
functional JJ 0
scales NNS 0
at IN 0
baseline NN 0
and CC 0
after IN 0
treatment NN 0
by IN 0
a DT 0
physician NN 0
blinded VBD 0
to TO 0
group NN 0
assignment NN 0
. . 0

MAIN NNP 0
OUTCOMES NNP 0
MEASURES NNP 0
Changes NNP 0
in IN 0
FIM NNP 0
and CC 0
Tinetti NNP 0
scale NN 0
scores NNS 0
, , 0
and CC 0
dependence NN 0
on IN 0
walking VBG 0
aids NNS 0
. . 0

RESULTS NNP 0
At IN 0
baseline NN 0
, , 0
groups NNS 0
did VBD 0
not RB 0
differ VB 0
in IN 0
clinical JJ 0
and CC 0
functional JJ 0
scale NN 0
scores NNS 0
. . 0

After IN 0
treatment NN 0
, , 0
patients NNS 0
in IN 0
the DT 0
case NN 0
group NN 0
scored VBD 0
better JJR 0
than IN 0
patients NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
( ( 0
FIM NNP 0
total NN 0
score NN 0
, , 0
P=.02 NNP 0
; : 0
FIM NNP 0
motor NN 0
subscore NN 0
, , 0
P=.001 NNP 0
; : 0
Tinetti NNP 0
scale NN 0
score NN 0
, , 0
P=.04 NNP 0
) ) 0
; : 0
patients NNS 0
in IN 0
the DT 0
case NN 0
group NN 0
were VBD 0
assigned VBN 0
more RBR 0
frequently RB 0
to TO 0
1 CD 0
crutch NN 0
( ( 0
P=.01 NNP 0
) ) 0
. . 0

CONCLUSIONS NNP 0
In IN 0
addition NN 0
to TO 0
conventional JJ 0
physiotherapy NN 0
, , 0
AOT NNP 0
is VBZ 0
effective JJ 0
in IN 0
the DT 0
rehabilitation NN 0
of IN 0
postsurgical JJ 0
orthopedic JJ 0
patients NNS 0
. . 0

The DT 0
present JJ 0
results NNS 0
strongly RB 0
support VB 0
top-down JJ 0
effects NNS 0
of IN 0
this DT 0
treatment NN 0
in IN 0
motor NN 0
recovery NN 0
, , 0
even RB 0
in IN 0
nonneurologic JJ 0
patients NNS 0
. . 0

Fine NNP 0
needle JJ 0
aspiration NN 0
coupled VBN 0
with IN 0
real-time JJ 0
PCR NNP 0
: : 0
a DT 0
painless JJ 0
methodology NN 0
to TO 0
study VB 0
adaptive JJ 0
functional JJ 0
changes NNS 0
in IN 0
skeletal JJ 0
muscle NN 0
. . 0

BACKGROUND NNP 0
AND NNP 0
AIM NNP 0
In IN 0
this DT 0
study NN 0
we PRP 0
developed VBD 0
a DT 0
new JJ 0
methodology NN 0
for IN 0
obtaining VBG 0
human JJ 0
skeletal JJ 0
muscle NN 0
samples NNS 0
to TO 0
evaluate VB 0
gene NN 0
expression NN 0
. . 0

This DT 0
approach NN 0
is VBZ 0
based VBN 0
on IN 0
a DT 0
fine JJ 0
needle JJ 0
aspiration NN 0
technique NN 0
, , 0
which WDT 0
allows VBZ 0
us PRP 0
to TO 0
extract VB 0
a DT 0
small JJ 0
tissue NN 0
sample NN 0
in IN 0
a DT 0
significantly RB 0
less RBR 0
invasive JJ 0
manner NN 0
than IN 0
with IN 0
classic JJ 0
biopsy NN 0
. . 0

METHODS NNP 0
AND CC 0
RESULTS NNP 0
Multiplex NNP 0
tandem VBD 0
RT-PCR NNP 0
was VBD 0
used VBN 0
to TO 0
determine VB 0
the DT 0
mRNA NN 0
levels NNS 0
of IN 0
genes NNS 0
involved VBN 0
in IN 0
ATP NNP 0
production NN 0
and CC 0
mitochondrial JJ 0
biogenesis NN 0
in IN 0
muscle NN 0
tissue NN 0
. . 0

Samples NNS 0
of IN 0
vastus NN 0
lateralis NNS 0
muscle NN 0
were VBD 0
obtained VBN 0
from IN 0
21 CD 3
healthy JJ 4
subjects NNS 4
with IN 0
different JJ 0
fitness NN 4
levels NNS 4
. . 0

The DT 0
principal JJ 0
findings NNS 0
in IN 0
our PRP$ 0
study NN 0
show VB 0
a DT 0
strong JJ 0
correlation NN 0
between IN 0
PGC-1alpha NNP 0
and CC 0
COX5B NNP 0
( ( 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
and CC 0
between IN 0
PGC-1alpha NNP 0
and CC 0
MT-CO2 NNP 0
( ( 0
p=0.017 NN 0
) ) 0
expression NN 0
. . 0

Furthermore NNP 0
, , 0
a DT 0
significant JJ 0
positive JJ 0
correlation NN 0
between IN 0
mtDNA NN 0
content NN 0
and CC 0
the DT 0
percentage NN 0
of IN 0
MHCI NNP 0
present NN 0
in IN 0
the DT 0
aspired JJ 0
samples NNS 0
were VBD 0
found VBN 0
( ( 0
p=0.028 NN 0
) ) 0
. . 0

These DT 0
data NNS 0
are VBP 0
in IN 0
agreement NN 0
with IN 0
current JJ 0
knowledge NN 0
on IN 0
skeletal JJ 0
muscle NN 0
physiology NN 0
and CC 0
show VB 0
the DT 0
reliability NN 0
of IN 0
the DT 0
proposed VBN 0
method NN 0
. . 0

CONCLUSION VB 0
This DT 0
painless JJ 0
methodology NN 0
can MD 0
be VB 0
used VBN 0
to TO 0
investigate VB 0
, , 0
in IN 0
vivo NN 0
, , 0
human JJ 0
muscle NN 0
RNA NNP 0
and CC 0
DNA NNP 0
adaptations NNS 0
in IN 0
response NN 0
to TO 0
either DT 0
physiological JJ 0
and/or NN 0
pharmacological JJ 0
stimuli NN 0
. . 0

This DT 0
method NN 0
has VBZ 0
major JJ 0
clinical JJ 0
relevance NN 0
, , 0
such JJ 0
as IN 0
its PRP$ 0
application NN 0
in IN 0
clarifying VBG 0
the DT 0
mechanisms NN 0
underling VBG 0
metabolic JJ 0
and CC 0
systemic JJ 0
disorders NNS 0
. . 0

Take VB 0
a DT 0
walk NN 0
in IN 0
the DT 0
park NN 0
? . 0
A DT 0
cross-over NN 0
pilot NN 0
trial NN 0
comparing VBG 0
brisk JJ 0
walking VBG 0
in IN 0
two CD 0
different JJ 0
environments NNS 0
: : 0
park NN 0
and CC 0
urban JJ 0
. . 0

OBJECTIVE CC 0
The DT 0
objective NN 0
of IN 0
the DT 0
present JJ 0
study NN 0
is VBZ 0
to TO 0
investigate VB 0
whether IN 0
differences NNS 0
exist VBP 0
between IN 0
a DT 0
30 CD 0
minute NN 0
brisk NN 0
walk VBP 0
taken VBN 0
in IN 0
two CD 0
different JJ 0
environments NNS 0
in IN 0
order NN 0
to TO 0
determine VB 0
which WDT 0
environment NN 0
best JJS 0
facilitates NNS 0
current JJ 0
physical JJ 0
activity NN 0
guidelines NNS 0
: : 0
park NN 0
or CC 0
urban JJ 0
. . 0

METHODS NNP 0
In IN 0
this DT 0
randomised JJ 0
cross-over NN 0
pilot NN 0
study NN 0
, , 0
participants NNS 0
performed VBD 0
a DT 0
self-timed JJ 0
30 CD 0
minute NN 0
brisk NN 4
walk VBP 4
in IN 0
two CD 0
different JJ 0
environments NNS 0
, , 0
park NN 0
and CC 0
urban JJ 0
, , 0
in IN 0
Glasgow NNP 0
, , 0
Scotland NNP 0
( ( 0
October NNP 0
2009 CD 0
to TO 0
January NNP 0
2010 CD 0
) ) 0
. . 0

Cadence NN 0
, , 0
recorded VBD 0
using VBG 0
the DT 0
activPAL? NN 0
activity NN 0
monitor NN 0
, , 0
was VBD 0
used VBN 0
to TO 0
measure VB 0
intensity NN 0
. . 0

Outcome CC 0
measures NNS 0
were VBD 0
: : 0
mean JJ 0
cadence NN 0
; : 0
moderate-to-vigorous JJ 0
physical JJ 0
activity NN 0
time NN 0
accumulated VBN 0
in IN 0
bouts NNS 0
lasting VBG 0
? . 0
10 CD 0
min NN 0
; : 0
number NN 0
of IN 0
walking VBG 0
breaks NNS 0
; : 0
and CC 0
duration NN 0
. . 0

RESULTS VB 0
A DT 0
convenience NN 0
sample NN 0
of IN 0
40 CD 0
healthy JJ 0
adults NNS 0
was VBD 0
recruited VBN 0
: : 0
16 CD 0
males NNS 0
, , 0
24 CD 0
females NNS 0
, , 0
mean JJ 0
age NN 0
22.9 CD 0
( ( 0
5.5 CD 0
) ) 0
years NNS 0
. . 0

The DT 0
mean JJ 0
cadence NN 0
for IN 0
the DT 0
whole JJ 0
walk NN 0
was VBD 0
higher RBR 0
in IN 0
the DT 0
park NN 0
: : 0
119.3 CD 0
( ( 0
8.3 CD 0
) ) 0
vs. FW 0
110.9 CD 0
( ( 0
8.9 CD 0
) ) 0
steps/min NN 0
. . 0

Participants NNS 0
accumulated VBD 0
more RBR 0
moderate-to-vigorous JJ 0
physical JJ 0
activity NN 0
in IN 0
? . 0
10 CD 0
minute NN 0
bouts NNS 0
during IN 0
park JJ 0
walks NNS 0
: : 0
25.5 CD 0
( ( 0
9.6 CD 0
) ) 0
[ NN 0
median JJ 0
( ( 0
interquartile JJ 0
range NN 0
) ) 0
] VBZ 0
vs. FW 0
14.0 CD 0
( ( 0
20.3 CD 0
) ) 0
min NN 0
. . 0

There EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
self-timed JJ 0
duration NN 0
between IN 0
locations NNS 0
. . 0

CONCLUSION NNP 0
Participants NNPS 0
accumulated VBD 0
more RBR 0
moderate-to-vigorous JJ 0
physical JJ 0
activity NN 0
in IN 0
bouts NNS 0
? . 0
10 CD 0
min NN 0
in IN 0
duration NN 0
on IN 0
park NN 0
walks NNS 0
due JJ 0
to TO 0
the DT 0
lack NN 0
of IN 0
interruptions NNS 0
in IN 0
walking VBG 0
. . 0

Hence NNP 0
the DT 0
park NN 0
environment NN 0
better RBR 0
facilitated VBD 0
the DT 0
achievement NN 0
of IN 0
current JJ 0
physical JJ 0
activity NN 0
guidelines NNS 0
. . 0

Further JJ 0
research NN 0
involving VBG 0
a DT 0
larger JJR 0
, , 0
more RBR 0
heterogeneous JJ 0
sample NN 0
is VBZ 0
recommended VBN 0
. . 0

Computer-navigated JJ 0
versus NN 0
conventional JJ 0
total JJ 0
knee NN 0
arthroplasty IN 0
a DT 0
prospective JJ 0
randomized VBN 0
trial NN 0
. . 0

BACKGROUND VB 0
The DT 0
literature NN 0
lacks VBZ 0
studies NNS 0
that IN 0
confirm VBP 0
whether IN 0
the DT 0
improved JJ 0
radiographic JJ 0
alignment NN 0
that WDT 0
can MD 0
be VB 0
achieved VBN 0
with IN 0
computer-navigated JJ 0
total JJ 0
knee NN 0
arthroplasty NN 0
improves VBZ 0
patients? JJ 0
activities NNS 0
of IN 0
daily JJ 0
living NN 0
or CC 0
the DT 0
durability NN 0
of IN 0
total JJ 0
knee NN 0
prostheses NNS 0
. . 0

The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
determine VB 0
whether IN 0
computer-navigated JJ 0
total JJ 0
knee NN 0
arthroplasty NN 0
improves VBZ 0
the DT 0
clinical JJ 0
function NN 0
, , 0
alignment NN 0
, , 0
and CC 0
survivorship NN 0
of IN 0
the DT 0
components NNS 0
. . 0

METHODS NNP 0
We PRP 0
prospectively RB 0
compared VBN 0
the DT 0
results NNS 0
of IN 0
520 CD 0
patients NNS 0
with IN 0
osteoarthritis NN 0
who WP 0
underwent VBD 0
computer-navigated JJ 0
total JJ 0
knee NN 0
arthroplasty NN 0
for IN 0
one CD 0
knee NN 0
and CC 0
conventional JJ 0
total JJ 0
knee NN 0
arthroplasty NN 0
for IN 0
the DT 0
other JJ 0
. . 0

The DT 0
assignment NN 0
of IN 0
the DT 0
knee NN 0
to TO 0
navigation NN 0
or CC 0
not RB 0
was VBD 0
done VBN 0
randomly RB 0
. . 0

There EX 0
were VBD 0
452 CD 0
women NNS 0
( ( 0
904 CD 0
knees NNS 0
) ) 0
and CC 0
sixty-eight JJ 0
men NNS 0
( ( 0
136 CD 0
knees NNS 0
) ) 0
with IN 0
a DT 0
mean JJ 0
age NN 0
of IN 0
sixty-eight JJ 0
years NNS 0
( ( 0
range NN 0
, , 0
forty-nine JJ 0
to TO 0
eighty-eight JJ 0
years NNS 0
) ) 0
at IN 0
the DT 0
time NN 0
of IN 0
the DT 0
index NN 0
arthroplasty NN 0
. . 0

The DT 0
mean JJ 0
follow-up JJ 0
period NN 0
was VBD 0
10.8 CD 0
years NNS 0
( ( 0
range NN 0
, , 0
ten VB 0
to TO 0
twelve VB 0
years NNS 0
) ) 0
. . 0

The DT 0
patients NNS 0
were VBD 0
assessed VBN 0
clinically RB 0
and CC 0
radiographically RB 0
with IN 0
the DT 0
rating NN 0
system NN 0
of IN 0
the DT 0
Knee NNP 0
Society NNP 0
and CC 0
with IN 0
the DT 0
Western NNP 0
Ontario NNP 0
and CC 0
McMaster NNP 0
Universities NNP 0
Osteoarthritis NNP 0
Index NNP 0
( ( 0
WOMAC NNP 0
) ) 0
score NN 0
at IN 0
three CD 0
months NNS 0
, , 0
one CD 0
year NN 0
, , 0
and CC 0
annually RB 0
thereafter RB 0
. . 0

RESULTS NNP 0
Total JJ 0
knee NN 0
scores NNS 0
, , 0
knee NN 0
function NN 0
scores NNS 0
, , 0
pain NN 0
scores NNS 0
, , 0
WOMAC NNP 0
scores VBZ 0
, , 0
knee VB 0
motion NN 0
, , 0
and CC 0
activity NN 0
scores NNS 0
did VBD 0
not RB 0
show VB 0
statistically RB 0
significant JJ 0
differences NNS 0
between IN 0
the DT 0
two CD 0
groups NNS 0
preoperatively RB 0
or CC 0
at IN 0
the DT 0
time NN 0
of IN 0
the DT 0
final JJ 0
follow-up NN 0
. . 0

Alignment NNP 0
and CC 0
the DT 0
survivorship NN 0
of IN 0
the DT 0
components NNS 0
were VBD 0
not RB 0
significantly RB 0
different JJ 0
between IN 0
the DT 0
two CD 0
groups NNS 0
. . 0

The DT 0
Kaplan-Meier NNP 0
survivorship NN 0
with IN 0
revision NN 0
as IN 0
the DT 0
end NN 0
point NN 0
at IN 0
10.8 CD 0
years NNS 0
was VBD 0
98.8 CD 0
% NN 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
[ NNP 0
CI NNP 0
] NNP 0
, , 0
0.96 CD 0
to TO 0
1.00 CD 0
) ) 0
in IN 0
the DT 0
computernavigated JJ 0
total JJ 0
knee NN 0
arthroplasty NN 0
group NN 0
and CC 0
99.2 CD 0
% NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
0.96 CD 0
to TO 0
1.00 CD 0
) ) 0
in IN 0
the DT 0
conventional JJ 0
total JJ 0
knee NN 0
arthroplasty NN 0
group NN 0
. . 0

CONCLUSIONS NNP 0
Our PRP$ 0
data NNS 0
demonstrated VBD 0
no DT 0
difference NN 0
in IN 0
clinical JJ 0
function NN 0
or CC 0
alignment NN 0
and CC 0
survivorship NN 0
of IN 0
the DT 0
components NNS 0
between IN 0
the DT 0
knees NNS 0
that WDT 0
underwent VBD 0
computer-navigated JJ 0
total JJ 0
knee NN 0
arthroplasty NN 0
and CC 0
those DT 0
that WDT 0
underwent JJ 0
conventional JJ 0
total JJ 0
knee NN 0
arthroplasty NN 0
. . 0

The DT 0
evaluation NN 0
of IN 0
pulmonary JJ 0
hypertension NN 0
using VBG 0
right JJ 0
ventricular JJ 0
myocardial JJ 0
isovolumic JJ 0
relaxation NN 0
time NN 0
. . 0

Right JJ 0
ventricular NN 0
( ( 0
RV NNP 0
) ) 0
blood VBD 0
pool-derived JJ 0
isovolumic JJ 0
relaxation NN 0
time NN 0
( ( 0
IVRT NNP 0
) ) 0
correlates VBZ 0
well RB 0
with IN 0
systolic JJ 0
pulmonary JJ 0
arterial JJ 0
pressure NN 0
( ( 0
PAP NNP 0
) ) 0
. . 0

However RB 0
, , 0
because IN 0
of IN 0
complex JJ 0
parameter NN 0
derivation NN 0
, , 0
the DT 0
method NN 0
is VBZ 0
rarely RB 0
used VBN 0
. . 0

The DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
validate VB 0
the DT 0
measurement NN 0
of IN 0
myocardial JJ 0
velocity NN 0
imaging-derived JJ 0
RV NNP 0
IVRT NNP 0
( ( 0
IVRT NNP 0
' POS 0
) ) 0
against IN 0
invasively RB 0
measured VBN 0
PAP NNP 0
. . 0

Transthoracic NNP 0
echocardiography NN 0
with IN 0
myocardial JJ 0
velocity NN 0
imaging NN 0
and CC 0
right JJ 0
heart NN 0
catheterization NN 0
were VBD 0
performed VBN 0
in IN 0
33 CD 3
patients NNS 0
with IN 0
pulmonary JJ 4
hypertension NN 4
. . 0

Blood NNP 0
pool NN 0
IVRT NNP 0
and CC 0
myocardial JJ 0
IVRTs NNP 0
for IN 0
the DT 0
tricuspid JJ 0
valve NN 0
annulus NN 0
ring NN 0
, , 0
basal NN 0
and CC 0
apical JJ 0
RV NNP 0
free JJ 0
wall NN 0
segments NNS 0
were VBD 0
measured VBN 0
and CC 0
compared VBN 0
with IN 0
data NNS 0
from IN 0
33 CD 3
age- JJ 0
and CC 0
sex-matched JJ 0
control NN 0
subjects NNS 0
. . 0

Measured VBN 0
IVRTs NNP 0
were VBD 0
significantly RB 0
longer RBR 0
in IN 0
patients NNS 0
with IN 0
pulmonary JJ 0
hypertension NN 0
than IN 0
in IN 0
control NN 0
subjects NNS 0
. . 0

The DT 0
strongest JJS 0
correlation NN 0
( ( 0
R NNP 0
= NNP 0
0.74 CD 0
, , 0
P NNP 0
< NNP 0
.0001 NNP 0
) ) 0
was VBD 0
found VBN 0
between IN 0
systolic JJ 0
PAP NNP 0
and CC 0
the DT 0
heart NN 0
rate-corrected JJ 0
IVRT NNP 0
' POS 0
derived VBN 0
from IN 0
the DT 0
basal NN 0
RV NNP 0
free JJ 0
wall NN 0
segment NN 0
. . 0

The DT 0
basal NN 0
segment NN 0
IVRT NNP 0
' POS 0
corrected VBN 0
for IN 0
heart NN 0
rate NN 0
correlates NNS 0
well RB 0
with IN 0
the DT 0
invasive JJ 0
PAP NNP 0
measurement NN 0
and CC 0
, , 0
therefore RB 0
, , 0
can MD 0
be VB 0
used VBN 0
to TO 0
predict VB 0
systolic JJ 0
PAP NNP 0
. . 0

It PRP 0
can MD 0
even RB 0
be VB 0
considered VBN 0
as IN 0
an DT 0
alternative NN 0
to TO 0
tricuspid VB 0
regurgitation-derived JJ 0
PAP NNP 0
systolic NN 0
when WRB 0
tricuspid JJ 0
regurgitation NN 0
is VBZ 0
nonrecordable JJ 0
. . 0

A DT 0
proposed VBN 0
method NN 0
to TO 0
derive VB 0
systolic JJ 0
PAP NNP 0
should MD 0
be VB 0
used VBN 0
while IN 0
screening VBG 0
the DT 0
patients NNS 0
at IN 0
risk NN 0
for IN 0
pulmonary JJ 0
hypertension NN 0
, , 0
monitoring VBG 0
the DT 0
disease NN 0
progression NN 0
and CC 0
the DT 0
effect NN 0
of IN 0
treatment NN 0
. . 0

Effect NN 0
of IN 0
entacapone NN 0
, , 0
a DT 0
peripherally RB 0
acting VBG 0
catechol-O-methyltransferase NN 0
inhibitor NN 0
, , 0
on IN 0
the DT 0
motor NN 0
response NN 0
to TO 0
acute VB 0
treatment NN 0
with IN 0
levodopa NN 0
in IN 0
patients NNS 0
with IN 0
Parkinson NNP 4
's POS 4
disease NN 4
. . 0

Catechol-O-methyltransferase NNP 0
( ( 0
COMT NNP 0
) ) 0
inhibitors NNS 0
may MD 0
be VB 0
useful JJ 0
in IN 0
the DT 0
treatment NN 0
of IN 0
Parkinson NNP 0
's POS 0
disease NN 0
by IN 0
improving VBG 0
the DT 0
bioavailability NN 0
of IN 0
levodopa NN 0
and CC 0
by IN 0
prolonging VBG 0
its PRP$ 0
effects NNS 0
. . 0

Entacapone NNP 0
( ( 0
OR-611 NNP 0
) ) 0
, , 0
a DT 0
novel JJ 0
COMT NNP 0
inhibitor NN 0
, , 0
which WDT 0
does VBZ 0
not RB 0
cross VB 0
the DT 0
blood NN 0
brain NN 0
barrier NN 0
, , 0
was VBD 0
assessed VBN 0
in IN 0
12 CD 3
patients NNS 0
with IN 0
Parkinson NNP 4
's POS 4
disease NN 4
and CC 0
motor NN 4
fluctuations NNS 4
in IN 0
a DT 0
randomised JJ 0
, , 0
double-blind JJ 0
, , 0
cross-over JJ 0
, , 0
single JJ 0
dose NN 0
study NN 0
. . 0

The DT 0
magnitude NN 0
and CC 0
duration NN 0
of IN 0
the DT 0
therapeutic JJ 0
response NN 0
to TO 0
a DT 0
single JJ 0
dose NN 0
of IN 0
200 CD 0
mg NNS 0
levodopa/50 JJ 0
mg FW 0
carbidopa NN 0
was VBD 0
evaluated VBN 0
after IN 0
concomitant JJ 0
placebo NN 0
, , 0
or CC 0
200 CD 0
or CC 0
800 CD 0
mg NN 0
entacapone NN 0
. . 0

A DT 0
significant JJ 0
increase NN 0
in IN 0
the DT 0
duration NN 0
of IN 0
the DT 0
motor NN 0
response NN 0
to TO 0
levodopa NN 0
was VBD 0
seen VBN 0
when WRB 0
200 CD 0
mg NN 0
entacapone NN 0
was VBD 0
given VBN 0
with IN 0
levodopa/carbidopa NN 0
. . 0

Plasma NNP 0
levodopa JJ 0
concentrations NNS 0
were VBD 0
increased VBN 0
with IN 0
both DT 0
doses NNS 0
of IN 0
the DT 0
COMT NNP 0
inhibitor NN 0
. . 0

The DT 0
latency NN 0
to TO 0
onset VB 0
of IN 0
motor NN 0
response NN 0
did VBD 0
not RB 0
differ VB 0
significantly RB 0
between IN 0
active JJ 0
drug NN 0
and CC 0
placebo NN 0
. . 0

Entacapone NN 0
may MD 0
prove VB 0
useful JJ 0
in IN 0
prolonging VBG 0
the DT 0
duration NN 0
of IN 0
the DT 0
benefit NN 0
obtained VBN 0
from IN 0
individual JJ 0
doses NNS 0
of IN 0
levodopa NN 0
. . 0

The DT 0
influence NN 0
of IN 0
breast NN 0
size NN 0
on IN 0
late JJ 0
radiation NN 0
effects NNS 0
and CC 0
association NN 0
with IN 0
radiotherapy NN 0
dose JJ 0
inhomogeneity NN 0
. . 0

A DT 0
prospective JJ 0
assessment NN 0
of IN 0
late JJ 0
changes NNS 0
in IN 0
breast NN 0
appearance NN 0
in IN 0
559 CD 3
patients NNS 0
after IN 0
tumour JJ 4
excision NN 4
and CC 0
radiotherapy NN 4
for IN 0
early JJ 4
breast NN 4
cancer NN 4
noted VBD 0
a DT 0
strong JJ 0
association NN 0
with IN 0
breast NN 0
size NN 0
. . 0

Only RB 0
3/48 CD 0
( ( 0
6 CD 0
% NN 0
) ) 0
patients NNS 0
with IN 0
small JJ 0
breasts NNS 0
developed VBD 0
moderate JJ 0
or CC 0
severe JJ 0
late JJ 0
changes NNS 0
compared VBN 0
with IN 0
94/423 CD 0
( ( 0
22 CD 0
% NN 0
) ) 0
with IN 0
medium NN 0
sized VBN 0
breasts NNS 0
and CC 0
34/88 CD 0
( ( 0
39 CD 0
% NN 0
) ) 0
patients NNS 0
with IN 0
large JJ 0
breasts NNS 0
( ( 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

One CD 0
possibility NN 0
is VBZ 0
that IN 0
greater JJR 0
radiation NN 0
changes NNS 0
are VBP 0
related VBN 0
to TO 0
greater JJR 0
dose JJ 0
inhomogeneity NN 0
in IN 0
women NNS 0
with IN 0
large JJ 0
breasts NNS 0
. . 0

To TO 0
explore VB 0
this DT 0
hypothesis NN 0
, , 0
radiation NN 0
dose JJ 0
distributions NNS 0
were VBD 0
assessed VBN 0
in IN 0
a DT 0
separate JJ 0
group NN 0
of IN 0
37 CD 0
women NNS 0
in IN 0
whom WP 0
three-level JJ 0
transverse NN 0
computer NN 0
tomographic JJ 0
images NNS 0
of IN 0
the DT 0
breast NN 0
in IN 0
the DT 0
treatment NN 0
position NN 0
were VBD 0
available JJ 0
. . 0

A DT 0
significant JJ 0
correlation NN 0
was VBD 0
found VBN 0
between IN 0
breast NN 0
size NN 0
and CC 0
dose NN 0
inhomogeneity NN 0
which WDT 0
may MD 0
account VB 0
for IN 0
the DT 0
marked JJ 0
changes NNS 0
in IN 0
breast NN 0
appearance NN 0
reported VBD 0
in IN 0
women NNS 0
with IN 0
large JJ 0
breasts NNS 0
. . 0

The DT 0
effect NN 0
of IN 0
a DT 0
parent-implemented JJ 0
imitation NN 0
intervention NN 0
on IN 0
spontaneous JJ 0
imitation NN 0
skills NNS 0
in IN 0
young JJ 1
children NNS 1
with IN 0
autism NN 4
. . 0

Children NNP 0
with IN 0
autism NN 0
exhibit NN 0
significant JJ 0
deficits NNS 0
in IN 0
their PRP$ 0
ability NN 0
to TO 0
spontaneously RB 0
imitate VB 0
the DT 0
play NN 0
actions NNS 0
and CC 0
descriptive JJ 0
gestures NNS 0
of IN 0
others NNS 0
. . 0

Reciprocal JJ 0
imitation NN 0
training NN 0
( ( 0
RIT NNP 0
) ) 0
is VBZ 0
a DT 0
naturalistic JJ 0
imitation NN 0
intervention NN 0
designed VBN 0
to TO 0
teach VB 0
spontaneous JJ 0
imitation NN 0
skills NNS 0
during IN 0
play NN 0
. . 0

This DT 0
study NN 0
assessed VBD 0
the DT 0
effectiveness NN 0
of IN 0
parent-implemented JJ 0
RIT NNP 0
using VBG 0
a DT 0
multiple-baseline JJ 0
design NN 0
across IN 0
three CD 3
young JJ 0
children NNS 0
with IN 0
autism NN 0
and CC 0
their PRP$ 0
mothers NNS 0
. . 0

After IN 0
an DT 0
initial JJ 0
baseline NN 0
, , 0
mothers NNS 0
were VBD 0
taught VBN 0
to TO 0
implement VB 0
RIT NNP 0
techniques NNS 0
with IN 0
their PRP$ 0
child NN 0
twice RB 0
a DT 0
week NN 0
for IN 0
10 CD 0
weeks NNS 0
in IN 0
a DT 0
clinic JJ 0
setting NN 0
. . 0

Two CD 0
mothers NNS 0
were VBD 0
taught VBN 0
to TO 0
use VB 0
RIT NNP 0
to TO 0
teach VB 0
object JJ 0
imitation NN 0
. . 0

The DT 0
third JJ 0
mother NN 0
was VBD 0
taught VBN 0
to TO 0
use VB 0
RIT NNP 0
to TO 0
target VB 0
both DT 0
object JJ 0
and CC 0
gesture JJ 0
imitation NN 0
in IN 0
a DT 0
multiple-baseline JJ 0
design NN 0
across IN 0
behaviors NNS 0
. . 0

Generalization NNP 0
was VBD 0
assessed VBN 0
in IN 0
the DT 0
families NNS 0
' POS 0
homes NNS 0
at IN 0
the DT 0
end NN 0
of IN 0
treatment NN 0
and CC 0
a DT 0
1-month JJ 0
follow-up NN 0
. . 0

Parents NNS 0
learned VBD 0
to TO 0
use VB 0
the DT 0
intervention NN 0
strategies NNS 0
and CC 0
their PRP$ 0
children NNS 0
exhibited VBN 0
increases NNS 0
in IN 0
spontaneous JJ 0
imitation NN 0
. . 0

These DT 0
findings NNS 0
replicate VBP 0
the DT 0
results NNS 0
from IN 0
previous JJ 0
studies NNS 0
, , 0
indicating VBG 0
that IN 0
RIT NNP 0
is VBZ 0
effective JJ 0
for IN 0
teaching VBG 0
imitation NN 0
skills NNS 0
to TO 0
young JJ 0
children NNS 0
with IN 0
autism NN 0
in IN 0
a DT 0
naturalistic JJ 0
setting NN 0
and CC 0
extend VB 0
the DT 0
findings NNS 0
to TO 0
parents NNS 0
. . 0

Coagulation NNP 0
factor NN 0
concentrate NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
the DT 0
haemorrhagic JJ 4
diathesis NN 4
of IN 0
fulminant JJ 4
hepatic JJ 4
failure NN 4
. . 0

To TO 0
assess VB 0
the DT 0
value NN 0
of IN 0
clotting VBG 0
factor NN 0
concentrate NN 0
infusions NNS 0
in IN 0
fulminant JJ 4
hepatic JJ 4
failure NN 4
, , 0
a DT 0
controlled JJ 0
trial NN 0
was VBD 0
performed VBN 0
in IN 0
which WDT 0
nine CD 3
patients NNS 0
were VBD 0
randomly RB 0
allocated VBN 0
to TO 0
treatment NN 0
with IN 0
either DT 0
concentrate NN 0
alone RB 0
or CC 0
concentrate VB 0
plus CC 0
heparin VB 0
. . 0

The DT 0
five CD 0
patients NNS 0
receiving VBG 0
concentrate VB 0
alone RB 0
all DT 0
died VBD 0
, , 0
with IN 0
major JJ 0
bleeding VBG 0
as IN 0
the DT 0
direct JJ 0
cause NN 0
of IN 0
death NN 0
in IN 0
three CD 0
, , 0
whereas NNS 0
in IN 0
the DT 0
four CD 0
receiving VBG 0
heparin NN 0
as RB 0
well RB 0
there EX 0
was VBD 0
only RB 0
one CD 0
instance NN 0
of IN 0
bleeding NN 0
and CC 0
one CD 0
patient NN 0
survived VBD 0
. . 0

Clinical JJ 0
evidence NN 0
of IN 0
intravascular JJ 0
coagulation NN 0
appeared VBD 0
in IN 0
two CD 0
patients NNS 0
treated VBD 0
with IN 0
concentrate NN 0
alone RB 0
and CC 0
the DT 0
laboratory JJ 0
evidence NN 0
of IN 0
this DT 0
progressed VBN 0
during IN 0
the DT 0
period NN 0
of IN 0
infusions NNS 0
in IN 0
all DT 0
patients NNS 0
in IN 0
both DT 0
treatment NN 0
groups NNS 0
, , 0
although IN 0
to TO 0
a DT 0
lesser JJR 0
extent NN 0
in IN 0
those DT 0
receiving VBG 0
heparin NN 0
. . 0

Additional JJ 0
evidence NN 0
for IN 0
intravascular JJ 0
coagulation NN 0
came VBD 0
from IN 0
the DT 0
changes NNS 0
observed VBN 0
in IN 0
factor NN 0
VIII NNP 0
levels NNS 0
which WDT 0
, , 0
although IN 0
initially RB 0
high JJ 0
in IN 0
all DT 0
patients NNS 0
, , 0
fell VBD 0
subsequently RB 0
, , 0
particularly RB 0
in IN 0
those DT 0
given VBN 0
concentrate VBP 0
alone RB 0
. . 0

There EX 0
was VBD 0
some DT 0
improvement NN 0
in IN 0
the DT 0
prothrombin NN 0
ratio NN 0
in IN 0
both DT 0
groups NNS 0
of IN 0
patients NNS 0
but CC 0
not RB 0
complete JJ 0
correction NN 0
, , 0
and CC 0
serial JJ 0
assays NNS 0
of IN 0
clotting VBG 0
factors NNS 0
showed VBD 0
that IN 0
although IN 0
factor NN 0
II NNP 0
rose VBD 0
to TO 0
high JJ 0
levels NNS 0
during IN 0
treatment NN 0
, , 0
factors NNS 0
IX NNP 0
and CC 0
X NNP 0
showed VBD 0
little JJ 0
response NN 0
. . 0

Thus RB 0
, , 0
the DT 0
use NN 0
of IN 0
concentrate NN 0
of IN 0
factor NN 0
IX NNP 0
in IN 0
this DT 0
trial NN 0
, , 0
as RB 0
well RB 0
as IN 0
potentiating VBG 0
intravascular JJ 0
coagulation NN 0
, , 0
was VBD 0
inadequate JJ 0
as IN 0
replacement NN 0
for IN 0
the DT 0
clotting NN 0
factor NN 0
deficiencies NNS 0
. . 0

An DT 0
evaluation NN 0
of IN 0
chemical JJ 0
arthrodesis NN 0
of IN 0
the DT 0
proximal JJ 4
interphalangeal NN 4
joint NN 4
in IN 0
the DT 0
horse NN 0
by IN 0
using VBG 0
monoiodoacetate NN 0
. . 0

The DT 0
use NN 0
of IN 0
monoiodoacetate NN 0
( ( 0
MIA NNP 0
) ) 0
for IN 0
arthrodesis NN 0
of IN 0
the DT 0
proximal JJ 0
interphalangeal NN 0
joint NN 0
( ( 0
PIJ NNP 0
) ) 0
and CC 0
the DT 0
effect NN 0
of IN 0
exercise NN 0
on IN 0
the DT 0
degree NN 0
of IN 0
fusion NN 0
were VBD 0
investigated VBN 0
. . 0

Eight JJ 3
horses NNS 0
received VBD 0
3 CD 0
injections NNS 0
( ( 0
Weeks NNP 0
0 CD 0
, , 0
3 CD 0
, , 0
6 CD 0
) ) 0
of IN 0
MIA NNP 0
( ( 0
2 CD 0
mL NN 0
; : 0
60 CD 0
mg/mL NN 0
) ) 0
into IN 0
the DT 0
right NN 0
or CC 0
left VBD 0
front JJ 0
PIJ NNP 0
. . 0

Peri-operatively RB 0
, , 0
the DT 0
horses NNS 0
received VBD 0
phenylbutazone NN 0
, , 0
butorphanol NN 0
, , 0
and CC 0
abaxial JJ 0
sesamoidean NN 0
nerve NN 0
blocks NNS 0
to TO 0
relieve VB 0
pain NN 0
. . 0

During IN 0
the DT 0
study NN 0
, , 0
the DT 0
horses NNS 0
were VBD 0
monitored VBN 0
for IN 0
general JJ 0
health NN 0
, , 0
lameness NN 0
, , 0
and CC 0
swelling VBG 0
around IN 0
the DT 0
injection NN 0
area NN 0
. . 0

Radiographs NNP 0
were VBD 0
taken VBN 0
biweekly RB 0
to TO 0
evaluate VB 0
bony NN 0
fusion NN 0
. . 0

Horses NNS 0
were VBD 0
randomly RB 0
divided VBN 0
into IN 0
non-exercised JJ 0
and CC 0
exercised JJ 0
groups NNS 0
. . 0

Exercise NNP 0
consisted VBD 0
of IN 0
20 CD 0
minutes NNS 0
of IN 0
trotting VBG 0
on IN 0
a DT 0
treadmill NN 0
( ( 0
4 CD 0
m/s NN 0
) ) 0
, , 0
3 CD 0
days NNS 0
per IN 0
week NN 0
for IN 0
13 CD 0
weeks NNS 0
. . 0

The DT 0
horses NNS 0
were VBD 0
euthanized VBN 0
at IN 0
24 CD 0
weeks NNS 0
. . 0

Slab NNP 0
sections NNS 0
of IN 0
the DT 0
PIJ NNP 0
were VBD 0
evaluated VBN 0
grossly RB 0
and CC 0
radiographically RB 0
for IN 0
bony NN 0
fusion NN 0
. . 0

Histologic JJ 0
examinations NNS 0
were VBD 0
performed VBN 0
to TO 0
evaluate VB 0
articular JJ 0
cartilage NN 0
. . 0

Three CD 0
horses NNS 0
were VBD 0
excluded VBN 0
from IN 0
the DT 0
study NN 0
after IN 0
developing VBG 0
soft JJ 0
tissue NN 0
necrosis NN 0
around IN 0
the DT 0
injection NN 0
site NN 0
, , 0
septic JJ 0
arthritis NN 0
, , 0
and CC 0
necrotic JJ 0
tendinitis NN 0
. . 0

The DT 0
remaining VBG 0
horses NNS 0
remained VBD 0
healthy JJ 0
, , 0
developed VBD 0
a DT 0
grade NN 0
1 CD 0
to TO 0
4 CD 0
lameness NN 0
with IN 0
minimal JJ 0
to TO 0
severe VB 0
swelling VBG 0
in IN 0
the DT 0
PIJ NNP 0
region NN 0
. . 0

All DT 0
5 CD 0
horses NNS 0
showed VBD 0
radiographic JJ 0
evidence NN 0
of IN 0
bony NN 0
fusion NN 0
, , 0
however RB 0
, , 0
no DT 0
fusion NN 0
was VBD 0
present JJ 0
when WRB 0
injected JJ 0
joints NNS 0
were VBD 0
examined VBN 0
on IN 0
postmortem NN 0
examination NN 0
. . 0

Histologic NNP 0
examination NN 0
revealed VBD 0
thinning NN 0
of IN 0
the DT 0
cartilage NN 0
, , 0
diffuse VBP 0
necrosis NN 0
of IN 0
chondrocytes NNS 0
, , 0
with IN 0
the DT 0
calcified JJ 0
zone NN 0
intact JJ 0
. . 0

Subjectively RB 0
, , 0
exercise NN 0
did VBD 0
not RB 0
influence VB 0
the DT 0
degree NN 0
of IN 0
cartilage NN 0
destruction NN 0
. . 0

Based VBN 0
on IN 0
this DT 0
study NN 0
, , 0
chemical JJ 0
arthrodesis NN 0
can MD 0
not RB 0
be VB 0
advocated VBN 0
in IN 0
clinical JJ 0
cases NNS 0
because IN 0
of IN 0
the DT 0
high JJ 0
complication NN 0
rate NN 0
and CC 0
lack NN 0
of IN 0
bony NN 0
fusion NN 0
. . 0

Comparison NNP 0
of IN 0
intravenous JJ 0
and CC 0
intra-arterial JJ 0
urokinase JJ 0
thrombolysis NN 0
for IN 0
acute JJ 4
ischaemic JJ 4
stroke NN 4
. . 0

Intravenous JJ 0
fibrinolysis NN 0
( ( 0
IVF NNP 0
) ) 0
with IN 0
rt-PA NN 0
( ( 0
alteplase NN 0
) ) 0
provides VBZ 0
significant JJ 0
benefits NNS 0
in IN 0
acute JJ 0
ischaemic JJ 0
stroke NN 0
when WRB 0
it PRP 0
is VBZ 0
given VBN 0
within IN 0
the DT 0
first JJ 0
three CD 0
hours NNS 0
following VBG 0
stroke NN 0
onset VBN 0
. . 0

Intra-arterial JJ 0
fibrinolysis NN 0
( ( 0
IAF NNP 0
) ) 0
with IN 0
pro-urokinase NN 0
in IN 0
PROACT NNP 0
II NNP 0
study NN 0
provides VBZ 0
quite RB 0
the DT 0
same JJ 0
benefit NN 0
in IN 0
the DT 0
first JJ 0
6 CD 0
hours NNS 0
. . 0

IVF NNP 0
and CC 0
IAF NNP 0
have VBP 0
never RB 0
been VBN 0
compared VBN 0
. . 0

To TO 0
compare VB 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
IVF NNP 0
and CC 0
IAF NNP 0
with IN 0
urokinase JJ 0
given VBN 0
within IN 0
the DT 0
first JJ 0
6 CD 0
hours NNS 0
of IN 0
acute JJ 4
ischaemic JJ 4
stroke NN 4
. . 0

Patients NNS 0
fulfilling VBG 0
the DT 0
selection NN 0
criteria NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
urokinase JJ 0
900,000 CD 0
units NNS 0
via IN 0
intravenous JJ 0
or CC 0
intra-arterial JJ 0
routes NNS 0
. . 0

This DT 0
randomised VBD 0
monocentre NN 0
study NN 0
was VBD 0
done VBN 0
between IN 0
December NNP 0
1995 CD 0
and CC 0
August NNP 0
1997 CD 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
was VBD 0
defined VBN 0
as IN 0
the DT 0
number NN 0
of IN 0
patients NNS 0
with IN 0
a DT 0
modified JJ 0
Rankin NNP 0
score NN 0
of IN 0
2 CD 0
or CC 0
less JJR 0
. . 0

Secondary JJ 0
outcomes NNS 0
included VBD 0
mortality NN 0
, , 0
frequency NN 0
of IN 0
symptomatic JJ 0
intracranial JJ 0
haemorrhage NN 0
( ( 0
SIH NNP 0
) ) 0
, , 0
neurological JJ 0
and CC 0
functional JJ 0
scores NNS 0
. . 0

Fourteen CD 3
patients NNS 0
were VBD 0
given VBN 0
IVF NNP 0
and CC 0
13 CD 3
IAF NNP 0
. . 0

The DT 0
study NN 0
was VBD 0
terminated VBN 0
by IN 0
the DT 0
National NNP 0
Health NNP 0
Authorities NNP 0
when WRB 0
27 CD 3
patients NNS 0
had VBD 0
been VBN 0
included VBN 0
because IN 0
of IN 0
the DT 0
mortality NN 0
rate NN 0
. . 0

Seven CD 0
patients NNS 0
( ( 0
26 CD 0
% NN 0
) ) 0
died VBD 0
, , 0
4 CD 0
in IN 0
the DT 0
IV NNP 0
group NN 0
( ( 0
oedematous JJ 0
infarct NN 0
in IN 0
3 CD 0
and CC 0
recurrence NN 0
in IN 0
1 CD 0
) ) 0
, , 0
3 CD 0
in IN 0
the DT 0
IA NNP 0
group NN 0
( ( 0
SIH NNP 0
in IN 0
2 CD 0
, , 0
and CC 0
oedematous JJ 0
infarct NN 0
in IN 0
1 CD 0
) ) 0
. . 0

Patients NNS 0
given VBN 0
IVF NNP 0
were VBD 0
treated VBN 0
significantly RB 0
earlier RBR 0
( ( 0
4:16 CD 0
h NN 0
vs NN 0
5:24 CD 0
h NN 0
; : 0
p=.007 NN 0
) ) 0
. . 0

Although IN 0
IA NNP 0
patients NNS 0
showed VBD 0
greater JJR 0
and CC 0
earlier RBR 0
improvement NN 0
there EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
in IN 0
primary JJ 0
and CC 0
secondary JJ 0
outcomes NNS 0
. . 0

Because IN 0
of IN 0
premature NN 0
termination NN 0
, , 0
the DT 0
trial NN 0
was VBD 0
too RB 0
small JJ 0
to TO 0
provide VB 0
any DT 0
reliable JJ 0
and CC 0
conclusive JJ 0
results NNS 0
. . 0

Intra-arterial JJ 0
fibrinolysis NN 0
began VBD 0
significantly RB 0
later RBR 0
than IN 0
IV NNP 0
fibrinolysis NN 0
but CC 0
it PRP 0
gave VBD 0
non-significantly RB 0
better JJ 0
results NNS 0
in IN 0
this DT 0
prematurely RB 0
terminated VBN 0
study NN 0
. . 0

B-domain NNP 0
deleted VBD 0
recombinant JJ 0
factor NN 0
VIII NNP 0
preparations NNS 0
are VBP 0
bioequivalent JJ 0
to TO 0
a DT 0
monoclonal JJ 0
antibody NN 0
purified VBD 0
plasma-derived JJ 0
factor NN 0
VIII NNP 0
concentrate NN 0
: : 0
a DT 0
randomized JJ 0
, , 0
three-way JJ 0
crossover NN 0
study NN 0
. . 0

BACKGROUND NNP 0
Deletion NNP 0
of IN 0
the DT 0
B-domain NNP 0
of IN 0
recombinant JJ 0
blood NN 0
coagulation NN 0
factor NN 0
VIII NNP 0
( ( 0
BDDrFVIII NNP 0
) ) 0
increases VBZ 0
the DT 0
manufacturing VBG 0
yield NN 0
of IN 0
the DT 0
product NN 0
but CC 0
does VBZ 0
not RB 0
impair VB 0
in IN 0
vitro NN 0
or CC 0
in IN 0
vivo JJ 0
functionality NN 0
. . 0

BDDrFVIII NNP 0
( ( 0
ReFacto NNP 0
) ) 0
has VBZ 0
been VBN 0
developed VBN 0
with IN 0
the DT 0
additional JJ 0
benefit NN 0
of IN 0
being VBG 0
formulated VBN 0
without IN 0
human JJ 0
albumin NN 0
. . 0

OBJECTIVE CC 0
The DT 0
primary JJ 0
objective NN 0
of IN 0
this DT 0
three-way JJ 0
crossover-design NN 0
study NN 0
was VBD 0
to TO 0
compare VB 0
the DT 0
pharmacokinetic JJ 0
( ( 0
PK NNP 0
) ) 0
parameters NNS 0
of IN 0
two CD 0
BDDrFVIII NNP 0
formulations NNS 0
( ( 0
one CD 0
reconstituted VBN 0
with IN 0
5 CD 0
mL NNS 0
of IN 0
sterile JJ 0
water NN 0
, , 0
the DT 0
other JJ 0
reconstituted VBD 0
with IN 0
4 CD 0
mL NNS 0
sodium JJ 0
chloride RB 0
0.9 CD 0
% NN 0
USP NNP 0
) ) 0
with IN 0
those DT 0
of IN 0
a DT 0
plasma-derived JJ 0
, , 0
full-length JJ 0
FVIII NNP 0
preparation NN 0
( ( 0
Hemofil NNP 0
M NNP 0
) ) 0
in IN 0
patients NNS 0
with IN 0
haemophilia PDT 4
A DT 4
to TO 0
determine VB 0
bioequivalence NN 0
. . 0

METHODS VB 0
A NNP 0
series NN 0
of IN 0
blood NN 0
samples NNS 0
were VBD 0
collected VBN 0
over IN 0
a DT 0
period NN 0
of IN 0
48 CD 0
h NN 0
after IN 0
i.v NN 0
. . 0

administration NN 0
of IN 0
each DT 0
of IN 0
the DT 0
FVIII NNP 0
preparations NNS 0
. . 0

Plasma NNP 0
FVIII NNP 0
activity NN 0
was VBD 0
determined VBN 0
using VBG 0
a DT 0
validated JJ 0
chromogenic JJ 0
substrate NN 0
assay NN 0
. . 0

Plasma NNP 0
FVIII NNP 0
activity NN 0
vs. FW 0
time NN 0
curves NNS 0
was VBD 0
characterized VBN 0
for IN 0
a DT 0
standard JJ 0
set NN 0
of IN 0
PK NNP 0
parameter NN 0
estimates NNS 0
. . 0

Two CD 0
parameter NN 0
estimates NNS 0
, , 0
the DT 0
maximum JJ 0
plasma JJ 0
concentration NN 0
( ( 0
Cmax NNP 0
) ) 0
and CC 0
the DT 0
area NN 0
under IN 0
plasma JJ 0
concentration NN 0
vs. FW 0
time NN 0
curves NNS 0
( ( 0
AUCs NNP 0
) ) 0
, , 0
were VBD 0
used VBN 0
to TO 0
evaluate VB 0
bioequivalence NN 0
. . 0

The DT 0
two CD 0
preparations NNS 0
were VBD 0
considered VBN 0
bioequivalent NN 0
if IN 0
the DT 0
90 CD 0
% NN 0
confidence NN 0
intervals NNS 0
for IN 0
the DT 0
ratio NN 0
of IN 0
geometric JJ 0
means NNS 0
for IN 0
Cmax NNP 0
and CC 0
AUCs NNP 0
fell VBD 0
within IN 0
the DT 0
bioequivalence NN 0
window NN 0
of IN 0
80 CD 0
% NN 0
to TO 0
125 CD 0
% NN 0
. . 0

RESULTS/CONCLUSION NNP 0
Results NNP 0
show VBP 0
that IN 0
each DT 0
BDDrFVIII NNP 0
formulation NN 0
is VBZ 0
bioequivalent JJ 0
to TO 0
Hemofil NNP 0
M NNP 0
and CC 0
the DT 0
two CD 0
formulations NNS 0
of IN 0
BDDrFVIII NNP 0
are VBP 0
bioequivalent JJ 0
to TO 0
each DT 0
other JJ 0
. . 0

Gefitinib NNP 0
plus CC 0
best JJS 0
supportive JJ 0
care NN 0
in IN 0
previously RB 0
treated VBN 0
patients NNS 0
with IN 0
refractory JJ 4
advanced JJ 4
non-small-cell JJ 4
lung NN 4
cancer NN 4
: : 0
results NNS 0
from IN 0
a DT 0
randomised VBN 0
, , 0
placebo-controlled JJ 0
, , 0
multicentre JJ 0
study NN 0
( ( 0
Iressa NNP 0
Survival NNP 0
Evaluation NNP 0
in IN 0
Lung NNP 0
Cancer NNP 0
) ) 0
. . 0

BACKGROUND VB 0
This DT 0
placebo-controlled JJ 0
phase NN 0
III NNP 0
study NN 0
investigated VBD 0
the DT 0
effect NN 0
on IN 0
survival NN 0
of IN 0
gefitinib NN 0
as IN 0
second-line JJ 0
or CC 0
third-line JJ 0
treatment NN 0
for IN 0
patients NNS 0
with IN 0
locally RB 4
advanced JJ 4
or CC 4
metastatic JJ 4
non-small-cell JJ 4
lung NN 4
cancer NN 4
. . 0

METHODS NNP 0
1692 CD 3
patients NNS 0
who WP 0
were VBD 0
refractory JJ 4
to TO 4
or CC 4
intolerant VB 4
of IN 0
their PRP$ 0
latest JJS 4
chemotherapy NN 4
regimen NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
in IN 0
a DT 0
ratio NN 0
of IN 0
two CD 0
to TO 0
one CD 0
either DT 0
gefitinib NN 0
( ( 0
250 CD 0
mg/day NN 0
) ) 0
or CC 0
placebo NN 0
, , 0
plus CC 0
best JJS 0
supportive JJ 0
care NN 0
. . 0

The DT 0
primary JJ 0
endpoint NN 0
was VBD 0
survival VBN 0
in IN 0
the DT 0
overall JJ 0
population NN 0
of IN 0
patients NNS 0
and CC 0
those DT 0
with IN 0
adenocarcinoma NN 0
. . 0

The DT 0
primary JJ 0
analysis NN 0
of IN 0
the DT 0
population NN 0
for IN 0
survival NN 0
was VBD 0
by IN 0
intention NN 0
to TO 0
treat VB 0
. . 0

This DT 0
study NN 0
has VBZ 0
been VBN 0
submitted VBN 0
for IN 0
registration NN 0
with IN 0
ClinicalTrials.gov NNP 0
, , 0
number NN 0
1839IL/709 CD 0
. . 0

FINDINGS JJ 0
1129 CD 3
patients NNS 0
were VBD 0
assigned VBN 0
gefitinib NNS 0
and CC 0
563 CD 3
placebo NN 0
. . 0

At IN 0
median JJ 0
follow-up NN 0
of IN 0
7.2 CD 0
months NNS 0
, , 0
median JJ 0
survival NN 0
did VBD 0
not RB 0
differ VB 0
significantly RB 0
between IN 0
the DT 0
groups NNS 0
in IN 0
the DT 0
overall JJ 0
population NN 0
( ( 0
5.6 CD 0
months NNS 0
for IN 0
gefitinib NN 0
and CC 0
5.1 CD 0
months NNS 0
for IN 0
placebo NN 0
; : 0
hazard CC 0
ratio VB 0
0.89 CD 0
[ JJ 0
95 CD 0
% NN 0
CI NNP 0
0.77-1.02 CD 0
] NNP 0
, , 0
p=0.087 NN 0
) ) 0
or CC 0
among IN 0
the DT 0
812 CD 3
patients NNS 0
with IN 0
adenocarcinoma NN 4
( ( 0
6.3 CD 0
months NNS 0
vs RB 0
5.4 CD 0
months NNS 0
; : 0
0.84 CD 0
[ IN 0
0.68-1.03 JJ 0
] NN 0
, , 0
p=0.089 NN 0
) ) 0
. . 0

Preplanned VBN 0
subgroup NN 0
analyses VBZ 0
showed VBN 0
significantly RB 0
longer RBR 0
survival NN 0
in IN 0
the DT 0
gefitinib NN 0
group NN 0
than IN 0
the DT 0
placebo NN 0
group NN 0
for IN 0
never-smokers NNS 0
( ( 0
n=375 NN 0
; : 0
0.67 CD 0
[ IN 0
0.49-0.92 JJ 0
] NN 0
, , 0
p=0.012 NN 0
; : 0
median JJ 0
survival NN 0
8.9 CD 0
vs NN 0
6.1 CD 0
months NNS 0
) ) 0
and CC 0
patients NNS 0
of IN 0
Asian JJ 0
origin NN 0
( ( 0
n=342 JJ 0
; : 0
0.66 CD 0
[ IN 0
0.48-0.91 JJ 0
] NN 0
, , 0
p=0.01 NN 0
; : 0
median JJ 0
survival NN 0
9.5 CD 0
vs NN 0
5.5 CD 0
months NNS 0
) ) 0
. . 0

Gefitinib NNP 0
was VBD 0
well RB 0
tolerated VBN 0
, , 0
as IN 0
in IN 0
previous JJ 0
studies NNS 0
. . 0

INTERPRETATION NNP 0
Treatment NNP 0
with IN 0
gefitinib NN 0
was VBD 0
not RB 0
associated VBN 0
with IN 0
significant JJ 0
improvement NN 0
in IN 0
survival NN 0
in IN 0
either DT 0
coprimary JJ 0
population NN 0
. . 0

There EX 0
was VBD 0
pronounced JJ 0
heterogeneity NN 0
in IN 0
survival JJ 0
outcomes NNS 0
between IN 0
groups NNS 0
of IN 0
patients NNS 0
, , 0
with IN 0
some DT 0
evidence NN 0
of IN 0
benefit NN 0
among IN 0
never-smokers NNS 0
and CC 0
patients NNS 0
of IN 0
Asian JJ 0
origin NN 0
. . 0

Clinically RB 0
relevant JJ 0
improvement NN 0
of IN 0
recurrence-free JJ 0
survival NN 0
with IN 0
5-aminolevulinic JJ 0
acid NN 0
induced VBD 0
fluorescence NN 0
diagnosis NN 0
in IN 0
patients NNS 0
with IN 0
superficial JJ 4
bladder NN 4
tumors NNS 4
. . 0

PURPOSES NNP 0
Fluorescence NNP 0
diagnosis NN 0
induced VBN 0
by IN 0
5-aminolevulinic JJ 0
acid NN 0
enables VBZ 0
more RBR 0
thorough JJ 0
transurethral JJ 0
resection NN 0
of IN 0
superficial JJ 4
bladder NN 4
carcinoma NNS 4
compared VBN 0
with IN 0
conventional JJ 0
white JJ 0
light NN 0
. . 0

We PRP 0
performed VBD 0
a DT 0
prospective JJ 0
, , 0
single JJ 0
institution NN 0
, , 0
randomized VBN 0
trial NN 0
to TO 0
investigate VB 0
whether IN 0
the DT 0
residual JJ 0
tumor NN 0
rate NN 0
and CC 0
long-term JJ 0
tumor NN 0
recurrence NN 0
can MD 0
be VB 0
decreased VBN 0
by IN 0
fluorescence NN 0
diagnosis NN 0
. . 0

MATERIALS NNP 0
AND NNP 0
METHODS NNP 0
A NNP 0
total NN 0
of IN 0
301 CD 3
patients NNS 0
underwent JJ 0
transurethral JJ 4
resection NN 4
of IN 0
bladder NN 4
tumors NNS 4
with IN 0
white JJ 0
light NN 0
or CC 0
fluorescence NN 0
diagnosis NN 0
. . 0

Transurethral JJ 0
resection NN 0
was VBD 0
repeated VBN 0
5 CD 0
to TO 0
6 CD 0
weeks NNS 0
later RB 0
to TO 0
evaluate VB 0
the DT 0
residual JJ 0
tumor NN 0
rate NN 0
. . 0

To TO 0
determine VB 0
recurrence-free JJ 0
survival JJ 0
patient NN 0
followup NN 0
was VBD 0
performed VBN 0
every DT 0
3 CD 0
months NNS 0
by IN 0
white JJ 0
light JJ 0
cystoscopy NN 0
and CC 0
urine JJ 0
cytology NN 0
. . 0

Recurrence-free JJ 0
survival NN 0
was VBD 0
analyzed VBN 0
via IN 0
Kaplan-Meier NNP 0
methods NNS 0
and CC 0
multivariable JJ 0
Cox NNP 0
regression NN 0
analysis NN 0
. . 0

RESULTS VB 0
A DT 0
total NN 0
of IN 0
191 CD 3
patients NNS 0
with IN 0
superficial JJ 4
bladder NN 4
carcinoma NN 4
were VBD 0
available JJ 0
for IN 0
efficacy NN 0
analysis NN 0
. . 0

The DT 0
residual JJ 0
tumor NN 0
rate NN 0
was VBD 0
25.2 CD 0
% NN 0
in IN 0
the DT 0
white JJ 0
light JJ 0
arm NN 0
versus NN 0
4.5 CD 0
% NN 0
in IN 0
the DT 0
fluorescence NN 0
diagnosis NN 0
arm NN 0
( ( 0
p JJ 0
< NNP 0
0.0001 CD 0
) ) 0
. . 0

Median JJ 0
followup NN 0
in IN 0
the DT 0
white JJ 0
light JJ 0
arm NN 0
in IN 0
103 CD 0
cases NNS 0
was VBD 0
21.2 CD 0
months NNS 0
( ( 0
range VB 0
4 CD 0
to TO 0
40 CD 0
) ) 0
compared VBN 0
with IN 0
20.5 CD 0
( ( 0
range NN 0
3 CD 0
to TO 0
40 CD 0
) ) 0
in IN 0
the DT 0
88 CD 0
in IN 0
the DT 0
fluorescence NN 0
diagnosis NN 0
arm NN 0
. . 0

Recurrence-free JJ 0
survival NN 0
in IN 0
the DT 0
fluorescence NN 0
diagnosis NN 0
group NN 0
was VBD 0
89.6 CD 0
% NN 0
after IN 0
12 CD 0
and CC 0
24 CD 0
months NNS 0
compared VBN 0
with IN 0
73.8 CD 0
% NN 0
and CC 0
65.9 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
in IN 0
the DT 0
white JJ 0
light NN 0
group NN 0
( ( 0
p JJ 0
= NNP 0
0.004 CD 0
) ) 0
. . 0

This DT 0
superiority NN 0
proved VBD 0
to TO 0
be VB 0
independent JJ 0
of IN 0
risk NN 0
group NN 0
. . 0

The DT 0
adjusted JJ 0
hazard NN 0
ratio NN 0
of IN 0
fluorescence NN 0
diagnosis NN 0
versus IN 0
white JJ 0
light JJ 0
transurethral JJ 0
resection NN 0
was VBD 0
0.33 CD 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
0.16 CD 0
to TO 0
0.67 CD 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Fluorescence NNP 0
diagnosis NN 0
is VBZ 0
significantly RB 0
superior JJ 0
to TO 0
conventional JJ 0
white JJ 0
light JJ 0
transurethral JJ 0
resection NN 0
with IN 0
respect NN 0
to TO 0
the DT 0
residual JJ 0
tumor NN 0
rate NN 0
and CC 0
recurrence-free JJ 0
survival NN 0
. . 0

The DT 0
differences NNS 0
in IN 0
recurrence-free JJ 0
survival NN 0
imply NN 0
that WDT 0
fluorescence NN 0
diagnosis NN 0
is VBZ 0
a DT 0
clinically RB 0
relevant JJ 0
procedure NN 0
for IN 0
decreasing VBG 0
the DT 0
number NN 0
of IN 0
tumor NN 0
recurrences NNS 0
. . 0

Effect NN 0
of IN 0
testosterone NN 0
and CC 0
a DT 0
nutritional JJ 0
supplement NN 0
, , 0
alone RB 0
and CC 0
in IN 0
combination NN 0
, , 0
on IN 0
hospital JJ 0
admissions NNS 0
in IN 0
undernourished JJ 4
older JJR 1
men NNS 2
and CC 2
women NNS 2
. . 0

BACKGROUND NNP 0
In IN 0
older JJR 1
people NNS 1
, , 0
undernutrition NN 0
is VBZ 0
associated VBN 0
with IN 0
increased JJ 0
hospitalization NN 0
rates NNS 0
and CC 0
mortality NN 0
. . 0

Because IN 0
weight JJ 0
loss NN 0
in IN 0
older JJR 0
people NNS 0
often RB 0
reflects VBZ 0
a DT 0
disproportionate JJ 0
reduction NN 0
of IN 0
skeletal JJ 0
muscle NN 0
, , 0
anabolic JJ 0
treatments NNS 0
may MD 0
be VB 0
beneficial JJ 0
. . 0

OBJECTIVE NNP 0
Our PRP$ 0
aim NN 0
was VBD 0
to TO 0
evaluate VB 0
the DT 0
hypothesis NN 0
that WDT 0
testosterone NN 0
treatment NN 0
and CC 0
a DT 0
nutritional JJ 0
supplement NN 0
have VBP 0
additive JJ 0
benefits NNS 0
. . 0

DESIGN NNP 0
Oral NNP 0
testosterone NN 0
undecanoate NN 0
( ( 0
40 CD 0
mg NNS 0
daily RB 0
for IN 0
women NNS 0
, , 0
80 CD 0
mg NN 0
twice RB 0
daily RB 0
for IN 0
men NNS 0
) ) 0
and CC 0
an DT 0
oral JJ 0
nutritional JJ 0
supplement NN 0
( ( 0
475 CD 0
kcal/d NN 0
) ) 0
were VBD 0
administered VBN 0
, , 0
alone RB 0
or CC 0
combined VBN 0
, , 0
for IN 0
1 CD 0
y NNS 0
to TO 0
49 CD 3
community-dwelling NN 0
, , 0
undernourished JJ 4
people NNS 0
[ VBP 0
Mini NNP 4
Nutritional NNP 4
Assessment NNP 4
score VBD 4
< JJ 4
24 CD 4
and CC 0
low JJ 4
body NN 4
weight NN 4
( ( 0
body JJ 4
mass NN 4
index NN 4
, , 4
in IN 4
kg/m NN 4
( ( 4
2 CD 4
) ) 4
: : 4
< $ 4
22 CD 4
) ) 0
or CC 0
recent JJ 4
weight JJ 4
loss NN 4
( ( 0
> JJ 0
7.5 CD 0
% NN 0
over IN 0
3 CD 0
mo NNS 0
) ) 0
] VBP 0
aged VBN 1
> $ 1
65 CD 1
y NN 0
( ( 0
mean JJ 0
age NN 0
: : 0
77 CD 1
y NN 0
; : 0
26 CD 3
women NNS 2
and CC 0
23 CD 3
men NNS 2
) ) 0
. . 0

Hospital JJ 0
admissions NNS 0
and CC 0
other JJ 0
variables NNS 0
were VBD 0
assessed VBN 0
. . 0

RESULTS NNP 0
In IN 0
subjects NNS 0
receiving VBG 0
combined VBN 0
testosterone NN 0
and CC 0
nutritional JJ 0
supplements NNS 0
( ( 0
n JJ 0
= NNP 0
11 CD 0
) ) 0
, , 0
there EX 0
were VBD 0
no DT 0
hospital NN 0
admissions NNS 0
, , 0
whereas IN 0
there EX 0
were VBD 0
9 CD 0
admissions NNS 0
( ( 0
2 CD 0
elective NN 0
) ) 0
in IN 0
13 CD 0
subjects NNS 0
in IN 0
the DT 0
no-treatment JJ 0
group NN 0
, , 0
4 CD 0
in IN 0
the DT 0
testosterone-treated JJ 0
group NN 0
( ( 0
n JJ 0
= NNP 0
12 CD 0
) ) 0
, , 0
and CC 0
5 CD 0
in IN 0
the DT 0
supplement-treated JJ 0
group NN 0
( ( 0
n JJ 0
= NNP 0
13 CD 0
) ) 0
; : 0
P NNP 0
= VBD 0
0.06 CD 0
with IN 0
no-treatment JJ 0
compared VBN 0
with IN 0
combined JJ 0
treatment NN 0
. . 0

When WRB 0
compared VBN 0
with IN 0
the DT 0
no-treatment JJ 0
group NN 0
, , 0
the DT 0
combined-treatment JJ 0
group NN 0
had VBD 0
significantly RB 0
fewer JJR 0
subjects NNS 0
admitted VBN 0
to TO 0
hospital VB 0
( ( 0
0 CD 0
compared VBN 0
with IN 0
5 CD 0
, , 0
P NNP 0
= NNP 0
0.03 CD 0
) ) 0
, , 0
fewer JJR 0
days NNS 0
in IN 0
hospital NN 0
( ( 0
0 CD 0
compared VBN 0
with IN 0
74 CD 0
, , 0
P NNP 0
= NNP 0
0.041 CD 0
) ) 0
, , 0
and CC 0
a DT 0
longer JJR 0
time NN 0
to TO 0
hospital VB 0
admission NN 0
( ( 0
P NNP 0
= NNP 0
0.017 CD 0
) ) 0
. . 0

CONCLUSIONS NNP 0
In IN 0
undernourished JJ 4
older JJR 1
people NNS 0
, , 0
combined VBN 0
treatment NN 0
with IN 0
testosterone NN 0
and CC 0
nutritional JJ 0
supplementation NN 0
reduced VBD 0
the DT 0
number NN 0
of IN 0
people NNS 0
hospitalized VBN 0
and CC 0
the DT 0
duration NN 0
of IN 0
hospital NN 0
admissions NNS 0
, , 0
which WDT 0
are VBP 0
important JJ 0
endpoints NNS 0
in IN 0
this DT 0
group NN 0
. . 0

Larger NNP 0
, , 0
confirmatory NN 0
studies NNS 0
are VBP 0
now RB 0
needed VBN 0
. . 0

This DT 0
trial NN 0
was VBD 0
registered VBN 0
before IN 0
commencement NN 0
at IN 0
clinical JJ 0
trials.gov NN 0
as IN 0
NCT00117000 NNP 0
. . 0

Immunogenicity NN 0
and CC 0
safety NN 0
of IN 0
a DT 0
plasma-derived JJ 0
heat-inactivated JJ 0
hepatitis NN 0
B NNP 0
vaccine NN 0
( ( 0
CLB NNP 0
) ) 0
. . 0

Studies NNPS 0
in IN 0
volunteers NNS 0
at IN 0
a DT 0
low JJ 4
risk NN 4
of IN 0
infection NN 0
with IN 0
hepatitis NN 4
B NNP 4
virus NN 4
. . 0

The DT 0
safety NN 0
and CC 0
immunogenicity NN 0
of IN 0
a DT 0
plasma-derived JJ 0
heat-inactivated JJ 0
hepatitis NN 0
B NNP 0
vaccine NN 0
( ( 0
CLB NNP 0
) ) 0
were VBD 0
evaluated VBN 0
in IN 0
471 CD 3
healthy JJ 4
human JJ 0
volunteers NNS 0
, , 0
who WP 0
, , 0
both DT 0
in IN 0
their PRP$ 0
occupations NNS 0
and CC 0
in IN 0
their PRP$ 0
private JJ 0
lives NNS 0
, , 0
had VBD 0
been VBN 0
at IN 0
minimal JJ 4
risk NN 4
of IN 0
being VBG 0
infected VBN 0
with IN 0
hepatitis NN 4
B NNP 4
virus NN 4
. . 0

The DT 0
first JJ 0
202 JJ 0
individuals NNS 0
received VBD 0
three CD 0
3-micrograms JJ 0
doses NNS 0
of IN 0
heat-inactivated JJ 0
hepatitis NN 0
B NNP 0
surface NN 0
antigen NN 0
( ( 0
HBsAg NNP 0
) ) 0
at IN 0
one-month JJ 0
intervals NNS 0
( ( 0
trial NN 0
A DT 0
) ) 0
. . 0

A DT 0
total NN 0
of IN 0
42 CD 0
% NN 0
one CD 0
month NN 0
after IN 0
the DT 0
first JJ 0
injection NN 0
, , 0
84 CD 0
% NN 0
after IN 0
two CD 0
months NNS 0
, , 0
and CC 0
93 CD 0
% NN 0
after IN 0
five CD 0
months NNS 0
had VBD 0
become VBN 0
anti-HBs JJ 0
( ( 0
antibody NN 0
to TO 0
hepatitis VB 0
B NNP 0
surface NN 0
antigen NN 0
) ) 0
positive JJ 0
. . 0

In IN 0
a DT 0
second JJ 0
randomized VBN 0
study NN 0
( ( 0
trial NN 0
B NNP 0
) ) 0
, , 0
the DT 0
immunogenicity NN 0
of IN 0
five CD 0
different JJ 0
dosages NNS 0
of IN 0
the DT 0
vaccine NN 0
was VBD 0
compared VBN 0
in IN 0
269 CD 0
volunteers NNS 0
. . 0

When WRB 0
the DT 0
dose NN 0
of IN 0
HBsAg NNP 0
was VBD 0
diminished VBN 0
from IN 0
3 CD 0
micrograms NNS 0
to TO 0
1.5 CD 0
, , 0
0.6 CD 0
, , 0
and CC 0
0.25 CD 0
microgram NN 0
, , 0
no DT 0
decrease NN 0
of IN 0
the DT 0
anti-HBs JJ 0
response NN 0
was VBD 0
observed VBN 0
. . 0

However RB 0
, , 0
when WRB 0
the DT 0
dose NN 0
was VBD 0
diminished VBN 0
to TO 0
0.1 CD 0
microgram NN 0
of IN 0
HBsAg NNP 0
, , 0
the DT 0
anti-HBs JJ 0
response NN 0
dropped VBD 0
significantly RB 0
to TO 0
63 CD 0
% NN 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
. . 0

In IN 0
the DT 0
recipients NNS 0
of IN 0
all DT 0
five CD 0
vaccine NN 0
dosages NNS 0
, , 0
no DT 0
influence NN 0
of IN 0
sex NN 0
and CC 0
age NN 0
was VBD 0
found VBN 0
on IN 0
the DT 0
anti-HBs JJ 0
conversion NN 0
rates NNS 0
. . 0

During IN 0
the DT 0
eight-month JJ 0
observation NN 0
period NN 0
, , 0
none NN 0
of IN 0
the DT 0
vaccinees NNS 0
became VBD 0
HBsAg NNP 0
and/or IN 0
anti-HBc JJ 0
( ( 0
antibody NN 0
to TO 0
hepatitis VB 0
B NNP 0
core NN 0
antigen NN 0
) ) 0
positive JJ 0
, , 0
and CC 0
none NN 0
developed VBD 0
antibodies NNS 0
associated VBN 0
with IN 0
autoimmune JJ 0
liver NN 0
disease NN 0
. . 0

No DT 0
serious JJ 0
side NN 0
effects NNS 0
were VBD 0
observed VBN 0
. . 0

Transcutaneous JJ 0
electrical JJ 0
nerve NN 0
stimulation NN 0
following VBG 0
appendicectomy NN 4
: : 0
the DT 0
placebo NN 0
effect NN 0
. . 0

A DT 0
controlled JJ 0
trial NN 0
was VBD 0
undertaken VBN 0
to TO 0
compare VB 0
the DT 0
efficacy NN 0
of IN 0
transcutaneous JJ 0
electrical JJ 0
nerve NN 0
stimulation NN 0
( ( 0
TENS NNP 0
) ) 0
with IN 0
standard JJ 0
intramuscular JJ 0
opiate NN 0
analgesia NN 0
in IN 0
the DT 0
management NN 0
of IN 0
postoperative JJ 0
pain NN 0
following VBG 0
appendicectomy NN 4
. . 0

Consecutive JJ 0
patients NNS 0
undergoing VBG 0
emergency NN 0
appendicectomy NN 4
were VBD 0
randomised VBN 0
into IN 0
control NN 0
, , 0
sham NN 0
TENS NNP 0
and CC 0
active JJ 0
TENS NNP 0
groups NNS 0
. . 0

There EX 0
was VBD 0
a DT 0
significant JJ 0
decrease NN 0
in IN 0
pain NN 0
severity NN 0
and CC 0
analgesic JJ 0
intake NN 0
in IN 0
both DT 0
active JJ 0
and CC 0
sham JJ 0
TENS NNP 0
groups NNS 0
when WRB 0
compared VBN 0
with IN 0
the DT 0
control NN 0
group NN 0
( ( 0
P NNP 0
less JJR 0
than IN 0
0.01 CD 0
) ) 0
. . 0

No DT 0
difference NN 0
was VBD 0
demonstrated VBN 0
in IN 0
pain NN 0
severity NN 0
between IN 0
active JJ 0
and CC 0
sham JJ 0
TENS NNP 0
groups NNS 0
but CC 0
the DT 0
active JJ 0
TENS NNP 0
group NN 0
required VBD 0
slightly RB 0
less JJR 0
analgesia NN 0
. . 0

These DT 0
results NNS 0
suggest VBP 0
that IN 0
the DT 0
major JJ 0
benefit NN 0
of IN 0
TENS NNP 0
in IN 0
the DT 0
postappendicectomy NN 4
patient NN 0
is VBZ 0
due JJ 0
to TO 0
its PRP$ 0
'placebo JJ 0
effect NN 0
' POS 0
and CC 0
its PRP$ 0
use NN 0
in IN 0
this DT 0
situation NN 0
can MD 0
not RB 0
be VB 0
recommended VBN 0
. . 0

Is VBZ 0
chronic JJ 0
sildenafil NN 0
therapy NN 0
safe JJ 0
and CC 0
clinically RB 0
beneficial JJ 0
in IN 0
patients NNS 0
with IN 0
systolic JJ 4
heart NN 4
failure NN 4
? . 0
Sildenafil NNP 0
is VBZ 0
a DT 0
selective JJ 0
phosphodiesterase-5 JJ 0
inhibitor NN 0
and CC 0
causes VBZ 0
vasodilatation NN 0
, , 0
particularly RB 0
in IN 0
pulmonary JJ 0
circulation NN 0
. . 0

Since IN 0
left JJ 4
heart NN 4
failure NN 4
may MD 0
be VB 0
associated VBN 0
with IN 0
pulmonary JJ 0
hypertension NN 0
out IN 0
of IN 0
proportion NN 0
to TO 0
left VB 0
heart NN 0
disease NN 0
, , 0
sildenafil NN 0
may MD 0
have VB 0
beneficial JJ 0
effect NN 0
in IN 0
such JJ 0
patients NNS 0
. . 0

The DT 0
present JJ 0
investigation NN 0
was VBD 0
designed VBN 0
as IN 0
a DT 0
12-week JJ 0
, , 0
single-center JJ 0
, , 0
randomized VBN 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
study NN 0
evaluating VBG 0
the DT 0
effects NNS 0
of IN 0
sildenafil NN 0
on IN 0
mean JJ 0
blood NN 0
pressure NN 0
( ( 0
primary JJ 0
endpoint NN 0
) ) 0
in IN 0
patients NNS 0
with IN 0
left JJ 4
systolic JJ 4
heart NN 4
failure NN 4
. . 0

Secondary JJ 0
endpoints NNS 0
included VBD 0
exercise NN 0
capacity NN 0
assessed VBN 0
by IN 0
6-minute JJ 0
walk NN 0
test NN 0
. . 0

A DT 0
total NN 0
of IN 0
106 CD 3
patients NNS 0
were VBD 0
randomized VBN 0
1:1 CD 0
to TO 0
sildenafil VB 0
( ( 0
n=53 NN 3
) ) 0
or CC 0
placebo NN 0
( ( 0
n=53 JJ 3
) ) 0
. . 0

Patients NNS 0
received VBD 0
sildenafil JJ 0
25 CD 0
mg NN 0
twice RB 0
a DT 0
day NN 0
or CC 0
matching VBG 0
placebo NN 0
for IN 0
the DT 0
first JJ 0
2 CD 0
weeks NNS 0
and CC 0
50 CD 0
mg NN 0
3 CD 0
times NNS 0
a DT 0
week NN 0
for IN 0
the DT 0
remainder NN 0
of IN 0
the DT 0
trial NN 0
. . 0

The DT 0
placebo-corrected JJ 0
effect NN 0
on IN 0
mean JJ 0
blood NN 0
pressure NN 0
was VBD 0
1.16 CD 0
mm NN 0
Hg NNP 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
, , 0
-1.6 VBP 0
to TO 0
5.1 CD 0
, , 0
P NNP 0
> NNP 0
.05 NNP 0
) ) 0
, , 0
demonstrating VBG 0
that IN 0
sildenafil NN 0
did VBD 0
not RB 0
decrease VB 0
mean JJ 0
blood NN 0
pressure NN 0
. . 0

Compared VBN 0
with IN 0
placebo NN 0
, , 0
sildenafil NN 0
increased VBD 0
the DT 0
6-minute JJ 0
walk NN 0
test NN 0
by IN 0
a DT 0
nonsignificant JJ 0
treatment NN 0
effect NN 0
of IN 0
14 CD 0
m NN 0
( ( 0
P=.67 NNP 0
) ) 0
. . 0

Adverse JJ 0
effects NNS 0
occurred VBD 0
in IN 0
a DT 0
comparable JJ 0
proportion NN 0
of IN 0
patients NNS 0
taking VBG 0
sildenafil JJ 0
and CC 0
placebo NN 0
, , 0
and CC 0
none NN 0
of IN 0
the DT 0
patients NNS 0
needed VBN 0
to TO 0
discontinue VB 0
therapy NN 0
. . 0

Sildenafil NNP 0
is VBZ 0
well RB 0
tolerated VBN 0
in IN 0
left JJ 0
heart NN 0
failure NN 0
patients NNS 0
and CC 0
does VBZ 0
not RB 0
decrease VB 0
blood NN 0
pressure NN 0
. . 0

It PRP 0
can MD 0
be VB 0
safely RB 0
added VBN 0
to TO 0
standard VB 0
heart NN 0
failure NN 0
therapy NN 0
. . 0

Differential JJ 0
effects NNS 0
of IN 0
amino NN 0
acid NN 0
and CC 0
ketoacid VB 0
on IN 0
protein NN 0
metabolism NN 0
in IN 0
humans NNS 0
. . 0

We PRP 0
examined VBD 0
the DT 0
effects NNS 0
of IN 0
insulin NN 0
, , 0
amino JJ 0
acid NN 0
( ( 0
AA NNP 0
) ) 0
, , 0
and CC 0
branched-chain JJ 0
ketoacid NN 0
( ( 0
KA NNP 0
) ) 0
availability NN 0
on IN 0
leucine JJ 0
kinetics NNS 0
in IN 0
eight CD 3
healthy JJ 4
volunteers NNS 0
( ( 0
age NN 0
= VBZ 0
22 CD 1
+/- JJ 1
2 CD 1
y NN 0
, , 0
body NN 0
mass NN 0
index NN 0
= VBD 0
24 CD 4
+/- JJ 4
1 CD 4
kg NN 4
) ) 0
by IN 0
using VBG 0
the DT 0
euglycemic JJ 0
insulin NN 0
clamp NN 0
and CC 0
[ JJ 0
1-14C JJ 0
] NNP 0
leucine NN 0
turnover NN 0
techniques NNS 0
. . 0

Four CD 0
experimental JJ 0
conditions NNS 0
were VBD 0
studied VBN 0
: : 0
study NN 0
I PRP 0
, , 0
hyperinsulinemia NN 0
; : 0
study NN 0
II NNP 0
, , 0
hyperinsulinemia NN 0
with IN 0
maintenance NN 0
of IN 0
basal NN 0
plasma NN 0
AA NNP 0
and CC 0
branched-chain JJ 0
KA NNP 0
concentrations NNS 0
; : 0
study NN 0
III NNP 0
, , 0
hyperinsulinemia NN 0
with IN 0
hyperaminoacidemia NN 0
and CC 0
basal NN 0
plasma VBP 0
branched-chain NN 0
KA NNP 0
concentrations NNS 0
; : 0
and CC 0
study VB 0
IV NNP 0
, , 0
hyperinsulinemia NN 0
plus CC 0
basal NN 0
plasma VBP 0
AA NNP 0
concentrations NNS 0
and CC 0
elevated VBD 0
branched-chain NN 0
KA NNP 0
levels NNS 0
. . 0

Basal NNP 0
endogenous JJ 0
leucine NN 0
flux NN 0
( ( 0
ELF NNP 0
) ) 0
averaged VBD 0
1.20 CD 0
+/- JJ 0
0.05 CD 0
( ( 0
mumol.kg-1.min-1 NN 0
, , 0
mean JJ 0
+/- JJ 0
SE NNP 0
) ) 0
; : 0
basal CC 0
leucine JJ 0
oxidation NN 0
( ( 0
LOX NNP 0
) ) 0
was VBD 0
0.25 CD 0
+/- JJ 0
0.01 CD 0
; : 0
and CC 0
basal VB 0
non-oxidative JJ 0
leucine NN 0
disposal NN 0
( ( 0
NOLD NNP 0
) ) 0
was VBD 0
0.95 CD 0
+/- JJ 0
0.04 CD 0
. . 0

ELF NNP 0
significantly RB 0
decreased VBD 0
in IN 0
study NN 0
I PRP 0
( ( 0
0.77 CD 0
+/- JJ 0
0.06 CD 0
mumol.kg-1.min-1 NN 0
, , 0
P NNP 0
< VBZ 0
0.01 CD 0
versus NN 0
basal NN 0
) ) 0
. . 0

When WRB 0
plasma NN 0
AA NNP 0
and CC 0
branched-chain JJ 0
KA NNP 0
were VBD 0
either RB 0
maintained VBN 0
at IN 0
their PRP$ 0
basal NN 0
levels NNS 0
( ( 0
study VB 0
II NNP 0
) ) 0
or CC 0
increased VBN 0
above IN 0
baseline NN 0
values NNS 0
( ( 0
studies NNS 0
III NNP 0
and CC 0
IV NNP 0
) ) 0
, , 0
ELF NNP 0
declined VBD 0
further RBR 0
( ( 0
0.64 CD 0
+/- JJ 0
0.05 CD 0
, , 0
0.66 CD 0
+/- JJ 0
0.02 CD 0
, , 0
and CC 0
0.66 CD 0
+/- JJ 0
0.03 CD 0
mumol.kg-1.min-1 NN 0
, , 0
respectively RB 0
; : 0
all DT 0
Ps NNP 0
< NNP 0
0.01 CD 0
versus NN 0
basal NN 0
and CC 0
P NNP 0
< NNP 0
0.01 CD 0
versus NN 0
study NN 0
I PRP 0
) ) 0
. . 0

LOX NNP 0
declined VBD 0
in IN 0
study NN 0
I PRP 0
( ( 0
0.12 CD 0
+/- JJ 0
0.02 CD 0
mumol.kg-1.min-1 NN 0
, , 0
P NNP 0
< VBZ 0
0.01 CD 0
versus NN 0
basal NN 0
) ) 0
but CC 0
increased VBD 0
significantly RB 0
in IN 0
studies NNS 0
II NNP 0
, , 0
III NNP 0
, , 0
and CC 0
IV NNP 0
( ( 0
0.31 CD 0
+/- JJ 0
0.04 CD 0
, , 0
0.37 CD 0
+/- JJ 0
0.03 CD 0
, , 0
and CC 0
0.40 CD 0
+/- JJ 0
0.03 CD 0
mumol.kg-1.min-1 NN 0
, , 0
respectively RB 0
, , 0
all DT 0
Ps NNP 0
< NNP 0
0.01 CD 0
versus NN 0
basal NN 0
, , 0
P NNP 0
< NNP 0
0.05 CD 0
study NN 0
IV NNP 0
versus NN 0
study NN 0
II NNP 0
, , 0
and CC 0
P NNP 0
< NNP 0
0.05 CD 0
study NN 0
III NNP 0
versus NN 0
study NN 0
II NNP 0
) ) 0
. . 0

NOLD NNP 0
declined VBD 0
in IN 0
study NN 0
I PRP 0
( ( 0
0.65 CD 0
+/- JJ 0
0.05 CD 0
mumol/kg.min NN 0
, , 0
P NNP 0
< VBZ 0
0.01 CD 0
versus NN 0
basal NN 0
) ) 0
, , 0
whereas IN 0
neither CC 0
the DT 0
maintenance NN 0
of IN 0
basal NN 0
plasma IN 0
AA/branched-chain NNP 0
KA NNP 0
levels NNS 0
( ( 0
study NN 0
II NNP 0
; : 0
0.89 CD 0
+/- JJ 0
0.2 CD 0
mumol.kg-1.min-1 NN 0
) ) 0
nor CC 0
the DT 0
elevation NN 0
of IN 0
plasma JJ 0
branched-chain JJ 0
KA NNP 0
concentration NN 0
( ( 0
study JJ 0
IV NNP 0
; : 0
0.96 CD 0
+/- JJ 0
0.1 CD 0
mumol.kg-1.min-1 NN 0
) ) 0
increased VBD 0
NOLD NNP 0
above IN 0
baseline NN 0
level NN 0
. . 0

A DT 0
stimulation NN 0
of IN 0
NOLD NNP 0
was VBD 0
observed VBN 0
only RB 0
when WRB 0
plasma JJ 0
AA NNP 0
levels NNS 0
were VBD 0
increased VBN 0
( ( 0
study NN 0
III NNP 0
; : 0
1.23 CD 0
+/- JJ 0
0.03 CD 0
mumol/kg.min NN 0
, , 0
P NNP 0
< VBZ 0
0.01 CD 0
versus NN 0
basal NN 0
) ) 0
. . 0

In IN 0
conclusion NN 0
, , 0
the DT 0
present JJ 0
data NNS 0
do VBP 0
not RB 0
support VB 0
the DT 0
concept NN 0
of IN 0
a DT 0
direct JJ 0
anabolic JJ 0
action NN 0
of IN 0
ketoanalogs NNS 0
but CC 0
do VBP 0
provide VB 0
additional JJ 0
evidence NN 0
for IN 0
the DT 0
pivotal JJ 0
role NN 0
of IN 0
AA NNP 0
availability NN 0
in IN 0
the DT 0
stimulation NN 0
of IN 0
whole-body NN 0
protein NN 0
synthesis NN 0
. . 0

Outcomes NNS 0
in IN 0
a DT 0
nursing NN 0
home NN 0
transition NN 0
case-management JJ 0
program NN 0
targeting VBG 0
new JJ 0
admissions NNS 0
. . 0

PURPOSE VB 0
The DT 0
Providing VBG 0
Assistance NNP 0
to TO 0
Caregivers NNPS 0
in IN 0
Transition NNP 0
( ( 0
PACT NNP 0
) ) 0
program NN 0
offers NNS 0
nursing VBG 0
home NN 0
discharge NN 0
planning NN 0
and CC 0
case NN 0
management NN 0
for IN 0
individuals NNS 0
in IN 0
the DT 0
transitional JJ 0
period NN 0
following VBG 0
a DT 0
return NN 0
to TO 0
the DT 0
community NN 0
. . 0

The DT 0
PACT NNP 0
program NN 0
targeted VBN 0
individuals NNS 0
newly RB 0
admitted VBN 0
to TO 0
nursing VBG 4
homes NNS 4
and CC 0
worked VBD 0
with IN 0
a DT 0
family NN 0
caregiver NN 0
to TO 0
develop VB 0
and CC 0
implement VB 0
a DT 0
nursing NN 0
home NN 0
discharge NN 0
plan NN 0
. . 0

DESIGN NNP 0
AND CC 0
METHOD NNP 0
Reported NNP 0
are VBP 0
the DT 0
results NNS 0
of IN 0
a DT 0
randomized JJ 0
control NN 0
design NN 0
evaluating VBG 0
the DT 0
program NN 0
's POS 0
effectiveness NN 0
. . 0

Those DT 0
individuals NNS 0
randomly RB 0
assigned VBN 0
to TO 0
the DT 0
intervention NN 0
group NN 0
( ( 0
n JJ 0
= NNP 0
33 CD 3
) ) 0
received VBN 0
PACT NNP 0
case NN 0
management NN 0
in IN 0
addition NN 0
to TO 0
their PRP$ 0
usual JJ 0
medical JJ 0
and CC 0
nursing NN 0
home NN 0
care NN 0
. . 0

The DT 0
individuals NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
( ( 0
n JJ 0
= NNP 0
29 CD 3
) ) 0
continued VBD 0
their PRP$ 0
usual JJ 0
care NN 0
. . 0

RESULT CC 0
There EX 0
were VBD 0
no DT 0
statistical JJ 0
differences NNS 0
in IN 0
the DT 0
discharge NN 0
rate NN 0
( ( 0
84 CD 0
% NN 0
treatment NN 0
vs RB 0
76 CD 0
% NN 0
controls NNS 0
) ) 0
or CC 0
in IN 0
the DT 0
median JJ 0
length NN 0
of IN 0
stay NN 0
( ( 0
42 CD 0
days NNS 0
vs RB 0
55 CD 0
days NNS 0
) ) 0
between IN 0
the DT 0
two CD 0
groups NNS 0
of IN 0
individuals NNS 0
. . 0

IMPLICATIONS NNP 0
Replications NNPS 0
or CC 0
extensions NNS 0
of IN 0
a DT 0
PACT-type JJ 0
intervention NN 0
might MD 0
consider VB 0
a DT 0
broader JJR 0
mix NN 0
of IN 0
nursing NN 0
homes NNS 0
, , 0
working VBG 0
directly RB 0
with IN 0
the DT 0
nursing NN 0
home NN 0
's POS 0
admission NN 0
Minimum NNP 0
Data NNP 0
Set NNP 0
coordinator NN 0
in IN 0
patient JJ 0
selection NN 0
, , 0
or CC 0
working VBG 0
with IN 0
Medicare NNP 0
or CC 0
Medicaid NNP 0
HMO NNP 0
plans VBZ 0
. . 0

Physostigmine JJ 0
reverses VBZ 0
propofol-induced JJ 0
unconsciousness NN 0
and CC 0
attenuation NN 0
of IN 0
the DT 0
auditory NN 0
steady JJ 0
state NN 0
response NN 0
and CC 0
bispectral JJ 0
index NN 0
in IN 0
human JJ 0
volunteers NNS 0
. . 0

BACKGROUND IN 0
It PRP 0
is VBZ 0
postulated VBN 0
that IN 0
alteration NN 0
of IN 0
central JJ 0
cholinergic JJ 0
transmission NN 0
plays VBZ 0
an DT 0
important JJ 0
role NN 0
in IN 0
the DT 0
mechanism NN 0
by IN 0
which WDT 0
anesthetics NNS 0
produce VBP 0
unconsciousness JJ 0
. . 0

The DT 0
authors NNS 0
investigated VBD 0
the DT 0
effect NN 0
of IN 0
altering VBG 0
central JJ 0
cholinergic JJ 0
transmission NN 0
, , 0
by IN 0
physostigmine NN 0
and CC 0
scopolamine NN 0
, , 0
on IN 0
unconsciousness NN 0
produced VBN 0
by IN 0
propofol NN 0
. . 0

METHODS NNP 0
Propofol NNP 0
was VBD 0
administered VBN 0
to TO 0
American NNP 0
Society NNP 0
of IN 0
Anesthesiologists NNP 0
physical JJ 4
status NN 4
1 CD 4
( ( 0
n JJ 0
= NNP 0
17 CD 3
) ) 0
volunteers NNS 0
with IN 0
use NN 0
of IN 0
a DT 0
computer-controlled JJ 0
infusion NN 0
pump NN 0
at IN 0
increasing VBG 0
concentrations NNS 0
until IN 0
unconsciousness JJ 0
resulted VBD 0
( ( 0
inability NN 0
to TO 0
respond VB 0
to TO 0
verbal VB 0
commands NNS 0
, , 0
abolition NN 0
of IN 0
spontaneous JJ 0
movement NN 0
) ) 0
. . 0

Central NNP 0
nervous JJ 0
system NN 0
function NN 0
was VBD 0
assessed VBN 0
by IN 0
use NN 0
of IN 0
the DT 0
Auditory NNP 0
Steady NNP 0
State NNP 0
Response NNP 0
( ( 0
ASSR NNP 0
) ) 0
and CC 0
Bispectral NNP 0
Index NNP 0
( ( 0
BIS NNP 0
) ) 0
analysis NN 0
of IN 0
electrooculogram NN 0
. . 0

During IN 0
continuous JJ 0
administration NN 0
of IN 0
propofol NN 0
, , 0
reversal NN 0
of IN 0
unconsciousness NN 0
produced VBN 0
by IN 0
physostigmine NN 0
( ( 0
28 CD 0
microgram/kg NN 0
) ) 0
and CC 0
block NN 0
of IN 0
this DT 0
reversal NN 0
by IN 0
scopolamine NN 0
( ( 0
8.6 CD 0
microgram/kg NN 0
) ) 0
were VBD 0
evaluated VBN 0
. . 0

RESULTS NNP 0
Propofol NNP 0
produced VBD 0
unconsciousness JJ 0
at IN 0
a DT 0
plasma JJ 0
concentration NN 0
of IN 0
3.2 CD 0
+/- JJ 0
0.8 CD 0
( ( 0
+/- JJ 0
SD NNP 0
) ) 0
microgram/ml NN 0
( ( 0
n JJ 0
= NNP 0
17 CD 0
) ) 0
. . 0

Unconsciousness NN 0
was VBD 0
associated VBN 0
with IN 0
reductions NNS 0
in IN 0
ASSR NNP 0
( ( 0
0.10 CD 0
+/- JJ 0
0.08 CD 0
microV NN 0
[ NNP 0
awake VBP 0
baseline JJ 0
0.32 CD 0
+/- JJ 0
0.18 CD 0
microV NN 0
] NN 0
, , 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
and CC 0
BIS NNP 0
( ( 0
55.7 CD 0
+/- JJ 0
8.8 CD 0
[ JJ 0
awake NN 0
baseline NN 0
92.4 CD 0
+/- JJ 0
3.9 CD 0
] NN 0
, , 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

Physostigmine NNP 0
restored VBD 0
consciousness NN 0
in IN 0
9 CD 0
of IN 0
11 CD 0
subjects NNS 0
, , 0
with IN 0
concomitant JJ 0
increases NNS 0
in IN 0
ASSR NNP 0
( ( 0
0.38 CD 0
+/- JJ 0
0.17 CD 0
microV NN 0
, , 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
and CC 0
BIS NNP 0
( ( 0
75.3 CD 0
+/- JJ 0
8.3 CD 0
, , 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

In IN 0
all DT 0
subjects NNS 0
( ( 0
n JJ 0
= NNP 0
6 CD 0
) ) 0
scopolamine NN 0
blocked VBD 0
the DT 0
physostigmine-induced JJ 0
reversal NN 0
of IN 0
unconsciousness NN 0
and CC 0
the DT 0
increase NN 0
of IN 0
the DT 0
ASSR NNP 0
and CC 0
BIS NNP 0
( ( 0
ASSR NNP 0
and CC 0
BIS NNP 0
during IN 0
propofol-induced JJ 0
unconsciousness NN 0
: : 0
0.09 CD 0
+/- JJ 0
0.09 CD 0
microV NN 0
and CC 0
58.2 CD 0
+/- JJ 0
7.5 CD 0
, , 0
respectively RB 0
; : 0
ASSR NNP 0
and CC 0
BIS NNP 0
after IN 0
physostigmine JJ 0
administration NN 0
: : 0
0.08 CD 0
+/- JJ 0
0.06 CD 0
microV NN 0
and CC 0
56.8 CD 0
+/- JJ 0
6.7 CD 0
, , 0
respectively RB 0
, , 0
NS NNP 0
) ) 0
. . 0

CONCLUSIONS NNP 0
These DT 0
findings NNS 0
suggest VBP 0
that IN 0
the DT 0
unconsciousness NN 0
produced VBN 0
by IN 0
propofol NN 0
is VBZ 0
mediated VBN 0
at IN 0
least JJS 0
in IN 0
part NN 0
via IN 0
interruption NN 0
of IN 0
central JJ 0
cholinergic NN 0
muscarinic JJ 0
transmission NN 0
. . 0

Phytase NNP 0
and CC 0
1alpha-hydroxycholecalciferol JJ 0
supplementation NN 0
of IN 0
broiler NN 4
chickens NNS 4
during IN 0
the DT 0
starting NN 0
and CC 0
growing/finishing NN 0
phases NNS 0
. . 0

Supplemental JJ 0
1alpha-hydroxycholecalciferol JJ 0
( ( 0
1alpha-OHD3 JJ 0
) ) 0
has VBZ 0
been VBN 0
shown VBN 0
to TO 0
have VB 0
qualitatively RB 0
similar JJ 0
and CC 0
quantitatively RB 0
additive JJ 0
effects NNS 0
to TO 0
exogenous JJ 0
phytase NN 0
. . 0

Two CD 0
experiments NNS 0
were VBD 0
conducted VBN 0
from IN 0
0 CD 0
to TO 0
35 CD 0
d NN 0
in IN 0
floor NN 0
pens NNS 0
to TO 0
determine VB 0
the DT 0
additive JJ 0
effect NN 0
of IN 0
phytase NN 0
and CC 0
1alpha-OHD3 JJ 0
when WRB 0
supplemented VBN 0
to TO 0
Ca- NNP 0
and CC 0
P-deficient NNP 0
diets NNS 0
. . 0

In IN 0
both DT 0
experiments NNS 0
, , 0
at IN 0
least JJS 0
4 CD 0
replicates NNS 0
per IN 0
treatment NN 0
( ( 0
50 CD 3
chicks NNS 0
per IN 0
replicate NN 0
) ) 0
were VBD 0
used VBN 0
. . 0

Corn-soybean-meal-and JJ 0
soybean-oil-based JJ 0
diets NNS 0
were VBD 0
fed VBN 0
and CC 0
birds NNS 0
were VBD 0
raised VBN 0
in IN 0
a DT 0
house NN 0
impervious JJ 0
to TO 0
ultraviolet VB 0
light NN 0
. . 0

During IN 0
the DT 0
starter JJ 0
phase NN 0
( ( 0
ST NNP 0
) ) 0
, , 0
from IN 0
0 CD 0
to TO 0
18 CD 0
d NN 0
, , 0
chicks NNS 0
were VBD 0
fed VBN 0
a DT 0
23 CD 0
% NN 0
CP NNP 0
diet JJ 0
containing VBG 0
0.60 CD 0
% NN 0
Ca NNP 0
and CC 0
0.47 CD 0
% NN 0
total JJ 0
P NNP 0
( ( 0
tP NN 0
) ) 0
. . 0

During IN 0
the DT 0
grower/finisher NN 0
phase NN 0
( ( 0
GF NNP 0
) ) 0
, , 0
from IN 0
19 CD 0
to TO 0
35 CD 0
d NN 0
, , 0
birds NNS 0
were VBD 0
fed VBN 0
a DT 0
19 CD 0
% NN 0
CP NNP 0
diet JJ 0
containing VBG 0
0.30 CD 0
% NN 0
Ca NNP 0
and CC 0
0.37 CD 0
% NN 0
tP NN 0
. . 0

A DT 0
combination NN 0
of IN 0
1,000 CD 0
phytase NN 0
units/kg NN 0
of IN 0
Natuphos NNP 0
phytase NN 0
and CC 0
5 CD 0
microg/kg NN 0
of IN 0
1alpha-OHD3 JJ 0
( ( 0
P+1A NNP 0
) ) 0
was VBD 0
supplemented VBN 0
to TO 0
some DT 0
of IN 0
the DT 0
feed NN 0
during IN 0
the DT 0
ST NNP 0
and CC 0
GF NNP 0
. . 0

Diets NNS 0
containing VBG 0
adequate NN 0
Ca NNP 0
and CC 0
P NNP 0
were VBD 0
also RB 0
fed VBN 0
during IN 0
the DT 0
ST NNP 0
( ( 0
0.90 CD 0
% NN 0
Ca NNP 0
, , 0
0.68 CD 0
% NN 0
tP NN 0
) ) 0
and CC 0
GF NNP 0
( ( 0
0.80 CD 0
% NN 0
Ca NNP 0
, , 0
0.67 CD 0
% NN 0
tP NN 0
) ) 0
. . 0

Performance NN 0
characteristics NNS 0
and CC 0
the DT 0
incidence NN 0
of IN 0
rickets NNS 0
and CC 0
tibial JJ 0
dyschondroplasia NN 0
were VBD 0
measured VBN 0
at IN 0
18 CD 0
and CC 0
35 CD 0
d. NN 0
In IN 0
experiment JJ 0
1 CD 0
, , 0
unsupplemented JJ 0
chicks NNS 0
performed VBN 0
well RB 0
but CC 0
had VBD 0
considerable JJ 0
leg JJ 0
problems NNS 0
. . 0

Chicks NNP 0
fed VBD 0
P+1A NNP 0
during IN 0
the DT 0
ST NNP 0
or CC 0
GF NNP 0
did VBD 0
not RB 0
perform VB 0
as RB 0
well RB 0
as IN 0
birds NNS 0
fed VBN 0
P+1A NNP 0
throughout IN 0
. . 0

Birds NNS 0
fed VBD 0
P+1A NNP 0
throughout IN 0
performed VBN 0
as IN 0
well RB 0
birds NNS 0
fed VBD 0
the DT 0
adequate JJ 0
diets NNS 0
without IN 0
any DT 0
indication NN 0
of IN 0
leg NN 0
problems NNS 0
. . 0

In IN 0
experiment JJ 0
2 CD 0
, , 0
unsupplemented JJ 0
birds NNS 0
performed VBD 0
similarly RB 0
to TO 0
unsupplemented JJ 0
birds NNS 0
in IN 0
experiment JJ 0
1 CD 0
. . 0

However RB 0
, , 0
chicks NNS 0
fed VBP 0
the DT 0
supplements NNS 0
or CC 0
the DT 0
control JJ 0
diets NNS 0
did VBD 0
not RB 0
perform VB 0
as RB 0
well RB 0
or CC 0
accumulate VB 0
as IN 0
much JJ 0
bone NN 0
ash NN 0
as IN 0
birds NNS 0
in IN 0
experiment JJ 0
1 CD 0
, , 0
although IN 0
the DT 0
diets NNS 0
were VBD 0
formulated VBN 0
identically RB 0
in IN 0
both DT 0
experiments NNS 0
. . 0

Diets NNS 0
with IN 0
as RB 0
little JJ 0
as IN 0
0.30 CD 0
% NN 0
Ca NNP 0
and CC 0
0.37 CD 0
% NN 0
tP NN 0
appear VBP 0
to TO 0
be VB 0
adequate JJ 0
for IN 0
broilers NNS 0
older JJR 0
than IN 0
18 CD 0
d NN 0
if IN 0
supplemented VBN 0
with IN 0
the DT 0
correct JJ 0
amounts NNS 0
of IN 0
phytase NN 0
and CC 0
1alpha-OHD3 JJ 0
. . 0

However RB 0
, , 0
there EX 0
are VBP 0
unknown JJ 0
variables NNS 0
that WDT 0
may MD 0
limit VB 0
the DT 0
potential NN 0
of IN 0
broilers NNS 0
in IN 0
terms NNS 0
of IN 0
bone NN 0
mineralization NN 0
and CC 0
bone NN 0
pathology NN 0
, , 0
even RB 0
when WRB 0
adequate JJ 0
diets NNS 0
are VBP 0
fed VBN 0
. . 0

Effects NNS 0
of IN 0
long-term JJ 0
vitamin NN 0
E NNP 0
supplementation NN 0
on IN 0
cardiovascular JJ 4
events NNS 4
and CC 0
cancer NN 4
: : 0
a DT 0
randomized NN 0
controlled VBN 0
trial NN 0
. . 0

CONTEXT NNP 0
Experimental NNP 0
and CC 0
epidemiological JJ 0
data NNS 0
suggest VBP 0
that IN 0
vitamin NN 0
E NNP 0
supplementation NN 0
may MD 0
prevent VB 0
cancer NN 4
and CC 0
cardiovascular JJ 4
events NNS 4
. . 0

Clinical JJ 0
trials NNS 0
have VBP 0
generally RB 0
failed VBN 0
to TO 0
confirm VB 0
benefits NNS 0
, , 0
possibly RB 0
due JJ 0
to TO 0
their PRP$ 0
relatively RB 0
short JJ 0
duration NN 0
. . 0

OBJECTIVE UH 0
To TO 0
evaluate VB 0
whether IN 0
long-term JJ 0
supplementation NN 0
with IN 0
vitamin JJ 0
E NN 0
decreases VBZ 0
the DT 0
risk NN 0
of IN 0
cancer NN 0
, , 0
cancer NN 0
death NN 0
, , 0
and CC 0
major JJ 0
cardiovascular JJ 0
events NNS 0
. . 0

DESIGN NNP 0
, , 0
SETTING NNP 0
, , 0
AND NNP 0
PATIENTS NNP 0
A NNP 0
randomized JJ 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
international JJ 0
trial NN 0
( ( 0
the DT 0
initial JJ 0
Heart NNP 0
Outcomes NNP 0
Prevention NNP 0
Evaluation NNP 0
[ NNP 0
HOPE NNP 0
] NNP 0
trial NN 0
conducted VBD 0
between IN 0
December NNP 0
21 CD 0
, , 0
1993 CD 0
, , 0
and CC 0
April NNP 0
15 CD 0
, , 0
1999 CD 0
) ) 0
of IN 0
patients NNS 0
at IN 0
least JJS 0
55 CD 1
years NNS 0
old JJ 0
with IN 0
vascular JJ 4
disease NN 4
or CC 0
diabetes VBZ 4
mellitus NN 4
was VBD 0
extended VBN 0
( ( 0
HOPE-The NNP 0
Ongoing NNP 0
Outcomes NNP 0
[ NNP 0
HOPE-TOO NNP 0
] NNP 0
) ) 0
between IN 0
April NNP 0
16 CD 0
, , 0
1999 CD 0
, , 0
and CC 0
May NNP 0
26 CD 0
, , 0
2003 CD 0
. . 0

Of IN 0
the DT 0
initial JJ 0
267 CD 0
HOPE NNP 0
centers NNS 0
that WDT 0
had VBD 0
enrolled VBN 0
9541 CD 3
patients NNS 0
, , 0
174 CD 0
centers NNS 0
participated VBN 0
in IN 0
the DT 0
HOPE-TOO NNP 0
trial NN 0
. . 0

Of IN 0
7030 CD 3
patients NNS 0
enrolled VBN 0
at IN 0
these DT 0
centers NNS 0
, , 0
916 CD 0
were VBD 0
deceased VBN 0
at IN 0
the DT 0
beginning NN 0
of IN 0
the DT 0
extension NN 0
, , 0
1382 CD 0
refused VBD 0
participation NN 0
, , 0
3994 CD 0
continued VBD 0
to TO 0
take VB 0
the DT 0
study NN 0
intervention NN 0
, , 0
and CC 0
738 CD 0
agreed VBD 0
to TO 0
passive VB 0
follow-up NN 0
. . 0

Median JJ 0
duration NN 0
of IN 0
follow-up NN 0
was VBD 0
7.0 CD 0
years NNS 0
. . 0

INTERVENTION NNP 0
Daily NNP 0
dose NN 0
of IN 0
natural JJ 0
source NN 0
vitamin NN 0
E NNP 0
( ( 0
400 CD 0
IU NNP 0
) ) 0
or CC 0
matching VBG 0
placebo NN 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURES NNP 0
Primary NNP 0
outcomes NNS 0
included VBD 0
cancer NN 0
incidence NN 0
, , 0
cancer NN 0
deaths NNS 0
, , 0
and CC 0
major JJ 0
cardiovascular JJ 0
events NNS 0
( ( 0
myocardial JJ 0
infarction NN 0
, , 0
stroke NN 0
, , 0
and CC 0
cardiovascular JJ 0
death NN 0
) ) 0
. . 0

Secondary JJ 0
outcomes NNS 0
included VBD 0
heart NN 0
failure NN 0
, , 0
unstable JJ 0
angina NN 0
, , 0
and CC 0
revascularizations NNS 0
. . 0

RESULTS NNP 0
Among IN 0
all DT 0
HOPE NNP 0
patients NNS 0
, , 0
there EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
the DT 0
primary JJ 0
analysis NN 0
: : 0
for IN 0
cancer NN 0
incidence NN 0
, , 0
there EX 0
were VBD 0
552 CD 0
patients NNS 0
( ( 0
11.6 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
vitamin NN 0
E NNP 0
group NN 0
vs VBD 0
586 CD 0
( ( 0
12.3 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
placebo NN 0
group NN 0
( ( 0
relative JJ 0
risk NN 0
[ NNP 0
RR NNP 0
] NNP 0
, , 0
0.94 CD 0
; : 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
[ NNP 0
CI NNP 0
] NNP 0
, , 0
0.84-1.06 NNP 0
; : 0
P NNP 0
= NNP 0
.30 NNP 0
) ) 0
; : 0
for IN 0
cancer NN 0
deaths NNS 0
, , 0
156 CD 0
( ( 0
3.3 CD 0
% NN 0
) ) 0
vs NN 0
178 CD 0
( ( 0
3.7 CD 0
% NN 0
) ) 0
, , 0
respectively RB 0
( ( 0
RR NNP 0
, , 0
0.88 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
0.71-1.09 NNP 0
; : 0
P NNP 0
= NNP 0
.24 NNP 0
) ) 0
; : 0
and CC 0
for IN 0
major JJ 0
cardiovascular JJ 0
events NNS 0
, , 0
1022 CD 0
( ( 0
21.5 CD 0
% NN 0
) ) 0
vs NN 0
985 CD 0
( ( 0
20.6 CD 0
% NN 0
) ) 0
, , 0
respectively RB 0
( ( 0
RR NNP 0
, , 0
1.04 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
0.96-1.14 NNP 0
; : 0
P NNP 0
= NNP 0
.34 NNP 0
) ) 0
. . 0

Patients NNS 0
in IN 0
the DT 0
vitamin NN 0
E NNP 0
group NN 0
had VBD 0
a DT 0
higher JJR 0
risk NN 0
of IN 0
heart NN 0
failure NN 0
( ( 0
RR NNP 0
, , 0
1.13 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
1.01-1.26 JJ 0
; : 0
P NNP 0
= NNP 0
.03 NNP 0
) ) 0
and CC 0
hospitalization NN 0
for IN 0
heart NN 0
failure NN 0
( ( 0
RR NNP 0
, , 0
1.21 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
, , 0
1.00-1.47 JJ 0
; : 0
P NNP 0
= NNP 0
.045 NNP 0
) ) 0
. . 0

Similarly RB 0
, , 0
among IN 0
patients NNS 0
enrolled VBN 0
at IN 0
the DT 0
centers NNS 0
participating VBG 0
in IN 0
the DT 0
HOPE-TOO NNP 0
trial NN 0
, , 0
there EX 0
were VBD 0
no DT 0
differences NNS 0
in IN 0
cancer NN 0
incidence NN 0
, , 0
cancer NN 0
deaths NNS 0
, , 0
and CC 0
major JJ 0
cardiovascular JJ 0
events NNS 0
, , 0
but CC 0
higher JJR 0
rates NNS 0
of IN 0
heart NN 0
failure NN 0
and CC 0
hospitalizations NNS 0
for IN 0
heart NN 0
failure NN 0
. . 0

CONCLUSION NNP 0
In IN 0
patients NNS 0
with IN 0
vascular JJ 0
disease NN 0
or CC 0
diabetes VBZ 0
mellitus NNS 0
, , 0
long-term JJ 0
vitamin NN 0
E NNP 0
supplementation NN 0
does VBZ 0
not RB 0
prevent VB 0
cancer NN 0
or CC 0
major JJ 0
cardiovascular JJ 0
events NNS 0
and CC 0
may MD 0
increase VB 0
the DT 0
risk NN 0
for IN 0
heart NN 0
failure NN 0
. . 0

Enhancing VBG 0
attitudes NNS 0
and CC 0
intentions NNS 0
in IN 0
prospective JJ 4
blood NN 4
donors NNS 4
: : 0
evaluation NN 0
of IN 0
a DT 0
new JJ 0
donor NN 0
recruitment NN 0
brochure NN 0
. . 0

BACKGROUND NNP 0
Although IN 0
little JJ 0
empiric JJ 0
evidence NN 0
has VBZ 0
been VBN 0
published VBN 0
concerning VBG 0
the DT 0
efficacy NN 0
of IN 0
blood NN 0
donor NN 0
recruitment NN 0
materials NNS 0
, , 0
research NN 0
suggests VBZ 0
that IN 0
simple JJ 0
attempts NNS 0
to TO 0
enhance VB 0
knowledge NN 0
may MD 0
not RB 0
be VB 0
sufficient JJ 0
to TO 0
motivate VB 0
donation NN 0
. . 0

In IN 0
contrast NN 0
, , 0
recent JJ 0
donor NN 0
motivation NN 0
studies NNS 0
highlight VBD 0
the DT 0
importance NN 0
of IN 0
anxiety NN 0
, , 0
attitudes NNS 0
, , 0
and CC 0
perceived VBD 0
ability NN 0
to TO 0
cope VB 0
with IN 0
donation NN 0
( ( 0
i.e. JJ 0
, , 0
self-efficacy NN 0
) ) 0
as IN 0
crucial JJ 0
determinants NNS 0
of IN 0
donation NN 0
intention NN 0
. . 0

Therefore RB 0
, , 0
recruitment JJ 0
materials NNS 0
that WDT 0
specifically RB 0
address VBP 0
these DT 0
constructs NNS 0
have VBP 0
the DT 0
potential JJ 0
to TO 0
outperform VB 0
traditional JJ 0
educational JJ 0
brochures NNS 0
. . 0

STUDY NNP 0
DESIGN NNP 0
AND NNP 0
METHODS NNP 0
Participants NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
read VB 0
one CD 0
of IN 0
three CD 0
brochures NNS 0
: : 0
1 CD 0
) ) 0
a DT 0
new JJ 0
brochure NN 0
addressing VBG 0
common JJ 0
donor NN 0
concerns NNS 0
and CC 0
suggesting VBG 0
specific JJ 0
coping VBG 0
strategies NNS 0
, , 0
2 CD 0
) ) 0
a DT 0
standard JJ 0
blood NN 0
center NN 0
brochure NN 0
, , 0
or CC 0
3 CD 0
) ) 0
a DT 0
control JJ 0
brochure NN 0
on IN 0
healthy JJ 0
eating NN 0
and CC 0
exercise NN 0
. . 0

Standardized JJ 0
questionnaires NNS 0
were VBD 0
completed VBN 0
before IN 0
and CC 0
after IN 0
the DT 0
brochures NNS 0
to TO 0
assess VB 0
change NN 0
in IN 0
blood NN 0
donation NN 0
anxiety NN 0
, , 0
attitude NN 0
, , 0
self-efficacy NN 0
, , 0
and CC 0
intention NN 0
. . 0

RESULTS NNP 0
Although IN 0
no DT 0
significant JJ 0
changes NNS 0
were VBD 0
noted VBN 0
for IN 0
the DT 0
control NN 0
brochure NN 0
, , 0
after IN 0
reading VBG 0
the DT 0
new JJ 0
brochure NN 0
participants NNS 0
reported VBD 0
significant JJ 0
improvements NNS 0
in IN 0
attitude NN 0
, , 0
anxiety NN 0
, , 0
self-efficacy NN 0
, , 0
and CC 0
donation NN 0
intention NN 0
. . 0

The DT 0
standard JJ 0
donation NN 0
brochure NN 0
had VBD 0
an DT 0
intermediate JJ 0
effect NN 0
. . 0

CONCLUSION NNP 0
Efforts NNPS 0
to TO 0
address VB 0
common JJ 0
donor NN 0
fears NNS 0
and CC 0
to TO 0
provide VB 0
useful JJ 0
coping VBG 0
suggestions NNS 0
may MD 0
improve VB 0
the DT 0
effectiveness NN 0
of IN 0
blood NN 0
donation NN 0
recruitment NN 0
materials NNS 0
. . 0

Effects NNS 0
of IN 0
a DT 0
leisure NN 0
programme NN 0
on IN 0
quality NN 0
of IN 0
life NN 0
and CC 0
stress NN 0
of IN 0
individuals NNS 0
with IN 0
ASD NNP 4
. . 0

BACKGROUND NNP 0
Even RB 0
though IN 0
there EX 0
is VBZ 0
research NN 0
demonstrating VBG 0
a DT 0
positive JJ 0
relationship NN 0
between IN 0
leisure NN 0
participation NN 0
and CC 0
the DT 0
two CD 0
constructs NNS 0
of IN 0
quality NN 0
of IN 0
life NN 0
and CC 0
stress NN 0
reduction NN 0
, , 0
current JJ 0
conceptualisation NN 0
of IN 0
leisure NN 0
as IN 0
a DT 0
contributor NN 0
to TO 0
quality NN 0
of IN 0
life NN 0
is VBZ 0
limited VBN 0
. . 0

In IN 0
addition NN 0
, , 0
in IN 0
spite NN 0
of IN 0
improvements NNS 0
in IN 0
accurate JJ 0
diagnosis NN 0
of IN 0
autism NN 4
spectrum NN 4
disorder NN 4
( ( 0
ASD NNP 0
) ) 0
at IN 0
increasingly RB 0
earlier JJR 0
ages NNS 0
and CC 0
proliferation NN 0
of IN 0
interventions NNS 0
, , 0
research NN 0
associated VBN 0
with IN 0
leisure NN 0
and CC 0
quality NN 0
of IN 0
life NN 0
for IN 0
people NNS 0
with IN 0
ASD NNP 0
is VBZ 0
lacking VBG 0
. . 0

METHODS NNP 0
Therefore NNP 0
, , 0
a DT 0
study NN 0
using VBG 0
a DT 0
repeated JJ 0
measures NNS 0
design NN 0
was VBD 0
used VBN 0
to TO 0
measure VB 0
effects NNS 0
of IN 0
a DT 0
1-year JJ 0
group NN 0
leisure NN 0
programme NN 0
intended VBN 0
to TO 0
facilitate VB 0
interaction NN 0
with IN 0
media NNS 0
, , 0
engagement NN 0
in IN 0
exercise NN 0
, , 0
playing VBG 0
games NNS 0
and CC 0
doing VBG 0
crafts NNS 0
, , 0
attending VBG 0
events NNS 0
, , 0
and CC 0
participating VBG 0
in IN 0
other JJ 0
recreation NN 0
activities NNS 0
on IN 0
quality NN 0
of IN 0
life NN 0
and CC 0
stress NN 0
of IN 0
37 CD 3
participants NNS 0
( ( 0
22 CD 3
male NN 2
, , 0
15 CD 3
female NN 2
) ) 0
, , 0
ages VBZ 0
17-39 JJ 1
( ( 0
M NNP 0
= NNP 0
31.49 CD 1
) ) 0
years NNS 0
at IN 0
the DT 0
beginning NN 0
of IN 0
the DT 0
programme NN 0
) ) 0
diagnosed VBD 0
with IN 0
an DT 0
ASD NNP 0
and CC 0
a DT 0
group NN 0
of IN 0
34 CD 3
adults NNS 0
with IN 0
ASD NNP 0
as IN 0
control NN 0
group NN 0
( ( 0
waiting VBG 0
list NN 0
) ) 0
( ( 0
19 CD 3
male NN 2
, , 0
15 CD 3
female NN 2
) ) 0
, , 0
ages VBZ 0
24-38 JJ 1
( ( 0
M NNP 0
= VBZ 0
30 CD 1
at IN 0
programme JJ 0
initiation NN 0
) ) 0
years NNS 0
. . 0

RESULTS NNP 0
There EX 0
was VBD 0
a DT 0
significant JJ 0
decrease NN 0
in IN 0
overall JJ 0
scores NNS 0
of IN 0
stress NN 0
levels NNS 0
for IN 0
participants NNS 0
over IN 0
the DT 0
course NN 0
of IN 0
the DT 0
study NN 0
and CC 0
there EX 0
was VBD 0
a DT 0
significant JJ 0
increase NN 0
in IN 0
the DT 0
four CD 0
factors NNS 0
of IN 0
quality NN 0
of IN 0
life NN 0
that WDT 0
were VBD 0
measured VBN 0
( ( 0
satisfaction NN 0
, , 0
independence NN 0
, , 0
competence NN 0
and CC 0
social JJ 0
interaction NN 0
) ) 0
as RB 0
well RB 0
as IN 0
the DT 0
total JJ 0
score NN 0
for IN 0
quality NN 0
of IN 0
life NN 0
from IN 0
baseline NN 0
to TO 0
the DT 0
end NN 0
of IN 0
the DT 0
intervention NN 0
12 CD 0
months NNS 0
later RB 0
. . 0

In IN 0
contrast NN 0
, , 0
the DT 0
control NN 0
group NN 0
demonstrated VBD 0
no DT 0
significant JJ 0
improvements NNS 0
related VBN 0
to TO 0
stress VB 0
or CC 0
quality NN 0
of IN 0
life NN 0
. . 0

Implications NNS 0
of IN 0
these DT 0
findings NNS 0
to TO 0
leisure VB 0
services NNS 0
and CC 0
the DT 0
quality NN 0
of IN 0
life NN 0
of IN 0
individuals NNS 0
with IN 0
ASD NNP 0
are VBP 0
discussed VBN 0
. . 0

CONCLUSION NNP 0
Findings NNP 0
support NN 0
the DT 0
contention NN 0
that WDT 0
participation NN 0
in IN 0
recreation NN 0
activities NNS 0
positively RB 0
influenced VBD 0
the DT 0
stress NN 0
and CC 0
quality NN 0
of IN 0
life NN 0
of IN 0
adults NNS 1
with IN 0
ASD NNP 0
. . 0

Anti-angiogenic JJ 0
effects NNS 0
of IN 0
epigallocatechin-3-gallate NN 0
in IN 0
human JJ 0
skin NN 0
. . 0

Epigallocatechin-3-gallate NNP 0
( ( 0
EGCG NNP 0
) ) 0
is VBZ 0
the DT 0
main JJ 0
polyphenol JJ 0
component NN 0
of IN 0
green JJ 0
tea NN 0
. . 0

This DT 0
compound NN 0
exhibits VBZ 0
antioxidant JJ 0
, , 0
immunomodulatory JJ 0
, , 0
photoprotective JJ 0
, , 0
anti-angiogenic JJ 0
, , 0
and CC 0
anti-inflammatory JJ 0
properties NNS 0
. . 0

We PRP 0
conducted VBD 0
a DT 0
small JJ 0
randomized NN 0
, , 0
double JJ 0
blind NN 0
, , 0
split VBD 0
face NN 0
trial NN 0
using VBG 0
a DT 0
cream NN 0
containing VBG 0
2.5 CD 0
% NN 0
w/w NN 0
of IN 0
EGCG NNP 0
. . 0

Four CD 3
healthy JJ 4
volunteers NNS 0
with IN 0
significant JJ 0
erythema NN 4
and CC 0
telangiectasia NN 4
on IN 4
the DT 4
face NN 4
applied VBD 0
EGCG NNP 0
cream NN 0
to TO 0
one CD 0
side NN 0
of IN 0
the DT 0
face NN 0
, , 0
and CC 0
vehicle NN 0
control NN 0
cream NN 0
to TO 0
the DT 0
other JJ 0
, , 0
twice JJ 0
daily RB 0
for IN 0
six CD 0
weeks NNS 0
. . 0

After IN 0
six CD 0
weeks NNS 0
, , 0
biopsies NNS 0
were VBD 0
taken VBN 0
from IN 0
EGCG NNP 0
and CC 0
vehicle NN 0
treated VBN 0
sites NNS 0
. . 0

Immunohistochemistry NN 0
was VBD 0
used VBN 0
to TO 0
measure VB 0
VEGF NNP 0
and CC 0
HIF-1 NNP 0
?. NNP 0
HIF-1 NNP 0
? . 0
expression NN 0
was VBD 0
decreased VBN 0
in IN 0
EGCG NNP 0
treated VBD 0
sites NNS 0
, , 0
such JJ 0
that IN 0
28.4 CD 0
% NN 0
of IN 0
the DT 0
epidermis NN 0
showed VBD 0
positive JJ 0
staining NN 0
in IN 0
vehicle NN 0
treated VBD 0
vs. FW 0
13.8 CD 0
% NN 0
in IN 0
EGCG NNP 0
treated VBD 0
sites NNS 0
( ( 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

A DT 0
similar JJ 0
decrease NN 0
in IN 0
VEGF NNP 0
expression NN 0
was VBD 0
found VBN 0
( ( 0
6.7 CD 0
% NN 0
in IN 0
EGCG NNP 0
vs. FW 0
11.0 CD 0
% NN 0
in IN 0
in IN 0
vehicle-treated JJ 0
skin NN 0
( ( 0
p JJ 0
< NNP 0
0.005 CD 0
) ) 0
. . 0

EGCG NNP 0
topical JJ 0
treatments NNS 0
influence VB 0
HIF-1 NNP 0
? . 0
induction NN 0
and CC 0
VEGF NNP 0
expression NN 0
and CC 0
may MD 0
serve VB 0
as IN 0
a DT 0
potential JJ 0
agent NN 0
in IN 0
the DT 0
prevention NN 0
of IN 0
telangiectasias NN 0
. . 0

Cyclosporin NNP 0
versus NN 0
cyclophosphamide NN 0
for IN 0
patients NNS 0
with IN 0
steroid-dependent JJ 4
and CC 0
frequently RB 4
relapsing VBG 4
idiopathic JJ 4
nephrotic JJ 4
syndrome NN 4
: : 0
a DT 0
multicentre NN 0
randomized VBN 0
controlled VBN 0
trial NN 0
. . 0

OBJECTIVE UH 0
To TO 0
compare VB 0
the DT 0
efficacy NN 0
( ( 0
maintenance NN 0
of IN 0
remission NN 0
) ) 0
, , 0
safety NN 0
and CC 0
tolerability NN 0
of IN 0
cyclosporin NN 0
( ( 0
CsA NNP 0
) ) 0
with IN 0
those DT 0
of IN 0
cyclophosphamide NN 0
in IN 0
patients NNS 0
with IN 0
steroid-dependent JJ 4
or CC 0
frequently RB 4
relapsing VBG 4
nephrotic JJ 4
syndrome NN 4
( ( 0
NS NNP 4
) ) 0
. . 0

DESIGN NNP 0
Open NNP 0
, , 0
prospective JJ 0
, , 0
randomized VBN 0
, , 0
multicentre FW 0
, , 0
controlled VBD 0
study NN 0
for IN 0
parallel JJ 0
groups NNS 0
, , 0
stratified VBN 0
for IN 0
adults NNS 1
and CC 0
children NNS 1
. . 0

The DT 0
setting NN 0
was VBD 0
in IN 0
nephrological JJ 0
departments NNS 0
in IN 0
Italy NNP 0
. . 0

SUBJECTS NNP 0
AND CC 0
INTERVENTIONS NNP 0
Seventy-three JJ 3
patients NNS 0
with IN 0
steroid-sensitive JJ 4
idiopathic JJ 4
NS NNP 4
admitted VBD 0
to TO 0
the DT 0
study NN 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
cyclophosphamide VB 0
( ( 0
2.5 CD 0
mg/kg/day NN 0
) ) 0
for IN 0
8 CD 0
weeks NNS 0
or CC 0
CsA NNP 0
( ( 0
5 CD 0
mg/kg/day NN 0
in IN 0
adults NNS 0
, , 0
6 CD 0
mg/kg/day NN 0
in IN 0
children NNS 0
) ) 0
for IN 0
9 CD 0
months NNS 0
, , 0
tapered VBD 0
off RP 0
by IN 0
25 CD 0
% NN 0
every DT 0
month NN 0
until IN 0
complete JJ 0
discontinuation NN 0
at IN 0
month NN 0
12 CD 0
. . 0

Seven CD 0
patients NNS 0
lost VBN 0
to TO 0
follow VB 0
up RP 0
were VBD 0
not RB 0
considered VBN 0
in IN 0
the DT 0
analysis NN 0
. . 0

The DT 0
remaining VBG 0
66 CD 0
patients NNS 0
were VBD 0
followed VBN 0
up RP 0
for IN 0
3-24 JJ 0
months NNS 0
after IN 0
randomization NN 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURES NNP 0
Relapse-free NNP 0
survival NN 0
; : 0
number NN 0
of IN 0
N.S NNP 0
. . 0

relapses/patient/year NN 0
; : 0
cumulative JJ 0
dose NN 0
of IN 0
prednisone/patient NN 0
; : 0
laboratory JJ 0
investigations NNS 0
( ( 0
kidney NN 0
and CC 0
liver NN 0
functions NNS 0
, , 0
haematological JJ 0
parameters NNS 0
) ) 0
; : 0
incidence NN 0
of IN 0
adverse JJ 0
events NNS 0
. . 0

RESULTS NNP 0
At IN 0
month NN 0
9 CD 0
, , 0
26 CD 0
of IN 0
35 CD 0
CsA-treated JJ 0
patients NNS 0
were VBD 0
still RB 0
in IN 0
complete JJ 0
remission NN 0
and CC 0
a DT 0
further JJ 0
five CD 0
patients NNS 0
were VBD 0
in IN 0
partial JJ 0
remission NN 0
; : 0
18 CD 0
of IN 0
28 CD 0
cyclophosphamide-treated JJ 0
patients NNS 0
were VBD 0
in IN 0
complete JJ 0
remission NN 0
, , 0
and CC 0
one CD 0
in IN 0
partial JJ 0
remission NN 0
( ( 0
P NNP 0
= NNP 0
NS NNP 0
) ) 0
. . 0

No DT 0
difference NN 0
between IN 0
adults NNS 0
and CC 0
children NNS 0
was VBD 0
seen VBN 0
with IN 0
either DT 0
treatment NN 0
. . 0

The DT 0
risk NN 0
of IN 0
relapse NN 0
was VBD 0
similar JJ 0
between IN 0
frequent JJ 0
relapsers NNS 0
( ( 0
19 CD 0
of IN 0
22 CD 0
) ) 0
and CC 0
steroid-dependent JJ 0
patients NNS 0
( ( 0
8 CD 0
of IN 0
14 CD 0
) ) 0
given VBN 0
CsA NNP 0
, , 0
and CC 0
those DT 0
given VBN 0
cyclophosphamide NN 0
( ( 0
5 CD 0
of IN 0
15 CD 0
and CC 0
6 CD 0
of IN 0
15 CD 0
) ) 0
. . 0

The DT 0
mean JJ 0
number NN 0
of IN 0
relapses NNS 0
per IN 0
year NN 0
and CC 0
the DT 0
mean NN 0
dose NN 0
of IN 0
prednisone NN 0
per IN 0
year NN 0
were VBD 0
significantly RB 0
less JJR 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
in IN 0
both DT 0
groups NNS 0
for IN 0
the DT 0
experimental JJ 0
year NN 0
than IN 0
for IN 0
the DT 0
year NN 0
before IN 0
randomization NN 0
. . 0

At IN 0
2 CD 0
years NNS 0
, , 0
25 CD 0
% NN 0
of IN 0
the DT 0
patients NNS 0
given VBN 0
CsA NNP 0
( ( 0
50 CD 0
% NN 0
adults NNS 0
and CC 0
20 CD 0
% NN 0
children NNS 0
) ) 0
and CC 0
63 CD 0
% NN 0
of IN 0
those DT 0
given VBN 0
cyclophosphamide NN 0
( ( 0
40 CD 0
% NN 0
adults NNS 0
and CC 0
68 CD 0
% NN 0
children NNS 0
) ) 0
had VBD 0
not RB 0
had VBN 0
any DT 0
relapse NN 0
of IN 0
NS NNP 0
. . 0

Tolerance NN 0
to TO 0
the DT 0
two CD 0
drugs NNS 0
was VBD 0
generally RB 0
good JJ 0
. . 0

The DT 0
CsA-related JJ 0
side-effects NNS 0
were VBD 0
mild JJ 0
and CC 0
disappeared VBD 0
after IN 0
drug NN 0
discontinuation NN 0
. . 0

CONCLUSIONS VB 0
This DT 0
study NN 0
shows VBZ 0
that IN 0
both DT 0
treatments NNS 0
are VBP 0
effective JJ 0
and CC 0
well RB 0
tolerated VBD 0
; : 0
more RBR 0
patients NNS 0
given VBN 0
cyclophosphamide JJ 0
had VBD 0
stable JJ 0
remissions NNS 0
. . 0

Randomized VBN 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
trial NN 0
of IN 0
oral JJ 0
sirolimus NN 0
for IN 0
restenosis NN 0
prevention NN 0
in IN 0
patients NNS 0
with IN 0
in-stent JJ 4
restenosis NN 4
: : 0
the DT 0
Oral NNP 0
Sirolimus NNP 0
to TO 0
Inhibit NNP 0
Recurrent NNP 0
In-stent JJ 0
Stenosis NNP 0
( ( 0
OSIRIS NNP 0
) ) 0
trial NN 0
. . 0

BACKGROUND NNP 0
Despite IN 0
recent JJ 0
advances NNS 0
in IN 0
interventional JJ 0
cardiology NN 0
, , 0
including VBG 0
the DT 0
introduction NN 0
of IN 0
drug-eluting JJ 0
stents NNS 0
for IN 0
de FW 0
novo FW 0
coronary JJ 0
lesions NNS 0
, , 0
the DT 0
treatment NN 0
of IN 0
in-stent JJ 0
restenosis NN 0
( ( 0
ISR NNP 0
) ) 0
remains VBZ 0
a DT 0
challenging JJ 0
clinical JJ 0
issue NN 0
. . 0

Given VBN 0
the DT 0
efficacy NN 0
of IN 0
systemic JJ 0
sirolimus JJ 0
administration NN 0
to TO 0
prevent VB 0
neointimal JJ 0
hyperplasia NN 0
in IN 0
animal JJ 0
models NNS 0
and CC 0
to TO 0
halt VB 0
and CC 0
even RB 0
reverse VB 0
the DT 0
progression NN 0
of IN 0
allograft NN 0
vasculopathy NN 0
, , 0
the DT 0
aim NN 0
of IN 0
the DT 0
present JJ 0
double-blind NN 0
, , 0
placebo-controlled JJ 0
study NN 0
was VBD 0
to TO 0
evaluate VB 0
the DT 0
efficacy NN 0
of IN 0
a DT 0
10-day JJ 0
oral JJ 0
sirolimus NN 0
treatment NN 0
with IN 0
2 CD 0
different JJ 0
loading VBG 0
regimens NNS 0
for IN 0
the DT 0
prevention NN 0
of IN 0
recurrent JJ 0
restenosis NN 0
in IN 0
patients NNS 0
with IN 0
ISR NNP 4
. . 0

METHODS NNP 0
AND CC 0
RESULTS NNP 0
Three NNP 3
hundred VBD 3
symptomatic JJ 4
patients NNS 0
with IN 0
ISR NNP 4
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
1 CD 0
of IN 0
3 CD 0
treatment NN 0
arms NNS 0
: : 0
placebo NN 0
or CC 0
usual-dose JJ 0
or CC 0
high-dose JJ 0
sirolimus NN 0
. . 0

Patients NNS 0
received VBD 0
a DT 0
cumulative JJ 0
loading NN 0
dose NN 0
of IN 0
0 CD 0
, , 0
8 CD 0
, , 0
or CC 0
24 CD 0
mg NN 0
of IN 0
sirolimus JJ 0
2 CD 0
days NNS 0
before IN 0
and CC 0
the DT 0
day NN 0
of IN 0
repeat NN 0
intervention NN 0
followed VBN 0
by IN 0
maintenance NN 0
therapy NN 0
of IN 0
2 CD 0
mg/d NN 0
for IN 0
7 CD 0
days NNS 0
. . 0

Angiographic JJ 0
restenosis NN 0
at IN 0
6-month JJ 0
angiography NN 0
was VBD 0
the DT 0
primary JJ 0
end NN 0
point NN 0
of IN 0
the DT 0
study NN 0
. . 0

Restenosis NNP 0
was VBD 0
significantly RB 0
reduced VBN 0
from IN 0
42.2 CD 0
% NN 0
to TO 0
38.6 CD 0
% NN 0
and CC 0
to TO 0
22.1 CD 0
% NN 0
in IN 0
the DT 0
placebo NN 0
, , 0
usual-dose JJ 0
, , 0
and CC 0
high-dose JJ 0
sirolimus NN 0
groups NNS 0
, , 0
respectively RB 0
( ( 0
P=0.005 NNP 0
) ) 0
. . 0

Similarly RB 0
, , 0
the DT 0
need NN 0
for IN 0
target NN 0
vessel JJ 0
revascularization NN 0
was VBD 0
reduced VBN 0
from IN 0
25.5 CD 0
% NN 0
to TO 0
24.2 CD 0
% NN 0
and CC 0
to TO 0
15.2 CD 0
% NN 0
in IN 0
the DT 0
placebo NN 0
, , 0
usual-dose JJ 0
, , 0
and CC 0
high-dose JJ 0
groups NNS 0
, , 0
respectively RB 0
( ( 0
P=0.08 NNP 0
) ) 0
. . 0

The DT 0
sirolimus JJ 0
blood NN 0
concentration NN 0
on IN 0
the DT 0
day NN 0
of IN 0
the DT 0
procedure NN 0
correlated VBD 0
significantly RB 0
with IN 0
the DT 0
late JJ 0
lumen NNS 0
loss NN 0
at IN 0
follow-up JJ 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

CONCLUSIONS NNP 0
In IN 0
patients NNS 0
with IN 0
ISR NNP 0
, , 0
an DT 0
oral JJ 0
adjunctive JJ 0
sirolimus NN 0
treatment NN 0
with IN 0
an DT 0
intensified JJ 0
loading NN 0
regimen NNS 0
before IN 0
coronary JJ 0
intervention NN 0
resulted VBD 0
in IN 0
a DT 0
significant JJ 0
improvement NN 0
in IN 0
the DT 0
angiographic JJ 0
parameters NNS 0
of IN 0
restenosis NN 0
. . 0

Behavioral JJ 0
effects NNS 0
of IN 0
Org NNP 0
2766 CD 0
, , 0
a DT 0
synthetic JJ 0
analog NN 0
of IN 0
the DT 0
adrenocorticotrophic JJ 0
hormone NN 0
( ( 0
4-9 JJ 0
) ) 0
, , 0
in IN 0
14 CD 3
outpatient JJ 0
autistic JJ 4
children NNS 1
. . 0

Fourteen NNP 3
children NNS 1
( ( 0
12 CD 3
infantile NN 4
autism NN 4
full JJ 0
syndrome NN 0
present NN 0
, , 0
2 CD 3
atypical JJ 4
pervasive JJ 4
developmental JJ 4
disorder NN 4
) ) 0
between IN 0
5 CD 1
and CC 1
13 CD 1
years NNS 0
of IN 0
age NN 0
participated VBN 0
in IN 0
a DT 0
double-blind JJ 0
placebo-controlled JJ 0
cross-over JJ 0
trial NN 0
. . 0

Each DT 0
child NN 0
received VBD 0
20 CD 0
mg NNS 0
Org JJ 0
2766 CD 0
( ( 0
synthetic JJ 0
analog NN 0
of IN 0
ACTH NNP 0
4-9 JJ 0
) ) 0
/day NN 0
during IN 0
4 CD 0
weeks NNS 0
, , 0
or CC 0
placebo NN 0
in IN 0
a DT 0
randomly NN 0
assigned VBN 0
sequence NN 0
. . 0

Drug JJ 0
effects NNS 0
were VBD 0
monitored VBN 0
by IN 0
ethological JJ 0
playroom NN 0
observation NN 0
and CC 0
by IN 0
Aberrant NNP 0
Behavior NNP 0
Checklist NNP 0
ratings NNS 0
by IN 0
parents NNS 0
and CC 0
teachers NNS 0
. . 0

Data NNP 0
of IN 0
the DT 0
playroom NN 0
observation NN 0
pointed VBD 0
to TO 0
an DT 0
activating VBG 0
influence NN 0
of IN 0
Org NNP 0
2766 CD 0
, , 0
as IN 0
revealed VBN 0
by IN 0
a DT 0
significant JJ 0
decrease NN 0
of IN 0
stereotypic NN 0
behavior NN 0
and CC 0
significant JJ 0
increases NNS 0
in IN 0
change NN 0
toys NNS 0
, , 0
locomote NN 0
, , 0
and CC 0
talk NN 0
. . 0

Checklist JJ 0
ratings NNS 0
did VBD 0
not RB 0
show VB 0
significant JJ 0
changes NNS 0
. . 0

The DT 0
clinical JJ 0
implications NNS 0
of IN 0
these DT 0
findings NNS 0
are VBP 0
discussed VBN 0
. . 0

Parent-mediated JJ 0
communication-focused JJ 0
treatment NN 0
in IN 0
children NNS 1
with IN 0
autism NN 4
( ( 0
PACT NNP 0
) ) 0
: : 0
a DT 0
randomised JJ 0
controlled VBN 0
trial NN 0
. . 0

BACKGROUND NNP 0
Results NNP 0
of IN 0
small JJ 0
trials NNS 0
suggest VBP 0
that IN 0
early JJ 0
interventions NNS 0
for IN 0
social JJ 0
communication NN 0
are VBP 0
effective JJ 0
for IN 0
the DT 0
treatment NN 0
of IN 0
autism NN 0
in IN 0
children NNS 0
. . 0

We PRP 0
therefore RB 0
investigated VBD 0
the DT 0
efficacy NN 0
of IN 0
such JJ 0
an DT 0
intervention NN 0
in IN 0
a DT 0
larger JJR 0
trial NN 0
. . 0

METHODS NNP 0
Children NNP 0
with IN 0
core NN 4
autism NN 4
( ( 0
aged VBN 0
2 CD 1
years NNS 1
to TO 1
4 CD 1
years NNS 1
and CC 1
11 CD 1
months NNS 1
) ) 0
were VBD 0
randomly RB 0
assigned VBN 0
in IN 0
a DT 0
one-to-one JJ 0
ratio NN 0
to TO 0
a DT 0
parent-mediated JJ 0
communication-focused JJ 0
( ( 0
Preschool NNP 0
Autism NNP 0
Communication NNP 0
Trial NNP 0
[ NNP 0
PACT NNP 0
] NNP 0
) ) 0
intervention NN 0
or CC 0
treatment NN 0
as IN 0
usual JJ 0
at IN 0
three CD 0
specialist NN 0
centres NNS 0
in IN 0
the DT 0
UK NNP 0
. . 0

Those DT 0
assigned VBN 0
to TO 0
PACT NNP 0
were VBD 0
also RB 0
given VBN 0
treatment NN 0
as IN 0
usual JJ 0
. . 0

Randomisation NN 0
was VBD 0
by IN 0
use NN 0
of IN 0
minimisation NN 0
of IN 0
probability NN 0
in IN 0
the DT 0
marginal JJ 0
distribution NN 0
of IN 0
treatment NN 0
centre NN 0
, , 0
age NN 0
( ( 0
< JJ 0
/=42 NNP 0
months NNS 0
or CC 0
> $ 0
42 CD 0
months NNS 0
) ) 0
, , 0
and CC 0
autism NN 0
severity NN 0
( ( 0
Autism NNP 0
Diagnostic NNP 0
Observation NNP 0
Schedule-Generic NNP 0
[ NNP 0
ADOS-G NNP 0
] NNP 0
algorithm VBZ 0
score RB 0
12-17 JJ 0
or CC 0
18-24 JJ 0
) ) 0
. . 0

Primary JJ 0
outcome NN 0
was VBD 0
severity NN 0
of IN 0
autism NN 0
symptoms NNS 0
( ( 0
a DT 0
total NN 0
score NN 0
of IN 0
social JJ 0
communication NN 0
algorithm NNS 0
items NNS 0
from IN 0
ADOS-G NNP 0
, , 0
higher JJR 0
score NN 0
indicating VBG 0
greater JJR 0
severity NN 0
) ) 0
at IN 0
13 CD 0
months NNS 0
. . 0

Complementary NNP 0
secondary JJ 0
outcomes NNS 0
were VBD 0
measures NNS 0
of IN 0
parent-child JJ 0
interaction NN 0
, , 0
child JJ 0
language NN 0
, , 0
and CC 0
adaptive JJ 0
functioning NN 0
in IN 0
school NN 0
. . 0

Analysis NN 0
was VBD 0
by IN 0
intention NN 0
to TO 0
treat VB 0
. . 0

This DT 0
study NN 0
is VBZ 0
registered VBN 0
as IN 0
an DT 0
International NNP 0
Standard NNP 0
Randomised VBD 0
Controlled NNP 0
Trial NNP 0
, , 0
number NN 0
ISRCTN58133827 NNP 0
. . 0

RESULTS NNP 0
152 CD 3
children NNS 0
were VBD 0
recruited VBN 0
. . 0

77 CD 3
were VBD 0
assigned VBN 0
to TO 0
PACT NNP 0
( ( 0
London NNP 0
[ NNP 0
n=26 MD 0
] VB 0
, , 0
Manchester NNP 0
[ NNP 0
n=26 MD 0
] VB 0
, , 0
and CC 0
Newcastle NNP 0
[ NNP 0
n=25 FW 0
] NNP 0
) ) 0
; : 0
and CC 0
75 CD 3
to TO 0
treatment NN 0
as IN 0
usual JJ 0
( ( 0
London NNP 0
[ NNP 0
n=26 MD 0
] VB 0
, , 0
Manchester NNP 0
[ NNP 0
n=26 MD 0
] VB 0
, , 0
and CC 0
Newcastle NNP 0
[ NNP 0
n=23 FW 0
] NNP 0
) ) 0
. . 0

At IN 0
the DT 0
13-month JJ 0
endpoint NN 0
, , 0
the DT 0
severity NN 0
of IN 0
symptoms NNS 0
was VBD 0
reduced VBN 0
by IN 0
3.9 CD 0
points NNS 0
( ( 0
SD NNP 0
4.7 CD 0
) ) 0
on IN 0
the DT 0
ADOS-G NNP 0
algorithm NN 0
in IN 0
the DT 0
group NN 0
assigned VBD 0
to TO 0
PACT NNP 0
, , 0
and CC 0
2.9 CD 0
( ( 0
3.9 CD 0
) ) 0
in IN 0
the DT 0
group NN 0
assigned VBD 0
to TO 0
treatment NN 0
as IN 0
usual JJ 0
, , 0
representing VBG 0
a DT 0
between-group JJ 0
effect NN 0
size NN 0
of IN 0
-0.24 NNP 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
-0.59 NNP 0
to TO 0
0.11 CD 0
) ) 0
, , 0
after IN 0
adjustment NN 0
for IN 0
centre NN 0
, , 0
sex NN 0
, , 0
socioeconomic JJ 0
status NN 0
, , 0
age NN 0
, , 0
and CC 0
verbal JJ 0
and CC 0
non-verbal JJ 0
abilities NNS 0
. . 0

Treatment NNP 0
effect NN 0
was VBD 0
positive JJ 0
for IN 0
parental JJ 0
synchronous JJ 0
response NN 0
to TO 0
child VB 0
( ( 0
1.22 CD 0
, , 0
0.85 CD 0
to TO 0
1.59 CD 0
) ) 0
, , 0
child JJ 0
initiations NNS 0
with IN 0
parent NN 0
( ( 0
0.41 CD 0
, , 0
0.08 CD 0
to TO 0
0.74 CD 0
) ) 0
, , 0
and CC 0
for IN 0
parent-child JJ 0
shared VBN 0
attention NN 0
( ( 0
0.33 CD 0
, , 0
-0.02 NN 0
to TO 0
0.68 CD 0
) ) 0
. . 0

Effects NNS 0
on IN 0
directly RB 0
assessed VBN 0
language NN 0
and CC 0
adaptive JJ 0
functioning NN 0
in IN 0
school NN 0
were VBD 0
small JJ 0
. . 0

INTERPRETATION NN 0
On IN 0
the DT 0
basis NN 0
of IN 0
our PRP$ 0
findings NNS 0
, , 0
we PRP 0
can MD 0
not RB 0
recommend VB 0
the DT 0
addition NN 0
of IN 0
the DT 0
PACT NNP 0
intervention NN 0
to TO 0
treatment NN 0
as IN 0
usual JJ 0
for IN 0
the DT 0
reduction NN 0
of IN 0
autism NN 0
symptoms NNS 0
; : 0
however RB 0
, , 0
a DT 0
clear JJ 0
benefit NN 0
was VBD 0
noted VBN 0
for IN 0
parent-child JJ 0
dyadic JJ 0
social JJ 0
communication NN 0
. . 0

FUNDING NN 0
UK NNP 0
Medical NNP 0
Research NNP 0
Council NNP 0
, , 0
and CC 0
UK NNP 0
Department NNP 0
for IN 0
Children NNP 0
, , 0
Schools NNP 0
and CC 0
Families NNP 0
. . 0

Utility NN 0
of IN 0
the DT 0
bladder NN 0
flap NN 0
at IN 0
cesarean JJ 4
delivery NN 4
: : 0
a DT 0
randomized NN 0
controlled VBN 0
trial NN 0
. . 0

OBJECTIVE UH 0
To TO 0
test VB 0
the DT 0
hypothesis NN 0
that IN 0
omission NN 0
of IN 0
the DT 0
bladder NN 0
flap NN 0
in IN 0
primary JJ 4
and CC 0
repeat JJ 4
cesarean JJ 4
deliveries NNS 4
shortens VBZ 0
operating VBG 0
time NN 0
without IN 0
increasing VBG 0
intraoperative JJ 0
and CC 0
postoperative JJ 0
complications NNS 0
. . 0

METHODS NNP 0
We PRP 0
randomized VBD 0
258 CD 3
women NNS 2
undergoing VBG 0
primary JJ 0
and CC 0
repeat JJ 0
cesarean JJ 0
deliveries NNS 0
at IN 0
32 CD 0
weeks NNS 0
of IN 0
gestation NN 0
or CC 0
more JJR 0
to TO 0
creation NN 0
( ( 0
n=131 JJ 3
) ) 0
or CC 0
omission NN 0
( ( 0
n=127 JJ 3
) ) 0
of IN 0
the DT 0
bladder NN 0
flap NN 0
. . 0

Emergency NNP 0
cesarean JJ 0
deliveries NNS 0
, , 0
planned VBD 0
vertical JJ 0
uterine NN 0
incisions NNS 0
, , 0
and CC 0
previous JJ 0
abdominal JJ 0
surgeries NNS 0
besides IN 0
cesarean JJ 0
deliveries NNS 0
were VBD 0
excluded VBN 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
measure NN 0
was VBD 0
total JJ 0
operating NN 0
time NN 0
. . 0

Secondary JJ 0
outcomes NNS 0
were VBD 0
bladder JJ 0
injury NN 0
, , 0
incision-to-delivery JJ 0
time NN 0
, , 0
incision-to-fascial JJ 0
closure NN 0
time NN 0
, , 0
estimated VBN 0
blood NN 0
loss NN 0
, , 0
postoperative JJ 0
microhematuria NN 0
, , 0
postoperative JJ 0
pain NN 0
, , 0
hospital NN 0
days NNS 0
, , 0
endometritis NN 0
, , 0
and CC 0
urinary JJ 0
tract NN 0
infection NN 0
. . 0

Analysis NN 0
followed VBD 0
the DT 0
intention-to-treat JJ 0
principle NN 0
. . 0

RESULTS VB 0
The DT 0
median JJ 0
skin NN 0
incision NN 0
to TO 0
delivery NN 0
interval NN 0
was VBD 0
shorter JJR 0
with IN 0
omission NN 0
of IN 0
the DT 0
bladder NN 0
flap NN 0
( ( 0
9 CD 0
[ NN 0
range NN 0
1-43 JJ 0
] NNS 0
compared VBN 0
with IN 0
10 CD 0
[ JJ 0
range NN 0
2-70 JJ 0
] NNP 0
minutes NNS 0
; : 0
P=.04 NNP 0
) ) 0
, , 0
but CC 0
there EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
total JJ 0
operating NN 0
time NN 0
( ( 0
51 CD 0
[ NN 0
range NN 0
18-124 JJ 0
] NNP 0
minutes NNS 0
compared VBN 0
with IN 0
51 CD 0
[ JJ 0
range NN 0
16-178 JJ 0
] NN 0
; : 0
P=.10 NNP 0
) ) 0
. . 0

No DT 0
bladder NN 0
injuries NNS 0
occurred VBD 0
in IN 0
either DT 0
group NN 0
and CC 0
there EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
estimated VBN 0
blood NN 0
loss NN 0
, , 0
change NN 0
in IN 0
hemoglobin JJ 0
level NN 0
, , 0
postoperative JJ 0
microhematuria NN 0
, , 0
postoperative JJ 0
pain NN 0
, , 0
hospital NN 0
days NNS 0
, , 0
endometritis NN 0
, , 0
or CC 0
urinary JJ 0
tract NN 0
infection NN 0
. . 0

CONCLUSION NNP 0
Omission NNP 0
of IN 0
the DT 0
bladder NN 0
flap NN 0
at IN 0
primary JJ 0
and CC 0
repeat JJ 0
cesarean JJ 0
deliveries NNS 0
does VBZ 0
not RB 0
increase VB 0
intraoperative JJ 0
or CC 0
postoperative JJ 0
complications NNS 0
. . 0

Incision-to-delivery JJ 0
time NN 0
is VBZ 0
shortened VBN 0
but CC 0
total JJ 0
operating NN 0
time NN 0
appears VBZ 0
unchanged JJ 0
. . 0

CLINICAL JJ 0
TRIAL NNP 0
REGISTRATION NNP 0
ClinicalTrials.gov NNP 0
, , 0
www.ClinicalTrials.gov NN 0
, , 0
NCT00918996 NNP 0
. . 0

LEVEL NNP 0
OF IN 0
EVIDENCE NNP 0
I PRP 0
. . 0

White NNP 0
coat NN 0
effect NN 0
detected VBD 0
using VBG 0
self-monitoring NN 0
of IN 0
blood NN 0
pressure NN 0
at IN 0
home NN 0
: : 0
comparison NN 0
with IN 0
ambulatory JJ 0
blood NN 0
pressure NN 0
. . 0

The DT 0
objective NN 0
of IN 0
the DT 0
study NN 0
was VBD 0
to TO 0
investigate VB 0
whether IN 0
home NN 0
blood NN 0
pressure NN 0
( ( 0
HBP NNP 0
) ) 0
is VBZ 0
a DT 0
reliable JJ 0
alternative NN 0
to TO 0
ambulatory VB 0
blood NN 0
pressure NN 0
( ( 0
ABP NNP 0
) ) 0
for IN 0
the DT 0
detection NN 0
of IN 0
the DT 0
white JJ 0
coat NN 0
effect NN 0
( ( 0
WCE NNP 0
) ) 0
. . 0

Hypertensive JJ 4
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
measure VB 0
HBP NNP 0
for IN 0
2 CD 0
weeks NNS 0
or CC 0
ABP NNP 0
for IN 0
24 CD 0
h. PDT 0
The DT 0
alternative JJ 0
measurement NN 0
was VBD 0
then RB 0
performed VBN 0
. . 0

Clinic NNP 0
blood NN 0
pressure NN 0
( ( 0
CBP NNP 0
) ) 0
was VBD 0
measured VBN 0
in IN 0
the DT 0
beginning NN 0
and CC 0
end NN 0
of IN 0
the DT 0
study NN 0
. . 0

Subjects NNS 0
with IN 0
a DT 0
difference NN 0
of IN 0
> NN 0
or CC 0
= $ 0
20 CD 0
mm NN 0
Hg NNP 0
systolic NN 0
or CC 0
> NN 0
or CC 0
= $ 0
10 CD 0
mm NN 0
Hg NNP 0
diastolic VBZ 0
BP NNP 0
between IN 0
CBP NNP 0
and CC 0
awake VB 0
ABP NNP 0
or CC 0
CBP NNP 0
and CC 0
HBP NNP 0
, , 0
were VBD 0
classified VBN 0
as IN 0
clinic JJ 0
reactors NNS 0
. . 0

A DT 0
total NN 0
of IN 0
189 CD 3
patients NNS 0
completed VBD 0
the DT 0
study NN 0
( ( 0
79 CD 3
on IN 0
stable JJ 0
antihypertensive JJ 0
treatment NN 0
) ) 0
. . 0

There EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
the DT 0
magnitude NN 0
of IN 0
WCE NNP 0
assessed VBD 0
using VBG 0
the DT 0
ABP NNP 0
or CC 0
the DT 0
HBP NNP 0
method NN 0
( ( 0
mean JJ 0
discrepancy NN 0
, , 0
systolic JJ 0
BP NNP 0
: : 0
-1.5 JJ 0
+/- JJ 0
11.7 CD 0
mm NN 0
Hg NNP 0
, , 0
95 CD 0
% NN 0
CI NNP 0
-3.2 NNP 0
, , 0
0.2 CD 0
; : 0
diastolic JJ 0
BP NNP 0
: : 0
0.9 CD 0
+/- JJ 0
7.0 CD 0
, , 0
95 CD 0
% NN 0
CI NNP 0
-0.1 NNP 0
, , 0
1.9 CD 0
) ) 0
. . 0

A NNP 0
strong JJ 0
association NN 0
existed VBD 0
between IN 0
WCE NNP 0
calculated VBD 0
using VBG 0
the DT 0
HBP NNP 0
or CC 0
the DT 0
ABP NNP 0
method NN 0
( ( 0
r VB 0
= RB 0
0.64/0.59 CD 0
systolic/diastolic JJ 0
, , 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

The DT 0
proportion NN 0
of IN 0
patients NNS 0
classified VBN 0
as IN 0
clinic JJ 0
reactors NNS 0
was VBD 0
identical JJ 0
using VBG 0
the DT 0
HBP NNP 0
or CC 0
the DT 0
ABP NNP 0
method NN 0
( ( 0
25.9 CD 0
% NN 0
) ) 0
. . 0

Agreement NN 0
between IN 0
methods NNS 0
in IN 0
the DT 0
classification NN 0
of IN 0
clinic JJ 0
reactors NNS 0
was VBD 0
found VBN 0
in IN 0
147 CD 0
patients NNS 0
( ( 0
78 CD 0
% NN 0
) ) 0
. . 0

The DT 0
sensitivity NN 0
and CC 0
specificity NN 0
of IN 0
the DT 0
HBP NNP 0
method NN 0
to TO 0
classify VB 0
correctly RB 0
clinic JJ 0
reactors NNS 0
( ( 0
ABP NNP 0
method RB 0
used VBD 0
as IN 0
the DT 0
standard NN 0
) ) 0
were VBD 0
57 CD 0
% NN 0
and CC 0
85 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
whereas VBD 0
its PRP$ 0
positive JJ 0
and CC 0
negative JJ 0
predictive JJ 0
value NN 0
were VBD 0
57 CD 0
% NN 0
and CC 0
85 CD 0
% NN 0
. . 0

These DT 0
results NNS 0
indicate VBP 0
that IN 0
HBP NNP 0
is VBZ 0
not RB 0
appropriate JJ 0
as IN 0
an DT 0
alternative NN 0
to TO 0
ABP NNP 0
diagnostic JJ 0
testing NN 0
in IN 0
the DT 0
detection NN 0
of IN 0
WCE NNP 0
. . 0

Nevertheless NNP 0
, , 0
HBP NNP 0
appears VBZ 0
useful JJ 0
as IN 0
a DT 0
screening JJ 0
test NN 0
for IN 0
the DT 0
detection NN 0
of IN 0
this DT 0
phenomenon NN 0
. . 0

Problem-based JJ 0
learning NN 0
: : 0
is VBZ 0
anatomy IN 0
a DT 0
casualty NN 0
? . 0
INTRODUCTION NNP 0
The DT 0
teaching NN 0
of IN 0
medical JJ 0
anatomy NN 0
is VBZ 0
changing VBG 0
. . 0

Medical JJ 0
schools NNS 0
worldwide WDT 0
are VBP 0
moving VBG 0
away RB 0
from IN 0
dissection NN 0
and CC 0
lectures VBZ 0
to TO 0
a DT 0
more RBR 0
integrated JJ 0
course NN 0
, , 0
where WRB 0
basic JJ 0
science NN 0
and CC 0
clinical JJ 0
skills NNS 0
are VBP 0
taught JJ 0
simultaneously RB 0
. . 0

Medical JJ 0
students NNS 0
on IN 0
these DT 0
integrated VBN 0
courses NNS 0
have VBP 0
reported VBN 0
a DT 0
lack NN 0
of IN 0
confidence NN 0
in IN 0
their PRP$ 0
basic JJ 0
science NN 0
knowledge NN 0
, , 0
especially RB 0
concerning VBG 0
anatomy NN 0
. . 0

Our PRP$ 0
aim NN 0
was VBD 0
to TO 0
perform VB 0
a DT 0
randomised JJ 0
controlled VBN 0
trial NN 0
( ( 0
RCT NNP 0
) ) 0
to TO 0
compare VB 0
anatomical JJ 0
knowledge NN 0
of IN 0
two CD 0
groups NNS 0
of IN 0
second-year JJ 0
medical JJ 0
students NNS 0
, , 0
the DT 0
first JJ 0
group NN 0
taught NN 0
on IN 0
a DT 0
traditional JJ 0
course NN 0
, , 0
the DT 0
second JJ 0
on IN 0
an DT 0
integrated JJ 0
course NN 0
. . 0

MATERIALS NNP 0
AND CC 0
METHODS NNP 0
Testing NNP 0
was VBD 0
done VBN 0
using VBG 0
a DT 0
Questionnaire NN 0
in IN 0
a DT 0
True/False NNP 0
format NN 0
. . 0

There EX 0
were VBD 0
80 CD 3
students NNS 0
in IN 0
each DT 0
group NN 0
. . 0

There EX 0
was VBD 0
no DT 0
penalty NN 0
for IN 0
an DT 0
incorrect JJ 0
answer NN 0
. . 0

The DT 0
test NN 0
was VBD 0
performed VBN 0
under IN 0
examination NN 0
conditions NNS 0
. . 0

Papers NNS 0
were VBD 0
marked VBN 0
under IN 0
blind JJ 0
conditions NNS 0
. . 0

Results NNS 0
were VBD 0
analysed VBN 0
using VBG 0
a DT 0
Student NN 0
's POS 0
t JJ 0
test NN 0
analysis NN 0
. . 0

RESULTS NNP 0
Those DT 0
students NNS 0
taught VBP 0
on IN 0
a DT 0
traditional JJ 0
course NN 0
exhibited VBD 0
a DT 0
significantly RB 0
higher JJR 0
level NN 0
of IN 0
basic JJ 0
anatomical JJ 0
knowledge NN 0
( ( 0
p JJ 0
< NNP 0
0.001 CD 0
) ) 0
than IN 0
those DT 0
taught VBN 0
on IN 0
an DT 0
integrated JJ 0
course NN 0
. . 0

The DT 0
students NNS 0
taught VBD 0
on IN 0
an DT 0
integrated JJ 0
course NN 0
showed VBD 0
a DT 0
much RB 0
greater JJR 0
range NN 0
of IN 0
results NNS 0
. . 0

CONCLUSIONS JJ 0
Students NNS 0
taught VBD 0
on IN 0
a DT 0
traditional JJ 0
course NN 0
have VBP 0
a DT 0
higher JJR 0
level NN 0
of IN 0
anatomical JJ 0
knowledge NN 0
than IN 0
those DT 0
taught VBN 0
on IN 0
an DT 0
integrated JJ 0
course NN 0
. . 0

Our PRP$ 0
results NNS 0
differ VBP 0
from IN 0
previous JJ 0
studies NNS 0
done VBN 0
in IN 0
Europe NNP 0
which WDT 0
show VBP 0
no DT 0
difference NN 0
between IN 0
the DT 0
courses NNS 0
. . 0

Social JJ 0
support NN 0
and CC 0
abstinence NN 0
from IN 0
opiates NNS 0
and CC 0
cocaine NN 0
during IN 0
opioid JJ 4
maintenance NN 4
treatment NN 4
. . 0

Social NNP 0
support NN 0
may MD 0
play VB 0
an DT 0
important JJ 0
role NN 0
in IN 0
helping VBG 0
drug NN 4
users NNS 4
achieve VBP 0
abstinence NN 0
; : 0
however RB 0
these DT 0
benefits NNS 0
may MD 0
depend VB 0
on IN 0
the DT 0
type NN 0
of IN 0
support NN 0
experienced VBN 0
. . 0

In IN 0
this DT 0
prospective JJ 0
observational NN 0
study NN 0
, , 0
we PRP 0
examined VBD 0
the DT 0
extent NN 0
to TO 0
which WDT 0
general JJ 0
and CC 0
abstinence-specific JJ 0
support NN 0
, , 0
both DT 0
structural JJ 0
and CC 0
functional JJ 0
, , 0
predicted JJ 0
opiate NN 0
and CC 0
cocaine NN 0
abstinence NN 0
in IN 0
128 CD 3
opioid JJ 4
maintenance NN 4
patients NNS 4
receiving VBG 0
either CC 0
methadone NN 0
or CC 0
LAAM NNP 0
. . 0

A DT 0
new JJ 0
multidimensional JJ 0
self-report NN 0
instrument NN 0
assessing VBG 0
abstinence-specific JJ 0
functional JJ 0
support NN 0
was VBD 0
developed VBN 0
for IN 0
the DT 0
study NN 0
. . 0

Previously RB 0
validated VBN 0
measures NNS 0
were VBD 0
used VBN 0
to TO 0
assess VB 0
the DT 0
remaining VBG 0
types NNS 0
of IN 0
support NN 0
. . 0

With IN 0
baseline JJ 0
abstinence NN 0
and CC 0
other JJ 0
statistically RB 0
important JJ 0
covariates NNS 0
adjusted VBN 0
, , 0
hierarchical JJ 0
logistic JJ 0
regression NN 0
analyses NNS 0
demonstrated VBD 0
that IN 0
the DT 0
associations NNS 0
between IN 0
social JJ 0
support NN 0
at IN 0
study NN 0
baseline NN 0
and CC 0
biochemically RB 0
confirmed VBN 0
abstinence NN 0
3 CD 0
months NNS 0
later RB 0
varied VBN 0
by IN 0
type NN 0
of IN 0
support NN 0
and CC 0
by IN 0
drug NN 0
. . 0

Greater NNP 0
abstinence-specific JJ 0
structural JJ 0
support NN 0
( ( 0
operationalized VBN 0
as IN 0
fewer JJR 0
drug NN 0
users NNS 0
in IN 0
the DT 0
social JJ 0
network NN 0
) ) 0
and CC 0
decreases VBZ 0
in IN 0
three CD 0
types NNS 0
of IN 0
negative JJ 0
abstinence-specific JJ 0
functional JJ 0
support NN 0
( ( 0
Complaints NNS 0
about IN 0
Drug NNP 0
Use NNP 0
, , 0
Drug NNP 0
Exposure NNP 0
, , 0
and CC 0
Demoralization NNP 0
) ) 0
predicted VBD 0
cocaine NN 0
, , 0
but CC 0
not RB 0
opiate JJ 0
abstinence NN 0
. . 0

There EX 0
were VBD 0
no DT 0
effects NNS 0
for IN 0
general JJ 0
support NN 0
, , 0
whether IN 0
structural JJ 0
or CC 0
functional JJ 0
, , 0
on IN 0
abstinence NN 0
from IN 0
either DT 0
drug NN 0
. . 0

Interventions NNS 0
that WDT 0
focus VBP 0
on IN 0
modifying VBG 0
patients NNS 0
' POS 0
abstinence-specific JJ 0
support NN 0
may MD 0
be VB 0
helpful JJ 0
in IN 0
reducing VBG 0
the DT 0
high JJ 0
rates NNS 0
of IN 0
cocaine NN 4
use NN 4
disorders NNS 4
in IN 0
this DT 0
population NN 0
. . 0

Efficacy NN 0
and CC 0
safety NN 0
of IN 0
routine JJ 0
blood NN 0
pressure NN 0
lowering VBG 0
in IN 0
older JJR 0
patients NNS 0
with IN 0
diabetes NNS 4
: : 0
results NNS 0
from IN 0
the DT 0
ADVANCE NNP 0
trial NN 0
. . 0

OBJECTIVE CC 0
The DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
blood NN 0
pressure NN 0
lowering VBG 0
in IN 0
elderly JJ 1
patients NNS 0
have VBP 0
not RB 0
been VBN 0
sufficiently RB 0
investigated VBN 0
in IN 0
patients NNS 0
with IN 0
diabetes NNS 4
. . 0

Using VBG 0
data NNS 0
from IN 0
the DT 0
Action NNP 0
in IN 0
Diabetes NNP 0
and CC 0
Vascular NNP 0
disease NN 0
: : 0
preterAx NN 0
and CC 0
diamicroN-MR NN 0
Controlled NNP 0
Evaluation NNP 0
study NN 0
, , 0
we PRP 0
assessed VBD 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
routine JJ 0
blood NN 0
pressure NN 0
lowering VBG 0
to TO 0
prevent VB 0
major JJ 0
clinical JJ 0
outcomes NNS 0
in IN 0
elderly JJ 0
patients NNS 0
with IN 0
type JJ 4
2 CD 4
diabetes NNS 4
. . 0

METHODS NNP 0
Eleven NNP 3
thousand VBP 3
one CD 3
hundred CD 3
and CC 3
forty JJ 3
patients NNS 0
aged VBN 0
at IN 0
least JJS 0
55 CD 1
years NNS 0
with IN 0
type NN 0
2 CD 0
diabetes NNS 0
( ( 0
mean JJ 0
66+/-6 CD 1
years NNS 0
) ) 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
perindopril-indapamide JJ 0
or CC 0
placebo NN 0
. . 0

The DT 0
primary JJ 0
endpoint NN 0
was VBD 0
a DT 0
composite NN 0
of IN 0
major JJ 0
macrovascular NN 0
and CC 0
microvascular JJ 0
disease NN 0
. . 0

The DT 0
effects NNS 0
of IN 0
active JJ 0
treatment NN 0
on IN 0
outcomes NNS 0
were VBD 0
estimated VBN 0
in IN 0
subgroups NNS 0
according VBG 0
to TO 0
age NN 0
: : 0
below IN 1
65 CD 1
, , 0
65-74 JJ 1
and CC 0
at IN 1
least JJS 1
75 CD 1
years NNS 1
. . 0

RESULTS NNP 0
During IN 0
a DT 0
mean JJ 0
4.3-year JJ 0
follow-up NN 0
, , 0
1799 CD 0
( ( 0
16.1 CD 0
% NN 0
) ) 0
patients NNS 0
experienced VBD 0
a DT 0
major JJ 0
event NN 0
. . 0

Active JJ 0
treatment NN 0
produced VBD 0
similar JJ 0
relative JJ 0
risk NN 0
reductions NNS 0
for IN 0
the DT 0
primary JJ 0
outcome NN 0
, , 0
major JJ 0
macrovascular JJ 0
disease NN 0
, , 0
death NN 0
and CC 0
renal JJ 0
events NNS 0
across IN 0
age NN 0
groups NNS 0
( ( 0
all DT 0
P NNP 0
heterogeneity NN 0
> NNP 0
0.3 CD 0
) ) 0
. . 0

Over IN 0
5 CD 0
years NNS 0
, , 0
active JJ 0
treatment NN 0
was VBD 0
estimated VBN 0
to TO 0
prevent VB 0
one CD 0
primary JJ 0
outcome NN 0
in IN 0
every DT 0
21 CD 0
, , 0
71 CD 0
and CC 0
118 CD 0
patients NNS 0
of IN 0
at IN 0
least JJS 0
75 CD 0
, , 0
65-74 JJ 0
and CC 0
below IN 0
65 CD 0
years NNS 0
, , 0
respectively RB 0
. . 0

Similar JJ 0
patterns NNS 0
of IN 0
benefits NNS 0
were VBD 0
observed VBN 0
for IN 0
secondary JJ 0
outcomes NNS 0
. . 0

There EX 0
were VBD 0
no DT 0
differences NNS 0
in IN 0
the DT 0
tolerability NN 0
between IN 0
randomized VBN 0
allocations NNS 0
across IN 0
age NN 0
groups NNS 0
( ( 0
all DT 0
P NNP 0
heterogeneity NN 0
> NNP 0
0.6 CD 0
) ) 0
CONCLUSION NNP 0
Routine NNP 0
administration NN 0
of IN 0
perindopril-indapamide JJ 0
lowers NNS 0
blood NN 0
pressure NN 0
safely RB 0
and CC 0
reduces VBZ 0
the DT 0
risk NN 0
of IN 0
major JJ 0
clinical JJ 0
outcomes NNS 0
in IN 0
patients NNS 0
of IN 0
at IN 0
least JJS 0
75 CD 0
years NNS 0
with IN 0
type NN 0
2 CD 0
diabetes NNS 0
. . 0

The DT 0
greater JJR 0
absolute JJ 0
benefits NNS 0
in IN 0
older JJR 0
patients NNS 0
in IN 0
this DT 0
age NN 0
group NN 0
were VBD 0
not RB 0
offset VBN 0
by IN 0
an DT 0
increased VBN 0
risk NN 0
of IN 0
side NN 0
effects NNS 0
. . 0

Ten-year JJ 0
incidence NN 0
of IN 0
myocardial JJ 0
infarction NN 0
and CC 0
prognosis NN 0
after IN 0
infarction NN 0
. . 0

Department NNP 0
of IN 0
Veterans NNP 0
Affairs NNP 0
Cooperative NNP 0
Study NNP 0
of IN 0
Coronary NNP 0
Artery NNP 0
Bypass NNP 0
Surgery NNP 0
. . 0

BACKGROUND NNP 0
The DT 0
10-year JJ 0
incidence NN 0
of IN 0
myocardial JJ 0
infarction NN 0
( ( 0
fatal JJ 0
and CC 0
nonfatal JJ 0
) ) 0
and CC 0
the DT 0
prognosis NN 0
after IN 0
infarction NN 0
were VBD 0
evaluated VBN 0
in IN 0
686 CD 3
patients NNS 0
with IN 0
stable JJ 4
angina NNS 4
who WP 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
medical JJ 0
or CC 0
surgical JJ 0
treatment NN 0
in IN 0
the DT 0
Veterans NNPS 0
Administration NNP 0
Cooperative NNP 0
Study NNP 0
of IN 0
Coronary NNP 0
Artery NNP 0
Bypass NNP 0
Surgery NNP 0
. . 0

METHODS NNP 0
AND CC 0
RESULTS NNP 0
Myocardial NNP 0
infarction NN 0
was VBD 0
defined VBN 0
by IN 0
either DT 0
new JJ 0
Q NNP 0
wave VBP 0
findings NNS 0
or CC 0
clinical JJ 0
symptoms NNS 0
compatible JJ 0
with IN 0
myocardial JJ 4
infarction NN 4
accompanied VBN 0
by IN 0
serum NN 0
enzyme NN 0
elevations NNS 0
with IN 0
or CC 0
without IN 0
electrocardiographic JJ 0
findings NNS 0
. . 0

Treatment JJ 0
comparisons NNS 0
were VBD 0
made VBN 0
according VBG 0
to TO 0
original JJ 0
treatment NN 0
assignment NN 0
; : 0
35 CD 0
% NN 0
of IN 0
the DT 0
medical JJ 0
cohort NN 0
had VBD 0
bypass NN 0
surgery NN 0
during IN 0
the DT 0
10-year JJ 0
follow-up JJ 0
period NN 0
. . 0

The DT 0
overall JJ 0
cumulative JJ 0
infarction NN 0
rate NN 0
was VBD 0
somewhat RB 0
higher JJR 0
in IN 0
patients NNS 0
assigned VBN 0
to TO 0
surgery VB 0
( ( 0
36 CD 0
% NN 0
) ) 0
than IN 0
in IN 0
medical JJ 0
patients NNS 0
( ( 0
31 CD 0
% NN 0
) ) 0
( ( 0
p JJ 0
= NNP 0
0.13 CD 0
) ) 0
due JJ 0
to TO 0
perioperative JJ 0
infarctions NNS 0
( ( 0
13 CD 0
% NN 0
) ) 0
and CC 0
an DT 0
accelerated JJ 0
infarction NN 0
rate NN 0
after IN 0
the DT 0
fifth JJ 0
year NN 0
of IN 0
follow-up NN 0
( ( 0
average JJ 0
, , 0
2.4 CD 0
% NN 0
/yr NN 0
in IN 0
the DT 0
surgical JJ 0
group NN 0
versus VBD 0
1.4 CD 0
% NN 0
/yr NN 0
in IN 0
the DT 0
medical JJ 0
group NN 0
) ) 0
. . 0

The DT 0
10-year JJ 0
cumulative JJ 0
incidence NN 0
of IN 0
death NN 0
or CC 0
myocardial JJ 0
infarction NN 0
was VBD 0
also RB 0
higher JJR 0
in IN 0
surgical JJ 0
( ( 0
54 CD 0
% NN 0
) ) 0
than IN 0
in IN 0
medical JJ 0
( ( 0
49 CD 0
% NN 0
) ) 0
patients NNS 0
( ( 0
p JJ 0
= NNP 0
0.20 CD 0
) ) 0
. . 0

According VBG 0
to TO 0
the DT 0
Cox NNP 0
model NN 0
, , 0
the DT 0
estimated VBN 0
risk NN 0
of IN 0
death NN 0
after IN 0
infarction NN 0
was VBD 0
59 CD 0
% NN 0
lower JJR 0
in IN 0
surgical JJ 0
than IN 0
in IN 0
medical JJ 0
patients NNS 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.0001 CD 0
) ) 0
. . 0

The DT 0
reduction NN 0
in IN 0
postinfarction NN 0
mortality NN 0
with IN 0
surgery NN 0
was VBD 0
most RBS 0
striking JJ 0
in IN 0
the DT 0
first JJ 0
month NN 0
after IN 0
the DT 0
event NN 0
: : 0
99 CD 0
% NN 0
in IN 0
the DT 0
first JJ 0
month NN 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.0001 CD 0
) ) 0
and CC 0
49 CD 0
% NN 0
subsequently RB 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.0001 CD 0
) ) 0
. . 0

The DT 0
estimated VBN 0
risk NN 0
of IN 0
death NN 0
in IN 0
the DT 0
absence NN 0
of IN 0
infarction NN 0
was VBD 0
nearly RB 0
identical JJ 0
regardless NN 0
of IN 0
treatment NN 0
( ( 0
p JJ 0
= NNP 0
0.75 CD 0
) ) 0
. . 0

Exclusion NN 0
of IN 0
perioperative JJ 0
infarctions NNS 0
did VBD 0
not RB 0
alter VB 0
the DT 0
findings NNS 0
. . 0

CONCLUSIONS NNP 0
Although IN 0
surgery NN 0
does VBZ 0
not RB 0
reduce VB 0
the DT 0
incidence NN 0
of IN 0
myocardial JJ 0
infarction NN 0
overall RB 0
, , 0
it PRP 0
does VBZ 0
reduce VB 0
the DT 0
risk NN 0
of IN 0
mortality NN 0
after IN 0
infarction NN 0
, , 0
particularly RB 0
in IN 0
the DT 0
first JJ 0
30 CD 0
days NNS 0
after IN 0
the DT 0
event NN 0
( ( 0
fatal JJ 0
infarctions NNS 0
) ) 0
. . 0

In-hospital JJ 0
costs NNS 0
of IN 0
self-expanding JJ 0
nitinol JJ 0
stent NN 0
implantation NN 0
versus NN 0
balloon NN 0
angioplasty NN 0
in IN 0
the DT 0
femoropopliteal JJ 0
artery NN 0
( ( 0
the DT 0
VascuCoil NNP 0
Trial NNP 0
) ) 0
. . 0

PURPOSE NNP 0
Although IN 0
several JJ 0
prospective JJ 0
studies NNS 0
have VBP 0
examined VBN 0
the DT 0
safety NN 0
and CC 0
efficacy NN 0
of IN 0
stent JJ 0
placement NN 0
for IN 0
femoropopliteal JJ 4
arterial JJ 4
disease NN 4
, , 0
the DT 0
current JJ 0
cost NN 0
of IN 0
these DT 0
procedures NNS 0
is VBZ 0
unknown JJ 0
. . 0

To TO 0
estimate VB 0
and CC 0
compare VB 0
hospital NN 0
costs NNS 0
associated VBN 0
with IN 0
conventional JJ 0
balloon NN 0
angioplasty NN 0
( ( 0
percutaneous JJ 0
transluminal NN 0
angioplasty NN 0
[ NNP 0
PTA NNP 0
] NNP 0
) ) 0
and CC 0
stent JJ 0
placement NN 0
for IN 0
patients NNS 0
with IN 0
symptomatic JJ 0
peripheral JJ 0
arterial JJ 0
disease NN 0
, , 0
the DT 0
authors NNS 0
performed VBD 0
a DT 0
prospective JJ 0
economic JJ 0
evaluation NN 0
in IN 0
conjunction NN 0
with IN 0
the DT 0
Intracoil NNP 0
Femoropopliteal NNP 0
Stent NNP 0
Trial NNP 0
( ( 0
VascuCoil NNP 0
) ) 0
. . 0

MATERIALS NNP 0
AND CC 0
METHODS NNP 0
Between NNP 0
May NNP 0
1997 CD 0
and CC 0
December NNP 0
1999 CD 0
, , 0
266 CD 3
patients NNS 0
with IN 0
stenotic JJ 4
or CC 4
occluded VBN 4
superficial JJ 4
femoral JJ 4
or CC 4
popliteal JJ 4
arteries NNS 4
were VBD 0
prospectively RB 0
randomized VBN 0
to TO 0
treatment NN 0
with IN 0
the DT 0
IntraCoil NNP 0
stent NN 0
or CC 0
PTA NNP 0
. . 0

Detailed NNP 0
resource NN 0
use NN 0
and CC 0
cost NN 0
data NNS 0
for IN 0
each DT 0
patient NN 0
's POS 0
initial JJ 0
revascularization NN 0
procedure NN 0
and CC 0
ensuing VBG 0
hospitalization NN 0
were VBD 0
collected VBN 0
and CC 0
analyzed VBN 0
on IN 0
an DT 0
intention-to-treat JJ 0
basis NN 0
. . 0

RESULTS NNP 0
Compared VBD 0
with IN 0
conventional JJ 0
balloon NN 0
angioplasty NN 0
, , 0
stent JJ 0
placement NN 0
did VBD 0
not RB 0
improve VB 0
clinical JJ 0
outcomes NNS 0
but CC 0
increased JJ 0
procedure NN 0
duration NN 0
, , 0
equipment NN 0
costs NNS 0
, , 0
and CC 0
physician JJ 0
services NNS 0
. . 0

As IN 0
a DT 0
result NN 0
, , 0
initial JJ 0
hospital NN 0
costs NNS 0
were VBD 0
approximately RB 0
3,500 CD 0
dollars NNS 0
higher JJR 0
for IN 0
patients NNS 0
randomized VBN 0
to TO 0
the DT 0
IntraCoil NNP 0
stent NN 0
, , 0
compared VBN 0
with IN 0
PTA NNP 0
( ( 0
8,435 CD 0
dollars NNS 0
vs RB 0
4,980 CD 0
dollars NNS 0
; : 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

CONCLUSIONS NNP 0
As IN 0
performed VBN 0
in IN 0
the DT 0
VascuCoil NNP 0
trial NN 0
, , 0
primary JJ 0
stent NN 0
placement NN 0
for IN 0
femoropopliteal JJ 0
disease NN 0
did VBD 0
not RB 0
improve VB 0
clinical JJ 0
outcomes NNS 0
but CC 0
increased VBD 0
initial JJ 0
treatment NN 0
costs NNS 0
by IN 0
more JJR 0
than IN 0
3,000 CD 0
dollars NNS 0
. . 0

Because IN 0
there EX 0
were VBD 0
no DT 0
substantial JJ 0
differences NNS 0
in IN 0
subsequent JJ 0
clinical JJ 0
outcomes NNS 0
between IN 0
the DT 0
two CD 0
treatments NNS 0
, , 0
it PRP 0
is VBZ 0
unlikely JJ 0
that IN 0
these DT 0
increased VBN 0
initial JJ 0
costs NNS 0
would MD 0
be VB 0
offset VBN 0
by IN 0
savings NNS 0
in IN 0
follow-up JJ 0
costs NNS 0
. . 0

These DT 0
findings NNS 0
suggest VBP 0
that IN 0
a DT 0
strategy NN 0
of IN 0
routine JJ 0
stent NN 0
implantation NN 0
for IN 0
patients NNS 0
undergoing VBG 0
femoropopliteal JJ 4
PTA NNP 4
is VBZ 0
not RB 0
optimal JJ 0
on IN 0
economic JJ 0
grounds NNS 0
and CC 0
that DT 0
PTA NNP 0
with IN 0
provisional JJ 0
stent JJ 0
implantation NN 0
is VBZ 0
preferred VBN 0
. . 0

Propofol NNP 0
sedation NN 0
with IN 0
bispectral JJ 0
index NN 0
monitoring NN 0
is VBZ 0
useful JJ 0
for IN 0
endoscopic NN 0
submucosal JJ 0
dissection NN 0
: : 0
a DT 0
randomized JJ 0
prospective JJ 0
phase NN 0
II NNP 0
clinical JJ 0
trial NN 0
. . 0

BACKGROUND NNP 0
AND NNP 0
STUDY NNP 0
AIMS NNP 0
Endoscopic NNP 0
submucosal NN 0
dissection NN 0
( ( 0
ESD NNP 0
) ) 0
has VBZ 0
become VBN 0
a DT 0
standard JJ 0
treatment NN 0
. . 0

However RB 0
, , 0
the DT 0
treatment NN 0
time NN 0
tends VBZ 0
to TO 0
be VB 0
relatively RB 0
long JJ 0
and CC 0
insufflation NN 0
and CC 0
manipulation NN 0
of IN 0
the DT 0
endoscope NN 0
can MD 0
increase VB 0
pain NN 0
and CC 0
discomfort NN 0
. . 0

We PRP 0
aimed VBD 0
to TO 0
find VB 0
an DT 0
optimal JJ 0
method NN 0
for IN 0
sedation NN 0
during IN 0
ESD NNP 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
Patients NNP 0
scheduled VBD 0
to TO 0
undergo VB 0
ESD NNP 0
for IN 0
early JJ 4
gastric JJ 4
cancer NN 4
or CC 4
adenoma NN 4
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
sedation NN 0
with IN 0
midazolam NN 0
or CC 0
propofol NN 0
, , 0
and CC 0
consciousness JJ 0
level NN 0
was VBD 0
evaluated VBN 0
by IN 0
bispectral JJ 0
index NN 0
( ( 0
BIS NNP 0
) ) 0
monitoring NN 0
. . 0

Primary JJ 0
end NN 0
points NNS 0
of IN 0
effectiveness NN 0
( ( 0
three CD 0
parameters NNS 0
) ) 0
and CC 0
secondary JJ 0
end NN 0
points NNS 0
of IN 0
safety NN 0
during IN 0
ESD NNP 0
and CC 0
after IN 0
return NN 0
to TO 0
the DT 0
ward NN 0
were VBD 0
compared VBN 0
between IN 0
the DT 0
groups NNS 0
. . 0

Study NNP 0
registration NN 0
was VBD 0
in IN 0
the DT 0
UMIN NNP 0
Clinical NNP 0
Trial NNP 0
Registry NNP 0
( ( 0
UMIN NNP 0
000001497 CD 0
) ) 0
, , 0
and CC 0
the DT 0
institutional JJ 0
trial NN 0
number NN 0
was VBD 0
KDOG NNP 0
0801 CD 0
. . 0

RESULTS VBN 0
From IN 0
June NNP 0
2008 CD 0
through IN 0
June NNP 0
2009 CD 0
, , 0
we PRP 0
enrolled VBD 0
178 CD 3
patients NNS 0
( ( 0
90 CD 0
midazolam NN 0
, , 0
88 CD 0
propofol NN 0
) ) 0
. . 0

Regarding VBG 0
safety NN 0
after IN 0
ESD NNP 0
, , 0
recovery NN 0
was VBD 0
significantly RB 0
better RBR 0
in IN 0
the DT 0
propofol NN 0
group NN 0
immediately RB 0
after IN 0
and CC 0
at IN 0
1 CD 0
hour NN 0
and CC 0
2 CD 0
hours NNS 0
after IN 0
return NN 0
to TO 0
the DT 0
ward NN 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

The DT 0
number NN 0
of IN 0
patients NNS 0
who WP 0
required VBD 0
a DT 0
continuous JJ 0
supply NN 0
of IN 0
oxygen NN 0
2 CD 0
hours NNS 0
after IN 0
returning VBG 0
to TO 0
the DT 0
ward NN 0
was VBD 0
significantly RB 0
lower JJR 0
in IN 0
the DT 0
propofol NN 0
group NN 0
( ( 0
midazolam JJ 0
18 CD 0
; : 0
propofol CC 0
6 CD 0
; : 0
P NNP 0
= NNP 0
0.010 CD 0
) ) 0
. . 0

Though IN 0
propofol NN 0
seemed VBD 0
to TO 0
be VB 0
better JJR 0
for IN 0
effectiveness NN 0
and CC 0
safety NN 0
, , 0
there EX 0
were VBD 0
no DT 0
statistically RB 0
significant JJ 0
differences NNS 0
for IN 0
all DT 0
three CD 0
primary JJ 0
end NN 0
points NNS 0
and CC 0
the DT 0
safety NN 0
parameters NNS 0
( ( 0
hypotension NN 0
, , 0
hypoxia NN 0
, , 0
bradycardia NN 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Propofol NNP 0
with IN 0
BIS NNP 0
monitoring VBG 0
improved JJ 0
recovery NN 0
of IN 0
patients NNS 0
after IN 0
ESD NNP 0
, , 0
though IN 0
this DT 0
study NN 0
was VBD 0
underpowered VBN 0
to TO 0
prove VB 0
the DT 0
effectiveness NN 0
and CC 0
safety NN 0
of IN 0
propofol NN 0
. . 0

Multiple JJ 0
courses NNS 0
of IN 0
rituximab NN 0
produce NN 0
sustained VBD 0
clinical JJ 0
and CC 0
radiographic JJ 0
efficacy NN 0
and CC 0
safety NN 0
in IN 0
patients NNS 0
with IN 0
rheumatoid JJ 4
arthritis NN 4
and CC 0
an DT 0
inadequate JJ 0
response NN 0
to TO 0
1 CD 0
or CC 0
more JJR 0
tumor JJ 0
necrosis NN 0
factor NN 0
inhibitors NNS 0
: : 0
5-year JJ 0
data NNS 0
from IN 0
the DT 0
REFLEX NNP 0
study NN 0
. . 0

OBJECTIVE VB 0
This DT 0
5-year JJ 0
observational JJ 0
posthoc NN 0
analysis NN 0
of IN 0
the DT 0
REFLEX NNP 0
study NN 0
and CC 0
its PRP$ 0
open-label JJ 0
extension NN 0
assessed VBD 0
clinical JJ 0
efficacy NN 0
, , 0
radiographic JJ 0
response NN 0
, , 0
and CC 0
safety NN 0
of IN 0
rituximab NN 0
( ( 0
RTX NNP 0
) ) 0
in IN 0
patients NNS 0
with IN 0
rheumatoid JJ 0
arthritis NN 0
( ( 0
RA NNP 4
) ) 0
who WP 0
had VBD 0
an DT 0
inadequate JJ 0
response NN 0
to TO 0
tumor VB 0
necrosis NN 0
factor NN 0
( ( 0
TNF NNP 0
) ) 0
inhibitors NNS 0
. . 0

METHODS NNP 0
Patients NNPS 0
in IN 0
REFLEX NNP 0
were VBD 0
originally RB 0
randomized VBN 0
to TO 0
placebo VB 0
( ( 0
PBO NNP 0
) ) 0
+ NN 0
methotrexate NN 0
( ( 0
MTX NNP 0
; : 0
PBO-randomized NNP 0
) ) 0
or CC 0
RTX NNP 0
+ NNP 0
MTX NNP 0
( ( 0
RTX-randomized NNP 0
) ) 0
. . 0

PBO-randomized JJ 0
patients NNS 0
were VBD 0
rescued VBN 0
with IN 0
RTX NNP 0
as IN 0
appropriate JJ 0
. . 0

Patients NNS 0
responding VBG 0
to TO 0
initial JJ 0
RTX NNP 0
treatment NN 0
could MD 0
receive VB 0
further JJ 0
RTX NNP 0
courses NNS 0
. . 0

For IN 0
clinical JJ 0
efficacy NN 0
and CC 0
safety NN 0
analyses NNS 0
, , 0
PBO-randomized JJ 0
patients NNS 0
were VBD 0
re-baselined JJ 0
prior NN 0
to TO 0
first JJ 0
RTX NNP 0
treatment NN 0
and CC 0
the DT 0
data NNS 0
were VBD 0
pooled VBN 0
with IN 0
RTX-randomized JJ 0
patient NN 0
data NNS 0
. . 0

Efficacy NNP 0
outcomes RB 0
24 CD 0
weeks NNS 0
after IN 0
each DT 0
course NN 0
were VBD 0
calculated VBN 0
relative JJ 0
to TO 0
first JJ 0
RTX NNP 0
pretreatment NN 0
baseline NN 0
. . 0

Radiographic JJ 0
outcomes NNS 0
were VBD 0
assessed VBN 0
relative JJ 0
to TO 0
randomization VB 0
baseline NN 0
for IN 0
both DT 0
PBO-randomized NNP 0
and CC 0
RTX-randomized NNP 0
groups NNS 0
. . 0

RESULTS VB 0
A DT 0
total NN 0
of IN 0
480 CD 0
patients NNS 0
received VBN 0
? . 0
1 CD 0
RTX NNP 0
course NN 0
. . 0

At IN 0
24 CD 0
weeks NNS 0
, , 0
American NNP 0
College NNP 0
of IN 0
Rheumatology NNP 0
20/50/70 CD 0
responses NNS 0
were VBD 0
62.0 CD 0
% NN 0
, , 0
30.8 CD 0
% NN 0
, , 0
and CC 0
13.0 CD 0
% NN 0
, , 0
respectively RB 0
at IN 0
course NN 0
1 CD 0
( ( 0
n JJ 0
= NNP 0
400 CD 0
) ) 0
and CC 0
70.3 CD 0
% NN 0
, , 0
41.8 CD 0
% NN 0
, , 0
and CC 0
22.0 CD 0
% NN 0
at IN 0
course NN 0
5 CD 0
( ( 0
n JJ 0
= NNP 0
91 CD 0
) ) 0
. . 0

European JJ 0
League NNP 0
Against NNP 0
Rheumatism NNP 0
good/moderate NN 0
responses NNS 0
were VBD 0
77.2 CD 0
% NN 0
and CC 0
84.4 CD 0
% NN 0
at IN 0
courses NNS 0
1 CD 0
( ( 0
n JJ 0
= NNP 0
390 CD 0
) ) 0
and CC 0
5 CD 0
( ( 0
n JJ 0
= NNP 0
90 CD 0
) ) 0
. . 0

Rates NNS 0
of IN 0
adverse JJ 0
events NNS 0
( ( 0
AE NNP 0
) ) 0
, , 0
serious JJ 0
AE NNP 0
, , 0
and CC 0
infections NNS 0
generally RB 0
remained VBD 0
stable JJ 0
. . 0

Rate NNP 0
of IN 0
progressive JJ 0
joint JJ 0
damage NN 0
( ( 0
PJD NNP 0
; : 0
change NN 0
in IN 0
mean JJ 0
Total NNP 0
Sharp NNP 0
Score NNP 0
) ) 0
decreased VBD 0
over RP 0
time NN 0
in IN 0
both DT 0
PBO-randomized NNP 0
( ( 0
n JJ 0
= NNP 0
79 CD 0
) ) 0
and CC 0
RTX-randomized NNP 0
( ( 0
n JJ 0
= NNP 0
105 CD 0
) ) 0
groups NNS 0
. . 0

Mean JJ 0
change NN 0
from IN 0
baseline NN 0
in IN 0
PJD NNP 0
over IN 0
5 CD 0
years NNS 0
was VBD 0
greater JJR 0
in IN 0
PBO-randomized NNP 0
versus NN 0
RTX-randomized JJ 0
patients NNS 0
( ( 0
5.51 CD 0
vs RB 0
3.21 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
RTX NNP 0
re-treatment NN 0
over IN 0
5 CD 0
years NNS 0
is VBZ 0
associated VBN 0
with IN 0
maintained VBN 0
or CC 0
improved VBN 0
efficacy NN 0
, , 0
continued VBD 0
inhibition NN 0
of IN 0
PJD NNP 0
, , 0
and CC 0
a DT 0
safety NN 0
profile NN 0
consistent JJ 0
with IN 0
that DT 0
previously RB 0
reported VBN 0
. . 0

A DT 0
delay NN 0
in IN 0
initiating VBG 0
RTX NNP 0
treatment NN 0
may MD 0
result VB 0
in IN 0
increased JJ 0
PJD NNP 0
. . 0

Dose NNP 0
response NN 0
effect NN 0
of IN 0
cyclical JJ 0
medroxyprogesterone NN 0
on IN 0
blood NN 0
pressure NN 0
in IN 0
postmenopausal JJ 4
women NNS 2
. . 0

OBJECTIVE VB 0
This DT 0
study NN 0
was VBD 0
designed VBN 0
to TO 0
compare VB 0
with IN 0
placebo PDT 0
the DT 0
dose-response JJ 0
effect NN 0
of IN 0
cyclical JJ 0
doses NNS 0
of IN 0
the DT 0
C21 NNP 0
progestogen NN 0
, , 0
medroxyprogesterone NN 0
acetate NN 0
( ( 0
MPA NNP 0
) ) 0
on IN 0
blood NN 0
pressure NN 0
( ( 0
BP NNP 0
) ) 0
when WRB 0
administered VBN 0
to TO 0
normotensive JJ 4
postmenopausal NN 4
women NNS 2
receiving VBG 0
a DT 0
fixed JJ 0
mid-range JJ 0
daily JJ 0
dose NN 0
of IN 0
conjugated JJ 0
equine NN 0
oestrogen NN 0
( ( 0
CEE NNP 0
) ) 0
. . 0

MATERIALS NNP 0
AND CC 0
METHODS NNP 0
Twenty NNP 3
normotensive JJ 4
postmenopausal NN 4
women NNS 2
( ( 0
median JJ 0
age NN 0
53 CD 1
years NNS 0
) ) 0
participated VBD 0
in IN 0
the DT 0
study NN 0
which WDT 0
used VBD 0
a DT 0
double-blind JJ 0
crossover NN 0
design NN 0
. . 0

There EX 0
were VBD 0
four CD 0
randomised VBN 0
treatment NN 0
phases NNS 0
, , 0
each DT 0
of IN 0
4 CD 0
weeks NNS 0
duration NN 0
. . 0

The DT 0
four CD 0
blinded VBD 0
treatments NNS 0
were VBD 0
MPA NNP 0
2.5 CD 0
mg NN 0
, , 0
MPA NNP 0
5 CD 0
mg NN 0
, , 0
MPA NNP 0
10 CD 0
mg NN 0
and CC 0
matching VBG 0
placebo NN 0
, , 0
taken VBN 0
for IN 0
the DT 0
last JJ 0
14 CD 0
days NNS 0
of IN 0
each DT 0
28 CD 0
day NN 0
treatment NN 0
cycle NN 0
. . 0

CEE NNP 0
0.625 CD 0
mg NN 0
was VBD 0
also RB 0
administered VBN 0
once RB 0
daily JJ 0
as IN 0
open JJ 0
labelled VBD 0
tablets NNS 0
to TO 0
all DT 0
subjects NNS 0
throughout IN 0
the DT 0
study NN 0
. . 0

Clinic NNP 0
BP NNP 0
was VBD 0
measured VBN 0
weekly RB 0
with IN 0
the DT 0
mean JJ 0
values NNS 0
of IN 0
weeks NNS 0
3 CD 0
and CC 0
4 CD 0
of IN 0
each DT 0
phase NN 0
used VBN 0
for IN 0
analysis NN 0
. . 0

Ambulatory NNP 0
BP NNP 0
was VBD 0
performed VBN 0
in IN 0
the DT 0
final JJ 0
week NN 0
of IN 0
each DT 0
phase NN 0
. . 0

RESULTS NNP 0
Compared VBD 0
with IN 0
the DT 0
placebo NN 0
phase NN 0
, , 0
end NN 0
of IN 0
phase NN 0
clinic JJ 0
BP NNP 0
was VBD 0
unchanged JJ 0
by IN 0
any DT 0
of IN 0
the DT 0
progestogen NN 0
treatments NNS 0
. . 0

There EX 0
was VBD 0
a DT 0
dose-dependent JJ 0
decrease NN 0
in IN 0
ambulatory JJ 0
daytime JJ 0
diastolic NN 0
and CC 0
mean JJ 0
arterial JJ 0
BP NNP 0
with IN 0
the DT 0
progestogen NN 0
treatments NNS 0
compared VBN 0
with IN 0
placebo NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
In IN 0
a DT 0
regimen NN 0
of IN 0
postmenopausal NN 0
hormone NN 0
replacement NN 0
therapy NN 0
with IN 0
a DT 0
fixed JJ 0
mid-range JJ 0
daily JJ 0
dose NN 0
of IN 0
CEE NNP 0
combined VBD 0
with IN 0
a DT 0
cyclical JJ 0
regimen NN 0
of IN 0
a DT 0
C21 NNP 0
progestogen NN 0
spanning VBG 0
the DT 0
current JJ 0
clinical JJ 0
dose NN 0
range NN 0
, , 0
the DT 0
progestogen NN 0
has VBZ 0
either CC 0
no DT 0
effect NN 0
or CC 0
a DT 0
small JJ 0
dose-dependent JJ 0
reduction NN 0
in IN 0
clinic NN 0
and CC 0
ambulatory JJ 0
BPs NNP 0
over IN 0
one CD 0
treatment NN 0
cycle NN 0
. . 0

Smoking VBG 0
cessation NN 0
with IN 0
smokeless JJ 0
tobacco NN 0
and CC 0
group NN 0
therapy NN 0
: : 0
an DT 0
open JJ 0
, , 0
randomized VBN 0
, , 0
controlled VBN 0
trial NN 0
. . 0

Smokeless NNP 0
tobacco NN 0
might MD 0
be VB 0
effective JJ 0
as IN 0
an DT 0
adjunct NN 0
for IN 0
smoking VBG 0
cessation NN 0
. . 0

We PRP 0
evaluated VBD 0
the DT 0
efficacy NN 0
of IN 0
smokeless NN 0
tobacco NN 0
and CC 0
group NN 0
support NN 0
for IN 0
smoking VBG 0
cessation NN 0
in IN 0
an DT 0
open JJ 0
, , 0
randomized VBN 0
study NN 0
that WDT 0
compared VBN 0
smokeless NN 0
tobacco NN 0
plus CC 0
group NN 0
support NN 0
versus NN 0
group NN 0
support NN 0
only RB 0
. . 0

The DT 0
study NN 0
enrolled VBD 0
263 CD 3
healthy JJ 4
smokers NNS 4
( ( 0
M NNP 0
( ( 0
age NN 0
) ) 0
= VBZ 0
49 CD 1
years NNS 1
) ) 0
who WP 0
smoked VBD 4
a DT 0
mean NN 0
of IN 0
24 CD 4
cigarettes/day NN 4
, , 0
with IN 0
a DT 0
mean NN 0
of IN 0
31 CD 4
pack-years NNS 4
. . 0

Smokeless NNP 0
tobacco NN 0
was VBD 0
provided VBN 0
for IN 0
7 CD 0
weeks NNS 0
( ( 0
or CC 0
up RB 0
to TO 0
12 CD 0
) ) 0
, , 0
combined VBN 0
with IN 0
eight CD 0
group NN 0
support NN 0
visits NNS 0
provided VBN 0
by IN 0
nurses NNS 0
. . 0

The DT 0
control NN 0
group NN 0
received VBD 0
group NN 0
support NN 0
only RB 0
. . 0

Smoking VBG 0
cessation NN 0
rates NNS 0
were VBD 0
statistically RB 0
significantly RB 0
better RBR 0
in IN 0
the DT 0
smokeless NN 0
tobacco NN 0
group NN 0
than IN 0
in IN 0
the DT 0
control NN 0
group NN 0
during IN 0
the DT 0
first JJ 0
7 CD 0
weeks NNS 0
. . 0

Point-prevalence NN 0
abstinence NN 0
rates NNS 0
at IN 0
7 CD 0
weeks NNS 0
were VBD 0
36.4 CD 0
% NN 0
versus IN 0
20.8 CD 0
% NN 0
( ( 0
OR NNP 0
= VBZ 0
2.52 CD 0
, , 0
p NN 0
= NNP 0
.001 NNP 0
) ) 0
, , 0
respectively RB 0
; : 0
and CC 0
continuous JJ 0
abstinence NN 0
rates NNS 0
from IN 0
weeks NNS 0
4 CD 0
to TO 0
7 CD 0
were VBD 0
31.5 CD 0
% NN 0
versus IN 0
19.2 CD 0
% NN 0
( ( 0
OR NNP 0
= VBZ 0
1.94 CD 0
, , 0
p NN 0
= NNP 0
.023 NNP 0
) ) 0
, , 0
respectively RB 0
. . 0

The DT 0
primary JJ 0
outcomes NNS 0
( ( 0
i.e. JJ 0
, , 0
6-month JJ 0
point NN 0
prevalence NN 0
) ) 0
were VBD 0
23.1 CD 0
% NN 0
versus IN 0
20.8 CD 0
% NN 0
, , 0
respectively RB 0
( ( 0
OR NNP 0
= VBZ 0
1.31 CD 0
, , 0
ns NN 0
) ) 0
. . 0

Smokeless NNP 0
tobacco NN 0
was VBD 0
relatively RB 0
well RB 0
tolerated VBN 0
, , 0
although IN 0
15 CD 0
subjects NNS 0
( ( 0
11.2 CD 0
% NN 0
) ) 0
stopped VBD 0
use NN 0
due JJ 0
to TO 0
adverse JJ 0
events NNS 0
. . 0

A DT 0
total NN 0
of IN 0
25 CD 0
subjects NNS 0
( ( 0
17.5 CD 0
% NN 0
) ) 0
were VBD 0
still RB 0
using VBG 0
smokeless JJ 0
tobacco NN 0
after IN 0
6 CD 0
months NNS 0
. . 0

This DT 0
trial NN 0
demonstrated VBD 0
short-term JJ 0
efficacy NN 0
of IN 0
smokeless JJ 0
tobacco NN 0
in IN 0
combination NN 0
with IN 0
group NN 0
support NN 0
for IN 0
smoking VBG 0
cessation NN 0
but CC 0
no DT 0
long-term JJ 0
efficacy NN 0
. . 0

[ JJ 0
Observation NNP 0
of IN 0
curative JJ 0
effect NN 0
on IN 0
fixed-point NN 0
spin NN 0
reduction NN 0
of IN 0
spinal JJ 0
manipulation NN 0
therapy NN 0
for IN 0
cervical JJ 4
vertigo NN 4
] NN 0
. . 0

OBJECTIVE UH 0
To TO 0
explore VB 0
the DT 0
role NN 0
of IN 0
fixed-point JJ 0
spin JJ 0
reduction NN 0
of IN 0
spinal JJ 0
manipulation NN 0
therapy NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
cervical JJ 4
vertigo NN 4
and CC 0
its PRP$ 0
effect NN 0
on IN 0
cervical JJ 0
artery NN 0
spasm NN 0
index NN 0
( ( 0
RI NNP 0
) ) 0
and CC 0
atlantoaxial JJ 0
displacement NN 0
index NN 0
( ( 0
ADI NNP 0
) ) 0
. . 0

METHODS NN 0
From IN 0
January NNP 0
2002 CD 0
to TO 0
May NNP 0
2008 CD 0
, , 0
168 CD 3
patients NNS 0
with IN 0
cervical JJ 0
vertigo NNS 0
were VBD 0
randomly RB 0
divided VBN 0
into IN 0
treatment NN 0
group NN 0
( ( 0
84 CD 3
cases NNS 0
) ) 0
and CC 0
the DT 0
control NN 0
group NN 0
( ( 0
84 CD 3
cases NNS 0
) ) 0
, , 0
22 CD 3
males NNS 2
and CC 0
62 CD 3
females NNS 2
in IN 0
treatment NN 0
group NN 0
; : 0
24 CD 3
males NNS 2
and CC 0
60 CD 3
females NNS 2
in IN 0
control NN 0
group NN 0
. . 0

The DT 0
patients NNS 0
of IN 0
treatment NN 0
group NN 0
and CC 0
control NN 0
group NN 0
were VBD 0
respectively RB 0
treated VBN 0
with IN 0
fixed-point JJ 0
spin NN 0
reduction NN 0
of IN 0
spinal JJ 0
manipulation NN 0
therapy NN 0
and CC 0
dialectical JJ 0
prescription NN 0
. . 0

The DT 0
score NN 0
of IN 0
symptoms NNS 0
and CC 0
signs NNS 0
, , 0
RI NNP 0
, , 0
ADI NNP 0
were VBD 0
observed VBN 0
and CC 0
compared VBN 0
between IN 0
two CD 0
groups NNS 0
. . 0

RESULTS VB 0
The DT 0
score NN 0
of IN 0
symptoms NNS 0
and CC 0
signs NNS 0
markedly RB 0
decreased VBD 0
after IN 0
treatment NN 0
, , 0
in IN 0
treatment NN 0
group NN 0
: : 0
vertigo NN 0
had VBD 0
( ( 0
2.75 CD 0
+/- JJ 0
1.01 CD 0
) ) 0
scores NNS 0
, , 0
neck-shoulder JJ 0
pain NN 0
( ( 0
1.58 CD 0
+/- JJ 0
0.36 CD 0
) ) 0
, , 0
headache NN 0
( ( 0
0.39 CD 0
+/- JJ 0
0.09 CD 0
) ) 0
, , 0
nausea-vomiting JJ 0
( ( 0
1.58 CD 0
+/- JJ 0
1.30 CD 0
) ) 0
, , 0
ear JJ 0
noises NNS 0
( ( 0
0.48 CD 0
+/- JJ 0
0.32 CD 0
) ) 0
, , 0
positive JJ 0
neck NN 0
rotation NN 0
test NN 0
( ( 0
0.59 CD 0
+/- JJ 0
0.21 CD 0
) ) 0
; : 0
and CC 0
in IN 0
control NN 0
group NN 0
: : 0
vertigo NN 0
had VBD 0
( ( 0
5.68 CD 0
+/- JJ 0
2.02 CD 0
) ) 0
scores NNS 0
, , 0
neck-shoulder JJ 0
pain NN 0
( ( 0
3.12 CD 0
+/- JJ 0
1.82 CD 0
) ) 0
, , 0
headache NN 0
( ( 0
1.86 CD 0
+/- JJ 0
0.65 CD 0
) ) 0
, , 0
nausea-vomiting JJ 0
( ( 0
3.25 CD 0
+/- JJ 0
0.69 CD 0
) ) 0
, , 0
ear JJ 0
noises NNS 0
( ( 0
1.64 CD 0
+/- JJ 0
0.61 CD 0
) ) 0
, , 0
positive JJ 0
neck NN 0
rotation NN 0
test NN 0
( ( 0
1.79 CD 0
+/- JJ 0
0.67 CD 0
) ) 0
. . 0

Cervical JJ 0
artery NN 0
spasm NN 0
index NN 0
and CC 0
atlantoaxial JJ 0
displacement NN 0
index NN 0
had VBD 0
been VBN 0
significantly RB 0
improved VBN 0
, , 0
cervical JJ 0
artery NN 0
spasm NN 0
index NN 0
was VBD 0
respectively RB 0
0.54 CD 0
+/- JJ 0
0.07 CD 0
and CC 0
0.52 CD 0
+/- JJ 0
0.13 CD 0
, , 0
atlantoaxial JJ 0
displacement NN 0
index NN 0
was VBD 0
respectively RB 0
2.92 CD 0
+/- JJ 0
0.82 CD 0
and CC 0
4.50 CD 0
+/- JJ 0
1.32 CD 0
between IN 0
treatment NN 0
group NN 0
and CC 0
control NN 0
group NN 0
. . 0

CONCLUSION NNP 0
Fixed-point NNP 0
spin NN 0
reduction NN 0
of IN 0
spinal JJ 0
manipulation NN 0
therapy NN 0
for IN 0
cervical JJ 0
vertigo NN 0
can MD 0
accurately RB 0
correct VB 0
single JJ 0
or CC 0
multiple JJ 0
vertebral JJ 4
body NN 4
displacement NN 4
, , 0
restore VB 0
normal JJ 0
spinal JJ 0
position NN 0
, , 0
reduce VB 0
the DT 0
oppression NN 0
and CC 0
stimulus NN 0
of IN 0
the DT 0
vertebral JJ 0
artery NN 0
, , 0
release NN 0
ischemia NN 0
of IN 0
vestibular JJ 0
labyrinth NN 0
, , 0
eliminate VB 0
symptoms NNS 0
of IN 0
vertigo NN 0
. . 0

International NNP 0
Czech NNP 0
and CC 0
Slovak NNP 0
cooperation NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
patients NNS 0
with IN 0
differentiated JJ 4
thyroid NN 4
cancer NN 4
. . 0

BACKGROUND IN 0
The DT 0
aim NN 0
of IN 0
this DT 0
paper NN 0
is VBZ 0
to TO 0
present VB 0
our PRP$ 0
experience NN 0
concerning VBG 0
cooperation NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
Slovak NNP 0
patients NNS 0
with IN 0
differentiated JJ 0
thyroid NN 0
cancer NN 0
in IN 0
Slovak NNP 0
and CC 0
Czech NNP 0
hospitals NNS 0
. . 0

The DT 0
objectives NNS 0
of IN 0
this DT 0
study NN 0
were VBD 0
to TO 0
demonstrate VB 0
the DT 0
means NNS 0
of IN 0
this DT 0
cooperation NN 0
and CC 0
the DT 0
results NNS 0
of IN 0
therapy NN 0
. . 0

MATERIAL NNP 0
AND CC 0
METHODS NNP 0
From NNP 0
September NNP 0
1991 CD 0
to TO 0
October NNP 0
2005 CD 0
in IN 0
the DT 0
Department NNP 0
of IN 0
Nuclear NNP 0
Medicine NNP 0
in IN 0
Ostrava NNP 0
357 CD 3
patients NNS 0
from IN 0
the DT 0
Slovak NNP 0
Republic NNP 0
with IN 0
differentiated VBN 4
thyroid NN 4
cancers NNS 4
( ( 0
follicular JJ 4
and CC 4
papillary JJ 4
) ) 0
underwent NN 0
complex JJ 0
therapy NN 0
. . 0

They PRP 0
were VBD 0
diagnosed VBN 0
and CC 0
operated VBN 0
due JJ 0
to TO 0
the DT 0
cancer NN 0
( ( 0
near-total JJ 4
thyroidectomy NN 4
and CC 0
removal NN 4
of IN 4
lymph JJ 4
node JJ 4
metastases NNS 4
) ) 0
in IN 0
Slovak NNP 0
hospitals NNS 0
. . 0

Then RB 0
they PRP 0
were VBD 0
sent VBN 0
to TO 0
the DT 0
Department NNP 0
of IN 0
Nuclear NNP 0
Medicine NNP 0
in IN 0
Ostrava NNP 0
in IN 0
the DT 0
Czech NNP 0
Republic NNP 0
. . 0

In IN 0
this DT 0
department NN 0
a DT 0
radioiodine JJ 0
ablation NN 0
of IN 0
thyroid JJ 0
remnants NNS 0
, , 0
by IN 0
means NNS 0
of IN 0
the DT 0
treatment NN 0
amount NN 0
of IN 0
radioiodine NN 0
of IN 0
a DT 0
standard JJ 0
activity NN 0
of IN 0
3.7 CD 0
GBq NNP 0
, , 0
was VBD 0
performed VBN 0
, , 0
and CC 0
then RB 0
a DT 0
suppression NN 0
and CC 0
substitution NN 0
therapy NN 0
of IN 0
thyroid JJ 0
hormones NNS 0
was VBD 0
started VBN 0
. . 0

After IN 0
3-6 JJ 0
months NNS 0
some DT 0
patients NNS 0
were VBD 0
examined VBN 0
by IN 0
means NNS 0
of IN 0
diagnostic JJ 0
whole JJ 0
body NN 0
scintigraphy NN 0
after IN 0
application NN 0
of IN 0
300 CD 0
MBq NNP 0
131I CD 0
. . 0

Some DT 0
patients NNS 0
were VBD 0
treated VBN 0
by IN 0
means NNS 0
of IN 0
a DT 0
standard JJ 0
activity NN 0
of IN 0
7.4 CD 0
GBq NNP 0
131I CD 0
and CC 0
after IN 0
5 CD 0
days NNS 0
whole JJ 0
body NN 0
scintigraphy NN 0
( ( 0
WBS NNP 0
) ) 0
was VBD 0
performed VBN 0
. . 0

In IN 0
both DT 0
of IN 0
these DT 0
groups NNS 0
of IN 0
patients NNS 0
the DT 0
diagnostic JJ 0
or CC 0
therapeutic JJ 0
radioiodine NN 0
application NN 0
was VBD 0
done VBN 0
after IN 0
withdrawal NN 0
of IN 0
thyroid JJ 0
hormone NN 0
treatment NN 0
. . 0

If IN 0
thyroglobulin JJ 0
levels NNS 0
were VBD 0
low JJ 0
and CC 0
WBSs NNP 0
were VBD 0
negative JJ 0
, , 0
patients NNS 0
were VBD 0
followed VBN 0
up RP 0
in IN 0
the DT 0
Department NNP 0
of IN 0
Nuclear NNP 0
Medicine NNP 0
in IN 0
Martin NNP 0
. . 0

Patients NNS 0
with IN 0
radioiodine NN 0
accumulated VBN 0
metastases NNS 0
were VBD 0
again RB 0
treated VBN 0
with IN 0
radioiodine NN 0
in IN 0
Ostrava NNP 0
. . 0

If IN 0
indicated VBN 0
, , 0
external JJ 0
radiation NN 0
therapy NN 0
targeted VBN 0
on IN 0
the DT 0
neck NN 0
and CC 0
upper JJ 0
mediastinum NN 0
was VBD 0
performed VBN 0
in IN 0
the DT 0
Slovak NNP 0
Republic NNP 0
, , 0
in IN 0
the DT 0
University NNP 0
Hospital NNP 0
in IN 0
Martin NNP 0
. . 0

Newly RB 0
formed VBN 0
lymph JJ 0
node NN 0
metastases NNS 0
were VBD 0
surgically RB 0
treated VBN 0
in IN 0
Slovakia NNP 0
, , 0
too RB 0
. . 0

Generally RB 0
we PRP 0
have VBP 0
very RB 0
good JJ 0
treatment NN 0
results NNS 0
. . 0

Also RB 0
, , 0
economically RB 0
our PRP$ 0
partnership NN 0
is VBZ 0
cost VBN 0
effective JJ 0
. . 0

Our PRP$ 0
collaboration NN 0
also RB 0
successfully RB 0
continues VBZ 0
after IN 0
entrance NN 0
of IN 0
the DT 0
Slovak NNP 0
Republic NNP 0
and CC 0
the DT 0
Czech NNP 0
Republic NNP 0
to TO 0
the DT 0
European NNP 0
Union NNP 0
in IN 0
2004 CD 0
. . 0

CONCLUSIONS VB 0
The DT 0
results NNS 0
of IN 0
this DT 0
multi-centre JJ 0
study NN 0
show NN 0
that IN 0
international JJ 0
Czech NNP 0
and CC 0
Slovak NNP 0
cooperation NN 0
in IN 0
the DT 0
complex JJ 0
therapy NN 0
of IN 0
patients NNS 0
with IN 0
differentiated JJ 0
thyroid NN 0
cancers NNS 0
is VBZ 0
successful JJ 0
, , 0
with IN 0
high JJ 0
efficacy NN 0
. . 0

The DT 0
treatment NN 0
results NNS 0
were VBD 0
very RB 0
similar JJ 0
to TO 0
therapeutic JJ 0
results NNS 0
in IN 0
our PRP$ 0
patients NNS 0
from IN 0
the DT 0
Czech NNP 0
Republic NNP 0
. . 0

Efficacy NN 0
and CC 0
long-term JJ 0
tolerability NN 0
of IN 0
sublingual JJ 0
fentanyl NN 0
orally RB 0
disintegrating VBG 0
tablet NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
breakthrough NN 0
cancer NN 0
pain NN 0
. . 0

BACKGROUND NNP 0
AND NNP 0
OBJECTIVES NNP 0
Breakthrough NNP 0
cancer NN 0
pain NN 0
( ( 0
BTcP NNP 0
) ) 0
represents VBZ 0
an DT 0
important JJ 0
clinical JJ 0
challenge NN 0
in IN 0
the DT 0
care NN 0
of IN 0
patients NNS 0
with IN 0
cancer NN 4
. . 0

This DT 0
trial NN 0
evaluated VBD 0
the DT 0
efficacy NN 0
and CC 0
long-term JJ 0
tolerability NN 0
of IN 0
a DT 0
sublingual JJ 0
formulation NN 0
of IN 0
the DT 0
fast-acting JJ 0
opioid NN 0
fentanyl NN 0
, , 0
for IN 0
the DT 0
treatment NN 0
of IN 0
BTcP NNP 0
in IN 0
opioid-tolerant JJ 0
patients NNS 0
with IN 0
cancer NN 0
. . 0

RESEARCH NNP 0
DESIGN NNP 0
AND NNP 0
METHODS NNP 0
This DT 0
was VBD 0
a DT 0
randomized JJ 0
, , 0
placebo-controlled JJ 0
, , 0
multi-center JJ 0
, , 0
phase JJ 0
III NNP 0
trial NN 0
, , 0
conducted VBN 0
in IN 0
opioid-tolerant JJ 0
male NN 2
and CC 2
female JJ 2
patients NNS 0
( ( 0
aged VBN 0
> NN 1
or CC 1
=17 CD 1
years NNS 0
) ) 0
with IN 0
BTcP NNP 0
. . 0

The DT 0
study NN 0
was VBD 0
conducted VBN 0
at IN 0
36 CD 0
centers NNS 0
across IN 0
the DT 0
USA NNP 0
. . 0

The DT 0
study NN 0
comprised VBD 0
a DT 0
2-week JJ 0
open-label JJ 0
titration NN 0
phase NN 0
, , 0
followed VBN 0
by IN 0
a DT 0
double-blind JJ 0
efficacy NN 0
phase NN 0
, , 0
during IN 0
which WDT 0
patients NNS 0
received VBD 0
sublingual JJ 0
fentanyl NN 0
citrate NN 0
orally RB 0
disintegrating VBG 0
tablet NN 0
( ( 0
sublingual JJ 0
fentanyl NN 0
ODT NNP 0
) ) 0
or CC 0
placebo NN 0
, , 0
in IN 0
a DT 0
random JJ 0
order NN 0
. . 0

The DT 0
primary JJ 0
efficacy NN 0
endpoint NN 0
was VBD 0
the DT 0
sum NN 0
of IN 0
pain NN 0
intensity NN 0
difference NN 0
( ( 0
SPID NNP 0
) ) 0
over IN 0
30 CD 0
min JJ 0
post-administration NN 0
. . 0

Secondary JJ 0
efficacy NN 0
endpoints NNS 0
included VBD 0
pain NN 0
intensity NN 0
difference NN 0
( ( 0
PID NNP 0
) ) 0
and CC 0
pain NN 0
relief NN 0
( ( 0
PR NNP 0
) ) 0
throughout IN 0
the DT 0
60-min JJ 0
post-dose JJ 0
assessment NN 0
period NN 0
. . 0

Following VBG 0
efficacy NN 0
evaluation NN 0
, , 0
patients NNS 0
entered VBD 0
a DT 0
long-term JJ 0
safety NN 0
phase NN 0
of IN 0
up IN 0
to TO 0
12 CD 0
months NNS 0
. . 0

Adverse JJ 0
events NNS 0
were VBD 0
recorded VBN 0
throughout IN 0
the DT 0
study NN 0
. . 0

[ VB 0
CLINICAL NNP 0
TRIAL NNP 0
REGISTRATION NNP 0
NCT00262678 NNP 0
] NNP 0
RESULTS NNP 0
A NNP 0
total NN 0
of IN 0
131 CD 3
patients NNS 0
entered VBD 0
the DT 0
titration NN 0
phase NN 0
, , 0
of IN 0
whom WP 0
61 CD 3
were VBD 0
included VBN 0
in IN 0
the DT 0
primary JJ 0
efficacy NN 0
analysis NN 0
. . 0

Sublingual JJ 0
fentanyl NN 0
ODT NNP 0
provided VBD 0
significant JJ 0
improvements NNS 0
in IN 0
SPID NNP 0
relative VBP 0
to TO 0
placebo VB 0
at IN 0
30 CD 0
min NN 0
( ( 0
49.5 CD 0
vs. FW 0
36.6 CD 0
, , 0
p NN 0
= NNP 0
0.0004 CD 0
) ) 0
and CC 0
60 CD 0
min NNS 0
post-administration NN 0
( ( 0
143.0 CD 0
vs. FW 0
104.5 CD 0
, , 0
p NN 0
= NNP 0
0.0002 CD 0
) ) 0
. . 0

Furthermore UH 0
, , 0
sublingual JJ 0
fentanyl NN 0
ODT NNP 0
provided VBD 0
significant JJ 0
improvements NNS 0
in IN 0
PID NNP 0
and CC 0
PR NNP 0
compared VBN 0
to TO 0
placebo VB 0
, , 0
from IN 0
10 CD 0
min NNS 0
post-dose JJ 0
( ( 0
p JJ 0
= NN 0
0.0055 CD 0
and CC 0
p VB 0
= $ 0
0.049 CD 0
for IN 0
PID NNP 0
and CC 0
PR NNP 0
, , 0
respectively RB 0
) ) 0
. . 0

Patient JJ 0
recruitment NN 0
was VBD 0
stopped VBN 0
early RB 0
, , 0
due JJ 0
to TO 0
positive JJ 0
interim JJ 0
analysis NN 0
results NNS 0
( ( 0
significant JJ 0
at IN 0
prespecified JJ 0
level NN 0
, , 0
p JJ 0
< NN 0
or CC 0
= VB 0
0.0414 CD 0
) ) 0
. . 0

Overall JJ 0
, , 0
sublingual JJ 0
fentanyl NN 0
ODT NNP 0
was VBD 0
well-tolerated JJ 0
both DT 0
systemically RB 0
and CC 0
sublingually RB 0
, , 0
with IN 0
41 CD 0
patients NNS 0
experiencing VBG 0
> NN 0
or CC 0
=1 NN 0
study NN 0
drug-related JJ 0
adverse JJ 0
event NN 0
( ( 0
AE NNP 0
) ) 0
. . 0

The DT 0
most RBS 0
common JJ 0
AEs NNP 0
included VBD 0
nausea NN 0
( ( 0
12.2 CD 0
% NN 0
) ) 0
, , 0
vomiting VBG 0
( ( 0
5.3 CD 0
% NN 0
) ) 0
and CC 0
somnolence NN 0
( ( 0
4.6 CD 0
% NN 0
) ) 0
. . 0

One CD 0
serious JJ 0
AE NNP 0
( ( 0
mild JJ 0
affect VBP 0
lability NN 0
) ) 0
was VBD 0
considered VBN 0
possibly RB 0
related VBN 0
to TO 0
study VB 0
medication NN 0
. . 0

The DT 0
observed JJ 0
pattern NN 0
of IN 0
AEs NNP 0
was VBD 0
consistent JJ 0
with IN 0
that DT 0
previously RB 0
observed VBN 0
with IN 0
fentanyl NN 0
. . 0

CONCLUSIONS NNP 0
Sublingual NNP 0
fentanyl NN 0
ODT NNP 0
was VBD 0
efficacious JJ 0
and CC 0
well-tolerated JJ 0
for IN 0
the DT 0
treatment NN 0
of IN 0
BTcP NNP 0
in IN 0
opioid-tolerant JJ 0
patients NNS 0
with IN 0
cancer NN 0
. . 0

Sublingual JJ 0
fentanyl NN 0
ODT NNP 0
provided VBD 0
significant JJ 0
improvements NNS 0
in IN 0
pain NN 0
intensity NN 0
compared VBN 0
to TO 0
placebo VB 0
, , 0
from IN 0
10 CD 0
min JJ 0
post-administration NN 0
and CC 0
throughout IN 0
the DT 0
60-min JJ 0
post-dose JJ 0
assessment NN 0
period NN 0
. . 0

Sublingual JJ 0
fentanyl NN 0
ODT NNP 0
was VBD 0
well RB 0
tolerated VBN 0
over IN 0
12 CD 0
months NNS 0
of IN 0
treatment NN 0
. . 0

Intravenous JJ 0
or CC 0
intramuscular JJ 0
teicoplanin NN 0
once RB 0
daily JJ 0
for IN 0
skin NN 4
and CC 4
soft-tissue JJ 4
infections NNS 4
. . 0

Teicoplanin NNP 0
is VBZ 0
a DT 0
new JJ 0
glycopeptide NN 0
antibiotic JJ 0
with IN 0
potent JJ 0
activity NN 0
against IN 0
gram-positive JJ 0
bacteria NNS 0
and CC 0
pharmacokinetics NNS 0
that WDT 0
allow VBP 0
once RB 0
daily JJ 0
administration NN 0
. . 0

To TO 0
study VB 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
teicoplanin NN 0
for IN 0
skin NN 0
and CC 0
soft-tissue NN 0
infections NNS 0
, , 0
75 CD 3
patients NNS 0
received VBD 0
teicoplanin JJ 0
intravenously RB 0
( ( 0
38 CD 3
) ) 0
or CC 0
intramuscularly RB 0
( ( 0
37 CD 3
, , 0
of IN 0
which WDT 0
16 CD 3
were VBD 0
outpatients NNS 0
) ) 0
. . 0

Of IN 0
62 CD 3
clinically RB 0
evaluable JJ 0
patients NNS 0
, , 0
97 CD 0
percent NN 0
of IN 0
teicoplanin NN 0
iv NN 0
and CC 0
93 CD 0
percent NN 0
of IN 0
teicoplanin NN 0
im NN 0
patients NNS 0
were VBD 0
cured VBN 0
or CC 0
improved VBN 0
. . 0

All DT 0
teicoplanin JJ 0
iv NN 0
patients NNS 0
and CC 0
64 CD 0
percent NN 0
of IN 0
teicoplanin NN 0
im NN 0
patients NNS 0
were VBD 0
cured VBN 0
microbiologically RB 0
at IN 0
24-48 JJ 0
hours NNS 0
posttherapy NN 0
. . 0

Persistence NN 0
of IN 0
organisms NNS 0
frequently RB 0
was VBD 0
associated VBN 0
with IN 0
skin JJ 0
ulcers NNS 0
or CC 0
abscess JJ 0
cavities NNS 0
and CC 0
usually RB 0
had VBD 0
no DT 0
bearing NN 0
on IN 0
clinical JJ 0
outcome NN 0
. . 0

Possible JJ 0
adverse JJ 0
clinical JJ 0
and CC 0
laboratory JJ 0
reactions NNS 0
caused VBN 0
by IN 0
teicoplanin NN 0
occurred VBD 0
in IN 0
4 CD 0
of IN 0
38 CD 0
teicoplanin JJ 0
iv NN 0
patients NNS 0
( ( 0
11 CD 0
percent NN 0
) ) 0
and CC 0
in IN 0
8 CD 0
of IN 0
37 CD 0
teicoplanin JJ 0
im NN 0
patients NNS 0
( ( 0
22 CD 0
percent NN 0
) ) 0
. . 0

Reactions NNPS 0
were VBD 0
mild JJ 0
and CC 0
resolved VBN 0
with IN 0
discontinuation NN 0
of IN 0
teicoplanin NN 0
in IN 0
most JJS 0
cases NNS 0
. . 0

In IN 0
this DT 0
study NN 0
, , 0
teicoplanin NN 0
appeared VBD 0
to TO 0
be VB 0
safe JJ 0
, , 0
efficacious JJ 0
, , 0
and CC 0
convenient NN 0
for IN 0
both DT 0
hospital JJ 0
staff NN 0
and CC 0
patients NNS 0
, , 0
and CC 0
potentially RB 0
cost-effective JJ 0
for IN 0
the DT 0
treatment NN 0
of IN 0
skin NN 0
and CC 0
soft-tissue JJ 0
infections NNS 0
. . 0

In IN 0
particular JJ 0
, , 0
teicoplanin JJ 0
appears VBZ 0
to TO 0
be VB 0
appropriate JJ 0
for IN 0
outpatient JJ 0
parenteral JJ 0
therapy NN 0
. . 0

Hyperbaric NNP 0
oxygen NN 0
attenuation NN 0
of IN 0
lipopolysaccharide-induced JJ 4
acute NN 4
lung NN 4
injury NN 4
involves VBZ 0
heme JJ 0
oxygenase-1 NN 0
. . 0

BACKGROUND NNP 0
Hyperbaric NNP 0
oxygen NN 0
( ( 0
HBO NNP 0
) ) 0
attenuates VBZ 0
lipopolysaccharide JJ 0
( ( 0
LPS NNP 0
) ) 0
-induced VBD 0
acute JJ 4
lung NN 4
injury NN 4
. . 0

This DT 0
beneficial JJ 0
effect NN 0
of IN 0
HBO NNP 0
involves VBZ 0
inhibition NN 0
of IN 0
inducible JJ 0
nitric JJ 0
oxide NN 0
synthase NN 0
( ( 0
iNOS NN 0
) ) 0
expression NN 0
and CC 0
subsequent JJ 0
nitric JJ 0
oxide NN 0
( ( 0
NO NNP 0
) ) 0
biosynthesis NN 0
. . 0

We PRP 0
sought VBD 0
to TO 0
investigate VB 0
the DT 0
role NN 0
of IN 0
heme JJ 0
oxygenase-1 JJ 0
( ( 0
HO-1 NNP 0
) ) 0
on IN 0
this DT 0
HBO NNP 0
inhibition NN 0
of IN 0
iNOS JJ 0
induction NN 0
and CC 0
acute NN 0
lung NN 0
injury NN 0
in IN 0
septic JJ 0
rat NN 0
lungs NNS 0
. . 0

METHODS NNP 0
Before IN 0
the DT 0
experiment NN 0
, , 0
72 CD 3
rats NNS 0
were VBD 0
randomly RB 0
allocated VBN 0
to TO 0
receive VB 0
HBO NNP 0
or CC 0
air NN 0
treatment NN 0
. . 0

With IN 0
or CC 0
without IN 0
HBO NNP 0
pre-treatment NN 0
, , 0
the DT 0
rats NNS 0
were VBD 0
further RB 0
divided VBN 0
into IN 0
the DT 0
following JJ 0
subgroups NNS 0
( ( 0
n JJ 0
= NNP 0
6 CD 0
) ) 0
: : 0
( ( 0
i NN 0
) ) 0
LPS NNP 0
injection NN 0
, , 0
( ( 0
ii NN 0
) ) 0
normal JJ 0
saline NN 0
( ( 0
N/S NNP 0
) ) 0
injection NN 0
, , 0
( ( 0
iii NN 0
) ) 0
hemin NN 0
( ( 0
a DT 0
HO-1 NNP 0
inducer NN 0
) ) 0
plus CC 0
LPS NNP 0
, , 0
( ( 0
iv NN 0
) ) 0
hemin NN 0
alone RB 0
, , 0
( ( 0
v NN 0
) ) 0
tin NN 0
protoporphyrin NN 0
( ( 0
SnPP NNP 0
; : 0
a DT 0
HO-1 NNP 0
inhibitor NN 0
) ) 0
plus CC 0
LPS NNP 0
, , 0
and CC 0
( ( 0
vi NN 0
) ) 0
SnPP NNP 0
alone RB 0
. . 0

All DT 0
rats NNS 0
were VBD 0
maintained VBN 0
for IN 0
6 CD 0
h NN 0
and CC 0
then RB 0
sacrificed VBD 0
with IN 0
a DT 0
high-dose JJ 0
pentobarbital JJ 0
injection NN 0
. . 0

Lung NNP 0
injuries NNS 0
and CC 0
relevant JJ 0
enzymes NNS 0
expression NN 0
were VBD 0
thus RB 0
assayed VBN 0
. . 0

RESULTS NNP 0
Histological NNP 0
analysis NN 0
, , 0
PMNs/alveoli NNP 0
ratio NN 0
, , 0
and CC 0
wet/dry JJ 0
weight NN 0
ratio NN 0
measurements NNS 0
demonstrated VBD 0
that IN 0
LPS NNP 0
caused VBD 0
significant JJ 0
lung JJ 0
injury NN 0
and CC 0
HBO NNP 0
and/or VBP 0
hemin NN 0
significantly RB 0
attenuated VBD 0
this DT 0
LPS-induced JJ 0
lung NN 0
injury NN 0
. . 0

Increased VBD 0
pulmonary JJ 0
iNOS NN 0
expression NN 0
and CC 0
NO DT 0
production NN 0
were VBD 0
associated VBN 0
with IN 0
lung JJ 0
injury NN 0
. . 0

Induction NN 0
of IN 0
HO-1 NNP 0
, , 0
by IN 0
HBO NNP 0
and/or NN 0
hemin NN 0
, , 0
significantly RB 0
attenuated VBD 0
this DT 0
LPS-induced JJ 0
iNOS NN 0
expression NN 0
and CC 0
acute NN 0
lung NN 0
injury NN 0
. . 0

SnPP NNP 0
, , 0
on IN 0
the DT 0
contrary JJ 0
, , 0
offset VB 0
the DT 0
effects NNS 0
of IN 0
HBO NNP 0
and CC 0
worsened VBD 0
the DT 0
LPS-induced NNP 0
lung NN 0
injury NN 0
. . 0

CONCLUSIONS NNP 0
HBO NNP 0
may MD 0
act VB 0
through IN 0
inhibiting VBG 0
pulmonary JJ 0
iNOS NN 0
expression NN 0
to TO 0
attenuate VB 0
LPS-induced NNP 0
acute NN 0
lung NN 0
injury NN 0
in IN 0
septic JJ 4
rats NNS 4
. . 0

Furthermore RB 0
, , 0
this DT 0
HBO NNP 0
attenuation NN 0
of IN 0
iNOS JJ 0
expression NN 0
involves VBZ 0
HO-1 NNP 0
induction NN 0
. . 0

Are NNP 0
tyrosine JJ 0
kinase NN 0
inhibitors NNS 0
still RB 0
active JJ 0
in IN 0
patients NNS 0
with IN 0
metastatic JJ 4
renal NN 4
cell NN 4
carcinoma VBZ 4
previously RB 0
treated VBN 0
with IN 0
a DT 0
tyrosine JJ 0
kinase NN 0
inhibitor NN 0
and CC 0
everolimus VB 0
? . 0
Experience NNP 0
of IN 0
36 CD 3
patients NNS 0
treated VBN 0
in IN 0
France NNP 0
in IN 0
the DT 0
RECORD-1 JJ 0
Trial NNP 0
. . 0

BACKGROUND NNP 0
Because IN 0
the DT 0
response NN 0
to TO 0
treatment NN 0
is VBZ 0
limited JJ 0
, , 0
patients NNS 0
with IN 0
metastatic JJ 0
renal NN 0
cell NN 0
carcinoma NN 0
( ( 0
mRCC NN 4
) ) 0
typically RB 0
receive JJ 0
multiple NN 0
treatments NNS 0
. . 0

Guidelines NNS 0
recommend VBP 0
everolimus NN 0
for IN 0
patients NNS 0
previously RB 0
treated VBN 0
with IN 0
tyrosine JJ 0
kinase NN 0
inhibitors NNS 0
( ( 0
TKI NNP 0
) ) 0
sunitinib NN 0
or CC 0
sorafenib NN 0
. . 0

This DT 0
study NN 0
evaluated VBD 0
the DT 0
efficacy NN 0
of IN 0
TKI NNP 0
re-treatment NN 0
in IN 0
patients NNS 0
with IN 0
disease JJ 0
progression NN 0
after IN 0
a DT 0
TKI-everolimus JJ 0
sequence NN 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
Data NNP 0
were VBD 0
reviewed VBN 0
for IN 0
patients NNS 0
enrolled VBN 0
in IN 0
RECORD-1 NNP 0
( ( 0
Renal NNP 4
Cell NNP 4
Cancer NNP 4
Treatment NNP 0
With IN 0
Oral NNP 0
RAD001 NNP 0
Given NNP 0
Daily NNP 0
) ) 0
at IN 0
French JJ 0
sites NNS 0
. . 0

Response NNP 0
, , 0
progression-free JJ 0
survival NN 0
( ( 0
PFS NNP 0
) ) 0
, , 0
and CC 0
overall JJ 0
survival NN 0
were VBD 0
evaluated VBN 0
in IN 0
patients NNS 0
treated VBN 0
with IN 0
a DT 0
TKI-everolimus-TKI JJ 0
sequence NN 0
. . 0

RESULTS NNP 0
Thirty-six JJ 0
patients NNS 0
received VBD 0
a DT 0
TKI NNP 0
after IN 0
everolimus NN 0
: : 0
sunitinib NN 0
in IN 0
17 CD 0
patients NNS 0
, , 0
sorafenib NN 0
in IN 0
15 CD 0
, , 0
and CC 0
dovitinib NN 0
( ( 0
TKI258 NNP 0
) ) 0
in IN 0
4 CD 0
. . 0

The DT 0
response NN 0
rate NN 0
with IN 0
TKI NNP 0
re-treatment NN 0
was VBD 0
8 CD 0
% NN 0
, , 0
and CC 0
the DT 0
disease-control JJ 0
rate NN 0
( ( 0
response NN 0
plus CC 0
stable JJ 0
disease NN 0
) ) 0
was VBD 0
75 CD 0
% NN 0
. . 0

The DT 0
median JJ 0
PFS NNP 0
with IN 0
each DT 0
component NN 0
of IN 0
the DT 0
TKI-everolimus-TKI NNP 0
sequence NN 0
was VBD 0
10.7 CD 0
months NNS 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
1.8-28.5 JJ 0
months NNS 0
) ) 0
, , 0
8.9 CD 0
months NNS 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
1.7-34.6 JJ 0
months NNS 0
) ) 0
, , 0
and CC 0
8.2 CD 0
months NNS 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
, , 0
5.2-11.9 JJ 0
months NNS 0
) ) 0
, , 0
respectively RB 0
. . 0

The DT 0
median JJ 0
overall JJ 0
survival NN 0
from IN 0
the DT 0
start NN 0
of IN 0
everolimus NN 0
was VBD 0
29.1 CD 0
months NNS 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
21.1 CD 0
to TO 0
not RB 0
reached VB 0
months NNS 0
) ) 0
, , 0
which WDT 0
suggests VBZ 0
a DT 0
benefit NN 0
in IN 0
using VBG 0
TKI NNP 0
in IN 0
this DT 0
setting NN 0
. . 0

CONCLUSIONS NNP 0
Administration NNP 0
of IN 0
a DT 0
TKI-everolimus-TKI JJ 0
sequence NN 0
may MD 0
be VB 0
associated VBN 0
with IN 0
clinical JJ 0
benefit NN 0
and CC 0
should MD 0
be VB 0
prospectively RB 0
investigated VBN 0
. . 0

Penetration NN 0
and CC 0
accumulation NN 0
of IN 0
moxifloxacin NN 0
in IN 0
uterine JJ 0
tissue NN 0
. . 0

OBJECTIVE NN 0
To TO 0
determine VB 0
whether IN 0
moxifloxacin NN 0
penetrates VBZ 0
the DT 0
uterine JJ 0
tissue NN 0
and CC 0
accumulates NNS 0
at IN 0
levels NNS 0
sufficient JJ 0
to TO 0
eradicate VB 0
the DT 0
major JJ 0
pathogens NNS 0
causing VBG 0
pelvic JJ 4
inflammatory JJ 4
disease NN 4
( ( 0
PID NNP 4
) ) 0
. . 0

METHOD NNP 0
In IN 0
a DT 0
prospective JJ 0
, , 0
multicenter NN 0
, , 0
open-label JJ 0
, , 0
parallel-group JJ 0
study NN 0
we PRP 0
determined VBD 0
the DT 0
concentration NN 0
of IN 0
moxifloxacin NN 0
in IN 0
plasma NN 0
and CC 0
uterine JJ 0
tissue NN 0
after IN 0
a DT 0
single JJ 0
, , 0
400-mg JJ 0
intravenous JJ 0
dose NN 0
of IN 0
moxifloxacin NN 0
. . 0

Study NN 0
participants NNS 0
were VBD 0
randomized VBN 0
for IN 0
time NN 0
of IN 0
tissue NN 0
sampling NN 0
, , 0
which WDT 0
was VBD 0
performed VBN 0
1 CD 0
, , 0
2 CD 0
, , 0
4 CD 0
, , 0
7 CD 0
, , 0
or CC 0
24 CD 0
hours NNS 0
following VBG 0
the DT 0
moxifloxacin JJ 0
infusion NN 0
. . 0

RESULTS NNP 0
Of IN 0
43 CD 3
participants NNS 0
, , 0
40 CD 3
were VBD 0
randomized VBN 0
to TO 0
tissue VB 0
sampling VBG 0
. . 0

Moxifloxacin NNP 0
accumulated VBD 0
in IN 0
uterine JJ 0
tissue NN 0
and CC 0
concentrations NNS 0
were VBD 0
highest JJS 0
1 CD 0
hour NN 0
after IN 0
infusion NN 0
in IN 0
both DT 0
plasma NN 0
and CC 0
tissue NN 0
. . 0

Tissue NN 0
to TO 0
plasma VB 0
ratios NNS 0
remained VBD 0
between IN 0
1.7 CD 0
and CC 0
2.1 CD 0
for IN 0
24 CD 0
hours NNS 0
. . 0

Moxifloxacin NNP 0
was VBD 0
found VBN 0
to TO 0
be VB 0
safe JJ 0
and CC 0
well RB 0
tolerated VBN 0
. . 0

CONCLUSION NNP 0
Based VBD 0
on IN 0
known VBN 0
minimum JJ 0
inhibitory JJ 0
concentration NN 0
data NNS 0
, , 0
the DT 0
uterine JJ 0
tissue NN 0
concentrations NNS 0
of IN 0
moxifloxacin NN 0
achieved VBN 0
over IN 0
24 CD 0
hours NNS 0
would MD 0
be VB 0
sufficient JJ 0
to TO 0
eradicate VB 0
the DT 0
range NN 0
of IN 0
bacterial JJ 0
pathogens NNS 0
responsible JJ 0
for IN 0
PID NNP 0
. . 0

Comparative JJ 0
drug NN 0
effects NNS 0
and CC 0
abuse NN 0
liability NN 0
of IN 0
lorazepam NN 0
, , 0
buspirone NN 0
, , 0
and CC 0
secobarbital NN 0
in IN 0
nondependent JJ 4
subjects NNS 0
. . 0

The DT 0
pharmacologic JJ 0
effects NNS 0
of IN 0
lorazepam NN 0
( ( 0
2 CD 0
mg NN 0
) ) 0
, , 0
buspirone NN 0
( ( 0
20 CD 0
mg NN 0
, , 0
10 CD 0
mg NN 0
) ) 0
, , 0
secobarbital JJ 0
( ( 0
100 CD 0
mg NN 0
) ) 0
, , 0
and CC 0
placebo NN 0
were VBD 0
compared VBN 0
in IN 0
15 CD 3
male NN 2
, , 0
experienced VBD 0
, , 0
intermittent JJ 0
nontherapeutic JJ 0
drug NN 4
users NNS 4
. . 0

All DT 0
drugs NNS 0
produced VBD 0
a DT 0
drug NN 0
effect NN 0
, , 0
however RB 0
, , 0
buspirone RB 0
20 CD 0
mg NN 0
was VBD 0
significantly RB 0
less JJR 0
liked JJ 0
than IN 0
were VBD 0
lorazepam JJ 0
, , 0
secobarbital JJ 0
, , 0
or CC 0
buspirone RB 0
10 CD 0
mg NN 0
( ( 0
p NN 0
less JJR 0
than IN 0
.05 NN 0
) ) 0
but CC 0
not RB 0
placebo VB 0
. . 0

Lorazepam NNP 0
was VBD 0
liked VBN 0
better RBR 0
than IN 0
were VBD 0
other JJ 0
drugs NNS 0
only RB 0
at IN 0
1 CD 0
hour NN 0
and CC 0
only RB 0
compared VBN 0
with IN 0
buspirone NN 0
20 CD 0
and CC 0
placebo NN 0
. . 0

Compared VBN 0
with IN 0
other JJ 0
drugs NNS 0
, , 0
lorazepam JJ 0
drug NN 0
effects NNS 0
were VBD 0
greater JJR 0
and CC 0
resulted VBD 0
in IN 0
more RBR 0
prolonged JJ 0
impairment NN 0
of IN 0
a DT 0
motor NN 0
tracking VBG 0
task NN 0
, , 0
standing VBG 0
steadiness NN 0
, , 0
and CC 0
memory NN 0
. . 0

Buspirone CD 0
20 CD 0
mg NNS 0
significantly RB 0
impaired JJ 0
memory NN 0
at IN 0
1 CD 0
hour NN 0
compared VBN 0
with IN 0
placebo NN 0
. . 0

Subjects NNS 0
were VBD 0
more RBR 0
likely JJ 0
to TO 0
identify VB 0
buspirone NN 0
as IN 0
unfamiliar JJ 0
. . 0

Because IN 0
buspirone NN 0
20 CD 0
mg NN 0
was VBD 0
less JJR 0
liked JJ 0
than IN 0
were VBD 0
other JJ 0
drugs NNS 0
, , 0
dose JJ 0
escalation NN 0
as IN 0
part NN 0
of IN 0
drug NN 0
abuse NN 0
is VBZ 0
not RB 0
likely JJ 0
to TO 0
occur VB 0
. . 0

Lorazepam NNP 0
also RB 0
was VBD 0
not RB 0
particularly RB 0
liked VBN 0
and CC 0
was VBD 0
not RB 0
different JJ 0
from IN 0
placebo NN 0
on IN 0
most JJS 0
subjective JJ 0
abuse-relevant JJ 0
measures NNS 0
. . 0

Efficacy NN 0
and CC 0
safety NN 0
of IN 0
transient JJ 0
ulnar JJ 0
artery NN 0
compression NN 0
to TO 0
recanalize VB 0
acute JJ 0
radial JJ 0
artery NN 0
occlusion NN 0
after IN 0
transradial JJ 0
catheterization NN 0
. . 0

Radial JJ 0
artery NN 0
occlusion NN 0
( ( 0
RAO NNP 0
) ) 0
can MD 0
result VB 0
from IN 0
transradial JJ 0
catheterization NN 0
. . 0

We PRP 0
compared VBN 0
the DT 0
incidence NN 0
of IN 0
RAO NNP 0
with IN 0
2 CD 0
heparin JJ 0
dosage NN 0
regimens NNS 0
after IN 0
transradial JJ 0
coronary JJ 0
angiography NN 0
, , 0
and CC 0
we PRP 0
evaluated VBD 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
transient JJ 0
homolateral JJ 0
ulnar JJ 0
artery NN 0
compression NN 0
to TO 0
achieve VB 0
acute JJ 0
radial JJ 0
artery NN 0
recanalization NN 0
. . 0

Patients NNS 0
referred VBD 0
for IN 0
coronary JJ 4
angiography NN 4
were VBD 0
randomized VBN 0
to TO 0
very-low-dose JJ 0
heparin NN 0
( ( 0
2,000 CD 0
IU NNP 0
) ) 0
or CC 0
low-dose JJ 0
heparin NN 0
( ( 0
5,000 CD 0
IU NNP 0
) ) 0
. . 0

On IN 0
sheath NN 0
removal NN 0
, , 0
hemostasis NN 0
was VBD 0
obtained VBN 0
using VBG 0
the DT 0
TR NNP 0
band NN 0
with IN 0
a DT 0
plethysmography-guided JJ 0
patent NN 0
hemostasis NN 0
technique NN 0
. . 0

In IN 0
the DT 0
case NN 0
of IN 0
RAO NNP 0
as IN 0
assessed VBN 0
by IN 0
duplex JJ 0
ultrasonography NN 0
3 CD 0
to TO 0
4 CD 0
hours NNS 0
after IN 0
hemostasis NN 0
, , 0
immediate JJ 0
1-hour JJ 0
ulnar JJ 0
artery NN 0
compression NN 0
was VBD 0
applied VBN 0
. . 0

Hematomas NNP 0
> VBD 0
15 CD 0
cm NN 0
( ( 0
2 CD 0
) ) 0
were VBD 0
also RB 0
assessed VBN 0
. . 0

We PRP 0
randomized VBD 0
465 CD 3
patients NNS 0
, , 0
222 CD 0
in IN 0
the DT 0
2,000-IU JJ 0
group NN 0
and CC 0
243 CD 0
in IN 0
the DT 0
5,000-IU JJ 0
group NN 0
. . 0

The DT 0
baseline NN 0
and CC 0
procedural JJ 0
characteristics NNS 0
were VBD 0
comparable JJ 0
in IN 0
both DT 0
groups NNS 0
. . 0

The DT 0
incidence NN 0
of IN 0
initial JJ 0
RAO NNP 0
was VBD 0
5.9 CD 0
% NN 0
in IN 0
the DT 0
2,000-IU JJ 0
group NN 0
and CC 0
2.9 CD 0
% NN 0
in IN 0
the DT 0
5,000-IU JJ 0
group NN 0
( ( 0
p JJ 0
= NNP 0
0.17 CD 0
) ) 0
, , 0
with IN 0
a DT 0
compression NN 0
time NN 0
of IN 0
2.10 CD 0
? . 0
0.78 CD 0
hours NNS 0
and CC 0
2.25 CD 0
? . 0
0.82 CD 0
hours NNS 0
, , 0
respectively RB 0
( ( 0
p JJ 0
= NNP 0
0.051 CD 0
) ) 0
. . 0

After IN 0
ulnar JJ 0
artery NN 0
compression NN 0
, , 0
the DT 0
final JJ 0
incidence NN 0
of IN 0
RAO NNP 0
was VBD 0
4.1 CD 0
% NN 0
in IN 0
the DT 0
2,000-IU JJ 0
group NN 0
and CC 0
0.8 CD 0
% NN 0
in IN 0
the DT 0
5,000-IU JJ 0
group NN 0
( ( 0
p JJ 0
= NNP 0
0.03 CD 0
) ) 0
. . 0

The DT 0
incidence NN 0
of IN 0
local JJ 0
hematoma NN 0
was VBD 0
2.3 CD 0
% NN 0
and CC 0
3.7 CD 0
% NN 0
in IN 0
the DT 0
2,000- JJ 0
and CC 0
5,000-IU JJ 0
groups NNS 0
, , 0
respectively RB 0
( ( 0
p JJ 0
= NNP 0
0.42 CD 0
) ) 0
. . 0

In IN 0
conclusion NN 0
, , 0
acute JJ 0
RAO NNP 0
after IN 0
transradial JJ 0
catheterization NN 0
can MD 0
be VB 0
recanalized VBN 0
by IN 0
early JJ 0
1-hour JJ 0
homolateral JJ 0
ulnar JJ 0
artery NN 0
compression NN 0
. . 0

This DT 0
simple JJ 0
nonpharmacologic JJ 0
method NN 0
was VBD 0
effective JJ 0
and CC 0
safe JJ 0
in IN 0
patients NNS 0
with IN 0
very-low- JJ 0
and CC 0
low-dose JJ 0
heparin NN 0
. . 0

Nevertheless NNP 0
, , 0
the DT 0
incidence NN 0
of IN 0
final JJ 0
RAO NNP 0
remained VBD 0
significantly RB 0
lower JJR 0
after IN 0
a DT 0
higher JJR 0
anticoagulation NN 0
level NN 0
. . 0

Diode NNP 0
laser NN 0
photocoagulation NN 0
for IN 0
threshold JJ 0
retinopathy NN 4
of IN 4
prematurity NN 4
. . 0

A DT 0
randomized JJ 0
study NN 0
. . 0

BACKGROUND NNP 0
Although IN 0
peripheral JJ 0
cryotherapy NN 0
decreases VBZ 0
the DT 0
incidence NN 0
of IN 0
unfavorable JJ 0
anatomic JJ 0
outcomes NNS 0
in IN 0
threshold JJ 0
retinopathy NN 4
of IN 4
prematurity NN 4
( ( 0
ROP NNP 4
) ) 0
, , 0
apnea RB 0
, , 0
bradycardia NN 0
, , 0
and CC 0
lid JJ 0
edema NN 0
can MD 0
occur VB 0
. . 0

Argon NNP 0
laser NN 0
indirect JJ 0
ophthalmoscope NN 0
photocoagulation NN 0
has VBZ 0
been VBN 0
used VBN 0
as IN 0
an DT 0
alternative NN 0
to TO 0
cryotherapy VB 0
, , 0
with IN 0
fewer JJR 0
adverse JJ 0
effects NNS 0
. . 0

Retinal JJ 0
lesions NNS 0
placed VBN 0
with IN 0
diode NN 0
lasers NNS 0
are VBP 0
deeper JJR 0
than IN 0
similar JJ 0
argon NN 0
laser NN 0
lesions NNS 0
, , 0
and CC 0
it PRP 0
is VBZ 0
not RB 0
known VBN 0
whether IN 0
this DT 0
difference NN 0
could MD 0
influence VB 0
the DT 0
response NN 0
to TO 0
ablative JJ 0
therapy NN 0
. . 0

METHODS JJ 0
Patients NNPS 0
were VBD 0
enrolled VBN 0
under IN 0
a DT 0
prospective JJ 0
, , 0
randomized VBN 0
protocol NN 0
. . 0

One CD 0
eye NN 0
of IN 0
each DT 0
patient NN 0
with IN 0
symmetric JJ 0
, , 0
threshold JJ 0
ROP NNP 0
was VBD 0
treated VBN 0
with IN 0
an DT 0
814/815 CD 0
nm JJ 0
diode NN 0
laser NN 0
, , 0
while IN 0
the DT 0
other JJ 0
eye NN 0
was VBD 0
treated VBN 0
with IN 0
cryotherapy NN 0
. . 0

Patients NNS 0
with IN 0
asymmetric JJ 0
diseases NNS 0
also RB 0
were VBD 0
randomized VBN 0
for IN 0
treatment NN 0
in IN 0
the DT 0
threshold NN 0
eye NN 0
. . 0

RESULTS NNP 0
Nineteen JJ 3
infants NNS 0
( ( 0
33 CD 3
eyes NNS 0
) ) 0
were VBD 0
treated VBN 0
, , 0
ranging VBG 0
from IN 0
485 CD 0
to TO 0
863 CD 0
g NNS 0
birth JJ 0
weight NN 0
( ( 0
23 CD 0
to TO 0
27 CD 0
weeks NNS 0
gestational JJ 0
age NN 0
) ) 0
; : 0
18 CD 3
patients NNS 0
( ( 0
32 CD 3
eyes NNS 0
) ) 0
were VBD 0
followed VBN 0
for IN 0
3 CD 0
months NNS 0
or CC 0
longer JJR 0
. . 0

Four CD 3
patients NNS 0
( ( 0
8 CD 3
eyes NNS 0
) ) 0
had VBD 0
bilateral JJ 0
zone CD 0
1 CD 0
disease NN 0
. . 0

Postconceptional JJ 0
age NN 0
was VBD 0
36 CD 1
to TO 1
45 CD 1
weeks NNS 0
at IN 0
the DT 0
time NN 0
of IN 0
treatment NN 0
. . 0

The DT 0
diode NN 0
laser NN 0
treatment NN 0
was VBD 0
better RBR 0
tolerated VBN 0
than IN 0
cryotherapy NN 0
, , 0
and CC 0
the DT 0
treatment NN 0
apparatus NN 0
was VBD 0
more RBR 0
easily RB 0
transported VBN 0
. . 0

Apneic NNP 0
episodes VBZ 0
requiring VBG 0
intubation NN 0
resulted VBD 0
from IN 0
two CD 0
cryotherapy NN 0
sessions NNS 0
but CC 0
no DT 0
diode NN 0
laser NN 0
sessions NNS 0
. . 0

Five CD 0
cryotherapy-treated JJ 0
eyes NNS 0
required VBN 0
retreatment NN 0
because IN 0
of IN 0
persistent JJ 0
disease NN 0
with IN 0
adjacent JJ 0
skip NN 0
areas NNS 0
. . 0

In IN 0
the DT 0
group NN 0
followed VBD 0
for IN 0
3 CD 0
to TO 0
15 CD 0
months NNS 0
, , 0
1 CD 0
cryotherapy-treated JJ 0
eye NN 0
and CC 0
1 CD 0
diode NN 0
laser-treated JJ 0
eye NN 0
progressed VBD 0
to TO 0
stage VB 0
5 CD 0
retinal JJ 0
detachment NN 0
. . 0

CONCLUSION NNP 0
Compared NNP 0
with IN 0
cryotherapy NN 0
, , 0
the DT 0
diode NN 0
laser NN 0
was VBD 0
more RBR 0
convenient JJ 0
, , 0
technically RB 0
easier JJR 0
to TO 0
administer VB 0
, , 0
and CC 0
better RB 0
tolerated VBN 0
by IN 0
the DT 0
patient NN 0
. . 0

Although IN 0
the DT 0
number NN 0
of IN 0
patients NNS 0
was VBD 0
too RB 0
small JJ 0
for IN 0
meaningful JJ 0
statistical JJ 0
analysis NN 0
of IN 0
outcome NN 0
, , 0
diode VB 0
laser RBR 0
peripheral JJ 0
retinal JJ 0
ablation NN 0
appeared VBD 0
to TO 0
be VB 0
as RB 0
effective JJ 0
as IN 0
cryotherapy NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
threshold JJ 0
ROP NNP 0
. . 0

Clinical JJ 0
trial NN 0
: : 0
exposure NN 0
to TO 0
ribavirin VB 0
predicts NNS 0
EVR NNP 0
and CC 0
SVR NNP 0
in IN 0
patients NNS 0
with IN 0
HCV NNP 4
genotype NN 4
1 CD 4
infection NN 0
treated VBN 0
with IN 0
peginterferon NN 0
alpha-2a JJ 0
plus CC 0
ribavirin JJ 0
. . 0

BACKGROUND VB 0
The DT 0
impact NN 0
of IN 0
reduced JJ 0
drug NN 0
exposure NN 0
on IN 0
outcomes NNS 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 4
hepatitis NN 4
C NNP 4
has VBZ 0
not RB 0
been VBN 0
determined VBN 0
in IN 0
routine JJ 0
clinical JJ 0
practice NN 0
. . 0

AIM NNP 0
To TO 0
examine VB 0
the DT 0
impact NN 0
of IN 0
exposure NN 0
to TO 0
peginterferon VB 0
alpha-2a JJ 0
and CC 0
ribavirin VB 0
on IN 0
early JJ 0
virological JJ 0
response NN 0
( ( 0
EVR NNP 0
) ) 0
and CC 0
sustained VBD 0
virological JJ 0
response NN 0
( ( 0
SVR NNP 0
) ) 0
in IN 0
treatment-naive JJ 0
patients NNS 0
with IN 0
HCV NNP 0
genotype NN 0
1 CD 0
infection NN 0
enrolled VBN 0
in IN 0
a DT 0
large JJ 0
expanded JJ 0
access NN 0
programme NN 0
. . 0

METHODS NNP 0
Eight NNP 3
hundred VBD 3
and CC 3
ninety-one JJ 3
patients NNS 0
treated VBD 0
for IN 0
48 CD 0
weeks NNS 0
with IN 0
an DT 0
initial JJ 0
ribavirin NN 0
dose NN 0
of IN 0
800 CD 0
or CC 0
1000/1200 CD 0
mg/day NNS 0
were VBD 0
evaluated VBN 0
. . 0

Ribavirin JJ 0
1000 CD 0
mg/day NN 0
( ( 0
< JJ 0
75 CD 0
kg NN 0
) ) 0
or CC 0
1200 CD 0
mg/day NN 0
( ( 0
> JJ 0
or=75 RB 0
kg NN 0
) ) 0
and CC 0
peginterferon VB 0
alpha-2a JJ 0
180 CD 0
microg/week NN 0
were VBD 0
considered VBN 0
optimal JJ 0
. . 0

The DT 0
impact NN 0
of IN 0
reduced JJ 0
drug NN 0
exposure NN 0
( ( 0
expressed VBN 0
as IN 0
a DT 0
percentage NN 0
of IN 0
optimal NN 0
) ) 0
on IN 0
EVR NNP 0
and CC 0
SVR NNP 0
was VBD 0
evaluated VBN 0
. . 0

RESULTS JJ 0
Mean NNP 0
ribavirin NN 0
exposure NN 0
in IN 0
week NN 0
0-12 NN 0
was VBD 0
70 CD 0
% NN 0
and CC 0
96 CD 0
% NN 0
in IN 0
patients NNS 0
assigned VBN 0
to TO 0
ribavirin VB 0
800 CD 0
and CC 0
1000/1200 CD 0
mg/day NN 0
, , 0
respectively RB 0
. . 0

EVR NNP 0
and CC 0
SVR NNP 0
rates NNS 0
were VBD 0
lower JJR 0
in IN 0
patients NNS 0
assigned VBN 0
to TO 0
ribavirin VB 0
800 CD 0
than IN 0
1000/1200 CD 0
mg/day NN 0
( ( 0
EVR NNP 0
, , 0
75 CD 0
% NN 0
vs. FW 0
84 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
P NNP 0
< NNP 0
0.001 CD 0
; : 0
SVR NNP 0
, , 0
45 CD 0
% NN 0
vs. FW 0
54 CD 0
% NN 0
, , 0
respectively RB 0
, , 0
P NNP 0
= NNP 0
0.011 CD 0
) ) 0
. . 0

Furthermore RB 0
, , 0
there EX 0
was VBD 0
a DT 0
strong JJ 0
correlation NN 0
between IN 0
achievement NN 0
of IN 0
EVR NNP 0
and CC 0
SVR NNP 0
and CC 0
ribavirin VB 0
dose NN 0
over IN 0
the DT 0
first JJ 0
12 CD 0
weeks NNS 0
expressed VBD 0
either CC 0
as IN 0
absolute JJ 0
dose NN 0
or CC 0
proportion NN 0
of IN 0
optimal JJ 0
dose NN 0
received VBD 0
( ( 0
P NNP 0
< VBZ 0
0.001 CD 0
for IN 0
both DT 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Ribavirin NNP 0
exposure NN 0
to TO 0
week NN 0
12 CD 0
is VBZ 0
significantly RB 0
associated VBN 0
with IN 0
EVR NNP 0
and CC 0
SVR NNP 0
in IN 0
genotype JJ 0
1 CD 0
patients NNS 0
. . 0

Maintenance NNP 0
of IN 0
an DT 0
optimal JJ 0
ribavirin NN 0
dose NN 0
is VBZ 0
the DT 0
most RBS 0
important JJ 0
modifiable JJ 0
factor NN 0
during IN 0
combination NN 0
therapy NN 0
for IN 0
chronic JJ 0
hepatitis NN 0
C NNP 0
. . 0

The DT 0
acute JJ 0
effects NNS 0
of IN 0
fluid JJ 0
intake NN 0
on IN 0
urine JJ 0
specific JJ 0
gravity NN 0
and CC 0
fluid JJ 0
retention NN 0
in IN 0
a DT 0
mildly RB 4
dehydrated JJ 4
state NN 4
. . 0

Many JJ 0
athletes NNS 0
arrive VBP 0
at IN 0
training NN 0
sessions NNS 0
and CC 0
competitions NNS 0
in IN 0
a DT 0
mildly RB 0
hypohydrated VBN 0
( ( 0
HYPO NNP 4
) ) 0
state NN 0
and CC 0
are VBP 0
instructed VBN 0
to TO 0
drink VB 0
fluids NNS 0
before IN 0
exercise NN 0
to TO 0
reach VB 0
a DT 0
euhydrated JJ 0
( ( 0
HYD NNP 0
) ) 0
state NN 0
. . 0

Ten CD 0
recreational JJ 0
athletes NNS 0
( ( 0
6 CD 0
women NNS 0
, , 0
4 CD 0
men NNS 0
; : 0
71.9 CD 0
? . 0
4.6 CD 0
kg NN 0
, , 0
25.2 CD 0
? . 0
0.9 CD 0
years NNS 0
) ) 0
participated VBD 0
in IN 0
the DT 0
studies NNS 0
to TO 0
examine VB 0
( ( 0
a DT 0
) ) 0
the DT 0
day-to-day JJ 0
variability NN 0
of IN 0
morning NN 0
urine NN 0
specific JJ 0
gravity NN 0
( ( 0
USG NNP 0
) ) 0
, , 0
( ( 0
b NN 0
) ) 0
the DT 0
effects NNS 0
of IN 0
consuming VBG 0
600 CD 0
ml NN 0
of IN 0
water NN 0
on IN 0
the DT 0
hydration NN 0
status NN 0
of IN 0
HYD NNP 0
and CC 0
HYPO NNP 0
( ( 0
USG NNP 0
> NNP 0
1.020 CD 0
) ) 0
subjects NNS 0
, , 0
and CC 0
( ( 0
c NN 0
) ) 0
the DT 0
effects NNS 0
of IN 0
consuming VBG 0
water NN 0
( ( 0
W NNP 0
) ) 0
, , 0
salt-water JJ 0
( ( 0
SW NNP 0
, , 0
40 CD 0
mM NN 0
Na NNP 0
) ) 0
, , 0
a DT 0
carbohydrate-electrolyte JJ 0
solution NN 0
with IN 0
3 CD 0
% NN 0
or CC 0
light JJ 0
carbohydrate NN 0
( ( 0
CES-L NNP 0
, , 0
20 CD 0
mM NN 0
Na NNP 0
) ) 0
or CC 0
a DT 0
CES NN 0
with IN 0
6 CD 0
% NN 0
carbohydrate NN 0
( ( 0
CES NNP 0
, , 0
20 CD 0
mM NN 0
Na NNP 0
) ) 0
on IN 0
the DT 0
hydration NN 0
status NN 0
of IN 0
HYPO NNP 0
subjects NNS 0
. . 0

The DT 0
hydration NN 0
status NN 0
was VBD 0
assessed VBN 0
with IN 0
USG NNP 0
and CC 0
body NN 0
mass NN 0
measures NNS 0
and CC 0
urine JJ 0
volume NN 0
collections NNS 0
. . 0

The DT 0
day-to-day JJ 0
variability NN 0
in IN 0
morning NN 0
USG NNP 0
( ( 0
coefficient NN 0
of IN 0
variation NN 0
= FW 0
0.2 CD 0
? . 0
0.1 CD 0
% NN 0
) ) 0
was VBD 0
low JJ 0
and CC 0
the DT 0
responses NNS 0
to TO 0
600 CD 0
ml NN 0
of IN 0
W NNP 0
ingestion NN 0
were VBD 0
repeatable JJ 0
. . 0

Pretrial JJ 0
USG NNP 0
was VBD 0
1.022 CD 0
? . 0
0.001 CD 0
in IN 0
the DT 0
HYPO NNP 0
trial NN 0
and CC 0
decreased VBD 0
< NNS 0
1.020 CD 0
by IN 0
45 CD 0
minutes NNS 0
( ( 0
1.013 CD 0
? . 0
0.003 CD 0
) ) 0
. . 0

In IN 0
the DT 0
CES NNP 0
study NN 0
, , 0
HYPO NNP 0
subjects VBZ 0
reached VBN 0
HYD NNP 0
status NN 0
at IN 0
45 CD 0
minutes NNS 0
in IN 0
all DT 0
conditions NNS 0
( ( 0
W NNP 0
1.013 CD 0
? . 0
0.003 CD 0
, , 0
SW NNP 0
1.013 CD 0
? . 0
0.003 CD 0
, , 0
CES-L NNP 0
1.011 CD 0
? . 0
0.003 CD 0
, , 0
CES NNP 0
1.017 CD 0
? . 0
0.004 CD 0
) ) 0
because IN 0
salt NN 0
or CC 0
CES NNP 0
ingestion NN 0
did VBD 0
not RB 0
affect VB 0
fluid NN 0
retention NN 0
( ( 0
W NNP 0
68 CD 0
% NN 0
, , 0
SW NNP 0
72 CD 0
% NN 0
, , 0
CES-L JJ 0
68 CD 0
% NN 0
, , 0
CES NNP 0
76 CD 0
% NN 0
) ) 0
. . 0

This DT 0
study NN 0
demonstrated VBD 0
that IN 0
mildly RB 0
HYPO NNP 0
subjects NNS 0
could MD 0
reach VB 0
euhydration NN 0
within IN 0
45 CD 0
minutes NNS 0
of IN 0
the DT 0
ingestion NN 0
of IN 0
600 CD 0
ml NN 0
of IN 0
W NNP 0
or CC 0
a DT 0
combination NN 0
of IN 0
salt NN 0
and CC 0
CES NNP 0
solutions NNS 0
. . 0

Following VBG 0
this DT 0
practice NN 0
will MD 0
minimize VB 0
the DT 0
incidence NN 0
of IN 0
starting VBG 0
a DT 0
practice NN 0
or CC 0
competition NN 0
hypohydrated VBN 0
. . 0

Study NN 0
of IN 0
the DT 0
therapeutic JJ 0
effects NNS 0
of IN 0
a DT 0
hippotherapy NN 0
simulator NN 0
in IN 0
children NNS 1
with IN 0
cerebral JJ 4
palsy NN 4
: : 0
a DT 0
stratified JJ 0
single-blind NN 0
randomized VBD 0
controlled JJ 0
trial NN 0
. . 0

OBJECTIVE UH 0
To TO 0
investigate VB 0
whether IN 0
hippotherapy NN 0
( ( 0
when WRB 0
applied VBN 0
by IN 0
a DT 0
simulator NN 0
) ) 0
improves VBZ 0
postural JJ 0
control NN 0
and CC 0
balance NN 0
in IN 0
children NNS 1
with IN 0
cerebral JJ 4
palsy NN 4
. . 0

DESIGN NNP 0
Stratified VBD 0
single-blind JJ 0
randomized NN 0
controlled VBD 0
trial NN 0
with IN 0
an DT 0
independent JJ 0
assessor NN 0
. . 0

Stratification NN 0
was VBD 0
made VBN 0
by IN 0
gross JJ 0
motor NN 0
function NN 0
classification NN 0
system NN 0
levels NNS 0
, , 0
and CC 0
allocation NN 0
was VBD 0
concealed VBN 0
. . 0

SUBJECTS NNP 0
Children NNP 1
between IN 0
4 CD 1
and CC 1
18 CD 1
years NNS 0
old JJ 0
with IN 0
cerebral JJ 4
palsy NN 4
. . 0

INTERVENTIONS JJ 0
Participants NNS 0
were VBD 0
randomized VBN 0
to TO 0
an DT 0
intervention NN 0
( ( 0
simulator NN 0
ON NNP 0
) ) 0
or CC 0
control NN 0
( ( 0
simulator VB 0
OFF NNP 0
) ) 0
group NN 0
after IN 0
getting VBG 0
informed JJ 0
consent NN 0
. . 0

Treatment NNP 0
was VBD 0
provided VBN 0
once RB 0
a DT 0
week NN 0
( ( 0
15 CD 0
minutes NNS 0
) ) 0
for IN 0
10 CD 0
weeks NNS 0
. . 0

MAIN NNP 0
MEASURES NNP 0
Gross NNP 0
Motor NNP 0
Function NNP 0
Measure NNP 0
( ( 0
dimension NN 0
B NNP 0
for IN 0
balance NN 0
and CC 0
the DT 0
Total NNP 0
Score NNP 0
) ) 0
and CC 0
Sitting VBG 0
Assessment NNP 0
Scale NNP 0
were VBD 0
carried VBN 0
out RP 0
at IN 0
baseline NN 0
( ( 0
prior JJ 0
to TO 0
randomization NN 0
) ) 0
, , 0
end NN 0
of IN 0
intervention NN 0
and CC 0
12 CD 0
weeks NNS 0
after IN 0
completing VBG 0
the DT 0
intervention NN 0
. . 0

RESULTS NNP 0
Thirty-eight JJ 3
children NNS 1
participated VBN 0
. . 0

The DT 0
groups NNS 0
were VBD 0
balanced VBN 0
at IN 0
baseline NN 0
. . 0

Sitting VBG 0
balance NN 0
( ( 0
measured VBN 0
by IN 0
dimension NN 0
B NNP 0
of IN 0
the DT 0
Gross NNP 0
Motor NNP 0
Function NNP 0
Measure NNP 0
) ) 0
improved VBD 0
significantly RB 0
in IN 0
the DT 0
treatment NN 0
group NN 0
( ( 0
effect NN 0
size NN 0
= $ 0
0.36 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
0.01-0.71 NN 0
) ) 0
and CC 0
the DT 0
effect NN 0
size NN 0
was VBD 0
greater JJR 0
in IN 0
the DT 0
severely RB 0
disabled JJ 0
group NN 0
( ( 0
effect NN 0
size NN 0
= $ 0
0.80 CD 0
; : 0
95 CD 0
% NN 0
CI NNP 0
0.13-1.47 NN 0
) ) 0
. . 0

The DT 0
improvements NNS 0
in IN 0
sitting VBG 0
balance NN 0
were VBD 0
not RB 0
maintained VBN 0
over IN 0
the DT 0
follow-up JJ 0
period NN 0
. . 0

Changes NNS 0
in IN 0
the DT 0
total JJ 0
score NN 0
of IN 0
the DT 0
Gross NNP 0
Motor NNP 0
Function NNP 0
Measure NNP 0
and CC 0
the DT 0
Sitting NNP 0
Assessment NNP 0
Scale NNP 0
were VBD 0
not RB 0
significant JJ 0
. . 0

CONCLUSION NNP 0
Hippotherapy NNP 0
with IN 0
a DT 0
simulator NN 0
can MD 0
improve VB 0
sitting VBG 0
balance NN 0
in IN 0
cerebral JJ 4
palsy NN 4
children NNS 1
who WP 0
have VBP 0
higher JJR 0
levels NNS 0
of IN 0
disability NN 0
. . 0

However RB 0
, , 0
this DT 0
did VBD 0
not RB 0
lead VB 0
to TO 0
a DT 0
change NN 0
in IN 0
the DT 0
overall JJ 0
function NN 0
of IN 0
these DT 0
children NNS 0
( ( 0
Gross NNP 0
Motor NNP 0
Function NNP 0
Classification NNP 0
System NNP 0
level JJ 0
V NNP 0
) ) 0
. . 0

Randomized VBN 0
trial NN 0
of IN 0
tailored JJ 0
skin NN 4
cancer NN 4
prevention NN 0
for IN 0
children NNS 1
: : 0
the DT 0
Project NNP 0
SCAPE NNP 0
family NN 0
study NN 0
. . 0

This DT 0
study NN 0
evaluated VBD 0
a DT 0
tailored VBN 0
intervention NN 0
to TO 0
promote VB 0
sun NN 0
protection NN 0
in IN 0
parents NNS 1
and CC 0
their PRP$ 0
children NNS 0
, , 0
hypothesizing VBG 0
that IN 0
the DT 0
tailored VBN 0
intervention NN 0
would MD 0
lead VB 0
to TO 0
improved JJ 0
skin NN 0
cancer NN 0
prevention NN 0
behaviors NNS 0
compared VBN 0
to TO 0
generic JJ 0
materials NNS 0
. . 0

Families NNS 0
were VBD 0
recruited VBN 0
through IN 0
schools NNS 0
and CC 0
community NN 0
centers NNS 0
and CC 0
were VBD 0
included VBN 0
if IN 0
there EX 0
was VBD 0
1 CD 0
child NN 0
in IN 0
Grades NNP 0
1-3 JJ 0
at IN 0
moderate JJ 0
to TO 0
high JJ 0
risk NN 0
for IN 0
skin JJ 0
cancer NN 0
. . 0

Participants NNS 0
were VBD 0
randomized VBN 0
into IN 0
one CD 0
of IN 0
two CD 0
intervention NN 0
groups NNS 0
: : 0
a DT 0
tailored JJ 0
intervention NN 0
, , 0
in IN 0
which WDT 0
they PRP 0
received VBD 0
personalized JJ 0
skin NN 0
cancer NN 0
education NN 0
through IN 0
the DT 0
mail NN 0
; : 0
or CC 0
a DT 0
control NN 0
group NN 0
who WP 0
received VBD 0
generic JJ 0
skin NN 0
cancer NN 0
information NN 0
materials NNS 0
. . 0

Before IN 0
and CC 0
after IN 0
intervention NN 0
, , 0
parents NNS 0
completed VBD 0
questionnaires NNS 0
about IN 0
their PRP$ 0
and CC 0
their PRP$ 0
children NNS 0
's POS 0
skin NN 0
cancer NN 0
risk NN 0
and CC 0
prevention NN 0
knowledge NN 0
and CC 0
behaviors NNS 0
. . 0

Parents NNS 0
also RB 0
completed VBD 0
4-day JJ 0
sun NN 0
exposure NN 0
and CC 0
protection NN 0
diaries NNS 0
for IN 0
their PRP$ 0
child NN 0
and CC 0
themselves PRP 0
. . 0

Tailored VBN 0
group NN 0
participants NNS 0
demonstrated VBD 0
significantly RB 0
greater JJR 0
positive JJ 0
changes NNS 0
in IN 0
prevention NN 0
behavior NN 0
after IN 0
the DT 0
intervention NN 0
, , 0
including VBG 0
children NNS 0
's POS 0
use NN 0
of IN 0
sunscreen NN 0
, , 0
shirts NNS 0
, , 0
and CC 0
hats NNS 0
, , 0
and CC 0
parents NNS 0
' POS 0
use NN 0
of IN 0
shade NN 0
, , 0
and CC 0
skin JJ 0
examinations NNS 0
. . 0

Effect JJ 0
sizes NNS 0
were VBD 0
small JJ 0
and CC 0
perceived JJ 0
benefits NNS 0
and CC 0
social JJ 0
norms NNS 0
mediated VBN 0
intervention NN 0
effects NNS 0
. . 0

Findings NNS 0
from IN 0
this DT 0
study NN 0
support VBD 0
the DT 0
efficacy NN 0
of IN 0
focusing VBG 0
tailored VBN 0
communications NNS 0
to TO 0
families NNS 0
in IN 0
order NN 0
to TO 0
change VB 0
skin JJ 0
cancer NN 0
prevention NN 0
practices NNS 0
in IN 0
young JJ 1
children NNS 0
. . 0

Longitudinal JJ 0
follow-up NN 0
of IN 0
children NNS 1
with IN 0
autism NN 4
receiving VBG 0
targeted VBN 0
interventions NNS 0
on IN 0
joint JJ 0
attention NN 0
and CC 0
play NN 0
. . 0

OBJECTIVE CC 0
This DT 0
study NN 0
examines VBZ 0
the DT 0
cognitive NN 0
and CC 0
language NN 0
outcomes NNS 0
of IN 0
children NNS 0
with IN 0
an DT 0
autism NN 4
spectrum NN 4
disorder NN 4
( ( 0
ASD NNP 4
) ) 0
over IN 0
a DT 0
5-year JJ 0
period NN 0
after IN 0
receiving VBG 0
targeted VBD 0
early JJ 0
interventions NNS 0
that WDT 0
focused VBD 0
on IN 0
joint JJ 0
attention NN 0
and CC 0
play NN 0
skills NNS 0
. . 0

METHOD NNP 0
Forty NNP 3
children NNS 0
from IN 0
the DT 0
original JJ 0
study NN 0
( ( 0
n JJ 0
= NNP 0
58 CD 3
) ) 0
had VBD 0
complete JJ 0
data NNS 0
at IN 0
the DT 0
5-year JJ 0
follow-up NN 0
. . 0

RESULTS NNP 0
In IN 0
all DT 0
, , 0
80 CD 0
% NN 0
of IN 0
children NNS 0
had VBD 0
achieved VBN 0
functional JJ 0
use NN 0
of IN 0
spoken JJ 0
language NN 0
with IN 0
baseline JJ 0
play NN 0
level NN 0
predicting VBG 0
spoken JJ 0
language NN 0
at IN 0
the DT 0
5-year JJ 0
follow-up NN 0
. . 0

Of IN 0
children NNS 0
who WP 0
were VBD 0
using VBG 0
spoken JJ 0
language NN 0
at IN 0
age NN 0
8 CD 0
years NNS 0
, , 0
several JJ 0
baseline NN 0
behaviors NNS 0
predicted VBD 0
their PRP$ 0
later JJ 0
ability NN 0
, , 0
including VBG 0
earlier JJR 0
age NN 0
of IN 0
entry NN 0
into IN 0
the DT 0
study NN 0
, , 0
initiating VBG 0
joint JJ 0
attention NN 0
skill NN 0
, , 0
play VB 0
level NN 0
, , 0
and CC 0
assignment NN 0
to TO 0
either VB 0
the DT 0
joint JJ 0
attention NN 0
or CC 0
symbolic JJ 0
play NN 0
intervention NN 0
group NN 0
. . 0

Only RB 0
baseline JJ 0
play NN 0
diversity NN 0
predicted VBD 0
cognitive JJ 0
scores NNS 0
at IN 0
age NN 0
8 CD 0
years NNS 0
. . 0

CONCLUSIONS VB 0
This DT 0
study NN 0
is VBZ 0
one CD 0
of IN 0
the DT 0
only JJ 0
long-term JJ 0
follow-up JJ 0
studies NNS 0
of IN 0
children NNS 1
who WP 0
participated VBD 0
in IN 0
preschool NN 0
early JJ 0
interventions NNS 0
aimed VBN 0
at IN 0
targeting VBG 0
core NN 4
developmental NN 4
difficulties NNS 4
. . 0

The DT 0
study NN 0
findings NNS 0
suggest VBP 0
that IN 0
focusing VBG 0
on IN 0
joint JJ 0
attention NN 0
and CC 0
play NN 0
skills NNS 0
in IN 0
comprehensive JJ 0
treatment NN 0
models NNS 0
is VBZ 0
important JJ 0
for IN 0
long-term JJ 0
spoken JJ 0
language NN 0
outcomes NNS 0
. . 0

Intranasal NNP 0
nicotine NN 0
for IN 0
postoperative JJ 4
pain NN 4
treatment NN 0
. . 0

BACKGROUND NNP 0
Despite IN 0
pharmacological JJ 0
treatment NN 0
, , 0
70-80 CD 0
% NN 0
of IN 0
patients NNS 0
report NN 0
moderate VBP 0
to TO 0
severe VB 0
pain NN 0
after IN 0
surgery NN 0
. . 0

Because IN 0
nicotine NN 0
has VBZ 0
been VBN 0
reported VBN 0
to TO 0
have VB 0
analgesic JJ 0
properties NNS 0
in IN 0
animal NN 0
and CC 0
human JJ 0
volunteer NN 0
studies NNS 0
, , 0
the DT 0
authors NNS 0
assessed VBD 0
the DT 0
analgesic JJ 0
efficacy NN 0
of IN 0
a DT 0
single JJ 0
3 CD 0
mg NN 0
dose NN 0
of IN 0
nicotine JJ 0
nasal NN 0
spray NN 0
administered VBD 0
before IN 0
emergence NN 0
from IN 0
general JJ 0
anesthesia NN 0
. . 0

METHODS NNP 0
The DT 0
authors NNS 0
conducted VBD 0
a DT 0
randomized VBN 0
, , 0
double JJ 0
blind NN 0
, , 0
placebo NN 0
controlled VBD 0
trial NN 0
of IN 0
20 CD 3
healthy JJ 4
women NNS 2
( ( 0
mean JJ 0
age NN 0
45 CD 1
( ( 0
SD NNP 0
8 CD 0
) ) 0
yr NN 0
) ) 0
who WP 0
were VBD 0
to TO 0
undergo VB 0
uterine JJ 4
surgery NN 4
through IN 0
a DT 0
low JJ 4
transverse NN 4
incision NN 4
. . 0

After IN 0
the DT 0
conclusion NN 0
of IN 0
surgery NN 0
but CC 0
before IN 0
emergence NN 0
from IN 0
general JJ 0
anesthesia NN 0
, , 0
the DT 0
anesthesiologist NN 0
administered VBD 0
either CC 0
nicotine JJ 0
nasal NN 0
spray NN 0
or CC 0
a DT 0
placebo NN 0
. . 0

Numerical JJ 0
analog NN 0
pain NN 0
score NN 0
and CC 0
morphine JJ 0
utilization NN 0
and CC 0
hemodynamic JJ 0
values NNS 0
were VBD 0
measured VBN 0
for IN 0
24 CD 0
h. NN 0
RESULTS NNP 0
The DT 0
patients NNS 0
treated VBN 0
with IN 0
nicotine NN 0
reported VBN 0
lower JJR 0
pain NN 0
scores NNS 0
during IN 0
the DT 0
first JJ 0
hour NN 0
after IN 0
surgery NN 0
( ( 0
peak JJ 0
numerical JJ 0
analog NN 0
score NN 0
, , 0
7.6 CD 0
( ( 0
SD NNP 0
1.4 CD 0
) ) 0
versus NN 0
5.3 CD 0
( ( 0
SD NNP 0
1.6 CD 0
) ) 0
; : 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
and CC 0
used VBN 0
half PDT 0
the DT 0
amount NN 0
of IN 0
morphine NN 0
as IN 0
the DT 0
control NN 0
group NN 0
( ( 0
12 CD 0
( ( 0
SD NNP 0
6 CD 0
) ) 0
versus NN 0
6 CD 0
( ( 0
SD NNP 0
5 CD 0
) ) 0
mg NN 0
; : 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

Patients NNPS 0
who WP 0
received VBD 0
nicotine NN 0
still RB 0
reported VBD 0
less RBR 0
pain NN 0
than IN 0
those DT 0
in IN 0
the DT 0
control NN 0
group NN 0
24 CD 0
h NN 0
after IN 0
surgery NN 0
( ( 0
1.5 CD 0
( ( 0
SD NNP 0
0.5 CD 0
) ) 0
versus NN 0
4.9 CD 0
( ( 0
SD NNP 0
1.4 CD 0
) ) 0
; : 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

Systolic JJ 0
blood NN 0
pressure NN 0
was VBD 0
lower JJR 0
in IN 0
the DT 0
group NN 0
that WDT 0
received VBD 0
nicotine JJ 0
( ( 0
105 CD 0
( ( 0
SD NNP 0
3 CD 0
) ) 0
versus NN 0
122 CD 0
( ( 0
SD NNP 0
3 CD 0
) ) 0
; : 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
, , 0
but CC 0
there EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
diastolic JJ 0
blood NN 0
pressure NN 0
or CC 0
heart NN 0
rate NN 0
. . 0

CONCLUSIONS NNP 0
Treatment NNP 0
with IN 0
a DT 0
single JJ 0
dose NN 0
of IN 0
nicotine JJ 0
immediately RB 0
before IN 0
emergence NN 0
from IN 0
anesthesia NN 0
was VBD 0
associated VBN 0
with IN 0
significantly RB 0
lower JJR 0
reported VBD 0
pain JJ 0
scores NNS 0
during IN 0
the DT 0
first JJ 0
day NN 0
after IN 0
surgery NN 0
. . 0

The DT 0
decreased JJ 0
pain NN 0
was VBD 0
associated VBN 0
with IN 0
a DT 0
reduction NN 0
in IN 0
morphine JJ 0
utilization NN 0
and CC 0
the DT 0
analgesic JJ 0
effect NN 0
of IN 0
nicotine NN 0
was VBD 0
not RB 0
associated VBN 0
with IN 0
hypertension NN 0
or CC 0
tachycardia NN 0
. . 0

Effectiveness NN 0
of IN 0
Dader NNP 0
Method NNP 0
for IN 0
pharmaceutical JJ 0
care NN 0
on IN 0
control NN 0
of IN 0
blood NN 0
pressure NN 0
and CC 0
total JJ 0
cholesterol NN 0
in IN 0
outpatients NNS 0
with IN 0
cardiovascular JJ 4
disease NN 4
or CC 0
cardiovascular JJ 4
risk NN 4
: : 0
EMDADER-CV JJ 0
randomized NNS 0
controlled VBN 0
trial NN 0
. . 0

BACKGROUND NNP 0
Although IN 0
some DT 0
studies NNS 0
have VBP 0
demonstrated VBN 0
that IN 0
pharmacist JJ 0
intervention NN 0
can MD 0
improve VB 0
drug NN 0
therapy NN 0
among IN 0
patients NNS 0
with IN 0
cardiovascular JJ 4
disease NN 4
( ( 0
CVD NNP 4
) ) 0
, , 0
more JJR 0
evidence NN 0
derived VBN 0
from IN 0
randomized VBN 0
controlled VBN 0
trials NNS 0
( ( 0
RCTs NNP 0
) ) 0
is VBZ 0
needed VBN 0
, , 0
including VBG 0
assessment NN 0
of IN 0
the DT 0
effect NN 0
of IN 0
community NN 0
pharmacist NN 0
interventions NNS 0
in IN 0
patients NNS 0
with IN 0
CVD NNP 4
. . 0

OBJECTIVE NNP 0
To TO 0
assess VB 0
the DT 0
effectiveness NN 0
of IN 0
the DT 0
Dader NNP 0
Method NNP 0
for IN 0
pharmaceutical JJ 0
care NN 0
on IN 0
achieving VBG 0
therapeutic JJ 0
goals NNS 0
for IN 0
blood NN 0
pressure NN 0
( ( 0
BP NNP 0
) ) 0
, , 0
total JJ 0
cholesterol NN 0
( ( 0
TC NNP 0
) ) 0
, , 0
and CC 0
both DT 0
BP NNP 0
and CC 0
TC NNP 0
( ( 0
BP/TC NNP 0
) ) 0
in IN 0
patients NNS 0
with IN 0
CVD NNP 0
and/or VBP 0
high JJ 4
or CC 4
intermediate JJ 4
cardiovascular NN 4
( ( 4
CV NNP 4
) ) 4
risk NN 4
attending VBG 0
community NN 0
pharmacies NNS 0
in IN 0
Spain NNP 0
. . 0

METHODS NNP 0
Patients NNPS 0
aged VBD 0
25 CD 1
to TO 1
74 CD 1
years NNS 0
attending VBG 0
community NN 0
pharmacies NNS 0
with IN 0
a DT 0
prescription NN 0
for IN 0
at IN 0
least JJS 0
1 CD 0
drug NN 0
indicated VBN 0
for IN 0
CVD NNP 0
or CC 0
CV NNP 4
risk NN 0
factors NNS 0
were VBD 0
randomized VBN 0
to TO 0
2 CD 0
groups NNS 0
: : 0
an DT 0
intervention NN 0
group NN 0
that WDT 0
received VBD 0
pharmaceutical JJ 0
care NN 0
, , 0
which WDT 0
was VBD 0
provided VBN 0
by IN 0
specially RB 0
trained JJ 0
pharmacists NNS 0
working VBG 0
in IN 0
collaboration NN 0
with IN 0
physicians NNS 0
, , 0
and CC 0
a DT 0
control NN 0
group NN 0
that WDT 0
received VBD 0
usual JJ 0
care NN 0
( ( 0
routine JJ 0
dispensing VBG 0
counseling NN 0
) ) 0
and CC 0
verbal JJ 0
and CC 0
written VBN 0
counseling VBG 0
regarding VBG 0
CVD NNP 0
prevention NN 0
. . 0

Patients NNS 0
were VBD 0
recruited VBN 0
from IN 0
December NNP 0
2005 CD 0
to TO 0
September NNP 0
2006 CD 0
, , 0
and CC 0
both DT 0
groups NNS 0
were VBD 0
followed VBN 0
for IN 0
8 CD 0
months NNS 0
. . 0

Study NNP 0
outcomes NNS 0
were VBD 0
assessed VBN 0
at IN 0
baseline NN 0
and CC 0
at IN 0
16 CD 0
and CC 0
32 CD 0
weeks NNS 0
after IN 0
randomization NN 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
measures NNS 0
were VBD 0
the DT 0
proportions NNS 0
of IN 0
patients NNS 0
achieving VBG 0
BP NNP 0
, , 0
TC NNP 0
, , 0
and CC 0
BP/TC NNP 0
therapeutic JJ 0
goals NNS 0
( ( 0
BP NNP 0
lower JJR 0
than IN 0
140/90 CD 0
mm NNS 0
Hg NNP 0
for IN 0
patients NNS 0
with IN 0
uncomplicated JJ 0
hypertension NN 0
and CC 0
lower JJR 0
than IN 0
130/80 CD 0
mm NNS 0
Hg NNP 0
for IN 0
patients NNS 0
with IN 0
diabetes NNS 0
, , 0
chronic JJ 0
kidney NN 0
disease NN 0
, , 0
or CC 0
history NN 0
of IN 0
myocardial JJ 0
infarction NN 0
or CC 0
stroke NN 0
; : 0
TC NNP 0
lower JJR 0
than IN 0
200 CD 0
mg NNS 0
per IN 0
dL NN 0
for IN 0
patients NNS 0
without IN 0
CVD NNP 0
and CC 0
lower JJR 0
than IN 0
175 CD 0
mg NNS 0
per IN 0
dL NN 0
for IN 0
patients NNS 0
with IN 0
CVD NNP 0
) ) 0
. . 0

Secondary JJ 0
outcomes NNS 0
were VBD 0
mean JJ 0
BP NNP 0
and CC 0
TC NNP 0
values NNS 0
. . 0

BP NNP 0
was VBD 0
assessed VBN 0
manually RB 0
by IN 0
the DT 0
pharmacist NN 0
after IN 0
a DT 0
10-minute JJ 0
rest NN 0
in IN 0
the DT 0
supine JJ 0
position NN 0
. . 0

This DT 0
measurement NN 0
was VBD 0
performed VBN 0
twice RB 0
for IN 0
every DT 0
participant NN 0
, , 0
and CC 0
the DT 0
average NN 0
of IN 0
the DT 0
2 CD 0
measurements NNS 0
was VBD 0
calculated VBN 0
. . 0

TC NNP 0
was VBD 0
measured VBN 0
by IN 0
the DT 0
pharmacist NN 0
during IN 0
the DT 0
study NN 0
visit NN 0
using VBG 0
the DT 0
enzymatic JJ 0
dry JJ 0
method NN 0
. . 0

Statistical JJ 0
analyses NNS 0
were VBD 0
performed VBN 0
using VBG 0
2-tailed JJ 0
McNemar NNP 0
tests NNS 0
, , 0
Pearson NNP 0
chi-square NN 0
tests NNS 0
, , 0
and CC 0
Student NNP 0
's POS 0
t-tests NNS 0
; : 0
P NNP 0
< VBD 0
0.05 CD 0
was VBD 0
considered VBN 0
statistically RB 0
significant JJ 0
. . 0

RESULTS VB 0
714 CD 3
patients NNS 0
were VBD 0
included VBN 0
in IN 0
the DT 0
study NN 0
( ( 0
356 CD 0
intervention NN 0
, , 0
358 CD 0
control NN 0
) ) 0
, , 0
and CC 0
the DT 0
mean JJ 0
[ NNP 0
SD NNP 0
] NNP 0
age NN 0
was VBD 0
62.8 CD 1
[ JJ 0
8.1 CD 0
] JJ 0
years NNS 0
. . 0

The DT 0
2 CD 0
groups NNS 0
were VBD 0
similar JJ 0
at IN 0
baseline NN 0
in IN 0
clinical JJ 0
and CC 0
demographic JJ 0
characteristics NNS 0
, , 0
including VBG 0
the DT 0
proportion NN 0
of IN 0
patients NNS 0
at IN 0
therapeutic JJ 0
goals NNS 0
for IN 0
BP NNP 0
, , 0
TC NNP 0
, , 0
and CC 0
BP/TC NNP 0
. . 0

After IN 0
8 CD 0
months NNS 0
of IN 0
follow-up NN 0
, , 0
there EX 0
were VBD 0
statistically RB 0
significant JJ 0
differences NNS 0
in IN 0
favor NN 0
of IN 0
pharmaceutical JJ 0
care NN 0
in IN 0
the DT 0
proportions NNS 0
of IN 0
patients NNS 0
who WP 0
achieved VBD 0
therapeutic JJ 0
goals NNS 0
for IN 0
BP NNP 0
( ( 0
52.5 CD 0
% NN 0
vs. FW 0
43.0 CD 0
% NN 0
, , 0
P=0.017 NNP 0
) ) 0
, , 0
TC NNP 0
( ( 0
56.5 CD 0
% NN 0
vs. FW 0
44.1 CD 0
% NN 0
, , 0
P=0.001 NNP 0
) ) 0
, , 0
and CC 0
BP/TC NNP 0
( ( 0
37.1 CD 0
% NN 0
vs. FW 0
21.8 CD 0
% NN 0
, , 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
Compared NNP 0
with IN 0
usual JJ 0
care NN 0
plus CC 0
written VBN 0
education NN 0
, , 0
pharmaceutical JJ 0
care NN 0
focused VBN 0
on IN 0
patient JJ 0
evaluation NN 0
and CC 0
follow-up NN 0
in IN 0
collaboration NN 0
with IN 0
physicians NNS 0
improved VBN 0
the DT 0
achievement NN 0
of IN 0
BP NNP 0
, , 0
TC NNP 0
, , 0
and CC 0
BP/TC NNP 0
treatment NN 0
goals NNS 0
in IN 0
patients NNS 0
with IN 0
CVD NNP 0
and/or VBP 0
high JJ 0
or CC 0
intermediate JJ 0
CV NNP 0
risk NN 0
attending VBG 0
community NN 0
pharmacies NNS 0
in IN 0
Spain NNP 0
. . 0

Chemotherapy NN 0
of IN 0
large JJ 4
bowel NN 4
carcinoma NN 4
-- : 0
fluorouracil NN 0
( ( 0
FU NNP 0
) ) 0
+ VBP 0
hydroxyurea NN 0
( ( 0
HU NNP 0
) ) 0
vs. FW 0
methyl-CCNU NN 0
, , 0
oncovin NN 0
, , 0
fluorouracil NN 0
, , 0
and CC 0
streptozotocin NN 0
( ( 0
MOF-Strep NNP 0
) ) 0
. . 0

An DT 0
Eastern JJ 0
Cooperative NNP 0
Oncology NNP 0
Group NNP 0
study NN 0
. . 0

In IN 0
this DT 0
prospective JJ 0
randomized NN 0
study NN 0
of IN 0
initial JJ 0
chemotherapy NN 0
for IN 0
advanced JJ 4
measurable JJ 4
metastatic JJ 4
large JJ 4
bowel NN 4
carcinoma NN 4
, , 0
the DT 0
response NN 0
rate NN 0
was VBD 0
6/32 CD 0
( ( 0
19 CD 0
% NN 0
) ) 0
for IN 0
FU NNP 0
+ NNP 0
HU NNP 0
and CC 0
5/32 CD 0
( ( 0
16 CD 0
% NN 0
) ) 0
for IN 0
MOF-Strep NNP 0
; : 0
the DT 0
estimated JJ 0
median JJ 0
survival NN 0
is VBZ 0
43 CD 0
weeks NNS 0
for IN 0
both DT 0
treatments NNS 0
. . 0

Patients NNS 0
who WP 0
received VBD 0
MOF-Strep NNP 0
experienced VBD 0
substantially RB 0
greater JJR 0
vomiting VBG 0
and CC 0
hematologic JJ 0
toxicity NN 0
than IN 0
patients NNS 0
who WP 0
received VBD 0
FU NNP 0
+ NNP 0
HU NNP 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
. . 0

Memantine NNP 0
add-on JJ 0
to TO 0
risperidone VB 0
for IN 0
treatment NN 0
of IN 0
negative JJ 0
symptoms NNS 0
in IN 0
patients NNS 0
with IN 0
stable JJ 4
schizophrenia NN 4
: : 0
randomized VBN 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
study NN 0
. . 0

We PRP 0
aimed VBD 0
to TO 0
evaluate VB 0
the DT 0
efficacy NN 0
of IN 0
memantine JJ 0
add-on JJ 0
in IN 0
the DT 0
treatment NN 0
of IN 0
primary JJ 0
negative JJ 0
symptoms NNS 0
of IN 0
patients NNS 0
with IN 0
stable JJ 0
schizophrenia NN 0
. . 0

In IN 0
a DT 0
double-blind JJ 0
placebo-controlled JJ 0
clinical JJ 0
trial NN 0
, , 0
40 CD 3
patients NNS 0
with IN 0
schizophrenia NN 4
( ( 0
Diagnostic NNP 0
and CC 0
Statistical NNP 0
Manual NNP 0
of IN 0
Mental NNP 0
Disorders NNP 0
, , 0
Fourth NNP 0
Edition NNP 0
) ) 0
who WP 0
were VBD 0
stabilized VBN 0
on IN 0
risperidone NN 0
for IN 0
a DT 0
minimum NN 0
of IN 0
8 CD 0
weeks NNS 0
were VBD 0
randomized VBN 0
to TO 0
either DT 0
memantine NN 0
( ( 0
20 CD 0
mg NN 0
) ) 0
or CC 0
placebo NN 0
in IN 0
addition NN 0
to TO 0
risperidone VB 0
, , 0
6 CD 0
mg/d NN 0
, , 0
for IN 0
eight CD 0
weeks NNS 0
. . 0

Assessment NNP 0
was VBD 0
done VBN 0
using VBG 0
the DT 0
Positive NNP 0
and CC 0
Negative NNP 0
Syndrome NNP 0
Scale NNP 0
at IN 0
baseline NN 0
, , 0
week NN 0
4 CD 0
, , 0
and CC 0
week NN 0
8 CD 0
. . 0

The DT 0
Hamilton NNP 0
Depression NNP 0
Rating NNP 0
Scale NNP 0
and CC 0
the DT 0
Extrapyramidal NNP 0
Symptom NNP 0
Rating NNP 0
Scale NNP 0
at IN 0
baseline NN 0
and CC 0
week NN 0
8 CD 0
were VBD 0
used VBN 0
to TO 0
assess VB 0
depression NN 0
and CC 0
extrapyramidal NN 0
symptoms NNS 0
, , 0
respectively RB 0
. . 0

All DT 0
40 CD 0
patients NNS 0
had VBD 0
at IN 0
least JJS 0
one CD 0
postbaseline NN 0
measurement NN 0
, , 0
and CC 0
38 CD 3
patients NNS 0
completed VBD 0
the DT 0
trial NN 0
. . 0

Patients NNS 0
in IN 0
the DT 0
memantine NN 0
group NN 0
showed VBD 0
a DT 0
significantly RB 0
greater JJR 0
improvement NN 0
on IN 0
negative JJ 0
subscale NN 0
than IN 0
the DT 0
placebo NN 0
group NN 0
at IN 0
end NN 0
point NN 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

The DT 0
same JJ 0
effect NN 0
was VBD 0
observed VBN 0
for IN 0
the DT 0
total JJ 0
score NN 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
and CC 0
the DT 0
general JJ 0
psychopathology NN 0
subscale NN 0
score NN 0
( ( 0
P NNP 0
= NNP 0
0.002 CD 0
) ) 0
. . 0

There EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
in IN 0
reduction NN 0
of IN 0
positive JJ 0
symptoms NNS 0
score VBP 0
between IN 0
the DT 0
2 CD 0
groups NNS 0
( ( 0
P NNP 0
= NNP 0
0.757 CD 0
) ) 0
. . 0

Changes NNS 0
in IN 0
the DT 0
Hamilton NNP 0
Depression NNP 0
Rating NNP 0
Scale NNP 0
and CC 0
the DT 0
Extrapyramidal NNP 0
Symptom NNP 0
Rating NNP 0
Scale NNP 0
scores NNS 0
and CC 0
frequency NN 0
of IN 0
adverse JJ 0
effects NNS 0
did VBD 0
not RB 0
differ VB 0
between IN 0
the DT 0
2 CD 0
groups NNS 0
. . 0

Our PRP$ 0
study NN 0
showed VBD 0
that IN 0
memantine NN 0
is VBZ 0
a DT 0
tolerable JJ 0
and CC 0
efficacious JJ 0
add-on JJ 0
treatment NN 0
for IN 0
primary JJ 0
negative JJ 0
symptoms NNS 0
of IN 0
schizophrenia NN 0
. . 0

Influence NN 0
of IN 0
occlusal JJ 0
access NN 0
on IN 0
demineralized JJ 0
dentin NN 0
removal NN 0
in IN 0
the DT 0
atraumatic JJ 0
restorative JJ 0
treatment NN 0
( ( 0
ART NNP 0
) ) 0
approach NN 0
. . 0

PURPOSE NNP 0
To TO 0
verify VB 0
the DT 0
influence NN 0
of IN 0
cavity NN 0
access NN 0
diameter NN 0
on IN 0
demineralized JJ 0
dentin NN 0
removal NN 0
in IN 0
the DT 0
ART NNP 0
approach NN 0
. . 0

METHODS $ 0
40 CD 3
non-carious JJ 4
human JJ 4
premolars NNS 4
were VBD 0
randomly RB 0
divided VBN 0
into IN 0
four CD 0
groups NNS 0
. . 0

The DT 0
occlusal JJ 0
surface NN 0
was VBD 0
ground NN 0
flat JJ 0
and CC 0
the DT 0
teeth NNS 0
were VBD 0
sectioned VBN 0
mesio-distally RB 0
. . 0

The DT 0
hemi-sections NNS 0
were VBD 0
reassembled VBN 0
and CC 0
occlusal JJ 0
access NN 0
preparations NNS 0
were VBD 0
carried VBN 0
out RP 0
using VBG 0
ball-shaped JJ 0
diamonds NNS 0
. . 0

The DT 0
resulting VBG 0
size NN 0
of IN 0
the DT 0
occlusal NN 0
opening NN 0
was VBD 0
1.0 CD 0
mm NN 0
, , 0
1.4 CD 0
mm NN 0
, , 0
1.6 CD 0
mm NN 0
and CC 0
1.8 CD 0
mm NN 0
for IN 0
Groups NNP 0
A NNP 0
, , 0
B NNP 0
, , 0
C NNP 0
, , 0
and CC 0
D NNP 0
, , 0
respectively RB 0
. . 0

Standardized VBN 0
artificial JJ 0
carious JJ 0
lesions NNS 0
were VBD 0
created VBN 0
and CC 0
demineralized VBN 0
dentin NN 0
was VBD 0
excavated VBN 0
. . 0

After IN 0
excavation NN 0
, , 0
the DT 0
cavities NNS 0
were VBD 0
analyzed VBN 0
using VBG 0
: : 0
( ( 0
a DT 0
) ) 0
the DT 0
tactile NN 0
method NN 0
, , 0
( ( 0
b NN 0
) ) 0
caries-detection NN 0
dye NN 0
to TO 0
stain VB 0
demineralized JJ 0
dentin NN 0
, , 0
as IN 0
proposed VBN 0
by IN 0
Smales NNP 0
& CC 0
Fang NNP 0
, , 0
and CC 0
( ( 0
c NN 0
) ) 0
Demineralized NNP 0
Tissue NNP 0
Removal NNP 0
index NN 0
, , 0
as IN 0
proposed VBN 0
in IN 0
this DT 0
study NN 0
. . 0

Statistical JJ 0
analysis NN 0
was VBD 0
performed VBN 0
using VBG 0
Fisher NNP 0
, , 0
Spearman NNP 0
correlation NN 0
coefficient NN 0
, , 0
kappa NN 0
, , 0
Kruskal-Wallis NNP 0
and CC 0
Miller NNP 0
tests NNS 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

RESULTS VB 0
The DT 0
three CD 0
methods NNS 0
of IN 0
evaluation NN 0
showed VBD 0
no DT 0
significant JJ 0
difference NN 0
between IN 0
Groups NNP 0
A NNP 0
vs. NN 0
B NNP 0
, , 0
and CC 0
C NNP 0
vs. FW 0
D NNP 0
, , 0
while IN 0
statistically RB 0
significant JJ 0
differences NNS 0
were VBD 0
observed VBN 0
between IN 0
Groups NNP 0
A NNP 0
vs. FW 0
C NNP 0
, , 0
A NNP 0
vs. NN 0
D NNP 0
, , 0
B NNP 0
vs. FW 0
C NNP 0
and CC 0
B NNP 0
vs. FW 0
D. NNP 0
Based VBD 0
on IN 0
the DT 0
results NNS 0
of IN 0
this DT 0
study NN 0
, , 0
the DT 0
size NN 0
of IN 0
occlusal JJ 0
access NN 0
significantly RB 0
affected VBD 0
the DT 0
efficacy NN 0
of IN 0
demineralized JJ 0
tissue NN 0
removal NN 0
. . 0

Effect NNP 0
of IN 0
four CD 0
intermediate JJ 0
layer NN 0
treatments NNS 0
on IN 0
microleakage NN 4
of IN 0
Class NNP 4
II NNP 4
composite JJ 4
restorations NNS 4
. . 0

This DT 0
in IN 0
vitro NN 0
study NN 0
examines VBZ 0
the DT 0
marginal JJ 0
sealing NN 0
ability NN 0
of IN 0
four CD 0
different JJ 0
intermediate JJ 0
materials NNS 0
applied VBN 0
before IN 0
placement NN 0
of IN 0
a DT 0
condensable JJ 0
composite NN 0
. . 0

Class NNP 4
II NNP 4
preparations NNS 4
were VBD 0
made VBN 0
with IN 0
gingival JJ 0
margins NNS 0
placed VBD 0
1.0 CD 0
mm JJ 0
apical JJ 0
to TO 0
the DT 0
cementoenamel JJ 0
junction NN 0
of IN 0
60 CD 3
extracted JJ 4
teeth NNS 4
, , 0
randomly RB 0
assigned VBN 0
to TO 0
five CD 0
groups NNS 0
of IN 0
12 CD 3
. . 0

Following VBG 0
restoration NN 0
, , 0
teeth EX 0
were VBD 0
thermocycled VBN 0
, , 0
soaked VBN 0
in IN 0
0.5 CD 0
% NN 0
basic JJ 0
fuchsin NN 0
, , 0
and CC 0
sectioned VBD 0
longitudinally RB 0
. . 0

The DT 0
resin-modified JJ 0
glass NN 0
ionomer NN 0
cement NN 0
demonstrated VBD 0
significantly RB 0
less JJR 0
microleakage NN 0
than IN 0
the DT 0
use NN 0
of IN 0
a DT 0
dentin NN 0
bonding NN 0
agent NN 0
alone RB 0
or CC 0
in IN 0
combination NN 0
with IN 0
flowable JJ 0
composite JJ 0
, , 0
flowable JJ 0
compomer NN 0
, , 0
or CC 0
autoploymerizing VBG 0
composite JJ 0
( ( 0
p JJ 0
< NN 0
0.05 CD 0
, , 0
Dunn NNP 0
's POS 0
test NN 0
) ) 0
. . 0

This DT 0
study NN 0
supports VBZ 0
the DT 0
use NN 0
of IN 0
the DT 0
glass NN 0
ionomer NN 0
open JJ 0
sandwich NN 0
technique NN 0
in IN 0
deep JJ 4
Class NNP 4
II NNP 4
direct JJ 4
composite JJ 4
restorations NNS 4
. . 0

Long RB 0
pediatric JJ 0
colonoscope NN 0
versus NN 0
intermediate JJ 0
length NN 0
adult NN 0
colonoscope NN 0
for IN 0
colonoscopy NN 0
. . 0

BACKGROUND NNP 0
Controversy NNP 0
exists VBZ 0
on IN 0
how WRB 0
the DT 0
length NN 0
and CC 0
diameter NN 0
of IN 0
colonoscopes NNS 0
affect VBP 0
the DT 0
quality NN 0
of IN 0
colonoscopy NN 0
. . 0

The DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
compare VB 0
a DT 0
long JJ 0
pediatric JJ 0
colonoscope NN 0
with IN 0
an DT 0
intermediate JJ 0
length NN 0
adult NN 0
colonoscope NN 0
with IN 0
regards NNS 0
to TO 0
completion NN 0
rate NN 0
and CC 0
cecal JJ 0
intubation NN 0
time NN 0
. . 0

Whether CC 0
either DT 0
scope NN 0
may MD 0
be VB 0
more RBR 0
efficient JJ 0
in IN 0
any DT 0
subgroups NN 0
was VBD 0
also RB 0
investigated VBN 0
. . 0

METHODS NNP 0
Asymptomatic JJ 4
patients NNS 0
admitted VBN 0
to TO 0
the DT 0
physical JJ 0
check-up JJ 0
department NN 0
of IN 0
Buddhist NNP 0
Dalin NNP 0
Tzu NNP 0
Chi NNP 0
General NNP 0
Hospital NNP 0
were VBD 0
included VBN 0
. . 0

A DT 0
single JJ 0
endoscopist NN 0
performed VBD 0
all DT 0
of IN 0
the DT 0
colonoscopic NN 0
examinations NNS 0
under IN 0
sedation NN 0
. . 0

Consecutive JJ 0
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
undergo VB 0
colonoscopy NN 0
with IN 0
either DT 0
intermediate JJ 0
length NN 0
adult NN 0
colonoscope NN 0
( ( 0
CF-240I NNP 0
) ) 0
or CC 0
long JJ 0
pediatric JJ 0
colonoscope NN 0
( ( 0
PCF-240L NNP 0
) ) 0
. . 0

The DT 0
success NN 0
rate NN 0
and CC 0
time NN 0
required VBN 0
to TO 0
reach VB 0
cecum NN 0
were VBD 0
compared VBN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
. . 0

RESULTS NNP 0
Between NNP 0
April NNP 0
2005 CD 0
and CC 0
February NNP 0
2006 CD 0
, , 0
a DT 0
total NN 0
of IN 0
918 CD 3
patients NNS 0
were VBD 0
enrolled VBN 0
. . 0

Incomplete NNP 0
colonoscopy NN 0
occurred VBD 0
in IN 0
21 CD 0
( ( 0
2.3 CD 0
% NN 0
) ) 0
cases NNS 0
( ( 0
14 CD 0
in IN 0
the DT 0
CF-240I NNP 0
group NN 0
and CC 0
seven CD 0
in IN 0
the DT 0
PCF-240L NNP 0
group NN 0
, , 0
P NNP 0
> NNP 0
0.1 CD 0
) ) 0
. . 0

The DT 0
overall JJ 0
cecal JJ 0
mean NN 0
insertion NN 0
time NN 0
was VBD 0
6.00 CD 0
+/- JJ 0
3.66 CD 0
min NN 0
. . 0

There EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
between IN 0
the DT 0
CF-240I NNP 0
and CC 0
PCF NNP 0
240L CD 0
groups NNS 0
with IN 0
regard NN 0
to TO 0
the DT 0
cecal JJ 0
intubation NN 0
rate NN 0
( ( 0
96.9 CD 0
% NN 0
vs JJ 0
98.5 CD 0
% NN 0
, , 0
P NNP 0
= NNP 0
0.18 CD 0
) ) 0
, , 0
the DT 0
need NN 0
for IN 0
abdominal JJ 0
pressure NN 0
( ( 0
71.7 CD 0
% NN 0
vs JJ 0
73.4 CD 0
% NN 0
, , 0
P NNP 0
= NNP 0
0.55 CD 0
) ) 0
and CC 0
change NN 0
of IN 0
position NN 0
( ( 0
13.5 CD 0
% NN 0
vs JJ 0
11.5 CD 0
% NN 0
, , 0
P NNP 0
= NNP 0
0.37 CD 0
) ) 0
. . 0

However RB 0
, , 0
the DT 0
cecal JJ 0
intubation NN 0
time NN 0
was VBD 0
shorter RBR 0
in IN 0
the DT 0
CF-240I NNP 0
group NN 0
( ( 0
5.75 CD 0
+/- JJ 0
3.18 CD 0
vs JJ 0
6.26 CD 0
+/- JJ 0
3.30 CD 0
min NN 0
, , 0
P NNP 0
= NNP 0
0.02 CD 0
) ) 0
. . 0

Subgroup NNP 0
analysis NN 0
by IN 0
sex NN 0
, , 0
age NN 0
, , 0
and CC 0
body NN 0
mass NN 0
index NN 0
showed VBD 0
comparable JJ 0
outcomes NNS 0
between IN 0
the DT 0
two CD 0
groups NNS 0
except IN 0
that IN 0
the DT 0
cecal JJ 0
intubation NN 0
times NNS 0
were VBD 0
significantly RB 0
shorter JJR 0
in IN 0
the DT 0
CF-240I NNP 0
group NN 0
when WRB 0
only RB 0
men NNS 0
( ( 0
4.78 CD 0
+/- JJ 0
2.57 CD 0
vs JJ 0
5.50 CD 0
+/- JJ 0
2.93 CD 0
min NN 0
, , 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
or CC 0
those DT 0
younger JJR 0
than IN 0
50 CD 0
years NNS 0
( ( 0
5.50 CD 0
+/- JJ 0
2.90 CD 0
vs JJ 0
6.25 CD 0
+/- JJ 0
3.68 CD 0
min NN 0
, , 0
P NNP 0
= NNP 0
0.02 CD 0
) ) 0
were VBD 0
considered VBN 0
. . 0

CONCLUSION NNP 0
Cecal NNP 0
intubation NN 0
time NN 0
is VBZ 0
shorter RBR 0
in IN 0
patients NNS 0
examined VBN 0
with IN 0
an DT 0
intermediate JJ 0
length NN 0
adult NN 0
colonoscope NN 0
, , 0
mainly RB 0
in IN 0
the DT 0
subgroups NNS 0
of IN 0
men NNS 0
and CC 0
those DT 0
younger JJR 0
than IN 0
50 CD 0
years NNS 0
of IN 0
age NN 0
. . 0

No DT 0
effect NN 0
of IN 0
acetylsalicylic JJ 0
acid NN 0
on IN 0
B-thromboglobulin NNP 0
and CC 0
platelet VB 0
factor NN 0
4 CD 0
plasma NN 0
levels NNS 0
in IN 0
patients NNS 0
with IN 0
transient JJ 4
ischaemic JJ 4
attacks NNS 4
. . 0

We PRP 0
studied VBD 0
the DT 0
effect NN 0
of IN 0
acetylsalicylic JJ 0
acid NN 0
( ( 0
ASA NNP 0
) ) 0
versus NN 0
placebo NN 0
on IN 0
B-thromboglobulin NNP 0
( ( 0
B-TG NNP 0
) ) 0
and CC 0
platelet JJ 0
factor NN 0
4 CD 0
( ( 0
PF4 NNP 0
) ) 0
plasma NN 0
levels NNS 0
and CC 0
ADP-induced NNP 0
platelet NN 0
aggregation NN 0
in IN 0
25 CD 3
male JJ 2
patients NNS 0
with IN 0
transient JJ 4
ischaemic JJ 4
attacks NNS 4
( ( 0
TIA NNP 4
) ) 0
. . 0

The DT 0
patients NNS 0
were VBD 0
allocated VBN 0
randomly RB 0
to TO 0
two CD 0
groups NNS 0
: : 0
14 CD 0
patients NNS 0
received JJ 0
oral JJ 0
treatment NN 0
with IN 0
ASA NNP 0
500 CD 0
mg NN 0
b.i.d NN 0
. . 0

for IN 0
14 CD 0
days NNS 0
, , 0
11 CD 0
patients NNS 0
placebo JJ 0
b.i.d NN 0
. . 0

for IN 0
the DT 0
same JJ 0
period NN 0
. . 0

B-TG NNP 0
and CC 0
PF4 NNP 0
plasma NN 0
levels NNS 0
and CC 0
ADP-induced NNP 0
platelet NN 0
aggregation NN 0
were VBD 0
determined VBN 0
in IN 0
basal NN 0
conditions NNS 0
, , 0
and CC 0
two CD 0
hours NNS 0
, , 0
and CC 0
seven CD 0
and CC 0
fourteen JJ 0
days NNS 0
after IN 0
starting VBG 0
with IN 0
ASA NNP 0
or CC 0
placebo NN 0
. . 0

In IN 0
addition NN 0
, , 0
the DT 0
same JJ 0
parameters NNS 0
were VBD 0
studied VBN 0
in IN 0
a DT 0
group NN 0
of IN 0
20 CD 3
healthy JJ 4
males NNS 2
of IN 0
matched JJ 0
age NN 0
. . 0

Basal NNP 0
levels NNS 0
of IN 0
plasma JJ 0
B-TG NNP 0
and CC 0
PF4 NNP 0
and CC 0
the DT 0
maximal JJ 0
amplitude NN 0
of IN 0
ADP-induced NNP 0
platelet NN 0
aggregation NN 0
were VBD 0
abnormally RB 0
high JJ 0
in IN 0
TIA NNP 0
patients NNS 0
. . 0

ASA NNP 0
caused VBD 0
a DT 0
significant JJ 0
reduction NN 0
of IN 0
B-TG NNP 0
plasma NN 0
levels NNS 0
in IN 0
TIA NNP 0
patients NNS 0
2 CD 0
hours NNS 0
after IN 0
the DT 0
first JJ 0
administration NN 0
, , 0
but CC 0
no DT 0
effect NN 0
was VBD 0
observed VBN 0
at IN 0
the DT 0
7th CD 0
and CC 0
14th CD 0
day NN 0
of IN 0
treatment NN 0
. . 0

PF4 NNP 0
plasma NN 0
levels NNS 0
were VBD 0
unaffected VBN 0
by IN 0
ASA NNP 0
treatment NN 0
. . 0

It PRP 0
is VBZ 0
concluded VBN 0
that IN 0
ASA NNP 0
, , 0
at IN 0
the DT 0
dose NN 0
conventionally RB 0
used VBN 0
in IN 0
clinical JJ 0
trials NNS 0
, , 0
does VBZ 0
not RB 0
affect VB 0
the DT 0
release NN 0
of IN 0
two CD 0
alpha-granule JJ 0
proteins NNS 0
. . 0

Treatment NN 0
of IN 0
stable JJ 4
angina NN 4
of IN 4
effort NN 4
with IN 0
verapamil NN 0
: : 0
a DT 0
double-blind NN 0
, , 0
placebo-controlled JJ 0
randomized VBN 0
crossover NN 0
study NN 0
. . 0

The DT 0
effects NNS 0
of IN 0
verapamil NN 0
were VBD 0
assessed VBN 0
in IN 0
26 CD 3
patients NNS 0
with IN 0
stable JJ 4
exertional JJ 4
angina NN 4
pectoris NN 4
in IN 0
a DT 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
, , 0
randomized VBN 0
crossover NN 0
protocol NN 0
using VBG 0
serial JJ 0
treadmill NN 0
tests NNS 0
. . 0

Verapamil NNP 0
, , 0
480 CD 0
mg/day NN 0
, , 0
reduced VBD 0
anginal JJ 0
frequency NN 0
from IN 0
5.6 CD 0
+/- JJ 0
7.3 CD 0
to TO 0
2.2 CD 0
+/- JJ 0
3.9 CD 0
attacks NNS 0
per IN 0
week NN 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
and CC 0
nitroglycerin JJ 0
consumption NN 0
from IN 0
3.4 CD 0
+/- JJ 0
4.9 CD 0
to TO 0
1.2 CD 0
+/- JJ 0
2.5 CD 0
tablets NNS 0
per IN 0
week NN 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
compared VBN 0
with IN 0
placebo NN 0
. . 0

Treadmill NNP 0
time NN 0
increased VBD 0
from IN 0
6.4 CD 0
+/- JJ 0
2.1 CD 0
minutes NNS 0
during IN 0
the DT 0
placebo NN 0
phase NN 0
to TO 0
7.5 CD 0
+/- JJ 0
1.8 CD 0
minutes NNS 0
during IN 0
the DT 0
verapamil JJ 0
phase NN 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
. . 0

Verapamil NNP 0
's POS 0
beneficial JJ 0
effect NN 0
appeared VBD 0
to TO 0
be VB 0
related VBN 0
, , 0
in IN 0
part NN 0
, , 0
to TO 0
a DT 0
10 CD 0
% NN 0
reduction NN 0
of IN 0
the DT 0
rate-pressure JJ 0
product NN 0
at IN 0
rest NN 0
( ( 0
p IN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
and CC 0
a DT 0
12 CD 0
% NN 0
reduction NN 0
during IN 0
submaximal JJ 0
exercise NN 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.001 CD 0
) ) 0
. . 0

Verapamil NNP 0
also RB 0
caused VBD 0
less JJR 0
marked JJ 0
ST-segment JJ 0
depressions NNS 0
at IN 0
peak NN 0
exercise NN 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
at IN 0
a DT 0
similar JJ 0
rate-pressure NN 0
product NN 0
, , 0
suggesting VBG 0
a DT 0
favorable JJ 0
redistribution NN 0
of IN 0
coronary JJ 0
blood NN 0
flow NN 0
to TO 0
the DT 0
ischemic JJ 0
zone NN 0
. . 0

Side JJ 0
effects NNS 0
from IN 0
verapamil NN 0
were VBD 0
minimal JJ 0
, , 0
consisting VBG 0
mainly RB 0
of IN 0
constipation NN 0
( ( 0
six CD 0
patients NNS 0
) ) 0
. . 0

Verapamil NNP 0
appears VBZ 0
to TO 0
be VB 0
a DT 0
safe JJ 0
and CC 0
effective JJ 0
drug NN 0
for IN 0
treating VBG 0
angina NN 4
of IN 0
effort NN 0
. . 0

Comparison NNP 0
of IN 0
the DT 0
in IN 0
vitro NN 0
and CC 0
in IN 0
vivo JJ 0
release NN 0
of IN 0
digoxin NN 0
from IN 0
four CD 0
different JJ 0
soft JJ 0
gelatin NN 0
capsule NN 0
formulations NNS 0
. . 0

A DT 0
blinded JJ 0
, , 0
four-treatment JJ 0
crossover NN 0
study NN 0
in IN 0
16 CD 3
normal JJ 0
adult NN 1
male NN 2
volunteers NNS 0
compared VBN 0
plasma JJ 0
concentrations NNS 0
and CC 0
urinary JJ 0
excretion NN 0
of IN 0
digoxin NN 0
, , 0
measured VBN 0
by IN 0
radioimmunoassay NN 0
, , 0
after IN 0
oral JJ 0
administration NN 0
of IN 0
soft JJ 0
gelatin NN 0
capsule NN 0
formulations NNS 0
of IN 0
digoxin NN 0
. . 0

Four CD 0
0.4-mg JJ 0
formulations NNS 0
with IN 0
different JJ 0
in IN 0
vitro NN 0
burst NN 0
times NNS 0
and CC 0
dissolution NN 0
rates NNS 0
were VBD 0
administered VBN 0
, , 0
with IN 0
2-week JJ 0
intervals NNS 0
between IN 0
treatments NNS 0
. . 0

The DT 0
two CD 0
capsules NNS 0
with IN 0
lowest JJS 0
in IN 0
vitro NN 0
burst NN 0
times NNS 0
( ( 0
2.9 CD 0
and CC 0
16 CD 0
min NN 0
) ) 0
gave VBD 0
comparable JJ 0
in IN 0
vivo JJ 0
results NNS 0
. . 0

The DT 0
other JJ 0
two CD 0
capsules NNS 0
, , 0
with IN 0
in IN 0
vitro NN 0
burst NN 0
times NNS 0
of IN 0
62 CD 0
and CC 0
229 CD 0
min NN 0
, , 0
produced VBD 0
significant JJ 0
delays NNS 0
in IN 0
digoxin NN 0
absorption NN 0
. . 0

In IN 0
vitro-in JJ 0
vivo NN 0
correlations NNS 0
were VBD 0
obtained VBN 0
by IN 0
comparing VBG 0
the DT 0
logarithm NN 0
of IN 0
the DT 0
in IN 0
vitro JJ 0
burst NN 0
time NN 0
with IN 0
time NN 0
to TO 0
peak VB 0
plasma JJ 0
level NN 0
and CC 0
the DT 0
time NN 0
to TO 0
the DT 0
first JJ 0
measurable JJ 0
plasma NN 0
level NN 0
( ( 0
> CD 0
or CC 0
= VB 0
0 CD 0
. . 0

05 CD 0
ng/ml NN 0
) ) 0
. . 0

Also RB 0
, , 0
the DT 0
mean JJ 0
time NN 0
to TO 0
peak VB 0
plasma JJ 0
level NN 0
correlated VBN 0
with IN 0
the DT 0
logarithm NN 0
of IN 0
the DT 0
time NN 0
required VBN 0
to TO 0
release VB 0
either RB 0
50 CD 0
% NN 0
or CC 0
85 CD 0
% NN 0
of IN 0
the DT 0
digoxin NN 0
in IN 0
vitro NN 0
. . 0

No DT 0
significant JJ 0
changes NNS 0
were VBD 0
found VBN 0
in IN 0
the DT 0
amount NN 0
of IN 0
digoxin NN 0
absorbed VBN 0
from IN 0
each DT 0
capsule NN 0
as IN 0
determined VBN 0
by IN 0
urinary JJ 0
excretion NN 0
or CC 0
AUC0-infinity NN 0
. . 0

Study NN 0
of IN 0
the DT 0
vaginal JJ 0
tolerance NN 0
to TO 0
Acidform NNP 0
, , 0
an DT 0
acid-buffering JJ 0
, , 0
bioadhesive JJ 0
gel NN 0
. . 0

Vaginal JJ 0
tolerance NN 0
tests NNS 0
were VBD 0
performed VBN 0
with IN 0
a DT 0
new JJ 0
potential JJ 0
microbicidal NN 0
and CC 0
spermicidal JJ 0
product NN 0
, , 0
an DT 0
acid-buffering JJ 0
vaginal JJ 0
gel NN 0
( ( 0
Acidform NNP 0
) ) 0
without IN 0
or CC 0
with IN 0
nonoxynol-9 JJ 0
( ( 0
N-9 NNP 0
) ) 0
. . 0

The DT 0
potential JJ 0
advantages NNS 0
over IN 0
other JJ 0
vaginal JJ 0
products NNS 0
include VBP 0
keeping VBG 0
a DT 0
low JJ 0
pH NN 0
, , 0
decrease NN 0
of IN 0
the DT 0
irritating VBG 0
effect NN 0
of IN 0
N-9 NNP 0
on IN 0
the DT 0
cervix NN 0
or CC 0
vaginal JJ 0
mucosa NN 0
associated VBN 0
with IN 0
greater JJR 0
retention NN 0
of IN 0
the DT 0
product NN 0
after IN 0
application NN 0
, , 0
and CC 0
decreasing VBG 0
messiness NN 0
as IN 0
compared VBN 0
to TO 0
other JJ 0
vaginal JJ 0
products NNS 0
. . 0

Three CD 0
groups NNS 0
of IN 0
six CD 3
women NNS 2
were VBD 0
admitted VBN 0
and CC 0
randomly RB 0
assigned VBN 0
to TO 0
use VB 0
Acidform NNP 0
with IN 0
0 CD 0
% NN 0
, , 0
2.5 CD 0
% NN 0
, , 0
and CC 0
5 CD 0
% NN 0
N-9 NNP 0
. . 0

Colposcopic NNP 0
evaluation NN 0
for IN 0
vulvar NN 0
, , 0
vaginal JJ 0
, , 0
and CC 0
cervical JJ 0
signs NNS 0
of IN 0
irritation NN 0
was VBD 0
performed VBN 0
and CC 0
photographs NNS 0
were VBD 0
taken VBN 0
, , 0
following VBG 0
a DT 0
specific JJ 0
World NNP 0
Health NNP 0
Organization NNP 0
protocol NN 0
, , 0
at IN 0
time NN 0
0 CD 0
, , 0
and CC 0
after IN 0
24 CD 0
h NN 0
and CC 0
6 CD 0
days NNS 0
of IN 0
application NN 0
of IN 0
the DT 0
gel NN 0
. . 0

No DT 0
irritation NN 0
or CC 0
symptom NN 0
was VBD 0
reported VBN 0
by IN 0
users NNS 0
of IN 0
Acidform NNP 0
without IN 0
N-9 NNP 0
. . 0

A NNP 0
generalized JJ 0
and CC 0
intense JJ 0
erythema NN 0
in IN 0
cervix NN 0
was VBD 0
observed VBN 0
in IN 0
10 CD 0
of IN 0
12 CD 0
Acidform/N-9 JJ 0
users NNS 0
and CC 0
abrasion NN 0
occurred VBD 0
in IN 0
nine CD 0
of IN 0
them PRP 0
. . 0

Vulvar NNP 0
irritation NN 0
was VBD 0
seen VBN 0
in IN 0
seven CD 0
of IN 0
these DT 0
10 CD 3
volunteers NNS 0
. . 0

N-9 JJ 0
concentration NN 0
in IN 0
the DT 0
gel NN 0
( ( 0
2.5 CD 0
% NN 0
or CC 0
5.0 CD 0
% NN 0
) ) 0
was VBD 0
not RB 0
related VBN 0
to TO 0
the DT 0
findings NNS 0
. . 0

No DT 0
ulcer NN 0
, , 0
exulceration NN 0
, , 0
or CC 0
de-epithelialization NN 0
was VBD 0
observed VBN 0
. . 0

Acidform VB 0
without IN 0
N-9 NNP 0
was VBD 0
well RB 0
tolerated VBN 0
by IN 0
volunteers NNS 0
, , 0
but CC 0
it PRP 0
was VBD 0
unable JJ 0
to TO 0
protect VB 0
the DT 0
cervix NN 0
, , 0
vagina NN 0
, , 0
and CC 0
vulva NN 0
from IN 0
the DT 0
N-9 JJ 0
effects NNS 0
. . 0

Dissociation NN 0
between IN 0
cortical JJ 0
activation NN 0
and CC 0
cognitive JJ 0
performance NN 0
under IN 0
pharmacological JJ 0
blood NN 0
pressure NN 0
elevation NN 0
in IN 0
chronic JJ 0
hypotension NN 0
. . 0

The DT 0
present JJ 0
study NN 0
explored VBD 0
the DT 0
impact NN 0
of IN 0
pharmacological JJ 0
blood NN 0
pressure NN 0
elevation NN 0
on IN 0
cortical JJ 0
activation NN 0
and CC 0
reaction NN 0
time NN 0
in IN 0
chronic JJ 4
hypotension NN 4
. . 0

Effects NNS 0
of IN 0
the DT 0
sympathomimetic JJ 0
etilefrine NN 0
were VBD 0
investigated VBN 0
in IN 0
50 CD 3
hypotensive JJ 4
persons NNS 0
based VBN 0
on IN 0
a DT 0
randomized VBN 0
, , 0
placebo-controlled JJ 0
double JJ 0
blind NN 0
design NN 0
. . 0

As IN 0
an DT 0
indicator NN 0
of IN 0
cortical JJ 0
excitability NN 0
, , 0
the DT 0
contingent NN 0
negative JJ 0
variation NN 0
( ( 0
CNV NNP 0
) ) 0
, , 0
induced VBN 0
by IN 0
a DT 0
constant JJ 0
foreperiod NN 0
reaction NN 0
time NN 0
task NN 0
, , 0
was VBD 0
assessed VBN 0
at IN 0
frontal JJ 0
( ( 0
F3 NNP 0
, , 0
Fz NNP 0
, , 0
F4 NNP 0
) ) 0
and CC 0
central JJ 0
( ( 0
C3 NNP 0
, , 0
Cz NNP 0
, , 0
C4 NNP 0
) ) 0
scalp NN 0
sites NNS 0
. . 0

Etilefrine NNP 0
provoked VBD 0
a DT 0
decrease NN 0
in IN 0
the DT 0
frontal NN 0
and CC 0
central JJ 0
CNV NNP 0
. . 0

In IN 0
contrast NN 0
, , 0
shorter JJR 0
reaction NN 0
times NNS 0
were VBD 0
observed JJ 0
following JJ 0
drug NN 0
administration NN 0
. . 0

The DT 0
degree NN 0
of IN 0
pharmacologically RB 0
induced VBN 0
blood NN 0
pressure NN 0
elevation NN 0
was VBD 0
correlated VBN 0
to TO 0
CNV NNP 0
attrition NN 0
as RB 0
well RB 0
as IN 0
to TO 0
performance NN 0
enhancement NN 0
. . 0

Inhibitory JJ 0
effects NNS 0
of IN 0
baroreceptor NN 0
activation NN 0
on IN 0
cortical JJ 0
excitability NN 0
and CC 0
enhanced VBD 0
cerebral JJ 0
blood NN 0
flow NN 0
are VBP 0
considered VBN 0
to TO 0
be VB 0
involved VBN 0
in IN 0
mediating VBG 0
the DT 0
effects NNS 0
of IN 0
blood NN 0
pressure NN 0
elevation NN 0
on IN 0
cerebral JJ 0
functioning NN 0
. . 0

Implications NNS 0
for IN 0
the DT 0
treatment NN 0
of IN 0
chronic JJ 0
hypotension NN 0
are VBP 0
discussed VBN 0
. . 0

The DT 0
prophylactic JJ 0
effect NN 0
of IN 0
valproate NN 0
on IN 0
glyceryltrinitrate NN 0
induced VBN 0
migraine NN 4
. . 0

In IN 0
this DT 0
study NN 0
the DT 0
human JJ 0
glyceryltrinitrate NN 0
( ( 0
GTN NNP 0
) ) 0
model NN 0
of IN 0
migraine NN 0
was VBD 0
for IN 0
the DT 0
first JJ 0
time NN 0
used VBN 0
to TO 0
test VB 0
the DT 0
effect NN 0
of IN 0
a DT 0
prophylactic JJ 0
drug NN 0
. . 0

We PRP 0
chose VBD 0
to TO 0
test VB 0
valproate NN 0
due JJ 0
to TO 0
its PRP$ 0
well RB 0
documented JJ 0
effect NN 0
as IN 0
a DT 0
migraine JJ 0
prophylactic JJ 0
drug NN 0
. . 0

Efficacy NN 0
of IN 0
this DT 0
compound NN 0
would MD 0
support VB 0
the DT 0
usefulness NN 0
of IN 0
the DT 0
model NN 0
in IN 0
prophylactic JJ 0
antimigraine JJ 0
drug NN 0
development NN 0
. . 0

Twelve CD 3
patients NNS 0
with IN 0
migraine NN 4
without IN 4
aura NN 4
were VBD 0
included VBN 0
in IN 0
a DT 0
randomized JJ 0
double JJ 0
blind NN 0
crossover NN 0
study NN 0
. . 0

Valproate VB 0
1000 CD 0
mg NN 0
or CC 0
placebo NN 0
was VBD 0
given VBN 0
daily RB 0
, , 0
each DT 0
for IN 0
a DT 0
minimum NN 0
of IN 0
13 CD 0
days NNS 0
. . 0

On IN 0
the DT 0
last JJ 0
treatment NN 0
day NN 0
of IN 0
each DT 0
arm NN 0
a DT 0
20 CD 0
min NN 0
intravenous JJ 0
infusion NN 0
of IN 0
GTN NNP 0
( ( 0
0.25 CD 0
microg/kg/min NN 0
) ) 0
was VBD 0
given VBN 0
. . 0

Headache NNP 0
was VBD 0
registered VBN 0
for IN 0
12 CD 0
h NN 0
after IN 0
the DT 0
infusion NN 0
and CC 0
headache NN 0
intensity NN 0
was VBD 0
scored VBN 0
on IN 0
a DT 0
scale NN 0
from IN 0
0 CD 0
to TO 0
10 CD 0
. . 0

Fulfillment NN 0
of IN 0
IHS NNP 0
criteria NNS 0
was VBD 0
recorded VBN 0
for IN 0
24 CD 0
h. PDT 0
The DT 0
middle JJ 0
cerebral JJ 0
arteries NNS 0
were VBD 0
evaluated VBN 0
by IN 0
transcranial JJ 0
Doppler NNP 0
and CC 0
the DT 0
diameter NN 0
of IN 0
the DT 0
superficial JJ 0
temporal JJ 0
and CC 0
radial JJ 0
arteries NNS 0
were VBD 0
measured VBN 0
with IN 0
high JJ 0
frequency NN 0
ultrasound NN 0
. . 0

GTN NNP 0
evoked VBD 0
migraine JJ 0
fulfilling NN 0
IHS NNP 0
criteria NNS 0
1.1 CD 0
in IN 0
6 CD 0
patients NNS 0
after IN 0
placebo NN 0
and CC 0
in IN 0
2 CD 0
patients NNS 0
after IN 0
valproate NN 0
( ( 0
P NNP 0
= NNP 0
0.125 CD 0
) ) 0
. . 0

Including VBG 0
additionally RB 0
3 CD 0
patients NNS 0
on IN 0
placebo NN 0
and CC 0
1 CD 0
patient NN 0
on IN 0
valproate NN 0
who WP 0
felt VBD 0
they PRP 0
had VBD 0
suffered VBN 0
a DT 0
migraine JJ 0
attack NN 0
, , 0
but CC 0
who WP 0
had VBD 0
as IN 0
associated VBN 0
symptoms NNS 0
only RB 0
photophobia VBP 0
or CC 0
phonophobia VBP 0
, , 0
a DT 0
significant JJ 0
reduction NN 0
in IN 0
the DT 0
number NN 0
of IN 0
patients NNS 0
with IN 0
induced JJ 0
migraine NN 0
after IN 0
valproate NN 0
was VBD 0
seen VBN 0
( ( 0
P NNP 0
= NNP 0
0.031 CD 0
) ) 0
. . 0

Median JJ 0
peak NN 0
headache NN 0
intensity NN 0
was VBD 0
1 CD 0
( ( 0
range VB 0
0-9 NN 0
) ) 0
after IN 0
valproate NN 0
compared VBN 0
to TO 0
4.5 CD 0
( ( 0
range VB 0
0-8 NN 0
) ) 0
after IN 0
placebo NN 0
( ( 0
P NNP 0
= NNP 0
0.120 CD 0
) ) 0
. . 0

Pretreatment NN 0
with IN 0
valproate NN 0
as IN 0
compared VBN 0
to TO 0
placebo VB 0
reduced VBN 0
the DT 0
velocity NN 0
in IN 0
both DT 0
middle JJ 0
cerebral NN 0
arteries NNS 0
after IN 0
GTN NNP 0
( ( 0
left VBN 0
P NNP 0
= NNP 0
0.021 CD 0
, , 0
right JJ 0
P NNP 0
= NNP 0
0.031 CD 0
) ) 0
. . 0

No DT 0
effect NN 0
of IN 0
valproate NN 0
was VBD 0
seen VBN 0
in IN 0
the DT 0
diameter NN 0
of IN 0
the DT 0
superficial JJ 0
temporal JJ 0
artery NN 0
( ( 0
P NNP 0
= NNP 0
0.781 CD 0
) ) 0
or CC 0
the DT 0
radial JJ 0
artery NN 0
( ( 0
P NNP 0
= NNP 0
0.367 CD 0
) ) 0
before IN 0
or CC 0
after IN 0
GTN NNP 0
. . 0

The DT 0
study NN 0
indicates VBZ 0
that IN 0
a DT 0
prophylactic JJ 0
effect NN 0
of IN 0
valproate NN 0
may MD 0
be VB 0
demonstrated VBN 0
using VBG 0
the DT 0
GTN NNP 0
human JJ 0
migraine NN 0
model NN 0
. . 0

Although IN 0
, , 0
all DT 0
headache NN 0
parameters NNS 0
were VBD 0
reduced VBN 0
after IN 0
valproate NN 0
compared VBN 0
to TO 0
placebo VB 0
, , 0
only RB 0
one CD 0
parameter NN 0
was VBD 0
statistically RB 0
significantly RB 0
reduced VBN 0
probably RB 0
because IN 0
of IN 0
the DT 0
small JJ 0
number NN 0
of IN 0
patients NNS 0
. . 0

The DT 0
size NN 0
of IN 0
the DT 0
effect NN 0
was VBD 0
similar JJ 0
to TO 0
that DT 0
of IN 0
valproate NN 0
in IN 0
clinical JJ 0
trials NNS 0
. . 0

The DT 0
GTN NNP 0
model NN 0
may MD 0
therefore RB 0
be VB 0
a DT 0
valid JJ 0
tool NN 0
for IN 0
testing VBG 0
new JJ 0
prophylactic JJ 0
antimigraine NN 0
drugs NNS 0
. . 0

Sex NN 0
risk NN 0
behavior NN 0
among IN 0
adolescent JJ 1
and CC 0
young JJ 1
adult NN 1
children NNS 1
of IN 0
opiate JJ 4
addicts NNS 4
: : 0
outcomes NNS 0
from IN 0
the DT 0
focus NN 0
on IN 0
families NNS 0
prevention VBP 0
trial NN 0
and CC 0
an DT 0
examination NN 0
of IN 0
childhood NN 0
and CC 0
concurrent JJ 0
predictors NNS 0
of IN 0
sex NN 0
risk NN 0
behavior NN 0
. . 0

This DT 0
study NN 0
reports VBZ 0
on IN 0
rates NNS 0
and CC 0
predictors NNS 0
of IN 0
sex NN 0
risk NN 0
behavior NN 0
among IN 0
a DT 0
sample NN 0
of IN 0
adolescent NN 1
and CC 0
young JJ 1
adult NN 1
children NNS 1
of IN 0
parents NNS 0
enrolled VBN 0
in IN 0
methadone NN 0
treatment NN 0
for IN 0
opiate JJ 4
addiction NN 4
. . 0

Data NNS 0
are VBP 0
from IN 0
151 CD 3
participants NNS 0
( ( 0
80 CD 3
males NNS 2
, , 0
71 CD 3
females NNS 2
) ) 0
in IN 0
the DT 0
Focus NNP 0
on IN 0
Families NNP 0
( ( 0
FOF NNP 0
) ) 0
project NN 0
, , 0
a DT 0
randomized JJ 0
trial NN 0
of IN 0
a DT 0
family NN 0
intervention NN 0
and CC 0
a DT 0
study NN 0
of IN 0
the DT 0
development NN 0
of IN 0
at-risk JJ 0
children NNS 0
. . 0

The DT 0
study NN 0
participants NNS 0
are VBP 0
children NNS 0
of IN 0
parents NNS 0
enrolled VBN 0
in IN 0
methadone NN 0
treatment NN 0
between IN 0
1990 CD 0
and CC 0
1993 CD 0
. . 0

Participants NNS 0
were VBD 0
interviewed VBN 0
in IN 0
2005 CD 0
when WRB 0
they PRP 0
ranged VBD 0
in IN 0
age NN 0
from IN 0
15 CD 1
to TO 1
29 CD 1
years NNS 0
. . 0

In IN 0
the DT 0
year NN 0
prior RB 0
to TO 0
the DT 0
follow-up NN 0
, , 0
79 CD 0
% NN 0
of IN 0
the DT 0
males NNS 0
and CC 0
83 CD 0
% NN 0
of IN 0
females NNS 0
were VBD 0
sexually RB 0
active JJ 0
, , 0
26 CD 0
% NN 0
of IN 0
males NNS 0
and CC 0
10 CD 0
% NN 0
of IN 0
females NNS 0
had VBD 0
more JJR 0
than IN 0
one CD 0
partner NN 0
in IN 0
the DT 0
prior JJ 0
year NN 0
, , 0
and CC 0
34 CD 0
% NN 0
of IN 0
males NNS 0
and CC 0
24 CD 0
% NN 0
of IN 0
females NNS 0
reported VBN 0
having VBG 0
sex NN 0
outside IN 0
of IN 0
a DT 0
committed JJ 0
relationship NN 0
. . 0

Twenty-four CD 0
percent NN 0
of IN 0
males NNS 0
and CC 0
17 CD 0
% NN 0
of IN 0
females NNS 0
met VBD 0
criteria NNS 0
for IN 0
high-risk JJ 0
sexual JJ 0
behavior NN 0
, , 0
reporting VBG 0
casual JJ 0
or CC 0
multiple JJ 0
partners NNS 0
in IN 0
the DT 0
prior JJ 0
year NN 0
and CC 0
inconsistent NN 0
condom NN 0
use NN 0
. . 0

Participants NNS 0
in IN 0
the DT 0
intervention NN 0
and CC 0
control NN 0
conditions NNS 0
did VBD 0
not RB 0
differ VB 0
significantly RB 0
in IN 0
terms NNS 0
of IN 0
any DT 0
measure NN 0
of IN 0
sex NN 0
risk NN 0
behavior NN 0
examined VBN 0
. . 0

None NN 0
of IN 0
the DT 0
measures NNS 0
of IN 0
parent NN 0
behavior NN 0
and CC 0
family NN 0
processes NNS 0
derived VBN 0
from IN 0
data NNS 0
at IN 0
baseline NN 0
of IN 0
the DT 0
FOF NNP 0
study NN 0
predicted VBD 0
whether IN 0
participants NNS 0
engaged VBN 0
in IN 0
high-risk JJ 0
sex NN 0
. . 0

Among IN 0
measures NNS 0
derived VBN 0
from IN 0
data NNS 0
collected VBN 0
at IN 0
long-term JJ 0
follow-up NN 0
, , 0
however RB 0
, , 0
having VBG 0
ever RB 0
met VBN 0
criteria NNS 0
for IN 0
substance NN 0
abuse NN 0
or CC 0
dependence NN 0
predicted VBN 0
greater JJR 0
likelihood NN 0
of IN 0
high-risk JJ 0
sexual JJ 0
behavior NN 0
, , 0
and CC 0
being VBG 0
married VBD 0
or CC 0
being VBG 0
in IN 0
a DT 0
romantic JJ 0
relationship NN 0
was VBD 0
associated VBN 0
with IN 0
lower JJR 0
likelihood NN 0
of IN 0
high-risk JJ 0
sexual JJ 0
behavior NN 0
. . 0

The DT 0
findings NNS 0
point NN 0
to TO 0
the DT 0
important JJ 0
role NN 0
of IN 0
committed JJ 0
relationships NNS 0
in IN 0
regulating VBG 0
sex NN 0
risk NN 0
behavior NN 0
among IN 0
this DT 0
population NN 0
, , 0
as RB 0
well RB 0
as IN 0
heightened VBN 0
levels NNS 0
of IN 0
sex NN 0
risk NN 0
behavior NN 0
associated VBN 0
with IN 0
substance NN 0
abuse NN 0
or CC 0
dependence NN 0
. . 0

Atrial NNP 0
natriuretic JJ 0
factor NN 0
inhibits NNS 0
metoclopramide RB 0
stimulated VBD 0
aldosterone JJ 0
release NN 0
in IN 0
man NN 2
. . 0

1 CD 0
. . 0

Atrial NNP 0
natriuretic JJ 0
factor NN 0
( ( 0
ANF NNP 0
) ) 0
has VBZ 0
an DT 0
inhibitory JJ 0
effect NN 0
on IN 0
angiotensin NN 0
II NNP 0
and CC 0
ACTH NNP 0
stimulated VBD 0
aldosterone CD 0
secretion NN 0
in IN 0
man NN 0
. . 0

The DT 0
selectivity NN 0
of IN 0
this DT 0
aldosterone NN 0
suppressing VBG 0
effect NN 0
of IN 0
ANF NNP 0
is VBZ 0
unclear JJ 0
in IN 0
man NN 0
. . 0

The DT 0
present JJ 0
study NN 0
investigated VBD 0
the DT 0
effect NN 0
of IN 0
ANF NNP 0
on IN 0
the DT 0
increase NN 0
in IN 0
plasma JJ 0
aldosterone NN 0
due JJ 0
to TO 0
metoclopramide VB 0
in IN 0
man NN 2
. . 0

2 CD 0
. . 0

Eight NNP 3
normal JJ 4
male NN 2
volunteers NNS 0
were VBD 0
studied VBN 0
on IN 0
three CD 0
occasions NNS 0
. . 0

Metoclopramide NNP 0
( ( 0
10 CD 0
mg RB 0
slow JJ 0
i.v NN 0
. . 0

) ) 0
was VBD 0
given VBN 0
on IN 0
all DT 0
study NN 0
days NNS 0
and CC 0
each DT 0
volunteer NN 0
was VBD 0
randomised VBN 0
to TO 0
receive VB 0
45 CD 0
min JJ 0
infusion NN 0
of IN 0
either DT 0
5 CD 0
% NN 0
D-glucose NNP 0
( ( 0
placebo NN 0
) ) 0
or CC 0
ANF NNP 0
( ( 0
99-126 CD 0
) ) 0
3 CD 0
or CC 0
15 CD 0
pmol JJ 0
kg-1 JJ 0
min-1 NN 0
. . 0

3 CD 0
. . 0

Metoclopramide NNP 0
increased VBD 0
plasma RB 0
aldosterone NN 0
to TO 0
approximately RB 0
170 CD 0
% NN 0
of IN 0
baseline NN 0
levels NNS 0
( ( 0
P NNP 0
less JJR 0
than IN 0
0.01 CD 0
) ) 0
. . 0

Concomitant JJ 0
infusion NN 0
of IN 0
ANF NNP 0
3 CD 0
pmol JJ 0
kg-1 JJ 0
min-1 NN 0
and CC 0
15 CD 0
pmol JJ 0
kg-1 JJ 0
min-1 NN 0
significantly RB 0
attenuated VBD 0
this DT 0
rise NN 0
in IN 0
plasma NN 0
aldosterone NN 0
to TO 0
approximately RB 0
130 CD 0
% NN 0
( ( 0
P NNP 0
less JJR 0
than IN 0
0.05 CD 0
) ) 0
and CC 0
110 CD 0
% NN 0
( ( 0
P NNP 0
less JJR 0
than IN 0
0.01 CD 0
) ) 0
of IN 0
baseline NN 0
values NNS 0
respectively RB 0
. . 0

4 CD 0
. . 0

It PRP 0
is VBZ 0
suggested VBN 0
, , 0
in IN 0
the DT 0
light NN 0
of IN 0
previous JJ 0
findings NNS 0
, , 0
that IN 0
the DT 0
inhibitory JJ 0
effect NN 0
of IN 0
ANF NNP 0
represents VBZ 0
a DT 0
non-selective JJ 0
action NN 0
of IN 0
ANF NNP 0
on IN 0
aldosterone NN 0
release NN 0
. . 0

Is VBZ 0
a DT 0
calculated JJ 0
total JJ 0
hip NN 0
BMD NNP 0
of IN 0
clinical JJ 0
use NN 0
? . 0
The DT 0
diagnosis NN 0
of IN 0
osteoporosis NN 0
is VBZ 0
based VBN 0
on IN 0
bone NN 0
mass NN 0
measurement NN 0
. . 0

To TO 0
avoid VB 0
the DT 0
errors NNS 0
associated VBN 0
with IN 0
the DT 0
measurement NN 0
of IN 0
spinal JJ 0
bone NN 0
density NN 0
the DT 0
total JJ 0
hip NN 0
has VBZ 0
been VBN 0
accepted VBN 0
as IN 0
the DT 0
standard JJ 0
measurement NN 0
site NN 0
. . 0

This DT 0
information NN 0
is VBZ 0
not RB 0
available JJ 0
for IN 0
many JJ 0
early JJ 0
measurements NNS 0
. . 0

We PRP 0
have VBP 0
assessed VBN 0
whether IN 0
it PRP 0
is VBZ 0
possible JJ 0
to TO 0
derive VB 0
clinically RB 0
useful JJ 0
information NN 0
about IN 0
total JJ 0
hip NN 0
bone NN 0
mineral JJ 0
density NN 0
( ( 0
BMD NNP 0
) ) 0
from IN 0
measurements NNS 0
at IN 0
other JJ 0
hip NN 0
sites NNS 0
. . 0

The DT 0
bone NN 0
mass NN 0
measurements NNS 0
of IN 0
46 CD 3
patients NNS 0
participating VBG 0
in IN 0
a DT 0
current JJ 0
trial NN 0
of IN 0
therapy NN 0
for IN 0
osteoporosis NN 4
were VBD 0
reviewed VBN 0
. . 0

The DT 0
total JJ 0
hip NN 0
BMD NNP 0
as IN 0
directly RB 0
measured VBN 0
was VBD 0
compared VBN 0
with IN 0
that DT 0
obtained VBN 0
from IN 0
the DT 0
formula NN 0
: : 0
Total JJ 0
hip NN 0
BMD NNP 0
= VBZ 0
0.48 CD 0
x NN 0
Neck NNP 0
BMD NNP 0
+ VBD 0
0.62 CD 0
x NNP 0
Trochanteric NNP 0
BMD NNP 0
+ VBD 0
0.03 CD 0
. . 0

In IN 0
30 CD 3
patients NNS 0
with IN 0
follow-up JJ 0
data NNS 0
the DT 0
rate NN 0
of IN 0
change NN 0
in IN 0
hip NN 0
BMD NNP 0
over IN 0
a DT 0
year NN 0
was VBD 0
also RB 0
determined VBN 0
by IN 0
both DT 0
methods NNS 0
. . 0

In IN 0
the DT 0
pretreatment NN 0
state NN 0
there EX 0
was VBD 0
good JJ 0
agreement NN 0
between IN 0
the DT 0
two CD 0
measures NNS 0
( ( 0
r2 VB 0
= RB 0
0.96 CD 0
, , 0
SEE NNP 0
0.012 CD 0
g/cm2 NN 0
) ) 0
. . 0

If IN 0
the DT 0
formula NN 0
was VBD 0
used VBN 0
to TO 0
compute VB 0
a DT 0
change NN 0
in IN 0
total JJ 0
hip NN 0
BMD NNP 0
, , 0
the DT 0
agreement NN 0
between IN 0
both DT 0
methods NNS 0
remained VBD 0
good JJ 0
. . 0

However RB 0
, , 0
the DT 0
standard JJ 0
error NN 0
of IN 0
the DT 0
estimate NN 0
of IN 0
the DT 0
change NN 0
represented VBD 0
59 CD 0
% NN 0
of IN 0
the DT 0
observed JJ 0
change NN 0
. . 0

This DT 0
indicates VBZ 0
that IN 0
the DT 0
error NN 0
associated VBN 0
with IN 0
this DT 0
estimate NN 0
is VBZ 0
too RB 0
great JJ 0
to TO 0
allow VB 0
clinically RB 0
meaningful JJ 0
conclusions NNS 0
to TO 0
be VB 0
drawn VBN 0
from IN 0
calculated VBN 0
total JJ 0
hip NN 0
BMD NNP 0
. . 0

We PRP 0
conclude VBP 0
that IN 0
, , 0
whilst VB 0
it PRP 0
may MD 0
be VB 0
possible JJ 0
to TO 0
obtain VB 0
reasonable JJ 0
point NN 0
estimates NNS 0
of IN 0
total JJ 0
hip NN 0
BMD NNP 0
from IN 0
other JJ 0
measures NNS 0
in IN 0
the DT 0
hip NN 0
, , 0
these DT 0
estimates NNS 0
are VBP 0
too RB 0
imprecise JJ 0
to TO 0
allow VB 0
conclusions NNS 0
about IN 0
change NN 0
in IN 0
BMD NNP 0
to TO 0
be VB 0
made VBN 0
. . 0

Echocardiographic JJ 0
evaluation NN 0
of IN 0
children NNS 0
with IN 0
systemic JJ 0
ventricular JJ 0
dysfunction NN 0
treated VBN 0
with IN 0
carvedilol NN 0
. . 0

Echocardiography NN 0
is VBZ 0
used VBN 0
to TO 0
measure VB 0
the DT 0
therapeutic JJ 0
effectiveness NN 0
of IN 0
heart NN 0
failure NN 0
therapy NN 0
in IN 0
adults NNS 0
and CC 0
children NNS 0
. . 0

The DT 0
purposes NNS 0
of IN 0
this DT 0
study NN 0
were VBD 0
( ( 0
1 CD 0
) ) 0
to TO 0
assess VB 0
baseline JJ 0
echocardiographic JJ 0
predictors NNS 0
of IN 0
clinical JJ 0
outcome NN 0
, , 0
( ( 0
2 CD 0
) ) 0
to TO 0
investigate VB 0
changes NNS 0
in IN 0
echocardiographic JJ 0
parameters NNS 0
, , 0
and CC 0
( ( 0
3 CD 0
) ) 0
to TO 0
compare VB 0
these DT 0
echocardiographic JJ 0
changes NNS 0
with IN 0
changes NNS 0
in IN 0
plasma NN 0
levels NNS 0
of IN 0
b-type JJ 0
natriuretic JJ 0
peptide NN 0
( ( 0
BNP NNP 0
) ) 0
in IN 0
a DT 0
population NN 0
of IN 0
children NNS 0
with IN 0
systemic JJ 0
ventricular JJ 0
dysfunction NN 0
and CC 0
symptomatic JJ 0
heart NN 0
failure NN 0
treated VBN 0
with IN 0
carvedilol NN 0
or CC 0
placebo NN 0
. . 0

All DT 0
available JJ 0
baseline NN 0
and CC 0
6-month JJ 0
echocardiograms NNS 0
from IN 0
Pediatric NNP 0
Carvedilol NNP 0
Trial NNP 0
( ( 0
PCT NNP 0
) ) 0
participants NNS 0
( ( 0
carvedilol JJ 0
n RB 0
= JJ 0
161 CD 0
; : 0
placebo NN 0
n IN 0
= $ 0
55 CD 0
) ) 0
were VBD 0
reviewed VBN 0
. . 0

Systolic NNP 0
and CC 0
diastolic JJ 0
sphericity NN 0
index NN 0
( ( 0
SI NNP 0
; : 0
n CC 0
= VB 0
110 CD 0
) ) 0
, , 0
TEI NNP 0
index NN 0
( ( 0
n JJ 0
= NNP 0
145 CD 0
) ) 0
, , 0
and CC 0
systemic JJ 0
ventricular NN 0
dP/dt NN 0
( ( 0
n JJ 0
= NNP 0
70 CD 0
) ) 0
were VBD 0
measured VBN 0
. . 0

The DT 0
PCT NNP 0
composite JJ 0
definition NN 0
of IN 0
clinical JJ 0
outcome NN 0
( ( 0
i.e. FW 0
, , 0
worsened VBD 0
, , 0
improved VBN 0
, , 0
or CC 0
unchanged JJ 0
) ) 0
was VBD 0
used VBN 0
. . 0

For IN 0
all DT 0
patients NNS 0
, , 0
baseline VBP 0
TEI NNP 0
index NN 0
was VBD 0
a DT 0
predictor NN 0
of IN 0
worsened JJ 0
outcome NN 0
. . 0

Only RB 0
children NNS 0
treated VBD 0
with IN 0
carvedilol NN 0
showed VBD 0
a DT 0
significant JJ 0
decrease NN 0
in IN 0
systolic JJ 0
SI NNP 0
( ( 0
P NNP 0
B NNP 0
0.0001 CD 0
) ) 0
, , 0
diastolic JJ 0
SI NNP 0
( ( 0
P NNP 0
B NNP 0
0.0001 CD 0
) ) 0
, , 0
and CC 0
TEI NNP 0
index NN 0
( ( 0
P NNP 0
= NNP 0
0.02 CD 0
) ) 0
. . 0

An DT 0
inverse JJ 0
correlation NN 0
between IN 0
changes NNS 0
in IN 0
BNP NNP 0
and CC 0
changes NNS 0
in IN 0
dP/dt NN 0
( ( 0
r JJ 0
= NNP 0
-0.45 NNP 0
, , 0
P NNP 0
= NNP 0
0.04 CD 0
) ) 0
was VBD 0
found VBN 0
only RB 0
in IN 0
the DT 0
carvedilol NN 0
group NN 0
. . 0

In IN 0
conclusion NN 0
, , 0
TEI NNP 0
index NN 0
predicted VBD 0
outcome NN 0
in IN 0
children NNS 0
with IN 0
systemic JJ 0
ventricular JJ 0
dysfunction NN 0
and CC 0
heart NN 0
failure NN 0
. . 0

Carvedilol NN 0
may MD 0
have VB 0
a DT 0
beneficial JJ 0
effect NN 0
on IN 0
reversal NN 0
of IN 0
left JJ 0
ventricular JJ 0
remodeling NN 0
and CC 0
global JJ 0
ventricular NN 0
function NN 0
in IN 0
pediatric JJ 0
heart NN 0
failure NN 0
. . 0

Effect NN 0
of IN 0
patient NN 0
withdrawal NN 0
on IN 0
a DT 0
study NN 0
evaluating VBG 0
pharmacist JJ 0
management NN 0
of IN 0
hypertension NN 0
. . 0

STUDY NNP 0
OBJECTIVES NNP 0
To TO 0
examine VB 0
potential JJ 0
threats NNS 0
to TO 0
internal JJ 0
and CC 0
external JJ 0
study NN 0
validity NN 0
caused VBN 0
by IN 0
differential JJ 0
patient NN 0
withdrawal NN 0
from IN 0
a DT 0
randomized VBN 0
controlled VBN 0
trial NN 0
evaluating VBG 0
pharmacist JJ 0
management NN 0
of IN 0
hypertension NN 0
, , 0
to TO 0
compare VB 0
the DT 0
characteristics NNS 0
of IN 0
patients NNS 0
who WP 0
withdrew VBP 0
with IN 0
those DT 0
of IN 0
patients NNS 0
who WP 0
completed VBD 0
the DT 0
study NN 0
, , 0
and CC 0
to TO 0
identify VB 0
characteristics NNS 0
that WDT 0
predispose VBP 0
patients NNS 0
to TO 0
withdraw VB 0
from IN 0
hypertension NN 0
management NN 0
. . 0

DESIGN NNP 0
Prospective NNP 0
, , 0
randomized VBD 0
, , 0
comparative JJ 0
study NN 0
. . 0

SETTING NNP 0
Network NNP 0
of IN 0
primary JJ 0
care NN 0
clinics NNS 0
. . 0

PATIENTS VB 0
Four CD 0
hundred JJ 0
sixty-three JJ 0
patients NNS 0
with IN 0
a DT 0
diagnosis NN 0
of IN 0
hypertension NN 0
and CC 0
a DT 0
last JJ 0
documented JJ 0
systolic JJ 0
blood NN 0
pressure NN 0
of IN 0
160 CD 0
mm NNS 0
Hg NNP 0
or CC 0
greater JJR 0
and/or NNS 0
diastolic JJ 0
blood NN 0
pressure NN 0
of IN 0
100 CD 0
mm NNS 0
Hg NNP 0
or CC 0
greater JJR 0
. . 0

INTERVENTION NN 0
Patients NNPS 0
were VBD 0
randomly RB 0
allocated VBN 0
to TO 0
the DT 0
pharmacist NN 0
intervention NN 0
or CC 0
usual-care JJ 0
( ( 0
control NN 0
) ) 0
group NN 0
. . 0

Those DT 0
in IN 0
the DT 0
pharmacist NN 0
intervention NN 0
group NN 0
were VBD 0
collaboratively RB 0
managed VBN 0
by IN 0
a DT 0
primary JJ 0
care NN 0
clinical JJ 0
pharmacy NN 0
specialist NN 0
and CC 0
their PRP$ 0
primary JJ 0
care NN 0
provider NN 0
. . 0

Patients NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
received VBD 0
usual JJ 0
care NN 0
from IN 0
only RB 0
their PRP$ 0
primary JJ 0
care NN 0
provider NN 0
. . 0

MEASUREMENTS NNP 0
AND CC 0
MAIN NNP 0
RESULTS NNP 0
Of IN 0
the DT 0
463 CD 0
patients NNS 0
, , 0
191 CD 0
( ( 0
41 CD 0
% NN 0
) ) 0
withdrew NN 0
from IN 0
the DT 0
study NN 0
after IN 0
randomization NN 0
and CC 0
272 CD 0
( ( 0
59 CD 0
% NN 0
) ) 0
completed VBD 0
the DT 0
study NN 0
. . 0

Patients NNS 0
who WP 0
withdrew VBP 0
from IN 0
the DT 0
pharmacist NN 0
intervention NN 0
group NN 0
were VBD 0
similar JJ 0
to TO 0
patients NNS 0
who WP 0
withdrew VBP 0
from IN 0
the DT 0
usual-care JJ 0
group NN 0
with IN 0
respect NN 0
to TO 0
age NN 0
, , 0
sex NN 0
, , 0
insurance NN 0
status NN 0
, , 0
and CC 0
chronic JJ 0
conditions NNS 0
. . 0

Patients NNS 0
who WP 0
smoked VBD 0
or CC 0
had VBD 0
commercial JJ 0
insurance NN 0
were VBD 0
more RBR 0
likely JJ 0
to TO 0
withdraw VB 0
from IN 0
the DT 0
study NN 0
than IN 0
the DT 0
other JJ 0
participants NNS 0
. . 0

However RB 0
, , 0
multivariate JJ 0
analysis NN 0
of IN 0
all DT 0
variables NNS 0
, , 0
when WRB 0
adjusted VBN 0
for IN 0
the DT 0
effect NN 0
of IN 0
the DT 0
intervention NN 0
, , 0
revealed VBD 0
that IN 0
insurance NN 0
status NN 0
was VBD 0
the DT 0
only JJ 0
variable NN 0
associated VBN 0
with IN 0
a DT 0
heightened JJ 0
probability NN 0
of IN 0
withdrawal NN 0
( ( 0
p=0.002 NN 0
) ) 0
. . 0

CONCLUSION NNP 0
Although IN 0
this DT 0
study NN 0
had VBD 0
a DT 0
high JJ 0
withdrawal NN 0
rate NN 0
, , 0
between-group JJ 0
patient NN 0
characteristics NNS 0
remained VBD 0
balanced JJ 0
. . 0

Therefore RB 0
, , 0
internal JJ 0
validity NN 0
was VBD 0
preserved VBN 0
, , 0
and CC 0
outcomes RB 0
from IN 0
the DT 0
study NN 0
groups NNS 0
could MD 0
be VB 0
reliably RB 0
compared VBN 0
. . 0

A DT 0
lack NN 0
of IN 0
significant JJ 0
differences NNS 0
between IN 0
patients NNS 0
who WP 0
withdrew VBD 0
versus FW 0
those DT 0
who WP 0
completed VBD 0
, , 0
with IN 0
the DT 0
exception NN 0
of IN 0
insurance NN 0
status NN 0
, , 0
suggests VBZ 0
that IN 0
external JJ 0
validity NN 0
was VBD 0
not RB 0
jeopardized VBN 0
. . 0

Psychosocial JJ 0
nursing NN 0
therapy NN 0
following VBG 0
sudden JJ 0
cardiac JJ 0
arrest NN 0
: : 0
impact NN 0
on IN 0
two-year JJ 0
survival NN 0
. . 0

BACKGROUND NNP 0
Although IN 0
psychosocial JJ 0
therapy NN 0
has VBZ 0
been VBN 0
shown VBN 0
to TO 0
reduce VB 0
mortality NN 0
after IN 0
myocardial JJ 0
infarction NN 0
, , 0
it PRP 0
is VBZ 0
unknown JJ 0
whether IN 0
the DT 0
benefits NNS 0
of IN 0
psychosocial JJ 0
therapy NN 0
on IN 0
mortality NN 0
reduction NN 0
extend VBP 0
to TO 0
out-of-hospital JJ 0
sudden JJ 0
cardiac NN 0
arrest NN 0
, , 0
a DT 0
main JJ 0
cause NN 0
of IN 0
cardiovascular JJ 0
mortality NN 0
. . 0

OBJECTIVE NNP 0
Describe NNP 0
efficacy NN 0
of IN 0
psychosocial JJ 0
therapy NN 0
on IN 0
two-year JJ 0
cardiovascular JJ 0
mortality NN 0
in IN 0
sudden JJ 0
cardiac JJ 0
arrest NN 0
survivors NNS 0
. . 0

METHOD NNP 0
Survivors NNPS 0
of IN 0
out-of-hospital JJ 0
ventricular JJ 0
fibrillation NN 0
or CC 0
asystole NN 0
( ( 0
N NNP 0
= NNP 0
129 CD 0
) ) 0
, , 0
documented VBN 0
by IN 0
electrocardiograms NNS 0
from IN 0
registries NNS 0
of IN 0
a DT 0
citywide NN 0
Medic NNP 0
One NNP 0
unit NN 0
and CC 0
two CD 0
countywide NN 0
emergency NN 0
units NNS 0
, , 0
were VBD 0
randomized VBN 0
into IN 0
a DT 0
two CD 0
group NN 0
, , 0
experimental JJ 0
, , 0
longitudinal JJ 0
design NN 0
. . 0

The DT 0
intervention NN 0
consisted VBD 0
of IN 0
11 CD 0
individual JJ 0
sessions NNS 0
, , 0
implementing VBG 0
three CD 0
components NNS 0
: : 0
physiologic JJ 0
relaxation NN 0
with IN 0
biofeedback NN 0
training NN 0
focused VBD 0
on IN 0
altering VBG 0
autonomic JJ 0
tone NN 0
; : 0
cognitive JJ 0
behavioral JJ 0
therapy NN 0
aimed VBN 0
at IN 0
self-management JJ 0
and CC 0
coping VBG 0
strategies NNS 0
for IN 0
depression NN 0
, , 0
anxiety NN 0
, , 0
and CC 0
anger NN 0
; : 0
and CC 0
cardiovascular JJ 0
health NN 0
education NN 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
measure NN 0
was VBD 0
cardiovascular JJ 0
mortality NN 0
. . 0

RESULTS NNP 0
Risk NNP 0
of IN 0
cardiovascular JJ 0
death NN 0
was VBD 0
significantly RB 0
reduced VBN 0
86 CD 0
% NN 0
by IN 0
psychosocial JJ 0
therapy NN 0
, , 0
p NN 0
= NNP 0
.03 NNP 0
. . 0

Six NNP 0
of IN 0
the DT 0
seven CD 0
cardiovascular JJ 0
deaths NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
were VBD 0
caused VBN 0
by IN 0
ventricular JJ 0
arrhythmias NN 0
. . 0

The DT 0
cardiovascular JJ 0
death NN 0
in IN 0
the DT 0
therapy NN 0
group NN 0
was VBD 0
due JJ 0
to TO 0
stroke VB 0
. . 0

Controlling VBG 0
for IN 0
depression NN 0
, , 0
previous JJ 0
myocardial JJ 0
infarction NN 0
, , 0
low JJ 0
ejection NN 0
fraction NN 0
, , 0
decreased JJ 0
heart NN 0
rate NN 0
variability NN 0
, , 0
and CC 0
ventricular JJ 0
ectopic NN 0
beats NNS 0
had VBD 0
little JJ 0
impact NN 0
on IN 0
estimated VBN 0
treatment NN 0
effect NN 0
. . 0

The DT 0
risk NN 0
of IN 0
all-cause JJ 0
mortality NN 0
was VBD 0
reduced VBN 0
by IN 0
62 CD 0
% NN 0
in IN 0
the DT 0
therapy NN 0
group NN 0
, , 0
p VBP 0
= JJ 0
.13 NNP 0
. . 0

There EX 0
were VBD 0
a DT 0
total NN 0
of IN 0
three CD 0
deaths NNS 0
in IN 0
the DT 0
therapy NN 0
group NN 0
and CC 0
eight CD 0
deaths NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

CONCLUSIONS NNP 0
Psychosocial NNP 0
therapy NN 0
significantly RB 0
reduced VBD 0
the DT 0
risk NN 0
of IN 0
cardiovascular JJ 0
death NN 0
in IN 0
sudden JJ 0
cardiac JJ 0
arrest NN 0
survivors NNS 0
. . 0

The DT 0
ScanBrit NNP 0
randomised VBD 0
, , 0
controlled VBD 0
, , 0
single-blind JJ 0
study NN 0
of IN 0
a DT 0
gluten- JJ 0
and CC 0
casein-free JJ 0
dietary JJ 0
intervention NN 0
for IN 0
children NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorders NNS 0
. . 0

There EX 0
is VBZ 0
increasing VBG 0
interest NN 0
in IN 0
the DT 0
use NN 0
of IN 0
gluten- JJ 0
and CC 0
casein-free JJ 0
diets NNS 0
for IN 0
children NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorders NNS 0
( ( 0
ASDs NNP 0
) ) 0
. . 0

We PRP 0
report VBP 0
results NNS 0
from IN 0
a DT 0
two-stage NN 0
, , 0
24-month JJ 0
, , 0
randomised VBN 0
, , 0
controlled VBN 0
trial NN 0
incorporating VBG 0
an DT 0
adaptive JJ 0
'catch-up NN 0
' POS 0
design NN 0
and CC 0
interim JJ 0
analysis NN 0
. . 0

Stage NN 0
1 CD 0
of IN 0
the DT 0
trial NN 0
saw VBD 0
72 CD 0
Danish JJ 0
children NNS 0
( ( 0
aged VBN 0
4 CD 0
years NNS 0
to TO 0
10 CD 0
years NNS 0
11 CD 0
months NNS 0
) ) 0
assigned VBD 0
to TO 0
diet VB 0
( ( 0
A DT 0
) ) 0
or CC 0
non-diet JJ 0
( ( 0
B NNP 0
) ) 0
groups NNS 0
by IN 0
stratified JJ 0
randomisation NN 0
. . 0

Autism NNP 0
Diagnostic NNP 0
Observation NNP 0
Schedule NNP 0
( ( 0
ADOS NNP 0
) ) 0
and CC 0
the DT 0
Gilliam NNP 0
Autism NNP 0
Rating NNP 0
Scale NNP 0
( ( 0
GARS NNP 0
) ) 0
were VBD 0
used VBN 0
to TO 0
assess VB 0
core NN 0
autism NN 0
behaviours NNS 0
, , 0
Vineland NNP 0
Adaptive NNP 0
Behaviour NNP 0
Scales NNP 0
( ( 0
VABS NNP 0
) ) 0
to TO 0
ascertain VB 0
developmental JJ 0
level NN 0
, , 0
and CC 0
Attention-Deficit NNP 0
Hyperactivity NNP 0
Disorder NNP 0
- : 0
IV NNP 0
scale NN 0
( ( 0
ADHD-IV NNP 0
) ) 0
to TO 0
determine VB 0
inattention NN 0
and CC 0
hyperactivity NN 0
. . 0

Participants NNS 0
were VBD 0
tested VBN 0
at IN 0
baseline NN 0
, , 0
8 CD 0
, , 0
and CC 0
12 CD 0
months NNS 0
. . 0

Based VBN 0
on IN 0
per IN 0
protocol NN 0
repeated VBN 0
measures NNS 0
analysis NN 0
, , 0
data NNS 0
for IN 0
26 CD 0
diet JJ 0
children NNS 0
and CC 0
29 CD 0
controls NNS 0
were VBD 0
available JJ 0
at IN 0
12 CD 0
months NNS 0
. . 0

At IN 0
this DT 0
point NN 0
, , 0
there EX 0
was VBD 0
a DT 0
significant JJ 0
improvement NN 0
to TO 0
mean VB 0
diet JJ 0
group NN 0
scores NNS 0
( ( 0
time*treatment JJ 0
interaction NN 0
) ) 0
on IN 0
sub-domains NNS 0
of IN 0
ADOS NNP 0
, , 0
GARS NNP 0
and CC 0
ADHD-IV NNP 0
measures NNS 0
. . 0

Surpassing VBG 0
of IN 0
predefined JJ 0
statistical JJ 0
thresholds NNS 0
as IN 0
evidence NN 0
of IN 0
improvement NN 0
in IN 0
group NN 0
A NNP 0
at IN 0
12 CD 0
months NNS 0
sanctioned VBD 0
the DT 0
re-assignment NN 0
of IN 0
group NN 0
B NNP 0
participants NNS 0
to TO 0
active JJ 0
dietary JJ 0
treatment NN 0
. . 0

Stage NN 0
2 CD 0
data NNS 0
for IN 0
18 CD 0
group NN 0
A NNP 0
and CC 0
17 CD 0
group NN 0
B NNP 0
participants NNS 0
were VBD 0
available JJ 0
at IN 0
24 CD 0
months NNS 0
. . 0

Multiple NNP 0
scenario NN 0
analysis NN 0
based VBN 0
on IN 0
inter- JJ 0
and CC 0
intra-group JJ 0
comparisons NNS 0
showed VBD 0
some DT 0
evidence NN 0
of IN 0
sustained JJ 0
clinical JJ 0
group NN 0
improvements NNS 0
although IN 0
possibly RB 0
indicative JJ 0
of IN 0
a DT 0
plateau NN 0
effect NN 0
for IN 0
intervention NN 0
. . 0

Our PRP$ 0
results NNS 0
suggest VBP 0
that IN 0
dietary JJ 0
intervention NN 0
may MD 0
positively RB 0
affect VB 0
developmental JJ 0
outcome NN 0
for IN 0
some DT 0
children NNS 0
diagnosed VBN 0
with IN 0
ASD NNP 0
. . 0

In IN 0
the DT 0
absence NN 0
of IN 0
a DT 0
placebo NN 0
condition NN 0
to TO 0
the DT 0
current JJ 0
investigation NN 0
, , 0
we PRP 0
are VBP 0
, , 0
however RB 0
, , 0
unable JJ 0
to TO 0
disqualify VB 0
potential JJ 0
effects NNS 0
derived VBN 0
from IN 0
intervention NN 0
outside IN 0
of IN 0
dietary JJ 0
changes NNS 0
. . 0

Further JJ 0
studies NNS 0
are VBP 0
required VBN 0
to TO 0
ascertain VB 0
potential JJ 0
best- NN 0
and CC 0
non-responders NNS 0
to TO 0
intervention NN 0
. . 0

The DT 0
study NN 0
was VBD 0
registered VBN 0
with IN 0
ClincialTrials.gov NNP 0
, , 0
number NN 0
NCT00614198 NNP 0
. . 0

Migration NN 0
of IN 0
the DT 0
acetabular JJ 0
component NN 0
: : 0
effect NN 0
of IN 0
cement NN 0
pressurization NN 0
and CC 0
significance NN 0
of IN 0
early JJ 0
radiolucency NN 0
: : 0
a DT 0
randomized JJ 0
5-year JJ 0
study NN 0
using VBG 0
radiostereometry NN 0
. . 0

BACKGROUND NNP 0
Cementing NNP 0
technique NN 0
is VBZ 0
a DT 0
crucial JJ 0
factor NN 0
in IN 0
prosthesis NN 0
fixation NN 0
. . 0

No DT 0
randomized JJ 0
studies NNS 0
have VBP 0
been VBN 0
published VBN 0
, , 0
however RB 0
, , 0
comparing VBG 0
the DT 0
outcome NN 0
of IN 0
conventional JJ 0
fingerpacking NN 0
with IN 0
the DT 0
outcome NN 0
of IN 0
pressurization NN 0
of IN 0
the DT 0
cement NN 0
prior RB 0
to TO 0
cup VB 0
insertion NN 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
We PRP 0
randomized VBD 0
50 CD 0
THAs NNP 0
to TO 0
either VB 0
fingerpacking NN 0
or CC 0
sequential JJ 0
pressurization NN 0
( ( 0
including VBG 0
individual JJ 0
pressurization NN 0
of IN 0
each DT 0
anchorage NN 0
hole NN 0
) ) 0
and CC 0
followed VBD 0
the DT 0
patients NNS 0
with IN 0
RSA NNP 0
for IN 0
5 CD 0
years NNS 0
. . 0

The DT 0
penetration NN 0
of IN 0
cement NN 0
into IN 0
the DT 0
anchorage NN 0
holes NNS 0
was VBD 0
measured VBN 0
on IN 0
digital JJ 0
radiographs NN 0
. . 0

Postoperative JJ 0
radiolucent NN 0
lines NNS 0
around IN 0
the DT 0
cup NN 0
were VBD 0
correlated VBN 0
to TO 0
later RBR 0
RSA NNP 0
results NNS 0
. . 0

For IN 0
clinical JJ 0
evaluation NN 0
, , 0
we PRP 0
used VBD 0
SF-36 NNP 0
and CC 0
HHS NNP 0
. . 0

RESULTS VB 0
The DT 0
pressurized JJ 0
group NN 0
of IN 0
THAs NNP 0
was VBD 0
more RBR 0
stable JJ 0
regarding VBG 0
changes NNS 0
in IN 0
inclination NN 0
. . 0

We PRP 0
found VBD 0
no DT 0
other JJ 0
difference NN 0
in IN 0
the DT 0
migratory NN 0
behavior NN 0
. . 0

The DT 0
cement NN 0
penetration NN 0
into IN 0
the DT 0
anchorage NN 0
holes NNS 0
was VBD 0
deeper RBR 0
with IN 0
the DT 0
pressurization NN 0
technique NN 0
than IN 0
with IN 0
fingerpacking NN 0
. . 0

For IN 0
the DT 0
whole JJ 0
group NN 0
taken VBN 0
together RB 0
, , 0
there EX 0
was VBD 0
a DT 0
strong JJ 0
relation NN 0
between IN 0
the DT 0
presence NN 0
of IN 0
radiolucent NN 0
lines NNS 0
as IN 0
measured VBN 0
on IN 0
the DT 0
postoperative JJ 0
radiograph NN 0
and CC 0
later JJ 0
migration NN 0
observed VBN 0
by IN 0
RSA NNP 0
at IN 0
2 CD 0
and CC 0
5 CD 0
years NNS 0
. . 0

INTERPRETATION NNP 0
Pressurization NNP 0
of IN 0
the DT 0
cement NN 0
produced VBD 0
better JJR 0
cement NN 0
penetration NN 0
and CC 0
increased VBD 0
the DT 0
cup NN 0
stability NN 0
in IN 0
terms NNS 0
of IN 0
changes NNS 0
in IN 0
inclination NN 0
. . 0

Early JJ 0
findings NNS 0
of IN 0
radiolucent NN 0
lines NNS 0
can MD 0
predict VB 0
later RB 0
unfavorable JJ 0
cup NN 0
migration NN 0
. . 0

Tetracaine NNP 0
( ( 0
ametop NN 0
) ) 0
compared VBN 0
to TO 0
placebo VB 0
for IN 0
reducing VBG 0
pain NN 0
associated VBN 0
with IN 0
intramuscular JJ 0
injection NN 0
of IN 0
palivizumab NN 0
( ( 0
synagis NN 0
) ) 0
. . 0

Infants NNS 0
receive VBP 0
many JJ 0
painful JJ 0
immunizations NNS 0
before IN 0
they PRP 0
are VBP 0
2 CD 0
years NNS 0
old JJ 0
. . 0

The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
evaluate VB 0
if IN 0
topical JJ 0
tetracaine NN 0
reduces VBZ 0
the DT 0
pain NN 0
of IN 0
intramuscular JJ 0
palivizumab NNS 0
compared VBN 0
to TO 0
placebo VB 0
. . 0

There EX 0
were VBD 0
two CD 0
study NN 0
injections NNS 0
, , 0
one CD 0
with IN 0
tetracaine NN 0
and CC 0
one CD 0
with IN 0
placebo NN 0
. . 0

Pain NN 0
was VBD 0
scored VBN 0
by IN 0
their PRP$ 0
parents NNS 0
and CC 0
a DT 0
pediatric JJ 0
nurse NN 0
. . 0

Topical JJ 0
tetracaine NN 0
was VBD 0
not RB 0
associated VBN 0
with IN 0
a DT 0
significant JJ 0
reduction NN 0
in IN 0
pain NN 0
score NN 0
, , 0
although IN 0
it PRP 0
did VBD 0
lead VB 0
to TO 0
faster VB 0
recovery NN 0
times NNS 0
. . 0

Additional JJ 0
pain-reduction NN 0
strategies NNS 0
are VBP 0
required VBN 0
. . 0

Reactive JJ 0
balance NN 0
adjustments NNS 0
to TO 0
unexpected JJ 0
perturbations NNS 0
during IN 0
human JJ 0
walking NN 0
. . 0

The DT 0
purpose NN 0
of IN 0
this DT 0
investigation NN 0
was VBD 0
to TO 0
determine VB 0
the DT 0
effect NN 0
of IN 0
unexpected JJ 0
forward NN 0
perturbations NNS 0
( ( 0
FP NNP 0
) ) 0
during IN 0
gait NN 0
on IN 0
lower JJR 0
extremity NN 0
joint NN 0
mechanics NNS 0
and CC 0
muscle NN 0
Electromyographic NNP 0
( ( 0
EMG NNP 0
) ) 0
patterns VBZ 0
in IN 0
healthy JJ 0
adults NNS 0
. . 0

The DT 0
muscles NNS 0
surrounding VBG 0
the DT 0
hip NN 0
were VBD 0
found VBN 0
to TO 0
be VB 0
most RBS 0
important JJ 0
in IN 0
maintaining VBG 0
control NN 0
of IN 0
the DT 0
trunk NN 0
and CC 0
preventing VBG 0
collapse NN 0
in IN 0
response NN 0
to TO 0
the DT 0
FP NNP 0
. . 0

Distinct NNP 0
lower JJR 0
extremity NN 0
joint JJ 0
moment NN 0
and CC 0
power NN 0
patterns NNS 0
were VBD 0
observed VBN 0
in IN 0
response NN 0
to TO 0
the DT 0
FP NNP 0
but CC 0
an DT 0
overall JJ 0
positive JJ 0
moment NN 0
of IN 0
support NN 0
( ( 0
M NNP 0
( ( 0
s PRP 0
) ) 0
) ) 0
was VBD 0
maintained VBN 0
. . 0

Therefore RB 0
, , 0
reactive JJ 0
balance NN 0
control NN 0
was VBD 0
a DT 0
synchronized JJ 0
effort NN 0
of IN 0
the DT 0
lower JJR 0
extremity NN 0
joints NNS 0
to TO 0
prevent VB 0
collapse NN 0
during IN 0
the DT 0
FP NNP 0
. . 0

Long-term JJ 0
prospective JJ 0
, , 0
randomized VBN 0
, , 0
controlled VBN 0
study NN 0
using VBG 0
repetitive JJ 0
education NN 0
at IN 0
six-month JJ 0
intervals NNS 0
and CC 0
monitoring NN 0
for IN 0
adherence NN 0
in IN 0
heart NN 0
failure NN 0
outpatients NNS 0
: : 0
the DT 0
REMADHE NNP 0
trial NN 0
. . 0

BACKGROUND VB 0
The DT 0
effectiveness NN 0
of IN 0
heart NN 0
failure NN 0
disease NN 0
management NN 0
programs NNS 0
in IN 0
patients NNS 0
under IN 0
cardiologists NNS 0
' POS 0
care NN 0
over IN 0
long-term JJ 0
follow-up NN 0
is VBZ 0
not RB 0
established VBN 0
. . 0

METHODS NNP 0
AND CC 0
RESULTS NNP 0
We PRP 0
investigated VBD 0
the DT 0
effects NNS 0
of IN 0
a DT 0
disease JJ 0
management NN 0
program NN 0
with IN 0
repetitive JJ 0
education NN 0
and CC 0
telephone NN 0
monitoring NN 0
on IN 0
primary JJ 0
( ( 0
combined VBN 0
death NN 0
or CC 0
unplanned JJ 0
first JJ 0
hospitalization NN 0
and CC 0
quality-of-life JJ 0
changes NNS 0
) ) 0
and CC 0
secondary JJ 0
end NN 0
points NNS 0
( ( 0
hospitalization NN 0
, , 0
death NN 0
, , 0
and CC 0
adherence NN 0
) ) 0
. . 0

The DT 0
REMADHE NNP 0
[ NNP 0
Repetitive NNP 0
Education NNP 0
and CC 0
Monitoring NNP 0
for IN 0
ADherence NNP 0
for IN 0
Heart NNP 0
Failure NNP 0
] NNP 0
trial NN 0
is VBZ 0
a DT 0
long-term JJ 0
randomized NN 0
, , 0
prospective JJ 0
, , 0
parallel JJ 0
trial NN 0
designed VBN 0
to TO 0
compare VB 0
intervention NN 0
with IN 0
control NN 0
. . 0

One CD 0
hundred VBD 0
seventeen JJ 0
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
usual JJ 0
care NN 0
, , 0
and CC 0
233 CD 0
to TO 0
additional JJ 0
intervention NN 0
. . 0

The DT 0
mean JJ 0
follow-up NN 0
was VBD 0
2.47+/-1.75 CD 0
years NNS 0
, , 0
with IN 0
54 CD 0
% NN 0
adherence NN 0
to TO 0
the DT 0
program NN 0
. . 0

In IN 0
the DT 0
intervention NN 0
group NN 0
, , 0
the DT 0
primary JJ 0
end NN 0
point NN 0
composite NN 0
of IN 0
death NN 0
or CC 0
unplanned JJ 0
hospitalization NN 0
was VBD 0
reduced VBN 0
( ( 0
hazard JJ 0
ratio NN 0
, , 0
0.64 CD 0
; : 0
confidence NN 0
interval NN 0
, , 0
0.43 CD 0
to TO 0
0.88 CD 0
; : 0
P=0.008 NNP 0
) ) 0
, , 0
driven VBN 0
by IN 0
reduction NN 0
in IN 0
hospitalization NN 0
. . 0

The DT 0
quality-of-life JJ 0
questionnaire NN 0
score NN 0
improved VBD 0
only RB 0
in IN 0
the DT 0
intervention NN 0
group NN 0
( ( 0
P NNP 0
< NNP 0
0.003 CD 0
) ) 0
. . 0

Mortality NNP 0
was VBD 0
similar JJ 0
in IN 0
both DT 0
groups NNS 0
. . 0

Number NNP 0
of IN 0
hospitalizations NNS 0
( ( 0
1.3+/-1.7 JJ 0
versus NN 0
0.8+/-1.3 NN 0
, , 0
P NNP 0
< NNP 0
0.0001 CD 0
) ) 0
, , 0
total JJ 0
hospital NN 0
days NNS 0
during IN 0
the DT 0
follow-up JJ 0
( ( 0
19.9+/-51 JJ 0
versus NN 0
11.1+/-24 JJ 0
days NNS 0
, , 0
P NNP 0
< NNP 0
0.0001 CD 0
) ) 0
, , 0
and CC 0
the DT 0
need NN 0
for IN 0
emergency NN 0
visits NNS 0
( ( 0
4.5+/-10.6 JJ 0
versus NN 0
1.6+/-2.4 CD 0
, , 0
P NNP 0
< NNP 0
0.0001 CD 0
) ) 0
were VBD 0
lower JJR 0
in IN 0
the DT 0
intervention NN 0
group NN 0
. . 0

Beneficial JJ 0
effects NNS 0
were VBD 0
homogeneous JJ 0
for IN 0
sex NN 0
, , 0
race NN 0
, , 0
diabetes NNS 0
and CC 0
no DT 0
diabetes NN 0
, , 0
age NN 0
, , 0
functional JJ 0
class NN 0
, , 0
and CC 0
etiology NN 0
. . 0

CONCLUSIONS NNP 0
For IN 0
a DT 0
longer RBR 0
follow-up JJ 0
period NN 0
than IN 0
in IN 0
previous JJ 0
studies NNS 0
, , 0
this DT 0
heart NN 0
failure NN 0
disease JJ 0
management NN 0
program NN 0
model NN 0
of IN 0
patients NNS 0
under IN 0
the DT 0
supervision NN 0
of IN 0
a DT 0
cardiologist NN 0
is VBZ 0
associated VBN 0
with IN 0
a DT 0
reduction NN 0
in IN 0
unplanned JJ 0
hospitalization NN 0
, , 0
a DT 0
reduction NN 0
of IN 0
total JJ 0
hospital NN 0
days NNS 0
, , 0
and CC 0
a DT 0
reduced JJ 0
need NN 0
for IN 0
emergency NN 0
care NN 0
, , 0
as RB 0
well RB 0
as IN 0
improved VBN 0
quality NN 0
of IN 0
life NN 0
, , 0
despite IN 0
modest JJ 0
program NN 0
adherence NN 0
over IN 0
time NN 0
. . 0

Online NNP 0
conductivity NN 0
monitoring NN 0
: : 0
validation NN 0
and CC 0
usefulness NN 0
in IN 0
a DT 0
clinical JJ 0
trial NN 0
of IN 0
reduced JJ 0
dialysate NN 0
conductivity NN 0
. . 0

Relatively RB 0
low JJ 0
dialysate NN 0
conductivity NN 0
( ( 0
Cndi NNP 0
) ) 0
may MD 0
improve VB 0
outcomes NNS 0
by IN 0
reducing VBG 0
the DT 0
overall JJ 0
sodium NN 0
burden NN 0
in IN 0
dialysis NN 0
patients NNS 0
. . 0

Excess NNP 0
sodium NN 0
removal NN 0
, , 0
however RB 0
, , 0
could MD 0
lead VB 0
to TO 0
hemodynamic JJ 0
instability NN 0
. . 0

We PRP 0
performed VBD 0
a DT 0
randomized VBN 0
controlled JJ 0
trial NN 0
of IN 0
reduction NN 0
of IN 0
Cndi NNP 0
. . 0

For IN 0
the DT 0
study NN 0
, , 0
28 CD 0
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
maintenance NN 0
of IN 0
Cndi NNP 0
at IN 0
13.6 CD 0
mS/cm NNS 0
( ( 0
equivalent JJ 0
to TO 0
135 CD 0
mmol/L NN 0
of IN 0
Na+ NNP 0
) ) 0
or CC 0
serial JJ 0
reduction NN 0
of IN 0
Cndi NNP 0
in IN 0
steps NNS 0
of IN 0
0.2 CD 0
mS/cm NNS 0
, , 0
guided VBN 0
by IN 0
symptoms NNS 0
and CC 0
blood NN 0
pressure NN 0
. . 0

Sodium NNP 0
removal NN 0
estimated VBN 0
from IN 0
pre- NN 0
and CC 0
postplasma JJ 0
concentrations NNS 0
correlated VBN 0
well RB 0
with IN 0
removal NN 0
measured VBN 0
by IN 0
conductivity NN 0
monitoring NN 0
as IN 0
ionic JJ 0
mass NN 0
balance NN 0
( ( 0
R2 NNP 0
0.66 CD 0
, , 0
p NN 0
< NNP 0
0.0001 CD 0
) ) 0
. . 0

Of IN 0
the DT 0
16 CD 0
patients NNS 0
randomized VBN 0
to TO 0
reduction NN 0
of IN 0
Cndi NNP 0
, , 0
6 CD 0
achieved VBD 0
Cndi NNP 0
13.4 CD 0
mS/cm NN 0
, , 0
6 CD 0
achieved VBD 0
13.2 CD 0
mS/cm NN 0
, , 0
and CC 0
4 CD 0
achieved VBD 0
13.0 CD 0
mS/cm NN 0
. . 0

No DT 0
episodes NNS 0
of IN 0
disequilibrium NN 0
occurred VBD 0
. . 0

Interdialytic JJ 0
weight NN 0
gain NN 0
was VBD 0
reduced VBN 0
from IN 0
2.34 CD 0
+/- JJ 0
0.10 CD 0
kg NN 0
to TO 0
1.57 CD 0
+/- JJ 0
0.11 CD 0
kg NN 0
( ( 0
p JJ 0
< NNP 0
0.0001 CD 0
) ) 0
. . 0

Predialysis NNP 0
systolic JJ 0
blood NN 0
pressure NN 0
fell VBD 0
from IN 0
144 CD 0
+/- JJ 0
3 CD 0
mm NN 0
Hg NNP 0
to TO 0
137 CD 0
+/- JJ 0
4 CD 0
mm NN 0
Hg NNP 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

The DT 0
reduction NN 0
in IN 0
convective JJ 0
sodium NN 0
removal NN 0
was VBD 0
balanced VBN 0
by IN 0
an DT 0
increase NN 0
in IN 0
diffusive JJ 0
sodium NN 0
removal NN 0
( ( 0
95 CD 0
+/- JJ 0
9 CD 0
mmol NN 0
cf NN 0
. . 0

175 CD 0
+/- JJ 0
14 CD 0
mmol NN 0
, , 0
p NN 0
< NNP 0
0.0001 CD 0
) ) 0
. . 0

Reduction NN 0
in IN 0
Cndi NNP 0
monitored VBN 0
by IN 0
IMB NNP 0
is VBZ 0
safe JJ 0
and CC 0
practical JJ 0
and CC 0
leads VBZ 0
to TO 0
improved VBN 0
interdialytic JJ 0
weight NN 0
gains NNS 0
and CC 0
blood NN 0
pressure NN 0
control NN 0
, , 0
while IN 0
avoiding VBG 0
excessive JJ 0
sodium NN 0
removal NN 0
. . 0

Comparison NNP 0
of IN 0
the DT 0
effect NN 0
of IN 0
gonadotropin-releasing NN 0
hormone NN 0
analog NN 0
( ( 0
Diphereline NNP 0
) ) 0
and CC 0
Cabergoline NNP 0
( ( 0
Dostinex NNP 0
) ) 0
treatment NN 0
on IN 0
uterine JJ 0
myoma NN 0
regression NN 0
. . 0

OBJECTIVE UH 0
To TO 0
investigate VB 0
the DT 0
effect NN 0
of IN 0
cabergoline NN 0
( ( 0
Dostinex NNP 0
, , 0
a DT 0
dopamine JJ 0
agonist NN 0
) ) 0
on IN 0
the DT 0
myoma NN 0
growth NN 0
compared VBN 0
to TO 0
Diphereline NNP 0
( ( 0
a DT 0
gonadotropin-releasing NN 0
hormone NN 0
agonist NN 0
) ) 0
. . 0

METHODS NNP 0
This DT 0
study NN 0
took VBD 0
place NN 0
in IN 0
the DT 0
Department NNP 0
of IN 0
Obstetrics NNP 0
and CC 0
Gynecology NNP 0
of IN 0
Tabriz NNP 0
University NNP 0
of IN 0
Medical NNP 0
Sciences NNPS 0
, , 0
Tabriz NNP 0
, , 0
Iran NNP 0
from IN 0
July NNP 0
2004 CD 0
to TO 0
December NNP 0
2005 CD 0
. . 0

Fifty NNP 0
women NNS 0
with IN 0
uterine JJ 0
myoma NN 0
, , 0
who WP 0
met VBD 0
the DT 0
criteria NNS 0
of IN 0
the DT 0
study NN 0
thoroughly RB 0
, , 0
were VBD 0
randomly RB 0
allocated VBN 0
into IN 0
2 CD 0
equal JJ 0
groups NNS 0
to TO 0
take VB 0
either DT 0
Diphereline NNP 0
or CC 0
Cabergoline NNP 0
. . 0

The DT 0
first JJ 0
Group NNP 0
took VBD 0
3.75 CD 0
mg NN 0
of IN 0
Diphereline NNP 0
4 CD 0
times NNS 0
every DT 0
28 CD 0
days NNS 0
and CC 0
the DT 0
second JJ 0
group NN 0
took VBD 0
0.5 CD 0
mg NN 0
of IN 0
Cabergoline NNP 0
once RB 0
a DT 0
week NN 0
for IN 0
6 CD 0
weeks NNS 0
. . 0

RESULTS VB 0
The DT 0
Cabergoline NNP 0
was VBD 0
well RB 0
tolerated VBN 0
and CC 0
fewer JJR 0
adverse JJ 0
effects NNS 0
were VBD 0
noted VBN 0
. . 0

The DT 0
tumor NN 0
regressed VBD 0
significantly RB 0
and CC 0
volume NN 0
reduction NN 0
rate NN 0
of IN 0
individual JJ 0
tumor NN 0
nodule NN 0
varied VBD 0
from IN 0
46-53 CD 0
% NN 0
. . 0

The DT 0
gonadotropin NN 0
releasing VBG 0
hormone JJ 0
agonist NN 0
group NN 0
all DT 0
responded VBD 0
to TO 0
the DT 0
treatment NN 0
, , 0
and CC 0
volume NN 0
reduction NN 0
rate NN 0
of IN 0
the DT 0
individual JJ 0
tumor NN 0
nodule NN 0
varied VBD 0
from IN 0
21-97 CD 0
% NN 0
. . 0

The DT 0
extent NN 0
of IN 0
tumor NN 0
shrinkage NN 0
was VBD 0
positively RB 0
correlated VBN 0
to TO 0
the DT 0
number NN 0
of IN 0
nodules NNS 0
( ( 0
p=0.881 NN 0
, , 0
p NN 0
< VBD 0
0.005 CD 0
and CC 0
0.701 CD 0
, , 0
p NN 0
< NNP 0
0.005 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
In IN 0
light NN 0
of IN 0
therapeutic JJ 0
efficacy NN 0
and CC 0
few JJ 0
adverse JJ 0
effects NNS 0
, , 0
the DT 0
dopamine NN 0
agonists NNS 0
may MD 0
hold VB 0
promise NN 0
as IN 0
novel JJ 0
treatment NN 0
modalities NNS 0
for IN 0
leiomyoma NN 0
. . 0

Further JJ 0
studies NNS 0
are VBP 0
warranted VBN 0
to TO 0
determine VB 0
the DT 0
optimal JJ 0
strategy NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
leiomyoma NN 0
through IN 0
these DT 0
agents NNS 0
. . 0

Sodium NN 0
bicarbonate NN 0
, , 0
N-acetylcysteine NNP 0
, , 0
and CC 0
saline NN 0
for IN 0
prevention NN 0
of IN 0
radiocontrast-induced JJ 0
nephropathy NN 0
. . 0

A DT 0
comparison NN 0
of IN 0
3 CD 0
regimens NNS 0
for IN 0
protecting VBG 0
contrast-induced JJ 0
nephropathy JJ 0
in IN 0
patients NNS 0
undergoing VBG 0
coronary JJ 0
procedures NNS 0
. . 0

A DT 0
single-center JJ 0
prospective NN 0
controlled VBN 0
trial NN 0
. . 0

BACKGROUND NNP 0
Several NNP 0
protective JJ 0
therapies NNS 0
have VBP 0
been VBN 0
developed VBN 0
to TO 0
prevent VB 0
contrast-induced JJ 0
nephropathy JJ 0
( ( 0
CIN NNP 0
) ) 0
. . 0

We PRP 0
aimed VBD 0
to TO 0
investigate VB 0
the DT 0
efficacy NN 0
of IN 0
sodium NN 0
bicarbonate NN 0
by IN 0
comparing VBG 0
2 CD 0
other JJ 0
regimens NNS 0
, , 0
including VBG 0
combination NN 0
of IN 0
N-acetylcysteine NNP 0
( ( 0
NAC NNP 0
) ) 0
plus CC 0
sodium JJ 0
chloride NN 0
and CC 0
sodium NN 0
chloride NN 0
alone RB 0
, , 0
to TO 0
prevent VB 0
CIN NNP 0
in IN 0
patients NNS 0
undergoing VBG 0
cardiovascular JJ 0
procedures NNS 0
. . 0

METHODS NNP 0
We PRP 0
prospectively RB 0
enrolled VBD 0
264 CD 0
patients NNS 0
who WP 0
were VBD 0
scheduled VBN 0
for IN 0
cardiovascular JJ 0
procedures NNS 0
and CC 0
had VBD 0
a DT 0
baseline JJ 0
creatinine NN 0
level NN 0
> VBD 0
1.2 CD 0
mg/dL NN 0
. . 0

The DT 0
patients NNS 0
were VBD 0
assigned VBN 0
1 CD 0
of IN 0
3 CD 0
prophylactic JJ 0
regimens NNS 0
: : 0
infusion NN 0
of IN 0
sodium NN 0
bicarbonate NN 0
, , 0
sodium NN 0
chloride NN 0
, , 0
sodium NN 0
chloride NN 0
plus CC 0
oral JJ 0
NAC NNP 0
( ( 0
600 CD 0
mg RB 0
bid NN 0
) ) 0
. . 0

Contrast-induced JJ 0
nephropathy NN 0
was VBD 0
defined VBN 0
as IN 0
an DT 0
increase NN 0
in IN 0
serum JJ 0
creatinine NN 0
level NN 0
> VBD 0
25 CD 0
% NN 0
or CC 0
0.5 CD 0
mg/dL NNS 0
after IN 0
48 CD 0
hours NNS 0
. . 0

RESULTS VB 0
There EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
among IN 0
groups NNS 0
regarding VBG 0
baseline NN 0
demographic JJ 0
properties NNS 0
and CC 0
nephropathy JJ 0
risk NN 0
factors NNS 0
. . 0

The DT 0
change NN 0
in IN 0
creatinine JJ 0
clearance NN 0
was VBD 0
significantly RB 0
better RBR 0
in IN 0
the DT 0
sodium NN 0
bicarbonate NN 0
group NN 0
than IN 0
other JJ 0
2 CD 0
groups NNS 0
( ( 0
P NNP 0
= NNP 0
.007 NNP 0
) ) 0
. . 0

The DT 0
incidence NN 0
of IN 0
CIN NNP 0
was VBD 0
significantly RB 0
lower JJR 0
in IN 0
the DT 0
sodium NN 0
bicarbonate NN 0
group NN 0
( ( 0
4.5 CD 0
% NN 0
) ) 0
compared VBN 0
with IN 0
sodium JJ 0
chloride NN 0
alone RB 0
( ( 0
13.6 CD 0
% NN 0
, , 0
P NNP 0
= NNP 0
.036 NNP 0
) ) 0
and CC 0
tended VBD 0
to TO 0
be VB 0
lower JJR 0
than IN 0
in IN 0
the DT 0
combination NN 0
group NN 0
( ( 0
12.5 CD 0
% NN 0
, , 0
P NNP 0
= NNP 0
.059 NNP 0
) ) 0
. . 0

After IN 0
adjusting VBG 0
the DT 0
Mehran NNP 0
nephropathy NN 0
risk NN 0
score NN 0
, , 0
the DT 0
risk NN 0
of IN 0
CIN NNP 0
significantly RB 0
reduced VBD 0
with IN 0
sodium NN 0
bicarbonate NN 0
compared VBN 0
with IN 0
sodium JJ 0
chloride NN 0
alone RB 0
( ( 0
adjusted VBN 0
risk NN 0
ratio NN 0
0.29 CD 0
, , 0
P NNP 0
= NNP 0
.043 NNP 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Hydration NNP 0
with IN 0
sodium JJ 0
bicarbonate NN 0
provides VBZ 0
better JJR 0
protection NN 0
against IN 0
CIN NNP 0
than IN 0
the DT 0
sodium NN 0
chloride JJ 0
infusion NN 0
does VBZ 0
alone RB 0
. . 0

Combination NNP 0
therapy NN 0
of IN 0
NAC NNP 0
plus CC 0
sodium JJ 0
chloride NN 0
did VBD 0
not RB 0
offer VB 0
additional JJ 0
benefit NN 0
over IN 0
hydration NN 0
with IN 0
sodium JJ 0
chloride NN 0
alone RB 0
. . 0

Parents NNS 0
' POS 0
state NN 0
and CC 0
trait NN 0
anxiety NN 0
: : 0
relationships NNS 0
with IN 0
anxiety NN 0
severity NN 0
and CC 0
treatment NN 0
response NN 0
in IN 0
adolescents NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorders NNS 0
. . 0

Comorbid NNP 0
anxiety NN 0
is VBZ 0
common JJ 0
among IN 0
children NNS 0
with IN 0
Autism NNP 0
Spectrum NNP 0
Disorder NNP 0
( ( 0
ASD NNP 0
) ) 0
, , 0
and CC 0
parents NNS 0
of IN 0
children NNS 0
with IN 0
ASD NNP 0
are VBP 0
more RBR 0
likely JJ 0
to TO 0
have VB 0
anxiety NN 0
disorders NNS 0
. . 0

This DT 0
study NN 0
investigated VBD 0
the DT 0
relationship NN 0
between IN 0
parents NNS 0
' POS 0
state NN 0
and CC 0
trait NN 0
anxiety NN 0
and CC 0
parent-reported JJ 0
internalizing NN 0
and CC 0
externalizing VBG 0
symptoms NNS 0
among IN 0
adolescents NNS 0
( ( 0
n JJ 0
= NNP 0
30 CD 0
) ) 0
with IN 0
ASD NNP 0
, , 0
as RB 0
well RB 0
as IN 0
the DT 0
relationship NN 0
of IN 0
parents NNS 0
' POS 0
anxiety NN 0
symptoms NNS 0
and CC 0
adolescent JJ 0
treatment NN 0
response NN 0
in IN 0
the DT 0
context NN 0
of IN 0
a DT 0
randomized VBN 0
controlled VBN 0
trial NN 0
. . 0

Parental JJ 0
state NN 0
anxiety NN 0
correlated VBD 0
with IN 0
severity NN 0
of IN 0
adolescent JJ 0
anxiety NN 0
, , 0
and CC 0
trait NN 0
anxiety NN 0
in IN 0
parents NNS 0
correlated VBN 0
with IN 0
parent-reported JJ 0
adolescent NN 0
internalizing NN 0
and CC 0
externalizing NN 0
symptoms NNS 0
. . 0

Also RB 0
, , 0
parents NNS 0
of IN 0
adolescent JJ 0
treatment NN 0
responders NNS 0
experienced VBD 0
a DT 0
decrease NN 0
in IN 0
their PRP$ 0
own JJ 0
trait NN 0
anxiety NN 0
. . 0

Findings NNS 0
highlight VBD 0
the DT 0
importance NN 0
of IN 0
considering VBG 0
parental JJ 0
anxiety NN 0
when WRB 0
targeting VBG 0
anxiety NN 0
among IN 0
youth NN 0
with IN 0
ASD NNP 0
. . 0

Effects NNS 0
of IN 0
interaction NN 0
of IN 0
RRR-alpha-tocopheryl NNP 0
acetate NN 0
and CC 0
fish JJ 0
oil NN 0
on IN 0
low-density-lipoprotein JJ 0
oxidation NN 0
in IN 0
postmenopausal JJ 0
women NNS 0
with IN 0
and CC 0
without IN 0
hormone-replacement JJ 0
therapy NN 0
. . 0

We PRP 0
evaluated VBD 0
the DT 0
effects NNS 0
of IN 0
RRR-alpha-tocpheryl NNP 0
acetate NN 0
( ( 0
alpha-tocopheryl JJ 0
acetate NN 0
) ) 0
and CC 0
hormone-replacement JJ 0
therapy NN 0
( ( 0
HRT NNP 0
) ) 0
on IN 0
the DT 0
oxidative JJ 0
susceptibility NN 0
of IN 0
low-density NN 0
lipoprotein NN 0
( ( 0
LDL NNP 0
) ) 0
in IN 0
postmenopausal JJ 0
women NNS 0
consuming VBG 0
a DT 0
fish JJ 0
oil NN 0
supplement NN 0
. . 0

The DT 0
independent JJ 0
effect NN 0
of IN 0
fish JJ 0
oil NN 0
was VBD 0
also RB 0
assessed VBN 0
. . 0

Forty-eight JJ 0
women NNS 0
, , 0
equally RB 0
divided VBD 0
between IN 0
women NNS 0
using VBG 0
and CC 0
not RB 0
using VBG 0
HRT NNP 0
, , 0
participated VBD 0
in IN 0
a DT 0
double-blind JJ 0
crossover NN 0
trial NN 0
. . 0

Each DT 0
of IN 0
the DT 0
four CD 0
periods NNS 0
lasted VBD 0
5 CD 0
wk NN 0
and CC 0
was VBD 0
followed VBN 0
by IN 0
a DT 0
4-wk JJ 0
washout NN 0
interval NN 0
. . 0

During IN 0
each DT 0
period NN 0
all DT 0
subjects NNS 0
were VBD 0
given VBN 0
a DT 0
15-g JJ 0
supplement NN 0
of IN 0
fish JJ 0
oil NN 0
and CC 0
either RB 0
0 CD 0
( ( 0
placebo NN 0
) ) 0
, , 0
100 CD 0
, , 0
200 CD 0
, , 0
or CC 0
400 CD 0
mg JJ 0
alpha-tocopheryl JJ 0
acetate JJ 0
daily JJ 0
. . 0

LDL NNP 0
resistance NN 0
to TO 0
oxidative VB 0
modification NN 0
was VBD 0
assessed VBN 0
by IN 0
calculating VBG 0
lag NN 0
time NN 0
, , 0
propagation NN 0
rate NN 0
, , 0
and CC 0
maximum JJ 0
production NN 0
of IN 0
conjugated JJ 0
dienes NNS 0
. . 0

Supplementation NN 0
with IN 0
fish JJ 0
oil NN 0
and CC 0
placebo NN 0
shortened VBN 0
lag JJ 0
time NN 0
and CC 0
slowed VBN 0
propagation NN 0
rate NN 0
in IN 0
women NNS 0
both DT 0
using VBG 0
and CC 0
not RB 0
using VBG 0
HRT NNP 0
. . 0

After IN 0
subjects NNS 0
consumed VBD 0
fish JJ 0
oil NN 0
, , 0
supplementation NN 0
with IN 0
alpha-tocopheryl JJ 0
acetate NN 0
increased VBD 0
plasma NN 0
and CC 0
LDL NNP 0
alpha-tocopherol NN 0
contents NNS 0
significantly RB 0
and CC 0
lengthened VBD 0
lag NN 0
time NN 0
( ( 0
at IN 0
even RB 0
the DT 0
lowest JJS 0
concentration NN 0
) ) 0
but CC 0
had VBD 0
no DT 0
significant JJ 0
effect NN 0
on IN 0
propagation NN 0
rate NN 0
or CC 0
maximum JJ 0
production NN 0
compared VBN 0
with IN 0
values NNS 0
measured VBN 0
after IN 0
consumption NN 0
of IN 0
fish JJ 0
oil NN 0
alone RB 0
. . 0

Women NNP 0
not RB 0
using VBG 0
HRT NNP 0
had VBD 0
faster JJR 0
propagation NN 0
rates NNS 0
and CC 0
higher JJR 0
maximum NN 0
production NN 0
than IN 0
women NNS 0
using VBG 0
HRT NNP 0
; : 0
after IN 0
supplementation NN 0
with IN 0
fish JJ 0
oil NN 0
and CC 0
alpha-tocopheryl JJ 0
acetate NN 0
these DT 0
differences NNS 0
prevailed VBD 0
. . 0

Supplements NNS 0
as RB 0
low JJ 0
as IN 0
100 CD 0
mg JJ 0
alpha-tocopheryl JJ 0
acetate/d NN 0
increase VB 0
the DT 0
resistance NN 0
of IN 0
LDL NNP 0
to TO 0
oxidation VB 0
when WRB 0
fish JJ 0
oil NN 0
supplements NNS 0
are VBP 0
used VBN 0
. . 0

HRT NNP 0
and CC 0
fish JJ 0
oil NN 0
supplements NNS 0
may MD 0
independently RB 0
affect VB 0
LDL NNP 0
oxidative JJ 0
susceptibility NN 0
. . 0

Effects NNS 0
of IN 0
bifidobacterium NN 0
breve VBP 0
supplementation NN 0
on IN 0
intestinal JJ 0
flora NNS 0
of IN 0
low JJ 0
birth NN 0
weight NN 0
infants NNS 0
. . 0

BACKGROUND IN 0
It PRP 0
is VBZ 0
known VBN 0
that IN 0
the DT 0
bifidobacteria NN 0
flora VBP 0
play NN 0
important JJ 0
roles NNS 0
in IN 0
mucosal NN 0
host NN 0
defense NN 0
and CC 0
can MD 0
prevent VB 0
infectious JJ 0
diseases NNS 0
. . 0

Because IN 0
bacterial JJ 0
populations NNS 0
develop VBP 0
during IN 0
the DT 0
first JJ 0
day NN 0
of IN 0
life NN 0
, , 0
the DT 0
authors NNS 0
examined VBD 0
whether IN 0
the DT 0
early JJ 0
administration NN 0
of IN 0
bifidobacteria NN 0
has VBZ 0
a DT 0
positive JJ 0
effect NN 0
on IN 0
the DT 0
health NN 0
of IN 0
low JJ 0
birth NN 0
weight NN 0
infants NNS 0
. . 0

METHODS NNP 0
The DT 0
effects NNS 0
of IN 0
oral JJ 0
administration NN 0
of IN 0
Bifidobacterium NNP 0
breve NN 0
( ( 0
B. NNP 0
breve VBP 0
) ) 0
supplements NNS 0
were VBD 0
studied VBN 0
in IN 0
a DT 0
controlled JJ 0
trial NN 0
with IN 0
low JJ 0
birth NN 0
weight NN 0
infants NNS 0
( ( 0
average JJ 0
birth NN 0
weight NN 0
1489 CD 0
g NN 0
) ) 0
. . 0

The DT 0
infants NNS 0
were VBD 0
divided VBN 0
into IN 0
three CD 0
groups NNS 0
: : 0
Group NNP 0
A NNP 0
and CC 0
B NNP 0
received VBD 0
a DT 0
dose NN 0
of IN 0
1.6 CD 0
x NNS 0
10 CD 0
( ( 0
8 CD 0
) ) 0
cells NNS 0
of IN 0
B. NNP 0
breve VBP 0
supplement NN 0
twice RB 0
a DT 0
day NN 0
, , 0
commencing VBG 0
either CC 0
from IN 0
several JJ 0
hours NNS 0
after IN 0
birth NN 0
( ( 0
group NN 0
A NNP 0
) ) 0
or CC 0
24 CD 0
h NN 0
after IN 0
birth NN 0
( ( 0
group NN 0
B NNP 0
) ) 0
. . 0

Group NNP 0
C NNP 0
, , 0
the DT 0
control NN 0
group NN 0
, , 0
received VBD 0
no DT 0
supplement NN 0
. . 0

RESULTS CC 0
There EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
birth NN 0
weight NN 0
, , 0
treatment NN 0
with IN 0
antibiotics NNS 0
, , 0
and CC 0
the DT 0
starting JJ 0
time NN 0
of IN 0
breast-feeding NN 0
among IN 0
the DT 0
three CD 0
groups NNS 0
. . 0

A DT 0
Bifidobacterium-predominant JJ 0
flora NN 0
was VBD 0
formed VBN 0
at IN 0
an DT 0
average NN 0
of IN 0
2 CD 0
weeks NNS 0
after IN 0
birth NN 0
in IN 0
group NN 0
A NNP 0
and CC 0
at IN 0
an DT 0
average NN 0
of IN 0
4 CD 0
weeks NNS 0
after IN 0
birth NN 0
in IN 0
group NN 0
B NNP 0
, , 0
while IN 0
no DT 0
Bifidobacterium NNP 0
was VBD 0
isolated VBN 0
in IN 0
eight CD 0
out IN 0
of IN 0
10 CD 0
infants NNS 0
in IN 0
group NN 0
C NNP 0
during IN 0
the DT 0
observation NN 0
period NN 0
of IN 0
7 CD 0
weeks NNS 0
. . 0

In IN 0
comparison NN 0
between IN 0
group NN 0
A NNP 0
and CC 0
B NNP 0
, , 0
Bifidobacterium NNP 0
was VBD 0
detected VBN 0
significantly RB 0
earlier RBR 0
in IN 0
group NN 0
A NNP 0
, , 0
and CC 0
the DT 0
number NN 0
of IN 0
Enterobacteriaceae NNP 0
present NN 0
in IN 0
the DT 0
infants NNS 0
at IN 0
2 CD 0
weeks NNS 0
after IN 0
birth NN 0
was VBD 0
significantly RB 0
lower JJR 0
in IN 0
group NN 0
A NNP 0
. . 0

CONCLUSION NNP 0
The DT 0
results NNS 0
of IN 0
the DT 0
present JJ 0
study NN 0
suggest VBP 0
that IN 0
very RB 0
early JJ 0
administration NN 0
of IN 0
B. NNP 0
breve VBP 0
to TO 0
low JJ 0
birth NN 0
weight NN 0
infants NNS 0
is VBZ 0
useful JJ 0
in IN 0
promoting VBG 0
the DT 0
colonization NN 0
of IN 0
the DT 0
Bifidobacterium NNP 0
and CC 0
the DT 0
formation NN 0
of IN 0
a DT 0
normal JJ 0
intestinal JJ 0
flora NN 0
. . 0

Efficacy NN 0
of IN 0
a DT 0
family NN 0
practice-based JJ 0
lifestyle JJ 0
intervention NN 0
program NN 0
to TO 0
increase VB 0
physical JJ 0
activity NN 0
and CC 0
reduce VB 0
clinical JJ 0
and CC 0
physiological JJ 0
markers NNS 0
of IN 0
vascular JJ 0
health NN 0
in IN 0
patients NNS 0
with IN 0
high JJ 0
normal JJ 0
blood NN 0
pressure NN 0
and/or RB 0
high JJ 0
normal JJ 0
blood NN 0
glucose NN 0
( ( 0
SNAC NNP 0
) ) 0
: : 0
study NN 0
protocol NN 0
for IN 0
a DT 0
randomized VBN 0
controlled VBN 0
trial NN 0
. . 0

BACKGROUND NNP 0
Previous JJ 0
interventions NNS 0
to TO 0
increase VB 0
physical JJ 0
activity NN 0
and CC 0
reduce VB 0
cardiovascular JJ 0
risk NN 0
factors NNS 0
have VBP 0
been VBN 0
targeted VBN 0
at IN 0
individuals NNS 0
with IN 0
established VBN 0
disease NN 0
; : 0
less CC 0
attention NN 0
has VBZ 0
been VBN 0
given VBN 0
to TO 0
intervention VB 0
among IN 0
individuals NNS 0
with IN 0
high JJ 0
risk NN 0
for IN 0
disease NN 0
nor CC 0
has VBZ 0
there RB 0
been VBN 0
determination NN 0
of IN 0
the DT 0
influence NN 0
of IN 0
setting VBG 0
in IN 0
which WDT 0
the DT 0
intervention NN 0
is VBZ 0
provided VBN 0
. . 0

In IN 0
particular JJ 0
, , 0
family NN 0
practice NN 0
represents VBZ 0
an DT 0
ideal JJ 0
setting NN 0
for IN 0
the DT 0
provision NN 0
and CC 0
long-term JJ 0
maintenance NN 0
of IN 0
lifestyle JJ 0
interventions NNS 0
for IN 0
patients NNS 0
at IN 0
risk NN 0
( ( 0
ie JJ 0
high-normal JJ 0
blood NN 0
pressure NN 0
or CC 0
impaired JJ 0
glucose JJ 0
tolerance NN 0
) ) 0
. . 0

METHODS/DESIGN PDT 0
The DT 0
Staged NNP 0
Nutrition NNP 0
and CC 0
Activity NNP 0
Counseling NNP 0
( ( 0
SNAC NNP 0
) ) 0
study NN 0
is VBZ 0
a DT 0
randomized JJ 0
clustered JJ 0
design NN 0
clinical JJ 0
trial NN 0
that WDT 0
will MD 0
investigate VB 0
the DT 0
effectiveness NN 0
and CC 0
efficacy NN 0
of IN 0
a DT 0
multi-component JJ 0
lifestyle JJ 0
intervention NN 0
on IN 0
cardiovascular JJ 0
disease NN 0
risk NN 0
factors NNS 0
and CC 0
vascular JJ 0
function NN 0
in IN 0
patients NNS 0
at IN 0
risk NN 0
in IN 0
primary JJ 0
care NN 0
. . 0

Patients NNS 0
will MD 0
be VB 0
randomized VBN 0
by IN 0
practice NN 0
to TO 0
either VB 0
a DT 0
standard NN 0
of IN 0
care NN 0
lifestyle JJ 0
intervention NN 0
or CC 0
a DT 0
behaviourally-based JJ 0
, , 0
matched VBD 0
prescriptive JJ 0
physical JJ 0
activity NN 0
and CC 0
diet JJ 0
change NN 0
program NN 0
. . 0

The DT 0
primary JJ 0
goal NN 0
is VBZ 0
to TO 0
increase VB 0
physical JJ 0
activity NN 0
and CC 0
improve VB 0
dietary JJ 0
intake NN 0
according VBG 0
to TO 0
Canada NNP 0
's POS 0
Guides NNP 0
to TO 0
Physical NNP 0
Activity NNP 0
Healthy NNP 0
Eating NNP 0
over IN 0
24 CD 0
months NNS 0
. . 0

The DT 0
primary JJ 0
intention NN 0
to TO 0
treat VB 0
analysis NN 0
will MD 0
compare VB 0
behavioral JJ 0
, , 0
physiological JJ 0
and CC 0
metabolic JJ 0
outcomes NNS 0
at IN 0
6 CD 0
, , 0
12 CD 0
and CC 0
24 CD 0
months NNS 0
post-randomization JJ 0
including VBG 0
estimation NN 0
of IN 0
incident JJ 0
hypertension NN 0
and/or NN 0
diabetes VBZ 0
. . 0

DISCUSSION VB 0
The DT 0
design NN 0
features NNS 0
of IN 0
our PRP$ 0
trial NN 0
, , 0
and CC 0
the DT 0
practical JJ 0
problems NNS 0
( ( 0
and CC 0
solutions NNS 0
) ) 0
associated VBN 0
with IN 0
implementing VBG 0
these DT 0
design NN 0
features NNS 0
, , 0
particularly RB 0
those DT 0
that IN 0
result NN 0
in IN 0
potential JJ 0
delay NN 0
between IN 0
recruitment NN 0
, , 0
baseline NN 0
data NNS 0
collection NN 0
, , 0
randomization NN 0
, , 0
intervention NN 0
, , 0
and CC 0
assessment NN 0
will MD 0
be VB 0
discussed VBN 0
. . 0

Results NNS 0
of IN 0
the DT 0
SNAC NNP 0
trial NN 0
will MD 0
provide VB 0
scientific JJ 0
rationale NN 0
for IN 0
the DT 0
implementation NN 0
of IN 0
this DT 0
lifestyle JJ 0
intervention NN 0
in IN 0
primary JJ 0
care NN 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
ISRCTN NNP 0
: : 0
ISRCTN:42921300 NNP 0
. . 0

[ JJ 0
Effects NNS 0
of IN 0
small JJ 0
needle-knife JJ 0
comprehensive JJ 0
therapy NN 0
on IN 0
pain NN 0
and CC 0
lumbar NN 0
flexion NN 0
range NN 0
in IN 0
the DT 0
chronic JJ 0
nonspecific NN 0
low JJ 0
back RB 0
pain NN 0
patient NN 0
] NN 0
. . 0

OBJECTIVE UH 0
To TO 0
observe VB 0
therapeutic JJ 0
effect NN 0
of IN 0
small JJ 0
needle-knife JJ 0
comprehensive JJ 0
therapy NN 0
on IN 0
pain NN 0
and CC 0
lumbar NN 0
flexion NN 0
range NN 0
in IN 0
the DT 0
chronic JJ 0
nonspecific NN 0
low JJ 0
back RB 0
pain NN 0
patient NN 0
. . 0

METHODS NNP 0
Three CD 0
hundred VBD 0
and CC 0
five CD 0
cases NNS 0
were VBD 0
randomly RB 0
divided VBN 0
into IN 0
a DT 0
needle-knife JJ 0
group NN 0
of IN 0
153 CD 0
cases NNS 0
and CC 0
a DT 0
physiotherapy NN 0
group NN 0
of IN 0
152 CD 0
cases NNS 0
. . 0

The DT 0
needle-knife JJ 0
group NN 0
were VBD 0
treated VBN 0
with IN 0
small JJ 0
needle-knife JJ 0
releasing NN 0
therapy NN 0
, , 0
blocking VBG 0
and CC 0
functional JJ 0
training NN 0
. . 0

The DT 0
physiotherapy NN 0
group NN 0
were VBD 0
treated VBN 0
with IN 0
ultra-short JJ 0
wave NN 0
, , 0
modulated VBD 0
medium NN 0
frequency NN 0
current JJ 0
, , 0
massage NN 0
and CC 0
functional JJ 0
training NN 0
. . 0

Pain NN 0
was VBD 0
assessed VBN 0
by IN 0
visual JJ 0
analogue NN 0
scale NN 0
( ( 0
VAS NNP 0
) ) 0
and CC 0
the DT 0
lumbar NN 0
flexion NN 0
range NN 0
was VBD 0
determined VBN 0
before IN 0
and CC 0
after IN 0
treatment NN 0
. . 0

RESULTS NNP 0
After IN 0
treatment NN 0
, , 0
the DT 0
pain NN 0
and CC 0
the DT 0
lumbar NN 0
flexion NN 0
range NN 0
were VBD 0
significantly RB 0
improved VBN 0
in IN 0
the DT 0
two CD 0
groups NNS 0
; : 0
and CC 0
after IN 0
treatment NN 0
, , 0
the DT 0
VAS NNP 0
score NN 0
and CC 0
the DT 0
lumbar NN 0
flexion NN 0
range NN 0
were VBD 0
( ( 0
1.60 CD 0
+/- JJ 0
0.38 CD 0
) ) 0
points NNS 0
and CC 0
( ( 0
65.76 CD 0
+/- JJ 0
15.11 CD 0
) ) 0
cm NN 0
in IN 0
the DT 0
needle-knife JJ 0
group NN 0
and CC 0
( ( 0
4.59 CD 0
+/- JJ 0
1.09 CD 0
) ) 0
points NNS 0
and CC 0
( ( 0
53.74 CD 0
+/- JJ 0
15.13 CD 0
) ) 0
cm NN 0
in IN 0
the DT 0
physiotherapy NN 0
group NN 0
, , 0
respectively RB 0
, , 0
the DT 0
needle-knife JJ 0
group NN 0
being VBG 0
significantly RB 0
better JJR 0
than IN 0
the DT 0
physiotherapy NN 0
group NN 0
( ( 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

Follow-up NNP 0
survey NN 0
of IN 0
6-36 JJ 0
months NNS 0
showed VBD 0
that IN 0
the DT 0
VAS NNP 0
score NN 0
and CC 0
the DT 0
lumbar NN 0
flexion NN 0
range NN 0
in IN 0
the DT 0
needle-knife JJ 0
group NN 0
were VBD 0
superior JJ 0
to TO 0
those DT 0
in IN 0
the DT 0
physiotherapy NN 0
group NN 0
. . 0

CONCLUSION NNP 0
Small NNP 0
needle-knife JJ 0
comprehensive JJ 0
therapy NN 0
can MD 0
significantly RB 0
improve VB 0
pain NN 0
and CC 0
lumbar NN 0
flexion NN 0
range NN 0
in IN 0
the DT 0
chronic JJ 0
nonspecific NN 0
low JJ 0
back RB 0
pain NN 0
patient NN 0
, , 0
with IN 0
a DT 0
stable JJ 0
long-term JJ 0
therapeutic JJ 0
effect NN 0
. . 0

A DT 0
prospective JJ 0
randomised JJ 0
comparison NN 0
of IN 0
sublingual JJ 0
and CC 0
vaginal JJ 0
misoprostol NN 0
in IN 0
second JJ 0
trimester NN 0
termination NN 0
of IN 0
pregnancy NN 0
. . 0

OBJECTIVE UH 0
To TO 0
compare VB 0
the DT 0
efficacy NN 0
, , 0
side NN 0
effects NNS 0
and CC 0
acceptability NN 0
of IN 0
sublingual JJ 0
and CC 0
vaginal JJ 0
misoprostol NN 0
for IN 0
second JJ 0
trimester NN 0
medical JJ 0
abortion NN 0
. . 0

DESIGN NNP 0
Prospective NNP 0
randomised VBD 0
controlled VBN 0
trial NN 0
. . 0

SETTING NN 0
Tertiary JJ 0
referral JJ 0
unit NN 0
and CC 0
a DT 0
teaching JJ 0
hospital NN 0
. . 0

POPULATION NNP 0
Two CD 0
hundred VBD 0
and CC 0
twenty-four JJ 0
women NNS 0
at IN 0
12 CD 0
to TO 0
20 CD 0
weeks NNS 0
of IN 0
gestation NN 0
. . 0

METHODS NNP 0
The DT 0
women NNS 0
were VBD 0
randomised VBN 0
to TO 0
receive VB 0
either DT 0
sublingual JJ 0
or CC 0
vaginal JJ 0
misoprostol NN 0
400 CD 0
microg NN 0
every DT 0
3 CD 0
hours NNS 0
for IN 0
a DT 0
maximum NN 0
of IN 0
five CD 0
doses NNS 0
. . 0

The DT 0
course NN 0
of IN 0
misoprostol NN 0
was VBD 0
repeated VBN 0
if IN 0
the DT 0
woman NN 0
did VBD 0
not RB 0
abort VB 0
within IN 0
24 CD 0
hours NNS 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURES NNP 0
The DT 0
success NN 0
rate NN 0
at IN 0
48 CD 0
hours NNS 0
, , 0
induction-to-abortion NN 0
interval NN 0
and CC 0
the DT 0
side NN 0
effects NNS 0
. . 0

RESULTS NNP 0
There EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
in IN 0
the DT 0
success NN 0
rate NN 0
at IN 0
48 CD 0
hours NNS 0
( ( 0
sublingual JJ 0
: : 0
91 CD 0
% NN 0
; : 0
vaginal JJ 0
: : 0
95 CD 0
% NN 0
) ) 0
. . 0

However RB 0
, , 0
the DT 0
success NN 0
rate NN 0
at IN 0
24 CD 0
hours NNS 0
was VBD 0
significantly RB 0
higher JJR 0
in IN 0
the DT 0
vaginal JJ 0
group NN 0
( ( 0
85 CD 0
% NN 0
) ) 0
compared VBN 0
with IN 0
the DT 0
sublingual JJ 0
group NN 0
( ( 0
64 CD 0
% NN 0
) ) 0
. . 0

There EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
the DT 0
median JJ 0
induction-to-abortion NN 0
interval NN 0
( ( 0
sublingual JJ 0
: : 0
13.8 CD 0
hours NNS 0
; : 0
vaginal JJ 0
: : 0
12.0 CD 0
hours NNS 0
) ) 0
. . 0

Significantly RB 0
more JJR 0
women NNS 0
in IN 0
the DT 0
sublingual JJ 0
group NN 0
preferred VBD 0
the DT 0
route NN 0
to TO 0
which WDT 0
they PRP 0
were VBD 0
assigned VBN 0
when WRB 0
compared VBN 0
with IN 0
the DT 0
vaginal JJ 0
group NN 0
. . 0

The DT 0
incidence NN 0
of IN 0
fever NN 0
was VBD 0
also RB 0
less RBR 0
in IN 0
the DT 0
sublingual JJ 0
group NN 0
. . 0

CONCLUSION NNP 0
The DT 0
use NN 0
of IN 0
vaginal JJ 0
misoprostol NN 0
for IN 0
second JJ 0
trimester NN 0
medical JJ 0
abortion NN 0
resulted VBD 0
in IN 0
a DT 0
higher JJR 0
success NN 0
rate NN 0
than IN 0
sublingual JJ 0
misoprostol NN 0
at IN 0
24 CD 0
hours NNS 0
but CC 0
the DT 0
abortion NN 0
rate NN 0
was VBD 0
similar JJ 0
at IN 0
48 CD 0
hours NNS 0
. . 0

Vaginal NNP 0
misoprostol NN 0
should MD 0
be VB 0
the DT 0
regimen NNS 0
of IN 0
choice NN 0
but CC 0
sublingual JJ 0
misoprostol NN 0
is VBZ 0
also RB 0
an DT 0
effective JJ 0
alternative NN 0
. . 0

Hydrogen NNP 0
peroxide NN 0
mouth NN 0
rinse NN 0
: : 0
an DT 0
analgesic JJ 0
post-tonsillectomy NN 0
. . 0

OBJECTIVE UH 0
To TO 0
compare VB 0
the DT 0
analgesic JJ 0
efficacy NN 0
of IN 0
hydrogen NN 0
peroxide NN 0
( ( 0
H2O2 NNP 0
) ) 0
mouth NN 0
rinse NN 0
with IN 0
control NN 0
for IN 0
post-tonsillectomy JJ 0
pain NN 0
management NN 0
. . 0

DESIGN NNP 0
Double-blinded NNP 0
, , 0
prospective JJ 0
, , 0
randomized VBN 0
, , 0
controlled VBD 0
clinical JJ 0
trial NN 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
Thirty-seven JJ 0
patients NNS 0
from IN 0
5 CD 0
to TO 0
14 CD 0
years NNS 0
old JJ 0
undergoing JJ 0
electrocautery NN 0
tonsillectomy NN 0
were VBD 0
randomized VBN 0
to TO 0
either CC 0
the DT 0
H2O2 NNP 0
mouth NN 0
rinse NN 0
or CC 0
the DT 0
water NN 0
rinse NN 0
( ( 0
control NN 0
) ) 0
group NN 0
. . 0

For IN 0
14 CD 0
days NNS 0
, , 0
patients NNS 0
recorded VBD 0
pain NN 0
levels NNS 0
twice RB 0
daily RB 0
using VBG 0
a DT 0
visual JJ 0
analogue NN 0
scale NN 0
. . 0

Analgesic JJ 0
uses NNS 0
, , 0
as RB 0
well RB 0
as IN 0
any DT 0
complications NNS 0
, , 0
were VBD 0
also RB 0
noted VBN 0
by IN 0
the DT 0
patients NNS 0
. . 0

RESULTS NNP 0
Thirty-seven JJ 0
patients NNS 0
completed VBD 0
the DT 0
study NN 0
, , 0
21 CD 0
in IN 0
the DT 0
treatment NN 0
group NN 0
and CC 0
16 CD 0
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

Mean NNP 0
postoperative JJ 0
days NNS 0
of IN 0
pain NN 0
were VBD 0
10.3 CD 0
and CC 0
8.3 CD 0
, , 0
respectively RB 0
, , 0
and CC 0
differed VBD 0
significantly RB 0
( ( 0
p JJ 0
= NNP 0
.008 NNP 0
) ) 0
. . 0

Mean JJ 0
postoperative JJ 0
days NNS 0
of IN 0
analgesic JJ 0
use NN 0
were VBD 0
9.0 CD 0
and CC 0
6.7 CD 0
, , 0
respectively RB 0
, , 0
and CC 0
differed VBD 0
significantly RB 0
( ( 0
p JJ 0
= NNP 0
.005 NNP 0
) ) 0
. . 0

Only RB 0
one CD 0
incidence NN 0
of IN 0
postoperative JJ 0
hemorrhage NN 0
occurred VBD 0
in IN 0
the DT 0
study NN 0
group NN 0
. . 0

CONCLUSION NNP 0
In IN 0
our PRP$ 0
study NN 0
, , 0
the DT 0
H2O2 NNP 0
mouth NN 0
rinse NN 0
does VBZ 0
not RB 0
provide VB 0
a DT 0
better JJR 0
analgesic JJ 0
effect NN 0
than IN 0
the DT 0
water NN 0
rinse NN 0
for IN 0
post-tonsillectomy JJ 0
pain NN 0
relief NN 0
. . 0

Long-term JJ 0
exposure NN 0
to TO 0
belatacept VB 0
in IN 0
recipients NNS 0
of IN 0
extended JJ 0
criteria NNS 0
donor JJ 0
kidneys NNS 0
. . 0

Patients NNS 0
in IN 0
the DT 0
BENEFIT-EXT NNP 0
study NN 0
received VBD 0
extended JJ 0
criteria NNS 0
donor JJ 0
kidneys NNS 0
and CC 0
a DT 0
more RBR 0
intensive JJ 0
( ( 0
MI NNP 0
) ) 0
or CC 0
less RBR 0
intensive JJ 0
( ( 0
LI NNP 0
) ) 0
belatacept IN 0
immunosuppression NN 0
regimen NNS 0
, , 0
or CC 0
cyclosporine VB 0
A NNP 0
( ( 0
CsA NNP 0
) ) 0
. . 0

Patients NNS 0
who WP 0
remained VBD 0
on IN 0
assigned JJ 0
therapy NN 0
through IN 0
year NN 0
3 CD 0
were VBD 0
eligible JJ 0
to TO 0
enter VB 0
a DT 0
long-term JJ 0
extension NN 0
( ( 0
LTE NNP 0
) ) 0
study NN 0
. . 0

Three CD 0
hundred VBD 0
four CD 0
patients NNS 0
entered VBD 0
the DT 0
LTE NNP 0
( ( 0
n JJ 0
= $ 0
104 CD 0
MI NNP 0
; : 0
n CC 0
= $ 0
113 CD 0
LI NNP 0
; : 0
n CC 0
= $ 0
87 CD 0
CsA NNP 0
) ) 0
, , 0
and CC 0
260 CD 0
continued VBD 0
treatment NN 0
through IN 0
year NN 0
5 CD 0
( ( 0
n JJ 0
= $ 0
91 CD 0
MI NNP 0
; : 0
n CC 0
= $ 0
100 CD 0
LI NNP 0
; : 0
n CC 0
= $ 0
69 CD 0
CsA NNP 0
) ) 0
. . 0

Twenty CD 0
patients NNS 0
died VBD 0
during IN 0
the DT 0
LTE NNP 0
( ( 0
n JJ 0
= $ 0
5 CD 0
MI NNP 0
; : 0
n CC 0
= $ 0
9 CD 0
LI NNP 0
; : 0
n CC 0
= $ 0
6 CD 0
CsA NNP 0
) ) 0
, , 0
and CC 0
eight CD 0
experienced VBD 0
graft NN 0
loss NN 0
( ( 0
n JJ 0
= $ 0
2 CD 0
MI NNP 0
; : 0
n CC 0
= $ 0
1 CD 0
LI NNP 0
; : 0
n CC 0
= $ 0
5 CD 0
CsA NNP 0
) ) 0
. . 0

Three CD 0
patients NNS 0
experienced VBD 0
an DT 0
acute JJ 0
rejection NN 0
episode NN 0
( ( 0
n JJ 0
= $ 0
2 CD 0
MI NNP 0
; : 0
n CC 0
= $ 0
1 CD 0
LI NNP 0
) ) 0
. . 0

The DT 0
incidence NN 0
rate NN 0
of IN 0
serious JJ 0
adverse JJ 0
events NNS 0
, , 0
viral JJ 0
infections NNS 0
and CC 0
fungal JJ 0
infections NNS 0
was VBD 0
similar JJ 0
across IN 0
groups NNS 0
during IN 0
the DT 0
LTE NNP 0
. . 0

There EX 0
were VBD 0
four CD 0
cases NNS 0
of IN 0
posttransplant JJ 0
lymphoproliferative JJ 0
disorder NN 0
( ( 0
PTLD NNP 0
) ) 0
from IN 0
the DT 0
beginning NN 0
of IN 0
the DT 0
LTE NNP 0
to TO 0
year NN 0
5 CD 0
( ( 0
n JJ 0
= $ 0
3 CD 0
LI NNP 0
; : 0
n CC 0
= $ 0
1 CD 0
CsA NNP 0
) ) 0
; : 0
two CD 0
of IN 0
three CD 0
PTLD NNP 0
cases NNS 0
in IN 0
the DT 0
LI NNP 0
group NN 0
were VBD 0
in IN 0
patients NNS 0
who WP 0
were VBD 0
seronegative JJ 0
for IN 0
Epstein-Barr NNP 0
virus NN 0
( ( 0
EBV NNP 0
( ( 0
- : 0
) ) 0
) ) 0
at IN 0
transplantation NN 0
. . 0

Mean NNP 0
? . 0
SD NNP 0
calculated VBD 0
GFR NNP 0
at IN 0
year NN 0
5 CD 0
was VBD 0
55.9 CD 0
? . 0
17.5 CD 0
( ( 0
MI NNP 0
) ) 0
, , 0
59.0 CD 0
? . 0
29.1 CD 0
( ( 0
LI NNP 0
) ) 0
and CC 0
44.6 CD 0
? . 0
16.4 CD 0
( ( 0
CsA NNP 0
) ) 0
mL/min/1.73 NN 0
m NN 0
( ( 0
2 CD 0
) ) 0
. . 0

Continued VBN 0
treatment NN 0
with IN 0
belatacept NN 0
was VBD 0
associated VBN 0
with IN 0
a DT 0
consistent JJ 0
safety NN 0
profile NN 0
and CC 0
sustained VBD 0
improvement NN 0
in IN 0
renal JJ 0
function NN 0
versus NN 0
CsA NNP 0
over IN 0
time NN 0
. . 0

Clofarabine NNP 0
? . 0
fludarabine NN 0
with IN 0
once RB 0
daily JJ 0
i.v NN 0
. . 0

busulfan NN 0
as IN 0
pretransplant JJ 0
conditioning NN 0
therapy NN 0
for IN 0
advanced JJ 0
myeloid NN 0
leukemia NN 0
and CC 0
MDS NNP 0
. . 0

Although IN 0
a DT 0
combination NN 0
of IN 0
i.v NN 0
. . 0

busulfan NN 0
( ( 0
Bu NNP 0
) ) 0
and CC 0
fludarabine NN 0
( ( 0
Flu NNP 0
) ) 0
is VBZ 0
a DT 0
safe JJ 0
, , 0
reduced-toxicity JJ 0
conditioning NN 0
program NN 0
for IN 0
acute JJ 0
myelogenous JJ 0
leukemia/myelodysplastic JJ 0
syndromes NNS 0
( ( 0
AML/MDS NNP 0
) ) 0
, , 0
recurrent JJ 0
leukemia NN 0
posttransplantation NN 0
remains VBZ 0
a DT 0
problem NN 0
. . 0

To TO 0
enhance VB 0
the DT 0
conditioning NN 0
regimen NN 0
's POS 0
antileukemic JJ 0
effect NN 0
, , 0
we PRP 0
decided VBD 0
to TO 0
supplant VB 0
Flu NNP 0
with IN 0
clofarabine NN 0
( ( 0
Clo NNP 0
) ) 0
, , 0
and CC 0
assayed VBD 0
the DT 0
interactions NNS 0
of IN 0
these DT 0
nucleoside JJ 0
analogs NNS 0
alone RB 0
and CC 0
in IN 0
combination NN 0
with IN 0
Bu NNP 0
in IN 0
Bu-resistant NNP 0
human NN 0
cell NN 0
lines NNS 0
in IN 0
vitro NN 0
. . 0

We PRP 0
found VBD 0
pronounced VBD 0
synergy NN 0
between IN 0
each DT 0
nucleoside NN 0
and CC 0
the DT 0
alkylator NN 0
but CC 0
even RB 0
more RBR 0
enhanced JJ 0
cytotoxic NN 0
synergy NN 0
when WRB 0
the DT 0
nucleoside JJ 0
analogs NNS 0
were VBD 0
combined VBN 0
prior RB 0
to TO 0
exposing VBG 0
the DT 0
cells NNS 0
to TO 0
Bu NNP 0
. . 0

We PRP 0
then RB 0
designed VBD 0
a DT 0
4-arm JJ 0
clinical JJ 0
trial NN 0
in IN 0
patients NNS 0
with IN 0
myeloid JJ 0
leukemia NN 0
undergoing VBG 0
allogeneic JJ 0
stem NN 0
cell NN 0
transplantation NN 0
( ( 0
allo-SCT JJ 0
) ) 0
. . 0

Patients NNS 0
were VBD 0
adaptively RB 0
randomized VBN 0
as IN 0
follows VBZ 0
: : 0
Arm JJ 0
I-Clo NN 0
: : 0
Flu CD 0
10:30 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
, , 0
Arm NNP 0
II-20:20 NNP 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
, , 0
Arm NNP 0
III-30:10 NNP 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
, , 0
and CC 0
Arm NNP 0
IV-single-agent NNP 0
Clo NNP 0
at IN 0
40 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
. . 0

The DT 0
nucleoside JJ 0
analog NN 0
( ( 0
s PRP 0
) ) 0
were/was NN 0
infused VBN 0
over IN 0
1 CD 0
hour NN 0
once RB 0
daily JJ 0
for IN 0
4 CD 0
days NNS 0
, , 0
followed VBD 0
on IN 0
each DT 0
day NN 0
by IN 0
Bu NNP 0
, , 0
infused VBD 0
over IN 0
3 CD 0
hours NNS 0
to TO 0
a DT 0
pharmacokinetically RB 0
targeted VBN 0
daily JJ 0
area NN 0
under IN 0
the DT 0
curve NN 0
( ( 0
AUC NNP 0
) ) 0
of IN 0
6000 CD 0
?Mol-min NN 0
? . 0
10 CD 0
% NN 0
. . 0

Fifty-one CD 0
patients NNS 0
have VBP 0
been VBN 0
enrolled VBN 0
with IN 0
a DT 0
minimum JJ 0
follow-up JJ 0
exceeding VBG 0
100 CD 0
days NNS 0
. . 0

There EX 0
were VBD 0
32 CD 0
males NNS 0
and CC 0
19 CD 0
females NNS 0
, , 0
with IN 0
a DT 0
median JJ 0
age NN 0
of IN 0
45 CD 0
years NNS 0
( ( 0
range NN 0
: : 0
6-59 JJ 0
) ) 0
. . 0

Nine JJ 0
patients NNS 0
had VBD 0
chronic JJ 0
myeloid NN 0
leukemia NN 0
( ( 0
CML NNP 0
) ) 0
( ( 0
BC NNP 0
: : 0
2 CD 0
, , 0
second JJ 0
AP NNP 0
: : 0
3 CD 0
, , 0
and CC 0
tyrosine-kinase JJ 0
inhibitor NN 0
refractory NN 0
first RB 0
chronic JJ 0
phase NN 0
[ NNP 0
CP NNP 0
] NN 0
: : 0
4 CD 0
) ) 0
. . 0

Forty-two JJ 0
patients NNS 0
had VBD 0
AML NNP 0
: : 0
14 CD 0
were VBD 0
induction NN 0
failures NNS 0
, , 0
8 CD 0
in IN 0
first JJ 0
chemotherapy-refractory JJ 0
relapse NN 0
, , 0
7 CD 0
in IN 0
untreated JJ 0
relapse NN 0
, , 0
3 CD 0
in IN 0
second JJ 0
or CC 0
subsequent JJ 0
relapse NN 0
, , 0
4 CD 0
were VBD 0
in IN 0
second JJ 0
complete JJ 0
remission NN 0
( ( 0
CR NNP 0
) ) 0
, , 0
and CC 0
3 CD 0
in IN 0
second JJ 0
CR NNP 0
without IN 0
platelet NN 0
recovery NN 0
( ( 0
CRp NNP 0
) ) 0
, , 0
2 CD 0
were VBD 0
in IN 0
high-risk JJ 0
CR1 NNP 0
. . 0

Finally NNP 0
, , 0
1 CD 0
patient NN 0
was VBD 0
in IN 0
first JJ 0
CRp NNP 0
. . 0

Graft-versus-host NNP 0
disease NN 0
( ( 0
GVHD NNP 0
) ) 0
prophylaxis NN 0
was VBD 0
tacrolimus JJ 0
and CC 0
mini-methorexate JJ 0
( ( 0
MTX NNP 0
) ) 0
, , 0
and CC 0
those DT 0
who WP 0
had VBD 0
an DT 0
unrelated JJ 0
or CC 0
1 CD 0
antigen-mismatched JJ 0
donor NN 0
received VBD 0
low-dose JJ 0
rabbit-ATG NN 0
( ( 0
Thymoglobulin? NNP 0
) ) 0
. . 0

All DT 0
patients NNS 0
engrafted VBN 0
. . 0

Forty-one CD 0
patients NNS 0
had VBD 0
active JJ 0
leukemia NN 0
at IN 0
the DT 0
time NN 0
of IN 0
transplant NN 0
, , 0
and CC 0
35 CD 0
achieved VBN 0
CR NNP 0
( ( 0
85 CD 0
% NN 0
) ) 0
. . 0

Twenty CD 0
of IN 0
the DT 0
42 CD 0
AML NNP 0
patients NNS 0
and CC 0
5 CD 0
of IN 0
9 CD 0
CML NNP 0
patients NNS 0
are VBP 0
alive JJ 0
with IN 0
a DT 0
projected JJ 0
median JJ 0
overall JJ 0
survival NN 0
( ( 0
OS NNP 0
) ) 0
of IN 0
23 CD 0
months NNS 0
. . 0

Marrow NNP 0
and CC 0
blood NN 0
( ( 0
T NNP 0
cell NN 0
) ) 0
chimerism NN 0
studies NNS 0
at IN 0
day NN 0
+100 NNP 0
revealed VBD 0
that IN 0
both DT 0
in IN 0
the DT 0
lower-dose JJ 0
Clo NNP 0
groups NNS 0
( ( 0
groups NNS 0
1+2 CD 0
) ) 0
and CC 0
the DT 0
higher-dose JJ 0
Clo NNP 0
groups NNS 0
( ( 0
groups NNS 0
3+4 CD 0
) ) 0
, , 0
the DT 0
patients NNS 0
had VBD 0
a DT 0
median NN 0
of IN 0
100 CD 0
% NN 0
donor NN 0
( ( 0
T NNP 0
cell NN 0
) ) 0
-derived VBD 0
DNA NNP 0
. . 0

There EX 0
has VBZ 0
been VBN 0
no DT 0
secondary JJ 0
graft NN 0
failure NN 0
. . 0

In IN 0
the DT 0
first JJ 0
100 CD 0
days NNS 0
, , 0
1 CD 0
patient NN 0
died VBD 0
of IN 0
pneumonia NN 0
, , 0
and CC 0
1 CD 0
of IN 0
liver NN 0
GVHD NNP 0
. . 0

We PRP 0
conclude VBP 0
that IN 0
( ( 0
1 CD 0
) ) 0
Clo NNP 0
? . 0
Flu NNP 0
with IN 0
i.v NN 0
. . 0

Bu NNP 0
as IN 0
pretransplant JJ 0
conditioning NN 0
is VBZ 0
safe JJ 0
in IN 0
high-risk JJ 0
myeloid JJ 0
leukemia NN 0
patients NNS 0
; : 0
( ( 0
2 CD 0
) ) 0
clofarabine NN 0
is VBZ 0
sufficiently RB 0
immunosuppressive JJ 0
to TO 0
support VB 0
allo-SCT NN 0
in IN 0
myeloid JJ 0
leukemia NN 0
; : 0
and CC 0
( ( 0
3 CD 0
) ) 0
the DT 0
median JJ 0
OS NNP 0
of IN 0
23 CD 0
months NNS 0
in IN 0
this DT 0
high-risk JJ 0
patient NN 0
population NN 0
is VBZ 0
encouraging VBG 0
. . 0

Additional JJ 0
studies NNS 0
to TO 0
evaluate VB 0
the DT 0
antileukemic JJ 0
efficacy NN 0
of IN 0
Clo NNP 0
? . 0
Flu NNP 0
with IN 0
i.v NN 0
. . 0

Bu NNP 0
as IN 0
pretransplant JJ 0
conditioning NN 0
therapy NN 0
are VBP 0
warranted VBN 0
. . 0

Secretin NNP 0
and CC 0
sleep NN 0
in IN 0
children NNS 0
with IN 0
autism NN 0
. . 0

The DT 0
objectives NNS 0
of IN 0
this DT 0
pilot NN 0
study NN 0
were VBD 0
1 CD 0
) ) 0
to TO 0
examine VB 0
possible JJ 0
effects NNS 0
of IN 0
secretin JJ 0
infusions NNS 0
on IN 0
sleep-wake JJ 0
state NN 0
organization NN 0
in IN 0
children NNS 0
with IN 0
autism NN 0
, , 0
and CC 0
2 CD 0
) ) 0
to TO 0
assess VB 0
the DT 0
feasibility NN 0
of IN 0
home NN 0
recordings NNS 0
using VBG 0
time-lapse JJ 0
videosomnography NN 0
in IN 0
children NNS 0
with IN 0
autism NN 0
. . 0

Participants NNS 0
were VBD 0
a DT 0
subset NN 0
of IN 0
subjects NNS 0
from IN 0
two CD 0
double JJ 0
blind NN 0
, , 0
placebo-control NN 0
, , 0
multi-center JJ 0
clinical JJ 0
trials NNS 0
. . 0

One CD 0
trial NN 0
, , 0
the DT 0
UC NNP 0
Irvine NNP 0
study NN 0
, , 0
assessed VBD 0
the DT 0
effects NNS 0
of IN 0
porcine NN 0
secretin NN 0
vs. FW 0
saline NN 0
infusions NNS 0
on IN 0
children NNS 0
's POS 0
behavior NN 0
, , 0
language NN 0
and CC 0
IQ NNP 0
. . 0

The DT 0
UC NNP 0
Davis NNP 0
trial NN 0
assessed VBD 0
the DT 0
effects NNS 0
of IN 0
synthetic JJ 0
human JJ 0
secretin NN 0
vs. FW 0
saline NN 0
infusions NNS 0
on IN 0
behavior NN 0
, , 0
language NN 0
and CC 0
gastrointestinal JJ 0
function NN 0
. . 0

The DT 0
sleep NN 0
study NN 0
enrolled VBD 0
some DT 0
of IN 0
the DT 0
children NNS 0
from IN 0
each DT 0
of IN 0
the DT 0
two CD 0
trials NNS 0
to TO 0
observe VB 0
possible JJ 0
secretin JJ 0
effects NNS 0
on IN 0
sleep NN 0
. . 0

To TO 0
examine VB 0
sleep NN 0
, , 0
the DT 0
UC NNP 0
Irvine NNP 0
trial NN 0
used VBD 0
the DT 0
Children NNP 0
's POS 0
Sleep NNP 0
Habits NNP 0
Questionnaire NNP 0
and CC 0
daily JJ 0
sleep NN 0
diaries NNS 0
, , 0
whereas IN 0
the DT 0
UC NNP 0
Davis NNP 0
study NN 0
used VBD 0
home-recorded JJ 0
time-lapse JJ 0
videosomnography NN 0
. . 0

Because IN 0
of IN 0
the DT 0
small JJ 0
sample NN 0
size NN 0
, , 0
the DT 0
results NNS 0
from IN 0
both DT 0
trials NNS 0
are VBP 0
preliminary JJ 0
. . 0

They PRP 0
suggest VBP 0
that IN 0
secretin NN 0
, , 0
porcine NN 0
or CC 0
synthetic JJ 0
, , 0
does VBZ 0
not RB 0
improve VB 0
sleep-wake NN 0
state NN 0
organization NN 0
dramatically RB 0
. . 0

Endometrial JJ 0
cytodiagnosis NN 0
using VBG 0
a DT 0
new JJ 0
softcyte NN 0
versus NN 0
a DT 0
conventional JJ 0
endocyte NN 0
. . 0

A DT 0
new JJ 0
endometrial JJ 0
cytologic NN 0
sampling VBG 0
device NN 0
, , 0
softcyte NN 0
, , 0
was VBD 0
used VBN 0
in IN 0
cytological JJ 0
screening NN 0
for IN 0
endometrial JJ 0
cancer NN 0
, , 0
and CC 0
was VBD 0
compared VBN 0
with IN 0
the DT 0
endocyte NN 0
with IN 0
regard NN 0
to TO 0
manipulability NN 0
, , 0
adverse JJ 0
effects NNS 0
( ( 0
including VBG 0
pain NN 0
and CC 0
hemorrhage NN 0
) ) 0
, , 0
and CC 0
cellular JJ 0
findings NNS 0
( ( 0
including VBG 0
the DT 0
quantity NN 0
of IN 0
cells NNS 0
collected VBN 0
, , 0
the DT 0
success NN 0
rate NN 0
, , 0
cell NN 0
freshness NN 0
, , 0
and CC 0
cellular JJ 0
clumping NN 0
) ) 0
. . 0

A DT 0
total NN 0
of IN 0
315 CD 0
women NNS 0
( ( 0
premenopause IN 0
251 CD 0
, , 0
postmenopause RB 0
64 CD 0
) ) 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
two CD 0
groups NNS 0
who WP 0
underwent VBP 0
the DT 0
endometrial JJ 0
cytological JJ 0
screening NN 0
with IN 0
either CC 0
the DT 0
softcyte NN 0
or CC 0
the DT 0
endocyte NN 0
. . 0

To TO 0
assess VB 0
the DT 0
value NN 0
of IN 0
the DT 0
softcyte NN 0
we PRP 0
compared VBN 0
it PRP 0
with IN 0
the DT 0
endocyte NN 0
. . 0

Endometrial NNP 0
cytology NN 0
using VBG 0
a DT 0
softcyte NN 0
or CC 0
an DT 0
endocyte NN 0
achieved VBN 0
high JJ 0
correct JJ 0
diagnosis NN 0
rate NN 0
for IN 0
cancer NN 0
, , 0
and CC 0
both DT 0
instruments NNS 0
are VBP 0
valuable JJ 0
as IN 0
endometrial JJ 0
cytologic NN 0
sample NN 0
devices NNS 0
. . 0

The DT 0
softcyte NN 0
causes VBZ 0
only RB 0
mild JJ 0
pain NN 0
on IN 0
introduction NN 0
and CC 0
during IN 0
collection NN 0
, , 0
and CC 0
a DT 0
large JJ 0
quantity NN 0
of IN 0
cells NNS 0
could MD 0
be VB 0
harvested VBN 0
. . 0

These DT 0
results NNS 0
suggest VBP 0
that IN 0
the DT 0
softcyte NN 0
is VBZ 0
a DT 0
useful JJ 0
cytologic NN 0
sampling VBG 0
device NN 0
in IN 0
screening VBG 0
for IN 0
endometrial JJ 0
cancer NN 0
. . 0

Anxiety NN 0
sensitivity NN 0
as IN 0
an DT 0
incremental JJ 0
predictor NN 0
of IN 0
later JJ 0
anxiety NN 0
symptoms NNS 0
and CC 0
syndromes NNS 0
. . 0

Although IN 0
anxiety NN 0
sensitivity NN 0
( ( 0
AS NNP 0
) ) 0
has VBZ 0
been VBN 0
shown VBN 0
to TO 0
predict VB 0
anxiety NN 0
symptoms NNS 0
and CC 0
panic NN 0
, , 0
this DT 0
literature NN 0
is VBZ 0
limited VBN 0
in IN 0
regard NN 0
to TO 0
evaluating VBG 0
AS NNP 0
as IN 0
an DT 0
incremental JJ 0
predictor NN 0
of IN 0
anxiety NN 0
psychopathology NN 0
relative VBP 0
to TO 0
other JJ 0
established VBN 0
risk NN 0
factors NNS 0
including VBG 0
sex NN 0
and CC 0
negative JJ 0
affect NN 0
. . 0

The DT 0
present JJ 0
report NN 0
prospectively RB 0
evaluated VBD 0
whether IN 0
AS NNP 0
was VBD 0
predictive NN 0
of IN 0
later JJ 0
changes NNS 0
in IN 0
anxiety NN 0
symptoms NNS 0
after IN 0
controlling VBG 0
for IN 0
potential JJ 0
confounding NN 0
factors NNS 0
. . 0

Consistent JJ 0
with IN 0
hypothesis NN 0
, , 0
AS NNP 0
was VBD 0
found VBN 0
to TO 0
be VB 0
a DT 0
significant JJ 0
, , 0
incremental JJ 0
predictor NN 0
of IN 0
anxiety NN 0
symptoms NNS 0
over IN 0
time NN 0
, , 0
even RB 0
after IN 0
controlling VBG 0
for IN 0
sex NN 0
and CC 0
negative JJ 0
affectivity NN 0
. . 0

These DT 0
data NNS 0
provide VBP 0
novel JJ 0
evidence NN 0
for IN 0
the DT 0
unique JJ 0
association NN 0
between IN 0
AS NNP 0
of IN 0
the DT 0
development NN 0
of IN 0
anxiety NN 0
symptoms NNS 0
. . 0

Nutritional JJ 0
orientation NN 0
, , 0
knowledge NN 0
and CC 0
quality NN 0
of IN 0
diet NN 0
in IN 0
heart NN 0
failure NN 0
: : 0
randomized JJ 0
clinical JJ 0
trial NN 0
. . 0

BACKGROUND NNP 0
Non-pharmacological JJ 0
measures NNS 0
are VBP 0
recommended VBN 0
for IN 0
heart NN 0
failure NN 0
patients NNS 0
. . 0

However RB 0
, , 0
most JJS 0
studies NNS 0
evaluate VBP 0
low JJ 0
sodium NN 0
diet NN 0
, , 0
while IN 0
little JJ 0
is VBZ 0
known VBN 0
about IN 0
the DT 0
effects NNS 0
of IN 0
interventions NNS 0
to TO 0
improve VB 0
adherence NN 0
and CC 0
knowledge NN 0
of IN 0
patients NNS 0
about IN 0
diet JJ 0
content NN 0
. . 0

OBJECTIVE UH 0
To TO 0
evaluate VB 0
if IN 0
a DT 0
global JJ 0
nutritional JJ 0
orientation NN 0
could MD 0
affect VB 0
nutritional JJ 0
knowledge NN 0
, , 0
adherence NN 0
to TO 0
food NN 0
guidelines NNS 0
, , 0
anthropometrics NNS 0
and CC 0
quality NN 0
of IN 0
life NN 0
in IN 0
heart NN 0
failure NN 0
patients NNS 0
. . 0

METHODS NNP 0
Forty NNP 0
six CD 0
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
intervention VB 0
or CC 0
control VB 0
group NN 0
. . 0

Both DT 0
groups NNS 0
received VBD 0
usual JJ 0
care NN 0
with IN 0
medical JJ 0
and CC 0
nursing JJ 0
staff NN 0
; : 0
the DT 0
intervention NN 0
group NN 0
received VBD 0
additional JJ 0
nutritional JJ 0
guidance NN 0
about IN 0
diet JJ 0
and CC 0
its PRP$ 0
relationship NN 0
with IN 0
disease NN 0
, , 0
sources NNS 0
of IN 0
nutrients NNS 0
, , 0
and CC 0
reduction NN 0
of IN 0
dietary JJ 0
sodium NN 0
and CC 0
fats NNS 0
. . 0

Enforcement NN 0
of IN 0
the DT 0
nutritional JJ 0
guidance NN 0
was VBD 0
performed VBN 0
after IN 0
4 CD 0
weeks NNS 0
. . 0

Both DT 0
groups NNS 0
were VBD 0
evaluated VBN 0
at IN 0
baseline NN 0
, , 0
and CC 0
after IN 0
6 CD 0
weeks NNS 0
and CC 0
6 CD 0
months NNS 0
. . 0

Evaluations NNS 0
included VBD 0
anthropometric JJ 0
parameters NNS 0
, , 0
sodium NN 0
excretion NN 0
in IN 0
24-hour JJ 0
urine NN 0
, , 0
dietary JJ 0
recall NN 0
, , 0
nutrition NN 0
knowledge NN 0
and CC 0
quality NN 0
of IN 0
life NN 0
questionnaires NNS 0
. . 0

RESULTS NNP 0
Mean NNP 0
age NN 0
of IN 0
included JJ 0
patients NNS 0
was VBD 0
58 CD 0
? . 0
10 CD 0
years NNS 0
and CC 0
70 CD 0
% NN 0
were VBD 0
male JJ 0
. . 0

After IN 0
6 CD 0
months NNS 0
of IN 0
follow-up NN 0
, , 0
the DT 0
nutritional JJ 0
knowledge NN 0
of IN 0
intervention NN 0
group NN 0
increased VBD 0
compared VBN 0
to TO 0
control VB 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

Caloric NNP 0
, , 0
fat NN 0
and CC 0
sodium NN 0
intake NN 0
decreased VBN 0
in IN 0
the DT 0
intervention NN 0
group NN 0
compared VBN 0
to TO 0
control VB 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

No DT 0
significant JJ 0
differences NNS 0
were VBD 0
seen VBN 0
in IN 0
quality NN 0
of IN 0
life NN 0
or CC 0
anthropometric JJ 0
parameters NNS 0
. . 0

CONCLUSIONS NNP 0
Nutritional NNP 0
orientation NN 0
was VBD 0
effective JJ 0
to TO 0
modify VB 0
1 CD 0
) ) 0
knowledge NN 0
about IN 0
food NN 0
and CC 0
nutrition NN 0
, , 0
and CC 0
2 CD 0
) ) 0
quality NN 0
of IN 0
diet NN 0
in IN 0
outpatients NNS 0
with IN 0
heart NN 0
failure NN 0
. . 0

Further JJ 0
studies NNS 0
are VBP 0
necessary JJ 0
to TO 0
evaluate VB 0
the DT 0
benefits NNS 0
on IN 0
quality NN 0
of IN 0
life NN 0
and CC 0
prognosis NN 0
. . 0

Effect NN 0
of IN 0
a DT 0
vitamin/mineral JJ 0
supplement NN 0
on IN 0
children NNS 0
and CC 0
adults NNS 0
with IN 0
autism NN 0
. . 0

BACKGROUND NNP 0
Vitamin/mineral NNP 0
supplements NNS 0
are VBP 0
among IN 0
the DT 0
most RBS 0
commonly RB 0
used JJ 0
treatments NNS 0
for IN 0
autism NN 0
, , 0
but CC 0
the DT 0
research NN 0
on IN 0
their PRP$ 0
use NN 0
for IN 0
treating VBG 0
autism NN 0
has VBZ 0
been VBN 0
limited VBN 0
. . 0

METHOD NNP 0
This DT 0
study NN 0
is VBZ 0
a DT 0
randomized JJ 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
three CD 0
month NN 0
vitamin/mineral JJ 0
treatment NN 0
study NN 0
. . 0

The DT 0
study NN 0
involved VBD 0
141 CD 0
children NNS 0
and CC 0
adults NNS 0
with IN 0
autism NN 0
, , 0
and CC 0
pre NN 0
and CC 0
post NN 0
symptoms NNS 0
of IN 0
autism NN 0
were VBD 0
assessed VBN 0
. . 0

None NN 0
of IN 0
the DT 0
participants NNS 0
had VBD 0
taken VBN 0
a DT 0
vitamin/mineral JJ 0
supplement NN 0
in IN 0
the DT 0
two CD 0
months NNS 0
prior RB 0
to TO 0
the DT 0
start NN 0
of IN 0
the DT 0
study NN 0
. . 0

For IN 0
a DT 0
subset NN 0
of IN 0
the DT 0
participants NNS 0
( ( 0
53 CD 0
children NNS 0
ages VBZ 0
5-16 JJ 0
) ) 0
pre NN 0
and CC 0
post NN 0
measurements NNS 0
of IN 0
nutritional JJ 0
and CC 0
metabolic JJ 0
status NN 0
were VBD 0
also RB 0
conducted VBN 0
. . 0

RESULTS VB 0
The DT 0
vitamin/mineral JJ 0
supplement NN 0
was VBD 0
generally RB 0
well-tolerated JJ 0
, , 0
and CC 0
individually RB 0
titrated VBN 0
to TO 0
optimum JJ 0
benefit NN 0
. . 0

Levels NNP 0
of IN 0
many JJ 0
vitamins NNS 0
, , 0
minerals NNS 0
, , 0
and CC 0
biomarkers NNS 0
improved/increased VBD 0
showing VBG 0
good JJ 0
compliance NN 0
and CC 0
absorption NN 0
. . 0

Statistically NNP 0
significant JJ 0
improvements NNS 0
in IN 0
metabolic JJ 0
status NN 0
were VBD 0
many JJ 0
including VBG 0
: : 0
total JJ 0
sulfate NN 0
( ( 0
+17 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.001 CD 0
) ) 0
, , 0
S-adenosylmethionine NNP 0
( ( 0
SAM NNP 0
; : 0
+6 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.003 CD 0
) ) 0
, , 0
reduced VBD 0
glutathione NN 0
( ( 0
+17 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.0008 CD 0
) ) 0
, , 0
ratio NN 0
of IN 0
oxidized JJ 0
glutathione NN 0
to TO 0
reduced VB 0
glutathione NN 0
( ( 0
GSSG NNP 0
: : 0
GSH NNP 0
; : 0
-27 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.002 CD 0
) ) 0
, , 0
nitrotyrosine JJ 0
( ( 0
-29 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.004 CD 0
) ) 0
, , 0
ATP NNP 0
( ( 0
+25 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.000001 CD 0
) ) 0
, , 0
NADH NNP 0
( ( 0
+28 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.0002 CD 0
) ) 0
, , 0
and CC 0
NADPH NNP 0
( ( 0
+30 CD 0
% NN 0
, , 0
p NN 0
= NNP 0
0.001 CD 0
) ) 0
. . 0

Most JJS 0
of IN 0
these DT 0
metabolic JJ 0
biomarkers NNS 0
improved VBN 0
to TO 0
normal JJ 0
or CC 0
near-normal JJ 0
levels.The JJ 0
supplement NN 0
group NN 0
had VBD 0
significantly RB 0
greater JJR 0
improvements NNS 0
than IN 0
the DT 0
placebo NN 0
group NN 0
on IN 0
the DT 0
Parental NNP 0
Global NNP 0
Impressions-Revised JJ 0
( ( 0
PGI-R NNP 0
, , 0
Average NNP 0
Change NNP 0
, , 0
p NN 0
= NNP 0
0.008 CD 0
) ) 0
, , 0
and CC 0
on IN 0
the DT 0
subscores NNS 0
for IN 0
Hyperactivity NNP 0
( ( 0
p JJ 0
= NNP 0
0.003 CD 0
) ) 0
, , 0
Tantrumming NNP 0
( ( 0
p JJ 0
= NNP 0
0.009 CD 0
) ) 0
, , 0
Overall NNP 0
( ( 0
p NN 0
= RB 0
0.02 CD 0
) ) 0
, , 0
and CC 0
Receptive JJ 0
Language NNP 0
( ( 0
p JJ 0
= NNP 0
0.03 CD 0
) ) 0
. . 0

For IN 0
the DT 0
other JJ 0
three CD 0
assessment NN 0
tools VBZ 0
the DT 0
difference NN 0
between IN 0
treatment NN 0
group NN 0
and CC 0
placebo NN 0
group NN 0
was VBD 0
not RB 0
statistically RB 0
significant.Regression JJ 0
analysis NN 0
revealed VBD 0
that IN 0
the DT 0
degree NN 0
of IN 0
improvement NN 0
on IN 0
the DT 0
Average JJ 0
Change NN 0
of IN 0
the DT 0
PGI-R NNP 0
was VBD 0
strongly RB 0
associated VBN 0
with IN 0
several JJ 0
biomarkers NNS 0
( ( 0
adj NN 0
. . 0

R2 NNP 0
= VBD 0
0.61 CD 0
, , 0
p NN 0
< NNP 0
0.0005 CD 0
) ) 0
with IN 0
the DT 0
initial JJ 0
levels NNS 0
of IN 0
biotin NN 0
and CC 0
vitamin NN 0
K NNP 0
being VBG 0
the DT 0
most RBS 0
significant JJ 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
; : 0
both DT 0
biotin NN 0
and CC 0
vitamin NN 0
K NNP 0
are VBP 0
made VBN 0
by IN 0
beneficial JJ 0
intestinal JJ 0
flora NN 0
. . 0

CONCLUSIONS NNP 0
Oral NNP 0
vitamin/mineral JJ 0
supplementation NN 0
is VBZ 0
beneficial JJ 0
in IN 0
improving VBG 0
the DT 0
nutritional JJ 0
and CC 0
metabolic JJ 0
status NN 0
of IN 0
children NNS 0
with IN 0
autism NN 0
, , 0
including VBG 0
improvements NNS 0
in IN 0
methylation NN 0
, , 0
glutathione NN 0
, , 0
oxidative JJ 0
stress NN 0
, , 0
sulfation NN 0
, , 0
ATP NNP 0
, , 0
NADH NNP 0
, , 0
and CC 0
NADPH NNP 0
. . 0

The DT 0
supplement NN 0
group NN 0
had VBD 0
significantly RB 0
greater JJR 0
improvements NNS 0
than IN 0
did VBD 0
the DT 0
placebo NN 0
group NN 0
on IN 0
the DT 0
PGI-R JJ 0
Average JJ 0
Change NN 0
. . 0

This DT 0
suggests VBZ 0
that IN 0
a DT 0
vitamin/mineral JJ 0
supplement NN 0
is VBZ 0
a DT 0
reasonable JJ 0
adjunct JJ 0
therapy NN 0
to TO 0
consider VB 0
for IN 0
most JJS 0
children NNS 0
and CC 0
adults NNS 0
with IN 0
autism NN 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
CLINICAL NNP 0
TRIAL NNP 0
REGISTRATION NNP 0
NUMBER NNP 0
NCT01225198 NNP 0
. . 0

Small NN 0
but CC 0
important JJ 0
errors NNS 0
in IN 0
cardiovascular JJ 0
risk NN 0
calculation NN 0
by IN 0
practice NN 0
nurses NNS 0
: : 0
a DT 0
cross-sectional JJ 0
study NN 0
in IN 0
randomised JJ 0
trial NN 0
setting NN 0
. . 0

BACKGROUND NNP 0
Practice NNP 0
nurses NNS 0
play VBP 0
an DT 0
increasingly RB 0
important JJ 0
role NN 0
in IN 0
the DT 0
prevention NN 0
of IN 0
cardiovascular JJ 0
diseases NNS 0
but CC 0
we PRP 0
do VBP 0
not RB 0
have VB 0
evidence NN 0
about IN 0
the DT 0
accuracy NN 0
of IN 0
their PRP$ 0
cardiovascular JJ 0
risk NN 0
assessments NNS 0
during IN 0
real JJ 0
practice NN 0
consultations NNS 0
. . 0

OBJECTIVES NNP 0
To TO 0
examine VB 0
how WRB 0
nurses NNS 0
perform VBP 0
with IN 0
regard NN 0
to TO 0
absolute VB 0
10-year JJ 0
cardiovascular JJ 0
risk NN 0
assessment NN 0
in IN 0
actual JJ 0
practice NN 0
. . 0

DESIGN NNP 0
Cross-sectional JJ 0
study NN 0
. . 0

SETTING NN 0
This DT 0
study NN 0
was VBD 0
nested VBN 0
in IN 0
the DT 0
IMPALA NNP 0
study NN 0
, , 0
a DT 0
clustered VBN 0
randomised VBN 0
controlled VBN 0
trial NN 0
involving VBG 0
24 CD 0
general JJ 0
practices NNS 0
in IN 0
The DT 0
Netherlands NNP 0
. . 0

PARTICIPANTS VB 0
24 CD 0
practice NN 0
nurses NNS 0
, , 0
trained VBN 0
in IN 0
10-year JJ 0
cardiovascular JJ 0
risk NN 0
assessment NN 0
, , 0
calculated VBD 0
the DT 0
risk NN 0
of IN 0
a DT 0
total NN 0
of IN 0
421 CD 0
patients NNS 0
without IN 0
established VBN 0
cardiovascular JJ 0
diseases NNS 0
but CC 0
eligible JJ 0
for IN 0
cardiovascular JJ 0
risk NN 0
assessment NN 0
. . 0

METHODS NNP 0
The DT 0
main JJ 0
outcome NN 0
measure NN 0
was VBD 0
the DT 0
accuracy NN 0
of IN 0
risk NN 0
assessments NNS 0
, , 0
defined VBN 0
as IN 0
( ( 0
1 CD 0
) ) 0
the DT 0
difference NN 0
between IN 0
the DT 0
10-year JJ 0
cardiovascular JJ 0
risk NN 0
percentage NN 0
calculated VBN 0
by IN 0
nurses NNS 0
and CC 0
an DT 0
independent JJ 0
assessor NN 0
, , 0
and CC 0
( ( 0
2 CD 0
) ) 0
the DT 0
agreement NN 0
between IN 0
the DT 0
treatment NN 0
categories NNS 0
assigned VBN 0
by IN 0
the DT 0
nurses NNS 0
( ( 0
low JJ 0
, , 0
moderate JJ 0
or CC 0
high JJ 0
risk NN 0
) ) 0
and CC 0
those DT 0
assigned VBN 0
by IN 0
the DT 0
independent JJ 0
assessor NN 0
. . 0

RESULTS VB 0
Thirty-one NNP 0
( ( 0
7.4 CD 0
% NN 0
) ) 0
of IN 0
the DT 0
calculated JJ 0
risk NN 0
percentages NNS 0
differed VBN 0
by IN 0
more JJR 0
than IN 0
our PRP$ 0
preset NN 0
limits NNS 0
, , 0
25 CD 0
( ( 0
81 CD 0
% NN 0
) ) 0
being VBG 0
underestimations NNS 0
. . 0

Elderly JJ 0
patients NNS 0
( ( 0
OR NNP 0
1.1 CD 0
, , 0
95 CD 0
% NN 0
CI NNP 0
1.0-1.1 CD 0
) ) 0
, , 0
male JJ 0
patients NNS 0
( ( 0
vs. FW 0
female NN 0
OR NNP 0
3.1 CD 0
, , 0
95 CD 0
% NN 0
CI NNP 0
1.2-7.3 CD 0
) ) 0
, , 0
and CC 0
smoking NN 0
patients NNS 0
( ( 0
vs. IN 0
non-smoking NN 0
OR NNP 0
3.8 CD 0
, , 0
95 CD 0
% NN 0
CI NNP 0
1.7-8.9 CD 0
) ) 0
were VBD 0
more RBR 0
likely JJ 0
to TO 0
have VB 0
their PRP$ 0
cardiovascular JJ 0
risk NN 0
miscalculated VBD 0
. . 0

Ten NNP 0
( ( 0
28 CD 0
% NN 0
) ) 0
of IN 0
the DT 0
36 CD 0
patients NNS 0
who WP 0
should MD 0
be VB 0
assigned VBN 0
to TO 0
the DT 0
high-risk JJ 0
treatment NN 0
category NN 0
according VBG 0
to TO 0
the DT 0
independent JJ 0
calculation NN 0
, , 0
were VBD 0
missed VBN 0
as IN 0
high-risk JJ 0
patients NNS 0
by IN 0
the DT 0
practice NN 0
nurses NNS 0
. . 0

CONCLUSIONS VB 0
The DT 0
overall JJ 0
standard NN 0
of IN 0
accuracy NN 0
of IN 0
cardiovascular JJ 0
risk NN 0
assessment NN 0
by IN 0
trained JJ 0
practice NN 0
nurses NNS 0
in IN 0
actual JJ 0
practice NN 0
is VBZ 0
high JJ 0
. . 0

However RB 0
, , 0
a DT 0
significant JJ 0
number NN 0
of IN 0
high-risk JJ 0
patients NNS 0
were VBD 0
misclassified VBN 0
, , 0
with IN 0
the DT 0
probability NN 0
that IN 0
it PRP 0
led VBD 0
to TO 0
missed VBN 0
opportunities NNS 0
for IN 0
risk-reducing JJ 0
interventions NNS 0
. . 0

As IN 0
cardiovascular JJ 0
risk NN 0
assessments NNS 0
are VBP 0
frequently RB 0
done VBN 0
by IN 0
nurses NNS 0
in IN 0
general JJ 0
practice NN 0
, , 0
further JJ 0
specific JJ 0
training NN 0
should MD 0
be VB 0
considered VBN 0
to TO 0
prevent VB 0
undertreatment NN 0
. . 0

Menopausal NNP 0
quality NN 0
of IN 0
life NN 0
: : 0
RCT NNP 0
of IN 0
yoga NN 0
, , 0
exercise NN 0
, , 0
and CC 0
omega-3 JJ 0
supplements NNS 0
. . 0

OBJECTIVE IN 0
The DT 0
purpose NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
determine VB 0
the DT 0
efficacy NN 0
of IN 0
3 CD 0
nonhormonal JJ 0
therapies NNS 0
for IN 0
the DT 0
improvement NN 0
of IN 0
menopause-related JJ 0
quality NN 0
of IN 0
life NN 0
in IN 0
women NNS 0
with IN 0
vasomotor NN 0
symptoms NNS 0
. . 0

STUDY NNP 0
DESIGN NNP 0
We PRP 0
conducted VBD 0
a DT 0
12-week JJ 0
3 CD 0
? . 0
2 CD 0
randomized VBD 0
, , 0
controlled VBD 0
, , 0
factorial JJ 0
design NN 0
trial NN 0
. . 0

Peri- NN 0
and CC 0
postmenopausal JJ 0
women NNS 0
, , 0
40-62 JJ 0
years NNS 0
old JJ 0
, , 0
were VBD 0
assigned VBN 0
randomly RB 0
to TO 0
yoga VB 0
( ( 0
n JJ 0
= NNP 0
107 CD 0
) ) 0
, , 0
exercise NN 0
( ( 0
n JJ 0
= NNP 0
106 CD 0
) ) 0
, , 0
or CC 0
usual JJ 0
activity NN 0
( ( 0
n JJ 0
= NNP 0
142 CD 0
) ) 0
and CC 0
also RB 0
assigned VBD 0
randomly RB 0
to TO 0
a DT 0
double-blind JJ 0
comparison NN 0
of IN 0
omega-3 JJ 0
( ( 0
n JJ 0
= NNP 0
177 CD 0
) ) 0
or CC 0
placebo NN 0
( ( 0
n JJ 0
= NNP 0
178 CD 0
) ) 0
capsules NNS 0
. . 0

We PRP 0
performed VBD 0
the DT 0
following JJ 0
interventions NNS 0
: : 0
( ( 0
1 CD 0
) ) 0
weekly JJ 0
90-minute CD 0
yoga NN 0
classes NNS 0
with IN 0
daily JJ 0
at-home JJ 0
practice NN 0
, , 0
( ( 0
2 CD 0
) ) 0
individualized VBN 0
facility-based JJ 0
aerobic JJ 0
exercise NN 0
training NN 0
3 CD 0
times/week NN 0
, , 0
and CC 0
( ( 0
3 CD 0
) ) 0
0.615 CD 0
g JJ 0
omega-3 JJ 0
supplement NN 0
, , 0
3 CD 0
times/day NN 0
. . 0

The DT 0
outcomes NNS 0
were VBD 0
assessed VBN 0
with IN 0
the DT 0
following JJ 0
scores NNS 0
: : 0
Menopausal NNP 0
Quality NNP 0
of IN 0
Life NNP 0
Questionnaire NNP 0
( ( 0
MENQOL NNP 0
) ) 0
total NN 0
and CC 0
domain NN 0
( ( 0
vasomotor NN 0
symptoms NNS 0
, , 0
psychosocial JJ 0
, , 0
physical JJ 0
and CC 0
sexual JJ 0
) ) 0
. . 0

RESULTS NNP 0
Among IN 0
355 CD 0
randomly NNS 0
assigned VBN 0
women NNS 0
who WP 0
average VBP 0
age NN 0
was VBD 0
54.7 CD 0
years NNS 0
, , 0
338 CD 0
women NNS 0
( ( 0
95 CD 0
% NN 0
) ) 0
completed VBD 0
12-week JJ 0
assessments NNS 0
. . 0

Mean NNP 0
baseline NN 0
vasomotor NN 0
symptoms JJ 0
frequency NN 0
was VBD 0
7.6/day CD 0
, , 0
and CC 0
the DT 0
mean JJ 0
baseline NN 0
total JJ 0
MENQOL NNP 0
score NN 0
was VBD 0
3.8 CD 0
( ( 0
range NN 0
, , 0
1-8 CD 0
from IN 0
better JJR 0
to TO 0
worse VB 0
) ) 0
with IN 0
no DT 0
between-group JJ 0
differences NNS 0
. . 0

For IN 0
yoga NN 0
compared VBN 0
to TO 0
usual JJ 0
activity NN 0
, , 0
baseline NN 0
to TO 0
12-week JJ 0
improvements NNS 0
were VBD 0
seen VBN 0
for IN 0
MENQOL NNP 0
total JJ 0
-0.3 NNP 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
, , 0
-0.6 VBP 0
to TO 0
0 CD 0
; : 0
P NNP 0
= NNP 0
.02 NNP 0
) ) 0
, , 0
vasomotor NN 0
symptom NN 0
domain NN 0
( ( 0
P NNP 0
= NNP 0
.02 NNP 0
) ) 0
, , 0
and CC 0
sexuality NN 0
domain NN 0
( ( 0
P NNP 0
= NNP 0
.03 NNP 0
) ) 0
scores VBZ 0
. . 0

For IN 0
women NNS 0
who WP 0
underwent VBP 0
exercise NN 0
and CC 0
omega-3 JJ 0
therapy NN 0
compared VBN 0
with IN 0
control NN 0
subjects NNS 0
, , 0
improvements NNS 0
in IN 0
baseline NN 0
to TO 0
12-week JJ 0
total JJ 0
MENQOL NNP 0
scores NNS 0
were VBD 0
not RB 0
observed VBN 0
. . 0

Exercise NN 0
showed VBD 0
benefit NN 0
in IN 0
the DT 0
MENQOL NNP 0
physical JJ 0
domain NN 0
score NN 0
at IN 0
12 CD 0
weeks NNS 0
( ( 0
P NNP 0
= NNP 0
.02 NNP 0
) ) 0
. . 0

CONCLUSION NNP 0
All NNP 0
women NNS 0
become VBP 0
menopausal JJ 0
, , 0
and CC 0
many JJ 0
of IN 0
them PRP 0
seek VBP 0
medical JJ 0
advice NN 0
on IN 0
ways NNS 0
to TO 0
improve VB 0
quality NN 0
of IN 0
life NN 0
; : 0
little JJ 0
evidence-based JJ 0
information NN 0
exists NNS 0
. . 0

We PRP 0
found VBD 0
that IN 0
, , 0
among IN 0
healthy JJ 0
sedentary JJ 0
menopausal NN 0
women NNS 0
, , 0
yoga NN 0
appears VBZ 0
to TO 0
improve VB 0
menopausal NN 0
quality NN 0
of IN 0
life NN 0
; : 0
the DT 0
clinical JJ 0
significance NN 0
of IN 0
our PRP$ 0
finding NN 0
is VBZ 0
uncertain JJ 0
because IN 0
of IN 0
the DT 0
modest JJ 0
effect NN 0
. . 0

Step-down JJ 0
approach NN 0
using VBG 0
either CC 0
cyclosporin VB 0
A DT 0
or CC 0
methotrexate NN 0
as IN 0
maintenance NN 0
therapy NN 0
in IN 0
early JJ 0
rheumatoid NN 0
arthritis NN 0
. . 0

OBJECTIVE UH 0
To TO 0
evaluate VB 0
the DT 0
feasibility NN 0
and CC 0
outcome NN 0
of IN 0
the DT 0
step-down JJ 0
approach NN 0
using VBG 0
either CC 0
cyclosporin VB 0
A NNP 0
( ( 0
CSA NNP 0
) ) 0
or CC 0
methotrexate NN 0
( ( 0
MTX NNP 0
) ) 0
as IN 0
maintenance NN 0
therapy NN 0
following VBG 0
6 CD 0
months NNS 0
treatment NN 0
with IN 0
these DT 0
2 CD 0
agents NNS 0
in IN 0
combination NN 0
in IN 0
early JJ 0
, , 0
nonerosive JJ 0
rheumatoid NN 0
arthritis NN 0
( ( 0
RA NNP 0
) ) 0
. . 0

METHODS NNP 0
Fifty-seven JJ 0
patients NNS 0
younger JJR 0
than IN 0
65 CD 0
years NNS 0
with IN 0
early JJ 0
, , 0
nonerosive JJ 0
RA NNP 0
were VBD 0
first RB 0
treated VBN 0
with IN 0
CSA NNP 0
and CC 0
MTX NNP 0
in IN 0
combination NN 0
for IN 0
6 CD 0
months NNS 0
. . 0

They PRP 0
were VBD 0
then RB 0
randomly RB 0
stepped VBD 0
down RB 0
to TO 0
single-agent JJ 0
maintenance NN 0
treatment NN 0
for IN 0
another DT 0
18 CD 0
months NNS 0
. . 0

Safety NNP 0
, , 0
clinical JJ 0
efficacy NN 0
, , 0
survival NN 0
on IN 0
treatment NN 0
, , 0
and CC 0
radiographic JJ 0
progression NN 0
were VBD 0
evaluated VBN 0
. . 0

RESULTS VB 0
When WRB 0
being VBG 0
treated VBN 0
with IN 0
combination NN 0
therapy NN 0
, , 0
7 CD 0
of IN 0
the DT 0
57 CD 0
patients NNS 0
( ( 0
12.3 CD 0
% NN 0
) ) 0
withdrew NN 0
because IN 0
of IN 0
adverse JJ 0
events NNS 0
. . 0

Of IN 0
the DT 0
remaining VBG 0
50 CD 0
patients NNS 0
, , 0
42 CD 0
( ( 0
84.0 CD 0
% NN 0
) ) 0
were VBD 0
American JJ 0
College NNP 0
of IN 0
Rheumatology NNP 0
( ( 0
ACR NNP 0
) ) 0
20 CD 0
% NN 0
responders NNS 0
, , 0
30 CD 0
( ( 0
60.0 CD 0
% NN 0
) ) 0
were VBD 0
ACR NNP 0
50 CD 0
% NN 0
responders NNS 0
, , 0
and CC 0
23 CD 0
( ( 0
46.0 CD 0
% NN 0
) ) 0
were VBD 0
ACR NNP 0
70 CD 0
% NN 0
responders NNS 0
. . 0

At IN 0
month NN 0
6 CD 0
, , 0
22 CD 0
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
CSA NNP 0
and CC 0
27 CD 0
to TO 0
MTX NNP 0
. . 0

During IN 0
this DT 0
trial NN 0
period NN 0
, , 0
the DT 0
treatment NN 0
was VBD 0
discontinued VBN 0
by IN 0
16 CD 0
patients NNS 0
taking VBG 0
CSA NNP 0
( ( 0
mainly RB 0
because IN 0
of IN 0
loss NN 0
of IN 0
efficacy NN 0
) ) 0
and CC 0
by IN 0
4 CD 0
taking VBG 0
MTX NNP 0
. . 0

At IN 0
month NN 0
24 CD 0
, , 0
the DT 0
probability NN 0
( ( 0
+/- JJ 0
SEM NNP 0
) ) 0
of IN 0
survival NN 0
on IN 0
treatment NN 0
was VBD 0
0.273 CD 0
+/- JJ 0
0.09 CD 0
for IN 0
CSA NNP 0
and CC 0
0.852 CD 0
+/- JJ 0
0.07 CD 0
for IN 0
MTX NNP 0
. . 0

Of IN 0
the DT 0
6 CD 0
CSA NNP 0
patients NNS 0
who WP 0
completed VBD 0
the DT 0
trial NN 0
, , 0
4 CD 0
( ( 0
66.7 CD 0
% NN 0
) ) 0
were VBD 0
ACR NNP 0
20 CD 0
% NN 0
responders NNS 0
, , 0
and CC 0
3 CD 0
( ( 0
50 CD 0
% NN 0
) ) 0
were VBD 0
both DT 0
ACR NNP 0
50 CD 0
% NN 0
and CC 0
ACR NNP 0
70 CD 0
% NN 0
responders NNS 0
. . 0

Of IN 0
the DT 0
23 CD 0
completers NNS 0
in IN 0
the DT 0
MTX NNP 0
arm NN 0
, , 0
21 CD 0
( ( 0
91.3 CD 0
% NN 0
) ) 0
were VBD 0
ACR NNP 0
20 CD 0
% NN 0
responders NNS 0
, , 0
18 CD 0
( ( 0
78.3 CD 0
% NN 0
) ) 0
were VBD 0
ACR NNP 0
50 CD 0
% NN 0
, , 0
and CC 0
10 CD 0
( ( 0
43.5 CD 0
% NN 0
) ) 0
were VBD 0
ACR NNP 0
70 CD 0
% NN 0
responders NNS 0
. . 0

The DT 0
treatment NN 0
was VBD 0
not RB 0
responsible JJ 0
for IN 0
severe JJ 0
adverse JJ 0
events NNS 0
. . 0

Radiography NNP 0
showed VBD 0
a DT 0
slow JJ 0
progression NN 0
in IN 0
the DT 0
damage NN 0
score NN 0
and CC 0
number NN 0
of IN 0
eroded JJ 0
joints NNS 0
in IN 0
both DT 0
treatment NN 0
groups NNS 0
. . 0

CONCLUSION NNP 0
Stepping VBG 0
down RP 0
to TO 0
single JJ 0
agent JJ 0
maintenance NN 0
therapy NN 0
following VBG 0
6 CD 0
months NNS 0
of IN 0
combination NN 0
treatment NN 0
with IN 0
CSA NNP 0
and CC 0
MTX NNP 0
in IN 0
early JJ 0
RA NNP 0
was VBD 0
only RB 0
successful JJ 0
with IN 0
MTX NNP 0
. . 0

Because IN 0
this DT 0
treatment NN 0
did VBD 0
not RB 0
prevent VB 0
some DT 0
radiographic JJ 0
progression NN 0
, , 0
other JJ 0
approaches NNS 0
( ( 0
e.g. NN 0
, , 0
step-up JJ 0
approach NN 0
) ) 0
may MD 0
be VB 0
more JJR 0
appropriate JJ 0
in IN 0
early JJ 0
RA NNP 0
. . 0

Changes NNS 0
in IN 0
H NNP 0
reflex NN 0
and CC 0
V NNP 0
wave VBP 0
following VBG 0
short-term JJ 0
endurance NN 0
and CC 0
strength NN 0
training NN 0
. . 0

This DT 0
study NN 0
examined VBD 0
the DT 0
effects NNS 0
of IN 0
3 CD 0
wk NN 0
of IN 0
either DT 0
endurance NN 0
or CC 0
strength NN 0
training NN 0
on IN 0
plasticity NN 0
of IN 0
the DT 0
neural JJ 0
mechanisms NNS 0
involved VBN 0
in IN 0
the DT 0
soleus NN 0
H NNP 0
reflex NN 0
and CC 0
V NNP 0
wave VBP 0
. . 0

Twenty-five JJ 0
sedentary JJ 0
healthy JJ 0
subjects NNS 0
were VBD 0
randomized VBN 0
into IN 0
an DT 0
endurance NN 0
group NN 0
( ( 0
n JJ 0
= NNP 0
13 CD 0
) ) 0
or CC 0
strength NN 0
group NN 0
( ( 0
n JJ 0
= NNP 0
12 CD 0
) ) 0
. . 0

Evoked VBN 0
V-wave JJ 0
, , 0
H-reflex NNP 0
, , 0
and CC 0
M-wave NNP 0
recruitment NN 0
curves NNS 0
, , 0
maximal JJ 0
voluntary JJ 0
contraction NN 0
( ( 0
MVC NNP 0
) ) 0
, , 0
and CC 0
time-to-task-failure NN 0
( ( 0
isometric JJ 0
contraction NN 0
at IN 0
40 CD 0
% NN 0
MVC NNP 0
) ) 0
of IN 0
the DT 0
plantar NN 0
flexors NNS 0
were VBD 0
recorded VBN 0
before IN 0
and CC 0
after IN 0
training VBG 0
. . 0

Following VBG 0
strength NN 0
training NN 0
, , 0
MVC NNP 0
of IN 0
the DT 0
plantar NN 0
flexors NNS 0
increased VBN 0
by IN 0
14.4 CD 0
? . 0
5.2 CD 0
% NN 0
in IN 0
the DT 0
strength NN 0
group NN 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
, , 0
whereas JJ 0
time-to-task-failure NN 0
was VBD 0
prolonged VBN 0
in IN 0
the DT 0
endurance NN 0
group NN 0
( ( 0
22.7 CD 0
? . 0
17.1 CD 0
% NN 0
; : 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

The DT 0
V NNP 0
wave-to-maximal JJ 0
M NNP 0
wave NN 0
( ( 0
V/M NNP 0
( ( 0
max NN 0
) ) 0
) ) 0
ratio NN 0
increased VBN 0
significantly RB 0
( ( 0
55.1 CD 0
? . 0
28.3 CD 0
% NN 0
; : 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
following VBG 0
strength NN 0
training NN 0
, , 0
but CC 0
the DT 0
maximal JJ 0
H NNP 0
wave-to-maximal JJ 0
M NNP 0
wave NN 0
( ( 0
H NNP 0
( ( 0
max NN 0
) ) 0
/M NN 0
( ( 0
max NN 0
) ) 0
) ) 0
ratio NN 0
remained VBD 0
unchanged JJ 0
. . 0

Conversely RB 0
, , 0
in IN 0
the DT 0
endurance NN 0
group NN 0
the DT 0
V/M NNP 0
( ( 0
max NN 0
) ) 0
ratio NN 0
was VBD 0
not RB 0
altered VBN 0
, , 0
whereas IN 0
the DT 0
H NNP 0
( ( 0
max NN 0
) ) 0
/M NN 0
( ( 0
max NN 0
) ) 0
ratio NN 0
increased VBN 0
by IN 0
30.8 CD 0
? . 0
21.7 CD 0
% NN 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
. . 0

The DT 0
endurance NN 0
training NN 0
group NN 0
also RB 0
displayed VBD 0
a DT 0
reduction NN 0
in IN 0
the DT 0
H-reflex NNP 0
excitability NN 0
threshold NN 0
while IN 0
the DT 0
H-reflex NNP 0
amplitude NN 0
on IN 0
the DT 0
ascending VBG 0
limb NN 0
of IN 0
the DT 0
recruitment NN 0
curve NN 0
increased VBD 0
. . 0

Strength NNP 0
training VBG 0
only RB 0
elicited VBD 0
a DT 0
significant JJ 0
decrease NN 0
in IN 0
H-reflex NNP 0
excitability NN 0
threshold NN 0
, , 0
while IN 0
H-reflex NNP 0
amplitudes NNS 0
over IN 0
the DT 0
ascending VBG 0
limb NN 0
remained VBD 0
unchanged JJ 0
. . 0

These DT 0
observations NNS 0
indicate VBP 0
that IN 0
the DT 0
H-reflex NNP 0
pathway NN 0
is VBZ 0
strongly RB 0
involved VBN 0
in IN 0
the DT 0
enhanced JJ 0
endurance NN 0
resistance NN 0
that WDT 0
occurs VBZ 0
following VBG 0
endurance NN 0
training NN 0
. . 0

On IN 0
the DT 0
contrary JJ 0
, , 0
the DT 0
improvements NNS 0
in IN 0
MVC NNP 0
following VBG 0
strength NN 0
training NN 0
are VBP 0
likely JJ 0
attributed VBN 0
to TO 0
increased VBN 0
descending VBG 0
drive NN 0
and/or NN 0
modulation NN 0
in IN 0
afferents NNS 0
other JJ 0
than IN 0
Ia JJ 0
afferents NNS 0
. . 0

[ JJ 0
Effects NNS 0
of IN 0
transcutaneous JJ 0
electrical JJ 0
stimulation NN 0
of IN 0
auricular JJ 0
Shenmen NNP 0
point NN 0
on IN 0
postoperative JJ 0
nausea NN 0
and CC 0
vomiting NN 0
and CC 0
patient-controlled JJ 0
epidural JJ 0
analgesia NN 0
in IN 0
cesarean JJ 0
section NN 0
] NNP 0
. . 0

OBJECTIVE NNP 0
To TO 0
investigate VB 0
the DT 0
effects NNS 0
of IN 0
transcutaneous JJ 0
electrical JJ 0
stimulation NN 0
of IN 0
auricular JJ 0
Shenmen NNP 0
point NN 0
on IN 0
postoperative JJ 0
nausea NN 0
and CC 0
vomiting NN 0
and CC 0
patient-controlled JJ 0
epidural JJ 0
analgesia NN 0
in IN 0
cesarean JJ 0
section NN 0
. . 0

METHODS NNP 0
After IN 0
IRB NNP 0
approval NN 0
and CC 0
informed JJ 0
consent NN 0
, , 0
one CD 0
hundred CD 0
and CC 0
eighty VB 0
singleton NN 0
primiparas IN 0
undergoing VBG 0
elective JJ 0
cesarean JJ 0
section NN 0
, , 0
in IN 0
Qingdao NNP 0
Municipal NNP 0
Hospital NNP 0
, , 0
and CC 0
Qingdao NNP 0
Hiser NNP 0
Medical NNP 0
Center NNP 0
, , 0
from IN 0
November NNP 0
2011 CD 0
to TO 0
March NNP 0
2012 CD 0
, , 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
three CD 0
groups NNS 0
: : 0
transcutaneous JJ 0
electrical JJ 0
stimulation NN 0
of IN 0
auricular JJ 0
Shenmen NNP 0
point NN 0
group NN 0
( ( 0
group NN 0
A NNP 0
, , 0
n JJ 0
= NNP 0
60 CD 0
) ) 0
, , 0
transcutaneous JJ 0
electrical JJ 0
stimulation NN 0
of IN 0
auricular JJ 0
Eye NNP 0
point NN 0
group NN 0
( ( 0
group NN 0
B NNP 0
, , 0
n JJ 0
= NNP 0
60 CD 0
) ) 0
and CC 0
control NN 0
group NN 0
( ( 0
group NN 0
C NNP 0
, , 0
n JJ 0
= NNP 0
60 CD 0
) ) 0
. . 0

Women NNP 0
of IN 0
group NN 0
A NNP 0
received VBD 0
transcutaneous JJ 0
electrical JJ 0
stimulation NN 0
of IN 0
auricular JJ 0
Shenmen NNP 0
point NN 0
( ( 0
frequency NN 0
1.5 CD 0
HZ NNP 0
) ) 0
at IN 0
the DT 0
time NN 0
of IN 0
preoperation NN 0
, , 0
4 CD 0
, , 0
10 CD 0
and CC 0
22 CD 0
hours NNS 0
of IN 0
postoperation NN 0
for IN 0
30 CD 0
minutes NNS 0
. . 0

The DT 0
strength NN 0
was VBD 0
controlled VBN 0
by IN 0
themselves PRP 0
. . 0

Women NNP 0
of IN 0
group NN 0
B NNP 0
received VBD 0
stimulation NN 0
of IN 0
auricular JJ 0
Eye NNP 0
point NN 0
as IN 0
group NN 0
A NNP 0
. . 0

Women NNP 0
of IN 0
group NN 0
C NNP 0
received VBD 0
pressurization NN 0
and CC 0
connected VBN 0
line NN 0
were VBD 0
the DT 0
same JJ 0
with IN 0
group NN 0
A NNP 0
, , 0
but CC 0
without IN 0
electrical JJ 0
stimulation NN 0
. . 0

The DT 0
following JJ 0
indexes NNS 0
was VBD 0
observed VBN 0
: : 0
the DT 0
incidence NN 0
of IN 0
postoperative JJ 0
nausea NN 0
and CC 0
vomiting NN 0
( ( 0
PONV NNP 0
) ) 0
for IN 0
48 CD 0
hours NNS 0
; : 0
the DT 0
rate NN 0
of IN 0
metoclopramide NN 0
; : 0
the DT 0
visual JJ 0
analogue NN 0
scale NN 0
( ( 0
VAS NNP 0
) ) 0
score NN 0
of IN 0
rest NN 0
pain NN 0
, , 0
uterine JJ 0
contration NN 0
pain NN 0
and CC 0
dynamic JJ 0
pain NN 0
at IN 0
the DT 0
time NN 0
of IN 0
postoperation NN 0
for IN 0
6 CD 0
, , 0
12 CD 0
, , 0
24 CD 0
and CC 0
48 CD 0
hours NNS 0
( ( 0
T NNP 0
( ( 0
1 CD 0
) ) 0
-T NN 0
( ( 0
4 CD 0
) ) 0
) ) 0
; : 0
the DT 0
total JJ 0
number NN 0
and CC 0
effective JJ 0
compressions NNS 0
number NN 0
of IN 0
patient-controlled JJ 0
epidural JJ 0
analgesia NN 0
( ( 0
PCEA NNP 0
) ) 0
; : 0
the DT 0
dose NN 0
of IN 0
analgesia JJ 0
mixture NN 0
; : 0
the DT 0
anal JJ 0
exhaust JJ 0
time NN 0
; : 0
the DT 0
volume NN 0
of IN 0
postoperative JJ 0
bleeding NN 0
for IN 0
6 CD 0
hours NNS 0
of IN 0
postoperation NN 0
and CC 0
the DT 0
other JJ 0
side NN 0
effects NNS 0
. . 0

RESULTS NNP 0
Compared NNP 0
with IN 0
group NN 0
B NNP 0
and CC 0
group NN 0
C NNP 0
, , 0
the DT 0
incidence NN 0
of IN 0
PONV NNP 0
, , 0
the DT 0
rate NN 0
of IN 0
metoclopramide NN 0
, , 0
the DT 0
VAS NNP 0
score NN 0
at IN 0
the DT 0
time NN 0
T NNP 0
( ( 0
1 CD 0
) ) 0
-T NN 0
( ( 0
4 CD 0
) ) 0
, , 0
the DT 0
total JJ 0
number NN 0
and CC 0
effective JJ 0
compressions NNS 0
number NN 0
of IN 0
PCEA NNP 0
, , 0
the DT 0
ratio NN 0
of IN 0
the DT 0
total JJ 0
number NN 0
with IN 0
effective JJ 0
compressions NNS 0
number NN 0
and CC 0
the DT 0
dose NN 0
of IN 0
analgesia JJ 0
mixture NN 0
were VBD 0
decreased VBN 0
in IN 0
group NN 0
A NNP 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
, , 0
but CC 0
no DT 0
difference NN 0
compared VBN 0
group NN 0
B NNP 0
with IN 0
group NN 0
C NNP 0
( ( 0
P NNP 0
> NNP 0
0.05 CD 0
) ) 0
. . 0

The DT 0
anal JJ 0
exhaust NN 0
time NN 0
and CC 0
the DT 0
volume NN 0
of IN 0
postoperative JJ 0
bleeding NN 0
for IN 0
6 CD 0
hours NNS 0
of IN 0
postoperation NN 0
were VBD 0
no DT 0
difference NN 0
in IN 0
the DT 0
three CD 0
groups NNS 0
( ( 0
P NNP 0
> NNP 0
0.05 CD 0
) ) 0
. . 0

No UH 0
other JJ 0
side NN 0
effects NNS 0
were VBD 0
observed VBN 0
. . 0

CONCLUSION NNP 0
Transcutaneous NNP 0
electrical JJ 0
stimulation NN 0
of IN 0
auricular JJ 0
Shenmen NNS 0
point NN 0
can MD 0
reduce VB 0
the DT 0
incidence NN 0
of IN 0
PONV NNP 0
and CC 0
improves VBZ 0
analgesia JJ 0
effect NN 0
of IN 0
PCEA NNP 0
in IN 0
postoperation NN 0
of IN 0
cesarean JJ 0
section NN 0
. . 0

Aminocaproic NNP 0
acid VBZ 0
versus FW 0
prednisone NN 0
for IN 0
the DT 0
treatment NN 0
of IN 0
traumatic JJ 0
hyphema NN 0
. . 0

A DT 0
randomized JJ 0
clinical JJ 0
trial NN 0
. . 0

One CD 0
hundred VBD 0
twelve NN 0
patients NNS 0
who WP 0
sustained VBD 0
hyphema NN 0
after IN 0
blunt NN 0
trauma NN 0
were VBD 0
enrolled VBN 0
in IN 0
a DT 0
double-blind JJ 0
randomized JJ 0
clinical JJ 0
trial NN 0
to TO 0
determine VB 0
the DT 0
relative JJ 0
efficacies NNS 0
of IN 0
aminocaproic JJ 0
acid NN 0
( ( 0
Amicar NNP 0
) ) 0
and CC 0
systemic JJ 0
prednisone NN 0
for IN 0
reducing VBG 0
the DT 0
rate NN 0
of IN 0
secondary JJ 0
hemorrhage NN 0
. . 0

Fifty-six JJ 0
patients NNS 0
received VBD 0
an DT 0
oral JJ 0
dosage NN 0
of IN 0
50 CD 0
mg/kg NN 0
of IN 0
aminocaproic JJ 0
acid NN 0
every DT 0
4 CD 0
hours NNS 0
for IN 0
5 CD 0
days NNS 0
, , 0
up RB 0
to TO 0
a DT 0
maximum NN 0
of IN 0
30 CD 0
g JJ 0
daily JJ 0
, , 0
and CC 0
56 CD 0
patients NNS 0
received VBD 0
an DT 0
oral JJ 0
dosage NN 0
of IN 0
40 CD 0
mg NN 0
of IN 0
prednisone JJ 0
daily JJ 0
( ( 0
adjusted VBN 0
for IN 0
weight NN 0
) ) 0
in IN 0
two CD 0
divided JJ 0
doses NNS 0
. . 0

Placebo NNP 0
pills NNS 0
and CC 0
liquids NNS 0
were VBD 0
given VBN 0
to TO 0
each DT 0
patient NN 0
to TO 0
mask VB 0
the DT 0
treatment NN 0
schedules NNS 0
. . 0

There EX 0
were VBD 0
no DT 0
statistically RB 0
significant JJ 0
differences NNS 0
between IN 0
the DT 0
patient NN 0
populations NNS 0
for IN 0
any DT 0
demographic JJ 0
or CC 0
clinical JJ 0
characteristic NN 0
( ( 0
e.g. JJ 0
, , 0
visual JJ 0
acuity NN 0
, , 0
intraocular JJ 0
pressure NN 0
[ NNP 0
IOP NNP 0
] NNP 0
, , 0
initial JJ 0
hyphema NN 0
size NN 0
) ) 0
measured VBN 0
in IN 0
the DT 0
study NN 0
. . 0

Blacks NNS 0
comprised VBD 0
53 CD 0
% NN 0
of IN 0
the DT 0
study NN 0
population NN 0
, , 0
and CC 0
the DT 0
mean JJ 0
age NN 0
of IN 0
the DT 0
patients NNS 0
was VBD 0
23.5 CD 0
years NNS 0
. . 0

Four CD 0
patients NNS 0
in IN 0
each DT 0
of IN 0
the DT 0
treatment NN 0
groups NNS 0
experienced VBD 0
a DT 0
secondary JJ 0
hemorrhage NN 0
; : 0
the DT 0
rebleed NN 0
rate NN 0
was VBD 0
7.1 CD 0
% NN 0
in IN 0
each DT 0
group NN 0
. . 0

A DT 0
randomized VBN 0
controlled VBN 0
study NN 0
of IN 0
parent-assisted JJ 0
Children NNP 0
's POS 0
Friendship NNP 0
Training NNP 0
with IN 0
children NNS 0
having VBG 0
autism NN 0
spectrum NN 0
disorders NNS 0
. . 0

This DT 0
study NN 0
evaluated VBD 0
Children NNP 0
's POS 0
Friendship NNP 0
Training NNP 0
( ( 0
CFT NNP 0
) ) 0
, , 0
a DT 0
manualized JJ 0
parent-assisted JJ 0
intervention NN 0
to TO 0
improve VB 0
social JJ 0
skills NNS 0
among IN 0
second JJ 0
to TO 0
fifth VB 0
grade JJ 0
children NNS 0
with IN 0
autism NN 0
spectrum NN 0
disorders NNS 0
. . 0

Comparison NNP 0
was VBD 0
made VBN 0
with IN 0
a DT 0
delayed JJ 0
treatment NN 0
control NN 0
group NN 0
( ( 0
DTC NNP 0
) ) 0
. . 0

Targeted VBN 0
skills NNS 0
included VBD 0
conversational JJ 0
skills NNS 0
, , 0
peer VBP 0
entry NN 0
skills NNS 0
, , 0
developing VBG 0
friendship JJ 0
networks NNS 0
, , 0
good JJ 0
sportsmanship NN 0
, , 0
good JJ 0
host NN 0
behavior NN 0
during IN 0
play NN 0
dates NNS 0
, , 0
and CC 0
handling VBG 0
teasing NN 0
. . 0

At IN 0
post-testing NN 0
, , 0
the DT 0
CFT NNP 0
group NN 0
was VBD 0
superior JJ 0
to TO 0
the DT 0
DTC NNP 0
group NN 0
on IN 0
parent NN 0
measures NNS 0
of IN 0
social JJ 0
skill NN 0
and CC 0
play NN 0
date NN 0
behavior NN 0
, , 0
and CC 0
child JJ 0
measures NNS 0
of IN 0
popularity NN 0
and CC 0
loneliness NN 0
, , 0
At IN 0
3-month JJ 0
follow-up NN 0
, , 0
parent NN 0
measures NNS 0
showed VBD 0
significant JJ 0
improvement NN 0
from IN 0
baseline NN 0
. . 0

Post-hoc JJ 0
analysis NN 0
indicated VBD 0
more JJR 0
than IN 0
87 CD 0
% NN 0
of IN 0
children NNS 0
receiving VBG 0
CFT NNP 0
showed VBD 0
reliable JJ 0
change NN 0
on IN 0
at IN 0
least JJS 0
one CD 0
measure NN 0
at IN 0
post-test NN 0
and CC 0
66.7 CD 0
% NN 0
after IN 0
3 CD 0
months NNS 0
follow-up RB 0
. . 0

Concurrent NNP 0
alcohol NN 0
dependence NN 0
among IN 0
methadone-maintained JJ 0
cocaine NN 0
abusers NNS 0
is VBZ 0
associated VBN 0
with IN 0
greater JJR 0
abstinence NN 0
. . 0

Concurrent NNP 0
alcohol NN 0
dependence NN 0
( ( 0
AD NNP 0
) ) 0
among IN 0
polysubstance NN 0
abusers NNS 0
has VBZ 0
been VBN 0
associated VBN 0
with IN 0
negative JJ 0
consequences NNS 0
, , 0
although IN 0
it PRP 0
may MD 0
not RB 0
necessarily RB 0
lead VB 0
to TO 0
poor JJ 0
treatment NN 0
outcomes NNS 0
. . 0

One CD 0
of IN 0
the DT 0
most RBS 0
efficacious JJ 0
treatments NNS 0
for IN 0
cocaine NN 0
abuse NN 0
is VBZ 0
contingency JJ 0
management NN 0
( ( 0
CM NNP 0
) ) 0
, , 0
but CC 0
little JJ 0
research NN 0
has VBZ 0
explored VBN 0
the DT 0
impact NN 0
of IN 0
AD NNP 0
on IN 0
abstinence NN 0
outcomes NNS 0
, , 0
particularly RB 0
among IN 0
patients NNS 0
in IN 0
methadone JJ 0
maintenance NN 0
. . 0

Using VBG 0
data NNS 0
from IN 0
three CD 0
trials NNS 0
of IN 0
CM NNP 0
for IN 0
cocaine NN 0
use NN 0
, , 0
we PRP 0
compared VBN 0
baseline JJ 0
characteristics NNS 0
and CC 0
posttreatment NN 0
and CC 0
follow-up JJ 0
cocaine NN 0
outcomes NNS 0
between IN 0
methadone-maintained JJ 0
, , 0
cocaine-dependent JJ 0
patients NNS 0
( ( 0
N NNP 0
= NNP 0
193 CD 0
) ) 0
with IN 0
and CC 0
without IN 0
concurrent JJ 0
AD NNP 0
, , 0
randomized VBN 0
to TO 0
standard VB 0
care NN 0
( ( 0
SC NNP 0
) ) 0
with IN 0
or CC 0
without IN 0
CM NNP 0
. . 0

Patients NNS 0
with IN 0
and CC 0
without IN 0
concurrent JJ 0
AD NNP 0
had VBD 0
similar JJ 0
baseline NN 0
characteristics NNS 0
, , 0
with IN 0
the DT 0
exception NN 0
that WDT 0
AD NNP 0
patients NNS 0
reported VBD 0
more RBR 0
alcohol NN 0
use NN 0
. . 0

AD NN 0
patients NNS 0
achieved VBN 0
longer JJR 0
durations NNS 0
of IN 0
cocaine NN 0
abstinence NN 0
and CC 0
were VBD 0
more RBR 0
likely JJ 0
to TO 0
submit VB 0
a DT 0
cocaine-negative JJ 0
sample NN 0
at IN 0
follow-up JJ 0
than IN 0
non-AD JJ 0
patients NNS 0
. . 0

Patients NNS 0
randomized VBD 0
to TO 0
CM NNP 0
achieved VBD 0
better RBR 0
outcomes NNS 0
than IN 0
those DT 0
randomized VBN 0
to TO 0
SC NNP 0
, , 0
but CC 0
there EX 0
was VBD 0
no DT 0
interaction NN 0
between IN 0
treatment NN 0
condition NN 0
and CC 0
AD NNP 0
status NN 0
. . 0

These DT 0
findings NNS 0
suggest VBP 0
that IN 0
cocaine-using JJ 0
methadone NN 0
patients NNS 0
with IN 0
AD NNP 0
achieve VBP 0
greater JJR 0
cocaine NN 0
abstinence NN 0
than IN 0
their PRP$ 0
non-AD JJ 0
counterparts NNS 0
and CC 0
should MD 0
not RB 0
necessarily RB 0
be VB 0
viewed VBN 0
as IN 0
more RBR 0
difficult JJ 0
to TO 0
treat VB 0
. . 0

Maternal JJ 0
breast-milk NN 0
and CC 0
intestinal JJ 0
bifidobacteria NNS 0
guide VBP 0
the DT 0
compositional JJ 0
development NN 0
of IN 0
the DT 0
Bifidobacterium NNP 0
microbiota NN 0
in IN 0
infants NNS 0
at IN 0
risk NN 0
of IN 0
allergic JJ 0
disease NN 0
. . 0

BACKGROUND IN 0
The DT 0
sources NNS 0
and CC 0
the DT 0
impact NN 0
of IN 0
maternal JJ 0
bacteria NNS 0
on IN 0
the DT 0
initial JJ 0
inoculum NN 0
of IN 0
the DT 0
intestinal JJ 0
microflora NN 0
of IN 0
newborn JJ 0
infants NNS 0
remain VBP 0
elusive JJ 0
. . 0

OBJECTIVE NN 0
To TO 0
assess VB 0
the DT 0
association NN 0
between IN 0
maternal JJ 0
breast-milk NN 0
and CC 0
fecal JJ 0
bifidobacteria NN 0
and CC 0
infants NNS 0
' POS 0
fecal JJ 0
bifidobacteria NN 0
. . 0

METHODS NNP 0
Sixty-one JJ 0
mother-infant JJ 0
pairs NNS 0
were VBD 0
included VBN 0
, , 0
special JJ 0
emphasis NN 0
being VBG 0
placed VBN 0
on IN 0
the DT 0
maternal JJ 0
allergic NN 0
status NN 0
. . 0

Bifidobacteria NNP 0
were VBD 0
analysed VBN 0
by IN 0
a DT 0
direct JJ 0
PCR NNP 0
method NN 0
in IN 0
fecal JJ 0
samples NNS 0
from IN 0
mothers NNS 0
at IN 0
30-35 JJ 0
weeks NNS 0
of IN 0
gestation NN 0
and CC 0
from IN 0
infants NNS 0
at IN 0
1 CD 0
month NN 0
of IN 0
age NN 0
and CC 0
from IN 0
breast-milk JJ 0
samples NNS 0
1 CD 0
month NN 0
post-partum NN 0
. . 0

RESULTS NNP 0
Fecal NNP 0
Bifidobacterium NNP 0
adolescentis NN 0
and CC 0
Bifidobacterium NNP 0
bifidum NN 0
colonization NN 0
frequencies NNS 0
and CC 0
counts NNS 0
among IN 0
mother-infant JJ 0
pairs NNS 0
correlated VBN 0
significantly RB 0
( ( 0
P=0.005 NNP 0
and CC 0
0.02 CD 0
for IN 0
frequencies NNS 0
, , 0
respectively RB 0
, , 0
and CC 0
P=0.002 NNP 0
and CC 0
0.01 CD 0
for IN 0
counts NNS 0
, , 0
respectively RB 0
) ) 0
. . 0

Only JJ 0
infants NNS 0
of IN 0
allergic NN 0
, , 0
atopic NN 0
mothers NNS 0
were VBD 0
colonized VBN 0
with IN 0
B. NNP 0
adolescentis NN 0
. . 0

Each DT 0
of IN 0
the DT 0
breast-milk NN 0
samples NNS 0
contained VBN 0
bifidobacteria NNS 0
[ NNP 0
median JJ 0
1.4 CD 0
x JJ 0
10 CD 0
( ( 0
3 CD 0
) ) 0
bacterial JJ 0
cells/mL NN 0
; : 0
interquartile JJ 0
range NN 0
( ( 0
IQR NNP 0
) ) 0
48.7-3.8 CD 0
x $ 0
10 CD 0
( ( 0
3 CD 0
) ) 0
] NN 0
. . 0

Bifidobacterium NNP 0
longum NN 0
was VBD 0
the DT 0
most RBS 0
frequently RB 0
detected VBN 0
species NNS 0
in IN 0
breast-milk NN 0
. . 0

Allergic NNP 0
mothers NNS 0
had VBD 0
significantly RB 0
lower JJR 0
amounts NNS 0
of IN 0
bifidobacteria NN 0
in IN 0
breast-milk NN 0
compared VBN 0
with IN 0
non-allergic JJ 0
mothers NNS 0
[ VBP 0
median JJ 0
1.3 CD 0
x JJ 0
10 CD 0
( ( 0
3 CD 0
) ) 0
bacterial NN 0
cells/mL NN 0
( ( 0
IQR NNP 0
22.4-3.0 CD 0
x NNP 0
10 CD 0
( ( 0
3 CD 0
) ) 0
) ) 0
vs. FW 0
5.6 CD 0
x $ 0
10 CD 0
( ( 0
3 CD 0
) ) 0
bacterial NN 0
cells/mL NN 0
( ( 0
1.8 CD 0
x RB 0
10 CD 0
( ( 0
3 CD 0
) ) 0
-1.8 NN 0
x $ 0
10 CD 0
( ( 0
4 CD 0
) ) 0
) ) 0
, , 0
respectively RB 0
, , 0
( ( 0
P=0.004 NNP 0
) ) 0
] NN 0
, , 0
and CC 0
their PRP$ 0
infants NNS 0
had VBD 0
concurrently RB 0
lower JJR 0
counts NNS 0
of IN 0
bifidobacteria NN 0
in IN 0
feces NNS 0
[ VBP 0
3.9 CD 0
x JJ 0
10 CD 0
( ( 0
8 CD 0
) ) 0
bacterial NN 0
cells/g NN 0
( ( 0
IQR NNP 0
6.5 CD 0
x NN 0
10 CD 0
( ( 0
6 CD 0
) ) 0
-1.5 NN 0
x $ 0
10 CD 0
( ( 0
9 CD 0
) ) 0
) ) 0
in IN 0
infants NNS 0
of IN 0
allergic JJ 0
mothers NNS 0
, , 0
vs. FW 0
2.5 CD 0
x $ 0
10 CD 0
( ( 0
9 CD 0
) ) 0
bacterial NN 0
cells/g NN 0
( ( 0
6.5 CD 0
x RB 0
10 CD 0
( ( 0
8 CD 0
) ) 0
-3.2 NN 0
x $ 0
10 CD 0
( ( 0
10 CD 0
) ) 0
) ) 0
in IN 0
infants NNS 0
of IN 0
non-allergic JJ 0
mothers NNS 0
, , 0
P=0.013 NNP 0
] NNP 0
. . 0

CONCLUSIONS NNP 0
Breast-milk NNP 0
contains VBZ 0
significant JJ 0
numbers NNS 0
of IN 0
bifidobacteria NN 0
and CC 0
the DT 0
maternal JJ 0
allergic NN 0
status NN 0
further RBR 0
deranges VBZ 0
the DT 0
counts NNS 0
of IN 0
bifidobacteria NN 0
in IN 0
breast-milk NN 0
. . 0

Maternal NNP 0
fecal JJ 0
and CC 0
breast-milk JJ 0
bifidobacterial JJ 0
counts NNS 0
impacted VBN 0
on IN 0
the DT 0
infants NNS 0
' POS 0
fecal JJ 0
Bifidobacterium NN 0
levels NNS 0
. . 0

Breast-milk NNP 0
bacteria NN 0
should MD 0
thus RB 0
be VB 0
considered VBN 0
an DT 0
important JJ 0
source NN 0
of IN 0
bacteria NNS 0
in IN 0
the DT 0
establishment NN 0
of IN 0
infantile JJ 0
intestinal JJ 0
microbiota NN 0
. . 0

Transdermal NNP 0
scopolamine NN 0
patch NN 0
in IN 0
addition NN 0
to TO 0
ondansetron VB 0
for IN 0
postoperative JJ 0
nausea NN 0
and CC 0
vomiting VBG 0
prophylaxis NN 0
in IN 0
patients NNS 0
undergoing VBG 0
ambulatory JJ 0
cosmetic JJ 0
surgery NN 0
. . 0

STUDY NNP 0
OBJECTIVE NNP 0
To TO 0
determine VB 0
the DT 0
efficacy NN 0
of IN 0
transdermal JJ 0
scopolamine NN 0
in IN 0
addition NN 0
to TO 0
ondansetron VB 0
in IN 0
decreasing VBG 0
the DT 0
incidence NN 0
of IN 0
postoperative JJ 0
nausea NN 0
and CC 0
vomiting NN 0
( ( 0
PONV NNP 0
) ) 0
. . 0

DESIGN NNP 0
Randomized NNP 0
controlled VBD 0
trial NN 0
. . 0

SETTING NN 0
Academic NNP 0
hospital NN 0
. . 0

PATIENTS CC 0
126 CD 0
ASA NNP 0
physical JJ 0
status NN 0
I PRP 0
and CC 0
II NNP 0
patients NNS 0
undergoing VBG 0
outpatient JJ 0
plastic NN 0
surgery NN 0
with IN 0
three CD 0
or CC 0
more JJR 0
risk NN 0
factors NNS 0
for IN 0
PONV NNP 0
. . 0

INTERVENTIONS NNP 0
Patients NNPS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
one CD 0
of IN 0
two CD 0
groups NNS 0
to TO 0
receive VB 0
( ( 0
Group NNP 0
1 CD 0
) ) 0
a DT 0
transdermal JJ 0
scopolamine NN 0
( ( 0
TDS NNP 0
) ) 0
patch NN 0
or CC 0
( ( 0
Group NNP 0
2 CD 0
) ) 0
, , 0
a DT 0
placebo JJ 0
patch NN 0
two CD 0
hours NNS 0
before IN 0
surgery NN 0
. . 0

MEASUREMENTS NNP 0
Occurrence NNP 0
of IN 0
vomiting VBG 0
, , 0
severity NN 0
of IN 0
nausea NN 0
using VBG 0
a DT 0
visual JJ 0
analog NN 0
scale NN 0
( ( 0
VAS NNP 0
) ) 0
, , 0
rescue JJ 0
medication NN 0
, , 0
pain VBP 0
intensity NN 0
and CC 0
pain NN 0
medications NNS 0
, , 0
and CC 0
side JJ 0
effects NNS 0
were VBD 0
recorded VBN 0
every DT 0
hour NN 0
until IN 0
discharge NN 0
from IN 0
hospital NN 0
, , 0
then RB 0
every DT 0
4 CD 0
hours NNS 0
thereafter RB 0
for IN 0
a DT 0
total NN 0
of IN 0
24 CD 0
hours NNS 0
. . 0

MAIN NNP 0
RESULTS NNP 0
A NNP 0
statistically RB 0
significant JJ 0
reduction NN 0
in IN 0
postoperative JJ 0
nausea NN 0
between IN 0
8 CD 0
and CC 0
24 CD 0
hours NNS 0
in IN 0
patients NNS 0
receiving VBG 0
TDS NNP 0
was VBD 0
noted VBN 0
. . 0

CONCLUSIONS NNP 0
Transdermal NNP 0
scopolamine NN 0
in IN 0
addition NN 0
to TO 0
ondansetron VB 0
benefits NNS 0
patients NNS 0
at IN 0
high JJ 0
risk NN 0
for IN 0
PONV NNP 0
undergoing JJ 0
outpatient NN 0
plastic NN 0
surgery NN 0
for IN 0
up IN 0
to TO 0
20 CD 0
hours NNS 0
after IN 0
surgery NN 0
. . 0

Junctional NNP 0
ectopic NN 0
tachycardia NN 0
after IN 0
congenital JJ 0
heart NN 0
surgery NN 0
in IN 0
the DT 0
current JJ 0
surgical JJ 0
era NN 0
. . 0

To TO 0
determine VB 0
the DT 0
incidence NN 0
of IN 0
postoperative JJ 0
junctional JJ 0
ectopic NN 0
tachycardia NN 0
( ( 0
JET NNP 0
) ) 0
in IN 0
a DT 0
modern JJ 0
cohort NN 0
of IN 0
pediatric JJ 0
patients NNS 0
, , 0
evaluate VBP 0
possible JJ 0
risk NN 0
factors NNS 0
for IN 0
JET NNP 0
, , 0
and CC 0
examine VB 0
the DT 0
effects NNS 0
of IN 0
JET NNP 0
on IN 0
postoperative JJ 0
morbidity NN 0
and CC 0
mortality NN 0
. . 0

JET NN 0
is VBZ 0
common JJ 0
after IN 0
congenital JJ 0
heart NN 0
surgery NN 0
. . 0

JET-related JJ 0
mortality NN 0
has VBZ 0
been VBN 0
a DT 0
rare JJ 0
event NN 0
at IN 0
our PRP$ 0
center NN 0
, , 0
which WDT 0
is VBZ 0
different JJ 0
from IN 0
previous JJ 0
reports NNS 0
. . 0

We PRP 0
reviewed VBD 0
records NNS 0
for IN 0
pediatric JJ 0
patients NNS 0
who WP 0
had VBD 0
postoperative JJ 0
arrhythmias NN 0
between IN 0
January NNP 0
2006 CD 0
and CC 0
June NNP 0
2010 CD 0
at IN 0
a DT 0
large JJ 0
tertiary-care JJ 0
children NNS 0
's POS 0
hospital NN 0
. . 0

We PRP 0
performed VBD 0
a DT 0
matched VBN 0
case-control NN 0
study NN 0
to TO 0
identify VB 0
risk NN 0
factors NNS 0
for IN 0
JET NNP 0
and CC 0
a DT 0
matched-cohort NN 0
study NN 0
to TO 0
compare VB 0
outcomes NNS 0
between IN 0
patients NNS 0
and CC 0
controls NNS 0
. . 0

Whenever NNP 0
possible JJ 0
, , 0
each DT 0
JET NNP 0
case NN 0
was VBD 0
randomly RB 0
matched VBN 0
to TO 0
two CD 0
controls NNS 0
on IN 0
the DT 0
basis NN 0
of IN 0
lesion NN 0
, , 0
repair NN 0
, , 0
and CC 0
surgical JJ 0
period NN 0
. . 0

We PRP 0
identified VBD 0
54 CD 0
patients NNS 0
with IN 0
JET NNP 0
( ( 0
incidence NN 0
= RB 0
1.4 CD 0
% NN 0
) ) 0
. . 0

After IN 0
multivariate JJ 0
logistic JJ 0
regression NN 0
analysis NN 0
, , 0
low JJ 0
operative JJ 0
weight NN 0
, , 0
cardiopulmonary JJ 0
bypass NN 0
( ( 0
CPB NNP 0
) ) 0
duration NN 0
> $ 0
100 CD 0
min NN 0
, , 0
and CC 0
immediate JJ 0
postoperative JJ 0
serum NN 0
lactic JJ 0
acid NN 0
level NN 0
> VBD 0
20 CD 0
mg/dl NNS 0
were VBD 0
associated VBN 0
with IN 0
increased JJ 0
odds NNS 0
of IN 0
developing VBG 0
JET NNP 0
. . 0

Patients NNS 0
with IN 0
JET NNP 0
had VBD 0
longer RBR 0
mechanical JJ 0
ventilation NN 0
time NN 0
, , 0
cardiac JJ 0
intensive JJ 0
care NN 0
unit NN 0
( ( 0
CICU NNP 0
) ) 0
stay NN 0
, , 0
and CC 0
hospital NN 0
stay NN 0
. . 0

There EX 0
was VBD 0
only RB 0
one CD 0
death NN 0
in IN 0
JET NNP 0
group NN 0
( ( 0
1.8 CD 0
% NN 0
) ) 0
with IN 0
no DT 0
significant JJ 0
difference NN 0
compared VBN 0
with IN 0
the DT 0
control NN 0
group NN 0
. . 0

JET NNP 0
remains VBZ 0
a DT 0
relatively RB 0
common JJ 0
postoperative JJ 0
arrhythmia NN 0
, , 0
but CC 0
it PRP 0
is VBZ 0
less RBR 0
frequent JJ 0
than IN 0
previously RB 0
reported VBN 0
. . 0

JET NNP 0
occurs VBZ 0
more JJR 0
commonly RB 0
in IN 0
smaller JJR 0
patients NNS 0
with IN 0
longer JJR 0
CPB NNP 0
runs NNS 0
and CC 0
significant JJ 0
postoperative JJ 0
lactic JJ 0
acidosis NN 0
levels NNS 0
. . 0

Mortality NNP 0
associated VBD 0
with IN 0
JET NNP 0
is VBZ 0
lower JJR 0
than IN 0
historically RB 0
reported VBN 0
, , 0
but CC 0
morbidity NN 0
remains VBZ 0
high JJ 0
. . 0

A DT 0
double-blind JJ 0
randomized JJ 0
clinical JJ 0
evaluation NN 0
of IN 0
enamel JJ 0
matrix NNS 0
derivative JJ 0
proteins NNS 0
for IN 0
the DT 0
treatment NN 0
of IN 0
proximal JJ 0
class-II JJ 0
furcation NN 0
involvements NNS 0
. . 0

OBJECTIVE IN 0
The DT 0
aim NN 0
of IN 0
the DT 0
present JJ 0
randomized VBN 0
, , 0
double-blind JJ 0
study NN 0
was VBD 0
to TO 0
evaluate VB 0
the DT 0
clinical JJ 0
response NN 0
of IN 0
proximal JJ 0
furcations NNS 0
treated VBN 0
with IN 0
enamel JJ 0
matrix NNS 0
derivative JJ 0
proteins NNS 0
( ( 0
EMD NNP 0
) ) 0
. . 0

MATERIAL NNP 0
AND NNP 0
METHODS NNP 0
Fifteen NNP 0
patients NNS 0
, , 0
each DT 0
with IN 0
a DT 0
pair NN 0
of IN 0
contralateral JJ 0
class-II JJ 0
proximal JJ 0
furcation NN 0
involvements NNS 0
, , 0
presenting VBG 0
probing VBG 0
depths NNS 0
( ( 0
PDs NNP 0
) ) 0
> VBP 0
/=5 JJ 0
mm NN 0
and CC 0
bleeding NN 0
on IN 0
probing VBG 0
( ( 0
BOP NNP 0
) ) 0
were VBD 0
selected VBN 0
. . 0

The DT 0
patients NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
: : 0
control NN 0
group NN 0
( ( 0
n=15 NN 0
) ) 0
- : 0
open JJ 0
flap NN 0
debridement NN 0
( ( 0
OFD NNP 0
) ) 0
+24 CD 0
% NN 0
ethylenediaminetetraacetic JJ 0
acid NN 0
( ( 0
EDTA NNP 0
) ) 0
conditioning NN 0
; : 0
test CC 0
group NN 0
( ( 0
n=15 NN 0
) ) 0
- : 0
OFD+24 CD 0
% NN 0
EDTA NNP 0
conditioning+EMD NN 0
application NN 0
. . 0

Plaque NNP 0
index NN 0
( ( 0
PI NNP 0
) ) 0
, , 0
BOP NNP 0
, , 0
PD NNP 0
, , 0
gingival NN 0
margin NN 0
position NN 0
( ( 0
GMP NNP 0
) ) 0
, , 0
relative JJ 0
vertical NN 0
and CC 0
horizontal JJ 0
clinical JJ 0
attachment NN 0
level NN 0
( ( 0
RVCAL NNP 0
and CC 0
RHCAL NNP 0
) ) 0
, , 0
vertical JJ 0
and CC 0
horizontal JJ 0
bone NN 0
level NN 0
( ( 0
VBL NNP 0
and CC 0
HBL NNP 0
) ) 0
and CC 0
furcation JJ 0
closure NN 0
were VBD 0
evaluated VBN 0
immediately RB 0
before IN 0
and CC 0
2 CD 0
, , 0
4 CD 0
and CC 0
6 CD 0
months NNS 0
after IN 0
the DT 0
surgeries NNS 0
. . 0

RESULTS NNP 0
At IN 0
6 CD 0
months NNS 0
, , 0
the DT 0
RVCAL NNP 0
gains NNS 0
of IN 0
the DT 0
control NN 0
and CC 0
test NN 0
group NN 0
were VBD 0
0.39 CD 0
+/- JJ 0
1.00 CD 0
and CC 0
0.54 CD 0
+/- JJ 0
0.95 CD 0
mm NN 0
, , 0
while IN 0
the DT 0
RHCAL NNP 0
gains NNS 0
were VBD 0
1.21 CD 0
+/- JJ 0
2.28 CD 0
and CC 0
1.36 CD 0
+/- JJ 0
1.26 CD 0
mm NN 0
( ( 0
p JJ 0
> NNP 0
0.05 CD 0
) ) 0
. . 0

The DT 0
VBL NNP 0
and CC 0
HBL NNP 0
gains NNS 0
of IN 0
the DT 0
control NN 0
group NN 0
were VBD 0
1.04 CD 0
+/- JJ 0
1.12 CD 0
and CC 0
1.00 CD 0
+/- JJ 0
1.79 CD 0
mm NN 0
, , 0
and CC 0
0.82 CD 0
+/- JJ 0
1.82 CD 0
and CC 0
1.17 CD 0
+/- JJ 0
1.38 CD 0
mm NN 0
for IN 0
the DT 0
test NN 0
group NN 0
( ( 0
p JJ 0
> NNP 0
0.05 CD 0
) ) 0
. . 0

In IN 0
addition NN 0
, , 0
a DT 0
statistical JJ 0
difference NN 0
was VBD 0
observed VBN 0
in IN 0
the DT 0
number NN 0
of IN 0
the DT 0
remaining VBG 0
class-II JJ 0
furcations NNS 0
between IN 0
the DT 0
test NN 0
and CC 0
control NN 0
groups NNS 0
( ( 0
p JJ 0
< NNP 0
0.05 CD 0
) ) 0
in IN 0
this DT 0
period NN 0
. . 0

CONCLUSION VB 0
It PRP 0
may MD 0
be VB 0
concluded VBN 0
that IN 0
the DT 0
use NN 0
of IN 0
EMD NNP 0
in IN 0
proximal JJ 0
furcations NNS 0
did VBD 0
not RB 0
promote VB 0
a DT 0
superior JJ 0
reduction NN 0
in IN 0
PD NNP 0
or CC 0
a DT 0
gain NN 0
in IN 0
clinical JJ 0
and CC 0
osseous JJ 0
attachment NN 0
levels NNS 0
, , 0
but CC 0
resulted VBD 0
in IN 0
a DT 0
higher JJR 0
rate NN 0
of IN 0
class-II NN 0
to TO 0
class-I JJ 0
furcation NN 0
conversion NN 0
. . 0

Effect NN 0
of IN 0
cigarette NN 0
smoking NN 0
on IN 0
gastric JJ 0
emptying NN 0
of IN 0
solids NNS 0
in IN 0
Japanese JJ 0
smokers NNS 0
: : 0
a DT 0
crossover NN 0
study NN 0
using VBG 0
the DT 0
13C-octanoic JJ 0
acid NN 0
breath NN 0
test NN 0
. . 0

BACKGROUND NNP 0
Cigarette NNP 0
smoking NN 0
is VBZ 0
associated VBN 0
with IN 0
an DT 0
increased VBN 0
risk NN 0
of IN 0
peptic JJ 0
ulcer NN 0
and CC 0
gastroesophageal NN 0
reflux NN 0
disease NN 0
. . 0

Gastric NNP 0
emptying VBG 0
disorders NNS 0
may MD 0
play VB 0
a DT 0
role NN 0
in IN 0
the DT 0
development NN 0
of IN 0
these DT 0
upper JJ 0
gastrointestinal NN 0
diseases NNS 0
. . 0

Thus RB 0
, , 0
studies NNS 0
examining VBG 0
a DT 0
link NN 0
between IN 0
smoking VBG 0
and CC 0
gastric JJ 0
emptying VBG 0
disorders NNS 0
have VBP 0
clinical JJ 0
relevance NN 0
. . 0

This DT 0
study NN 0
was VBD 0
conducted VBN 0
to TO 0
investigate VB 0
the DT 0
effect NN 0
of IN 0
smoking VBG 0
on IN 0
gastric JJ 0
emptying NN 0
of IN 0
solids NNS 0
in IN 0
Japanese JJ 0
smokers NNS 0
. . 0

METHODS PDT 0
The DT 0
( ( 0
13 CD 0
) ) 0
C-octanoic NNP 0
acid JJ 0
breath NN 0
test NN 0
was VBD 0
performed VBN 0
in IN 0
eight CD 0
male JJ 0
habitual JJ 0
smokers NNS 0
on IN 0
two CD 0
randomized JJ 0
occasions NNS 0
( ( 0
either DT 0
sham NN 0
smoking NN 0
or CC 0
actively RB 0
smoking VBG 0
) ) 0
. . 0

The DT 0
time NN 0
vs NN 0
( ( 0
13 CD 0
) ) 0
CO NNP 0
( ( 0
2 CD 0
) ) 0
excretion NN 0
rate NN 0
curve NN 0
was VBD 0
mathematically RB 0
fitted VBN 0
to TO 0
a DT 0
conventional JJ 0
formula NN 0
of IN 0
y NN 0
( ( 0
t NN 0
) ) 0
= NN 0
m*k*beta*e NN 0
( ( 0
-k*t NNP 0
) ) 0
* NNP 0
( ( 0
1 CD 0
- : 0
e NN 0
( ( 0
-k*t NNP 0
) ) 0
) ) 0
( ( 0
beta-1 NN 0
) ) 0
, , 0
and CC 0
the DT 0
parameters NNS 0
of IN 0
k NN 0
and CC 0
beta NN 0
were VBD 0
determined VBN 0
: : 0
under IN 0
the DT 0
crossover NN 0
protocol NN 0
, , 0
a DT 0
larger JJR 0
( ( 0
smaller JJR 0
) ) 0
beta NN 0
indicates VBZ 0
slower JJR 0
( ( 0
faster RBR 0
) ) 0
emptying VBG 0
in IN 0
the DT 0
early JJ 0
phase NN 0
, , 0
and CC 0
a DT 0
larger JJR 0
( ( 0
smaller JJR 0
) ) 0
k NN 0
indicates VBZ 0
faster RBR 0
( ( 0
slower JJR 0
) ) 0
emptying VBG 0
in IN 0
the DT 0
later JJ 0
phase NN 0
. . 0

The DT 0
half NN 0
( ( 0
13 CD 0
) ) 0
CO NNP 0
( ( 0
2 CD 0
) ) 0
excretion NN 0
time NN 0
( ( 0
t NN 0
( ( 0
1/2b CD 0
) ) 0
= SYM 0
- : 0
[ NN 0
ln NN 0
( ( 0
1 CD 0
- : 0
2 CD 0
( ( 0
-1/beta NNP 0
) ) 0
) ) 0
] FW 0
/k NN 0
) ) 0
and CC 0
the DT 0
time NN 0
of IN 0
maximal NN 0
( ( 0
13 CD 0
) ) 0
CO NNP 0
( ( 0
2 CD 0
) ) 0
excretion NN 0
rate NN 0
( ( 0
t NN 0
( ( 0
max NN 0
) ) 0
= VBZ 0
[ JJ 0
lnbeta NN 0
] NNP 0
/k NNP 0
) ) 0
were VBD 0
also RB 0
calculated VBN 0
. . 0

Between IN 0
the DT 0
two CD 0
occasions NNS 0
, , 0
k NN 0
, , 0
beta NN 0
, , 0
t NN 0
( ( 0
1/2b CD 0
) ) 0
, , 0
and CC 0
t NN 0
( ( 0
max NN 0
) ) 0
were VBD 0
compared VBN 0
by IN 0
the DT 0
Wilcoxon NNP 0
signed-rank JJ 0
test NN 0
. . 0

RESULTS NNP 0
After IN 0
smoking VBG 0
, , 0
k NN 0
was VBD 0
significantly RB 0
increased VBN 0
. . 0

No DT 0
significant JJ 0
differences NNS 0
were VBD 0
found VBN 0
in IN 0
beta NN 0
, , 0
t NN 0
( ( 0
1/2 CD 0
) ) 0
, , 0
and CC 0
t NN 0
( ( 0
max NN 0
) ) 0
between IN 0
the DT 0
two CD 0
occasions NNS 0
. . 0

CONCLUSIONS VB 0
The DT 0
increase NN 0
in IN 0
k JJ 0
suggests VBZ 0
the DT 0
acceleration NN 0
of IN 0
gastric JJ 0
emptying VBG 0
in IN 0
the DT 0
later JJ 0
phase NN 0
. . 0

For IN 0
the DT 0
first JJ 0
time NN 0
, , 0
this DT 0
study NN 0
has VBZ 0
revealed VBN 0
that IN 0
acute JJ 0
smoking NN 0
speeds VBZ 0
the DT 0
gastric JJ 0
emptying NN 0
of IN 0
solids NNS 0
in IN 0
Japanese JJ 0
habitual JJ 0
smokers NNS 0
. . 0

Gastric JJ 0
ulcer NN 0
treatment NN 0
with IN 0
intravenous JJ 0
human JJ 0
epidermal JJ 0
growth NN 0
factor NN 0
: : 0
a DT 0
double-blind NN 0
controlled VBN 0
clinical JJ 0
study NN 0
. . 0

We PRP 0
introduced VBD 0
a DT 0
double-blind NN 0
controlled VBN 0
clinical JJ 0
study NN 0
to TO 0
compare VB 0
intravenous JJ 0
human JJ 0
epidermal JJ 0
growth NN 0
factor NN 0
( ( 0
hEGF NN 0
) ) 0
to TO 0
cetraxate VB 0
hydrochloride NN 0
( ( 0
CH NNP 0
) ) 0
, , 0
an DT 0
antiulcer JJ 0
drug NN 0
, , 0
for IN 0
their PRP$ 0
healing NN 0
effect NN 0
on IN 0
gastric JJ 0
ulcers NNS 0
. . 0

We PRP 0
also RB 0
prospected VBD 0
an DT 0
oral JJ 0
use NN 0
of IN 0
EGF NNP 0
on IN 0
the DT 0
basis NN 0
of IN 0
our PRP$ 0
experimental JJ 0
evidence NN 0
. . 0

In IN 0
the DT 0
clinical JJ 0
trial NN 0
, , 0
the DT 0
rate NN 0
of IN 0
ulcer NN 0
healing VBG 0
within IN 0
8 CD 0
weeks NNS 0
was VBD 0
77.9 CD 0
% NN 0
( ( 0
67/86 CD 0
) ) 0
in IN 0
patients NNS 0
receiving VBG 0
6 CD 0
micrograms NNS 0
EGF NNP 0
intravenously RB 0
twice RB 0
a DT 0
week NN 0
, , 0
being VBG 0
significantly RB 0
greater JJR 0
than IN 0
51.7 CD 0
% NN 0
( ( 0
45/87 CD 0
) ) 0
in IN 0
those DT 0
given VBN 0
CH NNP 0
. . 0

Taking VBG 0
together RB 0
all DT 0
aspects NNS 0
assessed VBD 0
including VBG 0
the DT 0
healing NN 0
rate NN 0
, , 0
pain NN 0
relief NN 0
, , 0
blood NN 0
examination NN 0
and CC 0
adverse JJ 0
reactions NNS 0
, , 0
we PRP 0
judged VBD 0
the DT 0
hEGF NN 0
to TO 0
be VB 0
a DT 0
useful JJ 0
and CC 0
safe JJ 0
anticuler NN 0
drug NN 0
. . 0

In IN 0
rats NNS 0
, , 0
50 CD 0
micrograms/kg NN 0
mouse NN 0
EGF NNP 0
( ( 0
mEGF NN 0
) ) 0
and CC 0
2 CD 0
% NN 0
hydroxypropyl NN 0
cellulose NN 0
( ( 0
HPC NNP 0
) ) 0
or CC 0
1.0 CD 0
g/kg JJ 0
sucralfate NN 0
given VBN 0
by IN 0
gastric JJ 0
intubation NN 0
significantly RB 0
raised VBD 0
the DT 0
residual JJ 0
mEGF NN 0
levels NNS 0
in IN 0
both DT 0
gastric JJ 0
luminal JJ 0
content NN 0
( ( 0
HPC NNP 0
: : 0
x JJ 0
30 CD 0
; : 0
sucralfate NN 0
: : 0
x RB 0
300 CD 0
as RB 0
high JJ 0
as IN 0
those DT 0
in IN 0
EGF NNP 0
alone RB 0
) ) 0
and CC 0
tissue NN 0
( ( 0
HPC NNP 0
: : 0
x JJ 0
60 CD 0
; : 0
sucralfate NN 0
: : 0
x JJ 0
100 CD 0
) ) 0
. . 0

In IN 0
addition NN 0
, , 0
the DT 0
combined JJ 0
treatments NNS 0
significantly RB 0
promoted VBD 0
healing NN 0
of IN 0
rat NN 0
gastric JJ 0
ulcers NNS 0
whereas VBP 0
each DT 0
agent NN 0
alone RB 0
had VBD 0
no DT 0
significant JJ 0
effect NN 0
as IN 0
compared VBN 0
with IN 0
control NN 0
( ( 0
saline NN 0
) ) 0
. . 0

This DT 0
indicated VBD 0
the DT 0
beneficial JJ 0
effect NN 0
on IN 0
ulcers NNS 0
of IN 0
oral JJ 0
administration NN 0
of IN 0
EGF NNP 0
with IN 0
agents NNS 0
allowing VBG 0
it PRP 0
to TO 0
remain VB 0
at IN 0
high JJ 0
levels NNS 0
in IN 0
the DT 0
stomach NN 0
, , 0
whereas IN 0
most JJS 0
reports NNS 0
suggested VBD 0
less RBR 0
effect NN 0
of IN 0
oral JJ 0
EGF NNP 0
on IN 0
healing NN 0
of IN 0
gastroduodenal JJ 0
ulcers NNS 0
. . 0

Subsequent JJ 0
to TO 0
the DT 0
clinical JJ 0
study NN 0
, , 0
evaluation NN 0
of IN 0
oral JJ 0
use NN 0
of IN 0
EGF NNP 0
may MD 0
be VB 0
expected VBN 0
as IN 0
the DT 0
next JJ 0
step NN 0
in IN 0
the DT 0
treatment NN 0
of IN 0
ulcers NNS 0
. . 0

The DT 0
experimental JJ 0
evidence NN 0
above IN 0
would MD 0
possibly RB 0
be VB 0
a DT 0
guide NN 0
for IN 0
such JJ 0
trial NN 0
. . 0

Double-blind NNP 0
comparison NN 0
of IN 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
trandolapril JJ 0
2 CD 0
mg NN 0
and CC 0
hydrochlorothiazide VB 0
25 CD 0
mg NNS 0
in IN 0
patients NNS 0
with IN 0
mild-to-moderate JJ 0
essential JJ 0
hypertension NN 0
. . 0

Investigator NNP 0
Study NNP 0
Group NNP 0
. . 0

This DT 0
multicenter NN 0
international JJ 0
trial NN 0
recruited VBD 0
205 CD 0
patients NNS 0
from IN 0
16 CD 0
investigators NNS 0
. . 0

After IN 0
a DT 0
4-week JJ 0
, , 0
single-blind JJ 0
placebo NN 0
run-in NN 0
, , 0
patients NNS 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
16 CD 0
weeks NNS 0
of IN 0
trandolapril JJ 0
2 CD 0
mg/day NN 0
( ( 0
68 CD 0
patients NNS 0
) ) 0
, , 0
hydrochlorothiazide RB 0
( ( 0
HCTZ NNP 0
) ) 0
25 CD 0
mg/day NN 0
( ( 0
68 CD 0
patients NNS 0
) ) 0
, , 0
or CC 0
the DT 0
combination NN 0
( ( 0
69 CD 0
patients NNS 0
) ) 0
. . 0

Morning VBG 0
predosing VBG 0
supine NN 0
diastolic JJ 0
blood NN 0
pressure NN 0
( ( 0
DBP NNP 0
) ) 0
was VBD 0
the DT 0
primary JJ 0
efficacy NN 0
measurement NN 0
. . 0

Intention-to-treat JJ 0
analysis NN 0
showed VBD 0
significant JJ 0
decreases NNS 0
in IN 0
all DT 0
three CD 0
groups NNS 0
in IN 0
mean JJ 0
( ( 0
+/- JJ 0
SEM NNP 0
) ) 0
supine NN 0
DBP NNP 0
throughout IN 0
the DT 0
study NN 0
, , 0
with IN 0
no DT 0
significant JJ 0
differences NNS 0
at IN 0
week NN 0
16 CD 0
between IN 0
trandolapril NN 0
( ( 0
-10.6 JJ 0
+/- JJ 0
1.3 CD 0
mm NN 0
Hg NNP 0
) ) 0
and CC 0
HCTZ NNP 0
( ( 0
-10.9 JJ 0
+/- JJ 0
1.3 CD 0
mm NN 0
Hg NNP 0
) ) 0
. . 0

The DT 0
combination NN 0
gave VBD 0
a DT 0
significantly RB 0
greater JJR 0
reduction NN 0
than IN 0
either DT 0
drug NN 0
alone RB 0
( ( 0
-15.1 JJ 0
+/- JJ 0
1.13 CD 0
mm NN 0
Hg NNP 0
) ) 0
. . 0

Blood NNP 0
pressure NN 0
was VBD 0
normalized VBN 0
in IN 0
the DT 0
combination NN 0
group NN 0
in IN 0
67 CD 0
% NN 0
of IN 0
patients NNS 0
, , 0
a DT 0
significantly RB 0
higher JJR 0
proportion NN 0
than IN 0
either DT 0
trandolapril NN 0
( ( 0
63 CD 0
% NN 0
) ) 0
or CC 0
HCTZ NNP 0
( ( 0
60 CD 0
% NN 0
; : 0
p CC 0
= VB 0
0.04 CD 0
) ) 0
. . 0

Each DT 0
treatment NN 0
was VBD 0
well RB 0
tolerated VBN 0
. . 0

The DT 0
incidence NN 0
of IN 0
adverse JJ 0
events NNS 0
was VBD 0
similar JJ 0
in IN 0
all DT 0
three CD 0
groups NNS 0
. . 0

Trandolapril NNP 0
2 CD 0
mg NN 0
once RB 0
daily JJ 0
is VBZ 0
an DT 0
effective JJ 0
antihypertensive JJ 0
agent NN 0
, , 0
comparable JJ 0
to TO 0
HCTZ NNP 0
. . 0

Furthermore NNP 0
, , 0
the DT 0
combination NN 0
of IN 0
the DT 0
two CD 0
drugs NNS 0
was VBD 0
shown VBN 0
to TO 0
enhance VB 0
the DT 0
antihypertensive JJ 0
effect NN 0
of IN 0
the DT 0
two CD 0
compounds NNS 0
alone RB 0
. . 0

Enhancing VBG 0
the DT 0
self-esteem NN 0
of IN 0
inpatient JJ 0
alcoholics NNS 0
. . 0

This DT 0
study NN 0
examined VBD 0
the DT 0
effect NN 0
of IN 0
pairing VBG 0
inpatient JJ 0
alcoholics NNS 0
with IN 0
nursing NN 0
home NN 0
residents NNS 0
( ( 0
NHRs NNP 0
) ) 0
on IN 0
the DT 0
alcoholics NNS 0
' POS 0
self-esteem NN 0
. . 0

In IN 0
this DT 0
PALS NNP 0
program NN 0
, , 0
the DT 0
alcoholic JJ 0
inpatients NNS 0
assumed VBD 0
a DT 0
helping-companion NN 0
relationship NN 0
with IN 0
the DT 0
NHRs NNP 0
for IN 0
2 CD 0
hr NNS 0
per IN 0
day NN 0
during IN 0
their PRP$ 0
last JJ 0
2 CD 0
weeks NNS 0
of IN 0
treatment NN 0
. . 0

Fifty NNP 0
alcoholic JJ 0
inpatients NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
the DT 0
PALS NNP 0
program NN 0
( ( 0
n JJ 0
= NNP 0
25 CD 0
) ) 0
or CC 0
to TO 0
the DT 0
library NN 0
for IN 0
free JJ 0
reading NN 0
time NN 0
( ( 0
n JJ 0
= NNP 0
25 CD 0
) ) 0
. . 0

The DT 0
Tennessee NNP 0
Self-Concept NNP 0
Scale NNP 0
( ( 0
TSCS NNP 0
) ) 0
was VBD 0
administered VBN 0
to TO 0
all DT 0
subjects NNS 0
in IN 0
both DT 0
groups NNS 0
before IN 0
and CC 0
after IN 0
the DT 0
interventions NNS 0
. . 0

Of IN 0
the DT 0
nine CD 0
TSCS NNP 0
scales NNS 0
, , 0
the DT 0
improvement NN 0
on IN 0
the DT 0
Moral-Ethical JJ 0
scale NN 0
was VBD 0
significantly RB 0
greater JJR 0
in IN 0
the DT 0
PALS NNP 0
group NN 0
. . 0

Because IN 0
the DT 0
alcoholic JJ 0
inpatients NNS 0
in IN 0
the DT 0
PALS NNP 0
group NN 0
engaged VBD 0
in IN 0
altruistic JJ 0
( ( 0
moral JJ 0
) ) 0
behavior NN 0
, , 0
this DT 0
study NN 0
provides VBZ 0
a DT 0
logical JJ 0
link NN 0
between IN 0
the DT 0
intervention NN 0
and CC 0
the DT 0
outcome NN 0
, , 0
which WDT 0
has VBZ 0
been VBN 0
a DT 0
prevalent JJ 0
weakness NN 0
in IN 0
previous JJ 0
studies NNS 0
of IN 0
self-esteem NN 0
in IN 0
alcoholics NNS 0
. . 0

Effects NNS 0
of IN 0
three CD 0
oral JJ 0
analgesics NNS 0
on IN 0
postoperative JJ 0
pain NN 0
following VBG 0
root JJ 0
canal JJ 0
preparation NN 0
: : 0
a DT 0
controlled JJ 0
clinical JJ 0
trial NN 0
. . 0

AIM NNP 0
To TO 0
compare VB 0
the DT 0
effects NNS 0
of IN 0
single JJ 0
doses NNS 0
of IN 0
three CD 0
oral JJ 0
medications NNS 0
on IN 0
postoperative JJ 0
pain NN 0
following VBG 0
instrumentation NN 0
of IN 0
root NN 0
canals NNS 0
in IN 0
teeth NN 0
with IN 0
irreversible JJ 0
pulpitis NN 0
. . 0

METHODOLOGY NNP 0
In IN 0
this DT 0
double-blind JJ 0
clinical JJ 0
trial NN 0
, , 0
100 CD 0
patients NNS 0
who WP 0
had VBD 0
anterior CC 0
or CC 0
premolar JJ 0
teeth NNS 0
with IN 0
irreversible JJ 0
pulpitis NN 0
without IN 0
any DT 0
signs NNS 0
and CC 0
symptoms NNS 0
of IN 0
acute NN 0
or CC 0
chronic JJ 0
apical JJ 0
periodontitis NN 0
and CC 0
moderate VB 0
to TO 0
severe VB 0
pain NN 0
were VBD 0
divided VBN 0
by IN 0
balanced JJ 0
block NN 0
random NN 0
allocation NN 0
into IN 0
four CD 0
groups NNS 0
of IN 0
25 CD 0
each DT 0
, , 0
a DT 0
control NN 0
group NN 0
receiving VBG 0
a DT 0
placebo NN 0
medication NN 0
, , 0
and CC 0
three CD 0
experimental JJ 0
groups NNS 0
receiving VBG 0
a DT 0
single JJ 0
dose NN 0
of IN 0
either DT 0
Tramadol NNP 0
( ( 0
100 CD 0
mg NN 0
) ) 0
, , 0
Novafen NNP 0
( ( 0
325 CD 0
mg NN 0
of IN 0
paracetamol NN 0
, , 0
200 CD 0
mg NN 0
ibuprofen NN 0
and CC 0
40 CD 0
mg NNS 0
caffeine VBP 0
anhydrous JJ 0
) ) 0
or CC 0
Naproxen NNP 0
( ( 0
500 CD 0
mg NN 0
) ) 0
immediately RB 0
after IN 0
the DT 0
first JJ 0
appointment NN 0
where WRB 0
the DT 0
pulp NN 0
was VBD 0
removed VBN 0
, , 0
and CC 0
the DT 0
canals NNS 0
were VBD 0
fully RB 0
prepared VBN 0
. . 0

The DT 0
intensity NN 0
of IN 0
pain NN 0
was VBD 0
scored VBN 0
based VBN 0
on IN 0
10-point JJ 0
VAS NNP 0
before IN 0
and CC 0
after IN 0
treatment NN 0
for IN 0
up IN 0
to TO 0
24 CD 0
h NN 0
postoperatively RB 0
. . 0

Data NNS 0
were VBD 0
submitted VBN 0
to TO 0
repeated VBN 0
analysis NN 0
of IN 0
variance NN 0
. . 0

RESULTS NNP 0
At IN 0
the DT 0
6 CD 0
, , 0
12 CD 0
and CC 0
24 CD 0
h NNS 0
postoperative JJ 0
intervals NNS 0
after IN 0
drug NN 0
administration NN 0
, , 0
the DT 0
intensity NN 0
of IN 0
pain NN 0
was VBD 0
significantly RB 0
lower JJR 0
in IN 0
the DT 0
experimental NN 0
groups NNS 0
than IN 0
in IN 0
the DT 0
placebo NN 0
group NN 0
( ( 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
. . 0

Tramadol NNP 0
was VBD 0
significantly RB 0
less RBR 0
effective JJ 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
than IN 0
Naproxen NNP 0
, , 0
and CC 0
Novafen NNP 0
that WDT 0
were VBD 0
similar JJ 0
to TO 0
each DT 0
other JJ 0
( ( 0
P NNP 0
> NNP 0
0.05 CD 0
) ) 0
. . 0

CONCLUSION VB 0
A DT 0
single JJ 0
oral JJ 0
dose NN 0
of IN 0
Naproxen NNP 0
, , 0
Novafen NNP 0
and CC 0
Tramadol NNP 0
taken VBN 0
immediately RB 0
after IN 0
treatment NN 0
reduced VBD 0
postoperative JJ 0
pain NN 0
following VBG 0
pulpectomy NN 0
and CC 0
root JJ 0
canal JJ 0
preparation NN 0
of IN 0
teeth NNS 0
with IN 0
irreversible JJ 0
pulpitis NN 0
. . 0

Acute JJ 0
exposure NN 0
to TO 0
acid VB 0
fog NN 0
: : 0
influence NN 0
of IN 0
breathing VBG 0
pattern NN 0
on IN 0
effective JJ 0
dose NN 0
. . 0

Concern JJ 0
about IN 0
the DT 0
possible JJ 0
adverse JJ 0
health NN 0
effects NNS 0
of IN 0
acid NN 0
fog NN 0
has VBZ 0
been VBN 0
fed VBN 0
by IN 0
two CD 0
observations NNS 0
: : 0
air NN 0
pollution NN 0
disasters NNS 0
earlier RBR 0
in IN 0
this DT 0
century NN 0
were VBD 0
typically RB 0
associated VBN 0
with IN 0
fog NN 0
, , 0
and CC 0
current JJ 0
samples NNS 0
of IN 0
fog JJ 0
water NN 0
can MD 0
be VB 0
strongly RB 0
acid JJ 0
. . 0

To TO 0
study VB 0
the DT 0
acute JJ 0
effects NNS 0
of IN 0
acid JJ 0
fog NN 0
on IN 0
the DT 0
lung NN 0
, , 0
the DT 0
authors NNS 0
generated VBD 0
a DT 0
monodisperse JJ 0
10 CD 0
microM NN 0
MMAD NNP 0
aerosol NN 0
of IN 0
H2SO4 NNP 0
with IN 0
a DT 0
pH NN 0
of IN 0
2.0 CD 0
and CC 0
a DT 0
nominal JJ 0
concentration NN 0
of IN 0
500 CD 0
micrograms/m3 NNS 0
. . 0

They PRP 0
exposed VBD 0
seven CD 0
healthy JJ 0
young JJ 0
men NNS 0
on IN 0
alternate NN 0
days NNS 0
to TO 0
acid VB 0
or CC 0
control VB 0
equiosmolar JJ 0
NaCl NNP 0
aerosol NN 0
during IN 0
40 CD 0
min NNS 0
of IN 0
resting VBG 0
ventilation NN 0
and CC 0
20 CD 0
min NN 0
of IN 0
exercise NN 0
; : 0
the DT 0
latter NN 0
was VBD 0
sufficiently RB 0
intense JJ 0
to TO 0
induce VB 0
oronasal RP 0
breathing VBG 0
. . 0

Exposure NN 0
was VBD 0
by IN 0
means NNS 0
of IN 0
a DT 0
head NN 0
dome NN 0
, , 0
a DT 0
head-only JJ 0
exposure NN 0
device NN 0
that WDT 0
permitted VBD 0
continuous JJ 0
measurement NN 0
( ( 0
unfettered JJ 0
breathing NN 0
) ) 0
of IN 0
Vr NNP 0
, , 0
f NN 0
, , 0
VE NNP 0
, , 0
and CC 0
the DT 0
onset NN 0
and CC 0
persistence NN 0
of IN 0
oronasal NN 0
breathing NN 0
. . 0

In IN 0
this DT 0
article NN 0
the DT 0
authors NNS 0
compare VBP 0
the DT 0
relative JJ 0
importance NN 0
of IN 0
parameters NNS 0
contributing VBG 0
to TO 0
the DT 0
between-subject JJ 0
variability NN 0
in IN 0
estimated VBN 0
hydrogen NN 0
ion NN 0
dose NN 0
to TO 0
the DT 0
lower JJR 0
airways NNS 0
( ( 0
H+LAW NNP 0
) ) 0
, , 0
based VBN 0
on IN 0
analysis NN 0
of IN 0
variance NN 0
. . 0

Physiologic NNP 0
parameters NNS 0
accounted VBD 0
for IN 0
70 CD 0
% NN 0
of IN 0
the DT 0
variability NN 0
, , 0
of IN 0
which WDT 0
34 CD 0
% NN 0
was VBD 0
due JJ 0
to TO 0
differences NNS 0
in IN 0
duration NN 0
of IN 0
oronasal NN 0
breathing NN 0
( ( 0
tON NN 0
) ) 0
and CC 0
36 CD 0
% NN 0
to TO 0
differences NNS 0
in IN 0
ventilation NN 0
rate NN 0
during IN 0
oronasal NN 0
breathing NN 0
( ( 0
VE NNP 0
( ( 0
ON NNP 0
) ) 0
) ) 0
; : 0
inhaled VBN 0
hydrogen NN 0
ion NN 0
concentration NN 0
[ NNP 0
H+ NNP 0
] NNP 0
, , 0
the DT 0
environmental JJ 0
parameter NN 0
, , 0
contributed VBD 0
only RB 0
30 CD 0
% NN 0
. . 0

Minute JJ 0
ventilation NN 0
at IN 0
the DT 0
time NN 0
of IN 0
transition NN 0
from IN 0
nasal NN 0
to TO 0
oronasal VB 0
breathing VBG 0
varied JJ 0
significantly RB 0
among IN 0
subjects NNS 0
even RB 0
if IN 0
normalized VBN 0
to TO 0
FVC NNP 0
, , 0
an DT 0
index NN 0
of IN 0
lung NN 0
size NN 0
. . 0

Combined VBN 0
typhoid JJ 0
fever NN 0
and CC 0
hepatitis VB 0
A DT 0
vaccine NN 0
: : 0
comparison NN 0
of IN 0
immunogenicity NN 0
and CC 0
safety NN 0
to TO 0
concomitant VB 0
monovalent JJ 0
vaccine NN 0
over IN 0
3 CD 0
years NNS 0
. . 0

BACKGROUND IN 0
The DT 0
safety NN 0
and CC 0
immunogenicity NN 0
of IN 0
Viatim NNP 0
, , 0
a DT 0
combined JJ 0
hepatitis NN 0
A NNP 0
( ( 0
HA NNP 0
) ) 0
and CC 0
typhoid JJ 0
fever NN 0
( ( 0
Vi NNP 0
) ) 0
vaccine NN 0
, , 0
were VBD 0
compared VBN 0
with IN 0
the DT 0
monovalent JJ 0
component NN 0
vaccines VBZ 0
up IN 0
to TO 0
and CC 0
1 CD 0
month NN 0
after IN 0
a DT 0
booster NN 0
dose NN 0
at IN 0
3 CD 0
years NNS 0
. . 0

METHODS NNP 0
Healthy NNP 0
, , 0
adult NN 0
volunteers NNS 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
Viatim NNP 0
( ( 0
group NN 0
A NNP 0
, , 0
n JJ 0
= NNP 0
179 CD 0
) ) 0
or CC 0
separate JJ 0
HA NNP 0
and CC 0
Vi NNP 0
vaccines NNS 0
( ( 0
group NN 0
B NNP 0
, , 0
n JJ 0
= NNP 0
181 CD 0
) ) 0
; : 0
subgroups NNS 0
were VBD 0
boosted VBN 0
after IN 0
3 CD 0
years NNS 0
with IN 0
Viatim NNP 0
( ( 0
groups NNS 0
C NNP 0
and CC 0
D NNP 0
, , 0
n JJ 0
= NN 0
56 CD 0
and CC 0
46 CD 0
, , 0
respectively RB 0
) ) 0
. . 0

Local JJ 0
and CC 0
systemic JJ 0
reactions NNS 0
were VBD 0
recorded VBN 0
for IN 0
28 CD 0
days NNS 0
postvaccination NN 0
. . 0

Seroconversion NN 0
and CC 0
seroprotection NN 0
rates NNS 0
and CC 0
geometric JJ 0
mean NN 0
antibody NN 0
concentrations NNS 0
were VBD 0
measured VBN 0
at IN 0
14 CD 0
and CC 0
28 CD 0
days NNS 0
, , 0
1 CD 0
, , 0
2 CD 0
, , 0
and CC 0
3 CD 0
years NNS 0
postvaccination NN 0
, , 0
and CC 0
28 CD 0
days NNS 0
after IN 0
the DT 0
booster NN 0
dose NN 0
. . 0

RESULTS NNP 0
Local NNP 0
and CC 0
systemic JJ 0
safety NN 0
profiles NNS 0
were VBD 0
equivalent JJ 0
between IN 0
the DT 0
two CD 0
groups NNS 0
. . 0

Immediate NNP 0
local JJ 0
reactions NNS 0
were VBD 0
infrequent JJ 0
( ( 0
1 CD 0
in IN 0
group NN 0
A NNP 0
and CC 0
2 CD 0
in IN 0
group NN 0
B NNP 0
) ) 0
. . 0

Local JJ 0
reactions NNS 0
, , 0
consisting VBG 0
mostly RB 0
of IN 0
mild NN 0
or CC 0
moderate JJ 0
pain NN 0
, , 0
were VBD 0
least JJS 0
frequent JJ 0
with IN 0
monovalent JJ 0
HA NNP 0
. . 0

Antibody NNP 0
concentrations NNS 0
to TO 0
both DT 0
antigens NNS 0
were VBD 0
similar JJ 0
in IN 0
groups NNS 0
A NNP 0
and CC 0
B NNP 0
, , 0
in IN 0
which WDT 0
HA NNP 0
seroprotection NN 0
rates NNS 0
( ( 0
> CD 0
or CC 0
= VB 0
20 CD 0
mIU/mL NN 0
) ) 0
were VBD 0
respectively RB 0
, , 0
98.7 CD 0
% NN 0
and CC 0
100 CD 0
% NN 0
at IN 0
day NN 0
28 CD 0
, , 0
and CC 0
99.1 CD 0
% NN 0
and CC 0
99.0 CD 0
% NN 0
after IN 0
3 CD 0
years NNS 0
, , 0
achieving VBG 0
100 CD 0
% NN 0
after IN 0
the DT 0
booster NN 0
. . 0

Vi NNP 0
seroprotection NN 0
rates NNS 0
( ( 0
> CD 0
or CC 0
= VB 0
1 CD 0
microg/mL NN 0
) ) 0
of IN 0
85.2 CD 0
% NN 0
and CC 0
84.9 CD 0
% NN 0
after IN 0
28 CD 0
days NNS 0
fell VBD 0
to TO 0
32.1 CD 0
% NN 0
and CC 0
35.6 CD 0
% NN 0
after IN 0
3 CD 0
years NNS 0
, , 0
increasing VBG 0
to TO 0
67.3 CD 0
% NN 0
and CC 0
69.8 CD 0
% NN 0
after IN 0
the DT 0
booster NN 0
dose NN 0
. . 0

CONCLUSIONS VB 0
The DT 0
combined JJ 0
HA/Vi NNP 0
vaccine NN 0
, , 0
Viatim NNP 0
, , 0
had VBD 0
equivalent JJ 0
tolerability NN 0
and CC 0
safety NN 0
and CC 0
was VBD 0
as IN 0
rapidly RB 0
immunogenic JJ 0
as IN 0
its PRP$ 0
component NN 0
monovalent NN 0
vaccines NNS 0
when WRB 0
given VBN 0
concurrently RB 0
. . 0

A DT 0
booster NN 0
dose NN 0
after IN 0
3 CD 0
years NNS 0
significantly RB 0
increased VBD 0
antibody NN 0
levels NNS 0
with IN 0
some DT 0
evidence NN 0
of IN 0
relative JJ 0
hyporesponsiveness NN 0
of IN 0
the DT 0
typhoid JJ 0
response NN 0
. . 0

Recombinant JJ 0
human JJ 0
erythropoietin NN 0
therapy NN 0
for IN 0
anemic JJ 0
cancer NN 0
patients NNS 0
on IN 0
combination NN 0
chemotherapy NN 0
. . 0

BACKGROUND NNP 0
Patients NNPS 0
with IN 0
advanced JJ 0
cancer NN 0
frequently RB 0
experience VBZ 0
clinically RB 0
significant JJ 0
anemia NN 0
, , 0
which WDT 0
is VBZ 0
often RB 0
exacerbated VBN 0
by IN 0
myelosuppressive JJ 0
chemotherapy NN 0
. . 0

Consistent JJ 0
with IN 0
the DT 0
anemia NN 0
of IN 0
chronic JJ 0
disease NN 0
, , 0
studies NNS 0
have VBP 0
documented VBN 0
serum JJ 0
erythropoietin NN 0
levels NNS 0
that WDT 0
are VBP 0
inappropriately RB 0
low JJ 0
for IN 0
the DT 0
degree NN 0
of IN 0
anemia NN 0
in IN 0
cancer NN 0
patients NNS 0
. . 0

Myelosuppressive JJ 0
chemotherapy NN 0
impairs NNS 0
erythropoiesis NN 0
, , 0
which WDT 0
may MD 0
not RB 0
fully RB 0
recover VB 0
between IN 0
treatment NN 0
cycles NNS 0
. . 0

Recombinant NNP 0
human JJ 0
erythropoietin NN 0
( ( 0
rHuEPO NN 0
) ) 0
has VBZ 0
been VBN 0
used VBN 0
safely RB 0
and CC 0
effectively RB 0
to TO 0
treat VB 0
anemia NN 0
in IN 0
AIDS NNP 0
patients NNS 0
receiving VBG 0
zidovudine NN 0
( ( 0
AZT NNP 0
) ) 0
and CC 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 0
renal JJ 0
failure NN 0
. . 0

PURPOSE VB 0
This DT 0
study NN 0
was VBD 0
designed VBN 0
to TO 0
evaluate VB 0
the DT 0
clinical JJ 0
role NN 0
of IN 0
rHuEPO NN 0
in IN 0
reducing VBG 0
symptomatic JJ 0
anemia NN 0
in IN 0
patients NNS 0
with IN 0
advanced JJ 0
cancer NN 0
who WP 0
were VBD 0
receiving VBG 0
myelosuppressive JJ 0
chemotherapy NN 0
( ( 0
excluding VBG 0
cisplatin NN 0
) ) 0
. . 0

METHODS NNP 0
We PRP 0
studied VBD 0
153 CD 0
anemic JJ 0
cancer NN 0
patients NNS 0
receiving VBG 0
cyclic JJ 0
combination NN 0
chemotherapy NN 0
in IN 0
a DT 0
prospective JJ 0
multicenter NN 0
, , 0
double-blind JJ 0
, , 0
placebo-controlled JJ 0
trial NN 0
. . 0

The DT 0
patients NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
either DT 0
rHuEPO NN 0
( ( 0
150 CD 0
U/kg NNP 0
) ) 0
or CC 0
placebo NN 0
subcutaneously RB 0
three CD 0
times NNS 0
a DT 0
week NN 0
for IN 0
a DT 0
maximum NN 0
of IN 0
12 CD 0
weeks NNS 0
or CC 0
until IN 0
the DT 0
hematocrit JJ 0
level NN 0
increased VBD 0
to TO 0
38 CD 0
% NN 0
-40 JJ 0
% NN 0
. . 0

If IN 0
the DT 0
hematocrit NN 0
reached VBD 0
this DT 0
target NN 0
level NN 0
before IN 0
12 CD 0
weeks NNS 0
, , 0
the DT 0
rHuEPO NN 0
dose NN 0
could MD 0
be VB 0
reduced VBN 0
to TO 0
maintain VB 0
the DT 0
hematocrit NN 0
at IN 0
that DT 0
level NN 0
for IN 0
the DT 0
duration NN 0
of IN 0
the DT 0
study NN 0
. . 0

Response NNP 0
to TO 0
rHuEPO VB 0
therapy NN 0
was VBD 0
assessed VBN 0
by IN 0
measuring VBG 0
changes NNS 0
in IN 0
hematocrit NN 0
level NN 0
, , 0
transfusion NN 0
requirements NNS 0
, , 0
and CC 0
quality NN 0
of IN 0
life NN 0
. . 0

Quality-of-life JJ 0
assessment NN 0
was VBD 0
based VBN 0
on IN 0
patients NNS 0
' POS 0
responses NNS 0
to TO 0
questionnaires NNS 0
before IN 0
and CC 0
after IN 0
the DT 0
courses NNS 0
of IN 0
therapy NN 0
. . 0

RESULTS VB 0
The DT 0
increase NN 0
in IN 0
hematocrit NN 0
in IN 0
the DT 0
rHuEPO-treated JJ 0
group NN 0
compared VBN 0
with IN 0
hematocrit NN 0
in IN 0
the DT 0
placebo-treated JJ 0
group NN 0
was VBD 0
statistically RB 0
significant JJ 0
( ( 0
P NNP 0
= NNP 0
.0001 NNP 0
) ) 0
as IN 0
measured VBN 0
by IN 0
percentage NN 0
point NN 0
of IN 0
change NN 0
from IN 0
baseline NN 0
to TO 0
final JJ 0
evaluation NN 0
, , 0
by IN 0
an DT 0
increase NN 0
in IN 0
hematocrit JJ 0
level NN 0
of IN 0
six CD 0
percentage NN 0
points NNS 0
or CC 0
more JJR 0
unrelated JJ 0
to TO 0
transfusion NN 0
, , 0
and CC 0
by IN 0
a DT 0
rise NN 0
in IN 0
hematocrit NN 0
level NN 0
to TO 0
38 CD 0
% NN 0
or CC 0
more JJR 0
unrelated JJ 0
to TO 0
transfusion NN 0
. . 0

There EX 0
was VBD 0
a DT 0
trend NN 0
toward IN 0
the DT 0
reduction NN 0
in IN 0
mean JJ 0
units NNS 0
of IN 0
blood NN 0
transfused VBN 0
per IN 0
patient NN 0
during IN 0
months NNS 0
2 CD 0
and CC 0
3 CD 0
of IN 0
therapy NN 0
combined VBN 0
in IN 0
rHuEPO-treated JJ 0
patients NNS 0
compared VBN 0
with IN 0
placebo-treated JJ 0
patients NNS 0
( ( 0
0.91 CD 0
U NNP 0
versus NN 0
1.65 CD 0
U NNP 0
; : 0
P NNP 0
= NNP 0
.056 NNP 0
) ) 0
. . 0

In IN 0
addition NN 0
, , 0
rHuEPO-treated JJ 0
patients NNS 0
experienced VBD 0
a DT 0
statistically RB 0
significant JJ 0
improvement NN 0
in IN 0
energy NN 0
level NN 0
and CC 0
ability NN 0
to TO 0
perform VB 0
daily JJ 0
activities NNS 0
( ( 0
P NNP 0
< NNP 0
or CC 0
= NNP 0
.05 NNP 0
) ) 0
. . 0

The DT 0
two CD 0
treatment NN 0
groups NNS 0
showed VBD 0
no DT 0
statistically RB 0
significant JJ 0
differences NNS 0
in IN 0
toxic JJ 0
effects NNS 0
except IN 0
for IN 0
increased JJ 0
incidence NN 0
of IN 0
diaphoresis NN 0
( ( 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
and CC 0
diarrhea NN 0
( ( 0
P NNP 0
= NNP 0
.05 NNP 0
) ) 0
in IN 0
the DT 0
rHuEPO-treated JJ 0
group NN 0
. . 0

CONCLUSIONS NNP 0
We PRP 0
conclude VBP 0
that DT 0
rHuEPO NN 0
is VBZ 0
safe JJ 0
and CC 0
effective JJ 0
for IN 0
reversing VBG 0
anemia RB 0
related VBN 0
to TO 0
advanced JJ 0
cancer NN 0
or CC 0
to TO 0
chemotherapy VB 0
for IN 0
cancer NN 0
. . 0

Epirubicin NNP 0
and CC 0
cyclophosphamide VB 0
versus NN 0
epirubicin NN 0
and CC 0
docetaxel NN 0
as IN 0
first-line JJ 0
therapy NN 0
for IN 0
women NNS 0
with IN 0
metastatic JJ 0
breast NN 0
cancer NN 0
: : 0
final JJ 0
results NNS 0
of IN 0
a DT 0
randomised JJ 0
phase NN 0
III NNP 0
trial NN 0
. . 0

BACKGROUND VB 0
This DT 0
randomised JJ 0
phase NN 0
III NNP 0
trial NN 0
was VBD 0
carried VBN 0
out IN 0
to TO 0
compare VB 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
epirubicin NN 0
and CC 0
cyclophosphamide NN 0
( ( 0
EC NNP 0
) ) 0
with IN 0
epirubicin NN 0
and CC 0
docetaxel NN 0
( ( 0
Taxotere NNP 0
) ) 0
( ( 0
ED NNP 0
) ) 0
as IN 0
first-line JJ 0
chemotherapy NN 0
for IN 0
metastatic JJ 0
breast NN 0
cancer NN 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
Patients NNP 0
( ( 0
n JJ 0
= NNP 0
240 CD 0
) ) 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
either DT 0
ED NNP 0
( ( 0
epirubicin JJ 0
75 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
and CC 0
docetaxel $ 0
75 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
) ) 0
or CC 0
EC NNP 0
( ( 0
epirubicin VBP 0
90 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
and CC 0
cyclophosphamide $ 0
600 CD 0
mg/m NN 0
( ( 0
2 CD 0
) ) 0
) ) 0
. . 0

The DT 0
primary JJ 0
end NN 0
point NN 0
was VBD 0
objective JJ 0
response NN 0
rate NN 0
( ( 0
ORR NNP 0
) ) 0
. . 0

Secondary JJ 0
end NN 0
points NNS 0
were VBD 0
progression-free JJ 0
survival NN 0
( ( 0
PFS NNP 0
) ) 0
, , 0
overall JJ 0
survival NN 0
( ( 0
OS NNP 0
) ) 0
, , 0
and CC 0
safety NN 0
. . 0

RESULTS NNP 0
ORR NNP 0
for IN 0
patients NNS 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
EC NNP 0
and CC 0
ED NNP 0
were VBD 0
42 CD 0
% NN 0
and CC 0
47 CD 0
% NN 0
, , 0
respectively RB 0
( ( 0
P NNP 0
= NNP 0
0.63 CD 0
) ) 0
. . 0

Median JJ 0
PFS NNP 0
[ NNP 0
10.1 CD 0
versus NN 0
10.3 CD 0
months NNS 0
; : 0
hazard VBN 0
ratio NN 0
( ( 0
HR NNP 0
) ) 0
0.98 CD 0
; : 0
log-rank JJ 0
P NNP 0
= NNP 0
0.38 CD 0
] NN 0
and CC 0
OS NNP 0
( ( 0
19.9 CD 0
versus NN 0
30.0 CD 0
months NNS 0
; : 0
HR NNP 0
0.663 CD 0
; : 0
log-rank JJ 0
P NNP 0
= NNP 0
0.21 CD 0
) ) 0
were VBD 0
comparable JJ 0
in IN 0
both DT 0
arms NNS 0
. . 0

Although IN 0
grade JJ 0
3/4 CD 0
leucopenia NN 0
occurred VBD 0
more RBR 0
frequently RB 0
with IN 0
ED NNP 0
( ( 0
81 CD 0
% NN 0
versus IN 0
73 CD 0
% NN 0
; : 0
P NNP 0
= NNP 0
0.01 CD 0
) ) 0
, , 0
there EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
in IN 0
the DT 0
incidence NN 0
of IN 0
febrile JJ 0
neutropenia NN 0
and CC 0
grade VBD 0
3/4 CD 0
infections NNS 0
. . 0

Grade VB 0
3/4 CD 0
non-haematologic JJ 0
toxicity NN 0
was VBD 0
infrequent JJ 0
in IN 0
both DT 0
arms NNS 0
. . 0

Congestive JJ 0
heart NN 0
failure NN 0
was VBD 0
observed VBN 0
in IN 0
one CD 0
patient NN 0
in IN 0
each DT 0
arm NN 0
. . 0

CONCLUSION NN 0
In IN 0
this DT 0
randomised JJ 0
trial NN 0
, , 0
no DT 0
differences NNS 0
in IN 0
the DT 0
efficacy NN 0
study VBD 0
end JJ 0
points NNS 0
were VBD 0
observed VBN 0
between IN 0
the DT 0
two CD 0
treatment NN 0
arms NNS 0
. . 0

Partial JJ 0
depletion NN 0
of IN 0
tissue NN 0
factor NN 0
pathway NN 0
inhibitor NN 0
during IN 0
subcutaneous JJ 0
administration NN 0
of IN 0
unfractionated JJ 0
heparin NN 0
, , 0
but CC 0
not RB 0
with IN 0
two CD 0
low JJ 0
molecular JJ 0
weight NN 0
heparins NNS 0
. . 0

Tissue NNP 0
factor NN 0
pathway NN 0
inhibitor NN 0
( ( 0
TFPI NNP 0
) ) 0
is VBZ 0
released VBN 0
to TO 0
circulating VBG 0
blood NN 0
after IN 0
intravenous JJ 0
( ( 0
i.v JJ 0
. . 0

) ) 0
and CC 0
subcutaneous JJ 0
( ( 0
s.c. NN 0
) ) 0
injections NNS 0
of IN 0
heparins NNS 0
, , 0
and CC 0
may MD 0
thus RB 0
contribute VB 0
to TO 0
the DT 0
antithrombotic JJ 0
effect NN 0
of IN 0
heparins NNS 0
. . 0

We PRP 0
have VBP 0
recently RB 0
shown VBN 0
that IN 0
total JJ 0
TFPI NNP 0
activity NN 0
, , 0
plasma VBP 0
free JJ 0
TFPI NNP 0
antigen NN 0
, , 0
and CC 0
heparin NN 0
releasable JJ 0
TFPI NNP 0
were VBD 0
partially RB 0
depleted VBN 0
during IN 0
repeated VBN 0
and CC 0
continuous JJ 0
i.v NN 0
. . 0

infusion NN 0
of IN 0
unfractionated JJ 0
heparin NN 0
( ( 0
UFH NNP 0
) ) 0
, , 0
but CC 0
not RB 0
during IN 0
s.c. JJ 0
treatment NN 0
with IN 0
a DT 0
low JJ 0
molecular JJ 0
weight NN 0
heparin NN 0
( ( 0
LMWH NNP 0
) ) 0
. . 0

The DT 0
difference NN 0
may MD 0
be VB 0
attributed VBN 0
to TO 0
a DT 0
different JJ 0
mode NN 0
of IN 0
action NN 0
or CC 0
the DT 0
different JJ 0
mode NN 0
of IN 0
administration NN 0
. . 0

In IN 0
the DT 0
present JJ 0
randomized VBN 0
cross-over NN 0
study NN 0
, , 0
s.c. JJ 0
administration NN 0
of IN 0
therapeutic JJ 0
doses NNS 0
of IN 0
UFH NNP 0
was VBD 0
compared VBN 0
with IN 0
s.c. JJ 0
administration NN 0
of IN 0
two CD 0
LMWHs NNP 0
. . 0

12 CD 0
healthy JJ 0
male NN 0
volunteers NNS 0
were VBD 0
treated VBN 0
for IN 0
3 CD 0
d NN 0
with IN 0
UFH NNP 0
, , 0
250 CD 0
U/kg NNP 0
twice RB 0
daily RB 0
, , 0
dalteparin NN 0
, , 0
200 CD 0
U/kg NNP 0
once RB 0
daily RB 0
, , 0
and CC 0
enoxaparin RB 0
, , 0
1.5 CD 0
mg/kg NN 0
once RB 0
daily JJ 0
. . 0

Six CD 0
participants NNS 0
were VBD 0
also RB 0
treated VBN 0
with IN 0
UFH NNP 0
, , 0
300 CD 0
U/kg NNP 0
once RB 0
daily RB 0
. . 0

On IN 0
day NN 0
5 CD 0
a DT 0
single JJ 0
dose NN 0
of IN 0
either DT 0
drug NN 0
was VBD 0
given VBN 0
. . 0

Peak NNP 0
levels NNS 0
of IN 0
total JJ 0
TFPI NNP 0
activity NN 0
and CC 0
free JJ 0
TFPI NNP 0
antigen NN 0
were VBD 0
detected VBN 0
1 CD 0
h NN 0
after IN 0
injection NN 0
, , 0
whereas IN 0
maximal JJ 0
prolongation NN 0
of IN 0
activated VBN 0
partial JJ 0
thromboplastin NN 0
time NN 0
( ( 0
APTT NNP 0
) ) 0
and CC 0
peak JJ 0
levels NNS 0
of IN 0
anti-factor JJ 0
Xa NNP 0
activity NN 0
and CC 0
anti-factor NN 0
IIa NNP 0
activity NN 0
were VBD 0
detected VBN 0
after IN 0
4 CD 0
h. NN 0
On IN 0
UFH NNP 0
administered VBD 0
twice RB 0
daily RB 0
, , 0
free JJ 0
TFPI NNP 0
antigen NN 0
decreased VBN 0
by IN 0
44 CD 0
% NN 0
from IN 0
baseline JJ 0
level NN 0
before IN 0
the DT 0
first JJ 0
injection NN 0
on IN 0
day NN 0
1 CD 0
to TO 0
pre-injection NN 0
level NN 0
on IN 0
day NN 0
5 CD 0
. . 0

On IN 0
UFH NNP 0
administered VBD 0
once RB 0
daily JJ 0
, , 0
basal JJ 0
free JJ 0
TFPI NNP 0
antigen NN 0
decreased VBN 0
by IN 0
50 CD 0
% NN 0
, , 0
56 CD 0
% NN 0
and CC 0
27 CD 0
% NN 0
on IN 0
day NN 0
2 CD 0
, , 0
3 CD 0
and CC 0
5 CD 0
respectively RB 0
, , 0
compared VBN 0
with IN 0
day NN 0
1 CD 0
. . 0

Minimal JJ 0
depletion NN 0
of IN 0
TFPI NNP 0
was VBD 0
detected VBN 0
during IN 0
treatment NN 0
with IN 0
LMWHs NNP 0
. . 0

The DT 0
study NN 0
demonstrates VBZ 0
the DT 0
different JJ 0
modes NNS 0
of IN 0
action NN 0
of IN 0
LMWHs NNP 0
and CC 0
UFH NNP 0
and CC 0
may MD 0
help VB 0
to TO 0
explain VB 0
the DT 0
superior JJ 0
antithrombotic JJ 0
efficacy NN 0
of IN 0
LMWHs NNP 0
. . 0

Comparison NNP 0
of IN 0
neodymium-doped JJ 0
yttrium NN 0
aluminum NN 0
garnet NN 0
laser NN 0
treatment NN 0
with IN 0
cold JJ 0
knife NN 0
endoscopic NN 0
incision NN 0
of IN 0
urethral JJ 0
strictures NNS 0
in IN 0
male JJ 0
patients NNS 0
. . 0

OBJECTIVE NNP 0
To TO 0
assess VB 0
the DT 0
effectiveness NN 0
of IN 0
visual JJ 0
laser NN 0
ablation NN 0
treatment NN 0
with IN 0
neodymium-doped JJ 0
yttrium NN 0
aluminum NN 0
garnet NN 0
( ( 0
Nd NNP 0
: : 0
YAG NN 0
) ) 0
laser NN 0
in IN 0
male JJ 0
patients NNS 0
with IN 0
urethral JJ 0
strictures NNS 0
and CC 0
to TO 0
compare VB 0
the DT 0
effects NNS 0
with IN 0
those DT 0
obtained VBN 0
in IN 0
patients NNS 0
treated VBN 0
with IN 0
Sachse NNP 0
's POS 0
optical JJ 0
urethrotomy NN 0
. . 0

MATERIALS NNP 0
AND CC 0
METHODS NNP 0
Fifty NNP 0
patients NNS 0
aged VBD 0
22 CD 0
to TO 0
83 CD 0
( ( 0
mean JJ 0
age NN 0
61.8 CD 0
) ) 0
with IN 0
primary JJ 0
( ( 0
n JJ 0
= NN 0
26 CD 0
, , 0
52 CD 0
% NN 0
) ) 0
and CC 0
recurrent NN 0
( ( 0
n JJ 0
= NN 0
24 CD 0
, , 0
48 CD 0
% NN 0
) ) 0
urethral JJ 0
strictures VBZ 0
0.3 CD 0
to TO 0
2.4 CD 0
cm NNS 0
long RB 0
qualified VBD 0
for IN 0
the DT 0
study NN 0
. . 0

The DT 0
patients NNS 0
were VBD 0
randomized VBN 0
into IN 0
two CD 0
groups NNS 0
: : 0
30 CD 0
men NNS 0
treated VBD 0
using VBG 0
visual JJ 0
laser NN 0
ablation NN 0
of IN 0
urethral JJ 0
strictures NNS 0
( ( 0
VLASU NNP 0
) ) 0
with IN 0
Nd NNP 0
: : 0
YAGlaser NN 0
and CC 0
20 CD 0
men NNS 0
treated VBN 0
by IN 0
correction NN 0
of IN 0
urethral JJ 0
strictures NNS 0
using VBG 0
Sachse NNP 0
's POS 0
optical JJ 0
urethrotomy NN 0
. . 0

RESULTS VB 0
At IN 0
12-month JJ 0
follow-up NN 0
, , 0
seven CD 0
( ( 0
35 CD 0
% NN 0
) ) 0
patients NNS 0
who WP 0
underwent JJ 0
optical JJ 0
urethrotomy NN 0
and CC 0
21 CD 0
( ( 0
70 CD 0
% NN 0
) ) 0
in IN 0
the DT 0
VLASU NNP 0
group NN 0
did VBD 0
not RB 0
require VB 0
repetition NN 0
of IN 0
the DT 0
procedure NN 0
. . 0

The DT 0
choice NN 0
of IN 0
VLASU NNP 0
as IN 0
a DT 0
method NN 0
of IN 0
treatment NN 0
significantly RB 0
decreased VBD 0
the DT 0
probability NN 0
of IN 0
therapeutic JJ 0
failure NN 0
and CC 0
recurrence NN 0
of IN 0
urethral JJ 0
strictures NNS 0
( ( 0
p JJ 0
= NNP 0
0.02 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
VLASU NNP 0
can MD 0
be VB 0
used VBN 0
as IN 0
a DT 0
method NN 0
of IN 0
treatment NN 0
of IN 0
this DT 0
disorder NN 0
. . 0

It PRP 0
is VBZ 0
an DT 0
effective JJ 0
, , 0
modern JJ 0
, , 0
low-invasive JJ 0
, , 0
and CC 0
repeatable JJ 0
technique NN 0
and CC 0
is VBZ 0
technically RB 0
simple JJ 0
and CC 0
easy JJ 0
to TO 0
master NN 0
. . 0

It PRP 0
can MD 0
be VB 0
used VBN 0
in IN 0
cases NNS 0
in IN 0
which WDT 0
introduction NN 0
of IN 0
a DT 0
22 CD 0
Char NNP 0
optical JJ 0
urethrotome NN 0
into IN 0
the DT 0
stricture NN 0
site NN 0
is VBZ 0
impossible JJ 0
, , 0
as RB 0
well RB 0
as IN 0
for IN 0
treatment NN 0
of IN 0
multiple JJ 0
strictures NNS 0
during IN 0
one CD 0
procedure NN 0
. . 0

[ JJ 0
Methodologic NNP 0
comparison NN 0
of IN 0
the DT 0
polyfrequency NN 0
oscillation NN 0
method NN 0
, , 0
transcutaneous JJ 0
oxygen NN 0
pressure NN 0
measurement NN 0
and CC 0
body NN 0
plethysmography NN 0
in IN 0
bronchial JJ 0
provocation NN 0
with IN 0
methacholine JJ 0
] NN 0
. . 0

A DT 0
bronchial JJ 0
provocation NN 0
challenge NN 0
test NN 0
was VBD 0
conducted VBN 0
with IN 0
30 CD 0
subjects NNS 0
using VBG 0
metacholin NN 0
. . 0

In IN 0
randomised JJ 0
sequence NN 0
lung NN 0
function NN 0
analysis NN 0
tests NNS 0
were VBD 0
carried VBN 0
out RP 0
with IN 0
the DT 0
bodyplethysmograph NN 0
( ( 0
Raw NNP 0
, , 0
FEV1 NNP 0
) ) 0
and CC 0
the DT 0
polyfrequent JJ 0
oscillation NN 0
method NN 0
( ( 0
resistance NN 0
, , 0
reactance NN 0
between IN 0
2 CD 0
and CC 0
52 CD 0
Hz NNP 0
) ) 0
, , 0
whereas IN 0
the DT 0
transcutaneous JJ 0
oxygen NN 0
pressure NN 0
( ( 0
tc-PO2 JJ 0
) ) 0
was VBD 0
measured VBN 0
continuously RB 0
. . 0

Correlations NNS 0
between IN 0
the DT 0
various JJ 0
parameters NNS 0
, , 0
the DT 0
change NN 0
of IN 0
the DT 0
values NNS 0
at IN 0
PD60 NNP 0
sGaw NN 0
in IN 0
relation NN 0
to TO 0
the DT 0
initial JJ 0
values NNS 0
, , 0
the DT 0
interindividual JJ 0
variability NN 0
and CC 0
the DT 0
reactivity NN 0
were VBD 0
determined VBN 0
. . 0

Medium JJ 0
correlations NNS 0
were VBD 0
found VBN 0
for IN 0
the DT 0
oscillatory NN 0
parameters NNS 0
and CC 0
Raw NNP 0
, , 0
whereas IN 0
for IN 0
tc-PO2 NN 0
and CC 0
Raw NNP 0
the DT 0
correlation NN 0
was VBD 0
markedly RB 0
lower JJR 0
. . 0

In IN 0
terms NNS 0
of IN 0
percentage NN 0
the DT 0
greatest JJS 0
change NN 0
was VBD 0
found VBN 0
in IN 0
reactance NN 0
, , 0
in IN 0
relation NN 0
to TO 0
the DT 0
initial JJ 0
value NN 0
, , 0
followed VBN 0
by IN 0
Raw NNP 0
and CC 0
FEV1 NNP 0
. . 0

The DT 0
interindividual JJ 0
variability NN 0
resulted VBD 0
in IN 0
the DT 0
highest JJS 0
values NNS 0
for IN 0
the DT 0
reactance NN 0
, , 0
followed VBN 0
by IN 0
Raw NNP 0
and CC 0
FEV1 NNP 0
. . 0

Interindividual NNP 0
variability NN 0
showed VBD 0
the DT 0
highest JJS 0
values NNS 0
for IN 0
the DT 0
reactance NN 0
before IN 0
oscillatory JJ 0
resistance NN 0
and CC 0
Raw NNP 0
. . 0

In IN 0
respect NN 0
of IN 0
reactivity NN 0
, , 0
reactance NN 0
also RB 0
had VBD 0
the DT 0
highest JJS 0
values NNS 0
. . 0

Overall JJ 0
evaluation NN 0
showed VBD 0
that IN 0
bodyplethysmography NN 0
and CC 0
the DT 0
polyfrequent JJ 0
oscillation NN 0
method NN 0
( ( 0
reactance NN 0
or CC 0
resonance NN 0
frequency NN 0
) ) 0
are VBP 0
comparably RB 0
sensitive JJ 0
. . 0

Autism-Spectrum JJ 0
Quotient-Japanese JJ 0
version NN 0
and CC 0
its PRP$ 0
short JJ 0
forms NNS 0
for IN 0
screening VBG 0
normally RB 0
intelligent JJ 0
persons NNS 0
with IN 0
pervasive JJ 0
developmental NN 0
disorders NNS 0
. . 0

A DT 0
Japanese JJ 0
version NN 0
of IN 0
the DT 0
Autism NNP 0
Spectrum NNP 0
Quotient NNP 0
( ( 0
AQ NNP 0
) ) 0
, , 0
AQ-J NNP 0
was VBD 0
administered VBN 0
to TO 0
25 CD 0
normally RB 0
intelligent JJ 0
high-functioning JJ 0
pervasive JJ 0
developmental NN 0
disorder NN 0
( ( 0
HPDD NNP 0
) ) 0
patients NNS 0
( ( 0
mean JJ 0
age NN 0
, , 0
24.2 CD 0
years NNS 0
; : 0
24 CD 0
male NN 0
, , 0
one CD 0
female NN 0
) ) 0
and CC 0
215 CD 0
controls NNS 0
( ( 0
mean JJ 0
age NN 0
, , 0
30.4 CD 0
years NNS 0
; : 0
86 CD 0
male NN 0
, , 0
129 CD 0
female NN 0
) ) 0
randomly RB 0
selected VBN 0
from IN 0
the DT 0
general JJ 0
population NN 0
. . 0

The DT 0
AQ-J NNP 0
had VBD 0
satisfactory JJ 0
internal JJ 0
consistency NN 0
reliability NN 0
( ( 0
Cronbach NNP 0
's POS 0
alpha NN 0
> VBD 0
0.70 CD 0
in IN 0
the DT 0
two CD 0
groups NNS 0
) ) 0
, , 0
test-retest JJ 0
reliability NN 0
, , 0
and CC 0
discriminant JJ 0
validity NN 0
[ NNP 0
i.e NN 0
. . 0

the DT 0
AQ-J NNP 0
score NN 0
was VBD 0
significantly RB 0
higher JJR 0
in IN 0
the DT 0
HPDD NNP 0
( ( 0
mean NN 0
, , 0
29.6 CD 0
) ) 0
than IN 0
controls NNS 0
( ( 0
mean VB 0
, , 0
22.2 CD 0
) ) 0
] NN 0
. . 0

At IN 0
a DT 0
cut-off NN 0
of IN 0
26 CD 0
, , 0
the DT 0
AQ-J NNP 0
had VBD 0
satisfactory JJ 0
sensitivity NN 0
, , 0
specificity NN 0
, , 0
and CC 0
negative JJ 0
predictive JJ 0
value NN 0
, , 0
but CC 0
it PRP 0
had VBD 0
low JJ 0
positive JJ 0
predictive NN 0
value NN 0
( ( 0
0.24 CD 0
) ) 0
possibly RB 0
due JJ 0
to TO 0
the DT 0
facts NNS 0
that IN 0
the DT 0
25 CD 0
mild JJ 0
HPDD NNP 0
patients NNS 0
scored VBD 0
lower JJR 0
and CC 0
the DT 0
controls NNS 0
scored VBD 0
higher JJR 0
on IN 0
the DT 0
AQ-J NNP 0
than IN 0
British NNP 0
counterparts NNS 0
on IN 0
the DT 0
AQ NNP 0
. . 0

The DT 0
AQ-J-21 NNP 0
( ( 0
consisting VBG 0
of IN 0
21 CD 0
items NNS 0
significantly RB 0
associated VBN 0
with IN 0
HPDD NNP 0
diagnosis NN 0
) ) 0
and CC 0
the DT 0
AQ-J-10 NNP 0
( ( 0
consisting VBG 0
of IN 0
10 CD 0
of IN 0
the DT 0
21 CD 0
items NNS 0
with IN 0
an DT 0
effect NN 0
size NN 0
> NNP 0
0.17 CD 0
) ) 0
had VBD 0
higher JJR 0
, , 0
although IN 0
not RB 0
satisfactory JJ 0
, , 0
positive JJ 0
predictive JJ 0
values NNS 0
of IN 0
0.35 CD 0
and CC 0
0.46 CD 0
at IN 0
cut-offs NNS 0
of IN 0
12 CD 0
and CC 0
7 CD 0
, , 0
respectively RB 0
, , 0
than IN 0
the DT 0
AQ-J NNP 0
. . 0

The DT 0
AQ-J JJ 0
and CC 0
two CD 0
short JJ 0
forms NNS 0
are VBP 0
useful JJ 0
not RB 0
to TO 0
predict VB 0
but CC 0
to TO 0
rule VB 0
out RP 0
mild NN 0
HPDD NNP 0
, , 0
the DT 0
most RBS 0
difficult JJ 0
part NN 0
of IN 0
HPDD NNP 0
to TO 0
be VB 0
distinguished VBN 0
from IN 0
non-PDD JJ 0
conditions NNS 0
, , 0
in IN 0
persons NNS 0
scoring VBG 0
under IN 0
the DT 0
cut-offs NNS 0
and CC 0
to TO 0
consider VB 0
professionals NNS 0
' POS 0
examination NN 0
of IN 0
HPDD NNP 0
in IN 0
persons NNS 0
scoring VBG 0
over IN 0
them PRP 0
, , 0
because IN 0
their PRP$ 0
negative JJ 0
predictive JJ 0
values NNS 0
were VBD 0
satisfactory JJ 0
. . 0

[ JJ 0
Radiotherapy NNP 0
of IN 0
malignant JJ 0
brain NN 0
gliomas NN 0
using VBG 0
teniposide JJ 0
] NNP 0
. . 0

Efficacy NN 0
of IN 0
radiochemotherapy NN 0
of IN 0
malignantly-converted JJ 0
brain NN 0
gliomas NN 0
using VBG 0
teniposide NN 0
was VBD 0
evaluated VBN 0
in IN 0
a DT 0
randomized JJ 0
prospective JJ 0
study NN 0
. . 0

Combined VBN 0
use NN 0
of IN 0
cytostatics NNS 0
and CC 0
irradiation NN 0
appeared VBD 0
safe JJ 0
, , 0
tolerable JJ 0
and CC 0
significantly RB 0
more RBR 0
effective JJ 0
than IN 0
radiotherapy RB 0
alone RB 0
as IN 0
assessed VBN 0
by IN 0
local JJ 0
control NN 0
of IN 0
tumor NN 0
and CC 0
survival NN 0
. . 0

Comparing VBG 0
the DT 0
effectiveness NN 0
of IN 0
peer NN 0
mentoring NN 0
and CC 0
student NN 0
mentoring NN 0
in IN 0
a DT 0
35-week JJ 0
fitness NN 0
program NN 0
for IN 0
older JJR 0
adults NNS 0
. . 0

To TO 0
investigate VB 0
the DT 0
applicability NN 0
and CC 0
effectiveness NN 0
of IN 0
a DT 0
peer-mentored JJ 0
exercise NN 0
program NN 0
, , 0
this DT 0
study NN 0
compared VBN 0
the DT 0
retention NN 0
and CC 0
participation NN 0
rates NNS 0
, , 0
and CC 0
physical JJ 0
improvements NNS 0
of IN 0
older JJR 0
adults NNS 0
trained VBN 0
by IN 0
peer NN 0
mentors NNS 0
( ( 0
PM NNP 0
) ) 0
to TO 0
a DT 0
group NN 0
trained VBN 0
by IN 0
young JJ 0
qualified JJ 0
student NN 0
mentors NNS 0
( ( 0
SM NNP 0
) ) 0
. . 0

A DT 0
group NN 0
of IN 0
older JJR 0
adults NNS 0
were VBD 0
prepared VBN 0
as IN 0
peer NN 0
mentors NNS 0
through IN 0
a DT 0
30-week JJ 0
preparation NN 0
program NN 0
. . 0

Later NNP 0
, , 0
60 CD 0
older JJR 0
adults NNS 0
( ( 0
mean VB 0
? . 0
SD NNP 0
age NN 0
: : 0
68.7 CD 0
? . 0
6.1 CD 0
years NNS 0
) ) 0
were VBD 0
recruited VBN 0
and CC 0
randomly RB 0
assigned VBN 0
to TO 0
either CC 0
the DT 0
PM NNP 0
or CC 0
SM NNP 0
group NN 0
. . 0

Both DT 0
groups NNS 0
completed VBD 0
an DT 0
identical JJ 0
35-week JJ 0
fitness NN 0
program NN 0
. . 0

Pre- NNP 0
, , 0
midterm- JJ 0
and CC 0
post-training JJ 0
assessments NNS 0
of IN 0
fitness NN 0
were VBD 0
completed VBN 0
and CC 0
rates NNS 0
of IN 0
participation NN 0
and CC 0
retention NN 0
were VBD 0
documented VBN 0
. . 0

The DT 0
same JJ 0
retention NN 0
rates NNS 0
were VBD 0
observed VBN 0
in IN 0
the DT 0
two CD 0
groups NNS 0
, , 0
but CC 0
SM NNP 0
group NN 0
had VBD 0
higher JJR 0
participation NN 0
. . 0

Both DT 0
groups NNS 0
improved VBN 0
significantly RB 0
in IN 0
all DT 0
measures NNS 0
of IN 0
fitness NN 0
and CC 0
there EX 0
were VBD 0
no DT 0
significant JJ 0
post-test JJ 0
differences NNS 0
between IN 0
the DT 0
groups NNS 0
in IN 0
the DT 0
fitness NN 0
measures NNS 0
. . 0

Findings NNS 0
suggest VBP 0
that IN 0
the DT 0
peer NN 0
mentor NN 0
model NN 0
is VBZ 0
applicable JJ 0
in IN 0
an DT 0
older JJR 0
adult NN 0
exercise NN 0
program NN 0
and CC 0
may MD 0
be VB 0
as RB 0
effective JJ 0
as IN 0
a DT 0
program NN 0
mentored VBN 0
by IN 0
young JJ 0
professionals NNS 0
. . 0

Bitewing NNP 0
film NN 0
quality NN 0
: : 0
a DT 0
clinical JJ 0
comparison NN 0
of IN 0
the DT 0
loop NN 0
vs. FW 0
holder NN 0
techniques NNS 0
. . 0

OBJECTIVE NNP 0
To TO 0
compare VB 0
in IN 0
vivo JJ 0
bitewing NN 0
film NN 0
quality NN 0
using VBG 0
the DT 0
holder NN 0
versus IN 0
the DT 0
paper NN 0
loop NN 0
technique NN 0
. . 0

METHOD NNP 0
AND CC 0
MATERIALS NNP 0
Four NNP 0
bitewing VBG 0
films NNS 0
were VBD 0
taken VBN 0
from IN 0
the DT 0
right NN 0
and CC 0
left VBD 0
premolar JJ 0
and CC 0
molar JJ 0
regions NNS 0
of IN 0
45 CD 0
dental JJ 0
students NNS 0
using VBG 0
both DT 0
the DT 0
bitewing NN 0
holder NN 0
and CC 0
paper NN 0
loop NN 0
techniques NNS 0
. . 0

A DT 0
total NN 0
of IN 0
360 CD 0
films NNS 0
were VBD 0
taken VBN 0
and CC 0
assessed VBN 0
by IN 0
an DT 0
experienced JJ 0
practitioner NN 0
not RB 0
apprised VBN 0
of IN 0
the DT 0
bitewing NN 0
technique NN 0
used VBN 0
. . 0

Of IN 0
interest NN 0
were VBD 0
: : 0
( ( 0
1 CD 0
) ) 0
the DT 0
number NN 0
of IN 0
overlaps NNS 0
and CC 0
the DT 0
percentage NN 0
of IN 0
teeth NNS 0
showing VBG 0
the DT 0
alveolar JJ 0
crest NN 0
; : 0
( ( 0
2 CD 0
) ) 0
proper NN 0
film NN 0
positioning NN 0
; : 0
and CC 0
( ( 0
3 CD 0
) ) 0
the DT 0
percentage NN 0
of IN 0
cone NN 0
cutting NN 0
. . 0

A DT 0
Poisson NNP 0
regression NN 0
using VBG 0
generalized VBN 0
estimating VBG 0
equations NNS 0
( ( 0
GEEs NNP 0
) ) 0
was VBD 0
used VBN 0
to TO 0
estimate VB 0
the DT 0
difference NN 0
in IN 0
overlap NN 0
between IN 0
the DT 0
two CD 0
techniques NNS 0
. . 0

For IN 0
proper JJ 0
positioning NN 0
and CC 0
cone NN 0
cutting NN 0
, , 0
logistic JJ 0
regressions NNS 0
using VBG 0
GEEs NNP 0
were VBD 0
used VBN 0
. . 0

RESULTS VB 0
The DT 0
average JJ 0
number NN 0
of IN 0
horizontal JJ 0
overlaps NNS 0
for IN 0
the DT 0
loop NN 0
and CC 0
holder NN 0
techniques NNS 0
at IN 0
the DT 0
right JJ 0
premolar NN 0
, , 0
right JJ 0
molar NN 0
, , 0
left VBD 0
premolar JJ 0
, , 0
and CC 0
left VBD 0
molar NN 0
were VBD 0
1.64 CD 0
, , 0
2.11 CD 0
, , 0
2.16 CD 0
, , 0
2.78 CD 0
, , 0
and CC 0
1.64 CD 0
, , 0
2.00 CD 0
, , 0
2.00 CD 0
, , 0
2.18 CD 0
, , 0
respectively RB 0
. . 0

The DT 0
loop NN 0
technique NN 0
was VBD 0
1.11 CD 0
times NNS 0
more RBR 0
likely JJ 0
to TO 0
cause VB 0
overlapping VBG 0
than IN 0
the DT 0
holder NN 0
technique NN 0
. . 0

The DT 0
highest JJS 0
percentage NN 0
of IN 0
teeth NNS 0
showing VBG 0
the DT 0
alveolar JJ 0
crest NN 0
by IN 0
the DT 0
loop NN 0
technique NN 0
was VBD 0
97.8 CD 0
% NN 0
in IN 0
the DT 0
mandibular JJ 0
second JJ 0
premolar NN 0
and CC 0
first JJ 0
molar NN 0
. . 0

With IN 0
respect NN 0
to TO 0
film NN 0
positioning NN 0
, , 0
the DT 0
loop NN 0
technique NN 0
was VBD 0
1.12 CD 0
times NNS 0
more RBR 0
likely JJ 0
to TO 0
cause VB 0
improper JJ 0
positioning NN 0
than IN 0
the DT 0
holder NN 0
technique NN 0
. . 0

Both DT 0
techniques NNS 0
demonstrated VBN 0
minimal JJ 0
cone NN 0
cutting NN 0
( ( 0
1 CD 0
in IN 0
the DT 0
loop NN 0
versus NN 0
0 CD 0
in IN 0
the DT 0
holder NN 0
) ) 0
. . 0

CONCLUSION VB 0
The DT 0
quality NN 0
of IN 0
bitewing VBG 0
films NNS 0
taken VBN 0
by IN 0
the DT 0
loop NN 0
and CC 0
holder NN 0
techniques NNS 0
was VBD 0
not RB 0
significantly RB 0
different JJ 0
. . 0

PROCLAIM NN 0
: : 0
pilot NN 0
study NN 0
to TO 0
examine VB 0
the DT 0
effects NNS 0
of IN 0
clopidogrel NN 0
on IN 0
inflammatory JJ 0
markers NNS 0
in IN 0
patients NNS 0
with IN 0
metabolic JJ 0
syndrome JJ 0
receiving VBG 0
low-dose JJ 0
aspirin NN 0
. . 0

Metabolic NNP 0
syndrome NN 0
is VBZ 0
associated VBN 0
with IN 0
intravascular JJ 0
inflammation NN 0
, , 0
as IN 0
determined VBN 0
by IN 0
increased JJ 0
levels NNS 0
of IN 0
inflammatory NN 0
biomarkers NNS 0
and CC 0
an DT 0
increased VBN 0
risk NN 0
of IN 0
ischemic JJ 0
atherothrombotic JJ 0
events NNS 0
. . 0

Evidence NN 0
suggests VBZ 0
that IN 0
atherothrombosis NN 0
and CC 0
intravascular JJ 0
inflammation NN 0
share NN 0
predictive JJ 0
biomarkers NNS 0
, , 0
including VBG 0
high-sensitivity JJ 0
C-reactive JJ 0
protein NN 0
, , 0
CD40 NNP 0
ligand NN 0
, , 0
P-selectin NNP 0
, , 0
and CC 0
N-terminal JJ 0
pro-brain JJ 0
natriuretic JJ 0
peptide NN 0
. . 0

Patients NNS 0
who WP 0
had VBD 0
metabolic JJ 0
syndrome NN 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
clopidogrel NN 0
75 CD 0
mg/day JJ 0
plus CC 0
aspirin JJ 0
81 CD 0
mg/day NN 0
( ( 0
n JJ 0
= NNP 0
89 CD 0
) ) 0
or CC 0
placebo JJ 0
plus CC 0
aspirin JJ 0
81 CD 0
mg/day NN 0
( ( 0
n JJ 0
= NNP 0
92 CD 0
) ) 0
for IN 0
9 CD 0
weeks NNS 0
to TO 0
assess VB 0
the DT 0
efficacy NN 0
of IN 0
each DT 0
treatment NN 0
in IN 0
suppression NN 0
of IN 0
inflammatory JJ 0
markers NNS 0
. . 0

Change NN 0
from IN 0
baseline NN 0
in IN 0
the DT 0
levels NNS 0
of IN 0
high-sensitivity NN 0
C-reactive JJ 0
protein NN 0
, , 0
CD40 NNP 0
ligand NN 0
, , 0
P-selectin NNP 0
, , 0
and CC 0
N-terminal JJ 0
pro-brain JJ 0
natriuretic JJ 0
peptide NN 0
at IN 0
6 CD 0
weeks NNS 0
was VBD 0
assessed VBN 0
to TO 0
evaluate VB 0
each DT 0
treatment NN 0
. . 0

There EX 0
was VBD 0
a DT 0
significant JJ 0
difference NN 0
at IN 0
Week JJ 0
6 CD 0
in IN 0
model-adjusted JJ 0
CD40-ligand NNP 0
levels NNS 0
in IN 0
favor NN 0
of IN 0
clopidogrel NN 0
plus CC 0
aspirin JJ 0
compared VBN 0
with IN 0
placebo NN 0
plus CC 0
aspirin NN 0
in IN 0
both DT 0
the DT 0
intent-to-treat JJ 0
population NN 0
( ( 0
difference NN 0
between IN 0
least-squares NNS 0
means NNS 0
= VBP 0
-186.5 NNP 0
; : 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
, , 0
-342.3 NN 0
to TO 0
-30.8 VB 0
; : 0
P NNP 0
= NNP 0
0.02 CD 0
) ) 0
and CC 0
the DT 0
per-protocol JJ 0
population NN 0
( ( 0
P NNP 0
= NNP 0
0.05 CD 0
) ) 0
. . 0

No DT 0
significant JJ 0
differences NNS 0
were VBD 0
observed VBN 0
between IN 0
the DT 0
treatment NN 0
arms NNS 0
for IN 0
high-sensitivity JJ 0
C-reactive JJ 0
protein NN 0
, , 0
P-selectin NNP 0
, , 0
and CC 0
N-terminal JJ 0
pro-brain JJ 0
natriuretic JJ 0
peptide NN 0
. . 0

There EX 0
were VBD 0
no DT 0
deaths NNS 0
or CC 0
serious JJ 0
adverse JJ 0
events NNS 0
in IN 0
either DT 0
treatment NN 0
arm NN 0
. . 0

Data NNS 0
from IN 0
this DT 0
study NN 0
suggest VBP 0
that IN 0
clopidogrel NN 0
can MD 0
decrease VB 0
the DT 0
expression NN 0
of IN 0
the DT 0
CD40-ligand NNP 0
biomarker NN 0
. . 0

Effect NN 0
of IN 0
ranolazine NN 0
on IN 0
A1C NNP 0
and CC 0
glucose JJ 0
levels NNS 0
in IN 0
hyperglycemic JJ 0
patients NNS 0
with IN 0
non-ST JJ 0
elevation NN 0
acute NN 0
coronary JJ 0
syndrome NN 0
. . 0

OBJECTIVE IN 0
We PRP 0
determined VBD 0
the DT 0
relationships NNS 0
between IN 0
glycemia NN 0
at IN 0
randomization NN 0
, , 0
concurrent JJ 0
antidiabetic JJ 0
therapy NN 0
, , 0
and CC 0
change NN 0
in IN 0
A1C NNP 0
and CC 0
fasting VBG 0
plasma NN 0
glucose NN 0
( ( 0
FPG NNP 0
) ) 0
in IN 0
patients NNS 0
with IN 0
diabetes NNS 0
receiving VBG 0
standard JJ 0
treatment NN 0
for IN 0
diabetes NNS 0
and CC 0
randomized VBN 0
to TO 0
ranolazine VB 0
or CC 0
placebo VB 0
within IN 0
the DT 0
MERLIN-TIMI-36 NNP 0
( ( 0
MERLIN NNP 0
) ) 0
study NN 0
. . 0

Ranolazine NNP 0
is VBZ 0
a DT 0
novel JJ 0
first-in-class JJ 0
drug NN 0
approved VBD 0
for IN 0
treating VBG 0
angina JJ 0
pectoris NN 0
. . 0

RESEARCH NNP 0
DESIGN NNP 0
AND NNP 0
METHODS NNP 0
Randomization NNP 0
and CC 0
4-month JJ 0
glycemic NN 0
and CC 0
antidiabetes VBZ 0
drug NN 0
usage NN 0
data NNS 0
from IN 0
MERLIN NNP 0
were VBD 0
analyzed VBN 0
using VBG 0
Spotfire NNP 0
and CC 0
SAS NNP 0
version NN 0
9.1 CD 0
software NN 0
. . 0

RESULTS NNP 0
In IN 0
patients NNS 0
with IN 0
diabetes NNS 0
and CC 0
A1C NNP 0
of IN 0
> NNP 0
or=8-10 JJ 0
% NN 0
at IN 0
randomization NN 0
( ( 0
n JJ 0
= NNP 0
171 CD 0
) ) 0
, , 0
there EX 0
was VBD 0
an DT 0
absolute JJ 0
A1C NNP 0
reduction NN 0
in IN 0
the DT 0
ranolazine NN 0
group NN 0
of IN 0
1.2 CD 0
% NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
-1.4 NNP 0
to TO 0
-1.0 VB 0
) ) 0
, , 0
and CC 0
the DT 0
placebo-adjusted JJ 0
( ( 0
n JJ 0
= NNP 0
182 CD 0
) ) 0
decrease NN 0
in IN 0
A1C NNP 0
by IN 0
ranolazine NN 0
was VBD 0
0.59 CD 0
% NN 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
-0.99 NNP 0
to TO 0
-0.20 VB 0
, , 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

In IN 0
patients NNS 0
with IN 0
FPG NNP 0
of IN 0
150-400 JJ 0
mg/dl NN 0
at IN 0
randomization NN 0
, , 0
ranolazine NN 0
( ( 0
n JJ 0
= NNP 0
131 CD 0
) ) 0
compared VBN 0
with IN 0
placebo NN 0
( ( 0
n JJ 0
= NNP 0
147 CD 0
) ) 0
reduced VBN 0
FPG NNP 0
by IN 0
25.7 CD 0
mg/dl NNS 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
-43.3 NNP 0
to TO 0
-8.1 VB 0
, , 0
P NNP 0
= NNP 0
0.001 CD 0
) ) 0
. . 0

When WRB 0
changes NNS 0
in IN 0
either DT 0
A1C NNP 0
or CC 0
FPG NNP 0
were VBD 0
correlated VBN 0
to TO 0
A1C NNP 0
or CC 0
FPG NNP 0
at IN 0
randomization NN 0
, , 0
the DT 0
slopes NNS 0
were VBD 0
significantly RB 0
steeper JJR 0
for IN 0
ranolazine NN 0
than IN 0
placebo NN 0
( ( 0
A1C NNP 0
, , 0
P NNP 0
= NNP 0
0.046 CD 0
; : 0
FPG NNP 0
, , 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
, , 0
indicating VBG 0
that IN 0
lowering VBG 0
of IN 0
A1C NNP 0
and CC 0
FPG NNP 0
by IN 0
ranolazine NN 0
is VBZ 0
related VBN 0
to TO 0
hyperglycemia VB 0
at IN 0
randomization NN 0
. . 0

Ranolazine NNP 0
, , 0
compared VBN 0
with IN 0
placebo NN 0
, , 0
was VBD 0
not RB 0
associated VBN 0
with IN 0
serious JJ 0
hypoglycemic JJ 0
events NNS 0
, , 0
associated VBN 0
with IN 0
significant JJ 0
changes NNS 0
in IN 0
concurrent JJ 0
antidiabetic JJ 0
therapy NN 0
, , 0
or CC 0
dependent NN 0
on IN 0
a DT 0
history NN 0
of IN 0
angina NN 0
. . 0

CONCLUSIONS NNP 0
Ranolazine NNP 0
, , 0
when WRB 0
added VBN 0
to TO 0
concurrent VB 0
antidiabetes NNS 0
treatment NN 0
, , 0
lowers NNS 0
FPG NNP 0
and CC 0
A1C NNP 0
in IN 0
patients NNS 0
with IN 0
cardiovascular JJ 0
disease NN 0
and CC 0
poorly RB 0
controlled VBN 0
diabetes NNS 0
. . 0

LNH-84 JJ 0
regimen NNS 0
: : 0
a DT 0
multicenter NN 0
study NN 0
of IN 0
intensive JJ 0
chemotherapy NN 0
in IN 0
737 CD 0
patients NNS 0
with IN 0
aggressive JJ 0
malignant JJ 0
lymphoma NN 0
. . 0

From IN 0
July NNP 0
1984 CD 0
to TO 0
September NNP 0
1987 CD 0
, , 0
737 CD 0
patients NNS 0
with IN 0
aggressive JJ 0
malignant JJ 0
lymphoma NN 0
( ( 0
ML NNP 0
) ) 0
were VBD 0
treated VBN 0
by IN 0
an DT 0
intensive JJ 0
regimen NNS 0
( ( 0
LNH-84 NNP 0
) ) 0
comprising VBG 0
three CD 0
or CC 0
four CD 0
courses NNS 0
of IN 0
doxorubicin NN 0
, , 0
75 CD 0
mg/m2 NN 0
; : 0
cyclophosphamide NN 0
, , 0
1,200 CD 0
mg/m2 NN 0
; : 0
vindesine NN 0
, , 0
2 CD 0
mg/m2 NN 0
x NN 0
2 CD 0
; : 0
bleomycin NN 0
, , 0
10 CD 0
mg NN 0
x NN 0
2 CD 0
; : 0
and CC 0
prednisolone NN 0
, , 0
60 CD 0
mg/m2 NN 0
x NN 0
5 CD 0
( ( 0
ACVB NNP 0
) ) 0
, , 0
consolidation NN 0
with IN 0
high-dose JJ 0
methotrexate NN 0
, , 0
ifosfamide NN 0
, , 0
etoposide RB 0
, , 0
asparaginase NN 0
, , 0
and CC 0
cytarabine NN 0
, , 0
and CC 0
a DT 0
randomized VBN 0
late JJ 0
intensification NN 0
with IN 0
two CD 0
courses NNS 0
of IN 0
cytarabine NN 0
, , 0
cyclophosphamide NN 0
, , 0
teniposide NN 0
, , 0
bleomycin NN 0
, , 0
and CC 0
prednisone NN 0
( ( 0
AraCVmB NNP 0
) ) 0
. . 0

Four CD 0
hundred VBD 0
forty-two JJ 0
patients NNS 0
had VBD 0
intermediate-grade JJ 0
ML NNP 0
, , 0
221 CD 0
highgrade NN 0
ML NNP 0
, , 0
and CC 0
74 CD 0
unclassified JJ 0
ML NNP 0
. . 0

Most JJS 0
of IN 0
the DT 0
patients NNS 0
had VBD 0
advanced JJ 0
disease NN 0
: : 0
stage NN 0
IIE NNP 0
( ( 0
23 CD 0
% NN 0
) ) 0
, , 0
III NNP 0
( ( 0
13 CD 0
% NN 0
) ) 0
, , 0
or CC 0
IV NNP 0
( ( 0
47 CD 0
% NN 0
) ) 0
; : 0
38 CD 0
% NN 0
disseminated JJ 0
nodes NNS 0
; : 0
38 CD 0
% NN 0
two CD 0
or CC 0
more JJR 0
extranodal JJ 0
sites NNS 0
; : 0
and CC 0
41 CD 0
% NN 0
a DT 0
tumoral JJ 0
mass NN 0
greater JJR 0
than IN 0
10 CD 0
cm NN 0
. . 0

Five CD 0
hundred VBD 0
fifty-three JJ 0
patients NNS 0
( ( 0
75 CD 0
% NN 0
) ) 0
went VBD 0
into IN 0
complete JJ 0
remission NN 0
( ( 0
CR NNP 0
) ) 0
, , 0
63 CD 0
( ( 0
9 CD 0
% NN 0
) ) 0
into IN 0
partial JJ 0
remission NN 0
, , 0
62 CD 0
( ( 0
8 CD 0
% NN 0
) ) 0
failed VBD 0
to TO 0
respond VB 0
, , 0
and CC 0
59 CD 0
( ( 0
8 CD 0
% NN 0
) ) 0
died VBD 0
during IN 0
ACVB NNP 0
courses NNS 0
, , 0
17 CD 0
of IN 0
them PRP 0
from IN 0
progression NN 0
of IN 0
the DT 0
disease NN 0
. . 0

With IN 0
a DT 0
median JJ 0
follow-up NN 0
of IN 0
23 CD 0
months NNS 0
, , 0
the DT 0
estimated VBN 0
2-year JJ 0
overall JJ 0
survival NN 0
time NN 0
to TO 0
failure NN 0
( ( 0
TTF NNP 0
) ) 0
, , 0
and CC 0
time NN 0
to TO 0
relapse VB 0
( ( 0
TTR NNP 0
) ) 0
survival NN 0
are VBP 0
67 CD 0
% NN 0
, , 0
56 CD 0
% NN 0
, , 0
and CC 0
67 CD 0
% NN 0
, , 0
respectively RB 0
. . 0

Patients NNS 0
receiving VBG 0
a DT 0
late JJ 0
intensification NN 0
had VBD 0
the DT 0
same JJ 0
relapse NN 0
rate NN 0
as IN 0
the DT 0
other JJ 0
patients NNS 0
. . 0

A DT 0
persistent JJ 0
fibronecrotic JJ 0
mass NN 0
was VBD 0
found VBN 0
in IN 0
150 CD 0
patients NNS 0
( ( 0
20 CD 0
% NN 0
) ) 0
and CC 0
did VBD 0
not RB 0
influence VB 0
the DT 0
relapse NN 0
rate NN 0
. . 0

Toxicity NNP 0
was VBD 0
mainly RB 0
neutropenia JJ 0
and CC 0
infection NN 0
during IN 0
the DT 0
ACVB NNP 0
courses NNS 0
, , 0
with IN 0
40 CD 0
patients NNS 0
( ( 0
5 CD 0
% NN 0
) ) 0
dying VBG 0
from IN 0
septic JJ 0
complications NNS 0
while IN 0
responding VBG 0
to TO 0
treatment NN 0
. . 0

Fifty-three JJ 0
percent NN 0
of IN 0
the DT 0
patients NNS 0
had VBD 0
a DT 0
neutropenia NN 0
less JJR 0
than IN 0
0.500 CD 0
x JJ 0
10 CD 0
( ( 0
9 CD 0
) ) 0
/L NN 0
, , 0
58 CD 0
% NN 0
fever NN 0
( ( 0
6 CD 0
% NN 0
grade JJ 0
4 CD 0
) ) 0
, , 0
and CC 0
49 CD 0
% NN 0
a DT 0
documented JJ 0
infection NN 0
( ( 0
8 CD 0
% NN 0
grade JJ 0
4 CD 0
) ) 0
. . 0

These DT 0
results NNS 0
obtained VBD 0
with IN 0
the DT 0
LNH-84 JJ 0
regimen NNS 0
demonstrate VBP 0
that IN 0
this DT 0
therapeutic JJ 0
scheme NN 0
is VBZ 0
an DT 0
effective JJ 0
treatment NN 0
for IN 0
aggressive JJ 0
ML NNP 0
. . 0

Clonidine NN 0
increases VBZ 0
the DT 0
sweating NN 0
threshold NN 0
, , 0
but CC 0
does VBZ 0
not RB 0
reduce VB 0
the DT 0
gain NN 0
of IN 0
sweating VBG 0
. . 0

We PRP 0
tested VBD 0
the DT 0
hypothesis NN 0
that WDT 0
clonidine NN 0
produces VBZ 0
a DT 0
dose-dependent JJ 0
increase NN 0
in IN 0
the DT 0
sweating NN 0
threshold NN 0
but CC 0
does VBZ 0
not RB 0
reduce VB 0
the DT 0
gain NN 0
of IN 0
sweating VBG 0
. . 0

Six NNP 0
healthy JJ 0
male NN 0
volunteers NNS 0
were VBD 0
evaluated VBN 0
, , 0
each DT 0
on IN 0
three CD 0
separate JJ 0
days NNS 0
in IN 0
random JJ 0
order NN 0
. . 0

In IN 0
one CD 0
, , 0
saline NN 0
was VBD 0
administered VBN 0
; : 0
in IN 0
another DT 0
, , 0
a DT 0
2-micrograms/kg JJ 0
bolus NN 0
of IN 0
clonidine NN 0
was VBD 0
followed VBN 0
by IN 0
an DT 0
infusion NN 0
at IN 0
2 CD 0
micrograms.kg-1.h-1 NN 0
, , 0
and CC 0
on IN 0
a DT 0
third JJ 0
day NN 0
, , 0
a DT 0
4-micrograms/kg JJ 0
bolus NN 0
was VBD 0
followed VBN 0
by IN 0
an DT 0
infusion NN 0
at IN 0
4 CD 0
micrograms.kg-1.h-1 JJ 0
. . 0

Core NN 0
temperature NN 0
was VBD 0
measured VBN 0
at IN 0
the DT 0
tympanic JJ 0
membrane NN 0
and CC 0
mean JJ 0
skin NN 0
temperature NN 0
was VBD 0
determined VBN 0
from IN 0
four CD 0
sites NNS 0
. . 0

A DT 0
chest JJ 0
sweating NN 0
rate NN 0
of IN 0
40 CD 0
g.m-2.h-1 NN 0
was VBD 0
considered VBN 0
significant JJ 0
. . 0

The DT 0
core NN 0
temperature NN 0
triggering VBG 0
sweating NN 0
, , 0
adjusted VBN 0
to TO 0
a DT 0
designated VBN 0
mean NN 0
skin JJ 0
temperature NN 0
of IN 0
34 CD 0
degrees NNS 0
C NNP 0
, , 0
identified VBD 0
the DT 0
threshold NN 0
for IN 0
this DT 0
response NN 0
. . 0

Gain NNP 0
was VBD 0
defined VBN 0
by IN 0
the DT 0
adjusted VBN 0
core NN 0
temperature NN 0
increase NN 0
required VBN 0
to TO 0
augment VB 0
sweating VBG 0
from IN 0
100 CD 0
to TO 0
300 CD 0
g.m-2.h-1 NN 0
. . 0

degree JJ 0
C-1 NNP 0
. . 0

Plasma NNP 0
clonidine JJ 0
concentrations NNS 0
were VBD 0
0.8 CD 0
+/- JJ 0
0.1 CD 0
and CC 0
1.6 CD 0
+/- JJ 0
0.2 CD 0
ng/mL NN 0
on IN 0
the DT 0
small- JJ 0
and CC 0
large-dose JJ 0
days NNS 0
, , 0
respectively RB 0
. . 0

Clonidine NNP 0
administration NN 0
increased VBD 0
the DT 0
sweating NN 0
threshold VBD 0
approximately RB 0
0.4 CD 0
degree JJ 0
C NNP 0
( ( 0
P NNP 0
< NNP 0
0.05 CD 0
) ) 0
, , 0
but CC 0
the DT 0
increase NN 0
was VBD 0
comparable JJ 0
at IN 0
each DT 0
dose NN 0
. . 0

The DT 0
gain NN 0
of IN 0
sweating NN 0
was VBD 0
approximately RB 0
0.2 CD 0
degree JJ 0
C NNP 0
and CC 0
was VBD 0
not RB 0
influenced VBN 0
by IN 0
clonidine JJ 0
administration NN 0
. . 0

The DT 0
thermoregulatory JJ 0
effects NNS 0
of IN 0
clonidine NN 0
thus RB 0
resemble JJ 0
those DT 0
of IN 0
volatile JJ 0
anesthetics NNS 0
, , 0
opioids NNS 0
, , 0
and CC 0
propofol NN 0
. . 0

These DT 0
data NNS 0
suggest VBP 0
that IN 0
the DT 0
antishivering VBG 0
effect NN 0
of IN 0
clonidine NN 0
results NNS 0
from IN 0
central JJ 0
thermoregulatory JJ 0
inhibition NN 0
rather RB 0
than IN 0
a DT 0
specific JJ 0
peripheral JJ 0
action NN 0
on IN 0
thermogenic JJ 0
muscular JJ 0
activity NN 0
. . 0

Unlike IN 0
other JJ 0
sedatives NNS 0
and CC 0
anesthetics NNS 0
, , 0
the DT 0
concentration-dependence NN 0
of IN 0
clonidine NN 0
demonstrates VBZ 0
a DT 0
ceiling NN 0
beyond IN 0
which WDT 0
the DT 0
administration NN 0
of IN 0
an DT 0
additional JJ 0
drug NN 0
fails NNS 0
to TO 0
enhance VB 0
the DT 0
effect NN 0
, , 0
suggesting VBG 0
that IN 0
the DT 0
thermoregulatory JJ 0
effect NN 0
of IN 0
clonidine NN 0
may MD 0
be VB 0
limited VBN 0
, , 0
even RB 0
at IN 0
high JJ 0
plasma NN 0
concentrations NNS 0
. . 0

The DT 0
gain NN 0
of IN 0
sweating NN 0
was VBD 0
well RB 0
preserved JJ 0
indicating VBG 0
that IN 0
this DT 0
response NN 0
remains VBZ 0
effective JJ 0
in IN 0
the DT 0
presence NN 0
of IN 0
sedatives NNS 0
and CC 0
anesthetics NNS 0
. . 0

Morphological JJ 0
onset NN 0
and CC 0
early JJ 0
diagnosis NN 0
in IN 0
apical JJ 0
hypertrophic JJ 0
cardiomyopathy NN 0
: : 0
a DT 0
long JJ 0
term NN 0
analysis NN 0
with IN 0
nuclear JJ 0
magnetic JJ 0
resonance NN 0
imaging NN 0
. . 0

OBJECTIVES VB 0
A DT 0
long-term JJ 0
follow-up NN 0
study NN 0
with IN 0
nuclear JJ 0
magnetic JJ 0
resonance NN 0
( ( 0
NMR NNP 0
) ) 0
imaging NN 0
was VBD 0
undertaken VBN 0
to TO 0
detect VB 0
the DT 0
morphological JJ 0
onset NN 0
and CC 0
to TO 0
establish VB 0
the DT 0
early JJ 0
diagnosis NN 0
in IN 0
apical JJ 0
hypertrophic JJ 0
cardiomyopathy NN 0
( ( 0
HCM NNP 0
) ) 0
. . 0

BACKGROUND VB 0
A DT 0
spadelike JJ 0
configuration NN 0
on IN 0
left JJ 0
ventriculogram NN 0
( ( 0
LVG NNP 0
) ) 0
is VBZ 0
regarded VBN 0
as IN 0
a DT 0
diagnostic JJ 0
criterion NN 0
for IN 0
the DT 0
classical JJ 0
apical JJ 0
HCM NNP 0
. . 0

There EX 0
also RB 0
exists VBZ 0
a DT 0
segmented JJ 0
hypertrophy NN 0
at IN 0
the DT 0
apical JJ 0
level NN 0
without IN 0
indicating VBG 0
the DT 0
spadelike NN 0
features NNS 0
( ( 0
a DT 0
nonspade NN 0
configuration NN 0
) ) 0
. . 0

To TO 0
detect VB 0
the DT 0
hypertrophied JJ 0
myocardium NN 0
of IN 0
the DT 0
nonspade JJ 0
configuration NN 0
, , 0
circumferential JJ 0
scrutiny NN 0
of IN 0
the DT 0
apex NN 0
is VBZ 0
required VBN 0
. . 0

Although IN 0
both DT 0
configurations NNS 0
can MD 0
be VB 0
underlying JJ 0
causes NNS 0
of IN 0
giant JJ 0
negative JJ 0
T NNP 0
waves NNS 0
, , 0
etiological JJ 0
relationship NN 0
between IN 0
the DT 0
two CD 0
is VBZ 0
not RB 0
clarified VBN 0
. . 0

METHODS NNP 0
The DT 0
criteria NN 0
for IN 0
the DT 0
spadelike NN 0
configuration NN 0
defined VBN 0
on IN 0
left JJ 0
ventricular JJ 0
short-axis JJ 0
NMR NNP 0
images NNS 0
were VBD 0
as IN 0
follows VBZ 0
: : 0
( ( 0
apical JJ 0
maximal NN 0
thickness NN 0
> NN 0
or CC 0
= $ 0
15 CD 0
mm NN 0
) ) 0
, , 0
( ( 0
apical JJ 0
anterior NN 0
thickness NN 0
over IN 0
basal JJ 0
anterior JJ 0
thickness NN 0
> NN 0
or CC 0
= VB 0
1.3 CD 0
) ) 0
and CC 0
( ( 0
apical JJ 0
posterior NN 0
thickness NN 0
over IN 0
basal JJ 0
posterior JJ 0
thickness NN 0
> NN 0
or CC 0
=1.3 NN 0
) ) 0
. . 0

Thirteen JJ 0
patients NNS 0
who WP 0
had VBD 0
predominant JJ 0
hypertrophy NN 0
( ( 0
> CD 0
or CC 0
= VB 0
15 CD 0
mm NN 0
) ) 0
at IN 0
the DT 0
apical JJ 0
level NN 0
without IN 0
the DT 0
spadelike NN 0
configuration NN 0
underwent JJ 0
NMR NNP 0
imaging VBG 0
twice RB 0
before RB 0
and CC 0
after IN 0
54+/-10 JJ 0
months NNS 0
' POS 0
follow-up NN 0
. . 0

RESULTS NNP 0
Apical NNP 0
hypertrophy NN 0
that WDT 0
had VBD 0
been VBN 0
confined VBN 0
to TO 0
the DT 0
lateral JJ 0
wall NN 0
in IN 0
four CD 0
, , 0
the DT 0
anterior-lateral JJ 0
wall NN 0
in IN 0
two CD 0
, , 0
and CC 0
the DT 0
septal-anterior JJ 0
wall NN 0
in IN 0
one CD 0
developed NN 0
to TO 0
become VB 0
circumferential JJ 0
hypertrophy NN 0
that WDT 0
fulfilled VBD 0
the DT 0
criteria NNS 0
for IN 0
the DT 0
spadelike NN 0
configuration NN 0
after IN 0
the DT 0
follow-up JJ 0
period NN 0
. . 0

CONCLUSIONS VB 0
The DT 0
spadelike NN 0
configuration NN 0
can MD 0
begin VB 0
with IN 0
the DT 0
nonspade JJ 0
configuration NN 0
and CC 0
therefore NN 0
, , 0
both DT 0
can MD 0
constitute VB 0
a DT 0
single JJ 0
disease NN 0
entity NN 0
of IN 0
apical JJ 0
HCM NNP 0
. . 0

The DT 0
early JJ 0
diagnosis NN 0
of IN 0
apical JJ 0
HCM NNP 0
can MD 0
be VB 0
achieved VBN 0
by IN 0
identifying VBG 0
the DT 0
hypertrophy NN 0
frequently RB 0
confined VBN 0
to TO 0
the DT 0
lateral JJ 0
wall NN 0
at IN 0
the DT 0
apical JJ 0
level NN 0
. . 0

18F-FDG JJ 0
PET/CT NNP 0
for IN 0
early JJ 0
prediction NN 0
of IN 0
response NN 0
to TO 0
neoadjuvant JJ 0
lapatinib NN 0
, , 0
trastuzumab NN 0
, , 0
and CC 0
their PRP$ 0
combination NN 0
in IN 0
HER2-positive JJ 0
breast NN 0
cancer NN 0
: : 0
results NNS 0
from IN 0
Neo-ALTTO NNP 0
. . 0

UNLABELLED NNP 0
Molecular NNP 0
imaging VBG 0
receives NNS 0
increased VBD 0
attention NN 0
for IN 0
selecting VBG 0
patients NNS 0
who WP 0
will MD 0
benefit VB 0
from IN 0
targeted JJ 0
anticancer NN 0
therapies NNS 0
. . 0

Neo-ALTTO NNP 0
( ( 0
Neoadjuvant NNP 0
Lapatinib NNP 0
and/or VBZ 0
Trastuzumab NNP 0
Treatment NNP 0
Optimisation NNP 0
) ) 0
enrolled VBD 0
455 CD 0
women NNS 0
with IN 0
invasive JJ 0
human JJ 0
epidermal JJ 0
growth NN 0
factor NN 0
receptor NN 0
2 CD 0
( ( 0
HER2 NNP 0
) ) 0
-positive VBP 0
breast NN 0
cancer NN 0
and CC 0
compared VBN 0
rates NNS 0
of IN 0
pathologic JJ 0
complete JJ 0
response NN 0
( ( 0
pCR NN 0
) ) 0
to TO 0
neoadjuvant JJ 0
lapatinib NN 0
, , 0
trastuzumab NN 0
, , 0
and CC 0
their PRP$ 0
combination NN 0
. . 0

Each DT 0
anti-HER2 JJ 0
therapy NN 0
was VBD 0
given VBN 0
alone RB 0
for IN 0
6 CD 0
wk NN 0
, , 0
followed VBN 0
by IN 0
12 CD 0
wk NN 0
of IN 0
the DT 0
same JJ 0
therapy NN 0
plus CC 0
weekly JJ 0
paclitaxel NN 0
. . 0

The DT 0
early JJ 0
metabolic JJ 0
effects NNS 0
of IN 0
the DT 0
anti-HER2 JJ 0
therapies NNS 0
on IN 0
the DT 0
primary JJ 0
tumors NNS 0
and CC 0
their PRP$ 0
predictive JJ 0
values NNS 0
for IN 0
pCR NN 0
were VBD 0
assessed VBN 0
in IN 0
a DT 0
subset NN 0
of IN 0
patients NNS 0
. . 0

METHODS NNP 0
Eighty-six JJ 0
patients NNS 0
underwent JJ 0
( ( 0
18 CD 0
) ) 0
F-FDG CD 0
PET/CT NNP 0
at IN 0
baseline NN 0
and CC 0
weeks NNS 0
2 CD 0
and CC 0
6 CD 0
of IN 0
anti-HER2 JJ 0
treatment NN 0
. . 0

An DT 0
imaging VBG 0
core NN 0
laboratory NN 0
provided VBD 0
central JJ 0
validation NN 0
, , 0
and CC 0
2 CD 0
independent JJ 0
reviewers NNS 0
, , 0
masked VBD 0
to TO 0
assigned VB 0
treatment NN 0
arm NN 0
and CC 0
clinical JJ 0
outcomes NNS 0
, , 0
performed VBN 0
consensus NN 0
( ( 0
18 CD 0
) ) 0
F-FDG NNP 0
PET/CT NNP 0
readings NNS 0
. . 0

Maximum NNP 0
standardized VBD 0
uptake JJ 0
value NN 0
( ( 0
SUVmax NNP 0
) ) 0
reductions NNS 0
from IN 0
baseline NN 0
were VBD 0
used VBN 0
to TO 0
measure VB 0
metabolic JJ 0
response NN 0
. . 0

RESULTS NNP 0
Seventy-seven NNP 0
of IN 0
the DT 0
86 CD 0
enrolled VBD 0
patients NNS 0
presented VBD 0
an DT 0
evaluable JJ 0
baseline NN 0
( ( 0
18 CD 0
) ) 0
F-FDG NNP 0
PET/CT NNP 0
scan JJ 0
; : 0
of IN 0
these DT 0
, , 0
68 CD 0
and CC 0
66 CD 0
were VBD 0
evaluable JJ 0
at IN 0
weeks NNS 0
2 CD 0
and CC 0
6 CD 0
, , 0
respectively RB 0
. . 0

Metabolic JJ 0
responses NNS 0
in IN 0
the DT 0
primary JJ 0
tumors NNS 0
were VBD 0
evident JJ 0
after IN 0
2 CD 0
wk NN 0
of IN 0
targeted JJ 0
therapy NN 0
and CC 0
correlated VBN 0
highly RB 0
with IN 0
metabolic JJ 0
responses NNS 0
at IN 0
week NN 0
6 CD 0
( ( 0
R NNP 0
( ( 0
2 CD 0
) ) 0
= FW 0
0.81 CD 0
) ) 0
. . 0

pCRs NN 0
were VBD 0
associated VBN 0
with IN 0
greater JJR 0
SUVmax NNP 0
reductions NNS 0
at IN 0
both DT 0
time NN 0
points NNS 0
. . 0

Mean NNP 0
SUVmax NNP 0
reductions NNS 0
for IN 0
pCR NN 0
and CC 0
non-pCR JJ 0
, , 0
respectively RB 0
, , 0
were VBD 0
54.3 CD 0
% NN 0
versus IN 0
32.8 CD 0
% NN 0
at IN 0
week NN 0
2 CD 0
( ( 0
P NNP 0
= NNP 0
0.02 CD 0
) ) 0
and CC 0
61.5 CD 0
% NN 0
versus IN 0
34.1 CD 0
% NN 0
at IN 0
week NN 0
6 CD 0
( ( 0
P NNP 0
= NNP 0
0.02 CD 0
) ) 0
. . 0

( ( 0
18 CD 0
) ) 0
F-FDG NNP 0
PET/CT NNP 0
metabolic JJ 0
response NN 0
rates NNS 0
at IN 0
weeks NNS 0
2 CD 0
and CC 0
6 CD 0
were VBD 0
71.6 CD 0
% NN 0
and CC 0
60 CD 0
% NN 0
, , 0
respectively RB 0
using VBG 0
European JJ 0
Organization NNP 0
for IN 0
Research NNP 0
and CC 0
Treatment NNP 0
of IN 0
Cancer NNP 0
criteria NNS 0
; : 0
pCR VBN 0
rates NNS 0
were VBD 0
twice RB 0
as RB 0
high JJ 0
for IN 0
( ( 0
18 CD 0
) ) 0
F-FDG NNP 0
PET/CT NNP 0
responders NNS 0
than IN 0
nonresponders NNS 0
( ( 0
week NN 0
2 CD 0
: : 0
42 CD 0
% NN 0
vs. FW 0
21 CD 0
% NN 0
, , 0
P NNP 0
= NNP 0
0.12 CD 0
; : 0
week NN 0
6 CD 0
: : 0
44 CD 0
% NN 0
vs. FW 0
19 CD 0
% NN 0
, , 0
P NNP 0
= NNP 0
0.05 CD 0
) ) 0
. . 0

CONCLUSION NNP 0
Early NNP 0
metabolic JJ 0
assessment NN 0
using VBG 0
( ( 0
18 CD 0
) ) 0
F-FDG CD 0
PET/CT NNP 0
can MD 0
identify VB 0
patients NNS 0
with IN 0
an DT 0
increased VBN 0
likelihood NN 0
of IN 0
pCR NN 0
after IN 0
neoadjuvant JJ 0
trastuzumab NN 0
, , 0
lapatinib NN 0
, , 0
or CC 0
their PRP$ 0
combination NN 0
when WRB 0
given VBN 0
with IN 0
chemotherapy NN 0
. . 0

Motion NNP 0
style NN 0
acupuncture NN 0
treatment NN 0
( ( 0
MSAT NNP 0
) ) 0
for IN 0
acute NN 0
low JJ 0
back RB 0
pain NN 0
with IN 0
severe JJ 0
disability NN 0
: : 0
a DT 0
multicenter NN 0
, , 0
randomized VBN 0
, , 0
controlled VBN 0
trial NN 0
protocol NN 0
. . 0

BACKGROUND NNP 0
Acupuncture NNP 0
is VBZ 0
widely-used JJ 0
to TO 0
treat VB 0
patients NNS 0
with IN 0
low JJ 0
back RB 0
pain NN 0
, , 0
despite IN 0
insufficient JJ 0
evidence NN 0
of IN 0
the DT 0
technique NN 0
's POS 0
efficacy NN 0
for IN 0
acute NN 0
back RB 0
pain NN 0
. . 0

Motion NNP 0
style NN 0
acupuncture NN 0
treatment NN 0
( ( 0
MSAT NNP 0
) ) 0
is VBZ 0
a DT 0
non-traditional JJ 0
acupuncture NN 0
treatment NN 0
requiring VBG 0
a DT 0
patient NN 0
to TO 0
exercise VB 0
while IN 0
receiving VBG 0
acupuncture NN 0
. . 0

In IN 0
Korea NNP 0
, , 0
MSAT NNP 0
is VBZ 0
used VBN 0
to TO 0
reduce VB 0
musculoskeletal JJ 0
pain NN 0
and CC 0
improve VB 0
functional JJ 0
status NN 0
. . 0

The DT 0
study NN 0
aims VBZ 0
to TO 0
evaluate VB 0
the DT 0
effect NN 0
of IN 0
MSAT NNP 0
on IN 0
acute NN 0
low JJ 0
back RB 0
pain NN 0
with IN 0
severe JJ 0
disability NN 0
. . 0

METHODS/DESIGN NNP 0
This DT 0
study NN 0
is VBZ 0
a DT 0
multicenter NN 0
, , 0
randomized VBN 0
, , 0
active-controlled JJ 0
trial NN 0
with IN 0
two CD 0
parallel JJ 0
arms NNS 0
. . 0

Participants NNS 0
with IN 0
acute NN 0
low JJ 0
back RB 0
pain NN 0
and CC 0
severe JJ 0
functional JJ 0
disability NN 0
, , 0
defined VBD 0
as IN 0
an DT 0
Oswestry NNP 0
Disability NNP 0
Index NNP 0
( ( 0
ODI NNP 0
) ) 0
value NN 0
> $ 0
60 CD 0
% NN 0
, , 0
will MD 0
be VB 0
randomly RB 0
allocated VBN 0
to TO 0
the DT 0
acupuncture NN 0
group NN 0
and CC 0
the DT 0
nonsteroidal JJ 0
anti-inflammatory JJ 0
drug NN 0
( ( 0
NSAID NNP 0
) ) 0
injection NN 0
group NN 0
. . 0

The DT 0
acupuncture NN 0
group NN 0
will MD 0
receive VB 0
MSAT NNP 0
and CC 0
the DT 0
NSAID NNP 0
injection NN 0
group NN 0
will MD 0
receive VB 0
an DT 0
intramuscular JJ 0
injection NN 0
of IN 0
diclofenac NN 0
. . 0

All DT 0
procedures NNS 0
will MD 0
be VB 0
limited VBN 0
to TO 0
one CD 0
session NN 0
and CC 0
the DT 0
symptoms NNS 0
before IN 0
and CC 0
after IN 0
treatment NN 0
will MD 0
be VB 0
measured VBN 0
by IN 0
assessors NNS 0
blinded VBD 0
to TO 0
treatment NN 0
allocation NN 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
will MD 0
be VB 0
measured VBN 0
at IN 0
30 CD 0
minutes NNS 0
after IN 0
treatment NN 0
using VBG 0
the DT 0
numerical JJ 0
rating NN 0
scale NN 0
( ( 0
NRS NNP 0
) ) 0
of IN 0
low JJ 0
back RB 0
pain NN 0
while IN 0
the DT 0
patient NN 0
is VBZ 0
moving VBG 0
. . 0

Secondary JJ 0
outcomes NNS 0
will MD 0
be VB 0
measured VBN 0
at IN 0
30 CD 0
minutes NNS 0
after IN 0
treatment NN 0
using VBG 0
the DT 0
NRS NNP 0
of IN 0
leg NN 0
pain NN 0
, , 0
ODI NNP 0
, , 0
patient NN 0
global JJ 0
impression NN 0
of IN 0
change NN 0
, , 0
range NN 0
of IN 0
motion NN 0
( ( 0
ROM NNP 0
) ) 0
of IN 0
the DT 0
lumbar NN 0
spine NN 0
, , 0
and CC 0
degrees NNS 0
of IN 0
straight JJ 0
leg NN 0
raising VBG 0
( ( 0
SLR NNP 0
) ) 0
. . 0

Post-treatment JJ 0
follow-up NN 0
will MD 0
be VB 0
performed VBN 0
to TO 0
measure VB 0
primary JJ 0
and CC 0
secondary JJ 0
outcomes NNS 0
with IN 0
the DT 0
exception NN 0
of IN 0
ROM NNP 0
and CC 0
SLR NNP 0
at IN 0
2 CD 0
, , 0
4 CD 0
, , 0
and CC 0
24 CD 0
weeks NNS 0
after IN 0
treatment NN 0
. . 0

DISCUSSION NNP 0
The DT 0
results NNS 0
of IN 0
this DT 0
trial NN 0
will MD 0
be VB 0
discussed VBN 0
. . 0

TRIAL NNP 0
REGISTRATION NNP 0
ClinicalTrial.gov NNP 0
NCT01315561 NNP 0
. . 0

An DT 0
open JJ 0
and CC 0
randomized JJ 0
study NN 0
comparing VBG 0
the DT 0
efficacy NN 0
of IN 0
standard JJ 0
danazol NN 0
and CC 0
modified VBD 0
triptorelin NN 0
regimens NNS 0
for IN 0
postoperative JJ 0
disease NN 0
management NN 0
of IN 0
moderate JJ 0
to TO 0
severe JJ 0
endometriosis NN 0
. . 0

OBJECTIVE UH 0
To TO 0
compare VB 0
the DT 0
efficacy NN 0
of IN 0
danazol NN 0
and CC 0
triptorelin NN 0
( ( 0
Decapeptyl NNP 0
CR NNP 0
, , 0
Ferring NNP 0
, , 0
Kiel NNP 0
, , 0
Germany NNP 0
) ) 0
in IN 0
the DT 0
management NN 0
of IN 0
moderate JJ 0
and CC 0
severe JJ 0
endometriosis NN 0
in IN 0
terms NNS 0
of IN 0
symptom NN 0
control NN 0
and CC 0
revised VBN 0
American JJ 0
Fertility NNP 0
Society NNP 0
( ( 0
AFS NNP 0
) ) 0
score NN 0
reduction NN 0
, , 0
and CC 0
to TO 0
evaluate VB 0
the DT 0
hormonal JJ 0
profile NN 0
of IN 0
patients NNS 0
treated VBN 0
with IN 0
triptorelin NN 0
every DT 0
6 CD 0
weeks NNS 0
. . 0

DESIGN NNP 0
Open NNP 0
and CC 0
randomized VBN 0
trial NN 0
. . 0

SETTING NN 0
Kwong NNP 0
Wah NNP 0
Hospital NNP 0
, , 0
a DT 0
large JJ 0
public JJ 0
hospital NN 0
in IN 0
an DT 0
urban JJ 0
location NN 0
( ( 0
Hong NNP 0
Kong NNP 0
) ) 0
. . 0

PATIENT NNP 0
( ( 0
S NNP 0
) ) 0
Forty NNP 0
patients NNS 0
after IN 0
their PRP$ 0
first JJ 0
conservative JJ 0
operation NN 0
for IN 0
endometriosis NN 0
, , 0
with IN 0
surgical JJ 0
confirmation NN 0
of IN 0
revised VBN 0
AFS NNP 0
stage NN 0
III NNP 0
or CC 0
IV NNP 0
endometriosis NN 0
. . 0

INTERVENTION NNP 0
( ( 0
S NNP 0
) ) 0
Postoperative VBP 0
6 CD 0
months NNS 0
' POS 0
therapy NN 0
of IN 0
danazol NN 0
or CC 0
triptorelin NN 0
every DT 0
6 CD 0
weeks NNS 0
, , 0
postmedical JJ 0
therapy NN 0
second-look NN 0
laparoscopy NN 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURE NNP 0
( ( 0
S NNP 0
) ) 0
Symptom NNP 0
control NN 0
and CC 0
patients NNS 0
' POS 0
tolerance NN 0
during IN 0
medical JJ 0
therapy NN 0
, , 0
posttherapy NN 0
revised VBD 0
AFS NNP 0
score NN 0
, , 0
hormonal JJ 0
profile NN 0
during IN 0
triptorelin JJ 0
therapy NN 0
. . 0

RESULT NNP 0
( ( 0
S NNP 0
) ) 0
Pain NNP 0
control NN 0
was VBD 0
similar JJ 0
between IN 0
danazol NN 0
and CC 0
triptorelin NN 0
therapy NN 0
. . 0

There EX 0
was VBD 0
less JJR 0
breakthrough IN 0
bleeding NN 0
with IN 0
triptorelin NN 0
. . 0

More JJR 0
patients NNS 0
failed VBD 0
to TO 0
complete VB 0
the DT 0
whole JJ 0
course NN 0
of IN 0
danazol NN 0
because IN 0
of IN 0
its PRP$ 0
side NN 0
effects NNS 0
. . 0

The DT 0
revised JJ 0
AFS NNP 0
score NN 0
at IN 0
second-look JJ 0
laparoscopy NN 0
did VBD 0
not RB 0
show VB 0
a DT 0
significant JJ 0
difference NN 0
between IN 0
the DT 0
two CD 0
medications NNS 0
. . 0

Adequate NNP 0
pituitary JJ 0
suppression NN 0
was VBD 0
observed VBN 0
with IN 0
injection NN 0
of IN 0
triptorelin NN 0
every DT 0
6 CD 0
weeks NNS 0
. . 0

CONCLUSION NNP 0
( ( 0
S NNP 0
) ) 0
Lengthening NNP 0
of IN 0
triptorelin JJ 0
administration NN 0
intervals NNS 0
from IN 0
4 CD 0
weeks NNS 0
to TO 0
6 CD 0
weeks NNS 0
is VBZ 0
effective JJ 0
in IN 0
maintaining VBG 0
a DT 0
hypoestrogenic JJ 0
state NN 0
. . 0

Patients NNS 0
were VBD 0
more RBR 0
compliant JJ 0
with IN 0
triptorelin NN 0
than IN 0
danazol NN 0
. . 0

Thus RB 0
, , 0
triptorelin JJ 0
injection NN 0
every DT 0
6 CD 0
weeks NNS 0
is VBZ 0
more JJR 0
cost-effective JJ 0
than IN 0
conventional JJ 0
regimens NNS 0
. . 0

The DT 0
relationship NN 0
between IN 0
repetitive JJ 0
behaviors NNS 0
and CC 0
growth NN 0
hormone NN 0
response NN 0
to TO 0
sumatriptan VB 0
challenge NN 0
in IN 0
adult NN 0
autistic JJ 0
disorder NN 0
. . 0

Autism NNP 0
is VBZ 0
heterogeneous JJ 0
with IN 0
respect NN 0
to TO 0
clinical JJ 0
symptoms NNS 0
and CC 0
etiology NN 0
. . 0

To TO 0
sort VB 0
out RP 0
this DT 0
heterogeneity NN 0
in IN 0
autism NN 0
, , 0
we PRP 0
investigated VBD 0
whether IN 0
specific JJ 0
neurobiological JJ 0
markers NNS 0
vary VBP 0
in IN 0
parallel NN 0
to TO 0
core VB 0
symptomatology NN 0
. . 0

Specifically RB 0
, , 0
we PRP 0
assessed VBD 0
growth NN 0
hormone NN 0
response NN 0
to TO 0
the DT 0
5-HT JJ 0
1d CD 0
agonist NN 0
, , 0
sumatriptan NN 0
, , 0
and CC 0
linked VBD 0
this DT 0
measure NN 0
of IN 0
serotonergic JJ 0
function NN 0
to TO 0
the DT 0
severity NN 0
of IN 0
repetitive JJ 0
behaviors NNS 0
in IN 0
adult NN 0
autistic JJ 0
patients NNS 0
. . 0

Eleven NNP 0
adult NN 0
patients NNS 0
with IN 0
autism NN 0
or CC 0
Asperger NNP 0
's POS 0
disorder NN 0
were VBD 0
randomized VBN 0
to TO 0
single JJ 0
dose JJ 0
sumatriptan NN 0
( ( 0
6 CD 0
mg RB 0
SQ NNP 0
) ) 0
and CC 0
placebo NN 0
challenges NNS 0
, , 0
separated VBN 0
by IN 0
a DT 0
one-week JJ 0
interval NN 0
. . 0

In IN 0
adult JJ 0
autistic JJ 0
disorders NNS 0
, , 0
severity NN 0
of IN 0
repetitive JJ 0
behaviors NNS 0
at IN 0
baseline NN 0
, , 0
as IN 0
measured VBN 0
by IN 0
YBOCS-compulsion NNP 0
score NN 0
, , 0
significantly RB 0
positively RB 0
correlated VBN 0
with IN 0
both DT 0
peak JJ 0
delta NN 0
growth NN 0
hormone NN 0
response NN 0
and CC 0
area NN 0
under IN 0
the DT 0
curve NN 0
growth NN 0
hormone NN 0
response NN 0
to TO 0
sumatriptan VB 0
. . 0

Thus RB 0
, , 0
the DT 0
severity NN 0
of IN 0
a DT 0
specific JJ 0
behavioral JJ 0
dimension NN 0
in IN 0
autism NN 0
( ( 0
repetitive JJ 0
behaviors NNS 0
) ) 0
parallels VBP 0
the DT 0
sensitivity NN 0
of IN 0
the DT 0
5-HT JJ 0
1d CD 0
receptor NN 0
, , 0
as IN 0
manifest NN 0
by IN 0
sumatriptan NN 0
elicited VBN 0
GH NNP 0
response NN 0
. . 0

Whole-body JJ 0
CT NNP 0
screening NN 0
: : 0
scan JJ 0
delay NN 0
and CC 0
contrast NN 0
injection NN 0
duration NN 0
for IN 0
optimal JJ 0
enhancement NN 0
of IN 0
abdominal JJ 0
organs NNS 0
and CC 0
deep JJ 0
vessels NNS 0
. . 0

PURPOSE NNP 0
To TO 0
assess VB 0
the DT 0
optimal JJ 0
scan JJ 0
delays NNS 0
and CC 0
contrast NN 0
injection NN 0
durations NNS 0
for IN 0
contrast-enhanced JJ 0
whole-body NN 0
computed VBN 0
tomography NN 0
( ( 0
CT NNP 0
) ) 0
. . 0

MATERIALS NNP 0
AND CC 0
METHODS NNP 0
One CD 0
hundred VBD 0
forty-two JJ 0
patients NNS 0
were VBD 0
randomized VBN 0
into IN 0
three CD 0
groups NNS 0
: : 0
protocol NN 0
A-scan JJ 0
delay NN 0
of IN 0
65 CD 0
s NNS 0
after IN 0
starting VBG 0
contrast NN 0
injection NN 0
over IN 0
30 CD 0
s NNS 0
; : 0
protocol CC 0
B-105 NNP 0
and CC 0
70 CD 0
s NN 0
; : 0
and CC 0
protocol VB 0
C-145 NNP 0
and CC 0
110 CD 0
s NN 0
, , 0
respectively RB 0
. . 0

Contrast NNP 0
enhancement NN 0
and CC 0
diagnostic JJ 0
acceptability NN 0
were VBD 0
assessed VBN 0
. . 0

RESULTS NNP 0
Qualitative JJ 0
assessment NN 0
was VBD 0
subtle JJ 0
among IN 0
the DT 0
three CD 0
protocols NNS 0
. . 0

Homogenous JJ 0
enhancement NN 0
of IN 0
deep JJ 0
veins NNS 0
was VBD 0
more RBR 0
assuredly RB 0
achieved VBN 0
with IN 0
protocol NN 0
C. NNP 0
CONCLUSION NNP 0
With IN 0
protocol NN 0
C NNP 0
, , 0
qualitatively RB 0
acceptable JJ 0
enhancement NN 0
can MD 0
be VB 0
obtained VBN 0
in IN 0
whole-body JJ 0
CT NNP 0
. . 0

Co-administration NN 0
of IN 0
pethidine NN 0
and CC 0
clonidine NN 0
: : 0
a DT 0
spinal JJ 0
anaesthetic JJ 0
technique NN 0
for IN 0
total JJ 0
hip NN 0
replacement NN 0
. . 0

Co-administration NN 0
of IN 0
pethidine NN 0
0.75 CD 0
mg NN 0
kg-1 NN 0
and CC 0
clonidine NN 0
75 CD 0
micrograms NNS 0
intrathecally RB 0
provided VBD 0
good JJ 0
intraoperative JJ 0
anaesthesia NN 0
for IN 0
total JJ 0
hip NN 0
replacement NN 0
, , 0
similar JJ 0
to TO 0
that DT 0
obtained VBN 0
using VBG 0
0.5 CD 0
% NN 0
isobaric JJ 0
bupivacaine NN 0
. . 0

Sensory NNP 0
and CC 0
motor NN 0
block NN 0
were VBD 0
of IN 0
shorter JJR 0
duration NN 0
than IN 0
that DT 0
after IN 0
0.5 CD 0
% NN 0
isobaric JJ 0
bupivacaine NN 0
and CC 0
0.5 CD 0
% NN 0
isobaric JJ 0
bupivacaine NN 0
with IN 0
morphine JJ 0
0.5 CD 0
mg NN 0
( ( 0
P NNP 0
< VBZ 0
0.001 CD 0
sensory JJ 0
block NN 0
, , 0
P NNP 0
< VBZ 0
0.001 CD 0
motor NN 0
block NN 0
) ) 0
. . 0

Postoperative JJ 0
morphine NN 0
consumption NN 0
, , 0
measured VBN 0
using VBG 0
a DT 0
patient-controlled JJ 0
system NN 0
, , 0
was VBD 0
similar JJ 0
to TO 0
that DT 0
in IN 0
patients NNS 0
in IN 0
the DT 0
bupivacaine NN 0
only RB 0
group NN 0
( ( 0
pethidine-clonidine JJ 0
: : 0
median JJ 0
39 CD 0
mg/24 NN 0
h NN 0
; : 0
bupivacaine NN 0
: : 0
median JJ 0
34 CD 0
mg/24 NN 0
h NN 0
) ) 0
but CC 0
greater JJR 0
than IN 0
that DT 0
in IN 0
the DT 0
bupivacaine-morphine JJ 0
group NN 0
( ( 0
median JJ 0
8 CD 0
mg/24 NN 0
h NN 0
) ) 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

Visual JJ 0
analogue NN 0
pain NN 0
scores NNS 0
after IN 0
operation NN 0
were VBD 0
similar JJ 0
to TO 0
those DT 0
with IN 0
bupivacaine JJ 0
alone NN 0
at IN 0
all DT 0
but CC 0
one CD 0
of IN 0
the DT 0
recording NN 0
times NNS 0
but CC 0
were VBD 0
greater JJR 0
than IN 0
those DT 0
in IN 0
patients NNS 0
who WP 0
received VBD 0
bupivacaine NN 0
and CC 0
morphine NN 0
at IN 0
4 CD 0
, , 0
6 CD 0
and CC 0
10 CD 0
h NN 0
after IN 0
operation NN 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
, , 0
P NNP 0
< NNP 0
0.04 CD 0
, , 0
P NNP 0
< NNP 0
0.02 CD 0
) ) 0
. . 0

The DT 0
combination NN 0
did VBD 0
not RB 0
offer VB 0
any DT 0
major JJ 0
advantage NN 0
over IN 0
conventional JJ 0
agents NNS 0
. . 0

Perioperative JJ 0
fever NN 0
and CC 0
outcome NN 0
in IN 0
surgical JJ 0
patients NNS 0
with IN 0
aneurysmal JJ 0
subarachnoid JJ 0
hemorrhage NN 0
. . 0

OBJECTIVE IN 0
We PRP 0
examined VBD 0
the DT 0
incidence NN 0
of IN 0
perioperative JJ 0
fever NN 0
and CC 0
its PRP$ 0
relationship NN 0
to TO 0
outcome VB 0
among IN 0
patients NNS 0
enrolled VBN 0
in IN 0
the DT 0
Intraoperative NNP 0
Hypothermia NNP 0
for IN 0
Aneurysm NNP 0
Surgery NNP 0
Trial NNP 0
. . 0

METHODS NNP 0
One CD 0
thousand NN 0
patients NNS 0
with IN 0
initial JJ 0
World NNP 0
Federation NNP 0
of IN 0
Neurological NNP 0
Surgeons NNP 0
grades NNS 0
of IN 0
I PRP 0
to TO 0
III NNP 0
undergoing VBG 0
clipping NN 0
of IN 0
intracranial JJ 0
aneurysms NNS 0
after IN 0
subarachnoid JJ 0
hemorrhage NN 0
were VBD 0
randomized VBN 0
to TO 0
intraoperative VB 0
normothermia NN 0
( ( 0
36 CD 0
degrees NNS 0
C-37 JJ 0
degrees NNS 0
C NNP 0
) ) 0
or CC 0
hypothermia NN 0
( ( 0
32.5 CD 0
degrees NNS 0
C-33.5 JJ 0
degrees NNS 0
C NNP 0
) ) 0
. . 0

Fever NNP 0
( ( 0
> CD 0
or CC 0
=38.5 VB 0
degrees NNS 0
C NNP 0
) ) 0
and CC 0
other JJ 0
complications NNS 0
( ( 0
including VBG 0
infections NNS 0
) ) 0
occurring VBG 0
between IN 0
admission NN 0
and CC 0
discharge NN 0
( ( 0
or CC 0
death NN 0
) ) 0
were VBD 0
recorded VBN 0
. . 0

Functional NNP 0
and CC 0
neuropsychologic JJ 0
outcomes NNS 0
were VBD 0
assessed VBN 0
3 CD 0
months NNS 0
postoperatively RB 0
. . 0

The DT 0
primary JJ 0
outcome NN 0
variable NN 0
for IN 0
the DT 0
trial NN 0
was VBD 0
dichotomized VBN 0
Glasgow NNP 0
Outcome NNP 0
Scale NNP 0
( ( 0
good JJ 0
outcome NN 0
versus IN 0
all DT 0
others NNS 0
) ) 0
. . 0

RESULTS NNP 0
Fever NNP 0
was VBD 0
reported VBN 0
in IN 0
41 CD 0
% NN 0
of IN 0
patients NNS 0
. . 0

In IN 0
97 CD 0
% NN 0
of IN 0
these DT 0
, , 0
fever RB 0
occurred VBD 0
in IN 0
the DT 0
postoperative JJ 0
period NN 0
. . 0

The DT 0
median JJ 0
time NN 0
from IN 0
surgery NN 0
to TO 0
first VB 0
fever NN 0
was VBD 0
3 CD 0
days NNS 0
. . 0

All DT 0
measures NNS 0
of IN 0
outcome NN 0
were VBD 0
worse JJR 0
in IN 0
patients NNS 0
who WP 0
developed VBD 0
fever NN 0
, , 0
even RB 0
in IN 0
those DT 0
without IN 0
infections NNS 0
or CC 0
who WP 0
were VBD 0
World NNP 0
Federation NNP 0
of IN 0
Neurological NNP 0
Surgeons NNP 0
grade VBD 0
I. NNP 0
Logistic NNP 0
regression NN 0
analyses NNS 0
were VBD 0
performed VBN 0
to TO 0
adjust VB 0
for IN 0
differences NNS 0
in IN 0
preoperative JJ 0
factors NNS 0
( ( 0
e.g. NN 0
, , 0
age NN 0
, , 0
Fisher NNP 0
grade NN 0
, , 0
initial JJ 0
neurological JJ 0
status NN 0
) ) 0
. . 0

This DT 0
demonstrated VBD 0
that IN 0
fever NN 0
continued VBD 0
to TO 0
be VB 0
significantly RB 0
associated VBN 0
with IN 0
most JJS 0
outcome JJ 0
measures NNS 0
, , 0
even RB 0
when WRB 0
infection NN 0
was VBD 0
added VBN 0
to TO 0
the DT 0
model NN 0
. . 0

An DT 0
alternative JJ 0
stepwise NN 0
model NN 0
selection NN 0
process NN 0
including VBG 0
all DT 0
fever-related JJ 0
measures NNS 0
from IN 0
the DT 0
preoperative NN 0
and CC 0
intraoperative JJ 0
period NN 0
( ( 0
e.g. JJ 0
, , 0
hydrocephalus JJ 0
, , 0
duration NN 0
of IN 0
surgery NN 0
, , 0
intraoperative JJ 0
blood NN 0
loss NN 0
) ) 0
resulted VBD 0
in IN 0
the DT 0
loss NN 0
of IN 0
significance NN 0
for IN 0
dichotomized JJ 0
Glasgow NNP 0
Outcome NNP 0
Scale NNP 0
, , 0
but CC 0
significant JJ 0
associations NNS 0
between IN 0
fever NN 0
and CC 0
several JJ 0
other JJ 0
outcome JJ 0
measures NNS 0
remained VBD 0
. . 0

After IN 0
adding VBG 0
postoperative JJ 0
delayed VBN 0
ischemic JJ 0
neurological JJ 0
deficits NNS 0
to TO 0
the DT 0
model NN 0
, , 0
only RB 0
worsened VBD 0
National NNP 0
Institutes NNPS 0
of IN 0
Health NNP 0
Stroke NNP 0
Scale NNP 0
score NN 0
, , 0
Barthel NNP 0
Activities NNP 0
of IN 0
Daily NNP 0
Living NNP 0
index NN 0
, , 0
and CC 0
discharge NN 0
destination NN 0
( ( 0
home NN 0
versus IN 0
other JJ 0
) ) 0
remained VBD 0
independently RB 0
associated VBN 0
with IN 0
fever NN 0
. . 0

CONCLUSION NNP 0
These DT 0
findings NNS 0
suggest VBP 0
that IN 0
fever NN 0
is VBZ 0
associated VBN 0
with IN 0
worsened JJ 0
outcome NN 0
in IN 0
surgical JJ 0
subarachnoid JJ 0
hemorrhage NN 0
patients NNS 0
, , 0
although IN 0
, , 0
because IN 0
the DT 0
association NN 0
between IN 0
fever NN 0
and CC 0
the DT 0
primary JJ 0
outcome NN 0
measure NN 0
for IN 0
the DT 0
trial NN 0
is VBZ 0
dependent JJ 0
on IN 0
the DT 0
covariates NNS 0
used VBN 0
in IN 0
the DT 0
analysis NN 0
( ( 0
particularly RB 0
operative JJ 0
events NNS 0
and CC 0
delayed VBN 0
ischemic JJ 0
neurological JJ 0
deficits NNS 0
) ) 0
, , 0
we PRP 0
can MD 0
not RB 0
rule VB 0
out IN 0
the DT 0
possibility NN 0
that IN 0
fever NN 0
is VBZ 0
a DT 0
marker NN 0
for IN 0
other JJ 0
events NNS 0
. . 0

Only RB 0
a DT 0
formal JJ 0
trial NN 0
of IN 0
fever NN 0
treatment NN 0
or CC 0
prevention NN 0
can MD 0
address VB 0
this DT 0
issue NN 0
. . 0

Controlled VBN 0
clinical JJ 0
trial NN 0
of IN 0
IV NNP 0
cyclophosphamide NN 0
versus NN 0
IV NNP 0
methylprednisolone NN 0
in IN 0
severe JJ 0
neurological JJ 0
manifestations NNS 0
in IN 0
systemic JJ 0
lupus NN 0
erythematosus NN 0
. . 0

BACKGROUND NNP 0
Severe NNP 0
neurological JJ 0
involvement NN 0
in IN 0
systemic JJ 0
lupus NN 0
erythematosus NN 0
( ( 0
NPSLE NNP 0
) ) 0
is VBZ 0
one CD 0
of IN 0
the DT 0
most RBS 0
dreadful JJ 0
complications NNS 0
of IN 0
the DT 0
disease NN 0
. . 0

OBJECTIVE UH 0
To TO 0
identify VB 0
the DT 0
best JJS 0
drug NN 0
, , 0
dose NN 0
, , 0
and CC 0
treatment NN 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
The DT 0
study NN 0
was VBD 0
a DT 0
controlled JJ 0
clinical JJ 0
trial NN 0
at IN 0
two CD 0
tertiary JJ 0
care NN 0
centres NNS 0
of IN 0
patients NNS 0
with IN 0
SLE NNP 0
according VBG 0
to TO 0
the DT 0
ACR NNP 0
criteria NNS 0
, , 0
with IN 0
incident NN 0
( ( 0
no DT 0
more JJR 0
than IN 0
15 CD 0
days NNS 0
) ) 0
onset NN 0
of IN 0
severe JJ 0
NP NNP 0
manifestations NNS 0
such JJ 0
as IN 0
seizures NNS 0
, , 0
optic JJ 0
neuritis NN 0
, , 0
peripheral JJ 0
or CC 0
cranial JJ 0
neuropathy NN 0
, , 0
coma NN 0
, , 0
brainstem NN 0
disease NN 0
, , 0
or CC 0
transverse JJ 0
myelitis NN 0
. . 0

Induction NNP 0
treatment NN 0
with IN 0
3 CD 0
g NN 0
of IN 0
IV NNP 0
methylprednisolone NN 0
( ( 0
MP NNP 0
) ) 0
followed VBN 0
by IN 0
either DT 0
IV NNP 0
monthly JJ 0
cyclophosphamide NN 0
( ( 0
Cy NNP 0
) ) 0
versus NN 0
IV NNP 0
MP NNP 0
bimonthly RB 0
every DT 0
4 CD 0
months NNS 0
for IN 0
1 CD 0
year NN 0
and CC 0
then RB 0
IV NNP 0
Cy NNP 0
or CC 0
IV NNP 0
MP NNP 0
every DT 0
3 CD 0
months NNS 0
for IN 0
another DT 0
year NN 0
. . 0

The DT 0
primary JJ 0
end NN 0
point NN 0
was VBD 0
response NN 0
to TO 0
treatment NN 0
: : 0
at IN 0
least JJS 0
20 CD 0
% NN 0
improvement NN 0
from IN 0
basal JJ 0
conditions NNS 0
on IN 0
clinical JJ 0
, , 0
laboratory NN 0
, , 0
or CC 0
specific JJ 0
neurological JJ 0
testing NN 0
variables NNS 0
. . 0

RESULTS NNP 0
Overall NNP 0
, , 0
a DT 0
response NN 0
rate NN 0
of IN 0
75 CD 0
% NN 0
was VBD 0
observed VBN 0
. . 0

Of IN 0
the DT 0
32 CD 0
patients NNS 0
studied VBN 0
, , 0
18/19 CD 0
receiving VBG 0
Cy NNP 0
and CC 0
7/13 CD 0
receiving VBG 0
MP NNP 0
responded VBD 0
to TO 0
treatment NN 0
( ( 0
p JJ 0
< NNP 0
0.03 CD 0
) ) 0
. . 0

CONCLUSIONS NNP 0
Cy NNP 0
seems VBZ 0
to TO 0
be VB 0
more RBR 0
effective JJ 0
than IN 0
MP NNP 0
in IN 0
the DT 0
treatment NN 0
of IN 0
acute NN 0
, , 0
severe JJ 0
NPSLE NNP 0
. . 0

Factors NNS 0
predictive VBP 0
of IN 0
severe JJ 0
hypoglycemia NN 0
in IN 0
type NN 0
1 CD 0
diabetes NNS 0
: : 0
analysis NN 0
from IN 0
the DT 0
Juvenile NNP 0
Diabetes NNP 0
Research NNP 0
Foundation NNP 0
continuous JJ 0
glucose JJ 0
monitoring VBG 0
randomized VBN 0
control NN 0
trial NN 0
dataset NN 0
. . 0

OBJECTIVE NNP 0
Identify NNP 0
factors NNS 0
predictive VBP 0
of IN 0
severe JJ 0
hypoglycemia NN 0
( ( 0
SH NNP 0
) ) 0
and CC 0
assess VB 0
the DT 0
clinical JJ 0
utility NN 0
of IN 0
continuous JJ 0
glucose JJ 0
monitoring NN 0
( ( 0
CGM NNP 0
) ) 0
to TO 0
warn VB 0
of IN 0
impending VBG 0
SH NNP 0
. . 0

RESEARCH NNP 0
DESIGN NNP 0
AND NNP 0
METHODS NNP 0
In IN 0
a DT 0
multicenter NN 0
randomized VBN 0
clinical JJ 0
trial NN 0
, , 0
436 CD 0
children NNS 0
and CC 0
adults NNS 0
with IN 0
type JJ 0
1 CD 0
diabetes NNS 0
were VBD 0
randomized VBN 0
to TO 0
a DT 0
treatment NN 0
group NN 0
that WDT 0
used VBD 0
CGM NNP 0
( ( 0
N NNP 0
= NNP 0
224 CD 0
) ) 0
, , 0
or CC 0
a DT 0
control NN 0
group NN 0
that WDT 0
used VBD 0
standard JJ 0
home NN 0
blood NN 0
glucose JJ 0
monitoring NN 0
( ( 0
N NNP 0
= NNP 0
212 CD 0
) ) 0
and CC 0
completed VBD 0
12 CD 0
months NNS 0
of IN 0
follow-up NN 0
. . 0

After IN 0
6 CD 0
months NNS 0
, , 0
the DT 0
original JJ 0
control NN 0
group NN 0
initiated VBD 0
CGM NNP 0
while IN 0
the DT 0
treatment NN 0
group NN 0
continued VBD 0
use NN 0
of IN 0
CGM NNP 0
for IN 0
6 CD 0
months NNS 0
. . 0

Baseline NNP 0
risk NN 0
factors NNS 0
for IN 0
SH NNP 0
were VBD 0
evaluated VBN 0
over IN 0
12 CD 0
months NNS 0
of IN 0
follow-up JJ 0
using VBG 0
proportional JJ 0
hazards NNS 0
regression NN 0
. . 0

CGM-derived JJ 0
indices NNS 0
of IN 0
hypoglycemia NN 0
were VBD 0
used VBN 0
to TO 0
predict VB 0
episodes NNS 0
of IN 0
SH NNP 0
over IN 0
a DT 0
24-h JJ 0
time NN 0
horizon NN 0
. . 0

RESULTS VB 0
The DT 0
SH NNP 0
rate NN 0
was VBD 0
17.9 CD 0
per IN 0
100 CD 0
person-years NNS 0
, , 0
and CC 0
a DT 0
higher JJR 0
rate NN 0
was VBD 0
associated VBN 0
with IN 0
the DT 0
occurrence NN 0
of IN 0
SH NNP 0
in IN 0
the DT 0
prior JJ 0
6 CD 0
months NNS 0
and CC 0
female JJ 0
sex NN 0
. . 0

SH NNP 0
frequency NN 0
increased VBD 0
eightfold RB 0
when WRB 0
30 CD 0
% NN 0
of IN 0
CGM NNP 0
values NNS 0
were VBD 0
? . 0
70 CD 0
mg/dL NN 0
on IN 0
the DT 0
prior JJ 0
day NN 0
( ( 0
4.5 CD 0
vs. FW 0
0.5 CD 0
% NN 0
; : 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
, , 0
but CC 0
the DT 0
positive JJ 0
predictive JJ 0
value NN 0
( ( 0
PPV NNP 0
) ) 0
was VBD 0
low JJ 0
( ( 0
< JJ 0
5 CD 0
% NN 0
) ) 0
. . 0

Results NNS 0
were VBD 0
similar JJ 0
for IN 0
hypoglycemic JJ 0
area NN 0
under IN 0
the DT 0
curve NN 0
and CC 0
the DT 0
low JJ 0
blood NN 0
glucose NN 0
index NN 0
calculated VBN 0
by IN 0
CGM NNP 0
. . 0

CONCLUSIONS NNP 0
SH NNP 0
in IN 0
the DT 0
6 CD 0
months NNS 0
prior RB 0
to TO 0
the DT 0
study NN 0
was VBD 0
the DT 0
strongest JJS 0
predictor NN 0
of IN 0
SH NNP 0
during IN 0
the DT 0
study NN 0
. . 0

CGM-measured JJ 0
hypoglycemia NN 0
over IN 0
a DT 0
24-h JJ 0
span NN 0
is VBZ 0
highly RB 0
associated VBN 0
with IN 0
SH NNP 0
the DT 0
following JJ 0
day NN 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
, , 0
but CC 0
the DT 0
PPV NNP 0
is VBZ 0
low JJ 0
. . 0

Creon NNP 0
10,000 CD 0
Minimicrospheres NNP 0
vs. FW 0
Creon NNP 0
8,000 CD 0
microspheres NNS 0
-- : 0
an DT 0
open JJ 0
randomised VBN 0
crossover NN 0
preference NN 0
study NN 0
. . 0

Creon NNP 0
10,000 CD 0
Minimicrospherestrade NNP 0
mark NN 0
( ( 0
Creon NNP 0
) ) 0
10,000 CD 0
MMS NNP 0
) ) 0
is VBZ 0
a DT 0
pancreatic JJ 0
enzyme NN 0
formulation NN 0
that IN 0
contains VBZ 0
smaller JJR 0
spheres NNS 0
of IN 0
pancreatin NN 0
in IN 0
a DT 0
50 CD 0
% NN 0
smaller JJR 0
capsule NN 0
than IN 0
conventional JJ 0
microspheres NNS 0
( ( 0
Creon NNP 0
) ) 0
8,000 CD 0
) ) 0
. . 0

This DT 0
three-centre JJ 0
study NN 0
investigated VBD 0
the DT 0
preference NN 0
of IN 0
cystic JJ 0
fibrosis NN 0
( ( 0
CF NNP 0
) ) 0
patients NNS 0
for IN 0
these DT 0
products NNS 0
. . 0

In IN 0
one CD 0
centre NN 0
, , 0
72 CD 0
h NN 0
stool NN 0
fat JJ 0
excretion NN 0
and CC 0
coefficient NN 0
of IN 0
fat JJ 0
absorption NN 0
( ( 0
CFA NNP 0
) ) 0
were VBD 0
also RB 0
compared VBN 0
. . 0

Fifty-nine JJ 0
patients NNS 0
with IN 0
a DT 0
mean JJ 0
age NN 0
10 CD 0
years NNS 0
( ( 0
range VB 0
3-17 NNP 0
) ) 0
took VBD 0
Creon NNP 0
8,000 CD 0
ms NN 0
for IN 0
14 CD 0
days NNS 0
and CC 0
were VBD 0
then RB 0
randomised VBN 0
to TO 0
28 CD 0
days NNS 0
of IN 0
Creon NNP 0
8,000 CD 0
ms NN 0
followed VBN 0
by IN 0
28 CD 0
days NNS 0
of IN 0
Creon NNP 0
10,000 CD 0
MMS NNP 0
, , 0
or CC 0
vice NN 0
versa NN 0
. . 0

Dosing NNP 0
was VBD 0
lipase NN 0
for IN 0
lipase NN 0
according VBG 0
to TO 0
the DT 0
labelled VBN 0
declaration NN 0
. . 0

At IN 0
the DT 0
end NN 0
of IN 0
the DT 0
second JJ 0
treatment NN 0
period NN 0
, , 0
51 CD 0
of IN 0
54 CD 0
patients NNS 0
who WP 0
completed VBD 0
the DT 0
study NN 0
expressed VBD 0
a DT 0
preference NN 0
, , 0
with IN 0
a DT 0
statistically RB 0
significant JJ 0
preference NN 0
in IN 0
favour NN 0
of IN 0
Creon NNP 0
10,000 CD 0
MMS NNP 0
( ( 0
47/51 CD 0
; : 0
87 CD 0
% NN 0
) ) 0
vs. FW 0
Creon NNP 0
8,000 CD 0
ms NN 0
( ( 0
4/51 CD 0
; : 0
7.4 CD 0
% NN 0
; : 0
P NNP 0
< NNP 0
0.0001 CD 0
) ) 0
. . 0

Stool NNP 0
fat NN 0
( ( 0
g/day NN 0
) ) 0
and CC 0
CFA NNP 0
( ( 0
% NN 0
) ) 0
were VBD 0
measured VBN 0
in IN 0
24 CD 0
patients NNS 0
at IN 0
the DT 0
end NN 0
of IN 0
each DT 0
treatment NN 0
period NN 0
: : 0
the DT 0
products NNS 0
were VBD 0
therapeutically RB 0
equivalent JJ 0
( ( 0
Creon JJ 0
10,000 CD 0
: : 0
8.4 CD 0
g/day NN 0
, , 0
91.3 CD 0
% NN 0
CFA NNP 0
; : 0
Creon NNP 0
8,000 CD 0
: : 0
6.7 CD 0
g/day NN 0
, , 0
93.5 CD 0
% NN 0
CFA NNP 0
) ) 0
. . 0

Both DT 0
products NNS 0
were VBD 0
well RB 0
tolerated VBN 0
. . 0

In IN 0
conclusion NN 0
, , 0
in IN 0
CF NNP 0
children NNS 0
we PRP 0
found VBD 0
a DT 0
clear JJ 0
preference NN 0
for IN 0
Creon NNP 0
10,000 CD 0
MMS NNP 0
compared VBN 0
with IN 0
Creon NNP 0
8,000 CD 0
ms NN 0
with IN 0
no DT 0
difference NN 0
in IN 0
fat JJ 0
absorption NN 0
between IN 0
the DT 0
two CD 0
products NNS 0
. . 0

Creon NNP 0
10,000s CD 0
smaller JJR 0
capsules NNS 0
are VBP 0
easier JJR 0
to TO 0
take VB 0
and CC 0
should MD 0
aid VB 0
patient NN 0
compliance NN 0
. . 0

A DT 0
randomized JJ 0
comparison NN 0
of IN 0
the DT 0
Endeavor NNP 0
zotarolimus-eluting JJ 0
stent NN 0
versus IN 0
the DT 0
TAXUS NNP 0
paclitaxel-eluting JJ 0
stent NN 0
in IN 0
de FW 0
novo FW 0
native JJ 0
coronary JJ 0
lesions NNS 0
12-month JJ 0
outcomes NNS 0
from IN 0
the DT 0
ENDEAVOR NNP 0
IV NNP 0
trial NN 0
. . 0

OBJECTIVES CC 0
The DT 0
ENDEAVOR NNP 0
IV NNP 0
( ( 0
Randomized NNP 0
Comparison NNP 0
of IN 0
Zotarolimus-Eluting NNP 0
and CC 0
Paclitaxel-Eluting NNP 0
Stents NNP 0
in IN 0
Patients NNP 0
with IN 0
Coronary NNP 0
Artery NNP 0
Disease NNP 0
) ) 0
trial NN 0
evaluated VBD 0
the DT 0
safety NN 0
and CC 0
efficacy NN 0
of IN 0
the DT 0
zotarolimus-eluting JJ 0
stent NN 0
( ( 0
ZES NNP 0
) ) 0
compared VBN 0
with IN 0
the DT 0
paclitaxel-eluting JJ 0
stent NN 0
( ( 0
PES NNP 0
) ) 0
. . 0

BACKGROUND NNP 0
First-generation NNP 0
drug-eluting NN 0
stents NNS 0
have VBP 0
reduced VBN 0
angiographic JJ 0
and CC 0
clinical JJ 0
restenosis NN 0
, , 0
but CC 0
long-term JJ 0
safety NN 0
remains VBZ 0
controversial JJ 0
. . 0

A DT 0
second-generation JJ 0
drug-eluting JJ 0
stent NN 0
, , 0
which WDT 0
delivers VBZ 0
zotarolimus NN 0
, , 0
a DT 0
potent JJ 0
antiproliferative JJ 0
agent NN 0
, , 0
via IN 0
a DT 0
biocompatible JJ 0
phosphorylcholine NN 0
polymer NN 0
on IN 0
a DT 0
cobalt JJ 0
alloy NN 0
thin-strut JJ 0
stent NN 0
has VBZ 0
shown VBN 0
promising JJ 0
experimental JJ 0
and CC 0
early JJ 0
clinical JJ 0
results NNS 0
. . 0

METHODS NNP 0
This DT 0
is VBZ 0
a DT 0
prospective JJ 0
, , 0
randomized VBN 0
( ( 0
1:1 CD 0
) ) 0
, , 0
single-blind JJ 0
, , 0
controlled JJ 0
trial NN 0
comparing VBG 0
outcomes NNS 0
of IN 0
patients NNS 0
with IN 0
single JJ 0
de FW 0
novo FW 0
coronary JJ 0
lesions NNS 0
treated VBN 0
with IN 0
ZES NNP 0
or CC 0
PES NNP 0
. . 0

The DT 0
primary JJ 0
end NN 0
point NN 0
was VBD 0
noninferiority NN 0
of IN 0
9-month JJ 0
target NN 0
vessel JJ 0
failure NN 0
defined VBD 0
as IN 0
cardiac JJ 0
death NN 0
, , 0
myocardial JJ 0
infarction NN 0
, , 0
or CC 0
target VB 0
vessel JJ 0
revascularization NN 0
. . 0

RESULTS NNP 0
Among IN 0
a DT 0
total NN 0
of IN 0
1,548 CD 0
patients NNS 0
assigned VBN 0
to TO 0
ZES NNP 0
( ( 0
n JJ 0
= NNP 0
773 CD 0
) ) 0
or CC 0
PES NNP 0
( ( 0
n JJ 0
= NNP 0
775 CD 0
) ) 0
, , 0
at IN 0
9 CD 0
months NNS 0
, , 0
ZES NNP 0
was VBD 0
noninferior JJ 0
to TO 0
PES VB 0
with IN 0
rates NNS 0
of IN 0
target NN 0
vessel JJ 0
failure NN 0
6.6 CD 0
% NN 0
versus IN 0
7.1 CD 0
% NN 0
, , 0
respectively RB 0
( ( 0
p NN 0
( ( 0
noninferiority NN 0
) ) 0
< NN 0
or CC 0
= VB 0
0.001 CD 0
) ) 0
. . 0

There EX 0
were VBD 0
fewer JJR 0
periprocedural JJ 0
myocardial JJ 0
infarctions NNS 0
with IN 0
ZES NNP 0
( ( 0
0.5 CD 0
% NN 0
vs. FW 0
2.2 CD 0
% NN 0
; : 0
p CC 0
= VB 0
0.007 CD 0
) ) 0
, , 0
whereas VBP 0
at IN 0
12 CD 0
months NNS 0
, , 0
there EX 0
were VBD 0
no DT 0
significant JJ 0
differences NNS 0
between IN 0
groups NNS 0
in IN 0
rates NNS 0
of IN 0
cardiac JJ 0
death NN 0
, , 0
myocardial JJ 0
infarction NN 0
, , 0
target NN 0
vessel NN 0
revascularization NN 0
, , 0
or CC 0
stent JJ 0
thrombosis NN 0
. . 0

Although IN 0
incidence NN 0
of IN 0
8-month JJ 0
binary JJ 0
angiographic JJ 0
in-segment JJ 0
restenosis NN 0
was VBD 0
higher RBR 0
in IN 0
patients NNS 0
treated VBN 0
with IN 0
ZES NNP 0
versus NN 0
PES NNP 0
( ( 0
15.3 CD 0
% NN 0
vs. FW 0
10.4 CD 0
% NN 0
; : 0
p CC 0
= VB 0
0.284 CD 0
) ) 0
, , 0
rates NNS 0
of IN 0
12-month JJ 0
target NN 0
lesion NN 0
revascularization NN 0
were VBD 0
similar JJ 0
( ( 0
4.5 CD 0
% NN 0
vs. FW 0
3.2 CD 0
% NN 0
; : 0
p CC 0
= VB 0
0.228 CD 0
) ) 0
, , 0
especially RB 0
in IN 0
patients NNS 0
without IN 0
planned JJ 0
angiographic JJ 0
follow-up NN 0
( ( 0
3.6 CD 0
% NN 0
vs. FW 0
3.2 CD 0
% NN 0
; : 0
p CC 0
= VB 0
0.756 CD 0
) ) 0
. . 0

CONCLUSIONS NNP 0
These DT 0
findings NNS 0
demonstrate VBP 0
that IN 0
ZES NNP 0
has VBZ 0
similar JJ 0
clinical JJ 0
safety NN 0
and CC 0
efficacy NN 0
compared VBN 0
with IN 0
PES NNP 0
in IN 0
simple JJ 0
and CC 0
medium JJ 0
complexity NN 0
single JJ 0
de FW 0
novo FW 0
coronary JJ 0
lesions NNS 0
. . 0

( ( 0
ENDEAVOR NNP 0
IV NNP 0
Clinical NNP 0
Trial NNP 0
; : 0
NCT00217269 NNP 0
) ) 0
. . 0

Effect NN 0
of IN 0
hydrochlorothiazide NN 0
therapy NN 0
on IN 0
cardiac JJ 0
arrhythmias NN 0
in IN 0
African-American JJ 0
men NNS 0
with IN 0
systemic JJ 0
hypertension NN 0
and CC 0
moderate VB 0
to TO 0
severe VB 0
left JJ 0
ventricular JJ 0
hypertrophy NN 0
. . 0

The DT 0
effect NN 0
of IN 0
hydrochlorothiazide NN 0
therapy NN 0
on IN 0
ventricular JJ 0
arrhythmias NN 0
was VBD 0
studied VBN 0
in IN 0
45 CD 0
hypertensive JJ 0
African-American JJ 0
men NNS 0
with IN 0
moderate JJ 0
to TO 0
severe VB 0
left VBN 0
ventricular JJ 0
( ( 0
LV NNP 0
) ) 0
hypertrophy NN 0
. . 0

After IN 0
medication NN 0
washout NN 0
, , 0
patients NNS 0
were VBD 0
treated VBN 0
with IN 0
placebo NN 0
followed VBN 0
by IN 0
hydrochlorothiazide NN 0
. . 0

Clinical NNP 0
, , 0
biochemical JJ 0
, , 0
and CC 0
48-hour JJ 0
ambulatory NN 0
electrocardiographic JJ 0
data NN 0
was VBD 0
collected VBN 0
after IN 0
each DT 0
treatment NN 0
phase NN 0
. . 0

Signal-averaged JJ 0
electrocardiograms NNS 0
were VBD 0
recorded VBN 0
in IN 0
a DT 0
subgroup NN 0
of IN 0
24 CD 0
patients NNS 0
. . 0

Average JJ 0
LV NNP 0
posterior NN 0
wall NN 0
thickness NN 0
was VBD 0
15 CD 0
+/- JJ 0
1.1 CD 0
mm NN 0
, , 0
septum VBD 0
16 CD 0
+/- JJ 0
2 CD 0
mm NN 0
, , 0
LV NNP 0
mass VBD 0
420 CD 0
+/- JJ 0
90 CD 0
g NN 0
, , 0
and CC 0
LV NNP 0
mass NNP 0
index NN 0
212 CD 0
= NN 0
51 CD 0
g/m2 NN 0
. . 0

Systolic NNP 0
blood NN 0
pressure NN 0
( ( 0
BP NNP 0
) ) 0
was VBD 0
168 CD 0
+/- JJ 0
18 CD 0
mm NN 0
Hg NNP 0
after IN 0
the DT 0
placebo NN 0
phase NN 0
and CC 0
146 CD 0
+/- JJ 0
15 CD 0
mm NN 0
Hg NNP 0
after IN 0
hydrochlorothiazide NN 0
; : 0
diastolic JJ 0
BP NNP 0
was VBD 0
103 CD 0
+/- JJ 0
6 CD 0
mm NN 0
Hg NNP 0
and CC 0
89 CD 0
+/- JJ 0
9 CD 0
mm NN 0
Hg NNP 0
, , 0
respectively RB 0
. . 0

Serum NNP 0
potassium NN 0
decreased VBD 0
significantly RB 0
from IN 0
4.2 CD 0
+/- JJ 0
0.4 CD 0
mmol/L NN 0
to TO 0
3.7 CD 0
+/- JJ 0
0.6 CD 0
mmol/L NN 0
after IN 0
hydrochlorothiazide JJ 0
therapy NN 0
. . 0

The DT 0
average JJ 0
hourly JJ 0
incidence NN 0
of IN 0
ventricular JJ 0
premature NN 0
contractions NNS 0
was VBD 0
22 CD 0
with IN 0
placebo NN 0
and CC 0
25 CD 0
with IN 0
hydrochlorothiazide NN 0
. . 0

There EX 0
were VBD 0
3 CD 0
and CC 0
1 CD 0
couplets NNS 0
and CC 0
0.2 CD 0
and CC 0
0.2 CD 0
runs NNS 0
of IN 0
ventricular JJ 0
tachycardia NN 0
per IN 0
patient NN 0
per IN 0
hour NN 0
, , 0
respectively RB 0
. . 0

Variables NNS 0
of IN 0
signal-averaged JJ 0
electrocardiography NN 0
did VBD 0
not RB 0
differ VB 0
between IN 0
the DT 0
2 CD 0
treatments NNS 0
. . 0

Thus RB 0
, , 0
in IN 0
hypertensive JJ 0
African-American JJ 0
men NNS 0
with IN 0
moderate JJ 0
to TO 0
severe VB 0
LV NNP 0
hypertrophy NN 0
, , 0
hydrochlorothiazide NN 0
does VBZ 0
not RB 0
worsen VB 0
ventricular JJ 0
arrhythmias NNS 0
or CC 0
signal-averaged JJ 0
electrocardiographic JJ 0
variables NNS 0
. . 0

Monitoring VBG 0
tumour NN 0
cells NNS 0
in IN 0
the DT 0
peripheral JJ 0
blood NN 0
of IN 0
small JJ 0
cell NN 0
lung NN 0
cancer NN 0
patients NNS 0
. . 0

BACKGROUND NNP 0
Flow NNP 0
cytometry NN 0
was VBD 0
used VBN 0
to TO 0
enumerate VB 0
tumour JJ 0
cells NNS 0
in IN 0
longitudinal JJ 0
studies NNS 0
of IN 0
peripheral JJ 0
blood NN 0
from IN 0
small JJ 0
cell NN 0
lung NN 0
cancer NN 0
( ( 0
SCLC NNP 0
) ) 0
patients NNS 0
, , 0
together RB 0
with IN 0
magnetic JJ 0
bead NN 0
selection NN 0
to TO 0
isolate VB 0
and CC 0
identify VB 0
these DT 0
cells NNS 0
. . 0

As IN 0
part NN 0
of IN 0
a DT 0
trial NN 0
, , 0
11 CD 0
patients NNS 0
received VBD 0
either RB 0
standard JJ 0
( ( 0
four CD 0
weekly RB 0
) ) 0
chemotherapy NN 0
with IN 0
ifosfamide NN 0
, , 0
carboplatin NN 0
, , 0
and CC 0
etoposide RB 0
( ( 0
ICE NNP 0
) ) 0
or CC 0
accelerated VBN 0
( ( 0
two CD 0
weekly RB 0
) ) 0
ICE NNP 0
with IN 0
filgrastim NN 0
( ( 0
granulocyte JJ 0
colony-stimulating NN 0
factor NN 0
[ IN 0
G-CSF NNP 0
] NNP 0
) ) 0
and CC 0
autologous JJ 0
stem NN 0
cell NN 0
support NN 0
. . 0

METHODS NNP 0
Fresh NNP 0
venous JJ 0
blood NN 0
was VBD 0
taken VBN 0
throughout IN 0
treatment NN 0
and CC 0
follow-up NN 0
. . 0

Aliquots NNS 0
were VBD 0
stained VBN 0
with IN 0
a DT 0
tumour-specific JJ 0
antibody NN 0
against IN 0
epithelial JJ 0
tissue NN 0
( ( 0
Ber NNP 0
EP4 NNP 0
) ) 0
, , 0
verified VBD 0
as IN 0
a DT 0
good JJ 0
marker NN 0
of IN 0
SCLC NNP 0
cells NNS 0
by IN 0
immunohistochemistry NN 0
. . 0

Matched NNP 0
samples NNS 0
labelled VBD 0
with IN 0
Ber NNP 0
EP4 NNP 0
were VBD 0
separated VBN 0
magnetically RB 0
by IN 0
adding VBG 0
a DT 0
secondary JJ 0
bead-antibody NN 0
conjugate NN 0
for IN 0
confirmation NN 0
of IN 0
tumour NN 0
cell NN 0
identity NN 0
. . 0

RESULTS NNP 0
Circulating NNP 0
tumour JJ 0
cells NNS 0
were VBD 0
detected VBN 0
and CC 0
monitored VBN 0
throughout IN 0
treatment NN 0
periods NNS 0
. . 0

An DT 0
initial JJ 0
rise NN 0
in IN 0
circulating VBG 0
cells NNS 0
after IN 0
the DT 0
first JJ 0
cycle NN 0
was VBD 0
followed VBN 0
by IN 0
a DT 0
fall NN 0
in IN 0
both DT 0
treatment NN 0
arms NNS 0
to TO 0
baseline NN 0
levels NNS 0
set VBN 0
by IN 0
normal JJ 0
controls NNS 0
. . 0

This DT 0
was VBD 0
achieved VBN 0
by IN 0
week NN 0
12 CD 0
in IN 0
the DT 0
accelerated JJ 0
treatment NN 0
arm NN 0
and CC 0
by IN 0
week NN 0
24 CD 0
in IN 0
the DT 0
standard JJ 0
arm NN 0
. . 0

CONCLUSIONS NNP 0
Flow NNP 0
cytometry NN 0
and CC 0
magnetic JJ 0
bead NN 0
isolation NN 0
can MD 0
be VB 0
used VBN 0
to TO 0
identify VB 0
changes NNS 0
in IN 0
numbers NNS 0
of IN 0
circulating VBG 0
tumour JJ 0
cells NNS 0
in IN 0
patients NNS 0
undergoing JJ 0
chemotherapy NN 0
for IN 0
SCLC NNP 0
and CC 0
thereafter RB 0
during IN 0
follow-up JJ 0
periods NNS 0
. . 0

Absence NN 0
of IN 0
tumour JJ 0
cells NNS 0
may MD 0
indicate VB 0
a DT 0
more RBR 0
favourable JJ 0
patient NN 0
group NN 0
who WP 0
would MD 0
benefit VB 0
from IN 0
a DT 0
more RBR 0
intense JJ 0
course NN 0
of IN 0
treatment NN 0
. . 0

Extracorporeal NNP 0
shock NN 0
wave NN 0
therapy NN 0
( ( 0
ESWT NNP 0
) ) 0
in IN 0
patients NNS 0
with IN 0
chronic JJ 0
proximal JJ 0
plantar NN 0
fasciitis NN 0
: : 0
a DT 0
2-year JJ 0
follow-up NN 0
. . 0

The DT 0
aim NN 0
of IN 0
this DT 0
study NN 0
was VBD 0
to TO 0
compare VB 0
the DT 0
effect NN 0
of IN 0
extracorporeal NN 0
shock NN 0
wave VBP 0
therapy NN 0
( ( 0
ESWT NNP 0
) ) 0
in IN 0
patients NNS 0
with IN 0
chronically RB 0
painful JJ 0
proximal JJ 0
plantar NN 0
fasciitis NN 0
with IN 0
a DT 0
further JJ 0
conventional JJ 0
conservative JJ 0
treatment NN 0
. . 0

Forty-seven JJ 0
patients NNS 0
( ( 0
49 CD 0
feet NNS 0
) ) 0
with IN 0
a DT 0
previously RB 0
unsuccessful JJ 0
nonsurgical JJ 0
treatment NN 0
of IN 0
at IN 0
least JJS 0
6 CD 0
months NNS 0
were VBD 0
randomized VBN 0
to TO 0
two CD 0
groups NNS 0
. . 0

Heel NNP 0
cups NNS 0
had VBD 0
to TO 0
be VB 0
worn VBN 0
throughout IN 0
the DT 0
study NN 0
. . 0

Group NNP 0
1 CD 0
( ( 0
25 CD 0
heels NNS 0
) ) 0
was VBD 0
treated VBN 0
immediately RB 0
with IN 0
three CD 0
sessions NNS 0
of IN 0
ESWT NNP 0
( ( 0
3000 CD 0
shock NN 0
waves/session NN 0
of IN 0
0.2 CD 0
mJ/mm2 NN 0
) ) 0
at IN 0
weekly JJ 0
intervals NNS 0
. . 0

The DT 0
patients NNS 0
of IN 0
group NN 0
2 CD 0
( ( 0
24 CD 0
heels NNS 0
) ) 0
continued VBD 0
nonsurgical JJ 0
treatment NN 0
( ( 0
iontophoresis NN 0
with IN 0
diclofenac NN 0
and CC 0
an DT 0
oral JJ 0
nonsteroidal JJ 0
anti-inflammatory JJ 0
drug NN 0
) ) 0
for IN 0
12 CD 0
weeks NNS 0
. . 0

After IN 0
this DT 0
period NN 0
they PRP 0
were VBD 0
treated VBN 0
using VBG 0
the DT 0
protocol NN 0
of IN 0
group NN 0
1 CD 0
. . 0

No DT 0
significant JJ 0
difference NN 0
of IN 0
pain NN 0
and CC 0
walking NN 0
time NN 0
after IN 0
further JJ 0
nonsurgical JJ 0
treatment NN 0
( ( 0
3 CD 0
months NNS 0
) ) 0
was VBD 0
seen VBN 0
in IN 0
group NN 0
2 CD 0
. . 0

At IN 0
12 CD 0
weeks NNS 0
after IN 0
ESWT NNP 0
, , 0
the DT 0
pain NN 0
estimation NN 0
on IN 0
the DT 0
visual JJ 0
analogue NN 0
scale NN 0
( ( 0
VAS NNP 0
) ) 0
for IN 0
activities NNS 0
of IN 0
daily JJ 0
living NN 0
diminished VBN 0
significantly RB 0
by IN 0
62.9 CD 0
% NN 0
in IN 0
group NN 0
1 CD 0
and CC 0
by IN 0
63.0 CD 0
% NN 0
in IN 0
group NN 0
2 CD 0
. . 0

The DT 0
comfortable JJ 0
walking NN 0
time NN 0
had VBD 0
increased VBN 0
significantly RB 0
in IN 0
both DT 0
groups NNS 0
. . 0

Two CD 0
years NNS 0
after IN 0
ESWT NNP 0
, , 0
pain NN 0
during IN 0
activities NNS 0
of IN 0
daily JJ 0
living NN 0
decreased VBN 0
by IN 0
94 CD 0
% NN 0
in IN 0
group NN 0
1 CD 0
and CC 0
by IN 0
90 CD 0
% NN 0
in IN 0
group NN 0
2 CD 0
on IN 0
the DT 0
VAS NNP 0
and CC 0
the DT 0
comfortable JJ 0
walking NN 0
time NN 0
had VBD 0
increased VBN 0
significantly RB 0
in IN 0
both DT 0
groups NNS 0
. . 0

[ RB 0
Long NNP 0
term NN 0
observation NN 0
in IN 0
effects NNS 0
of IN 0
potassium NN 0
and CC 0
calcium NN 0
supplementation NN 0
on IN 0
arterial JJ 0
blood NN 0
pressure NN 0
and CC 0
sodium NN 0
metabolism NN 0
in IN 0
adolescents NNS 0
with IN 0
higher JJR 0
blood NN 0
pressure NN 0
] NNP 0
. . 0

OBJECTIVE NNP 0
To TO 0
investigate VB 0
the DT 0
effects NNS 0
of IN 0
potassium NN 0
and CC 0
calcium NN 0
supplementation NN 0
in IN 0
table JJ 0
salt NN 0
on IN 0
reduction NN 0
of IN 0
arterial JJ 0
blood NN 0
pressure NN 0
and CC 0
sodium NN 0
metabolism NN 0
in IN 0
adolescents NNS 0
with IN 0
higher JJR 0
blood NN 0
pressure NN 0
. . 0

METHODS CC 0
A DT 0
single JJ 0
blind NN 0
placebo-controlled JJ 0
trial NN 0
was VBD 0
carried VBN 0
out RP 0
for IN 0
two CD 0
years NNS 0
in IN 0
220 CD 0
adolescents NNS 0
with IN 0
higher JJR 0
blood NN 0
pressure NN 0
, , 0
aged VBD 0
18 CD 0
- : 0
22 CD 0
years NNS 0
, , 0
who WP 0
were VBD 0
randomly RB 0
divided VBN 0
into IN 0
supplementary JJ 0
group NN 0
( ( 0
n JJ 0
= NNP 0
110 CD 0
) ) 0
and CC 0
control NN 0
group NN 0
( ( 0
n JJ 0
= NNP 0
110 CD 0
) ) 0
. . 0

Each DT 0
of IN 0
the DT 0
subjects NNS 0
in IN 0
the DT 0
supplementary JJ 0
group NN 0
and CC 0
their PRP$ 0
family NN 0
members NNS 0
was VBD 0
given VBN 0
10 CD 0
mmol NN 0
of IN 0
potassium NN 0
and CC 0
10 CD 0
mmol NN 0
of IN 0
calcium NN 0
mixed VBN 0
in IN 0
their PRP$ 0
table JJ 0
salt JJ 0
daily RB 0
for IN 0
24 CD 0
months NNS 0
. . 0

RESULTS NNP 0
Night NNP 0
urinary JJ 0
sodium NN 0
and CC 0
potassium JJ 0
excretion NN 0
increased VBD 0
( ( 0
urinary JJ 0
Na NNP 0
( ( 0
+ NNP 0
) ) 0
, , 0
P NNP 0
< NNP 0
0.05 CD 0
; : 0
urinary JJ 0
K NNP 0
( ( 0
+ NNP 0
) ) 0
, , 0
P NNP 0
< NNP 0
0.01 CD 0
) ) 0
and CC 0
blood NN 0
pressure NN 0
lowered VBN 0
by IN 0
5.3 CD 0
mm NNS 0
Hg/1.8 NNP 0
mm NN 0
Hg NNP 0
in IN 0
average NN 0
from IN 0
the DT 0
baseline NN 0
in IN 0
the DT 0
supplementary JJ 0
group NN 0
two CD 0
years NNS 0
after IN 0
potassium NN 0
and CC 0
calcium NN 0
supplementation NN 0
, , 0
as IN 0
compared VBN 0
with IN 0
that DT 0
in IN 0
the DT 0
control NN 0
group NN 0
increased VBN 0
by IN 0
( ( 0
1.3/1.7 CD 0
) ) 0
mm NN 0
Hg NNP 0
. . 0

CONCLUSIONS NNP 0
Adequate NNP 0
supplement NN 0
of IN 0
potassium NN 0
and CC 0
calcium NN 0
in IN 0
daily JJ 0
table JJ 0
salt NN 0
intake NN 0
was VBD 0
an DT 0
effective JJ 0
way NN 0
to TO 0
prevent VB 0
form NN 0
hypertension NN 0
and CC 0
could MD 0
promote VB 0
their PRP$ 0
urinary JJ 0
sodium NN 0
excretion NN 0
and CC 0
reduction NN 0
of IN 0
arterial JJ 0
blood NN 0
pressure NN 0
in IN 0
adolescents NNS 0
with IN 0
higher JJR 0
blood NN 0
pressure NN 0
. . 0

Pilot NNP 0
comparison NN 0
between IN 0
potassium NN 0
titanyl NN 0
phosphate NN 0
laser NN 0
and CC 0
bipolar JJ 0
radiofrequency NN 0
in IN 0
paediatric JJ 0
tonsillectomy NN 0
. . 0

OBJECTIVES NNP 0
To TO 0
compare VB 0
the DT 0
advantages NNS 0
and CC 0
disadvantages NNS 0
of IN 0
potassium NN 0
titanyl NN 0
phosphate NN 0
laser NN 0
with IN 0
those DT 0
of IN 0
bipolar JJ 0
radiofrequency NN 0
techniques NNS 0
, , 0
in IN 0
paediatric JJ 0
tonsillectomy NN 0
. . 0

STUDY NNP 0
DESIGN NNP 0
Prospective NNP 0
, , 0
randomised VBD 0
, , 0
clinical JJ 0
study NN 0
. . 0

PATIENTS NNP 0
AND CC 0
METHODS NNP 0
From NNP 0
July NNP 0
2004 CD 0
to TO 0
April NNP 0
2006 CD 0
, , 0
80 CD 0
patients NNS 0
aged VBN 0
between IN 0
10 CD 0
and CC 0
15 CD 0
years NNS 0
, , 0
with IN 0
tonsillectomy NN 0
planned VBN 0
for IN 0
chronic JJ 0
tonsillitis NN 0
, , 0
were VBD 0
included VBN 0
in IN 0
the DT 0
study NN 0
. . 0

Children NNP 0
were VBD 0
prospectively RB 0
randomised VBN 0
into IN 0
two CD 0
equal JJ 0
groups NNS 0
: : 0
potassium NN 0
titanyl NN 0
phosphate NN 0
laser NN 0
tonsillectomy NN 0
and CC 0
bipolar JJ 0
radiofrequency NN 0
tonsillectomy NN 0
. . 0

Operative JJ 0
time NN 0
and CC 0
intra-operative JJ 0
blood NN 0
loss NN 0
were VBD 0
recorded VBN 0
. . 0

Patients NNS 0
were VBD 0
scheduled VBN 0
for IN 0
follow VB 0
up RP 0
during IN 0
the DT 0
first JJ 0
, , 0
second JJ 0
and CC 0
fourth JJ 0
post-operative JJ 0
weeks NNS 0
. . 0

They PRP 0
were VBD 0
asked VBN 0
to TO 0
record VB 0
their PRP$ 0
pain NN 0
and CC 0
discomfort NN 0
on IN 0
a DT 0
standardised JJ 0
visual JJ 0
analogue NN 0
scale NN 0
, , 0
from IN 0
zero CD 0
( ( 0
no DT 0
pain NN 0
) ) 0
to TO 0
10 CD 0
( ( 0
severe JJ 0
pain NN 0
) ) 0
. . 0

Post-operative JJ 0
complications NNS 0
were VBD 0
also RB 0
recorded VBN 0
and CC 0
managed VBN 0
. . 0

RESULTS VB 0
The DT 0
potassium NN 0
titanyl NN 0
phosphate VBP 0
laser NN 0
group NN 0
showed VBD 0
a DT 0
slightly RB 0
longer RBR 0
operative JJ 0
time NN 0
( ( 0
mean JJ 0
12 CD 0
minutes NNS 0
) ) 0
than IN 0
the DT 0
bipolar JJ 0
radiofrequency NN 0
group NN 0
( ( 0
mean JJ 0
10 CD 0
minutes NNS 0
) ) 0
. . 0

Intra-operative JJ 0
blood NN 0
loss NN 0
was VBD 0
significantly RB 0
less RBR 0
in IN 0
the DT 0
potassium NN 0
titanyl NN 0
phosphate VBP 0
laser NN 0
group NN 0
( ( 0
mean JJ 0
21 CD 0
cm3 NN 0
) ) 0
than IN 0
in IN 0
the DT 0
bipolar JJ 0
radiofrequency NN 0
group NN 0
( ( 0
mean JJ 0
30 CD 0
cm3 NN 0
) ) 0
. . 0

In IN 0
the DT 0
first JJ 0
week NN 0
, , 0
post-operative JJ 0
pain NN 0
scores NNS 0
were VBD 0
less RBR 0
in IN 0
the DT 0
potassium NN 0
titanyl NN 0
phosphate VBP 0
laser NN 0
group NN 0
than IN 0
in IN 0
the DT 0
bipolar JJ 0
radiofrequency NN 0
group NN 0
( ( 0
means VBZ 0
7.5 CD 0
and CC 0
8.5 CD 0
, , 0
respectively RB 0
) ) 0
. . 0

However RB 0
, , 0
in IN 0
the DT 0
second JJ 0
week NN 0
pain NN 0
scores NNS 0
increased VBD 0
more RBR 0
in IN 0
the DT 0
potassium NN 0
titanyl NN 0
phosphate VBP 0
laser NN 0
group NN 0
than IN 0
in IN 0
the DT 0
bipolar JJ 0
radiofrequency NN 0
group NN 0
( ( 0
means VBZ 0
8.5 CD 0
and CC 0
6 CD 0
, , 0
respectively RB 0
) ) 0
. . 0

In IN 0
the DT 0
fourth JJ 0
week NN 0
, , 0
both DT 0
groups NNS 0
showed VBD 0
equal JJ 0
and CC 0
nearly RB 0
normal JJ 0
pain NN 0
scores NNS 0
. . 0

No DT 0
case NN 0
of IN 0
reactionary JJ 0
post-tonsillectomy JJ 0
haemorrhage NN 0
was VBD 0
recorded VBN 0
in IN 0
either DT 0
group NN 0
. . 0

Only RB 0
one CD 0
case NN 0
of IN 0
secondary JJ 0
post-tonsillectomy JJ 0
haemorrhage NN 0
was VBD 0
recorded VBN 0
, , 0
in IN 0
the DT 0
potassium NN 0
titanyl NN 0
phosphate VBP 0
laser NN 0
group NN 0
( ( 0
2.5 CD 0
per IN 0
cent NN 0
) ) 0
, , 0
managed VBD 0
conservatively RB 0
. . 0

CONCLUSION NNP 0
Both NNP 0
the DT 0
potassium NN 0
titanyl NN 0
phosphate NN 0
and CC 0
the DT 0
bipolar JJ 0
radiofrequency NN 0
techniques NNS 0
were VBD 0
safe JJ 0
and CC 0
easy JJ 0
to TO 0
use VB 0
for IN 0
tonsillectomy NN 0
, , 0
with IN 0
reduced VBN 0
operative JJ 0
time NN 0
, , 0
blood NN 0
loss NN 0
and CC 0
complication NN 0
rates NNS 0
and CC 0
better JJR 0
post-operative JJ 0
general JJ 0
patient NN 0
condition NN 0
. . 0

Potassium NNP 0
titanyl JJ 0
phosphate NN 0
laser NN 0
resulted VBD 0
in IN 0
reduced JJ 0
operative JJ 0
bleeding NN 0
and CC 0
immediate JJ 0
post-operative JJ 0
pain NN 0
, , 0
compared VBN 0
with IN 0
the DT 0
bipolar JJ 0
radiofrequency NN 0
technique NN 0
. . 0

However RB 0
, , 0
potassium NN 0
titanyl NN 0
phosphate VBP 0
laser NN 0
required VBN 0
slightly RB 0
more RBR 0
operative JJ 0
time NN 0
and CC 0
caused VBD 0
more JJR 0
late JJ 0
post-operative JJ 0
pain NN 0
than IN 0
the DT 0
bipolar JJ 0
radiofrequency NN 0
technique NN 0
. . 0

The DT 0
low JJ 0
rate NN 0
of IN 0
recorded VBN 0
complications NNS 0
showed VBD 0
that IN 0
both DT 0
techniques NNS 0
cause VBP 0
little JJ 0
damage NN 0
to TO 0
the DT 0
tonsillar JJ 0
bed NN 0
during IN 0
dissection NN 0
, , 0
thus RB 0
minimising VBG 0
complications NNS 0
. . 0

The DT 0
effect NN 0
of IN 0
use NN 0
of IN 0
pyridostigmine NN 0
and CC 0
requirement NN 0
of IN 0
vecuronium NN 0
in IN 0
patients NNS 0
with IN 0
myasthenia JJ 0
gravis NN 0
. . 0

CONTEXT NNP 0
Patients NNPS 0
with IN 0
myasthenia NNP 0
gravis FW 0
receive JJ 0
pyridostigmine NN 0
, , 0
an DT 0
anticholinesterase NN 0
agent NN 0
, , 0
as IN 0
a DT 0
part NN 0
of IN 0
therapy NN 0
. . 0

These DT 0
patients NNS 0
demonstrate VBP 0
a DT 0
heightened JJ 0
sensitivity NN 0
towards IN 0
non-depolarising JJ 0
muscle NN 0
relaxants NNS 0
. . 0

Continuing VBG 0
pyridostigmine NN 0
till IN 0
the DT 0
day NN 0
of IN 0
the DT 0
surgery NN 0
or CC 0
omitting VBG 0
it PRP 0
on IN 0
the DT 0
night NN 0
before IN 0
surgery NN 0
could MD 0
provide VB 0
variable JJ 0
results NNS 0
with IN 0
regards NNS 0
to TO 0
the DT 0
effect NN 0
of IN 0
vecuronium NN 0
. . 0

AIMS NNP 0
Myographic NNP 0
evaluation NN 0
of IN 0
a DT 0
dose NN 0
of IN 0
vecuronium NN 0
in IN 0
patients NNS 0
with IN 0
myasthenia JJ 0
gravis NN 0
on IN 0
pyridostigmine NN 0
therapy NN 0
. . 0

SETTING NN 0
AND CC 0
DESIGN NNP 0
A NNP 0
randomised JJ 0
, , 0
double-blind JJ 0
, , 0
clinical JJ 0
study NN 0
conducted VBN 0
in IN 0
a DT 0
teaching JJ 0
hospital NN 0
. . 0

SUBJECTS NNP 0
AND NNP 0
METHODS NNP 0
Medically NNP 0
( ( 0
oral JJ 0
pyridostigmine NN 0
) ) 0
well-controlled JJ 0
adult NN 0
patients NNS 0
with IN 0
myasthenia JJ 0
gravis NNS 0
who WP 0
were VBD 0
posted VBN 0
for IN 0
thymectomy NN 0
, , 0
were VBD 0
randomly RB 0
divided VBN 0
into IN 0
two CD 0
groups NNS 0
. . 0

Patients NNS 0
in IN 0
Group NNP 0
1 CD 0
received VBD 0
their PRP$ 0
last JJ 0
dose NN 0
of IN 0
pyridostigmine NN 0
on IN 0
the DT 0
night NN 0
before IN 0
surgery NN 0
while IN 0
those DT 0
in IN 0
Group NNP 0
2 CD 0
received VBD 0
even RB 0
the DT 0
morning NN 0
dose NN 0
of IN 0
the DT 0
drug NN 0
on IN 0
the DT 0
day NN 0
of IN 0
surgery NN 0
. . 0

Neostigmine NNP 0
( ( 0
1-2 JJ 0
mg NN 0
) ) 0
intravenously RB 0
was VBD 0
used VBN 0
as IN 0
rescue JJ 0
medication NN 0
. . 0

Vecuronium NNP 0
( ( 0
0.01 CD 0
mg/kg NN 0
) ) 0
was VBD 0
used VBN 0
for IN 0
intubation NN 0
and CC 0
muscle NN 0
relaxation NN 0
during IN 0
trans-sternal JJ 0
thymectomy NN 0
and CC 0
its PRP$ 0
effect NN 0
was VBD 0
reversed VBN 0
using VBG 0
neostigmine NN 0
and CC 0
atropine NN 0
. . 0

RESULTS NNP 0
Fourteen JJ 0
patients NNS 0
( ( 0
7 CD 0
in IN 0
each DT 0
group NN 0
) ) 0
belonging NN 0
to TO 0
both DT 0
sexes NNS 0
were VBD 0
enrolled VBN 0
in IN 0
the DT 0
study NN 0
. . 0

The DT 0
intubating VBG 0
dose NN 0
of IN 0
vecuronium NN 0
showed VBD 0
quicker JJR 0
onset JJ 0
time NN 0
( ( 0
155 CD 0
sec NN 0
or CC 0
2.7 CD 0
min NN 0
approx NN 0
. . 0

) ) 0
and CC 0
peak JJ 0
effect NN 0
( ( 0
99 CD 0
% NN 0
T1 NNP 0
suppression NN 0
) ) 0
in IN 0
patients NNS 0
belonging VBG 0
to TO 0
Group NNP 0
1 CD 0
, , 0
and CC 0
3/7 CD 0
( ( 0
43 CD 0
% NN 0
) ) 0
complained VBD 0
of IN 0
respiratory JJ 0
discomfort NN 0
while IN 0
waiting VBG 0
for IN 0
surgery NN 0
. . 0

By IN 0
giving VBG 0
the DT 0
morning NN 0
dose NN 0
of IN 0
pyridostigmine NN 0
( ( 0
Group NNP 0
2 CD 0
) ) 0
, , 0
an DT 0
identical JJ 0
intubating NN 0
dose NN 0
of IN 0
vecuronium NN 0
showed VBD 0
relative JJ 0
resistance NN 0
( ( 0
peak JJ 0
effect-97 NN 0
% NN 0
T1 NNP 0
suppression NN 0
) ) 0
and CC 0
delayed VBN 0
onset NN 0
time NN 0
( ( 0
198 CD 0
sec NN 0
approx. NN 0
) ) 0
. . 0

However RB 0
, , 0
the DT 0
reversal NN 0
was VBD 0
complete JJ 0
at IN 0
the DT 0
end NN 0
of IN 0
surgery NN 0
in IN 0
both CC 0
the DT 0
regimens NNS 0
. . 0

CONCLUSIONS NNP 0
Omission NNP 0
of IN 0
the DT 0
pyridostigmine NN 0
dose NN 0
on IN 0
the DT 0
day NN 0
of IN 0
surgery NN 0
predisposed VBN 0
patients NNS 0
with IN 0
myasthenia JJ 0
gravis NN 0
to TO 0
the DT 0
possibility NN 0
of IN 0
respiratory JJ 0
discomfort NN 0
and CC 0
sensitivity NN 0
to TO 0
vecuronium NN 0
. . 0

Continued VBN 0
administration NN 0
significantly RB 0
prolonged VBD 0
the DT 0
onset JJ 0
time NN 0
of IN 0
vecuronium NN 0
and CC 0
the DT 0
patients NNS 0
required VBD 0
a DT 0
higher JJR 0
dose NN 0
of IN 0
vecuronium NN 0
. . 0

Low-dose JJ 0
aspirin NN 0
and CC 0
incidence NN 0
of IN 0
colorectal JJ 0
tumors NNS 0
in IN 0
a DT 0
randomized JJ 0
trial NN 0
. . 0

BACKGROUND NNP 0
Laboratory NNP 0
, , 0
clinical JJ 0
, , 0
and CC 0
epidemiologic JJ 0
studies NNS 0
have VBP 0
recently RB 0
suggested VBN 0
that IN 0
regular JJ 0
use NN 0
of IN 0
aspirin NN 0
can MD 0
reduce VB 0
colorectal JJ 0
cancer NN 0
incidence NN 0
or CC 0
mortality NN 0
. . 0

However RB 0
, , 0
observational JJ 0
epidemiologic NN 0
analyses NNS 0
have VBP 0
had VBN 0
limited VBN 0
opportunity NN 0
to TO 0
control VB 0
for IN 0
confounding VBG 0
bias NN 0
or CC 0
to TO 0
specify VB 0
aspirin JJ 0
doses NNS 0
used VBN 0
. . 0

PURPOSE VB 0
Our PRP$ 0
purpose NN 0
was VBD 0
to TO 0
examine VB 0
the DT 0
relationship NN 0
between IN 0
regular JJ 0
use NN 0
of IN 0
low-dose JJ 0
aspirin NN 0
and CC 0
incidence NN 0
of IN 0
invasive JJ 0
and CC 0
noninvasive JJ 0
colorectal NN 0
tumors NNS 0
by IN 0
utilizing VBG 0
data NNS 0
from IN 0
the DT 0
Physicians NNPS 0
' POS 0
Health NNP 0
Study NNP 0
, , 0
a DT 0
randomized VBN 0
, , 0
double-blinded JJ 0
, , 0
placebo-controlled JJ 0
trial NN 0
of IN 0
aspirin NN 0
and CC 0
beta NN 0
carotene NN 0
. . 0

We PRP 0
also RB 0
attempted VBD 0
to TO 0
determine VB 0
whether IN 0
invasive JJ 0
cancers NNS 0
among IN 0
aspirin JJ 0
users NNS 0
were VBD 0
associated VBN 0
with IN 0
rectal JJ 0
bleeding NN 0
and CC 0
early JJ 0
stage NN 0
at IN 0
diagnosis NN 0
. . 0

METHODS NNP 0
The DT 0
Physicians NNPS 0
' POS 0
Health NNP 0
Study NNP 0
includes VBZ 0
22071 CD 0
U.S. NNP 0
male JJ 0
physicians NNS 0
. . 0

The DT 0
aspirin JJ 0
arm NN 0
was VBD 0
terminated VBN 0
in IN 0
1988 CD 0
after IN 0
a DT 0
mean JJ 0
follow-up NN 0
of IN 0
5 CD 0
years NNS 0
. . 0

Stage NN 0
at IN 0
diagnosis NN 0
and CC 0
signs NNS 0
and/or VBP 0
symptoms NNS 0
during IN 0
presentation NN 0
were VBD 0
abstracted VBN 0
from IN 0
medical JJ 0
records NNS 0
. . 0

Cox NNP 0
proportional JJ 0
hazards NNS 0
models NNS 0
were VBD 0
used VBN 0
to TO 0
estimate VB 0
relative JJ 0
risk NN 0
( ( 0
RR NNP 0
) ) 0
, , 0
95 CD 0
% NN 0
confidence NN 0
intervals NNS 0
( ( 0
CIs NNP 0
) ) 0
, , 0
and CC 0
the DT 0
association NN 0
between IN 0
aspirin NN 0
and CC 0
bleeding NN 0
. . 0

Differences NNS 0
between IN 0
aspirin NN 0
and CC 0
placebo NN 0
groups NNS 0
in IN 0
tumor NN 0
risk NN 0
over IN 0
time NN 0
were VBD 0
visualized VBN 0
with IN 0
Kaplan-Meier NNP 0
curves NNS 0
. . 0

We PRP 0
assessed VBD 0
the DT 0
association NN 0
between IN 0
aspirin NN 0
and CC 0
stage NN 0
at IN 0
diagnosis NN 0
with IN 0
a DT 0
Mann-Whitney NNP 0
rank NN 0
sum NN 0
statistic NN 0
for IN 0
non-parametric JJ 0
comparison NN 0
of IN 0
two CD 0
ordinal JJ 0
distributions NNS 0
. . 0

RESULTS VB 0
The DT 0
RR NNP 0
of IN 0
developing VBG 0
colorectal JJ 0
cancer NN 0
for IN 0
aspirin NNS 0
compared VBN 0
with IN 0
placebo NN 0
was VBD 0
1.15 CD 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
= NNP 0
0.80-1.65 NN 0
) ) 0
. . 0

For IN 0
in IN 0
situ NN 0
cancers NNS 0
and CC 0
polyps NNS 0
, , 0
the DT 0
RR NNP 0
was VBD 0
0.86 CD 0
( ( 0
95 CD 0
% NN 0
CI NNP 0
= NNP 0
0.68-1.10 NN 0
) ) 0
. . 0

There EX 0
was VBD 0
no DT 0
significant JJ 0
trend NN 0
for IN 0
decreasing VBG 0
RR NNP 0
by IN 0
year NN 0
of IN 0
follow-up NN 0
for IN 0
invasive JJ 0
cancers NNS 0
( ( 0
P NNP 0
= NNP 0
.09 NNP 0
) ) 0
or CC 0
noninvasive JJ 0
tumors NNS 0
( ( 0
P NNP 0
= NNP 0
.96 NNP 0
) ) 0
. . 0

Aspirin NNP 0
and CC 0
placebo NN 0
groups NNS 0
did VBD 0
not RB 0
differ VB 0
in IN 0
stage NN 0
or CC 0
prevalence NN 0
of IN 0
rectal JJ 0
bleeding NN 0
at IN 0
diagnosis NN 0
. . 0

CONCLUSIONS NNP 0
Regular NNP 0
aspirin NN 0
use NN 0
, , 0
at IN 0
a DT 0
dose JJ 0
adequate NN 0
for IN 0
preventing VBG 0
myocardial JJ 0
infarction NN 0
, , 0
was VBD 0
not RB 0
associated VBN 0
with IN 0
a DT 0
substantial JJ 0
reduction NN 0
in IN 0
the DT 0
incidence NN 0
of IN 0
colorectal JJ 0
cancer NN 0
during IN 0
5 CD 0
years NNS 0
of IN 0
randomized JJ 0
treatment NN 0
and CC 0
follow-up NN 0
. . 0

A DT 0
small JJ 0
decrease NN 0
in IN 0
polyps NNS 0
in IN 0
the DT 0
aspirin NN 0
group NN 0
could MD 0
not RB 0
be VB 0
reliably RB 0
distinguished VBN 0
from IN 0
a DT 0
chance NN 0
association NN 0
. . 0

Our PRP$ 0
results NNS 0
suggest VBP 0
that IN 0
among IN 0
low-dose JJ 0
aspirin NN 0
users NNS 0
, , 0
( ( 0
a DT 0
) ) 0
colorectal NN 0
cancer NN 0
mortality NN 0
is VBZ 0
not RB 0
likely JJ 0
to TO 0
be VB 0
reduced VBN 0
by IN 0
earlier JJR 0
detection NN 0
and CC 0
( ( 0
b NN 0
) ) 0
incidence NN 0
is VBZ 0
not RB 0
likely JJ 0
to TO 0
be VB 0
increased VBN 0
due JJ 0
to TO 0
aspirin-induced JJ 0
gastrointestinal JJ 0
bleeding NN 0
. . 0

IMPLICATIONS VBZ 0
The DT 0
potential NN 0
for IN 0
a DT 0
benefit NN 0
from IN 0
higher JJR 0
doses NNS 0
of IN 0
aspirin NN 0
or CC 0
longer JJR 0
duration NN 0
of IN 0
use NN 0
should MD 0
be VB 0
addressed VBN 0
by IN 0
more JJR 0
detailed JJ 0
observational JJ 0
epidemiologic NN 0
studies NNS 0
and CC 0
prevention NN 0
trials NNS 0
with IN 0
longer JJR 0
follow-up NN 0
of IN 0
randomized JJ 0
participants NNS 0
. . 0

B-type JJ 0
natriuretic JJ 0
peptide NN 0
in IN 0
the DT 0
evaluation NN 0
and CC 0
management NN 0
of IN 0
dyspnoea NN 0
in IN 0
primary JJ 0
care NN 0
. . 0

OBJECTIVES IN 0
The DT 0
rapid JJ 0
and CC 0
accurate JJ 0
diagnosis NN 0
of IN 0
heart NN 0
failure NN 0
in IN 0
primary JJ 0
care NN 0
is VBZ 0
a DT 0
major JJ 0
unmet JJ 0
clinical JJ 0
need NN 0
. . 0

We PRP 0
evaluated VBD 0
the DT 0
additional JJ 0
use NN 0
of IN 0
B-type NNP 0
natriuretic JJ 0
peptide NN 0
( ( 0
BNP NNP 0
) ) 0
levels NNS 0
. . 0

DESIGN VB 0
A DT 0
randomized NN 0
controlled VBN 0
trial NN 0
. . 0

SETTING CC 0
Twenty-nine JJ 0
primary JJ 0
care NN 0
physicians NNS 0
in IN 0
Switzerland NNP 0
and CC 0
Germany NNP 0
coordinated VBN 0
by IN 0
the DT 0
University NNP 0
Hospital NNP 0
Basel NNP 0
, , 0
Switzerland NNP 0
. . 0

SUBJECTS NNP 0
A NNP 0
total NN 0
of IN 0
323 CD 0
consecutive JJ 0
patients NNS 0
presenting VBG 0
with IN 0
dyspnoea NN 0
. . 0

INTERVENTIONS NNP 0
Assignment NNP 0
in IN 0
a DT 0
1 CD 0
: : 0
1 CD 0
ratio NN 0
to TO 0
a DT 0
diagnostic JJ 0
strategy NN 0
including VBG 0
point-of-care JJ 0
measurement NN 0
of IN 0
BNP NNP 0
( ( 0
n JJ 0
= NNP 0
163 CD 0
) ) 0
or CC 0
standard JJ 0
assessment NN 0
without IN 0
BNP NNP 0
( ( 0
n JJ 0
= NNP 0
160 CD 0
) ) 0
. . 0

The DT 0
total JJ 0
medical JJ 0
cost NN 0
at IN 0
3 CD 0
months NNS 0
was VBD 0
the DT 0
primary JJ 0
end-point NN 0
. . 0

Secondary JJ 0
end-points NNS 0
were VBD 0
diagnostic JJ 0
certainty NN 0
, , 0
time NN 0
to TO 0
appropriate VB 0
therapy NN 0
, , 0
functional JJ 0
capacity NN 0
, , 0
hospitalization NN 0
and CC 0
mortality NN 0
. . 0

The DT 0
final JJ 0
diagnosis NN 0
was VBD 0
adjudicated VBN 0
by IN 0
a DT 0
physician NN 0
blinded VBN 0
to TO 0
the DT 0
BNP NNP 0
levels NNS 0
. . 0

RESULTS NNP 0
Heart NNP 0
failure NN 0
was VBD 0
the DT 0
final JJ 0
diagnosis NN 0
in IN 0
34 CD 0
% NN 0
of IN 0
patients NNS 0
. . 0

The DT 0
number NN 0
of IN 0
hospitalizations NNS 0
, , 0
functional JJ 0
status NN 0
and CC 0
total JJ 0
medical JJ 0
cost NN 0
at IN 0
3 CD 0
months NNS 0
[ JJ 0
median JJ 0
$ $ 0
1655 CD 0
, , 0
interquartile JJ 0
range NN 0
( ( 0
IQR NNP 0
) ) 0
, , 0
850-3331 JJ 0
vs. IN 0
$ $ 0
1541 CD 0
, , 0
IQR NNP 0
859-2827 CD 0
; : 0
P NNP 0
= VBD 0
0.68 CD 0
] NNS 0
were VBD 0
similar JJ 0
in IN 0
both DT 0
groups NNS 0
. . 0

BNP NNP 0
increased VBD 0
diagnostic JJ 0
certainty NN 0
as IN 0
defined VBN 0
by IN 0
the DT 0
need NN 0
for IN 0
further JJ 0
diagnostic JJ 0
work-up NN 0
( ( 0
33 CD 0
% NN 0
vs. FW 0
45 CD 0
% NN 0
; : 0
P NNP 0
= NNP 0
0.02 CD 0
) ) 0
and CC 0
accelerated VBD 0
the DT 0
initiation NN 0
of IN 0
the DT 0
appropriate JJ 0
treatment NN 0
( ( 0
13 CD 0
days NNS 0
vs. FW 0
25 CD 0
days NNS 0
; : 0
P NNP 0
= NNP 0
0.01 CD 0
) ) 0
. . 0

The DT 0
area NN 0
under IN 0
the DT 0
receiver-operating JJ 0
characteristics NNS 0
curve NN 0
for IN 0
BNP NNP 0
to TO 0
identify VB 0
heart NN 0
failure NN 0
was VBD 0
0.87 CD 0
( ( 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
, , 0
0.81-0.93 JJ 0
) ) 0
. . 0

CONCLUSIONS VB 0
The DT 0
use NN 0
of IN 0
BNP NNP 0
levels NNS 0
in IN 0
primary JJ 0
care NN 0
did VBD 0
not RB 0
reduce VB 0
total JJ 0
medical JJ 0
cost NN 0
, , 0
but CC 0
improved VBD 0
some DT 0
of IN 0
the DT 0
secondary JJ 0
end-points NNS 0
including VBG 0
diagnostic JJ 0
certainty NN 0
and CC 0
time NN 0
to TO 0
initiation NN 0
of IN 0
appropriate JJ 0
treatment NN 0
. . 0

The DT 0
effects NNS 0
of IN 0
hypoxemia NN 0
on IN 0
cardiac JJ 0
output NN 0
. . 0

A DT 0
dose-response JJ 0
curve NN 0
. . 0

To TO 0
establish VB 0
a DT 0
dose-response JJ 0
curve NN 0
for IN 0
the DT 0
effects NNS 0
of IN 0
isocapnic JJ 0
hypoxemia NN 0
on IN 0
cardiac JJ 0
output NN 0
( ( 0
CO NNP 0
) ) 0
, , 0
we PRP 0
studied VBD 0
20 CD 0
healthy JJ 0
men NNS 0
, , 0
aged VBD 0
20 CD 0
to TO 0
34 CD 0
years NNS 0
, , 0
using VBG 0
a DT 0
tight-fitting JJ 0
face NN 0
mask NN 0
and CC 0
an DT 0
isocapnic JJ 0
partial NN 0
rebreathing NN 0
system NN 0
( ( 0
a DT 0
modified VBN 0
anesthesia NN 0
machine NN 0
) ) 0
. . 0

We PRP 0
blended VBD 0
oxygen NN 0
and CC 0
hypoxic NN 0
gas NN 0
to TO 0
achieve VB 0
arterial JJ 0
oxygen NN 0
saturations NNS 0
( ( 0
SaO2 NNP 0
) ) 0
of IN 0
80 CD 0
, , 0
85 CD 0
, , 0
and CC 0
90 CD 0
percent NN 0
; : 0
subjects NNS 0
also RB 0
breathed VBD 0
100 CD 0
percent NN 0
oxygen NN 0
and CC 0
room NN 0
air NN 0
( ( 0
RA NNP 0
) ) 0
. . 0

Target NNP 0
SaO2 NNP 0
and CC 0
end-tidal JJ 0
carbon NN 0
dioxide NN 0
were VBD 0
continuously RB 0
monitored VBN 0
using VBG 0
an DT 0
ear JJ 0
oximeter NN 0
and CC 0
CO2 NNP 0
gas NN 0
analyzer NN 0
. . 0

Subjects NNS 0
experienced VBD 0
the DT 0
five CD 0
SaO2 NNP 0
measurements NNS 0
in IN 0
random JJ 0
order NN 0
. . 0

CO NNP 0
was VBD 0
measured VBN 0
noninvasively RB 0
at IN 0
approximately RB 0
two-minute JJ 0
intervals NNS 0
, , 0
using VBG 0
continuous-wave JJ 0
Doppler NNP 0
echocardiography NN 0
. . 0

Mean NNP 0
cardiac JJ 0
output NN 0
increased VBD 0
with IN 0
increasing VBG 0
hypoxemia NN 0
from IN 0
6.84 CD 0
L/min NNP 0
at IN 0
FIo2 NNP 0
1.0 CD 0
to TO 0
8.44 CD 0
L/min NNP 0
at IN 0
SaO2 NNP 0
80 CD 0
percent NN 0
( ( 0
p NN 0
less JJR 0
than IN 0
0.0005 CD 0
) ) 0
; : 0
the DT 0
increase NN 0
was VBD 0
entirely RB 0
due JJ 0
to TO 0
increased JJ 0
heart NN 0
rate NN 0
. . 0

We PRP 0
concluded VBD 0
that IN 0
cardiac JJ 0
output NN 0
increases NNS 0
significantly RB 0
in IN 0
a DT 0
dose-response JJ 0
manner NN 0
in IN 0
response NN 0
to TO 0
acute VB 0
isocapnic JJ 0
hypoxemia NN 0
in IN 0
normal JJ 0
persons NNS 0
. . 0

Effects NNS 0
of IN 0
weight-bearing JJ 0
versus NN 0
nonweight-bearing JJ 0
exercise NN 0
on IN 0
function NN 0
, , 0
walking VBG 0
speed NN 0
, , 0
and CC 0
position NN 0
sense NN 0
in IN 0
participants NNS 0
with IN 0
knee NN 0
osteoarthritis NN 0
: : 0
a DT 0
randomized NN 0
controlled VBN 0
trial NN 0
. . 0

OBJECTIVE UH 0
To TO 0
investigate VB 0
whether IN 0
weight-bearing NN 0
( ( 0
WB NNP 0
) ) 0
exercise NN 0
enhances VBZ 0
functional JJ 0
capacity NN 0
to TO 0
a DT 0
greater JJR 0
extent NN 0
than IN 0
nonweight-bearing JJ 0
( ( 0
NWB NNP 0
) ) 0
exercise NN 0
in IN 0
participants NNS 0
with IN 0
knee NN 0
osteoarthritis NN 0
. . 0

DESIGN NNP 0
Randomized NNP 0
controlled VBD 0
trial NN 0
. . 0

SETTING NNP 0
Kinesiology NNP 0
laboratory NN 0
. . 0

PARTICIPANTS JJ 0
Participants NNS 0
( ( 0
N=106 NNP 0
) ) 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
WB NNP 0
exercise NN 0
, , 0
NWB NNP 0
exercise NN 0
, , 0
or CC 0
a DT 0
control NN 0
group NN 0
( ( 0
no DT 0
exercise NN 0
) ) 0
. . 0

INTERVENTION NNP 0
WB NNP 0
exercise NN 0
and CC 0
NWB NNP 0
exercise NN 0
groups NNS 0
underwent VBD 0
an DT 0
8-week JJ 0
knee NN 0
extension-flexion NN 0
exercise NN 0
program NN 0
. . 0

MAIN NNP 0
OUTCOME NNP 0
MEASURES NNP 0
Western NNP 0
Ontario NNP 0
and CC 0
McMaster NNP 0
Universities NNP 0
Osteoarthritis NNP 0
Index NNP 0
( ( 0
WOMAC NNP 0
) ) 0
function NN 0
scale NN 0
, , 0
walking VBG 0
speed NN 0
, , 0
muscle NN 0
torque NN 0
, , 0
and CC 0
knee VB 0
reposition NN 0
error NN 0
were VBD 0
assessed VBN 0
before IN 0
and CC 0
after IN 0
intervention NN 0
. . 0

RESULTS NNP 0
Equally NNP 0
significant JJ 0
improvements NNS 0
were VBD 0
apparent JJ 0
for IN 0
all DT 0
outcomes NNS 0
after IN 0
WB NNP 0
exercise NN 0
and CC 0
NWB NNP 0
exercise NN 0
, , 0
except IN 0
for IN 0
reposition NN 0
error NN 0
, , 0
for IN 0
which WDT 0
improvement NN 0
was VBD 0
greater JJR 0
in IN 0
the DT 0
WB NNP 0
exercise NN 0
group NN 0
. . 0

In IN 0
contrast NN 0
, , 0
there EX 0
were VBD 0
no DT 0
improvements NNS 0
in IN 0
the DT 0
control NN 0
group NN 0
. . 0

CONCLUSIONS NNP 0
Simple NNP 0
knee NNP 0
flexion NN 0
and CC 0
extension NN 0
exercises NNS 0
( ( 0
WB NNP 0
and CC 0
NWB NNP 0
) ) 0
performed VBD 0
over IN 0
8 CD 0
weeks NNS 0
resulted VBD 0
in IN 0
significant JJ 0
improvement NN 0
in IN 0
the DT 0
WOMAC NNP 0
function NN 0
scale NN 0
and CC 0
knee NN 0
strength NN 0
compared VBN 0
with IN 0
the DT 0
control NN 0
group NN 0
. . 0

NWB NNP 0
exercise NN 0
alone RB 0
may MD 0
be VB 0
sufficient JJ 0
enough RB 0
to TO 0
improve VB 0
function NN 0
and CC 0
muscle NN 0
strength NN 0
. . 0

The DT 0
additional JJ 0
benefit NN 0
of IN 0
WB NNP 0
exercise NN 0
was VBD 0
improved VBN 0
position NN 0
sense NN 0
, , 0
which WDT 0
may MD 0
enhance VB 0
complex JJ 0
walking NN 0
tasks NNS 0
( ( 0
walking VBG 0
on IN 0
figure NN 0
of IN 0
8 CD 0
route NN 0
and CC 0
spongy JJ 0
surface NN 0
) ) 0
. . 0

A DT 0
randomized JJ 0
trial NN 0
of IN 0
radiation NN 0
therapy NN 0
compared VBN 0
to TO 0
split VB 0
course NN 0
radiation NN 0
therapy NN 0
combined VBN 0
with IN 0
mitomycin JJ 0
C NNP 0
and CC 0
5 CD 0
fluorouracil NN 0
as IN 0
initial JJ 0
treatment NN 0
for IN 0
advanced JJ 0
laryngeal NN 0
and CC 0
hypopharyngeal NN 0
squamous JJ 0
carcinoma NN 0
. . 0

Two CD 0
hundred VBD 0
and CC 0
twelve JJ 0
patients NNS 0
with IN 0
previously RB 0
untreated VBN 0
advanced JJ 0
squamous JJ 0
carcinoma NN 0
of IN 0
the DT 0
larynx NN 0
or CC 0
hypopharynx NN 0
were VBD 0
randomized VBN 0
to TO 0
receive VB 0
initial JJ 0
treatment NN 0
with IN 0
radiotherapy NN 0
, , 0
50 CD 0
Gy NNP 0
in IN 0
20 CD 0
fractions NNS 0
in IN 0
28 CD 0
days NNS 0
or CC 0
split JJ 0
course NN 0
radiotherapy NN 0
and CC 0
concurrent NN 0
chemotherapy NN 0
, , 0
25 CD 0
Gy NNP 0
in IN 0
10 CD 0
fractions NNS 0
in IN 0
14 CD 0
days NNS 0
followed VBN 0
by IN 0
a DT 0
4 CD 0
week NN 0
rest NN 0
and CC 0
a DT 0
further JJ 0
25 CD 0
Gy NNP 0
in IN 0
10 CD 0
fractions NNS 0
in IN 0
14 CD 0
days NNS 0
starting VBG 0
on IN 0
day NN 0
43 CD 0
; : 0
Mitomycin NNP 0
C NNP 0
was VBD 0
given VBN 0
on IN 0
day NN 0
1 CD 0
and CC 0
day NN 0
43 CD 0
and CC 0
5FU CD 0
continuous JJ 0
infusions NNS 0
on IN 0
days NNS 0
1 CD 0
-- : 0
4 CD 0
and CC 0
days NNS 0
43 CD 0
-- : 0
46 CD 0
. . 0

Surgery NN 0
was VBD 0
reserved VBN 0
for IN 0
persistent NN 0
or CC 0
recurrent JJ 0
disease NN 0
. . 0

Two CD 0
hundred VBD 0
and CC 0
nine CD 0
of IN 0
the DT 0
212 CD 0
patients NNS 0
randomized VBN 0
were VBD 0
included VBN 0
in IN 0
the DT 0
analyses NNS 0
. . 0

Outcome NN 0
analyses NNS 0
were VBD 0
performed VBN 0
at IN 0
a DT 0
median JJ 0
follow-up JJ 0
interval NN 0
of IN 0
4.4 CD 0
years NNS 0
. . 0

No DT 0
patients NNS 0
were VBD 0
lost VBN 0
to TO 0
follow-up NN 0
. . 0

No DT 0
significant JJ 0
difference NN 0
was VBD 0
found VBN 0
between IN 0
the DT 0
two CD 0
arms NNS 0
for IN 0
the DT 0
end NN 0
points NNS 0
of IN 0
local JJ 0
relapse-free JJ 0
rate NN 0
( ( 0
p JJ 0
= NNP 0
0.91 CD 0
) ) 0
, , 0
regional JJ 0
relapse-free JJ 0
rate NN 0
( ( 0
p JJ 0
= NN 0
0.17 CD 0
, , 0
adjusted VBN 0
) ) 0
or CC 0
overall JJ 0
survival NN 0
( ( 0
p JJ 0
= NNP 0
0.86 CD 0
) ) 0
. . 0

Eight-eight JJ 0
patients NNS 0
had VBD 0
attempted VBN 0
surgical JJ 0
resection NN 0
following VBG 0
radiotherapy JJ 0
failure NN 0
. . 0

The DT 0
contribution NN 0
of IN 0
salvage NN 0
surgery NN 0
to TO 0
overall JJ 0
survival NN 0
was VBD 0
similar JJ 0
for IN 0
both DT 0
arms NNS 0
of IN 0
the DT 0
study NN 0
as IN 0
was VBD 0
the DT 0
surgical JJ 0
complication NN 0
rate NN 0
. . 0

Serious JJ 0
late JJ 0
radiation NN 0
toxicity NN 0
was VBD 0
minimal JJ 0
( ( 0
3 CD 0
% NN 0
in IN 0
the DT 0
RT NNP 0
group NN 0
, , 0
0 CD 0
% NN 0
in IN 0
the DT 0
radiation NN 0
therapy NN 0
plus CC 0
chemotherapy NN 0
group NN 0
) ) 0
. . 0

The DT 0
result NN 0
of IN 0
the DT 0
trial NN 0
shows VBZ 0
no DT 0
advantage NN 0
in IN 0
terms NNS 0
of IN 0
local JJ 0
control NN 0
or CC 0
survival NN 0
for IN 0
the DT 0
experimental JJ 0
treatment NN 0
arm NN 0
of IN 0
split NN 0
course NN 0
radiotherapy NN 0
and CC 0
concurrent JJ 0
chemotherapy NN 0
with IN 0
Mitomycin NNP 0
C NNP 0
and CC 0
5 CD 0
Fluorouracil NNP 0
compared VBN 0
to TO 0
radiotherapy VB 0
alone RB 0
. . 0

Mechanical JJ 0
efficiency NN 0
and CC 0
propulsion NN 0
technique NN 0
after IN 0
7 CD 0
weeks NNS 0
of IN 0
low-intensity JJ 0
wheelchair NN 0
training NN 0
. . 0

BACKGROUND NNP 0
To TO 0
evaluate VB 0
the DT 0
effect NN 0
of IN 0
a DT 0
7-week JJ 0
low-intensity NN 0
hand NN 0
rim VBZ 0
wheelchair JJ 0
training VBG 0
on IN 0
the DT 0
submaximal JJ 0
metabolic NN 0
cost NN 0
, , 0
mechanical JJ 0
efficiency NN 0
and CC 0
propulsion NN 0
technique NN 0
in IN 0
able-bodied JJ 0
participants NNS 0
. . 0

METHODS JJ 0
Participants NNS 0
were VBD 0
randomly RB 0
divided VBN 0
over RP 0
an DT 0
experimental JJ 0
group NN 0
( ( 0
n=14 CC 0
) ) 0
and CC 0
a DT 0
control NN 0
group NN 0
( ( 0
n=7 RB 0
) ) 0
. . 0

The DT 0
experimental JJ 0
group NN 0
received VBD 0
7 CD 0
weeks NNS 0
wheelchair JJ 0
training NN 0
( ( 0
3 CD 0
week NN 0
( ( 0
-1 NN 0
) ) 0
, , 0
70 CD 0
min NN 0
) ) 0
at IN 0
a DT 0
low JJ 0
intensity NN 0
( ( 0
30 CD 0
% NN 0
of IN 0
the DT 0
heart NN 0
rate NN 0
reserve NN 0
) ) 0
, , 0
whereas IN 0
the DT 0
control NN 0
group NN 0
did VBD 0
not RB 0
receive VB 0
training NN 0
. . 0

During IN 0
pre- JJ 0
and CC 0
post-tests NNS 0
, , 0
submaximal JJ 0
exercise NN 0
was VBD 0
performed VBN 0
on IN 0
a DT 0
stationary JJ 0
wheelchair NN 0
ergometer NN 0
at IN 0
fixed JJ 0
levels NNS 0
of IN 0
power NN 0
output NN 0
. . 0

Mechanical JJ 0
efficiency NN 0
, , 0
oxygen NN 0
uptake NN 0
, , 0
heart NN 0
rate NN 0
, , 0
timing VBG 0
parameters NNS 0
and CC 0
stroke NN 0
angles NNS 0
were VBD 0
measured VBN 0
. . 0

Video NNP 0
recordings NNS 0
were VBD 0
made VBN 0
to TO 0
determine VB 0
the DT 0
stroke NN 0
pattern NN 0
. . 0

FINDINGS NNP 0
Mechanical NNP 0
efficiency NN 0
increased VBD 0
and CC 0
metabolic JJ 0
cost NN 0
decreased VBN 0
significantly RB 0
in IN 0
the DT 0
experimental JJ 0
group NN 0
compared VBN 0
to TO 0
the DT 0
control NN 0
group NN 0
. . 0

Push NNP 0
time NN 0
increased VBD 0
and CC 0
cycle NN 0
frequency NN 0
decreased VBD 0
as IN 0
a DT 0
result NN 0
of IN 0
training NN 0
. . 0

The DT 0
stroke NN 0
angle NN 0
increased VBD 0
in IN 0
the DT 0
experimental JJ 0
group NN 0
during IN 0
the DT 0
training NN 0
period NN 0
. . 0

The DT 0
experimental JJ 0
group NN 0
preferred VBD 0
double-looping NN 0
over IN 0
propulsion NN 0
, , 0
while IN 0
the DT 0
control NN 0
group NN 0
mainly RB 0
used VBD 0
single-looping NN 0
over IN 0
propulsion NN 0
patterns NNS 0
during IN 0
the DT 0
post-test JJ 0
. . 0

INTERPRETATION VB 0
A DT 0
low-intensity NN 0
, , 0
7-week JJ 0
training NN 0
protocol NN 0
has VBZ 0
a DT 0
beneficial JJ 0
effect NN 0
on IN 0
the DT 0
mechanical JJ 0
efficiency NN 0
and CC 0
metabolic JJ 0
cost NN 0
of IN 0
wheelchair NN 0
propulsion NN 0
in IN 0
able-bodied JJ 0
participants NNS 0
. . 0

The DT 0
improved JJ 0
mechanical JJ 0
efficiency NN 0
seems VBZ 0
to TO 0
be VB 0
the DT 0
result NN 0
of IN 0
changes NNS 0
in IN 0
propulsion NN 0
technique NN 0
that WDT 0
were VBD 0
found VBN 0
. . 0

VLDL NNP 0
, , 0
apolipoproteins VBZ 0
B NNP 0
, , 0
CIII NNP 0
, , 0
and CC 0
E NNP 0
, , 0
and CC 0
risk NN 0
of IN 0
recurrent JJ 0
coronary JJ 0
events NNS 0
in IN 0
the DT 0
Cholesterol NNP 0
and CC 0
Recurrent NNP 0
Events NNP 0
( ( 0
CARE NNP 0
) ) 0
trial NN 0
. . 0

BACKGROUND NNP 0
Plasma NNP 0
triglyceride NN 0
concentration NN 0
has VBZ 0
been VBN 0
an DT 0
inconsistent JJ 0
independent JJ 0
risk NN 0
factor NN 0
for IN 0
coronary JJ 0
heart NN 0
disease NN 0
, , 0
perhaps RB 0
because IN 0
of IN 0
the DT 0
metabolic JJ 0
heterogeneity NN 0
among IN 0
VLDL NNP 0
particles NNS 0
, , 0
the DT 0
main JJ 0
carriers NNS 0
of IN 0
triglycerides NNS 0
in IN 0
plasma NN 0
. . 0

METHODS NNP 0
AND CC 0
RESULTS NNP 0
We PRP 0
conducted VBD 0
a DT 0
prospective JJ 0
, , 0
nested JJ 0
case-control NN 0
study NN 0
in IN 0
the DT 0
Cholesterol NNP 0
and CC 0
Recurrent NNP 0
Events NNP 0
( ( 0
CARE NNP 0
) ) 0
trial NN 0
, , 0
a DT 0
randomized JJ 0
placebo-controlled JJ 0
trial NN 0
of IN 0
pravastatin NN 0
in IN 0
4159 CD 0
patients NNS 0
with IN 0
myocardial JJ 0
infarction NN 0
and CC 0
average JJ 0
LDL NNP 0
concentrations NNS 0
at IN 0
baseline NN 0
( ( 0
115 CD 0
to TO 0
174 CD 0
mg/dL NNS 0
, , 0
mean VBP 0
139 CD 0
mg/dL NN 0
) ) 0
. . 0

Baseline NNP 0
concentrations NNS 0
of IN 0
VLDL-apolipoprotein NNP 0
( ( 0
apo NN 0
) ) 0
B NNP 0
( ( 0
the DT 0
VLDL NNP 0
particle NN 0
concentration NN 0
) ) 0
, , 0
VLDL NNP 0
lipids NNS 0
, , 0
and CC 0
apoCIII NN 0
and CC 0
apoE NN 0
in IN 0
VLDL+LDL NNP 0
and CC 0
in IN 0
HDL NNP 0
were VBD 0
compared VBN 0
in IN 0
patients NNS 0
who WP 0
had VBD 0
either CC 0
a DT 0
myocardial JJ 0
infarction NN 0
or CC 0
coronary JJ 0
death NN 0
( ( 0
cases NNS 0
, , 0
n=418 NN 0
) ) 0
with IN 0
those DT 0
in IN 0
patients NNS 0
who WP 0
did VBD 0
not RB 0
have VB 0
a DT 0
cardiovascular JJ 0
event NN 0
( ( 0
control NN 0
subjects VBZ 0
, , 0
n=370 NN 0
) ) 0
in IN 0
5 CD 0
years NNS 0
of IN 0
follow-up JJ 0
. . 0

VLDL-cholesterol NN 0
, , 0
VLDL-triglyceride NNP 0
, , 0
VLDL-apoB NNP 0
, , 0
apoCIII NN 0
and CC 0
apoE NN 0
in IN 0
VLDL+LDL NNP 0
and CC 0
apoE NN 0
in IN 0
HDL NNP 0
were VBD 0
all DT 0
interrelated VBN 0
, , 0
and CC 0
each DT 0
was VBD 0
a DT 0
univariate JJ 0
predictor NN 0
of IN 0
subsequent JJ 0
coronary JJ 0
events NNS 0
. . 0

The DT 0
significant JJ 0
independent JJ 0
predictors NNS 0
were VBD 0
VLDL-apoB NNP 0
( ( 0
relative JJ 0
risk NN 0
[ NNP 0
RR NNP 0
] VBZ 0
3.2 CD 0
for IN 0
highest JJS 0
to TO 0
lowest JJS 0
quintiles NNS 0
, , 0
P NNP 0
: : 0
=0.04 NN 0
) ) 0
, , 0
apoCIII RB 0
in IN 0
VLDL+LDL NNP 0
( ( 0
RR NNP 0
2.3 CD 0
, , 0
P NNP 0
: : 0
=0.04 NN 0
) ) 0
, , 0
and CC 0
apoE NN 0
in IN 0
HDL NNP 0
( ( 0
RR NNP 0
1.8 CD 0
, , 0
P NNP 0
: : 0
=0.02 NN 0
) ) 0
. . 0

Plasma NNP 0
triglycerides NNS 0
, , 0
a DT 0
univariate JJ 0
predictor NN 0
of IN 0
coronary JJ 0
events NNS 0
( ( 0
RR NNP 0
1.6 CD 0
, , 0
P NNP 0
: : 0
=0.03 NN 0
) ) 0
, , 0
was VBD 0
not RB 0
related VBN 0
to TO 0
coronary JJ 0
events NNS 0
( ( 0
RR NNP 0
1.3 CD 0
, , 0
P NNP 0
: : 0
=0.6 NN 0
) ) 0
when WRB 0
apoCIII NN 0
in IN 0
VLDL+LDL NNP 0
was VBD 0
included VBN 0
in IN 0
the DT 0
model NN 0
, , 0
whereas JJ 0
apoCIII NN 0
remained VBD 0
significant JJ 0
. . 0

Adjustment NN 0
for IN 0
LDL- NNP 0
and CC 0
HDL-cholesterol NNP 0
did VBD 0
not RB 0
affect VB 0
these DT 0
results NNS 0
. . 0

CONCLUSIONS NNP 0
The DT 0
plasma JJ 0
concentrations NNS 0
of IN 0
VLDL NNP 0
particles NNS 0
and CC 0
apoCIII NN 0
in IN 0
VLDL NNP 0
and CC 0
LDL NNP 0
are VBP 0
more RBR 0
specific JJ 0
measures NNS 0
of IN 0
coronary JJ 0
heart NN 0
disease NN 0
risk NN 0
than IN 0
plasma JJ 0
triglycerides NNS 0
perhaps RB 0
because IN 0
their PRP$ 0
known VBN 0
metabolic NN 0
properties NNS 0
link VBP 0
them PRP 0
more RBR 0
closely RB 0
to TO 0
atherosclerosis NN 0
. . 0

The DT 0
additional JJ 0
value NN 0
of IN 0
a DT 0
night NN 0
splint NN 0
to TO 0
eccentric VB 0
exercises NNS 0
in IN 0
chronic JJ 0
midportion NN 0
Achilles NNP 0
tendinopathy NN 0
: : 0
a DT 0
randomised JJ 0
controlled VBN 0
trial NN 0
. . 0

AIM NNP 0
To TO 0
assess VB 0
whether IN 0
the DT 0
use NN 0
of IN 0
a DT 0
night NN 0
splint NN 0
is VBZ 0
of IN 0
added JJ 0
benefit NN 0
on IN 0
functional JJ 0
outcome NN 0
in IN 0
treating VBG 0
chronic JJ 0
midportion NN 0
Achilles NNP 0
tendinopathy NN 0
. . 0

METHODS NNP 0
This DT 0
was VBD 0
a DT 0
single-blind JJ 0
, , 0
prospective JJ 0
, , 0
single JJ 0
centre NN 0
, , 0
randomised VBD 0
controlled VBN 0
trial NN 0
set NN 0
in IN 0
the DT 0
Sports NNP 0
Medical NNP 0
Department NNP 0
, , 0
The DT 0
Hague NNP 0
Medical NNP 0
Centre NNP 0
, , 0
The DT 0
Netherlands NNP 0
. . 0

Inclusion NNP 0
criteria NNS 0
were VBD 0
: : 0
age NN 0
18-70 CD 0
years NNS 0
, , 0
active JJ 0
participation NN 0
in IN 0
sports NNS 0
, , 0
and CC 0
tendon VB 0
pain NN 0
localised VBN 0
at IN 0
2-7 JJ 0
cm NN 0
from IN 0
distal JJ 0
insertion NN 0
. . 0

Exclusion NN 0
criteria NNS 0
were VBD 0
: : 0
insertional JJ 0
disorders NNS 0
, , 0
partial JJ 0
or CC 0
complete JJ 0
ruptures NNS 0
, , 0
or CC 0
systemic JJ 0
illness NN 0
. . 0

70 CD 0
tendons NNS 0
were VBD 0
included VBN 0
and CC 0
randomised VBN 0
into IN 0
one CD 0
of IN 0
two CD 0
treatment NN 0
groups NNS 0
: : 0
eccentric JJ 0
exercises NNS 0
with IN 0
a DT 0
night NN 0
splint NN 0
( ( 0
night NN 0
splint NN 0
group NN 0
, , 0
n RB 0
= VBZ 0
36 CD 0
) ) 0
or CC 0
eccentric JJ 0
exercises NNS 0
only RB 0
( ( 0
eccentric JJ 0
group NN 0
, , 0
n RB 0
= VBZ 0
34 CD 0
) ) 0
. . 0

INTERVENTIONS NNP 0
Both DT 0
groups NNS 0
completed VBD 0
a DT 0
12-week JJ 0
heavy-load NN 0
eccentric JJ 0
training NN 0
programme NN 0
. . 0

One CD 0
group NN 0
received VBD 0
a DT 0
night NN 0
splint NN 0
in IN 0
addition NN 0
to TO 0
eccentric JJ 0
exercises NNS 0
. . 0

At IN 0
baseline NN 0
and CC 0
follow-up NN 0
at IN 0
12 CD 0
weeks NNS 0
, , 0
patient JJ 0
satisfaction NN 0
, , 0
Victorian NNP 0
Institute NNP 0
of IN 0
Sport NNP 0
Assessment-Achilles NNP 0
questionnaire NN 0
( ( 0
VISA-A NNP 0
) ) 0
score NN 0
and CC 0
reported VBD 0
compliance NN 0
were VBD 0
recorded VBN 0
by IN 0
a DT 0
single-blind NN 0
trained JJ 0
researcher NN 0
who WP 0
was VBD 0
blinded VBN 0
to TO 0
the DT 0
treatment NN 0
. . 0

RESULTS NNP 0
After IN 0
12 CD 0
weeks NNS 0
, , 0
patient JJ 0
satisfaction NN 0
in IN 0
the DT 0
eccentric JJ 0
group NN 0
was VBD 0
63 CD 0
% NN 0
compared VBN 0
with IN 0
48 CD 0
% NN 0
in IN 0
the DT 0
night NN 0
splint NN 0
group NN 0
. . 0

The DT 0
VISA-A NNP 0
score NN 0
significantly RB 0
improved VBN 0
in IN 0
both DT 0
groups NNS 0
; : 0
in IN 0
the DT 0
eccentric JJ 0
group NN 0
from IN 0
50.1 CD 0
to TO 0
68.8 CD 0
( ( 0
p NN 0
= RB 0
0.001 CD 0
) ) 0
and CC 0
in IN 0
the DT 0
night NN 0
splint NN 0
group NN 0
from IN 0
49.4 CD 0
to TO 0
67.0 CD 0
( ( 0
p NN 0
< RB 0
0.001 CD 0
) ) 0
. . 0

There EX 0
was VBD 0
no DT 0
significant JJ 0
difference NN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
in IN 0
VISA-A NNP 0
score NN 0
( ( 0
p JJ 0
= NNP 0
0.815 CD 0
) ) 0
and CC 0
patient JJ 0
satisfaction NN 0
( ( 0
p JJ 0
= NNP 0
0.261 CD 0
) ) 0
. . 0

CONCLUSION VB 0
A DT 0
night NN 0
splint NN 0
is VBZ 0
not RB 0
beneficial JJ 0
in IN 0
addition NN 0
to TO 0
eccentric VB 0
exercises NNS 0
in IN 0
the DT 0
treatment NN 0
of IN 0
chronic JJ 0
midportion NN 0
Achilles NNP 0
tendinopathy NN 0
. . 0

Effects NNS 0
of IN 0
sibutramine NN 0
on IN 0
thermogenesis NN 0
in IN 0
obese JJ 0
patients NNS 0
assessed VBD 0
via IN 0
immersion NN 0
calorimetry NN 0
. . 0

Glucose NNP 0
utilization JJ 0
studies NNS 0
show VBP 0
that IN 0
sibutramine-induced JJ 0
thermogenesis NN 0
is VBZ 0
mediated VBN 0
via IN 0
selective JJ 0
sympathetic JJ 0
activation NN 0
of IN 0
brown JJ 0
adipose JJ 0
tissue NN 0
. . 0

The DT 0
goal NN 0
of IN 0
the DT 0
present JJ 0
study NN 0
was VBD 0
to TO 0
use VB 0
a DT 0
new JJ 0
calorimetry NN 0
method NN 0
in IN 0
which WDT 0
resting VBG 0
metabolic JJ 0
rate NN 0
is VBZ 0
enhanced VBN 0
to TO 0
evaluate VB 0
the DT 0
effects NNS 0
of IN 0
sibutramine JJ 0
treatment NN 0
on IN 0
thermogenesis NN 0
. . 0

Sixty NNP 0
obese JJ 0
women NNS 0
were VBD 0
included VBN 0
in IN 0
the DT 0
study NN 0
. . 0

Subjects NNS 0
were VBD 0
divided VBN 0
into IN 0
2 CD 0
equal JJ 0
groups-the JJ 0
placebo NN 0
and CC 0
sibutramine JJ 0
treatment NN 0
groups NNS 0
. . 0

The DT 0
sibutramine NN 0
group NN 0
was VBD 0
given VBN 0
sibutramine JJ 0
10 CD 0
mg JJ 0
daily RB 0
for IN 0
12 CD 0
wk NN 0
. . 0

At IN 0
baseline NN 0
and CC 0
at IN 0
the DT 0
end NN 0
of IN 0
the DT 0
12-wk JJ 0
treatment NN 0
period NN 0
, , 0
thermogenic JJ 0
measurements NNS 0
were VBD 0
taken VBN 0
with IN 0
the DT 0
use NN 0
of IN 0
water NN 0
immersion NN 0
calorimetry NN 0
. . 0

Subjects NNS 0
were VBD 0
examined VBN 0
at IN 0
weeks NNS 0
4 CD 0
, , 0
8 CD 0
, , 0
and CC 0
12 CD 0
of IN 0
treatment NN 0
to TO 0
identify VB 0
adverse JJ 0
effects NNS 0
. . 0

Body NNP 0
mass NN 0
index NN 0
, , 0
measured VBN 0
at IN 0
31.5+/-2.05 JJ 0
kg/m2 NN 0
in IN 0
the DT 0
placebo NN 0
group NN 0
, , 0
decreased VBN 0
to TO 0
30.4+/-2.94 JJ 0
kg/m NN 0
( ( 0
2 CD 0
) ) 0
after IN 0
12 CD 0
wk NN 0
( ( 0
P=.07 NNP 0
) ) 0
. . 0

In IN 0
the DT 0
sibutramine NN 0
group NN 0
, , 0
it PRP 0
decreased VBD 0
from IN 0
33.5+/-4.1 JJ 0
kg/m NN 0
( ( 0
2 CD 0
) ) 0
to TO 0
30.9+/-4.8 JJ 0
kg/m NN 0
( ( 0
2 CD 0
) ) 0
( ( 0
P NNP 0
< NNP 0
.05 NNP 0
) ) 0
. . 0

In IN 0
the DT 0
sibutramine NN 0
group NN 0
, , 0
mean VBP 0
thermogenic JJ 0
response NN 0
changed VBD 0
from IN 0
a DT 0
baseline NN 0
value NN 0
of IN 0
1.27+/-0.29 JJ 0
kcal/kg/h NN 0
to TO 0
1.44+/-0.13 JJ 0
kcal/kg/h NN 0
after IN 0
12 CD 0
wk NN 0
of IN 0
treatment NN 0
. . 0

In IN 0
the DT 0
placebo NN 0
group NN 0
, , 0
the DT 0
baseline NN 0
value NN 0
was VBD 0
1.56+/-0.27 JJ 0
kcal/kg/h NN 0
; : 0
it PRP 0
changed VBD 0
to TO 0
1.33+/-0.36 JJ 0
kcal/kg/h NN 0
at IN 0
the DT 0
end NN 0
of IN 0
12 CD 0
wk NN 0
. . 0

The DT 0
findings NNS 0
of IN 0
this DT 0
study NN 0
suggest VBP 0
that IN 0
sibutramine NN 0
treatment NN 0
promotes VBZ 0
thermogenesis NN 0
, , 0
thus RB 0
facilitating VBG 0
weight JJ 0
loss NN 0
. . 0

Calorimetry NNP 0
enhances VBZ 0
resting VBG 0
metabolism NN 0
through IN 0
more RBR 0
efficient JJ 0
heat NN 0
transfer NN 0
from IN 0
the DT 0
body NN 0
. . 0

Moderate NNP 0
sodium NN 0
restriction NN 0
, , 0
angiotensin NN 0
converting VBG 0
enzyme JJ 0
inhibition NN 0
, , 0
and CC 0
thiazide RB 0
diuretic JJ 0
in IN 0
the DT 0
management NN 0
of IN 0
essential JJ 0
hypertension NN 0
. . 0

Dietary NNP 0
sodium JJ 0
restriction NN 0
alone RB 0
is VBZ 0
effective JJ 0
in IN 0
lowering VBG 0
blood NN 0
pressure NN 0
in IN 0
some DT 0
, , 0
but CC 0
not RB 0
all DT 0
, , 0
patients NNS 0
with IN 0
essential JJ 0
hypertension NN 0
. . 0

Homeostatic JJ 0
mechanisms NNS 0
, , 0
including VBG 0
activation NN 0
of IN 0
the DT 0
renin-aldosterone NN 0
system NN 0
, , 0
may MD 0
counteract VB 0
the DT 0
effects NNS 0
of IN 0
sodium JJ 0
restriction NN 0
. . 0

Angiotensin NNP 0
converting VBG 0
enzyme NN 0
( ( 0
ACE NNP 0
) ) 0
inhibitors NNS 0
are VBP 0
also RB 0
effective JJ 0
as IN 0
sole JJ 0
therapy NN 0
in IN 0
many JJ 0
patients NNS 0
with IN 0
essential JJ 0
hypertension NN 0
, , 0
but CC 0
may MD 0
be VB 0
less RBR 0
effective JJ 0
in IN 0
those DT 0
with IN 0
low-renin JJ 0
hypertension NN 0
. . 0

The DT 0
combination NN 0
of IN 0
dietary JJ 0
sodium NN 0
restriction NN 0
with IN 0
blockade NN 0
of IN 0
the DT 0
renin NN 0
system NN 0
by IN 0
an DT 0
ACE NNP 0
inhibitor NN 0
is VBZ 0
a DT 0
particularly RB 0
effective JJ 0
way NN 0
to TO 0
improve VB 0
blood NN 0
pressure NN 0
control NN 0
. . 0

Addition NNP 0
of IN 0
a DT 0
thiazide JJ 0
diuretic NN 0
will MD 0
reduce VB 0
pressure NN 0
further RBR 0
. . 0

Does NNP 0
temporary JJ 0
clamping NN 0
of IN 0
drains NNS 0
following VBG 0
knee NN 0
arthroplasty JJ 0
reduce VB 0
blood NN 0
loss NN 0
? . 0
A DT 0
randomised JJ 0
controlled VBN 0
trial NN 0
. . 0

In IN 0
a DT 0
randomised JJ 0
, , 0
blinded VBD 0
study NN 0
76 CD 0
patients NNS 0
undergoing JJ 0
primary JJ 0
total JJ 0
knee NN 0
arthroplasty NN 0
were VBD 0
assigned VBN 0
to TO 0
either DT 0
immediate JJ 0
drain NN 0
opening NN 0
( ( 0
n JJ 0
= NNP 0
45 CD 0
) ) 0
or CC 0
drains NNS 0
opened VBN 0
at IN 0
2 CD 0
h NN 0
( ( 0
n JJ 0
= NNP 0
31 CD 0
) ) 0
. . 0

No DT 0
significant JJ 0
differences NNS 0
were VBD 0
found VBN 0
between IN 0
the DT 0
groups NNS 0
for IN 0
the DT 0
volume NN 0
of IN 0
drained JJ 0
blood NN 0
, , 0
transfusion NN 0
requirements NNS 0
, , 0
knee JJ 0
motion NN 0
or CC 0
wound NN 0
status NN 0
. . 0

The DT 0
authors NNS 0
conclude VBP 0
that IN 0
the DT 0
practice NN 0
of IN 0
clamping VBG 0
drains NNS 0
has VBZ 0
no DT 0
benefit NN 0
in IN 0
routine JJ 0
knee NN 0
arthroplasty NN 0
. . 0

However RB 0
, , 0
when WRB 0
faced VBN 0
with IN 0
immediate JJ 0
brisk JJ 0
blood NN 0
loss NN 0
, , 0
the DT 0
results NNS 0
suggest VBP 0
that IN 0
drains NNS 0
can MD 0
be VB 0
clamped VBN 0
without IN 0
any DT 0
excess JJ 0
morbidity NN 0
. . 0

A DT 0
randomized JJ 0
, , 0
evaluator-blind JJ 0
, , 0
multicenter JJ 0
comparison NN 0
of IN 0
the DT 0
efficacy NN 0
and CC 0
tolerability NN 0
of IN 0
Perlane NNP 0
versus NN 0
Zyplast NNP 0
in IN 0
the DT 0
correction NN 0
of IN 0
nasolabial JJ 0
folds NNS 0
. . 0

Bovine NNP 0
collagen NN 0
is VBZ 0
widely RB 0
used VBN 0
as IN 0
a DT 0
dermal JJ 0
filler NN 0
for IN 0
facial JJ 0
soft-tissue JJ 0
augmentation NN 0
, , 0
but CC 0
it PRP 0
provides VBZ 0
only RB 0
temporary JJ 0
cosmetic JJ 0
improvement NN 0
. . 0

Nonanimal NNP 0
stabilized VBD 0
hyaluronic JJ 0
acid NN 0
has VBZ 0
reduced VBN 0
potential JJ 0
for IN 0
immunogenicity NN 0
and CC 0
hypersensitivity NN 0
and CC 0
may MD 0
provide VB 0
a DT 0
more RBR 0
durable JJ 0
aesthetic JJ 0
result NN 0
. . 0

Sixty-eight JJ 0
patients NNS 0
with IN 0
prominent JJ 0
nasolabial JJ 0
folds NNS 0
were VBD 0
randomized VBN 0
to TO 0
intradermal VB 0
treatment NN 0
with IN 0
nonanimal JJ 0
stabilized VBN 0
hyaluronic JJ 0
acid NN 0
gel NN 0
( ( 0
Perlane NNP 0
) ) 0
and CC 0
bovine JJ 0
collagen NN 0
( ( 0
Zyplast NNP 0
) ) 0
on IN 0
contralateral JJ 0
sides NNS 0
of IN 0
the DT 0
face NN 0
. . 0

On IN 0
achievement NN 0
of IN 0
optimal JJ 0
cosmetic JJ 0
result NN 0
( ( 0
baseline NN 0
) ) 0
, , 0
patients NNS 0
were VBD 0
followed VBN 0
up RP 0
for IN 0
6 CD 0
months NNS 0
; : 0
bilateral JJ 0
retreatment NN 0
with IN 0
Perlane NNP 0
was VBD 0
offered VBN 0
at IN 0
6 CD 0
or CC 0
9 CD 0
months NNS 0
after IN 0
baseline NN 0
. . 0

Responses NNS 0
were VBD 0
evaluated VBN 0
at IN 0
2 CD 0
, , 0
4 CD 0
, , 0
6 CD 0
, , 0
9 CD 0
, , 0
and CC 0
12 CD 0
months NNS 0
after IN 0
baseline NN 0
. . 0

Investigator-based JJ 0
and CC 0
patient-based JJ 0
ratings NNS 0
indicated VBD 0
that IN 0
Perlane NNP 0
was VBD 0
more RBR 0
effective JJ 0
than IN 0
Zyplast NNP 0
in IN 0
maintaining VBG 0
cosmetic JJ 0
correction NN 0
. . 0

According VBG 0
to TO 0
investigator-based JJ 0
Wrinkle NNP 0
Severity NNP 0
Rating NNP 0
Scale NNP 0
assessments NNS 0
at IN 0
6 CD 0
and CC 0
9 CD 0
months NNS 0
after IN 0
baseline NN 0
, , 0
Perlane NNP 0
was VBD 0
superior JJ 0
in IN 0
50.0 CD 0
percent NN 0
and CC 0
48.8 CD 0
percent NN 0
of IN 0
patients NNS 0
, , 0
respectively RB 0
, , 0
whereas IN 0
Zyplast NNP 0
was VBD 0
superior JJ 0
in IN 0
10.3 CD 0
percent NN 0
and CC 0
14.0 CD 0
percent NN 0
of IN 0
patients NNS 0
, , 0
respectively RB 0
( ( 0
p JJ 0
< NNP 0
0.0004 CD 0
) ) 0
. . 0

Investigator-based JJ 0
Global NNP 0
Aesthetic NNP 0
Improvement NNP 0
Scale NNP 0
assessment NN 0
at IN 0
9 CD 0
months NNS 0
after IN 0
baseline NN 0
indicated VBD 0
that IN 0
Perlane NNP 0
was VBD 0
superior JJ 0
in IN 0
48.8 CD 0
percent NN 0
of IN 0
patients NNS 0
, , 0
whereas IN 0
Zyplast NNP 0
was VBD 0
superior JJ 0
in IN 0
14.0 CD 0
percent NN 0
of IN 0
patients NNS 0
( ( 0
p JJ 0
= NNP 0
0.0025 CD 0
) ) 0
. . 0

Optimal NNP 0
cosmetic JJ 0
result NN 0
was VBD 0
achieved VBN 0
with IN 0
a DT 0
smaller JJR 0
volume NN 0
of IN 0
Perlane NNP 0
than IN 0
Zyplast NNP 0
( ( 0
mean NN 0
, , 0
1.2 CD 0
ml NN 0
versus NN 0
2.1 CD 0
ml NN 0
) ) 0
. . 0

Local JJ 0
injection-site JJ 0
reactions NNS 0
( ( 0
redness NN 0
, , 0
swelling VBG 0
, , 0
pruritus NN 0
, , 0
and CC 0
induration NN 0
) ) 0
were VBD 0
less RBR 0
frequent JJ 0
with IN 0
Perlane NNP 0
than IN 0
with IN 0
Zyplast NNP 0
. . 0

Delayed-onset JJ 0
reactions NNS 0
were VBD 0
rare JJ 0
and CC 0
did VBD 0
not RB 0
reoccur VB 0
after IN 0
Perlane NNP 0
retreatment NN 0
. . 0

Perlane NNP 0
has VBZ 0
acceptable JJ 0
long-term JJ 0
safety NN 0
and CC 0
offers VBZ 0
a DT 0
longer-lasting JJ 0
aesthetic JJ 0
improvement NN 0
than IN 0
Zyplast NNP 0
. . 0

How WRB 0
does VBZ 0
Cash NNP 0
and CC 0
Counseling NNP 0
affect NN 0
costs NNS 0
? . 0
OBJECTIVE NNP 0
To TO 0
test VB 0
the DT 0
effect NN 0
of IN 0
a DT 0
consumer-directed JJ 0
model NN 0
( ( 0
Cash NNP 0
and CC 0
Counseling NNP 0
) ) 0
of IN 0
Medicaid NNP 0
personal JJ 0
care NN 0
services NNS 0
( ( 0
PCS NNPS 0
) ) 0
or CC 0
home- JJ 0
and CC 0
community-based JJ 0
waiver NN 0
services NNS 0
( ( 0
HCBS NNP 0
) ) 0
on IN 0
the DT 0
cost NN 0
of IN 0
Medicaid NNP 0
services NNS 0
. . 0

DATA NNP 0
SOURCES/STUDY NNP 0
SETTING NNP 0
Medicaid NNP 0
claims NNS 0
data NNS 0
were VBD 0
collected VBN 0
for IN 0
all DT 0
enrollees NNS 0
in IN 0
the DT 0
Cash NNP 0
and CC 0
Counseling NNP 0
demonstration NN 0
. . 0

Demonstration NNP 0
enrollees NNS 0
included VBD 0
those DT 0
eligible JJ 0
for IN 0
PCS NNP 0
( ( 0
in IN 0
Arkansas NNP 0
) ) 0
, , 0
those DT 0
assessed VBN 0
to TO 0
receive VB 0
such JJ 0
services NNS 0
( ( 0
in IN 0
New NNP 0
Jersey NNP 0
) ) 0
, , 0
and CC 0
recipients NNS 0
of IN 0
Medicaid NNP 0
HCBS NNP 0
( ( 0
in IN 0
Florida NNP 0
) ) 0
. . 0

Enrollment NN 0
occurred VBD 0
from IN 0
December NNP 0
1998 CD 0
through IN 0
April NNP 0
2001 CD 0
. . 0

The DT 0
follow-up JJ 0
period NN 0
covered VBD 0
up RB 0
to TO 0
24 CD 0
months NNS 0
after IN 0
enrollment NN 0
. . 0

STUDY NNP 0
DESIGN NNP 0
Demonstration NNP 0
volunteers NNS 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
have VB 0
the DT 0
option NN 0
to TO 0
participate VB 0
in IN 0
Cash NNP 0
and CC 0
Counseling NNP 0
( ( 0
the DT 0
treatment NN 0
group NN 0
) ) 0
, , 0
or CC 0
to TO 0
receive VB 0
Medicaid NNP 0
services NNS 0
as RB 0
usual JJ 0
from IN 0
an DT 0
agency NN 0
( ( 0
the DT 0
control NN 0
group NN 0
) ) 0
. . 0

Ordinary JJ 0
least JJS 0
squares NNS 0
regressions NNS 0
were VBD 0
used VBN 0
to TO 0
estimate VB 0
the DT 0
effect NN 0
of IN 0
the DT 0
program NN 0
on IN 0
costs NNS 0
for IN 0
Medicaid NNP 0
PCS/waiver NNP 0
services NNS 0
and CC 0
other JJ 0
Medicaid NNP 0
services NNS 0
, , 0
while IN 0
controlling VBG 0
for IN 0
consumers NNS 0
' POS 0
preenrollment NN 0
characteristics NNS 0
and CC 0
preenrollment NN 0
Medicaid NNP 0
spending NN 0
. . 0

Models NNS 0
were VBD 0
estimated VBN 0
separately RB 0
for IN 0
nonelderly RB 0
and CC 0
elderly JJ 0
adults NNS 0
in IN 0
each DT 0
state NN 0
and CC 0
for IN 0
children NNS 0
in IN 0
Florida NNP 0
. . 0

DATA NNP 0
EXTRACTION NNP 0
METHODS NNP 0
Each DT 0
state NN 0
supplied VBD 0
claims NNS 0
data NNS 0
for IN 0
demonstration NN 0
enrollees NNS 0
. . 0

PRINCIPAL NNP 0
FINDINGS NNP 0
Largely NNP 0
because IN 0
the DT 0
program NN 0
increased VBD 0
consumers NNS 0
' POS 0
ability NN 0
to TO 0
get VB 0
the DT 0
authorized JJ 0
amount NN 0
of IN 0
paid VBN 0
care NN 0
, , 0
expenditures VBZ 0
for IN 0
personal JJ 0
care/waiver NN 0
services NNS 0
were VBD 0
higher JJR 0
for IN 0
the DT 0
treatment NN 0
group NN 0
than IN 0
for IN 0
the DT 0
control NN 0
group NN 0
in IN 0
each DT 0
state NN 0
and CC 0
age NN 0
group NN 0
, , 0
except IN 0
among IN 0
the DT 0
elderly JJ 0
in IN 0
Florida NNP 0
. . 0

Higher JJR 0
costs NNS 0
for IN 0
personal JJ 0
care/waiver NN 0
services NNS 0
were VBD 0
partially RB 0
offset VBN 0
by IN 0
savings NNS 0
in IN 0
other JJ 0
Medicaid NNP 0
services NNS 0
, , 0
particularly RB 0
those DT 0
related VBN 0
to TO 0
long-term JJ 0
care NN 0
. . 0

During IN 0
year NN 0
1 CD 0
, , 0
total JJ 0
Medicaid NNP 0
costs NNS 0
were VBD 0
generally RB 0
higher JJR 0
for IN 0
the DT 0
treatment NN 0
group NN 0
than IN 0
for IN 0
the DT 0
control NN 0
group NN 0
, , 0
with IN 0
treatment-control JJ 0
cost NN 0
differences NNS 0
ranging VBG 0
from IN 0
1 CD 0
percent NN 0
( ( 0
and CC 0
statistically RB 0
insignificant JJ 0
) ) 0
for IN 0
the DT 0
elderly JJ 0
in IN 0
Florida NNP 0
to TO 0
17 CD 0
percent NN 0
for IN 0
the DT 0
elderly JJ 0
in IN 0
Arkansas NNP 0
. . 0

In IN 0
year NN 0
2 CD 0
, , 0
these DT 0
cost NN 0
differences NNS 0
were VBD 0
generally RB 0
greater JJR 0
than IN 0
in IN 0
year NN 0
1 CD 0
. . 0

Only RB 0
in IN 0
Arkansas NNP 0
did VBD 0
the DT 0
treatment-control NN 0
difference NN 0
in IN 0
total JJ 0
cost NN 0
shrink NN 0
over IN 0
time-to JJ 0
less JJR 0
than IN 0
5 CD 0
percent NN 0
( ( 0
and CC 0
statistically RB 0
insignificant JJ 0
) ) 0
in IN 0
year NN 0
2 CD 0
. . 0

CONCLUSIONS NNP 0
Medicaid NNP 0
costs NNS 0
were VBD 0
generally RB 0
higher JJR 0
under IN 0
Cash NNP 0
and CC 0
Counseling NNP 0
because IN 0
those DT 0
in IN 0
the DT 0
traditional JJ 0
system NN 0
did VBD 0
not RB 0
get VB 0
the DT 0
services NNS 0
they PRP 0
were VBD 0
entitled VBN 0
to TO 0
. . 0

Compared VBN 0
with IN 0
the DT 0
treatment NN 0
group NN 0
, , 0
( ( 0
1 CD 0
) ) 0
control NN 0
group NN 0
members NNS 0
were VBD 0
less RBR 0
likely JJ 0
to TO 0
receive VB 0
any DT 0
services NNS 0
at IN 0
all DT 0
( ( 0
despite IN 0
being VBG 0
authorized VBN 0
for IN 0
them PRP 0
) ) 0
, , 0
and CC 0
( ( 0
2 CD 0
) ) 0
service NN 0
recipients NNS 0
received VBD 0
a DT 0
lower JJR 0
proportion NN 0
of IN 0
the DT 0
amount NN 0
of IN 0
care NN 0
that WDT 0
was VBD 0
authorized VBN 0
. . 0

In IN 0
addition NN 0
, , 0
a DT 0
flaw NN 0
in IN 0
Florida NNP 0
's POS 0
reassessment NN 0
procedures NNS 0
led VBD 0
to TO 0
treatment NN 0
group NN 0
members NNS 0
receiving VBG 0
more RBR 0
generous JJ 0
benefit NN 0
amounts NNS 0
than IN 0
control NN 0
group NN 0
members NNS 0
. . 0

To TO 0
keep VB 0
total JJ 0
Medicaid NNP 0
costs NNS 0
per IN 0
recipient NN 0
at IN 0
the DT 0
level NN 0
incurred VBN 0
under IN 0
the DT 0
traditional JJ 0
system NN 0
, , 0
consumer-directed JJ 0
programs NNS 0
need VBP 0
to TO 0
be VB 0
carefully RB 0
designed VBN 0
and CC 0
closely RB 0
monitored VBN 0
. . 0

The DT 0
aging VBG 0
motor NN 0
system NN 0
as IN 0
a DT 0
model NN 0
for IN 0
plastic JJ 0
changes NNS 0
of IN 0
GABA-mediated NNP 0
intracortical JJ 0
inhibition NN 0
and CC 0
their PRP$ 0
behavioral JJ 0
relevance NN 0
. . 0

Since IN 0
GABAA-mediated JJ 0
intracortical JJ 0
inhibition NN 0
has VBZ 0
been VBN 0
shown VBN 0
to TO 0
underlie VB 0
plastic NN 0
changes NNS 0
throughout IN 0
the DT 0
lifespan NN 0
from IN 0
development NN 0
to TO 0
aging VBG 0
, , 0
here RB 0
, , 0
the DT 0
aging VBG 0
motor NN 0
system NN 0
was VBD 0
used VBN 0
as IN 0
a DT 0
model NN 0
to TO 0
analyze VB 0
the DT 0
interdependence NN 0
of IN 0
plastic JJ 0
alterations NNS 0
within IN 0
the DT 0
inhibitory JJ 0
motorcortical JJ 0
network NN 0
and CC 0
level NN 0
of IN 0
behavioral JJ 0
performance NN 0
. . 0

Double-pulse JJ 0
transcranial JJ 0
magnetic JJ 0
stimulation NN 0
( ( 0
dpTMS NN 0
) ) 0
was VBD 0
used VBN 0
to TO 0
examine VB 0
inhibition NN 0
by IN 0
means NNS 0
of IN 0
short-interval JJ 0
intracortical JJ 0
inhibition NN 0
( ( 0
SICI NNP 0
) ) 0
of IN 0
the DT 0
contralateral JJ 0
primary JJ 0
motor NN 0
cortex NN 0
in IN 0
a DT 0
sample NN 0
of IN 0
64 CD 0
healthy JJ 0
right-handed JJ 0
human JJ 0
subjects NNS 0
covering VBG 0
a DT 0
wide JJ 0
range NN 0
of IN 0
the DT 0
adult NN 0
lifespan NN 0
( ( 0
age NN 0
range NN 0
20-88 CD 0
years NNS 0
, , 0
mean VB 0
47.6 CD 0
? . 0
20.7 CD 0
, , 0
34 CD 0
female NN 0
) ) 0
. . 0

SICI NNP 0
was VBD 0
evaluated VBN 0
during IN 0
resting VBG 0
state NN 0
and CC 0
in IN 0
an DT 0
event-related JJ 0
condition NN 0
during IN 0
movement NN 0
preparation NN 0
in IN 0
a DT 0
visually RB 0
triggered VBN 0
simple JJ 0
reaction NN 0
time NN 0
task NN 0
. . 0

In IN 0
a DT 0
subgroup NN 0
( ( 0
N NNP 0
= NNP 0
23 CD 0
) ) 0
, , 0
manual JJ 0
motor NN 0
performance NN 0
was VBD 0
tested VBN 0
with IN 0
tasks NNS 0
of IN 0
graded VBN 0
dexterous JJ 0
demand NN 0
. . 0

Weak JJ 0
resting-state JJ 0
inhibition NN 0
was VBD 0
associated VBN 0
with IN 0
an DT 0
overall JJ 0
lower JJR 0
manual JJ 0
motor NN 0
performance NN 0
. . 0

Better RBR 0
event-related JJ 0
modulation NN 0
of IN 0
inhibition NN 0
correlated VBN 0
with IN 0
better JJR 0
performance NN 0
in IN 0
more RBR 0
demanding JJ 0
tasks NNS 0
, , 0
in IN 0
which WDT 0
fast RB 0
alternating VBG 0
activation NN 0
of IN 0
cortical JJ 0
representations NNS 0
are VBP 0
necessary JJ 0
. . 0

Declining VBG 0
resting-state JJ 0
inhibition NN 0
was VBD 0
associated VBN 0
with IN 0
weakened JJ 0
event-related JJ 0
modulation NN 0
of IN 0
inhibition NN 0
. . 0

Therefore NN 0
, , 0
reduced VBD 0
resting-state JJ 0
inhibition NN 0
might MD 0
lead VB 0
to TO 0
a DT 0
subsequent JJ 0
loss NN 0
of IN 0
modulatory JJ 0
capacity NN 0
, , 0
possibly RB 0
reflecting VBG 0
malfunctioning VBG 0
precision NN 0
in IN 0
GABAAergic NNP 0
neurotransmission NN 0
; : 0
the DT 0
consequence NN 0
is VBZ 0
an DT 0
inevitable JJ 0
decline NN 0
in IN 0
motor NN 0
function NN 0
. . 0

Comparison NNP 0
of IN 0
the DT 0
time NN 0
required VBN 0
to TO 0
administer VB 0
three CD 0
different JJ 0
fluke NNS 0
and CC 0
worm VB 0
combination NN 0
products NNS 0
to TO 0
commercial JJ 0
beef NN 0
cattle NNS 0
at IN 0
housing NN 0
. . 0

Larger NNP 0
livestock VBD 0
units NNS 0
, , 0
a DT 0
decline NN 0
in IN 0
the DT 0
farm NN 0
labor NN 0
force NN 0
, , 0
animal JJ 0
welfare NN 0
concerns NNS 0
, , 0
and CC 0
a DT 0
trend NN 0
toward IN 0
more RBR 0
selective JJ 0
use NN 0
of IN 0
drugs NNS 0
have VBP 0
increased VBN 0
the DT 0
focus NN 0
on IN 0
animal NN 0
handling NN 0
, , 0
time NN 0
management NN 0
, , 0
convenience NN 0
, , 0
and CC 0
compliance NN 0
in IN 0
administering VBG 0
veterinary JJ 0
therapeutics NNS 0
. . 0

This DT 0
study NN 0
was VBD 0
undertaken VBN 0
to TO 0
quantify VB 0
and CC 0
compare VB 0
the DT 0
time NN 0
needed VBN 0
to TO 0
treat VB 0
commercial JJ 0
beef NN 0
cattle NNS 0
with IN 0
three CD 0
fluke NNS 0
and CC 0
worm VB 0
combination NN 0
products NNS 0
with IN 0
different JJ 0
administration NN 0
profiles NNS 0
. . 0

Young NNP 0
beef NN 0
cattle NNS 0
( ( 0
n JJ 0
= NNP 0
270 CD 0
) ) 0
weighing VBG 0
approximately RB 0
400 CD 0
kg NNS 0
were VBD 0
allocated VBN 0
to TO 0
batches NNS 0
of IN 0
five CD 0
, , 0
which WDT 0
were VBD 0
randomly RB 0
assigned VBN 0
to TO 0
receive VB 0
ivermectin NN 0
+ NNP 0
clorsulon NN 0
injection NN 0
, , 0
ivermectin JJ 0
+ JJ 0
closantel NN 0
injection NN 0
, , 0
or CC 0
levamisole JJ 0
+ JJ 0
triclabendazole JJ 0
oral JJ 0
drench NN 0
. . 0

The DT 0
mean JJ 0
time NN 0
needed VBN 0
to TO 0
administer VB 0
ivermectin JJ 0
+ NN 0
clorsulon NN 0
( ( 0
single JJ 0
injection NN 0
) ) 0
to TO 0
five CD 0
cattle NNS 0
was VBD 0
31 CD 0
seconds NNS 0
, , 0
which WDT 0
was VBD 0
significantly RB 0
less JJR 0
than IN 0
the DT 0
100 CD 0
seconds NNS 0
needed VBN 0
for IN 0
ivermectin JJ 0
+ JJ 0
closantel NN 0
( ( 0
two CD 0
injections NNS 0
) ) 0
and CC 0
the DT 0
126 CD 0
seconds NNS 0
needed VBN 0
for IN 0
levamisole JJ 0
+ JJ 0
triclabendazole NN 0
( ( 0
P NNP 0
< NNP 0
.001 NNP 0
) ) 0
. . 0

Such JJ 0
quantitative JJ 0
data NNS 0
can MD 0
allow VB 0
for IN 0
better JJR 0
planning NN 0
and CC 0
selection NN 0
of IN 0
parasiticide JJ 0
treatment NN 0
approaches NNS 0
at IN 0
the DT 0
farm NN 0
level NN 0
. . 0

Information NNP 0
source NN 0
affects VBZ 0
peers NNS 0
' POS 0
initial JJ 0
attitudes NNS 0
toward IN 0
autism NN 0
. . 0

Authors NNS 0
examined VBD 0
the DT 0
effects NNS 0
of IN 0
information NN 0
source NN 0
on IN 0
peers NNS 0
' POS 0
cognitive NN 0
and CC 0
behavioral JJ 0
attitudes NNS 0
toward IN 0
an DT 0
unfamiliar JJ 0
child NN 0
with IN 0
autism NN 0
. . 0

Children NNP 0
( ( 0
N=296 NNP 0
; : 0
M NNP 0
age=10.21 IN 0
years NNS 0
) ) 0
received VBD 0
information NN 0
about IN 0
an DT 0
unfamiliar JJ 0
child NN 0
with IN 0
autism NN 0
from IN 0
one CD 0
of IN 0
the DT 0
following JJ 0
sources NNS 0
: : 0
( ( 0
a DT 0
) ) 0
videotape NN 0
, , 0
( ( 0
b NN 0
) ) 0
teacher NN 0
, , 0
( ( 0
c NN 0
) ) 0
hypothetical JJ 0
mother NN 0
, , 0
( ( 0
d NN 0
) ) 0
hypothetical JJ 0
father NN 0
, , 0
or CC 0
( ( 0
e NN 0
) ) 0
hypothetical JJ 0
doctor NN 0
. . 0

Interactive JJ 0
effects NNS 0
between IN 0
source NN 0
, , 0
and CC 0
sex NN 0
and CC 0
grade NN 0
were VBD 0
found VBN 0
for IN 0
cognitive JJ 0
and CC 0
behavioral JJ 0
attitudes NNS 0
. . 0

Fifth-graders NNS 0
reported VBD 0
more RBR 0
favorable JJ 0
cognitive JJ 0
and CC 0
behavioral JJ 0
attitudes NNS 0
when WRB 0
information NN 0
was VBD 0
provided VBN 0
by IN 0
extra-familial JJ 0
sources NNS 0
( ( 0
i.e. NN 0
, , 0
doctor NN 0
) ) 0
versus NN 0
parent NN 0
sources NNS 0
. . 0

Mother NNP 0
yielded VBD 0
more RBR 0
persuasive JJ 0
effects NNS 0
on IN 0
behavioral JJ 0
attitudes NNS 0
for IN 0
third-graders NNS 0
versus JJ 0
fifth-graders NNS 0
. . 0

Attitudes NNS 0
toward IN 0
autism NN 0
differ VBP 0
depending VBG 0
on IN 0
who WP 0
provides VBZ 0
information NN 0
about IN 0
the DT 0
disability NN 0
. . 0

Persuasion NNP 0
theory NN 0
appears VBZ 0
useful JJ 0
to TO 0
guide VB 0
evaluation NN 0
of IN 0
educational JJ 0
interventions NNS 0
to TO 0
improve VB 0
attitudes NNS 0
towards IN 0
autism NN 0
. . 0

Implications NNS 0
of IN 0
the DT 0
findings NNS 0
, , 0
study NN 0
limitations NNS 0
, , 0
and CC 0
recommendations NNS 0
for IN 0
future JJ 0
research NN 0
are VBP 0
discussed VBN 0
. . 0

Failure NN 0
of IN 0
naltrexone NN 0
hydrochloride NN 0
to TO 0
reduce VB 0
self-injurious JJ 0
and CC 0
autistic JJ 0
behavior NN 0
in IN 0
mentally RB 0
retarded JJ 0
adults NNS 0
. . 0

Double-blind JJ 0
placebo-controlled JJ 0
studies NNS 0
. . 0

BACKGROUND IN 0
It PRP 0
is VBZ 0
hypothesized VBN 0
that IN 0
self-injurious JJ 0
behavior NN 0
( ( 0
SIB NNP 0
) ) 0
and CC 0
symptoms NNS 0
of IN 0
autism NN 0
may MD 0
be VB 0
due JJ 0
to TO 0
overactivity NN 0
in IN 0
some DT 0
opioid JJ 0
systems NNS 0
in IN 0
the DT 0
brain NN 0
. . 0

We PRP 0
examined VBD 0
the DT 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
naltrexone JJ 0
hydrochloride NN 0
, , 0
an DT 0
opioid JJ 0
antagonist NN 0
, , 0
in IN 0
the DT 0
treatment NN 0
of IN 0
SIB NNP 0
and CC 0
autism NN 0
in IN 0
mentally RB 0
retarded JJ 0
adults NNS 0
. . 0

METHOD NNP 0
Thirty-three NNP 0
mentally RB 0
retarded VBD 0
adults NNS 0
with IN 0
autism NN 0
and/or NN 0
SIB NNP 0
participated VBD 0
in IN 0
double-blind NN 0
, , 0
placebo-controlled JJ 0
crossover NN 0
studies NNS 0
. . 0

Active JJ 0
treatment NN 0
was VBD 0
first RB 0
a DT 0
single JJ 0
100-mg JJ 0
dose NN 0
of IN 0
naltrexone JJ 0
hydrochloride NN 0
. . 0

Subsequently NNP 0
, , 0
19 CD 0
subjects NNS 0
were VBD 0
treated VBN 0
with IN 0
50 CD 0
mg/d NNS 0
and CC 0
14 CD 0
with IN 0
150 CD 0
mg/d NNS 0
of IN 0
naltrexone NN 0
hydrochloride NN 0
for IN 0
4 CD 0
weeks NNS 0
. . 0

The DT 0
outcome NN 0
was VBD 0
assessed VBN 0
by IN 0
means NNS 0
of IN 0
direct JJ 0
observations NNS 0
( ( 0
n JJ 0
= NNP 0
11 CD 0
) ) 0
and CC 0
on IN 0
the DT 0
basis NN 0
of IN 0
scores NNS 0
on IN 0
a DT 0
list NN 0
of IN 0
target NN 0
behaviors NNS 0
, , 0
the DT 0
Aberrant NNP 0
Behavior NNP 0
Checklist NNP 0
, , 0
and CC 0
the DT 0
Clinical NNP 0
Global NNP 0
Impression NNP 0
Scale NNP 0
. . 0

RESULTS NNP 0
Thirty-two JJ 0
subjects NNS 0
( ( 0
seven CD 0
with IN 0
autism NN 0
, , 0
16 CD 0
with IN 0
autism NN 0
and CC 0
SIB NNP 0
, , 0
and CC 0
nine CD 0
with IN 0
SIB NNP 0
) ) 0
completed VBD 0
the DT 0
trial NN 0
. . 0

Naltrexone CD 0
treatment NN 0
failed VBD 0
to TO 0
have VB 0
therapeutic JJ 0
effects NNS 0
on IN 0
SIB NNP 0
and CC 0
autism NN 0
. . 0

On IN 0
the DT 0
contrary JJ 0
, , 0
naltrexone RB 0
increased VBD 0
the DT 0
incidence NN 0
of IN 0
stereotypic JJ 0
behavior NN 0
on IN 0
the DT 0
Aberrant NNP 0
Behavior NNP 0
Checklist NNP 0
, , 0
and CC 0
the DT 0
care NN 0
staff NN 0
evaluated VBD 0
the DT 0
effect NN 0
of IN 0
the DT 0
50-mg/d JJ 0
treatment NN 0
as IN 0
being VBG 0
significantly RB 0
worse JJR 0
than IN 0
that DT 0
of IN 0
the DT 0
placebo NN 0
treatment NN 0
as IN 0
measured VBN 0
by IN 0
the DT 0
Clinical NNP 0
Global NNP 0
Impression NNP 0
Scale NNP 0
. . 0

CONCLUSION NNP 0
Our PRP$ 0
findings NNS 0
suggest VBP 0
that IN 0
naltrexone NN 0
has VBZ 0
no DT 0
clinical JJ 0
value NN 0
for IN 0
a DT 0
broad JJ 0
group NN 0
of IN 0
mentally RB 0
retarded JJ 0
subjects NNS 0
with IN 0
SIB NNP 0
and/or JJ 0
autism NN 0
. . 0

Effects NNS 0
of IN 0
20 CD 0
mg NNS 0
rosuvastatin NN 0
on IN 0
VLDL1- NNP 0
, , 0
VLDL2- NNP 0
, , 0
IDL- NNP 0
and CC 0
LDL-ApoB NNP 0
kinetics NNS 0
in IN 0
type NN 0
2 CD 0
diabetes NNS 0
. . 0

AIMS/HYPOTHESIS NNP 0
In IN 0
addition NN 0
to TO 0
its PRP$ 0
efficacy NN 0
in IN 0
reducing VBG 0
LDL-cholesterol NNP 0
, , 0
rosuvastatin NN 0
has VBZ 0
been VBN 0
shown VBN 0
to TO 0
significantly RB 0
decrease VB 0
plasma NN 0
triacylglycerol NN 0
. . 0

The DT 0
use NN 0
of IN 0
rosuvastatin NN 0
may MD 0
be VB 0
beneficial JJ 0
in IN 0
patients NNS 0
with IN 0
type JJ 0
2 CD 0
diabetes NNS 0
, , 0
who WP 0
usually RB 0
have VBP 0
increased VBN 0
triacylglycerol NN 0
levels NNS 0
. . 0

However RB 0
, , 0
its PRP$ 0
effects NNS 0
on IN 0
the DT 0
metabolism NN 0
of IN 0
triacylglycerol-rich JJ 0
lipoproteins NNS 0
in IN 0
type NN 0
2 CD 0
diabetic JJ 0
patients NNS 0
remains VBZ 0
unknown JJ 0
. . 0

METHODS NNP 0
We PRP 0
performed VBD 0
a DT 0
randomised JJ 0
double-blind NN 0
crossover NN 0
trial NN 0
of IN 0
6-week JJ 0
treatment NN 0
with IN 0
placebo NN 0
or CC 0
rosuvastatin VB 0
20 CD 0
mg NN 0
in IN 0
eight CD 0
patients NNS 0
with IN 0
type JJ 0
2 CD 0
diabetes NNS 0
who WP 0
were VBD 0
being VBG 0
treated VBN 0
with IN 0
oral JJ 0
glucose-lowering JJ 0
agents NNS 0
. . 0

In IN 0
each DT 0
patient NN 0
, , 0
an DT 0
in IN 0
vivo NN 0
kinetic JJ 0
study NN 0
of IN 0
apolipoprotein NN 0
B NNP 0
( ( 0
ApoB NNP 0
) ) 0
-containing VBG 0
lipoproteins NNS 0
with IN 0
[ JJ 0
13C CD 0
] JJ 0
leucine NN 0
was VBD 0
performed VBN 0
at IN 0
the DT 0
end NN 0
of IN 0
each DT 0
treatment NN 0
period NN 0
. . 0

A DT 0
central JJ 0
randomisation NN 0
centre NN 0
used VBN 0
computer-generated JJ 0
tables NNS 0
to TO 0
allocate VB 0
treatments NNS 0
. . 0

Participants NNS 0
, , 0
caregivers NNS 0
and CC 0
those DT 0
assessing VBG 0
the DT 0
outcomes NNS 0
were VBD 0
blinded VBN 0
to TO 0
group NN 0
assignment NN 0
. . 0

RESULTS NNP 0
Rosuvastatin NNP 0
20 CD 0
mg NN 0
significantly RB 0
reduced VBN 0
plasma JJ 0
LDL-cholesterol NNP 0
, , 0
triacylglycerol NN 0
and CC 0
total JJ 0
ApoB NNP 0
. . 0

It PRP 0
also RB 0
significantly RB 0
reduced VBN 0
ApoB NNP 0
pool NN 0
sizes NNS 0
of IN 0
larger JJR 0
triacylglycerol-rich JJ 0
VLDL NNP 0
particles NNS 0
( ( 0
VLDL1 NNP 0
; : 0
p VBZ 0
= $ 0
0.011 CD 0
) ) 0
, , 0
smaller JJR 0
VLDL NNP 0
particles NNS 0
( ( 0
VLDL2 NNP 0
; : 0
p VBZ 0
= $ 0
0.011 CD 0
) ) 0
, , 0
intermediate JJ 0
density NN 0
lipoprotein NN 0
( ( 0
IDL NNP 0
; : 0
p VBZ 0
= $ 0
0.011 CD 0
) ) 0
and CC 0
LDL NNP 0
( ( 0
p JJ 0
= NNP 0
0.011 CD 0
) ) 0
. . 0

This DT 0
reduction NN 0
was VBD 0
associated VBN 0
with IN 0
a DT 0
significant JJ 0
increase NN 0
in IN 0
the DT 0
total JJ 0
fractional JJ 0
catabolic NN 0
rate NN 0
of IN 0
VLDL1-ApoB NNP 0
( ( 0
6.70 CD 0
+/- JJ 0
3.24 CD 0
vs JJ 0
4.52 CD 0
+/- JJ 0
2.34 CD 0
pool/day NN 0
, , 0
p NN 0
= NNP 0
0.049 CD 0
) ) 0
, , 0
VLDL2-ApoB NNP 0
( ( 0
8.72 CD 0
+/- JJ 0
3.37 CD 0
vs JJ 0
5.36 CD 0
+/- JJ 0
2.64 CD 0
, , 0
p NN 0
= NNP 0
0.011 CD 0
) ) 0
, , 0
IDL-ApoB NNP 0
( ( 0
7.06 CD 0
+/- JJ 0
1.68 CD 0
vs JJ 0
4.21 CD 0
+/- JJ 0
1.51 CD 0
, , 0
p NN 0
= NNP 0
0.011 CD 0
) ) 0
and CC 0
LDL-ApoB NNP 0
( ( 0
1.02 CD 0
+/- JJ 0
0.27 CD 0
vs JJ 0
0.59 CD 0
+/- JJ 0
0.13 CD 0
, , 0
p NN 0
= NNP 0
0.011 CD 0
) ) 0
. . 0

Rosuvastatin NNPS 0
did VBD 0
not RB 0
change VB 0
the DT 0
production NN 0
rates NNS 0
of IN 0
VLDL2- NNP 0
, , 0
IDL- NNP 0
or CC 0
LDL- NNP 0
, , 0
but CC 0
did VBD 0
reduce VB 0
VLDL1-ApoB NNP 0
production NN 0
rate NN 0
( ( 0
12.4 CD 0
+/- JJ 0
4.5 CD 0
vs JJ 0
19.5 CD 0
+/- JJ 0
8.4 CD 0
mg NN 0
kg NN 0
( ( 0
-1 JJ 0
) ) 0
day NN 0
( ( 0
-1 NNP 0
) ) 0
, , 0
p JJ 0
= NNP 0
0.035 CD 0
) ) 0
. . 0

No DT 0
side NN 0
effects NNS 0
of IN 0
rosuvastatin NN 0
were VBD 0
observed VBN 0
during IN 0
the DT 0
study NN 0
. . 0

CONCLUSIONS/INTERPRETATION NNP 0
In IN 0
type NN 0
2 CD 0
diabetic JJ 0
patients NNS 0
rosuvastatin VBP 0
20 CD 0
mg NN 0
not RB 0
only RB 0
induces VBZ 0
a DT 0
significant JJ 0
increase NN 0
of IN 0
LDL-ApoB JJ 0
catabolism NN 0
( ( 0
73 CD 0
% NN 0
) ) 0
, , 0
but CC 0
also RB 0
has VBZ 0
favourable JJ 0
effects NNS 0
on IN 0
the DT 0
catabolism NN 0
of IN 0
triacylglycerol-rich JJ 0
lipoproteins NNS 0
, , 0
e.g NN 0
. . 0

a DT 0
significant JJ 0
increase NN 0
in IN 0
the DT 0
catabolism NN 0
of IN 0
VLDL1-ApoB NNP 0
( ( 0
48 CD 0
% NN 0
) ) 0
, , 0
VLDL2-ApoB NNP 0
( ( 0
63 CD 0
% NN 0
) ) 0
and CC 0
IDL-ApoB NNP 0
( ( 0
68 CD 0
% NN 0
) ) 0
, , 0
and CC 0
a DT 0
reduction NN 0
in IN 0
the DT 0
production NN 0
rate NN 0
of IN 0
VLDL1-ApoB NNP 0
( ( 0
-36 CD 0
% NN 0
) ) 0
. . 0

The DT 0
effects NNS 0
of IN 0
rosuvastatin NN 0
on IN 0
the DT 0
metabolism NN 0
of IN 0
triacylglycerol-rich JJ 0
lipoproteins NNS 0
may MD 0
be VB 0
beneficial JJ 0
for IN 0
prevention NN 0
of IN 0
atherosclerosis NN 0
in IN 0
type NN 0
2 CD 0
diabetic JJ 0
patients NNS 0
. . 0

Long-term JJ 0
evaluation NN 0
of IN 0
tamsulosin NN 0
in IN 0
benign JJ 0
prostatic JJ 0
hyperplasia NN 0
: : 0
placebo-controlled JJ 0
, , 0
double-blind JJ 0
extension NN 0
of IN 0
phase NN 0
III NNP 0
trial NN 0
. . 0

Tamsulosin NNP 0
Investigator NNP 0
Group NNP 0
. . 0

OBJECTIVES NNP 0
To TO 0
evaluate VB 0
the DT 0
long-term JJ 0
efficacy NN 0
and CC 0
safety NN 0
of IN 0
once-daily JJ 0
tamsulosin NN 0
( ( 0
0.4 CD 0
and CC 0
0.8 CD 0
mg NN 0
) ) 0
, , 0
a DT 0
unique JJ 0
selective JJ 0
alpha1A-adrenoceptor NN 0
antagonist NN 0
in IN 0
patients NNS 0
with IN 0
benign JJ 0
prostatic JJ 0
hyperplasia NN 0
( ( 0
BPH NNP 0
) ) 0
. . 0

METHODS NNP 0
This DT 0
trial NN 0
extended VBD 0
a DT 0
13-week JJ 0
, , 0
Phase NNP 0
III NNP 0
multicenter NN 0
placebo-controlled JJ 0
, , 0
double-blind JJ 0
outpatient JJ 0
trial NN 0
for IN 0
an DT 0
additional JJ 0
40 CD 0
weeks NNS 0
. . 0

Of IN 0
618 CD 0
patients NNS 0
, , 0
418 CD 0
( ( 0
68 CD 0
% NN 0
) ) 0
continued VBD 0
into IN 0
the DT 0
extension NN 0
phase NN 0
on IN 0
the DT 0
same JJ 0
double-blind JJ 0
medication NN 0
and CC 0
dose NN 0
. . 0

The DT 0
primary JJ 0
efficacy NN 0
parameters NNS 0
were VBD 0
total JJ 0
American NNP 0
Urological NNP 0
Association NNP 0
( ( 0
AUA NNP 0
) ) 0
symptom NN 0
score NN 0
and CC 0
maximum JJ 0
urinary JJ 0
flow NN 0
( ( 0
Qmax NNP 0
) ) 0
. . 0

RESULTS VB 0
The DT 0
mean JJ 0
changes NNS 0
in IN 0
AUA NNP 0
symptom NN 0
score NN 0
from IN 0
baseline NN 0
to TO 0
end VB 0
point NN 0
were VBD 0
statistically RB 0
significant JJ 0
in IN 0
all DT 0
groups NNS 0
( ( 0
P NNP 0
< NNP 0
0.001 CD 0
) ) 0
. . 0

Significant JJ 0
improvements NNS 0
were VBD 0
observed VBN 0
in IN 0
Qmax NNP 0
for IN 0
both DT 0
tamsulosin JJ 0
groups NNS 0
but CC 0
not RB 0
for IN 0
the DT 0
placebo NN 0
group NN 0
. . 0

The DT 0
statistically RB 0
significant JJ 0
improvements NNS 0
from IN 0
baseline NN 0
in IN 0
efficacy NN 0
parameters NNS 0
observed VBD 0
for IN 0
each DT 0
tamsulosin NN 0
group NN 0
at IN 0
the DT 0
end NN 0
of IN 0
the DT 0
13-week JJ 0
Phase NNP 0
III NNP 0
trial NN 0
were VBD 0
maintained VBN 0
during IN 0
the DT 0
long-term JJ 0
extension NN 0
phase NN 0
. . 0

Tamsulosin NN 0
at IN 0
both DT 0
dosages NNS 0
was VBD 0
well RB 0
tolerated VBN 0
as IN 0
maintenance NN 0
therapy NN 0
. . 0

Clinically NNP 0
significant JJ 0
orthostatic JJ 0
hypotension NN 0
was VBD 0
not RB 0
observed VBN 0
. . 0

Vital JJ 0
sign NN 0
changes NNS 0
in IN 0
either DT 0
hypertensive JJ 0
or CC 0
normotensive JJ 0
patients NNS 0
were VBD 0
not RB 0
clinically RB 0
significantly RB 0
different JJ 0
across IN 0
the DT 0
three CD 0
groups NNS 0
. . 0

CONCLUSIONS NNP 0
Tamsulosin NNP 0
once-daily RB 0
at IN 0
0.4 CD 0
or CC 0
0.8 CD 0
mg NN 0
was VBD 0
shown VBN 0
to TO 0
be VB 0
effective JJ 0
, , 0
safe JJ 0
, , 0
and CC 0
well RB 0
tolerated VBN 0
in IN 0
the DT 0
target NN 0
BPH NNP 0
population NN 0
during IN 0
long-term JJ 0
use NN 0
. . 0

Comparison NNP 0
of IN 0
patient-controlled JJ 0
and CC 0
nurse-administered JJ 0
analgesia NN 0
using VBG 0
intravenous JJ 0
fentanyl NN 0
during IN 0
labor NN 0
. . 0

Preliminary JJ 0
observations NNS 0
have VBP 0
shown VBN 0
that IN 0
fentanyl NN 0
citrate NN 0
, , 0
a DT 0
potent JJ 0
narcotic JJ 0
, , 0
is VBZ 0
helpful JJ 0
during IN 0
labor NN 0
without IN 0
undue JJ 0
side NN 0
effects NNS 0
. . 0

This DT 0
randomized JJ 0
prospective JJ 0
investigation NN 0
compared VBN 0
the DT 0
patient-controlled JJ 0
administration NN 0
of IN 0
fentanyl NN 0
with IN 0
that DT 0
of IN 0
administration NN 0
by IN 0
nurses NNS 0
on IN 0
request NN 0
. . 0

Eighty NNP 0
healthy JJ 0
women NNS 0
beginning VBG 0
active JJ 0
labor NN 0
( ( 0
cervical JJ 0
dilation NN 0
4 CD 0
cm NN 0
) ) 0
at IN 0
term NN 0
were VBD 0
assigned VBN 0
to TO 0
receive VB 0
fentanyl NN 0
intravenously RB 0
by IN 0
either CC 0
patient-controlled JJ 0
administration NN 0
( ( 0
n=37 JJ 0
) ) 0
or CC 0
nurse JJ 0
administration NN 0
on IN 0
demand NN 0
( ( 0
n=43 JJ 0
) ) 0
. . 0

Pain NNP 0
intensity NN 0
measurements NNS 0
during IN 0
early JJ 0
and CC 0
late JJ 0
labor NN 0
revealed VBD 0
the DT 0
degree NN 0
of IN 0
analgesia NN 0
to TO 0
be VB 0
the DT 0
same JJ 0
in IN 0
both DT 0
groups NNS 0
. . 0

The DT 0
delay NN 0
in IN 0
setting VBG 0
up RP 0
the DT 0
infusion NN 0
system NN 0
and CC 0
the DT 0
short JJ 0
time NN 0
between IN 0
requesting VBG 0
analgesia NN 0
and CC 0
vaginal JJ 0
delivery NN 0
were VBD 0
limitations NNS 0
with IN 0
self-administration NN 0
. . 0

Maternal JJ 0
oversedation NN 0
and CC 0
vomiting VBG 0
did VBD 0
not RB 0
occur VB 0
. . 0

Neonatal NNP 0
naloxone NN 0
therapy NN 0
was VBD 0
used VBN 0
infrequently RB 0
, , 0
umbilical JJ 0
serum NN 0
levels NNS 0
of IN 0
fentanyl NN 0
were VBD 0
the DT 0
same JJ 0
in IN 0
both DT 0
groups NNS 0
, , 0
and CC 0
postnatal JJ 0
neuroadaptive JJ 0
testing NN 0
revealed VBD 0
comparable JJ 0
results NNS 0
in IN 0
both DT 0
groups NNS 0
. . 0

Despite IN 0
the DT 0
usefulness NN 0
of IN 0
fentanyl NN 0
during IN 0
labor NN 0
, , 0
administration NN 0
by IN 0
the DT 0
patient NN 0
had VBD 0
no DT 0
advantages NNS 0
over IN 0
administration NN 0
by IN 0
the DT 0
nurses NNS 0
in IN 0
significantly RB 0
reducing VBG 0
drug NN 0
use NN 0
, , 0
improving VBG 0
pain NN 0
relief NN 0
, , 0
or CC 0
avoiding VBG 0
drowsiness NN 0
. . 0

Randomized VBN 0
trial NN 0
of IN 0
fenretinide NN 0
in IN 0
superficial JJ 0
bladder NN 0
cancer NN 0
using VBG 0
DNA NNP 0
flow JJ 0
cytometry NN 0
as IN 0
an DT 0
intermediate JJ 0
end NN 0
point NN 0
. . 0

Retinoids NNS 0
have VBP 0
shown VBN 0
a DT 0
potential JJ 0
activity NN 0
in IN 0
preventing VBG 0
tumor NN 0
recurrence NN 0
in IN 0
superficial JJ 0
bladder NN 0
cancer NN 0
. . 0

We PRP 0
assessed VBD 0
the DT 0
activity NN 0
of IN 0
the DT 0
synthetic JJ 0
retinoid NN 0
fenretinide NN 0
in IN 0
superficial JJ 0
bladder NN 0
cancer NN 0
using VBG 0
DNA NNP 0
flow JJ 0
cytometry NN 0
and CC 0
conventional JJ 0
cytology NN 0
as IN 0
surrogate JJ 0
biomarkers NNS 0
. . 0

A DT 0
total NN 0
of IN 0
99 CD 0
subjects NNS 0
with IN 0
resected JJ 0
superficial JJ 0
bladder NN 0
cancer NN 0
( ( 0
pTa NN 0
, , 0
pT1 NN 0
) ) 0
were VBD 0
randomized VBN 0
to TO 0
either DT 0
fenretinide NN 0
( ( 0
200 CD 0
mg NNS 0
day NN 0
p.o NN 0
. . 0

for IN 0
24 CD 0
months NNS 0
) ) 0
or CC 0
no DT 0
intervention NN 0
. . 0

Cystoscopy NNP 0
and CC 0
bladder NN 0
washing NN 0
for IN 0
DNA NNP 0
flow NN 0
cytometry NN 0
end NN 0
points NNS 0
( ( 0
proportion NN 0
of IN 0
DNA NNP 0
aneuploid JJ 0
histograms NN 0
, , 0
hyperdiploid JJ 0
fraction NN 0
, , 0
and CC 0
percentage NN 0
of IN 0
apoptotic JJ 0
cells NNS 0
) ) 0
and CC 0
proportion NN 0
of IN 0
abnormal JJ 0
cytological JJ 0
examinations NNS 0
were VBD 0
repeated VBN 0
every DT 0
4 CD 0
months NNS 0
for IN 0
up IN 0
to TO 0
36 CD 0
months NNS 0
. . 0

The DT 0
primary JJ 0
study NN 0
end NN 0
point NN 0
was VBD 0
the DT 0
proportion NN 0
of IN 0
DNA NNP 0
aneuploid JJ 0
histograms NNS 0
after IN 0
12 CD 0
months NNS 0
. . 0

This DT 0
figure NN 0
was VBD 0
48.9 CD 0
% NN 0
in IN 0
the DT 0
fenretinide JJ 0
arm NN 0
and CC 0
41.9 CD 0
% NN 0
in IN 0
the DT 0
control NN 0
arm NN 0
( ( 0
odds NNS 0
ratio NN 0
, , 0
1.16 CD 0
; : 0
95 CD 0
% NN 0
confidence NN 0
interval NN 0
, , 0
0.44-3.07 JJ 0
) ) 0
. . 0

There EX 0
was VBD 0
no DT 0
difference NN 0
in IN 0
any DT 0
other JJ 0
response NN 0
biomarker NN 0
between IN 0
the DT 0
two CD 0
groups NNS 0
up RB 0
to TO 0
36 CD 0
months NNS 0
, , 0
nor CC 0
was VBD 0
any DT 0
biomarker NN 0
able JJ 0
to TO 0
predict VB 0
recurrence NN 0
risk NN 0
. . 0

Recurrence-free JJ 0
survival NN 0
was VBD 0
comparable JJ 0
between IN 0
the DT 0
arms NNS 0
( ( 0
27 CD 0
events NNS 0
in IN 0
the DT 0
fenretinide JJ 0
arm NN 0
versus NN 0
21 CD 0
in IN 0
the DT 0
control NN 0
arm NN 0
; : 0
P NNP 0
= NNP 0
0.36 CD 0
) ) 0
. . 0

Twelve NNP 0
subjects VBZ 0
in IN 0
the DT 0
fenretinide JJ 0
arm NN 0
complained VBD 0
of IN 0
diminished JJ 0
dark NN 0
adaptability NN 0
, , 0
and CC 0
nine CD 0
subjects NNS 0
in IN 0
the DT 0
fenretinide JJ 0
arm NN 0
versus IN 0
one CD 0
control NN 0
subject NN 0
had VBD 0
mild JJ 0
dermatological JJ 0
alterations NNS 0
. . 0

We PRP 0
conclude VBP 0
that DT 0
fenretinide NN 0
showed VBD 0
a DT 0
lack NN 0
of IN 0
effect NN 0
on IN 0
the DT 0
DNA NNP 0
content NN 0
distribution NN 0
and CC 0
the DT 0
morphology NN 0
of IN 0
urothelial JJ 0
cells NNS 0
obtained VBN 0
in IN 0
serial JJ 0
bladder NN 0
washings NNS 0
. . 0

Recurrence-free JJ 0
survival NN 0
was VBD 0
comparable JJ 0
between IN 0
groups NNS 0
. . 0

Because IN 0
our PRP$ 0
data NNS 0
are VBP 0
hampered VBN 0
by IN 0
the DT 0
lack NN 0
of IN 0
predictivity NN 0
of IN 0
the DT 0
selected VBN 0
biomarkers NNS 0
, , 0
additional JJ 0
studies NNS 0
are VBP 0
necessary JJ 0
to TO 0
assess VB 0
the DT 0
activity NN 0
of IN 0
fenretinide NN 0
in IN 0
preventing VBG 0
bladder NN 0
cancer NN 0
. . 0

